cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
HNSC	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	33.96	3.15e-128	9.65e-121	1.2	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	33.13	1.08e-124	3.29e-118	1.21	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	33.13	1.08e-124	3.29e-118	1.21	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	32.62	1.73e-122	2.31e-116	1.2	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	32.61	1.97e-122	2.31e-116	1.22	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	32.61	1.97e-122	2.31e-116	1.22	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	32.46	8.59e-122	9.74e-116	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	32.34	2.71e-121	2.96e-115	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	32.22	9.2e-121	9.71e-115	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	32.16	1.69e-120	1.73e-114	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-30.89	6.37e-115	1.93e-109	-1.16	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-30.58	1.51e-113	4.32e-108	-1.14	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	30.47	4.58e-113	1.3e-107	1.2	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	30.32	2.06e-112	5.72e-107	1.16	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-30.31	2.21e-112	5.99e-107	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-30.31	2.21e-112	5.99e-107	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-30.29	2.83e-112	7.53e-107	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	30.22	5.67e-112	1.48e-106	1.17	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	30.22	5.67e-112	1.48e-106	1.17	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-30.16	1.04e-111	2.62e-106	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-30.16	1.04e-111	2.62e-106	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	30.13	1.52e-111	3.79e-106	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-29.97	7.56e-111	1.87e-105	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-29.93	1.14e-110	2.78e-105	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-29.83	3.32e-110	8e-105	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-29.78	5.32e-110	1.27e-104	-1.11	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-29.65	1.99e-109	4.68e-104	-1.17	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-29.65	1.99e-109	4.68e-104	-1.17	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	28.8	1.28e-105	2.91e-100	1.06	0.8	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	28.74	2.36e-105	5.32e-100	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-28.74	2.51e-105	5.58e-100	-1.07	-0.8	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-28.67	4.93e-105	1.09e-99	-1.07	-0.8	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	28.67	5.3e-105	1.16e-99	1.08	0.8	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	28.62	8.24e-105	1.7e-99	1.07	0.8	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	28.62	8.24e-105	1.7e-99	1.07	0.8	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	28.54	2.02e-104	3.43e-99	1.07	0.8	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	28.5	2.96e-104	4.98e-99	1.07	0.8	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	28.46	4.62e-104	7.21e-99	1.07	0.8	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	28.43	6.21e-104	9.66e-99	1.07	0.8	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	28.35	1.46e-103	2.23e-98	1.15	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
HNSC	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	28.31	2.24e-103	3.4e-98	0.89	0.79	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	28.28	2.85e-103	4.28e-98	1.06	0.79	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	28.28	2.85e-103	4.28e-98	1.06	0.79	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	28.24	4.63e-103	6.89e-98	1.06	0.79	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	28.24	4.63e-103	6.89e-98	1.06	0.79	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-28.22	5.56e-103	8.22e-98	-1.05	-0.79	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	28.15	1.1e-102	1.61e-97	1.06	0.79	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	28.15	1.1e-102	1.61e-97	1.06	0.79	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	28.15	1.16e-102	1.69e-97	1.06	0.79	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	28.08	2.28e-102	3.25e-97	1.06	0.79	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	28.08	2.28e-102	3.25e-97	1.06	0.79	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	28.08	2.28e-102	3.25e-97	1.06	0.79	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	27.69	1.41e-100	1.83e-95	1.06	0.79	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	27.69	1.41e-100	1.83e-95	1.06	0.79	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	27.67	1.75e-100	2.27e-95	1.06	0.79	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	27.66	1.9e-100	2.46e-95	1.07	0.79	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	27.63	2.63e-100	3.39e-95	1.06	0.79	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	27.44	2e-99	2.49e-94	1.14	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	27.44	2e-99	2.49e-94	1.14	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	27.43	2.31e-99	2.86e-94	1.05	0.79	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	27.41	2.65e-99	3.26e-94	1.06	0.79	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	27.4	2.96e-99	3.61e-94	1.06	0.79	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	27.39	3.27e-99	3.97e-94	1.06	0.79	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	27.36	4.43e-99	5.12e-94	1.05	0.78	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	27.36	4.43e-99	5.12e-94	1.05	0.78	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	27.33	6.15e-99	7.08e-94	1.05	0.78	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	27.31	7.41e-99	8.5e-94	1.05	0.78	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	27.31	7.51e-99	8.58e-94	1.04	0.78	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	27.29	9.46e-99	1.07e-93	1.06	0.78	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	27.28	1.1e-98	1.25e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	27.24	1.67e-98	1.88e-93	1.05	0.78	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	27.23	1.77e-98	1.98e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	27.16	3.78e-98	4.2e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	27.16	3.78e-98	4.2e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	27.14	4.84e-98	5.33e-93	1.05	0.78	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	27.11	6.52e-98	7.16e-93	1.12	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	27.1	6.99e-98	7.64e-93	1.04	0.78	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	27.04	1.28e-97	1.39e-92	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	27.04	1.41e-97	1.52e-92	1.07	0.78	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	27.02	1.71e-97	1.84e-92	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	27.01	1.78e-97	1.91e-92	1.05	0.78	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	27.01	1.83e-97	1.95e-92	1.05	0.78	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	27.01	1.83e-97	1.95e-92	1.05	0.78	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	26.95	3.5e-97	3.71e-92	1.04	0.78	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	26.93	4.35e-97	4.59e-92	1.06	0.78	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	26.9	6.11e-97	6.43e-92	0.87	0.78	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
HNSC	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	26.88	7.04e-97	7.38e-92	1.03	0.78	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
HNSC	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	26.77	2.31e-96	2.39e-91	1.13	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	26.68	6.26e-96	6.47e-91	0.87	0.78	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	26.6	1.43e-95	1.47e-90	1.04	0.78	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-26.54	2.73e-95	2.77e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-26.54	2.73e-95	2.77e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-26.53	3.09e-95	3.09e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-26.53	3.09e-95	3.09e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
HNSC	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-26.51	3.58e-95	3.57e-90	-1.04	-0.78	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-26.5	4.25e-95	4.22e-90	-0.87	-0.77	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	26.35	2.07e-94	2.04e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
HNSC	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-26.31	2.99e-94	2.92e-89	-1.03	-0.77	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-26.3	3.24e-94	3.15e-89	-0.91	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	26.3	3.46e-94	3.35e-89	0.85	0.77	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	26.27	4.72e-94	4.56e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	26.26	4.93e-94	4.7e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	26.26	4.93e-94	4.7e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	26.06	4.41e-93	4.14e-88	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	26.06	4.51e-93	4.23e-88	1.03	0.77	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	25.97	1.15e-92	1.08e-87	0.86	0.77	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	25.88	2.79e-92	2.59e-87	1.14	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-25.85	3.89e-92	3.6e-87	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	25.81	6.13e-92	5.63e-87	0.86	0.77	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	25.7	1.96e-91	1.78e-86	0.85	0.77	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	25.7	1.96e-91	1.78e-86	0.85	0.77	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	25.62	4.66e-91	4.23e-86	1.13	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	25.61	5.14e-91	4.65e-86	1.1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-25.61	5.36e-91	4.84e-86	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	25.59	6.57e-91	5.91e-86	1.03	0.76	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	25.57	7.87e-91	7.06e-86	1.11	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	25.55	9.8e-91	8.74e-86	1.1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	25.55	9.8e-91	8.74e-86	1.1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-25.49	1.79e-90	1.58e-85	-1.11	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-25.49	1.79e-90	1.58e-85	-1.11	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-25.44	3.31e-90	2.92e-85	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	25.42	3.76e-90	3.31e-85	0.84	0.76	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	25.34	9.34e-90	8.12e-85	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-25.34	9.34e-90	8.12e-85	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-25.34	9.34e-90	8.12e-85	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
HNSC	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	25.31	1.26e-89	1.08e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	25.31	1.26e-89	1.08e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	25.31	1.26e-89	1.08e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	25.28	1.84e-89	1.58e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	25.26	2.2e-89	1.87e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	25.23	3.14e-89	2.65e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	25.23	3.14e-89	2.65e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	25.23	3.14e-89	2.65e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-25.19	4.5e-89	3.78e-84	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	25.18	5e-89	4.17e-84	1.01	0.76	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	25.18	5e-89	4.17e-84	1.01	0.76	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-25.18	5.07e-89	4.22e-84	-1.05	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	25.15	6.94e-89	5.76e-84	0.89	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	25.14	8e-89	6.62e-84	1.03	0.76	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	25.13	8.34e-89	6.88e-84	1.04	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	25.12	1e-88	8.26e-84	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
HNSC	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	25.09	1.3e-88	1.07e-83	1.01	0.76	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-25.07	1.66e-88	1.36e-83	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	25.06	1.86e-88	1.52e-83	1.03	0.76	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	25.04	2.3e-88	1.88e-83	0.85	0.76	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-25.04	2.34e-88	1.9e-83	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-25.04	2.34e-88	1.9e-83	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	25.03	2.57e-88	2.08e-83	0.86	0.76	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-24.98	4.46e-88	3.59e-83	-0.84	-0.76	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	24.97	4.8e-88	3.84e-83	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	24.94	6.93e-88	5.54e-83	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-24.88	1.23e-87	9.82e-83	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-24.87	1.43e-87	1.14e-82	-0.84	-0.75	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	24.82	2.47e-87	1.94e-82	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	24.76	4.54e-87	3.55e-82	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	24.74	5.87e-87	4.59e-82	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	24.74	5.89e-87	4.59e-82	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	24.67	1.24e-86	9.62e-82	1.1	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	24.66	1.3e-86	1e-81	0.84	0.75	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	24.62	2.08e-86	1.59e-81	1.01	0.75	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	24.62	2.08e-86	1.59e-81	1.01	0.75	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
HNSC	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-24.6	2.49e-86	1.9e-81	-1.01	-0.75	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
HNSC	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-24.59	2.72e-86	2.06e-81	-1.02	-0.75	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	24.59	2.85e-86	2.16e-81	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-24.55	4.25e-86	3.2e-81	-0.83	-0.75	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	24.47	1.03e-85	7.64e-81	0.99	0.75	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	24.35	3.8e-85	2.75e-80	1.09	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	24.34	4.06e-85	2.93e-80	1	0.75	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	24.34	4.06e-85	2.93e-80	1	0.75	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	24.27	8.53e-85	6.1e-80	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	24.25	1.09e-84	7.69e-80	0.99	0.75	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	24.25	1.09e-84	7.69e-80	0.99	0.75	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	24.22	1.55e-84	1.09e-79	0.99	0.75	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	24.22	1.55e-84	1.09e-79	0.99	0.75	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	24.19	2.09e-84	1.46e-79	0.9	0.75	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	24.18	2.47e-84	1.72e-79	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	24.17	2.68e-84	1.86e-79	1	0.75	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	24.17	2.68e-84	1.86e-79	1	0.75	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	24.15	3.2e-84	2.21e-79	0.99	0.75	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	24.13	3.97e-84	2.73e-79	0.99	0.74	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	24.13	3.97e-84	2.73e-79	0.99	0.74	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	24.12	4.28e-84	2.92e-79	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	24.08	6.8e-84	4.62e-79	0.99	0.74	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	24.04	1.08e-83	7.34e-79	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	24	1.66e-83	1.12e-78	0.99	0.74	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	23.98	2.01e-83	1.35e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	23.95	2.69e-83	1.8e-78	0.99	0.74	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-23.95	2.78e-83	1.85e-78	-0.9	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	23.94	2.96e-83	1.97e-78	0.99	0.74	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	23.93	3.57e-83	2.36e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	23.93	3.57e-83	2.36e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	23.89	5.04e-83	3.31e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	23.89	5.36e-83	3.51e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	23.89	5.44e-83	3.53e-78	0.99	0.74	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	23.89	5.44e-83	3.53e-78	0.99	0.74	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	23.88	6.11e-83	3.97e-78	0.99	0.74	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	23.85	8.18e-83	5.29e-78	0.99	0.74	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	23.85	8.54e-83	5.51e-78	1	0.74	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	23.84	8.81e-83	5.66e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	23.84	8.81e-83	5.66e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	23.84	9.41e-83	6.03e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	23.83	1.01e-82	6.43e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	23.83	1.02e-82	6.49e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	23.82	1.07e-82	6.82e-78	0.99	0.74	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	23.81	1.32e-82	8.39e-78	0.98	0.74	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	23.8	1.36e-82	8.54e-78	0.99	0.74	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	23.79	1.61e-82	1.01e-77	0.99	0.74	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	23.79	1.61e-82	1.01e-77	0.99	0.74	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	23.78	1.71e-82	1.07e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	23.77	1.98e-82	1.23e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	23.77	2.02e-82	1.26e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	23.76	2.22e-82	1.38e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	23.75	2.39e-82	1.48e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	23.75	2.39e-82	1.48e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	23.73	2.97e-82	1.83e-77	0.98	0.74	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	23.72	3.28e-82	2.02e-77	0.99	0.74	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	23.72	3.35e-82	2.05e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	23.7	3.97e-82	2.42e-77	0.98	0.74	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	23.7	3.97e-82	2.42e-77	0.98	0.74	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	23.7	4.16e-82	2.53e-77	0.98	0.74	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	23.7	4.3e-82	2.61e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	23.7	4.3e-82	2.61e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	23.68	5.14e-82	3.11e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	23.67	5.45e-82	3.29e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	23.66	6.02e-82	3.61e-77	0.98	0.74	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	23.66	6.02e-82	3.61e-77	0.98	0.74	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	23.66	6.46e-82	3.87e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	23.66	6.51e-82	3.89e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	23.66	6.51e-82	3.89e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	23.65	6.84e-82	4.08e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	23.64	8.04e-82	4.77e-77	0.98	0.74	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	23.63	8.8e-82	5.21e-77	0.88	0.74	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	23.62	9.69e-82	5.73e-77	0.98	0.74	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	23.61	1.12e-81	6.62e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	23.54	2.24e-81	1.3e-76	0.98	0.74	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	23.53	2.46e-81	1.43e-76	0.98	0.74	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	23.52	2.74e-81	1.58e-76	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-23.52	2.86e-81	1.65e-76	-1.04	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	23.52	3.01e-81	1.73e-76	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	23.52	3.01e-81	1.73e-76	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	23.5	3.51e-81	2.01e-76	0.99	0.74	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-23.49	3.82e-81	2.18e-76	-0.98	-0.74	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	23.45	5.99e-81	3.42e-76	0.98	0.74	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	23.44	6.51e-81	3.7e-76	0.97	0.74	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	23.44	6.78e-81	3.84e-76	0.98	0.74	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	23.44	6.78e-81	3.84e-76	0.98	0.74	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	23.42	8.19e-81	4.62e-76	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	23.42	8.3e-81	4.68e-76	0.98	0.73	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	23.38	1.36e-80	7.54e-76	0.98	0.73	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	23.36	1.64e-80	9e-76	0.97	0.73	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	23.36	1.64e-80	9e-76	0.97	0.73	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	23.36	1.64e-80	9e-76	0.97	0.73	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	23.32	2.61e-80	1.43e-75	0.97	0.73	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	23.31	2.83e-80	1.54e-75	1	0.73	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	23.3	2.97e-80	1.62e-75	0.97	0.73	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	23.27	4.26e-80	2.31e-75	0.97	0.73	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	23.27	4.26e-80	2.31e-75	0.97	0.73	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	23.27	4.48e-80	2.43e-75	0.97	0.73	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	23.24	5.91e-80	3.18e-75	0.97	0.73	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	23.21	8.13e-80	4.34e-75	1	0.73	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	23.21	8.13e-80	4.34e-75	1	0.73	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	23.19	1.02e-79	5.43e-75	0.92	0.73	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	23.14	1.72e-79	9.04e-75	0.97	0.73	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	23.14	1.72e-79	9.04e-75	0.97	0.73	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	23.13	1.95e-79	1.02e-74	0.83	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	23.12	2.19e-79	1.14e-74	0.97	0.73	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	23.1	2.8e-79	1.45e-74	0.84	0.73	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	23.09	2.93e-79	1.52e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	23.09	2.97e-79	1.53e-74	0.97	0.73	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	23.09	2.97e-79	1.53e-74	0.97	0.73	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	23.07	3.53e-79	1.79e-74	0.97	0.73	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	23.07	3.53e-79	1.79e-74	0.97	0.73	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	23.07	3.61e-79	1.83e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	23.07	3.7e-79	1.87e-74	0.96	0.73	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	23.06	4.16e-79	2.1e-74	0.99	0.73	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	23.05	4.53e-79	2.28e-74	0.97	0.73	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	23.04	5.38e-79	2.71e-74	0.97	0.73	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	23.03	5.44e-79	2.73e-74	0.97	0.73	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	23.03	5.67e-79	2.83e-74	0.97	0.73	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	22.97	1.07e-78	5.28e-74	0.99	0.73	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	22.95	1.41e-78	6.97e-74	0.96	0.73	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	22.94	1.45e-78	7.11e-74	0.99	0.73	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	22.94	1.56e-78	7.67e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	22.94	1.56e-78	7.67e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	22.93	1.67e-78	8.18e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	22.93	1.7e-78	8.32e-74	0.97	0.73	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	22.92	1.89e-78	9.23e-74	0.96	0.73	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	22.92	1.97e-78	9.6e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	22.9	2.34e-78	1.13e-73	0.99	0.73	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	22.9	2.36e-78	1.14e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	22.89	2.46e-78	1.18e-73	0.97	0.73	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	22.89	2.48e-78	1.19e-73	0.96	0.73	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	22.88	2.74e-78	1.31e-73	0.82	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	22.86	3.63e-78	1.73e-73	0.96	0.73	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	22.84	4.42e-78	2.09e-73	0.99	0.73	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	22.8	7.2e-78	3.39e-73	0.96	0.73	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	22.78	8.33e-78	3.89e-73	0.96	0.73	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	22.78	8.75e-78	4.08e-73	1	0.73	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	22.77	9.33e-78	4.35e-73	0.99	0.73	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	22.76	1.02e-77	4.71e-73	0.96	0.73	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	22.74	1.24e-77	5.75e-73	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	22.74	1.36e-77	6.25e-73	0.96	0.72	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	22.73	1.46e-77	6.66e-73	0.79	0.72	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-22.73	1.47e-77	6.68e-73	-0.88	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	22.73	1.47e-77	6.68e-73	0.96	0.72	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	22.73	1.47e-77	6.68e-73	0.96	0.72	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	22.71	1.73e-77	7.84e-73	0.95	0.72	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	22.71	1.74e-77	7.85e-73	0.96	0.72	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
HNSC	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-22.7	2.02e-77	9.01e-73	-0.89	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	22.69	2.28e-77	1.02e-72	0.99	0.72	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	22.68	2.6e-77	1.15e-72	0.83	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	22.68	2.61e-77	1.15e-72	0.99	0.72	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	22.67	2.91e-77	1.28e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	22.63	4.08e-77	1.8e-72	0.96	0.72	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
HNSC	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	22.63	4.25e-77	1.87e-72	1.05	0.72	Shingles;	chr7:38346957	chr7:38343894~38350022:-
HNSC	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	22.61	5.4e-77	2.37e-72	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	22.59	6.89e-77	3.01e-72	0.96	0.72	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	22.57	8.3e-77	3.62e-72	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	22.55	1.04e-76	4.49e-72	0.98	0.72	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	22.55	1.05e-76	4.51e-72	0.99	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	22.54	1.14e-76	4.9e-72	1	0.72	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	22.51	1.58e-76	6.77e-72	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	22.51	1.61e-76	6.87e-72	0.96	0.72	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	22.51	1.61e-76	6.87e-72	0.96	0.72	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	22.5	1.69e-76	7.2e-72	0.95	0.72	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	22.49	1.97e-76	8.39e-72	0.82	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	22.48	2.11e-76	8.96e-72	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	22.48	2.23e-76	9.43e-72	0.99	0.72	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	22.48	2.23e-76	9.43e-72	0.99	0.72	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-22.47	2.51e-76	1.06e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	22.39	5.68e-76	2.36e-71	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	22.39	5.68e-76	2.36e-71	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	22.36	7.85e-76	3.26e-71	0.96	0.72	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	22.36	8.16e-76	3.38e-71	0.96	0.72	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	22.36	8.24e-76	3.41e-71	0.97	0.72	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	22.36	8.28e-76	3.42e-71	0.95	0.72	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-22.34	9.95e-76	4.11e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-22.32	1.19e-75	4.89e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	22.32	1.23e-75	5.05e-71	0.83	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	22.32	1.25e-75	5.11e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	22.31	1.35e-75	5.51e-71	0.99	0.72	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-22.31	1.4e-75	5.74e-71	-1.05	-0.72	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	22.3	1.51e-75	6.14e-71	0.94	0.72	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	22.3	1.59e-75	6.46e-71	0.96	0.72	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	22.27	2.2e-75	8.92e-71	0.82	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	22.25	2.49e-75	1e-70	0.86	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	22.24	3.07e-75	1.23e-70	0.97	0.72	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	22.23	3.11e-75	1.25e-70	0.89	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	22.23	3.37e-75	1.35e-70	0.98	0.72	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	22.21	3.86e-75	1.54e-70	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	22.21	4.01e-75	1.6e-70	0.95	0.72	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-22.21	4.2e-75	1.67e-70	-0.88	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	22.2	4.58e-75	1.82e-70	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	22.19	5.12e-75	2.03e-70	0.97	0.72	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	22.17	5.97e-75	2.36e-70	0.95	0.72	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-22.15	7.91e-75	3.12e-70	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-22.15	7.91e-75	3.12e-70	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	22.13	1.01e-74	3.98e-70	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	22.12	1.05e-74	4.12e-70	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	22.12	1.11e-74	4.35e-70	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	22.12	1.11e-74	4.36e-70	0.98	0.72	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	22.11	1.22e-74	4.77e-70	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	22.08	1.58e-74	6.06e-70	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	22.06	2.15e-74	8.23e-70	0.88	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	22.05	2.38e-74	9.11e-70	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-22.02	3.13e-74	1.2e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-22.01	3.69e-74	1.41e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-22.01	3.69e-74	1.41e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-22.01	3.69e-74	1.41e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-22	4.07e-74	1.55e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	21.99	4.41e-74	1.67e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	21.99	4.41e-74	1.67e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	21.98	4.67e-74	1.76e-69	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-21.98	4.72e-74	1.78e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	21.98	5.1e-74	1.92e-69	0.87	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	21.97	5.14e-74	1.93e-69	0.97	0.71	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	21.97	5.19e-74	1.95e-69	0.96	0.71	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	21.96	6.24e-74	2.33e-69	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	21.96	6.24e-74	2.33e-69	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	21.94	7.26e-74	2.71e-69	0.96	0.71	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	21.93	8.09e-74	3.01e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-21.93	8.49e-74	3.15e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-21.92	9.58e-74	3.55e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-21.92	9.74e-74	3.61e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	21.91	9.94e-74	3.68e-69	0.9	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-21.89	1.23e-73	4.52e-69	-0.81	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	21.89	1.32e-73	4.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	21.89	1.32e-73	4.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	21.89	1.32e-73	4.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-21.89	1.32e-73	4.82e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-21.89	1.32e-73	4.82e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-21.88	1.41e-73	5.14e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	21.88	1.51e-73	5.5e-69	0.85	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	21.87	1.63e-73	5.93e-69	0.82	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-21.87	1.66e-73	6.02e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	21.87	1.67e-73	6.05e-69	0.85	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	21.86	1.7e-73	6.15e-69	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	21.86	1.77e-73	6.41e-69	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	21.86	1.77e-73	6.41e-69	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-21.86	1.8e-73	6.5e-69	-0.94	-0.71	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	21.84	2.19e-73	7.89e-69	1.04	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	21.83	2.46e-73	8.85e-69	0.95	0.71	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-21.83	2.49e-73	8.96e-69	-0.96	-0.71	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-21.83	2.53e-73	9.08e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	21.82	2.72e-73	9.71e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	21.82	2.75e-73	9.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-21.82	2.83e-73	1.01e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	21.82	2.83e-73	1.01e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	21.81	2.95e-73	1.05e-68	0.96	0.71	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	21.81	2.95e-73	1.05e-68	0.96	0.71	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	21.79	3.73e-73	1.31e-68	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	21.79	3.73e-73	1.31e-68	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	21.79	3.98e-73	1.4e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-21.76	5.4e-73	1.9e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	21.75	5.92e-73	2.08e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	21.75	6.13e-73	2.14e-68	0.89	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	21.74	6.65e-73	2.32e-68	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	21.73	6.92e-73	2.41e-68	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-21.73	7.33e-73	2.55e-68	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-21.73	7.35e-73	2.55e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-21.73	7.35e-73	2.55e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-21.72	8.35e-73	2.89e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	21.72	8.47e-73	2.93e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	21.71	8.65e-73	2.99e-68	0.96	0.71	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-21.71	8.81e-73	3.03e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	21.7	9.7e-73	3.32e-68	0.85	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	21.69	1.1e-72	3.72e-68	0.95	0.71	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	21.69	1.1e-72	3.72e-68	0.95	0.71	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-21.69	1.14e-72	3.86e-68	-0.8	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	21.69	1.15e-72	3.88e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	21.69	1.17e-72	3.96e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
HNSC	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	21.68	1.29e-72	4.36e-68	0.97	0.71	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-21.67	1.34e-72	4.48e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-21.67	1.34e-72	4.48e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-21.67	1.34e-72	4.48e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	21.66	1.6e-72	5.34e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	21.66	1.6e-72	5.34e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	21.65	1.66e-72	5.54e-68	0.96	0.71	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-21.65	1.78e-72	5.93e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-21.65	1.78e-72	5.93e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	21.64	1.84e-72	6.13e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-21.64	2.03e-72	6.74e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	21.62	2.34e-72	7.76e-68	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	21.62	2.48e-72	8.23e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-21.62	2.49e-72	8.25e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-21.61	2.7e-72	8.91e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-21.61	2.81e-72	9.26e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	21.59	3.4e-72	1.12e-67	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	21.58	3.89e-72	1.28e-67	0.95	0.71	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	21.57	4.09e-72	1.34e-67	0.87	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	21.57	4.24e-72	1.39e-67	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	21.57	4.27e-72	1.39e-67	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	21.57	4.27e-72	1.39e-67	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	21.57	4.27e-72	1.39e-67	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	21.57	4.33e-72	1.41e-67	0.89	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-21.56	4.62e-72	1.51e-67	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-21.54	5.55e-72	1.8e-67	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	21.54	5.85e-72	1.9e-67	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	21.54	5.87e-72	1.9e-67	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-21.52	7.36e-72	2.38e-67	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-21.49	9.56e-72	3.09e-67	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	21.47	1.16e-71	3.76e-67	0.88	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-21.45	1.45e-71	4.68e-67	-0.89	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	21.45	1.51e-71	4.87e-67	0.89	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	21.45	1.57e-71	5.04e-67	0.88	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-21.43	1.79e-71	5.7e-67	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-21.43	1.79e-71	5.7e-67	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	21.42	2.02e-71	6.4e-67	0.96	0.7	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	21.41	2.26e-71	7.16e-67	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	21.41	2.43e-71	7.64e-67	0.96	0.7	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-21.4	2.68e-71	8.45e-67	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	21.39	2.93e-71	9.19e-67	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-21.36	4e-71	1.25e-66	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	21.31	6.64e-71	2.07e-66	1.01	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	21.3	7.74e-71	2.42e-66	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	21.28	9.22e-71	2.87e-66	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	21.28	9.22e-71	2.87e-66	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	21.26	1.25e-70	3.85e-66	0.96	0.7	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-21.25	1.32e-70	4.08e-66	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	21.25	1.35e-70	4.16e-66	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	21.25	1.35e-70	4.16e-66	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	21.24	1.41e-70	4.31e-66	0.8	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	21.24	1.43e-70	4.39e-66	0.8	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	21.22	1.77e-70	5.42e-66	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-21.22	1.78e-70	5.43e-66	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-21.21	1.98e-70	6.02e-66	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-21.21	1.98e-70	6.02e-66	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-21.21	2.14e-70	6.51e-66	-0.94	-0.7	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-21.12	5.62e-70	1.7e-65	-0.86	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-21.11	6.2e-70	1.87e-65	-0.83	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	21.1	6.75e-70	2.02e-65	0.95	0.7	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	21.09	7.29e-70	2.18e-65	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	21.09	7.41e-70	2.22e-65	0.94	0.7	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	21.09	7.73e-70	2.31e-65	0.95	0.7	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-21.03	1.48e-69	4.41e-65	-0.79	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	20.99	2.1e-69	6.2e-65	0.87	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	20.99	2.3e-69	6.79e-65	0.98	0.7	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-20.97	2.67e-69	7.9e-65	-0.86	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-20.97	2.7e-69	7.96e-65	-0.85	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-20.94	3.6e-69	1.05e-64	-0.85	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	20.93	4.02e-69	1.18e-64	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	20.93	4.27e-69	1.25e-64	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-20.92	4.63e-69	1.35e-64	-1.01	-0.7	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-20.92	4.79e-69	1.39e-64	-1.01	-0.7	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-20.91	5.41e-69	1.57e-64	-0.85	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	20.9	5.65e-69	1.64e-64	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	20.89	6.35e-69	1.83e-64	0.78	0.7	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-20.89	6.85e-69	1.97e-64	-0.86	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-20.89	6.85e-69	1.97e-64	-0.86	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	20.87	8.46e-69	2.42e-64	0.93	0.69	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-20.86	9.12e-69	2.61e-64	-0.86	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-20.85	1.03e-68	2.93e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	20.84	1.13e-68	3.21e-64	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-20.83	1.2e-68	3.4e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-20.83	1.2e-68	3.4e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	20.83	1.29e-68	3.63e-64	0.85	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	20.83	1.29e-68	3.63e-64	0.85	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	20.83	1.29e-68	3.63e-64	0.85	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-20.83	1.3e-68	3.68e-64	-1.01	-0.69	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	20.82	1.35e-68	3.82e-64	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	20.81	1.5e-68	4.21e-64	0.84	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	20.81	1.56e-68	4.4e-64	0.97	0.69	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-20.8	1.76e-68	4.93e-64	-0.99	-0.69	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-20.79	2.01e-68	5.63e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-20.76	2.68e-68	7.48e-64	-1.02	-0.69	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	20.75	3.02e-68	8.42e-64	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	20.71	4.33e-68	1.2e-63	0.79	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	20.71	4.62e-68	1.28e-63	0.94	0.69	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	20.7	4.9e-68	1.36e-63	0.84	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	20.7	5.35e-68	1.48e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	20.69	5.55e-68	1.54e-63	0.97	0.69	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	20.68	5.98e-68	1.65e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	20.68	6.56e-68	1.81e-63	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-20.66	7.54e-68	2.07e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-20.66	7.54e-68	2.07e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-20.66	7.54e-68	2.07e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	20.66	7.59e-68	2.08e-63	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-20.65	9e-68	2.45e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-20.62	1.24e-67	3.35e-63	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-20.61	1.32e-67	3.56e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	20.61	1.33e-67	3.58e-63	0.95	0.69	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-20.6	1.51e-67	4.07e-63	-0.99	-0.69	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-20.59	1.62e-67	4.35e-63	-1.02	-0.69	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-20.59	1.62e-67	4.35e-63	-1.02	-0.69	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	20.59	1.7e-67	4.55e-63	0.97	0.69	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-20.59	1.71e-67	4.56e-63	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	20.59	1.71e-67	4.56e-63	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	20.58	1.79e-67	4.76e-63	0.97	0.69	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	20.58	1.88e-67	5e-63	0.95	0.69	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-20.57	2.13e-67	5.65e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-20.57	2.13e-67	5.65e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-20.57	2.13e-67	5.65e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	20.56	2.21e-67	5.86e-63	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	20.54	2.95e-67	7.81e-63	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	20.54	2.95e-67	7.81e-63	0.82	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	20.54	2.95e-67	7.81e-63	0.82	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	20.54	3.02e-67	7.98e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	20.52	3.63e-67	9.56e-63	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	20.51	3.99e-67	1.05e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-20.51	4.07e-67	1.07e-62	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	20.51	4.07e-67	1.07e-62	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	20.5	4.27e-67	1.12e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	20.5	4.27e-67	1.12e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	20.5	4.33e-67	1.13e-62	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-20.5	4.34e-67	1.13e-62	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-20.5	4.65e-67	1.21e-62	-0.78	-0.69	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	20.49	5.01e-67	1.3e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-20.48	5.45e-67	1.42e-62	-0.97	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
HNSC	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-20.48	5.65e-67	1.47e-62	-0.83	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	20.48	5.67e-67	1.47e-62	0.84	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	20.47	5.81e-67	1.51e-62	0.93	0.69	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-20.46	6.7e-67	1.73e-62	-0.99	-0.69	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-20.45	7.38e-67	1.9e-62	-1.02	-0.69	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	20.44	8.1e-67	2.07e-62	0.83	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	20.44	8.12e-67	2.08e-62	0.79	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	20.41	1.22e-66	3.11e-62	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	20.41	1.22e-66	3.11e-62	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-20.4	1.29e-66	3.27e-62	-0.94	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-20.39	1.48e-66	3.75e-62	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	20.39	1.51e-66	3.82e-62	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-20.38	1.61e-66	4.07e-62	-0.78	-0.69	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-20.37	1.83e-66	4.62e-62	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-20.37	1.85e-66	4.66e-62	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	20.33	2.73e-66	6.87e-62	0.83	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-20.33	2.78e-66	6.98e-62	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-20.31	3.56e-66	8.83e-62	-0.98	-0.68	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-20.3	3.7e-66	9.18e-62	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	20.29	4.16e-66	1.03e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-20.29	4.24e-66	1.05e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	20.29	4.47e-66	1.1e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-20.28	4.56e-66	1.12e-61	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	20.28	4.73e-66	1.16e-61	0.97	0.68	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	20.28	4.99e-66	1.22e-61	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	20.27	5.08e-66	1.24e-61	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	20.26	6.1e-66	1.49e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	20.26	6.1e-66	1.49e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	20.25	6.47e-66	1.58e-61	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	20.23	7.77e-66	1.88e-61	0.94	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	20.23	7.9e-66	1.91e-61	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	20.23	7.94e-66	1.92e-61	0.84	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-20.23	7.98e-66	1.93e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-20.23	7.98e-66	1.93e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-20.22	8.95e-66	2.15e-61	-0.82	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	20.22	9.42e-66	2.26e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	20.22	9.42e-66	2.26e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-20.21	9.96e-66	2.38e-61	-0.82	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	20.2	1.13e-65	2.7e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-20.2	1.17e-65	2.78e-61	-0.84	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-20.19	1.24e-65	2.95e-61	-0.92	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-20.18	1.36e-65	3.24e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-20.18	1.38e-65	3.28e-61	-0.84	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-20.18	1.38e-65	3.28e-61	-0.84	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-20.17	1.63e-65	3.86e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-20.17	1.63e-65	3.86e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-20.17	1.65e-65	3.9e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-20.16	1.78e-65	4.22e-61	-0.93	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
HNSC	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	20.16	1.8e-65	4.26e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-20.13	2.3e-65	5.41e-61	-0.91	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-20.13	2.5e-65	5.87e-61	-0.93	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	20.11	3.1e-65	7.25e-61	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-20.1	3.21e-65	7.52e-61	-0.87	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-20.09	3.55e-65	8.26e-61	-0.91	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-20.09	3.76e-65	8.73e-61	-0.83	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.08	3.94e-65	9.11e-61	-0.81	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	20.07	4.74e-65	1.09e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	20.07	4.74e-65	1.09e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	20.05	5.5e-65	1.27e-60	0.93	0.68	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	20.05	5.98e-65	1.38e-60	0.78	0.68	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	20.03	6.87e-65	1.58e-60	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-20.02	7.76e-65	1.78e-60	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-20.02	8.12e-65	1.86e-60	-0.87	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	20.02	8.34e-65	1.9e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	20.02	8.34e-65	1.9e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	20.02	8.34e-65	1.9e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	20.01	8.65e-65	1.97e-60	0.78	0.68	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	20	9.35e-65	2.13e-60	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	20	9.76e-65	2.21e-60	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	19.99	1.12e-64	2.53e-60	0.88	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	19.95	1.71e-64	3.83e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	19.95	1.71e-64	3.83e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	19.95	1.72e-64	3.86e-60	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-19.93	2.02e-64	4.52e-60	-0.77	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
HNSC	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	19.91	2.5e-64	5.58e-60	0.92	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	19.9	2.86e-64	6.37e-60	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	19.89	3.2e-64	7.11e-60	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-19.87	4.08e-64	9.04e-60	-1	-0.68	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	19.85	4.96e-64	1.1e-59	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-19.84	5.43e-64	1.2e-59	-0.82	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	19.83	6.05e-64	1.33e-59	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	19.81	7.79e-64	1.71e-59	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	19.8	8.64e-64	1.89e-59	0.92	0.68	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-19.79	9.4e-64	2.06e-59	-0.92	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	19.78	1.03e-63	2.24e-59	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	19.75	1.52e-63	3.3e-59	0.82	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	19.73	1.86e-63	4.02e-59	0.92	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
HNSC	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	19.71	2.16e-63	4.66e-59	0.78	0.67	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	19.69	2.94e-63	6.32e-59	0.84	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	19.66	3.78e-63	8.12e-59	0.94	0.67	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	19.65	4.07e-63	8.74e-59	0.87	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	19.65	4.37e-63	9.35e-59	0.87	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	19.6	7.42e-63	1.58e-58	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	19.57	1.02e-62	2.17e-58	0.92	0.67	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	19.56	1.15e-62	2.45e-58	0.76	0.67	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	19.55	1.32e-62	2.8e-58	0.9	0.67	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	19.54	1.33e-62	2.82e-58	0.83	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	19.53	1.57e-62	3.33e-58	0.88	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	19.51	1.89e-62	4e-58	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	19.49	2.49e-62	5.26e-58	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-19.48	2.61e-62	5.51e-58	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-19.47	2.93e-62	6.14e-58	-0.83	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	19.47	3.03e-62	6.35e-58	0.84	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	19.46	3.49e-62	7.32e-58	0.92	0.67	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	19.43	4.71e-62	9.85e-58	0.94	0.67	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	19.42	4.9e-62	1.03e-57	0.85	0.67	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	19.41	5.42e-62	1.13e-57	0.87	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
HNSC	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	19.39	6.71e-62	1.4e-57	0.93	0.67	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
HNSC	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	19.39	7.17e-62	1.49e-57	0.85	0.67	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	19.37	8.49e-62	1.77e-57	0.82	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	19.37	8.84e-62	1.84e-57	0.92	0.67	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	19.37	8.84e-62	1.84e-57	0.92	0.67	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	19.37	8.87e-62	1.84e-57	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	19.36	1e-61	2.07e-57	0.77	0.67	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	19.34	1.18e-61	2.45e-57	0.76	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-19.3	1.89e-61	3.91e-57	-0.81	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	19.29	1.99e-61	4.11e-57	0.75	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	19.27	2.56e-61	5.28e-57	0.83	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
HNSC	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	19.26	2.78e-61	5.72e-57	0.95	0.67	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
HNSC	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-19.26	2.96e-61	6.09e-57	-0.82	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-19.25	3.04e-61	6.25e-57	-1.01	-0.67	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	19.22	4.34e-61	8.9e-57	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	19.18	6.8e-61	1.39e-56	0.76	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-19.16	8.62e-61	1.76e-56	-0.85	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	19.16	8.72e-61	1.78e-56	0.82	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	19.15	9.7e-61	1.98e-56	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	19.08	2e-60	4.03e-56	0.82	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	19.07	2.24e-60	4.52e-56	0.87	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	19.04	3.2e-60	6.43e-56	0.92	0.66	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	19.01	4.32e-60	8.66e-56	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	18.98	5.92e-60	1.18e-55	0.85	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	18.96	7.4e-60	1.47e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-18.95	7.63e-60	1.52e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	18.95	7.76e-60	1.54e-55	0.75	0.66	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	18.94	9.18e-60	1.82e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-18.94	9.33e-60	1.85e-55	-0.75	-0.66	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-18.94	9.33e-60	1.85e-55	-0.75	-0.66	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	18.92	1.1e-59	2.16e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-18.9	1.34e-59	2.63e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-18.88	1.68e-59	3.3e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-18.88	1.79e-59	3.5e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-18.83	2.84e-59	5.56e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
HNSC	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	18.82	3.09e-59	6.04e-55	0.92	0.66	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	18.81	3.7e-59	7.2e-55	0.93	0.66	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	18.78	5.11e-59	9.94e-55	0.91	0.66	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	18.73	8.78e-59	1.69e-54	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	18.72	9.36e-59	1.8e-54	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	18.72	9.45e-59	1.82e-54	0.83	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	18.72	9.53e-59	1.84e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	18.71	1.08e-58	2.08e-54	0.74	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
HNSC	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	18.7	1.14e-58	2.19e-54	0.93	0.65	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
HNSC	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	18.69	1.32e-58	2.53e-54	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-18.68	1.51e-58	2.89e-54	-0.96	-0.65	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-18.67	1.61e-58	3.08e-54	-0.97	-0.65	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
HNSC	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	18.67	1.62e-58	3.11e-54	0.94	0.65	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
HNSC	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	18.67	1.68e-58	3.2e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	18.67	1.68e-58	3.2e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	18.64	2.24e-58	4.23e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-18.6	3.42e-58	6.39e-54	-0.78	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-18.6	3.54e-58	6.62e-54	-0.88	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	18.58	4.25e-58	7.91e-54	0.74	0.65	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	18.58	4.25e-58	7.91e-54	0.74	0.65	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	18.57	4.82e-58	8.93e-54	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	18.57	4.9e-58	9.06e-54	0.74	0.65	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	18.53	7.3e-58	1.34e-53	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	18.51	8.92e-58	1.63e-53	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	18.5	9.77e-58	1.78e-53	0.91	0.65	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-18.5	1.03e-57	1.89e-53	-0.86	-0.65	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	18.44	1.81e-57	3.28e-53	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	18.43	2.03e-57	3.68e-53	0.76	0.65	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	18.36	4.53e-57	8.17e-53	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	18.35	4.99e-57	8.96e-53	0.91	0.65	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	18.34	5.71e-57	1.02e-52	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
HNSC	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	18.31	7.27e-57	1.3e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-18.31	7.68e-57	1.37e-52	-0.91	-0.65	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	18.3	8.54e-57	1.52e-52	0.73	0.65	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
HNSC	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	18.29	9.03e-57	1.61e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	18.29	9.03e-57	1.61e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	18.29	9.03e-57	1.61e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-18.26	1.26e-56	2.24e-52	-0.73	-0.65	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	18.25	1.52e-56	2.7e-52	0.82	0.65	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-18.22	2.1e-56	3.71e-52	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
HNSC	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	18.2	2.36e-56	4.17e-52	0.9	0.64	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	18.2	2.36e-56	4.17e-52	0.9	0.64	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	18.2	2.49e-56	4.38e-52	0.9	0.64	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	18.18	2.93e-56	5.16e-52	0.88	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
HNSC	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-18.18	3.08e-56	5.41e-52	-0.82	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	18.17	3.43e-56	6.02e-52	0.93	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-18.13	5.37e-56	9.38e-52	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	18.07	9.54e-56	1.66e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	18.03	1.56e-55	2.71e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	18.01	1.81e-55	3.13e-51	0.88	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-18.01	1.85e-55	3.21e-51	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	18	2.1e-55	3.63e-51	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-18	2.17e-55	3.75e-51	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	17.97	2.76e-55	4.75e-51	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-17.97	2.9e-55	5e-51	-0.74	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
HNSC	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-17.91	5.71e-55	9.81e-51	-0.86	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
HNSC	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	17.9	6.24e-55	1.07e-50	0.89	0.64	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	17.86	8.87e-55	1.51e-50	0.73	0.64	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	17.85	1.07e-54	1.83e-50	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
HNSC	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-17.85	1.07e-54	1.83e-50	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	17.82	1.38e-54	2.34e-50	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
HNSC	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	17.78	2.17e-54	3.68e-50	0.86	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
HNSC	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	17.78	2.23e-54	3.78e-50	0.88	0.64	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	17.77	2.45e-54	4.14e-50	0.75	0.64	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	17.73	3.66e-54	6.2e-50	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-17.7	5.14e-54	8.68e-50	-0.7	-0.63	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-17.69	5.72e-54	9.66e-50	-0.86	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-17.66	7.85e-54	1.32e-49	-0.85	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	17.65	8.63e-54	1.45e-49	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
HNSC	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-17.63	1.04e-53	1.75e-49	-1.03	-0.63	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-17.59	1.69e-53	2.83e-49	-0.78	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	17.58	1.89e-53	3.17e-49	0.78	0.63	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	17.55	2.52e-53	4.21e-49	0.77	0.63	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	17.5	4.13e-53	6.89e-49	0.74	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	17.42	9.92e-53	1.64e-48	0.71	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
HNSC	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	17.4	1.24e-52	2.03e-48	0.73	0.63	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	17.38	1.46e-52	2.38e-48	0.71	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-17.36	1.85e-52	3.01e-48	-0.8	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
HNSC	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-17.35	2.17e-52	3.52e-48	-0.93	-0.63	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	17.33	2.59e-52	4.18e-48	0.8	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
HNSC	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	17.31	3.21e-52	5.16e-48	0.85	0.63	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	17.31	3.21e-52	5.16e-48	0.85	0.63	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
HNSC	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-17.31	3.35e-52	5.39e-48	-0.76	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-17.3	3.44e-52	5.52e-48	-0.71	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
HNSC	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-17.3	3.47e-52	5.56e-48	-0.91	-0.62	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	17.3	3.55e-52	5.69e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-17.28	4.16e-52	6.66e-48	-0.76	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	17.28	4.31e-52	6.89e-48	0.9	0.62	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	17.26	5.21e-52	8.31e-48	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
HNSC	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	17.25	5.89e-52	9.37e-48	0.83	0.62	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
HNSC	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	17.25	6.07e-52	9.65e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	17.25	6.28e-52	9.99e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	17.2	1.02e-51	1.61e-47	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	17.2	1.07e-51	1.68e-47	0.73	0.62	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	17.15	1.68e-51	2.61e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	17.15	1.7e-51	2.62e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	17.11	2.57e-51	3.94e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-17.1	2.81e-51	4.3e-47	-0.76	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	17.1	3.07e-51	4.68e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	17.07	3.95e-51	6.03e-47	0.76	0.62	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	17.07	4.22e-51	6.42e-47	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	17.07	4.22e-51	6.42e-47	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-17.06	4.5e-51	6.85e-47	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
HNSC	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	17.05	4.77e-51	7.24e-47	0.88	0.62	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	17.05	4.77e-51	7.24e-47	0.88	0.62	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-17.04	5.56e-51	8.41e-47	-0.7	-0.62	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	17.01	7.64e-51	1.15e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	17	8.5e-51	1.28e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-16.99	9.42e-51	1.41e-46	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	16.98	9.9e-51	1.48e-46	0.74	0.62	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-16.98	1.08e-50	1.62e-46	-0.7	-0.62	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-16.95	1.5e-50	2.23e-46	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	16.95	1.5e-50	2.23e-46	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	16.94	1.61e-50	2.39e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-16.93	1.76e-50	2.61e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	16.92	1.94e-50	2.88e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-16.92	1.94e-50	2.88e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-16.92	1.94e-50	2.88e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-16.92	1.94e-50	2.88e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	16.91	2.06e-50	3.05e-46	0.74	0.62	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-16.91	2.13e-50	3.15e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-16.91	2.2e-50	3.24e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	16.91	2.2e-50	3.24e-46	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-16.9	2.43e-50	3.58e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-16.9	2.43e-50	3.58e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-16.9	2.53e-50	3.72e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-16.9	2.53e-50	3.72e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	16.86	3.79e-50	5.54e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	16.85	4.11e-50	6e-46	0.76	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	16.85	4.12e-50	6.01e-46	0.68	0.61	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	16.82	5.32e-50	7.73e-46	0.72	0.61	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-16.82	5.7e-50	8.28e-46	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	16.82	5.7e-50	8.28e-46	0.76	0.61	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	16.82	5.73e-50	8.32e-46	0.77	0.61	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	16.81	6.06e-50	8.78e-46	0.68	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
HNSC	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	16.81	6.51e-50	9.41e-46	0.74	0.61	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-16.8	6.78e-50	9.8e-46	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	16.79	7.79e-50	1.12e-45	0.73	0.61	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	16.78	8.16e-50	1.18e-45	0.72	0.61	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	16.78	8.71e-50	1.25e-45	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-16.78	8.75e-50	1.26e-45	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-16.78	8.75e-50	1.26e-45	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	16.76	1.05e-49	1.5e-45	0.68	0.61	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	16.75	1.12e-49	1.6e-45	0.68	0.61	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	16.75	1.12e-49	1.61e-45	0.75	0.61	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-16.71	1.75e-49	2.5e-45	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-16.7	1.88e-49	2.67e-45	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-16.7	1.9e-49	2.7e-45	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-16.66	3.15e-49	4.44e-45	-0.75	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-16.63	3.96e-49	5.56e-45	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	16.63	4.13e-49	5.78e-45	0.75	0.61	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	16.63	4.13e-49	5.78e-45	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-16.6	5.61e-49	7.83e-45	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-16.58	6.72e-49	9.36e-45	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-16.58	7.03e-49	9.78e-45	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	16.56	8.92e-49	1.24e-44	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
HNSC	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	16.56	8.94e-49	1.24e-44	0.75	0.61	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-16.52	1.25e-48	1.73e-44	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	16.5	1.67e-48	2.29e-44	0.7	0.61	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-16.49	1.69e-48	2.33e-44	-0.73	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	16.46	2.54e-48	3.48e-44	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	16.44	2.85e-48	3.9e-44	0.75	0.61	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	16.44	2.86e-48	3.91e-44	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-16.44	3.09e-48	4.21e-44	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-16.42	3.64e-48	4.94e-44	-0.62	-0.61	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-16.42	3.64e-48	4.94e-44	-0.62	-0.61	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
HNSC	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	16.42	3.81e-48	5.17e-44	0.91	0.6	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	16.41	4.08e-48	5.54e-44	0.74	0.6	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-16.4	4.78e-48	6.46e-44	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-16.4	4.78e-48	6.46e-44	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
HNSC	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	16.39	4.88e-48	6.59e-44	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
HNSC	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	16.39	5.13e-48	6.91e-44	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-16.38	5.45e-48	7.33e-44	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	16.38	5.56e-48	7.48e-44	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-16.38	5.59e-48	7.51e-44	-0.62	-0.6	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
HNSC	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	16.38	5.85e-48	7.85e-44	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-16.36	7.01e-48	9.39e-44	-0.62	-0.6	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-16.36	7.01e-48	9.39e-44	-0.62	-0.6	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-16.35	7.95e-48	1.06e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-16.35	7.95e-48	1.06e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
HNSC	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-16.34	8.28e-48	1.1e-43	-0.99	-0.6	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-16.33	9.03e-48	1.2e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	16.33	9.65e-48	1.28e-43	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	16.31	1.16e-47	1.53e-43	0.62	0.6	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-16.31	1.22e-47	1.62e-43	-0.89	-0.6	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-16.28	1.53e-47	2.01e-43	-0.71	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-16.27	1.82e-47	2.39e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-16.27	1.82e-47	2.39e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-16.27	1.84e-47	2.42e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-16.26	2.06e-47	2.7e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-16.24	2.49e-47	3.26e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-16.24	2.49e-47	3.26e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
HNSC	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	16.23	2.57e-47	3.36e-43	0.67	0.6	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-16.23	2.57e-47	3.36e-43	-0.67	-0.6	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-16.23	2.64e-47	3.45e-43	-0.67	-0.6	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	16.21	3.45e-47	4.49e-43	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-16.19	4.16e-47	5.41e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-16.19	4.16e-47	5.41e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	16.17	5.18e-47	6.69e-43	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
HNSC	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	16.17	5.22e-47	6.74e-43	0.74	0.6	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-16.16	5.79e-47	7.46e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-16.14	6.74e-47	8.64e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	16.14	7e-47	8.96e-43	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-16.13	7.48e-47	9.56e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-16.12	8.25e-47	1.05e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	16.12	8.31e-47	1.06e-42	0.68	0.6	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-16.11	9.37e-47	1.19e-42	-0.67	-0.6	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
HNSC	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	16.11	9.53e-47	1.21e-42	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	16.1	1.02e-46	1.3e-42	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-16.09	1.15e-46	1.46e-42	-0.63	-0.6	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-16.09	1.2e-46	1.52e-42	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-16.08	1.22e-46	1.54e-42	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	16.08	1.33e-46	1.69e-42	0.65	0.6	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	16.08	1.34e-46	1.69e-42	0.73	0.6	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
HNSC	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	16.07	1.39e-46	1.76e-42	0.81	0.6	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
HNSC	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-16.07	1.46e-46	1.85e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-16.07	1.46e-46	1.85e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-16.07	1.46e-46	1.85e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
HNSC	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	16.05	1.82e-46	2.3e-42	0.88	0.6	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
HNSC	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	16.04	1.94e-46	2.44e-42	0.75	0.6	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
HNSC	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	16.04	2.04e-46	2.57e-42	0.9	0.6	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
HNSC	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-16.03	2.17e-46	2.73e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-16.01	2.72e-46	3.39e-42	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-16	2.9e-46	3.61e-42	-0.63	-0.6	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-16	2.9e-46	3.61e-42	-0.63	-0.6	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-15.97	3.86e-46	4.79e-42	-0.63	-0.59	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-15.97	3.95e-46	4.89e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	15.95	4.82e-46	5.96e-42	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	15.94	5.64e-46	6.91e-42	1.06	0.59	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	15.94	5.71e-46	6.99e-42	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-15.93	6.09e-46	7.42e-42	-0.61	-0.59	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-15.93	6.09e-46	7.42e-42	-0.61	-0.59	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-15.93	6.09e-46	7.42e-42	-0.61	-0.59	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	15.91	7.66e-46	9.3e-42	0.49	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
HNSC	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	15.9	8.26e-46	1e-41	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-15.89	9.11e-46	1.1e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-15.89	9.27e-46	1.12e-41	-0.63	-0.59	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-15.88	9.88e-46	1.19e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-15.87	1.08e-45	1.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-15.87	1.08e-45	1.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-15.87	1.08e-45	1.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	15.86	1.2e-45	1.44e-41	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	15.85	1.42e-45	1.68e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	15.85	1.45e-45	1.72e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-15.84	1.58e-45	1.87e-41	-0.64	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
HNSC	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-15.84	1.62e-45	1.91e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	15.83	1.68e-45	1.98e-41	0.48	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
HNSC	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-15.83	1.69e-45	1.99e-41	-0.75	-0.59	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-15.83	1.71e-45	2.02e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-15.83	1.78e-45	2.09e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
HNSC	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-15.82	1.94e-45	2.28e-41	-0.7	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-15.82	1.95e-45	2.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-15.82	1.97e-45	2.31e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-15.82	1.97e-45	2.31e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-15.8	2.24e-45	2.61e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-15.8	2.24e-45	2.61e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-15.8	2.38e-45	2.77e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	15.77	3.18e-45	3.66e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	15.77	3.18e-45	3.66e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-15.76	3.58e-45	4.11e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-15.76	3.58e-45	4.11e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-15.74	4.3e-45	4.89e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-15.74	4.3e-45	4.89e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-15.74	4.3e-45	4.89e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-15.74	4.31e-45	4.91e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-15.74	4.43e-45	5.03e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-15.73	4.89e-45	5.54e-41	-0.72	-0.59	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-15.72	5.26e-45	5.9e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-15.72	5.47e-45	6.1e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	15.71	5.67e-45	6.33e-41	0.49	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	15.71	5.94e-45	6.63e-41	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
HNSC	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-15.68	7.85e-45	8.68e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-15.68	7.85e-45	8.68e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-15.68	8.12e-45	8.96e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-15.68	8.39e-45	9.25e-41	-0.71	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
HNSC	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	15.66	9.51e-45	1.04e-40	0.91	0.59	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
HNSC	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-15.66	9.79e-45	1.07e-40	-0.74	-0.59	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-15.66	1e-44	1.1e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-15.66	1e-44	1.1e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-15.66	1.02e-44	1.11e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-15.65	1.09e-44	1.18e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-15.65	1.09e-44	1.18e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-15.65	1.09e-44	1.18e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	15.64	1.26e-44	1.36e-40	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-15.63	1.32e-44	1.42e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-15.63	1.32e-44	1.42e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-15.63	1.32e-44	1.42e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	15.61	1.58e-44	1.68e-40	0.61	0.59	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	15.6	1.76e-44	1.86e-40	0.48	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
HNSC	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-15.6	1.84e-44	1.95e-40	-0.6	-0.59	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-15.6	1.84e-44	1.95e-40	-0.6	-0.59	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-15.6	1.84e-44	1.95e-40	-0.6	-0.59	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.6	1.88e-44	1.99e-40	0.66	0.59	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-15.6	1.89e-44	2e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-15.58	2.28e-44	2.39e-40	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-15.58	2.31e-44	2.42e-40	-0.66	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
HNSC	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-15.57	2.37e-44	2.48e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-15.55	3.12e-44	3.2e-40	-0.73	-0.58	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-15.54	3.36e-44	3.45e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
HNSC	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-15.53	3.94e-44	4.03e-40	-0.64	-0.58	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
HNSC	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-15.52	4.15e-44	4.24e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-15.52	4.29e-44	4.37e-40	-0.75	-0.58	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-15.51	4.59e-44	4.67e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-15.51	4.59e-44	4.67e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-15.49	5.88e-44	5.97e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	15.46	7.37e-44	7.46e-40	0.48	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	15.46	7.38e-44	7.47e-40	0.48	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
HNSC	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-15.43	1.03e-43	1.03e-39	-0.62	-0.58	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-15.43	1.09e-43	1.09e-39	-0.75	-0.58	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-15.42	1.15e-43	1.15e-39	-0.61	-0.58	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
HNSC	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-15.42	1.2e-43	1.2e-39	-0.81	-0.58	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
HNSC	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-15.41	1.23e-43	1.23e-39	-0.64	-0.58	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-15.41	1.23e-43	1.23e-39	-0.64	-0.58	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
HNSC	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	15.4	1.48e-43	1.47e-39	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	15.39	1.58e-43	1.57e-39	0.67	0.58	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-15.38	1.69e-43	1.68e-39	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	15.38	1.74e-43	1.73e-39	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
HNSC	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	15.37	2.03e-43	2.01e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
HNSC	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	15.36	2.06e-43	2.03e-39	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
HNSC	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-15.32	3.36e-43	3.27e-39	-0.64	-0.58	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-15.32	3.36e-43	3.27e-39	-0.64	-0.58	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	15.31	3.63e-43	3.52e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	15.31	3.67e-43	3.55e-39	0.67	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	15.31	3.75e-43	3.63e-39	0.8	0.58	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-15.3	3.89e-43	3.73e-39	-0.64	-0.58	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
HNSC	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	15.3	3.94e-43	3.77e-39	0.84	0.58	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-15.29	4.41e-43	4.19e-39	-0.64	-0.58	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	15.29	4.5e-43	4.28e-39	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.27	5.56e-43	5.24e-39	-0.74	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
HNSC	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	15.27	5.56e-43	5.24e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
HNSC	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-15.26	5.9e-43	5.56e-39	-0.64	-0.58	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-15.26	6.13e-43	5.76e-39	-0.64	-0.58	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-15.26	6.13e-43	5.76e-39	-0.64	-0.58	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
HNSC	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	15.25	6.6e-43	6.19e-39	0.85	0.58	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-15.23	7.78e-43	7.28e-39	-0.64	-0.58	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-15.23	7.78e-43	7.28e-39	-0.64	-0.58	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
HNSC	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	15.23	7.99e-43	7.47e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
HNSC	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-15.22	8.59e-43	8.03e-39	-0.7	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
HNSC	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	15.21	9.72e-43	9.06e-39	0.46	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	15.21	9.87e-43	9.19e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-15.21	1e-42	9.31e-39	-0.63	-0.58	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-15.21	1e-42	9.31e-39	-0.63	-0.58	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-15.2	1.1e-42	1.02e-38	-0.63	-0.58	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
HNSC	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-15.19	1.2e-42	1.11e-38	-0.68	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-15.19	1.26e-42	1.17e-38	-0.64	-0.57	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	15.18	1.4e-42	1.3e-38	0.71	0.57	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-15.17	1.56e-42	1.44e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-15.16	1.6e-42	1.47e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	15.16	1.67e-42	1.53e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-15.15	1.83e-42	1.68e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-15.15	1.86e-42	1.71e-38	-0.62	-0.57	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.704	rs466240	ENSG00000230658.1	KLHL7-AS1	-15.14	2.04e-42	1.87e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23101228~23105703:-
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-15.13	2.16e-42	1.97e-38	-0.64	-0.57	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-15.13	2.23e-42	2.04e-38	-0.64	-0.57	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
HNSC	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-15.13	2.29e-42	2.09e-38	-0.61	-0.57	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-15.13	2.3e-42	2.1e-38	-0.64	-0.57	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-15.12	2.39e-42	2.18e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-15.12	2.39e-42	2.18e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	15.12	2.42e-42	2.21e-38	0.75	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-15.1	3.02e-42	2.7e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	15.1	3.09e-42	2.76e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
HNSC	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-15.09	3.24e-42	2.89e-38	-0.64	-0.57	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-15.09	3.37e-42	3e-38	-0.64	-0.57	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	15.07	4.29e-42	3.8e-38	0.63	0.57	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	15.07	4.29e-42	3.8e-38	0.63	0.57	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	15.07	4.29e-42	3.8e-38	0.63	0.57	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	15.07	4.31e-42	3.81e-38	0.63	0.57	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	15.07	4.31e-42	3.81e-38	0.63	0.57	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
HNSC	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	15.05	5.37e-42	4.74e-38	0.61	0.57	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
HNSC	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	15.04	5.39e-42	4.74e-38	0.68	0.57	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	15.04	5.6e-42	4.93e-38	0.62	0.57	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	15.04	5.87e-42	5.15e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	15.04	5.87e-42	5.15e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	15.04	5.91e-42	5.19e-38	0.63	0.57	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-15.03	6.42e-42	5.62e-38	-0.63	-0.57	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	15.02	6.78e-42	5.93e-38	0.65	0.57	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	15.02	7.08e-42	6.18e-38	0.63	0.57	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-15.02	7.12e-42	6.21e-38	-0.61	-0.57	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	15	8.12e-42	7.04e-38	0.63	0.57	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
HNSC	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	15	8.34e-42	7.23e-38	0.63	0.57	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-14.99	9.16e-42	7.92e-38	-0.64	-0.57	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	14.98	1.03e-41	8.87e-38	0.64	0.57	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-14.98	1.08e-41	9.24e-38	-0.64	-0.57	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-14.97	1.12e-41	9.61e-38	-0.64	-0.57	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-14.97	1.21e-41	1.03e-37	-0.64	-0.57	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-14.96	1.22e-41	1.04e-37	-0.63	-0.57	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-14.96	1.31e-41	1.11e-37	-0.59	-0.57	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	14.96	1.33e-41	1.13e-37	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
HNSC	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	14.96	1.34e-41	1.14e-37	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	14.95	1.45e-41	1.23e-37	0.65	0.57	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
HNSC	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	14.95	1.45e-41	1.23e-37	0.46	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
HNSC	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-14.94	1.55e-41	1.3e-37	-0.63	-0.57	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-14.94	1.55e-41	1.3e-37	-0.63	-0.57	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	14.93	1.68e-41	1.41e-37	0.63	0.57	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	14.93	1.68e-41	1.41e-37	0.63	0.57	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	14.92	1.85e-41	1.54e-37	0.63	0.57	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	14.91	2.02e-41	1.68e-37	0.63	0.57	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-14.91	2.05e-41	1.7e-37	-0.63	-0.57	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-14.9	2.44e-41	2.01e-37	-0.67	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	14.9	2.46e-41	2.03e-37	0.64	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	14.88	2.75e-41	2.26e-37	0.63	0.57	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-14.84	4.51e-41	3.66e-37	-0.6	-0.57	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
HNSC	cis	rs875971	1	rs6460296	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66430152	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4717292	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66430611	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420591	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66447394	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs10755833	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66448930	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs12668936	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66449417	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs12698520	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66453720	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs1833495	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66456608	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6945032	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66457499	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs12673810	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66458866	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs35149210	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66464938	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs34406470	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66464969	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2042133	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66466935	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs2161065	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66467918	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6961155	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66468308	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7789768	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66473993	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12698521	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66474502	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1363055	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66478288	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs9691480	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66479319	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7789554	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66481051	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4717300	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66482393	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs1974769	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66485627	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs6460300	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66487937	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7803416	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66489212	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1981799	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66490572	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs2277911	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66493638	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	14.82	5.52e-41	4.43e-37	0.62	0.57	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	14.81	5.74e-41	4.6e-37	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	14.81	5.8e-41	4.65e-37	0.63	0.57	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12532998	ENSG00000179406.6	LINC00174	-14.8	6.5e-41	5.19e-37	-0.73	-0.57	Aortic root size;	chr7:66502472	chr7:66376044~66401338:-
HNSC	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-14.79	7.06e-41	5.63e-37	-0.72	-0.56	Breast cancer;	chr11:743813	chr11:779617~780755:+
HNSC	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-14.78	7.56e-41	6.02e-37	-0.46	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
HNSC	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	14.78	7.77e-41	6.19e-37	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-14.78	8.24e-41	6.54e-37	-0.64	-0.56	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs3857684	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66473171	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6978429	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66494889	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4718357	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66495891	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs12535036	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66499076	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs12533997	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66500390	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs12698523	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66503126	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6970030	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66503692	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.928	rs6970357	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66503891	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs3735148	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66506022	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs10950041	ENSG00000179406.6	LINC00174	-14.77	9.05e-41	7.15e-37	-0.73	-0.56	Aortic root size;	chr7:66508888	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs6970860	ENSG00000179406.6	LINC00174	-14.77	9.05e-41	7.15e-37	-0.73	-0.56	Aortic root size;	chr7:66511647	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6945019	ENSG00000179406.6	LINC00174	-14.75	1.1e-40	8.71e-37	-0.72	-0.56	Aortic root size;	chr7:66457471	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs11974219	ENSG00000179406.6	LINC00174	14.75	1.11e-40	8.72e-37	0.73	0.56	Aortic root size;	chr7:66182423	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs55962648	ENSG00000179406.6	LINC00174	14.75	1.11e-40	8.77e-37	0.73	0.56	Aortic root size;	chr7:66160764	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs875971	ENSG00000179406.6	LINC00174	14.74	1.15e-40	9.03e-37	0.73	0.56	Aortic root size;	chr7:66152608	chr7:66376044~66401338:-
HNSC	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-14.74	1.19e-40	9.36e-37	-0.46	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
HNSC	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	14.74	1.21e-40	9.52e-37	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs1565531	ENSG00000179406.6	LINC00174	14.74	1.25e-40	9.77e-37	0.73	0.56	Aortic root size;	chr7:66198126	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6957199	ENSG00000179406.6	LINC00174	-14.73	1.26e-40	9.88e-37	-0.72	-0.56	Aortic root size;	chr7:66513532	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420168	ENSG00000179406.6	LINC00174	14.73	1.35e-40	1.06e-36	0.73	0.56	Aortic root size;	chr7:66165644	chr7:66376044~66401338:-
HNSC	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	14.72	1.38e-40	1.08e-36	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-14.71	1.6e-40	1.25e-36	-0.71	-0.56	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	14.71	1.65e-40	1.29e-36	0.73	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-14.71	1.65e-40	1.29e-36	-0.52	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	14.7	1.76e-40	1.37e-36	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
HNSC	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-14.7	1.84e-40	1.43e-36	-0.63	-0.56	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
HNSC	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	14.69	1.95e-40	1.52e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs2077593	ENSG00000179406.6	LINC00174	-14.69	1.98e-40	1.55e-36	-0.72	-0.56	Aortic root size;	chr7:66427543	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs4718349	ENSG00000179406.6	LINC00174	-14.69	2.06e-40	1.6e-36	-0.72	-0.56	Aortic root size;	chr7:66444024	chr7:66376044~66401338:-
HNSC	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	14.68	2.19e-40	1.71e-36	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
HNSC	cis	rs875971	1	rs6963646	ENSG00000179406.6	LINC00174	14.67	2.44e-40	1.89e-36	0.72	0.56	Aortic root size;	chr7:66220780	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs28682868	ENSG00000179406.6	LINC00174	14.67	2.49e-40	1.93e-36	0.72	0.56	Aortic root size;	chr7:66224822	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7781698	ENSG00000179406.6	LINC00174	-14.66	2.64e-40	2.04e-36	-0.72	-0.56	Aortic root size;	chr7:66431325	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	14.66	2.66e-40	2.06e-36	0.76	0.56	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
HNSC	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	14.66	2.73e-40	2.11e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	14.65	2.98e-40	2.3e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.964	rs60193905	ENSG00000179406.6	LINC00174	-14.63	3.6e-40	2.77e-36	-0.72	-0.56	Aortic root size;	chr7:66506273	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs1643388	ENSG00000179406.6	LINC00174	-14.62	3.98e-40	3.06e-36	-0.72	-0.56	Aortic root size;	chr7:66379575	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778722	ENSG00000179406.6	LINC00174	-14.62	3.98e-40	3.06e-36	-0.72	-0.56	Aortic root size;	chr7:66379841	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs11765965	ENSG00000179406.6	LINC00174	-14.62	4.06e-40	3.12e-36	-0.72	-0.56	Aortic root size;	chr7:66377234	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	14.62	4.14e-40	3.17e-36	0.62	0.56	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	14.62	4.15e-40	3.18e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs778726	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66363744	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs778723	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66364510	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.767	rs1695815	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66366357	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778685	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66371189	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs778682	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66372947	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs778721	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66380410	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs778712	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66384991	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778710	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66389847	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs778708	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66391332	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778706	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66395437	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs778700	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66401463	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778699	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66403303	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778696	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66405826	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778694	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66406571	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs778692	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66407462	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4718343	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66409301	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4718344	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66409394	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1968225	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66409786	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.737	rs7803424	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66415618	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs7799834	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66415707	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6460295	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66417741	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6978721	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66418217	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-14.61	4.54e-40	3.46e-36	-0.62	-0.56	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709595	ENSG00000179406.6	LINC00174	-14.56	7.02e-40	5.28e-36	-0.72	-0.56	Aortic root size;	chr7:66352346	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs811880	ENSG00000179406.6	LINC00174	-14.56	7.02e-40	5.28e-36	-0.72	-0.56	Aortic root size;	chr7:66353659	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	14.56	7.12e-40	5.35e-36	0.62	0.56	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	14.56	7.26e-40	5.46e-36	0.62	0.56	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718307	ENSG00000179406.6	LINC00174	14.55	7.94e-40	5.96e-36	0.72	0.56	Aortic root size;	chr7:66146001	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7801282	ENSG00000179406.6	LINC00174	14.55	7.94e-40	5.96e-36	0.72	0.56	Aortic root size;	chr7:66148700	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs4122249	ENSG00000179406.6	LINC00174	-14.55	8.25e-40	6.19e-36	-0.72	-0.56	Aortic root size;	chr7:66455949	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	14.55	8.31e-40	6.23e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	14.54	9.29e-40	6.95e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
HNSC	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-14.52	1.12e-39	8.38e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	14.51	1.21e-39	9.03e-36	0.62	0.56	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-14.51	1.25e-39	9.33e-36	-0.63	-0.56	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	14.5	1.3e-39	9.71e-36	0.64	0.56	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-14.5	1.31e-39	9.74e-36	-0.52	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
HNSC	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	14.5	1.38e-39	1.03e-35	0.63	0.56	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
HNSC	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-14.49	1.47e-39	1.09e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
HNSC	cis	rs875971	1	rs3981131	ENSG00000179406.6	LINC00174	-14.47	1.75e-39	1.3e-35	-0.71	-0.56	Aortic root size;	chr7:66486690	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	14.47	1.78e-39	1.32e-35	0.74	0.56	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
HNSC	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	14.47	1.89e-39	1.39e-35	0.81	0.56	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	14.46	1.97e-39	1.46e-35	0.62	0.56	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	14.46	2.02e-39	1.49e-35	0.73	0.56	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	14.45	2.09e-39	1.54e-35	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
HNSC	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	14.43	2.58e-39	1.9e-35	0.62	0.56	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	14.43	2.76e-39	2.02e-35	0.61	0.56	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	14.43	2.76e-39	2.02e-35	0.61	0.56	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709597	ENSG00000179406.6	LINC00174	14.42	2.86e-39	2.1e-35	0.73	0.56	Aortic root size;	chr7:66360996	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
HNSC	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.42	3.01e-39	2.19e-35	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	14.42	3.08e-39	2.25e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-14.41	3.22e-39	2.34e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-14.41	3.22e-39	2.34e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
HNSC	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	14.41	3.24e-39	2.36e-35	0.8	0.55	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
HNSC	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-14.41	3.35e-39	2.43e-35	-1.05	-0.55	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.965	rs10267430	ENSG00000179406.6	LINC00174	14.4	3.61e-39	2.62e-35	0.72	0.55	Aortic root size;	chr7:66278036	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-14.4	3.7e-39	2.68e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
HNSC	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	14.4	3.76e-39	2.72e-35	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	14.4	3.76e-39	2.72e-35	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
HNSC	cis	rs875971	1	rs10257427	ENSG00000179406.6	LINC00174	14.38	4.39e-39	3.15e-35	0.72	0.55	Aortic root size;	chr7:66278221	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs55748098	ENSG00000179406.6	LINC00174	14.38	4.39e-39	3.15e-35	0.72	0.55	Aortic root size;	chr7:66298631	chr7:66376044~66401338:-
HNSC	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-14.38	4.46e-39	3.2e-35	-0.46	-0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-14.38	4.46e-39	3.2e-35	-0.46	-0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
HNSC	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-14.38	4.57e-39	3.28e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-14.38	4.57e-39	3.28e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-14.37	4.82e-39	3.46e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
HNSC	cis	rs875971	1	rs10215948	ENSG00000179406.6	LINC00174	14.36	5.2e-39	3.73e-35	0.71	0.55	Aortic root size;	chr7:66282799	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000179406.6	LINC00174	14.36	5.2e-39	3.73e-35	0.71	0.55	Aortic root size;	chr7:66316668	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2087647	ENSG00000179406.6	LINC00174	14.36	5.25e-39	3.76e-35	0.72	0.55	Aortic root size;	chr7:66128201	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	14.36	5.31e-39	3.8e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
HNSC	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-14.36	5.31e-39	3.81e-35	-0.61	-0.55	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-14.36	5.58e-39	4e-35	-1.1	-0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
HNSC	cis	rs875971	1	rs6958484	ENSG00000179406.6	LINC00174	14.35	5.76e-39	4.12e-35	0.72	0.55	Aortic root size;	chr7:66134459	chr7:66376044~66401338:-
HNSC	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-14.35	6.16e-39	4.4e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-14.35	6.16e-39	4.4e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-14.35	6.16e-39	4.4e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	14.35	6.22e-39	4.44e-35	0.83	0.55	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	14.34	6.49e-39	4.63e-35	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	14.34	6.49e-39	4.63e-35	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
HNSC	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-14.34	6.82e-39	4.86e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
HNSC	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	14.32	7.98e-39	5.67e-35	1.1	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
HNSC	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-14.32	8.17e-39	5.79e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
HNSC	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-14.32	8.17e-39	5.79e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
HNSC	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-14.32	8.18e-39	5.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-14.32	8.18e-39	5.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-14.32	8.26e-39	5.85e-35	-0.67	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-14.31	8.91e-39	6.3e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.867	rs1002053	ENSG00000179406.6	LINC00174	14.31	9.38e-39	6.62e-35	0.71	0.55	Aortic root size;	chr7:66333558	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6460292	ENSG00000179406.6	LINC00174	14.31	9.38e-39	6.62e-35	0.71	0.55	Aortic root size;	chr7:66345088	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6961717	ENSG00000179406.6	LINC00174	14.29	1.06e-38	7.48e-35	0.71	0.55	Aortic root size;	chr7:66122550	chr7:66376044~66401338:-
HNSC	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-14.29	1.11e-38	7.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-14.29	1.11e-38	7.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
HNSC	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-14.28	1.23e-38	8.68e-35	-0.62	-0.55	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
HNSC	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-14.27	1.27e-38	8.96e-35	-0.71	-0.55	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	14.27	1.28e-38	8.99e-35	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
HNSC	cis	rs875971	1	rs6946143	ENSG00000179406.6	LINC00174	-14.27	1.34e-38	9.4e-35	-0.72	-0.55	Aortic root size;	chr7:66114735	chr7:66376044~66401338:-
HNSC	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-14.27	1.34e-38	9.4e-35	-0.45	-0.55	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	14.27	1.34e-38	9.41e-35	0.61	0.55	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	14.27	1.36e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	14.27	1.37e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	14.27	1.37e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	14.27	1.37e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	14.27	1.38e-38	9.68e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
HNSC	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-14.26	1.48e-38	1.03e-34	-0.59	-0.55	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-14.24	1.73e-38	1.2e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-14.23	1.9e-38	1.32e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs6945843	ENSG00000179406.6	LINC00174	14.22	2.09e-38	1.45e-34	0.71	0.55	Aortic root size;	chr7:66269796	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-14.22	2.15e-38	1.49e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
HNSC	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	14.22	2.17e-38	1.51e-34	0.63	0.55	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	14.22	2.21e-38	1.53e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
HNSC	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-14.22	2.29e-38	1.58e-34	-1.05	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-14.21	2.43e-38	1.68e-34	-1.02	-0.55	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
HNSC	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-14.21	2.43e-38	1.69e-34	-0.63	-0.55	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
HNSC	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	14.21	2.45e-38	1.69e-34	0.51	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.895	rs7788984	ENSG00000179406.6	LINC00174	-14.2	2.69e-38	1.86e-34	-0.71	-0.55	Aortic root size;	chr7:66450629	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1981798	ENSG00000179406.6	LINC00174	-14.2	2.69e-38	1.86e-34	-0.71	-0.55	Aortic root size;	chr7:66489916	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-14.2	2.77e-38	1.91e-34	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-14.18	3.12e-38	2.15e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-14.18	3.17e-38	2.18e-34	-0.68	-0.55	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
HNSC	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	14.18	3.21e-38	2.21e-34	0.67	0.55	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
HNSC	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-14.18	3.26e-38	2.24e-34	-1.06	-0.55	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-14.18	3.26e-38	2.24e-34	-1.06	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-14.18	3.26e-38	2.24e-34	-1.06	-0.55	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
HNSC	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-14.18	3.29e-38	2.26e-34	-0.83	-0.55	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
HNSC	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-14.18	3.35e-38	2.3e-34	-0.67	-0.55	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
HNSC	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	14.18	3.39e-38	2.33e-34	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-14.17	3.59e-38	2.46e-34	-0.7	-0.55	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-14.17	3.62e-38	2.48e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-14.17	3.62e-38	2.48e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-14.17	3.62e-38	2.48e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-14.17	3.64e-38	2.49e-34	-0.59	-0.55	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
HNSC	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	14.17	3.65e-38	2.5e-34	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
HNSC	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	14.16	3.9e-38	2.67e-34	1.1	0.55	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-14.16	3.91e-38	2.68e-34	-0.59	-0.55	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
HNSC	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	14.16	4.08e-38	2.79e-34	1.1	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	14.16	4.08e-38	2.79e-34	1.1	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-14.15	4.24e-38	2.9e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-14.15	4.29e-38	2.93e-34	-0.58	-0.55	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
HNSC	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-14.15	4.46e-38	3.03e-34	-0.62	-0.55	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
HNSC	cis	rs875971	1	rs6958271	ENSG00000179406.6	LINC00174	-14.15	4.5e-38	3.06e-34	-0.71	-0.55	Aortic root size;	chr7:66514344	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6958277	ENSG00000179406.6	LINC00174	-14.15	4.5e-38	3.06e-34	-0.71	-0.55	Aortic root size;	chr7:66514362	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	14.14	4.68e-38	3.18e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-14.14	4.69e-38	3.18e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	14.14	4.82e-38	3.27e-34	0.63	0.55	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs11974264	ENSG00000179406.6	LINC00174	14.14	5.09e-38	3.45e-34	0.72	0.55	Aortic root size;	chr7:66182595	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1540651	ENSG00000179406.6	LINC00174	14.14	5.09e-38	3.45e-34	0.72	0.55	Aortic root size;	chr7:66185134	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs9986696	ENSG00000179406.6	LINC00174	14.13	5.22e-38	3.54e-34	0.71	0.55	Aortic root size;	chr7:66239589	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	14.13	5.3e-38	3.59e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
HNSC	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-14.13	5.39e-38	3.65e-34	-0.68	-0.55	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
HNSC	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-14.13	5.56e-38	3.77e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
HNSC	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	14.13	5.57e-38	3.77e-34	0.64	0.55	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs11971949	ENSG00000179406.6	LINC00174	14.13	5.58e-38	3.77e-34	0.72	0.55	Aortic root size;	chr7:66161027	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	14.12	5.68e-38	3.84e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
HNSC	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-14.12	5.87e-38	3.96e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-14.12	6e-38	4.05e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
HNSC	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-14.12	6e-38	4.05e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-14.12	6e-38	4.05e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
HNSC	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-14.12	6.1e-38	4.11e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-14.12	6.13e-38	4.13e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-14.12	6.16e-38	4.15e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
HNSC	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
HNSC	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	14.11	6.38e-38	4.26e-34	0.66	0.55	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	14.11	6.53e-38	4.35e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
HNSC	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-14.11	6.65e-38	4.42e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000231760.4	RP11-350J20.5	14.11	6.67e-38	4.43e-34	0.75	0.55	Lung cancer;	chr6:149863746	chr6:149796151~149826294:-
HNSC	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
HNSC	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-14.1	6.96e-38	4.61e-34	-0.88	-0.55	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-14.1	7.02e-38	4.65e-34	-0.58	-0.55	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.83	rs4718358	ENSG00000179406.6	LINC00174	-14.1	7.14e-38	4.72e-34	-0.71	-0.55	Aortic root size;	chr7:66508681	chr7:66376044~66401338:-
HNSC	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.22e-38	4.78e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.22e-38	4.78e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.24e-38	4.78e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-14.1	7.24e-38	4.78e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	14.1	7.49e-38	4.94e-34	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
HNSC	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.5e-38	4.95e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-14.09	7.63e-38	5.03e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-14.09	7.63e-38	5.03e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	14.09	7.97e-38	5.25e-34	0.63	0.55	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
HNSC	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-14.09	8.17e-38	5.38e-34	-0.45	-0.55	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
HNSC	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	14.09	8.19e-38	5.39e-34	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-14.08	8.46e-38	5.57e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	14.08	8.66e-38	5.69e-34	0.62	0.55	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	14.08	8.85e-38	5.82e-34	0.66	0.55	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-14.08	9.22e-38	6.06e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-14.07	9.94e-38	6.5e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
HNSC	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-14.07	9.95e-38	6.5e-34	-0.68	-0.55	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	14.07	1e-37	6.55e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-14.07	1.02e-37	6.65e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-14.07	1.02e-37	6.65e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-14.07	1.02e-37	6.65e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	14.06	1.09e-37	7.09e-34	0.67	0.55	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	14.06	1.09e-37	7.09e-34	0.67	0.55	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	14.06	1.1e-37	7.16e-34	0.67	0.55	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	14.06	1.1e-37	7.16e-34	0.67	0.55	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	14.06	1.1e-37	7.16e-34	0.67	0.55	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
HNSC	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-14.06	1.13e-37	7.35e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-14.06	1.13e-37	7.35e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
HNSC	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-14.05	1.14e-37	7.39e-34	-0.63	-0.55	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-14.05	1.14e-37	7.41e-34	-0.6	-0.55	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
HNSC	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	14.05	1.15e-37	7.48e-34	0.67	0.55	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	14.05	1.15e-37	7.5e-34	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
HNSC	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	14.05	1.19e-37	7.74e-34	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14.05	1.22e-37	7.95e-34	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
HNSC	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-14.04	1.26e-37	8.19e-34	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-14.04	1.26e-37	8.19e-34	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	14.04	1.27e-37	8.25e-34	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
HNSC	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-14.04	1.28e-37	8.28e-34	-1.04	-0.54	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
HNSC	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-14.04	1.29e-37	8.35e-34	-0.61	-0.54	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-14.04	1.3e-37	8.44e-34	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
HNSC	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-14.04	1.32e-37	8.51e-34	-0.63	-0.54	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-14.03	1.4e-37	9.04e-34	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
HNSC	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-14.03	1.42e-37	9.18e-34	-0.63	-0.54	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
HNSC	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-14.03	1.47e-37	9.48e-34	-0.69	-0.54	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
HNSC	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-14.02	1.53e-37	9.9e-34	-0.7	-0.54	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	14.02	1.65e-37	1.06e-33	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	14.02	1.66e-37	1.07e-33	0.73	0.54	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
HNSC	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-14.01	1.73e-37	1.12e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-14.01	1.82e-37	1.17e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-14.01	1.82e-37	1.17e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-14	1.87e-37	1.2e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-14	1.87e-37	1.2e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-14	1.94e-37	1.24e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-14	1.94e-37	1.24e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	14	1.94e-37	1.25e-33	0.65	0.54	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-14	1.95e-37	1.25e-33	-0.75	-0.54	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-14	1.99e-37	1.27e-33	-0.61	-0.54	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-14	2e-37	1.28e-33	-1.03	-0.54	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
HNSC	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	14	2.03e-37	1.3e-33	0.61	0.54	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
HNSC	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-14	2.03e-37	1.3e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-14	2.03e-37	1.3e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-14	2.03e-37	1.3e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-14	2.04e-37	1.31e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
HNSC	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-14	2.05e-37	1.31e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-13.99	2.13e-37	1.36e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs6979382	ENSG00000179406.6	LINC00174	-13.99	2.17e-37	1.38e-33	-0.71	-0.54	Aortic root size;	chr7:66421388	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6961990	ENSG00000179406.6	LINC00174	-13.99	2.17e-37	1.38e-33	-0.71	-0.54	Aortic root size;	chr7:66423583	chr7:66376044~66401338:-
HNSC	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	13.99	2.2e-37	1.4e-33	0.67	0.54	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	13.99	2.2e-37	1.4e-33	0.67	0.54	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	13.99	2.25e-37	1.43e-33	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-13.99	2.26e-37	1.44e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	13.98	2.45e-37	1.56e-33	0.66	0.54	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
HNSC	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	13.98	2.49e-37	1.58e-33	0.62	0.54	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	13.98	2.5e-37	1.59e-33	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	13.97	2.55e-37	1.62e-33	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
HNSC	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-13.97	2.58e-37	1.63e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
HNSC	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-13.96	2.81e-37	1.78e-33	-1.02	-0.54	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000179406.6	LINC00174	13.96	2.87e-37	1.81e-33	0.71	0.54	Aortic root size;	chr7:66313559	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-13.96	3.03e-37	1.91e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
HNSC	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-13.95	3.17e-37	2e-33	-0.61	-0.54	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
HNSC	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-13.95	3.34e-37	2.11e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.83	rs427973	ENSG00000179406.6	LINC00174	-13.94	3.52e-37	2.22e-33	-0.71	-0.54	Aortic root size;	chr7:66061661	chr7:66376044~66401338:-
HNSC	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-13.93	3.78e-37	2.38e-33	-0.68	-0.54	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
HNSC	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-13.93	3.84e-37	2.42e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	13.93	3.92e-37	2.47e-33	0.62	0.54	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	13.92	4.15e-37	2.61e-33	0.6	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
HNSC	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	13.92	4.36e-37	2.74e-33	1.1	0.54	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	13.91	4.71e-37	2.95e-33	0.73	0.54	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-13.91	4.92e-37	3.08e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-13.91	4.92e-37	3.08e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-13.9	5.07e-37	3.17e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	13.9	5.12e-37	3.21e-33	0.73	0.54	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
HNSC	cis	rs875971	1	rs6956179	ENSG00000179406.6	LINC00174	13.9	5.14e-37	3.22e-33	0.69	0.54	Aortic root size;	chr7:66341672	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-13.9	5.25e-37	3.28e-33	-0.6	-0.54	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.898	rs6977501	ENSG00000179406.6	LINC00174	13.9	5.4e-37	3.37e-33	0.71	0.54	Aortic root size;	chr7:66228355	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs6971509	ENSG00000179406.6	LINC00174	13.9	5.4e-37	3.37e-33	0.71	0.54	Aortic root size;	chr7:66249983	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	13.9	5.48e-37	3.42e-33	0.66	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
HNSC	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-13.89	5.53e-37	3.45e-33	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-13.89	5.74e-37	3.57e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-13.89	5.87e-37	3.66e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-13.89	5.87e-37	3.66e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.964	rs778735	ENSG00000179406.6	LINC00174	-13.89	6.09e-37	3.78e-33	-0.71	-0.54	Aortic root size;	chr7:66349822	chr7:66376044~66401338:-
HNSC	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-13.88	6.27e-37	3.88e-33	-0.6	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-13.88	6.38e-37	3.95e-33	-0.6	-0.54	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	13.88	6.47e-37	4e-33	0.64	0.54	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
HNSC	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	13.88	6.7e-37	4.14e-33	0.78	0.54	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
HNSC	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-13.87	7.08e-37	4.37e-33	-0.62	-0.54	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	13.87	7.21e-37	4.45e-33	0.69	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
HNSC	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	13.87	7.32e-37	4.51e-33	1.08	0.54	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
HNSC	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-13.87	7.4e-37	4.56e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
HNSC	cis	rs17270561	0.514	rs10946805	ENSG00000272462.2	U91328.19	-13.86	7.62e-37	4.7e-33	-0.67	-0.54	Iron status biomarkers;	chr6:26077663	chr6:25992662~26001775:+
HNSC	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-13.86	7.62e-37	4.7e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
HNSC	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-13.86	8.02e-37	4.93e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-13.85	8.32e-37	5.11e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
HNSC	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-13.85	8.72e-37	5.36e-33	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	13.85	8.88e-37	5.45e-33	0.51	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
HNSC	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-13.84	9.58e-37	5.87e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-13.84	9.58e-37	5.87e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-13.84	9.69e-37	5.93e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-13.84	9.9e-37	6.06e-33	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	13.84	9.92e-37	6.07e-33	0.5	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-13.83	1e-36	6.14e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-13.83	1.01e-36	6.18e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-13.83	1.07e-36	6.55e-33	-1.05	-0.54	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
HNSC	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-13.83	1.09e-36	6.64e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-13.82	1.13e-36	6.87e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.793	rs460678	ENSG00000179406.6	LINC00174	-13.82	1.13e-36	6.88e-33	-0.7	-0.54	Aortic root size;	chr7:66062213	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs160635	ENSG00000179406.6	LINC00174	-13.82	1.13e-36	6.88e-33	-0.7	-0.54	Aortic root size;	chr7:66063931	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-13.81	1.25e-36	7.59e-33	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-13.81	1.25e-36	7.59e-33	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-13.81	1.3e-36	7.92e-33	-0.71	-0.54	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
HNSC	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	13.81	1.32e-36	7.99e-33	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	13.81	1.32e-36	7.99e-33	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-13.81	1.34e-36	8.15e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-13.8	1.35e-36	8.16e-33	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
HNSC	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-13.8	1.41e-36	8.57e-33	-0.61	-0.54	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-13.8	1.46e-36	8.85e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-13.79	1.49e-36	9e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-13.79	1.51e-36	9.12e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-13.79	1.6e-36	9.66e-33	-0.6	-0.54	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-13.79	1.64e-36	9.87e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
HNSC	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	13.78	1.75e-36	1.05e-32	1.06	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
HNSC	cis	rs875971	1	rs937495	ENSG00000179406.6	LINC00174	13.78	1.77e-36	1.07e-32	0.7	0.54	Aortic root size;	chr7:66314811	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2036264	ENSG00000179406.6	LINC00174	13.78	1.77e-36	1.07e-32	0.7	0.54	Aortic root size;	chr7:66334917	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7783613	ENSG00000179406.6	LINC00174	13.78	1.77e-36	1.07e-32	0.7	0.54	Aortic root size;	chr7:66340274	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-13.78	1.81e-36	1.09e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-13.77	1.81e-36	1.09e-32	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-13.77	1.81e-36	1.09e-32	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-13.77	1.86e-36	1.11e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-13.77	1.88e-36	1.13e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs2220626	ENSG00000179406.6	LINC00174	13.77	1.9e-36	1.13e-32	0.71	0.54	Aortic root size;	chr7:66081075	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-13.77	1.92e-36	1.14e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000179406.6	LINC00174	13.77	1.97e-36	1.18e-32	0.7	0.54	Aortic root size;	chr7:66297976	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs697968	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66070046	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1183245	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66076198	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1144895	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66076320	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1144894	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66077907	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-13.76	2.07e-36	1.23e-32	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
HNSC	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-13.76	2.08e-36	1.24e-32	-0.62	-0.54	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
HNSC	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-13.76	2.08e-36	1.24e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	13.76	2.18e-36	1.29e-32	0.65	0.54	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	13.76	2.18e-36	1.29e-32	0.65	0.54	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
HNSC	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-13.75	2.3e-36	1.36e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
HNSC	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	13.75	2.35e-36	1.39e-32	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
HNSC	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	13.75	2.36e-36	1.4e-32	0.64	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-13.74	2.65e-36	1.57e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-13.72	2.98e-36	1.75e-32	-0.62	-0.54	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
HNSC	cis	rs10256972	0.527	rs2949170	ENSG00000229043.2	AC091729.9	-13.72	3.22e-36	1.89e-32	-0.62	-0.54	Endometriosis;Longevity;	chr7:1176802	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.8	rs427557	ENSG00000179406.6	LINC00174	-13.72	3.24e-36	1.9e-32	-0.71	-0.54	Aortic root size;	chr7:66054263	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs587360	ENSG00000179406.6	LINC00174	-13.72	3.24e-36	1.9e-32	-0.71	-0.54	Aortic root size;	chr7:66057711	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-13.72	3.25e-36	1.91e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-13.71	3.38e-36	1.98e-32	-0.68	-0.54	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.83	rs427575	ENSG00000179406.6	LINC00174	-13.71	3.52e-36	2.06e-32	-0.71	-0.54	Aortic root size;	chr7:66054232	chr7:66376044~66401338:-
HNSC	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	13.71	3.58e-36	2.1e-32	0.78	0.54	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
HNSC	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-13.7	3.67e-36	2.15e-32	-0.5	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
HNSC	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-13.7	3.72e-36	2.18e-32	-0.68	-0.54	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
HNSC	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-13.7	3.8e-36	2.22e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-13.7	3.86e-36	2.26e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-13.7	3.86e-36	2.26e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-13.69	4e-36	2.33e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-13.69	4e-36	2.33e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-13.69	4.01e-36	2.34e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-13.69	4.01e-36	2.34e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-13.69	4.02e-36	2.34e-32	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	13.69	4.07e-36	2.37e-32	0.73	0.54	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	13.69	4.07e-36	2.37e-32	0.73	0.54	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
HNSC	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-13.69	4.16e-36	2.42e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs1167411	ENSG00000179406.6	LINC00174	13.69	4.34e-36	2.52e-32	0.71	0.54	Aortic root size;	chr7:66074277	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	13.68	4.38e-36	2.55e-32	0.72	0.54	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
HNSC	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-13.68	4.4e-36	2.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-13.68	4.4e-36	2.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-13.68	4.4e-36	2.55e-32	-0.6	-0.53	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
HNSC	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-13.68	4.47e-36	2.59e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	13.68	4.52e-36	2.62e-32	0.73	0.53	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
HNSC	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-13.68	4.58e-36	2.65e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-13.68	4.6e-36	2.66e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-13.68	4.71e-36	2.72e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-13.68	4.71e-36	2.73e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	13.68	4.78e-36	2.76e-32	0.65	0.53	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	13.68	4.81e-36	2.78e-32	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-13.67	4.97e-36	2.87e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-13.67	5.09e-36	2.94e-32	-0.6	-0.53	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-13.67	5.3e-36	3.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-13.67	5.3e-36	3.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-13.67	5.3e-36	3.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-13.66	5.41e-36	3.12e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-13.66	5.41e-36	3.12e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-13.66	5.41e-36	3.12e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-13.66	5.52e-36	3.17e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs1167612	ENSG00000179406.6	LINC00174	13.66	5.53e-36	3.18e-32	0.71	0.53	Aortic root size;	chr7:66102989	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-13.66	5.56e-36	3.2e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-13.66	5.56e-36	3.2e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-13.66	5.72e-36	3.28e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	13.66	5.76e-36	3.31e-32	0.72	0.53	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-13.65	5.93e-36	3.4e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-13.65	6.12e-36	3.5e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-13.65	6.21e-36	3.55e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	13.65	6.29e-36	3.6e-32	0.73	0.53	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	13.65	6.29e-36	3.6e-32	0.73	0.53	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-13.65	6.29e-36	3.6e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-13.64	6.53e-36	3.73e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-13.64	6.53e-36	3.73e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-13.64	7.05e-36	4e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-13.63	7.39e-36	4.19e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	13.63	7.58e-36	4.3e-32	0.72	0.53	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.564	rs313804	ENSG00000179406.6	LINC00174	-13.63	7.65e-36	4.34e-32	-0.7	-0.53	Aortic root size;	chr7:66049635	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.662	rs448725	ENSG00000179406.6	LINC00174	-13.63	7.65e-36	4.34e-32	-0.7	-0.53	Aortic root size;	chr7:66049641	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.658	rs432667	ENSG00000179406.6	LINC00174	-13.63	7.65e-36	4.34e-32	-0.7	-0.53	Aortic root size;	chr7:66049646	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-13.63	7.69e-36	4.36e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
HNSC	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	13.63	7.72e-36	4.37e-32	1	0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-13.63	7.81e-36	4.42e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
HNSC	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-13.63	7.84e-36	4.44e-32	-0.44	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
HNSC	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	13.62	8.07e-36	4.57e-32	0.6	0.53	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-13.62	8.33e-36	4.71e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	13.62	8.36e-36	4.72e-32	0.71	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-13.62	8.37e-36	4.73e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-13.62	8.37e-36	4.73e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
HNSC	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	13.61	8.78e-36	4.95e-32	0.76	0.53	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-13.61	8.89e-36	5.01e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-13.61	8.95e-36	5.04e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-13.61	9.18e-36	5.17e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-13.61	9.19e-36	5.17e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-13.61	9.44e-36	5.31e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-13.61	9.49e-36	5.34e-32	-0.69	-0.53	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-13.6	9.6e-36	5.4e-32	-0.6	-0.53	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
HNSC	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-13.6	9.65e-36	5.42e-32	-0.44	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
HNSC	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-13.6	9.72e-36	5.46e-32	-0.59	-0.53	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-13.6	1e-35	5.61e-32	-0.69	-0.53	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-13.6	1e-35	5.62e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-13.6	1e-35	5.62e-32	-0.65	-0.53	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-13.6	1.01e-35	5.66e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-13.6	1.01e-35	5.66e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-13.59	1.06e-35	5.93e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-13.59	1.08e-35	6.03e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-13.59	1.08e-35	6.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-13.59	1.09e-35	6.06e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-13.59	1.09e-35	6.06e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-13.59	1.1e-35	6.12e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-13.59	1.1e-35	6.13e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-13.59	1.11e-35	6.19e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-13.59	1.12e-35	6.26e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-13.59	1.15e-35	6.38e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.964	rs697969	ENSG00000179406.6	LINC00174	13.58	1.17e-35	6.51e-32	0.7	0.53	Aortic root size;	chr7:66093491	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1182882	ENSG00000179406.6	LINC00174	13.58	1.17e-35	6.51e-32	0.7	0.53	Aortic root size;	chr7:66097076	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-13.58	1.18e-35	6.57e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-13.58	1.18e-35	6.57e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-13.58	1.18e-35	6.57e-32	-0.71	-0.53	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
HNSC	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-13.58	1.22e-35	6.8e-32	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	13.58	1.24e-35	6.91e-32	0.69	0.53	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-13.57	1.35e-35	7.47e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-13.57	1.36e-35	7.55e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-13.57	1.37e-35	7.57e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
HNSC	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-13.57	1.39e-35	7.67e-32	-0.98	-0.53	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
HNSC	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-13.56	1.44e-35	7.97e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
HNSC	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	13.56	1.54e-35	8.52e-32	0.54	0.53	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-13.55	1.57e-35	8.66e-32	-0.65	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
HNSC	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-13.55	1.62e-35	8.93e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-13.55	1.66e-35	9.13e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-13.54	1.79e-35	9.88e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	13.54	1.8e-35	9.92e-32	0.55	0.53	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
HNSC	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-13.54	1.81e-35	9.94e-32	-0.66	-0.53	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
HNSC	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-13.54	1.81e-35	9.94e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-13.54	1.82e-35	9.99e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-13.54	1.83e-35	1e-31	-0.7	-0.53	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
HNSC	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	13.54	1.84e-35	1.01e-31	0.64	0.53	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
HNSC	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-13.54	1.88e-35	1.03e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
HNSC	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-13.53	1.95e-35	1.07e-31	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-13.53	1.95e-35	1.07e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-13.53	1.96e-35	1.07e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
HNSC	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	13.53	2.03e-35	1.11e-31	0.77	0.53	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
HNSC	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	13.53	2.1e-35	1.15e-31	0.72	0.53	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
HNSC	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	13.52	2.13e-35	1.17e-31	0.63	0.53	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-13.52	2.14e-35	1.17e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
HNSC	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	13.52	2.18e-35	1.19e-31	0.75	0.53	Migraine;	chr16:75350086	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	13.52	2.21e-35	1.2e-31	0.72	0.53	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	13.52	2.27e-35	1.23e-31	0.59	0.53	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	13.52	2.27e-35	1.23e-31	0.59	0.53	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	13.52	2.27e-35	1.23e-31	0.59	0.53	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-13.52	2.27e-35	1.23e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-13.52	2.27e-35	1.23e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-13.52	2.3e-35	1.25e-31	-0.65	-0.53	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
HNSC	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-13.51	2.38e-35	1.29e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	13.51	2.42e-35	1.31e-31	0.72	0.53	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
HNSC	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-13.51	2.49e-35	1.35e-31	-0.68	-0.53	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
HNSC	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-13.51	2.5e-35	1.36e-31	-0.65	-0.53	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-13.51	2.51e-35	1.36e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
HNSC	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
HNSC	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-13.5	2.64e-35	1.42e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-13.5	2.71e-35	1.46e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-13.5	2.74e-35	1.48e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	13.49	2.81e-35	1.51e-31	0.64	0.53	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	13.49	2.81e-35	1.51e-31	0.64	0.53	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
HNSC	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	13.49	2.93e-35	1.57e-31	0.65	0.53	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-13.49	2.97e-35	1.59e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-13.49	2.99e-35	1.61e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
HNSC	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-13.49	3.01e-35	1.62e-31	-0.43	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
HNSC	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-13.49	3.04e-35	1.63e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-13.49	3.04e-35	1.63e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
HNSC	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-13.49	3.08e-35	1.65e-31	-0.5	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
HNSC	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-13.48	3.12e-35	1.67e-31	-0.64	-0.53	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
HNSC	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	13.48	3.16e-35	1.69e-31	0.61	0.53	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-13.48	3.21e-35	1.71e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-13.48	3.22e-35	1.72e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-13.48	3.22e-35	1.72e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-13.48	3.28e-35	1.75e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-13.48	3.28e-35	1.75e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-13.48	3.28e-35	1.75e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-13.47	3.5e-35	1.86e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-13.47	3.59e-35	1.91e-31	-0.65	-0.53	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	13.47	3.6e-35	1.91e-31	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
HNSC	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-13.47	3.75e-35	1.99e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
HNSC	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	13.46	3.9e-35	2.07e-31	0.59	0.53	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-13.46	3.92e-35	2.08e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-13.46	3.99e-35	2.12e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-13.46	4e-35	2.12e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-13.46	4.03e-35	2.14e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-13.46	4.05e-35	2.15e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-13.46	4.05e-35	2.15e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-13.45	4.18e-35	2.22e-31	-0.59	-0.53	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-13.45	4.22e-35	2.24e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-13.45	4.33e-35	2.29e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-13.45	4.41e-35	2.33e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-13.45	4.41e-35	2.33e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-13.45	4.46e-35	2.36e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-13.45	4.46e-35	2.36e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	13.44	4.59e-35	2.42e-31	0.59	0.53	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
HNSC	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	13.44	4.73e-35	2.49e-31	0.5	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-13.44	4.77e-35	2.52e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	13.44	4.85e-35	2.56e-31	0.62	0.53	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
HNSC	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-13.44	4.91e-35	2.59e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-13.44	4.91e-35	2.59e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-13.44	4.91e-35	2.59e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
HNSC	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-13.44	4.98e-35	2.62e-31	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-13.44	5.04e-35	2.65e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-13.43	5.07e-35	2.67e-31	-0.59	-0.53	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-13.43	5.28e-35	2.78e-31	-0.55	-0.53	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-13.43	5.48e-35	2.88e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-13.43	5.5e-35	2.89e-31	-0.65	-0.53	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-13.42	5.65e-35	2.96e-31	-0.55	-0.53	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
HNSC	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	13.42	5.72e-35	3e-31	0.59	0.53	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-13.42	5.82e-35	3.05e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-13.42	5.84e-35	3.06e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-13.42	5.93e-35	3.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-13.41	6.72e-35	3.51e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-13.4	7.12e-35	3.71e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-13.4	7.24e-35	3.77e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-13.4	7.24e-35	3.77e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-13.4	7.36e-35	3.83e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
HNSC	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	13.4	7.39e-35	3.84e-31	0.76	0.53	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
HNSC	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-13.39	7.75e-35	4.02e-31	-0.67	-0.53	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-13.39	7.77e-35	4.03e-31	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-13.38	8.35e-35	4.32e-31	-0.59	-0.53	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-13.38	8.35e-35	4.32e-31	-0.59	-0.53	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-13.38	8.4e-35	4.34e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-13.38	8.4e-35	4.34e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-13.38	8.43e-35	4.36e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-13.38	8.73e-35	4.51e-31	-0.55	-0.53	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
HNSC	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-13.38	8.76e-35	4.52e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-13.38	9e-35	4.64e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-13.38	9.01e-35	4.65e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-13.37	9.2e-35	4.75e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	13.37	9.49e-35	4.89e-31	0.62	0.53	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	13.37	9.71e-35	5.01e-31	0.64	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-13.37	9.94e-35	5.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-13.37	9.94e-35	5.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-13.37	9.94e-35	5.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	13.36	1e-34	5.14e-31	0.63	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-13.36	1.01e-34	5.17e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-13.36	1.01e-34	5.19e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	13.36	1.02e-34	5.22e-31	0.51	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-13.36	1.03e-34	5.27e-31	-0.7	-0.53	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-13.36	1.03e-34	5.27e-31	-0.7	-0.53	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
HNSC	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-13.36	1.03e-34	5.27e-31	-1.04	-0.53	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
HNSC	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	13.36	1.05e-34	5.35e-31	0.65	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-13.36	1.05e-34	5.36e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-13.36	1.05e-34	5.36e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-13.36	1.05e-34	5.36e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	13.36	1.05e-34	5.38e-31	0.58	0.53	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
HNSC	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	13.36	1.06e-34	5.41e-31	0.64	0.53	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
HNSC	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-13.36	1.06e-34	5.41e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-13.36	1.06e-34	5.41e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-13.35	1.11e-34	5.65e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-13.35	1.13e-34	5.77e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-13.35	1.16e-34	5.88e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
HNSC	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	13.35	1.17e-34	5.95e-31	0.54	0.53	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
HNSC	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-13.35	1.17e-34	5.95e-31	-0.58	-0.53	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-13.35	1.18e-34	5.99e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-13.35	1.18e-34	5.99e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.552	rs6953538	ENSG00000229043.2	AC091729.9	-13.34	1.22e-34	6.16e-31	-0.61	-0.53	Endometriosis;Longevity;	chr7:1157338	chr7:1160374~1165267:+
HNSC	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-13.34	1.22e-34	6.16e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-13.34	1.22e-34	6.18e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
HNSC	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-13.34	1.26e-34	6.36e-31	-0.64	-0.53	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
HNSC	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-13.34	1.29e-34	6.52e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-13.34	1.31e-34	6.6e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-13.34	1.31e-34	6.6e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-13.34	1.31e-34	6.6e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-13.33	1.37e-34	6.86e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	13.33	1.38e-34	6.91e-31	0.5	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	13.33	1.4e-34	7.02e-31	0.58	0.53	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	13.33	1.4e-34	7.04e-31	0.51	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
HNSC	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-13.33	1.45e-34	7.26e-31	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
HNSC	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-13.33	1.45e-34	7.29e-31	-0.63	-0.52	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-13.33	1.45e-34	7.29e-31	-0.63	-0.52	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-13.33	1.46e-34	7.3e-31	-0.64	-0.52	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-13.33	1.46e-34	7.3e-31	-0.64	-0.52	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
HNSC	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-13.32	1.54e-34	7.72e-31	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	13.32	1.58e-34	7.89e-31	0.58	0.52	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	13.32	1.58e-34	7.89e-31	0.58	0.52	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-13.31	1.64e-34	8.21e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-13.31	1.71e-34	8.51e-31	-0.69	-0.52	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-13.31	1.74e-34	8.69e-31	-0.61	-0.52	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	13.3	1.85e-34	9.22e-31	0.58	0.52	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-13.3	1.87e-34	9.32e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	13.29	2.03e-34	1.01e-30	0.62	0.52	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-13.29	2.11e-34	1.05e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	13.29	2.13e-34	1.05e-30	0.66	0.52	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-13.29	2.15e-34	1.06e-30	-0.62	-0.52	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-13.29	2.15e-34	1.06e-30	-0.62	-0.52	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
HNSC	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-13.29	2.17e-34	1.07e-30	-0.84	-0.52	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
HNSC	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	13.29	2.17e-34	1.07e-30	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-13.28	2.2e-34	1.09e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-13.28	2.26e-34	1.12e-30	-0.5	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-13.28	2.27e-34	1.12e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-13.28	2.27e-34	1.12e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	13.28	2.28e-34	1.13e-30	0.58	0.52	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-13.28	2.31e-34	1.14e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
HNSC	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	13.28	2.35e-34	1.16e-30	0.67	0.52	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
HNSC	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-13.28	2.35e-34	1.16e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-13.28	2.35e-34	1.16e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-13.27	2.41e-34	1.19e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
HNSC	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-13.27	2.43e-34	1.2e-30	-0.69	-0.52	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-13.27	2.45e-34	1.2e-30	-0.59	-0.52	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	13.27	2.58e-34	1.26e-30	0.58	0.52	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	13.27	2.61e-34	1.28e-30	0.58	0.52	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-13.26	2.65e-34	1.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-13.26	2.65e-34	1.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
HNSC	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	13.26	2.68e-34	1.31e-30	0.59	0.52	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	13.26	2.69e-34	1.32e-30	0.58	0.52	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	13.26	2.79e-34	1.36e-30	0.58	0.52	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	13.26	2.8e-34	1.36e-30	0.59	0.52	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-13.26	2.84e-34	1.38e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-13.26	2.86e-34	1.39e-30	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-13.26	2.87e-34	1.4e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-13.26	2.9e-34	1.41e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	13.25	2.94e-34	1.43e-30	0.54	0.52	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
HNSC	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-13.25	2.95e-34	1.44e-30	-0.65	-0.52	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-13.25	2.98e-34	1.45e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-13.25	2.98e-34	1.45e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs7792762	ENSG00000179406.6	LINC00174	-13.25	3.11e-34	1.51e-30	-0.69	-0.52	Aortic root size;	chr7:66539151	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-13.25	3.15e-34	1.53e-30	-0.59	-0.52	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
HNSC	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	13.24	3.23e-34	1.57e-30	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-13.24	3.23e-34	1.57e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-13.24	3.26e-34	1.58e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-13.24	3.26e-34	1.58e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-13.24	3.44e-34	1.67e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-13.24	3.44e-34	1.67e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
HNSC	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	13.24	3.44e-34	1.67e-30	0.59	0.52	Breast cancer;	chr11:750849	chr11:779617~780755:+
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-13.24	3.5e-34	1.69e-30	-0.59	-0.52	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-13.23	3.55e-34	1.72e-30	-0.65	-0.52	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
HNSC	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-13.23	3.68e-34	1.78e-30	-0.74	-0.52	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
HNSC	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	13.23	3.69e-34	1.78e-30	0.68	0.52	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000216906.2	RP11-350J20.9	13.23	3.73e-34	1.8e-30	0.68	0.52	Lung cancer;	chr6:149863746	chr6:149904243~149906418:+
HNSC	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	13.23	3.86e-34	1.86e-30	0.68	0.52	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-13.22	3.93e-34	1.89e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-13.22	3.96e-34	1.91e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
HNSC	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-13.22	3.99e-34	1.93e-30	-0.58	-0.52	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
HNSC	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-13.22	4.07e-34	1.96e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.66	rs2659897	ENSG00000179406.6	LINC00174	13.22	4.14e-34	1.99e-30	0.69	0.52	Aortic root size;	chr7:66722728	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-13.22	4.16e-34	2e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-13.21	4.4e-34	2.11e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-13.21	4.4e-34	2.11e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-13.21	4.41e-34	2.12e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-13.21	4.54e-34	2.18e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
HNSC	cis	rs17270561	0.723	rs12192635	ENSG00000272462.2	U91328.19	-13.2	4.76e-34	2.28e-30	-0.58	-0.52	Iron status biomarkers;	chr6:25880679	chr6:25992662~26001775:+
HNSC	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	13.2	4.86e-34	2.33e-30	0.61	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-13.2	4.9e-34	2.34e-30	-0.58	-0.52	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-13.2	4.98e-34	2.38e-30	-0.58	-0.52	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-13.2	5.01e-34	2.4e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-13.2	5.01e-34	2.4e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-13.19	5.26e-34	2.51e-30	-0.64	-0.52	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-13.19	5.47e-34	2.61e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-13.19	5.67e-34	2.7e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-13.18	5.79e-34	2.76e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-13.18	5.79e-34	2.76e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-13.18	5.85e-34	2.78e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
HNSC	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	13.18	5.91e-34	2.82e-30	0.59	0.52	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
HNSC	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-13.18	5.95e-34	2.83e-30	-0.58	-0.52	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
HNSC	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-13.18	6.12e-34	2.91e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-13.18	6.19e-34	2.94e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-13.18	6.21e-34	2.95e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-13.17	6.34e-34	3.01e-30	-0.58	-0.52	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-13.17	6.5e-34	3.09e-30	-0.65	-0.52	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-13.17	6.51e-34	3.09e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	13.17	6.71e-34	3.18e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-13.17	6.73e-34	3.19e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-13.17	6.73e-34	3.19e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-13.16	7.1e-34	3.36e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-13.16	7.2e-34	3.41e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-13.16	7.2e-34	3.41e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-13.16	7.21e-34	3.41e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-13.16	7.21e-34	3.41e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-13.16	7.5e-34	3.55e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-13.16	7.5e-34	3.55e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-13.16	7.5e-34	3.55e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-13.15	7.72e-34	3.65e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-13.15	7.95e-34	3.75e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-13.14	8.47e-34	3.99e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	13.14	8.5e-34	4e-30	0.75	0.52	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
HNSC	cis	rs801193	0.636	rs10233806	ENSG00000179406.6	LINC00174	13.14	8.55e-34	4.02e-30	0.68	0.52	Aortic root size;	chr7:66653261	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-13.14	8.57e-34	4.03e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-13.14	8.6e-34	4.04e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-13.14	8.6e-34	4.04e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-13.14	8.82e-34	4.14e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-13.14	8.82e-34	4.14e-30	-0.58	-0.52	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-13.14	8.86e-34	4.16e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-13.14	9.07e-34	4.25e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-13.14	9.07e-34	4.25e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-13.13	1e-33	4.68e-30	-0.53	-0.52	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
HNSC	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	13.12	1.05e-33	4.88e-30	0.5	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs697970	ENSG00000179406.6	LINC00174	13.12	1.05e-33	4.88e-30	0.7	0.52	Aortic root size;	chr7:66095065	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	13.12	1.05e-33	4.92e-30	0.69	0.52	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	13.12	1.1e-33	5.12e-30	0.6	0.52	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-13.11	1.16e-33	5.41e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-13.11	1.17e-33	5.47e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-13.11	1.21e-33	5.65e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
HNSC	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-13.1	1.26e-33	5.87e-30	-0.49	-0.52	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-13.1	1.26e-33	5.88e-30	-0.57	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
HNSC	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	13.1	1.27e-33	5.88e-30	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-13.1	1.28e-33	5.93e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	13.1	1.29e-33	6e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
HNSC	cis	rs17270561	0.723	rs12213243	ENSG00000272462.2	U91328.19	-13.1	1.29e-33	6e-30	-0.61	-0.52	Iron status biomarkers;	chr6:25889880	chr6:25992662~26001775:+
HNSC	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-13.1	1.3e-33	6.02e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
HNSC	cis	rs801193	0.66	rs2659914	ENSG00000179406.6	LINC00174	-13.1	1.31e-33	6.08e-30	-0.68	-0.52	Aortic root size;	chr7:66691927	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-13.1	1.36e-33	6.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-13.1	1.36e-33	6.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	13.09	1.4e-33	6.49e-30	0.63	0.52	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-13.09	1.42e-33	6.58e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-13.09	1.45e-33	6.72e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-13.09	1.45e-33	6.72e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-13.09	1.47e-33	6.8e-30	-0.59	-0.52	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-13.09	1.47e-33	6.8e-30	-0.59	-0.52	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	13.09	1.47e-33	6.81e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
HNSC	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	13.09	1.5e-33	6.93e-30	0.53	0.52	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-13.08	1.53e-33	7.07e-30	-0.59	-0.52	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.636	rs2659895	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66731484	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.66	rs974239	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66748504	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.66	rs1016265	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66749580	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.66	rs4610622	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66759510	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs10244498	ENSG00000179406.6	LINC00174	-13.08	1.56e-33	7.18e-30	-0.68	-0.52	Aortic root size;	chr7:66651069	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	13.08	1.64e-33	7.55e-30	0.65	0.52	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
HNSC	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-13.07	1.66e-33	7.66e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.7e-33	7.81e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.72e-33	7.91e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.72e-33	7.91e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.74e-33	8e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	13.07	1.77e-33	8.13e-30	0.65	0.52	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
HNSC	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	13.07	1.77e-33	8.13e-30	0.54	0.52	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	13.07	1.78e-33	8.18e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-13.06	1.86e-33	8.53e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-13.06	1.86e-33	8.53e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-13.06	1.91e-33	8.75e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
HNSC	cis	rs17270561	0.578	rs76182885	ENSG00000272462.2	U91328.19	-13.06	1.92e-33	8.81e-30	-0.62	-0.52	Iron status biomarkers;	chr6:25903857	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.541	rs12192932	ENSG00000272462.2	U91328.19	-13.06	1.92e-33	8.81e-30	-0.62	-0.52	Iron status biomarkers;	chr6:25911274	chr6:25992662~26001775:+
HNSC	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-13.06	1.93e-33	8.85e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-13.06	1.93e-33	8.85e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-13.06	1.96e-33	8.98e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-13.06	1.97e-33	9e-30	-0.6	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-13.06	1.97e-33	9.03e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-13.06	1.99e-33	9.08e-30	-0.62	-0.52	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-13.05	2.03e-33	9.3e-30	-0.58	-0.52	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-13.05	2.06e-33	9.42e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-13.05	2.07e-33	9.45e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-13.05	2.07e-33	9.45e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
HNSC	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	13.05	2.09e-33	9.55e-30	0.61	0.52	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
HNSC	cis	rs801193	0.66	rs10950049	ENSG00000179406.6	LINC00174	-13.05	2.13e-33	9.71e-30	-0.68	-0.52	Aortic root size;	chr7:66765873	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	13.05	2.16e-33	9.83e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-13.05	2.17e-33	9.87e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-13.05	2.18e-33	9.91e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
HNSC	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-13.04	2.31e-33	1.05e-29	-0.66	-0.52	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
HNSC	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-13.04	2.38e-33	1.08e-29	-0.66	-0.52	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-13.04	2.38e-33	1.08e-29	-0.66	-0.52	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-13.03	2.44e-33	1.11e-29	-0.58	-0.52	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-13.03	2.45e-33	1.11e-29	-0.58	-0.52	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-13.03	2.49e-33	1.13e-29	-0.58	-0.52	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
HNSC	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-13.03	2.6e-33	1.17e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	13.03	2.61e-33	1.18e-29	0.59	0.52	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	13.03	2.63e-33	1.19e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
HNSC	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-13.02	2.76e-33	1.25e-29	-0.66	-0.52	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
HNSC	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	13.02	2.86e-33	1.28e-29	0.7	0.52	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	13.02	2.86e-33	1.28e-29	0.7	0.52	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	13.02	2.86e-33	1.28e-29	0.7	0.52	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-13.02	2.88e-33	1.29e-29	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	13.02	2.94e-33	1.31e-29	0.66	0.52	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
HNSC	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	13.01	3.05e-33	1.37e-29	0.42	0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-13.01	3.2e-33	1.43e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-13	3.25e-33	1.45e-29	-0.58	-0.52	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-13	3.28e-33	1.46e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-13	3.3e-33	1.47e-29	-0.58	-0.52	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	13	3.37e-33	1.5e-29	0.79	0.52	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-13	3.45e-33	1.53e-29	-0.58	-0.52	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-13	3.49e-33	1.55e-29	-0.58	-0.52	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-12.99	3.6e-33	1.6e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-12.99	3.69e-33	1.63e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	12.99	3.79e-33	1.67e-29	0.7	0.52	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	12.99	3.79e-33	1.67e-29	0.7	0.52	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.613	rs2659900	ENSG00000179406.6	LINC00174	-12.99	3.81e-33	1.68e-29	-0.68	-0.52	Aortic root size;	chr7:66719456	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-12.99	3.9e-33	1.72e-29	-0.66	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
HNSC	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-12.99	3.92e-33	1.73e-29	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	12.98	4.05e-33	1.79e-29	0.58	0.51	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-12.98	4.15e-33	1.83e-29	-0.58	-0.51	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-12.98	4.15e-33	1.83e-29	-0.58	-0.51	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-12.98	4.28e-33	1.89e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-12.98	4.31e-33	1.9e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
HNSC	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	12.97	4.38e-33	1.93e-29	0.98	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-12.97	4.57e-33	2.01e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
HNSC	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-12.97	4.63e-33	2.04e-29	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-12.97	4.74e-33	2.08e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
HNSC	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-12.96	4.83e-33	2.12e-29	-0.53	-0.51	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-12.96	4.92e-33	2.16e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-12.96	4.99e-33	2.19e-29	-0.58	-0.51	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-12.96	4.99e-33	2.19e-29	-0.58	-0.51	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-12.95	5.24e-33	2.3e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-12.95	5.29e-33	2.32e-29	-0.58	-0.51	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-12.95	5.33e-33	2.33e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
HNSC	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	12.95	5.4e-33	2.36e-29	0.71	0.51	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
HNSC	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	12.95	5.41e-33	2.37e-29	0.71	0.51	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
HNSC	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	12.95	5.53e-33	2.42e-29	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
HNSC	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	12.95	5.54e-33	2.42e-29	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
HNSC	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	12.95	5.72e-33	2.5e-29	0.41	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-12.94	5.84e-33	2.55e-29	-0.58	-0.51	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-12.94	6.12e-33	2.67e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	12.94	6.14e-33	2.68e-29	0.8	0.51	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	12.94	6.14e-33	2.68e-29	0.76	0.51	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
HNSC	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-12.94	6.26e-33	2.73e-29	-0.58	-0.51	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	12.94	6.31e-33	2.75e-29	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs709596	ENSG00000179406.6	LINC00174	-12.93	6.35e-33	2.77e-29	-0.68	-0.51	Aortic root size;	chr7:66360926	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-12.93	6.66e-33	2.9e-29	-0.58	-0.51	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
HNSC	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	12.92	7.11e-33	3.09e-29	0.7	0.51	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
HNSC	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	12.92	7.27e-33	3.16e-29	0.71	0.51	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	12.92	7.42e-33	3.22e-29	0.65	0.51	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
HNSC	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	12.92	7.49e-33	3.25e-29	0.62	0.51	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-12.92	7.61e-33	3.31e-29	-0.62	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	12.92	7.65e-33	3.32e-29	0.63	0.51	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.591	rs2707839	ENSG00000179406.6	LINC00174	-12.91	7.67e-33	3.33e-29	-0.68	-0.51	Aortic root size;	chr7:66728097	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	12.91	7.82e-33	3.4e-29	0.66	0.51	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-12.91	7.96e-33	3.46e-29	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	12.91	7.99e-33	3.47e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	12.91	7.99e-33	3.47e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
HNSC	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	12.91	8.19e-33	3.55e-29	0.63	0.51	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
HNSC	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	12.91	8.19e-33	3.55e-29	0.65	0.51	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
HNSC	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
HNSC	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-12.91	8.27e-33	3.58e-29	-0.58	-0.51	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
HNSC	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	12.91	8.38e-33	3.62e-29	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	12.9	8.79e-33	3.8e-29	0.69	0.51	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	12.9	8.85e-33	3.83e-29	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	12.9	8.85e-33	3.83e-29	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
HNSC	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-12.9	9.22e-33	3.98e-29	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs6460302	ENSG00000179406.6	LINC00174	-12.9	9.26e-33	3.99e-29	-0.68	-0.51	Aortic root size;	chr7:66495270	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-12.9	9.26e-33	4e-29	-0.58	-0.51	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-12.89	9.41e-33	4.05e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-12.89	9.41e-33	4.05e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-12.89	9.41e-33	4.05e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
HNSC	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-12.89	9.6e-33	4.13e-29	-0.59	-0.51	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
HNSC	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-12.89	9.64e-33	4.15e-29	-0.93	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-12.89	9.64e-33	4.15e-29	-0.93	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
HNSC	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	12.89	9.66e-33	4.15e-29	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
HNSC	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-12.89	9.68e-33	4.16e-29	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-12.89	1.01e-32	4.33e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	12.89	1.02e-32	4.37e-29	0.66	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	12.89	1.02e-32	4.37e-29	0.66	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
HNSC	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-12.88	1.05e-32	4.52e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-12.88	1.05e-32	4.52e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-12.88	1.08e-32	4.64e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	12.88	1.1e-32	4.71e-29	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-12.87	1.16e-32	4.96e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	12.87	1.16e-32	4.99e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	12.87	1.17e-32	5.01e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
HNSC	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-12.87	1.18e-32	5.04e-29	-0.58	-0.51	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-12.87	1.22e-32	5.24e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-12.87	1.23e-32	5.25e-29	-0.65	-0.51	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.862	rs10256544	ENSG00000179406.6	LINC00174	-12.86	1.24e-32	5.29e-29	-0.7	-0.51	Aortic root size;	chr7:66210141	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-12.86	1.26e-32	5.38e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	12.85	1.36e-32	5.81e-29	0.66	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-12.85	1.37e-32	5.84e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-12.85	1.38e-32	5.87e-29	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	12.85	1.43e-32	6.09e-29	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-12.85	1.43e-32	6.11e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-12.85	1.43e-32	6.11e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-12.85	1.43e-32	6.11e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	12.85	1.47e-32	6.27e-29	0.58	0.51	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	12.84	1.5e-32	6.39e-29	0.58	0.51	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1544549	ENSG00000179406.6	LINC00174	12.84	1.52e-32	6.48e-29	0.68	0.51	Aortic root size;	chr7:66625676	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420820	ENSG00000179406.6	LINC00174	12.84	1.52e-32	6.48e-29	0.68	0.51	Aortic root size;	chr7:66626920	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	12.84	1.53e-32	6.5e-29	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	12.84	1.56e-32	6.65e-29	0.58	0.51	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	12.84	1.58e-32	6.7e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
HNSC	cis	rs17270561	0.541	rs17586946	ENSG00000272462.2	U91328.19	-12.84	1.61e-32	6.83e-29	-0.62	-0.51	Iron status biomarkers;	chr6:25938825	chr6:25992662~26001775:+
HNSC	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	12.83	1.72e-32	7.29e-29	0.58	0.51	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	12.83	1.79e-32	7.58e-29	0.58	0.51	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
HNSC	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	12.83	1.79e-32	7.6e-29	0.62	0.51	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
HNSC	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-12.82	1.86e-32	7.88e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-12.82	1.86e-32	7.88e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-12.82	1.88e-32	7.97e-29	-0.57	-0.51	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
HNSC	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	12.82	1.92e-32	8.14e-29	0.62	0.51	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	12.82	1.92e-32	8.14e-29	0.62	0.51	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	12.82	1.92e-32	8.14e-29	0.62	0.51	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-12.81	2e-32	8.45e-29	-0.58	-0.51	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-12.81	2e-32	8.46e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
HNSC	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	12.81	2.02e-32	8.53e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
HNSC	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	12.81	2.17e-32	9.15e-29	0.62	0.51	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-12.8	2.22e-32	9.36e-29	-0.76	-0.51	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	12.8	2.22e-32	9.37e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	12.8	2.22e-32	9.37e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
HNSC	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	12.8	2.23e-32	9.39e-29	0.71	0.51	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
HNSC	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	12.8	2.28e-32	9.6e-29	0.62	0.51	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.651	rs2420596	ENSG00000179406.6	LINC00174	-12.8	2.29e-32	9.66e-29	-0.68	-0.51	Aortic root size;	chr7:66450996	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.52	rs2420597	ENSG00000179406.6	LINC00174	-12.8	2.29e-32	9.66e-29	-0.68	-0.51	Aortic root size;	chr7:66450999	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	12.8	2.33e-32	9.82e-29	0.58	0.51	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	12.8	2.35e-32	9.87e-29	0.58	0.51	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	12.8	2.35e-32	9.87e-29	0.58	0.51	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
HNSC	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-12.8	2.36e-32	9.91e-29	-0.65	-0.51	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.862	rs778724	ENSG00000179406.6	LINC00174	-12.8	2.37e-32	9.97e-29	-0.68	-0.51	Aortic root size;	chr7:66364304	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	12.8	2.39e-32	1.01e-28	0.58	0.51	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	12.8	2.39e-32	1.01e-28	0.58	0.51	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-12.8	2.4e-32	1.01e-28	-0.58	-0.51	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	12.8	2.4e-32	1.01e-28	0.64	0.51	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-12.79	2.41e-32	1.01e-28	-0.58	-0.51	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-12.79	2.41e-32	1.01e-28	-0.58	-0.51	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	12.79	2.5e-32	1.05e-28	0.58	0.51	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
HNSC	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-12.79	2.52e-32	1.06e-28	-0.59	-0.51	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
HNSC	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	12.79	2.56e-32	1.08e-28	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	12.79	2.61e-32	1.1e-28	0.48	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
HNSC	cis	rs17270561	0.579	rs10456326	ENSG00000272462.2	U91328.19	-12.78	2.68e-32	1.12e-28	-0.62	-0.51	Iron status biomarkers;	chr6:25919434	chr6:25992662~26001775:+
HNSC	cis	rs12216125	0.537	rs12207059	ENSG00000272462.2	U91328.19	-12.78	2.68e-32	1.12e-28	-0.62	-0.51	Iron status biomarkers;	chr6:25922157	chr6:25992662~26001775:+
HNSC	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-12.78	2.68e-32	1.12e-28	-0.91	-0.51	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-12.78	2.69e-32	1.13e-28	-0.91	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-12.78	2.7e-32	1.13e-28	-0.66	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
HNSC	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	12.78	2.7e-32	1.13e-28	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-12.78	2.75e-32	1.15e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-12.78	2.81e-32	1.18e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-12.78	2.81e-32	1.18e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-12.78	2.83e-32	1.18e-28	-0.65	-0.51	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
HNSC	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	12.78	2.86e-32	1.2e-28	0.71	0.51	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
HNSC	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-12.77	2.94e-32	1.23e-28	-0.66	-0.51	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-12.77	2.96e-32	1.23e-28	-0.57	-0.51	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	12.77	2.98e-32	1.24e-28	0.58	0.51	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	12.77	3e-32	1.25e-28	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
HNSC	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	12.77	3.02e-32	1.26e-28	0.48	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
HNSC	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-12.77	3.03e-32	1.26e-28	-0.62	-0.51	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
HNSC	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-12.77	3.07e-32	1.28e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
HNSC	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	12.77	3.13e-32	1.3e-28	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-12.77	3.2e-32	1.33e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
HNSC	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	12.76	3.25e-32	1.35e-28	0.58	0.51	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
HNSC	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-12.76	3.25e-32	1.35e-28	-0.91	-0.51	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
HNSC	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	12.76	3.31e-32	1.38e-28	0.56	0.51	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	12.76	3.33e-32	1.38e-28	0.66	0.51	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	12.76	3.33e-32	1.38e-28	0.66	0.51	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	12.76	3.34e-32	1.39e-28	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-12.76	3.45e-32	1.43e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-12.76	3.51e-32	1.46e-28	-0.58	-0.51	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs11773628	ENSG00000179406.6	LINC00174	12.76	3.52e-32	1.46e-28	0.68	0.51	Aortic root size;	chr7:66517644	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	12.75	3.65e-32	1.52e-28	0.58	0.51	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
HNSC	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-12.75	3.69e-32	1.53e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	12.75	3.71e-32	1.54e-28	0.58	0.51	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	12.75	3.71e-32	1.54e-28	0.58	0.51	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1983372	ENSG00000179406.6	LINC00174	12.75	3.72e-32	1.54e-28	0.68	0.51	Aortic root size;	chr7:66146364	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	12.75	3.78e-32	1.57e-28	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-12.75	3.8e-32	1.57e-28	-0.58	-0.51	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-12.75	3.8e-32	1.57e-28	-0.58	-0.51	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
HNSC	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	12.75	3.83e-32	1.59e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
HNSC	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-12.74	3.88e-32	1.61e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-12.74	3.9e-32	1.61e-28	-0.65	-0.51	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-12.74	4e-32	1.66e-28	-0.55	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
HNSC	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-12.74	4.04e-32	1.67e-28	-0.53	-0.51	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
HNSC	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	12.74	4.05e-32	1.67e-28	0.72	0.51	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
HNSC	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-12.74	4.07e-32	1.68e-28	-0.53	-0.51	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.798	rs6460304	ENSG00000179406.6	LINC00174	-12.74	4.11e-32	1.7e-28	-0.68	-0.51	Aortic root size;	chr7:66499741	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6945775	ENSG00000179406.6	LINC00174	-12.74	4.11e-32	1.7e-28	-0.68	-0.51	Aortic root size;	chr7:66503987	chr7:66376044~66401338:-
HNSC	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	12.74	4.23e-32	1.75e-28	0.72	0.51	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
HNSC	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	12.73	4.33e-32	1.79e-28	0.62	0.51	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	12.73	4.4e-32	1.81e-28	0.62	0.51	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
HNSC	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	12.73	4.5e-32	1.85e-28	0.59	0.51	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	12.73	4.57e-32	1.88e-28	0.68	0.51	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	12.73	4.57e-32	1.88e-28	0.75	0.51	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
HNSC	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-12.73	4.58e-32	1.89e-28	-0.53	-0.51	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.798	rs57739047	ENSG00000179406.6	LINC00174	-12.72	4.81e-32	1.98e-28	-0.68	-0.51	Aortic root size;	chr7:66507579	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs6950137	ENSG00000179406.6	LINC00174	-12.72	4.94e-32	2.03e-28	-0.68	-0.51	Aortic root size;	chr7:66511623	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-12.72	5.04e-32	2.07e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	12.71	5.17e-32	2.12e-28	0.57	0.51	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	12.71	5.17e-32	2.12e-28	0.57	0.51	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-12.71	5.21e-32	2.14e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	12.71	5.21e-32	2.14e-28	0.57	0.51	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs1962050	ENSG00000179406.6	LINC00174	12.71	5.29e-32	2.17e-28	0.68	0.51	Aortic root size;	chr7:66775021	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	12.71	5.36e-32	2.2e-28	0.59	0.51	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	12.71	5.36e-32	2.2e-28	0.59	0.51	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
HNSC	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-12.71	5.46e-32	2.24e-28	-0.65	-0.51	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
HNSC	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-12.71	5.49e-32	2.25e-28	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-12.7	5.94e-32	2.43e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-12.7	6.14e-32	2.51e-28	-0.52	-0.51	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.862	rs11763189	ENSG00000179406.6	LINC00174	-12.7	6.19e-32	2.53e-28	-0.68	-0.51	Aortic root size;	chr7:66518542	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-12.7	6.2e-32	2.53e-28	-0.65	-0.51	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.83	rs6976714	ENSG00000179406.6	LINC00174	-12.69	6.36e-32	2.6e-28	-0.68	-0.51	Aortic root size;	chr7:66426474	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-12.69	6.85e-32	2.79e-28	-0.64	-0.51	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	12.68	7.11e-32	2.9e-28	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-12.68	7.13e-32	2.9e-28	-0.93	-0.51	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
HNSC	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	12.68	7.54e-32	3.06e-28	0.59	0.51	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-12.67	7.64e-32	3.1e-28	-0.59	-0.51	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
HNSC	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	12.67	7.81e-32	3.17e-28	0.57	0.51	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	12.67	7.92e-32	3.21e-28	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-12.67	7.95e-32	3.23e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
HNSC	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	12.67	7.99e-32	3.24e-28	0.6	0.51	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	12.67	7.99e-32	3.24e-28	0.65	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	12.67	8.12e-32	3.29e-28	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	12.66	8.32e-32	3.37e-28	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
HNSC	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	12.65	9.83e-32	3.97e-28	0.59	0.51	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
HNSC	cis	rs10853057	0.85	rs62065479	ENSG00000214174.7	AMZ2P1	12.65	9.98e-32	4.03e-28	0.82	0.51	White matter microstructure (global fractional anisotropy);	chr17:65002593	chr17:64966550~64975576:-
HNSC	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	12.65	9.98e-32	4.03e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	12.65	9.98e-32	4.03e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
HNSC	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-12.65	1e-31	4.05e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	12.64	1.03e-31	4.17e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	12.64	1.04e-31	4.2e-28	0.57	0.5	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-12.64	1.05e-31	4.24e-28	-0.95	-0.5	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-12.64	1.05e-31	4.24e-28	-0.95	-0.5	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-12.64	1.05e-31	4.24e-28	-0.95	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	12.64	1.07e-31	4.31e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
HNSC	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-12.64	1.09e-31	4.4e-28	-0.93	-0.5	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-12.64	1.09e-31	4.4e-28	-0.93	-0.5	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-12.64	1.09e-31	4.4e-28	-0.93	-0.5	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-12.63	1.15e-31	4.62e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.862	rs908915	ENSG00000179406.6	LINC00174	12.63	1.18e-31	4.75e-28	0.68	0.5	Aortic root size;	chr7:66149664	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-12.63	1.19e-31	4.8e-28	-0.55	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
HNSC	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-12.63	1.2e-31	4.83e-28	-0.53	-0.5	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
HNSC	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-12.63	1.21e-31	4.84e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
HNSC	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	12.63	1.21e-31	4.86e-28	0.48	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
HNSC	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-12.62	1.23e-31	4.93e-28	-0.96	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
HNSC	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-12.62	1.24e-31	4.96e-28	-0.6	-0.5	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-12.62	1.24e-31	4.96e-28	-0.6	-0.5	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
HNSC	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-12.62	1.27e-31	5.09e-28	-0.67	-0.5	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-12.62	1.27e-31	5.09e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.548	rs2659904	ENSG00000179406.6	LINC00174	-12.62	1.27e-31	5.09e-28	-0.67	-0.5	Aortic root size;	chr7:66713615	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	12.61	1.35e-31	5.39e-28	0.96	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-12.61	1.37e-31	5.5e-28	-0.58	-0.5	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-12.61	1.37e-31	5.5e-28	-0.77	-0.5	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
HNSC	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-12.61	1.38e-31	5.52e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	12.61	1.42e-31	5.69e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	12.6	1.51e-31	6.01e-28	0.65	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs2420174	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66180374	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2420173	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66180412	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4718319	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66187797	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.723	rs28391294	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66189328	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs6967708	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66192326	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs7782806	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66192910	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	12.6	1.56e-31	6.24e-28	0.96	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-12.6	1.57e-31	6.25e-28	-0.66	-0.5	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-12.6	1.57e-31	6.25e-28	-0.66	-0.5	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	12.6	1.59e-31	6.32e-28	0.76	0.5	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-12.59	1.62e-31	6.44e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	12.59	1.62e-31	6.45e-28	0.66	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	12.59	1.63e-31	6.47e-28	0.78	0.5	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
HNSC	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-12.59	1.67e-31	6.61e-28	-0.93	-0.5	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-12.59	1.74e-31	6.88e-28	-0.95	-0.5	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-12.58	1.8e-31	7.11e-28	-0.92	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs11769079	ENSG00000179406.6	LINC00174	-12.58	1.83e-31	7.24e-28	-0.67	-0.5	Aortic root size;	chr7:66377141	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1695820	ENSG00000179406.6	LINC00174	-12.58	1.83e-31	7.24e-28	-0.67	-0.5	Aortic root size;	chr7:66379576	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	12.58	1.84e-31	7.28e-28	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	12.58	1.84e-31	7.28e-28	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-12.58	1.88e-31	7.43e-28	-0.66	-0.5	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.83	rs778715	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66384222	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs809025	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66384832	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778702	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66399848	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1643375	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66407690	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6962717	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66418748	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.767	rs1643394	ENSG00000179406.6	LINC00174	-12.57	1.97e-31	7.79e-28	-0.68	-0.5	Aortic root size;	chr7:66371107	chr7:66376044~66401338:-
HNSC	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	12.57	1.99e-31	7.84e-28	0.6	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	12.57	2e-31	7.91e-28	0.57	0.5	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	12.57	2.13e-31	8.39e-28	0.77	0.5	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	12.57	2.13e-31	8.39e-28	0.77	0.5	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs778686	ENSG00000179406.6	LINC00174	-12.56	2.17e-31	8.54e-28	-0.68	-0.5	Aortic root size;	chr7:66370923	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778684	ENSG00000179406.6	LINC00174	-12.56	2.17e-31	8.54e-28	-0.68	-0.5	Aortic root size;	chr7:66371416	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778680	ENSG00000179406.6	LINC00174	-12.56	2.17e-31	8.54e-28	-0.68	-0.5	Aortic root size;	chr7:66375427	chr7:66376044~66401338:-
HNSC	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-12.56	2.18e-31	8.57e-28	-0.58	-0.5	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
HNSC	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	12.56	2.21e-31	8.71e-28	0.56	0.5	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
HNSC	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-12.56	2.26e-31	8.88e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
HNSC	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	12.55	2.4e-31	9.43e-28	0.97	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
HNSC	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	12.55	2.41e-31	9.49e-28	0.62	0.5	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	12.55	2.49e-31	9.77e-28	0.59	0.5	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	12.55	2.53e-31	9.94e-28	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-12.55	2.56e-31	1e-27	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
HNSC	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	12.55	2.57e-31	1.01e-27	0.57	0.5	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
HNSC	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	12.54	2.65e-31	1.04e-27	0.56	0.5	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
HNSC	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	12.54	2.65e-31	1.04e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
HNSC	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	12.54	2.68e-31	1.05e-27	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
HNSC	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-12.54	2.68e-31	1.05e-27	-0.58	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	12.54	2.69e-31	1.05e-27	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
HNSC	cis	rs875971	0.862	rs880166	ENSG00000179406.6	LINC00174	12.54	2.69e-31	1.05e-27	0.68	0.5	Aortic root size;	chr7:66205775	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	12.54	2.72e-31	1.06e-27	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	12.54	2.73e-31	1.07e-27	0.48	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
HNSC	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	12.54	2.74e-31	1.07e-27	0.58	0.5	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
HNSC	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	12.54	2.76e-31	1.08e-27	0.57	0.5	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-12.54	2.78e-31	1.09e-27	-0.75	-0.5	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-12.54	2.78e-31	1.09e-27	-0.63	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-12.53	2.92e-31	1.14e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
HNSC	cis	rs17270561	0.779	rs12209218	ENSG00000272462.2	U91328.19	-12.53	3.1e-31	1.21e-27	-0.59	-0.5	Iron status biomarkers;	chr6:25887548	chr6:25992662~26001775:+
HNSC	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-12.52	3.24e-31	1.26e-27	-0.48	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
HNSC	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	12.52	3.34e-31	1.3e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
HNSC	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-12.51	3.45e-31	1.34e-27	-0.56	-0.5	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
HNSC	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	12.51	3.65e-31	1.42e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
HNSC	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-12.51	3.66e-31	1.42e-27	-0.58	-0.5	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	12.51	3.75e-31	1.46e-27	0.78	0.5	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.825	rs1129531	ENSG00000179406.6	LINC00174	12.5	3.8e-31	1.48e-27	0.68	0.5	Aortic root size;	chr7:66154117	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7786892	ENSG00000179406.6	LINC00174	12.5	3.8e-31	1.48e-27	0.68	0.5	Aortic root size;	chr7:66163889	chr7:66376044~66401338:-
HNSC	cis	rs17270561	0.779	rs12210620	ENSG00000272462.2	U91328.19	-12.5	3.82e-31	1.48e-27	-0.59	-0.5	Iron status biomarkers;	chr6:25884557	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-12.5	3.85e-31	1.49e-27	-0.76	-0.5	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-12.5	3.85e-31	1.49e-27	-0.76	-0.5	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-12.5	3.85e-31	1.49e-27	-0.76	-0.5	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
HNSC	cis	rs17270561	0.779	rs17271767	ENSG00000272462.2	U91328.19	-12.5	3.86e-31	1.5e-27	-0.58	-0.5	Iron status biomarkers;	chr6:25886693	chr6:25992662~26001775:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	12.5	3.94e-31	1.53e-27	0.55	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
HNSC	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	12.5	3.98e-31	1.54e-27	0.56	0.5	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-12.5	4.03e-31	1.56e-27	-0.75	-0.5	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
HNSC	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-12.5	4.06e-31	1.57e-27	-0.47	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
HNSC	cis	rs875971	0.862	rs6460290	ENSG00000179406.6	LINC00174	12.5	4.06e-31	1.57e-27	0.67	0.5	Aortic root size;	chr7:66344119	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-12.5	4.12e-31	1.6e-27	-0.57	-0.5	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-12.5	4.12e-31	1.6e-27	-0.57	-0.5	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	12.5	4.13e-31	1.6e-27	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	12.5	4.13e-31	1.6e-27	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
HNSC	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-12.49	4.53e-31	1.75e-27	-0.61	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	12.48	4.59e-31	1.77e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	12.48	4.67e-31	1.8e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	12.48	4.71e-31	1.81e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
HNSC	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	12.48	4.74e-31	1.82e-27	0.48	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
HNSC	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-12.48	4.81e-31	1.85e-27	-0.93	-0.5	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-12.48	4.91e-31	1.89e-27	-0.57	-0.5	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-12.47	5.06e-31	1.95e-27	-0.57	-0.5	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-12.47	5.06e-31	1.95e-27	-0.57	-0.5	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-12.47	5.39e-31	2.07e-27	-0.58	-0.5	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-12.47	5.4e-31	2.08e-27	-0.95	-0.5	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
HNSC	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	12.47	5.47e-31	2.1e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
HNSC	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-12.47	5.48e-31	2.1e-27	-0.52	-0.5	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-12.46	5.56e-31	2.13e-27	-0.95	-0.5	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
HNSC	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	12.46	5.56e-31	2.14e-27	0.61	0.5	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	12.46	5.79e-31	2.22e-27	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	12.46	5.91e-31	2.26e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	12.46	5.96e-31	2.28e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
HNSC	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-12.45	6.17e-31	2.36e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
HNSC	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	12.45	6.34e-31	2.42e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
HNSC	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	12.45	6.46e-31	2.47e-27	0.56	0.5	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	12.45	6.61e-31	2.52e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
HNSC	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-12.44	6.71e-31	2.56e-27	-0.57	-0.5	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
HNSC	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	12.44	6.98e-31	2.66e-27	0.62	0.5	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-12.44	6.98e-31	2.66e-27	-0.62	-0.5	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
HNSC	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	12.44	7.11e-31	2.71e-27	0.62	0.5	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
HNSC	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-12.43	7.31e-31	2.78e-27	-0.53	-0.5	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	12.43	7.41e-31	2.81e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
HNSC	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	12.43	7.7e-31	2.93e-27	0.4	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
HNSC	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-12.43	7.71e-31	2.93e-27	-0.57	-0.5	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-12.43	7.71e-31	2.93e-27	-0.57	-0.5	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-12.43	7.71e-31	2.93e-27	-0.57	-0.5	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
HNSC	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-12.43	7.93e-31	3.01e-27	-0.57	-0.5	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	12.42	8.25e-31	3.13e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
HNSC	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	12.42	8.7e-31	3.29e-27	0.62	0.5	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	12.42	8.72e-31	3.3e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
HNSC	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	12.41	8.83e-31	3.34e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	12.41	9.24e-31	3.49e-27	0.53	0.5	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
HNSC	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	12.41	9.36e-31	3.54e-27	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
HNSC	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	12.4	9.68e-31	3.65e-27	0.56	0.5	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
HNSC	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	12.4	9.83e-31	3.71e-27	0.6	0.5	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs7809814	ENSG00000179406.6	LINC00174	12.4	1.01e-30	3.8e-27	0.67	0.5	Aortic root size;	chr7:66150410	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12537823	ENSG00000179406.6	LINC00174	-12.4	1.02e-30	3.83e-27	-0.67	-0.5	Aortic root size;	chr7:66255897	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	12.4	1.02e-30	3.86e-27	0.64	0.5	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
HNSC	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-12.39	1.11e-30	4.17e-27	-0.65	-0.5	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
HNSC	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	12.39	1.13e-30	4.24e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-12.38	1.19e-30	4.47e-27	-0.52	-0.5	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	12.38	1.23e-30	4.61e-27	0.64	0.5	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	12.38	1.27e-30	4.75e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
HNSC	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	12.38	1.27e-30	4.76e-27	0.62	0.5	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	12.37	1.28e-30	4.82e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	12.37	1.3e-30	4.86e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-12.37	1.35e-30	5.05e-27	-0.9	-0.5	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-12.37	1.39e-30	5.21e-27	-0.93	-0.5	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	12.37	1.39e-30	5.21e-27	0.75	0.5	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.756	rs4718328	ENSG00000179406.6	LINC00174	12.37	1.39e-30	5.21e-27	0.67	0.5	Aortic root size;	chr7:66228350	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4718330	ENSG00000179406.6	LINC00174	12.37	1.39e-30	5.21e-27	0.67	0.5	Aortic root size;	chr7:66250256	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	12.37	1.39e-30	5.21e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
HNSC	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	12.35	1.55e-30	5.8e-27	0.61	0.5	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
HNSC	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	12.35	1.57e-30	5.87e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	12.35	1.58e-30	5.88e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs778734	ENSG00000179406.6	LINC00174	-12.35	1.6e-30	5.96e-27	-0.67	-0.5	Aortic root size;	chr7:66349862	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	12.35	1.64e-30	6.12e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	12.35	1.66e-30	6.2e-27	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
HNSC	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	12.34	1.75e-30	6.51e-27	0.64	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	12.34	1.79e-30	6.64e-27	0.6	0.5	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	12.34	1.82e-30	6.75e-27	0.75	0.5	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	12.33	1.9e-30	7.07e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	12.33	1.98e-30	7.35e-27	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	12.33	1.98e-30	7.36e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
HNSC	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	12.33	1.99e-30	7.38e-27	0.61	0.5	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
HNSC	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	12.33	1.99e-30	7.38e-27	0.58	0.5	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
HNSC	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-12.33	2.01e-30	7.46e-27	-0.52	-0.5	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
HNSC	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-12.33	2.04e-30	7.57e-27	-0.93	-0.5	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	12.32	2.08e-30	7.71e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	12.32	2.09e-30	7.73e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	12.32	2.1e-30	7.77e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	12.32	2.1e-30	7.77e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
HNSC	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	12.32	2.11e-30	7.79e-27	0.96	0.5	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs10282433	ENSG00000179406.6	LINC00174	12.32	2.13e-30	7.89e-27	0.67	0.5	Aortic root size;	chr7:66256452	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	12.32	2.18e-30	8.05e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	12.32	2.18e-30	8.05e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	12.32	2.2e-30	8.12e-27	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
HNSC	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	12.31	2.25e-30	8.31e-27	0.62	0.5	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
HNSC	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	12.31	2.26e-30	8.35e-27	0.57	0.5	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
HNSC	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	12.31	2.29e-30	8.45e-27	0.57	0.5	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-12.31	2.33e-30	8.59e-27	-0.95	-0.5	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	12.3	2.48e-30	9.14e-27	0.64	0.49	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
HNSC	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-12.3	2.63e-30	9.7e-27	-0.57	-0.49	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-12.3	2.65e-30	9.77e-27	-0.93	-0.49	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	12.29	2.8e-30	1.03e-26	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	12.29	2.8e-30	1.03e-26	0.57	0.49	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	12.29	2.8e-30	1.03e-26	0.57	0.49	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
HNSC	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-12.29	2.85e-30	1.05e-26	-0.92	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-12.29	2.85e-30	1.05e-26	-0.92	-0.49	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	12.29	2.88e-30	1.06e-26	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
HNSC	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-12.28	3.08e-30	1.13e-26	-0.55	-0.49	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
HNSC	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	12.28	3.08e-30	1.13e-26	0.57	0.49	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	12.28	3.08e-30	1.13e-26	0.57	0.49	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	12.28	3.08e-30	1.13e-26	0.57	0.49	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-12.28	3.11e-30	1.14e-26	-0.63	-0.49	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
HNSC	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-12.28	3.24e-30	1.19e-26	-0.9	-0.49	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
HNSC	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-12.27	3.34e-30	1.22e-26	-0.61	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
HNSC	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	12.27	3.38e-30	1.23e-26	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	12.27	3.54e-30	1.29e-26	0.75	0.49	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs4149461	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66279745	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4236208	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66284091	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10261398	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66285177	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10224872	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66294786	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.928	rs2036263	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66335210	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10240949	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66339430	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7782704	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66340379	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6959268	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66347979	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	12.27	3.58e-30	1.31e-26	0.49	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	12.27	3.58e-30	1.31e-26	0.49	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
HNSC	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-12.26	3.72e-30	1.35e-26	-0.6	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.893	rs62465470	ENSG00000179406.6	LINC00174	12.26	3.82e-30	1.39e-26	0.67	0.49	Aortic root size;	chr7:66136231	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4368860	ENSG00000179406.6	LINC00174	12.26	3.82e-30	1.39e-26	0.67	0.49	Aortic root size;	chr7:66143495	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	12.26	3.83e-30	1.39e-26	0.63	0.49	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
HNSC	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	12.25	3.96e-30	1.44e-26	0.48	0.49	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
HNSC	cis	rs875971	0.862	rs10276077	ENSG00000179406.6	LINC00174	12.25	3.97e-30	1.44e-26	0.66	0.49	Aortic root size;	chr7:66263424	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	12.25	3.97e-30	1.44e-26	0.57	0.49	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	12.25	3.97e-30	1.44e-26	0.57	0.49	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-12.25	4.01e-30	1.46e-26	-0.95	-0.49	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.825	rs4587224	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66271195	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.792	rs6971752	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66272999	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10950033	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66274686	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs11760844	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66274896	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs949930	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66301835	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	12.25	4.09e-30	1.48e-26	0.94	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	12.25	4.11e-30	1.49e-26	0.78	0.49	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
HNSC	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-12.25	4.21e-30	1.53e-26	-0.57	-0.49	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs1000464	ENSG00000179406.6	LINC00174	12.25	4.26e-30	1.55e-26	0.67	0.49	Aortic root size;	chr7:66312922	chr7:66376044~66401338:-
HNSC	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	12.25	4.28e-30	1.55e-26	0.61	0.49	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	12.24	4.36e-30	1.58e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	12.24	4.45e-30	1.61e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	12.24	4.56e-30	1.65e-26	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
HNSC	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-12.23	4.79e-30	1.73e-26	-0.66	-0.49	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	12.23	4.88e-30	1.77e-26	0.65	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
HNSC	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-12.23	5.07e-30	1.83e-26	-0.52	-0.49	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-12.23	5.07e-30	1.83e-26	-0.52	-0.49	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-12.23	5.07e-30	1.83e-26	-0.52	-0.49	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	12.22	5.59e-30	2.02e-26	0.6	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
HNSC	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	12.22	5.67e-30	2.05e-26	0.61	0.49	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
HNSC	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	12.22	5.67e-30	2.05e-26	0.61	0.49	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
HNSC	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-12.21	5.88e-30	2.12e-26	-0.52	-0.49	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-12.21	5.88e-30	2.12e-26	-0.52	-0.49	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
HNSC	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	12.21	6.08e-30	2.19e-26	0.67	0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	12.21	6.18e-30	2.23e-26	0.56	0.49	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-12.21	6.27e-30	2.26e-26	-0.58	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	12.2	6.58e-30	2.37e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
HNSC	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	12.2	6.68e-30	2.4e-26	0.48	0.49	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
HNSC	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-12.2	6.71e-30	2.41e-26	-0.52	-0.49	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	12.19	6.99e-30	2.51e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-12.19	7.1e-30	2.55e-26	-0.47	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
HNSC	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	12.19	7.29e-30	2.62e-26	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-12.18	7.75e-30	2.78e-26	-0.74	-0.49	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs778720	ENSG00000179406.6	LINC00174	12.18	7.79e-30	2.8e-26	0.65	0.49	Aortic root size;	chr7:66381288	chr7:66376044~66401338:-
HNSC	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-12.18	7.97e-30	2.86e-26	-0.51	-0.49	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
HNSC	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	12.18	7.97e-30	2.86e-26	0.54	0.49	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	12.17	8.51e-30	3.05e-26	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
HNSC	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	12.17	8.98e-30	3.22e-26	0.61	0.49	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
HNSC	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	12.16	9.41e-30	3.37e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
HNSC	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	12.16	9.54e-30	3.41e-26	0.61	0.49	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.895	rs6460278	ENSG00000179406.6	LINC00174	12.15	1.03e-29	3.7e-26	0.67	0.49	Aortic root size;	chr7:66197749	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6460279	ENSG00000179406.6	LINC00174	12.15	1.03e-29	3.7e-26	0.67	0.49	Aortic root size;	chr7:66197774	chr7:66376044~66401338:-
HNSC	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-12.15	1.04e-29	3.71e-26	-0.56	-0.49	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
HNSC	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	12.15	1.04e-29	3.73e-26	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-12.15	1.06e-29	3.78e-26	-0.61	-0.49	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
HNSC	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
HNSC	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-12.14	1.14e-29	4.07e-26	-0.59	-0.49	Height;	chr11:118703207	chr11:118704607~118750263:+
HNSC	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-12.14	1.14e-29	4.08e-26	-0.52	-0.49	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	12.14	1.16e-29	4.13e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
HNSC	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-12.14	1.17e-29	4.18e-26	-0.56	-0.49	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
HNSC	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-12.13	1.2e-29	4.28e-26	-0.52	-0.49	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	12.13	1.3e-29	4.62e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-12.12	1.32e-29	4.7e-26	-0.52	-0.49	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
HNSC	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	12.12	1.34e-29	4.77e-26	0.71	0.49	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
HNSC	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-12.12	1.38e-29	4.92e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
HNSC	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-12.11	1.46e-29	5.19e-26	-0.64	-0.49	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	12.11	1.48e-29	5.24e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	12.11	1.52e-29	5.38e-26	0.57	0.49	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	12.11	1.57e-29	5.58e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-12.1	1.65e-29	5.84e-26	-0.64	-0.49	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	12.1	1.68e-29	5.95e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs28491091	ENSG00000179406.6	LINC00174	12.09	1.74e-29	6.18e-26	0.66	0.49	Aortic root size;	chr7:66204077	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-12.09	1.78e-29	6.29e-26	-0.59	-0.49	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.861	rs801215	ENSG00000179406.6	LINC00174	12.09	1.8e-29	6.37e-26	0.66	0.49	Aortic root size;	chr7:66546951	chr7:66376044~66401338:-
HNSC	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-12.09	1.81e-29	6.42e-26	-0.59	-0.49	Height;	chr11:118703185	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-12.09	1.81e-29	6.42e-26	-0.59	-0.49	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
HNSC	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	12.09	1.85e-29	6.53e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-12.08	2.01e-29	7.08e-26	-0.96	-0.49	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
HNSC	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-12.08	2.05e-29	7.25e-26	-0.56	-0.49	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
HNSC	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	12.07	2.1e-29	7.42e-26	0.68	0.49	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
HNSC	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	12.07	2.16e-29	7.61e-26	0.61	0.49	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-12.07	2.18e-29	7.67e-26	-0.72	-0.49	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs6964437	ENSG00000179406.6	LINC00174	12.07	2.23e-29	7.84e-26	0.66	0.49	Aortic root size;	chr7:66221457	chr7:66376044~66401338:-
HNSC	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	12.07	2.23e-29	7.84e-26	0.61	0.49	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	12.07	2.23e-29	7.84e-26	0.61	0.49	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
HNSC	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	12.07	2.25e-29	7.93e-26	0.6	0.49	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
HNSC	cis	rs17270561	0.779	rs78589800	ENSG00000272462.2	U91328.19	-12.07	2.26e-29	7.95e-26	-0.58	-0.49	Iron status biomarkers;	chr6:25883272	chr6:25992662~26001775:+
HNSC	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-12.07	2.27e-29	8e-26	-0.56	-0.49	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
HNSC	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	12.07	2.28e-29	8.01e-26	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-12.06	2.35e-29	8.28e-26	-0.56	-0.49	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
HNSC	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-12.06	2.37e-29	8.33e-26	-0.52	-0.49	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	12.06	2.39e-29	8.41e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	12.06	2.41e-29	8.46e-26	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	12.06	2.52e-29	8.85e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	12.05	2.54e-29	8.9e-26	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
HNSC	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	12.05	2.58e-29	9.04e-26	0.52	0.49	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs11765791	ENSG00000179406.6	LINC00174	-12.05	2.6e-29	9.13e-26	-0.66	-0.49	Aortic root size;	chr7:66471587	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-12.05	2.67e-29	9.35e-26	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
HNSC	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	12.05	2.74e-29	9.6e-26	0.6	0.49	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	12.05	2.74e-29	9.61e-26	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
HNSC	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	12.04	2.78e-29	9.71e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-12.04	2.86e-29	1e-25	-0.57	-0.49	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-12.04	2.89e-29	1.01e-25	-0.56	-0.49	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	12.04	2.9e-29	1.01e-25	0.56	0.49	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	12.04	2.91e-29	1.02e-25	0.66	0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	12.04	2.97e-29	1.04e-25	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	12.04	2.98e-29	1.04e-25	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.895	rs4145009	ENSG00000179406.6	LINC00174	12.03	3.04e-29	1.06e-25	0.67	0.49	Aortic root size;	chr7:66261628	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6952182	ENSG00000179406.6	LINC00174	12.03	3.11e-29	1.09e-25	0.66	0.49	Aortic root size;	chr7:66218330	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	12.03	3.12e-29	1.09e-25	0.66	0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	12.03	3.14e-29	1.1e-25	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs1612452	ENSG00000179406.6	LINC00174	12.03	3.2e-29	1.12e-25	0.66	0.49	Aortic root size;	chr7:66108909	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1167390	ENSG00000179406.6	LINC00174	12.03	3.27e-29	1.14e-25	0.66	0.49	Aortic root size;	chr7:66110906	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs35034167	ENSG00000179406.6	LINC00174	12.03	3.27e-29	1.14e-25	0.66	0.49	Aortic root size;	chr7:66115179	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-12.03	3.33e-29	1.16e-25	-0.61	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-12.03	3.33e-29	1.16e-25	-0.52	-0.49	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-12.02	3.37e-29	1.17e-25	-0.46	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-12.02	3.37e-29	1.17e-25	-0.46	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-12.02	3.4e-29	1.18e-25	-0.46	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
HNSC	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-12.02	3.56e-29	1.24e-25	-0.56	-0.49	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-12.02	3.56e-29	1.24e-25	-0.56	-0.49	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
HNSC	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-12.02	3.56e-29	1.24e-25	-0.56	-0.49	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
HNSC	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-12.02	3.57e-29	1.24e-25	-0.52	-0.49	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-12.02	3.64e-29	1.27e-25	-0.52	-0.49	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-12.02	3.64e-29	1.27e-25	-0.52	-0.49	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-12.01	3.71e-29	1.29e-25	-0.51	-0.49	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.798	rs12698522	ENSG00000179406.6	LINC00174	-12.01	3.94e-29	1.37e-25	-0.65	-0.49	Aortic root size;	chr7:66502354	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	12	4.13e-29	1.43e-25	0.64	0.49	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
HNSC	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-12	4.14e-29	1.44e-25	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
HNSC	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-12	4.18e-29	1.45e-25	-0.61	-0.49	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-12	4.18e-29	1.45e-25	-0.61	-0.49	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-12	4.18e-29	1.45e-25	-0.61	-0.49	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
HNSC	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-11.99	4.4e-29	1.53e-25	-1.19	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.83	rs28714531	ENSG00000179406.6	LINC00174	-11.99	4.66e-29	1.62e-25	-0.65	-0.49	Aortic root size;	chr7:66503250	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12698526	ENSG00000179406.6	LINC00174	-11.99	4.66e-29	1.62e-25	-0.65	-0.49	Aortic root size;	chr7:66504118	chr7:66376044~66401338:-
HNSC	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	11.99	4.68e-29	1.62e-25	0.47	0.49	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
HNSC	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-11.98	4.86e-29	1.68e-25	-0.51	-0.48	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
HNSC	cis	rs17270561	0.541	rs2009610	ENSG00000272462.2	U91328.19	-11.98	5.01e-29	1.73e-25	-0.61	-0.48	Iron status biomarkers;	chr6:25966840	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.862	rs2460432	ENSG00000179406.6	LINC00174	11.98	5.07e-29	1.75e-25	0.67	0.48	Aortic root size;	chr7:66089398	chr7:66376044~66401338:-
HNSC	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	11.97	5.71e-29	1.97e-25	0.96	0.48	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-11.97	5.78e-29	1.99e-25	-0.51	-0.48	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
HNSC	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	11.96	5.98e-29	2.06e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
HNSC	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	11.95	6.66e-29	2.29e-25	0.6	0.48	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
HNSC	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	11.94	7.01e-29	2.41e-25	0.54	0.48	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs6460282	ENSG00000179406.6	LINC00174	11.94	7.03e-29	2.42e-25	0.65	0.48	Aortic root size;	chr7:66226259	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000179406.6	LINC00174	11.94	7.24e-29	2.49e-25	0.64	0.48	Aortic root size;	chr7:66221942	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-11.93	7.69e-29	2.64e-25	-0.59	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-11.93	7.82e-29	2.69e-25	-0.52	-0.48	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	11.93	8.06e-29	2.76e-25	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
HNSC	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-11.93	8.38e-29	2.87e-25	-0.56	-0.48	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-11.92	8.54e-29	2.93e-25	-0.56	-0.48	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-11.92	8.54e-29	2.93e-25	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	11.92	8.92e-29	3.05e-25	0.54	0.48	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
HNSC	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-11.92	8.95e-29	3.06e-25	-0.57	-0.48	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
HNSC	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	11.91	9.2e-29	3.15e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	11.91	9.2e-29	3.15e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs28470208	ENSG00000179406.6	LINC00174	11.91	9.25e-29	3.17e-25	0.66	0.48	Aortic root size;	chr7:66119713	chr7:66376044~66401338:-
HNSC	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-11.91	9.25e-29	3.17e-25	-0.59	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
HNSC	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	11.91	9.5e-29	3.25e-25	0.96	0.48	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	11.9	1.02e-28	3.5e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
HNSC	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	11.9	1.03e-28	3.5e-25	0.56	0.48	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-11.89	1.16e-28	3.94e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-11.89	1.16e-28	3.95e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
HNSC	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-11.89	1.18e-28	4.02e-25	-0.57	-0.48	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
HNSC	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	11.89	1.18e-28	4.03e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	11.88	1.22e-28	4.14e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs13232191	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66521661	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs35378740	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66522725	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10950043	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66523623	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs17747530	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66529742	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs13226170	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66534311	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2420611	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66534333	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.767	rs61348003	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66540947	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.756	rs2901210	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66552518	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs13536	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66554203	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801209	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66554403	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801206	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66556979	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801204	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66557934	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801203	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66558025	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs801202	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66558942	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801195	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66561128	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	11.88	1.3e-28	4.38e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	11.88	1.3e-28	4.4e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-11.88	1.32e-28	4.45e-25	-0.55	-0.48	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-11.88	1.32e-28	4.45e-25	-0.55	-0.48	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	11.88	1.32e-28	4.45e-25	0.66	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-11.87	1.38e-28	4.67e-25	-0.69	-0.48	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
HNSC	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-11.87	1.41e-28	4.75e-25	-0.56	-0.48	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-11.87	1.42e-28	4.8e-25	-0.56	-0.48	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	11.87	1.43e-28	4.8e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-11.87	1.43e-28	4.83e-25	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-11.87	1.45e-28	4.87e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-11.86	1.48e-28	4.97e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
HNSC	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	11.86	1.5e-28	5.06e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
HNSC	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-11.86	1.51e-28	5.07e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
HNSC	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-11.86	1.53e-28	5.16e-25	-0.51	-0.48	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	11.86	1.58e-28	5.32e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	11.86	1.58e-28	5.32e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
HNSC	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	11.85	1.61e-28	5.4e-25	0.62	0.48	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
HNSC	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-11.85	1.61e-28	5.4e-25	-0.55	-0.48	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460307	ENSG00000179406.6	LINC00174	-11.85	1.61e-28	5.41e-25	-0.65	-0.48	Aortic root size;	chr7:66595884	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	11.85	1.68e-28	5.63e-25	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
HNSC	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	11.85	1.71e-28	5.75e-25	0.65	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	11.85	1.71e-28	5.75e-25	0.65	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
HNSC	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	11.85	1.73e-28	5.79e-25	0.58	0.48	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-11.85	1.74e-28	5.85e-25	-0.58	-0.48	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	11.84	1.75e-28	5.87e-25	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	11.84	1.76e-28	5.91e-25	0.78	0.48	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-11.84	1.85e-28	6.22e-25	-0.84	-0.48	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	11.84	1.87e-28	6.28e-25	0.53	0.48	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	11.84	1.89e-28	6.34e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-11.83	1.92e-28	6.44e-25	-0.56	-0.48	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000179406.6	LINC00174	-11.83	1.94e-28	6.48e-25	-0.65	-0.48	Aortic root size;	chr7:66376625	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs778711	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66386670	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1083554	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66387354	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778707	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66392040	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778705	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66396128	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778697	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66405439	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.798	rs7789615	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66413674	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6978028	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66421313	chr7:66376044~66401338:-
HNSC	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-11.83	2e-28	6.67e-25	-0.55	-0.48	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
HNSC	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	11.83	2.01e-28	6.72e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
HNSC	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-11.82	2.1e-28	7.03e-25	-0.8	-0.48	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs7783779	ENSG00000179406.6	LINC00174	11.82	2.12e-28	7.07e-25	0.65	0.48	Aortic root size;	chr7:66331639	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-11.82	2.17e-28	7.24e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	11.82	2.21e-28	7.37e-25	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
HNSC	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-11.82	2.22e-28	7.4e-25	-0.64	-0.48	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
HNSC	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-11.82	2.25e-28	7.49e-25	-0.51	-0.48	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	11.81	2.33e-28	7.76e-25	0.62	0.48	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-11.81	2.41e-28	8.02e-25	-0.6	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	11.81	2.45e-28	8.15e-25	0.56	0.48	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	11.81	2.45e-28	8.15e-25	0.56	0.48	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	11.79	2.78e-28	9.23e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	11.79	2.81e-28	9.33e-25	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
HNSC	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-11.79	2.87e-28	9.49e-25	-0.5	-0.48	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	11.79	2.92e-28	9.65e-25	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
HNSC	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-11.79	2.97e-28	9.81e-25	-0.51	-0.48	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
HNSC	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-11.78	3.05e-28	1.01e-24	-0.63	-0.48	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.767	rs12668005	ENSG00000179406.6	LINC00174	-11.78	3.08e-28	1.02e-24	-0.65	-0.48	Aortic root size;	chr7:66444034	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	11.78	3.14e-28	1.04e-24	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.825	rs6951503	ENSG00000179406.6	LINC00174	11.77	3.35e-28	1.1e-24	0.65	0.48	Aortic root size;	chr7:66253949	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	11.77	3.44e-28	1.13e-24	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	11.77	3.44e-28	1.13e-24	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-11.77	3.44e-28	1.13e-24	-0.58	-0.48	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.862	rs801194	ENSG00000179406.6	LINC00174	11.77	3.48e-28	1.14e-24	0.65	0.48	Aortic root size;	chr7:66563508	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2024192	ENSG00000179406.6	LINC00174	11.77	3.48e-28	1.14e-24	0.65	0.48	Aortic root size;	chr7:66576460	chr7:66376044~66401338:-
HNSC	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-11.77	3.51e-28	1.15e-24	-0.84	-0.48	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	11.77	3.58e-28	1.17e-24	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	11.76	3.78e-28	1.24e-24	0.46	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	11.76	3.78e-28	1.24e-24	0.46	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.825	rs59466412	ENSG00000179406.6	LINC00174	11.76	3.8e-28	1.25e-24	0.66	0.48	Aortic root size;	chr7:66100371	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	11.76	3.82e-28	1.25e-24	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	11.76	3.82e-28	1.25e-24	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.88e-28	1.27e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.91e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.91e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.92e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.92e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
HNSC	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-11.76	3.97e-28	1.3e-24	-0.52	-0.48	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
HNSC	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-11.75	3.99e-28	1.3e-24	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-11.75	3.99e-28	1.3e-24	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
HNSC	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	11.75	4.01e-28	1.31e-24	0.6	0.48	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
HNSC	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	11.75	4.09e-28	1.33e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
HNSC	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	11.75	4.1e-28	1.34e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	11.75	4.1e-28	1.34e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	11.75	4.1e-28	1.34e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
HNSC	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	11.75	4.16e-28	1.36e-24	0.51	0.48	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
HNSC	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-11.75	4.23e-28	1.38e-24	-0.72	-0.48	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
HNSC	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-11.75	4.34e-28	1.41e-24	-0.51	-0.48	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
HNSC	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	11.74	4.41e-28	1.44e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000179406.6	LINC00174	11.74	4.44e-28	1.45e-24	0.65	0.48	Aortic root size;	chr7:66345205	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000179406.6	LINC00174	11.74	4.49e-28	1.46e-24	0.64	0.48	Aortic root size;	chr7:66658097	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6947339	ENSG00000179406.6	LINC00174	-11.74	4.69e-28	1.52e-24	-0.65	-0.48	Aortic root size;	chr7:66423483	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	11.74	4.77e-28	1.55e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
HNSC	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	11.73	4.81e-28	1.56e-24	0.79	0.48	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
HNSC	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	11.73	4.82e-28	1.57e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
HNSC	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-11.73	4.92e-28	1.6e-24	-0.91	-0.48	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	11.73	5e-28	1.63e-24	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
HNSC	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-11.73	5.12e-28	1.66e-24	-0.59	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs778736	ENSG00000179406.6	LINC00174	-11.73	5.17e-28	1.68e-24	-0.65	-0.48	Aortic root size;	chr7:66348861	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.79	rs10257911	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66278783	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7796162	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66280771	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66325720	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66330724	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66331087	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66343621	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	11.73	5.18e-28	1.68e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	11.73	5.18e-28	1.68e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	11.73	5.18e-28	1.68e-24	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.755	rs76288834	ENSG00000179406.6	LINC00174	11.72	5.36e-28	1.74e-24	0.65	0.48	Aortic root size;	chr7:66604815	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6971059	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66602045	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.789	rs7808013	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66606209	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs7384021	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66612917	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs66981195	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66614048	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs3926380	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66615658	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.789	rs10260426	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66271055	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2901152	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66300017	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10263690	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66301466	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10250544	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66301574	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs12531677	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66304099	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7798630	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66306492	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.755	rs10228885	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66315542	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6958294	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66329809	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-11.71	5.89e-28	1.9e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs11984115	ENSG00000179406.6	LINC00174	11.71	5.95e-28	1.92e-24	0.65	0.48	Aortic root size;	chr7:66308872	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	11.71	5.96e-28	1.92e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	11.71	5.98e-28	1.93e-24	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	11.71	6.15e-28	1.98e-24	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66735006	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66735318	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66736127	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66737884	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66744266	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66752983	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66753209	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66758701	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-11.7	6.45e-28	2.07e-24	-0.55	-0.48	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1167408	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66091121	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs1167406	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66091949	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs709609	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66095574	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1167399	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66096890	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs57866200	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66100405	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-11.69	7.05e-28	2.25e-24	-0.56	-0.48	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.18e-28	2.29e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.18e-28	2.29e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.18e-28	2.29e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.31e-28	2.33e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.31e-28	2.33e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.35e-28	2.34e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-11.69	7.39e-28	2.36e-24	-0.55	-0.48	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	11.69	7.41e-28	2.36e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
HNSC	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-11.69	7.44e-28	2.37e-24	-0.54	-0.48	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs1968126	ENSG00000179406.6	LINC00174	11.69	7.54e-28	2.4e-24	0.64	0.48	Aortic root size;	chr7:66592017	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	11.68	7.62e-28	2.43e-24	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	11.68	8e-28	2.54e-24	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-11.68	8e-28	2.54e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-11.68	8.21e-28	2.61e-24	-0.55	-0.48	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-11.68	8.21e-28	2.61e-24	-0.55	-0.48	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	11.67	8.28e-28	2.63e-24	0.57	0.48	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-11.67	8.38e-28	2.66e-24	-0.56	-0.48	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	11.67	8.41e-28	2.67e-24	0.44	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs6955837	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66578155	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs10281499	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66583979	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4718377	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66584691	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10278014	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66586277	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-11.67	8.5e-28	2.7e-24	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.825	rs1860472	ENSG00000179406.6	LINC00174	11.67	8.84e-28	2.8e-24	0.65	0.48	Aortic root size;	chr7:66617736	chr7:66376044~66401338:-
HNSC	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66651104	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs881285	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66654433	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66655048	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66656082	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66656898	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66657397	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000179406.6	LINC00174	-11.67	9.01e-28	2.84e-24	-0.64	-0.48	Aortic root size;	chr7:66695835	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.591	rs721717	ENSG00000179406.6	LINC00174	11.67	9.01e-28	2.84e-24	0.64	0.48	Aortic root size;	chr7:66665305	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000179406.6	LINC00174	11.67	9.01e-28	2.84e-24	0.64	0.48	Aortic root size;	chr7:66667525	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000179406.6	LINC00174	11.67	9.01e-28	2.84e-24	0.64	0.48	Aortic root size;	chr7:66670470	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	11.67	9.01e-28	2.85e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-11.66	9.44e-28	2.98e-24	-0.54	-0.47	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	11.66	9.62e-28	3.03e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	11.66	9.75e-28	3.07e-24	0.59	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs6460306	ENSG00000179406.6	LINC00174	11.66	9.8e-28	3.08e-24	0.64	0.47	Aortic root size;	chr7:66595806	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000179406.6	LINC00174	-11.65	9.93e-28	3.12e-24	-0.64	-0.47	Aortic root size;	chr7:66713338	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000179406.6	LINC00174	-11.65	9.93e-28	3.12e-24	-0.64	-0.47	Aortic root size;	chr7:66716086	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000179406.6	LINC00174	-11.65	9.93e-28	3.12e-24	-0.64	-0.47	Aortic root size;	chr7:66724256	chr7:66376044~66401338:-
HNSC	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-11.65	1.01e-27	3.17e-24	-0.9	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	11.65	1.04e-27	3.25e-24	0.62	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
HNSC	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	11.65	1.07e-27	3.35e-24	0.56	0.47	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	11.65	1.08e-27	3.39e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	11.65	1.08e-27	3.39e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
HNSC	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-11.64	1.1e-27	3.46e-24	-0.59	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
HNSC	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-11.64	1.13e-27	3.56e-24	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
HNSC	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	11.64	1.16e-27	3.64e-24	0.59	0.47	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
HNSC	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-11.62	1.38e-27	4.32e-24	-0.56	-0.47	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-11.62	1.38e-27	4.32e-24	-0.56	-0.47	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000179406.6	LINC00174	-11.62	1.39e-27	4.34e-24	-0.64	-0.47	Aortic root size;	chr7:66699045	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000179406.6	LINC00174	-11.62	1.39e-27	4.34e-24	-0.64	-0.47	Aortic root size;	chr7:66701485	chr7:66376044~66401338:-
HNSC	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-11.62	1.4e-27	4.37e-24	-0.89	-0.47	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
HNSC	cis	rs17270561	0.887	rs717551	ENSG00000272462.2	U91328.19	-11.62	1.4e-27	4.38e-24	-0.6	-0.47	Iron status biomarkers;	chr6:25855396	chr6:25992662~26001775:+
HNSC	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	11.62	1.41e-27	4.39e-24	0.58	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
HNSC	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	11.61	1.44e-27	4.47e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	11.61	1.44e-27	4.47e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	11.61	1.44e-27	4.47e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-11.61	1.5e-27	4.66e-24	-0.55	-0.47	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-11.61	1.5e-27	4.66e-24	-0.55	-0.47	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-11.61	1.5e-27	4.66e-24	-0.55	-0.47	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	11.61	1.51e-27	4.7e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	11.61	1.51e-27	4.7e-24	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-11.61	1.52e-27	4.72e-24	-0.93	-0.47	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	11.61	1.56e-27	4.83e-24	0.62	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	11.6	1.62e-27	5.04e-24	0.62	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	11.6	1.63e-27	5.06e-24	0.45	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-11.6	1.71e-27	5.29e-24	-0.62	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
HNSC	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	11.59	1.76e-27	5.46e-24	0.55	0.47	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	11.59	1.78e-27	5.5e-24	0.44	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-11.58	1.91e-27	5.91e-24	-0.55	-0.47	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-11.58	1.91e-27	5.91e-24	-0.55	-0.47	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1875057	ENSG00000179406.6	LINC00174	11.58	2e-27	6.16e-24	0.64	0.47	Aortic root size;	chr7:66266868	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6960446	ENSG00000179406.6	LINC00174	11.58	2e-27	6.16e-24	0.64	0.47	Aortic root size;	chr7:66268272	chr7:66376044~66401338:-
HNSC	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-11.58	2.02e-27	6.23e-24	-0.49	-0.47	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000179406.6	LINC00174	-11.58	2.03e-27	6.27e-24	-0.64	-0.47	Aortic root size;	chr7:66768636	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-11.57	2.19e-27	6.74e-24	-0.55	-0.47	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-11.57	2.19e-27	6.74e-24	-0.55	-0.47	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	11.57	2.22e-27	6.84e-24	0.53	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-11.56	2.26e-27	6.94e-24	-0.56	-0.47	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-11.56	2.26e-27	6.94e-24	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-11.56	2.27e-27	6.99e-24	-0.55	-0.47	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-11.56	2.32e-27	7.14e-24	-0.56	-0.47	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-11.56	2.32e-27	7.14e-24	-0.56	-0.47	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-11.56	2.32e-27	7.14e-24	-0.56	-0.47	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	11.56	2.41e-27	7.38e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
HNSC	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-11.56	2.44e-27	7.47e-24	-0.56	-0.47	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	11.55	2.46e-27	7.53e-24	0.55	0.47	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	11.55	2.49e-27	7.63e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
HNSC	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-11.55	2.49e-27	7.63e-24	-0.9	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-11.55	2.51e-27	7.69e-24	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
HNSC	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	11.55	2.66e-27	8.14e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
HNSC	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-11.55	2.69e-27	8.21e-24	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	11.54	2.69e-27	8.23e-24	0.56	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-11.54	2.73e-27	8.34e-24	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
HNSC	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-11.54	2.77e-27	8.44e-24	-0.5	-0.47	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
HNSC	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-11.54	2.92e-27	8.89e-24	-0.54	-0.47	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
HNSC	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-11.53	2.95e-27	8.99e-24	-0.61	-0.47	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-11.52	3.33e-27	1.01e-23	-0.89	-0.47	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	11.51	3.63e-27	1.1e-23	0.53	0.47	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-11.51	3.72e-27	1.13e-23	-0.55	-0.47	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-11.51	3.8e-27	1.15e-23	-0.55	-0.47	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	11.51	3.8e-27	1.15e-23	0.45	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	11.5	3.88e-27	1.17e-23	0.51	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-11.5	4.04e-27	1.22e-23	-0.52	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
HNSC	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-11.5	4.14e-27	1.25e-23	-0.5	-0.47	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
HNSC	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-11.49	4.27e-27	1.29e-23	-0.46	-0.47	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
HNSC	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-11.49	4.27e-27	1.29e-23	-0.55	-0.47	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
HNSC	cis	rs17270561	0.887	rs12201170	ENSG00000272462.2	U91328.19	-11.49	4.51e-27	1.36e-23	-0.6	-0.47	Iron status biomarkers;	chr6:25866019	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-11.49	4.56e-27	1.37e-23	-0.56	-0.47	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	11.48	4.72e-27	1.42e-23	0.55	0.47	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	11.48	4.8e-27	1.44e-23	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	11.48	4.94e-27	1.48e-23	0.56	0.47	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
HNSC	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	11.48	4.95e-27	1.49e-23	0.6	0.47	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
HNSC	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	11.48	4.95e-27	1.49e-23	0.88	0.47	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
HNSC	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	11.47	5.08e-27	1.52e-23	0.47	0.47	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
HNSC	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	11.47	5.21e-27	1.56e-23	0.52	0.47	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
HNSC	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-11.47	5.3e-27	1.59e-23	-0.48	-0.47	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
HNSC	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	11.47	5.37e-27	1.61e-23	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	11.47	5.37e-27	1.61e-23	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
HNSC	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	11.47	5.46e-27	1.63e-23	0.47	0.47	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
HNSC	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-11.46	5.66e-27	1.69e-23	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
HNSC	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	11.46	5.71e-27	1.71e-23	0.63	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
HNSC	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	11.46	5.72e-27	1.71e-23	0.76	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
HNSC	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	11.46	5.83e-27	1.74e-23	0.51	0.47	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
HNSC	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	11.46	5.95e-27	1.78e-23	0.47	0.47	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
HNSC	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	11.46	6.01e-27	1.79e-23	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
HNSC	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	11.45	6.21e-27	1.85e-23	0.61	0.47	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	11.45	6.45e-27	1.92e-23	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
HNSC	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-11.44	7.11e-27	2.12e-23	-0.55	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
HNSC	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-11.43	7.41e-27	2.2e-23	-0.5	-0.47	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
HNSC	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-11.43	7.59e-27	2.26e-23	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
HNSC	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-11.43	7.68e-27	2.28e-23	-0.44	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-11.43	7.73e-27	2.29e-23	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
HNSC	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-11.43	7.83e-27	2.32e-23	-0.85	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
HNSC	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-11.42	8.33e-27	2.47e-23	-0.59	-0.47	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	11.42	8.34e-27	2.47e-23	0.55	0.47	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
HNSC	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	11.42	8.6e-27	2.55e-23	0.51	0.47	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	11.42	8.61e-27	2.55e-23	0.53	0.47	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
HNSC	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	11.42	8.66e-27	2.56e-23	0.51	0.47	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
HNSC	cis	rs17270561	1	rs12211184	ENSG00000272462.2	U91328.19	-11.41	8.88e-27	2.63e-23	-0.58	-0.47	Iron status biomarkers;	chr6:25823546	chr6:25992662~26001775:+
HNSC	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-11.41	9e-27	2.66e-23	-0.5	-0.47	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
HNSC	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	11.41	9.25e-27	2.74e-23	0.49	0.47	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000179406.6	LINC00174	-11.41	9.45e-27	2.79e-23	-0.63	-0.47	Aortic root size;	chr7:66774601	chr7:66376044~66401338:-
HNSC	cis	rs17270561	1	rs79867288	ENSG00000272462.2	U91328.19	-11.41	9.46e-27	2.79e-23	-0.59	-0.47	Iron status biomarkers;	chr6:25828188	chr6:25992662~26001775:+
HNSC	cis	rs17270561	1	rs12200962	ENSG00000272462.2	U91328.19	-11.41	9.46e-27	2.79e-23	-0.59	-0.47	Iron status biomarkers;	chr6:25828758	chr6:25992662~26001775:+
HNSC	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-11.4	9.68e-27	2.86e-23	-0.58	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	11.4	9.8e-27	2.89e-23	0.59	0.47	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	11.4	9.94e-27	2.93e-23	0.59	0.47	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	11.4	9.98e-27	2.94e-23	0.57	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
HNSC	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	11.38	1.17e-26	3.44e-23	0.63	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.55	0.47	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
HNSC	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-11.38	1.22e-26	3.57e-23	-0.51	-0.47	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
HNSC	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-11.38	1.22e-26	3.59e-23	-0.51	-0.47	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
HNSC	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-11.37	1.24e-26	3.65e-23	-0.5	-0.47	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
HNSC	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-11.37	1.27e-26	3.73e-23	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
HNSC	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	11.37	1.29e-26	3.79e-23	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
HNSC	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	11.37	1.32e-26	3.87e-23	0.46	0.47	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
HNSC	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-11.37	1.33e-26	3.9e-23	-0.6	-0.47	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs4718383	ENSG00000179406.6	LINC00174	11.36	1.36e-26	3.98e-23	0.64	0.47	Aortic root size;	chr7:66643422	chr7:66376044~66401338:-
HNSC	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-11.36	1.38e-26	4.05e-23	-0.53	-0.47	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	11.36	1.4e-26	4.11e-23	0.55	0.47	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-11.36	1.47e-26	4.29e-23	-0.56	-0.47	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	11.36	1.49e-26	4.34e-23	0.55	0.47	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	11.36	1.49e-26	4.34e-23	0.55	0.47	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
HNSC	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-11.35	1.5e-26	4.38e-23	-0.6	-0.47	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
HNSC	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	11.35	1.51e-26	4.4e-23	0.48	0.47	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	11.35	1.52e-26	4.44e-23	0.55	0.47	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
HNSC	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-11.35	1.56e-26	4.56e-23	-0.53	-0.46	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
HNSC	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	11.35	1.61e-26	4.7e-23	0.49	0.46	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
HNSC	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-11.34	1.63e-26	4.75e-23	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
HNSC	cis	rs11650106	0.529	rs35391268	ENSG00000266992.1	DHX40P1	-11.33	1.92e-26	5.57e-23	-0.55	-0.46	Lipoprotein-associated phospholipase A2 activity and mass;	chr17:59692637	chr17:59976009~60002384:-
HNSC	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	11.31	2.13e-26	6.17e-23	0.51	0.46	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-11.31	2.19e-26	6.33e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
HNSC	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	11.31	2.22e-26	6.43e-23	0.59	0.46	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-11.31	2.22e-26	6.43e-23	-0.59	-0.46	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.825	rs28480509	ENSG00000179406.6	LINC00174	11.31	2.27e-26	6.56e-23	0.63	0.46	Aortic root size;	chr7:66634237	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs9791712	ENSG00000179406.6	LINC00174	11.31	2.27e-26	6.56e-23	0.63	0.46	Aortic root size;	chr7:66640176	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs9791713	ENSG00000179406.6	LINC00174	11.31	2.27e-26	6.56e-23	0.63	0.46	Aortic root size;	chr7:66640211	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	11.31	2.29e-26	6.62e-23	0.52	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
HNSC	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	11.3	2.34e-26	6.78e-23	1.05	0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-11.3	2.4e-26	6.94e-23	-0.55	-0.46	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-11.3	2.4e-26	6.94e-23	-0.55	-0.46	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-11.3	2.4e-26	6.94e-23	-0.55	-0.46	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-11.3	2.42e-26	7e-23	-0.53	-0.46	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-11.3	2.44e-26	7.03e-23	-0.55	-0.46	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-11.3	2.44e-26	7.03e-23	-0.55	-0.46	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
HNSC	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-11.3	2.47e-26	7.12e-23	-0.5	-0.46	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	11.29	2.58e-26	7.43e-23	0.44	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-11.29	2.68e-26	7.72e-23	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
HNSC	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	11.29	2.68e-26	7.72e-23	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
HNSC	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-11.29	2.76e-26	7.94e-23	-0.49	-0.46	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-11.29	2.77e-26	7.97e-23	-0.49	-0.46	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
HNSC	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	11.28	2.81e-26	8.07e-23	0.55	0.46	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
HNSC	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	11.28	2.81e-26	8.07e-23	0.58	0.46	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
HNSC	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-11.28	2.9e-26	8.33e-23	-0.53	-0.46	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-11.28	2.92e-26	8.38e-23	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	11.28	2.96e-26	8.48e-23	0.51	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
HNSC	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-11.28	2.96e-26	8.49e-23	-0.49	-0.46	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-11.28	2.96e-26	8.49e-23	-0.49	-0.46	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
HNSC	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.98e-26	8.53e-23	-0.58	-0.46	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	11.27	3.11e-26	8.9e-23	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
HNSC	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-11.27	3.16e-26	9.04e-23	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-11.27	3.16e-26	9.04e-23	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
HNSC	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-11.27	3.32e-26	9.5e-23	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	11.26	3.33e-26	9.53e-23	0.5	0.46	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
HNSC	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	11.26	3.51e-26	1e-22	0.63	0.46	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
HNSC	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.54e-26	1.01e-22	-0.58	-0.46	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	11.26	3.54e-26	1.01e-22	0.56	0.46	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	11.26	3.57e-26	1.02e-22	0.55	0.46	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	11.25	3.65e-26	1.04e-22	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	11.25	3.67e-26	1.05e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	11.25	3.67e-26	1.05e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	11.25	3.67e-26	1.05e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
HNSC	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	11.25	3.72e-26	1.06e-22	0.48	0.46	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
HNSC	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	11.25	3.74e-26	1.07e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	11.25	3.74e-26	1.07e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
HNSC	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-11.25	3.83e-26	1.09e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
HNSC	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-11.25	3.84e-26	1.09e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
HNSC	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-11.25	3.94e-26	1.12e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.04e-26	1.15e-22	-0.57	-0.46	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
HNSC	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	11.24	4.11e-26	1.17e-22	0.56	0.46	Height;	chr11:118758322	chr11:118704607~118750263:+
HNSC	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.12e-26	1.17e-22	-0.59	-0.46	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.32e-26	1.23e-22	-0.57	-0.46	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	11.24	4.34e-26	1.24e-22	0.56	0.46	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
HNSC	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-11.23	4.39e-26	1.25e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
HNSC	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-11.23	4.4e-26	1.25e-22	-0.56	-0.46	Height;	chr11:118760944	chr11:118704607~118750263:+
HNSC	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-11.23	4.42e-26	1.26e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
HNSC	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.44e-26	1.26e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.62e-26	1.31e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.62e-26	1.31e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	11.23	4.64e-26	1.32e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
HNSC	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.68e-26	1.33e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
HNSC	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-11.23	4.68e-26	1.33e-22	-0.53	-0.46	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
HNSC	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	11.22	4.9e-26	1.39e-22	0.55	0.46	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-11.22	4.92e-26	1.39e-22	-0.56	-0.46	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-11.22	5.08e-26	1.44e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-11.22	5.08e-26	1.44e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	11.22	5.18e-26	1.46e-22	0.55	0.46	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	11.21	5.23e-26	1.48e-22	0.5	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	11.21	5.34e-26	1.51e-22	0.51	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
HNSC	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-11.21	5.43e-26	1.53e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
HNSC	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	11.21	5.64e-26	1.59e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
HNSC	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-11.2	5.84e-26	1.65e-22	-0.49	-0.46	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
HNSC	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-11.2	5.96e-26	1.68e-22	-0.56	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
HNSC	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	11.2	5.97e-26	1.68e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	11.2	6.19e-26	1.74e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
HNSC	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	11.19	6.41e-26	1.8e-22	0.48	0.46	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
HNSC	cis	rs1865760	0.534	rs2032444	ENSG00000272462.2	U91328.19	-11.19	6.43e-26	1.81e-22	-0.48	-0.46	Height;	chr6:26046516	chr6:25992662~26001775:+
HNSC	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-11.19	6.45e-26	1.81e-22	-0.9	-0.46	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
HNSC	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-11.19	6.66e-26	1.87e-22	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-11.19	6.66e-26	1.87e-22	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
HNSC	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-11.18	7.02e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-11.18	7.32e-26	2.05e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
HNSC	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	11.18	7.32e-26	2.05e-22	0.48	0.46	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs1860469	ENSG00000179406.6	LINC00174	11.18	7.37e-26	2.06e-22	0.63	0.46	Aortic root size;	chr7:66641888	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-11.17	7.49e-26	2.1e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-11.17	7.49e-26	2.1e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
HNSC	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	11.17	7.62e-26	2.13e-22	0.5	0.46	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
HNSC	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	11.17	7.7e-26	2.15e-22	0.55	0.46	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-11.17	8.07e-26	2.26e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
HNSC	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-11.17	8.11e-26	2.27e-22	-0.53	-0.46	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
HNSC	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-11.16	8.21e-26	2.29e-22	-0.9	-0.46	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-11.16	8.21e-26	2.29e-22	-0.9	-0.46	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
HNSC	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	11.16	8.32e-26	2.33e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	11.16	8.32e-26	2.33e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
HNSC	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-11.16	8.36e-26	2.34e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	11.16	8.5e-26	2.37e-22	0.55	0.46	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-11.16	8.7e-26	2.43e-22	-0.56	-0.46	Height;	chr11:118737823	chr11:118704607~118750263:+
HNSC	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-11.16	8.77e-26	2.45e-22	-0.49	-0.46	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-11.16	8.82e-26	2.46e-22	-0.56	-0.46	Height;	chr11:118747911	chr11:118704607~118750263:+
HNSC	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-11.16	8.83e-26	2.46e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	11.15	8.89e-26	2.48e-22	0.54	0.46	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	11.15	8.89e-26	2.48e-22	0.54	0.46	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	11.15	8.89e-26	2.48e-22	0.54	0.46	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-11.15	8.89e-26	2.48e-22	-0.54	-0.46	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
HNSC	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	11.15	8.93e-26	2.49e-22	0.6	0.46	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	11.15	9.11e-26	2.54e-22	0.48	0.46	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
HNSC	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-11.15	9.12e-26	2.54e-22	-0.56	-0.46	Height;	chr11:118773873	chr11:118704607~118750263:+
HNSC	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-11.15	9.22e-26	2.57e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	11.15	9.26e-26	2.58e-22	0.55	0.46	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	11.15	9.46e-26	2.63e-22	0.5	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
HNSC	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	11.15	9.48e-26	2.64e-22	0.59	0.46	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
HNSC	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-11.15	9.51e-26	2.64e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-11.15	9.51e-26	2.64e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
HNSC	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	11.15	9.57e-26	2.66e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	11.14	9.81e-26	2.72e-22	0.55	0.46	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	11.14	9.92e-26	2.75e-22	0.56	0.46	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-11.14	9.98e-26	2.77e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	11.14	1.02e-25	2.84e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	11.14	1.02e-25	2.84e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
HNSC	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-11.14	1.03e-25	2.87e-22	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
HNSC	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	11.14	1.04e-25	2.89e-22	0.62	0.46	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-11.14	1.05e-25	2.91e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-11.14	1.05e-25	2.91e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
HNSC	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-11.13	1.09e-25	3.03e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
HNSC	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-11.13	1.13e-25	3.14e-22	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
HNSC	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	11.12	1.18e-25	3.26e-22	0.48	0.46	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	11.12	1.18e-25	3.27e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
HNSC	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	11.12	1.19e-25	3.29e-22	0.44	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
HNSC	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	11.11	1.28e-25	3.54e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
HNSC	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	11.11	1.28e-25	3.54e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	11.11	1.29e-25	3.57e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	11.11	1.3e-25	3.59e-22	0.54	0.46	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	11.11	1.3e-25	3.59e-22	0.54	0.46	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
HNSC	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-11.11	1.37e-25	3.78e-22	-0.49	-0.46	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
HNSC	cis	rs6867032	0.527	rs4975777	ENSG00000249731.1	RP11-259O2.3	-11.1	1.44e-25	3.97e-22	-0.63	-0.46	Gut microbiome composition (winter);	chr5:1973210	chr5:1968094~1969013:+
HNSC	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-11.1	1.45e-25	4e-22	-0.56	-0.46	Height;	chr11:118764443	chr11:118704607~118750263:+
HNSC	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	11.1	1.48e-25	4.08e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
HNSC	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-11.1	1.49e-25	4.11e-22	-0.48	-0.46	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-11.1	1.49e-25	4.11e-22	-0.48	-0.46	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	11.09	1.55e-25	4.27e-22	0.52	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
HNSC	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-11.08	1.7e-25	4.66e-22	-0.56	-0.46	Breast cancer;	chr11:825777	chr11:779617~780755:+
HNSC	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	11.08	1.78e-25	4.87e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
HNSC	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.85e-25	5.07e-22	-0.56	-0.46	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	11.07	1.86e-25	5.09e-22	0.54	0.46	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	11.07	1.86e-25	5.09e-22	0.54	0.46	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
HNSC	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.88e-25	5.15e-22	-0.57	-0.46	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-11.07	1.88e-25	5.15e-22	-0.62	-0.46	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	11.07	1.88e-25	5.16e-22	0.53	0.46	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.89e-25	5.16e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
HNSC	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-11.07	1.89e-25	5.17e-22	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
HNSC	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.94e-25	5.29e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.96e-25	5.36e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
HNSC	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-11.05	2.18e-25	5.95e-22	-0.56	-0.46	Height;	chr11:118761813	chr11:118704607~118750263:+
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-11.05	2.22e-25	6.04e-22	-0.54	-0.46	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-11.05	2.28e-25	6.22e-22	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
HNSC	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	11.05	2.3e-25	6.26e-22	0.61	0.46	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	11.04	2.36e-25	6.44e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-11.04	2.4e-25	6.54e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
HNSC	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-11.04	2.42e-25	6.59e-22	-0.46	-0.45	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-11.04	2.44e-25	6.65e-22	-0.54	-0.45	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-11.04	2.45e-25	6.68e-22	-0.56	-0.45	Height;	chr11:118746590	chr11:118704607~118750263:+
HNSC	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-11.04	2.49e-25	6.79e-22	-0.5	-0.45	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000179406.6	LINC00174	-11.04	2.51e-25	6.84e-22	-0.62	-0.45	Aortic root size;	chr7:66762495	chr7:66376044~66401338:-
HNSC	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-11.04	2.52e-25	6.85e-22	-0.55	-0.45	Height;	chr11:118737916	chr11:118704607~118750263:+
HNSC	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-11.03	2.57e-25	6.99e-22	-0.51	-0.45	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
HNSC	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-11.03	2.7e-25	7.35e-22	-0.49	-0.45	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
HNSC	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-11.03	2.75e-25	7.48e-22	-0.56	-0.45	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
HNSC	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-11.03	2.76e-25	7.51e-22	-0.56	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
HNSC	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-11.03	2.77e-25	7.52e-22	-0.48	-0.45	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
HNSC	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	11.02	2.82e-25	7.66e-22	0.44	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
HNSC	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	11.02	2.83e-25	7.69e-22	0.59	0.45	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
HNSC	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-11.02	2.83e-25	7.7e-22	-0.44	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
HNSC	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-11.02	2.89e-25	7.84e-22	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
HNSC	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-11.02	2.95e-25	7.99e-22	-0.56	-0.45	Height;	chr11:118742526	chr11:118704607~118750263:+
HNSC	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-11.02	2.99e-25	8.1e-22	-0.55	-0.45	Height;	chr11:118749988	chr11:118704607~118750263:+
HNSC	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-11.02	3e-25	8.13e-22	-0.52	-0.45	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
HNSC	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-11.02	3.03e-25	8.21e-22	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
HNSC	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	11.02	3.05e-25	8.26e-22	0.54	0.45	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-11.01	3.16e-25	8.55e-22	-0.5	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
HNSC	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	11.01	3.18e-25	8.61e-22	0.54	0.45	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	11.01	3.2e-25	8.65e-22	0.6	0.45	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	11.01	3.29e-25	8.89e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-11.01	3.32e-25	8.97e-22	-0.62	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
HNSC	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	11	3.35e-25	9.04e-22	0.48	0.45	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
HNSC	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-11	3.38e-25	9.12e-22	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	11	3.44e-25	9.28e-22	0.56	0.45	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	11	3.48e-25	9.39e-22	0.52	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	11	3.49e-25	9.43e-22	0.62	0.45	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	11	3.49e-25	9.43e-22	0.62	0.45	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
HNSC	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	11	3.52e-25	9.51e-22	0.52	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
HNSC	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	11	3.55e-25	9.57e-22	0.66	0.45	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
HNSC	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	11	3.62e-25	9.75e-22	0.63	0.45	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
HNSC	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	11	3.63e-25	9.79e-22	0.48	0.45	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
HNSC	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-11	3.63e-25	9.8e-22	-0.47	-0.45	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
HNSC	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	10.99	3.72e-25	1e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
HNSC	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	10.99	3.8e-25	1.02e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	10.99	3.8e-25	1.02e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	10.99	3.83e-25	1.03e-21	0.49	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-10.99	3.83e-25	1.03e-21	-0.54	-0.45	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-10.99	3.86e-25	1.04e-21	-0.54	-0.45	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	10.99	3.93e-25	1.06e-21	0.54	0.45	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
HNSC	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-10.99	3.98e-25	1.07e-21	-0.53	-0.45	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
HNSC	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-10.98	4.03e-25	1.08e-21	-0.57	-0.45	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-10.98	4.03e-25	1.08e-21	-0.57	-0.45	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
HNSC	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-10.98	4.04e-25	1.09e-21	-0.41	-0.45	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
HNSC	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	10.98	4.09e-25	1.1e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	10.98	4.25e-25	1.14e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
HNSC	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-10.98	4.26e-25	1.14e-21	-0.47	-0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
HNSC	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-10.98	4.29e-25	1.15e-21	-0.6	-0.45	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-10.98	4.35e-25	1.17e-21	-0.53	-0.45	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
HNSC	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-10.97	4.37e-25	1.17e-21	-0.49	-0.45	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-10.97	4.59e-25	1.23e-21	-0.48	-0.45	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
HNSC	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	10.96	4.76e-25	1.27e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-10.96	5.18e-25	1.38e-21	-0.53	-0.45	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	10.95	5.19e-25	1.39e-21	0.54	0.45	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	10.95	5.33e-25	1.42e-21	0.63	0.45	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	10.95	5.33e-25	1.42e-21	0.63	0.45	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
HNSC	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-10.95	5.35e-25	1.43e-21	-0.5	-0.45	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-10.95	5.37e-25	1.43e-21	-0.54	-0.45	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-10.95	5.4e-25	1.44e-21	-0.53	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
HNSC	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-10.95	5.4e-25	1.44e-21	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
HNSC	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-10.95	5.45e-25	1.45e-21	-0.57	-0.45	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
HNSC	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-10.95	5.49e-25	1.46e-21	-0.62	-0.45	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-10.95	5.5e-25	1.47e-21	-0.56	-0.45	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.672	rs2291248	ENSG00000279233.1	RP11-158L12.4	10.95	5.56e-25	1.48e-21	0.47	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125134762	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	10.95	5.58e-25	1.49e-21	0.51	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
HNSC	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	10.94	5.72e-25	1.52e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
HNSC	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	10.94	5.8e-25	1.54e-21	0.67	0.45	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	10.94	5.8e-25	1.54e-21	0.67	0.45	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	10.94	5.8e-25	1.54e-21	0.67	0.45	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
HNSC	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	10.94	5.81e-25	1.55e-21	0.58	0.45	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-10.94	5.91e-25	1.57e-21	-0.53	-0.45	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-10.94	5.91e-25	1.57e-21	-0.53	-0.45	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	10.94	5.96e-25	1.59e-21	0.53	0.45	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
HNSC	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-10.94	5.98e-25	1.59e-21	-0.54	-0.45	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
HNSC	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	10.93	6.28e-25	1.67e-21	0.48	0.45	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
HNSC	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-10.93	6.33e-25	1.68e-21	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-10.93	6.33e-25	1.68e-21	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	10.93	6.52e-25	1.73e-21	0.49	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
HNSC	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	10.92	6.77e-25	1.8e-21	0.5	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
HNSC	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	10.92	6.79e-25	1.8e-21	0.54	0.45	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	10.92	6.79e-25	1.8e-21	0.54	0.45	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
HNSC	cis	rs17270561	1	rs17270561	ENSG00000272462.2	U91328.19	10.92	6.81e-25	1.81e-21	0.53	0.45	Iron status biomarkers;	chr6:25820211	chr6:25992662~26001775:+
HNSC	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-10.92	6.9e-25	1.83e-21	-0.36	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
HNSC	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	10.92	7.01e-25	1.86e-21	0.48	0.45	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	10.92	7.06e-25	1.87e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	10.92	7.07e-25	1.87e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-10.92	7.09e-25	1.88e-21	-0.5	-0.45	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
HNSC	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-10.91	7.52e-25	1.99e-21	-0.56	-0.45	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	10.91	7.85e-25	2.08e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	10.9	8.39e-25	2.21e-21	0.5	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
HNSC	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	10.9	8.7e-25	2.29e-21	0.5	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
HNSC	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	10.9	8.7e-25	2.29e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
HNSC	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-10.9	8.75e-25	2.31e-21	-0.53	-0.45	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
HNSC	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	10.89	8.79e-25	2.32e-21	0.49	0.45	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	10.89	8.86e-25	2.33e-21	0.59	0.45	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-10.89	9.26e-25	2.43e-21	-0.53	-0.45	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
HNSC	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-10.89	9.3e-25	2.45e-21	-1.06	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	10.89	9.52e-25	2.5e-21	0.53	0.45	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	10.89	9.53e-25	2.5e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	10.89	9.53e-25	2.5e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	10.89	9.53e-25	2.5e-21	0.61	0.45	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	10.88	9.61e-25	2.53e-21	0.54	0.45	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
HNSC	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-10.88	9.71e-25	2.55e-21	-0.48	-0.45	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
HNSC	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	10.88	1e-24	2.64e-21	0.66	0.45	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-10.88	1.03e-24	2.69e-21	-0.54	-0.45	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	10.87	1.05e-24	2.75e-21	0.44	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
HNSC	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	10.87	1.05e-24	2.75e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	10.87	1.05e-24	2.75e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
HNSC	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	10.87	1.07e-24	2.79e-21	0.51	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
HNSC	cis	rs12931792	0.782	rs13331817	ENSG00000183604.13	SMG1P5	10.87	1.08e-24	2.83e-21	0.45	0.45	Tonsillectomy;	chr16:30161306	chr16:30267553~30335374:-
HNSC	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	10.86	1.17e-24	3.06e-21	0.47	0.45	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-10.86	1.18e-24	3.08e-21	-0.61	-0.45	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-10.86	1.21e-24	3.16e-21	-0.57	-0.45	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	10.86	1.22e-24	3.19e-21	0.52	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
HNSC	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-10.86	1.23e-24	3.21e-21	-0.5	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	10.85	1.26e-24	3.27e-21	0.54	0.45	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	10.85	1.26e-24	3.27e-21	0.54	0.45	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-10.85	1.26e-24	3.28e-21	-0.47	-0.45	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-10.85	1.27e-24	3.3e-21	-0.61	-0.45	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-10.85	1.27e-24	3.3e-21	-0.61	-0.45	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
HNSC	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-10.85	1.27e-24	3.31e-21	-0.47	-0.45	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	10.85	1.29e-24	3.37e-21	0.53	0.45	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
HNSC	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	10.85	1.31e-24	3.4e-21	0.61	0.45	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	10.85	1.34e-24	3.47e-21	0.53	0.45	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-10.85	1.34e-24	3.47e-21	-0.47	-0.45	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-10.85	1.34e-24	3.47e-21	-0.47	-0.45	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	10.85	1.34e-24	3.48e-21	0.58	0.45	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	10.85	1.35e-24	3.51e-21	0.54	0.45	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-10.84	1.36e-24	3.53e-21	-0.44	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
HNSC	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-10.84	1.41e-24	3.64e-21	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
HNSC	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	10.84	1.44e-24	3.73e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	10.84	1.44e-24	3.73e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
HNSC	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	10.84	1.45e-24	3.76e-21	0.45	0.45	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
HNSC	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	10.84	1.47e-24	3.8e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-10.84	1.47e-24	3.81e-21	-0.52	-0.45	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
HNSC	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-10.84	1.48e-24	3.82e-21	-0.47	-0.45	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-10.83	1.5e-24	3.89e-21	-0.56	-0.45	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	10.83	1.55e-24	4e-21	0.49	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
HNSC	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	10.83	1.56e-24	4.03e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-10.82	1.63e-24	4.22e-21	-0.56	-0.45	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	10.82	1.66e-24	4.27e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
HNSC	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-10.82	1.66e-24	4.27e-21	-0.46	-0.45	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	10.82	1.69e-24	4.36e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs12673450	ENSG00000179406.6	LINC00174	-10.81	1.78e-24	4.57e-21	-0.63	-0.45	Aortic root size;	chr7:66544233	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	10.81	1.81e-24	4.66e-21	0.59	0.45	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	10.81	1.81e-24	4.66e-21	0.59	0.45	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	10.81	1.82e-24	4.68e-21	0.5	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
HNSC	cis	rs6867032	0.527	rs4246752	ENSG00000249731.1	RP11-259O2.3	-10.81	1.82e-24	4.69e-21	-0.62	-0.45	Gut microbiome composition (winter);	chr5:1975461	chr5:1968094~1969013:+
HNSC	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	10.81	1.82e-24	4.69e-21	0.58	0.45	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	10.81	1.82e-24	4.69e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	10.81	1.82e-24	4.69e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	10.81	1.83e-24	4.71e-21	0.58	0.45	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-10.81	1.86e-24	4.78e-21	-0.46	-0.45	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-10.81	1.86e-24	4.78e-21	-0.46	-0.45	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-10.81	1.86e-24	4.78e-21	-0.46	-0.45	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-10.81	1.88e-24	4.83e-21	-0.47	-0.45	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	10.81	1.88e-24	4.84e-21	0.61	0.45	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-10.81	1.92e-24	4.92e-21	-0.47	-0.45	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-10.81	1.92e-24	4.92e-21	-0.47	-0.45	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	10.8	1.95e-24	5.01e-21	0.54	0.45	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
HNSC	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-10.8	1.96e-24	5.03e-21	-0.61	-0.45	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	10.8	1.97e-24	5.04e-21	0.58	0.45	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-10.8	1.98e-24	5.08e-21	-0.48	-0.45	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
HNSC	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-10.8	2e-24	5.12e-21	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-10.8	2.01e-24	5.15e-21	-0.59	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
HNSC	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-10.8	2.1e-24	5.37e-21	-0.48	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
HNSC	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	10.79	2.16e-24	5.53e-21	0.54	0.45	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
HNSC	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	10.79	2.16e-24	5.53e-21	0.56	0.45	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
HNSC	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-10.79	2.19e-24	5.61e-21	-0.47	-0.45	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-10.79	2.22e-24	5.66e-21	-0.57	-0.45	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	10.79	2.22e-24	5.68e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
HNSC	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	10.79	2.25e-24	5.73e-21	0.47	0.45	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-10.79	2.27e-24	5.79e-21	-0.47	-0.45	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
HNSC	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	10.79	2.28e-24	5.81e-21	0.6	0.45	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	10.79	2.28e-24	5.81e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	10.79	2.29e-24	5.83e-21	0.59	0.45	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-10.78	2.31e-24	5.9e-21	-0.47	-0.45	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-10.78	2.31e-24	5.9e-21	-0.47	-0.45	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-10.78	2.35e-24	6e-21	-0.61	-0.45	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	10.78	2.36e-24	6.01e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	10.78	2.38e-24	6.07e-21	0.53	0.45	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	10.78	2.38e-24	6.07e-21	0.53	0.45	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	10.78	2.39e-24	6.1e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	10.78	2.39e-24	6.1e-21	0.61	0.45	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-10.78	2.42e-24	6.17e-21	-0.55	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-10.78	2.42e-24	6.17e-21	-0.46	-0.45	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	10.78	2.46e-24	6.25e-21	0.6	0.45	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	10.77	2.53e-24	6.43e-21	0.61	0.45	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
HNSC	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	10.77	2.54e-24	6.47e-21	0.55	0.45	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
HNSC	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-10.77	2.6e-24	6.6e-21	-0.56	-0.45	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-10.77	2.6e-24	6.6e-21	-0.56	-0.45	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	10.77	2.63e-24	6.69e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	10.77	2.65e-24	6.73e-21	0.59	0.45	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-10.77	2.7e-24	6.86e-21	-0.47	-0.45	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	10.77	2.72e-24	6.9e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	10.76	2.73e-24	6.94e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-10.76	2.74e-24	6.96e-21	-0.53	-0.45	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
HNSC	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	10.76	2.82e-24	7.14e-21	0.47	0.45	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-10.76	2.86e-24	7.25e-21	-0.61	-0.45	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-10.76	2.86e-24	7.25e-21	-0.61	-0.45	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
HNSC	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-10.76	2.88e-24	7.29e-21	-0.47	-0.45	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	10.75	2.98e-24	7.56e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	10.75	3e-24	7.6e-21	0.42	0.45	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
HNSC	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-10.75	3.03e-24	7.67e-21	-0.49	-0.45	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
HNSC	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-10.75	3.1e-24	7.84e-21	-0.86	-0.45	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
HNSC	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-10.75	3.12e-24	7.89e-21	-0.56	-0.45	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
HNSC	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	10.75	3.14e-24	7.95e-21	0.64	0.45	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
HNSC	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-10.75	3.18e-24	8.04e-21	-0.55	-0.45	Height;	chr11:118791319	chr11:118704607~118750263:+
HNSC	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	10.75	3.2e-24	8.08e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	10.75	3.2e-24	8.08e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
HNSC	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-10.75	3.21e-24	8.11e-21	-0.57	-0.45	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	10.74	3.28e-24	8.29e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
HNSC	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-10.74	3.29e-24	8.29e-21	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	10.74	3.39e-24	8.54e-21	0.49	0.45	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
HNSC	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	10.74	3.53e-24	8.89e-21	0.67	0.44	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
HNSC	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-10.73	3.55e-24	8.94e-21	-0.59	-0.44	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	10.73	3.6e-24	9.07e-21	0.56	0.44	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-10.73	3.61e-24	9.09e-21	-0.6	-0.44	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
HNSC	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-10.73	3.67e-24	9.24e-21	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
HNSC	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	10.73	3.69e-24	9.29e-21	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-10.73	3.71e-24	9.34e-21	-0.49	-0.44	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
HNSC	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	10.73	3.79e-24	9.53e-21	0.47	0.44	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
HNSC	cis	rs1865760	0.622	rs9968910	ENSG00000272462.2	U91328.19	-10.73	3.8e-24	9.55e-21	-0.47	-0.44	Height;	chr6:26071867	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.622	rs10946807	ENSG00000272462.2	U91328.19	-10.73	3.8e-24	9.55e-21	-0.47	-0.44	Height;	chr6:26079410	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-10.72	3.88e-24	9.76e-21	-0.61	-0.44	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	10.72	3.95e-24	9.92e-21	0.61	0.44	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	10.72	3.95e-24	9.92e-21	0.61	0.44	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-10.72	4.11e-24	1.03e-20	-0.46	-0.44	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	10.72	4.12e-24	1.03e-20	0.57	0.44	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	10.71	4.22e-24	1.06e-20	0.46	0.44	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	10.71	4.25e-24	1.06e-20	0.46	0.44	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-10.71	4.41e-24	1.11e-20	-0.61	-0.44	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
HNSC	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-10.71	4.47e-24	1.12e-20	-0.56	-0.44	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
HNSC	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	10.71	4.47e-24	1.12e-20	0.46	0.44	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
HNSC	cis	rs34375054	0.672	rs2291247	ENSG00000279233.1	RP11-158L12.4	10.71	4.55e-24	1.14e-20	0.47	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125134407	chr12:125138245~125141711:+
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000179406.6	LINC00174	-10.7	4.65e-24	1.16e-20	-0.61	-0.44	Aortic root size;	chr7:66773096	chr7:66376044~66401338:-
HNSC	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-10.7	4.67e-24	1.17e-20	-0.6	-0.44	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
HNSC	cis	rs12216125	0.801	rs56107510	ENSG00000272462.2	U91328.19	-10.7	4.68e-24	1.17e-20	-0.47	-0.44	Iron status biomarkers;	chr6:25987208	chr6:25992662~26001775:+
HNSC	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	10.7	4.69e-24	1.17e-20	0.47	0.44	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
HNSC	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-10.7	4.72e-24	1.18e-20	-0.52	-0.44	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
HNSC	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-10.7	4.73e-24	1.18e-20	-0.61	-0.44	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	10.7	4.77e-24	1.19e-20	0.5	0.44	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
HNSC	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	10.7	4.82e-24	1.21e-20	0.55	0.44	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
HNSC	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	10.7	4.88e-24	1.22e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
HNSC	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	10.69	5.03e-24	1.25e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-10.69	5.19e-24	1.29e-20	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
HNSC	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	10.69	5.3e-24	1.32e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.47e-24	1.36e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.47e-24	1.36e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	10.68	5.48e-24	1.36e-20	0.49	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
HNSC	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	10.68	5.54e-24	1.38e-20	0.55	0.44	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-10.68	5.66e-24	1.41e-20	-0.61	-0.44	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
HNSC	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	10.68	5.72e-24	1.42e-20	0.46	0.44	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.74e-24	1.43e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
HNSC	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	10.68	5.88e-24	1.46e-20	0.4	0.44	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
HNSC	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.93e-24	1.48e-20	-0.56	-0.44	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
HNSC	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-10.67	6.08e-24	1.51e-20	-0.48	-0.44	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-10.67	6.08e-24	1.51e-20	-0.48	-0.44	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
HNSC	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	10.67	6.19e-24	1.53e-20	0.41	0.44	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
HNSC	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-10.67	6.32e-24	1.57e-20	-0.6	-0.44	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	10.67	6.35e-24	1.57e-20	0.6	0.44	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
HNSC	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	10.67	6.39e-24	1.58e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-10.67	6.4e-24	1.59e-20	-0.59	-0.44	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
HNSC	cis	rs6867032	0.527	rs1017924	ENSG00000249731.1	RP11-259O2.3	10.66	6.91e-24	1.71e-20	0.61	0.44	Gut microbiome composition (winter);	chr5:1976073	chr5:1968094~1969013:+
HNSC	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	10.66	6.92e-24	1.71e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
HNSC	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-10.66	7.05e-24	1.74e-20	-0.55	-0.44	Height;	chr11:118786602	chr11:118704607~118750263:+
HNSC	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-10.65	7.14e-24	1.76e-20	-0.48	-0.44	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
HNSC	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	10.65	7.28e-24	1.8e-20	0.85	0.44	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
HNSC	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-10.65	7.38e-24	1.82e-20	-0.53	-0.44	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
HNSC	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	10.65	7.41e-24	1.83e-20	0.55	0.44	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
HNSC	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-10.65	7.44e-24	1.83e-20	-0.59	-0.44	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-10.65	7.57e-24	1.87e-20	-0.61	-0.44	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
HNSC	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-10.65	7.64e-24	1.88e-20	-0.56	-0.44	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
HNSC	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-10.64	7.78e-24	1.92e-20	-0.6	-0.44	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
HNSC	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-10.64	7.92e-24	1.95e-20	-0.35	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-10.64	7.92e-24	1.95e-20	-0.35	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
HNSC	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	10.64	7.93e-24	1.95e-20	0.59	0.44	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
HNSC	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	10.64	7.99e-24	1.97e-20	0.48	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
HNSC	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-10.64	8.02e-24	1.98e-20	-0.46	-0.44	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-10.64	8.03e-24	1.98e-20	-0.6	-0.44	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
HNSC	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-10.64	8.23e-24	2.03e-20	-0.53	-0.44	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
HNSC	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	10.64	8.26e-24	2.03e-20	0.63	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	10.64	8.4e-24	2.07e-20	0.6	0.44	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-10.63	8.51e-24	2.09e-20	-0.59	-0.44	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
HNSC	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	10.63	8.54e-24	2.1e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
HNSC	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	10.63	8.71e-24	2.14e-20	0.43	0.44	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
HNSC	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-10.63	8.72e-24	2.14e-20	-0.35	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
HNSC	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
HNSC	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	10.63	8.95e-24	2.2e-20	0.43	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	10.63	8.97e-24	2.2e-20	0.61	0.44	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	10.63	8.97e-24	2.2e-20	0.61	0.44	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	10.63	8.97e-24	2.2e-20	0.61	0.44	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-10.63	8.98e-24	2.2e-20	-0.6	-0.44	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
HNSC	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-10.63	9.06e-24	2.22e-20	-0.55	-0.44	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	10.63	9.08e-24	2.23e-20	0.48	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
HNSC	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-10.63	9.18e-24	2.25e-20	-0.59	-0.44	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
HNSC	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	10.62	9.23e-24	2.26e-20	0.86	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	10.62	9.49e-24	2.32e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
HNSC	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	10.62	9.51e-24	2.33e-20	0.56	0.44	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
HNSC	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-10.62	9.55e-24	2.34e-20	-0.46	-0.44	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	10.62	9.64e-24	2.36e-20	0.6	0.44	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-10.62	9.72e-24	2.38e-20	-0.54	-0.44	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
HNSC	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	10.62	9.74e-24	2.38e-20	0.5	0.44	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
HNSC	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-10.62	9.95e-24	2.43e-20	-0.59	-0.44	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
HNSC	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	10.61	1e-23	2.45e-20	0.54	0.44	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
HNSC	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-10.61	1.01e-23	2.47e-20	-0.55	-0.44	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	10.61	1.03e-23	2.53e-20	0.6	0.44	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	10.61	1.07e-23	2.62e-20	0.4	0.44	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
HNSC	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-10.61	1.08e-23	2.64e-20	-0.56	-0.44	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
HNSC	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	10.61	1.09e-23	2.65e-20	0.6	0.44	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-10.6	1.12e-23	2.73e-20	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-10.6	1.15e-23	2.8e-20	-0.55	-0.44	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-10.6	1.15e-23	2.8e-20	-0.55	-0.44	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	10.59	1.21e-23	2.94e-20	0.6	0.44	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
HNSC	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.27e-23	3.08e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-10.59	1.27e-23	3.08e-20	-0.58	-0.44	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
HNSC	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-10.59	1.29e-23	3.14e-20	-0.59	-0.44	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	10.59	1.29e-23	3.14e-20	0.57	0.44	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
HNSC	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-10.59	1.29e-23	3.14e-20	-0.6	-0.44	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	10.58	1.3e-23	3.15e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	10.58	1.34e-23	3.26e-20	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
HNSC	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	10.58	1.35e-23	3.27e-20	0.53	0.44	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
HNSC	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-10.58	1.37e-23	3.33e-20	-0.55	-0.44	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
HNSC	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-10.58	1.38e-23	3.34e-20	-0.48	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
HNSC	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	10.58	1.38e-23	3.35e-20	0.6	0.44	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
HNSC	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	10.58	1.38e-23	3.36e-20	0.55	0.44	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
HNSC	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	10.58	1.4e-23	3.4e-20	0.62	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-10.57	1.44e-23	3.48e-20	-0.49	-0.44	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
HNSC	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
HNSC	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
HNSC	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
HNSC	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	10.57	1.49e-23	3.61e-20	0.48	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
HNSC	cis	rs6867032	0.834	rs10043083	ENSG00000249731.1	RP11-259O2.3	-10.57	1.5e-23	3.62e-20	-0.55	-0.44	Gut microbiome composition (winter);	chr5:1995573	chr5:1968094~1969013:+
HNSC	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	10.57	1.5e-23	3.63e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	10.57	1.5e-23	3.63e-20	0.53	0.44	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	10.57	1.5e-23	3.63e-20	0.53	0.44	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	10.57	1.5e-23	3.63e-20	0.53	0.44	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
HNSC	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-10.57	1.52e-23	3.67e-20	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
HNSC	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	10.57	1.53e-23	3.69e-20	0.86	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
HNSC	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	10.56	1.54e-23	3.73e-20	0.6	0.44	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	10.56	1.58e-23	3.81e-20	0.61	0.44	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-10.56	1.61e-23	3.88e-20	-0.58	-0.44	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
HNSC	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-10.56	1.61e-23	3.89e-20	-0.53	-0.44	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
HNSC	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	10.56	1.62e-23	3.9e-20	0.6	0.44	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-10.55	1.69e-23	4.06e-20	-0.6	-0.44	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
HNSC	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-10.55	1.69e-23	4.07e-20	-0.59	-0.44	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-10.55	1.69e-23	4.07e-20	-0.58	-0.44	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
HNSC	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	10.55	1.7e-23	4.09e-20	0.85	0.44	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
HNSC	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	10.55	1.73e-23	4.14e-20	0.63	0.44	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
HNSC	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-10.55	1.73e-23	4.16e-20	-0.52	-0.44	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
HNSC	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-10.55	1.74e-23	4.17e-20	-0.55	-0.44	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-10.55	1.74e-23	4.18e-20	-0.6	-0.44	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
HNSC	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	10.55	1.75e-23	4.19e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	10.55	1.76e-23	4.21e-20	0.57	0.44	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	10.55	1.78e-23	4.27e-20	0.61	0.44	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
HNSC	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	10.55	1.79e-23	4.29e-20	0.45	0.44	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-10.55	1.81e-23	4.33e-20	-0.54	-0.44	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-10.55	1.81e-23	4.33e-20	-0.54	-0.44	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000179406.6	LINC00174	10.55	1.81e-23	4.34e-20	0.55	0.44	Aortic root size;	chr7:66622178	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000179406.6	LINC00174	10.55	1.81e-23	4.34e-20	0.55	0.44	Aortic root size;	chr7:66622208	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	10.55	1.82e-23	4.37e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	10.55	1.82e-23	4.37e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	10.55	1.82e-23	4.37e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
HNSC	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-10.55	1.83e-23	4.37e-20	-0.48	-0.44	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
HNSC	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-10.54	1.85e-23	4.43e-20	-0.55	-0.44	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	10.54	1.87e-23	4.47e-20	0.6	0.44	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	10.54	1.87e-23	4.48e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
HNSC	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	10.54	1.89e-23	4.53e-20	0.58	0.44	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000179406.6	LINC00174	-10.54	1.93e-23	4.62e-20	-0.55	-0.44	Aortic root size;	chr7:66519618	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000179406.6	LINC00174	-10.54	1.93e-23	4.62e-20	-0.55	-0.44	Aortic root size;	chr7:66521858	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	10.54	1.98e-23	4.73e-20	0.6	0.44	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	10.53	2e-23	4.77e-20	0.58	0.44	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-10.53	2.03e-23	4.84e-20	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000179406.6	LINC00174	-10.53	2.03e-23	4.86e-20	-0.55	-0.44	Aortic root size;	chr7:66542376	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs801217	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66545590	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs801216	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66546680	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs801211	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66550702	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs801205	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66557157	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.617	rs810400	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66557902	chr7:66376044~66401338:-
HNSC	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-10.53	2.06e-23	4.91e-20	-0.58	-0.44	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	10.53	2.07e-23	4.95e-20	0.6	0.44	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	10.53	2.07e-23	4.95e-20	0.6	0.44	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	10.53	2.07e-23	4.95e-20	0.6	0.44	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	10.53	2.08e-23	4.96e-20	0.45	0.44	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	10.53	2.11e-23	5.03e-20	0.53	0.44	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
HNSC	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	10.53	2.14e-23	5.11e-20	0.49	0.44	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	10.53	2.14e-23	5.11e-20	0.49	0.44	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
HNSC	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-10.52	2.17e-23	5.18e-20	-0.58	-0.44	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000179406.6	LINC00174	-10.52	2.18e-23	5.19e-20	-0.55	-0.44	Aortic root size;	chr7:66540031	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000179406.6	LINC00174	-10.52	2.18e-23	5.19e-20	-0.55	-0.44	Aortic root size;	chr7:66540165	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
HNSC	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	10.52	2.21e-23	5.25e-20	0.6	0.44	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
HNSC	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-10.52	2.22e-23	5.27e-20	-0.52	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
HNSC	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.22e-23	5.27e-20	-0.55	-0.44	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	10.52	2.25e-23	5.35e-20	0.45	0.44	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
HNSC	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.31e-23	5.48e-20	-0.55	-0.44	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-10.52	2.35e-23	5.58e-20	-0.58	-0.44	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
HNSC	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-10.51	2.4e-23	5.7e-20	-0.41	-0.44	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
HNSC	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	10.51	2.44e-23	5.78e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	10.51	2.47e-23	5.86e-20	0.54	0.44	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-10.51	2.52e-23	5.97e-20	-0.58	-0.44	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
HNSC	cis	rs1865760	0.534	rs72834629	ENSG00000272462.2	U91328.19	-10.51	2.55e-23	6.04e-20	-0.46	-0.44	Height;	chr6:26022804	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	10.51	2.55e-23	6.04e-20	0.41	0.44	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	10.51	2.55e-23	6.05e-20	0.58	0.44	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	10.5	2.61e-23	6.19e-20	0.58	0.44	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-10.5	2.67e-23	6.32e-20	-0.58	-0.44	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
HNSC	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	10.5	2.79e-23	6.59e-20	0.6	0.44	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	10.5	2.79e-23	6.6e-20	0.58	0.44	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	10.5	2.81e-23	6.64e-20	0.58	0.44	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
HNSC	cis	rs6867032	0.695	rs3902820	ENSG00000249731.1	RP11-259O2.3	-10.49	2.9e-23	6.86e-20	-0.55	-0.44	Gut microbiome composition (winter);	chr5:2000216	chr5:1968094~1969013:+
HNSC	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	10.49	2.91e-23	6.87e-20	0.6	0.44	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	10.49	3.03e-23	7.16e-20	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	10.48	3.08e-23	7.28e-20	0.59	0.44	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
HNSC	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	10.48	3.09e-23	7.29e-20	0.35	0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
HNSC	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.16e-23	7.46e-20	-0.55	-0.44	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.19e-23	7.51e-20	-0.55	-0.44	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.19e-23	7.51e-20	-0.55	-0.44	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	10.48	3.2e-23	7.54e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
HNSC	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.21e-23	7.56e-20	-0.54	-0.44	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	10.48	3.21e-23	7.57e-20	0.41	0.44	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
HNSC	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-10.48	3.22e-23	7.59e-20	-0.53	-0.44	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
HNSC	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	10.48	3.24e-23	7.63e-20	0.4	0.44	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
HNSC	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	10.48	3.27e-23	7.71e-20	0.73	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
HNSC	cis	rs6952407	1	rs6952407	ENSG00000179406.6	LINC00174	10.48	3.31e-23	7.79e-20	0.55	0.44	Cotinine glucuronidation;	chr7:66580525	chr7:66376044~66401338:-
HNSC	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-10.48	3.32e-23	7.82e-20	-0.58	-0.44	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
HNSC	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-10.48	3.33e-23	7.84e-20	-0.58	-0.44	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-10.47	3.42e-23	8.04e-20	-0.6	-0.44	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	10.47	3.42e-23	8.04e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	10.47	3.42e-23	8.04e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-10.47	3.44e-23	8.09e-20	-0.55	-0.44	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	10.47	3.49e-23	8.2e-20	0.59	0.44	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	10.47	3.49e-23	8.2e-20	0.59	0.44	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	10.47	3.49e-23	8.21e-20	0.45	0.44	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	10.47	3.57e-23	8.38e-20	0.87	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	10.47	3.58e-23	8.41e-20	0.57	0.44	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	10.47	3.61e-23	8.48e-20	0.49	0.44	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
HNSC	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-10.47	3.62e-23	8.5e-20	-0.55	-0.44	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
HNSC	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	10.46	3.66e-23	8.59e-20	0.46	0.44	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
HNSC	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	10.46	3.67e-23	8.61e-20	0.45	0.44	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	10.46	3.7e-23	8.68e-20	0.59	0.44	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	10.46	3.7e-23	8.68e-20	0.57	0.44	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
HNSC	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
HNSC	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	10.46	3.74e-23	8.77e-20	0.84	0.44	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-10.46	3.75e-23	8.78e-20	-0.58	-0.44	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	10.46	3.8e-23	8.91e-20	0.6	0.44	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	10.46	3.82e-23	8.95e-20	0.6	0.44	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	10.46	3.82e-23	8.95e-20	0.6	0.44	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	10.46	3.82e-23	8.95e-20	0.6	0.44	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
HNSC	cis	rs801193	1	rs2707856	ENSG00000179406.6	LINC00174	-10.46	3.82e-23	8.95e-20	-0.55	-0.44	Aortic root size;	chr7:66746023	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000179406.6	LINC00174	10.46	3.83e-23	8.97e-20	0.55	0.44	Aortic root size;	chr7:66619753	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	10.46	3.83e-23	8.97e-20	0.6	0.44	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	10.46	3.83e-23	8.97e-20	0.6	0.44	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	10.46	3.84e-23	9e-20	0.5	0.44	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
HNSC	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	10.46	3.85e-23	9.01e-20	0.45	0.44	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.86e-23	9.05e-20	-0.53	-0.44	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.93e-23	9.2e-20	-0.54	-0.44	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.93e-23	9.2e-20	-0.54	-0.44	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	10.45	3.96e-23	9.26e-20	0.55	0.44	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
HNSC	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	10.45	4e-23	9.36e-20	0.5	0.44	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
HNSC	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	10.45	4.07e-23	9.51e-20	0.58	0.44	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
HNSC	cis	rs7615952	0.8	rs11915699	ENSG00000241288.6	RP11-379B18.5	-10.45	4.07e-23	9.52e-20	-0.62	-0.44	Blood pressure (smoking interaction);	chr3:125913841	chr3:125827238~125916384:-
HNSC	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	10.45	4.09e-23	9.56e-20	0.5	0.44	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
HNSC	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	10.45	4.12e-23	9.62e-20	0.6	0.44	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-10.45	4.22e-23	9.86e-20	-0.57	-0.44	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-10.45	4.25e-23	9.92e-20	-0.54	-0.44	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	10.45	4.26e-23	9.95e-20	0.45	0.44	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	10.45	4.27e-23	9.97e-20	0.6	0.44	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-10.45	4.31e-23	1e-19	-0.54	-0.44	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	10.44	4.32e-23	1.01e-19	0.6	0.44	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	10.44	4.33e-23	1.01e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
HNSC	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	10.44	4.36e-23	1.02e-19	0.41	0.44	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
HNSC	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	10.44	4.38e-23	1.02e-19	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
HNSC	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	10.44	4.39e-23	1.02e-19	0.58	0.44	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	10.44	4.4e-23	1.02e-19	0.59	0.44	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	10.44	4.4e-23	1.02e-19	0.59	0.44	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
HNSC	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	10.44	4.47e-23	1.04e-19	0.6	0.44	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	10.44	4.47e-23	1.04e-19	0.6	0.44	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-10.44	4.52e-23	1.05e-19	-0.54	-0.43	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
HNSC	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	10.44	4.57e-23	1.06e-19	0.53	0.43	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
HNSC	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-10.44	4.59e-23	1.06e-19	-0.58	-0.43	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
HNSC	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	10.44	4.62e-23	1.07e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
HNSC	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-10.44	4.63e-23	1.07e-19	-0.35	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
HNSC	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	10.44	4.63e-23	1.07e-19	0.54	0.43	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
HNSC	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	10.44	4.63e-23	1.07e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
HNSC	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.72e-23	1.09e-19	-0.55	-0.43	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	10.43	4.77e-23	1.1e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
HNSC	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	10.43	4.85e-23	1.12e-19	0.54	0.43	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
HNSC	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.92e-23	1.13e-19	-0.54	-0.43	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.92e-23	1.13e-19	-0.54	-0.43	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.92e-23	1.13e-19	-0.54	-0.43	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
HNSC	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-10.43	4.98e-23	1.15e-19	-0.58	-0.43	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-10.43	4.98e-23	1.15e-19	-0.58	-0.43	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
HNSC	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-10.43	5.04e-23	1.16e-19	-0.53	-0.43	Height;	chr11:118808920	chr11:118704607~118750263:+
HNSC	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	10.43	5.06e-23	1.16e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
HNSC	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-10.42	5.13e-23	1.18e-19	-0.54	-0.43	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000179406.6	LINC00174	10.42	5.14e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66603522	chr7:66376044~66401338:-
HNSC	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	10.42	5.23e-23	1.2e-19	0.48	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
HNSC	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	10.42	5.31e-23	1.22e-19	0.57	0.43	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
HNSC	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	10.42	5.38e-23	1.24e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	10.42	5.38e-23	1.24e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
HNSC	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-10.42	5.47e-23	1.26e-19	-0.54	-0.43	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	10.42	5.52e-23	1.27e-19	0.59	0.43	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-10.42	5.56e-23	1.28e-19	-0.55	-0.43	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	10.41	5.71e-23	1.31e-19	0.6	0.43	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66566965	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs801190	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66568046	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66571204	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66571411	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66572000	chr7:66376044~66401338:-
HNSC	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	10.41	5.92e-23	1.36e-19	0.45	0.43	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
HNSC	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	10.41	5.94e-23	1.36e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
HNSC	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-10.41	6.01e-23	1.38e-19	-0.58	-0.43	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
HNSC	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-10.41	6.05e-23	1.38e-19	-0.54	-0.43	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
HNSC	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	10.41	6.05e-23	1.38e-19	0.59	0.43	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	10.4	6.06e-23	1.39e-19	0.59	0.43	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
HNSC	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-10.4	6.08e-23	1.39e-19	-0.54	-0.43	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000179406.6	LINC00174	10.4	6.18e-23	1.41e-19	0.55	0.43	Aortic root size;	chr7:66606610	chr7:66376044~66401338:-
HNSC	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-10.4	6.19e-23	1.42e-19	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
HNSC	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	10.39	6.66e-23	1.52e-19	0.49	0.43	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
HNSC	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-10.39	6.66e-23	1.52e-19	-0.46	-0.43	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
HNSC	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-10.39	6.69e-23	1.53e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
HNSC	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	10.39	6.76e-23	1.54e-19	0.84	0.43	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	10.39	6.78e-23	1.55e-19	0.57	0.43	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	10.39	6.78e-23	1.55e-19	0.57	0.43	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-10.39	6.84e-23	1.56e-19	-0.53	-0.43	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
HNSC	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	10.38	7.29e-23	1.66e-19	0.56	0.43	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-10.38	7.3e-23	1.66e-19	-0.58	-0.43	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
HNSC	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	10.38	7.51e-23	1.71e-19	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	10.38	7.51e-23	1.71e-19	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	10.38	7.51e-23	1.71e-19	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
HNSC	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	10.38	7.54e-23	1.72e-19	0.59	0.43	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
HNSC	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-10.38	7.66e-23	1.75e-19	-0.54	-0.43	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
HNSC	cis	rs1865760	0.623	rs12216125	ENSG00000272462.2	U91328.19	-10.38	7.73e-23	1.76e-19	-0.45	-0.43	Height;	chr6:25997230	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-10.38	7.78e-23	1.77e-19	-0.56	-0.43	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
HNSC	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	10.38	7.82e-23	1.78e-19	0.55	0.43	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
HNSC	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-10.37	7.87e-23	1.79e-19	-0.58	-0.43	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	10.37	7.93e-23	1.81e-19	0.59	0.43	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000179406.6	LINC00174	10.37	7.96e-23	1.81e-19	0.55	0.43	Aortic root size;	chr7:66581737	chr7:66376044~66401338:-
HNSC	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	10.37	8.02e-23	1.83e-19	0.49	0.43	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	10.37	8.11e-23	1.84e-19	0.55	0.43	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	10.37	8.37e-23	1.9e-19	0.56	0.43	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	10.37	8.42e-23	1.91e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
HNSC	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	10.37	8.49e-23	1.93e-19	0.54	0.43	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
HNSC	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
HNSC	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-10.36	8.66e-23	1.96e-19	-0.46	-0.43	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
HNSC	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	10.36	8.69e-23	1.97e-19	0.48	0.43	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66749023	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2659889	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66752125	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs3800812	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66758474	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs4279493	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66761633	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-10.36	8.82e-23	1.99e-19	-0.59	-0.43	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000179406.6	LINC00174	-10.36	8.82e-23	1.99e-19	-0.55	-0.43	Aortic root size;	chr7:66765184	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	10.36	9.02e-23	2.03e-19	0.58	0.43	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
HNSC	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	10.36	9.14e-23	2.06e-19	0.84	0.43	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
HNSC	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	10.36	9.25e-23	2.08e-19	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
HNSC	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-10.36	9.27e-23	2.09e-19	-0.54	-0.43	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
HNSC	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-10.36	9.27e-23	2.09e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
HNSC	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	10.35	9.29e-23	2.09e-19	0.5	0.43	Depression;	chr6:28240757	chr6:28176188~28176674:+
HNSC	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	10.35	9.47e-23	2.13e-19	0.61	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
HNSC	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	10.35	9.49e-23	2.13e-19	0.4	0.43	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
HNSC	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	10.35	9.67e-23	2.17e-19	0.57	0.43	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.66	rs801193	ENSG00000179406.6	LINC00174	10.35	9.71e-23	2.18e-19	0.54	0.43	Aortic root size;	chr7:66565625	chr7:66376044~66401338:-
HNSC	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-10.35	9.71e-23	2.18e-19	-0.57	-0.43	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
HNSC	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	10.35	9.79e-23	2.2e-19	0.42	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
HNSC	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	10.35	9.79e-23	2.2e-19	0.4	0.43	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
HNSC	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	10.35	9.88e-23	2.22e-19	0.62	0.43	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
HNSC	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-10.35	9.89e-23	2.22e-19	-0.54	-0.43	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	10.35	1e-22	2.25e-19	0.58	0.43	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	10.35	1.01e-22	2.26e-19	0.4	0.43	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.686	rs12210098	ENSG00000272462.2	U91328.19	-10.34	1.02e-22	2.29e-19	-0.44	-0.43	Height;	chr6:25963738	chr6:25992662~26001775:+
HNSC	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	10.34	1.03e-22	2.3e-19	0.44	0.43	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
HNSC	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	10.34	1.03e-22	2.31e-19	0.84	0.43	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	10.34	1.03e-22	2.32e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000179406.6	LINC00174	10.34	1.04e-22	2.33e-19	0.54	0.43	Aortic root size;	chr7:66595421	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000179406.6	LINC00174	10.34	1.04e-22	2.33e-19	0.54	0.43	Aortic root size;	chr7:66598087	chr7:66376044~66401338:-
HNSC	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	10.34	1.04e-22	2.34e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000179406.6	LINC00174	10.34	1.06e-22	2.38e-19	0.54	0.43	Aortic root size;	chr7:66577454	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000179406.6	LINC00174	10.34	1.06e-22	2.38e-19	0.54	0.43	Aortic root size;	chr7:66577989	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000179406.6	LINC00174	10.34	1.06e-22	2.38e-19	0.54	0.43	Aortic root size;	chr7:66591816	chr7:66376044~66401338:-
HNSC	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-10.34	1.07e-22	2.39e-19	-0.53	-0.43	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
HNSC	cis	rs1823913	1	rs13019004	ENSG00000227542.1	AC092614.2	10.34	1.08e-22	2.41e-19	0.5	0.43	Obesity-related traits;	chr2:191245493	chr2:191229165~191246172:-
HNSC	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-10.34	1.08e-22	2.42e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
HNSC	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-10.34	1.08e-22	2.42e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
HNSC	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-10.34	1.08e-22	2.42e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-10.34	1.09e-22	2.45e-19	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.1e-22	2.47e-19	-0.54	-0.43	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.1e-22	2.47e-19	-0.54	-0.43	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.1e-22	2.47e-19	-0.54	-0.43	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	10.33	1.11e-22	2.5e-19	0.59	0.43	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-10.33	1.17e-22	2.62e-19	-0.44	-0.43	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
HNSC	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	10.33	1.17e-22	2.63e-19	0.42	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	10.33	1.19e-22	2.67e-19	0.58	0.43	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	10.33	1.19e-22	2.67e-19	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
HNSC	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	10.32	1.22e-22	2.73e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
HNSC	cis	rs4972806	0.849	rs2857535	ENSG00000226363.3	HAGLROS	-10.32	1.23e-22	2.75e-19	-0.51	-0.43	IgG glycosylation;	chr2:176171483	chr2:176177717~176179008:+
HNSC	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	10.32	1.23e-22	2.75e-19	0.57	0.43	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-10.32	1.25e-22	2.78e-19	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
HNSC	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	10.32	1.26e-22	2.8e-19	0.48	0.43	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
HNSC	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	10.32	1.27e-22	2.83e-19	0.84	0.43	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
HNSC	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	10.32	1.29e-22	2.87e-19	0.47	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	10.32	1.3e-22	2.89e-19	0.56	0.43	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	10.31	1.31e-22	2.91e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	10.31	1.31e-22	2.92e-19	0.59	0.43	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-10.31	1.32e-22	2.94e-19	-0.54	-0.43	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-10.31	1.32e-22	2.94e-19	-0.54	-0.43	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-10.31	1.32e-22	2.94e-19	-0.54	-0.43	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-10.31	1.39e-22	3.09e-19	-0.56	-0.43	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-10.31	1.39e-22	3.09e-19	-0.57	-0.43	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000179406.6	LINC00174	10.31	1.39e-22	3.09e-19	0.54	0.43	Aortic root size;	chr7:66589419	chr7:66376044~66401338:-
HNSC	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	10.31	1.39e-22	3.09e-19	0.48	0.43	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
HNSC	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-10.31	1.4e-22	3.11e-19	-0.56	-0.43	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000179406.6	LINC00174	10.31	1.41e-22	3.14e-19	0.54	0.43	Aortic root size;	chr7:66624003	chr7:66376044~66401338:-
HNSC	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-10.31	1.42e-22	3.15e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
HNSC	cis	rs801193	1	rs6958520	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66686466	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66687725	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66692033	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707836	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66695448	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs4717310	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66696020	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66696803	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs1553609	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66732152	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs1553610	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66732246	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707845	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66733811	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707850	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66738883	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66740595	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7783924	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66744070	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7789184	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66745208	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707854	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66747610	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66651646	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs6975195	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66659787	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs3857688	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66662819	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2286684	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66664843	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66664856	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs10274773	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66668591	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7785213	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66673991	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs11773829	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66676087	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66682191	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2003301	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66682669	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7788576	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66683315	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	10.3	1.44e-22	3.18e-19	0.57	0.43	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-10.3	1.45e-22	3.21e-19	-0.56	-0.43	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
HNSC	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-10.3	1.46e-22	3.23e-19	-0.59	-0.43	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	10.3	1.47e-22	3.26e-19	0.56	0.43	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
HNSC	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	10.3	1.48e-22	3.28e-19	0.61	0.43	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
HNSC	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	10.3	1.48e-22	3.29e-19	0.58	0.43	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	10.3	1.49e-22	3.29e-19	0.5	0.43	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
HNSC	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-10.3	1.49e-22	3.3e-19	-0.52	-0.43	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
HNSC	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-10.3	1.52e-22	3.36e-19	-0.45	-0.43	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
HNSC	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	10.3	1.53e-22	3.39e-19	0.86	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	10.29	1.56e-22	3.45e-19	0.54	0.43	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
HNSC	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-10.29	1.56e-22	3.46e-19	-0.53	-0.43	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-10.29	1.56e-22	3.46e-19	-0.53	-0.43	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-10.29	1.59e-22	3.51e-19	-0.47	-0.43	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
HNSC	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	10.29	1.59e-22	3.52e-19	0.5	0.43	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
HNSC	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	10.29	1.59e-22	3.52e-19	0.57	0.43	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
HNSC	cis	rs801193	1	rs2659912	ENSG00000179406.6	LINC00174	-10.29	1.6e-22	3.53e-19	-0.55	-0.43	Aortic root size;	chr7:66693012	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	10.29	1.64e-22	3.62e-19	0.55	0.43	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
HNSC	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	10.29	1.65e-22	3.65e-19	0.48	0.43	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
HNSC	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	10.28	1.7e-22	3.74e-19	0.57	0.43	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000179406.6	LINC00174	-10.28	1.71e-22	3.78e-19	-0.55	-0.43	Aortic root size;	chr7:66686365	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	10.28	1.72e-22	3.8e-19	0.55	0.43	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	10.28	1.72e-22	3.8e-19	0.55	0.43	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
HNSC	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-10.28	1.74e-22	3.84e-19	-0.59	-0.43	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	10.28	1.75e-22	3.86e-19	0.59	0.43	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	10.28	1.76e-22	3.89e-19	0.5	0.43	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
HNSC	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	10.28	1.76e-22	3.89e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
HNSC	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	10.28	1.8e-22	3.98e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000179406.6	LINC00174	10.28	1.81e-22	3.98e-19	0.54	0.43	Aortic root size;	chr7:66586553	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	10.28	1.82e-22	4e-19	0.61	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
HNSC	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	10.27	1.84e-22	4.06e-19	0.4	0.43	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
HNSC	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	10.27	1.86e-22	4.09e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
HNSC	cis	rs801193	1	rs4717319	ENSG00000179406.6	LINC00174	-10.27	1.87e-22	4.12e-19	-0.55	-0.43	Aortic root size;	chr7:66777606	chr7:66376044~66401338:-
HNSC	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	10.27	1.89e-22	4.16e-19	0.47	0.43	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
HNSC	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	10.27	1.91e-22	4.19e-19	0.58	0.43	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
HNSC	cis	rs2006771	0.846	rs6518754	ENSG00000236132.1	CTA-440B3.1	-10.27	1.91e-22	4.2e-19	-0.47	-0.43	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:31816379~31817491:-
HNSC	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.96e-22	4.3e-19	-0.53	-0.43	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.96e-22	4.3e-19	-0.53	-0.43	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000179406.6	LINC00174	-10.27	1.96e-22	4.3e-19	-0.55	-0.43	Aortic root size;	chr7:66777742	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	10.27	1.97e-22	4.33e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	10.26	2e-22	4.39e-19	0.59	0.43	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	10.26	2e-22	4.4e-19	0.54	0.43	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000179406.6	LINC00174	-10.26	2.01e-22	4.42e-19	-0.54	-0.43	Aortic root size;	chr7:66711400	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	10.26	2.02e-22	4.44e-19	0.56	0.43	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	10.26	2.02e-22	4.44e-19	0.57	0.43	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-10.26	2.04e-22	4.48e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
HNSC	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	10.26	2.04e-22	4.49e-19	0.52	0.43	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
HNSC	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	10.26	2.09e-22	4.59e-19	0.58	0.43	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	10.26	2.12e-22	4.66e-19	0.86	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
HNSC	cis	rs6867032	0.57	rs13166888	ENSG00000249731.1	RP11-259O2.3	-10.26	2.13e-22	4.69e-19	-0.59	-0.43	Gut microbiome composition (winter);	chr5:1982852	chr5:1968094~1969013:+
HNSC	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	10.26	2.14e-22	4.69e-19	0.57	0.43	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
HNSC	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	10.26	2.14e-22	4.71e-19	0.54	0.43	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
HNSC	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-10.26	2.15e-22	4.72e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-10.26	2.15e-22	4.72e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
HNSC	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-10.25	2.22e-22	4.86e-19	-0.45	-0.43	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
HNSC	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	10.25	2.25e-22	4.92e-19	0.6	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	10.25	2.25e-22	4.92e-19	0.6	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
HNSC	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-10.25	2.26e-22	4.95e-19	-0.53	-0.43	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
HNSC	cis	rs1933112	1	rs1024176	ENSG00000227777.1	RP4-738P11.3	-10.25	2.27e-22	4.96e-19	-0.48	-0.43	Blood protein levels;	chr1:168556865	chr1:168542737~168543354:+
HNSC	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	10.25	2.28e-22	4.99e-19	0.48	0.43	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
HNSC	cis	rs801193	1	rs2659906	ENSG00000179406.6	LINC00174	-10.25	2.28e-22	4.99e-19	-0.54	-0.43	Aortic root size;	chr7:66700323	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000179406.6	LINC00174	-10.25	2.28e-22	4.99e-19	-0.54	-0.43	Aortic root size;	chr7:66721734	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	10.24	2.38e-22	5.2e-19	0.58	0.43	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	10.24	2.38e-22	5.22e-19	0.55	0.43	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	10.24	2.4e-22	5.25e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-10.24	2.45e-22	5.35e-19	-0.53	-0.43	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
HNSC	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	10.24	2.53e-22	5.53e-19	0.58	0.43	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.24	2.53e-22	5.53e-19	0.55	0.43	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
HNSC	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	10.24	2.55e-22	5.57e-19	0.6	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	10.23	2.57e-22	5.61e-19	0.54	0.43	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	10.23	2.57e-22	5.61e-19	0.54	0.43	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-10.23	2.57e-22	5.61e-19	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
HNSC	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-10.23	2.61e-22	5.69e-19	-0.53	-0.43	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
HNSC	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	10.23	2.66e-22	5.8e-19	0.48	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
HNSC	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	10.23	2.67e-22	5.82e-19	0.61	0.43	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
HNSC	cis	rs7615952	0.688	rs7624806	ENSG00000241288.6	RP11-379B18.5	-10.23	2.69e-22	5.87e-19	-0.61	-0.43	Blood pressure (smoking interaction);	chr3:125880231	chr3:125827238~125916384:-
HNSC	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-10.23	2.7e-22	5.89e-19	-0.58	-0.43	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	10.22	2.88e-22	6.26e-19	0.57	0.43	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-10.22	2.9e-22	6.3e-19	-0.54	-0.43	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
HNSC	cis	rs17270561	0.779	rs1165200	ENSG00000272462.2	U91328.19	10.22	2.98e-22	6.47e-19	0.49	0.43	Iron status biomarkers;	chr6:25874984	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-10.22	3.01e-22	6.55e-19	-0.59	-0.43	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
HNSC	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-10.22	3.03e-22	6.58e-19	-0.6	-0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-10.22	3.03e-22	6.59e-19	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	10.21	3.05e-22	6.64e-19	0.54	0.43	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	10.21	3.07e-22	6.67e-19	0.57	0.43	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	10.21	3.09e-22	6.71e-19	0.57	0.43	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	10.21	3.12e-22	6.77e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	10.21	3.14e-22	6.81e-19	0.61	0.43	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	10.21	3.17e-22	6.87e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	10.21	3.23e-22	7.01e-19	0.47	0.43	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
HNSC	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	10.21	3.29e-22	7.13e-19	0.57	0.43	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	10.2	3.3e-22	7.16e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000179406.6	LINC00174	10.2	3.34e-22	7.24e-19	0.54	0.43	Aortic root size;	chr7:66629021	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	10.2	3.34e-22	7.24e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	10.2	3.34e-22	7.24e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	10.2	3.35e-22	7.25e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000179406.6	LINC00174	-10.2	3.36e-22	7.26e-19	-0.55	-0.43	Calcium levels;	chr7:65837419	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-10.2	3.36e-22	7.26e-19	-0.51	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
HNSC	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	10.2	3.37e-22	7.29e-19	0.47	0.43	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
HNSC	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	10.2	3.5e-22	7.56e-19	0.58	0.43	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	10.2	3.53e-22	7.63e-19	0.57	0.43	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	10.2	3.53e-22	7.63e-19	0.57	0.43	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
HNSC	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-10.19	3.61e-22	7.8e-19	-0.53	-0.43	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
HNSC	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	10.19	3.62e-22	7.83e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
HNSC	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	10.19	3.65e-22	7.88e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	10.19	3.65e-22	7.88e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	10.19	3.65e-22	7.88e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	10.19	3.7e-22	7.99e-19	0.55	0.43	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	10.19	3.72e-22	8.02e-19	0.49	0.43	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	10.19	3.76e-22	8.12e-19	0.57	0.43	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	10.19	3.77e-22	8.14e-19	0.6	0.43	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	10.19	3.77e-22	8.15e-19	0.55	0.43	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	10.19	3.84e-22	8.28e-19	0.85	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
HNSC	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	10.18	3.93e-22	8.47e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
HNSC	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-10.18	3.95e-22	8.51e-19	-0.47	-0.43	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	10.18	3.98e-22	8.59e-19	0.55	0.43	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	10.18	4e-22	8.62e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
HNSC	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-10.18	4.08e-22	8.79e-19	-0.54	-0.43	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
HNSC	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	10.18	4.09e-22	8.82e-19	0.51	0.43	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
HNSC	cis	rs801193	1	rs62466793	ENSG00000179406.6	LINC00174	-10.17	4.25e-22	9.16e-19	-0.54	-0.43	Aortic root size;	chr7:66726530	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs62466794	ENSG00000179406.6	LINC00174	-10.17	4.25e-22	9.16e-19	-0.54	-0.43	Aortic root size;	chr7:66726592	chr7:66376044~66401338:-
HNSC	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	10.17	4.26e-22	9.16e-19	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
HNSC	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	10.17	4.26e-22	9.18e-19	0.45	0.43	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	10.17	4.27e-22	9.19e-19	0.62	0.43	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-10.17	4.28e-22	9.21e-19	-0.6	-0.43	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.66	rs2013222	ENSG00000179406.6	LINC00174	10.17	4.32e-22	9.28e-19	0.53	0.43	Aortic root size;	chr7:66570949	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
HNSC	cis	rs801193	1	rs10234018	ENSG00000179406.6	LINC00174	10.17	4.33e-22	9.29e-19	0.54	0.43	Aortic root size;	chr7:66681297	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	10.17	4.33e-22	9.3e-19	0.57	0.43	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	10.17	4.42e-22	9.48e-19	0.57	0.43	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000179406.6	LINC00174	-10.17	4.43e-22	9.5e-19	-0.54	-0.43	Aortic root size;	chr7:66712111	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	10.17	4.49e-22	9.63e-19	0.57	0.43	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	10.17	4.5e-22	9.66e-19	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	10.17	4.52e-22	9.69e-19	0.55	0.43	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	10.17	4.57e-22	9.79e-19	0.56	0.43	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	10.17	4.58e-22	9.8e-19	0.57	0.43	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	10.17	4.58e-22	9.81e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
HNSC	cis	rs801193	1	rs3778909	ENSG00000179406.6	LINC00174	-10.16	4.72e-22	1.01e-18	-0.54	-0.43	Aortic root size;	chr7:66790659	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-10.16	4.74e-22	1.01e-18	-0.54	-0.43	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
HNSC	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-10.16	4.74e-22	1.01e-18	-0.59	-0.43	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
HNSC	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-10.16	4.79e-22	1.02e-18	-0.47	-0.43	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
HNSC	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-10.16	4.85e-22	1.04e-18	-0.47	-0.43	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	10.16	4.91e-22	1.05e-18	0.54	0.43	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	10.16	4.91e-22	1.05e-18	0.63	0.43	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-10.16	4.93e-22	1.05e-18	-0.53	-0.43	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
HNSC	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	10.16	4.99e-22	1.06e-18	0.57	0.43	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	10.16	4.99e-22	1.06e-18	0.57	0.43	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	10.16	4.99e-22	1.06e-18	0.39	0.43	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
HNSC	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-10.16	5e-22	1.07e-18	-0.55	-0.43	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	10.15	5.09e-22	1.09e-18	0.54	0.43	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
HNSC	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-10.15	5.19e-22	1.11e-18	-1	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	10.15	5.21e-22	1.11e-18	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
HNSC	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-10.15	5.23e-22	1.11e-18	-0.52	-0.43	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
HNSC	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	10.15	5.27e-22	1.12e-18	0.59	0.43	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
HNSC	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	10.15	5.32e-22	1.13e-18	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
HNSC	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-10.15	5.37e-22	1.14e-18	-0.57	-0.43	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	10.15	5.37e-22	1.14e-18	0.58	0.43	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	10.15	5.37e-22	1.14e-18	0.58	0.43	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	10.15	5.44e-22	1.16e-18	0.53	0.42	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	10.15	5.44e-22	1.16e-18	0.54	0.42	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
HNSC	cis	rs17270561	0.887	rs9358870	ENSG00000272462.2	U91328.19	-10.15	5.45e-22	1.16e-18	-0.51	-0.42	Iron status biomarkers;	chr6:25718982	chr6:25992662~26001775:+
HNSC	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-10.14	5.48e-22	1.17e-18	-0.56	-0.42	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
HNSC	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	10.14	5.57e-22	1.18e-18	0.53	0.42	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	10.14	5.58e-22	1.19e-18	0.54	0.42	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	10.14	5.58e-22	1.19e-18	0.54	0.42	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	10.14	5.64e-22	1.2e-18	0.54	0.42	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	10.14	5.64e-22	1.2e-18	0.54	0.42	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	10.14	5.87e-22	1.25e-18	0.54	0.42	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	10.14	5.9e-22	1.25e-18	0.54	0.42	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	10.14	5.9e-22	1.25e-18	0.54	0.42	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	10.13	5.96e-22	1.27e-18	0.54	0.42	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	10.13	6.02e-22	1.28e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
HNSC	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	10.13	6.09e-22	1.29e-18	0.54	0.42	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	10.13	6.11e-22	1.3e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
HNSC	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	10.13	6.15e-22	1.3e-18	0.58	0.42	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	10.13	6.16e-22	1.31e-18	0.54	0.42	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.619	rs2302918	ENSG00000179406.6	LINC00174	-10.13	6.18e-22	1.31e-18	-0.54	-0.42	Aortic root size;	chr7:66535945	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	10.13	6.23e-22	1.32e-18	0.54	0.42	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	10.13	6.25e-22	1.33e-18	0.54	0.42	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	10.12	6.5e-22	1.38e-18	0.54	0.42	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	10.12	6.51e-22	1.38e-18	0.49	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
HNSC	cis	rs801193	1	rs10252765	ENSG00000179406.6	LINC00174	-10.12	6.66e-22	1.41e-18	-0.54	-0.42	Aortic root size;	chr7:66763745	chr7:66376044~66401338:-
HNSC	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	10.12	6.78e-22	1.43e-18	0.46	0.42	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
HNSC	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	10.12	6.86e-22	1.45e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	10.12	6.86e-22	1.45e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	10.12	6.86e-22	1.45e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	10.12	6.87e-22	1.45e-18	0.46	0.42	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
HNSC	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	10.12	6.9e-22	1.46e-18	0.51	0.42	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	10.12	6.9e-22	1.46e-18	0.53	0.42	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	10.12	6.9e-22	1.46e-18	0.54	0.42	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	10.12	6.97e-22	1.47e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-10.12	6.99e-22	1.48e-18	-0.54	-0.42	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.12	7e-22	1.48e-18	0.55	0.42	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	10.11	7.06e-22	1.49e-18	0.55	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
HNSC	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	10.11	7.07e-22	1.49e-18	0.57	0.42	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-10.11	7.11e-22	1.5e-18	-0.49	-0.42	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
HNSC	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	10.11	7.23e-22	1.53e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
HNSC	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	10.11	7.35e-22	1.55e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	10.11	7.41e-22	1.56e-18	0.53	0.42	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	10.11	7.41e-22	1.56e-18	0.53	0.42	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	10.11	7.51e-22	1.58e-18	0.53	0.42	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
HNSC	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	10.11	7.52e-22	1.58e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	10.11	7.52e-22	1.58e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	10.11	7.52e-22	1.58e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
HNSC	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-10.11	7.62e-22	1.6e-18	-0.53	-0.42	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
HNSC	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	10.1	7.67e-22	1.61e-18	0.48	0.42	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
HNSC	cis	rs131777	0.577	rs5770928	ENSG00000205559.3	CHKB-AS1	-10.1	7.72e-22	1.63e-18	-0.49	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50583026~50583877:+
HNSC	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	10.1	7.83e-22	1.65e-18	0.57	0.42	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	10.1	7.83e-22	1.65e-18	0.57	0.42	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-10.1	7.88e-22	1.66e-18	-0.6	-0.42	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-10.1	7.91e-22	1.66e-18	-0.72	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
HNSC	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-10.1	7.98e-22	1.68e-18	-0.47	-0.42	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
HNSC	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	10.1	8.01e-22	1.69e-18	0.54	0.42	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
HNSC	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	10.1	8.11e-22	1.71e-18	0.52	0.42	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
HNSC	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	10.1	8.26e-22	1.74e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	10.1	8.26e-22	1.74e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	10.09	8.42e-22	1.77e-18	0.57	0.42	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
HNSC	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-10.09	8.45e-22	1.78e-18	-0.51	-0.42	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
HNSC	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	10.09	8.46e-22	1.78e-18	0.51	0.42	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
HNSC	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-10.09	8.48e-22	1.78e-18	-0.63	-0.42	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
HNSC	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-10.09	8.52e-22	1.79e-18	-0.51	-0.42	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
HNSC	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	10.09	8.54e-22	1.8e-18	0.46	0.42	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	10.09	8.54e-22	1.8e-18	0.46	0.42	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
HNSC	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-10.09	8.55e-22	1.8e-18	-0.52	-0.42	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
HNSC	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	10.09	8.56e-22	1.8e-18	0.55	0.42	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	10.09	8.58e-22	1.8e-18	0.56	0.42	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	10.09	8.65e-22	1.82e-18	0.57	0.42	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000179406.6	LINC00174	-10.09	8.66e-22	1.82e-18	-0.54	-0.42	Aortic root size;	chr7:65827777	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	10.09	8.66e-22	1.82e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
HNSC	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-10.09	8.76e-22	1.84e-18	-0.46	-0.42	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
HNSC	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	10.09	8.92e-22	1.87e-18	0.55	0.42	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
HNSC	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-10.09	9.02e-22	1.89e-18	-0.51	-0.42	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	10.08	9.08e-22	1.91e-18	0.54	0.42	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	10.08	9.13e-22	1.92e-18	0.58	0.42	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	10.08	9.16e-22	1.92e-18	0.59	0.42	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	10.08	9.24e-22	1.94e-18	0.56	0.42	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000179406.6	LINC00174	10.08	9.25e-22	1.94e-18	0.53	0.42	Aortic root size;	chr7:66633495	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000179406.6	LINC00174	10.08	9.25e-22	1.94e-18	0.53	0.42	Aortic root size;	chr7:66638707	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	10.08	9.27e-22	1.94e-18	0.82	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000179406.6	LINC00174	-10.08	9.28e-22	1.95e-18	-0.54	-0.42	Aortic root size;	chr7:66517181	chr7:66376044~66401338:-
HNSC	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	10.08	9.32e-22	1.95e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	10.08	9.33e-22	1.96e-18	0.53	0.42	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
HNSC	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-10.08	9.39e-22	1.97e-18	-0.46	-0.42	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
HNSC	cis	rs2006771	0.81	rs2006648	ENSG00000236132.1	CTA-440B3.1	10.08	9.44e-22	1.98e-18	0.46	0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31685943	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	10.08	9.5e-22	1.99e-18	0.58	0.42	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
HNSC	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	10.07	9.98e-22	2.09e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	10.07	1e-21	2.1e-18	0.53	0.42	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	10.07	1e-21	2.1e-18	0.55	0.42	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
HNSC	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
HNSC	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	10.07	1.01e-21	2.11e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	10.07	1.01e-21	2.11e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	10.07	1.01e-21	2.11e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-10.07	1.02e-21	2.13e-18	-0.53	-0.42	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
HNSC	cis	rs1933112	1	rs2223583	ENSG00000227777.1	RP4-738P11.3	-10.07	1.03e-21	2.15e-18	-0.47	-0.42	Blood protein levels;	chr1:168556178	chr1:168542737~168543354:+
HNSC	cis	rs1933112	0.966	rs4656605	ENSG00000227777.1	RP4-738P11.3	-10.07	1.03e-21	2.15e-18	-0.47	-0.42	Blood protein levels;	chr1:168556659	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	10.07	1.03e-21	2.16e-18	0.53	0.42	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
HNSC	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-10.07	1.05e-21	2.2e-18	-0.46	-0.42	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
HNSC	cis	rs12594515	0.548	rs55932467	ENSG00000273972.1	CTD-2306A12.1	-10.07	1.05e-21	2.2e-18	-0.58	-0.42	Weight;Waist circumference;	chr15:45704926	chr15:45702640~45703183:+
HNSC	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	10.07	1.06e-21	2.2e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
HNSC	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	10.06	1.09e-21	2.27e-18	0.53	0.42	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
HNSC	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	10.06	1.1e-21	2.3e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
HNSC	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-10.06	1.15e-21	2.39e-18	-0.52	-0.42	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
HNSC	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-10.06	1.15e-21	2.4e-18	-0.46	-0.42	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
HNSC	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	10.05	1.18e-21	2.46e-18	0.55	0.42	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	10.05	1.19e-21	2.47e-18	0.56	0.42	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	10.05	1.19e-21	2.47e-18	0.56	0.42	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	10.05	1.2e-21	2.49e-18	0.53	0.42	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.53	rs28883606	ENSG00000255769.6	GOLGA2P10	-10.05	1.2e-21	2.49e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	10.05	1.2e-21	2.5e-18	0.54	0.42	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
HNSC	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	10.05	1.21e-21	2.51e-18	0.51	0.42	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
HNSC	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-10.05	1.23e-21	2.55e-18	-0.8	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.55e-18	0.54	0.42	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.56e-18	0.53	0.42	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.56e-18	0.53	0.42	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.56e-18	0.53	0.42	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	10.05	1.24e-21	2.57e-18	0.54	0.42	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	10.05	1.24e-21	2.57e-18	0.54	0.42	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	10.05	1.25e-21	2.6e-18	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	10.05	1.25e-21	2.6e-18	0.58	0.42	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	10.05	1.25e-21	2.6e-18	0.57	0.42	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	10.05	1.25e-21	2.6e-18	0.57	0.42	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	10.05	1.25e-21	2.6e-18	0.54	0.42	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	10.05	1.25e-21	2.6e-18	0.54	0.42	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	10.05	1.25e-21	2.6e-18	0.54	0.42	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	10.04	1.26e-21	2.62e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
HNSC	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-10.04	1.27e-21	2.63e-18	-0.82	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	10.04	1.27e-21	2.64e-18	0.52	0.42	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	10.04	1.27e-21	2.64e-18	0.53	0.42	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
HNSC	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-10.04	1.29e-21	2.67e-18	-0.46	-0.42	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
HNSC	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	10.04	1.29e-21	2.67e-18	0.55	0.42	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	10.04	1.3e-21	2.69e-18	0.53	0.42	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
HNSC	cis	rs35955747	0.539	rs738685	ENSG00000236132.1	CTA-440B3.1	10.04	1.3e-21	2.7e-18	0.46	0.42	Neutrophil count;Sum basophil neutrophil counts;	chr22:31636292	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	10.04	1.31e-21	2.72e-18	0.54	0.42	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
HNSC	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-10.04	1.32e-21	2.73e-18	-0.81	-0.42	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	10.04	1.36e-21	2.82e-18	0.53	0.42	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
HNSC	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	10.03	1.37e-21	2.85e-18	0.52	0.42	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
HNSC	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-10.03	1.39e-21	2.88e-18	-0.54	-0.42	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
HNSC	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	10.03	1.4e-21	2.9e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
HNSC	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	10.03	1.4e-21	2.9e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
HNSC	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-10.03	1.4e-21	2.9e-18	-0.41	-0.42	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
HNSC	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	10.03	1.41e-21	2.92e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.93e-18	0.53	0.42	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	10.03	1.42e-21	2.93e-18	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	10.03	1.42e-21	2.93e-18	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	10.03	1.42e-21	2.93e-18	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.94e-18	0.53	0.42	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.94e-18	0.53	0.42	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.94e-18	0.53	0.42	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	10.03	1.43e-21	2.95e-18	0.53	0.42	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	10.03	1.45e-21	2.99e-18	0.53	0.42	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	10.03	1.45e-21	2.99e-18	0.53	0.42	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	10.03	1.47e-21	3.05e-18	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	10.03	1.49e-21	3.07e-18	0.47	0.42	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
HNSC	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-10.02	1.5e-21	3.1e-18	-0.47	-0.42	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-10.02	1.5e-21	3.1e-18	-0.47	-0.42	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
HNSC	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-10.02	1.51e-21	3.12e-18	-0.34	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	10.02	1.51e-21	3.12e-18	0.61	0.42	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	10.02	1.51e-21	3.12e-18	0.61	0.42	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	10.02	1.53e-21	3.16e-18	0.56	0.42	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	10.02	1.56e-21	3.22e-18	0.55	0.42	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	10.02	1.56e-21	3.22e-18	0.55	0.42	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	10.02	1.57e-21	3.24e-18	0.53	0.42	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
HNSC	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-10.02	1.57e-21	3.24e-18	-0.51	-0.42	Height;	chr11:118781100	chr11:118704607~118750263:+
HNSC	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	10.02	1.57e-21	3.24e-18	0.34	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
HNSC	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	10.02	1.57e-21	3.25e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
HNSC	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	10.02	1.58e-21	3.26e-18	0.69	0.42	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
HNSC	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	10.02	1.59e-21	3.27e-18	0.54	0.42	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	10.02	1.6e-21	3.3e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	10.02	1.6e-21	3.3e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	10.02	1.6e-21	3.3e-18	0.55	0.42	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
HNSC	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-10.02	1.62e-21	3.33e-18	-0.54	-0.42	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000179406.6	LINC00174	-10.01	1.63e-21	3.36e-18	-0.54	-0.42	Calcium levels;	chr7:65892789	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-10.01	1.66e-21	3.41e-18	-0.5	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
HNSC	cis	rs7615952	0.688	rs12638240	ENSG00000241288.6	RP11-379B18.5	-10.01	1.7e-21	3.49e-18	-0.59	-0.42	Blood pressure (smoking interaction);	chr3:125822395	chr3:125827238~125916384:-
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000179406.6	LINC00174	-10.01	1.72e-21	3.53e-18	-0.54	-0.42	Calcium levels;	chr7:65853042	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000179406.6	LINC00174	-10.01	1.73e-21	3.56e-18	-0.54	-0.42	Calcium levels;	chr7:65872915	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	10	1.76e-21	3.62e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	10	1.76e-21	3.62e-18	0.53	0.42	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
HNSC	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	10	1.77e-21	3.63e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	10	1.77e-21	3.63e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
HNSC	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-10	1.77e-21	3.63e-18	-0.34	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
HNSC	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	10	1.8e-21	3.69e-18	0.53	0.42	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
HNSC	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	10	1.8e-21	3.69e-18	0.46	0.42	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
HNSC	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	10	1.82e-21	3.74e-18	0.81	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
HNSC	cis	rs7615952	0.688	rs12638224	ENSG00000241288.6	RP11-379B18.5	-10	1.83e-21	3.75e-18	-0.59	-0.42	Blood pressure (smoking interaction);	chr3:125822477	chr3:125827238~125916384:-
HNSC	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-10	1.83e-21	3.76e-18	-0.54	-0.42	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
HNSC	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	10	1.84e-21	3.77e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	10	1.84e-21	3.77e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
HNSC	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-10	1.88e-21	3.86e-18	-1.06	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
HNSC	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	9.99	1.92e-21	3.94e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	9.99	1.94e-21	3.96e-18	0.53	0.42	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	9.99	1.94e-21	3.98e-18	0.57	0.42	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
HNSC	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	9.99	1.95e-21	3.99e-18	0.5	0.42	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
HNSC	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	9.99	1.96e-21	4.01e-18	0.71	0.42	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
HNSC	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-9.99	1.96e-21	4.01e-18	-0.39	-0.42	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	9.99	1.96e-21	4.02e-18	0.53	0.42	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
HNSC	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	9.99	1.98e-21	4.04e-18	0.57	0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
HNSC	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	9.99	1.98e-21	4.05e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	9.99	1.98e-21	4.05e-18	0.86	0.42	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
HNSC	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	9.99	1.98e-21	4.06e-18	0.53	0.42	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	9.99	1.99e-21	4.07e-18	0.53	0.42	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	9.99	2.01e-21	4.11e-18	0.53	0.42	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	9.99	2.02e-21	4.12e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
HNSC	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	9.99	2.04e-21	4.16e-18	0.54	0.42	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-9.99	2.05e-21	4.18e-18	-0.51	-0.42	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	9.99	2.05e-21	4.19e-18	0.53	0.42	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	9.99	2.05e-21	4.19e-18	0.53	0.42	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
HNSC	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-9.98	2.14e-21	4.36e-18	-0.54	-0.42	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
HNSC	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-9.98	2.15e-21	4.38e-18	-0.56	-0.42	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
HNSC	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	9.98	2.15e-21	4.4e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
HNSC	cis	rs801193	1	rs2420824	ENSG00000179406.6	LINC00174	9.98	2.17e-21	4.42e-18	0.53	0.42	Aortic root size;	chr7:66666129	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2659909	ENSG00000179406.6	LINC00174	-9.98	2.17e-21	4.42e-18	-0.53	-0.42	Aortic root size;	chr7:66695292	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	9.98	2.18e-21	4.44e-18	0.53	0.42	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	9.98	2.2e-21	4.49e-18	0.53	0.42	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	9.98	2.21e-21	4.51e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	9.98	2.22e-21	4.53e-18	0.54	0.42	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	9.98	2.23e-21	4.54e-18	0.59	0.42	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
HNSC	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	9.98	2.23e-21	4.55e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
HNSC	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-9.98	2.23e-21	4.55e-18	-0.39	-0.42	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
HNSC	cis	rs7615952	0.558	rs17334039	ENSG00000241288.6	RP11-379B18.5	-9.98	2.24e-21	4.56e-18	-0.58	-0.42	Blood pressure (smoking interaction);	chr3:125821465	chr3:125827238~125916384:-
HNSC	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	9.98	2.26e-21	4.6e-18	0.57	0.42	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
HNSC	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	9.97	2.27e-21	4.62e-18	0.46	0.42	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
HNSC	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-9.97	2.27e-21	4.62e-18	-0.58	-0.42	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-9.97	2.27e-21	4.63e-18	-0.53	-0.42	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	9.97	2.3e-21	4.68e-18	0.53	0.42	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
HNSC	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
HNSC	cis	rs12439619	0.693	rs28665836	ENSG00000255769.6	GOLGA2P10	-9.97	2.34e-21	4.76e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	9.97	2.43e-21	4.94e-18	0.54	0.42	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	9.97	2.43e-21	4.94e-18	0.53	0.42	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	9.97	2.43e-21	4.94e-18	0.53	0.42	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	9.97	2.44e-21	4.96e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	9.97	2.44e-21	4.96e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	9.97	2.45e-21	4.97e-18	0.61	0.42	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
HNSC	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-9.96	2.48e-21	5.04e-18	-0.51	-0.42	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
HNSC	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-9.96	2.51e-21	5.09e-18	-0.54	-0.42	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
HNSC	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	9.96	2.55e-21	5.17e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	9.96	2.56e-21	5.19e-18	0.53	0.42	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	9.96	2.56e-21	5.19e-18	0.53	0.42	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	9.96	2.57e-21	5.23e-18	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	9.96	2.6e-21	5.27e-18	0.47	0.42	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-9.96	2.61e-21	5.29e-18	-0.48	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
HNSC	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	9.96	2.61e-21	5.3e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	9.96	2.61e-21	5.3e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	9.96	2.62e-21	5.31e-18	0.53	0.42	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	9.96	2.64e-21	5.35e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	9.96	2.64e-21	5.35e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	9.96	2.64e-21	5.35e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	9.96	2.66e-21	5.39e-18	0.6	0.42	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	9.96	2.66e-21	5.39e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	9.96	2.66e-21	5.39e-18	0.54	0.42	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
HNSC	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-9.95	2.68e-21	5.43e-18	-0.51	-0.42	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000179406.6	LINC00174	9.95	2.7e-21	5.46e-18	0.53	0.42	Aortic root size;	chr7:66642265	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	9.95	2.7e-21	5.47e-18	0.53	0.42	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
HNSC	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-9.95	2.72e-21	5.5e-18	-0.52	-0.42	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	9.95	2.72e-21	5.5e-18	0.53	0.42	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	9.95	2.82e-21	5.7e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	9.94	2.92e-21	5.9e-18	0.41	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	9.94	2.92e-21	5.91e-18	0.53	0.42	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	9.94	2.97e-21	5.99e-18	0.54	0.42	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
HNSC	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	9.94	2.99e-21	6.03e-18	0.54	0.42	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
HNSC	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	9.94	2.99e-21	6.03e-18	0.54	0.42	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	9.94	2.99e-21	6.03e-18	0.54	0.42	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
HNSC	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	9.94	3e-21	6.06e-18	0.75	0.42	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
HNSC	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	9.94	3.04e-21	6.14e-18	0.52	0.42	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	9.94	3.05e-21	6.15e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	9.94	3.05e-21	6.16e-18	0.53	0.42	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
HNSC	cis	rs6969780	0.915	rs7341470	ENSG00000233429.8	HOTAIRM1	-9.94	3.06e-21	6.17e-18	-0.63	-0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27145223	chr7:27095647~27100265:+
HNSC	cis	rs1933112	1	rs1933112	ENSG00000227777.1	RP4-738P11.3	-9.94	3.07e-21	6.2e-18	-0.47	-0.42	Blood protein levels;	chr1:168552179	chr1:168542737~168543354:+
HNSC	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	9.93	3.15e-21	6.36e-18	0.57	0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	9.93	3.22e-21	6.49e-18	0.46	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
HNSC	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-9.93	3.22e-21	6.49e-18	-0.33	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
HNSC	cis	rs12439619	0.508	rs8032033	ENSG00000255769.6	GOLGA2P10	-9.93	3.35e-21	6.75e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472993~82513950:-
HNSC	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	9.93	3.36e-21	6.76e-18	0.88	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
HNSC	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	9.93	3.38e-21	6.8e-18	0.53	0.42	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	9.93	3.38e-21	6.81e-18	0.53	0.42	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
HNSC	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	9.93	3.38e-21	6.81e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	9.93	3.39e-21	6.82e-18	0.55	0.42	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	9.93	3.39e-21	6.82e-18	0.55	0.42	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
HNSC	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-9.93	3.4e-21	6.84e-18	-0.56	-0.42	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
HNSC	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	9.92	3.47e-21	6.98e-18	0.75	0.42	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
HNSC	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-9.92	3.53e-21	7.1e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
HNSC	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-9.92	3.54e-21	7.11e-18	-0.49	-0.42	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
HNSC	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	9.92	3.67e-21	7.37e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
HNSC	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	9.91	3.73e-21	7.48e-18	0.38	0.42	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
HNSC	cis	rs7615952	0.932	rs13321217	ENSG00000241288.6	RP11-379B18.5	-9.91	3.74e-21	7.52e-18	-0.59	-0.42	Blood pressure (smoking interaction);	chr3:125912928	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	9.91	3.78e-21	7.59e-18	0.52	0.42	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-9.91	3.78e-21	7.59e-18	-0.53	-0.42	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs10753777	ENSG00000227777.1	RP4-738P11.3	-9.91	3.8e-21	7.63e-18	-0.47	-0.42	Blood protein levels;	chr1:168558549	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	9.91	3.86e-21	7.73e-18	0.53	0.42	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
HNSC	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-9.91	3.87e-21	7.75e-18	-0.53	-0.42	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-9.91	3.95e-21	7.92e-18	-0.53	-0.42	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
HNSC	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	9.91	4.01e-21	8.03e-18	0.53	0.42	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
HNSC	cis	rs6969780	0.915	rs4722659	ENSG00000233429.8	HOTAIRM1	-9.91	4.03e-21	8.06e-18	-0.63	-0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127131	chr7:27095647~27100265:+
HNSC	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	9.9	4.03e-21	8.07e-18	0.39	0.42	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	9.9	4.04e-21	8.09e-18	0.54	0.42	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	9.9	4.12e-21	8.23e-18	0.53	0.42	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	9.9	4.15e-21	8.3e-18	0.53	0.42	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	9.9	4.15e-21	8.3e-18	0.53	0.42	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000179406.6	LINC00174	-9.9	4.19e-21	8.38e-18	-0.53	-0.42	Aortic root size;	chr7:65827018	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	9.9	4.2e-21	8.39e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	9.9	4.23e-21	8.46e-18	0.55	0.42	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
HNSC	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-9.9	4.24e-21	8.47e-18	-0.63	-0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	9.9	4.26e-21	8.5e-18	0.53	0.42	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	9.9	4.29e-21	8.55e-18	0.39	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	9.9	4.29e-21	8.55e-18	0.39	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	9.89	4.4e-21	8.77e-18	0.54	0.42	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
HNSC	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-9.89	4.47e-21	8.92e-18	-0.92	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
HNSC	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	9.89	4.48e-21	8.93e-18	0.56	0.42	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
HNSC	cis	rs1933112	1	rs1024177	ENSG00000227777.1	RP4-738P11.3	-9.89	4.48e-21	8.94e-18	-0.47	-0.42	Blood protein levels;	chr1:168557477	chr1:168542737~168543354:+
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000179406.6	LINC00174	9.89	4.5e-21	8.97e-18	0.53	0.42	Calcium levels;	chr7:65808508	chr7:66376044~66401338:-
HNSC	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	9.89	4.62e-21	9.2e-18	0.5	0.42	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
HNSC	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	9.89	4.74e-21	9.42e-18	0.78	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	9.88	4.76e-21	9.47e-18	0.53	0.42	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	9.88	4.76e-21	9.47e-18	0.53	0.42	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	9.88	4.8e-21	9.53e-18	0.56	0.42	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	9.88	4.8e-21	9.53e-18	0.56	0.42	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
HNSC	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-9.88	4.83e-21	9.6e-18	-0.55	-0.42	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
HNSC	cis	rs17711722	1	rs17711722	ENSG00000179406.6	LINC00174	9.88	4.83e-21	9.6e-18	0.54	0.42	Calcium levels;	chr7:65806210	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	9.88	4.85e-21	9.64e-18	0.54	0.42	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	9.88	4.89e-21	9.72e-18	0.55	0.42	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	9.88	4.92e-21	9.77e-18	0.48	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
HNSC	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	9.88	4.95e-21	9.83e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	9.88	4.95e-21	9.83e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	9.88	5.03e-21	9.98e-18	0.54	0.42	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	9.88	5.06e-21	1e-17	0.46	0.42	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	9.88	5.08e-21	1.01e-17	0.6	0.42	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-9.88	5.09e-21	1.01e-17	-0.82	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
HNSC	cis	rs6969780	0.915	rs3801320	ENSG00000233429.8	HOTAIRM1	9.88	5.09e-21	1.01e-17	0.63	0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27124745	chr7:27095647~27100265:+
HNSC	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	9.88	5.11e-21	1.01e-17	0.56	0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
HNSC	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	9.88	5.12e-21	1.01e-17	0.59	0.42	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
HNSC	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	9.88	5.15e-21	1.02e-17	0.39	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
HNSC	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-9.87	5.18e-21	1.03e-17	-0.55	-0.42	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
HNSC	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-9.87	5.18e-21	1.03e-17	-0.53	-0.42	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-9.87	5.18e-21	1.03e-17	-0.53	-0.42	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-9.87	5.18e-21	1.03e-17	-0.53	-0.42	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
HNSC	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	9.87	5.23e-21	1.04e-17	0.48	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
HNSC	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	9.87	5.24e-21	1.04e-17	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
HNSC	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	9.87	5.25e-21	1.04e-17	0.53	0.42	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
HNSC	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	9.87	5.27e-21	1.04e-17	0.46	0.42	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
HNSC	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-9.87	5.32e-21	1.05e-17	-0.5	-0.42	Height;	chr11:118809363	chr11:118704607~118750263:+
HNSC	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	9.87	5.36e-21	1.06e-17	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	9.87	5.38e-21	1.07e-17	0.53	0.42	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	9.87	5.39e-21	1.07e-17	0.54	0.42	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
HNSC	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	9.87	5.46e-21	1.08e-17	0.5	0.42	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	9.87	5.46e-21	1.08e-17	0.5	0.42	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	9.87	5.46e-21	1.08e-17	0.54	0.42	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	9.87	5.46e-21	1.08e-17	0.54	0.42	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
HNSC	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	9.87	5.48e-21	1.08e-17	0.46	0.42	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	9.87	5.49e-21	1.09e-17	0.53	0.42	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
HNSC	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	9.87	5.53e-21	1.09e-17	0.74	0.42	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-9.87	5.59e-21	1.11e-17	-0.64	-0.42	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
HNSC	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-9.86	5.62e-21	1.11e-17	-0.51	-0.42	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-9.86	5.62e-21	1.11e-17	-0.51	-0.42	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
HNSC	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	9.86	5.64e-21	1.11e-17	0.54	0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	9.86	5.65e-21	1.12e-17	0.59	0.42	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	9.86	5.7e-21	1.12e-17	0.53	0.42	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	9.86	5.7e-21	1.12e-17	0.53	0.42	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	9.86	5.7e-21	1.12e-17	0.56	0.42	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	9.86	5.71e-21	1.13e-17	0.53	0.42	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	9.86	5.71e-21	1.13e-17	0.53	0.42	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	9.86	5.77e-21	1.14e-17	0.83	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	9.86	5.89e-21	1.16e-17	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	9.86	5.92e-21	1.17e-17	0.55	0.42	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	9.86	5.92e-21	1.17e-17	0.55	0.42	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	9.86	5.92e-21	1.17e-17	0.55	0.42	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	9.86	6.05e-21	1.19e-17	0.52	0.41	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs1933109	ENSG00000227777.1	RP4-738P11.3	-9.86	6.07e-21	1.2e-17	-0.47	-0.41	Blood protein levels;	chr1:168554386	chr1:168542737~168543354:+
HNSC	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-9.85	6.14e-21	1.21e-17	-0.5	-0.41	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-9.85	6.14e-21	1.21e-17	-0.5	-0.41	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-9.85	6.14e-21	1.21e-17	-0.5	-0.41	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	9.85	6.26e-21	1.23e-17	0.53	0.41	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	9.85	6.26e-21	1.23e-17	0.53	0.41	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	9.85	6.31e-21	1.24e-17	0.53	0.41	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	9.85	6.31e-21	1.24e-17	0.52	0.41	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	9.85	6.31e-21	1.24e-17	0.47	0.41	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	9.85	6.35e-21	1.25e-17	0.54	0.41	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-9.85	6.37e-21	1.25e-17	-0.59	-0.41	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-9.85	6.37e-21	1.25e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
HNSC	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	9.85	6.37e-21	1.25e-17	0.6	0.41	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000179406.6	LINC00174	-9.85	6.44e-21	1.27e-17	-0.53	-0.41	Aortic root size;	chr7:66376994	chr7:66376044~66401338:-
HNSC	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	9.85	6.44e-21	1.27e-17	0.57	0.41	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	9.85	6.55e-21	1.29e-17	0.53	0.41	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
HNSC	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-9.85	6.58e-21	1.29e-17	-0.55	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
HNSC	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-9.85	6.58e-21	1.29e-17	-0.55	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
HNSC	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-9.85	6.58e-21	1.29e-17	-0.55	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
HNSC	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	9.84	6.67e-21	1.31e-17	0.78	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
HNSC	cis	rs1933112	1	rs1933110	ENSG00000227777.1	RP4-738P11.3	-9.84	6.69e-21	1.31e-17	-0.47	-0.41	Blood protein levels;	chr1:168554217	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	9.84	6.78e-21	1.33e-17	0.59	0.41	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
HNSC	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-9.84	6.91e-21	1.35e-17	-0.52	-0.41	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	9.84	6.92e-21	1.36e-17	0.5	0.41	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
HNSC	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	9.84	6.93e-21	1.36e-17	0.56	0.41	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
HNSC	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	9.84	6.96e-21	1.37e-17	0.45	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
HNSC	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	9.84	6.97e-21	1.37e-17	0.4	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
HNSC	cis	rs6969780	0.915	rs4722657	ENSG00000233429.8	HOTAIRM1	-9.83	7.26e-21	1.42e-17	-0.63	-0.41	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27118137	chr7:27095647~27100265:+
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	9.83	7.36e-21	1.44e-17	0.54	0.41	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-9.83	7.37e-21	1.44e-17	-0.52	-0.41	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	9.83	7.39e-21	1.45e-17	0.53	0.41	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	9.83	7.47e-21	1.46e-17	0.53	0.41	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000179406.6	LINC00174	-9.83	7.53e-21	1.47e-17	-0.53	-0.41	Aortic root size;	chr7:65930047	chr7:66376044~66401338:-
HNSC	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	9.83	7.59e-21	1.48e-17	0.48	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
HNSC	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-9.82	7.83e-21	1.53e-17	-0.48	-0.41	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000179406.6	LINC00174	-9.82	7.84e-21	1.53e-17	-0.53	-0.41	Calcium levels;	chr7:65903721	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	9.82	7.92e-21	1.55e-17	0.53	0.41	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	9.82	7.92e-21	1.55e-17	0.53	0.41	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-9.82	7.96e-21	1.55e-17	-0.45	-0.41	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-9.82	8.1e-21	1.58e-17	-0.53	-0.41	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	9.82	8.15e-21	1.59e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
HNSC	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	9.82	8.16e-21	1.59e-17	0.43	0.41	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-9.82	8.19e-21	1.6e-17	-0.49	-0.41	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
HNSC	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	9.82	8.25e-21	1.61e-17	0.4	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000179406.6	LINC00174	-9.82	8.26e-21	1.61e-17	-0.53	-0.41	Aortic root size;	chr7:65871069	chr7:66376044~66401338:-
HNSC	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-9.82	8.27e-21	1.61e-17	-0.43	-0.41	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
HNSC	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	9.82	8.42e-21	1.64e-17	0.47	0.41	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
HNSC	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	9.82	8.42e-21	1.64e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
HNSC	cis	rs1933112	1	rs1933104	ENSG00000227777.1	RP4-738P11.3	-9.81	8.54e-21	1.67e-17	-0.47	-0.41	Blood protein levels;	chr1:168559648	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	9.81	8.67e-21	1.69e-17	0.52	0.41	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-9.81	8.71e-21	1.7e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	9.81	8.84e-21	1.72e-17	0.52	0.41	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	9.81	8.84e-21	1.72e-17	0.52	0.41	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-9.81	8.85e-21	1.72e-17	-0.43	-0.41	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	9.81	9.08e-21	1.77e-17	0.5	0.41	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
HNSC	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	9.8	9.3e-21	1.81e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	9.8	9.3e-21	1.81e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	9.8	9.3e-21	1.81e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	9.8	9.34e-21	1.82e-17	0.54	0.41	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	9.8	9.35e-21	1.82e-17	0.53	0.41	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	9.8	9.45e-21	1.84e-17	0.53	0.41	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-9.8	9.5e-21	1.85e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-9.8	9.5e-21	1.85e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
HNSC	cis	rs6867032	0.958	rs9312970	ENSG00000249731.1	RP11-259O2.3	-9.8	9.64e-21	1.87e-17	-0.51	-0.41	Gut microbiome composition (winter);	chr5:2002301	chr5:1968094~1969013:+
HNSC	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	9.8	9.77e-21	1.9e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000179406.6	LINC00174	-9.8	9.87e-21	1.92e-17	-0.52	-0.41	Aortic root size;	chr7:66407695	chr7:66376044~66401338:-
HNSC	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	9.79	1e-20	1.94e-17	0.38	0.41	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	9.79	1e-20	1.94e-17	0.53	0.41	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-9.79	1.02e-20	1.98e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	9.79	1.02e-20	1.98e-17	0.54	0.41	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
HNSC	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-9.79	1.03e-20	2e-17	-0.93	-0.41	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
HNSC	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-9.79	1.03e-20	2.01e-17	-0.51	-0.41	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	9.79	1.06e-20	2.06e-17	0.44	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	9.79	1.07e-20	2.08e-17	0.53	0.41	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs10918925	ENSG00000227777.1	RP4-738P11.3	9.79	1.07e-20	2.08e-17	0.47	0.41	Blood protein levels;	chr1:168556009	chr1:168542737~168543354:+
HNSC	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	9.78	1.09e-20	2.11e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	9.78	1.1e-20	2.13e-17	0.53	0.41	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	9.78	1.1e-20	2.13e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	9.78	1.11e-20	2.14e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	9.78	1.13e-20	2.18e-17	0.53	0.41	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	9.78	1.13e-20	2.19e-17	0.52	0.41	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000173295.6	FAM86B3P	9.78	1.14e-20	2.2e-17	0.46	0.41	Systolic blood pressure;	chr8:8273016	chr8:8228595~8244865:+
HNSC	cis	rs11763147	1	rs11763147	ENSG00000179406.6	LINC00174	9.78	1.16e-20	2.25e-17	0.53	0.41	Corneal structure;	chr7:65861834	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	9.78	1.17e-20	2.27e-17	0.53	0.41	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
HNSC	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	9.78	1.17e-20	2.27e-17	0.52	0.41	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	9.78	1.17e-20	2.27e-17	0.52	0.41	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	9.78	1.17e-20	2.27e-17	0.52	0.41	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
HNSC	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	9.77	1.18e-20	2.29e-17	0.39	0.41	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
HNSC	cis	rs1933112	1	rs2179500	ENSG00000227777.1	RP4-738P11.3	-9.77	1.18e-20	2.29e-17	-0.47	-0.41	Blood protein levels;	chr1:168546589	chr1:168542737~168543354:+
HNSC	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-9.77	1.19e-20	2.29e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
HNSC	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-9.77	1.2e-20	2.31e-17	-0.53	-0.41	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
HNSC	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-9.77	1.2e-20	2.31e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
HNSC	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	9.77	1.22e-20	2.36e-17	0.57	0.41	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
HNSC	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	9.77	1.24e-20	2.39e-17	0.47	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
HNSC	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-9.77	1.27e-20	2.45e-17	-0.49	-0.41	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
HNSC	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-9.77	1.28e-20	2.46e-17	-0.49	-0.41	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
HNSC	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-9.76	1.29e-20	2.48e-17	-0.55	-0.41	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
HNSC	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	9.76	1.29e-20	2.49e-17	0.47	0.41	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
HNSC	cis	rs6867032	0.917	rs10474733	ENSG00000249731.1	RP11-259O2.3	-9.76	1.3e-20	2.51e-17	-0.51	-0.41	Gut microbiome composition (winter);	chr5:2004046	chr5:1968094~1969013:+
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	9.76	1.32e-20	2.54e-17	0.52	0.41	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	9.76	1.33e-20	2.56e-17	0.47	0.41	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	9.76	1.33e-20	2.57e-17	0.55	0.41	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	9.76	1.34e-20	2.58e-17	0.52	0.41	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	9.76	1.34e-20	2.59e-17	0.41	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
HNSC	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-9.76	1.35e-20	2.6e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
HNSC	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	9.76	1.35e-20	2.6e-17	0.51	0.41	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
HNSC	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-9.76	1.37e-20	2.63e-17	-0.33	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
HNSC	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-9.76	1.38e-20	2.66e-17	-0.49	-0.41	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	9.75	1.39e-20	2.67e-17	0.53	0.41	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	9.75	1.42e-20	2.73e-17	0.53	0.41	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
HNSC	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-9.75	1.44e-20	2.77e-17	-0.55	-0.41	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-9.75	1.46e-20	2.8e-17	-0.55	-0.41	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
HNSC	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	9.75	1.46e-20	2.81e-17	0.87	0.41	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
HNSC	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	9.75	1.48e-20	2.85e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
HNSC	cis	rs1933112	1	rs7529824	ENSG00000227777.1	RP4-738P11.3	-9.74	1.52e-20	2.92e-17	-0.47	-0.41	Blood protein levels;	chr1:168531220	chr1:168542737~168543354:+
HNSC	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	9.74	1.55e-20	2.97e-17	0.53	0.41	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
HNSC	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-9.74	1.55e-20	2.97e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	9.74	1.56e-20	2.99e-17	0.52	0.41	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-9.74	1.56e-20	3e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-9.74	1.56e-20	3e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	9.73	1.64e-20	3.14e-17	0.52	0.41	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	9.73	1.65e-20	3.16e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	9.73	1.65e-20	3.17e-17	0.52	0.41	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
HNSC	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-9.73	1.68e-20	3.21e-17	-0.44	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
HNSC	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-9.73	1.69e-20	3.23e-17	-0.49	-0.41	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	9.73	1.71e-20	3.27e-17	0.51	0.41	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
HNSC	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	9.73	1.73e-20	3.31e-17	0.59	0.41	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	9.73	1.74e-20	3.32e-17	0.61	0.41	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-9.73	1.75e-20	3.35e-17	-0.59	-0.41	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	9.72	1.79e-20	3.42e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	9.72	1.79e-20	3.42e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
HNSC	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	9.72	1.8e-20	3.43e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
HNSC	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-9.72	1.82e-20	3.48e-17	-0.54	-0.41	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	9.72	1.86e-20	3.54e-17	0.53	0.41	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	9.72	1.87e-20	3.57e-17	0.53	0.41	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	9.72	1.89e-20	3.6e-17	0.45	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-9.72	1.9e-20	3.63e-17	-0.63	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000179406.6	LINC00174	-9.71	1.93e-20	3.67e-17	-0.52	-0.41	Calcium levels;	chr7:65975383	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000179406.6	LINC00174	-9.71	1.97e-20	3.75e-17	-0.53	-0.41	Aortic root size;	chr7:65832759	chr7:66376044~66401338:-
HNSC	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-9.71	2.02e-20	3.85e-17	-0.54	-0.41	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-9.71	2.02e-20	3.85e-17	-0.54	-0.41	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-9.71	2.03e-20	3.86e-17	-0.52	-0.41	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	9.71	2.06e-20	3.91e-17	0.52	0.41	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	9.71	2.06e-20	3.91e-17	0.52	0.41	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	9.71	2.08e-20	3.96e-17	0.52	0.41	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	9.71	2.08e-20	3.96e-17	0.52	0.41	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
HNSC	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	9.71	2.08e-20	3.96e-17	0.51	0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
HNSC	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	9.7	2.17e-20	4.13e-17	0.52	0.41	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	9.7	2.2e-20	4.18e-17	0.53	0.41	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-9.7	2.2e-20	4.18e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-9.7	2.2e-20	4.18e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
HNSC	cis	rs1933112	1	rs2223582	ENSG00000227777.1	RP4-738P11.3	-9.7	2.24e-20	4.24e-17	-0.47	-0.41	Blood protein levels;	chr1:168537297	chr1:168542737~168543354:+
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	9.69	2.27e-20	4.29e-17	0.55	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
HNSC	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	9.69	2.32e-20	4.39e-17	0.52	0.41	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	9.69	2.32e-20	4.39e-17	0.52	0.41	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000173295.6	FAM86B3P	9.69	2.39e-20	4.51e-17	0.46	0.41	Mood instability;	chr8:8277287	chr8:8228595~8244865:+
HNSC	cis	rs2834288	0.613	rs2834297	ENSG00000237945.6	LINC00649	-9.69	2.43e-20	4.58e-17	-0.48	-0.41	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33915534~33977691:+
HNSC	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.46e-20	4.64e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
HNSC	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-9.68	2.48e-20	4.68e-17	-0.77	-0.41	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
HNSC	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	9.68	2.48e-20	4.69e-17	0.44	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-9.68	2.48e-20	4.69e-17	-0.42	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
HNSC	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-9.68	2.5e-20	4.72e-17	-0.5	-0.41	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
HNSC	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	9.68	2.52e-20	4.76e-17	0.63	0.41	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	9.68	2.64e-20	4.97e-17	0.51	0.41	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	9.68	2.65e-20	5e-17	0.52	0.41	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
HNSC	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	9.67	2.68e-20	5.05e-17	0.6	0.41	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
HNSC	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000179406.6	LINC00174	-9.67	2.74e-20	5.16e-17	-0.52	-0.41	Aortic root size;	chr7:65943052	chr7:66376044~66401338:-
HNSC	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	9.67	2.79e-20	5.25e-17	0.73	0.41	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
HNSC	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	9.67	2.81e-20	5.29e-17	0.51	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000173295.6	FAM86B3P	9.67	2.86e-20	5.38e-17	0.46	0.41	Mood instability;	chr8:8278888	chr8:8228595~8244865:+
HNSC	cis	rs1933112	1	rs7514168	ENSG00000227777.1	RP4-738P11.3	-9.67	2.86e-20	5.38e-17	-0.46	-0.41	Blood protein levels;	chr1:168561499	chr1:168542737~168543354:+
HNSC	cis	rs7615952	0.609	rs13088451	ENSG00000241288.6	RP11-379B18.5	-9.66	2.93e-20	5.5e-17	-0.56	-0.41	Blood pressure (smoking interaction);	chr3:125834656	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	9.66	3.01e-20	5.64e-17	0.52	0.41	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
HNSC	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	9.66	3.01e-20	5.64e-17	0.46	0.41	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
HNSC	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	9.66	3.07e-20	5.76e-17	0.57	0.41	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
HNSC	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	9.66	3.1e-20	5.82e-17	0.56	0.41	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
HNSC	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	9.66	3.11e-20	5.83e-17	0.59	0.41	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
HNSC	cis	rs7615952	0.932	rs13065725	ENSG00000241288.6	RP11-379B18.5	-9.65	3.16e-20	5.92e-17	-0.6	-0.41	Blood pressure (smoking interaction);	chr3:125913446	chr3:125827238~125916384:-
HNSC	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	9.65	3.17e-20	5.95e-17	0.39	0.41	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
HNSC	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-9.65	3.19e-20	5.97e-17	-0.52	-0.41	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	9.65	3.26e-20	6.11e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
HNSC	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-9.65	3.26e-20	6.11e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	9.65	3.28e-20	6.15e-17	0.52	0.41	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	9.65	3.28e-20	6.15e-17	0.52	0.41	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
HNSC	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	9.65	3.3e-20	6.18e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
HNSC	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	9.65	3.3e-20	6.18e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-9.65	3.3e-20	6.18e-17	-0.58	-0.41	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
HNSC	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	9.65	3.31e-20	6.19e-17	0.63	0.41	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
HNSC	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	9.65	3.33e-20	6.22e-17	0.46	0.41	Temperament;	chr17:13996939	chr17:14024514~14025488:+
HNSC	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	9.65	3.39e-20	6.35e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	9.64	3.41e-20	6.37e-17	0.44	0.41	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
HNSC	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-9.64	3.41e-20	6.38e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
HNSC	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-9.64	3.48e-20	6.5e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
HNSC	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-9.64	3.51e-20	6.57e-17	-0.48	-0.41	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-9.64	3.51e-20	6.57e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
HNSC	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	9.64	3.54e-20	6.61e-17	0.39	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000179406.6	LINC00174	-9.64	3.54e-20	6.62e-17	-0.52	-0.41	Aortic root size;	chr7:65931217	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	9.64	3.56e-20	6.64e-17	0.52	0.41	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	9.64	3.6e-20	6.73e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	9.64	3.62e-20	6.76e-17	0.52	0.41	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	9.64	3.62e-20	6.76e-17	0.52	0.41	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
HNSC	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-9.64	3.65e-20	6.82e-17	-0.52	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
HNSC	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-9.64	3.66e-20	6.83e-17	-0.44	-0.41	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
HNSC	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-9.63	3.79e-20	7.06e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-9.63	3.84e-20	7.15e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	9.63	3.84e-20	7.16e-17	0.52	0.41	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000179406.6	LINC00174	9.63	3.97e-20	7.39e-17	0.52	0.41	Aortic root size;	chr7:66301001	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.688	rs17334074	ENSG00000241288.6	RP11-379B18.5	9.62	4.02e-20	7.48e-17	0.56	0.41	Blood pressure (smoking interaction);	chr3:125821617	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	9.62	4.07e-20	7.57e-17	0.51	0.41	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.967	rs2420827	ENSG00000179406.6	LINC00174	9.62	4.09e-20	7.61e-17	0.52	0.41	Aortic root size;	chr7:66682114	chr7:66376044~66401338:-
HNSC	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-9.62	4.18e-20	7.77e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-9.62	4.18e-20	7.77e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000179406.6	LINC00174	-9.62	4.3e-20	8e-17	-0.53	-0.41	Aortic root size;	chr7:65963835	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	9.61	4.42e-20	8.21e-17	0.53	0.41	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-9.61	4.42e-20	8.21e-17	-0.4	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
HNSC	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-9.61	4.44e-20	8.25e-17	-0.49	-0.41	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
HNSC	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	9.61	4.53e-20	8.41e-17	0.51	0.41	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-9.61	4.66e-20	8.65e-17	-0.59	-0.41	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-9.61	4.69e-20	8.69e-17	-0.41	-0.41	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
HNSC	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-9.6	4.71e-20	8.72e-17	-0.42	-0.41	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	9.6	4.71e-20	8.73e-17	0.42	0.41	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
HNSC	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	9.6	4.73e-20	8.76e-17	0.39	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
HNSC	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-9.6	4.78e-20	8.86e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-9.6	4.78e-20	8.86e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
HNSC	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	9.6	4.82e-20	8.93e-17	0.62	0.41	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	9.6	4.83e-20	8.94e-17	0.45	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
HNSC	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-9.6	4.87e-20	9.01e-17	-0.49	-0.41	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
HNSC	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-9.6	4.9e-20	9.06e-17	-0.46	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-9.6	4.91e-20	9.08e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
HNSC	cis	rs1933112	0.808	rs55863344	ENSG00000227777.1	RP4-738P11.3	-9.6	4.91e-20	9.08e-17	-0.47	-0.41	Blood protein levels;	chr1:168542884	chr1:168542737~168543354:+
HNSC	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	9.6	4.91e-20	9.08e-17	0.63	0.41	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
HNSC	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-9.59	5.11e-20	9.45e-17	-0.48	-0.41	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
HNSC	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	9.59	5.18e-20	9.57e-17	0.39	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
HNSC	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-9.59	5.26e-20	9.72e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
HNSC	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-9.59	5.27e-20	9.74e-17	-0.46	-0.41	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
HNSC	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	9.59	5.32e-20	9.82e-17	0.44	0.41	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
HNSC	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-9.59	5.35e-20	9.88e-17	-0.46	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
HNSC	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	9.59	5.37e-20	9.92e-17	0.41	0.41	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	9.59	5.41e-20	9.98e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
HNSC	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-9.59	5.44e-20	1e-16	-0.47	-0.41	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
HNSC	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-9.59	5.46e-20	1.01e-16	-0.54	-0.41	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
HNSC	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	9.58	5.57e-20	1.03e-16	0.49	0.41	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
HNSC	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-9.58	5.58e-20	1.03e-16	-0.56	-0.41	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
HNSC	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-9.58	5.6e-20	1.03e-16	-0.47	-0.41	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-9.58	5.6e-20	1.03e-16	-0.47	-0.41	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
HNSC	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-9.58	5.61e-20	1.03e-16	-0.44	-0.41	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
HNSC	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
HNSC	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	9.58	5.69e-20	1.05e-16	0.44	0.41	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
HNSC	cis	rs1933112	0.9	rs7519937	ENSG00000227777.1	RP4-738P11.3	-9.58	5.88e-20	1.08e-16	-0.47	-0.41	Blood protein levels;	chr1:168535403	chr1:168542737~168543354:+
HNSC	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-9.58	5.99e-20	1.1e-16	-0.51	-0.41	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
HNSC	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-9.58	5.99e-20	1.1e-16	-0.46	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	9.57	6.04e-20	1.11e-16	0.46	0.41	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
HNSC	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-9.57	6.19e-20	1.14e-16	-0.44	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
HNSC	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	9.57	6.2e-20	1.14e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
HNSC	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	9.57	6.22e-20	1.14e-16	0.44	0.4	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
HNSC	cis	rs801193	0.967	rs3800823	ENSG00000179406.6	LINC00174	9.57	6.26e-20	1.15e-16	0.51	0.4	Aortic root size;	chr7:66682123	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	9.57	6.31e-20	1.16e-16	0.4	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	9.56	6.52e-20	1.2e-16	0.53	0.4	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000179406.6	LINC00174	9.56	6.56e-20	1.2e-16	0.51	0.4	Aortic root size;	chr7:66039646	chr7:66376044~66401338:-
HNSC	cis	rs1933112	1	rs1323534	ENSG00000227777.1	RP4-738P11.3	-9.56	6.58e-20	1.21e-16	-0.47	-0.4	Blood protein levels;	chr1:168534039	chr1:168542737~168543354:+
HNSC	cis	rs17826219	0.5	rs117560728	ENSG00000263531.1	RP13-753N3.1	9.56	6.61e-20	1.21e-16	0.87	0.4	Body mass index;	chr17:30743920	chr17:30863921~30864940:-
HNSC	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	9.56	6.62e-20	1.22e-16	0.44	0.4	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
HNSC	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	9.56	6.63e-20	1.22e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
HNSC	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-9.56	6.68e-20	1.23e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
HNSC	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	9.56	6.78e-20	1.24e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
HNSC	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-9.56	6.84e-20	1.26e-16	-0.56	-0.4	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
HNSC	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-9.56	6.85e-20	1.26e-16	-0.56	-0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.522	rs781144	ENSG00000179406.6	LINC00174	-9.56	6.86e-20	1.26e-16	-0.51	-0.4	Aortic root size;	chr7:65975357	chr7:66376044~66401338:-
HNSC	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	9.56	6.89e-20	1.26e-16	0.52	0.4	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
HNSC	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-9.56	6.9e-20	1.26e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
HNSC	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	9.56	6.95e-20	1.27e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000179406.6	LINC00174	-9.56	7.01e-20	1.28e-16	-0.52	-0.4	Calcium levels;	chr7:65996954	chr7:66376044~66401338:-
HNSC	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	9.56	7.03e-20	1.29e-16	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
HNSC	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	9.55	7.17e-20	1.31e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
HNSC	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-9.55	7.18e-20	1.32e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
HNSC	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	9.55	7.21e-20	1.32e-16	0.46	0.4	Depression;	chr6:28327262	chr6:28176188~28176674:+
HNSC	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-9.55	7.33e-20	1.34e-16	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
HNSC	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-9.55	7.41e-20	1.35e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-9.55	7.41e-20	1.35e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
HNSC	cis	rs12550612	0.614	rs6983885	ENSG00000253616.4	RP11-875O11.3	9.55	7.44e-20	1.36e-16	0.59	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23087574	chr8:23071377~23074488:-
HNSC	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-9.55	7.48e-20	1.37e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
HNSC	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	9.55	7.5e-20	1.37e-16	0.52	0.4	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
HNSC	cis	rs12550612	0.567	rs7834950	ENSG00000253616.4	RP11-875O11.3	9.55	7.56e-20	1.38e-16	0.59	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084305	chr8:23071377~23074488:-
HNSC	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-9.55	7.57e-20	1.38e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000179406.6	LINC00174	9.55	7.62e-20	1.39e-16	0.52	0.4	Aortic root size;	chr7:65800193	chr7:66376044~66401338:-
HNSC	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-9.54	7.64e-20	1.39e-16	-0.46	-0.4	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
HNSC	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-9.54	7.79e-20	1.42e-16	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000179406.6	LINC00174	9.54	7.91e-20	1.44e-16	0.51	0.4	Aortic root size;	chr7:66174736	chr7:66376044~66401338:-
HNSC	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	9.54	7.99e-20	1.46e-16	0.52	0.4	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000179406.6	LINC00174	-9.54	8.05e-20	1.47e-16	-0.51	-0.4	Aortic root size;	chr7:65966699	chr7:66376044~66401338:-
HNSC	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	9.54	8.06e-20	1.47e-16	0.54	0.4	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
HNSC	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-9.54	8.11e-20	1.48e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
HNSC	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	9.54	8.11e-20	1.48e-16	0.47	0.4	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	9.54	8.14e-20	1.48e-16	0.51	0.4	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	9.54	8.14e-20	1.48e-16	0.51	0.4	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	9.54	8.14e-20	1.48e-16	0.51	0.4	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	9.54	8.18e-20	1.49e-16	0.51	0.4	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	9.53	8.47e-20	1.54e-16	0.52	0.4	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
HNSC	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-9.53	8.47e-20	1.54e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
HNSC	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-9.53	8.47e-20	1.54e-16	-0.53	-0.4	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
HNSC	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-9.53	8.47e-20	1.54e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	9.53	8.55e-20	1.55e-16	0.51	0.4	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	9.53	8.61e-20	1.56e-16	0.52	0.4	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs1040509	ENSG00000227777.1	RP4-738P11.3	-9.53	8.63e-20	1.57e-16	-0.45	-0.4	Blood protein levels;	chr1:168531746	chr1:168542737~168543354:+
HNSC	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-9.53	8.66e-20	1.57e-16	-0.47	-0.4	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
HNSC	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	9.53	8.74e-20	1.59e-16	0.44	0.4	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
HNSC	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-9.53	8.76e-20	1.59e-16	-0.52	-0.4	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
HNSC	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	9.53	8.78e-20	1.6e-16	0.56	0.4	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
HNSC	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-9.53	8.83e-20	1.6e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
HNSC	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	9.53	8.94e-20	1.62e-16	0.57	0.4	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
HNSC	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	9.53	8.94e-20	1.62e-16	0.54	0.4	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
HNSC	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	9.53	8.95e-20	1.62e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
HNSC	cis	rs801193	1	rs13239306	ENSG00000179406.6	LINC00174	9.53	8.97e-20	1.63e-16	0.52	0.4	Aortic root size;	chr7:66671030	chr7:66376044~66401338:-
HNSC	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-9.53	8.97e-20	1.63e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
HNSC	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	9.52	9.01e-20	1.63e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
HNSC	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	9.52	9.12e-20	1.65e-16	0.48	0.4	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
HNSC	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	9.52	9.16e-20	1.66e-16	0.52	0.4	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-9.52	9.19e-20	1.67e-16	-0.46	-0.4	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
HNSC	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
HNSC	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	9.52	9.44e-20	1.71e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000179406.6	LINC00174	-9.52	9.44e-20	1.71e-16	-0.52	-0.4	Calcium levels;	chr7:65974892	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000179406.6	LINC00174	-9.52	9.45e-20	1.71e-16	-0.51	-0.4	Aortic root size;	chr7:66771620	chr7:66376044~66401338:-
HNSC	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	9.52	9.47e-20	1.71e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
HNSC	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-9.52	9.47e-20	1.71e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
HNSC	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-9.52	9.47e-20	1.71e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
HNSC	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	9.52	9.54e-20	1.73e-16	0.68	0.4	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
HNSC	cis	rs7615952	0.551	rs6438945	ENSG00000241288.6	RP11-379B18.5	-9.52	9.69e-20	1.75e-16	-0.6	-0.4	Blood pressure (smoking interaction);	chr3:125915630	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.673	rs7632557	ENSG00000241288.6	RP11-379B18.5	-9.52	9.69e-20	1.75e-16	-0.6	-0.4	Blood pressure (smoking interaction);	chr3:125916038	chr3:125827238~125916384:-
HNSC	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-9.51	9.9e-20	1.79e-16	-0.58	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
HNSC	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-9.51	9.9e-20	1.79e-16	-0.51	-0.4	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
HNSC	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-9.51	9.95e-20	1.8e-16	-0.44	-0.4	Temperament;	chr17:14007232	chr17:14024514~14025488:+
HNSC	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	9.51	1.03e-19	1.87e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
HNSC	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	9.51	1.04e-19	1.88e-16	0.49	0.4	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000179406.6	LINC00174	9.51	1.04e-19	1.88e-16	0.51	0.4	Aortic root size;	chr7:66042405	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000179406.6	LINC00174	9.51	1.04e-19	1.88e-16	0.51	0.4	Aortic root size;	chr7:66048109	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000179406.6	LINC00174	9.51	1.04e-19	1.88e-16	0.51	0.4	Aortic root size;	chr7:66048321	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	9.51	1.04e-19	1.89e-16	0.52	0.4	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
HNSC	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-9.51	1.05e-19	1.89e-16	-0.37	-0.4	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
HNSC	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	9.51	1.05e-19	1.9e-16	0.51	0.4	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
HNSC	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	9.51	1.05e-19	1.9e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
HNSC	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	9.51	1.05e-19	1.9e-16	0.43	0.4	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
HNSC	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-9.5	1.06e-19	1.91e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	9.5	1.06e-19	1.92e-16	0.6	0.4	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
HNSC	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	9.5	1.07e-19	1.93e-16	0.43	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
HNSC	cis	rs875971	0.577	rs35072105	ENSG00000179406.6	LINC00174	9.5	1.07e-19	1.93e-16	0.51	0.4	Aortic root size;	chr7:66144830	chr7:66376044~66401338:-
HNSC	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-9.5	1.07e-19	1.94e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
HNSC	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	9.5	1.11e-19	2e-16	0.52	0.4	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
HNSC	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-9.5	1.11e-19	2e-16	-0.42	-0.4	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
HNSC	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	9.5	1.13e-19	2.03e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
HNSC	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	9.5	1.13e-19	2.04e-16	0.47	0.4	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
HNSC	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	9.49	1.17e-19	2.11e-16	0.43	0.4	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
HNSC	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	9.49	1.17e-19	2.12e-16	0.49	0.4	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-9.49	1.18e-19	2.12e-16	-0.58	-0.4	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-9.49	1.18e-19	2.12e-16	-0.58	-0.4	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-9.49	1.18e-19	2.12e-16	-0.58	-0.4	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
HNSC	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	9.49	1.19e-19	2.15e-16	0.5	0.4	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	9.49	1.19e-19	2.15e-16	0.51	0.4	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	9.49	1.24e-19	2.23e-16	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
HNSC	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-9.48	1.24e-19	2.23e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
HNSC	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-9.48	1.24e-19	2.23e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
HNSC	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-9.48	1.27e-19	2.29e-16	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
HNSC	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-9.48	1.28e-19	2.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
HNSC	cis	rs131777	0.575	rs131760	ENSG00000205559.3	CHKB-AS1	-9.48	1.29e-19	2.31e-16	-0.46	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50583026~50583877:+
HNSC	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-9.48	1.29e-19	2.32e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-9.48	1.29e-19	2.32e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
HNSC	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-9.48	1.3e-19	2.34e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
HNSC	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-9.48	1.32e-19	2.37e-16	-0.5	-0.4	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
HNSC	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-9.48	1.34e-19	2.4e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.651	rs313829	ENSG00000179406.6	LINC00174	9.48	1.34e-19	2.41e-16	0.59	0.4	Aortic root size;	chr7:66087510	chr7:66376044~66401338:-
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000173295.6	FAM86B3P	9.48	1.34e-19	2.41e-16	0.45	0.4	Mood instability;	chr8:8279561	chr8:8228595~8244865:+
HNSC	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	9.47	1.35e-19	2.43e-16	0.48	0.4	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
HNSC	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	9.47	1.38e-19	2.48e-16	0.59	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
HNSC	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	9.47	1.39e-19	2.49e-16	0.53	0.4	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
HNSC	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	9.47	1.4e-19	2.51e-16	0.72	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	9.47	1.4e-19	2.51e-16	0.72	0.4	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
HNSC	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	9.47	1.42e-19	2.55e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
HNSC	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	9.47	1.42e-19	2.55e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
HNSC	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	9.47	1.42e-19	2.55e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
HNSC	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-9.47	1.43e-19	2.57e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
HNSC	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	9.47	1.44e-19	2.58e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	9.47	1.45e-19	2.59e-16	0.51	0.4	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
HNSC	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	9.47	1.45e-19	2.59e-16	0.52	0.4	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
HNSC	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	9.47	1.45e-19	2.6e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
HNSC	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	9.46	1.48e-19	2.65e-16	0.52	0.4	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	9.46	1.48e-19	2.66e-16	0.51	0.4	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
HNSC	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-9.46	1.49e-19	2.66e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
HNSC	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-9.46	1.5e-19	2.69e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
HNSC	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	9.46	1.52e-19	2.72e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
HNSC	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-9.46	1.52e-19	2.72e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	9.46	1.54e-19	2.76e-16	0.53	0.4	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
HNSC	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-9.46	1.55e-19	2.76e-16	-0.42	-0.4	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
HNSC	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-9.46	1.55e-19	2.76e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
HNSC	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-9.45	1.59e-19	2.84e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-9.45	1.59e-19	2.84e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-9.45	1.59e-19	2.84e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
HNSC	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-9.45	1.59e-19	2.84e-16	-0.58	-0.4	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	9.45	1.6e-19	2.86e-16	0.56	0.4	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-9.45	1.62e-19	2.88e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
HNSC	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	9.45	1.64e-19	2.92e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	9.45	1.64e-19	2.92e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
HNSC	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-9.45	1.65e-19	2.94e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
HNSC	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	9.45	1.65e-19	2.94e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	9.45	1.65e-19	2.94e-16	0.5	0.4	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
HNSC	cis	rs6867032	0.874	rs4975786	ENSG00000249731.1	RP11-259O2.3	-9.45	1.69e-19	3.01e-16	-0.52	-0.4	Gut microbiome composition (winter);	chr5:2004610	chr5:1968094~1969013:+
HNSC	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	9.45	1.7e-19	3.03e-16	0.41	0.4	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	9.45	1.7e-19	3.03e-16	0.41	0.4	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
HNSC	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-9.44	1.73e-19	3.07e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	9.44	1.76e-19	3.13e-16	0.51	0.4	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	9.44	1.78e-19	3.17e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
HNSC	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-9.44	1.81e-19	3.21e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
HNSC	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
HNSC	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	9.44	1.83e-19	3.26e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	9.44	1.83e-19	3.26e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-9.43	1.85e-19	3.3e-16	-0.52	-0.4	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
HNSC	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
HNSC	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	9.43	1.86e-19	3.31e-16	0.46	0.4	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
HNSC	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-9.43	1.88e-19	3.33e-16	-0.47	-0.4	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	9.43	1.92e-19	3.42e-16	0.52	0.4	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	9.43	1.93e-19	3.43e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000173295.6	FAM86B3P	9.43	1.96e-19	3.47e-16	0.45	0.4	Mood instability;	chr8:8283379	chr8:8228595~8244865:+
HNSC	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
HNSC	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	9.43	1.96e-19	3.47e-16	0.45	0.4	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
HNSC	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	9.43	1.96e-19	3.48e-16	0.38	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	9.43	1.96e-19	3.48e-16	0.38	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
HNSC	cis	rs801193	1	rs2659915	ENSG00000179406.6	LINC00174	-9.43	1.99e-19	3.52e-16	-0.5	-0.4	Aortic root size;	chr7:66688114	chr7:66376044~66401338:-
HNSC	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-9.42	2.03e-19	3.6e-16	-0.38	-0.4	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-9.42	2.03e-19	3.6e-16	-0.38	-0.4	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	9.42	2.04e-19	3.6e-16	0.45	0.4	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
HNSC	cis	rs6867032	0.839	rs4314451	ENSG00000249731.1	RP11-259O2.3	-9.42	2.04e-19	3.61e-16	-0.51	-0.4	Gut microbiome composition (winter);	chr5:2001745	chr5:1968094~1969013:+
HNSC	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	9.42	2.08e-19	3.68e-16	0.39	0.4	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
HNSC	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-9.42	2.09e-19	3.7e-16	-0.53	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
HNSC	cis	rs801193	1	rs17566701	ENSG00000179406.6	LINC00174	-9.42	2.09e-19	3.7e-16	-0.51	-0.4	Aortic root size;	chr7:66728196	chr7:66376044~66401338:-
HNSC	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	9.42	2.1e-19	3.72e-16	0.49	0.4	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
HNSC	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
HNSC	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-9.42	2.15e-19	3.8e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-9.42	2.15e-19	3.8e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
HNSC	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	9.41	2.17e-19	3.84e-16	0.52	0.4	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
HNSC	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-9.41	2.18e-19	3.85e-16	-0.58	-0.4	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
HNSC	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-9.41	2.26e-19	3.99e-16	-0.46	-0.4	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
HNSC	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-9.41	2.26e-19	4e-16	-0.38	-0.4	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
HNSC	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-9.41	2.28e-19	4.02e-16	-0.5	-0.4	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
HNSC	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-9.41	2.32e-19	4.09e-16	-0.38	-0.4	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
HNSC	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
HNSC	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-9.41	2.35e-19	4.14e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
HNSC	cis	rs8072100	0.72	rs4794057	ENSG00000228782.6	CTD-2026D20.3	9.4	2.4e-19	4.23e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47709086	chr17:47450568~47492492:-
HNSC	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-9.4	2.46e-19	4.33e-16	-0.5	-0.4	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
HNSC	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-9.4	2.46e-19	4.34e-16	-0.52	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
HNSC	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-9.4	2.47e-19	4.35e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
HNSC	cis	rs5769707	0.935	rs739239	ENSG00000188511.11	C22orf34	9.4	2.49e-19	4.38e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49414524~49657542:-
HNSC	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-9.4	2.5e-19	4.4e-16	-0.42	-0.4	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
HNSC	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	9.4	2.51e-19	4.42e-16	0.52	0.4	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
HNSC	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-9.4	2.52e-19	4.43e-16	-0.43	-0.4	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
HNSC	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	9.39	2.59e-19	4.55e-16	0.5	0.4	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
HNSC	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-9.39	2.59e-19	4.55e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
HNSC	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-9.39	2.61e-19	4.6e-16	-0.51	-0.4	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	9.39	2.63e-19	4.63e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
HNSC	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-9.39	2.67e-19	4.69e-16	-0.54	-0.4	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
HNSC	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	9.39	2.72e-19	4.78e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
HNSC	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	9.38	2.76e-19	4.85e-16	0.45	0.4	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000173295.6	FAM86B3P	9.38	2.77e-19	4.87e-16	0.45	0.4	Mood instability;	chr8:8288087	chr8:8228595~8244865:+
HNSC	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	9.38	2.78e-19	4.88e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
HNSC	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	9.38	2.79e-19	4.89e-16	0.53	0.4	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
HNSC	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-9.38	2.8e-19	4.91e-16	-0.41	-0.4	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
HNSC	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	9.38	2.83e-19	4.95e-16	0.46	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
HNSC	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-9.38	2.83e-19	4.96e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
HNSC	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-9.38	2.85e-19	4.99e-16	-0.51	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
HNSC	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	9.38	2.86e-19	5e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000179406.6	LINC00174	9.38	2.86e-19	5.01e-16	0.51	0.4	Aortic root size;	chr7:66113790	chr7:66376044~66401338:-
HNSC	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-9.38	2.88e-19	5.04e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
HNSC	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	9.38	2.92e-19	5.11e-16	0.45	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
HNSC	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-9.37	3.11e-19	5.43e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
HNSC	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-9.37	3.13e-19	5.47e-16	-0.41	-0.4	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-9.37	3.17e-19	5.54e-16	-0.56	-0.4	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
HNSC	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	9.37	3.22e-19	5.62e-16	0.43	0.4	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
HNSC	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	9.37	3.22e-19	5.62e-16	0.37	0.4	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
HNSC	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
HNSC	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
HNSC	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	9.36	3.28e-19	5.73e-16	0.44	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
HNSC	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	9.36	3.31e-19	5.77e-16	0.43	0.4	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	9.36	3.31e-19	5.77e-16	0.43	0.4	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
HNSC	cis	rs5769707	0.874	rs9616714	ENSG00000188511.11	C22orf34	9.36	3.32e-19	5.79e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49414524~49657542:-
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	9.36	3.35e-19	5.84e-16	0.53	0.4	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
HNSC	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-9.36	3.37e-19	5.88e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-9.36	3.4e-19	5.93e-16	-0.46	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-9.36	3.4e-19	5.93e-16	-0.46	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
HNSC	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-9.36	3.44e-19	5.99e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	9.36	3.47e-19	6.04e-16	0.43	0.4	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
HNSC	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-9.36	3.5e-19	6.09e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000179406.6	LINC00174	-9.35	3.51e-19	6.11e-16	-0.5	-0.4	Aortic root size;	chr7:65967557	chr7:66376044~66401338:-
HNSC	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	9.35	3.52e-19	6.13e-16	0.55	0.4	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
HNSC	cis	rs6867032	0.917	rs10474734	ENSG00000249731.1	RP11-259O2.3	9.35	3.55e-19	6.17e-16	0.5	0.4	Gut microbiome composition (winter);	chr5:2004094	chr5:1968094~1969013:+
HNSC	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-9.35	3.55e-19	6.17e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
HNSC	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-9.35	3.57e-19	6.21e-16	-0.5	-0.4	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
HNSC	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	9.35	3.58e-19	6.21e-16	0.47	0.4	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
HNSC	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	9.35	3.58e-19	6.21e-16	0.47	0.4	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
HNSC	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	9.35	3.6e-19	6.25e-16	0.54	0.4	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
HNSC	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-9.35	3.61e-19	6.28e-16	-0.44	-0.4	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
HNSC	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
HNSC	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-9.35	3.68e-19	6.39e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
HNSC	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	9.35	3.68e-19	6.4e-16	0.38	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
HNSC	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	9.35	3.7e-19	6.41e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	9.35	3.7e-19	6.41e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
HNSC	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	9.35	3.7e-19	6.41e-16	0.45	0.4	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
HNSC	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-9.35	3.7e-19	6.42e-16	-0.43	-0.4	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-9.35	3.7e-19	6.42e-16	-0.43	-0.4	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-9.35	3.7e-19	6.42e-16	-0.43	-0.4	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
HNSC	cis	rs6867032	0.834	rs4526149	ENSG00000249731.1	RP11-259O2.3	-9.35	3.71e-19	6.43e-16	-0.53	-0.4	Gut microbiome composition (winter);	chr5:1990052	chr5:1968094~1969013:+
HNSC	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	9.35	3.73e-19	6.47e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
HNSC	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-9.35	3.79e-19	6.58e-16	-0.5	-0.4	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
HNSC	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	9.34	3.8e-19	6.59e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
HNSC	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-9.34	3.89e-19	6.74e-16	-0.52	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
HNSC	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	9.34	3.95e-19	6.84e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
HNSC	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	9.34	3.97e-19	6.87e-16	0.45	0.4	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
HNSC	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-9.34	3.97e-19	6.88e-16	-0.43	-0.4	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
HNSC	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-9.34	3.97e-19	6.88e-16	-0.43	-0.4	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
HNSC	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-9.34	3.98e-19	6.88e-16	-0.45	-0.4	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
HNSC	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-9.34	4.01e-19	6.93e-16	-0.47	-0.4	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
HNSC	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	9.34	4.03e-19	6.96e-16	0.55	0.4	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
HNSC	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	9.34	4.06e-19	7.02e-16	0.71	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	9.34	4.06e-19	7.02e-16	0.71	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.522	rs709604	ENSG00000179406.6	LINC00174	9.34	4.09e-19	7.07e-16	0.5	0.4	Aortic root size;	chr7:66032447	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2055682	ENSG00000179406.6	LINC00174	-9.33	4.11e-19	7.1e-16	-0.51	-0.4	Aortic root size;	chr7:66795302	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	9.33	4.13e-19	7.14e-16	0.73	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	9.33	4.14e-19	7.15e-16	0.43	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
HNSC	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-9.33	4.16e-19	7.17e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-9.33	4.16e-19	7.17e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-9.33	4.16e-19	7.17e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
HNSC	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
HNSC	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
HNSC	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	9.33	4.37e-19	7.53e-16	0.51	0.4	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
HNSC	cis	rs4972806	0.814	rs2113560	ENSG00000226363.3	HAGLROS	-9.33	4.4e-19	7.58e-16	-0.48	-0.4	IgG glycosylation;	chr2:176166258	chr2:176177717~176179008:+
HNSC	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	9.33	4.4e-19	7.58e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
HNSC	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	9.33	4.43e-19	7.64e-16	0.43	0.4	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
HNSC	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	9.33	4.45e-19	7.66e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
HNSC	cis	rs4972806	0.775	rs2857534	ENSG00000226363.3	HAGLROS	-9.32	4.52e-19	7.79e-16	-0.47	-0.4	IgG glycosylation;	chr2:176170948	chr2:176177717~176179008:+
HNSC	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	9.32	4.55e-19	7.82e-16	0.55	0.4	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
HNSC	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-9.32	4.63e-19	7.96e-16	-0.44	-0.4	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-9.32	4.68e-19	8.04e-16	-0.44	-0.4	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	9.32	4.69e-19	8.06e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
HNSC	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-9.32	4.75e-19	8.15e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
HNSC	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-9.32	4.82e-19	8.27e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
HNSC	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-9.31	4.85e-19	8.32e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
HNSC	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-9.31	4.93e-19	8.46e-16	-0.49	-0.4	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
HNSC	cis	rs12439619	0.508	rs17354842	ENSG00000255769.6	GOLGA2P10	9.31	4.97e-19	8.52e-16	0.48	0.4	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	9.31	5e-19	8.58e-16	0.5	0.4	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	9.31	5e-19	8.58e-16	0.5	0.4	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-9.31	5.03e-19	8.63e-16	-0.45	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
HNSC	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-9.31	5.07e-19	8.68e-16	-0.43	-0.4	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
HNSC	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	9.31	5.09e-19	8.72e-16	0.48	0.4	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
HNSC	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-9.31	5.1e-19	8.73e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
HNSC	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-9.31	5.11e-19	8.75e-16	-0.77	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
HNSC	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-9.31	5.13e-19	8.78e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
HNSC	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	9.31	5.21e-19	8.92e-16	0.51	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
HNSC	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	9.3	5.25e-19	8.98e-16	0.52	0.4	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	9.3	5.26e-19	8.98e-16	0.5	0.4	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
HNSC	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-9.3	5.27e-19	9.01e-16	-0.46	-0.4	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
HNSC	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-9.3	5.34e-19	9.12e-16	-0.38	-0.4	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
HNSC	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-9.3	5.39e-19	9.2e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-9.3	5.39e-19	9.2e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
HNSC	cis	rs7615952	0.932	rs9841157	ENSG00000241288.6	RP11-379B18.5	-9.3	5.42e-19	9.25e-16	-0.59	-0.4	Blood pressure (smoking interaction);	chr3:125916812	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.551	rs12695470	ENSG00000241288.6	RP11-379B18.5	-9.3	5.42e-19	9.25e-16	-0.59	-0.4	Blood pressure (smoking interaction);	chr3:125916875	chr3:125827238~125916384:-
HNSC	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-9.3	5.52e-19	9.42e-16	-0.42	-0.4	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
HNSC	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-9.3	5.54e-19	9.45e-16	-0.56	-0.4	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
HNSC	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	9.3	5.55e-19	9.47e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
HNSC	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-9.3	5.56e-19	9.48e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
HNSC	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	9.3	5.58e-19	9.51e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
HNSC	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	9.29	5.66e-19	9.64e-16	0.46	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
HNSC	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-9.29	5.83e-19	9.93e-16	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
HNSC	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	9.29	5.91e-19	1.01e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	9.29	5.91e-19	1.01e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	9.29	5.91e-19	1.01e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
HNSC	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-9.29	5.99e-19	1.02e-15	-0.47	-0.39	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	9.29	6.05e-19	1.03e-15	0.53	0.39	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-9.28	6.16e-19	1.05e-15	-0.54	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
HNSC	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	9.28	6.18e-19	1.05e-15	0.6	0.39	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
HNSC	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	9.28	6.19e-19	1.05e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	9.28	6.24e-19	1.06e-15	0.52	0.39	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
HNSC	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	9.28	6.32e-19	1.07e-15	0.52	0.39	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
HNSC	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-9.28	6.32e-19	1.07e-15	-0.43	-0.39	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-9.28	6.32e-19	1.07e-15	-0.43	-0.39	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
HNSC	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	9.28	6.41e-19	1.09e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
HNSC	cis	rs5769707	0.935	rs9616332	ENSG00000188511.11	C22orf34	9.28	6.42e-19	1.09e-15	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49414524~49657542:-
HNSC	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	9.28	6.44e-19	1.09e-15	0.42	0.39	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
HNSC	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	9.28	6.47e-19	1.1e-15	0.51	0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-9.28	6.47e-19	1.1e-15	-0.51	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
HNSC	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-9.28	6.54e-19	1.11e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
HNSC	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	9.28	6.61e-19	1.12e-15	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
HNSC	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	9.27	6.63e-19	1.12e-15	0.52	0.39	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
HNSC	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	9.27	6.68e-19	1.13e-15	0.76	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
HNSC	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-9.27	6.7e-19	1.14e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-9.27	6.7e-19	1.14e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
HNSC	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	9.27	6.76e-19	1.15e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
HNSC	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	9.27	6.84e-19	1.16e-15	0.59	0.39	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
HNSC	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-9.27	6.85e-19	1.16e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
HNSC	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-9.27	6.85e-19	1.16e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
HNSC	cis	rs16885979	1	rs17682328	ENSG00000224984.1	RP11-524H19.2	-9.27	6.92e-19	1.17e-15	-0.99	-0.39	Daytime sleep phenotypes;	chr6:54845278	chr6:54840118~54840855:-
HNSC	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-9.27	6.92e-19	1.17e-15	-0.51	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
HNSC	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-9.27	7.02e-19	1.19e-15	-0.45	-0.39	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
HNSC	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	9.27	7.05e-19	1.19e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	9.27	7.05e-19	1.19e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
HNSC	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	9.27	7.07e-19	1.2e-15	0.59	0.39	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
HNSC	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-9.27	7.1e-19	1.2e-15	-0.47	-0.39	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
HNSC	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-9.26	7.2e-19	1.22e-15	-0.41	-0.39	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
HNSC	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	9.26	7.2e-19	1.22e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
HNSC	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-9.26	7.28e-19	1.23e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
HNSC	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-9.26	7.36e-19	1.24e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
HNSC	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-9.26	7.52e-19	1.27e-15	-0.56	-0.39	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
HNSC	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	9.26	7.63e-19	1.29e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
HNSC	cis	rs7615952	0.932	rs11922218	ENSG00000241288.6	RP11-379B18.5	-9.26	7.67e-19	1.29e-15	-0.56	-0.39	Blood pressure (smoking interaction);	chr3:125912446	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.866	rs11922276	ENSG00000241288.6	RP11-379B18.5	-9.26	7.67e-19	1.29e-15	-0.56	-0.39	Blood pressure (smoking interaction);	chr3:125912483	chr3:125827238~125916384:-
HNSC	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-9.26	7.75e-19	1.31e-15	-0.38	-0.39	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
HNSC	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	9.25	7.76e-19	1.31e-15	0.48	0.39	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
HNSC	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	9.25	7.76e-19	1.31e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	9.25	7.76e-19	1.31e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	9.25	7.76e-19	1.31e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
HNSC	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-9.25	7.94e-19	1.34e-15	-0.51	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
HNSC	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	9.25	8e-19	1.35e-15	0.43	0.39	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
HNSC	cis	rs6867032	0.527	rs4371796	ENSG00000249731.1	RP11-259O2.3	-9.25	8.03e-19	1.35e-15	-0.58	-0.39	Gut microbiome composition (winter);	chr5:1977671	chr5:1968094~1969013:+
HNSC	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	9.25	8.13e-19	1.37e-15	0.5	0.39	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-9.25	8.2e-19	1.38e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
HNSC	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-9.25	8.24e-19	1.39e-15	-0.54	-0.39	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
HNSC	cis	rs4972806	0.814	rs966801	ENSG00000226363.3	HAGLROS	-9.25	8.33e-19	1.4e-15	-0.47	-0.39	IgG glycosylation;	chr2:176173099	chr2:176177717~176179008:+
HNSC	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	9.25	8.39e-19	1.41e-15	0.43	0.39	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
HNSC	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-9.24	8.41e-19	1.42e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000179406.6	LINC00174	-9.24	8.47e-19	1.43e-15	-0.51	-0.39	Calcium levels;	chr7:65941231	chr7:66376044~66401338:-
HNSC	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-9.24	8.49e-19	1.43e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-9.24	8.49e-19	1.43e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-9.24	8.58e-19	1.44e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
HNSC	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	9.24	8.68e-19	1.46e-15	0.56	0.39	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	9.24	8.74e-19	1.47e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	9.24	8.74e-19	1.47e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
HNSC	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	9.24	8.77e-19	1.48e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
HNSC	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-9.24	8.82e-19	1.48e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
HNSC	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-9.24	9.01e-19	1.51e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
HNSC	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-9.24	9.02e-19	1.52e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
HNSC	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-9.24	9.05e-19	1.52e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000179406.6	LINC00174	-9.24	9.07e-19	1.52e-15	-0.51	-0.39	Aortic root size;	chr7:65951183	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
HNSC	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	9.23	9.17e-19	1.54e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
HNSC	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-9.23	9.2e-19	1.55e-15	-0.37	-0.39	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-9.23	9.2e-19	1.55e-15	-0.37	-0.39	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000179406.6	LINC00174	-9.23	9.24e-19	1.55e-15	-0.51	-0.39	Aortic root size;	chr7:65964026	chr7:66376044~66401338:-
HNSC	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	9.23	9.25e-19	1.55e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	9.23	9.25e-19	1.55e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
HNSC	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-9.23	9.28e-19	1.56e-15	-0.4	-0.39	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-9.23	9.28e-19	1.56e-15	-0.4	-0.39	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
HNSC	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	9.23	9.39e-19	1.58e-15	0.52	0.39	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000179406.6	LINC00174	-9.23	9.44e-19	1.58e-15	-0.5	-0.39	Aortic root size;	chr7:66789659	chr7:66376044~66401338:-
HNSC	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	9.23	9.48e-19	1.59e-15	0.53	0.39	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
HNSC	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-9.23	9.48e-19	1.59e-15	-0.45	-0.39	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-9.23	9.48e-19	1.59e-15	-0.45	-0.39	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
HNSC	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	9.23	9.63e-19	1.61e-15	0.45	0.39	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
HNSC	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	9.23	9.64e-19	1.62e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
HNSC	cis	rs7615952	0.932	rs13325495	ENSG00000241288.6	RP11-379B18.5	-9.23	9.72e-19	1.63e-15	-0.59	-0.39	Blood pressure (smoking interaction);	chr3:125918573	chr3:125827238~125916384:-
HNSC	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-9.23	9.76e-19	1.63e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
HNSC	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-9.22	9.83e-19	1.65e-15	-0.52	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-9.22	9.83e-19	1.65e-15	-0.52	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
HNSC	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	9.22	9.83e-19	1.65e-15	0.42	0.39	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
HNSC	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	9.22	9.89e-19	1.66e-15	0.45	0.39	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
HNSC	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	9.22	9.9e-19	1.66e-15	0.41	0.39	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
HNSC	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	9.22	9.94e-19	1.66e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000179406.6	LINC00174	-9.22	9.95e-19	1.67e-15	-0.49	-0.39	Aortic root size;	chr7:66631041	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	9.22	9.95e-19	1.67e-15	0.5	0.39	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
HNSC	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	9.22	9.99e-19	1.67e-15	0.42	0.39	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
HNSC	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	9.22	1.01e-18	1.69e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
HNSC	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-9.22	1.01e-18	1.69e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
HNSC	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	9.22	1.02e-18	1.7e-15	0.51	0.39	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.577	rs34888281	ENSG00000179406.6	LINC00174	9.22	1.02e-18	1.7e-15	0.51	0.39	Aortic root size;	chr7:66120784	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	9.22	1.03e-18	1.73e-15	0.39	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000179406.6	LINC00174	-9.22	1.04e-18	1.74e-15	-0.51	-0.39	Calcium levels;	chr7:65967580	chr7:66376044~66401338:-
HNSC	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-9.22	1.06e-18	1.76e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
HNSC	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	9.22	1.06e-18	1.77e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
HNSC	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-9.21	1.07e-18	1.78e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
HNSC	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	9.21	1.07e-18	1.78e-15	0.42	0.39	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
HNSC	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	9.21	1.08e-18	1.8e-15	0.41	0.39	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
HNSC	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	9.21	1.08e-18	1.81e-15	0.51	0.39	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
HNSC	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-9.21	1.1e-18	1.84e-15	-0.5	-0.39	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-9.21	1.11e-18	1.85e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	9.21	1.11e-18	1.85e-15	0.6	0.39	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-9.21	1.13e-18	1.89e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	9.21	1.14e-18	1.89e-15	0.51	0.39	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
HNSC	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-9.2	1.15e-18	1.92e-15	-0.49	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-9.2	1.16e-18	1.93e-15	-0.58	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
HNSC	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	9.2	1.18e-18	1.97e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
HNSC	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
HNSC	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	9.2	1.2e-18	1.99e-15	0.43	0.39	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
HNSC	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-9.2	1.22e-18	2.03e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
HNSC	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	9.2	1.23e-18	2.04e-15	0.42	0.39	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
HNSC	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-9.2	1.23e-18	2.05e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
HNSC	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	9.2	1.23e-18	2.05e-15	0.52	0.39	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
HNSC	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-9.2	1.24e-18	2.06e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
HNSC	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
HNSC	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
HNSC	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	9.2	1.24e-18	2.06e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
HNSC	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	9.19	1.25e-18	2.08e-15	0.48	0.39	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
HNSC	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-9.19	1.26e-18	2.1e-15	-0.52	-0.39	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
HNSC	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	9.19	1.27e-18	2.11e-15	0.71	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
HNSC	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-9.19	1.27e-18	2.11e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-9.19	1.27e-18	2.11e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
HNSC	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-9.19	1.28e-18	2.13e-15	-0.5	-0.39	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
HNSC	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	9.19	1.28e-18	2.13e-15	0.71	0.39	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
HNSC	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	9.19	1.3e-18	2.15e-15	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	9.19	1.31e-18	2.17e-15	0.5	0.39	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-9.19	1.32e-18	2.18e-15	-0.49	-0.39	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
HNSC	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-9.19	1.32e-18	2.18e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
HNSC	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-9.19	1.33e-18	2.2e-15	-0.5	-0.39	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
HNSC	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	9.19	1.34e-18	2.21e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
HNSC	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-9.19	1.34e-18	2.23e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
HNSC	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-9.19	1.35e-18	2.23e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
HNSC	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-9.18	1.35e-18	2.24e-15	-0.52	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	9.18	1.35e-18	2.24e-15	0.46	0.39	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
HNSC	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-9.18	1.36e-18	2.25e-15	-0.49	-0.39	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-9.18	1.36e-18	2.26e-15	-0.44	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
HNSC	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-9.18	1.4e-18	2.31e-15	-0.43	-0.39	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
HNSC	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	9.18	1.4e-18	2.31e-15	0.49	0.39	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
HNSC	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	9.18	1.41e-18	2.33e-15	0.66	0.39	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
HNSC	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-9.18	1.41e-18	2.33e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
HNSC	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-9.18	1.43e-18	2.36e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
HNSC	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-9.18	1.43e-18	2.36e-15	-0.49	-0.39	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
HNSC	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-9.18	1.43e-18	2.36e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
HNSC	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	9.18	1.43e-18	2.37e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
HNSC	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-9.18	1.44e-18	2.37e-15	-0.37	-0.39	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
HNSC	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-9.18	1.44e-18	2.38e-15	-0.41	-0.39	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
HNSC	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	9.17	1.46e-18	2.41e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
HNSC	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-9.17	1.5e-18	2.47e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
HNSC	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	9.17	1.51e-18	2.48e-15	0.42	0.39	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
HNSC	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	9.17	1.51e-18	2.48e-15	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
HNSC	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	9.17	1.51e-18	2.49e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	9.17	1.51e-18	2.49e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	9.17	1.51e-18	2.49e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
HNSC	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	9.17	1.54e-18	2.53e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
HNSC	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-9.17	1.54e-18	2.54e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
HNSC	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-9.17	1.55e-18	2.55e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
HNSC	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	9.17	1.56e-18	2.56e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	9.17	1.56e-18	2.56e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
HNSC	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-9.16	1.58e-18	2.6e-15	-0.49	-0.39	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	9.16	1.59e-18	2.62e-15	0.51	0.39	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
HNSC	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-9.16	1.6e-18	2.63e-15	-0.37	-0.39	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-9.16	1.6e-18	2.63e-15	-0.37	-0.39	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
HNSC	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-9.16	1.61e-18	2.64e-15	-0.4	-0.39	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
HNSC	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-9.16	1.63e-18	2.68e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
HNSC	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-9.16	1.63e-18	2.68e-15	-0.45	-0.39	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
HNSC	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	9.16	1.64e-18	2.7e-15	0.44	0.39	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-9.16	1.64e-18	2.7e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-9.16	1.66e-18	2.72e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000179406.6	LINC00174	9.16	1.69e-18	2.78e-15	0.51	0.39	Aortic root size;	chr7:66836124	chr7:66376044~66401338:-
HNSC	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	9.16	1.7e-18	2.78e-15	0.35	0.39	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
HNSC	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-9.16	1.7e-18	2.79e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
HNSC	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-9.16	1.7e-18	2.79e-15	-0.47	-0.39	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
HNSC	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-9.16	1.7e-18	2.79e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-9.16	1.7e-18	2.79e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-9.15	1.71e-18	2.8e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
HNSC	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-9.15	1.72e-18	2.82e-15	-0.49	-0.39	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
HNSC	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	9.15	1.73e-18	2.83e-15	0.38	0.39	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
HNSC	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	9.15	1.73e-18	2.84e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	9.15	1.76e-18	2.88e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	9.15	1.76e-18	2.88e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-9.15	1.76e-18	2.88e-15	-0.43	-0.39	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
HNSC	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	9.15	1.76e-18	2.89e-15	0.44	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
HNSC	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-9.15	1.76e-18	2.89e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
HNSC	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-9.15	1.77e-18	2.89e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	9.15	1.79e-18	2.92e-15	0.42	0.39	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-9.15	1.8e-18	2.95e-15	-0.42	-0.39	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-9.15	1.83e-18	3e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
HNSC	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-9.15	1.84e-18	3.01e-15	-0.52	-0.39	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
HNSC	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-9.14	1.85e-18	3.03e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
HNSC	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-9.14	1.86e-18	3.04e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-9.14	1.86e-18	3.04e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000179406.6	LINC00174	9.14	1.87e-18	3.06e-15	0.5	0.39	Aortic root size;	chr7:65950660	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	9.14	1.88e-18	3.08e-15	0.44	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-9.14	1.89e-18	3.09e-15	-0.44	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
HNSC	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-9.14	1.91e-18	3.12e-15	-0.47	-0.39	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
HNSC	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-9.14	1.91e-18	3.13e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000173295.6	FAM86B3P	9.14	1.92e-18	3.14e-15	0.45	0.39	Neuroticism;	chr8:8241055	chr8:8228595~8244865:+
HNSC	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-9.14	1.97e-18	3.21e-15	-0.37	-0.39	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
HNSC	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-9.14	1.99e-18	3.25e-15	-0.39	-0.39	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
HNSC	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	9.13	2.01e-18	3.29e-15	0.45	0.39	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
HNSC	cis	rs5769707	0.967	rs8141807	ENSG00000188511.11	C22orf34	9.13	2.02e-18	3.3e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49414524~49657542:-
HNSC	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-9.13	2.02e-18	3.3e-15	-0.37	-0.39	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
HNSC	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-9.13	2.03e-18	3.31e-15	-0.5	-0.39	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
HNSC	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-9.13	2.03e-18	3.31e-15	-0.6	-0.39	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
HNSC	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-9.13	2.03e-18	3.31e-15	-0.6	-0.39	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	9.13	2.04e-18	3.32e-15	0.4	0.39	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
HNSC	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	9.13	2.06e-18	3.36e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	9.13	2.07e-18	3.37e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
HNSC	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-9.13	2.15e-18	3.5e-15	-0.44	-0.39	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
HNSC	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-9.12	2.16e-18	3.51e-15	-0.44	-0.39	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
HNSC	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-9.12	2.16e-18	3.52e-15	-0.43	-0.39	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
HNSC	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	9.12	2.16e-18	3.52e-15	0.44	0.39	Depression;	chr6:28317705	chr6:28176188~28176674:+
HNSC	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	9.12	2.23e-18	3.62e-15	0.49	0.39	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
HNSC	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
HNSC	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-9.12	2.25e-18	3.65e-15	-0.46	-0.39	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	9.12	2.28e-18	3.7e-15	0.44	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
HNSC	cis	rs16885979	1	rs9357819	ENSG00000224984.1	RP11-524H19.2	9.12	2.29e-18	3.71e-15	0.93	0.39	Daytime sleep phenotypes;	chr6:54843279	chr6:54840118~54840855:-
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	9.11	2.36e-18	3.83e-15	0.42	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
HNSC	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	9.11	2.36e-18	3.83e-15	0.51	0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
HNSC	cis	rs875971	0.54	rs781152	ENSG00000179406.6	LINC00174	-9.11	2.36e-18	3.83e-15	-0.5	-0.39	Aortic root size;	chr7:66014585	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000179406.6	LINC00174	-9.11	2.36e-18	3.83e-15	-0.5	-0.39	Calcium levels;	chr7:66014891	chr7:66376044~66401338:-
HNSC	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-9.11	2.37e-18	3.85e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	9.11	2.38e-18	3.86e-15	0.52	0.39	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-9.11	2.4e-18	3.88e-15	-0.42	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
HNSC	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	9.11	2.4e-18	3.88e-15	0.43	0.39	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
HNSC	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-9.11	2.4e-18	3.89e-15	-0.37	-0.39	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-9.11	2.41e-18	3.91e-15	-0.37	-0.39	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
HNSC	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	9.11	2.45e-18	3.97e-15	0.49	0.39	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	9.11	2.45e-18	3.97e-15	0.49	0.39	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
HNSC	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-9.11	2.45e-18	3.97e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
HNSC	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	9.11	2.46e-18	3.99e-15	0.41	0.39	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
HNSC	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-9.11	2.47e-18	4e-15	-0.49	-0.39	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-9.11	2.5e-18	4.04e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
HNSC	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-9.11	2.5e-18	4.04e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-9.11	2.51e-18	4.06e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
HNSC	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	9.11	2.52e-18	4.07e-15	0.44	0.39	Depression;	chr6:28323463	chr6:28176188~28176674:+
HNSC	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-9.1	2.55e-18	4.12e-15	-0.37	-0.39	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-9.1	2.55e-18	4.12e-15	-0.37	-0.39	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-9.1	2.55e-18	4.12e-15	-0.37	-0.39	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
HNSC	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-9.1	2.55e-18	4.13e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
HNSC	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-9.1	2.56e-18	4.15e-15	-0.41	-0.39	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
HNSC	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-9.1	2.57e-18	4.15e-15	-0.49	-0.39	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-9.1	2.58e-18	4.18e-15	-0.44	-0.39	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	9.1	2.59e-18	4.19e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
HNSC	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	9.1	2.62e-18	4.23e-15	0.43	0.39	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
HNSC	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	9.1	2.62e-18	4.23e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
HNSC	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-9.1	2.63e-18	4.25e-15	-0.41	-0.39	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-9.1	2.66e-18	4.3e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	9.1	2.69e-18	4.33e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
HNSC	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	9.1	2.69e-18	4.34e-15	0.47	0.39	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
HNSC	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-9.1	2.69e-18	4.34e-15	-0.44	-0.39	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
HNSC	cis	rs16885979	1	rs17749547	ENSG00000224984.1	RP11-524H19.2	9.1	2.71e-18	4.37e-15	0.93	0.39	Daytime sleep phenotypes;	chr6:54845642	chr6:54840118~54840855:-
HNSC	cis	rs16885979	0.793	rs62412648	ENSG00000224984.1	RP11-524H19.2	9.1	2.71e-18	4.37e-15	0.93	0.39	Daytime sleep phenotypes;	chr6:54847061	chr6:54840118~54840855:-
HNSC	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	9.09	2.78e-18	4.49e-15	0.42	0.39	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
HNSC	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-9.09	2.79e-18	4.49e-15	-0.51	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
HNSC	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	9.09	2.79e-18	4.5e-15	0.43	0.39	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
HNSC	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-9.09	2.8e-18	4.52e-15	-0.41	-0.39	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
HNSC	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	9.09	2.84e-18	4.58e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
HNSC	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-9.09	2.85e-18	4.59e-15	-0.49	-0.39	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	9.09	2.93e-18	4.71e-15	0.41	0.39	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
HNSC	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	9.08	2.97e-18	4.78e-15	0.51	0.39	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
HNSC	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	9.08	2.98e-18	4.79e-15	0.56	0.39	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
HNSC	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-9.08	3e-18	4.82e-15	-0.4	-0.39	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
HNSC	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-9.08	3.02e-18	4.85e-15	-0.49	-0.39	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
HNSC	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-9.08	3.06e-18	4.92e-15	-0.3	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
HNSC	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-9.08	3.07e-18	4.93e-15	-0.45	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
HNSC	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-9.08	3.09e-18	4.96e-15	-0.51	-0.39	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
HNSC	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-9.08	3.1e-18	4.97e-15	-0.49	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
HNSC	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-9.08	3.11e-18	4.99e-15	-0.53	-0.39	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
HNSC	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-9.08	3.11e-18	5e-15	-0.49	-0.39	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-9.08	3.12e-18	5.01e-15	-0.44	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
HNSC	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-9.08	3.16e-18	5.07e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
HNSC	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-9.08	3.16e-18	5.08e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
HNSC	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	9.08	3.19e-18	5.12e-15	0.43	0.39	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
HNSC	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	9.08	3.19e-18	5.12e-15	0.43	0.39	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
HNSC	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-9.07	3.2e-18	5.14e-15	-0.44	-0.39	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-9.07	3.2e-18	5.14e-15	-0.44	-0.39	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
HNSC	cis	rs5769707	0.967	rs9616713	ENSG00000188511.11	C22orf34	9.07	3.21e-18	5.15e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	9.07	3.22e-18	5.17e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
HNSC	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	9.07	3.24e-18	5.19e-15	0.53	0.39	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
HNSC	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-9.07	3.27e-18	5.24e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
HNSC	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	9.07	3.31e-18	5.31e-15	0.46	0.39	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
HNSC	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-9.06	3.47e-18	5.56e-15	-0.4	-0.39	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000179406.6	LINC00174	-9.06	3.5e-18	5.61e-15	-0.5	-0.39	Aortic root size;	chr7:66008093	chr7:66376044~66401338:-
HNSC	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	9.06	3.56e-18	5.7e-15	0.44	0.39	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-9.06	3.57e-18	5.72e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
HNSC	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	9.06	3.59e-18	5.74e-15	0.51	0.39	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
HNSC	cis	rs131777	0.563	rs5770927	ENSG00000205559.3	CHKB-AS1	-9.06	3.62e-18	5.78e-15	-0.43	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590516	chr22:50583026~50583877:+
HNSC	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-9.06	3.62e-18	5.79e-15	-0.4	-0.39	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	9.06	3.63e-18	5.8e-15	0.4	0.39	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000179406.6	LINC00174	-9.06	3.67e-18	5.87e-15	-0.49	-0.39	Aortic root size;	chr7:66008701	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-9.06	3.71e-18	5.93e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-9.05	3.75e-18	5.98e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	9.05	3.77e-18	6.02e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
HNSC	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	9.05	3.8e-18	6.07e-15	0.51	0.39	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
HNSC	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	9.05	3.8e-18	6.07e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
HNSC	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-9.05	3.85e-18	6.14e-15	-0.42	-0.39	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
HNSC	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-9.05	3.85e-18	6.14e-15	-0.42	-0.39	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
HNSC	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-9.05	3.85e-18	6.15e-15	-0.49	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
HNSC	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	9.05	3.9e-18	6.22e-15	0.72	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
HNSC	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-9.05	3.9e-18	6.23e-15	-0.52	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
HNSC	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	9.05	3.91e-18	6.24e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
HNSC	cis	rs2834288	0.613	rs2040113	ENSG00000237945.6	LINC00649	9.05	3.92e-18	6.26e-15	0.45	0.39	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33915534~33977691:+
HNSC	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-9.05	3.98e-18	6.35e-15	-0.59	-0.39	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
HNSC	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-9.04	4.04e-18	6.44e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	9.04	4.12e-18	6.56e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
HNSC	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	9.04	4.17e-18	6.64e-15	0.44	0.39	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
HNSC	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	9.04	4.17e-18	6.64e-15	0.33	0.39	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
HNSC	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-9.04	4.2e-18	6.69e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000179406.6	LINC00174	9.04	4.24e-18	6.76e-15	0.49	0.39	Aortic root size;	chr7:66018255	chr7:66376044~66401338:-
HNSC	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-9.04	4.26e-18	6.78e-15	-0.45	-0.39	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
HNSC	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-9.04	4.27e-18	6.79e-15	-0.5	-0.39	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
HNSC	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	9.03	4.39e-18	6.97e-15	0.37	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
HNSC	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-9.03	4.51e-18	7.17e-15	-0.35	-0.39	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
HNSC	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-9.03	4.59e-18	7.29e-15	-0.5	-0.39	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
HNSC	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	9.03	4.6e-18	7.29e-15	0.42	0.39	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
HNSC	cis	rs801193	0.844	rs732465	ENSG00000179406.6	LINC00174	-9.03	4.6e-18	7.29e-15	-0.48	-0.39	Aortic root size;	chr7:66533463	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	9.03	4.66e-18	7.39e-15	0.44	0.39	Depression;	chr6:28301886	chr6:28176188~28176674:+
HNSC	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	9.03	4.66e-18	7.39e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
HNSC	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	9.02	4.74e-18	7.5e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	9.02	4.74e-18	7.51e-15	0.52	0.39	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000179406.6	LINC00174	-9.02	4.75e-18	7.53e-15	-0.49	-0.39	Aortic root size;	chr7:65998108	chr7:66376044~66401338:-
HNSC	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	9.02	4.8e-18	7.6e-15	0.45	0.39	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
HNSC	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-9.02	4.81e-18	7.61e-15	-0.53	-0.39	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
HNSC	cis	rs2006771	0.81	rs4820988	ENSG00000236132.1	CTA-440B3.1	9.02	4.84e-18	7.66e-15	0.43	0.39	Nonsyndromic cleft lip with cleft palate;	chr22:31669821	chr22:31816379~31817491:-
HNSC	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-9.02	4.85e-18	7.68e-15	-0.44	-0.39	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
HNSC	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	9.02	4.86e-18	7.69e-15	0.43	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
HNSC	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
HNSC	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	9.02	4.87e-18	7.7e-15	0.45	0.39	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
HNSC	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-9.02	5.02e-18	7.93e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-9.02	5.08e-18	8.03e-15	-0.44	-0.39	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
HNSC	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	9.01	5.12e-18	8.09e-15	0.41	0.38	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
HNSC	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	9.01	5.23e-18	8.25e-15	0.54	0.38	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
HNSC	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-9.01	5.24e-18	8.26e-15	-0.43	-0.38	Temperament;	chr17:14013482	chr17:14024514~14025488:+
HNSC	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-9.01	5.29e-18	8.34e-15	-0.44	-0.38	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	9.01	5.29e-18	8.34e-15	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
HNSC	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	9.01	5.31e-18	8.36e-15	0.43	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
HNSC	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-9.01	5.34e-18	8.42e-15	-0.45	-0.38	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
HNSC	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	9.01	5.34e-18	8.42e-15	0.46	0.38	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
HNSC	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-9.01	5.39e-18	8.49e-15	-0.45	-0.38	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
HNSC	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	9.01	5.41e-18	8.53e-15	0.53	0.38	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
HNSC	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	9.01	5.48e-18	8.63e-15	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-9	5.52e-18	8.69e-15	-0.49	-0.38	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
HNSC	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	9	5.56e-18	8.75e-15	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
HNSC	cis	rs875971	0.545	rs316328	ENSG00000179406.6	LINC00174	9	5.61e-18	8.83e-15	0.54	0.38	Aortic root size;	chr7:66143851	chr7:66376044~66401338:-
HNSC	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-9	5.69e-18	8.94e-15	-0.3	-0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
HNSC	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-9	5.7e-18	8.96e-15	-0.42	-0.38	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
HNSC	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	9	5.76e-18	9.05e-15	0.53	0.38	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
HNSC	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-9	5.83e-18	9.15e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-9	5.83e-18	9.15e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
HNSC	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-9	5.83e-18	9.16e-15	-0.48	-0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
HNSC	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	9	5.83e-18	9.16e-15	0.53	0.38	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	9	5.83e-18	9.16e-15	0.53	0.38	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
HNSC	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-9	5.89e-18	9.25e-15	-0.41	-0.38	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
HNSC	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-9	5.94e-18	9.32e-15	-0.5	-0.38	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
HNSC	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
HNSC	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-8.99	6.06e-18	9.49e-15	-0.62	-0.38	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
HNSC	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
HNSC	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	8.99	6.21e-18	9.68e-15	0.53	0.38	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
HNSC	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-8.99	6.28e-18	9.79e-15	-0.51	-0.38	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
HNSC	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-8.99	6.36e-18	9.9e-15	-0.37	-0.38	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
HNSC	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-8.99	6.39e-18	9.95e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
HNSC	cis	rs189798	0.738	rs330911	ENSG00000254340.1	RP11-10A14.3	8.99	6.4e-18	9.97e-15	0.51	0.38	Myopia (pathological);	chr8:9138763	chr8:9141424~9145435:+
HNSC	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-8.98	6.48e-18	1.01e-14	-0.4	-0.38	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
HNSC	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	8.98	6.56e-18	1.02e-14	0.53	0.38	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
HNSC	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-8.98	6.65e-18	1.03e-14	-0.42	-0.38	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-8.98	6.74e-18	1.05e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
HNSC	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	8.98	6.74e-18	1.05e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	8.98	6.77e-18	1.05e-14	0.48	0.38	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
HNSC	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-8.98	6.81e-18	1.06e-14	-0.41	-0.38	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
HNSC	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	8.98	6.91e-18	1.07e-14	0.42	0.38	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
HNSC	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-8.97	6.95e-18	1.08e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-8.97	6.95e-18	1.08e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
HNSC	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-8.97	6.96e-18	1.08e-14	-0.53	-0.38	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-8.97	6.96e-18	1.08e-14	-0.53	-0.38	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
HNSC	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-8.97	6.96e-18	1.08e-14	-0.41	-0.38	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
HNSC	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	8.97	7.03e-18	1.09e-14	0.4	0.38	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
HNSC	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	8.97	7.05e-18	1.09e-14	0.43	0.38	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
HNSC	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	8.97	7.12e-18	1.1e-14	0.4	0.38	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	8.97	7.15e-18	1.11e-14	0.44	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
HNSC	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-8.97	7.21e-18	1.12e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-8.97	7.21e-18	1.12e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-8.97	7.21e-18	1.12e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.597	rs11771318	ENSG00000179406.6	LINC00174	8.97	7.22e-18	1.12e-14	0.5	0.38	Aortic root size;	chr7:66597493	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	8.97	7.23e-18	1.12e-14	0.48	0.38	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
HNSC	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	8.97	7.27e-18	1.12e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-8.97	7.27e-18	1.13e-14	-0.49	-0.38	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
HNSC	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-8.97	7.27e-18	1.13e-14	-0.4	-0.38	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-8.97	7.27e-18	1.13e-14	-0.4	-0.38	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
HNSC	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	8.97	7.33e-18	1.13e-14	0.41	0.38	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	8.97	7.35e-18	1.14e-14	0.42	0.38	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
HNSC	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-8.97	7.42e-18	1.15e-14	-0.35	-0.38	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-8.97	7.42e-18	1.15e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-8.97	7.42e-18	1.15e-14	-0.35	-0.38	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-8.97	7.5e-18	1.16e-14	-0.42	-0.38	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
HNSC	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	8.96	7.82e-18	1.21e-14	0.42	0.38	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
HNSC	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-8.96	7.84e-18	1.21e-14	-0.52	-0.38	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
HNSC	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-8.95	8.11e-18	1.25e-14	-0.35	-0.38	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	8.95	8.18e-18	1.26e-14	0.43	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
HNSC	cis	rs6969780	0.915	rs886339	ENSG00000233429.8	HOTAIRM1	-8.95	8.19e-18	1.26e-14	-0.59	-0.38	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27151051	chr7:27095647~27100265:+
HNSC	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.95	8.31e-18	1.28e-14	0.4	0.38	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
HNSC	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	8.95	8.35e-18	1.29e-14	0.49	0.38	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
HNSC	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-8.95	8.35e-18	1.29e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
HNSC	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-8.95	8.4e-18	1.29e-14	-0.37	-0.38	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
HNSC	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	8.95	8.65e-18	1.33e-14	0.49	0.38	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
HNSC	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-8.95	8.71e-18	1.34e-14	-0.49	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
HNSC	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-8.95	8.75e-18	1.35e-14	-0.49	-0.38	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-8.94	8.84e-18	1.36e-14	-0.43	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-8.94	8.84e-18	1.36e-14	-0.43	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
HNSC	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-8.94	8.85e-18	1.36e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
HNSC	cis	rs2834288	0.618	rs9977699	ENSG00000237945.6	LINC00649	-8.94	8.86e-18	1.36e-14	-0.47	-0.38	Gut microbiota (bacterial taxa);	chr21:33978601	chr21:33915534~33977691:+
HNSC	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	8.94	8.95e-18	1.38e-14	0.46	0.38	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
HNSC	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-8.94	8.96e-18	1.38e-14	-0.5	-0.38	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
HNSC	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	8.94	9.02e-18	1.39e-14	0.45	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
HNSC	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	8.94	9.04e-18	1.39e-14	0.64	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-8.94	9.11e-18	1.4e-14	-0.44	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
HNSC	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	8.94	9.12e-18	1.4e-14	0.55	0.38	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
HNSC	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	8.94	9.22e-18	1.42e-14	0.46	0.38	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
HNSC	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-8.94	9.32e-18	1.43e-14	-0.49	-0.38	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-8.94	9.34e-18	1.43e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
HNSC	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-8.94	9.45e-18	1.45e-14	-0.3	-0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
HNSC	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	8.93	9.47e-18	1.45e-14	0.53	0.38	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
HNSC	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	8.93	9.54e-18	1.46e-14	0.53	0.38	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
HNSC	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	8.93	9.59e-18	1.47e-14	0.37	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	8.93	9.59e-18	1.47e-14	0.37	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
HNSC	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-8.93	9.66e-18	1.48e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-8.93	9.66e-18	1.48e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
HNSC	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-8.93	9.87e-18	1.51e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
HNSC	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-8.93	1e-17	1.53e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-8.93	1e-17	1.54e-14	-0.44	-0.38	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-8.93	1e-17	1.54e-14	-0.44	-0.38	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-8.93	1e-17	1.54e-14	-0.44	-0.38	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
HNSC	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-8.93	1.01e-17	1.55e-14	-0.46	-0.38	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
HNSC	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-8.92	1.03e-17	1.57e-14	-0.42	-0.38	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
HNSC	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	8.92	1.03e-17	1.57e-14	0.52	0.38	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
HNSC	cis	rs9402743	0.775	rs4504492	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135648536	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs2876312	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135648714	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9483862	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135649541	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494315	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135649778	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.816	rs9402738	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135652112	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.74	rs9494318	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135653519	chr6:135636086~135636713:-
HNSC	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.92	1.04e-17	1.58e-14	0.4	0.38	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.92	1.04e-17	1.58e-14	0.4	0.38	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
HNSC	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-8.92	1.04e-17	1.59e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-8.92	1.04e-17	1.6e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
HNSC	cis	rs9402743	0.775	rs9494322	ENSG00000217482.2	HMGB1P17	-8.92	1.05e-17	1.6e-14	-0.42	-0.38	Systemic lupus erythematosus;	chr6:135660922	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-8.92	1.05e-17	1.6e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	8.92	1.08e-17	1.65e-14	0.44	0.38	Depression;	chr6:28303421	chr6:28176188~28176674:+
HNSC	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-8.92	1.09e-17	1.66e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
HNSC	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-8.92	1.09e-17	1.66e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
HNSC	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	8.92	1.09e-17	1.67e-14	0.4	0.38	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
HNSC	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	8.91	1.1e-17	1.68e-14	0.65	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
HNSC	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	8.91	1.11e-17	1.69e-14	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
HNSC	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-8.91	1.11e-17	1.7e-14	-0.52	-0.38	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-8.91	1.11e-17	1.7e-14	-0.52	-0.38	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
HNSC	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-8.91	1.12e-17	1.7e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-8.91	1.12e-17	1.7e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
HNSC	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-8.91	1.13e-17	1.72e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
HNSC	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	8.91	1.14e-17	1.73e-14	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
HNSC	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-8.91	1.14e-17	1.74e-14	-0.5	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-8.91	1.15e-17	1.76e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
HNSC	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-8.91	1.16e-17	1.77e-14	-0.43	-0.38	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
HNSC	cis	rs875971	0.545	rs73378304	ENSG00000179406.6	LINC00174	-8.91	1.17e-17	1.78e-14	-0.56	-0.38	Aortic root size;	chr7:66175760	chr7:66376044~66401338:-
HNSC	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	8.91	1.18e-17	1.79e-14	0.74	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
HNSC	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-8.9	1.19e-17	1.82e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	8.9	1.2e-17	1.83e-14	0.49	0.38	Depression;	chr6:28086929	chr6:28115628~28116551:+
HNSC	cis	rs801193	0.839	rs12534943	ENSG00000179406.6	LINC00174	8.9	1.21e-17	1.85e-14	0.48	0.38	Aortic root size;	chr7:66605533	chr7:66376044~66401338:-
HNSC	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	8.9	1.22e-17	1.85e-14	0.4	0.38	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
HNSC	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-8.9	1.22e-17	1.86e-14	-0.49	-0.38	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
HNSC	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-8.9	1.23e-17	1.87e-14	-0.44	-0.38	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
HNSC	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-8.9	1.24e-17	1.88e-14	-0.4	-0.38	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
HNSC	cis	rs801193	0.839	rs6968619	ENSG00000179406.6	LINC00174	8.9	1.24e-17	1.88e-14	0.48	0.38	Aortic root size;	chr7:66603880	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.805	rs12532355	ENSG00000179406.6	LINC00174	8.9	1.24e-17	1.89e-14	0.48	0.38	Aortic root size;	chr7:66605597	chr7:66376044~66401338:-
HNSC	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	8.9	1.25e-17	1.89e-14	0.47	0.38	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
HNSC	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-8.9	1.25e-17	1.89e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
HNSC	cis	rs1933112	0.9	rs1040508	ENSG00000227777.1	RP4-738P11.3	-8.9	1.26e-17	1.91e-14	-0.43	-0.38	Blood protein levels;	chr1:168531512	chr1:168542737~168543354:+
HNSC	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	8.9	1.26e-17	1.91e-14	0.4	0.38	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	8.9	1.28e-17	1.95e-14	0.42	0.38	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
HNSC	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-8.89	1.3e-17	1.97e-14	-0.44	-0.38	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
HNSC	cis	rs875971	0.543	rs801191	ENSG00000179406.6	LINC00174	8.89	1.31e-17	1.98e-14	0.48	0.38	Aortic root size;	chr7:66567968	chr7:66376044~66401338:-
HNSC	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-8.89	1.31e-17	1.98e-14	-0.52	-0.38	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
HNSC	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	8.89	1.31e-17	1.98e-14	0.47	0.38	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
HNSC	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	8.89	1.31e-17	1.98e-14	0.47	0.38	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
HNSC	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-8.89	1.31e-17	1.99e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-8.89	1.33e-17	2.01e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-8.89	1.35e-17	2.04e-14	-0.43	-0.38	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
HNSC	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-8.89	1.35e-17	2.05e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
HNSC	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-8.89	1.35e-17	2.05e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
HNSC	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	8.89	1.36e-17	2.06e-14	0.5	0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
HNSC	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-8.89	1.37e-17	2.08e-14	-0.42	-0.38	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-8.89	1.37e-17	2.08e-14	-0.42	-0.38	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
HNSC	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	8.89	1.38e-17	2.08e-14	0.4	0.38	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
HNSC	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-8.89	1.38e-17	2.09e-14	-0.54	-0.38	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
HNSC	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-8.89	1.39e-17	2.1e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
HNSC	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-8.88	1.41e-17	2.14e-14	-0.49	-0.38	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
HNSC	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-8.88	1.42e-17	2.14e-14	-0.47	-0.38	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
HNSC	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-8.88	1.42e-17	2.14e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-8.88	1.42e-17	2.14e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
HNSC	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-8.88	1.46e-17	2.21e-14	-0.36	-0.38	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
HNSC	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-8.88	1.46e-17	2.21e-14	-0.42	-0.38	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
HNSC	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	8.88	1.47e-17	2.21e-14	0.43	0.38	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
HNSC	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-8.88	1.48e-17	2.23e-14	-0.42	-0.38	Migraine;	chr4:56937339	chr4:56960927~56961373:-
HNSC	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-8.88	1.48e-17	2.23e-14	-0.51	-0.38	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
HNSC	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-8.88	1.48e-17	2.23e-14	-0.47	-0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
HNSC	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-8.88	1.5e-17	2.26e-14	-0.42	-0.38	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
HNSC	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-8.87	1.51e-17	2.28e-14	-0.5	-0.38	Depression;	chr6:28135913	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	8.87	1.51e-17	2.28e-14	0.34	0.38	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
HNSC	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
HNSC	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-8.87	1.52e-17	2.3e-14	-0.44	-0.38	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
HNSC	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-8.87	1.53e-17	2.31e-14	-0.52	-0.38	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
HNSC	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	8.87	1.54e-17	2.32e-14	0.53	0.38	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
HNSC	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	8.87	1.54e-17	2.32e-14	0.43	0.38	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
HNSC	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-8.87	1.55e-17	2.33e-14	-0.5	-0.38	Depression;	chr6:28071808	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-8.87	1.57e-17	2.36e-14	-0.4	-0.38	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
HNSC	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-8.87	1.57e-17	2.36e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-8.87	1.57e-17	2.36e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-8.87	1.57e-17	2.36e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
HNSC	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	8.87	1.6e-17	2.41e-14	0.41	0.38	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
HNSC	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-8.87	1.6e-17	2.41e-14	-0.42	-0.38	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
HNSC	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-8.87	1.61e-17	2.42e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
HNSC	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-8.86	1.63e-17	2.44e-14	-0.4	-0.38	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
HNSC	cis	rs2980439	0.818	rs2948300	ENSG00000173295.6	FAM86B3P	8.86	1.63e-17	2.45e-14	0.43	0.38	Neuroticism;	chr8:8248986	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-8.86	1.64e-17	2.47e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-8.86	1.64e-17	2.47e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-8.86	1.65e-17	2.47e-14	-0.52	-0.38	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-8.86	1.65e-17	2.48e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
HNSC	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-8.86	1.67e-17	2.5e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	8.86	1.67e-17	2.5e-14	0.44	0.38	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
HNSC	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-8.86	1.67e-17	2.51e-14	-0.45	-0.38	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
HNSC	cis	rs801193	0.773	rs801207	ENSG00000179406.6	LINC00174	8.86	1.67e-17	2.51e-14	0.48	0.38	Aortic root size;	chr7:66555603	chr7:66376044~66401338:-
HNSC	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	8.86	1.68e-17	2.52e-14	0.52	0.38	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
HNSC	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	8.86	1.69e-17	2.54e-14	0.41	0.38	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
HNSC	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	8.86	1.72e-17	2.58e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	8.86	1.72e-17	2.58e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
HNSC	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-8.86	1.73e-17	2.6e-14	-0.51	-0.38	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
HNSC	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	8.86	1.75e-17	2.62e-14	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
HNSC	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-8.85	1.75e-17	2.63e-14	-0.52	-0.38	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
HNSC	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-8.85	1.77e-17	2.65e-14	-0.5	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
HNSC	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-8.85	1.77e-17	2.65e-14	-0.5	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
HNSC	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-8.85	1.77e-17	2.66e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
HNSC	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	8.85	1.78e-17	2.66e-14	0.53	0.38	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
HNSC	cis	rs7615952	1	rs7615952	ENSG00000241288.6	RP11-379B18.5	8.85	1.81e-17	2.71e-14	0.5	0.38	Blood pressure (smoking interaction);	chr3:125930560	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
HNSC	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-8.85	1.84e-17	2.75e-14	-0.43	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
HNSC	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	8.85	1.85e-17	2.77e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	8.85	1.86e-17	2.78e-14	0.43	0.38	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
HNSC	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-8.85	1.87e-17	2.8e-14	-0.5	-0.38	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
HNSC	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	8.85	1.88e-17	2.81e-14	0.52	0.38	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
HNSC	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	8.85	1.89e-17	2.82e-14	0.51	0.38	Depression;	chr6:28110525	chr6:28115628~28116551:+
HNSC	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	8.84	1.9e-17	2.84e-14	0.4	0.38	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-8.84	1.9e-17	2.84e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-8.84	1.9e-17	2.84e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-8.84	1.9e-17	2.84e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
HNSC	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-8.84	1.91e-17	2.85e-14	-0.4	-0.38	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
HNSC	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-8.84	1.91e-17	2.85e-14	-0.41	-0.38	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
HNSC	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-8.84	1.92e-17	2.86e-14	-0.45	-0.38	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-8.84	1.92e-17	2.86e-14	-0.45	-0.38	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-8.84	1.92e-17	2.86e-14	-0.45	-0.38	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
HNSC	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-8.84	1.95e-17	2.91e-14	-0.5	-0.38	Depression;	chr6:28110254	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-8.84	1.97e-17	2.94e-14	-0.42	-0.38	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
HNSC	cis	rs9402743	0.577	rs111373814	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135644459	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.608	rs6918917	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135644473	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.673	rs56071012	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135646213	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.673	rs56976899	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135646262	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.673	rs9494312	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135646826	chr6:135636086~135636713:-
HNSC	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	8.84	1.98e-17	2.96e-14	0.42	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
HNSC	cis	rs10246939	0.543	rs11767947	ENSG00000228775.6	WEE2-AS1	8.84	2.01e-17	3e-14	0.46	0.38	Bitter taste perception;	chr7:141912821	chr7:141704338~141738346:-
HNSC	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-8.83	2.05e-17	3.06e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
HNSC	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	8.83	2.09e-17	3.11e-14	0.43	0.38	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
HNSC	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	8.83	2.13e-17	3.16e-14	0.46	0.38	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
HNSC	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	8.83	2.13e-17	3.17e-14	0.47	0.38	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	8.83	2.13e-17	3.17e-14	0.43	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
HNSC	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	8.83	2.15e-17	3.2e-14	0.41	0.38	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
HNSC	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	8.83	2.16e-17	3.21e-14	0.47	0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
HNSC	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-8.83	2.16e-17	3.21e-14	-0.5	-0.38	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-8.83	2.17e-17	3.22e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
HNSC	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-8.83	2.17e-17	3.23e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
HNSC	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	8.83	2.2e-17	3.27e-14	0.64	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	8.83	2.2e-17	3.27e-14	0.64	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
HNSC	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	8.83	2.2e-17	3.27e-14	0.42	0.38	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
HNSC	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-8.82	2.21e-17	3.29e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-8.82	2.21e-17	3.29e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-8.82	2.21e-17	3.29e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
HNSC	cis	rs875971	0.508	rs10258739	ENSG00000179406.6	LINC00174	8.82	2.23e-17	3.32e-14	0.48	0.38	Aortic root size;	chr7:66597948	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.508	rs6947808	ENSG00000179406.6	LINC00174	8.82	2.25e-17	3.35e-14	0.48	0.38	Aortic root size;	chr7:66580095	chr7:66376044~66401338:-
HNSC	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-8.82	2.26e-17	3.36e-14	-0.45	-0.38	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-8.82	2.26e-17	3.36e-14	-0.45	-0.38	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-8.82	2.26e-17	3.36e-14	-0.45	-0.38	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
HNSC	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-8.82	2.28e-17	3.38e-14	-0.5	-0.38	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
HNSC	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	8.82	2.28e-17	3.39e-14	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-8.82	2.29e-17	3.4e-14	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
HNSC	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-8.82	2.29e-17	3.41e-14	-0.45	-0.38	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
HNSC	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	8.82	2.3e-17	3.42e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.508	rs10242423	ENSG00000179406.6	LINC00174	8.82	2.33e-17	3.46e-14	0.48	0.38	Aortic root size;	chr7:66594188	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.508	rs10253883	ENSG00000179406.6	LINC00174	8.82	2.33e-17	3.46e-14	0.48	0.38	Aortic root size;	chr7:66596151	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28123153	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28124529	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28127577	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28131566	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-8.82	2.37e-17	3.51e-14	-0.4	-0.38	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
HNSC	cis	rs16885979	1	rs9396000	ENSG00000224984.1	RP11-524H19.2	8.81	2.39e-17	3.54e-14	0.9	0.38	Daytime sleep phenotypes;	chr6:54841785	chr6:54840118~54840855:-
HNSC	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	8.81	2.4e-17	3.56e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	8.81	2.41e-17	3.57e-14	0.49	0.38	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
HNSC	cis	rs9402743	0.775	rs7742843	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135654681	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494319	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135655122	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6916924	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135656563	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6916825	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135656739	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6917005	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135656842	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494320	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135657576	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs2068394	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135658279	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494321	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135658892	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.781	rs6935190	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135659553	chr6:135636086~135636713:-
HNSC	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28082231	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28082261	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28082984	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28083994	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28084025	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28085319	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-8.81	2.41e-17	3.58e-14	-0.4	-0.38	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
HNSC	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-8.81	2.45e-17	3.62e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
HNSC	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-8.81	2.45e-17	3.62e-14	-0.4	-0.38	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
HNSC	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-8.81	2.47e-17	3.66e-14	-0.43	-0.38	Temperament;	chr17:14007316	chr17:14024514~14025488:+
HNSC	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	8.81	2.48e-17	3.67e-14	0.42	0.38	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28074687	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28076559	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28076704	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28078391	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28080757	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28080760	chr6:28115628~28116551:+
HNSC	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	8.81	2.52e-17	3.72e-14	0.4	0.38	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	8.81	2.52e-17	3.72e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-8.81	2.54e-17	3.75e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-8.8	2.59e-17	3.82e-14	-0.42	-0.38	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
HNSC	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	8.8	2.59e-17	3.82e-14	0.34	0.38	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
HNSC	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-8.8	2.59e-17	3.82e-14	-0.38	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
HNSC	cis	rs9402743	0.673	rs9483860	ENSG00000217482.2	HMGB1P17	-8.8	2.61e-17	3.85e-14	-0.42	-0.38	Systemic lupus erythematosus;	chr6:135646872	chr6:135636086~135636713:-
HNSC	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28111382	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28111650	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28112175	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28113851	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28114487	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28114933	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28115743	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28116411	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
HNSC	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-8.8	2.66e-17	3.92e-14	-0.47	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-8.8	2.67e-17	3.94e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.508	rs10950045	ENSG00000179406.6	LINC00174	8.8	2.67e-17	3.94e-14	0.47	0.38	Aortic root size;	chr7:66601386	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	8.8	2.68e-17	3.95e-14	0.35	0.38	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
HNSC	cis	rs9402743	0.673	rs9483858	ENSG00000217482.2	HMGB1P17	8.8	2.7e-17	3.98e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135642670	chr6:135636086~135636713:-
HNSC	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-8.8	2.71e-17	4e-14	-0.44	-0.38	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
HNSC	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-8.8	2.71e-17	4e-14	-0.5	-0.38	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
HNSC	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	8.8	2.72e-17	4.01e-14	0.4	0.38	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
HNSC	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-8.8	2.74e-17	4.03e-14	-0.57	-0.38	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
HNSC	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	8.8	2.74e-17	4.04e-14	0.52	0.38	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
HNSC	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	8.8	2.77e-17	4.07e-14	0.4	0.38	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
HNSC	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-8.79	2.82e-17	4.15e-14	-0.42	-0.38	Temperament;	chr17:14007198	chr17:14024514~14025488:+
HNSC	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-8.79	2.83e-17	4.16e-14	-0.42	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
HNSC	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	8.79	2.84e-17	4.18e-14	0.8	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
HNSC	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-8.79	2.86e-17	4.2e-14	-0.49	-0.38	Depression;	chr6:28070115	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-8.79	2.86e-17	4.2e-14	-0.49	-0.38	Depression;	chr6:28071237	chr6:28115628~28116551:+
HNSC	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	8.79	2.86e-17	4.21e-14	0.45	0.38	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
HNSC	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	8.79	2.86e-17	4.21e-14	0.45	0.38	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
HNSC	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-8.79	2.87e-17	4.21e-14	-0.5	-0.38	Depression;	chr6:28113616	chr6:28115628~28116551:+
HNSC	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-8.79	2.9e-17	4.26e-14	-0.43	-0.38	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-8.79	2.95e-17	4.34e-14	-0.34	-0.38	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
HNSC	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
HNSC	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
HNSC	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-8.78	3.01e-17	4.42e-14	-0.41	-0.38	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
HNSC	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-8.78	3.06e-17	4.49e-14	-0.43	-0.38	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
HNSC	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-8.78	3.07e-17	4.5e-14	-0.48	-0.38	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
HNSC	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	8.78	3.08e-17	4.52e-14	0.41	0.38	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
HNSC	cis	rs10246939	0.543	rs11765106	ENSG00000228775.6	WEE2-AS1	8.78	3.1e-17	4.55e-14	0.45	0.38	Bitter taste perception;	chr7:141902676	chr7:141704338~141738346:-
HNSC	cis	rs10246939	0.543	rs11765974	ENSG00000228775.6	WEE2-AS1	8.78	3.1e-17	4.55e-14	0.45	0.38	Bitter taste perception;	chr7:141914390	chr7:141704338~141738346:-
HNSC	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-8.78	3.13e-17	4.58e-14	-0.43	-0.38	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
HNSC	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	8.78	3.15e-17	4.61e-14	0.62	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
HNSC	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-8.78	3.16e-17	4.62e-14	-0.4	-0.38	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
HNSC	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	8.78	3.2e-17	4.68e-14	0.46	0.38	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
HNSC	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-8.78	3.21e-17	4.69e-14	-0.43	-0.38	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-8.78	3.21e-17	4.69e-14	-0.43	-0.38	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
HNSC	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-8.78	3.21e-17	4.7e-14	-0.36	-0.38	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
HNSC	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-8.77	3.35e-17	4.89e-14	-0.43	-0.38	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
HNSC	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-8.77	3.36e-17	4.91e-14	-0.35	-0.38	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
HNSC	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-8.77	3.37e-17	4.92e-14	-0.48	-0.38	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	8.77	3.38e-17	4.93e-14	0.4	0.38	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
HNSC	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	8.77	3.39e-17	4.95e-14	0.42	0.38	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
HNSC	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-8.77	3.41e-17	4.98e-14	-0.45	-0.38	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
HNSC	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-8.77	3.42e-17	4.99e-14	-0.47	-0.38	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
HNSC	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-8.77	3.43e-17	5.01e-14	-0.48	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
HNSC	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-8.77	3.46e-17	5.05e-14	-0.5	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
HNSC	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-8.77	3.47e-17	5.06e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
HNSC	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	8.77	3.48e-17	5.08e-14	0.48	0.38	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
HNSC	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-8.76	3.49e-17	5.09e-14	-0.45	-0.38	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-8.76	3.5e-17	5.11e-14	-0.43	-0.38	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-8.76	3.52e-17	5.13e-14	-0.34	-0.38	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
HNSC	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	8.76	3.54e-17	5.16e-14	0.49	0.38	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
HNSC	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-8.76	3.56e-17	5.18e-14	-0.49	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
HNSC	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-8.76	3.56e-17	5.19e-14	-0.42	-0.38	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
HNSC	cis	rs10028773	0.632	rs34481394	ENSG00000245958.5	RP11-33B1.1	-8.76	3.58e-17	5.21e-14	-0.36	-0.38	Educational attainment;	chr4:119327219	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.666	rs35231872	ENSG00000245958.5	RP11-33B1.1	-8.76	3.58e-17	5.21e-14	-0.36	-0.38	Educational attainment;	chr4:119327221	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.7	rs35653026	ENSG00000245958.5	RP11-33B1.1	-8.76	3.58e-17	5.21e-14	-0.36	-0.38	Educational attainment;	chr4:119327223	chr4:119454791~119552025:+
HNSC	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-8.76	3.65e-17	5.31e-14	-0.43	-0.38	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
HNSC	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-8.76	3.7e-17	5.38e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-8.76	3.7e-17	5.38e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
HNSC	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	8.76	3.71e-17	5.39e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	8.76	3.71e-17	5.39e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	8.76	3.71e-17	5.39e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
HNSC	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-8.76	3.72e-17	5.41e-14	-0.54	-0.38	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-8.76	3.72e-17	5.41e-14	-0.5	-0.38	Depression;	chr6:28133900	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	8.76	3.72e-17	5.41e-14	0.4	0.38	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	8.76	3.72e-17	5.42e-14	0.4	0.38	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
HNSC	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-8.75	3.8e-17	5.52e-14	-0.5	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
HNSC	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-8.75	3.84e-17	5.57e-14	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-8.75	3.84e-17	5.57e-14	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
HNSC	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-8.75	3.85e-17	5.59e-14	-0.43	-0.38	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-8.75	3.85e-17	5.59e-14	-0.43	-0.38	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
HNSC	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-8.75	3.87e-17	5.62e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
HNSC	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	8.75	3.87e-17	5.62e-14	0.39	0.38	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
HNSC	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	8.75	3.89e-17	5.66e-14	0.38	0.38	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	8.75	3.91e-17	5.68e-14	0.26	0.38	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
HNSC	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-8.75	3.95e-17	5.74e-14	-0.52	-0.38	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
HNSC	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	8.75	3.98e-17	5.77e-14	0.44	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
HNSC	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-8.75	3.99e-17	5.8e-14	-0.45	-0.38	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-8.75	4.02e-17	5.83e-14	-0.43	-0.38	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
HNSC	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-8.75	4.03e-17	5.84e-14	-0.45	-0.38	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
HNSC	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	8.75	4.03e-17	5.85e-14	0.52	0.38	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
HNSC	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-8.74	4.06e-17	5.88e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-8.74	4.06e-17	5.88e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
HNSC	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	8.74	4.11e-17	5.95e-14	0.43	0.38	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
HNSC	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	8.74	4.13e-17	5.98e-14	0.41	0.38	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	8.74	4.13e-17	5.98e-14	0.41	0.38	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	8.74	4.13e-17	5.98e-14	0.41	0.38	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
HNSC	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-8.74	4.15e-17	6.02e-14	-0.48	-0.38	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
HNSC	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-8.74	4.16e-17	6.03e-14	-0.48	-0.37	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
HNSC	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-8.74	4.17e-17	6.04e-14	-0.42	-0.37	Migraine;	chr4:56943905	chr4:56960927~56961373:-
HNSC	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-8.74	4.18e-17	6.05e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	8.74	4.18e-17	6.06e-14	0.41	0.37	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
HNSC	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	8.74	4.26e-17	6.16e-14	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
HNSC	cis	rs12922040	0.607	rs8059739	ENSG00000263335.1	AF001548.5	-8.74	4.29e-17	6.2e-14	-0.48	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15772869	chr16:15726674~15732993:+
HNSC	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28136698	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28136856	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28137418	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28138363	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-8.74	4.33e-17	6.26e-14	-0.4	-0.37	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
HNSC	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	8.74	4.34e-17	6.27e-14	0.4	0.37	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	8.74	4.34e-17	6.27e-14	0.26	0.37	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
HNSC	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-8.74	4.34e-17	6.27e-14	-0.49	-0.37	Depression;	chr6:28126588	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-8.74	4.34e-17	6.27e-14	-0.49	-0.37	Depression;	chr6:28126953	chr6:28115628~28116551:+
HNSC	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-8.73	4.39e-17	6.34e-14	-0.42	-0.37	Migraine;	chr4:56940917	chr4:56960927~56961373:-
HNSC	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-8.73	4.39e-17	6.34e-14	-0.42	-0.37	Migraine;	chr4:56957291	chr4:56960927~56961373:-
HNSC	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	8.73	4.39e-17	6.35e-14	0.36	0.37	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
HNSC	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-8.73	4.41e-17	6.37e-14	-0.43	-0.37	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
HNSC	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	8.73	4.43e-17	6.4e-14	0.39	0.37	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
HNSC	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-8.73	4.43e-17	6.41e-14	-0.49	-0.37	Depression;	chr6:28079011	chr6:28115628~28116551:+
HNSC	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-8.73	4.44e-17	6.41e-14	-0.43	-0.37	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-8.73	4.44e-17	6.41e-14	-0.43	-0.37	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
HNSC	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-8.73	4.44e-17	6.42e-14	-0.48	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-8.73	4.45e-17	6.43e-14	-0.43	-0.37	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	8.73	4.47e-17	6.46e-14	0.26	0.37	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
HNSC	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-8.73	4.57e-17	6.6e-14	-0.49	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
HNSC	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-8.73	4.7e-17	6.78e-14	-0.49	-0.37	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
HNSC	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	8.72	4.76e-17	6.86e-14	0.48	0.37	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
HNSC	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-8.72	4.82e-17	6.94e-14	-0.52	-0.37	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
HNSC	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	8.72	4.84e-17	6.97e-14	0.41	0.37	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	8.72	4.86e-17	6.99e-14	0.26	0.37	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
HNSC	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-8.72	4.86e-17	7e-14	-0.44	-0.37	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
HNSC	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	8.72	4.87e-17	7.01e-14	0.5	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
HNSC	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-8.72	4.89e-17	7.03e-14	-0.38	-0.37	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
HNSC	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-8.72	4.91e-17	7.07e-14	-0.45	-0.37	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
HNSC	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-8.72	4.94e-17	7.11e-14	-0.48	-0.37	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-8.72	4.94e-17	7.11e-14	-0.48	-0.37	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
HNSC	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-8.72	4.97e-17	7.14e-14	-0.43	-0.37	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	8.72	5.01e-17	7.2e-14	0.26	0.37	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
HNSC	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	8.72	5.01e-17	7.2e-14	0.4	0.37	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
HNSC	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	8.72	5.03e-17	7.23e-14	0.48	0.37	Height;	chr6:109391084	chr6:109382795~109383666:+
HNSC	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-8.72	5.04e-17	7.24e-14	-0.41	-0.37	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
HNSC	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-8.72	5.07e-17	7.29e-14	-0.43	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
HNSC	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	8.72	5.08e-17	7.31e-14	0.39	0.37	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
HNSC	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-8.71	5.15e-17	7.4e-14	-0.5	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
HNSC	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	8.71	5.17e-17	7.43e-14	0.5	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
HNSC	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	8.71	5.2e-17	7.46e-14	0.4	0.37	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
HNSC	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	8.71	5.28e-17	7.58e-14	0.4	0.37	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
HNSC	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	8.71	5.29e-17	7.6e-14	0.48	0.37	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
HNSC	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-8.71	5.32e-17	7.63e-14	-0.38	-0.37	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
HNSC	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-8.71	5.34e-17	7.66e-14	-0.41	-0.37	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
HNSC	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-8.71	5.35e-17	7.67e-14	-0.42	-0.37	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
HNSC	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	8.71	5.39e-17	7.73e-14	0.62	0.37	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
HNSC	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-8.71	5.42e-17	7.77e-14	-0.39	-0.37	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
HNSC	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	8.71	5.44e-17	7.79e-14	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
HNSC	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	8.71	5.45e-17	7.82e-14	0.44	0.37	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
HNSC	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-8.7	5.6e-17	8.02e-14	-0.43	-0.37	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
HNSC	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-8.7	5.6e-17	8.02e-14	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
HNSC	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	8.7	5.63e-17	8.06e-14	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
HNSC	cis	rs2834288	0.5	rs881230	ENSG00000237945.6	LINC00649	8.7	5.66e-17	8.11e-14	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33915534~33977691:+
HNSC	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-8.7	5.71e-17	8.17e-14	-0.49	-0.37	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-8.7	5.71e-17	8.17e-14	-0.49	-0.37	Depression;	chr6:28138981	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-8.7	5.71e-17	8.17e-14	-0.49	-0.37	Depression;	chr6:28139012	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-8.7	5.89e-17	8.42e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
HNSC	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-8.69	5.95e-17	8.52e-14	-0.49	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
HNSC	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.03e-17	8.63e-14	-0.4	-0.37	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
HNSC	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	8.69	6.04e-17	8.64e-14	0.41	0.37	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-8.69	6.07e-17	8.68e-14	-0.43	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	8.69	6.12e-17	8.74e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
HNSC	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.15e-17	8.79e-14	-0.39	-0.37	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000268592.3	RAET1E-AS1	8.69	6.15e-17	8.79e-14	0.53	0.37	Lung cancer;	chr6:149863746	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.22e-17	8.87e-14	-0.39	-0.37	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.22e-17	8.87e-14	-0.39	-0.37	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.22e-17	8.87e-14	-0.39	-0.37	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
HNSC	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-8.69	6.24e-17	8.9e-14	-0.43	-0.37	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-8.69	6.24e-17	8.9e-14	-0.43	-0.37	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-8.69	6.29e-17	8.97e-14	-0.43	-0.37	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
HNSC	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-8.69	6.31e-17	9e-14	-0.43	-0.37	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
HNSC	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-8.69	6.32e-17	9.01e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
HNSC	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-8.69	6.33e-17	9.03e-14	-0.43	-0.37	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
HNSC	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.34e-17	9.04e-14	-0.4	-0.37	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.34e-17	9.04e-14	-0.4	-0.37	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
HNSC	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-8.69	6.36e-17	9.07e-14	-0.42	-0.37	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
HNSC	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
HNSC	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	8.68	6.42e-17	9.14e-14	0.5	0.37	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
HNSC	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-8.68	6.45e-17	9.18e-14	-0.43	-0.37	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
HNSC	cis	rs2834288	0.5	rs2834304	ENSG00000237945.6	LINC00649	8.68	6.46e-17	9.2e-14	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33915534~33977691:+
HNSC	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-8.68	6.48e-17	9.22e-14	-0.49	-0.37	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
HNSC	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-8.68	6.51e-17	9.26e-14	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
HNSC	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-8.68	6.52e-17	9.28e-14	-0.43	-0.37	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000179406.6	LINC00174	-8.68	6.54e-17	9.31e-14	-0.48	-0.37	Aortic root size;	chr7:65960907	chr7:66376044~66401338:-
HNSC	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	8.68	6.65e-17	9.45e-14	0.47	0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
HNSC	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	8.68	6.65e-17	9.45e-14	0.4	0.37	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
HNSC	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-8.68	6.65e-17	9.46e-14	-0.57	-0.37	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-8.68	6.65e-17	9.46e-14	-0.57	-0.37	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
HNSC	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-8.68	6.69e-17	9.51e-14	-0.4	-0.37	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
HNSC	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	8.68	6.72e-17	9.54e-14	0.4	0.37	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
HNSC	cis	rs2834288	0.5	rs766425	ENSG00000237945.6	LINC00649	8.68	6.73e-17	9.56e-14	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33915534~33977691:+
HNSC	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
HNSC	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-8.67	6.93e-17	9.83e-14	-0.42	-0.37	Migraine;	chr4:56956882	chr4:56960927~56961373:-
HNSC	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-8.67	6.97e-17	9.89e-14	-0.43	-0.37	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-8.67	7.08e-17	1e-13	-0.43	-0.37	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
HNSC	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	8.67	7.13e-17	1.01e-13	0.37	0.37	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
HNSC	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	8.67	7.13e-17	1.01e-13	0.38	0.37	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
HNSC	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	8.67	7.13e-17	1.01e-13	0.38	0.37	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
HNSC	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	8.67	7.17e-17	1.02e-13	0.75	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
HNSC	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-8.67	7.2e-17	1.02e-13	-0.43	-0.37	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
HNSC	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-8.67	7.33e-17	1.04e-13	-0.39	-0.37	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
HNSC	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	8.67	7.42e-17	1.05e-13	0.38	0.37	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
HNSC	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-8.66	7.47e-17	1.06e-13	-0.51	-0.37	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
HNSC	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	8.66	7.49e-17	1.06e-13	0.56	0.37	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
HNSC	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-8.66	7.68e-17	1.08e-13	-0.42	-0.37	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
HNSC	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-8.66	7.69e-17	1.09e-13	-0.43	-0.37	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
HNSC	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	8.66	7.69e-17	1.09e-13	0.48	0.37	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
HNSC	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-8.66	7.81e-17	1.1e-13	-0.48	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
HNSC	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	8.66	7.87e-17	1.11e-13	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-8.66	7.91e-17	1.12e-13	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
HNSC	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	8.66	7.95e-17	1.12e-13	0.4	0.37	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
HNSC	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28096855	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28099759	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28100648	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28104824	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28107222	chr6:28115628~28116551:+
HNSC	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-8.65	8.1e-17	1.14e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
HNSC	cis	rs9402743	0.775	rs2179724	ENSG00000217482.2	HMGB1P17	8.65	8.12e-17	1.14e-13	0.42	0.37	Systemic lupus erythematosus;	chr6:135647928	chr6:135636086~135636713:-
HNSC	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	8.65	8.34e-17	1.18e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
HNSC	cis	rs7404843	0.925	rs12600043	ENSG00000263065.1	AF001548.6	8.65	8.48e-17	1.19e-13	0.67	0.37	Testicular germ cell tumor;	chr16:15446095	chr16:15741151~15741791:+
HNSC	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	8.65	8.64e-17	1.22e-13	0.38	0.37	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
HNSC	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-8.64	8.69e-17	1.22e-13	-0.41	-0.37	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
HNSC	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-8.64	8.75e-17	1.23e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	8.64	8.93e-17	1.26e-13	0.4	0.37	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-8.64	8.96e-17	1.26e-13	-0.49	-0.37	Depression;	chr6:28108492	chr6:28115628~28116551:+
HNSC	cis	rs2834288	0.5	rs881231	ENSG00000237945.6	LINC00649	8.64	8.97e-17	1.26e-13	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33915534~33977691:+
HNSC	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-8.64	9.01e-17	1.27e-13	-0.44	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
HNSC	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-8.64	9.03e-17	1.27e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
HNSC	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-8.64	9.05e-17	1.27e-13	-0.49	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
HNSC	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-8.64	9.07e-17	1.27e-13	-0.43	-0.37	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
HNSC	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-8.64	9.26e-17	1.3e-13	-0.45	-0.37	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
HNSC	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-8.64	9.34e-17	1.31e-13	-0.49	-0.37	Depression;	chr6:28096077	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-8.63	9.41e-17	1.32e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
HNSC	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-8.63	9.41e-17	1.32e-13	-0.69	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
HNSC	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	8.63	9.43e-17	1.32e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
HNSC	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-8.63	9.56e-17	1.34e-13	-0.42	-0.37	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
HNSC	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	8.63	9.57e-17	1.34e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
HNSC	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-8.63	9.57e-17	1.34e-13	-0.43	-0.37	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
HNSC	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-8.63	9.76e-17	1.37e-13	-0.49	-0.37	Depression;	chr6:28139876	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-8.63	9.76e-17	1.37e-13	-0.49	-0.37	Depression;	chr6:28139998	chr6:28115628~28116551:+
HNSC	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-8.63	9.83e-17	1.38e-13	-0.41	-0.37	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
HNSC	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8.63	9.87e-17	1.38e-13	0.42	0.37	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
HNSC	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	8.63	9.89e-17	1.38e-13	0.49	0.37	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
HNSC	cis	rs801193	0.844	rs2244022	ENSG00000179406.6	LINC00174	-8.63	9.96e-17	1.39e-13	-0.47	-0.37	Aortic root size;	chr7:66737443	chr7:66376044~66401338:-
HNSC	cis	rs1865760	0.963	rs9356991	ENSG00000272462.2	U91328.19	-8.63	1e-16	1.4e-13	-0.37	-0.37	Height;	chr6:25901530	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-8.63	1e-16	1.4e-13	-0.42	-0.37	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-8.63	1e-16	1.4e-13	-0.42	-0.37	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
HNSC	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-8.62	1.02e-16	1.43e-13	-0.42	-0.37	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
HNSC	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	8.62	1.03e-16	1.44e-13	0.33	0.37	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
HNSC	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	8.62	1.03e-16	1.44e-13	0.49	0.37	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-8.62	1.04e-16	1.44e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-8.62	1.04e-16	1.44e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
HNSC	cis	rs2834288	0.645	rs2032313	ENSG00000237945.6	LINC00649	8.62	1.04e-16	1.45e-13	0.45	0.37	Gut microbiota (bacterial taxa);	chr21:33981946	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.5	rs4817602	ENSG00000237945.6	LINC00649	8.62	1.05e-16	1.46e-13	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.5	rs7280837	ENSG00000237945.6	LINC00649	8.62	1.05e-16	1.46e-13	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33915534~33977691:+
HNSC	cis	rs10256972	0.63	rs10282584	ENSG00000225146.1	AC073957.15	8.62	1.05e-16	1.47e-13	0.43	0.37	Endometriosis;Longevity;	chr7:1041806	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-8.62	1.05e-16	1.47e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-8.62	1.05e-16	1.47e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-8.62	1.05e-16	1.47e-13	-0.4	-0.37	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
HNSC	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-8.62	1.07e-16	1.49e-13	-0.36	-0.37	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
HNSC	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	8.62	1.07e-16	1.49e-13	0.45	0.37	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
HNSC	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	8.62	1.08e-16	1.51e-13	0.47	0.37	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	8.62	1.08e-16	1.51e-13	0.5	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
HNSC	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-8.61	1.09e-16	1.52e-13	-0.43	-0.37	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
HNSC	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-8.61	1.09e-16	1.52e-13	-0.4	-0.37	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-8.61	1.11e-16	1.54e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
HNSC	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-8.61	1.11e-16	1.55e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
HNSC	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-8.61	1.11e-16	1.55e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
HNSC	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	8.61	1.11e-16	1.55e-13	0.42	0.37	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
HNSC	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	8.61	1.12e-16	1.56e-13	0.39	0.37	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
HNSC	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
HNSC	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-8.61	1.14e-16	1.58e-13	-0.48	-0.37	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-8.61	1.15e-16	1.59e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-8.61	1.16e-16	1.6e-13	-0.41	-0.37	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
HNSC	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	8.61	1.16e-16	1.61e-13	0.38	0.37	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	8.61	1.17e-16	1.62e-13	0.42	0.37	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
HNSC	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	8.6	1.17e-16	1.62e-13	0.46	0.37	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
HNSC	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-8.6	1.18e-16	1.63e-13	-0.42	-0.37	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
HNSC	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-8.6	1.18e-16	1.63e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
HNSC	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	8.6	1.18e-16	1.64e-13	0.61	0.37	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	8.6	1.2e-16	1.66e-13	0.5	0.37	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
HNSC	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-8.6	1.2e-16	1.66e-13	-0.41	-0.37	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
HNSC	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-8.6	1.2e-16	1.66e-13	-0.34	-0.37	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
HNSC	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	8.6	1.2e-16	1.67e-13	0.42	0.37	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	8.6	1.21e-16	1.68e-13	0.41	0.37	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
HNSC	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-8.6	1.22e-16	1.69e-13	-0.41	-0.37	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-8.6	1.22e-16	1.69e-13	-0.41	-0.37	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
HNSC	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	8.6	1.22e-16	1.69e-13	0.38	0.37	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	8.6	1.23e-16	1.7e-13	0.42	0.37	Depression;	chr6:28363475	chr6:28176188~28176674:+
HNSC	cis	rs1865760	1	rs2071301	ENSG00000272462.2	U91328.19	-8.6	1.26e-16	1.74e-13	-0.37	-0.37	Height;	chr6:25914035	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-8.6	1.26e-16	1.74e-13	-0.42	-0.37	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-8.6	1.26e-16	1.74e-13	-0.42	-0.37	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-8.6	1.26e-16	1.74e-13	-0.42	-0.37	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-8.59	1.28e-16	1.76e-13	-0.42	-0.37	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
HNSC	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	8.59	1.28e-16	1.76e-13	0.38	0.37	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
HNSC	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	8.59	1.28e-16	1.77e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
HNSC	cis	rs1865760	1	rs6938233	ENSG00000272462.2	U91328.19	-8.59	1.28e-16	1.77e-13	-0.37	-0.37	Height;	chr6:25913849	chr6:25992662~26001775:+
HNSC	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	8.59	1.29e-16	1.78e-13	0.42	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
HNSC	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-8.59	1.31e-16	1.8e-13	-0.42	-0.37	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-8.59	1.31e-16	1.8e-13	-0.42	-0.37	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
HNSC	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	8.59	1.31e-16	1.81e-13	0.4	0.37	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
HNSC	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-8.59	1.31e-16	1.81e-13	-0.43	-0.37	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
HNSC	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-8.59	1.32e-16	1.82e-13	-0.4	-0.37	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
HNSC	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-8.59	1.32e-16	1.82e-13	-0.43	-0.37	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-8.59	1.33e-16	1.83e-13	-0.25	-0.37	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
HNSC	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	8.59	1.33e-16	1.83e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	8.59	1.33e-16	1.83e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
HNSC	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	8.59	1.34e-16	1.85e-13	0.69	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
HNSC	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-8.59	1.35e-16	1.85e-13	-0.43	-0.37	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-8.59	1.35e-16	1.85e-13	-0.43	-0.37	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-8.59	1.35e-16	1.86e-13	-0.43	-0.37	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
HNSC	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-8.59	1.35e-16	1.86e-13	-0.4	-0.37	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
HNSC	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	8.59	1.35e-16	1.86e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
HNSC	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-8.59	1.36e-16	1.87e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
HNSC	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-8.59	1.36e-16	1.87e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
HNSC	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
HNSC	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-8.58	1.37e-16	1.88e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
HNSC	cis	rs1865760	0.566	rs2858993	ENSG00000272462.2	U91328.19	-8.58	1.37e-16	1.89e-13	-0.36	-0.37	Height;	chr6:26087628	chr6:25992662~26001775:+
HNSC	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	8.58	1.38e-16	1.9e-13	0.43	0.37	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-8.58	1.4e-16	1.92e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	8.58	1.41e-16	1.93e-13	0.47	0.37	Height;	chr6:109464011	chr6:109382795~109383666:+
HNSC	cis	rs12439619	0.508	rs11856561	ENSG00000276710.3	CSPG4P8	-8.58	1.42e-16	1.95e-13	-0.41	-0.37	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82459472~82477258:+
HNSC	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	8.58	1.43e-16	1.95e-13	0.39	0.37	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
HNSC	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	8.58	1.43e-16	1.96e-13	0.61	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
HNSC	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	8.58	1.44e-16	1.98e-13	0.4	0.37	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
HNSC	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-8.58	1.45e-16	1.99e-13	-0.43	-0.37	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
HNSC	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	8.58	1.46e-16	2e-13	0.35	0.37	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
HNSC	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-8.57	1.47e-16	2.01e-13	-0.48	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-8.57	1.48e-16	2.03e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
HNSC	cis	rs9402743	0.775	rs12196952	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135662235	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494323	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135663249	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6917604	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135664161	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs7768645	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135664656	chr6:135636086~135636713:-
HNSC	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-8.57	1.5e-16	2.05e-13	-0.43	-0.37	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
HNSC	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-8.57	1.5e-16	2.05e-13	-0.49	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
HNSC	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-8.57	1.51e-16	2.06e-13	-0.46	-0.37	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
HNSC	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-8.57	1.51e-16	2.06e-13	-0.41	-0.37	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
HNSC	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	8.57	1.51e-16	2.07e-13	0.76	0.37	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
HNSC	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	8.57	1.52e-16	2.08e-13	0.42	0.37	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
HNSC	cis	rs7615952	1	rs7616044	ENSG00000241288.6	RP11-379B18.5	-8.57	1.52e-16	2.08e-13	-0.5	-0.37	Blood pressure (smoking interaction);	chr3:125930511	chr3:125827238~125916384:-
HNSC	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	8.57	1.53e-16	2.09e-13	0.45	0.37	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
HNSC	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	8.57	1.53e-16	2.09e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
HNSC	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-8.57	1.54e-16	2.11e-13	-0.42	-0.37	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
HNSC	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	8.57	1.58e-16	2.15e-13	0.75	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	8.56	1.59e-16	2.17e-13	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
HNSC	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	8.56	1.6e-16	2.18e-13	0.4	0.37	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
HNSC	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-8.56	1.61e-16	2.19e-13	-0.47	-0.37	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
HNSC	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-8.56	1.62e-16	2.21e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
HNSC	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-8.56	1.64e-16	2.23e-13	-0.42	-0.37	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
HNSC	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-8.56	1.64e-16	2.24e-13	-0.43	-0.37	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-8.56	1.64e-16	2.24e-13	-0.43	-0.37	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
HNSC	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	8.56	1.65e-16	2.25e-13	0.4	0.37	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	8.56	1.65e-16	2.25e-13	0.4	0.37	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
HNSC	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-8.56	1.65e-16	2.25e-13	-0.58	-0.37	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
HNSC	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-8.56	1.67e-16	2.28e-13	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
HNSC	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-8.56	1.69e-16	2.31e-13	-0.4	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
HNSC	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-8.56	1.69e-16	2.31e-13	-0.4	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
HNSC	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-8.56	1.69e-16	2.31e-13	-0.4	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
HNSC	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	8.55	1.71e-16	2.32e-13	0.38	0.37	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
HNSC	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	8.55	1.72e-16	2.35e-13	0.4	0.37	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
HNSC	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	8.55	1.73e-16	2.35e-13	0.43	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
HNSC	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	8.55	1.73e-16	2.35e-13	0.4	0.37	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	8.55	1.73e-16	2.35e-13	0.4	0.37	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
HNSC	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-8.55	1.73e-16	2.35e-13	-0.39	-0.37	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
HNSC	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-8.55	1.73e-16	2.36e-13	-0.38	-0.37	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
HNSC	cis	rs6951245	0.872	rs75280240	ENSG00000224079.1	AC091729.7	-8.55	1.74e-16	2.37e-13	-0.61	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018875	chr7:1074450~1078036:+
HNSC	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-8.55	1.74e-16	2.37e-13	-0.64	-0.37	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
HNSC	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-8.55	1.74e-16	2.37e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
HNSC	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	8.55	1.74e-16	2.37e-13	0.4	0.37	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
HNSC	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-8.55	1.78e-16	2.42e-13	-0.48	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
HNSC	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.55	1.82e-16	2.47e-13	0.47	0.37	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
HNSC	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	8.55	1.82e-16	2.47e-13	0.37	0.37	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
HNSC	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-8.54	1.85e-16	2.5e-13	-0.46	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
HNSC	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-8.54	1.85e-16	2.51e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	8.54	1.85e-16	2.51e-13	0.46	0.37	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
HNSC	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	8.54	1.87e-16	2.53e-13	0.4	0.37	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
HNSC	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-8.54	1.87e-16	2.53e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
HNSC	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-8.54	1.88e-16	2.55e-13	-0.44	-0.37	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
HNSC	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	8.54	1.88e-16	2.55e-13	0.75	0.37	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
HNSC	cis	rs6951245	1	rs6951245	ENSG00000224079.1	AC091729.7	-8.54	1.88e-16	2.55e-13	-0.61	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018557	chr7:1074450~1078036:+
HNSC	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-8.54	1.91e-16	2.58e-13	-0.54	-0.37	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
HNSC	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	8.54	1.92e-16	2.59e-13	0.41	0.37	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
HNSC	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-8.54	1.92e-16	2.59e-13	-0.45	-0.37	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
HNSC	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	8.54	1.93e-16	2.61e-13	0.42	0.37	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
HNSC	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-8.54	1.93e-16	2.61e-13	-0.39	-0.37	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-8.54	1.93e-16	2.62e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
HNSC	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-8.54	1.94e-16	2.62e-13	-0.39	-0.37	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	8.54	1.95e-16	2.63e-13	0.46	0.37	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
HNSC	cis	rs6867032	0.958	rs4246754	ENSG00000249731.1	RP11-259O2.3	8.54	1.95e-16	2.64e-13	0.46	0.37	Gut microbiome composition (winter);	chr5:2014662	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-8.53	1.98e-16	2.67e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-8.53	1.98e-16	2.67e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
HNSC	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.53	1.99e-16	2.68e-13	0.42	0.37	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.53	1.99e-16	2.68e-13	0.42	0.37	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	8.53	1.99e-16	2.68e-13	0.42	0.37	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
HNSC	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-8.53	1.99e-16	2.69e-13	-0.73	-0.37	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
HNSC	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	8.53	2e-16	2.7e-13	0.46	0.37	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
HNSC	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-8.53	2e-16	2.7e-13	-0.39	-0.37	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-8.53	2e-16	2.7e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
HNSC	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	8.53	2.01e-16	2.72e-13	0.75	0.37	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.545	rs73376401	ENSG00000179406.6	LINC00174	-8.53	2.04e-16	2.74e-13	-0.55	-0.37	Aortic root size;	chr7:66174841	chr7:66376044~66401338:-
HNSC	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	8.53	2.05e-16	2.76e-13	0.42	0.37	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
HNSC	cis	rs34375054	0.66	rs35941060	ENSG00000279233.1	RP11-158L12.4	8.53	2.06e-16	2.78e-13	0.42	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125109699	chr12:125138245~125141711:+
HNSC	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-8.53	2.06e-16	2.78e-13	-0.49	-0.37	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
HNSC	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
HNSC	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	8.53	2.08e-16	2.8e-13	0.48	0.37	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-8.53	2.1e-16	2.82e-13	-0.42	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
HNSC	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-8.53	2.12e-16	2.85e-13	-0.42	-0.37	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-8.53	2.13e-16	2.86e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	8.52	2.17e-16	2.91e-13	0.47	0.37	Height;	chr6:109498751	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	8.52	2.17e-16	2.91e-13	0.47	0.37	Height;	chr6:109500687	chr6:109382795~109383666:+
HNSC	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	8.52	2.18e-16	2.92e-13	0.39	0.37	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
HNSC	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	8.52	2.18e-16	2.93e-13	0.47	0.37	Height;	chr6:109407238	chr6:109382795~109383666:+
HNSC	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-8.52	2.19e-16	2.93e-13	-0.39	-0.37	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
HNSC	cis	rs2834288	0.5	rs2051189	ENSG00000237945.6	LINC00649	8.52	2.2e-16	2.95e-13	0.43	0.37	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33915534~33977691:+
HNSC	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-8.52	2.21e-16	2.96e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
HNSC	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-8.52	2.21e-16	2.97e-13	-0.39	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
HNSC	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-8.52	2.22e-16	2.98e-13	-0.74	-0.37	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
HNSC	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-8.52	2.22e-16	2.98e-13	-0.39	-0.37	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
HNSC	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-8.52	2.24e-16	3e-13	-0.41	-0.37	Migraine;	chr4:56950140	chr4:56960927~56961373:-
HNSC	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	8.52	2.24e-16	3e-13	0.46	0.37	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
HNSC	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	8.52	2.28e-16	3.05e-13	0.4	0.37	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	8.52	2.29e-16	3.07e-13	0.52	0.37	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-8.52	2.29e-16	3.07e-13	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
HNSC	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	8.51	2.32e-16	3.1e-13	0.39	0.37	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
HNSC	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	8.51	2.33e-16	3.11e-13	0.4	0.37	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
HNSC	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	8.51	2.33e-16	3.12e-13	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
HNSC	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-8.51	2.34e-16	3.12e-13	-0.42	-0.37	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
HNSC	cis	rs34375054	0.623	rs2297478	ENSG00000279233.1	RP11-158L12.4	8.51	2.34e-16	3.13e-13	0.42	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125107298	chr12:125138245~125141711:+
HNSC	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-8.51	2.35e-16	3.14e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
HNSC	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-8.51	2.36e-16	3.15e-13	-0.42	-0.37	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
HNSC	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-8.51	2.38e-16	3.18e-13	-0.4	-0.37	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
HNSC	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-8.51	2.41e-16	3.22e-13	-0.42	-0.37	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-8.51	2.42e-16	3.23e-13	-0.42	-0.37	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
HNSC	cis	rs1865760	0.964	rs6932113	ENSG00000272462.2	U91328.19	-8.51	2.43e-16	3.24e-13	-0.37	-0.37	Height;	chr6:25912870	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-8.51	2.43e-16	3.24e-13	-0.39	-0.37	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-8.5	2.48e-16	3.31e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	8.5	2.49e-16	3.32e-13	0.46	0.37	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
HNSC	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	8.5	2.49e-16	3.32e-13	0.38	0.37	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
HNSC	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	8.5	2.49e-16	3.33e-13	0.43	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	8.5	2.49e-16	3.33e-13	0.43	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
HNSC	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28089816	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28090857	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28091439	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28091659	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28092227	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28093966	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28094014	chr6:28115628~28116551:+
HNSC	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-8.5	2.53e-16	3.37e-13	-0.43	-0.37	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
HNSC	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-8.5	2.55e-16	3.4e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-8.5	2.56e-16	3.4e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	8.5	2.56e-16	3.42e-13	0.41	0.37	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
HNSC	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	8.5	2.57e-16	3.43e-13	0.61	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
HNSC	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	8.5	2.58e-16	3.43e-13	0.42	0.37	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	8.5	2.58e-16	3.43e-13	0.42	0.37	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	8.5	2.58e-16	3.43e-13	0.42	0.37	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	8.5	2.58e-16	3.43e-13	0.38	0.37	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	8.5	2.58e-16	3.43e-13	0.38	0.37	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-8.5	2.59e-16	3.44e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
HNSC	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	8.5	2.6e-16	3.46e-13	0.42	0.37	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
HNSC	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	8.5	2.62e-16	3.49e-13	0.4	0.37	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
HNSC	cis	rs875971	0.545	rs10950027	ENSG00000179406.6	LINC00174	-8.5	2.63e-16	3.5e-13	-0.54	-0.37	Aortic root size;	chr7:66169164	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs6460276	ENSG00000179406.6	LINC00174	-8.5	2.63e-16	3.5e-13	-0.54	-0.37	Aortic root size;	chr7:66182290	chr7:66376044~66401338:-
HNSC	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	8.5	2.63e-16	3.5e-13	0.35	0.37	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
HNSC	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
HNSC	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-8.5	2.64e-16	3.51e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
HNSC	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	8.5	2.65e-16	3.52e-13	0.48	0.37	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
HNSC	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	8.5	2.66e-16	3.54e-13	0.44	0.37	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
HNSC	cis	rs1865760	0.532	rs2794719	ENSG00000272462.2	U91328.19	-8.49	2.71e-16	3.6e-13	-0.36	-0.37	Height;	chr6:26088662	chr6:25992662~26001775:+
HNSC	cis	rs6951245	1	rs11763020	ENSG00000224079.1	AC091729.7	-8.49	2.72e-16	3.61e-13	-0.61	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020652	chr7:1074450~1078036:+
HNSC	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-8.49	2.73e-16	3.62e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
HNSC	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	8.49	2.74e-16	3.63e-13	0.34	0.37	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
HNSC	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-8.49	2.74e-16	3.63e-13	-0.5	-0.37	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-8.49	2.74e-16	3.63e-13	-0.5	-0.37	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
HNSC	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	8.49	2.77e-16	3.67e-13	0.42	0.37	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
HNSC	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	8.49	2.78e-16	3.69e-13	0.37	0.37	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	8.49	2.78e-16	3.69e-13	0.37	0.37	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
HNSC	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	8.49	2.78e-16	3.69e-13	0.39	0.37	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	8.49	2.79e-16	3.7e-13	0.4	0.37	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
HNSC	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-8.49	2.79e-16	3.7e-13	-0.48	-0.37	Depression;	chr6:28139049	chr6:28115628~28116551:+
HNSC	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-8.49	2.81e-16	3.72e-13	-0.34	-0.37	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
HNSC	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	8.49	2.81e-16	3.73e-13	0.54	0.37	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
HNSC	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-8.49	2.82e-16	3.74e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
HNSC	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-8.49	2.84e-16	3.76e-13	-0.41	-0.37	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
HNSC	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-8.49	2.86e-16	3.78e-13	-0.39	-0.37	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
HNSC	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	8.49	2.87e-16	3.8e-13	0.47	0.37	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
HNSC	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	8.48	2.88e-16	3.81e-13	0.46	0.37	Height;	chr6:109462738	chr6:109382795~109383666:+
HNSC	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-8.48	2.93e-16	3.88e-13	-0.47	-0.37	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
HNSC	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	8.48	2.95e-16	3.89e-13	0.43	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
HNSC	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-8.48	2.95e-16	3.9e-13	-0.54	-0.37	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
HNSC	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-8.48	2.96e-16	3.92e-13	-0.42	-0.37	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
HNSC	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	8.48	2.99e-16	3.95e-13	0.4	0.37	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
HNSC	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-8.48	3e-16	3.96e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-8.48	3e-16	3.96e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
HNSC	cis	rs1865760	0.566	rs9379825	ENSG00000272462.2	U91328.19	-8.48	3e-16	3.97e-13	-0.36	-0.37	Height;	chr6:26083643	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9467672	ENSG00000272462.2	U91328.19	-8.48	3e-16	3.97e-13	-0.36	-0.37	Height;	chr6:26083676	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9295688	ENSG00000272462.2	U91328.19	-8.48	3e-16	3.97e-13	-0.36	-0.37	Height;	chr6:26083989	chr6:25992662~26001775:+
HNSC	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-8.48	3.03e-16	4e-13	-0.42	-0.37	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
HNSC	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-8.48	3.04e-16	4.01e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
HNSC	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	8.48	3.04e-16	4.02e-13	0.38	0.37	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
HNSC	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	8.48	3.05e-16	4.02e-13	0.46	0.37	Height;	chr6:109392096	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	8.48	3.06e-16	4.04e-13	0.46	0.37	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
HNSC	cis	rs9341808	0.718	rs9352803	ENSG00000272129.1	RP11-250B2.6	8.48	3.06e-16	4.04e-13	0.44	0.37	Sitting height ratio;	chr6:80154950	chr6:80355424~80356859:+
HNSC	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	8.48	3.07e-16	4.05e-13	0.47	0.37	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
HNSC	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	8.48	3.08e-16	4.06e-13	0.46	0.37	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
HNSC	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	8.48	3.08e-16	4.06e-13	0.48	0.37	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	8.48	3.08e-16	4.06e-13	0.48	0.37	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
HNSC	cis	rs9341808	0.655	rs9350846	ENSG00000272129.1	RP11-250B2.6	8.48	3.08e-16	4.07e-13	0.44	0.37	Sitting height ratio;	chr6:80155764	chr6:80355424~80356859:+
HNSC	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-8.48	3.09e-16	4.08e-13	-0.43	-0.37	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
HNSC	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
HNSC	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-8.47	3.11e-16	4.1e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	-8.47	3.12e-16	4.11e-13	-0.42	-0.37	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
HNSC	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-8.47	3.12e-16	4.11e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
HNSC	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-8.47	3.13e-16	4.12e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-8.47	3.13e-16	4.12e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-8.47	3.13e-16	4.13e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-8.47	3.13e-16	4.13e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-8.47	3.13e-16	4.13e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
HNSC	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-8.47	3.16e-16	4.16e-13	-0.42	-0.37	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
HNSC	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-8.47	3.17e-16	4.18e-13	-0.35	-0.36	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
HNSC	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	8.47	3.17e-16	4.18e-13	0.38	0.36	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
HNSC	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	8.47	3.18e-16	4.19e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-8.47	3.19e-16	4.2e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
HNSC	cis	rs875971	0.545	rs316316	ENSG00000179406.6	LINC00174	8.47	3.19e-16	4.2e-13	0.54	0.36	Aortic root size;	chr7:66149270	chr7:66376044~66401338:-
HNSC	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-8.47	3.22e-16	4.23e-13	-0.39	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
HNSC	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	8.47	3.24e-16	4.26e-13	0.38	0.36	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
HNSC	cis	rs453301	0.653	rs7853	ENSG00000254340.1	RP11-10A14.3	8.47	3.24e-16	4.26e-13	0.45	0.36	Joint mobility (Beighton score);	chr8:9033304	chr8:9141424~9145435:+
HNSC	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	8.47	3.27e-16	4.3e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.566	rs2051544	ENSG00000272462.2	U91328.19	-8.47	3.28e-16	4.31e-13	-0.36	-0.36	Height;	chr6:26070865	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-8.47	3.28e-16	4.31e-13	-0.42	-0.36	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
HNSC	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-8.47	3.3e-16	4.34e-13	-0.42	-0.36	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
HNSC	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-8.47	3.31e-16	4.35e-13	-0.41	-0.36	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
HNSC	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-8.47	3.33e-16	4.38e-13	-0.55	-0.36	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
HNSC	cis	rs9402743	0.775	rs12210389	ENSG00000217482.2	HMGB1P17	8.47	3.34e-16	4.38e-13	0.41	0.36	Systemic lupus erythematosus;	chr6:135661977	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-8.46	3.36e-16	4.42e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-8.46	3.37e-16	4.42e-13	-0.35	-0.36	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
HNSC	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	8.46	3.39e-16	4.46e-13	0.4	0.36	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
HNSC	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-8.46	3.4e-16	4.47e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-8.46	3.4e-16	4.47e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
HNSC	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	8.46	3.41e-16	4.48e-13	0.46	0.36	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
HNSC	cis	rs7615952	0.673	rs3811677	ENSG00000241288.6	RP11-379B18.5	-8.46	3.44e-16	4.51e-13	-0.53	-0.36	Blood pressure (smoking interaction);	chr3:125929237	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.932	rs3811679	ENSG00000241288.6	RP11-379B18.5	-8.46	3.44e-16	4.51e-13	-0.53	-0.36	Blood pressure (smoking interaction);	chr3:125929440	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	8.46	3.48e-16	4.56e-13	0.46	0.36	Height;	chr6:109465777	chr6:109382795~109383666:+
HNSC	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.928	rs9295673	ENSG00000272462.2	U91328.19	-8.46	3.5e-16	4.58e-13	-0.37	-0.36	Height;	chr6:25911866	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-8.46	3.52e-16	4.62e-13	-0.39	-0.36	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
HNSC	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-8.46	3.53e-16	4.63e-13	-0.52	-0.36	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
HNSC	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-8.46	3.54e-16	4.64e-13	-0.4	-0.36	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
HNSC	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-8.46	3.55e-16	4.65e-13	-0.43	-0.36	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
HNSC	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-8.45	3.61e-16	4.73e-13	-0.39	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
HNSC	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	8.45	3.63e-16	4.74e-13	0.46	0.36	Height;	chr6:109383239	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	8.45	3.63e-16	4.74e-13	0.46	0.36	Height;	chr6:109383248	chr6:109382795~109383666:+
HNSC	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	8.45	3.63e-16	4.74e-13	0.46	0.36	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
HNSC	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-8.45	3.63e-16	4.75e-13	-0.39	-0.36	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
HNSC	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-8.45	3.65e-16	4.77e-13	-0.42	-0.36	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
HNSC	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	8.45	3.65e-16	4.78e-13	0.46	0.36	Height;	chr6:109384807	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.618	rs6916507	ENSG00000272129.1	RP11-250B2.6	8.45	3.66e-16	4.78e-13	0.44	0.36	Sitting height ratio;	chr6:80152548	chr6:80355424~80356859:+
HNSC	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	8.45	3.67e-16	4.79e-13	0.41	0.36	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
HNSC	cis	rs9341808	0.65	rs6909546	ENSG00000272129.1	RP11-250B2.6	8.45	3.68e-16	4.81e-13	0.44	0.36	Sitting height ratio;	chr6:80160206	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-8.45	3.68e-16	4.81e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	8.45	3.69e-16	4.82e-13	0.47	0.36	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
HNSC	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-8.45	3.7e-16	4.83e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-8.45	3.71e-16	4.84e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
HNSC	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	8.45	3.72e-16	4.85e-13	0.43	0.36	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
HNSC	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-8.45	3.75e-16	4.9e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.932	rs6438948	ENSG00000241288.6	RP11-379B18.5	8.45	3.79e-16	4.95e-13	0.48	0.36	Blood pressure (smoking interaction);	chr3:125931202	chr3:125827238~125916384:-
HNSC	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-8.45	3.83e-16	4.99e-13	-0.54	-0.36	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
HNSC	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109494148	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109494760	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109495102	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109496680	chr6:109382795~109383666:+
HNSC	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	8.45	3.84e-16	5.01e-13	0.45	0.36	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	8.45	3.86e-16	5.03e-13	0.48	0.36	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
HNSC	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	8.44	3.88e-16	5.06e-13	0.4	0.36	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
HNSC	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	8.44	3.93e-16	5.12e-13	0.52	0.36	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
HNSC	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.44	3.94e-16	5.13e-13	-0.42	-0.36	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
HNSC	cis	rs7615952	0.932	rs7629977	ENSG00000241288.6	RP11-379B18.5	-8.44	4e-16	5.21e-13	-0.5	-0.36	Blood pressure (smoking interaction);	chr3:125930730	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.932	rs7630077	ENSG00000241288.6	RP11-379B18.5	-8.44	4e-16	5.21e-13	-0.5	-0.36	Blood pressure (smoking interaction);	chr3:125930833	chr3:125827238~125916384:-
HNSC	cis	rs1865760	0.566	rs9379821	ENSG00000272462.2	U91328.19	-8.44	4e-16	5.21e-13	-0.36	-0.36	Height;	chr6:26054040	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9358902	ENSG00000272462.2	U91328.19	-8.44	4e-16	5.21e-13	-0.36	-0.36	Height;	chr6:26058342	chr6:25992662~26001775:+
HNSC	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-8.44	4.04e-16	5.25e-13	-0.43	-0.36	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-8.44	4.04e-16	5.25e-13	-0.43	-0.36	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
HNSC	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-8.44	4.07e-16	5.3e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
HNSC	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-8.44	4.1e-16	5.32e-13	-0.41	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
HNSC	cis	rs2006771	0.836	rs7285777	ENSG00000236132.1	CTA-440B3.1	8.44	4.12e-16	5.35e-13	0.4	0.36	Nonsyndromic cleft lip with cleft palate;	chr22:31586255	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-8.43	4.2e-16	5.45e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-8.43	4.2e-16	5.45e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
HNSC	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	8.43	4.26e-16	5.53e-13	0.4	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
HNSC	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-8.43	4.32e-16	5.61e-13	-0.47	-0.36	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-8.43	4.32e-16	5.61e-13	-0.47	-0.36	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
HNSC	cis	rs1865760	0.516	rs9393684	ENSG00000272462.2	U91328.19	-8.43	4.34e-16	5.63e-13	-0.36	-0.36	Height;	chr6:26075303	chr6:25992662~26001775:+
HNSC	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	8.43	4.35e-16	5.64e-13	0.4	0.36	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
HNSC	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	8.43	4.38e-16	5.68e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
HNSC	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-8.43	4.42e-16	5.72e-13	-0.47	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
HNSC	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-8.43	4.42e-16	5.73e-13	-0.43	-0.36	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
HNSC	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	8.43	4.43e-16	5.74e-13	0.38	0.36	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-8.43	4.43e-16	5.74e-13	-0.48	-0.36	Depression;	chr6:28091242	chr6:28115628~28116551:+
HNSC	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-8.43	4.46e-16	5.77e-13	-0.42	-0.36	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
HNSC	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	8.43	4.46e-16	5.77e-13	0.36	0.36	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
HNSC	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-8.43	4.46e-16	5.77e-13	-0.49	-0.36	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
HNSC	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	8.43	4.47e-16	5.79e-13	0.46	0.36	Height;	chr6:109497088	chr6:109382795~109383666:+
HNSC	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	8.43	4.47e-16	5.79e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
HNSC	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	8.43	4.47e-16	5.79e-13	0.41	0.36	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-8.43	4.48e-16	5.8e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
HNSC	cis	rs440932	1	rs378974	ENSG00000254340.1	RP11-10A14.3	8.43	4.48e-16	5.8e-13	0.47	0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9141424~9145435:+
HNSC	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	8.43	4.49e-16	5.81e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.508	rs9379820	ENSG00000272462.2	U91328.19	-8.42	4.5e-16	5.82e-13	-0.36	-0.36	Height;	chr6:26049696	chr6:25992662~26001775:+
HNSC	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-8.42	4.51e-16	5.84e-13	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-8.42	4.51e-16	5.84e-13	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
HNSC	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	8.42	4.52e-16	5.85e-13	0.46	0.36	Height;	chr6:109383848	chr6:109382795~109383666:+
HNSC	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	8.42	4.55e-16	5.88e-13	0.61	0.36	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
HNSC	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-8.42	4.64e-16	5.99e-13	-0.41	-0.36	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
HNSC	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	8.42	4.65e-16	6.01e-13	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
HNSC	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	8.42	4.7e-16	6.07e-13	0.48	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
HNSC	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	8.42	4.74e-16	6.12e-13	0.58	0.36	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
HNSC	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-8.42	4.74e-16	6.12e-13	-0.39	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
HNSC	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-8.42	4.75e-16	6.14e-13	-0.32	-0.36	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	8.42	4.79e-16	6.18e-13	0.42	0.36	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
HNSC	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	8.42	4.79e-16	6.19e-13	0.4	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
HNSC	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-8.42	4.8e-16	6.19e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-8.42	4.8e-16	6.19e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
HNSC	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-8.42	4.83e-16	6.23e-13	-0.42	-0.36	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
HNSC	cis	rs9341808	0.718	rs10080237	ENSG00000272129.1	RP11-250B2.6	8.41	4.86e-16	6.26e-13	0.44	0.36	Sitting height ratio;	chr6:80144753	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs2874829	ENSG00000272129.1	RP11-250B2.6	8.41	4.86e-16	6.26e-13	0.44	0.36	Sitting height ratio;	chr6:80146380	chr6:80355424~80356859:+
HNSC	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-8.41	4.9e-16	6.31e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
HNSC	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-8.41	4.91e-16	6.33e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-8.41	4.93e-16	6.35e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.69	rs2322634	ENSG00000272129.1	RP11-250B2.6	8.41	5e-16	6.44e-13	0.44	0.36	Sitting height ratio;	chr6:80164297	chr6:80355424~80356859:+
HNSC	cis	rs1865760	0.566	rs10807006	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26048524	chr6:25992662~26001775:+
HNSC	cis	rs12216125	0.554	rs6942196	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Iron status biomarkers;	chr6:26072576	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs1539183	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26074823	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9295686	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26081755	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.532	rs9295687	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26082482	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs4529296	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26082907	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs1971509	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26085549	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.532	rs2006736	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26085789	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs1800702	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26086235	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs2794720	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26086974	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-8.41	5.03e-16	6.48e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	8.41	5.05e-16	6.5e-13	0.37	0.36	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	8.41	5.05e-16	6.5e-13	0.37	0.36	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
HNSC	cis	rs12439619	0.53	rs28883606	ENSG00000276710.3	CSPG4P8	-8.41	5.05e-16	6.5e-13	-0.4	-0.36	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82459472~82477258:+
HNSC	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-8.41	5.05e-16	6.5e-13	-0.33	-0.36	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
HNSC	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-8.41	5.11e-16	6.57e-13	-0.43	-0.36	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
HNSC	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	8.41	5.13e-16	6.6e-13	0.39	0.36	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	8.41	5.16e-16	6.63e-13	0.34	0.36	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
HNSC	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	8.41	5.16e-16	6.64e-13	0.45	0.36	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	8.41	5.16e-16	6.64e-13	0.45	0.36	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
HNSC	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.41	5.17e-16	6.65e-13	0.4	0.36	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.41	5.17e-16	6.65e-13	0.4	0.36	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
HNSC	cis	rs7615952	0.932	rs1976458	ENSG00000241288.6	RP11-379B18.5	-8.41	5.21e-16	6.69e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125928669	chr3:125827238~125916384:-
HNSC	cis	rs875971	0.545	rs67397473	ENSG00000179406.6	LINC00174	-8.4	5.21e-16	6.69e-13	-0.54	-0.36	Aortic root size;	chr7:66168318	chr7:66376044~66401338:-
HNSC	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-8.4	5.25e-16	6.75e-13	-0.4	-0.36	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
HNSC	cis	rs7615952	0.741	rs13314845	ENSG00000241288.6	RP11-379B18.5	-8.4	5.27e-16	6.77e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125925939	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.733	rs13314847	ENSG00000241288.6	RP11-379B18.5	-8.4	5.27e-16	6.77e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125925945	chr3:125827238~125916384:-
HNSC	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	8.4	5.28e-16	6.77e-13	0.4	0.36	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
HNSC	cis	rs9341808	0.718	rs9343971	ENSG00000272129.1	RP11-250B2.6	8.4	5.3e-16	6.81e-13	0.43	0.36	Sitting height ratio;	chr6:80172339	chr6:80355424~80356859:+
HNSC	cis	rs1865760	0.566	rs7772312	ENSG00000272462.2	U91328.19	-8.4	5.33e-16	6.84e-13	-0.35	-0.36	Height;	chr6:26049388	chr6:25992662~26001775:+
HNSC	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-8.4	5.35e-16	6.86e-13	-0.48	-0.36	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
HNSC	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-8.4	5.37e-16	6.88e-13	-0.38	-0.36	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
HNSC	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	8.4	5.41e-16	6.94e-13	0.42	0.36	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
HNSC	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	8.4	5.48e-16	7.02e-13	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	8.4	5.48e-16	7.02e-13	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
HNSC	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	8.4	5.49e-16	7.03e-13	0.48	0.36	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
HNSC	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-8.4	5.5e-16	7.05e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
HNSC	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-8.4	5.51e-16	7.06e-13	-0.37	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
HNSC	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-8.4	5.59e-16	7.16e-13	-0.45	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
HNSC	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	8.39	5.67e-16	7.26e-13	0.46	0.36	Height;	chr6:109454233	chr6:109382795~109383666:+
HNSC	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	8.39	5.7e-16	7.29e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
HNSC	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	8.39	5.7e-16	7.29e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
HNSC	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	8.39	5.74e-16	7.34e-13	0.41	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
HNSC	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	8.39	5.76e-16	7.37e-13	0.39	0.36	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
HNSC	cis	rs9341808	0.718	rs3828754	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80190923	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs10943696	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80191555	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs6910201	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80195221	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.69	rs9448909	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80199314	chr6:80355424~80356859:+
HNSC	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	8.39	5.79e-16	7.4e-13	0.44	0.36	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
HNSC	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.39	5.82e-16	7.43e-13	0.47	0.36	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-8.39	5.82e-16	7.44e-13	-0.39	-0.36	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
HNSC	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	8.39	5.83e-16	7.45e-13	0.49	0.36	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
HNSC	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-8.39	5.85e-16	7.48e-13	-0.42	-0.36	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
HNSC	cis	rs1865760	1	rs6905887	ENSG00000272462.2	U91328.19	-8.39	5.88e-16	7.5e-13	-0.36	-0.36	Height;	chr6:25911875	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.69	rs3805926	ENSG00000272129.1	RP11-250B2.6	8.39	5.92e-16	7.56e-13	0.44	0.36	Sitting height ratio;	chr6:80169563	chr6:80355424~80356859:+
HNSC	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	8.39	5.96e-16	7.61e-13	0.46	0.36	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
HNSC	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	8.39	5.97e-16	7.62e-13	0.46	0.36	Height;	chr6:109382188	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-8.39	5.98e-16	7.63e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
HNSC	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-8.39	6e-16	7.65e-13	-0.42	-0.36	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
HNSC	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-8.39	6e-16	7.66e-13	-0.46	-0.36	Height;	chr6:109497253	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.69	rs9343970	ENSG00000272129.1	RP11-250B2.6	8.39	6.03e-16	7.68e-13	0.44	0.36	Sitting height ratio;	chr6:80171572	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.545	rs316305	ENSG00000179406.6	LINC00174	8.38	6.05e-16	7.71e-13	0.54	0.36	Aortic root size;	chr7:66152984	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs316306	ENSG00000179406.6	LINC00174	8.38	6.05e-16	7.71e-13	0.54	0.36	Aortic root size;	chr7:66153687	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.866	rs1976459	ENSG00000241288.6	RP11-379B18.5	-8.38	6.1e-16	7.78e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125928643	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	8.38	6.1e-16	7.78e-13	0.45	0.36	Height;	chr6:109393881	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-8.38	6.11e-16	7.78e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	8.38	6.17e-16	7.85e-13	0.54	0.36	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
HNSC	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	8.38	6.17e-16	7.86e-13	0.39	0.36	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
HNSC	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-8.38	6.18e-16	7.87e-13	-0.37	-0.36	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
HNSC	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-8.38	6.22e-16	7.91e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	8.38	6.29e-16	8e-13	0.45	0.36	Height;	chr6:109391534	chr6:109382795~109383666:+
HNSC	cis	rs7615952	0.932	rs13086087	ENSG00000241288.6	RP11-379B18.5	-8.38	6.29e-16	8e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125927438	chr3:125827238~125916384:-
HNSC	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-8.38	6.31e-16	8.02e-13	-0.38	-0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
HNSC	cis	rs9341808	0.718	rs9448908	ENSG00000272129.1	RP11-250B2.6	8.38	6.31e-16	8.03e-13	0.43	0.36	Sitting height ratio;	chr6:80188352	chr6:80355424~80356859:+
HNSC	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	8.38	6.32e-16	8.03e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-8.38	6.32e-16	8.04e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
HNSC	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	8.38	6.33e-16	8.04e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
HNSC	cis	rs7615952	0.8	rs11915699	ENSG00000248787.1	RP11-666A20.4	-8.38	6.33e-16	8.04e-13	-0.55	-0.36	Blood pressure (smoking interaction);	chr3:125913841	chr3:125908005~125910272:-
HNSC	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-8.38	6.34e-16	8.06e-13	-0.38	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
HNSC	cis	rs1865760	1	rs3799372	ENSG00000272462.2	U91328.19	-8.38	6.35e-16	8.07e-13	-0.36	-0.36	Height;	chr6:25922083	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.963	rs1540273	ENSG00000272462.2	U91328.19	-8.38	6.35e-16	8.07e-13	-0.36	-0.36	Height;	chr6:25923930	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs9358895	ENSG00000272462.2	U91328.19	-8.38	6.35e-16	8.07e-13	-0.36	-0.36	Height;	chr6:25924427	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs7757666	ENSG00000272462.2	U91328.19	-8.38	6.38e-16	8.1e-13	-0.36	-0.36	Height;	chr6:25902398	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs6910138	ENSG00000272462.2	U91328.19	-8.38	6.38e-16	8.1e-13	-0.36	-0.36	Height;	chr6:25904124	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs6910174	ENSG00000272462.2	U91328.19	-8.38	6.38e-16	8.1e-13	-0.36	-0.36	Height;	chr6:25904186	chr6:25992662~26001775:+
HNSC	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-8.38	6.38e-16	8.11e-13	-0.41	-0.36	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
HNSC	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-8.38	6.38e-16	8.11e-13	-0.41	-0.36	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
HNSC	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-8.38	6.39e-16	8.12e-13	-0.42	-0.36	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
HNSC	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	8.38	6.41e-16	8.14e-13	0.38	0.36	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
HNSC	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	8.38	6.42e-16	8.15e-13	0.45	0.36	Height;	chr6:109390116	chr6:109382795~109383666:+
HNSC	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	8.38	6.42e-16	8.16e-13	0.77	0.36	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
HNSC	cis	rs1865760	1	rs9467636	ENSG00000272462.2	U91328.19	-8.38	6.42e-16	8.16e-13	-0.36	-0.36	Height;	chr6:25919321	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs9358893	ENSG00000272462.2	U91328.19	-8.38	6.42e-16	8.16e-13	-0.36	-0.36	Height;	chr6:25921533	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-8.38	6.44e-16	8.17e-13	-0.39	-0.36	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
HNSC	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	8.38	6.46e-16	8.19e-13	0.49	0.36	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
HNSC	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	8.37	6.54e-16	8.29e-13	0.38	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
HNSC	cis	rs1865760	1	rs7739966	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25905812	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs56118523	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25908747	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs12209482	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25909001	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.963	rs3846838	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25911547	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	8.37	6.65e-16	8.43e-13	0.37	0.36	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
HNSC	cis	rs6951245	0.872	rs11768895	ENSG00000224079.1	AC091729.7	-8.37	6.67e-16	8.45e-13	-0.57	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024055	chr7:1074450~1078036:+
HNSC	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-8.37	6.68e-16	8.46e-13	-0.46	-0.36	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
HNSC	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	8.37	6.71e-16	8.51e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
HNSC	cis	rs34375054	0.66	rs12305181	ENSG00000279233.1	RP11-158L12.4	8.37	6.72e-16	8.51e-13	0.41	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125109610	chr12:125138245~125141711:+
HNSC	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-8.37	6.74e-16	8.54e-13	-0.32	-0.36	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
HNSC	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-8.37	6.75e-16	8.56e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
HNSC	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-8.37	6.75e-16	8.56e-13	-0.41	-0.36	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
HNSC	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-8.37	6.77e-16	8.58e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
HNSC	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-8.37	6.78e-16	8.58e-13	-0.4	-0.36	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
HNSC	cis	rs1865760	0.929	rs1816546	ENSG00000272462.2	U91328.19	-8.37	6.81e-16	8.62e-13	-0.36	-0.36	Height;	chr6:25938024	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.786	rs1436308	ENSG00000272462.2	U91328.19	-8.37	6.81e-16	8.62e-13	-0.36	-0.36	Height;	chr6:25939339	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.929	rs1436307	ENSG00000272462.2	U91328.19	-8.37	6.81e-16	8.62e-13	-0.36	-0.36	Height;	chr6:25939495	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.37	6.82e-16	8.64e-13	0.41	0.36	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
HNSC	cis	rs1865760	1	rs9393675	ENSG00000272462.2	U91328.19	-8.37	6.83e-16	8.64e-13	-0.37	-0.36	Height;	chr6:25929888	chr6:25992662~26001775:+
HNSC	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	8.37	6.84e-16	8.66e-13	0.47	0.36	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
HNSC	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	8.37	6.86e-16	8.68e-13	0.41	0.36	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	8.37	6.87e-16	8.7e-13	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	8.37	6.88e-16	8.7e-13	0.45	0.36	Height;	chr6:109390638	chr6:109382795~109383666:+
HNSC	cis	rs12216125	0.549	rs9358905	ENSG00000272462.2	U91328.19	-8.37	6.9e-16	8.73e-13	-0.35	-0.36	Iron status biomarkers;	chr6:26077611	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-8.37	6.94e-16	8.77e-13	-0.46	-0.36	Height;	chr6:109501793	chr6:109382795~109383666:+
HNSC	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-8.37	6.97e-16	8.82e-13	-0.34	-0.36	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
HNSC	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.37	6.98e-16	8.83e-13	0.46	0.36	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
HNSC	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	8.36	7.01e-16	8.86e-13	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
HNSC	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	8.36	7.01e-16	8.86e-13	0.48	0.36	Depression;	chr6:28142370	chr6:28115628~28116551:+
HNSC	cis	rs1865760	1	rs7770139	ENSG00000272462.2	U91328.19	-8.36	7.01e-16	8.87e-13	-0.36	-0.36	Height;	chr6:25925595	chr6:25992662~26001775:+
HNSC	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	8.36	7.03e-16	8.89e-13	0.4	0.36	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-8.36	7.07e-16	8.94e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.964	rs3799373	ENSG00000272462.2	U91328.19	-8.36	7.09e-16	8.96e-13	-0.36	-0.36	Height;	chr6:25928945	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs9348698	ENSG00000272462.2	U91328.19	-8.36	7.09e-16	8.96e-13	-0.36	-0.36	Height;	chr6:25929461	chr6:25992662~26001775:+
HNSC	cis	rs9341808	0.718	rs3805922	ENSG00000272129.1	RP11-250B2.6	8.36	7.12e-16	8.99e-13	0.43	0.36	Sitting height ratio;	chr6:80182272	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs3805920	ENSG00000272129.1	RP11-250B2.6	8.36	7.12e-16	8.99e-13	0.43	0.36	Sitting height ratio;	chr6:80183028	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000254340.1	RP11-10A14.3	-8.36	7.13e-16	9e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9044914	chr8:9141424~9145435:+
HNSC	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	8.36	7.19e-16	9.07e-13	0.46	0.36	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
HNSC	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-8.36	7.2e-16	9.08e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
HNSC	cis	rs2834288	0.5	rs2834305	ENSG00000237945.6	LINC00649	8.36	7.22e-16	9.1e-13	0.43	0.36	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.5	rs7277248	ENSG00000237945.6	LINC00649	8.36	7.22e-16	9.1e-13	0.43	0.36	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33915534~33977691:+
HNSC	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	8.36	7.25e-16	9.14e-13	0.43	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.545	rs10950025	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66158946	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.52	rs12666485	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66160135	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs67688847	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66161064	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs7787063	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66164012	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs12673308	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66166374	chr7:66376044~66401338:-
HNSC	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	8.36	7.3e-16	9.19e-13	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
HNSC	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	8.36	7.3e-16	9.2e-13	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-8.36	7.31e-16	9.2e-13	-0.35	-0.36	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-8.36	7.37e-16	9.28e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
HNSC	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-8.36	7.38e-16	9.29e-13	-0.48	-0.36	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
HNSC	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	8.36	7.4e-16	9.31e-13	0.47	0.36	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	8.36	7.4e-16	9.31e-13	0.33	0.36	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	8.36	7.4e-16	9.32e-13	0.37	0.36	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	8.36	7.41e-16	9.33e-13	0.46	0.36	Height;	chr6:109443332	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	8.36	7.42e-16	9.34e-13	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	8.36	7.42e-16	9.34e-13	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
HNSC	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	8.36	7.44e-16	9.36e-13	0.42	0.36	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
HNSC	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-8.36	7.45e-16	9.37e-13	-0.43	-0.36	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
HNSC	cis	rs6951245	0.935	rs11763765	ENSG00000224079.1	AC091729.7	-8.36	7.45e-16	9.37e-13	-0.6	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020874	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs11766669	ENSG00000224079.1	AC091729.7	-8.36	7.45e-16	9.37e-13	-0.6	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1023957	chr7:1074450~1078036:+
HNSC	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-8.36	7.45e-16	9.37e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.516	rs9295684	ENSG00000272462.2	U91328.19	-8.36	7.5e-16	9.43e-13	-0.35	-0.36	Height;	chr6:26069441	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-8.36	7.5e-16	9.43e-13	-0.42	-0.36	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
HNSC	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	8.36	7.51e-16	9.44e-13	0.46	0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
HNSC	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	8.36	7.52e-16	9.46e-13	0.41	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
HNSC	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	8.36	7.53e-16	9.47e-13	0.41	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
HNSC	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	8.35	7.56e-16	9.51e-13	0.51	0.36	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
HNSC	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-8.35	7.58e-16	9.53e-13	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
HNSC	cis	rs1865760	0.566	rs2032445	ENSG00000272462.2	U91328.19	-8.35	7.58e-16	9.53e-13	-0.35	-0.36	Height;	chr6:26044584	chr6:25992662~26001775:+
HNSC	cis	rs9341808	0.754	rs3805925	ENSG00000272129.1	RP11-250B2.6	8.35	7.62e-16	9.57e-13	0.43	0.36	Sitting height ratio;	chr6:80174116	chr6:80355424~80356859:+
HNSC	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	8.35	7.67e-16	9.63e-13	0.39	0.36	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-8.35	7.68e-16	9.65e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	8.35	7.72e-16	9.69e-13	0.39	0.36	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
HNSC	cis	rs1865760	0.892	rs9379806	ENSG00000272462.2	U91328.19	-8.35	7.72e-16	9.7e-13	-0.36	-0.36	Height;	chr6:25940730	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	8.35	7.72e-16	9.7e-13	0.46	0.36	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
HNSC	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	8.35	7.73e-16	9.71e-13	0.41	0.36	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	8.35	7.73e-16	9.71e-13	0.41	0.36	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
HNSC	cis	rs10256972	0.626	rs62433138	ENSG00000225146.1	AC073957.15	8.35	7.78e-16	9.77e-13	0.41	0.36	Endometriosis;Longevity;	chr7:1011241	chr7:1029025~1043891:+
HNSC	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-8.35	7.79e-16	9.78e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
HNSC	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	8.35	7.8e-16	9.79e-13	0.47	0.36	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	8.35	7.9e-16	9.91e-13	0.33	0.36	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
HNSC	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	8.35	7.93e-16	9.95e-13	0.41	0.36	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-8.35	7.94e-16	9.96e-13	-0.48	-0.36	Depression;	chr6:28140454	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-8.35	7.94e-16	9.96e-13	-0.48	-0.36	Depression;	chr6:28141189	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-8.35	7.94e-16	9.96e-13	-0.48	-0.36	Depression;	chr6:28141484	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-8.35	7.96e-16	9.99e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	8.35	7.98e-16	1e-12	0.41	0.36	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
HNSC	cis	rs35955747	0.601	rs5749302	ENSG00000236132.1	CTA-440B3.1	-8.35	7.98e-16	1e-12	-0.4	-0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31554632	chr22:31816379~31817491:-
HNSC	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-8.35	8.04e-16	1.01e-12	-0.42	-0.36	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
HNSC	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	8.35	8.05e-16	1.01e-12	0.41	0.36	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
HNSC	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-8.34	8.12e-16	1.02e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-8.34	8.12e-16	1.02e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-8.34	8.14e-16	1.02e-12	-0.4	-0.36	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	8.34	8.17e-16	1.02e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	8.34	8.19e-16	1.03e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	8.34	8.19e-16	1.03e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
HNSC	cis	rs7104764	0.879	rs511744	ENSG00000277290.1	RP11-326C3.16	-8.34	8.2e-16	1.03e-12	-0.36	-0.36	Menarche (age at onset);	chr11:219089	chr11:243099~243483:-
HNSC	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-8.34	8.28e-16	1.04e-12	-0.32	-0.36	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
HNSC	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	8.34	8.28e-16	1.04e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	8.34	8.29e-16	1.04e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	8.34	8.3e-16	1.04e-12	0.41	0.36	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	8.34	8.3e-16	1.04e-12	0.41	0.36	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	8.34	8.3e-16	1.04e-12	0.41	0.36	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
HNSC	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	8.34	8.31e-16	1.04e-12	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	8.34	8.31e-16	1.04e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
HNSC	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	8.34	8.32e-16	1.04e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
HNSC	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-8.34	8.34e-16	1.04e-12	-0.37	-0.36	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
HNSC	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-8.34	8.35e-16	1.04e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-8.34	8.35e-16	1.04e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-8.34	8.35e-16	1.04e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.8	rs13086460	ENSG00000241288.6	RP11-379B18.5	-8.34	8.44e-16	1.06e-12	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125927574	chr3:125827238~125916384:-
HNSC	cis	rs9341808	0.69	rs6930534	ENSG00000272129.1	RP11-250B2.6	8.34	8.48e-16	1.06e-12	0.43	0.36	Sitting height ratio;	chr6:80186333	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs2322636	ENSG00000272129.1	RP11-250B2.6	8.34	8.48e-16	1.06e-12	0.43	0.36	Sitting height ratio;	chr6:80187719	chr6:80355424~80356859:+
HNSC	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	8.34	8.48e-16	1.06e-12	0.34	0.36	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
HNSC	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-8.34	8.48e-16	1.06e-12	-0.34	-0.36	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
HNSC	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-8.34	8.51e-16	1.06e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
HNSC	cis	rs1865760	1	rs1865760	ENSG00000272462.2	U91328.19	-8.34	8.53e-16	1.07e-12	-0.36	-0.36	Height;	chr6:25916751	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
HNSC	cis	rs1865760	1	rs3830057	ENSG00000272462.2	U91328.19	-8.34	8.59e-16	1.07e-12	-0.36	-0.36	Height;	chr6:25918282	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs3752421	ENSG00000272462.2	U91328.19	-8.34	8.59e-16	1.07e-12	-0.36	-0.36	Height;	chr6:25918460	chr6:25992662~26001775:+
HNSC	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	8.34	8.64e-16	1.08e-12	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
HNSC	cis	rs7048146	0.899	rs7032590	ENSG00000213539.4	YBX1P6	8.34	8.64e-16	1.08e-12	0.43	0.36	Vascular brain injury;	chr9:109575480	chr9:109532830~109534332:-
HNSC	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-8.34	8.67e-16	1.08e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
HNSC	cis	rs1865760	0.566	rs9348706	ENSG00000272462.2	U91328.19	-8.33	8.75e-16	1.09e-12	-0.35	-0.36	Height;	chr6:26065253	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-8.33	8.8e-16	1.1e-12	-0.34	-0.36	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-8.33	8.81e-16	1.1e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.508	rs8032033	ENSG00000276710.3	CSPG4P8	-8.33	8.84e-16	1.1e-12	-0.4	-0.36	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82459472~82477258:+
HNSC	cis	rs2179367	1	rs2179367	ENSG00000231760.4	RP11-350J20.5	8.33	8.87e-16	1.11e-12	0.47	0.36	Dupuytren's disease;	chr6:149441401	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.545	rs10950029	ENSG00000179406.6	LINC00174	-8.33	8.88e-16	1.11e-12	-0.52	-0.36	Aortic root size;	chr7:66169334	chr7:66376044~66401338:-
HNSC	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-8.33	8.91e-16	1.11e-12	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
HNSC	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-8.33	8.92e-16	1.11e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-8.33	8.92e-16	1.11e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-8.33	8.92e-16	1.11e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.33	8.94e-16	1.11e-12	0.42	0.36	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.33	8.94e-16	1.11e-12	0.42	0.36	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.59	rs4706841	ENSG00000272129.1	RP11-250B2.6	8.33	8.97e-16	1.12e-12	0.42	0.36	Sitting height ratio;	chr6:80348110	chr6:80355424~80356859:+
HNSC	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	8.33	9.03e-16	1.12e-12	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
HNSC	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	8.33	9.05e-16	1.13e-12	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	8.33	9.07e-16	1.13e-12	0.45	0.36	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	8.33	9.12e-16	1.13e-12	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
HNSC	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	8.33	9.2e-16	1.15e-12	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-8.33	9.25e-16	1.15e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.964	rs1324084	ENSG00000272462.2	U91328.19	-8.33	9.28e-16	1.15e-12	-0.36	-0.36	Height;	chr6:25914906	chr6:25992662~26001775:+
HNSC	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	8.33	9.3e-16	1.16e-12	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
HNSC	cis	rs1865760	0.566	rs2032443	ENSG00000272462.2	U91328.19	-8.33	9.3e-16	1.16e-12	-0.35	-0.36	Height;	chr6:26046574	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.516	rs9358903	ENSG00000272462.2	U91328.19	-8.33	9.35e-16	1.16e-12	-0.35	-0.36	Height;	chr6:26061721	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-8.33	9.36e-16	1.16e-12	-0.38	-0.36	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
HNSC	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	8.33	9.37e-16	1.16e-12	0.44	0.36	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
HNSC	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-8.33	9.38e-16	1.17e-12	-0.39	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
HNSC	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	8.32	9.43e-16	1.17e-12	0.47	0.36	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.545	rs2460427	ENSG00000179406.6	LINC00174	8.32	9.44e-16	1.17e-12	0.54	0.36	Aortic root size;	chr7:66154218	chr7:66376044~66401338:-
HNSC	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	8.32	9.44e-16	1.17e-12	0.38	0.36	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-8.32	9.45e-16	1.17e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	8.32	9.5e-16	1.18e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	8.32	9.53e-16	1.18e-12	0.37	0.36	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
HNSC	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-8.32	9.56e-16	1.19e-12	-0.42	-0.36	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
HNSC	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-8.32	9.58e-16	1.19e-12	-0.58	-0.36	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-8.32	9.59e-16	1.19e-12	-0.57	-0.36	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-8.32	9.59e-16	1.19e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	8.32	9.6e-16	1.19e-12	0.33	0.36	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-8.32	9.6e-16	1.19e-12	-0.4	-0.36	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
HNSC	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-8.32	9.66e-16	1.2e-12	-0.44	-0.36	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-8.32	9.66e-16	1.2e-12	-0.44	-0.36	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
HNSC	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-8.32	9.73e-16	1.21e-12	-0.38	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
HNSC	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	8.32	9.77e-16	1.21e-12	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
HNSC	cis	rs7404843	0.778	rs72774864	ENSG00000263065.1	AF001548.6	8.32	9.78e-16	1.21e-12	0.66	0.36	Testicular germ cell tumor;	chr16:15418465	chr16:15741151~15741791:+
HNSC	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-8.32	9.82e-16	1.22e-12	-0.34	-0.36	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
HNSC	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	8.32	9.9e-16	1.23e-12	0.45	0.36	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	8.32	9.9e-16	1.23e-12	0.45	0.36	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
HNSC	cis	rs1865760	0.622	rs9295685	ENSG00000272462.2	U91328.19	-8.32	9.9e-16	1.23e-12	-0.35	-0.36	Height;	chr6:26071497	chr6:25992662~26001775:+
HNSC	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	8.32	9.92e-16	1.23e-12	0.44	0.36	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
HNSC	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-8.32	9.92e-16	1.23e-12	-0.41	-0.36	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
HNSC	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	8.32	9.95e-16	1.23e-12	0.47	0.36	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
HNSC	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-8.32	1e-15	1.24e-12	-0.41	-0.36	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
HNSC	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	8.32	1e-15	1.24e-12	0.4	0.36	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
HNSC	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-8.32	1e-15	1.24e-12	-0.41	-0.36	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
HNSC	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	8.32	1.01e-15	1.25e-12	0.46	0.36	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
HNSC	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	8.31	1.01e-15	1.25e-12	0.56	0.36	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
HNSC	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-8.31	1.01e-15	1.25e-12	-0.39	-0.36	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
HNSC	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-8.31	1.01e-15	1.26e-12	-0.57	-0.36	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
HNSC	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	8.31	1.02e-15	1.26e-12	0.38	0.36	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
HNSC	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	8.31	1.03e-15	1.27e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
HNSC	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.03e-15	1.28e-12	-0.42	-0.36	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.03e-15	1.28e-12	-0.42	-0.36	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
HNSC	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-8.31	1.04e-15	1.28e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
HNSC	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-8.31	1.04e-15	1.28e-12	-0.42	-0.36	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-8.31	1.04e-15	1.29e-12	-0.38	-0.36	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-8.31	1.05e-15	1.3e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
HNSC	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-8.31	1.05e-15	1.3e-12	-0.42	-0.36	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
HNSC	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-8.31	1.06e-15	1.31e-12	-0.4	-0.36	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
HNSC	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	8.31	1.06e-15	1.31e-12	0.46	0.36	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	8.31	1.06e-15	1.31e-12	0.51	0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
HNSC	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-8.31	1.07e-15	1.32e-12	-0.39	-0.36	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
HNSC	cis	rs12439619	0.693	rs28665836	ENSG00000276710.3	CSPG4P8	-8.31	1.07e-15	1.32e-12	-0.39	-0.36	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82459472~82477258:+
HNSC	cis	rs2276314	0.857	rs28540805	ENSG00000278986.1	RP11-723J4.3	-8.31	1.07e-15	1.32e-12	-0.47	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36062012	chr18:35972151~35973916:+
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	8.31	1.08e-15	1.33e-12	0.4	0.36	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
HNSC	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.08e-15	1.33e-12	-0.42	-0.36	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
HNSC	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-8.31	1.08e-15	1.33e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
HNSC	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-8.31	1.08e-15	1.34e-12	-0.31	-0.36	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
HNSC	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-8.31	1.09e-15	1.34e-12	-0.38	-0.36	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
HNSC	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.31	1.09e-15	1.34e-12	0.46	0.36	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	8.3	1.09e-15	1.35e-12	0.37	0.36	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	8.3	1.09e-15	1.35e-12	0.37	0.36	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-8.3	1.1e-15	1.36e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	8.3	1.1e-15	1.36e-12	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
HNSC	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-8.3	1.1e-15	1.36e-12	-0.44	-0.36	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
HNSC	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-8.3	1.11e-15	1.36e-12	-0.38	-0.36	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-8.3	1.11e-15	1.36e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-8.3	1.11e-15	1.36e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
HNSC	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	8.3	1.11e-15	1.37e-12	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.927	rs6915834	ENSG00000272462.2	U91328.19	-8.3	1.11e-15	1.37e-12	-0.36	-0.36	Height;	chr6:25935199	chr6:25992662~26001775:+
HNSC	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-8.3	1.12e-15	1.38e-12	-0.39	-0.36	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
HNSC	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	8.3	1.12e-15	1.38e-12	0.45	0.36	Height;	chr6:109470427	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	8.3	1.12e-15	1.38e-12	0.45	0.36	Height;	chr6:109470900	chr6:109382795~109383666:+
HNSC	cis	rs1865760	0.516	rs9393683	ENSG00000272462.2	U91328.19	-8.3	1.13e-15	1.39e-12	-0.35	-0.36	Height;	chr6:26065970	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.964	rs9379802	ENSG00000272462.2	U91328.19	-8.3	1.13e-15	1.39e-12	-0.36	-0.36	Height;	chr6:25933670	chr6:25992662~26001775:+
HNSC	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-8.3	1.14e-15	1.4e-12	-0.42	-0.36	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
HNSC	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-8.3	1.14e-15	1.4e-12	-0.42	-0.36	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
HNSC	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-8.3	1.14e-15	1.4e-12	-0.32	-0.36	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
HNSC	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	8.3	1.14e-15	1.4e-12	0.47	0.36	Height;	chr6:109424139	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-8.3	1.15e-15	1.41e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	8.3	1.15e-15	1.42e-12	0.54	0.36	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	8.3	1.15e-15	1.42e-12	0.54	0.36	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-8.3	1.15e-15	1.42e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
HNSC	cis	rs1021993	0.868	rs906351	ENSG00000231648.1	RP11-372M18.2	-8.3	1.16e-15	1.42e-12	-0.48	-0.36	Gut microbiome composition (winter);	chr1:209354580	chr1:209367662~209379690:+
HNSC	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-8.3	1.16e-15	1.42e-12	-0.45	-0.36	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
HNSC	cis	rs673078	0.562	rs61944672	ENSG00000275759.1	RP11-131L12.3	-8.3	1.17e-15	1.43e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118450123	chr12:118428281~118428870:+
HNSC	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	8.3	1.17e-15	1.43e-12	0.41	0.36	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.545	rs1796226	ENSG00000179406.6	LINC00174	-8.3	1.17e-15	1.43e-12	-0.54	-0.36	Aortic root size;	chr7:66622723	chr7:66376044~66401338:-
HNSC	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	8.3	1.17e-15	1.44e-12	0.37	0.36	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	8.3	1.17e-15	1.44e-12	0.46	0.36	Height;	chr6:109447092	chr6:109382795~109383666:+
HNSC	cis	rs7404843	0.852	rs111259294	ENSG00000263065.1	AF001548.6	8.29	1.17e-15	1.44e-12	0.66	0.36	Testicular germ cell tumor;	chr16:15418073	chr16:15741151~15741791:+
HNSC	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-8.29	1.18e-15	1.45e-12	-0.36	-0.36	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
HNSC	cis	rs992157	0.764	rs3731861	ENSG00000261338.2	RP11-378A13.1	-8.29	1.18e-15	1.45e-12	-0.4	-0.36	Colorectal cancer;	chr2:218326533	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-8.29	1.19e-15	1.46e-12	-0.48	-0.36	Depression;	chr6:28140307	chr6:28115628~28116551:+
HNSC	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-8.29	1.19e-15	1.46e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
HNSC	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	8.29	1.2e-15	1.46e-12	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
HNSC	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-8.29	1.2e-15	1.47e-12	-0.38	-0.36	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-8.29	1.2e-15	1.47e-12	-0.38	-0.36	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.545	rs67775320	ENSG00000179406.6	LINC00174	-8.29	1.2e-15	1.47e-12	-0.53	-0.36	Aortic root size;	chr7:66193792	chr7:66376044~66401338:-
HNSC	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	8.29	1.21e-15	1.47e-12	0.46	0.36	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
HNSC	cis	rs1865760	0.516	rs10807007	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.35	-0.36	Height;	chr6:26048703	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.516	rs9379819	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.35	-0.36	Height;	chr6:26049591	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.892	rs2328903	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.36	-0.36	Height;	chr6:25935537	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.892	rs6456705	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.36	-0.36	Height;	chr6:25935828	chr6:25992662~26001775:+
HNSC	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-8.29	1.21e-15	1.48e-12	-0.35	-0.36	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
HNSC	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-8.29	1.23e-15	1.5e-12	-0.4	-0.36	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
HNSC	cis	rs7942368	1	rs1440978	ENSG00000255100.1	RP11-21L23.3	8.29	1.23e-15	1.51e-12	0.45	0.36	Endometriosis;	chr11:76765236	chr11:76782581~76783062:-
HNSC	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-8.29	1.23e-15	1.51e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-8.29	1.23e-15	1.51e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-8.29	1.24e-15	1.51e-12	-0.4	-0.36	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
HNSC	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-8.29	1.24e-15	1.52e-12	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
HNSC	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-8.29	1.24e-15	1.52e-12	-0.39	-0.36	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
HNSC	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-8.29	1.25e-15	1.52e-12	-0.39	-0.36	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	8.29	1.26e-15	1.53e-12	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
HNSC	cis	rs875971	0.545	rs316324	ENSG00000179406.6	LINC00174	8.29	1.26e-15	1.53e-12	0.54	0.36	Aortic root size;	chr7:66145627	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs316323	ENSG00000179406.6	LINC00174	8.29	1.26e-15	1.53e-12	0.54	0.36	Aortic root size;	chr7:66146002	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	8.29	1.26e-15	1.53e-12	0.46	0.36	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	8.29	1.26e-15	1.53e-12	0.46	0.36	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
HNSC	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	8.28	1.26e-15	1.54e-12	0.48	0.36	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
HNSC	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	8.28	1.27e-15	1.55e-12	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
HNSC	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	8.28	1.27e-15	1.55e-12	0.47	0.36	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
HNSC	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	8.28	1.28e-15	1.56e-12	0.42	0.36	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
HNSC	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-8.28	1.28e-15	1.56e-12	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-8.28	1.28e-15	1.56e-12	-0.38	-0.36	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
HNSC	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-8.28	1.28e-15	1.56e-12	-0.41	-0.36	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000173295.6	FAM86B3P	8.28	1.29e-15	1.57e-12	0.4	0.36	Mood instability;	chr8:8410553	chr8:8228595~8244865:+
HNSC	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	8.28	1.29e-15	1.57e-12	0.45	0.36	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
HNSC	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-8.28	1.3e-15	1.59e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-8.28	1.31e-15	1.59e-12	-0.38	-0.36	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
HNSC	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	8.28	1.32e-15	1.6e-12	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	8.28	1.32e-15	1.61e-12	0.47	0.36	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	8.28	1.32e-15	1.61e-12	0.47	0.36	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-8.28	1.33e-15	1.62e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
HNSC	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	8.28	1.34e-15	1.63e-12	0.39	0.36	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
HNSC	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	8.28	1.34e-15	1.63e-12	0.45	0.36	Height;	chr6:109476101	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	8.27	1.36e-15	1.65e-12	0.37	0.36	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.27	1.37e-15	1.66e-12	0.41	0.36	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.27	1.37e-15	1.66e-12	0.41	0.36	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.27	1.37e-15	1.66e-12	0.41	0.36	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
HNSC	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	8.27	1.37e-15	1.66e-12	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
HNSC	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	8.27	1.38e-15	1.67e-12	0.41	0.36	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
HNSC	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-8.27	1.39e-15	1.68e-12	-0.43	-0.36	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
HNSC	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-8.27	1.39e-15	1.69e-12	-0.4	-0.36	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
HNSC	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-8.27	1.39e-15	1.69e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-8.27	1.39e-15	1.69e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
HNSC	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	8.27	1.4e-15	1.69e-12	0.46	0.36	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
HNSC	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	8.27	1.4e-15	1.69e-12	0.47	0.36	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-8.27	1.41e-15	1.7e-12	-0.55	-0.36	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-8.27	1.41e-15	1.7e-12	-0.55	-0.36	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-8.27	1.41e-15	1.7e-12	-0.55	-0.36	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
HNSC	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	8.27	1.41e-15	1.71e-12	0.41	0.36	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
HNSC	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-8.27	1.42e-15	1.71e-12	-0.37	-0.36	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
HNSC	cis	rs35955747	0.714	rs5997989	ENSG00000236132.1	CTA-440B3.1	8.27	1.42e-15	1.71e-12	0.39	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31443964	chr22:31816379~31817491:-
HNSC	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	8.27	1.42e-15	1.72e-12	0.36	0.36	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
HNSC	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	8.27	1.42e-15	1.72e-12	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
HNSC	cis	rs9402743	0.816	rs9402737	ENSG00000217482.2	HMGB1P17	8.27	1.43e-15	1.72e-12	0.41	0.36	Systemic lupus erythematosus;	chr6:135651778	chr6:135636086~135636713:-
HNSC	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	8.27	1.43e-15	1.73e-12	0.36	0.36	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	8.27	1.43e-15	1.73e-12	0.44	0.36	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-8.27	1.44e-15	1.74e-12	-0.32	-0.36	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
HNSC	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	8.27	1.46e-15	1.76e-12	0.41	0.36	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
HNSC	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	8.26	1.46e-15	1.77e-12	0.53	0.36	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
HNSC	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-8.26	1.47e-15	1.78e-12	-0.43	-0.36	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
HNSC	cis	rs7942368	1	rs12282785	ENSG00000255100.1	RP11-21L23.3	8.26	1.48e-15	1.78e-12	0.45	0.36	Endometriosis;	chr11:76764986	chr11:76782581~76783062:-
HNSC	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	8.26	1.48e-15	1.78e-12	0.41	0.36	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	8.26	1.48e-15	1.78e-12	0.36	0.36	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
HNSC	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-8.26	1.48e-15	1.79e-12	-0.46	-0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-8.26	1.49e-15	1.8e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
HNSC	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	8.26	1.5e-15	1.8e-12	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
HNSC	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	8.26	1.5e-15	1.8e-12	0.4	0.36	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
HNSC	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	8.26	1.5e-15	1.81e-12	0.51	0.36	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
HNSC	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-8.26	1.51e-15	1.82e-12	-0.42	-0.36	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
HNSC	cis	rs67180937	0.882	rs17163313	ENSG00000272750.1	RP11-378J18.8	-8.26	1.51e-15	1.82e-12	-0.39	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222626283	chr1:222658867~222661512:-
HNSC	cis	rs9341808	0.718	rs9448898	ENSG00000272129.1	RP11-250B2.6	8.26	1.53e-15	1.84e-12	0.43	0.36	Sitting height ratio;	chr6:80135624	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	8.26	1.53e-15	1.84e-12	0.37	0.36	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
HNSC	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	8.26	1.54e-15	1.85e-12	0.4	0.36	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
HNSC	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	8.26	1.54e-15	1.86e-12	0.45	0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
HNSC	cis	rs7615952	0.688	rs7624806	ENSG00000248787.1	RP11-666A20.4	-8.25	1.57e-15	1.89e-12	-0.54	-0.36	Blood pressure (smoking interaction);	chr3:125880231	chr3:125908005~125910272:-
HNSC	cis	rs2179367	0.919	rs4897124	ENSG00000231760.4	RP11-350J20.5	8.25	1.57e-15	1.89e-12	0.47	0.36	Dupuytren's disease;	chr6:149442073	chr6:149796151~149826294:-
HNSC	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-8.25	1.58e-15	1.9e-12	-0.48	-0.36	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
HNSC	cis	rs35955747	0.689	rs5997988	ENSG00000236132.1	CTA-440B3.1	8.25	1.58e-15	1.9e-12	0.39	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31442099	chr22:31816379~31817491:-
HNSC	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	8.25	1.58e-15	1.9e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-8.25	1.58e-15	1.9e-12	-0.45	-0.36	Height;	chr6:109432968	chr6:109382795~109383666:+
HNSC	cis	rs34375054	0.66	rs12303416	ENSG00000279233.1	RP11-158L12.4	8.25	1.58e-15	1.91e-12	0.4	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125108812	chr12:125138245~125141711:+
HNSC	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	8.25	1.59e-15	1.92e-12	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
HNSC	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	8.25	1.6e-15	1.92e-12	0.38	0.36	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
HNSC	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-8.25	1.6e-15	1.92e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-8.25	1.6e-15	1.92e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.727	rs10943697	ENSG00000272129.1	RP11-250B2.6	8.25	1.6e-15	1.93e-12	0.43	0.36	Sitting height ratio;	chr6:80221789	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs1324123	ENSG00000272129.1	RP11-250B2.6	8.25	1.6e-15	1.93e-12	0.43	0.36	Sitting height ratio;	chr6:80223177	chr6:80355424~80356859:+
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-8.25	1.61e-15	1.93e-12	-0.41	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
HNSC	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-8.25	1.61e-15	1.93e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
HNSC	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	8.25	1.61e-15	1.94e-12	0.42	0.36	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
HNSC	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	8.25	1.62e-15	1.94e-12	0.36	0.36	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	8.25	1.62e-15	1.94e-12	0.36	0.36	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
HNSC	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-8.25	1.62e-15	1.95e-12	-0.51	-0.36	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
HNSC	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109747411	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109748819	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109749564	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109763331	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	8.25	1.62e-15	1.95e-12	0.38	0.36	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
HNSC	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
HNSC	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-8.25	1.63e-15	1.96e-12	-0.27	-0.36	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
HNSC	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	8.25	1.63e-15	1.96e-12	0.4	0.36	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
HNSC	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-8.25	1.64e-15	1.97e-12	-0.42	-0.36	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
HNSC	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	8.25	1.64e-15	1.97e-12	0.47	0.36	Height;	chr6:109374782	chr6:109382795~109383666:+
HNSC	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-8.25	1.64e-15	1.97e-12	-0.36	-0.36	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
HNSC	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	8.25	1.64e-15	1.97e-12	0.4	0.36	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-8.25	1.65e-15	1.98e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-8.25	1.65e-15	1.98e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-8.25	1.65e-15	1.98e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
HNSC	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-8.25	1.65e-15	1.98e-12	-0.45	-0.36	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-8.25	1.67e-15	2e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
HNSC	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	8.25	1.68e-15	2.01e-12	0.47	0.36	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
HNSC	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	8.25	1.68e-15	2.01e-12	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000173295.6	FAM86B3P	8.25	1.68e-15	2.02e-12	0.4	0.36	Joint mobility (Beighton score);	chr8:8979093	chr8:8228595~8244865:+
HNSC	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	8.25	1.68e-15	2.02e-12	0.42	0.36	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
HNSC	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	8.25	1.68e-15	2.02e-12	0.42	0.36	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
HNSC	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-8.25	1.69e-15	2.02e-12	-0.38	-0.36	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
HNSC	cis	rs7942368	0.941	rs10899279	ENSG00000255100.1	RP11-21L23.3	8.24	1.69e-15	2.03e-12	0.45	0.36	Endometriosis;	chr11:76766200	chr11:76782581~76783062:-
HNSC	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	8.24	1.7e-15	2.04e-12	0.46	0.36	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	8.24	1.7e-15	2.04e-12	0.54	0.36	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
HNSC	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	8.24	1.71e-15	2.04e-12	0.45	0.36	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
HNSC	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-8.24	1.71e-15	2.05e-12	-0.45	-0.36	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	8.24	1.71e-15	2.05e-12	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
HNSC	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-8.24	1.71e-15	2.05e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
HNSC	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	8.24	1.71e-15	2.05e-12	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
HNSC	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	8.24	1.72e-15	2.06e-12	0.4	0.36	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
HNSC	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	8.24	1.73e-15	2.07e-12	0.39	0.36	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
HNSC	cis	rs6969780	0.632	rs11762730	ENSG00000233429.8	HOTAIRM1	-8.24	1.73e-15	2.07e-12	-0.48	-0.36	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150779	chr7:27095647~27100265:+
HNSC	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-8.24	1.73e-15	2.08e-12	-0.37	-0.36	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-8.24	1.73e-15	2.08e-12	-0.37	-0.36	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-8.24	1.73e-15	2.08e-12	-0.37	-0.36	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
HNSC	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-8.24	1.73e-15	2.08e-12	-0.38	-0.36	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
HNSC	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	8.24	1.74e-15	2.08e-12	0.43	0.36	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
HNSC	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-8.24	1.74e-15	2.09e-12	-0.48	-0.36	Depression;	chr6:28180209	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-8.24	1.76e-15	2.11e-12	-0.38	-0.36	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
HNSC	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-8.24	1.77e-15	2.11e-12	-0.38	-0.36	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-8.24	1.77e-15	2.12e-12	-0.36	-0.36	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
HNSC	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-8.24	1.77e-15	2.12e-12	-0.43	-0.36	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
HNSC	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-8.24	1.78e-15	2.13e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-8.24	1.78e-15	2.13e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
HNSC	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-8.24	1.78e-15	2.13e-12	-0.41	-0.36	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
HNSC	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-8.24	1.78e-15	2.13e-12	-0.33	-0.36	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
HNSC	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-8.24	1.78e-15	2.13e-12	-0.39	-0.36	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
HNSC	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-8.24	1.79e-15	2.14e-12	-0.55	-0.36	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
HNSC	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	8.24	1.8e-15	2.15e-12	0.41	0.36	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
HNSC	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-8.24	1.81e-15	2.17e-12	-0.37	-0.36	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-8.24	1.81e-15	2.17e-12	-0.37	-0.36	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-8.24	1.81e-15	2.17e-12	-0.37	-0.36	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000254340.1	RP11-10A14.3	8.24	1.82e-15	2.17e-12	0.44	0.36	Joint mobility (Beighton score);	chr8:9012918	chr8:9141424~9145435:+
HNSC	cis	rs1865760	1	rs2071299	ENSG00000272462.2	U91328.19	-8.23	1.82e-15	2.17e-12	-0.36	-0.36	Height;	chr6:25914573	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs2071298	ENSG00000272462.2	U91328.19	-8.23	1.82e-15	2.17e-12	-0.36	-0.36	Height;	chr6:25914673	chr6:25992662~26001775:+
HNSC	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
HNSC	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	8.23	1.82e-15	2.18e-12	0.36	0.36	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	8.23	1.82e-15	2.18e-12	0.36	0.36	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
HNSC	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	8.23	1.82e-15	2.18e-12	0.55	0.36	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
HNSC	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.23	1.83e-15	2.19e-12	0.41	0.36	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
HNSC	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	8.23	1.83e-15	2.19e-12	0.42	0.36	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	8.23	1.83e-15	2.19e-12	0.42	0.36	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
HNSC	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-8.23	1.84e-15	2.2e-12	-0.44	-0.36	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	8.23	1.86e-15	2.22e-12	0.44	0.36	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
HNSC	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-8.23	1.86e-15	2.22e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
HNSC	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	8.23	1.87e-15	2.23e-12	0.55	0.36	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	8.23	1.87e-15	2.23e-12	0.55	0.36	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
HNSC	cis	rs7404843	0.777	rs6498552	ENSG00000263065.1	AF001548.6	-8.23	1.87e-15	2.23e-12	-0.63	-0.36	Testicular germ cell tumor;	chr16:15446044	chr16:15741151~15741791:+
HNSC	cis	rs7404843	0.85	rs6498553	ENSG00000263065.1	AF001548.6	-8.23	1.87e-15	2.23e-12	-0.63	-0.36	Testicular germ cell tumor;	chr16:15446045	chr16:15741151~15741791:+
HNSC	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	8.23	1.88e-15	2.24e-12	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
HNSC	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-8.23	1.88e-15	2.24e-12	-0.44	-0.36	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
HNSC	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	8.23	1.88e-15	2.25e-12	0.46	0.36	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-8.23	1.9e-15	2.27e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-8.23	1.9e-15	2.27e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.718	rs2322631	ENSG00000272129.1	RP11-250B2.6	8.23	1.92e-15	2.28e-12	0.43	0.36	Sitting height ratio;	chr6:80134239	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9448899	ENSG00000272129.1	RP11-250B2.6	8.23	1.92e-15	2.28e-12	0.43	0.36	Sitting height ratio;	chr6:80136147	chr6:80355424~80356859:+
HNSC	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-8.23	1.93e-15	2.3e-12	-0.45	-0.36	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
HNSC	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	8.23	1.94e-15	2.31e-12	0.4	0.36	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
HNSC	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-8.23	1.95e-15	2.32e-12	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000223648.3	IGHV3-64	8.23	1.95e-15	2.32e-12	0.29	0.36	Kawasaki disease;	chr14:106656426	chr14:106643132~106658258:-
HNSC	cis	rs9341808	0.718	rs4437429	ENSG00000272129.1	RP11-250B2.6	8.23	1.95e-15	2.32e-12	0.43	0.36	Sitting height ratio;	chr6:80118875	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9448893	ENSG00000272129.1	RP11-250B2.6	8.23	1.95e-15	2.32e-12	0.43	0.36	Sitting height ratio;	chr6:80127522	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-8.22	1.97e-15	2.34e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-8.22	1.97e-15	2.35e-12	-0.32	-0.36	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28145952	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28147378	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28147406	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28148143	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28149979	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28151096	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28152885	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28153120	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28154567	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28156691	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28158424	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159056	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159666	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159843	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159925	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159932	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28161802	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28162053	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28162598	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28163375	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28163759	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28164580	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28164825	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28164948	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28165025	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28165528	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28168434	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169019	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169249	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169676	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169755	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169791	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28170075	chr6:28115628~28116551:+
HNSC	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	8.22	1.98e-15	2.35e-12	0.41	0.36	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
HNSC	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-8.22	1.98e-15	2.36e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
HNSC	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	8.22	1.98e-15	2.36e-12	0.38	0.36	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
HNSC	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	8.22	1.99e-15	2.36e-12	0.4	0.36	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
HNSC	cis	rs9341808	0.718	rs910266	ENSG00000272129.1	RP11-250B2.6	8.22	2e-15	2.38e-12	0.43	0.36	Sitting height ratio;	chr6:80211453	chr6:80355424~80356859:+
HNSC	cis	rs7048146	1	rs7046565	ENSG00000213539.4	YBX1P6	8.22	2.02e-15	2.39e-12	0.41	0.36	Vascular brain injury;	chr9:109539940	chr9:109532830~109534332:-
HNSC	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-8.22	2.02e-15	2.39e-12	-0.4	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
HNSC	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	8.22	2.02e-15	2.39e-12	0.45	0.36	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
HNSC	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-8.22	2.02e-15	2.4e-12	-0.41	-0.36	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
HNSC	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	8.22	2.03e-15	2.4e-12	0.47	0.36	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
HNSC	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.22	2.04e-15	2.42e-12	0.45	0.36	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	8.22	2.04e-15	2.42e-12	0.38	0.36	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	8.22	2.04e-15	2.42e-12	0.38	0.36	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	8.22	2.04e-15	2.42e-12	0.38	0.36	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-8.22	2.04e-15	2.42e-12	-0.38	-0.36	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-8.22	2.04e-15	2.42e-12	-0.38	-0.36	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-8.22	2.04e-15	2.42e-12	-0.38	-0.36	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-8.22	2.05e-15	2.42e-12	-0.45	-0.36	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	8.22	2.05e-15	2.43e-12	0.46	0.36	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	8.22	2.06e-15	2.43e-12	0.55	0.36	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	8.22	2.06e-15	2.43e-12	0.55	0.36	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	8.22	2.06e-15	2.43e-12	0.55	0.36	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
HNSC	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	8.22	2.06e-15	2.44e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	8.22	2.07e-15	2.45e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-8.22	2.07e-15	2.45e-12	-0.44	-0.36	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
HNSC	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	8.22	2.08e-15	2.46e-12	0.43	0.36	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	8.22	2.08e-15	2.46e-12	0.43	0.36	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
HNSC	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-8.22	2.09e-15	2.47e-12	-0.48	-0.36	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
HNSC	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	8.22	2.09e-15	2.48e-12	0.36	0.36	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	8.22	2.1e-15	2.48e-12	0.45	0.36	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
HNSC	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	8.22	2.1e-15	2.48e-12	0.41	0.36	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	8.21	2.1e-15	2.49e-12	0.41	0.36	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	8.21	2.1e-15	2.49e-12	0.41	0.36	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	8.21	2.1e-15	2.49e-12	0.41	0.36	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
HNSC	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	8.21	2.13e-15	2.52e-12	0.4	0.36	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
HNSC	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-8.21	2.14e-15	2.53e-12	-0.56	-0.36	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	8.21	2.14e-15	2.53e-12	0.41	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
HNSC	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-8.21	2.15e-15	2.54e-12	-0.41	-0.36	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
HNSC	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-8.21	2.15e-15	2.55e-12	-0.34	-0.36	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
HNSC	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
HNSC	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Height;	chr11:118856460	chr11:118704607~118750263:+
HNSC	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Height;	chr11:118856623	chr11:118704607~118750263:+
HNSC	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Height;	chr11:118857611	chr11:118704607~118750263:+
HNSC	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	8.21	2.17e-15	2.56e-12	0.43	0.36	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
HNSC	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-8.21	2.17e-15	2.56e-12	-0.42	-0.36	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
HNSC	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	8.21	2.17e-15	2.57e-12	0.44	0.36	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
HNSC	cis	rs9341808	0.683	rs7771449	ENSG00000272129.1	RP11-250B2.6	8.21	2.17e-15	2.57e-12	0.43	0.36	Sitting height ratio;	chr6:80210260	chr6:80355424~80356859:+
HNSC	cis	rs12439619	0.53	rs7162177	ENSG00000276710.3	CSPG4P8	-8.21	2.19e-15	2.59e-12	-0.39	-0.36	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82459472~82477258:+
HNSC	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-8.21	2.19e-15	2.59e-12	-0.4	-0.36	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-8.21	2.19e-15	2.59e-12	-0.34	-0.36	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
HNSC	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-8.21	2.19e-15	2.59e-12	-0.39	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
HNSC	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	8.21	2.2e-15	2.59e-12	0.42	0.36	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
HNSC	cis	rs9341808	0.754	rs9343973	ENSG00000272129.1	RP11-250B2.6	8.21	2.2e-15	2.6e-12	0.43	0.36	Sitting height ratio;	chr6:80203499	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs7740627	ENSG00000272129.1	RP11-250B2.6	8.21	2.2e-15	2.6e-12	0.43	0.36	Sitting height ratio;	chr6:80206630	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs2143887	ENSG00000272129.1	RP11-250B2.6	8.21	2.2e-15	2.6e-12	0.43	0.36	Sitting height ratio;	chr6:80207570	chr6:80355424~80356859:+
HNSC	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	8.21	2.21e-15	2.61e-12	0.41	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
HNSC	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-8.21	2.24e-15	2.65e-12	-0.37	-0.35	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
HNSC	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	8.21	2.25e-15	2.66e-12	0.47	0.35	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-8.21	2.26e-15	2.66e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
HNSC	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-8.21	2.26e-15	2.66e-12	-0.41	-0.35	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
HNSC	cis	rs10256972	0.647	rs10233430	ENSG00000225146.1	AC073957.15	8.21	2.26e-15	2.66e-12	0.4	0.35	Endometriosis;Longevity;	chr7:1012028	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-8.2	2.26e-15	2.67e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
HNSC	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-8.2	2.27e-15	2.67e-12	-0.41	-0.35	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
HNSC	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	8.2	2.27e-15	2.67e-12	0.42	0.35	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000254340.1	RP11-10A14.3	8.2	2.27e-15	2.68e-12	0.43	0.35	Joint mobility (Beighton score);	chr8:9001207	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-8.2	2.27e-15	2.68e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	8.2	2.28e-15	2.69e-12	0.44	0.35	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
HNSC	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	8.2	2.29e-15	2.7e-12	0.42	0.35	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
HNSC	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-8.2	2.29e-15	2.7e-12	-0.4	-0.35	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
HNSC	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	8.2	2.29e-15	2.7e-12	0.46	0.35	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
HNSC	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	8.2	2.3e-15	2.7e-12	0.37	0.35	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	8.2	2.3e-15	2.7e-12	0.37	0.35	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.532	rs1061482	ENSG00000272462.2	U91328.19	-8.2	2.3e-15	2.71e-12	-0.35	-0.35	Height;	chr6:26086471	chr6:25992662~26001775:+
HNSC	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	8.2	2.3e-15	2.71e-12	0.46	0.35	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
HNSC	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	8.2	2.31e-15	2.72e-12	0.54	0.35	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
HNSC	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-8.2	2.31e-15	2.72e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
HNSC	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	8.2	2.31e-15	2.73e-12	0.55	0.35	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	8.2	2.31e-15	2.73e-12	0.55	0.35	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
HNSC	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-8.2	2.32e-15	2.73e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
HNSC	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	8.2	2.33e-15	2.74e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	8.2	2.34e-15	2.75e-12	0.35	0.35	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
HNSC	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	8.2	2.34e-15	2.75e-12	0.39	0.35	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
HNSC	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.76e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.76e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.76e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
HNSC	cis	rs2179367	0.959	rs4895788	ENSG00000231760.4	RP11-350J20.5	8.2	2.35e-15	2.76e-12	0.46	0.35	Dupuytren's disease;	chr6:149426955	chr6:149796151~149826294:-
HNSC	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-8.2	2.35e-15	2.76e-12	-0.37	-0.35	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
HNSC	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.77e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
HNSC	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-8.2	2.4e-15	2.82e-12	-0.38	-0.35	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
HNSC	cis	rs12439619	0.508	rs8023960	ENSG00000276710.3	CSPG4P8	-8.2	2.41e-15	2.83e-12	-0.39	-0.35	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82459472~82477258:+
HNSC	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-8.2	2.41e-15	2.83e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
HNSC	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-8.2	2.41e-15	2.84e-12	-0.36	-0.35	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
HNSC	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-8.2	2.42e-15	2.84e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
HNSC	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-8.19	2.43e-15	2.86e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
HNSC	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-8.19	2.43e-15	2.86e-12	-0.38	-0.35	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
HNSC	cis	rs9402743	0.748	rs11754958	ENSG00000217482.2	HMGB1P17	8.19	2.43e-15	2.86e-12	0.42	0.35	Systemic lupus erythematosus;	chr6:135651462	chr6:135636086~135636713:-
HNSC	cis	rs6969780	0.63	rs3735530	ENSG00000233429.8	HOTAIRM1	-8.19	2.44e-15	2.87e-12	-0.45	-0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150363	chr7:27095647~27100265:+
HNSC	cis	rs7942368	0.818	rs10793194	ENSG00000255100.1	RP11-21L23.3	8.19	2.45e-15	2.88e-12	0.45	0.35	Endometriosis;	chr11:76764685	chr11:76782581~76783062:-
HNSC	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	8.19	2.45e-15	2.88e-12	0.43	0.35	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
HNSC	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-8.19	2.46e-15	2.88e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-8.19	2.46e-15	2.88e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
HNSC	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	8.19	2.46e-15	2.89e-12	0.4	0.35	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
HNSC	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	8.19	2.46e-15	2.89e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	8.19	2.46e-15	2.89e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
HNSC	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-8.19	2.47e-15	2.9e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
HNSC	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	8.19	2.47e-15	2.9e-12	0.4	0.35	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	8.19	2.48e-15	2.91e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
HNSC	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	8.19	2.48e-15	2.91e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-8.19	2.48e-15	2.91e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-8.19	2.48e-15	2.91e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.49e-15	2.92e-12	-0.38	-0.35	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.49e-15	2.92e-12	-0.38	-0.35	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.49e-15	2.92e-12	-0.38	-0.35	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
HNSC	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	8.19	2.49e-15	2.92e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	8.19	2.49e-15	2.92e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-8.19	2.49e-15	2.92e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
HNSC	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	8.19	2.51e-15	2.94e-12	0.44	0.35	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
HNSC	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-8.19	2.53e-15	2.96e-12	-0.4	-0.35	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
HNSC	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	8.19	2.53e-15	2.96e-12	0.42	0.35	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
HNSC	cis	rs7404843	0.925	rs12600043	ENSG00000263335.1	AF001548.5	8.19	2.53e-15	2.96e-12	0.71	0.35	Testicular germ cell tumor;	chr16:15446095	chr16:15726674~15732993:+
HNSC	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-8.19	2.54e-15	2.97e-12	-0.39	-0.35	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
HNSC	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-8.19	2.54e-15	2.97e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
HNSC	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
HNSC	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	8.19	2.56e-15	2.99e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
HNSC	cis	rs9341808	0.754	rs9361591	ENSG00000272129.1	RP11-250B2.6	8.19	2.58e-15	3.01e-12	0.43	0.35	Sitting height ratio;	chr6:80243538	chr6:80355424~80356859:+
HNSC	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-8.19	2.58e-15	3.01e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
HNSC	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-8.19	2.58e-15	3.01e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
HNSC	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-8.19	2.59e-15	3.03e-12	-0.41	-0.35	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
HNSC	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.61e-15	3.05e-12	-0.38	-0.35	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
HNSC	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-8.19	2.61e-15	3.05e-12	-0.48	-0.35	Depression;	chr6:28176973	chr6:28115628~28116551:+
HNSC	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-8.19	2.61e-15	3.05e-12	-0.6	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
HNSC	cis	rs1865760	0.929	rs9358896	ENSG00000272462.2	U91328.19	-8.19	2.61e-15	3.05e-12	-0.35	-0.35	Height;	chr6:25942969	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.19	2.61e-15	3.05e-12	-0.41	-0.35	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
HNSC	cis	rs7829975	0.514	rs2945873	ENSG00000173295.6	FAM86B3P	8.18	2.62e-15	3.06e-12	0.4	0.35	Mood instability;	chr8:8402935	chr8:8228595~8244865:+
HNSC	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-8.18	2.62e-15	3.06e-12	-0.41	-0.35	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	8.18	2.63e-15	3.07e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
HNSC	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	8.18	2.63e-15	3.08e-12	0.44	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
HNSC	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-8.18	2.64e-15	3.08e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-8.18	2.64e-15	3.08e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-8.18	2.64e-15	3.08e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
HNSC	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-8.18	2.64e-15	3.08e-12	-0.4	-0.35	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
HNSC	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-8.18	2.64e-15	3.09e-12	-0.46	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
HNSC	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	8.18	2.66e-15	3.1e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
HNSC	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.13e-12	0.38	0.35	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.13e-12	0.38	0.35	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.13e-12	0.38	0.35	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.14e-12	0.37	0.35	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
HNSC	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-8.18	2.69e-15	3.14e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
HNSC	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	8.18	2.7e-15	3.15e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
HNSC	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	8.18	2.73e-15	3.17e-12	0.55	0.35	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	8.18	2.73e-15	3.17e-12	0.55	0.35	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
HNSC	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	8.18	2.73e-15	3.18e-12	0.37	0.35	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
HNSC	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	8.18	2.74e-15	3.19e-12	0.41	0.35	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	8.18	2.74e-15	3.19e-12	0.41	0.35	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
HNSC	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-8.18	2.74e-15	3.19e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
HNSC	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-8.18	2.75e-15	3.2e-12	-0.41	-0.35	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
HNSC	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-8.18	2.75e-15	3.2e-12	-0.38	-0.35	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
HNSC	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-8.18	2.76e-15	3.21e-12	-0.38	-0.35	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
HNSC	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-8.18	2.77e-15	3.22e-12	-0.38	-0.35	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-8.18	2.77e-15	3.22e-12	-0.38	-0.35	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
HNSC	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	8.18	2.77e-15	3.22e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	8.18	2.78e-15	3.23e-12	0.38	0.35	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
HNSC	cis	rs9399135	0.967	rs11757577	ENSG00000232876.1	CTA-212D2.2	-8.18	2.78e-15	3.23e-12	-0.42	-0.35	Red blood cell count;	chr6:135070327	chr6:135055033~135060550:+
HNSC	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	8.18	2.79e-15	3.24e-12	0.47	0.35	Height;	chr6:109740895	chr6:109382795~109383666:+
HNSC	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-8.18	2.79e-15	3.25e-12	-0.48	-0.35	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
HNSC	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
HNSC	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
HNSC	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	8.18	2.81e-15	3.26e-12	0.45	0.35	Height;	chr6:109440234	chr6:109382795~109383666:+
HNSC	cis	rs1865760	0.82	rs9348697	ENSG00000272462.2	U91328.19	-8.17	2.81e-15	3.27e-12	-0.35	-0.35	Height;	chr6:25890606	chr6:25992662~26001775:+
HNSC	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	8.17	2.82e-15	3.27e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
HNSC	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-8.17	2.82e-15	3.28e-12	-0.38	-0.35	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-8.17	2.82e-15	3.28e-12	-0.38	-0.35	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
HNSC	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	8.17	2.83e-15	3.28e-12	0.47	0.35	Depression;	chr6:28167882	chr6:28115628~28116551:+
HNSC	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	8.17	2.83e-15	3.29e-12	0.45	0.35	Height;	chr6:109477209	chr6:109382795~109383666:+
HNSC	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	8.17	2.84e-15	3.3e-12	0.36	0.35	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	8.17	2.86e-15	3.32e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	8.17	2.86e-15	3.32e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
HNSC	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	8.17	2.86e-15	3.32e-12	0.54	0.35	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
HNSC	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	8.17	2.87e-15	3.33e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
HNSC	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
HNSC	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	8.17	2.9e-15	3.36e-12	0.46	0.35	Height;	chr6:109494237	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	8.17	2.9e-15	3.36e-12	0.46	0.35	Height;	chr6:109496073	chr6:109382795~109383666:+
HNSC	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-8.17	2.93e-15	3.4e-12	-0.41	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
HNSC	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	8.17	2.93e-15	3.4e-12	0.38	0.35	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
HNSC	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	8.17	2.94e-15	3.41e-12	0.45	0.35	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
HNSC	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-8.17	2.94e-15	3.41e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
HNSC	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	8.17	2.96e-15	3.43e-12	0.37	0.35	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-8.17	2.96e-15	3.43e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-8.17	2.96e-15	3.43e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
HNSC	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-8.17	2.96e-15	3.43e-12	-0.44	-0.35	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
HNSC	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-8.17	2.97e-15	3.44e-12	-0.37	-0.35	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000254340.1	RP11-10A14.3	8.17	2.97e-15	3.44e-12	0.44	0.35	Joint mobility (Beighton score);	chr8:9014200	chr8:9141424~9145435:+
HNSC	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	8.17	2.97e-15	3.44e-12	0.55	0.35	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	8.17	2.97e-15	3.44e-12	0.55	0.35	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-8.17	2.98e-15	3.45e-12	-0.55	-0.35	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
HNSC	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-8.17	2.99e-15	3.46e-12	-0.38	-0.35	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
HNSC	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	8.17	2.99e-15	3.46e-12	0.37	0.35	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
HNSC	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	8.17	2.99e-15	3.47e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
HNSC	cis	rs1865760	0.929	rs2876693	ENSG00000272462.2	U91328.19	-8.17	3e-15	3.47e-12	-0.35	-0.35	Height;	chr6:25954206	chr6:25992662~26001775:+
HNSC	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-8.17	3.01e-15	3.48e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	8.17	3.02e-15	3.49e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
HNSC	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-8.16	3.02e-15	3.5e-12	-0.46	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
HNSC	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-8.16	3.05e-15	3.53e-12	-0.38	-0.35	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	8.16	3.06e-15	3.54e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
HNSC	cis	rs9341808	0.718	rs11962614	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80113589	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs12208016	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80113846	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9448886	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80116184	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.683	rs9359409	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80117180	chr6:80355424~80356859:+
HNSC	cis	rs12439619	0.508	rs8042665	ENSG00000276710.3	CSPG4P8	-8.16	3.08e-15	3.56e-12	-0.39	-0.35	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82459472~82477258:+
HNSC	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-8.16	3.08e-15	3.56e-12	-0.38	-0.35	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
HNSC	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-8.16	3.08e-15	3.56e-12	-0.39	-0.35	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
HNSC	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.545	rs4441996	ENSG00000179406.6	LINC00174	8.16	3.09e-15	3.57e-12	0.53	0.35	Aortic root size;	chr7:66123233	chr7:66376044~66401338:-
HNSC	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-8.16	3.09e-15	3.58e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
HNSC	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.545	rs12670811	ENSG00000179406.6	LINC00174	-8.16	3.11e-15	3.59e-12	-0.53	-0.35	Aortic root size;	chr7:66358032	chr7:66376044~66401338:-
HNSC	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	8.16	3.13e-15	3.61e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.509	rs2945269	ENSG00000173295.6	FAM86B3P	8.16	3.15e-15	3.63e-12	0.41	0.35	Mood instability;	chr8:8258056	chr8:8228595~8244865:+
HNSC	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	8.16	3.15e-15	3.64e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
HNSC	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.17e-15	3.66e-12	-0.38	-0.35	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	8.16	3.18e-15	3.66e-12	0.37	0.35	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
HNSC	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.19e-15	3.68e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
HNSC	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	8.16	3.19e-15	3.68e-12	0.44	0.35	Height;	chr6:109397362	chr6:109382795~109383666:+
HNSC	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-8.16	3.19e-15	3.68e-12	-0.37	-0.35	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-8.16	3.2e-15	3.69e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-8.16	3.2e-15	3.69e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
HNSC	cis	rs1021993	0.818	rs906349	ENSG00000231648.1	RP11-372M18.2	-8.16	3.21e-15	3.7e-12	-0.48	-0.35	Gut microbiome composition (winter);	chr1:209354783	chr1:209367662~209379690:+
HNSC	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-8.16	3.22e-15	3.71e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-8.16	3.22e-15	3.71e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-8.16	3.22e-15	3.71e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
HNSC	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-8.16	3.22e-15	3.71e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
HNSC	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	8.16	3.23e-15	3.72e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
HNSC	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-8.16	3.25e-15	3.74e-12	-0.4	-0.35	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-8.15	3.25e-15	3.75e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-8.15	3.26e-15	3.75e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
HNSC	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	8.15	3.26e-15	3.76e-12	0.45	0.35	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
HNSC	cis	rs2834288	0.959	rs2834294	ENSG00000237945.6	LINC00649	-8.15	3.26e-15	3.76e-12	-0.43	-0.35	Gut microbiota (bacterial taxa);	chr21:33908326	chr21:33915534~33977691:+
HNSC	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	8.15	3.27e-15	3.76e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-8.15	3.27e-15	3.77e-12	-0.35	-0.35	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-8.15	3.28e-15	3.78e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
HNSC	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	8.15	3.29e-15	3.78e-12	0.42	0.35	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
HNSC	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	8.15	3.29e-15	3.79e-12	0.43	0.35	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
HNSC	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	8.15	3.3e-15	3.8e-12	0.36	0.35	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	8.15	3.3e-15	3.8e-12	0.36	0.35	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	8.15	3.3e-15	3.8e-12	0.36	0.35	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
HNSC	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	8.15	3.3e-15	3.8e-12	0.46	0.35	Depression;	chr6:28109824	chr6:28115628~28116551:+
HNSC	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-8.15	3.31e-15	3.8e-12	-0.47	-0.35	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-8.15	3.31e-15	3.8e-12	-0.47	-0.35	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
HNSC	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-8.15	3.31e-15	3.8e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
HNSC	cis	rs1865760	1	rs2071297	ENSG00000272462.2	U91328.19	8.15	3.32e-15	3.82e-12	0.35	0.35	Height;	chr6:25924285	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	8.15	3.33e-15	3.83e-12	0.45	0.35	Height;	chr6:109507364	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	8.15	3.33e-15	3.83e-12	0.45	0.35	Height;	chr6:109507366	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	8.15	3.33e-15	3.83e-12	0.48	0.35	Height;	chr6:109747119	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-8.15	3.34e-15	3.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	8.15	3.34e-15	3.84e-12	0.46	0.35	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
HNSC	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	8.15	3.37e-15	3.87e-12	0.37	0.35	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs17138156	ENSG00000179406.6	LINC00174	-8.15	3.37e-15	3.87e-12	-0.53	-0.35	Aortic root size;	chr7:66249708	chr7:66376044~66401338:-
HNSC	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	8.15	3.37e-15	3.87e-12	0.44	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
HNSC	cis	rs1865760	0.865	rs1541987	ENSG00000272462.2	U91328.19	8.15	3.37e-15	3.87e-12	0.35	0.35	Height;	chr6:25950169	chr6:25992662~26001775:+
HNSC	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	8.15	3.37e-15	3.88e-12	0.42	0.35	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
HNSC	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	8.15	3.39e-15	3.89e-12	0.49	0.35	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-8.15	3.4e-15	3.91e-12	-0.33	-0.35	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	8.15	3.4e-15	3.91e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	8.15	3.41e-15	3.92e-12	0.36	0.35	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	8.15	3.41e-15	3.92e-12	0.45	0.35	Height;	chr6:109375548	chr6:109382795~109383666:+
HNSC	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	8.15	3.41e-15	3.92e-12	0.53	0.35	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
HNSC	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-8.15	3.42e-15	3.92e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
HNSC	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	8.15	3.42e-15	3.93e-12	0.39	0.35	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-8.15	3.44e-15	3.94e-12	-0.47	-0.35	Depression;	chr6:28173770	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-8.15	3.44e-15	3.94e-12	-0.47	-0.35	Depression;	chr6:28174809	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-8.15	3.44e-15	3.94e-12	-0.47	-0.35	Depression;	chr6:28175233	chr6:28115628~28116551:+
HNSC	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	8.15	3.44e-15	3.95e-12	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
HNSC	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	8.15	3.46e-15	3.97e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
HNSC	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	8.15	3.46e-15	3.97e-12	0.4	0.35	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-8.15	3.46e-15	3.97e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
HNSC	cis	rs10256972	0.669	rs10229964	ENSG00000225146.1	AC073957.15	8.15	3.47e-15	3.98e-12	0.4	0.35	Endometriosis;Longevity;	chr7:1012140	chr7:1029025~1043891:+
HNSC	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	8.15	3.49e-15	4e-12	0.44	0.35	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
HNSC	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.608	rs12439484	ENSG00000259422.1	RP11-593F23.1	8.14	3.5e-15	4.01e-12	0.39	0.35	Blood metabolite levels;	chr15:76310596	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-8.14	3.51e-15	4.02e-12	-0.4	-0.35	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
HNSC	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-8.14	3.56e-15	4.08e-12	-0.49	-0.35	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
HNSC	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	8.14	3.57e-15	4.08e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
HNSC	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	8.14	3.57e-15	4.09e-12	0.46	0.35	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	8.14	3.57e-15	4.09e-12	0.46	0.35	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
HNSC	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
HNSC	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	8.14	3.6e-15	4.12e-12	0.44	0.35	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
HNSC	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	8.14	3.61e-15	4.13e-12	0.64	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
HNSC	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	8.14	3.61e-15	4.13e-12	0.64	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
HNSC	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-8.14	3.61e-15	4.13e-12	-0.38	-0.35	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
HNSC	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
HNSC	cis	rs9341808	0.718	rs9294171	ENSG00000272129.1	RP11-250B2.6	8.14	3.62e-15	4.14e-12	0.42	0.35	Sitting height ratio;	chr6:80130098	chr6:80355424~80356859:+
HNSC	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	8.14	3.62e-15	4.14e-12	0.45	0.35	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
HNSC	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	8.14	3.62e-15	4.14e-12	0.46	0.35	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
HNSC	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-8.14	3.62e-15	4.14e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
HNSC	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-8.14	3.63e-15	4.15e-12	-0.56	-0.35	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
HNSC	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-8.14	3.63e-15	4.15e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
HNSC	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-8.14	3.64e-15	4.16e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
HNSC	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.14	3.65e-15	4.17e-12	-0.38	-0.35	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
HNSC	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	8.14	3.66e-15	4.18e-12	0.41	0.35	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
HNSC	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-8.14	3.67e-15	4.19e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
HNSC	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-8.14	3.67e-15	4.19e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-8.14	3.67e-15	4.19e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
HNSC	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-8.14	3.68e-15	4.2e-12	-0.41	-0.35	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-8.14	3.68e-15	4.2e-12	-0.41	-0.35	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
HNSC	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	8.14	3.68e-15	4.21e-12	0.46	0.35	Height;	chr6:109741670	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	8.14	3.69e-15	4.21e-12	0.37	0.35	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	8.14	3.69e-15	4.21e-12	0.37	0.35	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
HNSC	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	8.14	3.7e-15	4.22e-12	0.37	0.35	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
HNSC	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-8.14	3.71e-15	4.23e-12	-0.33	-0.35	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
HNSC	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	8.14	3.71e-15	4.24e-12	0.42	0.35	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
HNSC	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	8.14	3.72e-15	4.24e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	8.14	3.72e-15	4.24e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	8.14	3.72e-15	4.24e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
HNSC	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	8.14	3.72e-15	4.25e-12	0.4	0.35	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
HNSC	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-8.14	3.72e-15	4.25e-12	-0.35	-0.35	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
HNSC	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	8.14	3.74e-15	4.27e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	8.14	3.75e-15	4.28e-12	0.41	0.35	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
HNSC	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-8.13	3.76e-15	4.29e-12	-0.54	-0.35	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
HNSC	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.13	3.76e-15	4.29e-12	-0.38	-0.35	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.13	3.76e-15	4.29e-12	-0.38	-0.35	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	8.13	3.76e-15	4.29e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
HNSC	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	8.13	3.77e-15	4.3e-12	0.55	0.35	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	8.13	3.77e-15	4.3e-12	0.55	0.35	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
HNSC	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-8.13	3.77e-15	4.3e-12	-0.41	-0.35	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
HNSC	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-8.13	3.77e-15	4.3e-12	-0.41	-0.35	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
HNSC	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-8.13	3.78e-15	4.31e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-8.13	3.78e-15	4.31e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
HNSC	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-8.13	3.79e-15	4.32e-12	-0.33	-0.35	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
HNSC	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-8.13	3.79e-15	4.32e-12	-0.33	-0.35	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
HNSC	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
HNSC	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-8.13	3.83e-15	4.36e-12	-0.38	-0.35	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-8.13	3.83e-15	4.36e-12	-0.38	-0.35	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
HNSC	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	8.13	3.84e-15	4.37e-12	0.4	0.35	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-8.13	3.84e-15	4.38e-12	-0.4	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
HNSC	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	8.13	3.86e-15	4.4e-12	0.55	0.35	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
HNSC	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	8.13	3.88e-15	4.42e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-8.13	3.9e-15	4.44e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
HNSC	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	8.13	3.9e-15	4.44e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-8.13	3.9e-15	4.44e-12	-0.41	-0.35	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
HNSC	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	8.13	3.91e-15	4.45e-12	0.38	0.35	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
HNSC	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	8.13	3.91e-15	4.46e-12	0.37	0.35	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
HNSC	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	8.13	3.92e-15	4.46e-12	0.38	0.35	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
HNSC	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-8.13	3.93e-15	4.47e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	8.13	3.94e-15	4.48e-12	0.36	0.35	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
HNSC	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	8.13	3.94e-15	4.48e-12	0.42	0.35	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	8.13	3.95e-15	4.49e-12	0.59	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
HNSC	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.13	3.95e-15	4.49e-12	-0.38	-0.35	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
HNSC	cis	rs1865760	1	rs3799371	ENSG00000272462.2	U91328.19	8.13	3.95e-15	4.49e-12	0.35	0.35	Height;	chr6:25912588	chr6:25992662~26001775:+
HNSC	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-8.13	3.96e-15	4.5e-12	-0.36	-0.35	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
HNSC	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
HNSC	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	8.13	3.97e-15	4.52e-12	0.44	0.35	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
HNSC	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
HNSC	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	8.13	3.99e-15	4.53e-12	0.4	0.35	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	8.13	3.99e-15	4.53e-12	0.4	0.35	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-8.13	3.99e-15	4.54e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
HNSC	cis	rs35955747	0.714	rs4820048	ENSG00000236132.1	CTA-440B3.1	8.13	3.99e-15	4.54e-12	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31458384	chr22:31816379~31817491:-
HNSC	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-8.13	4e-15	4.55e-12	-0.34	-0.35	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-8.13	4e-15	4.55e-12	-0.34	-0.35	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
HNSC	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	8.13	4.01e-15	4.55e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
HNSC	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-8.13	4.02e-15	4.56e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-8.13	4.02e-15	4.57e-12	-0.65	-0.35	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-8.13	4.02e-15	4.57e-12	-0.65	-0.35	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	8.13	4.04e-15	4.58e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-8.12	4.05e-15	4.59e-12	-0.33	-0.35	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
HNSC	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-8.12	4.05e-15	4.6e-12	-0.34	-0.35	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-8.12	4.05e-15	4.6e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	8.12	4.05e-15	4.6e-12	0.44	0.35	Height;	chr6:109402736	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	8.12	4.05e-15	4.6e-12	0.44	0.35	Height;	chr6:109403734	chr6:109382795~109383666:+
HNSC	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	8.12	4.11e-15	4.66e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	8.12	4.11e-15	4.66e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	8.12	4.11e-15	4.66e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
HNSC	cis	rs7048146	0.966	rs7046719	ENSG00000213539.4	YBX1P6	8.12	4.13e-15	4.68e-12	0.41	0.35	Vascular brain injury;	chr9:109540085	chr9:109532830~109534332:-
HNSC	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	8.12	4.15e-15	4.7e-12	0.36	0.35	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
HNSC	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-8.12	4.17e-15	4.72e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
HNSC	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	8.12	4.17e-15	4.73e-12	0.42	0.35	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
HNSC	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-8.12	4.18e-15	4.74e-12	-0.39	-0.35	Temperament;	chr17:14018109	chr17:14024514~14025488:+
HNSC	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-8.12	4.21e-15	4.76e-12	-0.33	-0.35	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-8.12	4.21e-15	4.76e-12	-0.33	-0.35	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
HNSC	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-8.12	4.24e-15	4.8e-12	-0.4	-0.35	Temperament;	chr17:14075460	chr17:14024514~14025488:+
HNSC	cis	rs9341808	0.718	rs3812121	ENSG00000272129.1	RP11-250B2.6	8.12	4.26e-15	4.82e-12	0.42	0.35	Sitting height ratio;	chr6:80259010	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-8.12	4.28e-15	4.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-8.12	4.28e-15	4.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-8.12	4.28e-15	4.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
HNSC	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-8.12	4.28e-15	4.85e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-8.12	4.28e-15	4.85e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
HNSC	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	8.12	4.29e-15	4.86e-12	0.4	0.35	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
HNSC	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	8.12	4.32e-15	4.88e-12	0.54	0.35	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
HNSC	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	8.12	4.34e-15	4.91e-12	0.44	0.35	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
HNSC	cis	rs7942368	1	rs10160660	ENSG00000255100.1	RP11-21L23.3	8.11	4.35e-15	4.92e-12	0.45	0.35	Endometriosis;	chr11:76763493	chr11:76782581~76783062:-
HNSC	cis	rs875971	0.545	rs1547529	ENSG00000179406.6	LINC00174	-8.11	4.35e-15	4.92e-12	-0.52	-0.35	Aortic root size;	chr7:66258859	chr7:66376044~66401338:-
HNSC	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	8.11	4.39e-15	4.96e-12	0.37	0.35	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
HNSC	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-8.11	4.4e-15	4.97e-12	-0.47	-0.35	Depression;	chr6:28144784	chr6:28115628~28116551:+
HNSC	cis	rs9341808	0.718	rs10943699	ENSG00000272129.1	RP11-250B2.6	8.11	4.4e-15	4.98e-12	0.42	0.35	Sitting height ratio;	chr6:80230824	chr6:80355424~80356859:+
HNSC	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-8.11	4.4e-15	4.98e-12	-0.39	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
HNSC	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-8.11	4.43e-15	5.01e-12	-0.37	-0.35	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
HNSC	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	8.11	4.43e-15	5.01e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
HNSC	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
HNSC	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-8.11	4.48e-15	5.06e-12	-0.38	-0.35	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
HNSC	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	8.11	4.49e-15	5.07e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	8.11	4.49e-15	5.07e-12	0.4	0.35	Depression;	chr6:28399886	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	8.11	4.49e-15	5.07e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	8.11	4.49e-15	5.07e-12	0.37	0.35	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-8.11	4.49e-15	5.07e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
HNSC	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-8.11	4.49e-15	5.07e-12	-0.43	-0.35	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-8.11	4.5e-15	5.08e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
HNSC	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-8.11	4.5e-15	5.08e-12	-0.4	-0.35	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
HNSC	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
HNSC	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
HNSC	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-8.11	4.52e-15	5.1e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
HNSC	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-8.11	4.54e-15	5.12e-12	-0.64	-0.35	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
HNSC	cis	rs7048146	0.966	rs4978824	ENSG00000213539.4	YBX1P6	8.11	4.55e-15	5.13e-12	0.41	0.35	Vascular brain injury;	chr9:109540112	chr9:109532830~109534332:-
HNSC	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
HNSC	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-8.11	4.56e-15	5.14e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
HNSC	cis	rs1865760	0.964	rs9295677	ENSG00000272462.2	U91328.19	-8.11	4.57e-15	5.15e-12	-0.35	-0.35	Height;	chr6:25933484	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	8.11	4.57e-15	5.15e-12	0.4	0.35	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	8.11	4.58e-15	5.16e-12	0.42	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
HNSC	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	8.11	4.58e-15	5.16e-12	0.46	0.35	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
HNSC	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-8.11	4.58e-15	5.17e-12	-0.34	-0.35	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-8.11	4.58e-15	5.17e-12	-0.34	-0.35	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
HNSC	cis	rs6969780	0.841	rs2301720	ENSG00000233429.8	HOTAIRM1	-8.11	4.6e-15	5.18e-12	-0.49	-0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156450	chr7:27095647~27100265:+
HNSC	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	8.11	4.61e-15	5.19e-12	0.4	0.35	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	8.11	4.61e-15	5.19e-12	0.4	0.35	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	8.11	4.61e-15	5.19e-12	0.4	0.35	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	8.11	4.62e-15	5.2e-12	0.4	0.35	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
HNSC	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-8.11	4.63e-15	5.22e-12	-0.37	-0.35	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
HNSC	cis	rs9341808	0.718	rs9443735	ENSG00000272129.1	RP11-250B2.6	8.1	4.66e-15	5.25e-12	0.42	0.35	Sitting height ratio;	chr6:80110757	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs12203867	ENSG00000272129.1	RP11-250B2.6	8.1	4.66e-15	5.25e-12	0.42	0.35	Sitting height ratio;	chr6:80111116	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	8.1	4.67e-15	5.25e-12	0.41	0.35	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	8.1	4.67e-15	5.25e-12	0.41	0.35	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
HNSC	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	8.1	4.7e-15	5.28e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
HNSC	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-8.1	4.7e-15	5.29e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
HNSC	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-8.1	4.71e-15	5.29e-12	-0.45	-0.35	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
HNSC	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-8.1	4.71e-15	5.3e-12	-0.4	-0.35	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
HNSC	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	8.1	4.74e-15	5.33e-12	0.39	0.35	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
HNSC	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	8.1	4.75e-15	5.34e-12	0.42	0.35	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
HNSC	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	8.1	4.75e-15	5.34e-12	0.36	0.35	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
HNSC	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	8.1	4.78e-15	5.37e-12	0.43	0.35	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	8.1	4.78e-15	5.37e-12	0.43	0.35	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
HNSC	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
HNSC	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	8.1	4.82e-15	5.42e-12	0.45	0.35	Height;	chr6:109498586	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	8.1	4.82e-15	5.42e-12	0.45	0.35	Height;	chr6:109499759	chr6:109382795~109383666:+
HNSC	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-8.1	4.82e-15	5.42e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
HNSC	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-8.1	4.83e-15	5.43e-12	-0.56	-0.35	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-8.1	4.86e-15	5.46e-12	-0.41	-0.35	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
HNSC	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
HNSC	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-8.1	4.92e-15	5.52e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-8.1	4.92e-15	5.52e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
HNSC	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	8.1	4.92e-15	5.52e-12	0.42	0.35	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
HNSC	cis	rs7404843	0.704	rs112251447	ENSG00000263065.1	AF001548.6	8.1	4.92e-15	5.52e-12	0.66	0.35	Testicular germ cell tumor;	chr16:15428015	chr16:15741151~15741791:+
HNSC	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	8.1	4.92e-15	5.53e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	8.1	4.94e-15	5.54e-12	0.44	0.35	Height;	chr6:109405536	chr6:109382795~109383666:+
HNSC	cis	rs1865760	0.865	rs1115920	ENSG00000272462.2	U91328.19	-8.1	4.95e-15	5.56e-12	-0.35	-0.35	Height;	chr6:25953799	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467645	ENSG00000272462.2	U91328.19	-8.1	4.95e-15	5.56e-12	-0.35	-0.35	Height;	chr6:25954948	chr6:25992662~26001775:+
HNSC	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	8.1	4.96e-15	5.57e-12	0.34	0.35	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
HNSC	cis	rs1865760	0.827	rs9295680	ENSG00000272462.2	U91328.19	-8.1	4.98e-15	5.58e-12	-0.35	-0.35	Height;	chr6:25943875	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.827	rs9295681	ENSG00000272462.2	U91328.19	-8.1	4.98e-15	5.58e-12	-0.35	-0.35	Height;	chr6:25943889	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-8.1	4.99e-15	5.6e-12	-0.34	-0.35	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	8.09	5.02e-15	5.62e-12	0.38	0.35	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
HNSC	cis	rs7942368	0.941	rs1465900	ENSG00000255100.1	RP11-21L23.3	8.09	5.03e-15	5.64e-12	0.45	0.35	Endometriosis;	chr11:76762094	chr11:76782581~76783062:-
HNSC	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-8.09	5.04e-15	5.64e-12	-0.33	-0.35	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
HNSC	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-8.09	5.06e-15	5.67e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
HNSC	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-8.09	5.07e-15	5.67e-12	-0.37	-0.35	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
HNSC	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-8.09	5.08e-15	5.69e-12	-0.57	-0.35	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
HNSC	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	8.09	5.08e-15	5.69e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-8.09	5.09e-15	5.7e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-8.09	5.1e-15	5.7e-12	-0.41	-0.35	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
HNSC	cis	rs9341808	0.754	rs3805885	ENSG00000272129.1	RP11-250B2.6	-8.09	5.14e-15	5.76e-12	-0.42	-0.35	Sitting height ratio;	chr6:80287034	chr6:80355424~80356859:+
HNSC	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	8.09	5.15e-15	5.76e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
HNSC	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	8.09	5.16e-15	5.78e-12	0.4	0.35	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	8.09	5.19e-15	5.81e-12	0.52	0.35	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
HNSC	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-8.09	5.2e-15	5.81e-12	-0.36	-0.35	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
HNSC	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-8.09	5.2e-15	5.81e-12	-0.55	-0.35	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
HNSC	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	8.09	5.21e-15	5.83e-12	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
HNSC	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-8.09	5.21e-15	5.83e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
HNSC	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	8.09	5.23e-15	5.85e-12	0.4	0.35	Depression;	chr6:28314871	chr6:28176188~28176674:+
HNSC	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	8.09	5.24e-15	5.86e-12	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-8.09	5.26e-15	5.88e-12	-0.37	-0.35	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
HNSC	cis	rs867371	1	rs13380317	ENSG00000276710.3	CSPG4P8	8.09	5.27e-15	5.89e-12	0.39	0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82459472~82477258:+
HNSC	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-8.09	5.27e-15	5.89e-12	-0.4	-0.35	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-8.09	5.27e-15	5.89e-12	-0.4	-0.35	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
HNSC	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	8.09	5.27e-15	5.89e-12	0.44	0.35	Height;	chr6:109424122	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-8.09	5.3e-15	5.93e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
HNSC	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	8.09	5.34e-15	5.97e-12	0.39	0.35	Temperament;	chr17:14068990	chr17:14024514~14025488:+
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	8.09	5.36e-15	5.99e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-8.09	5.37e-15	6e-12	-0.4	-0.35	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-8.09	5.38e-15	6.01e-12	-0.41	-0.35	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
HNSC	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-8.08	5.39e-15	6.02e-12	-0.4	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
HNSC	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	8.08	5.41e-15	6.05e-12	0.44	0.35	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-8.08	5.44e-15	6.08e-12	-0.42	-0.35	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
HNSC	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	8.08	5.47e-15	6.11e-12	0.37	0.35	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	-8.08	5.49e-15	6.13e-12	-0.4	-0.35	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-8.08	5.5e-15	6.14e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
HNSC	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-8.08	5.5e-15	6.14e-12	-0.38	-0.35	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
HNSC	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-8.08	5.51e-15	6.15e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
HNSC	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-8.08	5.51e-15	6.15e-12	-0.33	-0.35	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-8.08	5.51e-15	6.15e-12	-0.33	-0.35	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
HNSC	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-8.08	5.52e-15	6.16e-12	-0.41	-0.35	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
HNSC	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	8.08	5.53e-15	6.17e-12	0.45	0.35	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
HNSC	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	8.08	5.56e-15	6.2e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
HNSC	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	8.08	5.56e-15	6.2e-12	0.54	0.35	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	8.08	5.56e-15	6.2e-12	0.54	0.35	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
HNSC	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	8.08	5.57e-15	6.21e-12	0.4	0.35	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	8.08	5.57e-15	6.21e-12	0.4	0.35	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	8.08	5.57e-15	6.21e-12	0.4	0.35	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
HNSC	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	8.08	5.59e-15	6.23e-12	0.4	0.35	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
HNSC	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-8.08	5.61e-15	6.25e-12	-0.43	-0.35	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
HNSC	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	8.08	5.64e-15	6.28e-12	0.41	0.35	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	8.08	5.64e-15	6.28e-12	0.41	0.35	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	8.08	5.64e-15	6.28e-12	0.41	0.35	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
HNSC	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-8.08	5.64e-15	6.28e-12	-0.47	-0.35	Depression;	chr6:28143758	chr6:28115628~28116551:+
HNSC	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	8.08	5.67e-15	6.31e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	8.08	5.67e-15	6.31e-12	0.48	0.35	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
HNSC	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-8.08	5.7e-15	6.35e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-8.08	5.72e-15	6.37e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	8.08	5.74e-15	6.39e-12	0.37	0.35	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
HNSC	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	8.08	5.74e-15	6.39e-12	0.34	0.35	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
HNSC	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-8.08	5.75e-15	6.4e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
HNSC	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-8.08	5.77e-15	6.42e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
HNSC	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	8.08	5.78e-15	6.43e-12	0.7	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
HNSC	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	8.07	5.8e-15	6.45e-12	0.64	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
HNSC	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	8.07	5.89e-15	6.54e-12	0.4	0.35	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
HNSC	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	8.07	5.9e-15	6.55e-12	0.44	0.35	Height;	chr6:109360263	chr6:109382795~109383666:+
HNSC	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	8.07	5.93e-15	6.59e-12	0.46	0.35	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
HNSC	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	8.07	5.94e-15	6.6e-12	0.42	0.35	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	8.07	5.94e-15	6.6e-12	0.42	0.35	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
HNSC	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	8.07	5.94e-15	6.6e-12	0.39	0.35	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
HNSC	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	8.07	5.96e-15	6.62e-12	0.36	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
HNSC	cis	rs7048146	1	rs7030085	ENSG00000213539.4	YBX1P6	8.07	5.98e-15	6.63e-12	0.41	0.35	Vascular brain injury;	chr9:109539735	chr9:109532830~109534332:-
HNSC	cis	rs7048146	1	rs7021839	ENSG00000213539.4	YBX1P6	8.07	6e-15	6.66e-12	0.41	0.35	Vascular brain injury;	chr9:109538257	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816832	ENSG00000213539.4	YBX1P6	8.07	6e-15	6.66e-12	0.41	0.35	Vascular brain injury;	chr9:109538494	chr9:109532830~109534332:-
HNSC	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	8.07	6e-15	6.66e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	8.07	6e-15	6.66e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
HNSC	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-8.07	6e-15	6.66e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
HNSC	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	8.07	6.04e-15	6.7e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
HNSC	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-8.07	6.04e-15	6.7e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
HNSC	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-8.07	6.04e-15	6.7e-12	-0.42	-0.35	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
HNSC	cis	rs2179367	0.959	rs4897125	ENSG00000231760.4	RP11-350J20.5	8.07	6.04e-15	6.7e-12	0.46	0.35	Dupuytren's disease;	chr6:149445072	chr6:149796151~149826294:-
HNSC	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	8.07	6.05e-15	6.71e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
HNSC	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	8.07	6.06e-15	6.72e-12	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
HNSC	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	8.07	6.07e-15	6.72e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
HNSC	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-8.07	6.09e-15	6.75e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
HNSC	cis	rs7826238	0.509	rs2948288	ENSG00000173295.6	FAM86B3P	8.07	6.09e-15	6.75e-12	0.4	0.35	Systolic blood pressure;	chr8:8257782	chr8:8228595~8244865:+
HNSC	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	8.07	6.09e-15	6.75e-12	0.39	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
HNSC	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	8.07	6.11e-15	6.77e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
HNSC	cis	rs1865760	0.929	rs12195653	ENSG00000272462.2	U91328.19	-8.07	6.12e-15	6.78e-12	-0.35	-0.35	Height;	chr6:25958393	chr6:25992662~26001775:+
HNSC	cis	rs7048146	0.966	rs10816829	ENSG00000213539.4	YBX1P6	8.07	6.13e-15	6.79e-12	0.41	0.35	Vascular brain injury;	chr9:109536396	chr9:109532830~109534332:-
HNSC	cis	rs7048146	1	rs12336499	ENSG00000213539.4	YBX1P6	8.07	6.13e-15	6.79e-12	0.41	0.35	Vascular brain injury;	chr9:109537967	chr9:109532830~109534332:-
HNSC	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-8.07	6.13e-15	6.79e-12	-0.44	-0.35	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
HNSC	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-8.07	6.15e-15	6.81e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-8.07	6.15e-15	6.81e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-8.07	6.21e-15	6.87e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-8.07	6.21e-15	6.87e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-8.06	6.22e-15	6.89e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
HNSC	cis	rs7048146	1	rs7048146	ENSG00000213539.4	YBX1P6	8.06	6.24e-15	6.91e-12	0.41	0.35	Vascular brain injury;	chr9:109537042	chr9:109532830~109534332:-
HNSC	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-8.06	6.25e-15	6.91e-12	-0.37	-0.35	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-8.06	6.27e-15	6.94e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	8.06	6.28e-15	6.94e-12	0.39	0.35	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
HNSC	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	8.06	6.28e-15	6.95e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
HNSC	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	8.06	6.31e-15	6.98e-12	0.34	0.35	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
HNSC	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-8.06	6.31e-15	6.98e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
HNSC	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	8.06	6.38e-15	7.05e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	8.06	6.38e-15	7.05e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
HNSC	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-8.06	6.38e-15	7.06e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-8.06	6.38e-15	7.06e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-8.06	6.43e-15	7.1e-12	-0.41	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
HNSC	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-8.06	6.49e-15	7.17e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	8.06	6.5e-15	7.18e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109425054	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109426518	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109427644	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109430292	chr6:109382795~109383666:+
HNSC	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-8.06	6.52e-15	7.19e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
HNSC	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	8.06	6.53e-15	7.2e-12	0.36	0.35	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
HNSC	cis	rs35955747	0.738	rs2012451	ENSG00000236132.1	CTA-440B3.1	8.06	6.53e-15	7.21e-12	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31448387	chr22:31816379~31817491:-
HNSC	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-8.06	6.54e-15	7.22e-12	-0.37	-0.35	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.597	rs11763224	ENSG00000179406.6	LINC00174	-8.06	6.57e-15	7.25e-12	-0.53	-0.35	Aortic root size;	chr7:66518628	chr7:66376044~66401338:-
HNSC	cis	rs7048146	1	rs10979904	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538136	chr9:109532830~109534332:-
HNSC	cis	rs7048146	1	rs7022179	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538280	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816831	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538337	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816833	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538551	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816834	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538626	chr9:109532830~109534332:-
HNSC	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	8.06	6.59e-15	7.27e-12	0.45	0.35	Height;	chr6:109367528	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	8.06	6.59e-15	7.27e-12	0.45	0.35	Height;	chr6:109368704	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	8.06	6.6e-15	7.28e-12	0.44	0.35	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
HNSC	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	8.06	6.61e-15	7.28e-12	0.37	0.35	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
HNSC	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	8.06	6.62e-15	7.29e-12	0.42	0.35	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	8.06	6.62e-15	7.3e-12	0.41	0.35	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
HNSC	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-8.06	6.64e-15	7.31e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-8.06	6.64e-15	7.31e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	8.06	6.66e-15	7.34e-12	0.4	0.35	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
HNSC	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.06	6.68e-15	7.35e-12	-0.38	-0.35	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
HNSC	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-8.05	6.69e-15	7.37e-12	-0.31	-0.35	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
HNSC	cis	rs454422	0.812	rs13041190	ENSG00000275632.1	RP5-967N21.11	8.05	6.7e-15	7.37e-12	0.38	0.35	HIV-1 viral setpoint;	chr20:5980812	chr20:6000418~6000941:+
HNSC	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	8.05	6.72e-15	7.39e-12	0.54	0.35	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
HNSC	cis	rs7048146	0.966	rs4978401	ENSG00000213539.4	YBX1P6	-8.05	6.76e-15	7.43e-12	-0.4	-0.35	Vascular brain injury;	chr9:109540631	chr9:109532830~109534332:-
HNSC	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-8.05	6.76e-15	7.44e-12	-0.34	-0.35	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
HNSC	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	8.05	6.77e-15	7.45e-12	0.42	0.35	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-8.05	6.79e-15	7.47e-12	-0.41	-0.35	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-8.05	6.79e-15	7.47e-12	-0.41	-0.35	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
HNSC	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	8.05	6.81e-15	7.49e-12	0.42	0.35	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	8.05	6.82e-15	7.5e-12	0.42	0.35	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
HNSC	cis	rs9341808	0.754	rs10806185	ENSG00000272129.1	RP11-250B2.6	8.05	6.84e-15	7.53e-12	0.42	0.35	Sitting height ratio;	chr6:80244794	chr6:80355424~80356859:+
HNSC	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	8.05	6.86e-15	7.54e-12	0.54	0.35	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	8.05	6.86e-15	7.54e-12	0.54	0.35	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	8.05	6.86e-15	7.54e-12	0.54	0.35	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
HNSC	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.05	6.88e-15	7.56e-12	-0.38	-0.35	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
HNSC	cis	rs9341808	0.754	rs1015158	ENSG00000272129.1	RP11-250B2.6	8.05	6.89e-15	7.57e-12	0.42	0.35	Sitting height ratio;	chr6:80236028	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.791	rs1324122	ENSG00000272129.1	RP11-250B2.6	8.05	6.89e-15	7.57e-12	0.42	0.35	Sitting height ratio;	chr6:80236344	chr6:80355424~80356859:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-8.05	6.9e-15	7.58e-12	-0.55	-0.35	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
HNSC	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	8.05	6.9e-15	7.58e-12	0.37	0.35	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
HNSC	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-8.05	6.92e-15	7.6e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
HNSC	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-8.05	6.92e-15	7.6e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	8.05	6.94e-15	7.62e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
HNSC	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	8.05	6.97e-15	7.66e-12	0.54	0.35	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
HNSC	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	8.05	6.98e-15	7.66e-12	0.41	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
HNSC	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.05	6.98e-15	7.67e-12	-0.38	-0.35	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
HNSC	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-8.05	6.99e-15	7.67e-12	-0.43	-0.35	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
HNSC	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.05	7.01e-15	7.69e-12	-0.38	-0.35	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.05	7.01e-15	7.69e-12	-0.38	-0.35	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs73376394	ENSG00000179406.6	LINC00174	-8.05	7.02e-15	7.7e-12	-0.51	-0.35	Aortic root size;	chr7:66172694	chr7:66376044~66401338:-
HNSC	cis	rs6969780	0.841	rs10246712	ENSG00000233429.8	HOTAIRM1	8.05	7.06e-15	7.75e-12	0.48	0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27159241	chr7:27095647~27100265:+
HNSC	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-8.05	7.09e-15	7.78e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
HNSC	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-8.05	7.12e-15	7.81e-12	-0.34	-0.35	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
HNSC	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	8.05	7.14e-15	7.84e-12	0.46	0.35	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
HNSC	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	8.05	7.15e-15	7.84e-12	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
HNSC	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	8.05	7.16e-15	7.85e-12	0.44	0.35	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
HNSC	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-8.04	7.2e-15	7.89e-12	-0.38	-0.35	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.713	rs2013063	ENSG00000272462.2	U91328.19	-8.04	7.22e-15	7.92e-12	-0.34	-0.35	Height;	chr6:25993870	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	8.04	7.25e-15	7.94e-12	0.45	0.35	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
HNSC	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
HNSC	cis	rs7048146	0.966	rs10979907	ENSG00000213539.4	YBX1P6	8.04	7.26e-15	7.95e-12	0.41	0.35	Vascular brain injury;	chr9:109541739	chr9:109532830~109534332:-
HNSC	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-8.04	7.27e-15	7.96e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
HNSC	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	8.04	7.27e-15	7.96e-12	0.41	0.35	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
HNSC	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	8.04	7.29e-15	7.98e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
HNSC	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-8.04	7.31e-15	8e-12	-0.38	-0.35	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
HNSC	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-8.04	7.32e-15	8.01e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
HNSC	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	8.04	7.38e-15	8.07e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	8.04	7.38e-15	8.07e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	8.04	7.38e-15	8.07e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-8.04	7.41e-15	8.09e-12	-0.37	-0.35	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
HNSC	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-8.04	7.42e-15	8.1e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.566	rs9358904	ENSG00000272462.2	U91328.19	-8.04	7.44e-15	8.13e-12	-0.34	-0.35	Height;	chr6:26068338	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-8.04	7.44e-15	8.13e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-8.04	7.44e-15	8.13e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
HNSC	cis	rs17270561	0.666	rs4712976	ENSG00000272462.2	U91328.19	-8.04	7.44e-15	8.13e-12	-0.37	-0.35	Iron status biomarkers;	chr6:25841975	chr6:25992662~26001775:+
HNSC	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	8.04	7.45e-15	8.14e-12	0.4	0.35	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
HNSC	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	8.04	7.47e-15	8.16e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
HNSC	cis	rs9341808	0.718	rs9343978	ENSG00000272129.1	RP11-250B2.6	8.04	7.48e-15	8.17e-12	0.42	0.35	Sitting height ratio;	chr6:80262261	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	8.04	7.52e-15	8.21e-12	0.33	0.35	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	8.04	7.53e-15	8.22e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
HNSC	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-8.04	7.56e-15	8.26e-12	-0.45	-0.35	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
HNSC	cis	rs7048146	0.899	rs12550929	ENSG00000213539.4	YBX1P6	8.04	7.58e-15	8.27e-12	0.41	0.35	Vascular brain injury;	chr9:109541072	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10979906	ENSG00000213539.4	YBX1P6	8.04	7.58e-15	8.27e-12	0.41	0.35	Vascular brain injury;	chr9:109541401	chr9:109532830~109534332:-
HNSC	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-8.04	7.59e-15	8.28e-12	-0.49	-0.35	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
HNSC	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	8.04	7.63e-15	8.32e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
HNSC	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-8.04	7.64e-15	8.33e-12	-0.43	-0.35	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
HNSC	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	8.04	7.65e-15	8.35e-12	0.37	0.35	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
HNSC	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-8.04	7.66e-15	8.35e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	8.04	7.68e-15	8.38e-12	0.36	0.35	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
HNSC	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	8.04	7.68e-15	8.38e-12	0.39	0.35	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
HNSC	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	8.04	7.69e-15	8.38e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
HNSC	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-8.04	7.7e-15	8.39e-12	-0.52	-0.35	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
HNSC	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-8.04	7.71e-15	8.4e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-8.03	7.75e-15	8.45e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
HNSC	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	8.03	7.76e-15	8.45e-12	0.36	0.35	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	8.03	7.78e-15	8.47e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.754	rs1324121	ENSG00000272129.1	RP11-250B2.6	8.03	7.78e-15	8.48e-12	0.42	0.35	Sitting height ratio;	chr6:80236360	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	8.03	7.8e-15	8.5e-12	0.41	0.35	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
HNSC	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-8.03	7.82e-15	8.51e-12	-0.44	-0.35	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	8.03	7.84e-15	8.54e-12	0.4	0.35	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
HNSC	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	8.03	7.86e-15	8.55e-12	0.41	0.35	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
HNSC	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	8.03	7.87e-15	8.57e-12	0.41	0.35	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
HNSC	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-8.03	7.9e-15	8.6e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-8.03	7.9e-15	8.6e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-8.03	7.9e-15	8.6e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
HNSC	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	8.03	7.93e-15	8.63e-12	0.4	0.35	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
HNSC	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	8.03	7.93e-15	8.63e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	8.03	7.93e-15	8.63e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	8.03	7.93e-15	8.63e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
HNSC	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-8.03	7.96e-15	8.66e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
HNSC	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	8.03	7.97e-15	8.68e-12	0.44	0.35	Height;	chr6:109458989	chr6:109382795~109383666:+
HNSC	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	8.03	8.01e-15	8.71e-12	0.45	0.35	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
HNSC	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-8.03	8.03e-15	8.73e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
HNSC	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	8.03	8.03e-15	8.74e-12	0.36	0.35	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
HNSC	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-8.03	8.06e-15	8.76e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
HNSC	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	8.03	8.06e-15	8.77e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000235689.1	AP000351.13	8.03	8.1e-15	8.81e-12	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:24006305~24008258:-
HNSC	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-8.03	8.1e-15	8.81e-12	-0.47	-0.35	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
HNSC	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-8.03	8.12e-15	8.83e-12	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
HNSC	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-8.03	8.12e-15	8.83e-12	-0.34	-0.35	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-8.03	8.13e-15	8.84e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-8.03	8.13e-15	8.84e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
HNSC	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-8.03	8.17e-15	8.88e-12	-0.34	-0.35	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
HNSC	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-8.03	8.21e-15	8.93e-12	-0.36	-0.35	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	8.03	8.22e-15	8.93e-12	0.32	0.35	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	8.03	8.25e-15	8.96e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000173295.6	FAM86B3P	8.03	8.26e-15	8.97e-12	0.38	0.35	Systolic blood pressure;	chr8:8461832	chr8:8228595~8244865:+
HNSC	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-8.02	8.38e-15	9.1e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-8.02	8.38e-15	9.1e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
HNSC	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	8.02	8.41e-15	9.13e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
HNSC	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-8.02	8.45e-15	9.17e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	8.02	8.48e-15	9.2e-12	0.48	0.35	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-8.02	8.48e-15	9.21e-12	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
HNSC	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	8.02	8.49e-15	9.22e-12	0.32	0.35	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
HNSC	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-8.02	8.5e-15	9.22e-12	-0.34	-0.35	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.545	rs7783889	ENSG00000179406.6	LINC00174	-8.02	8.52e-15	9.24e-12	-0.53	-0.35	Aortic root size;	chr7:66283366	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs66594357	ENSG00000179406.6	LINC00174	-8.02	8.52e-15	9.24e-12	-0.53	-0.35	Aortic root size;	chr7:66327797	chr7:66376044~66401338:-
HNSC	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	8.02	8.57e-15	9.29e-12	0.42	0.35	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	8.02	8.58e-15	9.3e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
HNSC	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-8.02	8.58e-15	9.3e-12	-0.55	-0.35	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-8.02	8.58e-15	9.3e-12	-0.55	-0.35	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
HNSC	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	8.02	8.6e-15	9.32e-12	0.54	0.35	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	8.02	8.62e-15	9.34e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
HNSC	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-8.02	8.64e-15	9.36e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
HNSC	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	8.02	8.65e-15	9.37e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
HNSC	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-8.02	8.65e-15	9.37e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-8.02	8.65e-15	9.37e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-8.02	8.65e-15	9.37e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-8.02	8.66e-15	9.38e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
HNSC	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-8.02	8.71e-15	9.43e-12	-0.43	-0.35	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
HNSC	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-8.02	8.73e-15	9.45e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
HNSC	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	8.02	8.74e-15	9.47e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	8.02	8.75e-15	9.48e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
HNSC	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-8.02	8.79e-15	9.52e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	8.02	8.81e-15	9.53e-12	0.33	0.35	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
HNSC	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	8.02	8.85e-15	9.58e-12	0.4	0.35	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
HNSC	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	8.02	8.87e-15	9.61e-12	0.41	0.35	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	8.02	8.88e-15	9.61e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	8.02	8.88e-15	9.61e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	8.01	8.91e-15	9.64e-12	0.44	0.35	Height;	chr6:109409679	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	8.01	8.91e-15	9.64e-12	0.44	0.35	Height;	chr6:109424305	chr6:109382795~109383666:+
HNSC	cis	rs10129255	0.642	rs11624918	ENSG00000223648.3	IGHV3-64	8.01	8.93e-15	9.66e-12	0.28	0.35	Kawasaki disease;	chr14:106664672	chr14:106643132~106658258:-
HNSC	cis	rs7048146	0.899	rs1330846	ENSG00000213539.4	YBX1P6	-8.01	8.96e-15	9.69e-12	-0.41	-0.35	Vascular brain injury;	chr9:109574668	chr9:109532830~109534332:-
HNSC	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
HNSC	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-8.01	8.99e-15	9.72e-12	-0.56	-0.35	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-8.01	8.99e-15	9.72e-12	-0.43	-0.35	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
HNSC	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-8.01	9.01e-15	9.74e-12	-0.44	-0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
HNSC	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-8.01	9.03e-15	9.76e-12	-0.4	-0.35	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	8.01	9.05e-15	9.78e-12	0.48	0.35	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	8.01	9.05e-15	9.78e-12	0.48	0.35	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	8.01	9.06e-15	9.79e-12	0.48	0.35	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
HNSC	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	8.01	9.15e-15	9.88e-12	0.46	0.35	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	8.01	9.15e-15	9.88e-12	0.46	0.35	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	8.01	9.22e-15	9.95e-12	0.33	0.35	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
HNSC	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-8.01	9.22e-15	9.95e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
HNSC	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-8.01	9.22e-15	9.96e-12	-0.53	-0.35	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
HNSC	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-8.01	9.25e-15	9.98e-12	-0.42	-0.35	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
HNSC	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	8.01	9.28e-15	1e-11	0.45	0.35	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
HNSC	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	8.01	9.32e-15	1.01e-11	0.35	0.35	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-8.01	9.37e-15	1.01e-11	-0.39	-0.35	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-8.01	9.37e-15	1.01e-11	-0.39	-0.35	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
HNSC	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
HNSC	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-8.01	9.39e-15	1.01e-11	-0.45	-0.35	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	8.01	9.44e-15	1.02e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
HNSC	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	8.01	9.48e-15	1.02e-11	0.39	0.35	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
HNSC	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	8.01	9.5e-15	1.02e-11	0.4	0.35	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
HNSC	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	8.01	9.51e-15	1.02e-11	0.38	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
HNSC	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	8.01	9.51e-15	1.02e-11	0.54	0.35	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
HNSC	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	8.01	9.52e-15	1.02e-11	0.46	0.35	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
HNSC	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	8.01	9.54e-15	1.03e-11	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
HNSC	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	8	9.6e-15	1.03e-11	0.36	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
HNSC	cis	rs1021993	0.868	rs6661759	ENSG00000231648.1	RP11-372M18.2	-8	9.61e-15	1.03e-11	-0.47	-0.35	Gut microbiome composition (winter);	chr1:209357454	chr1:209367662~209379690:+
HNSC	cis	rs9341808	0.754	rs6918172	ENSG00000272129.1	RP11-250B2.6	8	9.62e-15	1.03e-11	0.41	0.35	Sitting height ratio;	chr6:80309525	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8	9.63e-15	1.04e-11	-0.38	-0.35	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
HNSC	cis	rs7048146	0.966	rs4978825	ENSG00000213539.4	YBX1P6	-8	9.64e-15	1.04e-11	-0.4	-0.35	Vascular brain injury;	chr9:109540184	chr9:109532830~109534332:-
HNSC	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	8	9.65e-15	1.04e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
HNSC	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	8	9.68e-15	1.04e-11	0.39	0.35	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-8	9.69e-15	1.04e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
HNSC	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	8	9.7e-15	1.04e-11	0.41	0.35	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
HNSC	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	8	9.7e-15	1.04e-11	0.41	0.35	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
HNSC	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	8	9.7e-15	1.04e-11	0.54	0.35	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
HNSC	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-8	9.71e-15	1.04e-11	-0.47	-0.35	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
HNSC	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	8	9.71e-15	1.04e-11	0.41	0.35	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	8	9.71e-15	1.04e-11	0.41	0.35	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	8	9.73e-15	1.05e-11	0.24	0.35	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
HNSC	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	8	9.79e-15	1.05e-11	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
HNSC	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-8	9.8e-15	1.05e-11	-0.4	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
HNSC	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	8	9.82e-15	1.06e-11	0.4	0.35	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
HNSC	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-8	9.85e-15	1.06e-11	-0.57	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-8	9.85e-15	1.06e-11	-0.24	-0.35	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
HNSC	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-8	9.85e-15	1.06e-11	-0.65	-0.35	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
HNSC	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	8	9.94e-15	1.07e-11	0.31	0.35	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.865	rs9467652	ENSG00000272462.2	U91328.19	-8	9.98e-15	1.07e-11	-0.34	-0.35	Height;	chr6:25958899	chr6:25992662~26001775:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000173295.6	FAM86B3P	8	9.99e-15	1.07e-11	0.4	0.35	Joint mobility (Beighton score);	chr8:9034711	chr8:8228595~8244865:+
HNSC	cis	rs6867032	1	rs10462750	ENSG00000249731.1	RP11-259O2.3	8	1e-14	1.08e-11	0.42	0.35	Gut microbiome composition (winter);	chr5:2012849	chr5:1968094~1969013:+
HNSC	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	8	1.01e-14	1.08e-11	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
HNSC	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	8	1.01e-14	1.08e-11	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
HNSC	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	8	1.01e-14	1.09e-11	0.41	0.35	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	8	1.02e-14	1.09e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	8	1.02e-14	1.09e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	8	1.02e-14	1.09e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-8	1.02e-14	1.09e-11	-0.44	-0.35	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
HNSC	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-8	1.02e-14	1.09e-11	-0.39	-0.35	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
HNSC	cis	rs1865760	0.713	rs7766342	ENSG00000272462.2	U91328.19	-8	1.02e-14	1.09e-11	-0.34	-0.35	Height;	chr6:25990446	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.713	rs9461229	ENSG00000272462.2	U91328.19	-8	1.02e-14	1.09e-11	-0.34	-0.35	Height;	chr6:25992051	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	8	1.02e-14	1.1e-11	0.46	0.35	Height;	chr6:109642186	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	8	1.02e-14	1.1e-11	0.4	0.35	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	8	1.02e-14	1.1e-11	0.4	0.35	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.754	rs10733162	ENSG00000272129.1	RP11-250B2.6	7.99	1.03e-14	1.1e-11	0.41	0.35	Sitting height ratio;	chr6:80313672	chr6:80355424~80356859:+
HNSC	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-7.99	1.03e-14	1.1e-11	-0.39	-0.35	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
HNSC	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-7.99	1.03e-14	1.11e-11	-0.57	-0.35	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
HNSC	cis	rs9326248	0.689	rs236916	ENSG00000280143.1	AP000892.6	-7.99	1.04e-14	1.11e-11	-0.49	-0.35	Blood protein levels;	chr11:117218912	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.545	rs11767262	ENSG00000179406.6	LINC00174	-7.99	1.04e-14	1.11e-11	-0.52	-0.35	Aortic root size;	chr7:66302237	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	7.99	1.04e-14	1.11e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
HNSC	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.99	1.04e-14	1.12e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
HNSC	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	7.99	1.04e-14	1.12e-11	0.46	0.35	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
HNSC	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-7.99	1.05e-14	1.12e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
HNSC	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-7.99	1.05e-14	1.12e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
HNSC	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-7.99	1.05e-14	1.12e-11	-0.4	-0.35	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
HNSC	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-7.99	1.05e-14	1.12e-11	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
HNSC	cis	rs1865760	0.568	rs2032450	ENSG00000272462.2	U91328.19	-7.99	1.05e-14	1.12e-11	-0.34	-0.35	Height;	chr6:25992886	chr6:25992662~26001775:+
HNSC	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-7.99	1.05e-14	1.12e-11	-0.53	-0.35	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
HNSC	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	7.99	1.06e-14	1.13e-11	0.39	0.35	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
HNSC	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	7.99	1.06e-14	1.13e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	7.99	1.06e-14	1.13e-11	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
HNSC	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	7.99	1.06e-14	1.14e-11	0.4	0.35	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
HNSC	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	7.99	1.07e-14	1.14e-11	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	7.99	1.07e-14	1.14e-11	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
HNSC	cis	rs35955747	0.633	rs5998002	ENSG00000236132.1	CTA-440B3.1	7.99	1.07e-14	1.14e-11	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485183	chr22:31816379~31817491:-
HNSC	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	7.99	1.07e-14	1.14e-11	0.33	0.35	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
HNSC	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	7.99	1.08e-14	1.15e-11	0.32	0.35	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
HNSC	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-7.99	1.08e-14	1.16e-11	-0.37	-0.35	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
HNSC	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-7.99	1.09e-14	1.16e-11	-0.57	-0.35	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-7.99	1.09e-14	1.16e-11	-0.57	-0.35	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
HNSC	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-7.99	1.09e-14	1.16e-11	-0.37	-0.35	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
HNSC	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	7.99	1.09e-14	1.16e-11	0.4	0.35	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	7.99	1.09e-14	1.17e-11	0.38	0.35	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
HNSC	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-7.99	1.09e-14	1.17e-11	-0.31	-0.35	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
HNSC	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-7.99	1.1e-14	1.17e-11	-0.41	-0.35	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-7.99	1.1e-14	1.17e-11	-0.41	-0.35	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
HNSC	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	7.99	1.1e-14	1.17e-11	0.43	0.35	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
HNSC	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	7.99	1.1e-14	1.18e-11	0.38	0.35	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
HNSC	cis	rs875971	0.545	rs1909508	ENSG00000179406.6	LINC00174	-7.98	1.11e-14	1.19e-11	-0.52	-0.35	Aortic root size;	chr7:66301366	chr7:66376044~66401338:-
HNSC	cis	rs35955747	0.533	rs5998004	ENSG00000236132.1	CTA-440B3.1	7.98	1.11e-14	1.19e-11	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485843	chr22:31816379~31817491:-
HNSC	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	7.98	1.11e-14	1.19e-11	0.44	0.35	Height;	chr6:109490935	chr6:109382795~109383666:+
HNSC	cis	rs7048146	0.966	rs4978826	ENSG00000213539.4	YBX1P6	7.98	1.12e-14	1.19e-11	0.4	0.35	Vascular brain injury;	chr9:109540221	chr9:109532830~109534332:-
HNSC	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	7.98	1.12e-14	1.2e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-7.98	1.12e-14	1.2e-11	-0.41	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
HNSC	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-7.98	1.13e-14	1.21e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
HNSC	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	7.98	1.13e-14	1.21e-11	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	7.98	1.13e-14	1.21e-11	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
HNSC	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-7.98	1.13e-14	1.21e-11	-0.33	-0.35	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
HNSC	cis	rs7404843	0.778	rs72774864	ENSG00000263335.1	AF001548.5	7.98	1.13e-14	1.21e-11	0.7	0.35	Testicular germ cell tumor;	chr16:15418465	chr16:15726674~15732993:+
HNSC	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-7.98	1.13e-14	1.21e-11	-0.4	-0.35	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-7.98	1.13e-14	1.21e-11	-0.44	-0.35	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-7.98	1.14e-14	1.22e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-7.98	1.14e-14	1.22e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-7.98	1.14e-14	1.22e-11	-0.33	-0.35	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-7.98	1.15e-14	1.22e-11	-0.33	-0.35	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-7.98	1.15e-14	1.22e-11	-0.33	-0.35	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
HNSC	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-7.98	1.15e-14	1.22e-11	-0.4	-0.35	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-7.98	1.15e-14	1.22e-11	-0.4	-0.35	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
HNSC	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-7.98	1.15e-14	1.23e-11	-0.53	-0.35	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
HNSC	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	7.98	1.15e-14	1.23e-11	0.43	0.35	Height;	chr6:109361200	chr6:109382795~109383666:+
HNSC	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	7.98	1.16e-14	1.23e-11	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
HNSC	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	7.98	1.16e-14	1.23e-11	0.4	0.35	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
HNSC	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-7.98	1.16e-14	1.23e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-7.98	1.16e-14	1.24e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
HNSC	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	7.98	1.18e-14	1.25e-11	0.44	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
HNSC	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	7.98	1.18e-14	1.26e-11	0.4	0.35	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
HNSC	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	7.98	1.18e-14	1.26e-11	0.36	0.35	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
HNSC	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-7.98	1.18e-14	1.26e-11	-0.35	-0.35	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-7.97	1.19e-14	1.27e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
HNSC	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-7.97	1.19e-14	1.27e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
HNSC	cis	rs9341808	0.754	rs6916405	ENSG00000272129.1	RP11-250B2.6	7.97	1.19e-14	1.27e-11	0.41	0.35	Sitting height ratio;	chr6:80314471	chr6:80355424~80356859:+
HNSC	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-7.97	1.19e-14	1.27e-11	-0.43	-0.35	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
HNSC	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-7.97	1.19e-14	1.27e-11	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
HNSC	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.27e-11	0.36	0.35	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.27e-11	0.36	0.35	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
HNSC	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	7.97	1.2e-14	1.28e-11	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-7.97	1.21e-14	1.28e-11	-0.39	-0.35	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	7.97	1.21e-14	1.29e-11	0.46	0.35	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
HNSC	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-7.97	1.21e-14	1.29e-11	-0.35	-0.35	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-7.97	1.22e-14	1.3e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	7.97	1.22e-14	1.3e-11	0.46	0.35	Height;	chr6:109646187	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	7.97	1.22e-14	1.3e-11	0.46	0.35	Height;	chr6:109652694	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	7.97	1.22e-14	1.3e-11	0.46	0.35	Height;	chr6:109655791	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	7.97	1.22e-14	1.3e-11	0.38	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-7.97	1.23e-14	1.31e-11	-0.46	-0.35	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
HNSC	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-7.97	1.23e-14	1.31e-11	-0.48	-0.35	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
HNSC	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-7.97	1.23e-14	1.31e-11	-0.36	-0.35	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.865	rs9467647	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25957414	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs10946800	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25957545	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467648	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25957705	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467650	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25958007	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467651	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25958029	chr6:25992662~26001775:+
HNSC	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-7.97	1.24e-14	1.31e-11	-0.39	-0.35	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	7.97	1.24e-14	1.31e-11	0.39	0.35	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	7.97	1.24e-14	1.31e-11	0.39	0.35	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
HNSC	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-7.97	1.24e-14	1.32e-11	-0.34	-0.35	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.786	rs2164487	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.32e-11	-0.35	-0.35	Height;	chr6:25950572	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs6929805	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.32e-11	-0.35	-0.35	Height;	chr6:25950606	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-7.97	1.24e-14	1.32e-11	-0.37	-0.35	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-7.97	1.26e-14	1.33e-11	-0.45	-0.35	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
HNSC	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-7.97	1.26e-14	1.33e-11	-0.37	-0.35	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
HNSC	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-7.97	1.26e-14	1.33e-11	-0.34	-0.35	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-7.97	1.26e-14	1.34e-11	-0.33	-0.35	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.827	rs9461227	ENSG00000272462.2	U91328.19	-7.97	1.27e-14	1.34e-11	-0.34	-0.35	Height;	chr6:25960587	chr6:25992662~26001775:+
HNSC	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	7.97	1.27e-14	1.34e-11	0.52	0.35	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
HNSC	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	7.96	1.27e-14	1.35e-11	0.44	0.35	Height;	chr6:109358227	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	7.96	1.28e-14	1.36e-11	0.4	0.35	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
HNSC	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	7.96	1.28e-14	1.36e-11	0.39	0.35	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	7.96	1.29e-14	1.37e-11	0.48	0.35	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
HNSC	cis	rs1021993	0.868	rs906350	ENSG00000231648.1	RP11-372M18.2	-7.96	1.29e-14	1.37e-11	-0.47	-0.35	Gut microbiome composition (winter);	chr1:209354763	chr1:209367662~209379690:+
HNSC	cis	rs6951245	0.608	rs10252234	ENSG00000224079.1	AC091729.7	-7.96	1.29e-14	1.37e-11	-0.45	-0.35	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074745	chr7:1074450~1078036:+
HNSC	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-7.96	1.3e-14	1.37e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
HNSC	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-7.96	1.3e-14	1.38e-11	-0.38	-0.35	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
HNSC	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	7.96	1.31e-14	1.38e-11	0.4	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
HNSC	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-7.96	1.31e-14	1.38e-11	-0.39	-0.35	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
HNSC	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	7.96	1.31e-14	1.39e-11	0.4	0.35	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
HNSC	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-7.96	1.31e-14	1.39e-11	-0.37	-0.35	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
HNSC	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-7.96	1.32e-14	1.39e-11	-0.47	-0.35	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	7.96	1.32e-14	1.39e-11	0.39	0.35	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.865	rs2164485	ENSG00000272462.2	U91328.19	-7.96	1.32e-14	1.39e-11	-0.35	-0.35	Height;	chr6:25951878	chr6:25992662~26001775:+
HNSC	cis	rs867371	1	rs13380319	ENSG00000276710.3	CSPG4P8	-7.96	1.32e-14	1.4e-11	-0.39	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82459472~82477258:+
HNSC	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-7.96	1.32e-14	1.4e-11	-0.34	-0.35	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-7.96	1.33e-14	1.4e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
HNSC	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-7.96	1.34e-14	1.41e-11	-0.37	-0.35	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
HNSC	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	7.96	1.34e-14	1.42e-11	0.42	0.35	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
HNSC	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-7.96	1.34e-14	1.42e-11	-0.37	-0.35	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
HNSC	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
HNSC	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	7.96	1.34e-14	1.42e-11	0.4	0.35	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
HNSC	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-7.96	1.35e-14	1.43e-11	-0.36	-0.35	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
HNSC	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-7.96	1.35e-14	1.43e-11	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
HNSC	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-7.96	1.36e-14	1.44e-11	-0.39	-0.35	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.713	rs6928951	ENSG00000272462.2	U91328.19	-7.96	1.36e-14	1.44e-11	-0.34	-0.35	Height;	chr6:25995326	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-7.95	1.37e-14	1.44e-11	-0.37	-0.35	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
HNSC	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-7.95	1.37e-14	1.44e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	7.95	1.37e-14	1.44e-11	0.48	0.35	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	7.95	1.37e-14	1.44e-11	0.48	0.35	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	7.95	1.37e-14	1.45e-11	0.39	0.35	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
HNSC	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.95	1.37e-14	1.45e-11	-0.38	-0.35	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
HNSC	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-7.95	1.38e-14	1.46e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-7.95	1.38e-14	1.46e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
HNSC	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	7.95	1.38e-14	1.46e-11	0.37	0.35	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000254340.1	RP11-10A14.3	7.95	1.38e-14	1.46e-11	0.43	0.35	Joint mobility (Beighton score);	chr8:9034711	chr8:9141424~9145435:+
HNSC	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-7.95	1.39e-14	1.46e-11	-0.37	-0.35	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-7.95	1.39e-14	1.47e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-7.95	1.39e-14	1.47e-11	-0.37	-0.35	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-7.95	1.4e-14	1.47e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000173295.6	FAM86B3P	7.95	1.4e-14	1.47e-11	0.38	0.35	Neuroticism;	chr8:8461672	chr8:8228595~8244865:+
HNSC	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-7.95	1.4e-14	1.47e-11	-0.33	-0.35	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs17138149	ENSG00000179406.6	LINC00174	-7.95	1.41e-14	1.48e-11	-0.52	-0.35	Aortic root size;	chr7:66228193	chr7:66376044~66401338:-
HNSC	cis	rs1021993	0.868	rs6685498	ENSG00000231648.1	RP11-372M18.2	-7.95	1.41e-14	1.48e-11	-0.47	-0.35	Gut microbiome composition (winter);	chr1:209357487	chr1:209367662~209379690:+
HNSC	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-7.95	1.42e-14	1.49e-11	-0.4	-0.35	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	7.95	1.42e-14	1.49e-11	0.49	0.35	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
HNSC	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-7.95	1.43e-14	1.5e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	7.95	1.43e-14	1.5e-11	0.48	0.35	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs6950988	ENSG00000179406.6	LINC00174	-7.95	1.43e-14	1.5e-11	-0.52	-0.35	Aortic root size;	chr7:66511428	chr7:66376044~66401338:-
HNSC	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-7.95	1.44e-14	1.51e-11	-0.37	-0.35	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-7.95	1.44e-14	1.51e-11	-0.44	-0.35	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
HNSC	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-7.95	1.44e-14	1.51e-11	-0.37	-0.35	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
HNSC	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	7.95	1.45e-14	1.52e-11	0.46	0.35	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
HNSC	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-7.95	1.45e-14	1.52e-11	-0.38	-0.35	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
HNSC	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-7.95	1.45e-14	1.53e-11	-0.53	-0.35	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
HNSC	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	7.95	1.45e-14	1.53e-11	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
HNSC	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-7.95	1.45e-14	1.53e-11	-0.37	-0.35	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
HNSC	cis	rs6969780	0.722	rs4722666	ENSG00000233429.8	HOTAIRM1	-7.95	1.45e-14	1.53e-11	-0.44	-0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157982	chr7:27095647~27100265:+
HNSC	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	7.95	1.45e-14	1.53e-11	0.36	0.35	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
HNSC	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.95	1.46e-14	1.53e-11	-0.38	-0.35	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
HNSC	cis	rs9341808	0.718	rs2322630	ENSG00000272129.1	RP11-250B2.6	7.95	1.46e-14	1.53e-11	0.41	0.35	Sitting height ratio;	chr6:80131316	chr6:80355424~80356859:+
HNSC	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-7.95	1.46e-14	1.53e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
HNSC	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	7.95	1.46e-14	1.53e-11	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
HNSC	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	7.95	1.46e-14	1.54e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	7.95	1.46e-14	1.54e-11	0.49	0.35	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	7.95	1.46e-14	1.54e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
HNSC	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-7.94	1.47e-14	1.54e-11	-0.46	-0.35	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
HNSC	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-7.94	1.47e-14	1.54e-11	-0.46	-0.35	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
HNSC	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	7.94	1.47e-14	1.55e-11	0.39	0.35	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
HNSC	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	7.94	1.47e-14	1.55e-11	0.43	0.35	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
HNSC	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	7.94	1.48e-14	1.55e-11	0.39	0.35	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	7.94	1.48e-14	1.55e-11	0.39	0.35	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	7.94	1.48e-14	1.55e-11	0.39	0.35	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000173295.6	FAM86B3P	7.94	1.48e-14	1.55e-11	0.38	0.35	Neuroticism;	chr8:8461340	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	7.94	1.48e-14	1.56e-11	0.43	0.35	Height;	chr6:109367335	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	7.94	1.48e-14	1.56e-11	0.43	0.35	Height;	chr6:109368228	chr6:109382795~109383666:+
HNSC	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	7.94	1.48e-14	1.56e-11	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
HNSC	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	7.94	1.48e-14	1.56e-11	0.57	0.35	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
HNSC	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.94	1.48e-14	1.56e-11	-0.36	-0.35	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
HNSC	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.56e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.882	rs2378584	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.57e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620290	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.733	rs34767248	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.57e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620428	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.882	rs17163301	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.57e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620749	chr1:222658867~222661512:-
HNSC	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
HNSC	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-7.94	1.5e-14	1.57e-11	-0.82	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	7.94	1.5e-14	1.57e-11	0.33	0.34	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	7.94	1.5e-14	1.57e-11	0.33	0.34	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-7.94	1.51e-14	1.58e-11	-0.41	-0.34	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
HNSC	cis	rs7404843	0.852	rs111259294	ENSG00000263335.1	AF001548.5	7.94	1.51e-14	1.58e-11	0.7	0.34	Testicular germ cell tumor;	chr16:15418073	chr16:15726674~15732993:+
HNSC	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	7.94	1.51e-14	1.58e-11	0.4	0.34	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	7.94	1.51e-14	1.59e-11	0.36	0.34	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	7.94	1.51e-14	1.59e-11	0.36	0.34	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	7.94	1.51e-14	1.59e-11	0.36	0.34	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-7.94	1.52e-14	1.59e-11	-0.53	-0.34	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	7.94	1.52e-14	1.59e-11	0.53	0.34	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
HNSC	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7.94	1.52e-14	1.59e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
HNSC	cis	rs875971	0.545	rs4718348	ENSG00000179406.6	LINC00174	-7.94	1.52e-14	1.59e-11	-0.53	-0.34	Aortic root size;	chr7:66441589	chr7:66376044~66401338:-
HNSC	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	7.94	1.52e-14	1.59e-11	0.39	0.34	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-7.94	1.52e-14	1.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
HNSC	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-7.94	1.53e-14	1.6e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
HNSC	cis	rs9341808	0.727	rs9352809	ENSG00000272129.1	RP11-250B2.6	7.94	1.53e-14	1.6e-11	0.41	0.34	Sitting height ratio;	chr6:80289599	chr6:80355424~80356859:+
HNSC	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	7.94	1.53e-14	1.6e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	7.94	1.53e-14	1.61e-11	0.4	0.34	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
HNSC	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
HNSC	cis	rs35955747	0.633	rs4541328	ENSG00000236132.1	CTA-440B3.1	7.94	1.54e-14	1.61e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31500186	chr22:31816379~31817491:-
HNSC	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-7.94	1.54e-14	1.62e-11	-0.39	-0.34	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-7.94	1.54e-14	1.62e-11	-0.39	-0.34	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
HNSC	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-7.94	1.55e-14	1.62e-11	-0.35	-0.34	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-7.94	1.55e-14	1.62e-11	-0.4	-0.34	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
HNSC	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	7.94	1.56e-14	1.63e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-7.94	1.56e-14	1.63e-11	-0.34	-0.34	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
HNSC	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-7.94	1.56e-14	1.63e-11	-0.34	-0.34	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
HNSC	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-7.94	1.57e-14	1.64e-11	-0.4	-0.34	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
HNSC	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	7.94	1.57e-14	1.64e-11	0.35	0.34	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
HNSC	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	7.94	1.57e-14	1.64e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	7.94	1.57e-14	1.64e-11	0.48	0.34	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-7.94	1.57e-14	1.64e-11	-0.4	-0.34	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-7.94	1.57e-14	1.64e-11	-0.32	-0.34	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	7.93	1.58e-14	1.65e-11	0.38	0.34	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	7.93	1.58e-14	1.65e-11	0.38	0.34	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
HNSC	cis	rs6951245	0.935	rs79067319	ENSG00000224079.1	AC091729.7	-7.93	1.58e-14	1.65e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025912	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.545	rs13311962	ENSG00000179406.6	LINC00174	7.93	1.58e-14	1.65e-11	0.52	0.34	Aortic root size;	chr7:66603142	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.528	rs801213	ENSG00000179406.6	LINC00174	7.93	1.59e-14	1.66e-11	0.52	0.34	Aortic root size;	chr7:66549931	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs801212	ENSG00000179406.6	LINC00174	7.93	1.59e-14	1.66e-11	0.52	0.34	Aortic root size;	chr7:66550643	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs801199	ENSG00000179406.6	LINC00174	7.93	1.59e-14	1.66e-11	0.52	0.34	Aortic root size;	chr7:66560286	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73152714	ENSG00000179406.6	LINC00174	-7.93	1.59e-14	1.66e-11	-0.52	-0.34	Aortic root size;	chr7:66534641	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs4718364	ENSG00000179406.6	LINC00174	-7.93	1.59e-14	1.66e-11	-0.52	-0.34	Aortic root size;	chr7:66536353	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs6961853	ENSG00000179406.6	LINC00174	-7.93	1.59e-14	1.66e-11	-0.52	-0.34	Aortic root size;	chr7:66537035	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	7.93	1.59e-14	1.66e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
HNSC	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-7.93	1.59e-14	1.66e-11	-0.4	-0.34	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
HNSC	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	7.93	1.61e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	7.93	1.61e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	7.93	1.61e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
HNSC	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-7.93	1.61e-14	1.68e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-7.93	1.61e-14	1.68e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
HNSC	cis	rs1021993	0.868	rs6674309	ENSG00000231648.1	RP11-372M18.2	-7.93	1.61e-14	1.68e-11	-0.47	-0.34	Gut microbiome composition (winter);	chr1:209357483	chr1:209367662~209379690:+
HNSC	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	7.93	1.61e-14	1.68e-11	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
HNSC	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-7.93	1.62e-14	1.69e-11	-0.33	-0.34	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-7.93	1.62e-14	1.69e-11	-0.33	-0.34	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	7.93	1.62e-14	1.69e-11	0.39	0.34	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	7.93	1.62e-14	1.69e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
HNSC	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	7.93	1.62e-14	1.69e-11	0.43	0.34	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
HNSC	cis	rs2921073	0.51	rs2976945	ENSG00000173295.6	FAM86B3P	7.93	1.63e-14	1.7e-11	0.39	0.34	Parkinson's disease;	chr8:8413361	chr8:8228595~8244865:+
HNSC	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	7.93	1.63e-14	1.7e-11	0.42	0.34	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
HNSC	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-7.93	1.63e-14	1.7e-11	-0.33	-0.34	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-7.93	1.63e-14	1.7e-11	-0.33	-0.34	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-7.93	1.64e-14	1.7e-11	-0.4	-0.34	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
HNSC	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	7.93	1.64e-14	1.71e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
HNSC	cis	rs9341808	0.718	rs35447745	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80107031	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9352801	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80107751	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9361584	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80110229	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9359408	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80110415	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9443734	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80110576	chr6:80355424~80356859:+
HNSC	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
HNSC	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	7.93	1.65e-14	1.72e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	7.93	1.65e-14	1.72e-11	0.33	0.34	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
HNSC	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	7.93	1.67e-14	1.73e-11	0.44	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
HNSC	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	7.93	1.67e-14	1.73e-11	0.43	0.34	Height;	chr6:109354092	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-7.93	1.67e-14	1.74e-11	-0.53	-0.34	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
HNSC	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	7.93	1.67e-14	1.74e-11	0.44	0.34	Height;	chr6:109506513	chr6:109382795~109383666:+
HNSC	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	7.93	1.68e-14	1.74e-11	0.52	0.34	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
HNSC	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-7.93	1.68e-14	1.75e-11	-0.4	-0.34	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
HNSC	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	7.93	1.68e-14	1.75e-11	0.33	0.34	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
HNSC	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	7.93	1.68e-14	1.75e-11	0.37	0.34	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.865	rs4478388	ENSG00000272462.2	U91328.19	-7.92	1.69e-14	1.76e-11	-0.34	-0.34	Height;	chr6:25953405	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-7.92	1.7e-14	1.76e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
HNSC	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-7.92	1.71e-14	1.77e-11	-0.4	-0.34	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	7.92	1.71e-14	1.78e-11	0.4	0.34	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.545	rs1796217	ENSG00000179406.6	LINC00174	7.92	1.71e-14	1.78e-11	0.52	0.34	Aortic root size;	chr7:66620931	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	7.92	1.72e-14	1.79e-11	0.48	0.34	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
HNSC	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-7.92	1.73e-14	1.79e-11	-0.54	-0.34	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	7.92	1.73e-14	1.79e-11	0.48	0.34	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-7.92	1.74e-14	1.8e-11	-0.4	-0.34	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
HNSC	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-7.92	1.74e-14	1.8e-11	-0.33	-0.34	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
HNSC	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.92	1.74e-14	1.8e-11	-0.41	-0.34	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
HNSC	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-7.92	1.75e-14	1.82e-11	-0.42	-0.34	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
HNSC	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
HNSC	cis	rs6867032	1	rs28392808	ENSG00000249731.1	RP11-259O2.3	7.92	1.76e-14	1.82e-11	0.41	0.34	Gut microbiome composition (winter);	chr5:2013363	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs16902318	ENSG00000249731.1	RP11-259O2.3	7.92	1.76e-14	1.82e-11	0.41	0.34	Gut microbiome composition (winter);	chr5:2013454	chr5:1968094~1969013:+
HNSC	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.92	1.77e-14	1.83e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
HNSC	cis	rs6951245	0.872	rs74360401	ENSG00000224079.1	AC091729.7	-7.92	1.77e-14	1.84e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1027767	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs118132455	ENSG00000224079.1	AC091729.7	-7.92	1.77e-14	1.84e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028596	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78628466	ENSG00000224079.1	AC091729.7	-7.92	1.77e-14	1.84e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028817	chr7:1074450~1078036:+
HNSC	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-7.92	1.79e-14	1.86e-11	-0.37	-0.34	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
HNSC	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	7.91	1.83e-14	1.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	7.91	1.83e-14	1.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
HNSC	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.91	1.83e-14	1.9e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
HNSC	cis	rs9341808	0.718	rs9352806	ENSG00000272129.1	RP11-250B2.6	7.91	1.83e-14	1.9e-11	0.41	0.34	Sitting height ratio;	chr6:80270340	chr6:80355424~80356859:+
HNSC	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	7.91	1.83e-14	1.9e-11	0.42	0.34	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
HNSC	cis	rs9341808	0.727	rs4706834	ENSG00000272129.1	RP11-250B2.6	7.91	1.84e-14	1.9e-11	0.41	0.34	Sitting height ratio;	chr6:80302888	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-7.91	1.85e-14	1.91e-11	-0.61	-0.34	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
HNSC	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-7.91	1.86e-14	1.92e-11	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	7.91	1.86e-14	1.93e-11	0.48	0.34	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	7.91	1.86e-14	1.93e-11	0.48	0.34	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
HNSC	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	7.91	1.86e-14	1.93e-11	0.35	0.34	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
HNSC	cis	rs6951245	1	rs11768761	ENSG00000224079.1	AC091729.7	-7.91	1.87e-14	1.93e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030171	chr7:1074450~1078036:+
HNSC	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	7.91	1.89e-14	1.95e-11	0.45	0.34	Height;	chr6:109446727	chr6:109382795~109383666:+
HNSC	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	7.91	1.89e-14	1.96e-11	0.37	0.34	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
HNSC	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-7.91	1.89e-14	1.96e-11	-0.37	-0.34	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
HNSC	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-7.91	1.9e-14	1.96e-11	-0.43	-0.34	Height;	chr6:109360458	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	7.91	1.9e-14	1.96e-11	0.47	0.34	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-7.91	1.9e-14	1.96e-11	-0.37	-0.34	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
HNSC	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-7.91	1.91e-14	1.97e-11	-0.37	-0.34	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
HNSC	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-7.91	1.91e-14	1.97e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	7.91	1.91e-14	1.97e-11	0.49	0.34	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	7.91	1.91e-14	1.97e-11	0.49	0.34	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
HNSC	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	7.91	1.91e-14	1.98e-11	0.39	0.34	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
HNSC	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-7.91	1.92e-14	1.98e-11	-0.45	-0.34	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
HNSC	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-7.91	1.92e-14	1.98e-11	-0.42	-0.34	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
HNSC	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-7.91	1.92e-14	1.98e-11	-0.42	-0.34	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
HNSC	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	7.91	1.94e-14	2e-11	0.32	0.34	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
HNSC	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	7.9	1.95e-14	2.01e-11	0.43	0.34	Height;	chr6:109370741	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	7.9	1.95e-14	2.01e-11	0.43	0.34	Height;	chr6:109371524	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-7.9	1.95e-14	2.01e-11	-0.41	-0.34	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
HNSC	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-7.9	1.95e-14	2.02e-11	-0.38	-0.34	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
HNSC	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-7.9	1.95e-14	2.02e-11	-0.49	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
HNSC	cis	rs6969780	0.722	rs983185	ENSG00000233429.8	HOTAIRM1	-7.9	1.96e-14	2.02e-11	-0.44	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27148988	chr7:27095647~27100265:+
HNSC	cis	rs1865760	0.713	rs1130000	ENSG00000272462.2	U91328.19	-7.9	1.96e-14	2.02e-11	-0.34	-0.34	Height;	chr6:25985168	chr6:25992662~26001775:+
HNSC	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	7.9	1.96e-14	2.02e-11	0.42	0.34	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
HNSC	cis	rs35955747	0.659	rs11704494	ENSG00000236132.1	CTA-440B3.1	7.9	1.97e-14	2.03e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31517285	chr22:31816379~31817491:-
HNSC	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	7.9	1.99e-14	2.05e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
HNSC	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-7.9	1.99e-14	2.05e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
HNSC	cis	rs4713118	0.5	rs9461434	ENSG00000219392.1	RP1-265C24.5	-7.9	1.99e-14	2.05e-11	-0.49	-0.34	Parkinson's disease;	chr6:28134687	chr6:28115628~28116551:+
HNSC	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.9	1.99e-14	2.06e-11	-0.38	-0.34	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
HNSC	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-7.9	2e-14	2.06e-11	-0.38	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	7.9	2e-14	2.06e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
HNSC	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	7.9	2.02e-14	2.08e-11	0.45	0.34	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
HNSC	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.9	2.03e-14	2.09e-11	0.38	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
HNSC	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	7.9	2.03e-14	2.09e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs6460281	ENSG00000179406.6	LINC00174	-7.9	2.03e-14	2.09e-11	-0.52	-0.34	Aortic root size;	chr7:66216128	chr7:66376044~66401338:-
HNSC	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.9	2.03e-14	2.09e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
HNSC	cis	rs6969780	0.63	rs10238095	ENSG00000233429.8	HOTAIRM1	-7.9	2.04e-14	2.1e-11	-0.44	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157024	chr7:27095647~27100265:+
HNSC	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	7.9	2.04e-14	2.1e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	7.9	2.04e-14	2.1e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
HNSC	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	7.9	2.04e-14	2.1e-11	0.39	0.34	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.545	rs10950036	ENSG00000179406.6	LINC00174	-7.9	2.05e-14	2.11e-11	-0.52	-0.34	Aortic root size;	chr7:66353241	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
HNSC	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	7.9	2.06e-14	2.12e-11	0.44	0.34	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
HNSC	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	7.9	2.07e-14	2.12e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	7.9	2.07e-14	2.13e-11	0.47	0.34	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
HNSC	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-7.9	2.07e-14	2.13e-11	-0.42	-0.34	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
HNSC	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	7.9	2.07e-14	2.13e-11	0.36	0.34	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	7.89	2.1e-14	2.16e-11	0.37	0.34	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
HNSC	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-7.89	2.1e-14	2.16e-11	-0.47	-0.34	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
HNSC	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	7.89	2.1e-14	2.16e-11	0.39	0.34	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
HNSC	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
HNSC	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	7.89	2.12e-14	2.18e-11	0.36	0.34	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	7.89	2.12e-14	2.18e-11	0.47	0.34	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
HNSC	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-7.89	2.13e-14	2.18e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
HNSC	cis	rs7048146	0.932	rs1576590	ENSG00000213539.4	YBX1P6	7.89	2.13e-14	2.19e-11	0.41	0.34	Vascular brain injury;	chr9:109542883	chr9:109532830~109534332:-
HNSC	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-7.89	2.14e-14	2.2e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
HNSC	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-7.89	2.14e-14	2.2e-11	-0.42	-0.34	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-7.89	2.14e-14	2.2e-11	-0.48	-0.34	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	7.89	2.15e-14	2.2e-11	0.33	0.34	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-7.89	2.15e-14	2.2e-11	-0.52	-0.34	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-7.89	2.16e-14	2.22e-11	-0.33	-0.34	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-7.89	2.17e-14	2.22e-11	-0.47	-0.34	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	7.89	2.17e-14	2.23e-11	0.34	0.34	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
HNSC	cis	rs7048146	0.966	rs1576591	ENSG00000213539.4	YBX1P6	7.89	2.18e-14	2.23e-11	0.4	0.34	Vascular brain injury;	chr9:109542724	chr9:109532830~109534332:-
HNSC	cis	rs867371	0.929	rs7176075	ENSG00000276710.3	CSPG4P8	-7.89	2.19e-14	2.24e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs8041868	ENSG00000276710.3	CSPG4P8	-7.89	2.19e-14	2.24e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82459472~82477258:+
HNSC	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-7.89	2.19e-14	2.25e-11	-0.36	-0.34	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-7.89	2.2e-14	2.25e-11	-0.37	-0.34	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	7.89	2.21e-14	2.26e-11	0.41	0.34	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
HNSC	cis	rs1865760	0.566	rs9366634	ENSG00000272462.2	U91328.19	-7.89	2.21e-14	2.26e-11	-0.34	-0.34	Height;	chr6:26072168	chr6:25992662~26001775:+
HNSC	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	7.89	2.22e-14	2.27e-11	0.4	0.34	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
HNSC	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-7.89	2.22e-14	2.27e-11	-0.43	-0.34	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
HNSC	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-7.89	2.22e-14	2.28e-11	-0.43	-0.34	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	7.89	2.23e-14	2.28e-11	0.48	0.34	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	7.89	2.23e-14	2.28e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
HNSC	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	7.89	2.23e-14	2.29e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	7.88	2.25e-14	2.3e-11	0.48	0.34	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
HNSC	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	7.88	2.25e-14	2.3e-11	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
HNSC	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-7.88	2.26e-14	2.31e-11	-0.37	-0.34	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
HNSC	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	7.88	2.26e-14	2.31e-11	0.43	0.34	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
HNSC	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-7.88	2.26e-14	2.31e-11	-0.33	-0.34	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-7.88	2.26e-14	2.31e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	7.88	2.27e-14	2.32e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	7.88	2.29e-14	2.33e-11	0.45	0.34	Height;	chr6:109546439	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.754	rs9294173	ENSG00000272129.1	RP11-250B2.6	7.88	2.29e-14	2.34e-11	0.41	0.34	Sitting height ratio;	chr6:80281913	chr6:80355424~80356859:+
HNSC	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	7.88	2.3e-14	2.34e-11	0.37	0.34	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	7.88	2.3e-14	2.34e-11	0.37	0.34	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	7.88	2.3e-14	2.34e-11	0.37	0.34	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
HNSC	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
HNSC	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-7.88	2.3e-14	2.35e-11	-0.46	-0.34	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
HNSC	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	7.88	2.3e-14	2.35e-11	0.35	0.34	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
HNSC	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-7.88	2.31e-14	2.35e-11	-0.37	-0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
HNSC	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	7.88	2.31e-14	2.36e-11	0.44	0.34	Height;	chr6:109501402	chr6:109382795~109383666:+
HNSC	cis	rs7404843	1	rs7404843	ENSG00000263065.1	AF001548.6	-7.88	2.32e-14	2.37e-11	-0.63	-0.34	Testicular germ cell tumor;	chr16:15436851	chr16:15741151~15741791:+
HNSC	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	7.88	2.32e-14	2.37e-11	0.37	0.34	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
HNSC	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-7.88	2.32e-14	2.37e-11	-0.37	-0.34	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
HNSC	cis	rs7048146	1	rs1411690	ENSG00000213539.4	YBX1P6	7.88	2.33e-14	2.38e-11	0.4	0.34	Vascular brain injury;	chr9:109542827	chr9:109532830~109534332:-
HNSC	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	7.88	2.34e-14	2.38e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
HNSC	cis	rs12922040	0.701	rs12149912	ENSG00000263065.1	AF001548.6	-7.88	2.34e-14	2.38e-11	-0.39	-0.34	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15741151~15741791:+
HNSC	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-7.88	2.35e-14	2.39e-11	-0.41	-0.34	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
HNSC	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	7.88	2.35e-14	2.4e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
HNSC	cis	rs7404843	0.925	rs72774861	ENSG00000263065.1	AF001548.6	7.88	2.35e-14	2.4e-11	0.63	0.34	Testicular germ cell tumor;	chr16:15415777	chr16:15741151~15741791:+
HNSC	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	7.88	2.36e-14	2.4e-11	0.35	0.34	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-7.88	2.36e-14	2.4e-11	-0.33	-0.34	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	7.88	2.37e-14	2.41e-11	0.32	0.34	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000173295.6	FAM86B3P	7.88	2.37e-14	2.41e-11	0.39	0.34	Joint mobility (Beighton score);	chr8:9001207	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	7.88	2.38e-14	2.42e-11	0.46	0.34	Height;	chr6:109732518	chr6:109382795~109383666:+
HNSC	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	7.88	2.38e-14	2.42e-11	0.39	0.34	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
HNSC	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-7.88	2.38e-14	2.43e-11	-0.36	-0.34	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-7.88	2.39e-14	2.44e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	7.88	2.4e-14	2.44e-11	0.48	0.34	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
HNSC	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	7.88	2.4e-14	2.44e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	7.88	2.4e-14	2.44e-11	0.36	0.34	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	7.88	2.41e-14	2.45e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
HNSC	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	7.87	2.41e-14	2.45e-11	0.45	0.34	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
HNSC	cis	rs867371	1	rs8041924	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs2088858	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs4778982	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs2867579	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs881308	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82459472~82477258:+
HNSC	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	7.87	2.41e-14	2.45e-11	0.36	0.34	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	7.87	2.42e-14	2.46e-11	0.36	0.34	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	7.87	2.42e-14	2.46e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
HNSC	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	7.87	2.42e-14	2.46e-11	0.39	0.34	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	7.87	2.42e-14	2.46e-11	0.39	0.34	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
HNSC	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	7.87	2.42e-14	2.46e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
HNSC	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	7.87	2.43e-14	2.46e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
HNSC	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	7.87	2.43e-14	2.47e-11	0.32	0.34	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-7.87	2.43e-14	2.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-7.87	2.43e-14	2.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
HNSC	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-7.87	2.43e-14	2.47e-11	-0.34	-0.34	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.571	rs160641	ENSG00000179406.6	LINC00174	7.87	2.44e-14	2.48e-11	0.52	0.34	Aortic root size;	chr7:66112359	chr7:66376044~66401338:-
HNSC	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-7.87	2.45e-14	2.48e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
HNSC	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-7.87	2.45e-14	2.49e-11	-0.36	-0.34	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-7.87	2.46e-14	2.5e-11	-0.32	-0.34	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
HNSC	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	7.87	2.47e-14	2.51e-11	0.37	0.34	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
HNSC	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-7.87	2.48e-14	2.51e-11	-0.44	-0.34	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	7.87	2.49e-14	2.52e-11	0.47	0.34	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
HNSC	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	7.87	2.5e-14	2.53e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
HNSC	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	7.87	2.5e-14	2.54e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
HNSC	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-7.87	2.51e-14	2.55e-11	-0.34	-0.34	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	7.87	2.52e-14	2.56e-11	0.47	0.34	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-7.87	2.54e-14	2.57e-11	-0.38	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	7.87	2.54e-14	2.57e-11	0.47	0.34	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	7.87	2.55e-14	2.58e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
HNSC	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	7.87	2.56e-14	2.59e-11	0.44	0.34	Height;	chr6:109501429	chr6:109382795~109383666:+
HNSC	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	7.87	2.57e-14	2.6e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
HNSC	cis	rs9341808	0.754	rs9352808	ENSG00000272129.1	RP11-250B2.6	7.87	2.58e-14	2.61e-11	0.41	0.34	Sitting height ratio;	chr6:80287625	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-7.86	2.59e-14	2.62e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
HNSC	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-7.86	2.59e-14	2.62e-11	-0.42	-0.34	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
HNSC	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-7.86	2.59e-14	2.62e-11	-0.42	-0.34	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
HNSC	cis	rs454422	0.812	rs236118	ENSG00000275632.1	RP5-967N21.11	7.86	2.6e-14	2.63e-11	0.37	0.34	HIV-1 viral setpoint;	chr20:5957561	chr20:6000418~6000941:+
HNSC	cis	rs35955747	0.633	rs7287937	ENSG00000236132.1	CTA-440B3.1	7.86	2.61e-14	2.63e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31624759	chr22:31816379~31817491:-
HNSC	cis	rs9341808	0.754	rs9341810	ENSG00000272129.1	RP11-250B2.6	7.86	2.61e-14	2.64e-11	0.41	0.34	Sitting height ratio;	chr6:80265121	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.7	rs12215236	ENSG00000272129.1	RP11-250B2.6	7.86	2.61e-14	2.64e-11	0.41	0.34	Sitting height ratio;	chr6:80265341	chr6:80355424~80356859:+
HNSC	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	7.86	2.61e-14	2.64e-11	0.53	0.34	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
HNSC	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	7.86	2.62e-14	2.65e-11	0.32	0.34	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	7.86	2.63e-14	2.66e-11	0.47	0.34	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	7.86	2.63e-14	2.66e-11	0.47	0.34	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
HNSC	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-7.86	2.63e-14	2.66e-11	-0.37	-0.34	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
HNSC	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	7.86	2.64e-14	2.66e-11	0.4	0.34	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
HNSC	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-7.86	2.64e-14	2.67e-11	-0.35	-0.34	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-7.86	2.64e-14	2.67e-11	-0.35	-0.34	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
HNSC	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-7.86	2.64e-14	2.67e-11	-0.4	-0.34	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.545	rs1267814	ENSG00000179406.6	LINC00174	7.86	2.64e-14	2.67e-11	0.51	0.34	Aortic root size;	chr7:66579422	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	7.86	2.65e-14	2.68e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
HNSC	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	7.86	2.65e-14	2.68e-11	0.36	0.34	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
HNSC	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-7.86	2.66e-14	2.68e-11	-0.38	-0.34	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
HNSC	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	7.86	2.66e-14	2.69e-11	0.35	0.34	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
HNSC	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	7.86	2.67e-14	2.69e-11	0.37	0.34	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
HNSC	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-7.86	2.67e-14	2.7e-11	-0.41	-0.34	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
HNSC	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	7.86	2.68e-14	2.7e-11	0.39	0.34	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
HNSC	cis	rs36423	0.528	rs1205066	ENSG00000266869.1	RP6-114E22.1	7.86	2.69e-14	2.71e-11	0.57	0.34	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71880340	chr14:71848606~71908430:+
HNSC	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-7.86	2.69e-14	2.71e-11	-0.4	-0.34	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	7.86	2.7e-14	2.72e-11	0.32	0.34	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	7.86	2.7e-14	2.73e-11	0.47	0.34	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-7.86	2.7e-14	2.73e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
HNSC	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-7.86	2.71e-14	2.73e-11	-0.5	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
HNSC	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	7.86	2.74e-14	2.76e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
HNSC	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	7.86	2.75e-14	2.77e-11	0.45	0.34	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
HNSC	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-7.86	2.76e-14	2.77e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
HNSC	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	7.86	2.76e-14	2.78e-11	0.41	0.34	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	7.86	2.76e-14	2.78e-11	0.47	0.34	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	7.86	2.76e-14	2.78e-11	0.47	0.34	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	7.86	2.77e-14	2.79e-11	0.24	0.34	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
HNSC	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	7.85	2.77e-14	2.79e-11	0.39	0.34	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
HNSC	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	7.85	2.77e-14	2.79e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	7.85	2.78e-14	2.79e-11	0.32	0.34	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	7.85	2.78e-14	2.79e-11	0.32	0.34	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
HNSC	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	7.85	2.79e-14	2.81e-11	0.48	0.34	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-7.85	2.79e-14	2.81e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
HNSC	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-7.85	2.8e-14	2.81e-11	-0.4	-0.34	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
HNSC	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	7.85	2.8e-14	2.81e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
HNSC	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-7.85	2.8e-14	2.82e-11	-0.39	-0.34	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
HNSC	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	7.85	2.8e-14	2.82e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	7.85	2.8e-14	2.82e-11	0.47	0.34	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	7.85	2.81e-14	2.83e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
HNSC	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-7.85	2.83e-14	2.84e-11	-0.47	-0.34	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
HNSC	cis	rs6969780	0.524	rs12530948	ENSG00000233429.8	HOTAIRM1	-7.85	2.83e-14	2.85e-11	-0.48	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161639	chr7:27095647~27100265:+
HNSC	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	7.85	2.83e-14	2.85e-11	0.45	0.34	Height;	chr6:109738307	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	7.85	2.83e-14	2.85e-11	0.45	0.34	Height;	chr6:109738751	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	7.85	2.84e-14	2.85e-11	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	7.85	2.84e-14	2.85e-11	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	7.85	2.84e-14	2.85e-11	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
HNSC	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-7.85	2.84e-14	2.85e-11	-0.35	-0.34	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
HNSC	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	7.85	2.84e-14	2.85e-11	0.57	0.34	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
HNSC	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-7.85	2.84e-14	2.85e-11	-0.33	-0.34	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
HNSC	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-7.85	2.85e-14	2.86e-11	-0.39	-0.34	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
HNSC	cis	rs6951245	1	rs76833820	ENSG00000224079.1	AC091729.7	-7.85	2.85e-14	2.86e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030642	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs28379681	ENSG00000224079.1	AC091729.7	-7.85	2.85e-14	2.86e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030903	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs28399710	ENSG00000224079.1	AC091729.7	-7.85	2.85e-14	2.86e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030995	chr7:1074450~1078036:+
HNSC	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	7.85	2.86e-14	2.87e-11	0.39	0.34	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
HNSC	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	7.85	2.86e-14	2.87e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	7.85	2.87e-14	2.88e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
HNSC	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-7.85	2.88e-14	2.89e-11	-0.56	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
HNSC	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-7.85	2.88e-14	2.89e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
HNSC	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	7.85	2.88e-14	2.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	7.85	2.88e-14	2.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	7.85	2.88e-14	2.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
HNSC	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	7.85	2.89e-14	2.89e-11	0.47	0.34	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	7.85	2.89e-14	2.89e-11	0.47	0.34	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	7.85	2.9e-14	2.91e-11	0.4	0.34	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
HNSC	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-7.85	2.92e-14	2.92e-11	-0.53	-0.34	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
HNSC	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-7.85	2.92e-14	2.93e-11	-0.45	-0.34	Height;	chr6:109731677	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
HNSC	cis	rs1021993	0.868	rs6674103	ENSG00000231648.1	RP11-372M18.2	-7.85	2.93e-14	2.94e-11	-0.46	-0.34	Gut microbiome composition (winter);	chr1:209357293	chr1:209367662~209379690:+
HNSC	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	7.85	2.94e-14	2.94e-11	0.47	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
HNSC	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	7.85	2.95e-14	2.96e-11	0.4	0.34	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	7.85	2.95e-14	2.96e-11	0.4	0.34	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	7.85	2.95e-14	2.96e-11	0.4	0.34	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
HNSC	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	7.85	2.96e-14	2.96e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
HNSC	cis	rs2579103	0.507	rs1371082	ENSG00000258183.4	RP11-753N8.1	-7.85	2.96e-14	2.96e-11	-0.4	-0.34	Body mass index;	chr12:90288307	chr12:90280894~90300340:+
HNSC	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
HNSC	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	7.84	2.99e-14	2.99e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	7.84	3e-14	3e-11	0.47	0.34	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	7.84	3.01e-14	3.01e-11	0.47	0.34	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
HNSC	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-7.84	3.01e-14	3.01e-11	-0.42	-0.34	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
HNSC	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	7.84	3.03e-14	3.03e-11	0.47	0.34	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
HNSC	cis	rs35955747	0.677	rs4820974	ENSG00000236132.1	CTA-440B3.1	7.84	3.03e-14	3.03e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31473481	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	7.84	3.06e-14	3.05e-11	0.47	0.34	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-7.84	3.06e-14	3.05e-11	-0.39	-0.34	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
HNSC	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	7.84	3.07e-14	3.06e-11	0.4	0.34	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-7.84	3.09e-14	3.08e-11	-0.4	-0.34	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
HNSC	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-7.84	3.09e-14	3.08e-11	-0.47	-0.34	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
HNSC	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-7.84	3.09e-14	3.08e-11	-0.49	-0.34	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000173295.6	FAM86B3P	7.84	3.1e-14	3.09e-11	0.37	0.34	Neuroticism;	chr8:8460377	chr8:8228595~8244865:+
HNSC	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	7.84	3.1e-14	3.1e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-7.84	3.11e-14	3.1e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	7.84	3.13e-14	3.12e-11	0.45	0.34	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
HNSC	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-7.84	3.13e-14	3.12e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	7.84	3.14e-14	3.13e-11	0.48	0.34	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
HNSC	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-7.84	3.16e-14	3.15e-11	-0.51	-0.34	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
HNSC	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-7.84	3.18e-14	3.17e-11	-0.33	-0.34	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
HNSC	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	7.83	3.2e-14	3.18e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
HNSC	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-7.83	3.2e-14	3.19e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000235689.1	AP000351.13	7.83	3.22e-14	3.21e-11	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:24006305~24008258:-
HNSC	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	7.83	3.22e-14	3.21e-11	0.44	0.34	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
HNSC	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	7.83	3.23e-14	3.21e-11	0.44	0.34	Height;	chr6:109357369	chr6:109382795~109383666:+
HNSC	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-7.83	3.23e-14	3.22e-11	-0.34	-0.34	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
HNSC	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-7.83	3.23e-14	3.22e-11	-0.41	-0.34	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
HNSC	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109608105	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109618620	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109620772	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109634150	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109640141	chr6:109382795~109383666:+
HNSC	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	7.83	3.25e-14	3.23e-11	0.41	0.34	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
HNSC	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-7.83	3.27e-14	3.25e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-7.83	3.31e-14	3.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-7.83	3.31e-14	3.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
HNSC	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	7.83	3.31e-14	3.29e-11	0.39	0.34	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	7.83	3.31e-14	3.29e-11	0.39	0.34	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	7.83	3.31e-14	3.29e-11	0.36	0.34	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	7.83	3.31e-14	3.29e-11	0.36	0.34	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
HNSC	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	7.83	3.31e-14	3.29e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	7.83	3.31e-14	3.29e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
HNSC	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	7.83	3.32e-14	3.3e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	7.83	3.32e-14	3.3e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
HNSC	cis	rs867371	0.964	rs7169961	ENSG00000276710.3	CSPG4P8	-7.83	3.32e-14	3.3e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs6495643	ENSG00000276710.3	CSPG4P8	-7.83	3.32e-14	3.3e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82459472~82477258:+
HNSC	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-7.83	3.32e-14	3.3e-11	-0.38	-0.34	Migraine;	chr4:56879297	chr4:56960927~56961373:-
HNSC	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.83	3.33e-14	3.3e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
HNSC	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
HNSC	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-7.83	3.34e-14	3.32e-11	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
HNSC	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-7.83	3.35e-14	3.32e-11	-0.33	-0.34	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	7.83	3.35e-14	3.32e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-7.83	3.36e-14	3.33e-11	-0.36	-0.34	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
HNSC	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	7.83	3.36e-14	3.34e-11	0.44	0.34	Height;	chr6:109551060	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	7.83	3.38e-14	3.35e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-7.83	3.38e-14	3.35e-11	-0.32	-0.34	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-7.83	3.38e-14	3.35e-11	-0.32	-0.34	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
HNSC	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-7.83	3.38e-14	3.35e-11	-0.37	-0.34	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
HNSC	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-7.83	3.39e-14	3.36e-11	-0.42	-0.34	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
HNSC	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-7.83	3.41e-14	3.37e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
HNSC	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-7.83	3.41e-14	3.38e-11	-0.36	-0.34	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
HNSC	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	7.83	3.42e-14	3.39e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
HNSC	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	7.82	3.42e-14	3.39e-11	0.39	0.34	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-7.82	3.43e-14	3.4e-11	-0.39	-0.34	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
HNSC	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-7.82	3.45e-14	3.41e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	7.82	3.45e-14	3.42e-11	0.32	0.34	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-7.82	3.46e-14	3.43e-11	-0.25	-0.34	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	7.82	3.46e-14	3.43e-11	0.47	0.34	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	7.82	3.46e-14	3.43e-11	0.47	0.34	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs12671152	ENSG00000179406.6	LINC00174	-7.82	3.47e-14	3.43e-11	-0.54	-0.34	Aortic root size;	chr7:66311140	chr7:66376044~66401338:-
HNSC	cis	rs867371	1	rs1846911	ENSG00000276710.3	CSPG4P8	-7.82	3.48e-14	3.44e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82459472~82477258:+
HNSC	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-7.82	3.51e-14	3.47e-11	-0.32	-0.34	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	7.82	3.52e-14	3.48e-11	0.39	0.34	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
HNSC	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	7.82	3.53e-14	3.49e-11	0.37	0.34	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
HNSC	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-7.82	3.54e-14	3.49e-11	-0.33	-0.34	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
HNSC	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	7.82	3.54e-14	3.5e-11	0.39	0.34	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-7.82	3.56e-14	3.52e-11	-0.4	-0.34	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-7.82	3.56e-14	3.52e-11	-0.4	-0.34	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
HNSC	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-7.82	3.57e-14	3.53e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
HNSC	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	7.82	3.58e-14	3.53e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
HNSC	cis	rs6951245	1	rs28528096	ENSG00000224079.1	AC091729.7	-7.82	3.58e-14	3.54e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031276	chr7:1074450~1078036:+
HNSC	cis	rs7615952	1	rs9289275	ENSG00000241288.6	RP11-379B18.5	-7.82	3.58e-14	3.54e-11	-0.48	-0.34	Blood pressure (smoking interaction);	chr3:125929816	chr3:125827238~125916384:-
HNSC	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	7.82	3.58e-14	3.54e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
HNSC	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-7.82	3.59e-14	3.54e-11	-0.36	-0.34	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
HNSC	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	7.82	3.59e-14	3.54e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-7.82	3.59e-14	3.55e-11	-0.44	-0.34	Height;	chr6:109531713	chr6:109382795~109383666:+
HNSC	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	7.82	3.59e-14	3.55e-11	0.45	0.34	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
HNSC	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	7.82	3.59e-14	3.55e-11	0.45	0.34	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
HNSC	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	7.82	3.6e-14	3.55e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
HNSC	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	7.82	3.6e-14	3.55e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
HNSC	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	7.82	3.6e-14	3.55e-11	0.42	0.34	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
HNSC	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-7.82	3.61e-14	3.56e-11	-0.4	-0.34	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
HNSC	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-7.82	3.61e-14	3.57e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
HNSC	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-7.82	3.62e-14	3.58e-11	-0.4	-0.34	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.545	rs313828	ENSG00000179406.6	LINC00174	7.82	3.63e-14	3.58e-11	0.53	0.34	Aortic root size;	chr7:66087627	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.571	rs160647	ENSG00000179406.6	LINC00174	7.82	3.63e-14	3.58e-11	0.53	0.34	Aortic root size;	chr7:66089365	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	7.82	3.63e-14	3.58e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
HNSC	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-7.82	3.64e-14	3.59e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
HNSC	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	7.82	3.65e-14	3.6e-11	0.36	0.34	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	7.82	3.65e-14	3.6e-11	0.36	0.34	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	7.82	3.65e-14	3.6e-11	0.36	0.34	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	7.82	3.65e-14	3.6e-11	0.47	0.34	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	7.82	3.65e-14	3.6e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
HNSC	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-7.82	3.65e-14	3.6e-11	-0.87	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
HNSC	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	7.82	3.66e-14	3.6e-11	0.41	0.34	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	7.82	3.66e-14	3.6e-11	0.44	0.34	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
HNSC	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-7.82	3.66e-14	3.61e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
HNSC	cis	rs35955747	0.633	rs1916	ENSG00000236132.1	CTA-440B3.1	-7.82	3.67e-14	3.61e-11	-0.37	-0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31496135	chr22:31816379~31817491:-
HNSC	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	7.81	3.67e-14	3.62e-11	0.4	0.34	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
HNSC	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-7.81	3.68e-14	3.62e-11	-0.4	-0.34	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-7.81	3.68e-14	3.62e-11	-0.4	-0.34	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
HNSC	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	7.81	3.68e-14	3.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	7.81	3.71e-14	3.66e-11	0.47	0.34	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	7.81	3.71e-14	3.66e-11	0.47	0.34	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	7.81	3.71e-14	3.66e-11	0.47	0.34	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
HNSC	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	7.81	3.71e-14	3.66e-11	0.42	0.34	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
HNSC	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	7.81	3.72e-14	3.66e-11	0.45	0.34	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
HNSC	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	7.81	3.72e-14	3.66e-11	0.36	0.34	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	7.81	3.72e-14	3.66e-11	0.36	0.34	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
HNSC	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-7.81	3.73e-14	3.67e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-7.81	3.73e-14	3.67e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	7.81	3.73e-14	3.67e-11	0.32	0.34	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
HNSC	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-7.81	3.75e-14	3.68e-11	-0.36	-0.34	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-7.81	3.75e-14	3.68e-11	-0.36	-0.34	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
HNSC	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-7.81	3.75e-14	3.69e-11	-0.43	-0.34	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	7.81	3.78e-14	3.71e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	7.81	3.78e-14	3.71e-11	0.45	0.34	Height;	chr6:109739615	chr6:109382795~109383666:+
HNSC	cis	rs440932	0.887	rs398801	ENSG00000254340.1	RP11-10A14.3	-7.81	3.78e-14	3.71e-11	-0.45	-0.34	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9141424~9145435:+
HNSC	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.81	3.79e-14	3.73e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	7.81	3.8e-14	3.74e-11	0.47	0.34	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	7.81	3.8e-14	3.74e-11	0.47	0.34	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	7.81	3.8e-14	3.74e-11	0.46	0.34	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
HNSC	cis	rs1865760	0.865	rs9393677	ENSG00000272462.2	U91328.19	-7.81	3.81e-14	3.74e-11	-0.34	-0.34	Height;	chr6:25945587	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9393678	ENSG00000272462.2	U91328.19	-7.81	3.81e-14	3.74e-11	-0.34	-0.34	Height;	chr6:25945591	chr6:25992662~26001775:+
HNSC	cis	rs9595066	0.627	rs9562538	ENSG00000227258.4	SMIM2-AS1	7.81	3.82e-14	3.75e-11	0.59	0.34	Schizophrenia;	chr13:44183532	chr13:44110451~44240517:+
HNSC	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	7.81	3.82e-14	3.75e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	7.81	3.83e-14	3.76e-11	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
HNSC	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	7.81	3.83e-14	3.76e-11	0.4	0.34	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-7.81	3.84e-14	3.77e-11	-0.32	-0.34	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
HNSC	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-7.81	3.86e-14	3.79e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
HNSC	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	7.81	3.88e-14	3.81e-11	0.4	0.34	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
HNSC	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	7.81	3.9e-14	3.83e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
HNSC	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-7.81	3.9e-14	3.83e-11	-0.32	-0.34	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
HNSC	cis	rs6951245	0.935	rs112554101	ENSG00000224079.1	AC091729.7	-7.81	3.91e-14	3.84e-11	-0.54	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1074450~1078036:+
HNSC	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	7.81	3.92e-14	3.85e-11	0.38	0.34	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	7.81	3.92e-14	3.85e-11	0.38	0.34	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-7.8	3.95e-14	3.88e-11	-0.33	-0.34	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	7.8	3.96e-14	3.88e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	7.8	3.96e-14	3.88e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
HNSC	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	7.8	3.96e-14	3.88e-11	0.42	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
HNSC	cis	rs875971	0.545	rs6979636	ENSG00000179406.6	LINC00174	-7.8	3.98e-14	3.91e-11	-0.52	-0.34	Aortic root size;	chr7:66276638	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73148639	ENSG00000179406.6	LINC00174	-7.8	4e-14	3.92e-11	-0.51	-0.34	Aortic root size;	chr7:66390342	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs35459055	ENSG00000179406.6	LINC00174	-7.8	4e-14	3.92e-11	-0.51	-0.34	Aortic root size;	chr7:66479399	chr7:66376044~66401338:-
HNSC	cis	rs6951245	1	rs76804143	ENSG00000224079.1	AC091729.7	-7.8	4e-14	3.92e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1074450~1078036:+
HNSC	cis	rs867371	1	rs8037224	ENSG00000276710.3	CSPG4P8	-7.8	4e-14	3.92e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82459472~82477258:+
HNSC	cis	rs34375054	0.752	rs12582808	ENSG00000279233.1	RP11-158L12.4	7.8	4.01e-14	3.93e-11	0.41	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125176913	chr12:125138245~125141711:+
HNSC	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	7.8	4.01e-14	3.93e-11	0.39	0.34	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
HNSC	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	7.8	4.02e-14	3.93e-11	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.545	rs313830	ENSG00000179406.6	LINC00174	7.8	4.02e-14	3.94e-11	0.53	0.34	Aortic root size;	chr7:66086944	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-7.8	4.02e-14	3.94e-11	-0.32	-0.34	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
HNSC	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-7.8	4.02e-14	3.94e-11	-0.41	-0.34	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
HNSC	cis	rs7404843	0.925	rs72774861	ENSG00000263335.1	AF001548.5	7.8	4.04e-14	3.95e-11	0.68	0.34	Testicular germ cell tumor;	chr16:15415777	chr16:15726674~15732993:+
HNSC	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	7.8	4.04e-14	3.95e-11	0.45	0.34	Height;	chr6:109693890	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	7.8	4.04e-14	3.95e-11	0.45	0.34	Height;	chr6:109694672	chr6:109382795~109383666:+
HNSC	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	7.8	4.04e-14	3.95e-11	0.48	0.34	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
HNSC	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	7.8	4.05e-14	3.96e-11	0.43	0.34	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
HNSC	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	7.8	4.05e-14	3.96e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
HNSC	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-7.8	4.06e-14	3.97e-11	-0.33	-0.34	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
HNSC	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	7.8	4.06e-14	3.98e-11	0.48	0.34	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	7.8	4.06e-14	3.98e-11	0.23	0.34	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
HNSC	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	7.8	4.07e-14	3.98e-11	0.36	0.34	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
HNSC	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-7.8	4.07e-14	3.99e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
HNSC	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	7.8	4.07e-14	3.99e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
HNSC	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	7.8	4.07e-14	3.99e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
HNSC	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000254340.1	RP11-10A14.3	-7.8	4.08e-14	3.99e-11	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9037960	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	7.8	4.09e-14	4e-11	0.32	0.34	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
HNSC	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	7.8	4.1e-14	4.01e-11	0.36	0.34	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	7.8	4.1e-14	4.01e-11	0.36	0.34	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	7.8	4.1e-14	4.01e-11	0.36	0.34	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
HNSC	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	7.8	4.11e-14	4.02e-11	0.47	0.34	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	7.8	4.11e-14	4.02e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-7.8	4.11e-14	4.02e-11	-0.35	-0.34	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
HNSC	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-7.8	4.14e-14	4.04e-11	-0.41	-0.34	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
HNSC	cis	rs875971	0.545	rs4718325	ENSG00000179406.6	LINC00174	-7.8	4.15e-14	4.06e-11	-0.52	-0.34	Aortic root size;	chr7:66215323	chr7:66376044~66401338:-
HNSC	cis	rs6867032	1	rs16902321	ENSG00000249731.1	RP11-259O2.3	7.8	4.17e-14	4.08e-11	0.4	0.34	Gut microbiome composition (winter);	chr5:2015034	chr5:1968094~1969013:+
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	7.8	4.18e-14	4.09e-11	0.48	0.34	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	7.8	4.18e-14	4.09e-11	0.48	0.34	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	7.8	4.18e-14	4.09e-11	0.47	0.34	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
HNSC	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	7.8	4.19e-14	4.09e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
HNSC	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	7.8	4.19e-14	4.09e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
HNSC	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-7.8	4.19e-14	4.09e-11	-0.35	-0.34	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	7.8	4.19e-14	4.09e-11	0.32	0.34	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	7.8	4.19e-14	4.09e-11	0.32	0.34	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	7.8	4.21e-14	4.11e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	7.79	4.23e-14	4.13e-11	0.36	0.34	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-7.79	4.23e-14	4.13e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	7.79	4.24e-14	4.14e-11	0.47	0.34	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
HNSC	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	7.79	4.25e-14	4.14e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	-7.79	4.25e-14	4.15e-11	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
HNSC	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-7.79	4.28e-14	4.18e-11	-0.39	-0.34	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	7.79	4.28e-14	4.18e-11	0.48	0.34	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	7.79	4.29e-14	4.19e-11	0.35	0.34	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
HNSC	cis	rs6951245	1	rs74369356	ENSG00000224079.1	AC091729.7	-7.79	4.3e-14	4.19e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032075	chr7:1074450~1078036:+
HNSC	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	7.79	4.31e-14	4.2e-11	0.35	0.34	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-7.79	4.31e-14	4.21e-11	-0.39	-0.34	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	7.79	4.32e-14	4.21e-11	0.55	0.34	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	7.79	4.34e-14	4.23e-11	0.32	0.34	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
HNSC	cis	rs9402743	0.775	rs12198378	ENSG00000217482.2	HMGB1P17	7.79	4.34e-14	4.23e-11	0.39	0.34	Systemic lupus erythematosus;	chr6:135662479	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-7.79	4.34e-14	4.23e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	7.79	4.35e-14	4.24e-11	0.35	0.34	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
HNSC	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	7.79	4.36e-14	4.25e-11	0.4	0.34	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
HNSC	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	7.79	4.37e-14	4.26e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
HNSC	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-7.79	4.38e-14	4.26e-11	-0.37	-0.34	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-7.79	4.38e-14	4.26e-11	-0.37	-0.34	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
HNSC	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-7.79	4.38e-14	4.27e-11	-0.49	-0.34	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
HNSC	cis	rs1865760	0.663	rs9467656	ENSG00000272462.2	U91328.19	-7.79	4.39e-14	4.27e-11	-0.33	-0.34	Height;	chr6:25993331	chr6:25992662~26001775:+
HNSC	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-7.79	4.39e-14	4.28e-11	-0.41	-0.34	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
HNSC	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	7.79	4.4e-14	4.29e-11	0.38	0.34	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
HNSC	cis	rs867371	1	rs1501372	ENSG00000276710.3	CSPG4P8	-7.79	4.41e-14	4.3e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82459472~82477258:+
HNSC	cis	rs1865760	0.566	rs2032449	ENSG00000272462.2	U91328.19	-7.79	4.41e-14	4.3e-11	-0.33	-0.34	Height;	chr6:26026371	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-7.79	4.42e-14	4.3e-11	-0.39	-0.34	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
HNSC	cis	rs6951245	1	rs77083167	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032187	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs74347384	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032804	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78308415	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032998	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs75493422	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs118059236	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033566	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs113858334	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033840	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79765398	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79443843	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	7.79	4.42e-14	4.31e-11	0.32	0.34	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-7.79	4.43e-14	4.31e-11	-0.45	-0.34	Depression;	chr6:28096845	chr6:28115628~28116551:+
HNSC	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	7.79	4.43e-14	4.31e-11	0.38	0.34	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
HNSC	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	7.79	4.45e-14	4.33e-11	0.35	0.34	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
HNSC	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	7.79	4.45e-14	4.33e-11	0.34	0.34	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
HNSC	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	7.79	4.47e-14	4.35e-11	0.4	0.34	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
HNSC	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	7.79	4.48e-14	4.36e-11	0.33	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
HNSC	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	7.79	4.49e-14	4.37e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
HNSC	cis	rs35955747	0.633	rs5998012	ENSG00000236132.1	CTA-440B3.1	7.79	4.5e-14	4.38e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31493858	chr22:31816379~31817491:-
HNSC	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	7.78	4.53e-14	4.41e-11	0.41	0.34	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
HNSC	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-7.78	4.54e-14	4.42e-11	-0.38	-0.34	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
HNSC	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-7.78	4.57e-14	4.44e-11	-0.37	-0.34	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	7.78	4.58e-14	4.45e-11	0.35	0.34	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-7.78	4.58e-14	4.46e-11	-0.35	-0.34	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
HNSC	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-7.78	4.6e-14	4.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-7.78	4.6e-14	4.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	7.78	4.6e-14	4.47e-11	0.47	0.34	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	7.78	4.6e-14	4.47e-11	0.47	0.34	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	7.78	4.62e-14	4.49e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-7.78	4.63e-14	4.5e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-7.78	4.63e-14	4.5e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
HNSC	cis	rs7048146	0.966	rs1411691	ENSG00000213539.4	YBX1P6	7.78	4.63e-14	4.5e-11	0.39	0.34	Vascular brain injury;	chr9:109542444	chr9:109532830~109534332:-
HNSC	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	7.78	4.63e-14	4.5e-11	0.36	0.34	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
HNSC	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	7.78	4.64e-14	4.5e-11	0.48	0.34	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
HNSC	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-7.78	4.64e-14	4.5e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-7.78	4.64e-14	4.5e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	7.78	4.64e-14	4.51e-11	0.47	0.34	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
HNSC	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	7.78	4.65e-14	4.51e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	7.78	4.65e-14	4.51e-11	0.24	0.34	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
HNSC	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-7.78	4.66e-14	4.52e-11	-0.39	-0.34	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
HNSC	cis	rs2404602	0.608	rs12911035	ENSG00000259422.1	RP11-593F23.1	7.78	4.67e-14	4.53e-11	0.38	0.34	Blood metabolite levels;	chr15:76314250	chr15:76174891~76181486:-
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-7.78	4.67e-14	4.54e-11	-0.41	-0.34	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
HNSC	cis	rs867371	0.896	rs8033831	ENSG00000255769.6	GOLGA2P10	-7.78	4.68e-14	4.54e-11	-0.42	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	7.78	4.69e-14	4.55e-11	0.46	0.34	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
HNSC	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-7.78	4.7e-14	4.56e-11	-0.53	-0.34	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
HNSC	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	7.78	4.72e-14	4.58e-11	0.35	0.34	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
HNSC	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-7.78	4.73e-14	4.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-7.78	4.73e-14	4.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-7.78	4.73e-14	4.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	7.78	4.74e-14	4.59e-11	0.36	0.34	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	7.78	4.74e-14	4.59e-11	0.36	0.34	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
HNSC	cis	rs6969780	0.722	rs985652	ENSG00000233429.8	HOTAIRM1	-7.78	4.74e-14	4.6e-11	-0.43	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27158464	chr7:27095647~27100265:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	7.78	4.75e-14	4.61e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	7.78	4.77e-14	4.62e-11	0.46	0.34	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	7.78	4.77e-14	4.62e-11	0.25	0.34	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
HNSC	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-7.78	4.79e-14	4.64e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
HNSC	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-7.78	4.79e-14	4.64e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	7.78	4.8e-14	4.65e-11	0.46	0.34	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
HNSC	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	7.78	4.8e-14	4.66e-11	0.48	0.34	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
HNSC	cis	rs6969780	0.673	rs2301721	ENSG00000233429.8	HOTAIRM1	-7.78	4.82e-14	4.67e-11	-0.43	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156494	chr7:27095647~27100265:+
HNSC	cis	rs6951245	1	rs1997243	ENSG00000224079.1	AC091729.7	-7.78	4.82e-14	4.67e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77760339	ENSG00000224079.1	AC091729.7	-7.78	4.82e-14	4.67e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1074450~1078036:+
HNSC	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	7.78	4.84e-14	4.69e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	7.78	4.84e-14	4.69e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
HNSC	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-7.78	4.86e-14	4.71e-11	-0.41	-0.34	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
HNSC	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-7.78	4.86e-14	4.71e-11	-0.41	-0.34	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
HNSC	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	7.78	4.86e-14	4.71e-11	0.35	0.34	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-7.77	4.87e-14	4.72e-11	-0.47	-0.34	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
HNSC	cis	rs9341808	0.754	rs9341811	ENSG00000272129.1	RP11-250B2.6	7.77	4.88e-14	4.72e-11	0.4	0.34	Sitting height ratio;	chr6:80272984	chr6:80355424~80356859:+
HNSC	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-7.77	4.89e-14	4.74e-11	-0.4	-0.34	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	7.77	4.89e-14	4.74e-11	0.32	0.34	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	7.77	4.89e-14	4.74e-11	0.32	0.34	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
HNSC	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	7.77	4.9e-14	4.75e-11	0.56	0.34	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
HNSC	cis	rs1865760	0.865	rs9467641	ENSG00000272462.2	U91328.19	-7.77	4.92e-14	4.76e-11	-0.34	-0.34	Height;	chr6:25947008	chr6:25992662~26001775:+
HNSC	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	7.77	4.93e-14	4.77e-11	0.41	0.34	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
HNSC	cis	rs875971	0.545	rs2420456	ENSG00000179406.6	LINC00174	-7.77	4.94e-14	4.78e-11	-0.52	-0.34	Aortic root size;	chr7:66280619	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	7.77	4.94e-14	4.78e-11	0.46	0.34	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-7.77	4.96e-14	4.8e-11	-0.4	-0.34	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
HNSC	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	7.77	4.96e-14	4.8e-11	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	7.77	4.96e-14	4.8e-11	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	7.77	4.96e-14	4.8e-11	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000173295.6	FAM86B3P	7.77	4.97e-14	4.81e-11	0.39	0.34	Joint mobility (Beighton score);	chr8:9005011	chr8:8228595~8244865:+
HNSC	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-7.77	4.97e-14	4.81e-11	-0.57	-0.34	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
HNSC	cis	rs9341808	0.727	rs1324120	ENSG00000272129.1	RP11-250B2.6	7.77	4.98e-14	4.82e-11	0.41	0.34	Sitting height ratio;	chr6:80266408	chr6:80355424~80356859:+
HNSC	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-7.77	4.98e-14	4.82e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
HNSC	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	7.77	4.99e-14	4.82e-11	0.35	0.34	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-7.77	5e-14	4.84e-11	-0.38	-0.34	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
HNSC	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	7.77	5e-14	4.84e-11	0.52	0.34	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	7.77	5.03e-14	4.86e-11	0.46	0.34	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	7.77	5.03e-14	4.86e-11	0.46	0.34	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	7.77	5.03e-14	4.87e-11	0.32	0.34	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	7.77	5.03e-14	4.87e-11	0.24	0.34	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
HNSC	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-7.77	5.04e-14	4.87e-11	-0.42	-0.34	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
HNSC	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	7.77	5.04e-14	4.87e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	7.77	5.04e-14	4.87e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	7.77	5.04e-14	4.87e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	7.77	5.04e-14	4.88e-11	0.44	0.34	Height;	chr6:109676091	chr6:109382795~109383666:+
HNSC	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	7.77	5.04e-14	4.88e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
HNSC	cis	rs7942368	0.941	rs10793195	ENSG00000255100.1	RP11-21L23.3	7.77	5.07e-14	4.9e-11	0.43	0.34	Endometriosis;	chr11:76793688	chr11:76782581~76783062:-
HNSC	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	7.77	5.07e-14	4.9e-11	0.39	0.34	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
HNSC	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	7.77	5.1e-14	4.93e-11	0.36	0.34	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
HNSC	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-7.77	5.12e-14	4.94e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
HNSC	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-7.77	5.13e-14	4.95e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
HNSC	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-7.77	5.13e-14	4.96e-11	-0.39	-0.34	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.754	rs3793000	ENSG00000272129.1	RP11-250B2.6	7.77	5.16e-14	4.97e-11	0.4	0.34	Sitting height ratio;	chr6:80285420	chr6:80355424~80356859:+
HNSC	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-7.77	5.17e-14	4.99e-11	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
HNSC	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	7.77	5.2e-14	5.02e-11	0.35	0.34	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
HNSC	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-7.76	5.21e-14	5.03e-11	-0.37	-0.34	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-7.76	5.21e-14	5.03e-11	-0.37	-0.34	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
HNSC	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	7.76	5.24e-14	5.05e-11	0.35	0.34	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	7.76	5.24e-14	5.05e-11	0.38	0.34	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	7.76	5.24e-14	5.06e-11	0.47	0.34	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
HNSC	cis	rs1865760	0.566	rs3752420	ENSG00000272462.2	U91328.19	-7.76	5.26e-14	5.07e-11	-0.33	-0.34	Height;	chr6:26026907	chr6:25992662~26001775:+
HNSC	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	7.76	5.26e-14	5.07e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
HNSC	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	7.76	5.26e-14	5.07e-11	0.41	0.34	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
HNSC	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	7.76	5.27e-14	5.08e-11	0.43	0.34	Depression;	chr6:28205232	chr6:28115628~28116551:+
HNSC	cis	rs867371	1	rs7166570	ENSG00000276710.3	CSPG4P8	-7.76	5.27e-14	5.08e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82459472~82477258:+
HNSC	cis	rs6951245	1	rs113575110	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs1881123	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs77569514	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11770909	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1074450~1078036:+
HNSC	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-7.76	5.3e-14	5.11e-11	-0.61	-0.34	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
HNSC	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	7.76	5.31e-14	5.11e-11	0.39	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
HNSC	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-7.76	5.31e-14	5.12e-11	-0.36	-0.34	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
HNSC	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	7.76	5.31e-14	5.12e-11	0.38	0.34	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	7.76	5.31e-14	5.12e-11	0.38	0.34	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	7.76	5.31e-14	5.12e-11	0.38	0.34	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-7.76	5.33e-14	5.13e-11	-0.45	-0.34	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
HNSC	cis	rs12439619	0.508	rs17354842	ENSG00000276710.3	CSPG4P8	7.76	5.33e-14	5.13e-11	0.37	0.34	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82459472~82477258:+
HNSC	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-7.76	5.34e-14	5.14e-11	-0.39	-0.34	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-7.76	5.35e-14	5.15e-11	-0.39	-0.34	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
HNSC	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-7.76	5.35e-14	5.15e-11	-0.45	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
HNSC	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	7.76	5.35e-14	5.15e-11	0.35	0.34	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	7.76	5.35e-14	5.15e-11	0.35	0.34	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	7.76	5.35e-14	5.15e-11	0.35	0.34	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
HNSC	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-7.76	5.36e-14	5.16e-11	-0.34	-0.34	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-7.76	5.36e-14	5.16e-11	-0.34	-0.34	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
HNSC	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	7.76	5.38e-14	5.17e-11	0.36	0.34	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	7.76	5.38e-14	5.18e-11	0.46	0.34	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	7.76	5.38e-14	5.18e-11	0.46	0.34	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
HNSC	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-7.76	5.39e-14	5.18e-11	-0.41	-0.34	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
HNSC	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	7.76	5.39e-14	5.19e-11	0.5	0.34	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
HNSC	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	7.76	5.4e-14	5.2e-11	0.44	0.34	Height;	chr6:109592105	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	7.76	5.4e-14	5.2e-11	0.32	0.34	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
HNSC	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	7.76	5.42e-14	5.21e-11	0.39	0.34	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-7.76	5.42e-14	5.21e-11	-0.32	-0.34	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	7.76	5.43e-14	5.22e-11	0.36	0.34	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
HNSC	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	7.76	5.43e-14	5.22e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	7.76	5.43e-14	5.22e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
HNSC	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	7.76	5.44e-14	5.23e-11	0.37	0.34	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
HNSC	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	7.76	5.44e-14	5.23e-11	0.38	0.34	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
HNSC	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	7.76	5.44e-14	5.23e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
HNSC	cis	rs6951245	1	rs78896566	ENSG00000224079.1	AC091729.7	-7.76	5.45e-14	5.24e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79422648	ENSG00000224079.1	AC091729.7	-7.76	5.45e-14	5.24e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs113119264	ENSG00000224079.1	AC091729.7	-7.76	5.45e-14	5.24e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1074450~1078036:+
HNSC	cis	rs1021993	0.868	rs906347	ENSG00000231648.1	RP11-372M18.2	-7.76	5.47e-14	5.26e-11	-0.46	-0.34	Gut microbiome composition (winter);	chr1:209355062	chr1:209367662~209379690:+
HNSC	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-7.76	5.47e-14	5.26e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-7.76	5.47e-14	5.26e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-7.76	5.47e-14	5.26e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
HNSC	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	7.76	5.48e-14	5.27e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
HNSC	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-7.76	5.48e-14	5.27e-11	-0.36	-0.34	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
HNSC	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	7.76	5.51e-14	5.29e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	7.76	5.51e-14	5.29e-11	0.46	0.34	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
HNSC	cis	rs7404843	0.704	rs112251447	ENSG00000263335.1	AF001548.5	7.76	5.51e-14	5.29e-11	0.7	0.34	Testicular germ cell tumor;	chr16:15428015	chr16:15726674~15732993:+
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	7.76	5.52e-14	5.3e-11	0.47	0.34	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	7.76	5.52e-14	5.3e-11	0.47	0.34	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
HNSC	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	7.76	5.53e-14	5.31e-11	0.43	0.34	Height;	chr6:109634847	chr6:109382795~109383666:+
HNSC	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-7.76	5.55e-14	5.33e-11	-0.33	-0.34	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
HNSC	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.76	5.55e-14	5.33e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
HNSC	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	7.76	5.56e-14	5.33e-11	0.33	0.34	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	7.76	5.57e-14	5.35e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	7.75	5.61e-14	5.39e-11	0.44	0.34	Height;	chr6:109672088	chr6:109382795~109383666:+
HNSC	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	7.75	5.62e-14	5.39e-11	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
HNSC	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	7.75	5.63e-14	5.39e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	7.75	5.63e-14	5.39e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	7.75	5.66e-14	5.42e-11	0.46	0.34	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
HNSC	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	7.75	5.67e-14	5.44e-11	0.4	0.34	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
HNSC	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	7.75	5.68e-14	5.45e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-7.75	5.68e-14	5.45e-11	-0.32	-0.34	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	7.75	5.68e-14	5.45e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	7.75	5.68e-14	5.45e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	7.75	5.68e-14	5.45e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
HNSC	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	7.75	5.69e-14	5.45e-11	0.39	0.34	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	7.75	5.71e-14	5.47e-11	0.46	0.34	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	7.75	5.71e-14	5.47e-11	0.46	0.34	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-7.75	5.73e-14	5.49e-11	-0.39	-0.34	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
HNSC	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-7.75	5.74e-14	5.5e-11	-0.34	-0.34	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
HNSC	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	7.75	5.74e-14	5.5e-11	0.43	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
HNSC	cis	rs801193	0.742	rs9969300	ENSG00000179406.6	LINC00174	7.75	5.75e-14	5.5e-11	0.43	0.34	Aortic root size;	chr7:66316659	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.52	rs160645	ENSG00000179406.6	LINC00174	7.75	5.75e-14	5.51e-11	0.53	0.34	Aortic root size;	chr7:66091320	chr7:66376044~66401338:-
HNSC	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-7.75	5.77e-14	5.53e-11	-0.4	-0.34	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
HNSC	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-7.75	5.8e-14	5.55e-11	-0.41	-0.34	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
HNSC	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	7.75	5.8e-14	5.55e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
HNSC	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-7.75	5.8e-14	5.56e-11	-0.37	-0.34	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-7.75	5.83e-14	5.58e-11	-0.32	-0.34	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
HNSC	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-7.75	5.83e-14	5.58e-11	-0.53	-0.34	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
HNSC	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	7.75	5.85e-14	5.59e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs73142245	ENSG00000179406.6	LINC00174	-7.75	5.85e-14	5.59e-11	-0.52	-0.34	Aortic root size;	chr7:66226662	chr7:66376044~66401338:-
HNSC	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	7.75	5.86e-14	5.6e-11	0.35	0.34	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
HNSC	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-7.75	5.87e-14	5.61e-11	-0.34	-0.34	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
HNSC	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	7.75	5.87e-14	5.61e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
HNSC	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-7.75	5.88e-14	5.61e-11	-0.34	-0.34	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-7.75	5.88e-14	5.61e-11	-0.34	-0.34	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
HNSC	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	7.75	5.89e-14	5.62e-11	0.47	0.34	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs11657053	ENSG00000267151.3	RP11-100E5.2	7.75	5.91e-14	5.64e-11	0.44	0.34	Menopause (age at onset);	chr17:43039112	chr17:43444707~43451200:+
HNSC	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-7.75	5.93e-14	5.66e-11	-0.42	-0.34	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
HNSC	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-7.75	5.94e-14	5.67e-11	-0.38	-0.34	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
HNSC	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	7.75	5.96e-14	5.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-7.74	5.99e-14	5.72e-11	-0.34	-0.34	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
HNSC	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-7.74	6e-14	5.73e-11	-0.39	-0.34	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	7.74	6e-14	5.73e-11	0.46	0.34	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-7.74	6.02e-14	5.74e-11	-0.32	-0.34	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
HNSC	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-7.74	6.03e-14	5.76e-11	-0.37	-0.34	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
HNSC	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	7.74	6.04e-14	5.76e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
HNSC	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
HNSC	cis	rs875971	0.789	rs28815324	ENSG00000179406.6	LINC00174	7.74	6.07e-14	5.79e-11	0.53	0.34	Aortic root size;	chr7:66100789	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	7.74	6.08e-14	5.8e-11	0.46	0.34	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs12951869	ENSG00000267151.3	RP11-100E5.2	7.74	6.08e-14	5.8e-11	0.44	0.34	Menopause (age at onset);	chr17:43035550	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11654452	ENSG00000267151.3	RP11-100E5.2	7.74	6.08e-14	5.8e-11	0.44	0.34	Menopause (age at onset);	chr17:43037366	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793189	ENSG00000267151.3	RP11-100E5.2	7.74	6.08e-14	5.8e-11	0.44	0.34	Menopause (age at onset);	chr17:43038698	chr17:43444707~43451200:+
HNSC	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-7.74	6.08e-14	5.8e-11	-0.39	-0.34	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
HNSC	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	7.74	6.12e-14	5.83e-11	0.36	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
HNSC	cis	rs7404843	0.925	rs7404803	ENSG00000263065.1	AF001548.6	-7.74	6.13e-14	5.84e-11	-0.62	-0.34	Testicular germ cell tumor;	chr16:15436597	chr16:15741151~15741791:+
HNSC	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	7.74	6.13e-14	5.85e-11	0.45	0.34	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.562	rs1038248	ENSG00000173295.6	FAM86B3P	-7.74	6.14e-14	5.85e-11	-0.36	-0.34	Joint mobility (Beighton score);	chr8:9183348	chr8:8228595~8244865:+
HNSC	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	7.74	6.17e-14	5.88e-11	0.38	0.34	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
HNSC	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	7.74	6.18e-14	5.89e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	7.74	6.19e-14	5.9e-11	0.38	0.34	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
HNSC	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-7.74	6.2e-14	5.9e-11	-0.52	-0.34	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
HNSC	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	7.74	6.23e-14	5.93e-11	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-7.74	6.24e-14	5.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
HNSC	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-7.74	6.24e-14	5.94e-11	-0.33	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
HNSC	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	7.74	6.25e-14	5.94e-11	0.34	0.34	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
HNSC	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	7.74	6.25e-14	5.95e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	7.74	6.26e-14	5.96e-11	0.32	0.34	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	7.74	6.27e-14	5.96e-11	0.24	0.34	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
HNSC	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	7.74	6.29e-14	5.98e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	7.74	6.31e-14	6e-11	0.38	0.34	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
HNSC	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	7.74	6.31e-14	6e-11	0.35	0.34	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
HNSC	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	7.74	6.33e-14	6.02e-11	0.51	0.34	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
HNSC	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	7.74	6.34e-14	6.03e-11	0.36	0.34	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
HNSC	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	7.74	6.34e-14	6.03e-11	0.35	0.34	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
HNSC	cis	rs1021993	0.587	rs78609792	ENSG00000231648.1	RP11-372M18.2	-7.74	6.35e-14	6.04e-11	-0.57	-0.34	Gut microbiome composition (winter);	chr1:209372669	chr1:209367662~209379690:+
HNSC	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	7.74	6.36e-14	6.05e-11	0.35	0.34	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
HNSC	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	7.74	6.38e-14	6.07e-11	0.4	0.34	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	7.74	6.4e-14	6.08e-11	0.24	0.34	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
HNSC	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	7.73	6.44e-14	6.11e-11	0.39	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
HNSC	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	7.73	6.45e-14	6.12e-11	0.35	0.34	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	7.73	6.49e-14	6.16e-11	0.35	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
HNSC	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	7.73	6.5e-14	6.17e-11	0.39	0.34	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.502	rs2465121	ENSG00000179406.6	LINC00174	7.73	6.51e-14	6.18e-11	0.52	0.34	Aortic root size;	chr7:66156017	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	7.73	6.51e-14	6.18e-11	0.47	0.34	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
HNSC	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	7.73	6.53e-14	6.19e-11	0.42	0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
HNSC	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-7.73	6.55e-14	6.21e-11	-0.37	-0.34	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	7.73	6.56e-14	6.23e-11	0.24	0.34	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
HNSC	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	7.73	6.6e-14	6.26e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
HNSC	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-7.73	6.61e-14	6.27e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
HNSC	cis	rs2404602	0.583	rs12898415	ENSG00000259422.1	RP11-593F23.1	7.73	6.62e-14	6.28e-11	0.38	0.34	Blood metabolite levels;	chr15:76281891	chr15:76174891~76181486:-
HNSC	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	7.73	6.64e-14	6.3e-11	0.35	0.34	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
HNSC	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-7.73	6.65e-14	6.31e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
HNSC	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	7.73	6.69e-14	6.34e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
HNSC	cis	rs7942368	1	rs1440977	ENSG00000255100.1	RP11-21L23.3	7.73	6.69e-14	6.34e-11	0.42	0.34	Endometriosis;	chr11:76765385	chr11:76782581~76783062:-
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	7.73	6.72e-14	6.37e-11	0.47	0.34	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-7.73	6.73e-14	6.38e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	7.73	6.73e-14	6.38e-11	0.46	0.34	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
HNSC	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-7.73	6.75e-14	6.39e-11	-0.33	-0.34	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
HNSC	cis	rs875971	0.545	rs73142233	ENSG00000179406.6	LINC00174	-7.73	6.79e-14	6.43e-11	-0.52	-0.34	Aortic root size;	chr7:66221293	chr7:66376044~66401338:-
HNSC	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	7.73	6.79e-14	6.43e-11	0.35	0.34	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	7.73	6.79e-14	6.43e-11	0.35	0.34	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
HNSC	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	7.73	6.8e-14	6.44e-11	0.41	0.34	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	7.73	6.8e-14	6.44e-11	0.41	0.34	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
HNSC	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	7.73	6.81e-14	6.45e-11	0.44	0.34	Height;	chr6:109507271	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	7.73	6.83e-14	6.46e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
HNSC	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-7.73	6.83e-14	6.46e-11	-0.39	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	7.73	6.85e-14	6.49e-11	0.48	0.34	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
HNSC	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	7.73	6.85e-14	6.49e-11	0.38	0.34	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	7.73	6.85e-14	6.49e-11	0.43	0.34	Height;	chr6:109586733	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	7.72	6.89e-14	6.52e-11	0.35	0.34	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	7.72	6.89e-14	6.52e-11	0.35	0.34	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
HNSC	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
HNSC	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	7.72	6.92e-14	6.54e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	-7.72	6.93e-14	6.55e-11	-0.38	-0.34	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
HNSC	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-7.72	6.93e-14	6.55e-11	-0.32	-0.34	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-7.72	6.94e-14	6.55e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	7.72	6.95e-14	6.56e-11	0.52	0.34	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	7.72	6.95e-14	6.56e-11	0.52	0.34	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
HNSC	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	7.72	6.97e-14	6.58e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	7.72	6.97e-14	6.58e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
HNSC	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-7.72	7.02e-14	6.62e-11	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
HNSC	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	7.72	7.03e-14	6.63e-11	0.25	0.34	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	7.72	7.04e-14	6.64e-11	0.47	0.34	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	7.72	7.04e-14	6.65e-11	0.47	0.34	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
HNSC	cis	rs36423	0.528	rs1205063	ENSG00000266869.1	RP6-114E22.1	7.72	7.05e-14	6.65e-11	0.56	0.34	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71881828	chr14:71848606~71908430:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	7.72	7.06e-14	6.66e-11	0.38	0.34	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	7.72	7.06e-14	6.66e-11	0.46	0.34	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	7.72	7.09e-14	6.69e-11	0.24	0.34	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	7.72	7.09e-14	6.69e-11	0.24	0.34	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	7.72	7.1e-14	6.69e-11	0.47	0.34	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-7.72	7.1e-14	6.7e-11	-0.33	-0.34	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-7.72	7.13e-14	6.73e-11	-0.38	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	7.72	7.13e-14	6.73e-11	0.46	0.34	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	7.72	7.14e-14	6.73e-11	0.47	0.34	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	7.72	7.14e-14	6.73e-11	0.39	0.34	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
HNSC	cis	rs867371	0.892	rs4344697	ENSG00000276710.3	CSPG4P8	-7.72	7.16e-14	6.75e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82459472~82477258:+
HNSC	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	7.72	7.17e-14	6.76e-11	0.42	0.34	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
HNSC	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	7.72	7.18e-14	6.76e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
HNSC	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	7.72	7.19e-14	6.77e-11	0.36	0.34	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
HNSC	cis	rs17270561	0.636	rs6456694	ENSG00000272462.2	U91328.19	-7.72	7.2e-14	6.78e-11	-0.35	-0.34	Iron status biomarkers;	chr6:25712666	chr6:25992662~26001775:+
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	7.72	7.21e-14	6.79e-11	0.24	0.34	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
HNSC	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	7.72	7.21e-14	6.8e-11	0.36	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
HNSC	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-7.72	7.23e-14	6.81e-11	-0.35	-0.34	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-7.72	7.28e-14	6.85e-11	-0.32	-0.34	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-7.72	7.29e-14	6.86e-11	-0.41	-0.34	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
HNSC	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	7.72	7.34e-14	6.9e-11	0.39	0.34	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	7.72	7.36e-14	6.92e-11	0.46	0.34	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	7.72	7.36e-14	6.92e-11	0.46	0.34	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	7.71	7.41e-14	6.97e-11	0.46	0.34	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	7.71	7.45e-14	7.01e-11	0.46	0.34	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
HNSC	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	7.71	7.47e-14	7.02e-11	0.39	0.34	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
HNSC	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	7.71	7.47e-14	7.02e-11	0.35	0.34	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
HNSC	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-7.71	7.48e-14	7.03e-11	-0.46	-0.34	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	7.71	7.48e-14	7.03e-11	0.47	0.34	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	7.71	7.52e-14	7.06e-11	0.34	0.34	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
HNSC	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	7.71	7.52e-14	7.07e-11	0.35	0.34	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
HNSC	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	7.71	7.53e-14	7.07e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
HNSC	cis	rs11079757	0.604	rs72823425	ENSG00000262879.4	RP11-156P1.3	7.71	7.58e-14	7.12e-11	0.43	0.34	Erythema nodosum in inflammatory bowel disease;	chr17:47111303	chr17:46984045~47100323:-
HNSC	cis	rs6951245	1	rs2363286	ENSG00000224079.1	AC091729.7	-7.71	7.59e-14	7.13e-11	-0.57	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1074450~1078036:+
HNSC	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
HNSC	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-7.71	7.63e-14	7.17e-11	-0.38	-0.34	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-7.71	7.64e-14	7.17e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
HNSC	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-7.71	7.65e-14	7.18e-11	-0.46	-0.34	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
HNSC	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-7.71	7.66e-14	7.19e-11	-0.38	-0.34	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
HNSC	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	7.71	7.68e-14	7.2e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
HNSC	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-7.71	7.7e-14	7.21e-11	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-7.71	7.7e-14	7.21e-11	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	7.71	7.75e-14	7.26e-11	0.32	0.34	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	7.71	7.75e-14	7.26e-11	0.32	0.34	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	7.71	7.75e-14	7.26e-11	0.32	0.34	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.69	rs7674713	ENSG00000245958.5	RP11-33B1.1	-7.71	7.76e-14	7.27e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119401102	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-7.71	7.78e-14	7.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
HNSC	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	7.71	7.83e-14	7.33e-11	0.34	0.34	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
HNSC	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	7.71	7.84e-14	7.34e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
HNSC	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-7.71	7.84e-14	7.34e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
HNSC	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	7.71	7.85e-14	7.35e-11	0.36	0.34	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
HNSC	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109558247	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109564443	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109571489	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109576414	chr6:109382795~109383666:+
HNSC	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-7.71	7.9e-14	7.39e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-7.71	7.9e-14	7.39e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
HNSC	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	7.7	7.92e-14	7.41e-11	0.35	0.34	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	7.7	7.96e-14	7.44e-11	0.47	0.34	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-7.7	7.97e-14	7.45e-11	-0.38	-0.34	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
HNSC	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-7.7	7.99e-14	7.47e-11	-0.48	-0.34	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	7.7	7.99e-14	7.47e-11	0.24	0.34	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
HNSC	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	7.7	8.03e-14	7.5e-11	0.44	0.34	Height;	chr6:109690255	chr6:109382795~109383666:+
HNSC	cis	rs867371	0.896	rs6495647	ENSG00000276710.3	CSPG4P8	-7.7	8.04e-14	7.51e-11	-0.38	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82459472~82477258:+
HNSC	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	7.7	8.06e-14	7.53e-11	0.39	0.34	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
HNSC	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-7.7	8.07e-14	7.54e-11	-0.41	-0.34	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
HNSC	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-7.7	8.1e-14	7.56e-11	-0.37	-0.34	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-7.7	8.1e-14	7.56e-11	-0.37	-0.34	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
HNSC	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.7	8.1e-14	7.57e-11	-0.36	-0.34	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.7	8.1e-14	7.57e-11	-0.36	-0.34	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
HNSC	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-7.7	8.11e-14	7.58e-11	-0.36	-0.34	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
HNSC	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	7.7	8.13e-14	7.59e-11	0.3	0.34	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
HNSC	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-7.7	8.14e-14	7.6e-11	-0.31	-0.34	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	7.7	8.18e-14	7.63e-11	0.46	0.34	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
HNSC	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	7.7	8.18e-14	7.64e-11	0.36	0.34	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	7.7	8.19e-14	7.65e-11	0.47	0.34	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
HNSC	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-7.7	8.3e-14	7.74e-11	-0.3	-0.34	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
HNSC	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-7.7	8.3e-14	7.74e-11	-0.37	-0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
HNSC	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	7.7	8.31e-14	7.74e-11	0.4	0.34	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
HNSC	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-7.7	8.31e-14	7.75e-11	-0.42	-0.34	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	7.7	8.31e-14	7.75e-11	0.24	0.34	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
HNSC	cis	rs6951245	0.938	rs112425403	ENSG00000224079.1	AC091729.7	-7.7	8.31e-14	7.75e-11	-0.57	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031895	chr7:1074450~1078036:+
HNSC	cis	rs7615952	1	rs7615952	ENSG00000248787.1	RP11-666A20.4	7.7	8.32e-14	7.76e-11	0.47	0.34	Blood pressure (smoking interaction);	chr3:125930560	chr3:125908005~125910272:-
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	7.7	8.35e-14	7.78e-11	0.23	0.34	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
HNSC	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	7.7	8.35e-14	7.79e-11	0.4	0.34	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
HNSC	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
HNSC	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-7.7	8.43e-14	7.85e-11	-0.3	-0.34	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
HNSC	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	7.7	8.47e-14	7.89e-11	0.39	0.34	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	7.7	8.47e-14	7.89e-11	0.39	0.34	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-7.7	8.47e-14	7.89e-11	-0.32	-0.34	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-7.7	8.47e-14	7.89e-11	-0.32	-0.34	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-7.7	8.47e-14	7.89e-11	-0.32	-0.34	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
HNSC	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	7.69	8.49e-14	7.9e-11	0.39	0.34	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
HNSC	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-7.69	8.49e-14	7.9e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
HNSC	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	7.69	8.5e-14	7.91e-11	0.42	0.34	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
HNSC	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	7.69	8.51e-14	7.92e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
HNSC	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-7.69	8.52e-14	7.93e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-7.69	8.57e-14	7.97e-11	-0.32	-0.34	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
HNSC	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	7.69	8.63e-14	8.03e-11	0.39	0.34	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-7.69	8.63e-14	8.03e-11	-0.46	-0.34	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	7.69	8.64e-14	8.03e-11	0.32	0.34	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	7.69	8.64e-14	8.03e-11	0.46	0.34	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
HNSC	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-7.69	8.67e-14	8.07e-11	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
HNSC	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	7.69	8.68e-14	8.07e-11	0.39	0.34	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	7.69	8.68e-14	8.07e-11	0.39	0.34	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	7.69	8.68e-14	8.07e-11	0.39	0.34	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	7.69	8.68e-14	8.07e-11	0.46	0.34	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
HNSC	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-7.69	8.68e-14	8.07e-11	-0.61	-0.34	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	7.69	8.68e-14	8.07e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
HNSC	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-7.69	8.72e-14	8.11e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
HNSC	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	7.69	8.74e-14	8.12e-11	0.37	0.34	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
HNSC	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	7.69	8.76e-14	8.14e-11	0.36	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
HNSC	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-7.69	8.79e-14	8.17e-11	-0.35	-0.34	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-7.69	8.79e-14	8.17e-11	-0.35	-0.34	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
HNSC	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	7.69	8.82e-14	8.2e-11	0.38	0.34	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-7.69	8.82e-14	8.2e-11	-0.41	-0.34	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	7.69	8.83e-14	8.2e-11	0.39	0.34	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
HNSC	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-7.69	8.83e-14	8.2e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
HNSC	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-7.69	8.87e-14	8.24e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
HNSC	cis	rs867371	1	rs7173339	ENSG00000276710.3	CSPG4P8	-7.69	8.87e-14	8.24e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82459472~82477258:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000235689.1	AP000351.13	7.69	8.9e-14	8.26e-11	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:24006305~24008258:-
HNSC	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	7.69	8.92e-14	8.29e-11	0.37	0.34	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
HNSC	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	7.69	8.96e-14	8.32e-11	0.46	0.34	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	7.69	8.96e-14	8.32e-11	0.46	0.34	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	7.69	8.97e-14	8.33e-11	0.35	0.34	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
HNSC	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	7.69	8.99e-14	8.34e-11	0.44	0.34	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	7.69	8.99e-14	8.35e-11	0.24	0.34	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
HNSC	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-7.69	9e-14	8.36e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	7.69	9.05e-14	8.4e-11	0.24	0.34	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
HNSC	cis	rs1865760	0.663	rs9348704	ENSG00000272462.2	U91328.19	-7.69	9.07e-14	8.41e-11	-0.33	-0.34	Height;	chr6:26000165	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	7.69	9.08e-14	8.42e-11	0.47	0.34	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-7.68	9.1e-14	8.44e-11	-0.34	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	7.68	9.12e-14	8.46e-11	0.47	0.34	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
HNSC	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	7.68	9.14e-14	8.47e-11	0.37	0.34	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
HNSC	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-7.68	9.19e-14	8.52e-11	-0.38	-0.34	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
HNSC	cis	rs2179367	0.959	rs4895789	ENSG00000231760.4	RP11-350J20.5	7.68	9.2e-14	8.53e-11	0.43	0.33	Dupuytren's disease;	chr6:149443518	chr6:149796151~149826294:-
HNSC	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-7.68	9.21e-14	8.53e-11	-0.37	-0.33	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
HNSC	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	7.68	9.21e-14	8.54e-11	0.42	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	7.68	9.23e-14	8.55e-11	0.47	0.33	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
HNSC	cis	rs9341808	0.621	rs2322627	ENSG00000272129.1	RP11-250B2.6	7.68	9.25e-14	8.58e-11	0.4	0.33	Sitting height ratio;	chr6:80096624	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	7.68	9.26e-14	8.58e-11	0.35	0.33	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	7.68	9.3e-14	8.61e-11	0.43	0.33	Height;	chr6:109358652	chr6:109382795~109383666:+
HNSC	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	7.68	9.3e-14	8.62e-11	0.43	0.33	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	7.68	9.31e-14	8.63e-11	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
HNSC	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-7.68	9.32e-14	8.63e-11	-0.36	-0.33	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
HNSC	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	7.68	9.34e-14	8.65e-11	0.36	0.33	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.47	0.33	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
HNSC	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
HNSC	cis	rs131777	0.576	rs131758	ENSG00000205559.3	CHKB-AS1	-7.68	9.38e-14	8.68e-11	-0.37	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50578653	chr22:50583026~50583877:+
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	7.68	9.42e-14	8.72e-11	0.24	0.33	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
HNSC	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	7.68	9.44e-14	8.73e-11	0.39	0.33	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-7.68	9.45e-14	8.75e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
HNSC	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-7.68	9.46e-14	8.76e-11	-0.43	-0.33	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
HNSC	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	7.68	9.47e-14	8.76e-11	0.46	0.33	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	7.68	9.47e-14	8.76e-11	0.46	0.33	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
HNSC	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-7.68	9.48e-14	8.77e-11	-0.35	-0.33	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
HNSC	cis	rs1865760	0.929	rs9467646	ENSG00000272462.2	U91328.19	-7.68	9.49e-14	8.78e-11	-0.33	-0.33	Height;	chr6:25957180	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-7.68	9.51e-14	8.79e-11	-0.39	-0.33	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
HNSC	cis	rs1865760	0.865	rs1436306	ENSG00000272462.2	U91328.19	-7.68	9.53e-14	8.81e-11	-0.34	-0.33	Height;	chr6:25948193	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	7.68	9.56e-14	8.84e-11	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	7.68	9.58e-14	8.86e-11	0.46	0.33	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs73142265	ENSG00000179406.6	LINC00174	-7.68	9.58e-14	8.86e-11	-0.51	-0.33	Aortic root size;	chr7:66234510	chr7:66376044~66401338:-
HNSC	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-7.68	9.58e-14	8.86e-11	-0.47	-0.33	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-7.68	9.58e-14	8.86e-11	-0.47	-0.33	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-7.68	9.59e-14	8.86e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-7.68	9.6e-14	8.87e-11	-0.38	-0.33	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
HNSC	cis	rs1799949	1	rs12944458	ENSG00000267151.3	RP11-100E5.2	7.68	9.63e-14	8.9e-11	0.44	0.33	Menopause (age at onset);	chr17:43028755	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	7.68	9.65e-14	8.92e-11	0.32	0.33	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
HNSC	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	7.68	9.71e-14	8.97e-11	0.37	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
HNSC	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-7.67	9.77e-14	9.02e-11	-0.36	-0.33	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
HNSC	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	7.67	9.77e-14	9.02e-11	0.38	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
HNSC	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	7.67	9.77e-14	9.02e-11	0.44	0.33	Height;	chr6:109526846	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	7.67	9.77e-14	9.02e-11	0.44	0.33	Height;	chr6:109533040	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	7.67	9.77e-14	9.02e-11	0.44	0.33	Height;	chr6:109534269	chr6:109382795~109383666:+
HNSC	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	7.67	9.77e-14	9.02e-11	0.39	0.33	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
HNSC	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-7.67	9.8e-14	9.05e-11	-0.5	-0.33	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
HNSC	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-7.67	9.81e-14	9.06e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
HNSC	cis	rs7942368	1	rs10437754	ENSG00000255100.1	RP11-21L23.3	7.67	9.81e-14	9.06e-11	0.42	0.33	Endometriosis;	chr11:76766823	chr11:76782581~76783062:-
HNSC	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-7.67	9.85e-14	9.08e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-7.67	9.86e-14	9.09e-11	-0.37	-0.33	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
HNSC	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-7.67	9.87e-14	9.1e-11	-0.38	-0.33	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	7.67	9.9e-14	9.12e-11	0.38	0.33	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-7.67	9.91e-14	9.13e-11	-0.23	-0.33	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-7.67	9.96e-14	9.18e-11	-0.24	-0.33	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
HNSC	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	7.67	1e-13	9.21e-11	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
HNSC	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	7.67	1e-13	9.23e-11	0.35	0.33	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
HNSC	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	7.67	1e-13	9.25e-11	0.44	0.33	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
HNSC	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	7.67	1.01e-13	9.31e-11	0.38	0.33	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
HNSC	cis	rs7942368	0.941	rs10899283	ENSG00000255100.1	RP11-21L23.3	7.67	1.01e-13	9.33e-11	0.42	0.33	Endometriosis;	chr11:76794158	chr11:76782581~76783062:-
HNSC	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-7.67	1.02e-13	9.36e-11	-0.36	-0.33	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	7.67	1.02e-13	9.38e-11	0.24	0.33	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
HNSC	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-7.67	1.03e-13	9.42e-11	-0.52	-0.33	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
HNSC	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	7.67	1.03e-13	9.45e-11	0.35	0.33	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
HNSC	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	7.67	1.03e-13	9.48e-11	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	7.67	1.03e-13	9.48e-11	0.46	0.33	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.844	rs4846770	ENSG00000272750.1	RP11-378J18.8	-7.67	1.04e-13	9.51e-11	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622227	chr1:222658867~222661512:-
HNSC	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	7.67	1.04e-13	9.52e-11	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
HNSC	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-7.67	1.04e-13	9.55e-11	-0.56	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	7.67	1.04e-13	9.55e-11	0.46	0.33	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-7.67	1.04e-13	9.55e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	7.67	1.04e-13	9.58e-11	0.46	0.33	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	7.66	1.04e-13	9.59e-11	0.46	0.33	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
HNSC	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-7.66	1.05e-13	9.59e-11	-0.42	-0.33	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
HNSC	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-7.66	1.05e-13	9.59e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
HNSC	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-7.66	1.05e-13	9.61e-11	-0.35	-0.33	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
HNSC	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-7.66	1.05e-13	9.61e-11	-0.51	-0.33	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	7.66	1.05e-13	9.61e-11	0.24	0.33	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
HNSC	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-7.66	1.05e-13	9.62e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-7.66	1.05e-13	9.65e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
HNSC	cis	rs1865760	0.663	rs9379815	ENSG00000272462.2	U91328.19	-7.66	1.05e-13	9.67e-11	-0.33	-0.33	Height;	chr6:25979888	chr6:25992662~26001775:+
HNSC	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	7.66	1.06e-13	9.7e-11	0.37	0.33	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
HNSC	cis	rs1021993	0.545	rs1006316	ENSG00000231648.1	RP11-372M18.2	-7.66	1.06e-13	9.76e-11	-0.56	-0.33	Gut microbiome composition (winter);	chr1:209377116	chr1:209367662~209379690:+
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	7.66	1.07e-13	9.77e-11	0.46	0.33	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	7.66	1.07e-13	9.8e-11	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
HNSC	cis	rs7615952	0.932	rs13321217	ENSG00000248787.1	RP11-666A20.4	-7.66	1.07e-13	9.82e-11	-0.5	-0.33	Blood pressure (smoking interaction);	chr3:125912928	chr3:125908005~125910272:-
HNSC	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-7.66	1.07e-13	9.84e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	7.66	1.07e-13	9.85e-11	0.38	0.33	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
HNSC	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	7.66	1.08e-13	9.86e-11	0.35	0.33	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-7.66	1.08e-13	9.87e-11	-0.32	-0.33	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
HNSC	cis	rs2286503	0.839	rs2240728	ENSG00000228649.7	AC005682.5	7.66	1.08e-13	9.88e-11	0.36	0.33	Fibrinogen;	chr7:22812880	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs1054471	ENSG00000228649.7	AC005682.5	7.66	1.08e-13	9.88e-11	0.36	0.33	Fibrinogen;	chr7:22813024	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2240726	ENSG00000228649.7	AC005682.5	7.66	1.08e-13	9.88e-11	0.36	0.33	Fibrinogen;	chr7:22813516	chr7:22854178~22861579:+
HNSC	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	7.66	1.08e-13	9.9e-11	0.4	0.33	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	7.66	1.08e-13	9.9e-11	0.4	0.33	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
HNSC	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-7.66	1.08e-13	9.91e-11	-0.29	-0.33	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-7.66	1.08e-13	9.91e-11	-0.29	-0.33	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
HNSC	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-7.66	1.08e-13	9.92e-11	-0.61	-0.33	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	7.66	1.08e-13	9.93e-11	0.4	0.33	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	7.66	1.09e-13	9.94e-11	0.44	0.33	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
HNSC	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-7.66	1.09e-13	9.95e-11	-0.36	-0.33	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	7.66	1.09e-13	9.99e-11	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
HNSC	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	7.66	1.09e-13	9.99e-11	0.42	0.33	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
HNSC	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-7.66	1.09e-13	1e-10	-0.29	-0.33	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
HNSC	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	7.66	1.09e-13	1e-10	0.41	0.33	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
HNSC	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	7.66	1.1e-13	1.01e-10	0.4	0.33	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
HNSC	cis	rs6951245	0.882	rs11764817	ENSG00000224079.1	AC091729.7	-7.66	1.1e-13	1.01e-10	-0.51	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024974	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-7.66	1.1e-13	1.01e-10	-0.29	-0.33	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	7.66	1.1e-13	1.01e-10	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	7.66	1.1e-13	1.01e-10	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
HNSC	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	7.66	1.11e-13	1.01e-10	0.44	0.33	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
HNSC	cis	rs1021993	0.868	rs6685289	ENSG00000231648.1	RP11-372M18.2	-7.66	1.11e-13	1.02e-10	-0.46	-0.33	Gut microbiome composition (winter);	chr1:209357324	chr1:209367662~209379690:+
HNSC	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-7.66	1.12e-13	1.02e-10	-0.34	-0.33	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	7.66	1.12e-13	1.02e-10	0.25	0.33	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
HNSC	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	7.65	1.12e-13	1.02e-10	0.36	0.33	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	7.65	1.13e-13	1.03e-10	0.38	0.33	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	7.65	1.13e-13	1.03e-10	0.38	0.33	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
HNSC	cis	rs875971	0.545	rs73136346	ENSG00000179406.6	LINC00174	7.65	1.13e-13	1.03e-10	0.53	0.33	Aortic root size;	chr7:66101095	chr7:66376044~66401338:-
HNSC	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-7.65	1.13e-13	1.03e-10	-0.38	-0.33	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
HNSC	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-7.65	1.13e-13	1.04e-10	-0.52	-0.33	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
HNSC	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-7.65	1.13e-13	1.04e-10	-0.41	-0.33	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
HNSC	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-7.65	1.13e-13	1.04e-10	-0.38	-0.33	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
HNSC	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-7.65	1.13e-13	1.04e-10	-0.36	-0.33	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
HNSC	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-7.65	1.13e-13	1.04e-10	-0.36	-0.33	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	7.65	1.13e-13	1.04e-10	0.46	0.33	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	7.65	1.13e-13	1.04e-10	0.46	0.33	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	7.65	1.14e-13	1.04e-10	0.46	0.33	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
HNSC	cis	rs11079757	0.681	rs34811916	ENSG00000262879.4	RP11-156P1.3	7.65	1.14e-13	1.04e-10	0.41	0.33	Erythema nodosum in inflammatory bowel disease;	chr17:47111431	chr17:46984045~47100323:-
HNSC	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-7.65	1.14e-13	1.04e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	7.65	1.14e-13	1.04e-10	0.23	0.33	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
HNSC	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	7.65	1.14e-13	1.04e-10	0.35	0.33	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
HNSC	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-7.65	1.14e-13	1.04e-10	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
HNSC	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-7.65	1.14e-13	1.04e-10	-0.39	-0.33	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
HNSC	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-7.65	1.14e-13	1.04e-10	-0.33	-0.33	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
HNSC	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-7.65	1.15e-13	1.05e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
HNSC	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	7.65	1.15e-13	1.05e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	7.65	1.15e-13	1.05e-10	0.23	0.33	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
HNSC	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-7.65	1.15e-13	1.05e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
HNSC	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	7.65	1.15e-13	1.05e-10	0.34	0.33	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
HNSC	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	7.65	1.15e-13	1.05e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
HNSC	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-7.65	1.16e-13	1.05e-10	-0.38	-0.33	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
HNSC	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
HNSC	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-7.65	1.16e-13	1.06e-10	-0.39	-0.33	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
HNSC	cis	rs6969780	0.524	rs875898	ENSG00000233429.8	HOTAIRM1	-7.65	1.16e-13	1.06e-10	-0.43	-0.33	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161286	chr7:27095647~27100265:+
HNSC	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	7.65	1.16e-13	1.06e-10	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
HNSC	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	7.65	1.16e-13	1.06e-10	0.48	0.33	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
HNSC	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	7.65	1.16e-13	1.06e-10	0.43	0.33	Height;	chr6:109584789	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-7.65	1.16e-13	1.06e-10	-0.32	-0.33	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
HNSC	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	7.65	1.17e-13	1.06e-10	0.37	0.33	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	7.65	1.17e-13	1.06e-10	0.37	0.33	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
HNSC	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	7.65	1.17e-13	1.07e-10	0.41	0.33	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
HNSC	cis	rs6951245	0.706	rs28483034	ENSG00000224079.1	AC091729.7	-7.65	1.17e-13	1.07e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1074450~1078036:+
HNSC	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	7.65	1.17e-13	1.07e-10	0.44	0.33	Height;	chr6:109706740	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-7.65	1.18e-13	1.07e-10	-0.4	-0.33	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	7.65	1.18e-13	1.07e-10	0.35	0.33	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
HNSC	cis	rs1865760	0.588	rs9467658	ENSG00000272462.2	U91328.19	-7.65	1.18e-13	1.07e-10	-0.33	-0.33	Height;	chr6:26010653	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	7.65	1.18e-13	1.08e-10	0.32	0.33	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	7.65	1.19e-13	1.08e-10	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-7.65	1.19e-13	1.08e-10	-0.46	-0.33	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs36036395	ENSG00000267151.3	RP11-100E5.2	7.65	1.19e-13	1.08e-10	0.44	0.33	Menopause (age at onset);	chr17:43029280	chr17:43444707~43451200:+
HNSC	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	7.65	1.19e-13	1.08e-10	0.33	0.33	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
HNSC	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	7.65	1.19e-13	1.09e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-7.65	1.2e-13	1.09e-10	-0.32	-0.33	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
HNSC	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	7.65	1.2e-13	1.09e-10	0.37	0.33	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	7.65	1.2e-13	1.09e-10	0.37	0.33	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
HNSC	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-7.64	1.2e-13	1.09e-10	-0.32	-0.33	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
HNSC	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	7.64	1.2e-13	1.09e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
HNSC	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	7.64	1.21e-13	1.1e-10	0.36	0.33	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-7.64	1.21e-13	1.1e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	7.64	1.21e-13	1.1e-10	0.48	0.33	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	7.64	1.21e-13	1.1e-10	0.46	0.33	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	7.64	1.21e-13	1.1e-10	0.46	0.33	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
HNSC	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-7.64	1.22e-13	1.11e-10	-0.51	-0.33	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
HNSC	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	7.64	1.22e-13	1.11e-10	0.34	0.33	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
HNSC	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	7.64	1.22e-13	1.11e-10	0.37	0.33	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
HNSC	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	7.64	1.23e-13	1.11e-10	0.37	0.33	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	7.64	1.23e-13	1.11e-10	0.37	0.33	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	7.64	1.23e-13	1.11e-10	0.37	0.33	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
HNSC	cis	rs9341808	0.718	rs2179842	ENSG00000272129.1	RP11-250B2.6	7.64	1.23e-13	1.12e-10	0.4	0.33	Sitting height ratio;	chr6:80269336	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.502	rs11769702	ENSG00000179406.6	LINC00174	-7.64	1.23e-13	1.12e-10	-0.51	-0.33	Aortic root size;	chr7:66255529	chr7:66376044~66401338:-
HNSC	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	7.64	1.24e-13	1.12e-10	0.36	0.33	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	7.64	1.24e-13	1.12e-10	0.25	0.33	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
HNSC	cis	rs6867032	1	rs6867032	ENSG00000249731.1	RP11-259O2.3	-7.64	1.24e-13	1.12e-10	-0.4	-0.33	Gut microbiome composition (winter);	chr5:2014989	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	7.64	1.24e-13	1.12e-10	0.32	0.33	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
HNSC	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	7.64	1.24e-13	1.13e-10	0.37	0.33	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
HNSC	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	7.64	1.24e-13	1.13e-10	0.32	0.33	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.545	rs11770063	ENSG00000179406.6	LINC00174	-7.64	1.24e-13	1.13e-10	-0.52	-0.33	Aortic root size;	chr7:66318029	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs3936065	ENSG00000179406.6	LINC00174	-7.64	1.24e-13	1.13e-10	-0.52	-0.33	Aortic root size;	chr7:66325577	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs4718335	ENSG00000179406.6	LINC00174	-7.64	1.24e-13	1.13e-10	-0.52	-0.33	Aortic root size;	chr7:66339619	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	7.64	1.24e-13	1.13e-10	0.46	0.33	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
HNSC	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	7.64	1.24e-13	1.13e-10	0.41	0.33	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
HNSC	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-7.64	1.25e-13	1.14e-10	-0.63	-0.33	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-7.64	1.25e-13	1.14e-10	-0.63	-0.33	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
HNSC	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	7.64	1.25e-13	1.14e-10	0.34	0.33	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-7.64	1.26e-13	1.14e-10	-0.63	-0.33	Gout;	chr7:66654674	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-7.64	1.26e-13	1.14e-10	-0.63	-0.33	Gout;	chr7:66661502	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-7.64	1.26e-13	1.14e-10	-0.31	-0.33	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	7.64	1.26e-13	1.15e-10	0.47	0.33	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-7.64	1.26e-13	1.15e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
HNSC	cis	rs1933112	0.624	rs1933107	ENSG00000227777.1	RP4-738P11.3	-7.64	1.26e-13	1.15e-10	-0.37	-0.33	Blood protein levels;	chr1:168555657	chr1:168542737~168543354:+
HNSC	cis	rs1799949	0.93	rs2298861	ENSG00000267151.3	RP11-100E5.2	7.64	1.27e-13	1.15e-10	0.44	0.33	Menopause (age at onset);	chr17:43024814	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	7.64	1.28e-13	1.16e-10	0.23	0.33	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
HNSC	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	7.64	1.28e-13	1.16e-10	0.46	0.33	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	7.63	1.29e-13	1.17e-10	0.46	0.33	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	7.63	1.29e-13	1.17e-10	0.46	0.33	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
HNSC	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-7.63	1.3e-13	1.18e-10	-0.4	-0.33	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
HNSC	cis	rs875971	0.545	rs2707851	ENSG00000179406.6	LINC00174	7.63	1.3e-13	1.18e-10	0.51	0.33	Aortic root size;	chr7:66624178	chr7:66376044~66401338:-
HNSC	cis	rs11089937	0.597	rs4821772	ENSG00000211638.2	IGLV8-61	7.63	1.3e-13	1.18e-10	0.32	0.33	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22098700~22099212:+
HNSC	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	7.63	1.3e-13	1.18e-10	0.35	0.33	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
HNSC	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-7.63	1.3e-13	1.18e-10	-0.35	-0.33	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
HNSC	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-7.63	1.3e-13	1.18e-10	-0.31	-0.33	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	7.63	1.3e-13	1.18e-10	0.47	0.33	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	7.63	1.31e-13	1.18e-10	0.34	0.33	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
HNSC	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	7.63	1.31e-13	1.18e-10	0.61	0.33	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
HNSC	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	7.63	1.31e-13	1.19e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
HNSC	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-7.63	1.32e-13	1.19e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-7.63	1.32e-13	1.19e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
HNSC	cis	rs1799949	1	rs72829113	ENSG00000267151.3	RP11-100E5.2	7.63	1.32e-13	1.19e-10	0.44	0.33	Menopause (age at onset);	chr17:43029818	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11653253	ENSG00000267151.3	RP11-100E5.2	7.63	1.32e-13	1.19e-10	0.44	0.33	Menopause (age at onset);	chr17:43030645	chr17:43444707~43451200:+
HNSC	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	1.19e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	7.63	1.33e-13	1.2e-10	0.39	0.33	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
HNSC	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-7.63	1.33e-13	1.2e-10	-0.38	-0.33	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
HNSC	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	7.63	1.33e-13	1.21e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
HNSC	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-7.63	1.34e-13	1.21e-10	-0.42	-0.33	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
HNSC	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
HNSC	cis	rs964184	0.63	rs2075290	ENSG00000254851.1	RP11-109L13.1	-7.63	1.34e-13	1.21e-10	-0.81	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116782580	chr11:117135528~117138582:+
HNSC	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-7.63	1.34e-13	1.21e-10	-0.46	-0.33	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	7.63	1.34e-13	1.21e-10	0.23	0.33	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
HNSC	cis	rs4706831	0.647	rs9350847	ENSG00000272129.1	RP11-250B2.6	7.63	1.35e-13	1.22e-10	0.39	0.33	Joint mobility (Beighton score);	chr6:80179300	chr6:80355424~80356859:+
HNSC	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	7.63	1.35e-13	1.22e-10	0.37	0.33	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
HNSC	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-7.63	1.36e-13	1.22e-10	-0.43	-0.33	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
HNSC	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-7.63	1.36e-13	1.23e-10	-0.35	-0.33	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-7.63	1.36e-13	1.23e-10	-0.35	-0.33	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
HNSC	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-7.63	1.36e-13	1.23e-10	-0.43	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
HNSC	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-7.63	1.36e-13	1.23e-10	-0.35	-0.33	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
HNSC	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-7.63	1.36e-13	1.23e-10	-0.38	-0.33	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
HNSC	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-7.63	1.36e-13	1.23e-10	-0.44	-0.33	Depression;	chr6:28206179	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	7.63	1.37e-13	1.23e-10	0.23	0.33	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
HNSC	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	7.63	1.37e-13	1.23e-10	0.45	0.33	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
HNSC	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-7.63	1.37e-13	1.24e-10	-0.37	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
HNSC	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-7.63	1.37e-13	1.24e-10	-0.31	-0.33	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
HNSC	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	7.63	1.38e-13	1.24e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	7.63	1.38e-13	1.24e-10	0.24	0.33	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	7.63	1.38e-13	1.24e-10	0.24	0.33	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	7.63	1.38e-13	1.24e-10	0.24	0.33	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
HNSC	cis	rs7829975	0.514	rs2979139	ENSG00000173295.6	FAM86B3P	7.62	1.38e-13	1.24e-10	0.38	0.33	Mood instability;	chr8:8410803	chr8:8228595~8244865:+
HNSC	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.24e-10	0.46	0.33	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
HNSC	cis	rs9402743	0.781	rs9494326	ENSG00000217482.2	HMGB1P17	7.62	1.38e-13	1.25e-10	0.37	0.33	Systemic lupus erythematosus;	chr6:135673400	chr6:135636086~135636713:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.25e-10	0.46	0.33	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.25e-10	0.46	0.33	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.25e-10	0.46	0.33	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
HNSC	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-7.62	1.39e-13	1.25e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
HNSC	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	7.62	1.39e-13	1.25e-10	0.37	0.33	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	7.62	1.39e-13	1.25e-10	0.37	0.33	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
HNSC	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-7.62	1.39e-13	1.25e-10	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-7.62	1.39e-13	1.25e-10	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
HNSC	cis	rs867371	1	rs1392976	ENSG00000276710.3	CSPG4P8	7.62	1.39e-13	1.25e-10	0.38	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82459472~82477258:+
HNSC	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	7.62	1.4e-13	1.26e-10	0.38	0.33	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-7.62	1.4e-13	1.26e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.583	rs3759853	ENSG00000259422.1	RP11-593F23.1	7.62	1.4e-13	1.26e-10	0.38	0.33	Blood metabolite levels;	chr15:76295436	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	7.62	1.4e-13	1.27e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-7.62	1.41e-13	1.27e-10	-0.35	-0.33	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
HNSC	cis	rs1799949	1	rs2298862	ENSG00000267151.3	RP11-100E5.2	7.62	1.41e-13	1.27e-10	0.44	0.33	Menopause (age at onset);	chr17:43024671	chr17:43444707~43451200:+
HNSC	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	7.62	1.41e-13	1.27e-10	0.38	0.33	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-7.62	1.41e-13	1.27e-10	-0.46	-0.33	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
HNSC	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	7.62	1.42e-13	1.27e-10	0.4	0.33	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-7.62	1.42e-13	1.28e-10	-0.4	-0.33	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
HNSC	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-7.62	1.42e-13	1.28e-10	-0.42	-0.33	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
HNSC	cis	rs7404843	1	rs7404843	ENSG00000263335.1	AF001548.5	-7.62	1.42e-13	1.28e-10	-0.68	-0.33	Testicular germ cell tumor;	chr16:15436851	chr16:15726674~15732993:+
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	7.62	1.42e-13	1.28e-10	0.46	0.33	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	7.62	1.42e-13	1.28e-10	0.46	0.33	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	7.62	1.44e-13	1.29e-10	0.46	0.33	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
HNSC	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	7.62	1.44e-13	1.29e-10	0.37	0.33	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
HNSC	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-7.62	1.44e-13	1.3e-10	-0.46	-0.33	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
HNSC	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	7.62	1.44e-13	1.3e-10	0.4	0.33	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	7.62	1.44e-13	1.3e-10	0.47	0.33	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-7.62	1.44e-13	1.3e-10	-0.36	-0.33	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
HNSC	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-7.62	1.45e-13	1.3e-10	-0.5	-0.33	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	7.62	1.45e-13	1.31e-10	0.36	0.33	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	7.62	1.46e-13	1.31e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	7.62	1.46e-13	1.31e-10	0.23	0.33	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
HNSC	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-7.62	1.47e-13	1.32e-10	-0.31	-0.33	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
HNSC	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-7.62	1.47e-13	1.32e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	7.62	1.47e-13	1.33e-10	0.47	0.33	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	7.61	1.48e-13	1.33e-10	0.38	0.33	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	7.61	1.48e-13	1.33e-10	0.46	0.33	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-7.61	1.49e-13	1.34e-10	-0.36	-0.33	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
HNSC	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-7.61	1.49e-13	1.34e-10	-0.38	-0.33	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-7.61	1.49e-13	1.34e-10	-0.37	-0.33	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-7.61	1.49e-13	1.34e-10	-0.37	-0.33	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
HNSC	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	7.61	1.49e-13	1.34e-10	0.39	0.33	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	7.61	1.5e-13	1.34e-10	0.24	0.33	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	7.61	1.5e-13	1.34e-10	0.46	0.33	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	7.61	1.5e-13	1.34e-10	0.46	0.33	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs6970498	ENSG00000179406.6	LINC00174	-7.61	1.5e-13	1.35e-10	-0.51	-0.33	Aortic root size;	chr7:66275908	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73146609	ENSG00000179406.6	LINC00174	-7.61	1.5e-13	1.35e-10	-0.51	-0.33	Aortic root size;	chr7:66302477	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs2173571	ENSG00000179406.6	LINC00174	-7.61	1.5e-13	1.35e-10	-0.51	-0.33	Aortic root size;	chr7:66305392	chr7:66376044~66401338:-
HNSC	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-7.61	1.5e-13	1.35e-10	-0.42	-0.33	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
HNSC	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	7.61	1.5e-13	1.35e-10	0.36	0.33	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	7.61	1.51e-13	1.35e-10	0.38	0.33	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
HNSC	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	7.61	1.51e-13	1.35e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
HNSC	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	7.61	1.51e-13	1.36e-10	0.38	0.33	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
HNSC	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
HNSC	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	7.61	1.52e-13	1.36e-10	0.36	0.33	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
HNSC	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	7.61	1.52e-13	1.36e-10	0.34	0.33	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
HNSC	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	7.61	1.52e-13	1.37e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	7.61	1.52e-13	1.37e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	7.61	1.52e-13	1.37e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
HNSC	cis	rs7942368	1	rs7933092	ENSG00000255100.1	RP11-21L23.3	7.61	1.52e-13	1.37e-10	0.42	0.33	Endometriosis;	chr11:76764444	chr11:76782581~76783062:-
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	7.61	1.53e-13	1.37e-10	0.46	0.33	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	7.61	1.53e-13	1.37e-10	0.46	0.33	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
HNSC	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-7.61	1.53e-13	1.37e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
HNSC	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	7.61	1.53e-13	1.37e-10	0.51	0.33	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	7.61	1.53e-13	1.37e-10	0.52	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
HNSC	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	7.61	1.53e-13	1.37e-10	0.37	0.33	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	7.61	1.53e-13	1.37e-10	0.37	0.33	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
HNSC	cis	rs12439619	0.693	rs9944185	ENSG00000276710.3	CSPG4P8	-7.61	1.53e-13	1.38e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82459472~82477258:+
HNSC	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-7.61	1.54e-13	1.38e-10	-0.41	-0.33	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	7.61	1.54e-13	1.38e-10	0.46	0.33	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	7.61	1.54e-13	1.38e-10	0.46	0.33	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs10261710	ENSG00000179406.6	LINC00174	-7.61	1.54e-13	1.38e-10	-0.52	-0.33	Aortic root size;	chr7:66249202	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-7.61	1.56e-13	1.39e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
HNSC	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-7.61	1.56e-13	1.4e-10	-0.44	-0.33	Depression;	chr6:28184805	chr6:28115628~28116551:+
HNSC	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-7.61	1.57e-13	1.4e-10	-0.33	-0.33	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
HNSC	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.61	1.57e-13	1.4e-10	0.35	0.33	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
HNSC	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	7.61	1.57e-13	1.4e-10	0.38	0.33	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	7.61	1.57e-13	1.4e-10	0.38	0.33	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
HNSC	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	7.61	1.57e-13	1.41e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
HNSC	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-7.61	1.58e-13	1.41e-10	-0.37	-0.33	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	7.61	1.58e-13	1.41e-10	0.46	0.33	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	7.61	1.58e-13	1.41e-10	0.46	0.33	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000173295.6	FAM86B3P	7.6	1.58e-13	1.42e-10	0.39	0.33	Joint mobility (Beighton score);	chr8:9014200	chr8:8228595~8244865:+
HNSC	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	7.6	1.59e-13	1.42e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
HNSC	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-7.6	1.59e-13	1.42e-10	-0.48	-0.33	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
HNSC	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	7.6	1.6e-13	1.43e-10	0.44	0.33	Height;	chr6:109706514	chr6:109382795~109383666:+
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	7.6	1.6e-13	1.43e-10	0.24	0.33	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
HNSC	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	7.6	1.6e-13	1.43e-10	0.61	0.33	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
HNSC	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	7.6	1.6e-13	1.43e-10	0.38	0.33	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
HNSC	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	7.6	1.6e-13	1.43e-10	0.45	0.33	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
HNSC	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	7.6	1.6e-13	1.43e-10	0.37	0.33	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
HNSC	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-7.6	1.62e-13	1.45e-10	-0.42	-0.33	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
HNSC	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	7.6	1.62e-13	1.45e-10	0.42	0.33	Depression;	chr6:28187640	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	7.6	1.62e-13	1.45e-10	0.23	0.33	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	7.6	1.62e-13	1.45e-10	0.38	0.33	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
HNSC	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	7.6	1.62e-13	1.45e-10	0.34	0.33	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
HNSC	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	7.6	1.63e-13	1.45e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	7.6	1.63e-13	1.46e-10	0.32	0.33	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
HNSC	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-7.6	1.64e-13	1.46e-10	-0.51	-0.33	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
HNSC	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	7.6	1.65e-13	1.48e-10	0.46	0.33	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
HNSC	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	7.6	1.65e-13	1.48e-10	0.46	0.33	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	7.6	1.66e-13	1.48e-10	0.23	0.33	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
HNSC	cis	rs867371	1	rs9944197	ENSG00000276710.3	CSPG4P8	-7.6	1.66e-13	1.48e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	7.6	1.66e-13	1.48e-10	0.23	0.33	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
HNSC	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	7.6	1.66e-13	1.49e-10	0.42	0.33	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
HNSC	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	7.6	1.67e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	7.6	1.67e-13	1.49e-10	0.45	0.33	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	7.6	1.69e-13	1.51e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
HNSC	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-7.59	1.7e-13	1.52e-10	-0.35	-0.33	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-7.59	1.7e-13	1.52e-10	-0.35	-0.33	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
HNSC	cis	rs9341808	0.754	rs978814	ENSG00000272129.1	RP11-250B2.6	7.59	1.7e-13	1.52e-10	0.4	0.33	Sitting height ratio;	chr6:80250195	chr6:80355424~80356859:+
HNSC	cis	rs6951245	0.832	rs10266519	ENSG00000224079.1	AC091729.7	-7.59	1.71e-13	1.52e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1074450~1078036:+
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	7.59	1.71e-13	1.53e-10	0.46	0.33	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	7.59	1.71e-13	1.53e-10	0.31	0.33	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
HNSC	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	7.59	1.71e-13	1.53e-10	0.45	0.33	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
HNSC	cis	rs454422	0.767	rs236126	ENSG00000275632.1	RP5-967N21.11	7.59	1.72e-13	1.53e-10	0.37	0.33	HIV-1 viral setpoint;	chr20:5997495	chr20:6000418~6000941:+
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	7.59	1.72e-13	1.53e-10	0.45	0.33	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-7.59	1.72e-13	1.53e-10	-0.37	-0.33	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
HNSC	cis	rs867371	1	rs1174543	ENSG00000276710.3	CSPG4P8	7.59	1.72e-13	1.54e-10	0.38	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs11855089	ENSG00000276710.3	CSPG4P8	-7.59	1.72e-13	1.54e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82459472~82477258:+
HNSC	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-7.59	1.73e-13	1.54e-10	-0.46	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
HNSC	cis	rs2579103	0.507	rs10777241	ENSG00000258183.4	RP11-753N8.1	7.59	1.73e-13	1.54e-10	0.38	0.33	Body mass index;	chr12:90279410	chr12:90280894~90300340:+
HNSC	cis	rs7048146	0.899	rs4595205	ENSG00000213539.4	YBX1P6	7.59	1.74e-13	1.55e-10	0.39	0.33	Vascular brain injury;	chr9:109575965	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.899	rs4978836	ENSG00000213539.4	YBX1P6	7.59	1.74e-13	1.55e-10	0.39	0.33	Vascular brain injury;	chr9:109576701	chr9:109532830~109534332:-
HNSC	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-7.59	1.75e-13	1.55e-10	-0.34	-0.33	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
HNSC	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	7.59	1.76e-13	1.56e-10	0.43	0.33	Height;	chr6:109588639	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	7.59	1.76e-13	1.56e-10	0.43	0.33	Height;	chr6:109589051	chr6:109382795~109383666:+
HNSC	cis	rs6951245	0.678	rs28600085	ENSG00000224079.1	AC091729.7	-7.59	1.76e-13	1.57e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1074450~1078036:+
HNSC	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	7.59	1.76e-13	1.57e-10	0.39	0.33	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
HNSC	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-7.59	1.76e-13	1.57e-10	-0.31	-0.33	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
HNSC	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-7.59	1.77e-13	1.57e-10	-0.32	-0.33	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.502	rs2946580	ENSG00000179406.6	LINC00174	7.59	1.77e-13	1.58e-10	0.52	0.33	Aortic root size;	chr7:66066855	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-7.59	1.78e-13	1.58e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
HNSC	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-7.59	1.78e-13	1.58e-10	-0.46	-0.33	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	7.59	1.79e-13	1.59e-10	0.23	0.33	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	7.59	1.79e-13	1.59e-10	0.23	0.33	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
HNSC	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	7.59	1.79e-13	1.59e-10	0.43	0.33	Height;	chr6:109347707	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	7.59	1.79e-13	1.59e-10	0.45	0.33	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-7.59	1.8e-13	1.59e-10	-0.38	-0.33	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
HNSC	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	7.59	1.8e-13	1.6e-10	0.43	0.33	Height;	chr6:109518783	chr6:109382795~109383666:+
HNSC	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-7.59	1.81e-13	1.6e-10	-0.31	-0.33	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	7.59	1.81e-13	1.61e-10	0.4	0.33	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
HNSC	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
HNSC	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
HNSC	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	7.58	1.81e-13	1.61e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
HNSC	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	7.58	1.82e-13	1.61e-10	0.39	0.33	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	7.58	1.82e-13	1.62e-10	0.24	0.33	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
HNSC	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.82e-13	1.62e-10	-0.37	-0.33	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
HNSC	cis	rs17270561	0.697	rs9366633	ENSG00000272462.2	U91328.19	-7.58	1.83e-13	1.62e-10	-0.34	-0.33	Iron status biomarkers;	chr6:25837826	chr6:25992662~26001775:+
HNSC	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	7.58	1.83e-13	1.63e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
HNSC	cis	rs9341808	0.617	rs9294170	ENSG00000272129.1	RP11-250B2.6	7.58	1.83e-13	1.63e-10	0.39	0.33	Sitting height ratio;	chr6:80104363	chr6:80355424~80356859:+
HNSC	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	7.58	1.84e-13	1.63e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
HNSC	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	7.58	1.84e-13	1.63e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
HNSC	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-7.58	1.84e-13	1.64e-10	-0.36	-0.33	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
HNSC	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	7.58	1.85e-13	1.64e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	7.58	1.85e-13	1.64e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
HNSC	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	7.58	1.85e-13	1.64e-10	0.36	0.33	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	7.58	1.85e-13	1.64e-10	0.36	0.33	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	7.58	1.85e-13	1.64e-10	0.36	0.33	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-7.58	1.86e-13	1.65e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
HNSC	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-7.58	1.86e-13	1.65e-10	-0.36	-0.33	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
HNSC	cis	rs1021993	0.545	rs1006317	ENSG00000231648.1	RP11-372M18.2	-7.58	1.86e-13	1.65e-10	-0.58	-0.33	Gut microbiome composition (winter);	chr1:209379291	chr1:209367662~209379690:+
HNSC	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	7.58	1.87e-13	1.65e-10	0.4	0.33	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
HNSC	cis	rs6951245	0.786	rs77943789	ENSG00000224079.1	AC091729.7	-7.58	1.87e-13	1.66e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1074450~1078036:+
HNSC	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-7.58	1.87e-13	1.66e-10	-0.41	-0.33	Height;	chr11:118855938	chr11:118704607~118750263:+
HNSC	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-7.58	1.88e-13	1.67e-10	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
HNSC	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	7.58	1.88e-13	1.67e-10	0.39	0.33	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
HNSC	cis	rs6471393	0.964	rs11549490	ENSG00000253848.1	RP11-10N23.5	-7.58	1.88e-13	1.67e-10	-0.4	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732822	chr8:93741193~93744534:+
HNSC	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-7.58	1.89e-13	1.67e-10	-0.43	-0.33	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs17647717	ENSG00000228638.1	FCF1P2	-7.58	1.89e-13	1.68e-10	-0.33	-0.33	Coronary artery disease;	chr3:48263966	chr3:48290793~48291375:-
HNSC	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.89e-13	1.68e-10	-0.38	-0.33	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
HNSC	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-7.58	1.9e-13	1.68e-10	-0.35	-0.33	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
HNSC	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-7.58	1.9e-13	1.68e-10	-0.34	-0.33	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
HNSC	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	7.58	1.92e-13	1.7e-10	0.37	0.33	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
HNSC	cis	rs7615952	0.673	rs16834637	ENSG00000241288.6	RP11-379B18.5	-7.58	1.92e-13	1.7e-10	-0.55	-0.33	Blood pressure (smoking interaction);	chr3:125886628	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	7.58	1.92e-13	1.7e-10	0.48	0.33	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
HNSC	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	7.58	1.93e-13	1.7e-10	0.42	0.33	Height;	chr6:109351795	chr6:109382795~109383666:+
HNSC	cis	rs4853012	0.752	rs13413795	ENSG00000257800.1	FNBP1P1	7.58	1.93e-13	1.71e-10	0.37	0.33	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74120680~74123218:+
HNSC	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	7.58	1.94e-13	1.71e-10	0.39	0.33	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	7.58	1.94e-13	1.71e-10	0.46	0.33	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs1638724	ENSG00000179406.6	LINC00174	7.57	1.94e-13	1.72e-10	0.5	0.33	Aortic root size;	chr7:66575494	chr7:66376044~66401338:-
HNSC	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-7.57	1.95e-13	1.72e-10	-0.35	-0.33	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
HNSC	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	7.57	1.95e-13	1.72e-10	0.47	0.33	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
HNSC	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	7.57	1.95e-13	1.73e-10	0.36	0.33	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	7.57	1.96e-13	1.73e-10	0.46	0.33	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	7.57	1.96e-13	1.73e-10	0.46	0.33	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	7.57	1.97e-13	1.74e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
HNSC	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	7.57	1.98e-13	1.75e-10	0.41	0.33	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
HNSC	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	7.57	1.98e-13	1.75e-10	0.41	0.33	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
HNSC	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-7.57	1.98e-13	1.75e-10	-0.29	-0.33	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
HNSC	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	7.57	1.98e-13	1.75e-10	0.41	0.33	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
HNSC	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-7.57	1.99e-13	1.76e-10	-0.31	-0.33	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
HNSC	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	7.57	2e-13	1.76e-10	0.36	0.33	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	7.57	2e-13	1.77e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
HNSC	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	7.57	2.01e-13	1.77e-10	0.41	0.33	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
HNSC	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	7.57	2.01e-13	1.77e-10	0.41	0.33	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
HNSC	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-7.57	2.01e-13	1.77e-10	-0.32	-0.33	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
HNSC	cis	rs867371	1	rs6495642	ENSG00000276710.3	CSPG4P8	-7.57	2.01e-13	1.78e-10	-0.39	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82459472~82477258:+
HNSC	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	7.57	2.01e-13	1.78e-10	0.38	0.33	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-7.57	2.02e-13	1.78e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	7.57	2.02e-13	1.78e-10	0.37	0.33	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
HNSC	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-7.57	2.03e-13	1.79e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	7.57	2.03e-13	1.79e-10	0.36	0.33	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	7.57	2.04e-13	1.79e-10	0.36	0.33	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-7.57	2.04e-13	1.8e-10	-0.31	-0.33	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-7.57	2.04e-13	1.8e-10	-0.45	-0.33	Depression;	chr6:28192182	chr6:28115628~28116551:+
HNSC	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	7.57	2.05e-13	1.8e-10	0.43	0.33	Height;	chr6:109503623	chr6:109382795~109383666:+
HNSC	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	7.57	2.05e-13	1.81e-10	0.41	0.33	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	7.57	2.05e-13	1.81e-10	0.24	0.33	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
HNSC	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	7.57	2.06e-13	1.81e-10	0.4	0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	7.57	2.07e-13	1.82e-10	0.23	0.33	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
HNSC	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	7.56	2.08e-13	1.83e-10	0.61	0.33	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-7.56	2.08e-13	1.83e-10	-0.38	-0.33	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
HNSC	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	7.56	2.08e-13	1.83e-10	0.42	0.33	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
HNSC	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-7.56	2.09e-13	1.83e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
HNSC	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	7.56	2.09e-13	1.84e-10	0.31	0.33	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	7.56	2.1e-13	1.85e-10	0.36	0.33	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	7.56	2.1e-13	1.85e-10	0.36	0.33	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	7.56	2.1e-13	1.85e-10	0.36	0.33	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	7.56	2.1e-13	1.85e-10	0.31	0.33	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-7.56	2.1e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-7.56	2.1e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-7.56	2.1e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-7.56	2.11e-13	1.85e-10	-0.43	-0.33	Depression;	chr6:28205175	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-7.56	2.11e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
HNSC	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	7.56	2.11e-13	1.86e-10	0.34	0.33	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
HNSC	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-7.56	2.13e-13	1.87e-10	-0.39	-0.33	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
HNSC	cis	rs7626444	1	rs7626444	ENSG00000272359.1	U4	-7.56	2.13e-13	1.87e-10	-0.38	-0.33	Monocyte count;	chr3:196778031	chr3:196747192~196747324:-
HNSC	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	7.56	2.13e-13	1.87e-10	0.33	0.33	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	7.56	2.13e-13	1.87e-10	0.45	0.33	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
HNSC	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-7.56	2.13e-13	1.87e-10	-0.42	-0.33	Depression;	chr6:28201380	chr6:28115628~28116551:+
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	7.56	2.14e-13	1.87e-10	0.37	0.33	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
HNSC	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	7.56	2.14e-13	1.88e-10	0.51	0.33	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	7.56	2.15e-13	1.89e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
HNSC	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-7.56	2.15e-13	1.89e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
HNSC	cis	rs6471393	0.929	rs56108220	ENSG00000253848.1	RP11-10N23.5	7.56	2.16e-13	1.9e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93736965	chr8:93741193~93744534:+
HNSC	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-7.56	2.17e-13	1.91e-10	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
HNSC	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-7.56	2.18e-13	1.91e-10	-0.31	-0.33	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
HNSC	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-7.56	2.19e-13	1.92e-10	-0.31	-0.33	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
HNSC	cis	rs6435862	0.5	rs12477063	ENSG00000229267.2	AC072062.1	7.56	2.2e-13	1.93e-10	0.39	0.33	Neuroblastoma (high-risk);	chr2:214808940	chr2:214810229~214963274:+
HNSC	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-7.56	2.2e-13	1.93e-10	-0.35	-0.33	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
HNSC	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	7.56	2.2e-13	1.93e-10	0.34	0.33	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
HNSC	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-7.56	2.22e-13	1.94e-10	-0.4	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
HNSC	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	7.56	2.23e-13	1.95e-10	0.41	0.33	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
HNSC	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
HNSC	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	7.55	2.23e-13	1.95e-10	0.31	0.33	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
HNSC	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-7.55	2.23e-13	1.96e-10	-0.48	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	7.55	2.24e-13	1.96e-10	0.46	0.33	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	7.55	2.25e-13	1.97e-10	0.23	0.33	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
HNSC	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-7.55	2.26e-13	1.98e-10	-0.29	-0.33	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
HNSC	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-7.55	2.26e-13	1.98e-10	-0.34	-0.33	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
HNSC	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-7.55	2.26e-13	1.98e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
HNSC	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.27e-13	1.99e-10	-0.36	-0.33	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
HNSC	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-7.55	2.28e-13	1.99e-10	-0.47	-0.33	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
HNSC	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	7.55	2.29e-13	2.01e-10	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	7.55	2.29e-13	2.01e-10	0.48	0.33	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	7.55	2.3e-13	2.01e-10	0.46	0.33	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-7.55	2.31e-13	2.02e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000211972.2	IGHV3-66	7.55	2.31e-13	2.02e-10	0.23	0.33	Kawasaki disease;	chr14:106767802	chr14:106675017~106675544:-
HNSC	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	7.55	2.32e-13	2.03e-10	0.72	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
HNSC	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	7.55	2.32e-13	2.03e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.32e-13	2.03e-10	-0.37	-0.33	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
HNSC	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-7.55	2.32e-13	2.03e-10	-0.31	-0.33	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	7.55	2.33e-13	2.03e-10	0.23	0.33	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
HNSC	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	7.55	2.34e-13	2.04e-10	0.34	0.33	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
HNSC	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	7.55	2.34e-13	2.05e-10	0.32	0.33	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	7.55	2.35e-13	2.06e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-7.55	2.36e-13	2.06e-10	-0.33	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	7.55	2.36e-13	2.07e-10	0.45	0.33	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.37e-13	2.07e-10	-0.37	-0.33	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
HNSC	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-7.55	2.37e-13	2.07e-10	-0.34	-0.33	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
HNSC	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-7.55	2.38e-13	2.08e-10	-0.34	-0.33	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
HNSC	cis	rs875971	0.545	rs2420612	ENSG00000179406.6	LINC00174	-7.55	2.38e-13	2.08e-10	-0.51	-0.33	Aortic root size;	chr7:66536825	chr7:66376044~66401338:-
HNSC	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-7.54	2.39e-13	2.08e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
HNSC	cis	rs7942368	1	rs1440979	ENSG00000255100.1	RP11-21L23.3	7.54	2.4e-13	2.1e-10	0.42	0.33	Endometriosis;	chr11:76784085	chr11:76782581~76783062:-
HNSC	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-7.54	2.41e-13	2.1e-10	-0.32	-0.33	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
HNSC	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-7.54	2.41e-13	2.1e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
HNSC	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
HNSC	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	7.54	2.41e-13	2.11e-10	0.41	0.33	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
HNSC	cis	rs1799949	1	rs915945	ENSG00000267151.3	RP11-100E5.2	7.54	2.41e-13	2.11e-10	0.44	0.33	Menopause (age at onset);	chr17:43027847	chr17:43444707~43451200:+
HNSC	cis	rs7404843	0.777	rs6498552	ENSG00000263335.1	AF001548.5	-7.54	2.43e-13	2.12e-10	-0.64	-0.33	Testicular germ cell tumor;	chr16:15446044	chr16:15726674~15732993:+
HNSC	cis	rs7404843	0.85	rs6498553	ENSG00000263335.1	AF001548.5	-7.54	2.43e-13	2.12e-10	-0.64	-0.33	Testicular germ cell tumor;	chr16:15446045	chr16:15726674~15732993:+
HNSC	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-7.54	2.43e-13	2.12e-10	-0.39	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	7.54	2.44e-13	2.13e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	7.54	2.45e-13	2.13e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	7.54	2.45e-13	2.13e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	7.54	2.45e-13	2.14e-10	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
HNSC	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-7.54	2.45e-13	2.14e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
HNSC	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	7.54	2.46e-13	2.15e-10	0.34	0.33	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	7.54	2.46e-13	2.15e-10	0.32	0.33	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
HNSC	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-7.54	2.47e-13	2.15e-10	-0.37	-0.33	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
HNSC	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	7.54	2.48e-13	2.16e-10	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
HNSC	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-7.54	2.48e-13	2.16e-10	-0.31	-0.33	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
HNSC	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-7.54	2.5e-13	2.18e-10	-0.32	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	7.54	2.51e-13	2.19e-10	0.23	0.33	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
HNSC	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-7.54	2.51e-13	2.19e-10	-0.35	-0.33	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	7.54	2.52e-13	2.19e-10	0.46	0.33	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
HNSC	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-7.54	2.52e-13	2.19e-10	-0.45	-0.33	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
HNSC	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-7.54	2.52e-13	2.2e-10	-0.35	-0.33	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
HNSC	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	7.54	2.53e-13	2.2e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
HNSC	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-7.54	2.54e-13	2.21e-10	-0.35	-0.33	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
HNSC	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	7.54	2.54e-13	2.21e-10	0.33	0.33	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
HNSC	cis	rs526231	0.697	rs168820	ENSG00000175749.11	EIF3KP1	7.54	2.55e-13	2.21e-10	0.48	0.33	Primary biliary cholangitis;	chr5:103306972	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	7.54	2.55e-13	2.22e-10	0.37	0.33	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	7.54	2.55e-13	2.22e-10	0.37	0.33	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
HNSC	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-7.54	2.55e-13	2.22e-10	-0.32	-0.33	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000254340.1	RP11-10A14.3	7.53	2.56e-13	2.23e-10	0.41	0.33	Joint mobility (Beighton score);	chr8:9002766	chr8:9141424~9145435:+
HNSC	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-7.53	2.56e-13	2.23e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
HNSC	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	7.53	2.57e-13	2.23e-10	0.37	0.33	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
HNSC	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	7.53	2.57e-13	2.23e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
HNSC	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-7.53	2.57e-13	2.23e-10	-0.41	-0.33	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
HNSC	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-7.53	2.59e-13	2.25e-10	-0.36	-0.33	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	7.53	2.59e-13	2.25e-10	0.46	0.33	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
HNSC	cis	rs7942368	1	rs1440980	ENSG00000255100.1	RP11-21L23.3	7.53	2.6e-13	2.26e-10	0.42	0.33	Endometriosis;	chr11:76784032	chr11:76782581~76783062:-
HNSC	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	7.53	2.6e-13	2.26e-10	0.37	0.33	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
HNSC	cis	rs8177876	0.584	rs2549899	ENSG00000261061.1	RP11-303E16.2	7.53	2.61e-13	2.27e-10	0.48	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81030770~81031485:+
HNSC	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	7.53	2.61e-13	2.27e-10	0.49	0.33	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
HNSC	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	7.53	2.62e-13	2.28e-10	0.62	0.33	Gout;	chr7:66682070	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	7.53	2.62e-13	2.28e-10	0.62	0.33	Gout;	chr7:66682162	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66679692	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66692349	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66693433	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66694214	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66701371	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66702658	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66706390	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66710076	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	7.53	2.63e-13	2.28e-10	0.45	0.33	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	7.53	2.64e-13	2.29e-10	0.34	0.33	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
HNSC	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-7.53	2.64e-13	2.29e-10	-0.31	-0.33	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	7.53	2.64e-13	2.29e-10	0.24	0.33	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
HNSC	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-7.53	2.65e-13	2.29e-10	-0.36	-0.33	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
HNSC	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	7.53	2.65e-13	2.3e-10	0.41	0.33	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
HNSC	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-7.53	2.65e-13	2.3e-10	-0.37	-0.33	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
HNSC	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	7.53	2.66e-13	2.3e-10	0.39	0.33	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	7.53	2.66e-13	2.3e-10	0.34	0.33	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-7.53	2.66e-13	2.31e-10	-0.41	-0.33	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	7.53	2.67e-13	2.32e-10	0.62	0.33	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	7.53	2.68e-13	2.32e-10	0.47	0.33	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
HNSC	cis	rs6471393	0.964	rs3813853	ENSG00000253848.1	RP11-10N23.5	7.53	2.68e-13	2.32e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93740526	chr8:93741193~93744534:+
HNSC	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-7.53	2.68e-13	2.32e-10	-0.31	-0.33	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	7.53	2.68e-13	2.32e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	7.53	2.68e-13	2.32e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	7.53	2.68e-13	2.32e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
HNSC	cis	rs6471393	0.929	rs4734251	ENSG00000253848.1	RP11-10N23.5	7.53	2.68e-13	2.32e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744195	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.929	rs4734252	ENSG00000253848.1	RP11-10N23.5	7.53	2.68e-13	2.32e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744286	chr8:93741193~93744534:+
HNSC	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	7.53	2.69e-13	2.33e-10	0.39	0.33	Height;	chr4:55363436	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-7.53	2.69e-13	2.33e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-7.53	2.7e-13	2.33e-10	-0.38	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-7.53	2.7e-13	2.33e-10	-0.43	-0.33	Depression;	chr6:28198669	chr6:28115628~28116551:+
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	7.53	2.7e-13	2.33e-10	0.31	0.33	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	7.53	2.7e-13	2.33e-10	0.31	0.33	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	7.53	2.71e-13	2.34e-10	0.35	0.33	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
HNSC	cis	rs6951245	0.744	rs10265758	ENSG00000224079.1	AC091729.7	-7.53	2.71e-13	2.34e-10	-0.51	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1074450~1078036:+
HNSC	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	7.53	2.71e-13	2.34e-10	0.38	0.33	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
HNSC	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-7.53	2.71e-13	2.35e-10	-0.38	-0.33	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
HNSC	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-7.53	2.71e-13	2.35e-10	-0.9	-0.33	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
HNSC	cis	rs10080237	0.564	rs2490232	ENSG00000272129.1	RP11-250B2.6	-7.53	2.72e-13	2.35e-10	-0.37	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80105085	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000173295.6	FAM86B3P	7.53	2.72e-13	2.35e-10	0.38	0.33	Joint mobility (Beighton score);	chr8:9012918	chr8:8228595~8244865:+
HNSC	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.53	2.73e-13	2.36e-10	-0.35	-0.33	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
HNSC	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-7.53	2.73e-13	2.36e-10	-0.36	-0.33	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	7.53	2.73e-13	2.36e-10	0.45	0.33	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
HNSC	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	7.53	2.73e-13	2.36e-10	0.5	0.33	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.502	rs1796227	ENSG00000179406.6	LINC00174	7.53	2.73e-13	2.36e-10	0.5	0.33	Aortic root size;	chr7:66622032	chr7:66376044~66401338:-
HNSC	cis	rs1799949	1	rs12942277	ENSG00000267151.3	RP11-100E5.2	7.52	2.75e-13	2.38e-10	0.44	0.33	Menopause (age at onset);	chr17:43035957	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs34616041	ENSG00000267151.3	RP11-100E5.2	7.52	2.75e-13	2.38e-10	0.44	0.33	Menopause (age at onset);	chr17:43036769	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
HNSC	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	7.52	2.75e-13	2.38e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
HNSC	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	7.52	2.76e-13	2.39e-10	0.37	0.33	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	7.52	2.77e-13	2.39e-10	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
HNSC	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	7.52	2.79e-13	2.41e-10	0.31	0.33	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
HNSC	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	7.52	2.8e-13	2.42e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	7.52	2.8e-13	2.42e-10	0.23	0.33	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
HNSC	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	7.52	2.8e-13	2.42e-10	0.43	0.33	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
HNSC	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-7.52	2.82e-13	2.43e-10	-0.32	-0.33	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
HNSC	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-7.52	2.82e-13	2.44e-10	-0.32	-0.33	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
HNSC	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-7.52	2.82e-13	2.44e-10	-0.49	-0.33	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
HNSC	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.82e-13	2.44e-10	-0.37	-0.33	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
HNSC	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	7.52	2.83e-13	2.45e-10	0.4	0.33	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
HNSC	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	7.52	2.84e-13	2.45e-10	0.36	0.33	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	7.52	2.84e-13	2.45e-10	0.36	0.33	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	7.52	2.84e-13	2.45e-10	0.36	0.33	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-7.52	2.85e-13	2.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-7.52	2.85e-13	2.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-7.52	2.85e-13	2.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
HNSC	cis	rs2980439	0.607	rs2980419	ENSG00000173295.6	FAM86B3P	7.52	2.85e-13	2.46e-10	0.39	0.33	Neuroticism;	chr8:8256619	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	7.52	2.85e-13	2.46e-10	0.23	0.33	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	7.52	2.85e-13	2.46e-10	0.23	0.33	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	7.52	2.85e-13	2.46e-10	0.23	0.33	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	7.52	2.85e-13	2.46e-10	0.37	0.33	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
HNSC	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-7.52	2.85e-13	2.46e-10	-0.46	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
HNSC	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-7.52	2.85e-13	2.46e-10	-0.46	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
HNSC	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-7.52	2.85e-13	2.46e-10	-0.32	-0.33	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
HNSC	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
HNSC	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-7.52	2.87e-13	2.47e-10	-0.62	-0.33	Gout;	chr7:66645053	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs1796222	ENSG00000179406.6	LINC00174	7.52	2.87e-13	2.48e-10	0.5	0.33	Aortic root size;	chr7:66592167	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	7.52	2.88e-13	2.48e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
HNSC	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	7.52	2.88e-13	2.48e-10	0.36	0.33	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
HNSC	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	7.52	2.88e-13	2.48e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
HNSC	cis	rs6867032	1	rs4975794	ENSG00000249731.1	RP11-259O2.3	-7.52	2.88e-13	2.48e-10	-0.4	-0.33	Gut microbiome composition (winter);	chr5:2015216	chr5:1968094~1969013:+
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	7.52	2.88e-13	2.49e-10	0.23	0.33	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
HNSC	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-7.52	2.89e-13	2.49e-10	-0.31	-0.33	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-7.52	2.89e-13	2.49e-10	-0.31	-0.33	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
HNSC	cis	rs4141404	0.582	rs5753630	ENSG00000236132.1	CTA-440B3.1	-7.52	2.89e-13	2.49e-10	-0.37	-0.33	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:31816379~31817491:-
HNSC	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-7.52	2.9e-13	2.5e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
HNSC	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	7.52	2.9e-13	2.5e-10	0.4	0.33	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
HNSC	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	7.52	2.9e-13	2.5e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.545	rs6460298	ENSG00000179406.6	LINC00174	-7.52	2.91e-13	2.51e-10	-0.49	-0.33	Aortic root size;	chr7:66442783	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs75577046	ENSG00000179406.6	LINC00174	-7.52	2.91e-13	2.51e-10	-0.49	-0.33	Aortic root size;	chr7:66493729	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs3735147	ENSG00000179406.6	LINC00174	-7.52	2.91e-13	2.51e-10	-0.49	-0.33	Aortic root size;	chr7:66505541	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	7.52	2.91e-13	2.51e-10	0.45	0.33	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	7.52	2.91e-13	2.51e-10	0.45	0.33	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
HNSC	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	7.52	2.92e-13	2.51e-10	0.39	0.33	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
HNSC	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	7.52	2.92e-13	2.51e-10	0.4	0.33	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
HNSC	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	7.52	2.92e-13	2.51e-10	0.45	0.33	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs75840613	ENSG00000179406.6	LINC00174	-7.52	2.92e-13	2.52e-10	-0.5	-0.33	Aortic root size;	chr7:66376399	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.63	-0.33	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	7.51	2.94e-13	2.53e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
HNSC	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-7.51	2.96e-13	2.55e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
HNSC	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-7.51	2.97e-13	2.55e-10	-0.43	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
HNSC	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	7.51	2.97e-13	2.55e-10	0.4	0.33	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
HNSC	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	7.51	2.97e-13	2.55e-10	0.35	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
HNSC	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	7.51	2.97e-13	2.55e-10	0.34	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
HNSC	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-7.51	2.99e-13	2.57e-10	-0.38	-0.33	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
HNSC	cis	rs7615952	0.673	rs34209763	ENSG00000241288.6	RP11-379B18.5	-7.51	3e-13	2.58e-10	-0.54	-0.33	Blood pressure (smoking interaction);	chr3:125880752	chr3:125827238~125916384:-
HNSC	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-7.51	3e-13	2.58e-10	-0.37	-0.33	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
HNSC	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	7.51	3.01e-13	2.59e-10	0.34	0.33	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
HNSC	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-7.51	3.01e-13	2.59e-10	-0.33	-0.33	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
HNSC	cis	rs7942368	1	rs1837680	ENSG00000255100.1	RP11-21L23.3	7.51	3.02e-13	2.59e-10	0.41	0.33	Endometriosis;	chr11:76790407	chr11:76782581~76783062:-
HNSC	cis	rs7942368	1	rs4309181	ENSG00000255100.1	RP11-21L23.3	7.51	3.02e-13	2.6e-10	0.41	0.33	Endometriosis;	chr11:76790661	chr11:76782581~76783062:-
HNSC	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	7.51	3.03e-13	2.6e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
HNSC	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-7.51	3.04e-13	2.61e-10	-0.37	-0.33	Migraine;	chr4:56879851	chr4:56960927~56961373:-
HNSC	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-7.51	3.04e-13	2.61e-10	-0.37	-0.33	Migraine;	chr4:56880007	chr4:56960927~56961373:-
HNSC	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	7.51	3.04e-13	2.61e-10	0.32	0.33	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
HNSC	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-7.51	3.04e-13	2.61e-10	-0.43	-0.33	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
HNSC	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	7.51	3.05e-13	2.61e-10	0.39	0.33	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
HNSC	cis	rs6951245	0.744	rs10265736	ENSG00000224079.1	AC091729.7	-7.51	3.07e-13	2.63e-10	-0.51	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1074450~1078036:+
HNSC	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	7.51	3.08e-13	2.64e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	7.51	3.08e-13	2.64e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-7.51	3.08e-13	2.65e-10	-0.56	-0.33	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
HNSC	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-7.51	3.09e-13	2.65e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
HNSC	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	7.51	3.09e-13	2.65e-10	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	7.51	3.1e-13	2.66e-10	0.59	0.33	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
HNSC	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-7.51	3.11e-13	2.66e-10	-0.51	-0.33	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
HNSC	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-7.51	3.11e-13	2.66e-10	-0.51	-0.33	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
HNSC	cis	rs867371	1	rs7181655	ENSG00000276710.3	CSPG4P8	-7.51	3.11e-13	2.66e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs7180584	ENSG00000276710.3	CSPG4P8	-7.51	3.11e-13	2.66e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82459472~82477258:+
HNSC	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-7.51	3.12e-13	2.67e-10	-0.31	-0.33	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-7.51	3.12e-13	2.67e-10	-0.31	-0.33	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-7.51	3.12e-13	2.67e-10	-0.31	-0.33	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
HNSC	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-7.51	3.13e-13	2.68e-10	-0.31	-0.33	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-7.51	3.13e-13	2.68e-10	-0.31	-0.33	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	7.51	3.13e-13	2.68e-10	0.46	0.33	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	7.5	3.15e-13	2.7e-10	0.34	0.33	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	7.5	3.15e-13	2.7e-10	0.34	0.33	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	7.5	3.15e-13	2.7e-10	0.34	0.33	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
HNSC	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	7.5	3.16e-13	2.7e-10	0.43	0.33	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-7.5	3.16e-13	2.7e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	7.5	3.16e-13	2.71e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
HNSC	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-7.5	3.16e-13	2.71e-10	-0.41	-0.33	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	7.5	3.18e-13	2.72e-10	0.45	0.33	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-7.5	3.18e-13	2.72e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-7.5	3.19e-13	2.73e-10	-0.39	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
HNSC	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	7.5	3.2e-13	2.74e-10	0.3	0.33	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
HNSC	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	7.5	3.21e-13	2.74e-10	0.4	0.33	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	7.5	3.21e-13	2.74e-10	0.4	0.33	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
HNSC	cis	rs17270561	0.609	rs9358885	ENSG00000272462.2	U91328.19	-7.5	3.21e-13	2.75e-10	-0.34	-0.33	Iron status biomarkers;	chr6:25757796	chr6:25992662~26001775:+
HNSC	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	7.5	3.21e-13	2.75e-10	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
HNSC	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	7.5	3.22e-13	2.75e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
HNSC	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-7.5	3.22e-13	2.75e-10	-0.39	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
HNSC	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-7.5	3.24e-13	2.77e-10	-0.52	-0.33	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
HNSC	cis	rs131777	0.545	rs131759	ENSG00000205559.3	CHKB-AS1	-7.5	3.24e-13	2.77e-10	-0.36	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50577052	chr22:50583026~50583877:+
HNSC	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-7.5	3.25e-13	2.77e-10	-0.43	-0.33	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
HNSC	cis	rs7942368	0.878	rs1866843	ENSG00000255100.1	RP11-21L23.3	7.5	3.25e-13	2.78e-10	0.42	0.33	Endometriosis;	chr11:76778292	chr11:76782581~76783062:-
HNSC	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
HNSC	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	7.5	3.27e-13	2.79e-10	0.41	0.33	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
HNSC	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	7.5	3.27e-13	2.8e-10	0.33	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
HNSC	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-7.5	3.28e-13	2.8e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
HNSC	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-7.5	3.28e-13	2.8e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
HNSC	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	7.5	3.28e-13	2.8e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
HNSC	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	7.5	3.29e-13	2.81e-10	0.36	0.33	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
HNSC	cis	rs6951245	1	rs74652290	ENSG00000224079.1	AC091729.7	-7.5	3.3e-13	2.82e-10	-0.56	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1074450~1078036:+
HNSC	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	7.5	3.3e-13	2.82e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
HNSC	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-7.5	3.32e-13	2.83e-10	-0.45	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
HNSC	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-7.5	3.33e-13	2.85e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
HNSC	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	7.5	3.33e-13	2.85e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
HNSC	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-7.5	3.34e-13	2.85e-10	-0.37	-0.33	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
HNSC	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	7.5	3.34e-13	2.85e-10	0.34	0.33	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
HNSC	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-7.49	3.35e-13	2.86e-10	-0.35	-0.33	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
HNSC	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-7.49	3.36e-13	2.86e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-7.49	3.38e-13	2.88e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
HNSC	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	7.49	3.39e-13	2.89e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
HNSC	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-7.49	3.41e-13	2.91e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	7.49	3.42e-13	2.91e-10	0.36	0.33	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	7.49	3.42e-13	2.91e-10	0.36	0.33	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	7.49	3.42e-13	2.91e-10	0.36	0.33	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
HNSC	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-7.49	3.42e-13	2.91e-10	-0.36	-0.33	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
HNSC	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	7.49	3.42e-13	2.92e-10	0.31	0.33	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
HNSC	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-7.49	3.43e-13	2.92e-10	-0.4	-0.33	Height;	chr11:118859432	chr11:118704607~118750263:+
HNSC	cis	rs6471393	0.929	rs7016930	ENSG00000253848.1	RP11-10N23.5	7.49	3.44e-13	2.93e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743185	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.929	rs7017036	ENSG00000253848.1	RP11-10N23.5	7.49	3.44e-13	2.93e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743216	chr8:93741193~93744534:+
HNSC	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	7.49	3.46e-13	2.95e-10	0.45	0.33	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	7.49	3.46e-13	2.95e-10	0.45	0.33	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	7.49	3.47e-13	2.95e-10	0.34	0.33	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	7.49	3.47e-13	2.95e-10	0.34	0.33	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
HNSC	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	7.49	3.47e-13	2.96e-10	0.36	0.33	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
HNSC	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-7.49	3.48e-13	2.96e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
HNSC	cis	rs451417	1	rs236110	ENSG00000275632.1	RP5-967N21.11	7.49	3.48e-13	2.96e-10	0.4	0.33	Menopause (age at onset);	chr20:5952462	chr20:6000418~6000941:+
HNSC	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	7.49	3.5e-13	2.98e-10	0.4	0.33	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	7.49	3.52e-13	2.99e-10	0.5	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
HNSC	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-7.49	3.53e-13	3e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
HNSC	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-7.49	3.53e-13	3e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
HNSC	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-7.49	3.53e-13	3e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	7.49	3.53e-13	3e-10	0.23	0.33	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
HNSC	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	7.49	3.53e-13	3e-10	0.61	0.33	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	7.49	3.55e-13	3.02e-10	0.45	0.33	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	7.49	3.56e-13	3.03e-10	0.23	0.33	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
HNSC	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	7.49	3.56e-13	3.03e-10	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
HNSC	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	7.49	3.56e-13	3.03e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
HNSC	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	7.49	3.57e-13	3.03e-10	0.41	0.33	Height;	chr6:109471826	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	7.49	3.57e-13	3.03e-10	0.42	0.33	Height;	chr6:109346560	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	7.49	3.58e-13	3.04e-10	0.36	0.33	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	7.49	3.58e-13	3.05e-10	0.37	0.33	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	7.48	3.6e-13	3.06e-10	0.31	0.33	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	7.48	3.6e-13	3.06e-10	0.37	0.33	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
HNSC	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-7.48	3.61e-13	3.06e-10	-0.46	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
HNSC	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	7.48	3.61e-13	3.07e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
HNSC	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	7.48	3.62e-13	3.07e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
HNSC	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	7.48	3.63e-13	3.08e-10	0.41	0.33	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
HNSC	cis	rs6471393	0.929	rs4464937	ENSG00000253848.1	RP11-10N23.5	7.48	3.63e-13	3.09e-10	0.39	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744689	chr8:93741193~93744534:+
HNSC	cis	rs60065504	1	rs60065504	ENSG00000251022.5	THAP9-AS1	-7.48	3.65e-13	3.1e-10	-0.31	-0.33	Lymphocyte percentage of white cells;	chr4:82964057	chr4:82893009~82900960:-
HNSC	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	7.48	3.65e-13	3.1e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
HNSC	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-7.48	3.66e-13	3.11e-10	-0.42	-0.33	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
HNSC	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-7.48	3.66e-13	3.11e-10	-0.47	-0.33	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000173295.6	FAM86B3P	-7.48	3.67e-13	3.12e-10	-0.35	-0.33	Joint mobility (Beighton score);	chr8:9226611	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	7.48	3.68e-13	3.12e-10	0.23	0.33	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
HNSC	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.69e-13	3.13e-10	-0.37	-0.33	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
HNSC	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	7.48	3.71e-13	3.15e-10	0.45	0.33	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
HNSC	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.71e-13	3.15e-10	-0.37	-0.33	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
HNSC	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-7.48	3.71e-13	3.15e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	7.48	3.71e-13	3.15e-10	0.47	0.33	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-7.48	3.72e-13	3.16e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.533	rs1408270	ENSG00000272462.2	U91328.19	-7.48	3.72e-13	3.16e-10	-0.35	-0.33	Height;	chr6:25872956	chr6:25992662~26001775:+
HNSC	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-7.48	3.72e-13	3.16e-10	-0.42	-0.33	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
HNSC	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	7.48	3.73e-13	3.16e-10	0.39	0.33	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	7.48	3.74e-13	3.17e-10	0.31	0.33	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	7.48	3.74e-13	3.17e-10	0.35	0.33	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
HNSC	cis	rs8062405	0.722	rs28729187	ENSG00000259982.1	CDC37P1	-7.48	3.75e-13	3.18e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615645	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.789	rs28480369	ENSG00000259982.1	CDC37P1	-7.48	3.75e-13	3.18e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615683	chr16:28700294~28701540:-
HNSC	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	7.48	3.75e-13	3.18e-10	0.34	0.33	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
HNSC	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	7.48	3.76e-13	3.19e-10	0.35	0.33	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	7.48	3.77e-13	3.19e-10	0.43	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
HNSC	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-7.48	3.77e-13	3.2e-10	-0.55	-0.33	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
HNSC	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.77e-13	3.2e-10	-0.37	-0.33	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
HNSC	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	7.48	3.79e-13	3.21e-10	0.61	0.33	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
HNSC	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	7.48	3.79e-13	3.21e-10	0.39	0.33	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
HNSC	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-7.48	3.79e-13	3.21e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-7.48	3.79e-13	3.21e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs12944597	ENSG00000267151.3	RP11-100E5.2	7.48	3.8e-13	3.22e-10	0.43	0.33	Menopause (age at onset);	chr17:43035667	chr17:43444707~43451200:+
HNSC	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	7.48	3.8e-13	3.22e-10	0.35	0.33	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	7.48	3.8e-13	3.22e-10	0.35	0.33	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
HNSC	cis	rs7615952	0.8	rs35390120	ENSG00000241288.6	RP11-379B18.5	-7.48	3.8e-13	3.22e-10	-0.53	-0.33	Blood pressure (smoking interaction);	chr3:125880966	chr3:125827238~125916384:-
HNSC	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-7.48	3.82e-13	3.23e-10	-0.35	-0.33	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
HNSC	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-7.48	3.82e-13	3.24e-10	-0.47	-0.33	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
HNSC	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-7.48	3.82e-13	3.24e-10	-0.47	-0.33	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
HNSC	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-7.48	3.84e-13	3.25e-10	-0.61	-0.33	Gout;	chr7:66671562	chr7:66654538~66669855:+
HNSC	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	7.47	3.84e-13	3.25e-10	0.41	0.33	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-7.47	3.85e-13	3.26e-10	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
HNSC	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-7.47	3.85e-13	3.26e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-7.47	3.86e-13	3.27e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-7.47	3.87e-13	3.28e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-7.47	3.87e-13	3.28e-10	-0.29	-0.33	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
HNSC	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-7.47	3.87e-13	3.28e-10	-0.42	-0.33	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
HNSC	cis	rs7942368	1	rs10899280	ENSG00000255100.1	RP11-21L23.3	7.47	3.88e-13	3.28e-10	0.41	0.33	Endometriosis;	chr11:76785693	chr11:76782581~76783062:-
HNSC	cis	rs6993244	1	rs6993244	ENSG00000254340.1	RP11-10A14.3	7.47	3.9e-13	3.3e-10	0.41	0.33	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9141424~9145435:+
HNSC	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-7.47	3.9e-13	3.3e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
HNSC	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-7.47	3.9e-13	3.3e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	7.47	3.92e-13	3.31e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-7.47	3.92e-13	3.32e-10	-0.36	-0.33	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-7.47	3.94e-13	3.33e-10	-0.4	-0.33	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
HNSC	cis	rs875971	0.545	rs6969224	ENSG00000179406.6	LINC00174	-7.47	3.95e-13	3.34e-10	-0.51	-0.33	Aortic root size;	chr7:66370011	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-7.47	3.95e-13	3.34e-10	-0.61	-0.33	Gout;	chr7:66715944	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-7.47	3.95e-13	3.34e-10	-0.61	-0.33	Gout;	chr7:66721259	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-7.47	3.95e-13	3.34e-10	-0.61	-0.33	Gout;	chr7:66732812	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	7.47	3.95e-13	3.34e-10	0.62	0.33	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	7.47	3.95e-13	3.34e-10	0.62	0.33	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	7.47	3.95e-13	3.34e-10	0.62	0.33	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
HNSC	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	7.47	3.96e-13	3.34e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
HNSC	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	7.47	3.96e-13	3.34e-10	0.61	0.33	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
HNSC	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-7.47	3.96e-13	3.34e-10	-0.42	-0.33	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	7.47	3.96e-13	3.35e-10	0.33	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
HNSC	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	7.47	3.96e-13	3.35e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	7.47	3.96e-13	3.35e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
HNSC	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-7.47	3.96e-13	3.35e-10	-0.35	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
HNSC	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	7.47	3.98e-13	3.36e-10	0.39	0.33	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	7.47	3.98e-13	3.36e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
HNSC	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	7.47	3.99e-13	3.37e-10	0.36	0.33	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
HNSC	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	7.47	3.99e-13	3.37e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	7.47	4.01e-13	3.39e-10	0.31	0.33	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
HNSC	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-7.47	4.02e-13	3.39e-10	-0.35	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
HNSC	cis	rs7615952	0.611	rs35321002	ENSG00000241288.6	RP11-379B18.5	-7.47	4.02e-13	3.39e-10	-0.54	-0.33	Blood pressure (smoking interaction);	chr3:125893222	chr3:125827238~125916384:-
HNSC	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-7.47	4.03e-13	3.4e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
HNSC	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-7.47	4.03e-13	3.4e-10	-0.47	-0.33	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
HNSC	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-7.47	4.04e-13	3.4e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
HNSC	cis	rs8081395	0.729	rs12453125	ENSG00000266992.1	DHX40P1	-7.47	4.04e-13	3.41e-10	-0.36	-0.33	White blood cell count;	chr17:59968715	chr17:59976009~60002384:-
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	7.47	4.05e-13	3.41e-10	0.31	0.33	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	7.47	4.05e-13	3.41e-10	0.31	0.33	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	7.47	4.05e-13	3.41e-10	0.31	0.33	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	7.47	4.05e-13	3.42e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	7.47	4.05e-13	3.42e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
HNSC	cis	rs131777	0.545	rs140514	ENSG00000205559.3	CHKB-AS1	-7.47	4.05e-13	3.42e-10	-0.36	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50583026~50583877:+
HNSC	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	7.47	4.07e-13	3.43e-10	0.54	0.33	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-7.47	4.11e-13	3.46e-10	-0.39	-0.33	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-7.47	4.11e-13	3.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
HNSC	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	7.46	4.11e-13	3.47e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	7.46	4.11e-13	3.47e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	7.46	4.11e-13	3.47e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
HNSC	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	7.46	4.15e-13	3.49e-10	0.33	0.33	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
HNSC	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-7.46	4.15e-13	3.49e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-7.46	4.15e-13	3.49e-10	-0.62	-0.33	Gout;	chr7:66642037	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-7.46	4.15e-13	3.49e-10	-0.4	-0.33	Height;	chr11:118860890	chr11:118704607~118750263:+
HNSC	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-7.46	4.15e-13	3.49e-10	-0.4	-0.33	Height;	chr11:118861053	chr11:118704607~118750263:+
HNSC	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-7.46	4.16e-13	3.5e-10	-0.35	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
HNSC	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-7.46	4.16e-13	3.5e-10	-0.4	-0.33	Height;	chr11:118855233	chr11:118704607~118750263:+
HNSC	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-7.46	4.18e-13	3.51e-10	-0.45	-0.33	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	7.46	4.18e-13	3.51e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
HNSC	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-7.46	4.19e-13	3.52e-10	-0.33	-0.33	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
HNSC	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	7.46	4.2e-13	3.53e-10	0.36	0.33	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	7.46	4.22e-13	3.54e-10	0.4	0.33	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
HNSC	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-7.46	4.22e-13	3.55e-10	-0.47	-0.33	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-7.46	4.22e-13	3.55e-10	-0.47	-0.33	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
HNSC	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	7.46	4.23e-13	3.55e-10	0.35	0.33	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
HNSC	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-7.46	4.23e-13	3.55e-10	-0.47	-0.33	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
HNSC	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
HNSC	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-7.46	4.24e-13	3.56e-10	-0.29	-0.33	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.583	rs4381566	ENSG00000259422.1	RP11-593F23.1	7.46	4.25e-13	3.57e-10	0.37	0.33	Blood metabolite levels;	chr15:76296921	chr15:76174891~76181486:-
HNSC	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	7.46	4.25e-13	3.57e-10	0.4	0.33	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
HNSC	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	7.46	4.25e-13	3.57e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	7.46	4.25e-13	3.57e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	7.46	4.25e-13	3.57e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	7.46	4.26e-13	3.58e-10	0.34	0.33	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-7.46	4.27e-13	3.58e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-7.46	4.27e-13	3.59e-10	-0.23	-0.33	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
HNSC	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-7.46	4.29e-13	3.6e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
HNSC	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-7.46	4.3e-13	3.61e-10	-0.47	-0.33	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
HNSC	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-7.46	4.3e-13	3.61e-10	-0.41	-0.33	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
HNSC	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	7.46	4.3e-13	3.61e-10	0.38	0.33	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
HNSC	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-7.46	4.3e-13	3.61e-10	-0.46	-0.33	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
HNSC	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-7.46	4.33e-13	3.63e-10	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
HNSC	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-7.46	4.33e-13	3.63e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
HNSC	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	7.46	4.33e-13	3.63e-10	0.36	0.33	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
HNSC	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-7.46	4.33e-13	3.63e-10	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
HNSC	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.59	-0.33	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
HNSC	cis	rs6061231	0.958	rs2427304	ENSG00000273619.1	RP5-908M14.9	-7.46	4.35e-13	3.64e-10	-0.31	-0.33	Colorectal cancer;	chr20:62378528	chr20:62386303~62386970:-
HNSC	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	7.46	4.35e-13	3.65e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
HNSC	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	7.46	4.35e-13	3.65e-10	0.34	0.33	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
HNSC	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	7.46	4.36e-13	3.65e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-7.46	4.36e-13	3.65e-10	-0.42	-0.33	Depression;	chr6:28197321	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-7.46	4.36e-13	3.65e-10	-0.42	-0.33	Depression;	chr6:28197412	chr6:28115628~28116551:+
HNSC	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-7.46	4.37e-13	3.66e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
HNSC	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-7.46	4.37e-13	3.66e-10	-0.41	-0.33	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
HNSC	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	7.46	4.39e-13	3.67e-10	0.39	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
HNSC	cis	rs1865760	0.566	rs9467663	ENSG00000272462.2	U91328.19	-7.46	4.39e-13	3.67e-10	-0.32	-0.33	Height;	chr6:26021228	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	7.46	4.39e-13	3.67e-10	0.41	0.33	Depression;	chr6:28200948	chr6:28115628~28116551:+
HNSC	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-7.46	4.39e-13	3.67e-10	-0.5	-0.33	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
HNSC	cis	rs7048146	0.832	rs10979945	ENSG00000213539.4	YBX1P6	7.46	4.39e-13	3.67e-10	0.38	0.33	Vascular brain injury;	chr9:109582456	chr9:109532830~109534332:-
HNSC	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	7.45	4.4e-13	3.69e-10	0.41	0.33	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
HNSC	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-7.45	4.42e-13	3.7e-10	-0.38	-0.33	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
HNSC	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	7.45	4.44e-13	3.71e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-7.45	4.44e-13	3.72e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
HNSC	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-7.45	4.46e-13	3.73e-10	-0.44	-0.33	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
HNSC	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-7.45	4.47e-13	3.74e-10	-0.4	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
HNSC	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	7.45	4.48e-13	3.74e-10	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
HNSC	cis	rs17270561	0.609	rs1937131	ENSG00000272462.2	U91328.19	7.45	4.48e-13	3.74e-10	0.34	0.33	Iron status biomarkers;	chr6:25744603	chr6:25992662~26001775:+
HNSC	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
HNSC	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	7.45	4.48e-13	3.75e-10	0.34	0.33	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
HNSC	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	7.45	4.52e-13	3.78e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
HNSC	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-7.45	4.52e-13	3.78e-10	-0.52	-0.33	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
HNSC	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-7.45	4.53e-13	3.79e-10	-0.52	-0.33	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	7.45	4.55e-13	3.8e-10	0.23	0.33	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
HNSC	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	7.45	4.57e-13	3.82e-10	0.34	0.33	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
HNSC	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-7.45	4.57e-13	3.82e-10	-0.5	-0.33	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
HNSC	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-7.45	4.57e-13	3.82e-10	-0.5	-0.33	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
HNSC	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	7.45	4.57e-13	3.82e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
HNSC	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-7.45	4.58e-13	3.82e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
HNSC	cis	rs7615952	0.688	rs12485622	ENSG00000241288.6	RP11-379B18.5	-7.45	4.58e-13	3.83e-10	-0.42	-0.33	Blood pressure (smoking interaction);	chr3:125991896	chr3:125827238~125916384:-
HNSC	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	7.45	4.58e-13	3.83e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
HNSC	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	7.45	4.59e-13	3.83e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
HNSC	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	7.45	4.59e-13	3.84e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
HNSC	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	7.45	4.59e-13	3.84e-10	0.41	0.33	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
HNSC	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	7.45	4.61e-13	3.85e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	7.45	4.61e-13	3.85e-10	0.36	0.33	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	7.45	4.61e-13	3.85e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	7.45	4.61e-13	3.85e-10	0.44	0.33	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-7.45	4.63e-13	3.86e-10	-0.37	-0.33	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
HNSC	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	7.45	4.63e-13	3.87e-10	0.39	0.33	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
HNSC	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	7.45	4.67e-13	3.9e-10	0.39	0.33	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	7.45	4.69e-13	3.91e-10	0.37	0.33	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
HNSC	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-7.45	4.7e-13	3.92e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
HNSC	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	7.45	4.7e-13	3.92e-10	0.36	0.33	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
HNSC	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-7.44	4.73e-13	3.94e-10	-0.44	-0.33	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-7.44	4.73e-13	3.94e-10	-0.44	-0.33	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-7.44	4.73e-13	3.94e-10	-0.44	-0.33	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
HNSC	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	7.44	4.73e-13	3.94e-10	0.4	0.33	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	7.44	4.73e-13	3.94e-10	0.4	0.33	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-7.44	4.73e-13	3.94e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-7.44	4.73e-13	3.94e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-7.44	4.73e-13	3.94e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	7.44	4.74e-13	3.95e-10	0.42	0.33	Depression;	chr6:28199145	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	7.44	4.75e-13	3.95e-10	0.4	0.33	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	7.44	4.75e-13	3.96e-10	0.43	0.33	Height;	chr6:109715504	chr6:109382795~109383666:+
HNSC	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-7.44	4.76e-13	3.96e-10	-0.36	-0.33	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
HNSC	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	7.44	4.77e-13	3.97e-10	0.36	0.33	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	7.44	4.77e-13	3.97e-10	0.45	0.33	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
HNSC	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-7.44	4.77e-13	3.97e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-7.44	4.78e-13	3.98e-10	-0.43	-0.33	Depression;	chr6:28206812	chr6:28115628~28116551:+
HNSC	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	7.44	4.78e-13	3.98e-10	0.42	0.33	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
HNSC	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	7.44	4.78e-13	3.98e-10	0.33	0.33	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
HNSC	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	7.44	4.79e-13	3.99e-10	0.36	0.33	Migraine;	chr4:56881468	chr4:56960927~56961373:-
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	7.44	4.8e-13	3.99e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
HNSC	cis	rs6951245	1	rs78185558	ENSG00000224079.1	AC091729.7	-7.44	4.8e-13	3.99e-10	-0.56	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1074450~1078036:+
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	7.44	4.8e-13	3.99e-10	0.23	0.33	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
HNSC	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	7.44	4.83e-13	4.02e-10	0.36	0.33	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-7.44	4.83e-13	4.02e-10	-0.37	-0.33	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-7.44	4.83e-13	4.02e-10	-0.37	-0.33	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
HNSC	cis	rs1865760	0.516	rs9379818	ENSG00000272462.2	U91328.19	-7.44	4.84e-13	4.02e-10	-0.32	-0.33	Height;	chr6:26022978	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-7.44	4.85e-13	4.03e-10	-0.43	-0.33	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	7.44	4.85e-13	4.03e-10	0.23	0.33	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
HNSC	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	7.44	4.86e-13	4.04e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
HNSC	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-7.44	4.86e-13	4.04e-10	-0.37	-0.33	Height;	chr3:52994359	chr3:53064283~53065091:-
HNSC	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	7.44	4.87e-13	4.05e-10	0.36	0.33	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	7.44	4.87e-13	4.05e-10	0.36	0.33	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
HNSC	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	7.44	4.88e-13	4.06e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
HNSC	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	7.44	4.88e-13	4.06e-10	0.34	0.33	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-7.44	4.89e-13	4.06e-10	-0.38	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
HNSC	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	7.44	4.91e-13	4.08e-10	0.37	0.33	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
HNSC	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-7.44	4.92e-13	4.09e-10	-0.32	-0.33	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
HNSC	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-7.44	4.93e-13	4.1e-10	-0.33	-0.33	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
HNSC	cis	rs7942368	1	rs11236924	ENSG00000255100.1	RP11-21L23.3	7.44	4.95e-13	4.11e-10	0.43	0.33	Endometriosis;	chr11:76756303	chr11:76782581~76783062:-
HNSC	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	7.44	4.95e-13	4.11e-10	0.44	0.33	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	7.44	4.97e-13	4.13e-10	0.36	0.33	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	7.44	5e-13	4.15e-10	0.23	0.33	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	7.44	5e-13	4.15e-10	0.23	0.33	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	7.44	5e-13	4.15e-10	0.23	0.33	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
HNSC	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-7.44	5e-13	4.15e-10	-0.51	-0.33	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
HNSC	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	7.44	5.03e-13	4.17e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
HNSC	cis	rs17270561	0.609	rs9358886	ENSG00000272462.2	U91328.19	-7.44	5.03e-13	4.18e-10	-0.34	-0.33	Iron status biomarkers;	chr6:25758025	chr6:25992662~26001775:+
HNSC	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	7.44	5.03e-13	4.18e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
HNSC	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	7.44	5.04e-13	4.18e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
HNSC	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-7.43	5.04e-13	4.19e-10	-0.49	-0.33	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
HNSC	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	7.43	5.06e-13	4.2e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
HNSC	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	7.43	5.07e-13	4.21e-10	0.72	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
HNSC	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-7.43	5.07e-13	4.21e-10	-0.37	-0.33	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
HNSC	cis	rs7615952	0.932	rs13065725	ENSG00000248787.1	RP11-666A20.4	-7.43	5.09e-13	4.22e-10	-0.51	-0.33	Blood pressure (smoking interaction);	chr3:125913446	chr3:125908005~125910272:-
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-7.43	5.09e-13	4.22e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	7.43	5.09e-13	4.23e-10	0.23	0.33	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
HNSC	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	7.43	5.13e-13	4.26e-10	0.36	0.33	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
HNSC	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	7.43	5.14e-13	4.26e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	7.43	5.15e-13	4.27e-10	0.23	0.33	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	7.43	5.15e-13	4.27e-10	0.23	0.33	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-7.43	5.15e-13	4.27e-10	-0.4	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
HNSC	cis	rs6844153	0.938	rs77926313	ENSG00000240005.4	RP11-293A21.1	-7.43	5.16e-13	4.28e-10	-0.49	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26965420	chr4:26859806~26860599:-
HNSC	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-7.43	5.18e-13	4.29e-10	-0.43	-0.33	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
HNSC	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-7.43	5.18e-13	4.3e-10	-0.32	-0.33	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
HNSC	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-7.43	5.19e-13	4.3e-10	-0.41	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
HNSC	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	7.43	5.19e-13	4.3e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
HNSC	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-7.43	5.22e-13	4.33e-10	-0.29	-0.33	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
HNSC	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-7.43	5.23e-13	4.33e-10	-0.49	-0.33	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
HNSC	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-7.43	5.28e-13	4.37e-10	-0.36	-0.33	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
HNSC	cis	rs1799949	1	rs11653231	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43179443	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1399323	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43180313	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs35954893	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43181769	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs4445938	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43185883	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8074136	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43190296	chr17:43444707~43451200:+
HNSC	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	7.43	5.29e-13	4.38e-10	0.34	0.33	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	7.43	5.29e-13	4.38e-10	0.34	0.33	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
HNSC	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-7.43	5.31e-13	4.39e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-7.43	5.32e-13	4.4e-10	-0.33	-0.33	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
HNSC	cis	rs867371	0.929	rs1501371	ENSG00000255769.6	GOLGA2P10	-7.43	5.33e-13	4.41e-10	-0.42	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472993~82513950:-
HNSC	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	7.43	5.35e-13	4.43e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
HNSC	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	7.43	5.37e-13	4.44e-10	0.34	0.32	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	7.43	5.38e-13	4.44e-10	0.33	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
HNSC	cis	rs875971	0.545	rs221986	ENSG00000179406.6	LINC00174	7.43	5.39e-13	4.45e-10	0.51	0.32	Aortic root size;	chr7:66105323	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.599	rs7652883	ENSG00000241288.6	RP11-379B18.5	-7.43	5.39e-13	4.45e-10	-0.42	-0.32	Blood pressure (smoking interaction);	chr3:125989134	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-7.42	5.39e-13	4.46e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-7.42	5.4e-13	4.46e-10	-0.36	-0.32	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
HNSC	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-7.42	5.4e-13	4.46e-10	-0.45	-0.32	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
HNSC	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-7.42	5.4e-13	4.47e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
HNSC	cis	rs6993244	1	rs6993244	ENSG00000173295.6	FAM86B3P	7.42	5.41e-13	4.47e-10	0.38	0.32	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8228595~8244865:+
HNSC	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-7.42	5.44e-13	4.5e-10	-0.37	-0.32	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
HNSC	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-7.42	5.45e-13	4.5e-10	-0.37	-0.32	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
HNSC	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	7.42	5.46e-13	4.51e-10	0.37	0.32	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
HNSC	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	7.42	5.47e-13	4.52e-10	0.39	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
HNSC	cis	rs875971	0.545	rs2279757	ENSG00000179406.6	LINC00174	-7.42	5.48e-13	4.53e-10	-0.5	-0.32	Aortic root size;	chr7:66363676	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs11766183	ENSG00000179406.6	LINC00174	-7.42	5.48e-13	4.53e-10	-0.5	-0.32	Aortic root size;	chr7:66374173	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs1065265	ENSG00000179406.6	LINC00174	-7.42	5.48e-13	4.53e-10	-0.5	-0.32	Aortic root size;	chr7:66376216	chr7:66376044~66401338:-
HNSC	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	7.42	5.5e-13	4.54e-10	0.41	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	7.42	5.5e-13	4.54e-10	0.23	0.32	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-7.42	5.5e-13	4.54e-10	-0.37	-0.32	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	7.42	5.5e-13	4.54e-10	0.32	0.32	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	7.42	5.5e-13	4.54e-10	0.32	0.32	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	7.42	5.55e-13	4.58e-10	0.31	0.32	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
HNSC	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-7.42	5.59e-13	4.62e-10	-0.37	-0.32	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
HNSC	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	7.42	5.61e-13	4.63e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	7.42	5.64e-13	4.65e-10	0.23	0.32	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
HNSC	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	7.42	5.65e-13	4.66e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs7811204	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66387213	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.571	rs78668714	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66474464	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73150604	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66480545	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs7810213	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66481592	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-7.42	5.66e-13	4.67e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
HNSC	cis	rs1021993	0.545	rs6681466	ENSG00000231648.1	RP11-372M18.2	-7.42	5.66e-13	4.67e-10	-0.53	-0.32	Gut microbiome composition (winter);	chr1:209355913	chr1:209367662~209379690:+
HNSC	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	7.42	5.69e-13	4.69e-10	0.28	0.32	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
HNSC	cis	rs1021993	0.545	rs55684110	ENSG00000231648.1	RP11-372M18.2	-7.42	5.7e-13	4.69e-10	-0.55	-0.32	Gut microbiome composition (winter);	chr1:209368487	chr1:209367662~209379690:+
HNSC	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-7.42	5.71e-13	4.7e-10	-0.39	-0.32	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
HNSC	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	7.42	5.72e-13	4.71e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
HNSC	cis	rs1799949	0.794	rs116409325	ENSG00000267151.3	RP11-100E5.2	7.42	5.73e-13	4.72e-10	0.42	0.32	Menopause (age at onset);	chr17:43368092	chr17:43444707~43451200:+
HNSC	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-7.42	5.74e-13	4.72e-10	-0.37	-0.32	Migraine;	chr4:56880659	chr4:56960927~56961373:-
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
HNSC	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-7.42	5.74e-13	4.73e-10	-0.32	-0.32	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
HNSC	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-7.42	5.76e-13	4.74e-10	-0.37	-0.32	Migraine;	chr4:56880190	chr4:56960927~56961373:-
HNSC	cis	rs875971	0.502	rs6460311	ENSG00000179406.6	LINC00174	7.41	5.78e-13	4.76e-10	0.5	0.32	Aortic root size;	chr7:66646886	chr7:66376044~66401338:-
HNSC	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-7.41	5.79e-13	4.76e-10	-0.42	-0.32	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
HNSC	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-7.41	5.82e-13	4.78e-10	-0.36	-0.32	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
HNSC	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	7.41	5.82e-13	4.79e-10	0.42	0.32	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
HNSC	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	7.41	5.82e-13	4.79e-10	0.41	0.32	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
HNSC	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	7.41	5.82e-13	4.79e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	7.41	5.86e-13	4.82e-10	0.6	0.32	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
HNSC	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	7.41	5.86e-13	4.82e-10	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
HNSC	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-7.41	5.87e-13	4.82e-10	-0.42	-0.32	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	7.41	5.87e-13	4.83e-10	0.23	0.32	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
HNSC	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-7.41	5.9e-13	4.85e-10	-0.35	-0.32	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
HNSC	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	7.41	5.9e-13	4.85e-10	0.29	0.32	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
HNSC	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-7.41	5.92e-13	4.86e-10	-0.29	-0.32	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
HNSC	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-7.41	5.93e-13	4.87e-10	-0.35	-0.32	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
HNSC	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-7.41	5.94e-13	4.88e-10	-0.35	-0.32	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
HNSC	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-7.41	5.96e-13	4.9e-10	-0.38	-0.32	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
HNSC	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-7.41	5.97e-13	4.9e-10	-0.35	-0.32	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
HNSC	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-7.41	5.98e-13	4.91e-10	-0.47	-0.32	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	7.41	6.01e-13	4.94e-10	0.45	0.32	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-7.41	6.01e-13	4.94e-10	-0.36	-0.32	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-7.41	6.01e-13	4.94e-10	-0.36	-0.32	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
HNSC	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-7.41	6.05e-13	4.97e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
HNSC	cis	rs451417	1	rs236102	ENSG00000275632.1	RP5-967N21.11	7.41	6.06e-13	4.97e-10	0.39	0.32	Menopause (age at onset);	chr20:5971320	chr20:6000418~6000941:+
HNSC	cis	rs6472866	1	rs6472866	ENSG00000254349.4	FLJ39080	7.41	6.06e-13	4.97e-10	0.36	0.32	Protein quantitative trait loci;	chr8:74600899	chr8:74599775~74823313:+
HNSC	cis	rs6472866	0.967	rs6472867	ENSG00000254349.4	FLJ39080	7.41	6.06e-13	4.97e-10	0.36	0.32	Protein quantitative trait loci;	chr8:74601596	chr8:74599775~74823313:+
HNSC	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	7.41	6.07e-13	4.98e-10	0.39	0.32	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	7.41	6.07e-13	4.98e-10	0.39	0.32	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	7.41	6.07e-13	4.98e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
HNSC	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	7.41	6.07e-13	4.98e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
HNSC	cis	rs9595066	0.627	rs2246432	ENSG00000227258.4	SMIM2-AS1	-7.41	6.07e-13	4.99e-10	-0.49	-0.32	Schizophrenia;	chr13:44182648	chr13:44110451~44240517:+
HNSC	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-7.41	6.08e-13	4.99e-10	-0.39	-0.32	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
HNSC	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	7.41	6.08e-13	4.99e-10	0.47	0.32	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
HNSC	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-7.41	6.11e-13	5.01e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
HNSC	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	7.4	6.22e-13	5.1e-10	0.41	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	7.4	6.22e-13	5.1e-10	0.41	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
HNSC	cis	rs7942368	1	rs1837679	ENSG00000255100.1	RP11-21L23.3	7.4	6.22e-13	5.1e-10	0.42	0.32	Endometriosis;	chr11:76790513	chr11:76782581~76783062:-
HNSC	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-7.4	6.23e-13	5.11e-10	-0.34	-0.32	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
HNSC	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-7.4	6.28e-13	5.15e-10	-0.29	-0.32	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
HNSC	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	7.4	6.29e-13	5.15e-10	0.4	0.32	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
HNSC	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-7.4	6.29e-13	5.15e-10	-0.33	-0.32	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
HNSC	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-7.4	6.29e-13	5.16e-10	-0.6	-0.32	Gout;	chr7:66693028	chr7:66654538~66669855:+
HNSC	cis	rs12922040	0.651	rs35288467	ENSG00000263065.1	AF001548.6	-7.4	6.32e-13	5.17e-10	-0.37	-0.32	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15741151~15741791:+
HNSC	cis	rs9326248	0.53	rs236918	ENSG00000280143.1	AP000892.6	-7.4	6.32e-13	5.18e-10	-0.52	-0.32	Blood protein levels;	chr11:117220893	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	7.4	6.33e-13	5.18e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
HNSC	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	7.4	6.33e-13	5.19e-10	0.44	0.32	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-7.4	6.34e-13	5.19e-10	-0.35	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
HNSC	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-7.4	6.35e-13	5.2e-10	-0.3	-0.32	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
HNSC	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-7.4	6.36e-13	5.21e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-7.4	6.36e-13	5.21e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-7.4	6.38e-13	5.22e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
HNSC	cis	rs7942368	0.941	rs11236936	ENSG00000255100.1	RP11-21L23.3	7.4	6.42e-13	5.26e-10	0.41	0.32	Endometriosis;	chr11:76789786	chr11:76782581~76783062:-
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	7.4	6.44e-13	5.27e-10	0.22	0.32	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
HNSC	cis	rs7048146	0.899	rs7861587	ENSG00000213539.4	YBX1P6	7.4	6.45e-13	5.28e-10	0.38	0.32	Vascular brain injury;	chr9:109584316	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.899	rs884919	ENSG00000213539.4	YBX1P6	7.4	6.45e-13	5.28e-10	0.38	0.32	Vascular brain injury;	chr9:109585693	chr9:109532830~109534332:-
HNSC	cis	rs9326248	0.53	rs11216316	ENSG00000280143.1	AP000892.6	-7.4	6.46e-13	5.29e-10	-0.51	-0.32	Blood protein levels;	chr11:117210784	chr11:117204967~117210292:+
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000223648.3	IGHV3-64	7.4	6.47e-13	5.29e-10	0.23	0.32	Kawasaki disease;	chr14:106767802	chr14:106643132~106658258:-
HNSC	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-7.4	6.48e-13	5.3e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.602	rs9467662	ENSG00000272462.2	U91328.19	-7.4	6.48e-13	5.3e-10	-0.32	-0.32	Height;	chr6:26021099	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-7.4	6.49e-13	5.31e-10	-0.43	-0.32	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
HNSC	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-7.4	6.49e-13	5.31e-10	-0.32	-0.32	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
HNSC	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	7.4	6.5e-13	5.32e-10	0.33	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
HNSC	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	7.4	6.51e-13	5.32e-10	0.41	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
HNSC	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-7.4	6.51e-13	5.32e-10	-0.29	-0.32	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-7.4	6.53e-13	5.34e-10	-0.38	-0.32	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	7.4	6.58e-13	5.38e-10	0.33	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	7.4	6.59e-13	5.39e-10	0.44	0.32	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	7.39	6.61e-13	5.4e-10	0.45	0.32	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
HNSC	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	7.39	6.62e-13	5.41e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
HNSC	cis	rs1799949	0.93	rs35292991	ENSG00000267151.3	RP11-100E5.2	7.39	6.62e-13	5.41e-10	0.42	0.32	Menopause (age at onset);	chr17:43181999	chr17:43444707~43451200:+
HNSC	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-7.39	6.62e-13	5.41e-10	-0.48	-0.32	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
HNSC	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	7.39	6.7e-13	5.47e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	7.39	6.7e-13	5.47e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	7.39	6.71e-13	5.48e-10	0.46	0.32	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
HNSC	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	7.39	6.71e-13	5.48e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
HNSC	cis	rs35955747	0.633	rs2006771	ENSG00000236132.1	CTA-440B3.1	7.39	6.71e-13	5.48e-10	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31602626	chr22:31816379~31817491:-
HNSC	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-7.39	6.72e-13	5.48e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	7.39	6.75e-13	5.51e-10	0.34	0.32	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
HNSC	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-7.39	6.77e-13	5.53e-10	-0.35	-0.32	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	7.39	6.78e-13	5.54e-10	0.23	0.32	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
HNSC	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	7.39	6.8e-13	5.55e-10	0.36	0.32	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	7.39	6.8e-13	5.55e-10	0.36	0.32	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000173295.6	FAM86B3P	-7.39	6.8e-13	5.55e-10	-0.35	-0.32	Joint mobility (Beighton score);	chr8:9225906	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-7.39	6.81e-13	5.56e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
HNSC	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	7.39	6.82e-13	5.56e-10	0.34	0.32	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
HNSC	cis	rs7404843	0.925	rs7404803	ENSG00000263335.1	AF001548.5	-7.39	6.84e-13	5.58e-10	-0.65	-0.32	Testicular germ cell tumor;	chr16:15436597	chr16:15726674~15732993:+
HNSC	cis	rs875971	0.545	rs1638735	ENSG00000179406.6	LINC00174	-7.39	6.85e-13	5.59e-10	-0.5	-0.32	Aortic root size;	chr7:66630751	chr7:66376044~66401338:-
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	7.39	6.89e-13	5.62e-10	0.23	0.32	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
HNSC	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-7.39	6.93e-13	5.65e-10	-0.46	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
HNSC	cis	rs1799949	1	rs2271574	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43175631	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33994002	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43176801	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33920795	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43176993	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33918839	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43177155	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-7.39	6.95e-13	5.67e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-7.39	6.95e-13	5.67e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
HNSC	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-7.39	6.95e-13	5.67e-10	-0.41	-0.32	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
HNSC	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	7.39	6.96e-13	5.68e-10	0.4	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
HNSC	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-7.39	6.99e-13	5.69e-10	-0.37	-0.32	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
HNSC	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-7.39	7e-13	5.71e-10	-0.39	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
HNSC	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-7.39	7e-13	5.71e-10	-0.39	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
HNSC	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	7.39	7.01e-13	5.71e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
HNSC	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-7.39	7.03e-13	5.73e-10	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
HNSC	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	7.39	7.06e-13	5.75e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
HNSC	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-7.39	7.06e-13	5.75e-10	-0.43	-0.32	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
HNSC	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	7.38	7.07e-13	5.76e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
HNSC	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	7.38	7.07e-13	5.76e-10	0.38	0.32	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	7.38	7.07e-13	5.76e-10	0.38	0.32	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
HNSC	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	7.38	7.09e-13	5.77e-10	0.33	0.32	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
HNSC	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	7.38	7.09e-13	5.78e-10	0.34	0.32	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
HNSC	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	7.38	7.1e-13	5.78e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
HNSC	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	7.38	7.11e-13	5.79e-10	0.42	0.32	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
HNSC	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	7.38	7.12e-13	5.8e-10	0.37	0.32	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.602	rs2157050	ENSG00000272462.2	U91328.19	-7.38	7.13e-13	5.81e-10	-0.31	-0.32	Height;	chr6:26020203	chr6:25992662~26001775:+
HNSC	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	7.38	7.14e-13	5.81e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-7.38	7.14e-13	5.81e-10	-0.39	-0.32	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
HNSC	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-7.38	7.16e-13	5.83e-10	-0.35	-0.32	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
HNSC	cis	rs867371	1	rs8042464	ENSG00000276710.3	CSPG4P8	-7.38	7.16e-13	5.83e-10	-0.37	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-7.38	7.16e-13	5.83e-10	-0.22	-0.32	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
HNSC	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	7.38	7.18e-13	5.84e-10	0.43	0.32	Height;	chr6:109715560	chr6:109382795~109383666:+
HNSC	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-7.38	7.2e-13	5.86e-10	-0.32	-0.32	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
HNSC	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	7.38	7.21e-13	5.86e-10	0.35	0.32	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
HNSC	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-7.38	7.21e-13	5.87e-10	-0.38	-0.32	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
HNSC	cis	rs36423	0.528	rs1205061	ENSG00000266869.1	RP6-114E22.1	7.38	7.22e-13	5.88e-10	0.53	0.32	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71882819	chr14:71848606~71908430:+
HNSC	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	7.38	7.29e-13	5.93e-10	0.32	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
HNSC	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	7.38	7.31e-13	5.94e-10	0.41	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
HNSC	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-7.38	7.32e-13	5.95e-10	-0.37	-0.32	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
HNSC	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-7.38	7.32e-13	5.95e-10	-0.3	-0.32	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
HNSC	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	7.38	7.33e-13	5.96e-10	0.39	0.32	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
HNSC	cis	rs10080237	0.564	rs2490230	ENSG00000272129.1	RP11-250B2.6	7.38	7.36e-13	5.98e-10	0.37	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80102747	chr6:80355424~80356859:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-7.38	7.36e-13	5.98e-10	-0.48	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
HNSC	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-7.38	7.39e-13	6.01e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
HNSC	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-7.38	7.41e-13	6.02e-10	-0.29	-0.32	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-7.38	7.43e-13	6.04e-10	-0.3	-0.32	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
HNSC	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-7.38	7.44e-13	6.04e-10	-0.4	-0.32	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
HNSC	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	7.38	7.45e-13	6.05e-10	0.37	0.32	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
HNSC	cis	rs1021993	0.868	rs906348	ENSG00000231648.1	RP11-372M18.2	-7.38	7.46e-13	6.06e-10	-0.44	-0.32	Gut microbiome composition (winter);	chr1:209355001	chr1:209367662~209379690:+
HNSC	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	7.38	7.46e-13	6.06e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
HNSC	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-7.38	7.46e-13	6.06e-10	-0.42	-0.32	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
HNSC	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	7.38	7.47e-13	6.06e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.561	rs4714070	ENSG00000204110.6	RP1-153P14.8	-7.38	7.49e-13	6.08e-10	-0.32	-0.32	Cognitive performance;	chr6:37505422	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	7.38	7.52e-13	6.1e-10	0.3	0.32	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	7.38	7.52e-13	6.1e-10	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	7.38	7.53e-13	6.11e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
HNSC	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-7.38	7.53e-13	6.11e-10	-0.43	-0.32	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-7.38	7.53e-13	6.11e-10	-0.37	-0.32	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-7.38	7.54e-13	6.12e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	7.38	7.54e-13	6.12e-10	0.45	0.32	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
HNSC	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	7.38	7.54e-13	6.12e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
HNSC	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-7.37	7.56e-13	6.14e-10	-0.32	-0.32	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
HNSC	cis	rs6061231	0.958	rs2379126	ENSG00000273619.1	RP5-908M14.9	-7.37	7.57e-13	6.14e-10	-0.31	-0.32	Colorectal cancer;	chr20:62377949	chr20:62386303~62386970:-
HNSC	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-7.37	7.57e-13	6.14e-10	-0.47	-0.32	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
HNSC	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-7.37	7.58e-13	6.15e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-7.37	7.58e-13	6.15e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
HNSC	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-7.37	7.59e-13	6.16e-10	-0.33	-0.32	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
HNSC	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-7.37	7.59e-13	6.16e-10	-0.29	-0.32	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	7.37	7.6e-13	6.16e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	7.37	7.6e-13	6.16e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
HNSC	cis	rs7942368	0.941	rs737185	ENSG00000255100.1	RP11-21L23.3	7.37	7.6e-13	6.16e-10	0.41	0.32	Endometriosis;	chr11:76774314	chr11:76782581~76783062:-
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	7.37	7.6e-13	6.17e-10	0.36	0.32	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
HNSC	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	7.37	7.61e-13	6.17e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
HNSC	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	7.37	7.61e-13	6.17e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
HNSC	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
HNSC	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	7.37	7.61e-13	6.17e-10	0.32	0.32	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
HNSC	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	7.37	7.62e-13	6.17e-10	0.31	0.32	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	7.37	7.62e-13	6.17e-10	0.31	0.32	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
HNSC	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	7.37	7.63e-13	6.18e-10	0.39	0.32	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
HNSC	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-7.37	7.65e-13	6.2e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	7.37	7.65e-13	6.2e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	7.37	7.67e-13	6.22e-10	0.46	0.32	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
HNSC	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	7.37	7.68e-13	6.23e-10	0.39	0.32	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
HNSC	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-7.37	7.74e-13	6.27e-10	-0.42	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
HNSC	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	7.37	7.79e-13	6.31e-10	0.38	0.32	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
HNSC	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-7.37	7.8e-13	6.32e-10	-0.32	-0.32	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
HNSC	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
HNSC	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-7.37	7.83e-13	6.33e-10	-0.37	-0.32	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-7.37	7.83e-13	6.33e-10	-0.37	-0.32	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
HNSC	cis	rs6471393	0.964	rs16916186	ENSG00000253848.1	RP11-10N23.5	7.37	7.83e-13	6.34e-10	0.39	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93733158	chr8:93741193~93744534:+
HNSC	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-7.37	7.87e-13	6.36e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
HNSC	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-7.37	7.92e-13	6.4e-10	-0.35	-0.32	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
HNSC	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-7.37	7.92e-13	6.41e-10	-0.48	-0.32	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
HNSC	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	7.37	7.93e-13	6.41e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
HNSC	cis	rs451417	1	rs236107	ENSG00000275632.1	RP5-967N21.11	7.37	7.94e-13	6.42e-10	0.39	0.32	Menopause (age at onset);	chr20:5985085	chr20:6000418~6000941:+
HNSC	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	7.37	7.94e-13	6.42e-10	0.38	0.32	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	7.37	7.94e-13	6.42e-10	0.38	0.32	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	7.37	7.94e-13	6.42e-10	0.38	0.32	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
HNSC	cis	rs6951245	0.872	rs57068908	ENSG00000224079.1	AC091729.7	-7.37	7.96e-13	6.44e-10	-0.51	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020448	chr7:1074450~1078036:+
HNSC	cis	rs17270561	0.666	rs3923725	ENSG00000272462.2	U91328.19	-7.36	8.09e-13	6.53e-10	-0.34	-0.32	Iron status biomarkers;	chr6:25734692	chr6:25992662~26001775:+
HNSC	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-7.36	8.11e-13	6.55e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
HNSC	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-7.36	8.13e-13	6.57e-10	-0.34	-0.32	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
HNSC	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	7.36	8.13e-13	6.57e-10	0.59	0.32	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-7.36	8.14e-13	6.58e-10	-0.36	-0.32	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	7.36	8.16e-13	6.59e-10	0.22	0.32	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
HNSC	cis	rs1075265	0.868	rs4671872	ENSG00000233266.1	HMGB1P31	7.36	8.16e-13	6.59e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54134035	chr2:54051334~54051760:+
HNSC	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-7.36	8.17e-13	6.59e-10	-0.49	-0.32	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
HNSC	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	7.36	8.17e-13	6.59e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	7.36	8.17e-13	6.59e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	7.36	8.17e-13	6.59e-10	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	7.36	8.18e-13	6.6e-10	0.23	0.32	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
HNSC	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	7.36	8.19e-13	6.61e-10	0.35	0.32	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
HNSC	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	7.36	8.19e-13	6.61e-10	0.36	0.32	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
HNSC	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	7.36	8.21e-13	6.62e-10	0.35	0.32	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	7.36	8.21e-13	6.62e-10	0.35	0.32	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
HNSC	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-7.36	8.21e-13	6.62e-10	-0.42	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	7.36	8.24e-13	6.65e-10	0.23	0.32	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
HNSC	cis	rs2179367	0.568	rs9498358	ENSG00000231760.4	RP11-350J20.5	7.36	8.28e-13	6.67e-10	0.52	0.32	Dupuytren's disease;	chr6:149458529	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.6	rs58747890	ENSG00000231760.4	RP11-350J20.5	7.36	8.28e-13	6.67e-10	0.52	0.32	Dupuytren's disease;	chr6:149459369	chr6:149796151~149826294:-
HNSC	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	7.36	8.29e-13	6.68e-10	0.36	0.32	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	7.36	8.29e-13	6.68e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
HNSC	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	7.36	8.3e-13	6.69e-10	0.44	0.32	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
HNSC	cis	rs1799949	1	rs11659028	ENSG00000267151.3	RP11-100E5.2	7.36	8.3e-13	6.69e-10	0.43	0.32	Menopause (age at onset);	chr17:43043008	chr17:43444707~43451200:+
HNSC	cis	rs12935418	0.832	rs79957369	ENSG00000261061.1	RP11-303E16.2	-7.36	8.3e-13	6.69e-10	-0.49	-0.32	Mean corpuscular volume;	chr16:81025654	chr16:81030770~81031485:+
HNSC	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	7.36	8.33e-13	6.71e-10	0.6	0.32	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
HNSC	cis	rs9341808	0.527	rs2505946	ENSG00000272129.1	RP11-250B2.6	7.36	8.34e-13	6.72e-10	0.37	0.32	Sitting height ratio;	chr6:80100966	chr6:80355424~80356859:+
HNSC	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	7.36	8.36e-13	6.73e-10	0.34	0.32	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
HNSC	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	7.36	8.36e-13	6.73e-10	0.34	0.32	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
HNSC	cis	rs10080237	0.564	rs2490224	ENSG00000272129.1	RP11-250B2.6	7.36	8.37e-13	6.75e-10	0.37	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80100116	chr6:80355424~80356859:+
HNSC	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-7.36	8.38e-13	6.75e-10	-0.3	-0.32	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
HNSC	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	7.36	8.38e-13	6.75e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
HNSC	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-7.36	8.39e-13	6.76e-10	-0.29	-0.32	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-7.36	8.39e-13	6.76e-10	-0.29	-0.32	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
HNSC	cis	rs12458462	0.665	rs2035085	ENSG00000274828.1	RP11-567M16.6	7.36	8.41e-13	6.77e-10	0.36	0.32	Monocyte count;	chr18:79725280	chr18:79677287~79679358:-
HNSC	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-7.36	8.41e-13	6.77e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-7.36	8.42e-13	6.78e-10	-0.37	-0.32	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
HNSC	cis	rs7615952	0.551	rs6438945	ENSG00000248787.1	RP11-666A20.4	-7.36	8.43e-13	6.79e-10	-0.51	-0.32	Blood pressure (smoking interaction);	chr3:125915630	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.673	rs7632557	ENSG00000248787.1	RP11-666A20.4	-7.36	8.43e-13	6.79e-10	-0.51	-0.32	Blood pressure (smoking interaction);	chr3:125916038	chr3:125908005~125910272:-
HNSC	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-7.36	8.44e-13	6.8e-10	-0.51	-0.32	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-7.36	8.46e-13	6.81e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
HNSC	cis	rs12439619	0.693	rs28689861	ENSG00000276710.3	CSPG4P8	-7.36	8.46e-13	6.81e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82459472~82477258:+
HNSC	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	7.36	8.47e-13	6.82e-10	0.35	0.32	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	7.36	8.47e-13	6.82e-10	0.35	0.32	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
HNSC	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-7.36	8.49e-13	6.83e-10	-0.34	-0.32	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
HNSC	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	7.36	8.51e-13	6.85e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-7.36	8.53e-13	6.86e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.932	rs13325495	ENSG00000248787.1	RP11-666A20.4	-7.36	8.55e-13	6.88e-10	-0.51	-0.32	Blood pressure (smoking interaction);	chr3:125918573	chr3:125908005~125910272:-
HNSC	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-7.36	8.55e-13	6.88e-10	-0.29	-0.32	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
HNSC	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	7.36	8.57e-13	6.89e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
HNSC	cis	rs1799949	1	rs8176126	ENSG00000267151.3	RP11-100E5.2	-7.36	8.58e-13	6.9e-10	-0.41	-0.32	Menopause (age at onset);	chr17:43107032	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-7.36	8.58e-13	6.9e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
HNSC	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	7.36	8.58e-13	6.9e-10	0.37	0.32	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
HNSC	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-7.36	8.59e-13	6.91e-10	-0.46	-0.32	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
HNSC	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-7.36	8.61e-13	6.92e-10	-0.4	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
HNSC	cis	rs4141404	0.604	rs5753625	ENSG00000236132.1	CTA-440B3.1	7.36	8.62e-13	6.93e-10	0.36	0.32	Paclitaxel-induced neuropathy;	chr22:31458860	chr22:31816379~31817491:-
HNSC	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-7.36	8.63e-13	6.93e-10	-0.31	-0.32	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
HNSC	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
HNSC	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	7.36	8.63e-13	6.94e-10	0.41	0.32	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
HNSC	cis	rs451417	1	rs379418	ENSG00000275632.1	RP5-967N21.11	7.35	8.67e-13	6.96e-10	0.39	0.32	Menopause (age at onset);	chr20:5961561	chr20:6000418~6000941:+
HNSC	cis	rs6951245	0.638	rs74976697	ENSG00000224079.1	AC091729.7	-7.35	8.67e-13	6.97e-10	-0.5	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1074450~1078036:+
HNSC	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-7.35	8.69e-13	6.98e-10	-0.5	-0.32	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
HNSC	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	7.35	8.72e-13	7e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
HNSC	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	7.35	8.74e-13	7.02e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	7.35	8.74e-13	7.02e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
HNSC	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	7.35	8.74e-13	7.02e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	7.35	8.74e-13	7.02e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
HNSC	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	7.35	8.75e-13	7.02e-10	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
HNSC	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	7.35	8.75e-13	7.03e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
HNSC	cis	rs451417	1	rs236105	ENSG00000275632.1	RP5-967N21.11	-7.35	8.76e-13	7.03e-10	-0.38	-0.32	Menopause (age at onset);	chr20:5979186	chr20:6000418~6000941:+
HNSC	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-7.35	8.76e-13	7.04e-10	-0.34	-0.32	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
HNSC	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-7.35	8.79e-13	7.05e-10	-0.44	-0.32	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
HNSC	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-7.35	8.85e-13	7.1e-10	-0.32	-0.32	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
HNSC	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	7.35	8.86e-13	7.11e-10	0.37	0.32	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	7.35	8.86e-13	7.11e-10	0.23	0.32	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
HNSC	cis	rs6951245	1	rs74785791	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs74366004	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77702926	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs78573577	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs76129108	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78523927	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1074450~1078036:+
HNSC	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-7.35	8.9e-13	7.14e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
HNSC	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-7.35	8.9e-13	7.14e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	7.35	8.92e-13	7.15e-10	0.35	0.32	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
HNSC	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-7.35	8.95e-13	7.17e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	7.35	9e-13	7.21e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-7.35	9.08e-13	7.28e-10	-0.42	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
HNSC	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	7.35	9.09e-13	7.28e-10	0.25	0.32	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
HNSC	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	7.35	9.14e-13	7.32e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
HNSC	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	7.35	9.14e-13	7.32e-10	0.37	0.32	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
HNSC	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	7.35	9.16e-13	7.34e-10	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
HNSC	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-7.35	9.18e-13	7.35e-10	-0.55	-0.32	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-7.35	9.19e-13	7.36e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-7.35	9.19e-13	7.36e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-7.35	9.19e-13	7.36e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
HNSC	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-7.35	9.21e-13	7.37e-10	-0.32	-0.32	Height;	chr5:36861889	chr5:36666214~36725195:-
HNSC	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-7.34	9.25e-13	7.41e-10	-0.36	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
HNSC	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-7.34	9.28e-13	7.43e-10	-0.32	-0.32	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-7.34	9.29e-13	7.44e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-7.34	9.3e-13	7.44e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	7.34	9.39e-13	7.51e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
HNSC	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-7.34	9.4e-13	7.52e-10	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
HNSC	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-7.34	9.44e-13	7.55e-10	-0.36	-0.32	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
HNSC	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-7.34	9.45e-13	7.55e-10	-0.42	-0.32	Depression;	chr6:28193021	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-7.34	9.45e-13	7.55e-10	-0.21	-0.32	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
HNSC	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	7.34	9.5e-13	7.59e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-7.34	9.53e-13	7.61e-10	-0.36	-0.32	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
HNSC	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	7.34	9.57e-13	7.64e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
HNSC	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-7.34	9.57e-13	7.64e-10	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
HNSC	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-7.34	9.61e-13	7.67e-10	-0.32	-0.32	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
HNSC	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	7.34	9.62e-13	7.68e-10	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
HNSC	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	7.34	9.74e-13	7.77e-10	0.4	0.32	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
HNSC	cis	rs1021993	0.545	rs79212878	ENSG00000231648.1	RP11-372M18.2	-7.34	9.76e-13	7.79e-10	-0.55	-0.32	Gut microbiome composition (winter);	chr1:209374072	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.545	rs80311419	ENSG00000231648.1	RP11-372M18.2	-7.34	9.76e-13	7.79e-10	-0.55	-0.32	Gut microbiome composition (winter);	chr1:209374073	chr1:209367662~209379690:+
HNSC	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-7.34	9.79e-13	7.81e-10	-0.38	-0.32	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
HNSC	cis	rs451417	1	rs236120	ENSG00000275632.1	RP5-967N21.11	7.34	9.81e-13	7.82e-10	0.39	0.32	Menopause (age at onset);	chr20:5959003	chr20:6000418~6000941:+
HNSC	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-7.34	9.86e-13	7.86e-10	-0.37	-0.32	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
HNSC	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	7.34	9.87e-13	7.87e-10	0.39	0.32	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
HNSC	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-7.33	9.89e-13	7.88e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
HNSC	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-7.33	9.89e-13	7.89e-10	-0.32	-0.32	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
HNSC	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	7.33	9.9e-13	7.89e-10	0.31	0.32	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
HNSC	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	7.33	9.91e-13	7.9e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
HNSC	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	7.33	9.95e-13	7.92e-10	0.39	0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
HNSC	cis	rs451417	1	rs236115	ENSG00000275632.1	RP5-967N21.11	7.33	1e-12	7.96e-10	0.39	0.32	Menopause (age at onset);	chr20:5954803	chr20:6000418~6000941:+
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	7.33	1e-12	7.97e-10	0.22	0.32	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
HNSC	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	7.33	1e-12	7.97e-10	0.35	0.32	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
HNSC	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.33	1e-12	7.97e-10	-0.36	-0.32	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
HNSC	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-7.33	1.01e-12	8.01e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
HNSC	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
HNSC	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-7.33	1.01e-12	8.06e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
HNSC	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	7.33	1.02e-12	8.15e-10	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	7.33	1.02e-12	8.15e-10	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	7.33	1.02e-12	8.15e-10	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
HNSC	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	7.33	1.02e-12	8.15e-10	0.39	0.32	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
HNSC	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	7.33	1.03e-12	8.17e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
HNSC	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-7.33	1.03e-12	8.17e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	7.33	1.03e-12	8.18e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	7.33	1.03e-12	8.2e-10	0.22	0.32	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	7.33	1.03e-12	8.2e-10	0.22	0.32	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	7.33	1.03e-12	8.2e-10	0.22	0.32	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-7.33	1.03e-12	8.21e-10	-0.37	-0.32	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
HNSC	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	7.33	1.03e-12	8.21e-10	0.59	0.32	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
HNSC	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-7.33	1.04e-12	8.24e-10	-0.46	-0.32	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	7.33	1.04e-12	8.26e-10	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	7.33	1.04e-12	8.29e-10	0.22	0.32	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
HNSC	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.33	1.05e-12	8.3e-10	0.36	0.32	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
HNSC	cis	rs7615952	1	rs7616044	ENSG00000248787.1	RP11-666A20.4	-7.33	1.05e-12	8.3e-10	-0.46	-0.32	Blood pressure (smoking interaction);	chr3:125930511	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs6803160	ENSG00000241288.6	RP11-379B18.5	-7.33	1.05e-12	8.3e-10	-0.42	-0.32	Blood pressure (smoking interaction);	chr3:125990711	chr3:125827238~125916384:-
HNSC	cis	rs1021993	0.545	rs17014375	ENSG00000231648.1	RP11-372M18.2	-7.33	1.05e-12	8.32e-10	-0.54	-0.32	Gut microbiome composition (winter);	chr1:209370215	chr1:209367662~209379690:+
HNSC	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-7.33	1.05e-12	8.34e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	7.33	1.05e-12	8.34e-10	0.31	0.32	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
HNSC	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-7.33	1.05e-12	8.35e-10	-0.39	-0.32	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
HNSC	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-7.33	1.05e-12	8.36e-10	-0.43	-0.32	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
HNSC	cis	rs1021993	0.597	rs2055698	ENSG00000231648.1	RP11-372M18.2	-7.32	1.06e-12	8.38e-10	-0.41	-0.32	Gut microbiome composition (winter);	chr1:209375201	chr1:209367662~209379690:+
HNSC	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-7.32	1.06e-12	8.41e-10	-0.38	-0.32	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-7.32	1.06e-12	8.41e-10	-0.38	-0.32	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
HNSC	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-7.32	1.06e-12	8.41e-10	-0.36	-0.32	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
HNSC	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	7.32	1.07e-12	8.45e-10	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
HNSC	cis	rs904251	0.561	rs4714071	ENSG00000204110.6	RP1-153P14.8	-7.32	1.07e-12	8.46e-10	-0.32	-0.32	Cognitive performance;	chr6:37506617	chr6:37507348~37535616:+
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	7.32	1.07e-12	8.51e-10	0.22	0.32	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
HNSC	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-7.32	1.08e-12	8.53e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
HNSC	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	7.32	1.08e-12	8.56e-10	0.52	0.32	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-7.32	1.08e-12	8.56e-10	-0.43	-0.32	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
HNSC	cis	rs6951245	1	rs80212261	ENSG00000224079.1	AC091729.7	-7.32	1.08e-12	8.58e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77346188	ENSG00000224079.1	AC091729.7	-7.32	1.08e-12	8.58e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1074450~1078036:+
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	7.32	1.08e-12	8.58e-10	0.46	0.32	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	7.32	1.08e-12	8.58e-10	0.46	0.32	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-7.32	1.09e-12	8.62e-10	-0.36	-0.32	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
HNSC	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-7.32	1.09e-12	8.64e-10	-0.32	-0.32	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
HNSC	cis	rs6951245	1	rs78158942	ENSG00000224079.1	AC091729.7	-7.32	1.09e-12	8.64e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1074450~1078036:+
HNSC	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	7.32	1.09e-12	8.64e-10	0.39	0.32	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	7.32	1.09e-12	8.64e-10	0.39	0.32	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
HNSC	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	7.32	1.1e-12	8.68e-10	0.36	0.32	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
HNSC	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	7.32	1.1e-12	8.72e-10	0.39	0.32	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
HNSC	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	7.32	1.1e-12	8.74e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
HNSC	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-7.32	1.1e-12	8.74e-10	-0.46	-0.32	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
HNSC	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	7.32	1.11e-12	8.76e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
HNSC	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-7.32	1.11e-12	8.78e-10	-0.31	-0.32	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
HNSC	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	7.32	1.11e-12	8.8e-10	0.73	0.32	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-7.32	1.12e-12	8.83e-10	-0.42	-0.32	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
HNSC	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	7.32	1.12e-12	8.85e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
HNSC	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-7.32	1.12e-12	8.89e-10	-0.37	-0.32	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
HNSC	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	7.32	1.13e-12	8.91e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-7.32	1.13e-12	8.91e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	7.31	1.13e-12	8.94e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
HNSC	cis	rs6951245	0.744	rs1133122	ENSG00000224079.1	AC091729.7	-7.31	1.13e-12	8.94e-10	-0.53	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1074450~1078036:+
HNSC	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-7.31	1.13e-12	8.95e-10	-0.43	-0.32	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-7.31	1.13e-12	8.95e-10	-0.43	-0.32	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
HNSC	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	7.31	1.13e-12	8.95e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
HNSC	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	7.31	1.13e-12	8.95e-10	0.37	0.32	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
HNSC	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-7.31	1.13e-12	8.96e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.693	rs8034801	ENSG00000276710.3	CSPG4P8	-7.31	1.13e-12	8.96e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82459472~82477258:+
HNSC	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	7.31	1.13e-12	8.97e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-7.31	1.14e-12	8.98e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
HNSC	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-7.31	1.14e-12	9.04e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
HNSC	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	7.31	1.15e-12	9.08e-10	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
HNSC	cis	rs12439619	0.693	rs17269819	ENSG00000276710.3	CSPG4P8	-7.31	1.15e-12	9.09e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82459472~82477258:+
HNSC	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	7.31	1.15e-12	9.09e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	7.31	1.15e-12	9.09e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
HNSC	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-7.31	1.15e-12	9.11e-10	-0.64	-0.32	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
HNSC	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	7.31	1.15e-12	9.12e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	7.31	1.16e-12	9.16e-10	0.36	0.32	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-7.31	1.16e-12	9.17e-10	-0.39	-0.32	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
HNSC	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	7.31	1.16e-12	9.19e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
HNSC	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	7.31	1.17e-12	9.21e-10	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
HNSC	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	7.31	1.17e-12	9.24e-10	0.34	0.32	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
HNSC	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	7.31	1.17e-12	9.26e-10	0.43	0.32	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
HNSC	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-7.31	1.18e-12	9.3e-10	-0.45	-0.32	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
HNSC	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	7.31	1.18e-12	9.32e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	7.31	1.18e-12	9.32e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	7.31	1.18e-12	9.32e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
HNSC	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-7.31	1.18e-12	9.33e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.693	rs7165536	ENSG00000276710.3	CSPG4P8	-7.31	1.19e-12	9.35e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82459472~82477258:+
HNSC	cis	rs7942368	1	rs3758711	ENSG00000255100.1	RP11-21L23.3	7.31	1.19e-12	9.36e-10	0.4	0.32	Endometriosis;	chr11:76784516	chr11:76782581~76783062:-
HNSC	cis	rs6951245	0.706	rs1133116	ENSG00000224079.1	AC091729.7	-7.31	1.19e-12	9.37e-10	-0.53	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1074450~1078036:+
HNSC	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-7.31	1.19e-12	9.37e-10	-0.38	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
HNSC	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-7.31	1.19e-12	9.42e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
HNSC	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-7.31	1.2e-12	9.46e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-7.31	1.2e-12	9.46e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
HNSC	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	7.3	1.21e-12	9.51e-10	0.28	0.32	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
HNSC	cis	rs6565180	0.888	rs8060853	ENSG00000183604.13	SMG1P5	7.3	1.21e-12	9.53e-10	0.34	0.32	Tonsillectomy;	chr16:30392537	chr16:30267553~30335374:-
HNSC	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	7.3	1.21e-12	9.54e-10	0.39	0.32	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
HNSC	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	7.3	1.21e-12	9.54e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
HNSC	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	7.3	1.21e-12	9.54e-10	0.41	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
HNSC	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	7.3	1.22e-12	9.57e-10	0.32	0.32	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
HNSC	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	7.3	1.22e-12	9.58e-10	0.31	0.32	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
HNSC	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-7.3	1.22e-12	9.6e-10	-0.41	-0.32	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
HNSC	cis	rs6061231	0.958	rs2427305	ENSG00000273619.1	RP5-908M14.9	-7.3	1.23e-12	9.65e-10	-0.31	-0.32	Colorectal cancer;	chr20:62378693	chr20:62386303~62386970:-
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	7.3	1.23e-12	9.67e-10	0.47	0.32	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-7.3	1.24e-12	9.75e-10	-0.35	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
HNSC	cis	rs36423	0.702	rs1205076	ENSG00000266869.1	RP6-114E22.1	7.3	1.24e-12	9.76e-10	0.56	0.32	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71871335	chr14:71848606~71908430:+
HNSC	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-7.3	1.24e-12	9.77e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
HNSC	cis	rs6951245	0.935	rs79143504	ENSG00000224079.1	AC091729.7	-7.3	1.24e-12	9.77e-10	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1074450~1078036:+
HNSC	cis	rs17270561	0.666	rs4712971	ENSG00000272462.2	U91328.19	-7.3	1.24e-12	9.79e-10	-0.33	-0.32	Iron status biomarkers;	chr6:25771672	chr6:25992662~26001775:+
HNSC	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	7.3	1.25e-12	9.84e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
HNSC	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-7.3	1.25e-12	9.86e-10	-0.44	-0.32	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
HNSC	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-7.3	1.26e-12	9.87e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	7.3	1.26e-12	9.91e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
HNSC	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	7.3	1.27e-12	9.95e-10	0.37	0.32	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
HNSC	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	7.3	1.27e-12	9.97e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	7.3	1.27e-12	9.97e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
HNSC	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	7.3	1.27e-12	1e-09	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
HNSC	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-7.3	1.27e-12	1e-09	-0.37	-0.32	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
HNSC	cis	rs9402743	0.816	rs9494332	ENSG00000217482.2	HMGB1P17	7.3	1.28e-12	1e-09	0.36	0.32	Systemic lupus erythematosus;	chr6:135687470	chr6:135636086~135636713:-
HNSC	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	7.3	1.28e-12	1e-09	0.35	0.32	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
HNSC	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	7.3	1.28e-12	1.01e-09	0.35	0.32	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
HNSC	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-7.3	1.28e-12	1.01e-09	-0.29	-0.32	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
HNSC	cis	rs1933112	0.527	rs12090218	ENSG00000227777.1	RP4-738P11.3	-7.3	1.29e-12	1.01e-09	-0.36	-0.32	Blood protein levels;	chr1:168529966	chr1:168542737~168543354:+
HNSC	cis	rs1799949	0.965	rs4793230	ENSG00000267151.3	RP11-100E5.2	7.29	1.31e-12	1.02e-09	0.41	0.32	Menopause (age at onset);	chr17:43350035	chr17:43444707~43451200:+
HNSC	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-7.29	1.31e-12	1.03e-09	-0.35	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
HNSC	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	7.29	1.31e-12	1.03e-09	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
HNSC	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	7.29	1.32e-12	1.04e-09	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
HNSC	cis	rs6471393	0.964	rs2914940	ENSG00000253848.1	RP11-10N23.5	7.29	1.32e-12	1.04e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93719598	chr8:93741193~93744534:+
HNSC	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-7.29	1.32e-12	1.04e-09	-0.35	-0.32	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-7.29	1.32e-12	1.04e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
HNSC	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.32e-12	1.04e-09	-0.34	-0.32	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	7.29	1.33e-12	1.04e-09	0.22	0.32	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	7.29	1.33e-12	1.04e-09	0.22	0.32	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
HNSC	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	7.29	1.33e-12	1.04e-09	0.37	0.32	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
HNSC	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-7.29	1.33e-12	1.04e-09	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-7.29	1.33e-12	1.04e-09	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
HNSC	cis	rs6951245	0.938	rs11764937	ENSG00000224079.1	AC091729.7	-7.29	1.33e-12	1.05e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs4793229	ENSG00000267151.3	RP11-100E5.2	-7.29	1.33e-12	1.05e-09	-0.41	-0.32	Menopause (age at onset);	chr17:43340966	chr17:43444707~43451200:+
HNSC	cis	rs17270561	0.609	rs9356984	ENSG00000272462.2	U91328.19	7.29	1.34e-12	1.05e-09	0.33	0.32	Iron status biomarkers;	chr6:25725253	chr6:25992662~26001775:+
HNSC	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-7.29	1.34e-12	1.05e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
HNSC	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-7.29	1.34e-12	1.05e-09	-0.39	-0.32	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
HNSC	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	7.29	1.34e-12	1.05e-09	0.51	0.32	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
HNSC	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-7.29	1.34e-12	1.05e-09	-0.39	-0.32	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-7.29	1.34e-12	1.05e-09	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
HNSC	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-7.29	1.34e-12	1.05e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
HNSC	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-7.29	1.34e-12	1.05e-09	-0.36	-0.32	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
HNSC	cis	rs12935418	0.887	rs3743503	ENSG00000261061.1	RP11-303E16.2	-7.29	1.34e-12	1.05e-09	-0.49	-0.32	Mean corpuscular volume;	chr16:81022836	chr16:81030770~81031485:+
HNSC	cis	rs6867032	0.958	rs4975795	ENSG00000249731.1	RP11-259O2.3	7.29	1.35e-12	1.06e-09	0.39	0.32	Gut microbiome composition (winter);	chr5:2015276	chr5:1968094~1969013:+
HNSC	cis	rs7615952	0.611	rs2971298	ENSG00000241288.6	RP11-379B18.5	-7.29	1.35e-12	1.06e-09	-0.5	-0.32	Blood pressure (smoking interaction);	chr3:125883870	chr3:125827238~125916384:-
HNSC	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	7.29	1.35e-12	1.06e-09	0.45	0.32	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	7.29	1.36e-12	1.06e-09	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
HNSC	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-7.29	1.36e-12	1.07e-09	-0.35	-0.32	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
HNSC	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
HNSC	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	7.29	1.37e-12	1.07e-09	0.44	0.32	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	7.29	1.37e-12	1.07e-09	0.44	0.32	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
HNSC	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
HNSC	cis	rs17507216	1	rs17507216	ENSG00000255769.6	GOLGA2P10	7.28	1.38e-12	1.08e-09	0.46	0.32	Excessive daytime sleepiness;	chr15:82558175	chr15:82472993~82513950:-
HNSC	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-7.28	1.39e-12	1.08e-09	-0.35	-0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
HNSC	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-7.28	1.39e-12	1.09e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
HNSC	cis	rs9341808	0.754	rs3812126	ENSG00000272129.1	RP11-250B2.6	-7.28	1.39e-12	1.09e-09	-0.38	-0.32	Sitting height ratio;	chr6:80242984	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	7.28	1.39e-12	1.09e-09	0.38	0.32	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-7.28	1.4e-12	1.1e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
HNSC	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	7.28	1.41e-12	1.1e-09	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
HNSC	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-7.28	1.41e-12	1.1e-09	-0.31	-0.32	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
HNSC	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-7.28	1.42e-12	1.11e-09	-0.34	-0.32	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
HNSC	cis	rs6471393	0.964	rs16916191	ENSG00000253848.1	RP11-10N23.5	7.28	1.42e-12	1.11e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737337	chr8:93741193~93744534:+
HNSC	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	7.28	1.42e-12	1.11e-09	0.35	0.32	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
HNSC	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-7.28	1.43e-12	1.12e-09	-0.4	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
HNSC	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-7.28	1.43e-12	1.12e-09	-0.39	-0.32	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
HNSC	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-7.28	1.43e-12	1.12e-09	-0.35	-0.32	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
HNSC	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-7.28	1.44e-12	1.12e-09	-0.29	-0.32	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-7.28	1.44e-12	1.12e-09	-0.29	-0.32	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
HNSC	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-7.28	1.44e-12	1.12e-09	-0.35	-0.32	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
HNSC	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-7.28	1.44e-12	1.13e-09	-0.36	-0.32	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
HNSC	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	7.28	1.45e-12	1.13e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-7.28	1.45e-12	1.13e-09	-0.58	-0.32	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
HNSC	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	7.28	1.46e-12	1.14e-09	0.32	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
HNSC	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	7.28	1.46e-12	1.14e-09	0.39	0.32	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
HNSC	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	7.28	1.46e-12	1.14e-09	0.34	0.32	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
HNSC	cis	rs875971	0.545	rs1796219	ENSG00000179406.6	LINC00174	7.28	1.46e-12	1.14e-09	0.5	0.32	Aortic root size;	chr7:66645977	chr7:66376044~66401338:-
HNSC	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-7.28	1.46e-12	1.14e-09	-0.43	-0.32	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
HNSC	cis	rs494459	0.536	rs7103067	ENSG00000255422.1	AP002954.4	-7.28	1.47e-12	1.15e-09	-0.39	-0.32	Height;	chr11:118852670	chr11:118704607~118750263:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000173295.6	FAM86B3P	7.28	1.47e-12	1.15e-09	0.37	0.32	Joint mobility (Beighton score);	chr8:9002766	chr8:8228595~8244865:+
HNSC	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-7.28	1.47e-12	1.15e-09	-0.33	-0.32	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
HNSC	cis	rs1799949	1	rs11653460	ENSG00000267151.3	RP11-100E5.2	7.28	1.47e-12	1.15e-09	0.42	0.32	Menopause (age at onset);	chr17:43179289	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11650913	ENSG00000267151.3	RP11-100E5.2	7.28	1.47e-12	1.15e-09	0.42	0.32	Menopause (age at onset);	chr17:43179580	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12936831	ENSG00000267151.3	RP11-100E5.2	7.28	1.47e-12	1.15e-09	0.42	0.32	Menopause (age at onset);	chr17:43179799	chr17:43444707~43451200:+
HNSC	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-7.27	1.48e-12	1.15e-09	-0.31	-0.32	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
HNSC	cis	rs6565180	0.926	rs4788413	ENSG00000183604.13	SMG1P5	7.27	1.48e-12	1.15e-09	0.34	0.32	Tonsillectomy;	chr16:30399124	chr16:30267553~30335374:-
HNSC	cis	rs1823913	0.538	rs6732537	ENSG00000227542.1	AC092614.2	7.27	1.48e-12	1.15e-09	0.36	0.32	Obesity-related traits;	chr2:191346755	chr2:191229165~191246172:-
HNSC	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-7.27	1.48e-12	1.16e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-7.27	1.48e-12	1.16e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-7.27	1.48e-12	1.16e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
HNSC	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	7.27	1.48e-12	1.16e-09	0.32	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
HNSC	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-7.27	1.49e-12	1.16e-09	-0.31	-0.32	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
HNSC	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-7.27	1.49e-12	1.16e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
HNSC	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-7.27	1.49e-12	1.16e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-7.27	1.49e-12	1.16e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-7.27	1.49e-12	1.16e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
HNSC	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-7.27	1.49e-12	1.16e-09	-0.39	-0.32	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	7.27	1.49e-12	1.16e-09	0.22	0.32	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
HNSC	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	7.27	1.49e-12	1.16e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
HNSC	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-7.27	1.49e-12	1.16e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
HNSC	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	7.27	1.5e-12	1.16e-09	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	7.27	1.5e-12	1.17e-09	0.46	0.32	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
HNSC	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-7.27	1.5e-12	1.17e-09	-0.39	-0.32	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
HNSC	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	7.27	1.5e-12	1.17e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
HNSC	cis	rs7942368	0.715	rs12788118	ENSG00000255100.1	RP11-21L23.3	7.27	1.5e-12	1.17e-09	0.4	0.32	Endometriosis;	chr11:76783176	chr11:76782581~76783062:-
HNSC	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	7.27	1.51e-12	1.17e-09	0.49	0.32	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
HNSC	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
HNSC	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-7.27	1.51e-12	1.18e-09	-0.35	-0.32	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
HNSC	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	7.27	1.52e-12	1.18e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-7.27	1.52e-12	1.18e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-7.27	1.52e-12	1.18e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
HNSC	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-7.27	1.52e-12	1.18e-09	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-7.27	1.52e-12	1.18e-09	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-7.27	1.52e-12	1.18e-09	-0.29	-0.32	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-7.27	1.52e-12	1.18e-09	-0.29	-0.32	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
HNSC	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-7.27	1.52e-12	1.18e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
HNSC	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	7.27	1.52e-12	1.18e-09	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
HNSC	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	7.27	1.52e-12	1.18e-09	0.32	0.32	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
HNSC	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	7.27	1.52e-12	1.18e-09	0.32	0.32	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
HNSC	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-7.27	1.53e-12	1.19e-09	-0.21	-0.32	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
HNSC	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	7.27	1.53e-12	1.19e-09	0.31	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
HNSC	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	7.27	1.53e-12	1.19e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
HNSC	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-7.27	1.53e-12	1.19e-09	-0.45	-0.32	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
HNSC	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-7.27	1.53e-12	1.19e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
HNSC	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-7.27	1.53e-12	1.19e-09	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
HNSC	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-7.27	1.53e-12	1.19e-09	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
HNSC	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-7.27	1.53e-12	1.19e-09	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
HNSC	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	7.27	1.54e-12	1.19e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
HNSC	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	7.27	1.54e-12	1.2e-09	0.27	0.32	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
HNSC	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-7.27	1.54e-12	1.2e-09	-0.54	-0.32	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
HNSC	cis	rs1799949	0.501	rs2343819	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43332285	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.501	rs35399157	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43334234	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.602	rs4600503	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43336956	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.501	rs9675035	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43337648	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11649954	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43342667	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1824889	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43344508	chr17:43444707~43451200:+
HNSC	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-7.27	1.54e-12	1.2e-09	-0.36	-0.32	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
HNSC	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-7.27	1.55e-12	1.21e-09	-0.36	-0.32	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
HNSC	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-7.27	1.57e-12	1.22e-09	-0.36	-0.32	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
HNSC	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-7.27	1.57e-12	1.22e-09	-0.36	-0.32	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
HNSC	cis	rs10791097	0.967	rs10750450	ENSG00000254842.5	RP11-890B15.2	-7.27	1.57e-12	1.22e-09	-0.28	-0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130849166	chr11:130844191~130865561:-
HNSC	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-7.27	1.57e-12	1.22e-09	-0.39	-0.32	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
HNSC	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	7.26	1.58e-12	1.22e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
HNSC	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-7.26	1.58e-12	1.22e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
HNSC	cis	rs10791097	1	rs10791098	ENSG00000254842.5	RP11-890B15.2	-7.26	1.58e-12	1.23e-09	-0.28	-0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848816	chr11:130844191~130865561:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000235689.1	AP000351.13	7.26	1.59e-12	1.23e-09	0.32	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:24006305~24008258:-
HNSC	cis	rs6471393	0.964	rs12056877	ENSG00000253848.1	RP11-10N23.5	-7.26	1.59e-12	1.23e-09	-0.38	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93710234	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.964	rs2914944	ENSG00000253848.1	RP11-10N23.5	-7.26	1.59e-12	1.23e-09	-0.38	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93711815	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.964	rs2914942	ENSG00000253848.1	RP11-10N23.5	-7.26	1.59e-12	1.23e-09	-0.38	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93714189	chr8:93741193~93744534:+
HNSC	cis	rs4218	0.689	rs11853828	ENSG00000259732.1	RP11-59H7.3	-7.26	1.59e-12	1.23e-09	-0.45	-0.32	Social communication problems;	chr15:59136031	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000254340.1	RP11-10A14.3	7.26	1.59e-12	1.23e-09	0.4	0.32	Joint mobility (Beighton score);	chr8:9009901	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-7.26	1.6e-12	1.24e-09	-0.39	-0.32	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
HNSC	cis	rs6504622	0.905	rs3851787	ENSG00000262879.4	RP11-156P1.3	7.26	1.6e-12	1.24e-09	0.34	0.32	Orofacial clefts;	chr17:46969616	chr17:46984045~47100323:-
HNSC	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
HNSC	cis	rs7615952	0.932	rs7629977	ENSG00000248787.1	RP11-666A20.4	-7.26	1.61e-12	1.25e-09	-0.47	-0.32	Blood pressure (smoking interaction);	chr3:125930730	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.932	rs7630077	ENSG00000248787.1	RP11-666A20.4	-7.26	1.61e-12	1.25e-09	-0.47	-0.32	Blood pressure (smoking interaction);	chr3:125930833	chr3:125908005~125910272:-
HNSC	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	7.26	1.62e-12	1.25e-09	0.31	0.32	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	7.26	1.62e-12	1.25e-09	0.31	0.32	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	7.26	1.62e-12	1.25e-09	0.31	0.32	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
HNSC	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	7.26	1.63e-12	1.26e-09	0.51	0.32	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
HNSC	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-7.26	1.63e-12	1.26e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-7.26	1.64e-12	1.27e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
HNSC	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-7.26	1.64e-12	1.27e-09	-0.36	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
HNSC	cis	rs10791097	0.967	rs10791099	ENSG00000254842.5	RP11-890B15.2	-7.26	1.64e-12	1.27e-09	-0.28	-0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848918	chr11:130844191~130865561:-
HNSC	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-7.26	1.64e-12	1.27e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
HNSC	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-7.26	1.64e-12	1.27e-09	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
HNSC	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	7.26	1.66e-12	1.28e-09	0.36	0.32	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
HNSC	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	7.26	1.66e-12	1.28e-09	0.41	0.32	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
HNSC	cis	rs12439619	0.693	rs4778989	ENSG00000276710.3	CSPG4P8	-7.26	1.66e-12	1.28e-09	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82459472~82477258:+
HNSC	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-7.26	1.67e-12	1.29e-09	-0.35	-0.32	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
HNSC	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.864	rs60309406	ENSG00000267151.3	RP11-100E5.2	7.26	1.67e-12	1.29e-09	0.42	0.32	Menopause (age at onset);	chr17:43358297	chr17:43444707~43451200:+
HNSC	cis	rs7048146	0.899	rs13284486	ENSG00000213539.4	YBX1P6	7.26	1.68e-12	1.29e-09	0.37	0.32	Vascular brain injury;	chr9:109586658	chr9:109532830~109534332:-
HNSC	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-7.26	1.68e-12	1.3e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
HNSC	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	7.26	1.68e-12	1.3e-09	0.36	0.32	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-7.26	1.68e-12	1.3e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-7.26	1.68e-12	1.3e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
HNSC	cis	rs1799949	1	rs4793197	ENSG00000267151.3	RP11-100E5.2	7.25	1.69e-12	1.3e-09	0.41	0.32	Menopause (age at onset);	chr17:43079885	chr17:43444707~43451200:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	-7.25	1.69e-12	1.3e-09	-0.35	-0.32	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.655	rs10444809	ENSG00000259422.1	RP11-593F23.1	-7.25	1.69e-12	1.31e-09	-0.36	-0.32	Blood metabolite levels;	chr15:76832195	chr15:76174891~76181486:-
HNSC	cis	rs1021993	0.545	rs17014370	ENSG00000231648.1	RP11-372M18.2	-7.25	1.7e-12	1.31e-09	-0.54	-0.32	Gut microbiome composition (winter);	chr1:209366746	chr1:209367662~209379690:+
HNSC	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	7.25	1.71e-12	1.32e-09	0.53	0.32	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
HNSC	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	7.25	1.71e-12	1.32e-09	0.51	0.32	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
HNSC	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	7.25	1.72e-12	1.32e-09	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	7.25	1.72e-12	1.32e-09	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-7.25	1.72e-12	1.32e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-7.25	1.72e-12	1.33e-09	-0.37	-0.32	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
HNSC	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-7.25	1.72e-12	1.33e-09	-0.36	-0.32	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
HNSC	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-7.25	1.72e-12	1.33e-09	-0.41	-0.32	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
HNSC	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-7.25	1.73e-12	1.34e-09	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-7.25	1.73e-12	1.34e-09	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
HNSC	cis	rs1799949	0.965	rs4793234	ENSG00000267151.3	RP11-100E5.2	7.25	1.73e-12	1.34e-09	0.42	0.32	Menopause (age at onset);	chr17:43358815	chr17:43444707~43451200:+
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-7.25	1.73e-12	1.34e-09	-0.37	-0.32	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-7.25	1.74e-12	1.34e-09	-0.35	-0.32	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
HNSC	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-7.25	1.74e-12	1.34e-09	-0.29	-0.32	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
HNSC	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-7.25	1.74e-12	1.34e-09	-0.35	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
HNSC	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	7.25	1.75e-12	1.35e-09	0.34	0.32	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
HNSC	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-7.25	1.76e-12	1.35e-09	-0.49	-0.32	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-7.25	1.76e-12	1.35e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
HNSC	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-7.25	1.76e-12	1.36e-09	-0.39	-0.32	Height;	chr11:118854014	chr11:118704607~118750263:+
HNSC	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-7.25	1.76e-12	1.36e-09	-0.42	-0.32	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
HNSC	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-7.25	1.76e-12	1.36e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
HNSC	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-7.25	1.77e-12	1.36e-09	-0.42	-0.32	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-7.25	1.77e-12	1.36e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	7.25	1.77e-12	1.36e-09	0.31	0.32	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
HNSC	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	7.25	1.77e-12	1.36e-09	0.38	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
HNSC	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	7.25	1.77e-12	1.37e-09	0.46	0.32	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
HNSC	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-7.25	1.78e-12	1.37e-09	-0.35	-0.32	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-7.25	1.79e-12	1.38e-09	-0.44	-0.32	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
HNSC	cis	rs17270561	0.609	rs9348692	ENSG00000272462.2	U91328.19	-7.25	1.8e-12	1.38e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25720584	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	7.24	1.8e-12	1.39e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
HNSC	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-7.24	1.8e-12	1.39e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
HNSC	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-7.24	1.81e-12	1.39e-09	-0.38	-0.32	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
HNSC	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-7.24	1.82e-12	1.4e-09	-0.29	-0.32	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-7.24	1.82e-12	1.4e-09	-0.29	-0.32	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
HNSC	cis	rs6951245	1	rs79327308	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.938	rs117729148	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79617366	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs111899361	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1074450~1078036:+
HNSC	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-7.24	1.82e-12	1.4e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-7.24	1.82e-12	1.4e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
HNSC	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-7.24	1.82e-12	1.4e-09	-0.39	-0.32	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
HNSC	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.83e-12	1.41e-09	-0.33	-0.32	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
HNSC	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-7.24	1.83e-12	1.41e-09	-0.42	-0.32	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
HNSC	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-7.24	1.84e-12	1.41e-09	-0.34	-0.32	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
HNSC	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-7.24	1.84e-12	1.41e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-7.24	1.84e-12	1.41e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
HNSC	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	7.24	1.84e-12	1.42e-09	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
HNSC	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-7.24	1.84e-12	1.42e-09	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
HNSC	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	7.24	1.85e-12	1.42e-09	0.45	0.32	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-7.24	1.85e-12	1.42e-09	-0.3	-0.32	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-7.24	1.85e-12	1.42e-09	-0.3	-0.32	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
HNSC	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	7.24	1.85e-12	1.42e-09	0.31	0.32	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
HNSC	cis	rs16885979	1	rs12664791	ENSG00000224984.1	RP11-524H19.2	7.24	1.85e-12	1.42e-09	0.7	0.32	Daytime sleep phenotypes;	chr6:54829547	chr6:54840118~54840855:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-7.24	1.85e-12	1.42e-09	-0.37	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
HNSC	cis	rs172166	0.637	rs1225597	ENSG00000204709.4	LINC01556	7.24	1.85e-12	1.42e-09	0.4	0.32	Cardiac Troponin-T levels;	chr6:28194309	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-7.24	1.86e-12	1.43e-09	-0.48	-0.32	Depression;	chr6:28103220	chr6:28115628~28116551:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000235689.1	AP000351.13	7.24	1.86e-12	1.43e-09	0.32	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:24006305~24008258:-
HNSC	cis	rs1799949	0.965	rs11650132	ENSG00000267151.3	RP11-100E5.2	7.24	1.87e-12	1.43e-09	0.41	0.32	Menopause (age at onset);	chr17:43174070	chr17:43444707~43451200:+
HNSC	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.87e-12	1.43e-09	-0.36	-0.32	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.87e-12	1.43e-09	-0.36	-0.32	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
HNSC	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	7.24	1.87e-12	1.44e-09	0.35	0.32	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
HNSC	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	7.24	1.87e-12	1.44e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
HNSC	cis	rs1799949	0.93	rs4584865	ENSG00000267151.3	RP11-100E5.2	7.24	1.87e-12	1.44e-09	0.41	0.32	Menopause (age at onset);	chr17:43347551	chr17:43444707~43451200:+
HNSC	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
HNSC	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	7.24	1.88e-12	1.44e-09	0.35	0.32	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
HNSC	cis	rs6951245	0.935	rs113365567	ENSG00000224079.1	AC091729.7	-7.24	1.88e-12	1.44e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1074450~1078036:+
HNSC	cis	rs7615952	0.599	rs16834938	ENSG00000241288.6	RP11-379B18.5	-7.24	1.88e-12	1.44e-09	-0.42	-0.32	Blood pressure (smoking interaction);	chr3:125987203	chr3:125827238~125916384:-
HNSC	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	7.24	1.88e-12	1.44e-09	0.27	0.32	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
HNSC	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-7.24	1.9e-12	1.45e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-7.24	1.9e-12	1.45e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-7.24	1.9e-12	1.45e-09	-0.38	-0.32	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
HNSC	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-7.24	1.9e-12	1.46e-09	-0.31	-0.32	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
HNSC	cis	rs7615952	0.932	rs9841157	ENSG00000248787.1	RP11-666A20.4	-7.24	1.91e-12	1.46e-09	-0.5	-0.32	Blood pressure (smoking interaction);	chr3:125916812	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.551	rs12695470	ENSG00000248787.1	RP11-666A20.4	-7.24	1.91e-12	1.46e-09	-0.5	-0.32	Blood pressure (smoking interaction);	chr3:125916875	chr3:125908005~125910272:-
HNSC	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	7.24	1.91e-12	1.46e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
HNSC	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-7.24	1.91e-12	1.46e-09	-0.41	-0.32	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
HNSC	cis	rs1799949	1	rs11651341	ENSG00000267151.3	RP11-100E5.2	7.24	1.91e-12	1.46e-09	0.41	0.32	Menopause (age at onset);	chr17:43350693	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34572725	ENSG00000267151.3	RP11-100E5.2	7.24	1.91e-12	1.46e-09	0.41	0.32	Menopause (age at onset);	chr17:43351298	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4534897	ENSG00000267151.3	RP11-100E5.2	7.24	1.91e-12	1.46e-09	0.41	0.32	Menopause (age at onset);	chr17:43354440	chr17:43444707~43451200:+
HNSC	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	7.24	1.92e-12	1.47e-09	0.35	0.32	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
HNSC	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	7.23	1.93e-12	1.47e-09	0.32	0.32	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	7.23	1.94e-12	1.48e-09	0.35	0.32	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-7.23	1.94e-12	1.48e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
HNSC	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	7.23	1.94e-12	1.48e-09	0.39	0.32	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
HNSC	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	7.23	1.94e-12	1.49e-09	0.4	0.32	Height;	chr6:109332929	chr6:109382795~109383666:+
HNSC	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	7.23	1.96e-12	1.5e-09	0.57	0.32	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-7.23	1.96e-12	1.5e-09	-0.29	-0.32	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	7.23	1.97e-12	1.5e-09	0.46	0.32	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-7.23	1.97e-12	1.5e-09	-0.32	-0.32	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	7.23	1.97e-12	1.5e-09	0.47	0.32	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
HNSC	cis	rs7615952	0.741	rs13314845	ENSG00000248787.1	RP11-666A20.4	-7.23	1.98e-12	1.51e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125925939	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.733	rs13314847	ENSG00000248787.1	RP11-666A20.4	-7.23	1.98e-12	1.51e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125925945	chr3:125908005~125910272:-
HNSC	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-7.23	1.99e-12	1.52e-09	-0.34	-0.32	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
HNSC	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-7.23	1.99e-12	1.52e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
HNSC	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	7.23	1.99e-12	1.52e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
HNSC	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	7.23	1.99e-12	1.52e-09	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
HNSC	cis	rs6951245	0.935	rs61753396	ENSG00000224079.1	AC091729.7	-7.23	2e-12	1.52e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.938	rs113642700	ENSG00000224079.1	AC091729.7	-7.23	2e-12	1.52e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000173295.6	FAM86B3P	-7.23	2.01e-12	1.53e-09	-0.35	-0.32	Joint mobility (Beighton score);	chr8:9226344	chr8:8228595~8244865:+
HNSC	cis	rs6471393	0.964	rs2914953	ENSG00000253848.1	RP11-10N23.5	7.23	2.01e-12	1.53e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93730122	chr8:93741193~93744534:+
HNSC	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-7.23	2.01e-12	1.54e-09	-0.39	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
HNSC	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-7.23	2.02e-12	1.54e-09	-0.32	-0.32	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-7.23	2.02e-12	1.54e-09	-0.32	-0.32	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-7.23	2.02e-12	1.54e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
HNSC	cis	rs6951245	0.872	rs112309216	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs76161580	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs76388414	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77305932	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs11768486	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11766526	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs76214082	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs113146460	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1074450~1078036:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	7.23	2.03e-12	1.54e-09	0.37	0.32	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
HNSC	cis	rs9402743	0.816	rs9494327	ENSG00000217482.2	HMGB1P17	7.23	2.03e-12	1.55e-09	0.36	0.32	Systemic lupus erythematosus;	chr6:135674898	chr6:135636086~135636713:-
HNSC	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	7.23	2.03e-12	1.55e-09	0.48	0.32	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
HNSC	cis	rs1799949	1	rs35956818	ENSG00000267151.3	RP11-100E5.2	7.23	2.03e-12	1.55e-09	0.41	0.32	Menopause (age at onset);	chr17:43345617	chr17:43444707~43451200:+
HNSC	cis	rs1865760	0.625	rs9393681	ENSG00000272462.2	U91328.19	-7.23	2.04e-12	1.56e-09	-0.31	-0.32	Height;	chr6:26008032	chr6:25992662~26001775:+
HNSC	cis	rs4978813	0.5	rs12685609	ENSG00000213539.4	YBX1P6	-7.23	2.05e-12	1.56e-09	-0.36	-0.32	Plantar warts;	chr9:109536303	chr9:109532830~109534332:-
HNSC	cis	rs1933112	0.545	rs10429892	ENSG00000227777.1	RP4-738P11.3	-7.23	2.05e-12	1.56e-09	-0.34	-0.32	Blood protein levels;	chr1:168532215	chr1:168542737~168543354:+
HNSC	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	7.23	2.05e-12	1.56e-09	0.27	0.32	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
HNSC	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	7.23	2.05e-12	1.56e-09	0.27	0.32	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
HNSC	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-7.23	2.05e-12	1.56e-09	-0.32	-0.32	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-7.23	2.05e-12	1.56e-09	-0.32	-0.32	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
HNSC	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-7.22	2.07e-12	1.57e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
HNSC	cis	rs1799949	0.55	rs2343818	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43332406	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.526	rs4352088	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43337311	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs34633610	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43342017	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11654051	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43342288	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs56729776	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43344763	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-7.22	2.07e-12	1.58e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
HNSC	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-7.22	2.07e-12	1.58e-09	-0.36	-0.32	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
HNSC	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	7.22	2.08e-12	1.58e-09	0.37	0.32	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
HNSC	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	7.22	2.09e-12	1.59e-09	0.27	0.32	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
HNSC	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-7.22	2.09e-12	1.59e-09	-0.39	-0.32	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
HNSC	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	7.22	2.1e-12	1.6e-09	0.48	0.32	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
HNSC	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	7.22	2.11e-12	1.6e-09	0.36	0.32	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	7.22	2.13e-12	1.62e-09	0.29	0.32	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
HNSC	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-7.22	2.13e-12	1.62e-09	-0.37	-0.32	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
HNSC	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	7.22	2.14e-12	1.62e-09	0.46	0.32	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
HNSC	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	7.22	2.15e-12	1.63e-09	0.36	0.32	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-7.22	2.15e-12	1.63e-09	-0.32	-0.32	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
HNSC	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	7.22	2.15e-12	1.64e-09	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
HNSC	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	7.22	2.15e-12	1.64e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
HNSC	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	7.22	2.16e-12	1.64e-09	0.43	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000173295.6	FAM86B3P	7.22	2.17e-12	1.65e-09	0.35	0.32	Joint mobility (Beighton score);	chr8:8977018	chr8:8228595~8244865:+
HNSC	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	7.22	2.17e-12	1.65e-09	0.37	0.32	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
HNSC	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	7.22	2.17e-12	1.65e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
HNSC	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	7.22	2.19e-12	1.66e-09	0.44	0.32	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-7.22	2.19e-12	1.66e-09	-0.35	-0.32	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
HNSC	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-7.21	2.2e-12	1.67e-09	-0.44	-0.32	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
HNSC	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-7.21	2.2e-12	1.67e-09	-0.39	-0.32	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
HNSC	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-7.21	2.2e-12	1.67e-09	-0.29	-0.32	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
HNSC	cis	rs7615952	0.641	rs6438951	ENSG00000241288.6	RP11-379B18.5	-7.21	2.2e-12	1.67e-09	-0.41	-0.32	Blood pressure (smoking interaction);	chr3:125978156	chr3:125827238~125916384:-
HNSC	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	7.21	2.21e-12	1.67e-09	0.39	0.32	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	7.21	2.23e-12	1.69e-09	0.37	0.32	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
HNSC	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	7.21	2.23e-12	1.69e-09	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
HNSC	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	7.21	2.24e-12	1.7e-09	0.34	0.32	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
HNSC	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	7.21	2.24e-12	1.7e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
HNSC	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-7.21	2.25e-12	1.7e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
HNSC	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	7.21	2.25e-12	1.71e-09	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
HNSC	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-7.21	2.25e-12	1.71e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
HNSC	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	7.21	2.26e-12	1.71e-09	0.65	0.32	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
HNSC	cis	rs17270561	0.609	rs9358883	ENSG00000272462.2	U91328.19	-7.21	2.26e-12	1.71e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25755287	chr6:25992662~26001775:+
HNSC	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	7.21	2.26e-12	1.71e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
HNSC	cis	rs7615952	0.599	rs6438953	ENSG00000241288.6	RP11-379B18.5	-7.21	2.26e-12	1.71e-09	-0.4	-0.32	Blood pressure (smoking interaction);	chr3:126006108	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs1044215	ENSG00000241288.6	RP11-379B18.5	-7.21	2.26e-12	1.71e-09	-0.4	-0.32	Blood pressure (smoking interaction);	chr3:126006716	chr3:125827238~125916384:-
HNSC	cis	rs9402743	1	rs6926161	ENSG00000217482.2	HMGB1P17	7.21	2.26e-12	1.71e-09	0.34	0.32	Systemic lupus erythematosus;	chr6:135653341	chr6:135636086~135636713:-
HNSC	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-7.21	2.26e-12	1.71e-09	-0.45	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
HNSC	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	7.21	2.27e-12	1.72e-09	0.34	0.32	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	7.21	2.27e-12	1.72e-09	0.34	0.32	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
HNSC	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-7.21	2.27e-12	1.72e-09	-0.36	-0.32	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
HNSC	cis	rs17270561	0.553	rs9379784	ENSG00000272462.2	U91328.19	-7.21	2.29e-12	1.73e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25725278	chr6:25992662~26001775:+
HNSC	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-7.21	2.29e-12	1.74e-09	-0.36	-0.32	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
HNSC	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	7.21	2.31e-12	1.74e-09	0.31	0.32	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
HNSC	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	7.21	2.32e-12	1.76e-09	0.44	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	7.21	2.32e-12	1.76e-09	0.44	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
HNSC	cis	rs1021993	0.545	rs1507336	ENSG00000231648.1	RP11-372M18.2	-7.21	2.33e-12	1.76e-09	-0.56	-0.32	Gut microbiome composition (winter);	chr1:209375580	chr1:209367662~209379690:+
HNSC	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-7.21	2.33e-12	1.76e-09	-0.47	-0.32	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
HNSC	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	7.21	2.34e-12	1.77e-09	0.41	0.32	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
HNSC	cis	rs9402743	0.811	rs6570024	ENSG00000217482.2	HMGB1P17	7.21	2.34e-12	1.77e-09	0.34	0.32	Systemic lupus erythematosus;	chr6:135649186	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.923	rs4896159	ENSG00000217482.2	HMGB1P17	7.21	2.34e-12	1.77e-09	0.34	0.32	Systemic lupus erythematosus;	chr6:135650304	chr6:135636086~135636713:-
HNSC	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	7.21	2.34e-12	1.77e-09	0.29	0.32	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
HNSC	cis	rs451417	1	rs236108	ENSG00000275632.1	RP5-967N21.11	7.21	2.34e-12	1.77e-09	0.39	0.32	Menopause (age at onset);	chr20:5987913	chr20:6000418~6000941:+
HNSC	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	7.2	2.35e-12	1.77e-09	0.29	0.32	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
HNSC	cis	rs2579103	0.708	rs1438988	ENSG00000258183.4	RP11-753N8.1	-7.2	2.36e-12	1.78e-09	-0.44	-0.32	Body mass index;	chr12:90290693	chr12:90280894~90300340:+
HNSC	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-7.2	2.37e-12	1.79e-09	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
HNSC	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-7.2	2.39e-12	1.8e-09	-0.42	-0.32	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
HNSC	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-7.2	2.39e-12	1.8e-09	-0.33	-0.32	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
HNSC	cis	rs875971	0.862	rs2460432	ENSG00000237310.1	GS1-124K5.4	-7.2	2.39e-12	1.8e-09	-0.31	-0.32	Aortic root size;	chr7:66089398	chr7:66493706~66495474:+
HNSC	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	7.2	2.39e-12	1.81e-09	0.37	0.32	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
HNSC	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-7.2	2.39e-12	1.81e-09	-0.33	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
HNSC	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	7.2	2.4e-12	1.81e-09	0.42	0.32	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
HNSC	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.41e-12	1.82e-09	-0.35	-0.32	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
HNSC	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-7.2	2.41e-12	1.82e-09	-0.26	-0.32	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
HNSC	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-7.2	2.41e-12	1.82e-09	-0.43	-0.32	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
HNSC	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	7.2	2.42e-12	1.83e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
HNSC	cis	rs7615952	0.673	rs3811677	ENSG00000248787.1	RP11-666A20.4	-7.2	2.43e-12	1.83e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125929237	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.932	rs3811679	ENSG00000248787.1	RP11-666A20.4	-7.2	2.43e-12	1.83e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125929440	chr3:125908005~125910272:-
HNSC	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	7.2	2.43e-12	1.84e-09	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
HNSC	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
HNSC	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
HNSC	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-7.2	2.45e-12	1.85e-09	-0.34	-0.32	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
HNSC	cis	rs17270561	0.609	rs1937132	ENSG00000272462.2	U91328.19	-7.2	2.45e-12	1.85e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25756789	chr6:25992662~26001775:+
HNSC	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	7.2	2.46e-12	1.85e-09	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
HNSC	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	7.2	2.46e-12	1.86e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
HNSC	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	7.2	2.46e-12	1.86e-09	0.42	0.32	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
HNSC	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	7.2	2.47e-12	1.86e-09	0.37	0.32	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
HNSC	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-7.2	2.47e-12	1.86e-09	-0.41	-0.32	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
HNSC	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	7.2	2.47e-12	1.86e-09	0.33	0.32	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
HNSC	cis	rs7048146	0.7	rs10759351	ENSG00000213539.4	YBX1P6	7.2	2.48e-12	1.87e-09	0.35	0.32	Vascular brain injury;	chr9:109582738	chr9:109532830~109534332:-
HNSC	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-7.2	2.48e-12	1.87e-09	-0.38	-0.32	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
HNSC	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-7.2	2.48e-12	1.87e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
HNSC	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	7.2	2.5e-12	1.88e-09	0.32	0.32	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
HNSC	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	7.2	2.5e-12	1.88e-09	0.36	0.32	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	7.2	2.5e-12	1.88e-09	0.36	0.32	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
HNSC	cis	rs1021993	0.62	rs17014326	ENSG00000231648.1	RP11-372M18.2	-7.2	2.5e-12	1.89e-09	-0.39	-0.32	Gut microbiome composition (winter);	chr1:209341940	chr1:209367662~209379690:+
HNSC	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	7.2	2.5e-12	1.89e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
HNSC	cis	rs1799949	1	rs9646417	ENSG00000267151.3	RP11-100E5.2	7.19	2.51e-12	1.89e-09	0.41	0.32	Menopause (age at onset);	chr17:43346885	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1545764	ENSG00000267151.3	RP11-100E5.2	7.19	2.51e-12	1.89e-09	0.41	0.32	Menopause (age at onset);	chr17:43347197	chr17:43444707~43451200:+
HNSC	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	7.19	2.51e-12	1.89e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
HNSC	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	7.19	2.52e-12	1.89e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
HNSC	cis	rs1799949	0.965	rs4793237	ENSG00000267151.3	RP11-100E5.2	7.19	2.52e-12	1.9e-09	0.41	0.32	Menopause (age at onset);	chr17:43359227	chr17:43444707~43451200:+
HNSC	cis	rs7615952	0.932	rs6438948	ENSG00000248787.1	RP11-666A20.4	7.19	2.53e-12	1.9e-09	0.44	0.32	Blood pressure (smoking interaction);	chr3:125931202	chr3:125908005~125910272:-
HNSC	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-7.19	2.53e-12	1.91e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
HNSC	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-7.19	2.54e-12	1.92e-09	-0.36	-0.32	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
HNSC	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	7.19	2.55e-12	1.92e-09	0.39	0.32	Height;	chr4:55361200	chr4:55363971~55395847:-
HNSC	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	7.19	2.55e-12	1.92e-09	0.46	0.32	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
HNSC	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-7.19	2.56e-12	1.92e-09	-0.36	-0.32	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
HNSC	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-7.19	2.56e-12	1.92e-09	-0.36	-0.32	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
HNSC	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-7.19	2.56e-12	1.92e-09	-0.38	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
HNSC	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	7.19	2.57e-12	1.93e-09	0.34	0.32	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
HNSC	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	7.19	2.58e-12	1.94e-09	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
HNSC	cis	rs1865760	0.551	rs9461230	ENSG00000272462.2	U91328.19	-7.19	2.59e-12	1.94e-09	-0.31	-0.32	Height;	chr6:26019012	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-7.19	2.59e-12	1.95e-09	-0.32	-0.32	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
HNSC	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-7.19	2.6e-12	1.95e-09	-0.31	-0.32	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
HNSC	cis	rs964184	0.63	rs6589566	ENSG00000254851.1	RP11-109L13.1	-7.19	2.6e-12	1.95e-09	-0.7	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116781707	chr11:117135528~117138582:+
HNSC	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	7.19	2.61e-12	1.96e-09	0.4	0.32	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
HNSC	cis	rs10791097	0.967	rs6590512	ENSG00000254842.5	RP11-890B15.2	7.19	2.61e-12	1.96e-09	0.27	0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848021	chr11:130844191~130865561:-
HNSC	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-7.19	2.61e-12	1.96e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
HNSC	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-7.19	2.61e-12	1.96e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
HNSC	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-7.19	2.61e-12	1.96e-09	-0.41	-0.32	Height;	chr6:109636120	chr6:109382795~109383666:+
HNSC	cis	rs867371	0.717	rs3858954	ENSG00000276710.3	CSPG4P8	-7.19	2.62e-12	1.97e-09	-0.37	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	7.19	2.62e-12	1.97e-09	0.22	0.32	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
HNSC	cis	rs7160336	0.604	rs4903150	ENSG00000259065.1	RP5-1021I20.1	7.19	2.64e-12	1.98e-09	0.38	0.32	Blood protein levels;	chr14:73844725	chr14:73787360~73803270:+
HNSC	cis	rs9595066	0.627	rs4942290	ENSG00000227258.4	SMIM2-AS1	7.19	2.65e-12	1.99e-09	0.53	0.32	Schizophrenia;	chr13:44183203	chr13:44110451~44240517:+
HNSC	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	7.19	2.65e-12	1.99e-09	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
HNSC	cis	rs1799949	1	rs4793231	ENSG00000267151.3	RP11-100E5.2	7.19	2.65e-12	1.99e-09	0.41	0.32	Menopause (age at onset);	chr17:43350101	chr17:43444707~43451200:+
HNSC	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-7.19	2.66e-12	1.99e-09	-0.57	-0.32	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
HNSC	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-7.19	2.66e-12	2e-09	-0.33	-0.32	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-7.18	2.68e-12	2e-09	-0.31	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
HNSC	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	7.18	2.68e-12	2e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
HNSC	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-7.18	2.68e-12	2.01e-09	-0.44	-0.32	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
HNSC	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-7.18	2.68e-12	2.01e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
HNSC	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-7.18	2.68e-12	2.01e-09	-0.47	-0.32	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
HNSC	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
HNSC	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	7.18	2.69e-12	2.01e-09	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
HNSC	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	7.18	2.69e-12	2.01e-09	0.39	0.32	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
HNSC	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-7.18	2.69e-12	2.01e-09	-0.5	-0.32	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
HNSC	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-7.18	2.7e-12	2.02e-09	-0.45	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
HNSC	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-7.18	2.71e-12	2.03e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	7.18	2.71e-12	2.03e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
HNSC	cis	rs1799949	0.896	rs35908185	ENSG00000267151.3	RP11-100E5.2	7.18	2.71e-12	2.03e-09	0.4	0.32	Menopause (age at onset);	chr17:43103094	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs8176130	ENSG00000267151.3	RP11-100E5.2	7.18	2.71e-12	2.03e-09	0.4	0.32	Menopause (age at onset);	chr17:43106026	chr17:43444707~43451200:+
HNSC	cis	rs6951245	1	rs74887741	ENSG00000224079.1	AC091729.7	-7.18	2.71e-12	2.03e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1074450~1078036:+
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	7.18	2.72e-12	2.04e-09	0.38	0.32	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-7.18	2.73e-12	2.04e-09	-0.36	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
HNSC	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-7.18	2.73e-12	2.04e-09	-0.29	-0.32	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	7.18	2.73e-12	2.04e-09	0.28	0.32	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
HNSC	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-7.18	2.75e-12	2.06e-09	-0.33	-0.32	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
HNSC	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-7.18	2.76e-12	2.06e-09	-0.36	-0.32	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
HNSC	cis	rs6471393	0.964	rs7001808	ENSG00000253848.1	RP11-10N23.5	7.18	2.77e-12	2.07e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93725043	chr8:93741193~93744534:+
HNSC	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	7.18	2.78e-12	2.08e-09	0.36	0.32	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-7.18	2.79e-12	2.09e-09	-0.57	-0.32	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
HNSC	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	7.18	2.81e-12	2.1e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
HNSC	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	7.18	2.81e-12	2.1e-09	0.39	0.32	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
HNSC	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-7.18	2.83e-12	2.11e-09	-0.31	-0.32	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
HNSC	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	7.18	2.83e-12	2.11e-09	0.45	0.32	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
HNSC	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.83e-12	2.12e-09	-0.36	-0.32	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
HNSC	cis	rs1865760	0.519	rs2275904	ENSG00000272462.2	U91328.19	-7.18	2.84e-12	2.12e-09	-0.33	-0.32	Height;	chr6:25767857	chr6:25992662~26001775:+
HNSC	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	7.18	2.84e-12	2.12e-09	0.36	0.32	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
HNSC	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	7.18	2.84e-12	2.12e-09	0.46	0.32	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
HNSC	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.85e-12	2.13e-09	-0.35	-0.32	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
HNSC	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-7.18	2.85e-12	2.13e-09	-0.41	-0.32	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
HNSC	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	7.17	2.86e-12	2.13e-09	0.48	0.32	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
HNSC	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-7.17	2.86e-12	2.14e-09	-0.34	-0.32	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
HNSC	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-7.17	2.86e-12	2.14e-09	-0.43	-0.32	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
HNSC	cis	rs1021993	0.545	rs76438740	ENSG00000231648.1	RP11-372M18.2	-7.17	2.87e-12	2.14e-09	-0.54	-0.32	Gut microbiome composition (winter);	chr1:209366381	chr1:209367662~209379690:+
HNSC	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	7.17	2.88e-12	2.15e-09	0.41	0.32	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
HNSC	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	7.17	2.89e-12	2.15e-09	0.33	0.32	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
HNSC	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-7.17	2.9e-12	2.16e-09	-0.4	-0.32	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
HNSC	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	7.17	2.91e-12	2.17e-09	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
HNSC	cis	rs61542988	1	rs61542988	ENSG00000228649.7	AC005682.5	7.17	2.91e-12	2.17e-09	0.35	0.31	Fibrinogen levels;	chr7:22842672	chr7:22854178~22861579:+
HNSC	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-7.17	2.92e-12	2.18e-09	-0.5	-0.31	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	7.17	2.93e-12	2.19e-09	0.6	0.31	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
HNSC	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-7.17	2.94e-12	2.19e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
HNSC	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	7.17	2.95e-12	2.19e-09	0.45	0.31	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	7.17	2.95e-12	2.19e-09	0.45	0.31	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
HNSC	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-7.17	2.95e-12	2.2e-09	-0.4	-0.31	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
HNSC	cis	rs1799949	1	rs16942	ENSG00000267151.3	RP11-100E5.2	7.17	2.95e-12	2.2e-09	0.4	0.31	Menopause (age at onset);	chr17:43091983	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176145	ENSG00000267151.3	RP11-100E5.2	7.17	2.95e-12	2.2e-09	0.4	0.31	Menopause (age at onset);	chr17:43097077	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs8176140	ENSG00000267151.3	RP11-100E5.2	7.17	2.95e-12	2.2e-09	0.4	0.31	Menopause (age at onset);	chr17:43099629	chr17:43444707~43451200:+
HNSC	cis	rs7615952	0.932	rs11922218	ENSG00000248787.1	RP11-666A20.4	-7.17	2.95e-12	2.2e-09	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125912446	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.866	rs11922276	ENSG00000248787.1	RP11-666A20.4	-7.17	2.95e-12	2.2e-09	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125912483	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.932	rs13086087	ENSG00000248787.1	RP11-666A20.4	-7.17	2.95e-12	2.2e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125927438	chr3:125908005~125910272:-
HNSC	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	7.17	2.95e-12	2.2e-09	0.39	0.31	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
HNSC	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	7.17	2.96e-12	2.21e-09	0.24	0.31	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
HNSC	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-7.17	2.96e-12	2.21e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
HNSC	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	7.17	2.97e-12	2.21e-09	0.44	0.31	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
HNSC	cis	rs1021993	0.545	rs17014337	ENSG00000231648.1	RP11-372M18.2	-7.17	2.98e-12	2.22e-09	-0.54	-0.31	Gut microbiome composition (winter);	chr1:209354120	chr1:209367662~209379690:+
HNSC	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	7.17	2.99e-12	2.22e-09	0.38	0.31	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
HNSC	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	7.17	2.99e-12	2.22e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
HNSC	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	7.17	2.99e-12	2.22e-09	0.39	0.31	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
HNSC	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	7.17	2.99e-12	2.22e-09	0.44	0.31	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
HNSC	cis	rs6951245	0.745	rs79788515	ENSG00000224079.1	AC091729.7	-7.17	2.99e-12	2.23e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1074450~1078036:+
HNSC	cis	rs867371	0.722	rs8033050	ENSG00000276710.3	CSPG4P8	-7.17	3e-12	2.23e-09	-0.37	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82459472~82477258:+
HNSC	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-7.17	3e-12	2.23e-09	-0.31	-0.31	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
HNSC	cis	rs1865760	0.566	rs3752419	ENSG00000272462.2	U91328.19	-7.17	3.01e-12	2.24e-09	-0.3	-0.31	Height;	chr6:26027205	chr6:25992662~26001775:+
HNSC	cis	rs1021993	0.553	rs1857966	ENSG00000231648.1	RP11-372M18.2	-7.17	3.04e-12	2.26e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209388370	chr1:209367662~209379690:+
HNSC	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-7.16	3.08e-12	2.29e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
HNSC	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-7.16	3.09e-12	2.3e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
HNSC	cis	rs6951245	0.935	rs61910751	ENSG00000224079.1	AC091729.7	-7.16	3.1e-12	2.3e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs77434655	ENSG00000224079.1	AC091729.7	-7.16	3.1e-12	2.3e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs75398423	ENSG00000224079.1	AC091729.7	-7.16	3.1e-12	2.3e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1074450~1078036:+
HNSC	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	7.16	3.11e-12	2.31e-09	0.27	0.31	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
HNSC	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-7.16	3.12e-12	2.32e-09	-0.39	-0.31	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-7.16	3.12e-12	2.32e-09	-0.31	-0.31	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
HNSC	cis	rs6867032	0.958	rs4975797	ENSG00000249731.1	RP11-259O2.3	7.16	3.16e-12	2.35e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015459	chr5:1968094~1969013:+
HNSC	cis	rs6867032	0.958	rs4975798	ENSG00000249731.1	RP11-259O2.3	7.16	3.16e-12	2.35e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015466	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-7.16	3.17e-12	2.35e-09	-0.3	-0.31	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
HNSC	cis	rs867371	0.762	rs12905578	ENSG00000276710.3	CSPG4P8	7.16	3.17e-12	2.35e-09	0.37	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82459472~82477258:+
HNSC	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	7.16	3.18e-12	2.36e-09	0.58	0.31	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
HNSC	cis	rs7615952	0.8	rs13086460	ENSG00000248787.1	RP11-666A20.4	-7.16	3.18e-12	2.36e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125927574	chr3:125908005~125910272:-
HNSC	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	7.16	3.18e-12	2.36e-09	0.39	0.31	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	7.16	3.18e-12	2.36e-09	0.39	0.31	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	7.16	3.18e-12	2.36e-09	0.39	0.31	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
HNSC	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-7.16	3.19e-12	2.37e-09	-0.36	-0.31	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
HNSC	cis	rs9402743	0.781	rs10223338	ENSG00000217482.2	HMGB1P17	7.16	3.2e-12	2.38e-09	0.37	0.31	Systemic lupus erythematosus;	chr6:135680889	chr6:135636086~135636713:-
HNSC	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	7.16	3.21e-12	2.38e-09	0.3	0.31	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	7.16	3.21e-12	2.38e-09	0.3	0.31	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
HNSC	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-7.16	3.21e-12	2.38e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-7.16	3.21e-12	2.38e-09	-0.36	-0.31	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
HNSC	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	7.16	3.22e-12	2.39e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
HNSC	cis	rs4978813	0.5	rs10759345	ENSG00000213539.4	YBX1P6	-7.16	3.22e-12	2.39e-09	-0.36	-0.31	Plantar warts;	chr9:109516765	chr9:109532830~109534332:-
HNSC	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	7.16	3.22e-12	2.39e-09	0.34	0.31	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
HNSC	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-7.16	3.23e-12	2.4e-09	-0.31	-0.31	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	7.16	3.24e-12	2.4e-09	0.44	0.31	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
HNSC	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	7.16	3.25e-12	2.41e-09	0.28	0.31	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
HNSC	cis	rs2286503	0.78	rs929464	ENSG00000228649.7	AC005682.5	7.16	3.25e-12	2.41e-09	0.34	0.31	Fibrinogen;	chr7:22835151	chr7:22854178~22861579:+
HNSC	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-7.16	3.25e-12	2.41e-09	-0.36	-0.31	Height;	chr3:53085518	chr3:53064283~53065091:-
HNSC	cis	rs1075265	0.868	rs1877906	ENSG00000233266.1	HMGB1P31	7.15	3.27e-12	2.42e-09	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54136700	chr2:54051334~54051760:+
HNSC	cis	rs1799949	1	rs9646412	ENSG00000267151.3	RP11-100E5.2	7.15	3.27e-12	2.42e-09	0.41	0.31	Menopause (age at onset);	chr17:43348525	chr17:43444707~43451200:+
HNSC	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
HNSC	cis	rs451417	0.841	rs12106220	ENSG00000275632.1	RP5-967N21.11	7.15	3.3e-12	2.44e-09	0.38	0.31	Menopause (age at onset);	chr20:5963609	chr20:6000418~6000941:+
HNSC	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	7.15	3.3e-12	2.44e-09	0.4	0.31	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
HNSC	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	7.15	3.31e-12	2.45e-09	0.24	0.31	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
HNSC	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-7.15	3.32e-12	2.45e-09	-0.36	-0.31	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
HNSC	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-7.15	3.32e-12	2.46e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
HNSC	cis	rs1021993	0.545	rs4844820	ENSG00000231648.1	RP11-372M18.2	-7.15	3.33e-12	2.46e-09	-0.55	-0.31	Gut microbiome composition (winter);	chr1:209381120	chr1:209367662~209379690:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-7.15	3.33e-12	2.46e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
HNSC	cis	rs17507216	1	rs17158413	ENSG00000255769.6	GOLGA2P10	-7.15	3.33e-12	2.46e-09	-0.46	-0.31	Excessive daytime sleepiness;	chr15:82566658	chr15:82472993~82513950:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000254340.1	RP11-10A14.3	7.15	3.37e-12	2.5e-09	0.4	0.31	Joint mobility (Beighton score);	chr8:8995760	chr8:9141424~9145435:+
HNSC	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	7.15	3.4e-12	2.51e-09	0.45	0.31	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
HNSC	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-7.15	3.42e-12	2.53e-09	-0.4	-0.31	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
HNSC	cis	rs1799949	1	rs8176103	ENSG00000267151.3	RP11-100E5.2	7.15	3.44e-12	2.54e-09	0.4	0.31	Menopause (age at onset);	chr17:43115033	chr17:43444707~43451200:+
HNSC	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-7.15	3.44e-12	2.54e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
HNSC	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	7.15	3.44e-12	2.55e-09	0.45	0.31	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
HNSC	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	7.15	3.44e-12	2.55e-09	0.3	0.31	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
HNSC	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	7.15	3.44e-12	2.55e-09	0.51	0.31	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	7.15	3.46e-12	2.56e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
HNSC	cis	rs440932	0.747	rs330946	ENSG00000254340.1	RP11-10A14.3	7.15	3.46e-12	2.56e-09	0.4	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-7.15	3.47e-12	2.56e-09	-0.34	-0.31	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
HNSC	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-7.14	3.48e-12	2.57e-09	-0.35	-0.31	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
HNSC	cis	rs6867032	1	rs4413568	ENSG00000249731.1	RP11-259O2.3	7.14	3.52e-12	2.6e-09	0.39	0.31	Gut microbiome composition (winter);	chr5:2016780	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-7.14	3.53e-12	2.6e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
HNSC	cis	rs1799949	1	rs8176109	ENSG00000267151.3	RP11-100E5.2	7.14	3.53e-12	2.61e-09	0.4	0.31	Menopause (age at onset);	chr17:43113759	chr17:43444707~43451200:+
HNSC	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	7.14	3.54e-12	2.62e-09	0.33	0.31	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
HNSC	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-7.14	3.57e-12	2.63e-09	-0.39	-0.31	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
HNSC	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	7.14	3.57e-12	2.64e-09	0.45	0.31	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
HNSC	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	7.14	3.58e-12	2.64e-09	0.28	0.31	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
HNSC	cis	rs1799949	0.896	rs8176098	ENSG00000267151.3	RP11-100E5.2	7.14	3.59e-12	2.65e-09	0.4	0.31	Menopause (age at onset);	chr17:43116189	chr17:43444707~43451200:+
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000255753.1	RP11-22B23.2	-7.14	3.6e-12	2.66e-09	-0.3	-0.31	IgG glycosylation;	chr12:9426513	chr12:9314402~9316173:-
HNSC	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-7.14	3.6e-12	2.66e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
HNSC	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-7.14	3.61e-12	2.67e-09	-0.31	-0.31	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
HNSC	cis	rs6867032	1	rs4975796	ENSG00000249731.1	RP11-259O2.3	-7.14	3.62e-12	2.67e-09	-0.38	-0.31	Gut microbiome composition (winter);	chr5:2015406	chr5:1968094~1969013:+
HNSC	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-7.14	3.63e-12	2.68e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-7.14	3.63e-12	2.68e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
HNSC	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-7.14	3.64e-12	2.68e-09	-0.33	-0.31	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
HNSC	cis	rs10504130	0.696	rs17212214	ENSG00000272024.1	RP11-546K22.3	7.14	3.66e-12	2.69e-09	0.43	0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51950284~51950690:+
HNSC	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-7.14	3.66e-12	2.69e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
HNSC	cis	rs867371	0.762	rs1846910	ENSG00000276710.3	CSPG4P8	-7.14	3.66e-12	2.7e-09	-0.37	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82459472~82477258:+
HNSC	cis	rs7115242	0.8	rs493134	ENSG00000280143.1	AP000892.6	7.14	3.67e-12	2.7e-09	0.46	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	7.14	3.67e-12	2.7e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-7.14	3.68e-12	2.71e-09	-0.35	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
HNSC	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	7.14	3.69e-12	2.72e-09	0.42	0.31	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
HNSC	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	7.14	3.71e-12	2.73e-09	0.45	0.31	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
HNSC	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	7.14	3.71e-12	2.73e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	7.13	3.73e-12	2.74e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
HNSC	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-7.13	3.73e-12	2.75e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
HNSC	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	7.13	3.73e-12	2.75e-09	0.28	0.31	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	7.13	3.74e-12	2.75e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
HNSC	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	7.13	3.74e-12	2.75e-09	0.41	0.31	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-7.13	3.74e-12	2.75e-09	-0.41	-0.31	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
HNSC	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-7.13	3.74e-12	2.75e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
HNSC	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	7.13	3.74e-12	2.75e-09	0.48	0.31	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
HNSC	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	7.13	3.75e-12	2.76e-09	0.28	0.31	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	7.13	3.75e-12	2.76e-09	0.28	0.31	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
HNSC	cis	rs9907295	0.591	rs4239252	ENSG00000270977.1	AC015849.16	7.13	3.76e-12	2.76e-09	0.36	0.31	Fibroblast growth factor basic levels;	chr17:35836561	chr17:35893707~35911023:-
HNSC	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-7.13	3.76e-12	2.76e-09	-0.5	-0.31	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
HNSC	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	7.13	3.76e-12	2.77e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
HNSC	cis	rs7615952	0.599	rs66532274	ENSG00000241288.6	RP11-379B18.5	-7.13	3.76e-12	2.77e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:126013002	chr3:125827238~125916384:-
HNSC	cis	rs1799949	0.965	rs8067269	ENSG00000267151.3	RP11-100E5.2	7.13	3.76e-12	2.77e-09	0.4	0.31	Menopause (age at onset);	chr17:43083782	chr17:43444707~43451200:+
HNSC	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-7.13	3.78e-12	2.78e-09	-0.28	-0.31	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
HNSC	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
HNSC	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-7.13	3.79e-12	2.79e-09	-0.37	-0.31	Height;	chr4:55364952	chr4:55363971~55395847:-
HNSC	cis	rs17270561	0.609	rs1892255	ENSG00000272462.2	U91328.19	-7.13	3.81e-12	2.8e-09	-0.33	-0.31	Iron status biomarkers;	chr6:25750126	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1892254	ENSG00000272462.2	U91328.19	-7.13	3.81e-12	2.8e-09	-0.33	-0.31	Iron status biomarkers;	chr6:25750302	chr6:25992662~26001775:+
HNSC	cis	rs6951245	1	rs75488469	ENSG00000224079.1	AC091729.7	-7.13	3.81e-12	2.8e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1074450~1078036:+
HNSC	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-7.13	3.82e-12	2.81e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
HNSC	cis	rs1799949	0.965	rs8176193	ENSG00000267151.3	RP11-100E5.2	7.13	3.82e-12	2.81e-09	0.4	0.31	Menopause (age at onset);	chr17:43079499	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176120	ENSG00000267151.3	RP11-100E5.2	7.13	3.82e-12	2.81e-09	0.4	0.31	Menopause (age at onset);	chr17:43109216	chr17:43444707~43451200:+
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-7.13	3.83e-12	2.81e-09	-0.6	-0.31	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	7.13	3.83e-12	2.81e-09	0.28	0.31	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
HNSC	cis	rs1021993	0.545	rs76234951	ENSG00000231648.1	RP11-372M18.2	-7.13	3.83e-12	2.81e-09	-0.55	-0.31	Gut microbiome composition (winter);	chr1:209377881	chr1:209367662~209379690:+
HNSC	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-7.13	3.85e-12	2.83e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
HNSC	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-7.13	3.85e-12	2.83e-09	-0.34	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
HNSC	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	7.13	3.85e-12	2.83e-09	0.38	0.31	Height;	chr3:53085313	chr3:53064283~53065091:-
HNSC	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	7.13	3.85e-12	2.83e-09	0.28	0.31	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	7.13	3.85e-12	2.83e-09	0.28	0.31	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	7.13	3.86e-12	2.83e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
HNSC	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-7.13	3.86e-12	2.83e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
HNSC	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-7.13	3.86e-12	2.83e-09	-0.39	-0.31	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
HNSC	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
HNSC	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-7.13	3.87e-12	2.84e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	7.13	3.87e-12	2.84e-09	0.28	0.31	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	7.13	3.87e-12	2.84e-09	0.28	0.31	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
HNSC	cis	rs1912483	0.505	rs3760372	ENSG00000228782.6	CTD-2026D20.3	7.13	3.87e-12	2.84e-09	0.33	0.31	Coronary artery disease;	chr17:47302636	chr17:47450568~47492492:-
HNSC	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	7.13	3.88e-12	2.85e-09	0.46	0.31	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	7.13	3.88e-12	2.85e-09	0.46	0.31	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
HNSC	cis	rs1799949	0.965	rs11651623	ENSG00000267151.3	RP11-100E5.2	7.13	3.89e-12	2.85e-09	0.41	0.31	Menopause (age at onset);	chr17:43177830	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11657883	ENSG00000267151.3	RP11-100E5.2	7.13	3.89e-12	2.85e-09	0.41	0.31	Menopause (age at onset);	chr17:43178007	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11656945	ENSG00000267151.3	RP11-100E5.2	7.13	3.89e-12	2.85e-09	0.41	0.31	Menopause (age at onset);	chr17:43178248	chr17:43444707~43451200:+
HNSC	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-7.13	3.89e-12	2.86e-09	-0.4	-0.31	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-7.13	3.89e-12	2.86e-09	-0.4	-0.31	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
HNSC	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-7.13	3.9e-12	2.86e-09	-0.46	-0.31	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
HNSC	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	7.13	3.91e-12	2.87e-09	0.31	0.31	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
HNSC	cis	rs1021993	0.597	rs1014817	ENSG00000231648.1	RP11-372M18.2	-7.13	3.91e-12	2.87e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209350319	chr1:209367662~209379690:+
HNSC	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-7.13	3.92e-12	2.88e-09	-0.32	-0.31	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
HNSC	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	7.13	3.93e-12	2.88e-09	0.34	0.31	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000254340.1	RP11-10A14.3	7.13	3.95e-12	2.89e-09	0.4	0.31	Mean corpuscular volume;	chr8:8994371	chr8:9141424~9145435:+
HNSC	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-7.13	3.96e-12	2.9e-09	-0.37	-0.31	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
HNSC	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	7.13	3.96e-12	2.9e-09	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
HNSC	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	7.12	3.98e-12	2.91e-09	0.38	0.31	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
HNSC	cis	rs1799949	0.965	rs8176161	ENSG00000267151.3	RP11-100E5.2	7.12	3.99e-12	2.92e-09	0.4	0.31	Menopause (age at onset);	chr17:43089373	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.894	rs8176160	ENSG00000267151.3	RP11-100E5.2	7.12	3.99e-12	2.92e-09	0.4	0.31	Menopause (age at onset);	chr17:43089486	chr17:43444707~43451200:+
HNSC	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	7.12	3.99e-12	2.92e-09	0.35	0.31	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
HNSC	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-7.12	3.99e-12	2.92e-09	-0.43	-0.31	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
HNSC	cis	rs1799949	0.965	rs4793233	ENSG00000267151.3	RP11-100E5.2	7.12	4.01e-12	2.93e-09	0.41	0.31	Menopause (age at onset);	chr17:43358069	chr17:43444707~43451200:+
HNSC	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	7.12	4.01e-12	2.94e-09	0.44	0.31	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
HNSC	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-7.12	4.01e-12	2.94e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
HNSC	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	7.12	4.04e-12	2.95e-09	0.27	0.31	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	7.12	4.04e-12	2.96e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
HNSC	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-7.12	4.05e-12	2.96e-09	-0.45	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
HNSC	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	7.12	4.05e-12	2.97e-09	0.47	0.31	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
HNSC	cis	rs1799949	1	rs12944430	ENSG00000267151.3	RP11-100E5.2	7.12	4.08e-12	2.98e-09	0.41	0.31	Menopause (age at onset);	chr17:43178803	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11658499	ENSG00000267151.3	RP11-100E5.2	7.12	4.08e-12	2.98e-09	0.41	0.31	Menopause (age at onset);	chr17:43182732	chr17:43444707~43451200:+
HNSC	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	7.12	4.09e-12	2.99e-09	0.29	0.31	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
HNSC	cis	rs1021993	0.597	rs10494922	ENSG00000231648.1	RP11-372M18.2	-7.12	4.09e-12	2.99e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209352085	chr1:209367662~209379690:+
HNSC	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-7.12	4.13e-12	3.02e-09	-0.28	-0.31	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
HNSC	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	7.12	4.14e-12	3.02e-09	0.46	0.31	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
HNSC	cis	rs17270561	0.609	rs7754733	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25744821	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs7754814	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25745015	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs7775354	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25745038	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9379789	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25745351	chr6:25992662~26001775:+
HNSC	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
HNSC	cis	rs9341808	0.527	rs7453746	ENSG00000272129.1	RP11-250B2.6	7.12	4.16e-12	3.04e-09	0.37	0.31	Sitting height ratio;	chr6:80100296	chr6:80355424~80356859:+
HNSC	cis	rs7048146	0.899	rs1541092	ENSG00000213539.4	YBX1P6	-7.12	4.16e-12	3.04e-09	-0.37	-0.31	Vascular brain injury;	chr9:109580279	chr9:109532830~109534332:-
HNSC	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-7.12	4.18e-12	3.05e-09	-0.32	-0.31	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-7.12	4.18e-12	3.05e-09	-0.44	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
HNSC	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	7.12	4.19e-12	3.06e-09	0.34	0.31	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
HNSC	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-7.12	4.19e-12	3.06e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
HNSC	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	7.12	4.2e-12	3.07e-09	0.31	0.31	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
HNSC	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-7.12	4.2e-12	3.07e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
HNSC	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-7.12	4.21e-12	3.07e-09	-0.31	-0.31	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
HNSC	cis	rs17270561	0.609	rs9379783	ENSG00000272462.2	U91328.19	-7.12	4.22e-12	3.08e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25724979	chr6:25992662~26001775:+
HNSC	cis	rs1659258	0.803	rs1258417	ENSG00000232508.1	MRPL45P1	7.12	4.23e-12	3.09e-09	0.66	0.31	Visceral fat;	chr2:88332624	chr2:88364695~88365608:-
HNSC	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-7.12	4.23e-12	3.09e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	7.11	4.24e-12	3.1e-09	0.44	0.31	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
HNSC	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	7.11	4.27e-12	3.11e-09	0.34	0.31	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
HNSC	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-7.11	4.28e-12	3.12e-09	-0.36	-0.31	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
HNSC	cis	rs7615952	0.932	rs1976458	ENSG00000248787.1	RP11-666A20.4	-7.11	4.3e-12	3.13e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125928669	chr3:125908005~125910272:-
HNSC	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-7.11	4.3e-12	3.14e-09	-0.36	-0.31	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
HNSC	cis	rs1799949	1	rs3950989	ENSG00000267151.3	RP11-100E5.2	7.11	4.33e-12	3.15e-09	0.4	0.31	Menopause (age at onset);	chr17:43085936	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs2070834	ENSG00000267151.3	RP11-100E5.2	7.11	4.33e-12	3.15e-09	0.4	0.31	Menopause (age at onset);	chr17:43090268	chr17:43444707~43451200:+
HNSC	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	7.11	4.33e-12	3.16e-09	0.36	0.31	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
HNSC	cis	rs2834288	0.536	rs762357	ENSG00000237945.6	LINC00649	7.11	4.34e-12	3.16e-09	0.39	0.31	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33915534~33977691:+
HNSC	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	7.11	4.34e-12	3.16e-09	0.33	0.31	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
HNSC	cis	rs1021993	0.545	rs17014395	ENSG00000231648.1	RP11-372M18.2	-7.11	4.35e-12	3.17e-09	-0.56	-0.31	Gut microbiome composition (winter);	chr1:209375462	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.545	rs17014396	ENSG00000231648.1	RP11-372M18.2	-7.11	4.35e-12	3.17e-09	-0.56	-0.31	Gut microbiome composition (winter);	chr1:209375540	chr1:209367662~209379690:+
HNSC	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	7.11	4.36e-12	3.17e-09	0.37	0.31	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
HNSC	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-7.11	4.37e-12	3.18e-09	-0.31	-0.31	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-7.11	4.37e-12	3.18e-09	-0.31	-0.31	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
HNSC	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-7.11	4.38e-12	3.19e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
HNSC	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	7.11	4.38e-12	3.19e-09	0.4	0.31	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	7.11	4.4e-12	3.2e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-7.11	4.4e-12	3.2e-09	-0.36	-0.31	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
HNSC	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-7.11	4.4e-12	3.2e-09	-0.35	-0.31	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
HNSC	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-7.11	4.4e-12	3.2e-09	-0.48	-0.31	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
HNSC	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-7.11	4.41e-12	3.21e-09	-0.28	-0.31	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
HNSC	cis	rs1659258	0.892	rs1659259	ENSG00000232508.1	MRPL45P1	7.11	4.41e-12	3.21e-09	0.66	0.31	Visceral fat;	chr2:88360376	chr2:88364695~88365608:-
HNSC	cis	rs13113518	0.513	rs13147861	ENSG00000249700.7	SRD5A3-AS1	7.11	4.43e-12	3.22e-09	0.39	0.31	Height;	chr4:55611014	chr4:55363971~55395847:-
HNSC	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-7.11	4.45e-12	3.24e-09	-0.38	-0.31	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	7.11	4.46e-12	3.24e-09	0.28	0.31	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
HNSC	cis	rs7000734	0.687	rs297550	ENSG00000245080.5	RP11-320N21.1	7.11	4.46e-12	3.24e-09	0.45	0.31	Radiation response;	chr8:95089566	chr8:95066808~95073182:-
HNSC	cis	rs62344088	0.59	rs62345236	ENSG00000277812.1	AC021087.1	7.11	4.48e-12	3.25e-09	0.71	0.31	Asthma (childhood onset);	chr5:283404	chr5:262769~262881:+
HNSC	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	7.11	4.48e-12	3.26e-09	0.3	0.31	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-7.11	4.49e-12	3.26e-09	-0.39	-0.31	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	7.11	4.5e-12	3.27e-09	0.28	0.31	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-7.11	4.5e-12	3.27e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	7.11	4.5e-12	3.27e-09	0.3	0.31	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
HNSC	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	7.11	4.51e-12	3.28e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	7.11	4.51e-12	3.28e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
HNSC	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	7.1	4.52e-12	3.29e-09	0.27	0.31	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
HNSC	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	7.1	4.52e-12	3.29e-09	0.27	0.31	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
HNSC	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	7.1	4.52e-12	3.29e-09	0.27	0.31	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
HNSC	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	7.1	4.52e-12	3.29e-09	0.37	0.31	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
HNSC	cis	rs4141404	0.604	rs2103853	ENSG00000236132.1	CTA-440B3.1	-7.1	4.53e-12	3.29e-09	-0.35	-0.31	Paclitaxel-induced neuropathy;	chr22:31459489	chr22:31816379~31817491:-
HNSC	cis	rs740698	0.521	rs9891713	ENSG00000265702.1	RP11-156L14.1	7.1	4.54e-12	3.3e-09	0.37	0.31	Pulse pressure;	chr17:62712044	chr17:62699244~62737922:+
HNSC	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	7.1	4.54e-12	3.3e-09	0.3	0.31	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
HNSC	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	7.1	4.54e-12	3.3e-09	0.39	0.31	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
HNSC	cis	rs9402743	0.962	rs11967412	ENSG00000217482.2	HMGB1P17	7.1	4.56e-12	3.31e-09	0.34	0.31	Systemic lupus erythematosus;	chr6:135648288	chr6:135636086~135636713:-
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	7.1	4.58e-12	3.32e-09	0.41	0.31	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-7.1	4.59e-12	3.33e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
HNSC	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-7.1	4.59e-12	3.33e-09	-0.38	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
HNSC	cis	rs7615952	0.866	rs1976459	ENSG00000248787.1	RP11-666A20.4	-7.1	4.61e-12	3.35e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125928643	chr3:125908005~125910272:-
HNSC	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
HNSC	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-7.1	4.63e-12	3.36e-09	-0.34	-0.31	Temperament;	chr17:14046511	chr17:14024514~14025488:+
HNSC	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-7.1	4.63e-12	3.36e-09	-0.29	-0.31	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-7.1	4.63e-12	3.36e-09	-0.29	-0.31	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
HNSC	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	7.1	4.63e-12	3.36e-09	0.27	0.31	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
HNSC	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	7.1	4.64e-12	3.37e-09	0.45	0.31	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
HNSC	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	7.1	4.64e-12	3.37e-09	0.43	0.31	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
HNSC	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	7.1	4.65e-12	3.37e-09	0.3	0.31	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
HNSC	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-7.1	4.65e-12	3.37e-09	-0.34	-0.31	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
HNSC	cis	rs6951245	1	rs80094748	ENSG00000224079.1	AC091729.7	-7.1	4.66e-12	3.38e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1074450~1078036:+
HNSC	cis	rs9326248	0.53	rs579890	ENSG00000280143.1	AP000892.6	7.1	4.67e-12	3.39e-09	0.47	0.31	Blood protein levels;	chr11:116928247	chr11:117204967~117210292:+
HNSC	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	7.1	4.67e-12	3.39e-09	0.4	0.31	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-7.1	4.68e-12	3.4e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
HNSC	cis	rs1799949	0.965	rs35521261	ENSG00000267151.3	RP11-100E5.2	7.1	4.69e-12	3.4e-09	0.4	0.31	Menopause (age at onset);	chr17:43161595	chr17:43444707~43451200:+
HNSC	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	7.1	4.71e-12	3.41e-09	0.31	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	7.1	4.71e-12	3.41e-09	0.31	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	7.1	4.71e-12	3.41e-09	0.31	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
HNSC	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-7.1	4.71e-12	3.42e-09	-0.34	-0.31	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
HNSC	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-7.1	4.72e-12	3.42e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
HNSC	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	7.1	4.72e-12	3.42e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
HNSC	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	7.1	4.72e-12	3.42e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
HNSC	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	7.1	4.73e-12	3.43e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
HNSC	cis	rs12922040	0.607	rs8059739	ENSG00000263065.1	AF001548.6	-7.1	4.74e-12	3.43e-09	-0.36	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15772869	chr16:15741151~15741791:+
HNSC	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	7.1	4.75e-12	3.44e-09	0.38	0.31	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
HNSC	cis	rs7115242	0.8	rs519794	ENSG00000280143.1	AP000892.6	7.1	4.77e-12	3.46e-09	0.44	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117204967~117210292:+
HNSC	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	7.1	4.78e-12	3.46e-09	0.3	0.31	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
HNSC	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-7.1	4.78e-12	3.46e-09	-0.34	-0.31	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
HNSC	cis	rs1799949	0.896	rs33933393	ENSG00000267151.3	RP11-100E5.2	7.1	4.79e-12	3.47e-09	0.4	0.31	Menopause (age at onset);	chr17:43165415	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33946455	ENSG00000267151.3	RP11-100E5.2	7.1	4.79e-12	3.47e-09	0.4	0.31	Menopause (age at onset);	chr17:43169829	chr17:43444707~43451200:+
HNSC	cis	rs394563	0.591	rs237019	ENSG00000231760.4	RP11-350J20.5	7.1	4.79e-12	3.47e-09	0.39	0.31	Dupuytren's disease;	chr6:149405928	chr6:149796151~149826294:-
HNSC	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	7.1	4.81e-12	3.48e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	7.1	4.81e-12	3.48e-09	0.28	0.31	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	7.1	4.81e-12	3.48e-09	0.28	0.31	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
HNSC	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-7.09	4.84e-12	3.5e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
HNSC	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	7.09	4.85e-12	3.5e-09	0.38	0.31	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
HNSC	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-7.09	4.86e-12	3.51e-09	-0.43	-0.31	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
HNSC	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	7.09	4.87e-12	3.52e-09	0.4	0.31	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
HNSC	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	7.09	4.87e-12	3.52e-09	0.4	0.31	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
HNSC	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-7.09	4.88e-12	3.53e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
HNSC	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	7.09	4.88e-12	3.53e-09	0.29	0.31	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
HNSC	cis	rs17270561	0.585	rs9393663	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25740805	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9366629	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25740988	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.553	rs6456696	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741180	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs6456697	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741206	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs6456698	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741436	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.666	rs4711099	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741581	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711100	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741726	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711101	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741742	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712965	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741794	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.608	rs4711102	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741847	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711103	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741996	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9379788	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25742531	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358879	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25742690	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs9358880	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25742933	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4145216	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25743331	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4145217	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25743769	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9393665	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25744056	chr6:25992662~26001775:+
HNSC	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	7.09	4.92e-12	3.56e-09	0.61	0.31	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
HNSC	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-7.09	4.95e-12	3.57e-09	-0.32	-0.31	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-7.09	4.95e-12	3.57e-09	-0.32	-0.31	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
HNSC	cis	rs7942368	1	rs7107409	ENSG00000255100.1	RP11-21L23.3	7.09	4.97e-12	3.59e-09	0.4	0.31	Endometriosis;	chr11:76781151	chr11:76782581~76783062:-
HNSC	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	7.09	4.97e-12	3.59e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
HNSC	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-7.09	4.98e-12	3.6e-09	-0.32	-0.31	Height;	chr2:231516587	chr2:231508426~231514339:-
HNSC	cis	rs9402743	1	rs7739635	ENSG00000217482.2	HMGB1P17	7.09	4.99e-12	3.61e-09	0.33	0.31	Systemic lupus erythematosus;	chr6:135676640	chr6:135636086~135636713:-
HNSC	cis	rs6951245	0.832	rs79808627	ENSG00000224079.1	AC091729.7	-7.09	4.99e-12	3.61e-09	-0.5	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052883	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-7.09	5e-12	3.61e-09	-0.29	-0.31	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
HNSC	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-7.09	5.02e-12	3.63e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
HNSC	cis	rs17270561	0.609	rs9348694	ENSG00000272462.2	U91328.19	-7.09	5.05e-12	3.65e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25753412	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-7.09	5.06e-12	3.65e-09	-0.31	-0.31	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
HNSC	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-7.09	5.06e-12	3.65e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
HNSC	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-7.09	5.07e-12	3.65e-09	-0.36	-0.31	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
HNSC	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	7.09	5.07e-12	3.66e-09	0.41	0.31	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
HNSC	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-7.09	5.08e-12	3.66e-09	-0.37	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-7.09	5.08e-12	3.66e-09	-0.37	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
HNSC	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-7.09	5.09e-12	3.67e-09	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
HNSC	cis	rs112744032	1	rs112744032	ENSG00000240350.2	AC017002.1	-7.09	5.11e-12	3.68e-09	-0.41	-0.31	Mean corpuscular hemoglobin;	chr2:111521757	chr2:111491273~111570974:+
HNSC	cis	rs62162297	1	rs62162297	ENSG00000240350.2	AC017002.1	-7.09	5.11e-12	3.68e-09	-0.41	-0.31	Red blood cell count;	chr2:111521758	chr2:111491273~111570974:+
HNSC	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-7.09	5.11e-12	3.68e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	7.09	5.12e-12	3.69e-09	0.35	0.31	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
HNSC	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	7.09	5.13e-12	3.7e-09	0.32	0.31	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
HNSC	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-7.09	5.13e-12	3.7e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	7.09	5.13e-12	3.7e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
HNSC	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-7.09	5.14e-12	3.7e-09	-0.32	-0.31	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
HNSC	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	7.09	5.14e-12	3.7e-09	0.41	0.31	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
HNSC	cis	rs9402743	0.962	rs6935033	ENSG00000217482.2	HMGB1P17	7.09	5.14e-12	3.71e-09	0.34	0.31	Systemic lupus erythematosus;	chr6:135659499	chr6:135636086~135636713:-
HNSC	cis	rs1799949	0.929	rs12937015	ENSG00000267151.3	RP11-100E5.2	7.08	5.17e-12	3.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43155456	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4340367	ENSG00000267151.3	RP11-100E5.2	7.08	5.17e-12	3.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43155755	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4792981	ENSG00000267151.3	RP11-100E5.2	7.08	5.17e-12	3.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43156257	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11654731	ENSG00000267151.3	RP11-100E5.2	7.08	5.2e-12	3.74e-09	0.4	0.31	Menopause (age at onset);	chr17:43174923	chr17:43444707~43451200:+
HNSC	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	7.08	5.2e-12	3.74e-09	0.45	0.31	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
HNSC	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-7.08	5.22e-12	3.76e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
HNSC	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-7.08	5.23e-12	3.76e-09	-0.3	-0.31	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	7.08	5.23e-12	3.77e-09	0.36	0.31	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
HNSC	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	7.08	5.24e-12	3.78e-09	0.45	0.31	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs35668327	ENSG00000267151.3	RP11-100E5.2	7.08	5.24e-12	3.78e-09	0.4	0.31	Menopause (age at onset);	chr17:43121078	chr17:43444707~43451200:+
HNSC	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-7.08	5.26e-12	3.79e-09	-0.31	-0.31	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
HNSC	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	7.08	5.26e-12	3.79e-09	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
HNSC	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	7.08	5.27e-12	3.79e-09	0.49	0.31	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
HNSC	cis	rs35955747	0.669	rs878718	ENSG00000236132.1	CTA-440B3.1	-7.08	5.27e-12	3.8e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31156716	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
HNSC	cis	rs2243480	0.706	rs6460257	ENSG00000179406.6	LINC00174	-7.08	5.32e-12	3.83e-09	-0.56	-0.31	Diabetic kidney disease;	chr7:65731813	chr7:66376044~66401338:-
HNSC	cis	rs2286503	0.78	rs2240727	ENSG00000228649.7	AC005682.5	7.08	5.32e-12	3.83e-09	0.34	0.31	Fibrinogen;	chr7:22812893	chr7:22854178~22861579:+
HNSC	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	7.08	5.32e-12	3.83e-09	0.39	0.31	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
HNSC	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	7.08	5.34e-12	3.84e-09	0.33	0.31	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
HNSC	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-7.08	5.36e-12	3.85e-09	-0.38	-0.31	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
HNSC	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	7.08	5.36e-12	3.86e-09	0.37	0.31	Depression;	chr6:28363475	chr6:28943877~28944537:+
HNSC	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	7.08	5.36e-12	3.86e-09	0.47	0.31	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
HNSC	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-7.08	5.36e-12	3.86e-09	-0.37	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
HNSC	cis	rs2579103	0.668	rs825965	ENSG00000258183.4	RP11-753N8.1	-7.08	5.38e-12	3.87e-09	-0.43	-0.31	Body mass index;	chr12:90309031	chr12:90280894~90300340:+
HNSC	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	7.08	5.39e-12	3.88e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
HNSC	cis	rs1021993	0.545	rs60534728	ENSG00000231648.1	RP11-372M18.2	-7.08	5.4e-12	3.89e-09	-0.56	-0.31	Gut microbiome composition (winter);	chr1:209374826	chr1:209367662~209379690:+
HNSC	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-7.08	5.4e-12	3.89e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
HNSC	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-7.08	5.41e-12	3.89e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
HNSC	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-7.08	5.41e-12	3.89e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
HNSC	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	7.08	5.43e-12	3.9e-09	0.35	0.31	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
HNSC	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-7.08	5.44e-12	3.91e-09	-0.39	-0.31	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
HNSC	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	7.08	5.44e-12	3.91e-09	0.44	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
HNSC	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-7.08	5.47e-12	3.93e-09	-0.39	-0.31	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
HNSC	cis	rs7942368	0.941	rs10160769	ENSG00000255100.1	RP11-21L23.3	7.07	5.51e-12	3.95e-09	0.39	0.31	Endometriosis;	chr11:76763783	chr11:76782581~76783062:-
HNSC	cis	rs1799949	0.965	rs8176087	ENSG00000267151.3	RP11-100E5.2	7.07	5.51e-12	3.96e-09	0.4	0.31	Menopause (age at onset);	chr17:43118649	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34942571	ENSG00000267151.3	RP11-100E5.2	7.07	5.51e-12	3.96e-09	0.4	0.31	Menopause (age at onset);	chr17:43121362	chr17:43444707~43451200:+
HNSC	cis	rs9402743	0.926	rs7762826	ENSG00000217482.2	HMGB1P17	7.07	5.56e-12	3.99e-09	0.33	0.31	Systemic lupus erythematosus;	chr6:135654485	chr6:135636086~135636713:-
HNSC	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-7.07	5.56e-12	3.99e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-7.07	5.56e-12	3.99e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
HNSC	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	7.07	5.57e-12	4e-09	0.45	0.31	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	7.07	5.57e-12	4e-09	0.45	0.31	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
HNSC	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	7.07	5.62e-12	4.04e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
HNSC	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
HNSC	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-7.07	5.66e-12	4.06e-09	-0.46	-0.31	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
HNSC	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-7.07	5.68e-12	4.07e-09	-0.28	-0.31	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
HNSC	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-7.07	5.71e-12	4.09e-09	-0.39	-0.31	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
HNSC	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-7.07	5.72e-12	4.1e-09	-0.39	-0.31	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
HNSC	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-7.07	5.72e-12	4.1e-09	-0.31	-0.31	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-7.07	5.73e-12	4.11e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-7.07	5.75e-12	4.12e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
HNSC	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	7.07	5.76e-12	4.13e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
HNSC	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-7.07	5.8e-12	4.15e-09	-0.41	-0.31	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
HNSC	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	7.07	5.81e-12	4.16e-09	0.45	0.31	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs473188	ENSG00000280143.1	AP000892.6	7.07	5.82e-12	4.17e-09	0.45	0.31	Blood protein levels;	chr11:116941313	chr11:117204967~117210292:+
HNSC	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	7.07	5.83e-12	4.18e-09	0.28	0.31	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
HNSC	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-7.07	5.84e-12	4.18e-09	-0.39	-0.31	Height;	chr3:53080524	chr3:53064283~53065091:-
HNSC	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	7.07	5.85e-12	4.19e-09	0.36	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
HNSC	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-7.07	5.85e-12	4.19e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
HNSC	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	7.07	5.86e-12	4.19e-09	0.45	0.31	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	7.07	5.86e-12	4.19e-09	0.45	0.31	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
HNSC	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	7.06	5.87e-12	4.2e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	7.06	5.87e-12	4.2e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
HNSC	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	7.06	5.87e-12	4.2e-09	0.46	0.31	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
HNSC	cis	rs1021993	0.597	rs2356722	ENSG00000231648.1	RP11-372M18.2	-7.06	5.88e-12	4.21e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209351389	chr1:209367662~209379690:+
HNSC	cis	rs9402743	0.781	rs9494331	ENSG00000217482.2	HMGB1P17	-7.06	5.89e-12	4.21e-09	-0.36	-0.31	Systemic lupus erythematosus;	chr6:135685163	chr6:135636086~135636713:-
HNSC	cis	rs7567389	0.511	rs61185143	ENSG00000236682.1	AC068282.3	7.06	5.89e-12	4.21e-09	0.37	0.31	Self-rated health;	chr2:127407902	chr2:127389130~127400580:+
HNSC	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	7.06	5.89e-12	4.22e-09	0.45	0.31	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
HNSC	cis	rs35955747	0.633	rs5998021	ENSG00000236132.1	CTA-440B3.1	7.06	5.9e-12	4.22e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31511441	chr22:31816379~31817491:-
HNSC	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
HNSC	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	7.06	5.92e-12	4.23e-09	0.5	0.31	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-7.06	5.92e-12	4.23e-09	-0.37	-0.31	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
HNSC	cis	rs36405	0.5	rs4622450	ENSG00000266869.1	RP6-114E22.1	-7.06	5.95e-12	4.26e-09	-0.4	-0.31	Yang-deficiency constitution;	chr14:71889095	chr14:71848606~71908430:+
HNSC	cis	rs380904	0.963	rs410822	ENSG00000254859.1	RP11-661A12.5	-7.06	5.97e-12	4.27e-09	-0.44	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:143492441	chr8:143541973~143549729:-
HNSC	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-7.06	5.98e-12	4.27e-09	-0.48	-0.31	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
HNSC	cis	rs6471393	0.929	rs58575315	ENSG00000253848.1	RP11-10N23.5	7.06	5.98e-12	4.28e-09	0.38	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749495	chr8:93741193~93744534:+
HNSC	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	7.06	6e-12	4.29e-09	0.42	0.31	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	7.06	6.04e-12	4.32e-09	0.23	0.31	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
HNSC	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-7.06	6.05e-12	4.32e-09	-0.31	-0.31	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
HNSC	cis	rs8081395	0.603	rs1292047	ENSG00000266992.1	DHX40P1	7.06	6.05e-12	4.32e-09	0.34	0.31	White blood cell count;	chr17:59877805	chr17:59976009~60002384:-
HNSC	cis	rs1799949	1	rs8176202	ENSG00000267151.3	RP11-100E5.2	7.06	6.07e-12	4.34e-09	0.4	0.31	Menopause (age at onset);	chr17:43078211	chr17:43444707~43451200:+
HNSC	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	7.06	6.08e-12	4.34e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
HNSC	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	7.06	6.1e-12	4.36e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	7.06	6.1e-12	4.36e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
HNSC	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	7.06	6.12e-12	4.37e-09	0.31	0.31	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
HNSC	cis	rs6867032	0.958	rs4463207	ENSG00000249731.1	RP11-259O2.3	7.06	6.12e-12	4.37e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2017004	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs61177713	ENSG00000249731.1	RP11-259O2.3	7.06	6.12e-12	4.37e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2017141	chr5:1968094~1969013:+
HNSC	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-7.06	6.13e-12	4.37e-09	-0.38	-0.31	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
HNSC	cis	rs9326248	0.53	rs1351452	ENSG00000280143.1	AP000892.6	-7.06	6.14e-12	4.38e-09	-0.48	-0.31	Blood protein levels;	chr11:117072638	chr11:117204967~117210292:+
HNSC	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-7.06	6.16e-12	4.4e-09	-0.31	-0.31	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
HNSC	cis	rs7942368	0.793	rs12273016	ENSG00000255100.1	RP11-21L23.3	-7.06	6.16e-12	4.4e-09	-0.38	-0.31	Endometriosis;	chr11:76779672	chr11:76782581~76783062:-
HNSC	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	7.06	6.19e-12	4.42e-09	0.37	0.31	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
HNSC	cis	rs17270561	0.639	rs9356989	ENSG00000272462.2	U91328.19	-7.06	6.2e-12	4.42e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25781722	chr6:25992662~26001775:+
HNSC	cis	rs36423	0.557	rs36457	ENSG00000266869.1	RP6-114E22.1	-7.06	6.24e-12	4.45e-09	-0.46	-0.31	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71864157	chr14:71848606~71908430:+
HNSC	cis	rs17270561	0.609	rs4132072	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25717615	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs7453371	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719028	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7450798	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719052	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712957	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719586	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.666	rs17320090	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719987	chr6:25992662~26001775:+
HNSC	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-7.06	6.25e-12	4.45e-09	-0.33	-0.31	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
HNSC	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-7.06	6.26e-12	4.46e-09	-0.33	-0.31	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
HNSC	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	7.05	6.27e-12	4.47e-09	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
HNSC	cis	rs4841097	0.876	rs6601288	ENSG00000173295.6	FAM86B3P	7.05	6.28e-12	4.48e-09	0.36	0.31	Platelet distribution width;	chr8:9085920	chr8:8228595~8244865:+
HNSC	cis	rs6920372	0.731	rs9386799	ENSG00000260273.1	RP11-425D10.10	7.05	6.3e-12	4.49e-09	0.39	0.31	Height;	chr6:109333398	chr6:109382795~109383666:+
HNSC	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-7.05	6.3e-12	4.49e-09	-0.5	-0.31	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
HNSC	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-7.05	6.31e-12	4.49e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
HNSC	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-7.05	6.31e-12	4.5e-09	-0.34	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
HNSC	cis	rs9326248	0.53	rs2513093	ENSG00000280143.1	AP000892.6	7.05	6.33e-12	4.51e-09	0.46	0.31	Blood protein levels;	chr11:116935971	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	7.05	6.34e-12	4.51e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
HNSC	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	7.05	6.34e-12	4.52e-09	0.44	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
HNSC	cis	rs17270561	0.609	rs9358887	ENSG00000272462.2	U91328.19	-7.05	6.37e-12	4.53e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25759178	chr6:25992662~26001775:+
HNSC	cis	rs451417	1	rs236125	ENSG00000275632.1	RP5-967N21.11	7.05	6.39e-12	4.55e-09	0.38	0.31	Menopause (age at onset);	chr20:5996328	chr20:6000418~6000941:+
HNSC	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
HNSC	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	7.05	6.41e-12	4.56e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
HNSC	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-7.05	6.43e-12	4.58e-09	-0.34	-0.31	Temperament;	chr17:14048649	chr17:14024514~14025488:+
HNSC	cis	rs11722779	0.844	rs7694724	ENSG00000246560.2	RP11-10L12.4	7.05	6.46e-12	4.6e-09	0.35	0.31	Schizophrenia;	chr4:103041375	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-7.05	6.46e-12	4.6e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
HNSC	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-7.05	6.47e-12	4.6e-09	-0.35	-0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
HNSC	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-7.05	6.49e-12	4.62e-09	-0.4	-0.31	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
HNSC	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-7.05	6.49e-12	4.62e-09	-0.39	-0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
HNSC	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	7.05	6.49e-12	4.62e-09	0.78	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	7.05	6.49e-12	4.62e-09	0.78	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
HNSC	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-7.05	6.51e-12	4.63e-09	-0.3	-0.31	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
HNSC	cis	rs2579103	0.708	rs825966	ENSG00000258183.4	RP11-753N8.1	-7.05	6.52e-12	4.64e-09	-0.43	-0.31	Body mass index;	chr12:90309109	chr12:90280894~90300340:+
HNSC	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-7.05	6.55e-12	4.66e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
HNSC	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	7.05	6.58e-12	4.68e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	7.05	6.58e-12	4.68e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	7.05	6.58e-12	4.68e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
HNSC	cis	rs7048146	0.51	rs10816827	ENSG00000213539.4	YBX1P6	-7.05	6.61e-12	4.7e-09	-0.35	-0.31	Vascular brain injury;	chr9:109529829	chr9:109532830~109534332:-
HNSC	cis	rs4978813	0.5	rs10816830	ENSG00000213539.4	YBX1P6	-7.05	6.61e-12	4.7e-09	-0.35	-0.31	Plantar warts;	chr9:109537404	chr9:109532830~109534332:-
HNSC	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-7.05	6.62e-12	4.7e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
HNSC	cis	rs2579103	0.708	rs2579101	ENSG00000258183.4	RP11-753N8.1	-7.05	6.64e-12	4.72e-09	-0.43	-0.31	Body mass index;	chr12:90293325	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.626	rs2579099	ENSG00000258183.4	RP11-753N8.1	-7.05	6.64e-12	4.72e-09	-0.43	-0.31	Body mass index;	chr12:90293578	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.708	rs2579095	ENSG00000258183.4	RP11-753N8.1	-7.05	6.64e-12	4.72e-09	-0.43	-0.31	Body mass index;	chr12:90294499	chr12:90280894~90300340:+
HNSC	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-7.05	6.65e-12	4.72e-09	-0.5	-0.31	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
HNSC	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-7.05	6.66e-12	4.73e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
HNSC	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-7.05	6.67e-12	4.74e-09	-0.31	-0.31	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-7.05	6.67e-12	4.74e-09	-0.31	-0.31	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-7.05	6.67e-12	4.74e-09	-0.31	-0.31	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
HNSC	cis	rs4218	0.731	rs11539756	ENSG00000259732.1	RP11-59H7.3	-7.04	6.69e-12	4.75e-09	-0.46	-0.31	Social communication problems;	chr15:59136912	chr15:59121034~59133250:+
HNSC	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	7.04	6.71e-12	4.76e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
HNSC	cis	rs1659258	0.803	rs1659248	ENSG00000232508.1	MRPL45P1	-7.04	6.71e-12	4.76e-09	-0.66	-0.31	Visceral fat;	chr2:88335454	chr2:88364695~88365608:-
HNSC	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-7.04	6.71e-12	4.76e-09	-0.38	-0.31	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
HNSC	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-7.04	6.71e-12	4.76e-09	-0.33	-0.31	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
HNSC	cis	rs35955747	0.601	rs7289941	ENSG00000236132.1	CTA-440B3.1	-7.04	6.72e-12	4.77e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31488419	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-7.04	6.73e-12	4.77e-09	-0.31	-0.31	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
HNSC	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	7.04	6.75e-12	4.79e-09	0.41	0.31	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
HNSC	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	7.04	6.77e-12	4.8e-09	0.5	0.31	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
HNSC	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-7.04	6.77e-12	4.8e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-7.04	6.77e-12	4.8e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-7.04	6.77e-12	4.8e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
HNSC	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	7.04	6.78e-12	4.81e-09	0.38	0.31	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
HNSC	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	7.04	6.78e-12	4.81e-09	0.46	0.31	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	7.04	6.79e-12	4.81e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
HNSC	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	7.04	6.81e-12	4.83e-09	0.38	0.31	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
HNSC	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	7.04	6.85e-12	4.85e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
HNSC	cis	rs10791097	0.967	rs10894268	ENSG00000254842.5	RP11-890B15.2	-7.04	6.85e-12	4.85e-09	-0.27	-0.31	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130847258	chr11:130844191~130865561:-
HNSC	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.04	6.86e-12	4.86e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
HNSC	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	7.04	6.88e-12	4.87e-09	0.28	0.31	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	7.04	6.88e-12	4.87e-09	0.28	0.31	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-7.04	6.91e-12	4.89e-09	-0.37	-0.31	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
HNSC	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	7.04	6.92e-12	4.9e-09	0.38	0.31	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
HNSC	cis	rs75422866	0.85	rs73111210	ENSG00000274902.1	RP1-197B17.4	7.04	6.93e-12	4.91e-09	0.81	0.31	Pneumonia;	chr12:47576949	chr12:47731908~47732351:+
HNSC	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-7.04	6.94e-12	4.91e-09	-0.33	-0.31	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-7.04	6.95e-12	4.92e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-7.04	6.95e-12	4.92e-09	-0.2	-0.31	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
HNSC	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-7.04	6.98e-12	4.94e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
HNSC	cis	rs1021993	0.597	rs10494924	ENSG00000231648.1	RP11-372M18.2	-7.04	6.98e-12	4.94e-09	-0.38	-0.31	Gut microbiome composition (winter);	chr1:209354361	chr1:209367662~209379690:+
HNSC	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	7.04	6.98e-12	4.94e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
HNSC	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-7.04	7.04e-12	4.98e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
HNSC	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-7.04	7.05e-12	4.99e-09	-0.46	-0.31	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
HNSC	cis	rs964184	0.63	rs2160669	ENSG00000254851.1	RP11-109L13.1	-7.04	7.09e-12	5.02e-09	-0.71	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116776891	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs8176234	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43067763	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176233	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43067787	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176220	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43070445	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1799966	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43071077	chr17:43444707~43451200:+
HNSC	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	7.04	7.13e-12	5.04e-09	0.44	0.31	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-7.03	7.13e-12	5.05e-09	-0.27	-0.31	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
HNSC	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	7.03	7.14e-12	5.05e-09	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
HNSC	cis	rs2834288	1	rs2834288	ENSG00000237945.6	LINC00649	7.03	7.17e-12	5.07e-09	0.37	0.31	Gut microbiota (bacterial taxa);	chr21:33892093	chr21:33915534~33977691:+
HNSC	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-7.03	7.18e-12	5.08e-09	-0.32	-0.31	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
HNSC	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	7.03	7.2e-12	5.09e-09	0.45	0.31	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	7.03	7.2e-12	5.09e-09	0.45	0.31	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
HNSC	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-7.03	7.2e-12	5.09e-09	-0.29	-0.31	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
HNSC	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	7.03	7.29e-12	5.15e-09	0.36	0.31	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
HNSC	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	7.03	7.29e-12	5.15e-09	0.36	0.31	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
HNSC	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-7.03	7.3e-12	5.16e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
HNSC	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	7.03	7.32e-12	5.17e-09	0.34	0.31	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
HNSC	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-7.03	7.33e-12	5.18e-09	-0.49	-0.31	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
HNSC	cis	rs451417	1	rs236122	ENSG00000275632.1	RP5-967N21.11	7.03	7.33e-12	5.18e-09	0.37	0.31	Menopause (age at onset);	chr20:5992882	chr20:6000418~6000941:+
HNSC	cis	rs1021993	0.545	rs79960084	ENSG00000231648.1	RP11-372M18.2	-7.03	7.34e-12	5.18e-09	-0.54	-0.31	Gut microbiome composition (winter);	chr1:209382825	chr1:209367662~209379690:+
HNSC	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-7.03	7.34e-12	5.19e-09	-0.31	-0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
HNSC	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-7.03	7.34e-12	5.19e-09	-0.32	-0.31	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
HNSC	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-7.03	7.35e-12	5.2e-09	-0.35	-0.31	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
HNSC	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-7.03	7.37e-12	5.2e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
HNSC	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-7.03	7.37e-12	5.21e-09	-0.4	-0.31	Depression;	chr6:28226851	chr6:28115628~28116551:+
HNSC	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	7.03	7.38e-12	5.22e-09	0.35	0.31	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
HNSC	cis	rs35955747	0.87	rs5997986	ENSG00000236132.1	CTA-440B3.1	7.03	7.39e-12	5.22e-09	0.33	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31438953	chr22:31816379~31817491:-
HNSC	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	7.03	7.4e-12	5.22e-09	0.37	0.31	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
HNSC	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	7.03	7.4e-12	5.23e-09	0.36	0.31	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
HNSC	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-7.03	7.41e-12	5.23e-09	-0.31	-0.31	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
HNSC	cis	rs6951245	0.872	rs75280240	ENSG00000225146.1	AC073957.15	-7.03	7.42e-12	5.24e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018875	chr7:1029025~1043891:+
HNSC	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	7.03	7.43e-12	5.25e-09	0.34	0.31	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	7.03	7.43e-12	5.25e-09	0.34	0.31	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
HNSC	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	7.03	7.44e-12	5.25e-09	0.52	0.31	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
HNSC	cis	rs1799949	0.965	rs9646418	ENSG00000267151.3	RP11-100E5.2	7.03	7.48e-12	5.28e-09	0.39	0.31	Menopause (age at onset);	chr17:43348533	chr17:43444707~43451200:+
HNSC	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-7.03	7.48e-12	5.28e-09	-0.32	-0.31	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
HNSC	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-7.03	7.49e-12	5.29e-09	-0.31	-0.31	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
HNSC	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-7.03	7.5e-12	5.29e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-7.03	7.53e-12	5.31e-09	-0.37	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
HNSC	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-7.03	7.54e-12	5.32e-09	-0.37	-0.31	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
HNSC	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-7.03	7.56e-12	5.33e-09	-0.33	-0.31	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-7.03	7.56e-12	5.33e-09	-0.33	-0.31	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-7.03	7.56e-12	5.33e-09	-0.33	-0.31	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
HNSC	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-7.02	7.64e-12	5.39e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-7.02	7.64e-12	5.39e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
HNSC	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	7.02	7.66e-12	5.4e-09	0.46	0.31	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
HNSC	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-7.02	7.68e-12	5.41e-09	-0.38	-0.31	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
HNSC	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	7.02	7.7e-12	5.43e-09	0.37	0.31	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	7.02	7.73e-12	5.45e-09	0.28	0.31	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
HNSC	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	7.02	7.74e-12	5.45e-09	0.35	0.31	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
HNSC	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-7.02	7.75e-12	5.46e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.597	rs5756991	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.54	rs5756992	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs9622919	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs9619793	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22098700~22099212:+
HNSC	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	7.02	7.78e-12	5.48e-09	0.46	0.31	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
HNSC	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-7.02	7.79e-12	5.49e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
HNSC	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-7.02	7.79e-12	5.49e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
HNSC	cis	rs6951245	1	rs77868187	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs75016635	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs113066613	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11763793	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11763835	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78861357	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs76713558	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.748	rs79658522	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs76525951	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79683221	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78185801	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs80031817	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78143408	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1074450~1078036:+
HNSC	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-7.02	7.86e-12	5.53e-09	-0.31	-0.31	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
HNSC	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	7.02	7.86e-12	5.53e-09	0.44	0.31	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
HNSC	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	7.02	7.89e-12	5.55e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
HNSC	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	7.02	7.89e-12	5.55e-09	0.4	0.31	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
HNSC	cis	rs6471393	0.929	rs62525162	ENSG00000253848.1	RP11-10N23.5	7.02	7.92e-12	5.58e-09	0.37	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749654	chr8:93741193~93744534:+
HNSC	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-7.02	7.93e-12	5.58e-09	-0.45	-0.31	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
HNSC	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-7.02	7.93e-12	5.58e-09	-0.47	-0.31	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
HNSC	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	7.02	7.93e-12	5.58e-09	0.33	0.31	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
HNSC	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-7.02	7.95e-12	5.59e-09	-0.3	-0.31	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
HNSC	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	7.02	7.97e-12	5.6e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
HNSC	cis	rs757110	0.803	rs7928810	ENSG00000260196.1	RP1-239B22.5	7.02	8.02e-12	5.64e-09	0.35	0.31	Type 2 diabetes;	chr11:17350896	chr11:17380649~17383531:+
HNSC	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	7.02	8.02e-12	5.64e-09	0.44	0.31	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
HNSC	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-7.02	8.05e-12	5.66e-09	-0.36	-0.31	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
HNSC	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	7.02	8.07e-12	5.67e-09	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
HNSC	cis	rs853679	1	rs2799079	ENSG00000219392.1	RP1-265C24.5	-7.02	8.07e-12	5.67e-09	-0.45	-0.31	Depression;	chr6:28267398	chr6:28115628~28116551:+
HNSC	cis	rs451417	1	rs451417	ENSG00000275632.1	RP5-967N21.11	7.02	8.07e-12	5.67e-09	0.37	0.31	Menopause (age at onset);	chr20:5961353	chr20:6000418~6000941:+
HNSC	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-7.02	8.08e-12	5.68e-09	-0.47	-0.31	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-7.02	8.11e-12	5.7e-09	-0.27	-0.31	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
HNSC	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-7.01	8.13e-12	5.71e-09	-0.32	-0.31	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
HNSC	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	7.01	8.13e-12	5.72e-09	0.38	0.31	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
HNSC	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-7.01	8.15e-12	5.73e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
HNSC	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-7.01	8.18e-12	5.75e-09	-0.43	-0.31	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
HNSC	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	7.01	8.19e-12	5.75e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	7.01	8.19e-12	5.75e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
HNSC	cis	rs1799949	0.965	rs11080034	ENSG00000267151.3	RP11-100E5.2	7.01	8.19e-12	5.76e-09	0.4	0.31	Menopause (age at onset);	chr17:43365646	chr17:43444707~43451200:+
HNSC	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	7.01	8.2e-12	5.76e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
HNSC	cis	rs17270561	0.636	rs9379782	ENSG00000272462.2	U91328.19	-7.01	8.21e-12	5.77e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25714795	chr6:25992662~26001775:+
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000254340.1	RP11-10A14.3	-7.01	8.22e-12	5.77e-09	-0.37	-0.31	Mood instability;	chr8:8937291	chr8:9141424~9145435:+
HNSC	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-7.01	8.23e-12	5.78e-09	-0.36	-0.31	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
HNSC	cis	rs172166	0.637	rs1225595	ENSG00000204709.4	LINC01556	7.01	8.24e-12	5.78e-09	0.39	0.31	Cardiac Troponin-T levels;	chr6:28183562	chr6:28943877~28944537:+
HNSC	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-7.01	8.24e-12	5.79e-09	-0.38	-0.31	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
HNSC	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	7.01	8.26e-12	5.8e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
HNSC	cis	rs6867032	1	rs4074914	ENSG00000249731.1	RP11-259O2.3	7.01	8.27e-12	5.8e-09	0.39	0.31	Gut microbiome composition (winter);	chr5:2020160	chr5:1968094~1969013:+
HNSC	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-7.01	8.27e-12	5.81e-09	-0.45	-0.31	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
HNSC	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	7.01	8.28e-12	5.81e-09	0.37	0.31	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
HNSC	cis	rs832187	0.64	rs56293138	ENSG00000280620.1	SCAANT1	7.01	8.29e-12	5.82e-09	0.4	0.31	Schizophrenia;	chr3:63903259	chr3:63911518~63911772:-
HNSC	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-7.01	8.36e-12	5.86e-09	-0.39	-0.31	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
HNSC	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-7.01	8.38e-12	5.88e-09	-0.35	-0.31	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
HNSC	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	7.01	8.4e-12	5.89e-09	0.39	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
HNSC	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	7.01	8.42e-12	5.9e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	7.01	8.42e-12	5.9e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
HNSC	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-7.01	8.45e-12	5.93e-09	-0.38	-0.31	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	7.01	8.45e-12	5.93e-09	0.22	0.31	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
HNSC	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	7.01	8.46e-12	5.94e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
HNSC	cis	rs17270561	0.609	rs9379785	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25725985	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358871	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726447	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711095	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726546	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712959	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726829	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712960	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727037	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712961	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727106	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358872	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727289	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9356985	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727870	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-7.01	8.48e-12	5.95e-09	-0.34	-0.31	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
HNSC	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	7.01	8.49e-12	5.95e-09	0.47	0.31	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
HNSC	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-7.01	8.51e-12	5.97e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-7.01	8.51e-12	5.97e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-7.01	8.51e-12	5.97e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	7.01	8.53e-12	5.98e-09	0.22	0.31	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
HNSC	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	7.01	8.54e-12	5.99e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
HNSC	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-7.01	8.55e-12	6e-09	-0.33	-0.31	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
HNSC	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-7.01	8.56e-12	6e-09	-0.49	-0.31	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
HNSC	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.28	-0.31	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.28	-0.31	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.28	-0.31	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.27	-0.31	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000254340.1	RP11-10A14.3	7.01	8.61e-12	6.03e-09	0.37	0.31	Joint mobility (Beighton score);	chr8:8977018	chr8:9141424~9145435:+
HNSC	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	7.01	8.63e-12	6.05e-09	0.5	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	7	8.67e-12	6.07e-09	0.44	0.31	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
HNSC	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-7	8.67e-12	6.07e-09	-0.28	-0.31	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
HNSC	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
HNSC	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-7	8.68e-12	6.08e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
HNSC	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-7	8.72e-12	6.11e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	7	8.75e-12	6.13e-09	0.32	0.31	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
HNSC	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	7	8.77e-12	6.14e-09	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
HNSC	cis	rs2579103	0.63	rs1222451	ENSG00000258183.4	RP11-753N8.1	-7	8.77e-12	6.14e-09	-0.42	-0.31	Body mass index;	chr12:90314445	chr12:90280894~90300340:+
HNSC	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-7	8.78e-12	6.14e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
HNSC	cis	rs1799949	1	rs35330014	ENSG00000267151.3	RP11-100E5.2	7	8.78e-12	6.14e-09	0.4	0.31	Menopause (age at onset);	chr17:43060530	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs3092994	ENSG00000267151.3	RP11-100E5.2	7	8.78e-12	6.14e-09	0.4	0.31	Menopause (age at onset);	chr17:43063808	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	7	8.82e-12	6.17e-09	0.32	0.31	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
HNSC	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-7	8.82e-12	6.17e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
HNSC	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-7	8.85e-12	6.19e-09	-0.44	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
HNSC	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	7	8.88e-12	6.21e-09	0.36	0.31	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
HNSC	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-7	8.89e-12	6.22e-09	-0.37	-0.31	Height;	chr3:53084188	chr3:53064283~53065091:-
HNSC	cis	rs6867032	1	rs7729761	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015669	chr5:1968094~1969013:+
HNSC	cis	rs6867032	0.687	rs4998338	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015796	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs2129471	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2016122	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs2129472	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2016133	chr5:1968094~1969013:+
HNSC	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	7	8.9e-12	6.23e-09	0.44	0.31	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
HNSC	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-7	8.91e-12	6.23e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
HNSC	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-7	8.91e-12	6.23e-09	-0.51	-0.31	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
HNSC	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	7	8.92e-12	6.24e-09	0.37	0.31	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
HNSC	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	7	8.94e-12	6.25e-09	0.37	0.31	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
HNSC	cis	rs1799949	1	rs8176318	ENSG00000267151.3	RP11-100E5.2	7	8.95e-12	6.26e-09	0.4	0.31	Menopause (age at onset);	chr17:43045257	chr17:43444707~43451200:+
HNSC	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	7	9e-12	6.29e-09	0.28	0.31	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-7	9.06e-12	6.33e-09	-0.39	-0.31	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
HNSC	cis	rs1799949	1	rs16941	ENSG00000267151.3	RP11-100E5.2	7	9.08e-12	6.34e-09	0.4	0.31	Menopause (age at onset);	chr17:43092418	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs67060599	ENSG00000267151.3	RP11-100E5.2	7	9.08e-12	6.34e-09	0.4	0.31	Menopause (age at onset);	chr17:43103085	chr17:43444707~43451200:+
HNSC	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	7	9.1e-12	6.36e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
HNSC	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-7	9.12e-12	6.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-7	9.12e-12	6.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
HNSC	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	7	9.12e-12	6.37e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
HNSC	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-7	9.15e-12	6.39e-09	-0.37	-0.31	Migraine;	chr4:56852029	chr4:56960927~56961373:-
HNSC	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-7	9.15e-12	6.39e-09	-0.32	-0.31	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	7	9.16e-12	6.4e-09	0.31	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
HNSC	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	7	9.17e-12	6.4e-09	0.33	0.31	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
HNSC	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-7	9.18e-12	6.41e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
HNSC	cis	rs1799949	1	rs12516	ENSG00000267151.3	RP11-100E5.2	7	9.18e-12	6.41e-09	0.4	0.31	Menopause (age at onset);	chr17:43044391	chr17:43444707~43451200:+
HNSC	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	7	9.21e-12	6.43e-09	0.33	0.31	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
HNSC	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	6.99	9.24e-12	6.45e-09	0.36	0.31	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	6.99	9.24e-12	6.45e-09	0.36	0.31	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
HNSC	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-6.99	9.26e-12	6.46e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
HNSC	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	6.99	9.26e-12	6.46e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-6.99	9.27e-12	6.47e-09	-0.27	-0.31	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
HNSC	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-6.99	9.28e-12	6.48e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
HNSC	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-6.99	9.29e-12	6.49e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
HNSC	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	6.99	9.29e-12	6.49e-09	0.35	0.31	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
HNSC	cis	rs17270561	0.609	rs9358873	ENSG00000272462.2	U91328.19	-6.99	9.33e-12	6.51e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25731555	chr6:25992662~26001775:+
HNSC	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-6.99	9.33e-12	6.51e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
HNSC	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-6.99	9.36e-12	6.53e-09	-0.32	-0.31	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
HNSC	cis	rs1659258	0.772	rs1659251	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88356679	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.772	rs1659252	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88358323	chr2:88364695~88365608:-
HNSC	cis	rs1659258	1	rs55909126	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88358580	chr2:88364695~88365608:-
HNSC	cis	rs1659258	1	rs1659258	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88360069	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.892	rs3114962	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88361383	chr2:88364695~88365608:-
HNSC	cis	rs1659258	1	rs1659267	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88366167	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.892	rs2679263	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88366444	chr2:88364695~88365608:-
HNSC	cis	rs10791097	0.967	rs1944142	ENSG00000254842.5	RP11-890B15.2	-6.99	9.38e-12	6.54e-09	-0.26	-0.31	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130847545	chr11:130844191~130865561:-
HNSC	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-6.99	9.39e-12	6.55e-09	-0.3	-0.31	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-6.99	9.39e-12	6.55e-09	-0.3	-0.31	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
HNSC	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	6.99	9.45e-12	6.59e-09	0.37	0.31	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
HNSC	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-6.99	9.46e-12	6.59e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
HNSC	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-6.99	9.5e-12	6.62e-09	-0.34	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
HNSC	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	6.99	9.51e-12	6.62e-09	0.44	0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
HNSC	cis	rs7615952	0.604	rs9837847	ENSG00000241288.6	RP11-379B18.5	-6.99	9.55e-12	6.65e-09	-0.51	-0.31	Blood pressure (smoking interaction);	chr3:125905076	chr3:125827238~125916384:-
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000173295.6	FAM86B3P	-6.99	9.56e-12	6.66e-09	-0.34	-0.31	Joint mobility (Beighton score);	chr8:9225923	chr8:8228595~8244865:+
HNSC	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	6.99	9.59e-12	6.68e-09	0.38	0.31	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
HNSC	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	6.99	9.61e-12	6.69e-09	0.47	0.31	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	6.99	9.64e-12	6.71e-09	0.45	0.31	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
HNSC	cis	rs17270561	0.636	rs9393656	ENSG00000272462.2	U91328.19	-6.99	9.67e-12	6.72e-09	-0.31	-0.31	Iron status biomarkers;	chr6:25721831	chr6:25992662~26001775:+
HNSC	cis	rs62344088	0.59	rs62346174	ENSG00000277812.1	AC021087.1	6.99	9.69e-12	6.74e-09	0.8	0.31	Asthma (childhood onset);	chr5:296193	chr5:262769~262881:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	6.99	9.69e-12	6.74e-09	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	6.99	9.72e-12	6.76e-09	0.43	0.31	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-6.99	9.73e-12	6.76e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
HNSC	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	6.99	9.73e-12	6.76e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
HNSC	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-6.99	9.76e-12	6.78e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
HNSC	cis	rs6951245	1	rs6951245	ENSG00000225146.1	AC073957.15	-6.99	9.78e-12	6.8e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018557	chr7:1029025~1043891:+
HNSC	cis	rs9326248	0.53	rs2127905	ENSG00000280143.1	AP000892.6	6.99	9.79e-12	6.8e-09	0.46	0.31	Blood protein levels;	chr11:117155658	chr11:117204967~117210292:+
HNSC	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-6.99	9.82e-12	6.83e-09	-0.35	-0.31	Height;	chr3:52994990	chr3:53064283~53065091:-
HNSC	cis	rs6951245	0.938	rs78351779	ENSG00000224079.1	AC091729.7	-6.99	9.86e-12	6.85e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11761941	ENSG00000224079.1	AC091729.7	-6.99	9.86e-12	6.85e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11767527	ENSG00000224079.1	AC091729.7	-6.99	9.86e-12	6.85e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs16940	ENSG00000267151.3	RP11-100E5.2	6.98	9.88e-12	6.86e-09	0.4	0.31	Menopause (age at onset);	chr17:43093220	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs66499067	ENSG00000267151.3	RP11-100E5.2	6.98	9.88e-12	6.86e-09	0.4	0.31	Menopause (age at onset);	chr17:43096467	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-6.98	9.91e-12	6.88e-09	-0.27	-0.31	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
HNSC	cis	rs2579103	0.708	rs1371080	ENSG00000258183.4	RP11-753N8.1	-6.98	1e-11	6.96e-09	-0.43	-0.31	Body mass index;	chr12:90288622	chr12:90280894~90300340:+
HNSC	cis	rs6951245	0.935	rs11763765	ENSG00000225146.1	AC073957.15	-6.98	1e-11	6.96e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020874	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs11766669	ENSG00000225146.1	AC073957.15	-6.98	1e-11	6.96e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1023957	chr7:1029025~1043891:+
HNSC	cis	rs17270561	0.609	rs4711096	ENSG00000272462.2	U91328.19	-6.98	1e-11	6.96e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726826	chr6:25992662~26001775:+
HNSC	cis	rs11089937	0.568	rs35626600	ENSG00000211638.2	IGLV8-61	-6.98	1e-11	6.97e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.539	rs34228957	ENSG00000211638.2	IGLV8-61	-6.98	1e-11	6.97e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22098700~22099212:+
HNSC	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	6.98	1.01e-11	6.98e-09	0.38	0.31	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
HNSC	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
HNSC	cis	rs116095464	1	rs55671190	ENSG00000277812.1	AC021087.1	6.98	1.01e-11	7e-09	0.7	0.31	Breast cancer;	chr5:287307	chr5:262769~262881:+
HNSC	cis	rs451417	1	rs236124	ENSG00000275632.1	RP5-967N21.11	6.98	1.02e-11	7.05e-09	0.38	0.31	Menopause (age at onset);	chr20:5995333	chr20:6000418~6000941:+
HNSC	cis	rs7615952	0.611	rs2947646	ENSG00000241288.6	RP11-379B18.5	6.98	1.02e-11	7.06e-09	0.49	0.31	Blood pressure (smoking interaction);	chr3:125874759	chr3:125827238~125916384:-
HNSC	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	6.98	1.02e-11	7.07e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	6.98	1.02e-11	7.09e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
HNSC	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	6.98	1.02e-11	7.09e-09	0.43	0.31	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
HNSC	cis	rs6867032	0.958	rs4505990	ENSG00000249731.1	RP11-259O2.3	6.98	1.03e-11	7.1e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015697	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs4398675	ENSG00000249731.1	RP11-259O2.3	6.98	1.03e-11	7.1e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015702	chr5:1968094~1969013:+
HNSC	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	6.98	1.03e-11	7.1e-09	0.45	0.31	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
HNSC	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-6.98	1.03e-11	7.11e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
HNSC	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-6.98	1.03e-11	7.16e-09	-0.56	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
HNSC	cis	rs1799949	0.965	rs8176323	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43043694	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793190	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43048092	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176297	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43051308	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176296	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43051574	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793191	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43052360	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793192	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43052373	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176289	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43054039	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	6.98	1.04e-11	7.17e-09	0.22	0.31	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	6.98	1.04e-11	7.17e-09	0.22	0.31	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
HNSC	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	6.98	1.04e-11	7.19e-09	0.56	0.31	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
HNSC	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-6.98	1.04e-11	7.19e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
HNSC	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-6.98	1.04e-11	7.19e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-6.98	1.04e-11	7.19e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
HNSC	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	6.98	1.04e-11	7.2e-09	0.38	0.31	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
HNSC	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-6.98	1.04e-11	7.2e-09	-0.33	-0.31	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
HNSC	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-6.98	1.04e-11	7.21e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
HNSC	cis	rs11089937	0.568	rs5756989	ENSG00000211638.2	IGLV8-61	-6.98	1.04e-11	7.21e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22098700~22099212:+
HNSC	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	6.98	1.04e-11	7.22e-09	0.36	0.31	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	6.98	1.04e-11	7.22e-09	0.36	0.31	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	6.98	1.04e-11	7.22e-09	0.36	0.31	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
HNSC	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	6.98	1.05e-11	7.23e-09	0.44	0.31	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
HNSC	cis	rs10791097	0.967	rs4366492	ENSG00000254842.5	RP11-890B15.2	-6.98	1.05e-11	7.26e-09	-0.27	-0.31	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130847361	chr11:130844191~130865561:-
HNSC	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-6.97	1.05e-11	7.28e-09	-0.35	-0.31	Height;	chr3:52994045	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	-6.97	1.05e-11	7.29e-09	-0.34	-0.31	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
HNSC	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-6.97	1.06e-11	7.32e-09	-0.36	-0.31	Height;	chr3:52998472	chr3:53064283~53065091:-
HNSC	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-6.97	1.06e-11	7.34e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
HNSC	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-6.97	1.06e-11	7.34e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
HNSC	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	6.97	1.07e-11	7.37e-09	0.46	0.31	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
HNSC	cis	rs9326248	0.53	rs7123517	ENSG00000280143.1	AP000892.6	6.97	1.07e-11	7.37e-09	0.46	0.31	Blood protein levels;	chr11:117157039	chr11:117204967~117210292:+
HNSC	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-6.97	1.07e-11	7.37e-09	-0.49	-0.31	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-6.97	1.07e-11	7.37e-09	-0.49	-0.31	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-6.97	1.07e-11	7.37e-09	-0.49	-0.31	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
HNSC	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	6.97	1.07e-11	7.39e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
HNSC	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-6.97	1.07e-11	7.39e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
HNSC	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	6.97	1.07e-11	7.4e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
HNSC	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-6.97	1.07e-11	7.42e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
HNSC	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	6.97	1.08e-11	7.45e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
HNSC	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-6.97	1.08e-11	7.46e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
HNSC	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	6.97	1.08e-11	7.46e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
HNSC	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	6.97	1.08e-11	7.48e-09	0.45	0.31	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-6.97	1.08e-11	7.49e-09	-0.27	-0.31	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
HNSC	cis	rs1659258	1	rs1258383	ENSG00000232508.1	MRPL45P1	6.97	1.09e-11	7.51e-09	0.64	0.31	Visceral fat;	chr2:88340213	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.803	rs72841297	ENSG00000232508.1	MRPL45P1	6.97	1.09e-11	7.51e-09	0.64	0.31	Visceral fat;	chr2:88347981	chr2:88364695~88365608:-
HNSC	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-6.97	1.09e-11	7.51e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-6.97	1.09e-11	7.53e-09	-0.37	-0.31	Depression;	chr6:28422360	chr6:28176188~28176674:+
HNSC	cis	rs78773383	0.505	rs13123782	ENSG00000249207.1	RP11-360F5.1	6.97	1.09e-11	7.54e-09	0.34	0.31	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39112677~39126818:-
HNSC	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-6.97	1.1e-11	7.58e-09	-0.31	-0.31	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
HNSC	cis	rs1799949	1	rs8176133	ENSG00000267151.3	RP11-100E5.2	6.97	1.1e-11	7.58e-09	0.4	0.31	Menopause (age at onset);	chr17:43105441	chr17:43444707~43451200:+
HNSC	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	6.97	1.1e-11	7.59e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
HNSC	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-6.97	1.1e-11	7.61e-09	-0.45	-0.31	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
HNSC	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-6.97	1.1e-11	7.62e-09	-0.36	-0.31	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
HNSC	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-6.97	1.11e-11	7.62e-09	-0.39	-0.31	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
HNSC	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-6.97	1.11e-11	7.63e-09	-0.37	-0.31	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs11655505	ENSG00000267151.3	RP11-100E5.2	6.97	1.11e-11	7.65e-09	0.39	0.31	Menopause (age at onset);	chr17:43126360	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs4793204	ENSG00000267151.3	RP11-100E5.2	6.97	1.11e-11	7.65e-09	0.39	0.31	Menopause (age at onset);	chr17:43127281	chr17:43444707~43451200:+
HNSC	cis	rs172166	0.637	rs1225592	ENSG00000204709.4	LINC01556	6.97	1.11e-11	7.67e-09	0.39	0.31	Cardiac Troponin-T levels;	chr6:28182464	chr6:28943877~28944537:+
HNSC	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-6.97	1.12e-11	7.69e-09	-0.32	-0.31	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
HNSC	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-6.97	1.12e-11	7.72e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-6.97	1.12e-11	7.72e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	6.97	1.12e-11	7.72e-09	0.22	0.31	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
HNSC	cis	rs1799949	1	rs4793215	ENSG00000267151.3	RP11-100E5.2	6.96	1.12e-11	7.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43166915	chr17:43444707~43451200:+
HNSC	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	6.96	1.13e-11	7.77e-09	0.36	0.31	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	6.96	1.13e-11	7.77e-09	0.36	0.31	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
HNSC	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-6.96	1.13e-11	7.79e-09	-0.29	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
HNSC	cis	rs6471393	0.798	rs55680024	ENSG00000253848.1	RP11-10N23.5	6.96	1.13e-11	7.79e-09	0.41	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93836533	chr8:93741193~93744534:+
HNSC	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	6.96	1.13e-11	7.8e-09	0.36	0.31	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
HNSC	cis	rs2579103	0.668	rs1222456	ENSG00000258183.4	RP11-753N8.1	-6.96	1.13e-11	7.81e-09	-0.43	-0.31	Body mass index;	chr12:90300134	chr12:90280894~90300340:+
HNSC	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-6.96	1.14e-11	7.84e-09	-0.42	-0.31	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
HNSC	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-6.96	1.14e-11	7.87e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
HNSC	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-6.96	1.14e-11	7.87e-09	-0.37	-0.31	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
HNSC	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-6.96	1.15e-11	7.88e-09	-0.29	-0.31	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
HNSC	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-6.96	1.15e-11	7.9e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
HNSC	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	6.96	1.15e-11	7.9e-09	0.3	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
HNSC	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-6.96	1.15e-11	7.9e-09	-0.48	-0.31	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	6.96	1.15e-11	7.91e-09	0.31	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
HNSC	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-6.96	1.15e-11	7.92e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
HNSC	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-6.96	1.15e-11	7.92e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
HNSC	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	6.96	1.15e-11	7.92e-09	0.28	0.31	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	6.96	1.15e-11	7.92e-09	0.28	0.31	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-6.96	1.15e-11	7.92e-09	-0.4	-0.31	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
HNSC	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-6.96	1.15e-11	7.93e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
HNSC	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-6.96	1.16e-11	7.95e-09	-0.43	-0.31	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
HNSC	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-6.96	1.16e-11	7.96e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
HNSC	cis	rs7083	1	rs512188	ENSG00000254851.1	RP11-109L13.1	-6.96	1.16e-11	7.98e-09	-0.39	-0.31	Blood protein levels;	chr11:117255994	chr11:117135528~117138582:+
HNSC	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	6.96	1.17e-11	8.02e-09	0.3	0.31	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
HNSC	cis	rs2579103	0.708	rs1561423	ENSG00000258183.4	RP11-753N8.1	-6.96	1.17e-11	8.05e-09	-0.43	-0.31	Body mass index;	chr12:90280416	chr12:90280894~90300340:+
HNSC	cis	rs440932	0.798	rs330942	ENSG00000254340.1	RP11-10A14.3	6.96	1.17e-11	8.06e-09	0.37	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:9141424~9145435:+
HNSC	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-6.96	1.18e-11	8.09e-09	-0.38	-0.31	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
HNSC	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-6.96	1.18e-11	8.09e-09	-0.41	-0.31	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
HNSC	cis	rs1799949	0.965	rs8176322	ENSG00000267151.3	RP11-100E5.2	6.96	1.18e-11	8.1e-09	0.4	0.31	Menopause (age at onset);	chr17:43043756	chr17:43444707~43451200:+
HNSC	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	6.96	1.18e-11	8.1e-09	0.3	0.31	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	6.96	1.18e-11	8.1e-09	0.3	0.31	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
HNSC	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	6.96	1.19e-11	8.14e-09	0.33	0.31	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	6.96	1.19e-11	8.14e-09	0.33	0.31	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
HNSC	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-6.96	1.19e-11	8.18e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
HNSC	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	6.96	1.19e-11	8.18e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
HNSC	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-6.95	1.2e-11	8.22e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
HNSC	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.23e-09	-0.27	-0.31	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.23e-09	-0.27	-0.31	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
HNSC	cis	rs17214007	0.518	rs56374730	ENSG00000263335.1	AF001548.5	-6.95	1.2e-11	8.25e-09	-0.44	-0.31	Cognitive function;	chr16:15773795	chr16:15726674~15732993:+
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.25e-09	-0.27	-0.31	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.25e-09	-0.27	-0.31	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.25e-09	-0.27	-0.31	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
HNSC	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-6.95	1.2e-11	8.25e-09	-0.47	-0.31	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
HNSC	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-6.95	1.21e-11	8.29e-09	-0.39	-0.31	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.21e-11	8.29e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
HNSC	cis	rs1659258	0.655	rs3107210	ENSG00000232508.1	MRPL45P1	6.95	1.21e-11	8.29e-09	0.65	0.31	Visceral fat;	chr2:88359241	chr2:88364695~88365608:-
HNSC	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	6.95	1.21e-11	8.32e-09	0.36	0.31	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
HNSC	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-6.95	1.22e-11	8.33e-09	-0.38	-0.31	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	6.95	1.22e-11	8.33e-09	0.38	0.31	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
HNSC	cis	rs5769707	0.777	rs8141219	ENSG00000188511.11	C22orf34	6.95	1.22e-11	8.34e-09	0.39	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49650898	chr22:49414524~49657542:-
HNSC	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	6.95	1.22e-11	8.35e-09	0.37	0.31	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
HNSC	cis	rs7615952	0.599	rs6779141	ENSG00000241288.6	RP11-379B18.5	-6.95	1.22e-11	8.35e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:125991152	chr3:125827238~125916384:-
HNSC	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	6.95	1.22e-11	8.35e-09	0.3	0.31	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
HNSC	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.22e-11	8.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.22e-11	8.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
HNSC	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	6.95	1.23e-11	8.4e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
HNSC	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-6.95	1.23e-11	8.4e-09	-0.38	-0.31	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-6.95	1.23e-11	8.4e-09	-0.38	-0.31	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
HNSC	cis	rs1799949	1	rs2175957	ENSG00000267151.3	RP11-100E5.2	6.95	1.23e-11	8.42e-09	0.39	0.31	Menopause (age at onset);	chr17:43134805	chr17:43444707~43451200:+
HNSC	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	6.95	1.23e-11	8.43e-09	0.46	0.31	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
HNSC	cis	rs1799949	1	rs4793194	ENSG00000267151.3	RP11-100E5.2	6.95	1.24e-11	8.5e-09	0.39	0.31	Menopause (age at onset);	chr17:43066316	chr17:43444707~43451200:+
HNSC	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	6.95	1.24e-11	8.5e-09	0.3	0.31	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
HNSC	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-6.95	1.25e-11	8.54e-09	-0.4	-0.31	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-6.95	1.25e-11	8.54e-09	-0.4	-0.31	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-6.95	1.25e-11	8.54e-09	-0.4	-0.31	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
HNSC	cis	rs1799949	1	rs11656097	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43138596	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11658754	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43140722	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs33968979	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43145975	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12952790	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43147590	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12950607	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43147911	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11079056	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43148782	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12936816	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43149692	chr17:43444707~43451200:+
HNSC	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	6.95	1.25e-11	8.57e-09	0.46	0.31	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
HNSC	cis	rs36405	0.5	rs8011906	ENSG00000266869.1	RP6-114E22.1	-6.95	1.26e-11	8.59e-09	-0.38	-0.31	Yang-deficiency constitution;	chr14:71893078	chr14:71848606~71908430:+
HNSC	cis	rs451417	0.643	rs34907229	ENSG00000275632.1	RP5-967N21.11	6.95	1.26e-11	8.6e-09	0.4	0.31	Menopause (age at onset);	chr20:6002207	chr20:6000418~6000941:+
HNSC	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-6.95	1.26e-11	8.62e-09	-0.3	-0.31	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
HNSC	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-6.95	1.26e-11	8.64e-09	-0.39	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
HNSC	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	6.95	1.26e-11	8.64e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
HNSC	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-6.95	1.27e-11	8.67e-09	-0.4	-0.31	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-6.95	1.27e-11	8.67e-09	-0.4	-0.31	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-6.95	1.27e-11	8.67e-09	-0.4	-0.31	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
HNSC	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-6.95	1.27e-11	8.69e-09	-0.3	-0.31	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
HNSC	cis	rs1799810	0.899	rs4662726	ENSG00000236682.1	AC068282.3	6.95	1.27e-11	8.71e-09	0.36	0.31	Self-rated health;	chr2:127413086	chr2:127389130~127400580:+
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-6.94	1.28e-11	8.71e-09	-0.57	-0.31	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
HNSC	cis	rs7115242	0.8	rs10736487	ENSG00000280143.1	AP000892.6	6.94	1.28e-11	8.71e-09	0.46	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117204967~117210292:+
HNSC	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	6.94	1.28e-11	8.73e-09	0.29	0.31	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
HNSC	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-6.94	1.28e-11	8.77e-09	-0.4	-0.31	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
HNSC	cis	rs7615952	0.599	rs12485717	ENSG00000241288.6	RP11-379B18.5	6.94	1.29e-11	8.79e-09	0.4	0.31	Blood pressure (smoking interaction);	chr3:125988232	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-6.94	1.29e-11	8.81e-09	-0.27	-0.31	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
HNSC	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	6.94	1.29e-11	8.81e-09	0.3	0.31	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
HNSC	cis	rs9326248	0.53	rs10750101	ENSG00000280143.1	AP000892.6	6.94	1.29e-11	8.81e-09	0.47	0.31	Blood protein levels;	chr11:117108973	chr11:117204967~117210292:+
HNSC	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	6.94	1.29e-11	8.84e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
HNSC	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	6.94	1.3e-11	8.85e-09	0.45	0.31	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
HNSC	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-6.94	1.3e-11	8.86e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
HNSC	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	6.94	1.3e-11	8.86e-09	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	6.94	1.3e-11	8.86e-09	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
HNSC	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-6.94	1.3e-11	8.88e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
HNSC	cis	rs2729354	0.817	rs2848626	ENSG00000265566.2	RN7SL605P	-6.94	1.3e-11	8.89e-09	-0.43	-0.31	Blood protein levels;	chr11:57516515	chr11:57528085~57528365:-
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	6.94	1.3e-11	8.9e-09	0.35	0.31	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
HNSC	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	6.94	1.31e-11	8.9e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	6.94	1.31e-11	8.9e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	6.94	1.31e-11	8.9e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
HNSC	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	6.94	1.31e-11	8.94e-09	0.28	0.31	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.558	rs17334039	ENSG00000248787.1	RP11-666A20.4	-6.94	1.31e-11	8.94e-09	-0.45	-0.31	Blood pressure (smoking interaction);	chr3:125821465	chr3:125908005~125910272:-
HNSC	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	6.94	1.31e-11	8.95e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	6.94	1.31e-11	8.95e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
HNSC	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-6.94	1.31e-11	8.96e-09	-0.41	-0.31	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
HNSC	cis	rs6951245	0.554	rs10246354	ENSG00000224079.1	AC091729.7	-6.94	1.32e-11	8.97e-09	-0.42	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1074450~1078036:+
HNSC	cis	rs4978813	0.5	rs7870600	ENSG00000213539.4	YBX1P6	-6.94	1.32e-11	8.97e-09	-0.35	-0.31	Plantar warts;	chr9:109535950	chr9:109532830~109534332:-
HNSC	cis	rs4978813	0.5	rs58522556	ENSG00000213539.4	YBX1P6	-6.94	1.32e-11	8.97e-09	-0.35	-0.31	Plantar warts;	chr9:109536728	chr9:109532830~109534332:-
HNSC	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	6.94	1.32e-11	8.97e-09	0.46	0.31	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
HNSC	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	6.94	1.32e-11	8.97e-09	0.33	0.31	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
HNSC	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-6.94	1.32e-11	9e-09	-0.32	-0.31	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
HNSC	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	6.94	1.32e-11	9.01e-09	0.36	0.31	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
HNSC	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	6.94	1.32e-11	9.01e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
HNSC	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-6.94	1.33e-11	9.06e-09	-0.39	-0.31	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
HNSC	cis	rs1799949	1	rs2292595	ENSG00000267151.3	RP11-100E5.2	6.94	1.33e-11	9.08e-09	0.39	0.31	Menopause (age at onset);	chr17:43138657	chr17:43444707~43451200:+
HNSC	cis	rs394563	0.591	rs237016	ENSG00000231760.4	RP11-350J20.5	6.94	1.34e-11	9.09e-09	0.38	0.31	Dupuytren's disease;	chr6:149423723	chr6:149796151~149826294:-
HNSC	cis	rs1799949	1	rs1973646	ENSG00000267151.3	RP11-100E5.2	6.94	1.34e-11	9.09e-09	0.4	0.31	Menopause (age at onset);	chr17:43158478	chr17:43444707~43451200:+
HNSC	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-6.94	1.34e-11	9.1e-09	-0.29	-0.31	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
HNSC	cis	rs9402743	0.962	rs9321521	ENSG00000217482.2	HMGB1P17	6.94	1.34e-11	9.1e-09	0.33	0.31	Systemic lupus erythematosus;	chr6:135668512	chr6:135636086~135636713:-
HNSC	cis	rs17270561	0.609	rs17267614	ENSG00000272462.2	U91328.19	-6.94	1.34e-11	9.11e-09	-0.31	-0.31	Iron status biomarkers;	chr6:25729799	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	6.94	1.34e-11	9.11e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
HNSC	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	6.94	1.34e-11	9.13e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
HNSC	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	6.94	1.35e-11	9.16e-09	0.3	0.31	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
HNSC	cis	rs17270561	0.609	rs4712970	ENSG00000272462.2	U91328.19	-6.94	1.35e-11	9.2e-09	-0.31	-0.31	Iron status biomarkers;	chr6:25770479	chr6:25992662~26001775:+
HNSC	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-6.94	1.35e-11	9.21e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-6.94	1.35e-11	9.21e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-6.94	1.35e-11	9.21e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
HNSC	cis	rs451417	0.818	rs236103	ENSG00000275632.1	RP5-967N21.11	6.94	1.35e-11	9.21e-09	0.4	0.31	Menopause (age at onset);	chr20:5977341	chr20:6000418~6000941:+
HNSC	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	6.94	1.36e-11	9.22e-09	0.44	0.31	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
HNSC	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-6.94	1.36e-11	9.24e-09	-0.4	-0.31	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
HNSC	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	6.94	1.36e-11	9.24e-09	0.37	0.31	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-6.94	1.36e-11	9.24e-09	-0.27	-0.31	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
HNSC	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	6.93	1.36e-11	9.25e-09	0.38	0.31	Height;	chr6:109370985	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	6.93	1.37e-11	9.29e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
HNSC	cis	rs1799949	0.896	rs8176086	ENSG00000267151.3	RP11-100E5.2	6.93	1.37e-11	9.29e-09	0.39	0.31	Menopause (age at onset);	chr17:43122761	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs3765640	ENSG00000267151.3	RP11-100E5.2	6.93	1.37e-11	9.29e-09	0.39	0.31	Menopause (age at onset);	chr17:43124230	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176077	ENSG00000267151.3	RP11-100E5.2	6.93	1.37e-11	9.29e-09	0.39	0.31	Menopause (age at onset);	chr17:43124331	chr17:43444707~43451200:+
HNSC	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-6.93	1.37e-11	9.31e-09	-0.47	-0.31	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
HNSC	cis	rs860295	0.967	rs6665227	ENSG00000203761.5	MSTO2P	-6.93	1.38e-11	9.37e-09	-0.22	-0.31	Body mass index;	chr1:155740669	chr1:155745829~155750137:+
HNSC	cis	rs11089937	0.512	rs34963809	ENSG00000211638.2	IGLV8-61	-6.93	1.38e-11	9.37e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22098700~22099212:+
HNSC	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	6.93	1.38e-11	9.39e-09	0.6	0.31	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
HNSC	cis	rs1355223	0.902	rs836467	ENSG00000271369.1	RP11-350D17.3	-6.93	1.39e-11	9.42e-09	-0.34	-0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715885	chr11:34709600~34710161:+
HNSC	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	6.93	1.39e-11	9.44e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
HNSC	cis	rs6867032	1	rs4975802	ENSG00000249731.1	RP11-259O2.3	6.93	1.39e-11	9.46e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2019636	chr5:1968094~1969013:+
HNSC	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	6.93	1.39e-11	9.46e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	6.93	1.39e-11	9.46e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
HNSC	cis	rs6951245	0.58	rs77101766	ENSG00000224079.1	AC091729.7	-6.93	1.4e-11	9.48e-09	-0.41	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1074450~1078036:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000254340.1	RP11-10A14.3	-6.93	1.4e-11	9.49e-09	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9044411	chr8:9141424~9145435:+
HNSC	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-6.93	1.41e-11	9.55e-09	-0.4	-0.31	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
HNSC	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-6.93	1.41e-11	9.56e-09	-0.31	-0.31	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
HNSC	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs8176083	ENSG00000267151.3	RP11-100E5.2	6.93	1.41e-11	9.58e-09	0.4	0.31	Menopause (age at onset);	chr17:43123134	chr17:43444707~43451200:+
HNSC	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	6.93	1.42e-11	9.6e-09	0.42	0.31	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
HNSC	cis	rs1799949	0.965	rs1842147	ENSG00000267151.3	RP11-100E5.2	6.93	1.42e-11	9.6e-09	0.4	0.31	Menopause (age at onset);	chr17:43357824	chr17:43444707~43451200:+
HNSC	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-6.93	1.42e-11	9.62e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
HNSC	cis	rs889014	1	rs7704555	ENSG00000253768.1	CTB-33O18.1	6.93	1.42e-11	9.66e-09	0.33	0.31	Height;	chr5:173572999	chr5:173562478~173573199:+
HNSC	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-6.93	1.42e-11	9.66e-09	-0.34	-0.31	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
HNSC	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.93	1.42e-11	9.66e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
HNSC	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
HNSC	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-6.93	1.43e-11	9.71e-09	-0.39	-0.31	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
HNSC	cis	rs2834288	0.608	rs2017190	ENSG00000237945.6	LINC00649	6.93	1.43e-11	9.72e-09	0.39	0.31	Gut microbiota (bacterial taxa);	chr21:33938609	chr21:33915534~33977691:+
HNSC	cis	rs11089937	0.54	rs9622920	ENSG00000211638.2	IGLV8-61	6.93	1.44e-11	9.75e-09	0.3	0.31	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22098700~22099212:+
HNSC	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	6.93	1.44e-11	9.76e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
HNSC	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	6.92	1.45e-11	9.84e-09	0.41	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
HNSC	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-6.92	1.45e-11	9.84e-09	-0.39	-0.31	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
HNSC	cis	rs11089937	0.568	rs12160317	ENSG00000211638.2	IGLV8-61	-6.92	1.46e-11	9.86e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22098700~22099212:+
HNSC	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-6.92	1.46e-11	9.9e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
HNSC	cis	rs12935418	1	rs62054589	ENSG00000261061.1	RP11-303E16.2	-6.92	1.46e-11	9.9e-09	-0.44	-0.31	Mean corpuscular volume;	chr16:81035143	chr16:81030770~81031485:+
HNSC	cis	rs12935418	1	rs12935418	ENSG00000261061.1	RP11-303E16.2	-6.92	1.46e-11	9.9e-09	-0.44	-0.31	Mean corpuscular volume;	chr16:81036403	chr16:81030770~81031485:+
HNSC	cis	rs7615952	0.599	rs2270986	ENSG00000241288.6	RP11-379B18.5	-6.92	1.47e-11	9.93e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:125982256	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs12496921	ENSG00000241288.6	RP11-379B18.5	-6.92	1.47e-11	9.93e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:125983105	chr3:125827238~125916384:-
HNSC	cis	rs7617773	0.851	rs13068288	ENSG00000228638.1	FCF1P2	-6.92	1.47e-11	9.95e-09	-0.3	-0.31	Coronary artery disease;	chr3:48290261	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	6.92	1.47e-11	9.95e-09	0.22	0.31	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
HNSC	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	6.92	1.47e-11	9.96e-09	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
HNSC	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	6.92	1.47e-11	9.96e-09	0.33	0.31	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	6.92	1.48e-11	1e-08	0.33	0.31	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
HNSC	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	6.92	1.48e-11	1e-08	0.33	0.31	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
HNSC	cis	rs6951245	0.872	rs57068908	ENSG00000225146.1	AC073957.15	-6.92	1.48e-11	1e-08	-0.47	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020448	chr7:1029025~1043891:+
HNSC	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	6.92	1.48e-11	1e-08	0.33	0.31	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
HNSC	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-6.92	1.49e-11	1.01e-08	-0.33	-0.31	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
HNSC	cis	rs2834288	0.5	rs766423	ENSG00000237945.6	LINC00649	6.92	1.49e-11	1.01e-08	0.38	0.3	Gut microbiota (bacterial taxa);	chr21:33962711	chr21:33915534~33977691:+
HNSC	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-6.92	1.5e-11	1.01e-08	-0.31	-0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
HNSC	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	6.92	1.5e-11	1.01e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	6.92	1.5e-11	1.01e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	6.92	1.5e-11	1.01e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
HNSC	cis	rs1355223	0.902	rs1453380	ENSG00000271369.1	RP11-350D17.3	-6.92	1.5e-11	1.01e-08	-0.34	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682135	chr11:34709600~34710161:+
HNSC	cis	rs11089937	0.512	rs6001073	ENSG00000211638.2	IGLV8-61	-6.92	1.5e-11	1.01e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22098700~22099212:+
HNSC	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-6.92	1.51e-11	1.02e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
HNSC	cis	rs5769707	0.681	rs739236	ENSG00000188511.11	C22orf34	6.92	1.51e-11	1.02e-08	0.4	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.681	rs1107514	ENSG00000188511.11	C22orf34	6.92	1.51e-11	1.02e-08	0.4	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-6.92	1.51e-11	1.02e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
HNSC	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	6.92	1.51e-11	1.02e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
HNSC	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-6.92	1.51e-11	1.02e-08	-0.3	-0.3	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
HNSC	cis	rs7615952	0.688	rs12638224	ENSG00000248787.1	RP11-666A20.4	-6.92	1.51e-11	1.02e-08	-0.45	-0.3	Blood pressure (smoking interaction);	chr3:125822477	chr3:125908005~125910272:-
HNSC	cis	rs1799949	0.965	rs12947782	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43127865	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33945274	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43128056	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs33925201	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43128665	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11653069	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43131360	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs33988650	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43135863	chr17:43444707~43451200:+
HNSC	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	6.92	1.51e-11	1.02e-08	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
HNSC	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-6.92	1.51e-11	1.02e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-6.92	1.51e-11	1.02e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-6.92	1.51e-11	1.02e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	6.92	1.52e-11	1.03e-08	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
HNSC	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-6.92	1.52e-11	1.03e-08	-0.36	-0.3	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
HNSC	cis	rs172166	0.637	rs1233691	ENSG00000204709.4	LINC01556	6.92	1.52e-11	1.03e-08	0.38	0.3	Cardiac Troponin-T levels;	chr6:28186119	chr6:28943877~28944537:+
HNSC	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	6.92	1.52e-11	1.03e-08	0.49	0.3	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
HNSC	cis	rs7615952	0.599	rs12486459	ENSG00000241288.6	RP11-379B18.5	-6.92	1.52e-11	1.03e-08	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126022622	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs67575510	ENSG00000241288.6	RP11-379B18.5	-6.92	1.52e-11	1.03e-08	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126023512	chr3:125827238~125916384:-
HNSC	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-6.92	1.53e-11	1.04e-08	-0.3	-0.3	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
HNSC	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	6.92	1.53e-11	1.04e-08	0.34	0.3	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
HNSC	cis	rs17270561	0.609	rs4711097	ENSG00000272462.2	U91328.19	-6.92	1.54e-11	1.04e-08	-0.32	-0.3	Iron status biomarkers;	chr6:25732086	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.608	rs9358875	ENSG00000272462.2	U91328.19	-6.92	1.54e-11	1.04e-08	-0.32	-0.3	Iron status biomarkers;	chr6:25737780	chr6:25992662~26001775:+
HNSC	cis	rs2579103	0.708	rs825981	ENSG00000258183.4	RP11-753N8.1	6.92	1.54e-11	1.04e-08	0.42	0.3	Body mass index;	chr12:90306162	chr12:90280894~90300340:+
HNSC	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-6.92	1.54e-11	1.04e-08	-0.45	-0.3	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
HNSC	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-6.92	1.54e-11	1.04e-08	-0.36	-0.3	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
HNSC	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	6.92	1.54e-11	1.04e-08	0.3	0.3	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
HNSC	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	6.91	1.55e-11	1.04e-08	0.31	0.3	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
HNSC	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	6.91	1.55e-11	1.04e-08	0.35	0.3	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
HNSC	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	6.91	1.55e-11	1.05e-08	0.3	0.3	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
HNSC	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-6.91	1.56e-11	1.05e-08	-0.32	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
HNSC	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-6.91	1.56e-11	1.05e-08	-0.4	-0.3	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
HNSC	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	6.91	1.56e-11	1.05e-08	0.36	0.3	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
HNSC	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	6.91	1.56e-11	1.05e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
HNSC	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	6.91	1.56e-11	1.05e-08	0.36	0.3	Depression;	chr6:28407125	chr6:28176188~28176674:+
HNSC	cis	rs4218	1	rs4218	ENSG00000259732.1	RP11-59H7.3	-6.91	1.56e-11	1.05e-08	-0.39	-0.3	Social communication problems;	chr15:59136459	chr15:59121034~59133250:+
HNSC	cis	rs9326248	0.52	rs2735183	ENSG00000280143.1	AP000892.6	6.91	1.57e-11	1.06e-08	0.31	0.3	Blood protein levels;	chr11:117144479	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	6.91	1.57e-11	1.06e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000254340.1	RP11-10A14.3	-6.91	1.57e-11	1.06e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9037242	chr8:9141424~9145435:+
HNSC	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-6.91	1.57e-11	1.06e-08	-0.38	-0.3	QT interval;	chr16:28845498	chr16:28700294~28701540:-
HNSC	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-6.91	1.57e-11	1.06e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
HNSC	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-6.91	1.57e-11	1.06e-08	-0.39	-0.3	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
HNSC	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	6.91	1.58e-11	1.06e-08	0.36	0.3	Depression;	chr6:28431469	chr6:28176188~28176674:+
HNSC	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	6.91	1.58e-11	1.06e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	6.91	1.58e-11	1.06e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
HNSC	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	6.91	1.58e-11	1.06e-08	0.44	0.3	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
HNSC	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-6.91	1.58e-11	1.07e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
HNSC	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	6.91	1.58e-11	1.07e-08	0.45	0.3	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-6.91	1.59e-11	1.07e-08	-0.27	-0.3	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-6.91	1.59e-11	1.07e-08	-0.27	-0.3	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
HNSC	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-6.91	1.6e-11	1.08e-08	-0.39	-0.3	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
HNSC	cis	rs11089937	0.568	rs12160318	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.08e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs12159174	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.08e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs11089919	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.08e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22098700~22099212:+
HNSC	cis	rs2579103	0.708	rs1103370	ENSG00000258183.4	RP11-753N8.1	-6.91	1.61e-11	1.08e-08	-0.42	-0.3	Body mass index;	chr12:90307356	chr12:90280894~90300340:+
HNSC	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	6.91	1.61e-11	1.08e-08	0.34	0.3	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
HNSC	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-6.91	1.61e-11	1.08e-08	-0.31	-0.3	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
HNSC	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-6.91	1.61e-11	1.08e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.553	rs35336247	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.09e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.553	rs34088081	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.09e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22098700~22099212:+
HNSC	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	6.91	1.62e-11	1.09e-08	0.36	0.3	Depression;	chr6:28430971	chr6:28176188~28176674:+
HNSC	cis	rs17507216	0.628	rs8028130	ENSG00000255769.6	GOLGA2P10	-6.91	1.63e-11	1.09e-08	-0.48	-0.3	Excessive daytime sleepiness;	chr15:82734974	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-6.91	1.64e-11	1.1e-08	-0.33	-0.3	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-6.91	1.64e-11	1.1e-08	-0.33	-0.3	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
HNSC	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	6.91	1.64e-11	1.1e-08	0.43	0.3	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
HNSC	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-6.91	1.64e-11	1.1e-08	-0.37	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
HNSC	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	6.91	1.64e-11	1.1e-08	0.43	0.3	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	6.91	1.64e-11	1.1e-08	0.22	0.3	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	6.91	1.64e-11	1.1e-08	0.22	0.3	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
HNSC	cis	rs6471393	0.964	rs2976366	ENSG00000253848.1	RP11-10N23.5	-6.9	1.65e-11	1.11e-08	-0.37	-0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93708829	chr8:93741193~93744534:+
HNSC	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-6.9	1.65e-11	1.11e-08	-0.35	-0.3	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
HNSC	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	6.9	1.66e-11	1.12e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
HNSC	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-6.9	1.66e-11	1.12e-08	-0.43	-0.3	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000173295.6	FAM86B3P	6.9	1.66e-11	1.12e-08	0.35	0.3	Joint mobility (Beighton score);	chr8:9009901	chr8:8228595~8244865:+
HNSC	cis	rs1659258	0.772	rs1659265	ENSG00000232508.1	MRPL45P1	6.9	1.66e-11	1.12e-08	0.65	0.3	Visceral fat;	chr2:88363231	chr2:88364695~88365608:-
HNSC	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-6.9	1.67e-11	1.12e-08	-0.36	-0.3	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
HNSC	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	6.9	1.68e-11	1.13e-08	0.39	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
HNSC	cis	rs7615952	0.688	rs12638240	ENSG00000248787.1	RP11-666A20.4	-6.9	1.68e-11	1.13e-08	-0.45	-0.3	Blood pressure (smoking interaction);	chr3:125822395	chr3:125908005~125910272:-
HNSC	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	6.9	1.69e-11	1.13e-08	0.31	0.3	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
HNSC	cis	rs6951245	1	rs11763020	ENSG00000225146.1	AC073957.15	-6.9	1.69e-11	1.14e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020652	chr7:1029025~1043891:+
HNSC	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-6.9	1.69e-11	1.14e-08	-0.35	-0.3	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
HNSC	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-6.9	1.7e-11	1.14e-08	-0.31	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
HNSC	cis	rs1799949	1	rs8070085	ENSG00000267151.3	RP11-100E5.2	-6.9	1.7e-11	1.14e-08	-0.4	-0.3	Menopause (age at onset);	chr17:43189967	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-6.9	1.7e-11	1.14e-08	-0.33	-0.3	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-6.9	1.7e-11	1.14e-08	-0.39	-0.3	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-6.9	1.7e-11	1.14e-08	-0.39	-0.3	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
HNSC	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	6.9	1.7e-11	1.14e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
HNSC	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-6.9	1.71e-11	1.15e-08	-0.37	-0.3	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
HNSC	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	6.9	1.72e-11	1.15e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
HNSC	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	6.9	1.72e-11	1.15e-08	0.37	0.3	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-6.9	1.72e-11	1.16e-08	-0.36	-0.3	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
HNSC	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	6.9	1.72e-11	1.16e-08	0.43	0.3	Height;	chr6:109387972	chr6:109382795~109383666:+
HNSC	cis	rs1021993	0.545	rs79950910	ENSG00000231648.1	RP11-372M18.2	-6.9	1.73e-11	1.16e-08	-0.53	-0.3	Gut microbiome composition (winter);	chr1:209344553	chr1:209367662~209379690:+
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	6.9	1.73e-11	1.16e-08	0.43	0.3	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
HNSC	cis	rs35955747	0.807	rs9619169	ENSG00000236132.1	CTA-440B3.1	6.9	1.73e-11	1.16e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31141356	chr22:31816379~31817491:-
HNSC	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
HNSC	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-6.9	1.73e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-6.9	1.73e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-6.9	1.73e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
HNSC	cis	rs1799949	0.93	rs8176194	ENSG00000267151.3	RP11-100E5.2	6.9	1.73e-11	1.16e-08	0.4	0.3	Menopause (age at onset);	chr17:43079204	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1060915	ENSG00000267151.3	RP11-100E5.2	6.9	1.73e-11	1.16e-08	0.4	0.3	Menopause (age at onset);	chr17:43082453	chr17:43444707~43451200:+
HNSC	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	6.9	1.74e-11	1.16e-08	0.32	0.3	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
HNSC	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	6.9	1.74e-11	1.17e-08	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
HNSC	cis	rs1799949	1	rs8176273	ENSG00000267151.3	RP11-100E5.2	6.9	1.74e-11	1.17e-08	0.4	0.3	Menopause (age at onset);	chr17:43059636	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176269	ENSG00000267151.3	RP11-100E5.2	6.9	1.74e-11	1.17e-08	0.4	0.3	Menopause (age at onset);	chr17:43061609	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176265	ENSG00000267151.3	RP11-100E5.2	6.9	1.74e-11	1.17e-08	0.4	0.3	Menopause (age at onset);	chr17:43061979	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	6.9	1.75e-11	1.17e-08	0.21	0.3	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
HNSC	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	6.9	1.75e-11	1.17e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
HNSC	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-6.9	1.75e-11	1.17e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
HNSC	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.75e-11	1.17e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.75e-11	1.17e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
HNSC	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-6.9	1.76e-11	1.18e-08	-0.39	-0.3	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.76e-11	1.18e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.76e-11	1.18e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	6.89	1.76e-11	1.18e-08	0.37	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
HNSC	cis	rs4218	0.597	rs12442301	ENSG00000259732.1	RP11-59H7.3	-6.89	1.77e-11	1.18e-08	-0.43	-0.3	Social communication problems;	chr15:59065968	chr15:59121034~59133250:+
HNSC	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	6.89	1.77e-11	1.18e-08	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
HNSC	cis	rs11089937	0.597	rs9619794	ENSG00000211638.2	IGLV8-61	-6.89	1.77e-11	1.19e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22098700~22099212:+
HNSC	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	6.89	1.77e-11	1.19e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
HNSC	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	6.89	1.77e-11	1.19e-08	0.37	0.3	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
HNSC	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-6.89	1.77e-11	1.19e-08	-0.33	-0.3	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
HNSC	cis	rs36405	0.5	rs11621704	ENSG00000266869.1	RP6-114E22.1	-6.89	1.77e-11	1.19e-08	-0.39	-0.3	Yang-deficiency constitution;	chr14:71888476	chr14:71848606~71908430:+
HNSC	cis	rs2286503	0.752	rs59538378	ENSG00000228649.7	AC005682.5	6.89	1.77e-11	1.19e-08	0.33	0.3	Fibrinogen;	chr7:22837478	chr7:22854178~22861579:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-6.89	1.77e-11	1.19e-08	-0.35	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
HNSC	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-6.89	1.77e-11	1.19e-08	-0.31	-0.3	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
HNSC	cis	rs2579103	0.708	rs2731256	ENSG00000258183.4	RP11-753N8.1	-6.89	1.78e-11	1.19e-08	-0.42	-0.3	Body mass index;	chr12:90289196	chr12:90280894~90300340:+
HNSC	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	6.89	1.78e-11	1.19e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
HNSC	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	6.89	1.78e-11	1.19e-08	0.43	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
HNSC	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-6.89	1.78e-11	1.19e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
HNSC	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	6.89	1.78e-11	1.19e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	6.89	1.78e-11	1.19e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
HNSC	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-6.89	1.8e-11	1.2e-08	-0.33	-0.3	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
HNSC	cis	rs9402743	0.781	rs2273069	ENSG00000217482.2	HMGB1P17	6.89	1.8e-11	1.2e-08	0.35	0.3	Systemic lupus erythematosus;	chr6:135689660	chr6:135636086~135636713:-
HNSC	cis	rs11089937	0.597	rs4821774	ENSG00000211638.2	IGLV8-61	-6.89	1.8e-11	1.21e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22098700~22099212:+
HNSC	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-6.89	1.81e-11	1.21e-08	-0.39	-0.3	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
HNSC	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	6.89	1.83e-11	1.22e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
HNSC	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-6.89	1.84e-11	1.23e-08	-0.51	-0.3	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-6.89	1.84e-11	1.23e-08	-0.51	-0.3	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-6.89	1.84e-11	1.23e-08	-0.51	-0.3	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
HNSC	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-6.89	1.84e-11	1.23e-08	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
HNSC	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-6.89	1.84e-11	1.23e-08	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
HNSC	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-6.89	1.84e-11	1.23e-08	-0.45	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
HNSC	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	6.89	1.84e-11	1.23e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
HNSC	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-6.89	1.85e-11	1.24e-08	-0.48	-0.3	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
HNSC	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-6.89	1.85e-11	1.24e-08	-0.35	-0.3	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
HNSC	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-6.89	1.86e-11	1.24e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-6.89	1.86e-11	1.24e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
HNSC	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	6.89	1.86e-11	1.24e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
HNSC	cis	rs10791097	1	rs10791097	ENSG00000254842.5	RP11-890B15.2	6.89	1.86e-11	1.24e-08	0.26	0.3	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848735	chr11:130844191~130865561:-
HNSC	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	6.89	1.86e-11	1.24e-08	0.44	0.3	Height;	chr6:109381443	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-6.89	1.86e-11	1.24e-08	-0.32	-0.3	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
HNSC	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	6.89	1.87e-11	1.25e-08	0.35	0.3	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000254340.1	RP11-10A14.3	-6.89	1.87e-11	1.25e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9033292	chr8:9141424~9145435:+
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000254340.1	RP11-10A14.3	-6.89	1.87e-11	1.25e-08	-0.37	-0.3	Myopia (pathological);Myopia;	chr8:9033866	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-6.88	1.87e-11	1.25e-08	-0.33	-0.3	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
HNSC	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-6.88	1.88e-11	1.26e-08	-0.37	-0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
HNSC	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	6.88	1.88e-11	1.26e-08	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
HNSC	cis	rs9341808	0.935	rs2298307	ENSG00000272129.1	RP11-250B2.6	6.88	1.88e-11	1.26e-08	0.36	0.3	Sitting height ratio;	chr6:80106579	chr6:80355424~80356859:+
HNSC	cis	rs394563	0.591	rs805026	ENSG00000231760.4	RP11-350J20.5	6.88	1.89e-11	1.26e-08	0.37	0.3	Dupuytren's disease;	chr6:149407118	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-6.88	1.89e-11	1.26e-08	-0.33	-0.3	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
HNSC	cis	rs6471393	0.929	rs62525164	ENSG00000253848.1	RP11-10N23.5	6.88	1.89e-11	1.26e-08	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93750084	chr8:93741193~93744534:+
HNSC	cis	rs1799949	0.965	rs12950779	ENSG00000267151.3	RP11-100E5.2	6.88	1.89e-11	1.26e-08	0.39	0.3	Menopause (age at onset);	chr17:43154506	chr17:43444707~43451200:+
HNSC	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	6.88	1.89e-11	1.26e-08	0.44	0.3	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
HNSC	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-6.88	1.89e-11	1.26e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-6.88	1.89e-11	1.26e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
HNSC	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-6.88	1.9e-11	1.26e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000173295.6	FAM86B3P	-6.88	1.9e-11	1.26e-08	-0.33	-0.3	Myopia (pathological);	chr8:9111923	chr8:8228595~8244865:+
HNSC	cis	rs7083	0.875	rs536648	ENSG00000254851.1	RP11-109L13.1	6.88	1.9e-11	1.27e-08	0.39	0.3	Blood protein levels;	chr11:117272469	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	6.88	1.9e-11	1.27e-08	0.28	0.3	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	6.88	1.9e-11	1.27e-08	0.28	0.3	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	6.88	1.91e-11	1.27e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
HNSC	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-6.88	1.91e-11	1.28e-08	-0.48	-0.3	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
HNSC	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-6.88	1.91e-11	1.28e-08	-0.48	-0.3	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
HNSC	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	6.88	1.91e-11	1.28e-08	0.34	0.3	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000254340.1	RP11-10A14.3	-6.88	1.92e-11	1.28e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9028444	chr8:9141424~9145435:+
HNSC	cis	rs6951245	1	rs11764748	ENSG00000224079.1	AC091729.7	-6.88	1.92e-11	1.28e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1074450~1078036:+
HNSC	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	6.88	1.92e-11	1.28e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
HNSC	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	6.88	1.92e-11	1.28e-08	0.35	0.3	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
HNSC	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	6.88	1.93e-11	1.28e-08	0.37	0.3	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	6.88	1.93e-11	1.28e-08	0.37	0.3	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
HNSC	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	6.88	1.93e-11	1.28e-08	0.36	0.3	Height;	chr4:55370412	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	6.88	1.93e-11	1.28e-08	0.43	0.3	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	6.88	1.93e-11	1.28e-08	0.43	0.3	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
HNSC	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	6.88	1.93e-11	1.29e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
HNSC	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-6.88	1.93e-11	1.29e-08	-0.33	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
HNSC	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-6.88	1.94e-11	1.29e-08	-0.48	-0.3	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
HNSC	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-6.88	1.94e-11	1.29e-08	-0.34	-0.3	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
HNSC	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-6.88	1.95e-11	1.3e-08	-0.33	-0.3	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
HNSC	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	6.88	1.96e-11	1.3e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
HNSC	cis	rs394563	0.591	rs6570963	ENSG00000231760.4	RP11-350J20.5	-6.88	1.96e-11	1.3e-08	-0.38	-0.3	Dupuytren's disease;	chr6:149370219	chr6:149796151~149826294:-
HNSC	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	6.88	1.96e-11	1.3e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
HNSC	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-6.88	1.96e-11	1.3e-08	-0.35	-0.3	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
HNSC	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	6.88	1.96e-11	1.3e-08	0.29	0.3	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
HNSC	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-6.88	1.96e-11	1.31e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
HNSC	cis	rs1799949	0.93	rs3092987	ENSG00000267151.3	RP11-100E5.2	6.88	1.97e-11	1.31e-08	0.39	0.3	Menopause (age at onset);	chr17:43070706	chr17:43444707~43451200:+
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000254340.1	RP11-10A14.3	-6.88	1.97e-11	1.31e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9026993	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-6.88	1.98e-11	1.32e-08	-0.33	-0.3	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.735	rs4886800	ENSG00000259422.1	RP11-593F23.1	-6.88	1.98e-11	1.32e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76386351	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs8176242	ENSG00000267151.3	RP11-100E5.2	6.88	1.99e-11	1.32e-08	0.39	0.3	Menopause (age at onset);	chr17:43065857	chr17:43444707~43451200:+
HNSC	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-6.88	1.99e-11	1.32e-08	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
HNSC	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	6.88	1.99e-11	1.33e-08	0.43	0.3	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
HNSC	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	6.87	2.01e-11	1.33e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
HNSC	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-6.87	2.01e-11	1.33e-08	-0.42	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
HNSC	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	6.87	2.01e-11	1.34e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
HNSC	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-6.87	2.01e-11	1.34e-08	-0.38	-0.3	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
HNSC	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	6.87	2.03e-11	1.35e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
HNSC	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	6.87	2.03e-11	1.35e-08	0.36	0.3	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
HNSC	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	6.87	2.03e-11	1.35e-08	0.39	0.3	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
HNSC	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-6.87	2.03e-11	1.35e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
HNSC	cis	rs1021993	1	rs2660640	ENSG00000231648.1	RP11-372M18.2	6.87	2.04e-11	1.36e-08	0.41	0.3	Gut microbiome composition (winter);	chr1:209336845	chr1:209367662~209379690:+
HNSC	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-6.87	2.04e-11	1.36e-08	-0.41	-0.3	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
HNSC	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-6.87	2.05e-11	1.36e-08	-0.39	-0.3	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-6.87	2.05e-11	1.36e-08	-0.39	-0.3	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
HNSC	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	6.87	2.06e-11	1.37e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
HNSC	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	6.87	2.06e-11	1.37e-08	0.3	0.3	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
HNSC	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-6.87	2.06e-11	1.37e-08	-0.46	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
HNSC	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	6.87	2.06e-11	1.37e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
HNSC	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-6.87	2.06e-11	1.37e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
HNSC	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-6.87	2.06e-11	1.37e-08	-0.35	-0.3	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-6.87	2.07e-11	1.37e-08	-0.39	-0.3	Depression;	chr6:28229408	chr6:28115628~28116551:+
HNSC	cis	rs11089937	0.539	rs6001075	ENSG00000211638.2	IGLV8-61	-6.87	2.07e-11	1.37e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs6001076	ENSG00000211638.2	IGLV8-61	-6.87	2.07e-11	1.37e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs5995560	ENSG00000211638.2	IGLV8-61	-6.87	2.07e-11	1.37e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22098700~22099212:+
HNSC	cis	rs394563	0.591	rs6570964	ENSG00000231760.4	RP11-350J20.5	-6.87	2.08e-11	1.38e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149370723	chr6:149796151~149826294:-
HNSC	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
HNSC	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-6.87	2.08e-11	1.38e-08	-0.28	-0.3	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-6.87	2.08e-11	1.38e-08	-0.28	-0.3	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	6.87	2.09e-11	1.38e-08	0.37	0.3	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
HNSC	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-6.87	2.09e-11	1.39e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
HNSC	cis	rs2579103	0.729	rs1344964	ENSG00000258183.4	RP11-753N8.1	-6.87	2.09e-11	1.39e-08	-0.39	-0.3	Body mass index;	chr12:90276876	chr12:90280894~90300340:+
HNSC	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-6.87	2.1e-11	1.39e-08	-0.31	-0.3	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
HNSC	cis	rs6471393	0.895	rs4255106	ENSG00000253848.1	RP11-10N23.5	6.87	2.1e-11	1.39e-08	0.36	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93766367	chr8:93741193~93744534:+
HNSC	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	6.87	2.1e-11	1.39e-08	0.45	0.3	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
HNSC	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	6.87	2.1e-11	1.39e-08	0.78	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
HNSC	cis	rs11089937	0.512	rs13054756	ENSG00000211638.2	IGLV8-61	-6.87	2.1e-11	1.39e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22098700~22099212:+
HNSC	cis	rs17270561	0.609	rs7754296	ENSG00000272462.2	U91328.19	-6.87	2.11e-11	1.4e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25744650	chr6:25992662~26001775:+
HNSC	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	6.87	2.11e-11	1.4e-08	0.43	0.3	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs3092988	ENSG00000267151.3	RP11-100E5.2	6.87	2.12e-11	1.4e-08	0.4	0.3	Menopause (age at onset);	chr17:43049685	chr17:43444707~43451200:+
HNSC	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.4e-08	-0.4	-0.3	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.4e-08	-0.4	-0.3	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.4e-08	-0.4	-0.3	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.41e-08	-0.39	-0.3	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
HNSC	cis	rs11089937	0.597	rs4821770	ENSG00000211638.2	IGLV8-61	-6.87	2.12e-11	1.41e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs4821771	ENSG00000211638.2	IGLV8-61	-6.87	2.12e-11	1.41e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22098700~22099212:+
HNSC	cis	rs4218	0.597	rs12438962	ENSG00000259732.1	RP11-59H7.3	-6.86	2.13e-11	1.41e-08	-0.43	-0.3	Social communication problems;	chr15:59065694	chr15:59121034~59133250:+
HNSC	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-6.86	2.13e-11	1.41e-08	-0.48	-0.3	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
HNSC	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	6.86	2.13e-11	1.41e-08	0.42	0.3	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
HNSC	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	6.86	2.14e-11	1.42e-08	0.38	0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
HNSC	cis	rs1021993	0.545	rs74155473	ENSG00000231648.1	RP11-372M18.2	-6.86	2.14e-11	1.42e-08	-0.5	-0.3	Gut microbiome composition (winter);	chr1:209372518	chr1:209367662~209379690:+
HNSC	cis	rs9326248	0.53	rs588918	ENSG00000280143.1	AP000892.6	6.86	2.14e-11	1.42e-08	0.44	0.3	Blood protein levels;	chr11:116985926	chr11:117204967~117210292:+
HNSC	cis	rs4218	0.551	rs12906212	ENSG00000259732.1	RP11-59H7.3	-6.86	2.14e-11	1.42e-08	-0.44	-0.3	Social communication problems;	chr15:59070556	chr15:59121034~59133250:+
HNSC	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-6.86	2.15e-11	1.42e-08	-0.33	-0.3	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
HNSC	cis	rs62344088	0.744	rs76038312	ENSG00000277812.1	AC021087.1	6.86	2.15e-11	1.42e-08	0.76	0.3	Asthma (childhood onset);	chr5:228890	chr5:262769~262881:+
HNSC	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	6.86	2.15e-11	1.42e-08	0.43	0.3	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
HNSC	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	6.86	2.15e-11	1.42e-08	0.28	0.3	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	6.86	2.15e-11	1.42e-08	0.36	0.3	Depression;	chr6:28432562	chr6:28176188~28176674:+
HNSC	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-6.86	2.16e-11	1.43e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
HNSC	cis	rs2834288	0.536	rs762356	ENSG00000237945.6	LINC00649	6.86	2.16e-11	1.43e-08	0.38	0.3	Gut microbiota (bacterial taxa);	chr21:33964582	chr21:33915534~33977691:+
HNSC	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-6.86	2.16e-11	1.43e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
HNSC	cis	rs2579103	0.767	rs1371084	ENSG00000258183.4	RP11-753N8.1	-6.86	2.17e-11	1.43e-08	-0.39	-0.3	Body mass index;	chr12:90273990	chr12:90280894~90300340:+
HNSC	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-6.86	2.17e-11	1.44e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
HNSC	cis	rs7615952	0.673	rs35955861	ENSG00000241288.6	RP11-379B18.5	-6.86	2.17e-11	1.44e-08	-0.51	-0.3	Blood pressure (smoking interaction);	chr3:125907358	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.673	rs35001498	ENSG00000241288.6	RP11-379B18.5	-6.86	2.17e-11	1.44e-08	-0.51	-0.3	Blood pressure (smoking interaction);	chr3:125909801	chr3:125827238~125916384:-
HNSC	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-6.86	2.17e-11	1.44e-08	-0.45	-0.3	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.895	rs5756985	ENSG00000211638.2	IGLV8-61	-6.86	2.18e-11	1.44e-08	-0.26	-0.3	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs4821773	ENSG00000211638.2	IGLV8-61	-6.86	2.19e-11	1.45e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22098700~22099212:+
HNSC	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	6.86	2.19e-11	1.45e-08	0.44	0.3	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
HNSC	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-6.86	2.19e-11	1.45e-08	-0.38	-0.3	Height;	chr3:53070344	chr3:53064283~53065091:-
HNSC	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-6.86	2.2e-11	1.46e-08	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
HNSC	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-6.86	2.2e-11	1.46e-08	-0.49	-0.3	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
HNSC	cis	rs673078	0.66	rs73220119	ENSG00000275409.1	RP11-131L12.4	-6.86	2.21e-11	1.46e-08	-0.5	-0.3	Glucose homeostasis traits;	chr12:118159864	chr12:118430147~118430699:+
HNSC	cis	rs853679	1	rs1778508	ENSG00000219392.1	RP1-265C24.5	6.86	2.21e-11	1.46e-08	0.45	0.3	Depression;	chr6:28262103	chr6:28115628~28116551:+
HNSC	cis	rs2239557	0.608	rs2041186	ENSG00000259065.1	RP5-1021I20.1	-6.86	2.21e-11	1.46e-08	-0.37	-0.3	Common traits (Other);	chr14:73815334	chr14:73787360~73803270:+
HNSC	cis	rs6951245	0.706	rs28685743	ENSG00000224079.1	AC091729.7	-6.86	2.21e-11	1.46e-08	-0.51	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1074450~1078036:+
HNSC	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	6.86	2.22e-11	1.46e-08	0.61	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
HNSC	cis	rs4218	0.597	rs62002544	ENSG00000259732.1	RP11-59H7.3	-6.86	2.22e-11	1.47e-08	-0.44	-0.3	Social communication problems;	chr15:59066663	chr15:59121034~59133250:+
HNSC	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	6.86	2.23e-11	1.47e-08	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
HNSC	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	6.86	2.23e-11	1.47e-08	0.29	0.3	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
HNSC	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	6.86	2.23e-11	1.48e-08	0.29	0.3	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	6.86	2.23e-11	1.48e-08	0.29	0.3	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
HNSC	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	6.86	2.24e-11	1.48e-08	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
HNSC	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	6.86	2.24e-11	1.48e-08	0.41	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
HNSC	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	6.86	2.24e-11	1.48e-08	0.35	0.3	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
HNSC	cis	rs1815787	1	rs1815787	ENSG00000280143.1	AP000892.6	6.86	2.24e-11	1.48e-08	0.44	0.3	Subjective well-being;	chr11:117050681	chr11:117204967~117210292:+
HNSC	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	6.86	2.24e-11	1.48e-08	0.38	0.3	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
HNSC	cis	rs75422866	0.85	rs73111212	ENSG00000274902.1	RP1-197B17.4	6.86	2.25e-11	1.48e-08	0.78	0.3	Pneumonia;	chr12:47577638	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.85	rs73111216	ENSG00000274902.1	RP1-197B17.4	6.86	2.25e-11	1.48e-08	0.78	0.3	Pneumonia;	chr12:47577671	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.85	rs73111217	ENSG00000274902.1	RP1-197B17.4	6.86	2.25e-11	1.48e-08	0.78	0.3	Pneumonia;	chr12:47577693	chr12:47731908~47732351:+
HNSC	cis	rs9402743	0.816	rs9494335	ENSG00000217482.2	HMGB1P17	-6.86	2.25e-11	1.49e-08	-0.33	-0.3	Systemic lupus erythematosus;	chr6:135690726	chr6:135636086~135636713:-
HNSC	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	6.86	2.25e-11	1.49e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
HNSC	cis	rs17270561	0.609	rs9358878	ENSG00000272462.2	U91328.19	-6.86	2.26e-11	1.49e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25740045	chr6:25992662~26001775:+
HNSC	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-6.86	2.26e-11	1.49e-08	-0.55	-0.3	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-6.86	2.26e-11	1.49e-08	-0.55	-0.3	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000254340.1	RP11-10A14.3	-6.86	2.26e-11	1.49e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9041808	chr8:9141424~9145435:+
HNSC	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	6.85	2.27e-11	1.5e-08	0.34	0.3	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
HNSC	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	6.85	2.27e-11	1.5e-08	0.23	0.3	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
HNSC	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	6.85	2.27e-11	1.5e-08	0.23	0.3	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
HNSC	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	6.85	2.27e-11	1.5e-08	0.43	0.3	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
HNSC	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	6.85	2.27e-11	1.5e-08	0.48	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	6.85	2.27e-11	1.5e-08	0.48	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
HNSC	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	6.85	2.27e-11	1.5e-08	0.36	0.3	Depression;	chr6:28402301	chr6:28176188~28176674:+
HNSC	cis	rs889014	1	rs7733195	ENSG00000253768.1	CTB-33O18.1	6.85	2.28e-11	1.51e-08	0.32	0.3	Height;	chr5:173567621	chr5:173562478~173573199:+
HNSC	cis	rs7829975	1	rs7829975	ENSG00000173295.6	FAM86B3P	-6.85	2.29e-11	1.51e-08	-0.35	-0.3	Mood instability;	chr8:8690607	chr8:8228595~8244865:+
HNSC	cis	rs11089937	0.597	rs4821768	ENSG00000211638.2	IGLV8-61	-6.85	2.3e-11	1.52e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22098700~22099212:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
HNSC	cis	rs7048146	0.715	rs34983370	ENSG00000213539.4	YBX1P6	6.85	2.31e-11	1.53e-08	0.36	0.3	Vascular brain injury;	chr9:109586983	chr9:109532830~109534332:-
HNSC	cis	rs1799949	1	rs33926631	ENSG00000267151.3	RP11-100E5.2	6.85	2.32e-11	1.53e-08	0.38	0.3	Menopause (age at onset);	chr17:43152446	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1960605	ENSG00000267151.3	RP11-100E5.2	6.85	2.32e-11	1.53e-08	0.38	0.3	Menopause (age at onset);	chr17:43153380	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs2037076	ENSG00000267151.3	RP11-100E5.2	6.85	2.32e-11	1.53e-08	0.38	0.3	Menopause (age at onset);	chr17:43153866	chr17:43444707~43451200:+
HNSC	cis	rs2579103	0.708	rs2731260	ENSG00000258183.4	RP11-753N8.1	-6.85	2.32e-11	1.53e-08	-0.42	-0.3	Body mass index;	chr12:90283433	chr12:90280894~90300340:+
HNSC	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	6.85	2.32e-11	1.53e-08	0.36	0.3	Depression;	chr6:28399846	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	6.85	2.32e-11	1.53e-08	0.38	0.3	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
HNSC	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	6.85	2.33e-11	1.53e-08	0.36	0.3	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	6.85	2.33e-11	1.53e-08	0.36	0.3	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
HNSC	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-6.85	2.33e-11	1.53e-08	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
HNSC	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.34e-11	1.54e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.34e-11	1.54e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.34e-11	1.54e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
HNSC	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-6.85	2.34e-11	1.55e-08	-0.44	-0.3	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
HNSC	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-6.85	2.35e-11	1.55e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
HNSC	cis	rs2579103	0.595	rs7301703	ENSG00000258183.4	RP11-753N8.1	-6.85	2.35e-11	1.55e-08	-0.39	-0.3	Body mass index;	chr12:90313548	chr12:90280894~90300340:+
HNSC	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	6.85	2.35e-11	1.55e-08	0.32	0.3	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-6.85	2.35e-11	1.55e-08	-0.21	-0.3	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
HNSC	cis	rs6600671	0.764	rs6600673	ENSG00000270231.3	NBPF8P	6.85	2.36e-11	1.55e-08	0.25	0.3	Hip geometry;	chr1:121426988	chr1:120436353~120467739:+
HNSC	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	6.85	2.36e-11	1.55e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
HNSC	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-6.85	2.36e-11	1.56e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
HNSC	cis	rs453301	0.507	rs2929306	ENSG00000173295.6	FAM86B3P	-6.85	2.37e-11	1.56e-08	-0.33	-0.3	Joint mobility (Beighton score);	chr8:9227399	chr8:8228595~8244865:+
HNSC	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-6.85	2.37e-11	1.56e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-6.85	2.37e-11	1.56e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
HNSC	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	6.85	2.37e-11	1.56e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
HNSC	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-6.85	2.38e-11	1.56e-08	-0.42	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
HNSC	cis	rs1799810	0.899	rs6753288	ENSG00000236682.1	AC068282.3	-6.85	2.39e-11	1.57e-08	-0.36	-0.3	Self-rated health;	chr2:127412323	chr2:127389130~127400580:+
HNSC	cis	rs7115242	0.8	rs7931770	ENSG00000280143.1	AP000892.6	6.85	2.39e-11	1.57e-08	0.44	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117204967~117210292:+
HNSC	cis	rs7115242	0.8	rs4245168	ENSG00000280143.1	AP000892.6	6.85	2.39e-11	1.57e-08	0.44	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs7122944	ENSG00000280143.1	AP000892.6	6.85	2.4e-11	1.58e-08	0.46	0.3	Blood protein levels;	chr11:117163903	chr11:117204967~117210292:+
HNSC	cis	rs7115242	0.514	rs4936367	ENSG00000280143.1	AP000892.6	6.85	2.4e-11	1.58e-08	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs4604928	ENSG00000280143.1	AP000892.6	6.85	2.4e-11	1.58e-08	0.46	0.3	Blood protein levels;	chr11:117173487	chr11:117204967~117210292:+
HNSC	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-6.85	2.4e-11	1.58e-08	-0.37	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
HNSC	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-6.85	2.41e-11	1.58e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000254340.1	RP11-10A14.3	-6.85	2.41e-11	1.58e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9032531	chr8:9141424~9145435:+
HNSC	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	6.85	2.41e-11	1.59e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
HNSC	cis	rs2579103	0.63	rs1222610	ENSG00000258183.4	RP11-753N8.1	-6.85	2.41e-11	1.59e-08	-0.41	-0.3	Body mass index;	chr12:90315578	chr12:90280894~90300340:+
HNSC	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	6.84	2.41e-11	1.59e-08	0.32	0.3	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
HNSC	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	6.84	2.44e-11	1.6e-08	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
HNSC	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-6.84	2.44e-11	1.61e-08	-0.56	-0.3	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
HNSC	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-6.84	2.44e-11	1.61e-08	-0.29	-0.3	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
HNSC	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	6.84	2.45e-11	1.61e-08	0.43	0.3	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
HNSC	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-6.84	2.46e-11	1.61e-08	-0.39	-0.3	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
HNSC	cis	rs9326248	0.53	rs7124741	ENSG00000280143.1	AP000892.6	6.84	2.46e-11	1.62e-08	0.47	0.3	Blood protein levels;	chr11:116881503	chr11:117204967~117210292:+
HNSC	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-6.84	2.47e-11	1.62e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	6.84	2.47e-11	1.63e-08	0.43	0.3	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-6.84	2.48e-11	1.63e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
HNSC	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	6.84	2.48e-11	1.63e-08	0.3	0.3	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
HNSC	cis	rs6471393	0.929	rs62525163	ENSG00000253848.1	RP11-10N23.5	6.84	2.48e-11	1.63e-08	0.36	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749824	chr8:93741193~93744534:+
HNSC	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-6.84	2.48e-11	1.63e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-6.84	2.48e-11	1.63e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
HNSC	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	6.84	2.49e-11	1.63e-08	0.34	0.3	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	6.84	2.49e-11	1.63e-08	0.34	0.3	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
HNSC	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	6.84	2.49e-11	1.64e-08	0.36	0.3	Depression;	chr6:28327262	chr6:28943877~28944537:+
HNSC	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	6.84	2.49e-11	1.64e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
HNSC	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-6.84	2.49e-11	1.64e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-6.84	2.49e-11	1.64e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-6.84	2.49e-11	1.64e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
HNSC	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-6.84	2.5e-11	1.64e-08	-0.3	-0.3	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
HNSC	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-6.84	2.5e-11	1.64e-08	-0.37	-0.3	Height;	chr4:55593918	chr4:55363971~55395847:-
HNSC	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-6.84	2.52e-11	1.65e-08	-0.27	-0.3	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
HNSC	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-6.84	2.52e-11	1.65e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
HNSC	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	6.84	2.52e-11	1.65e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
HNSC	cis	rs6504622	0.818	rs9898527	ENSG00000262879.4	RP11-156P1.3	6.84	2.53e-11	1.66e-08	0.31	0.3	Orofacial clefts;	chr17:46958844	chr17:46984045~47100323:-
HNSC	cis	rs17270561	0.609	rs6941933	ENSG00000272462.2	U91328.19	-6.84	2.53e-11	1.66e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745474	chr6:25992662~26001775:+
HNSC	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	6.84	2.54e-11	1.67e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
HNSC	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	6.84	2.54e-11	1.67e-08	0.38	0.3	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	6.84	2.54e-11	1.67e-08	0.38	0.3	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	6.84	2.54e-11	1.67e-08	0.38	0.3	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
HNSC	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	6.84	2.55e-11	1.67e-08	0.43	0.3	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
HNSC	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-6.84	2.55e-11	1.67e-08	-0.47	-0.3	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
HNSC	cis	rs172166	0.637	rs1233708	ENSG00000204709.4	LINC01556	6.84	2.55e-11	1.67e-08	0.37	0.3	Cardiac Troponin-T levels;	chr6:28205441	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	6.84	2.55e-11	1.68e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
HNSC	cis	rs7048146	0.51	rs7859790	ENSG00000213539.4	YBX1P6	-6.84	2.56e-11	1.68e-08	-0.34	-0.3	Vascular brain injury;	chr9:109528203	chr9:109532830~109534332:-
HNSC	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-6.84	2.56e-11	1.68e-08	-0.41	-0.3	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
HNSC	cis	rs4141404	0.737	rs5998067	ENSG00000236132.1	CTA-440B3.1	6.84	2.56e-11	1.68e-08	0.38	0.3	Paclitaxel-induced neuropathy;	chr22:31647644	chr22:31816379~31817491:-
HNSC	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	6.84	2.57e-11	1.68e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
HNSC	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-6.84	2.57e-11	1.68e-08	-0.31	-0.3	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
HNSC	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-6.84	2.57e-11	1.68e-08	-0.28	-0.3	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
HNSC	cis	rs4141404	0.737	rs5998058	ENSG00000236132.1	CTA-440B3.1	-6.84	2.57e-11	1.68e-08	-0.38	-0.3	Paclitaxel-induced neuropathy;	chr22:31610422	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	6.83	2.57e-11	1.69e-08	0.29	0.3	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	6.83	2.57e-11	1.69e-08	0.29	0.3	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	6.83	2.57e-11	1.69e-08	0.29	0.3	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	6.83	2.57e-11	1.69e-08	0.28	0.3	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
HNSC	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-6.83	2.59e-11	1.7e-08	-0.58	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
HNSC	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.59e-11	1.7e-08	-0.3	-0.3	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
HNSC	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-6.83	2.6e-11	1.7e-08	-0.32	-0.3	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
HNSC	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	6.83	2.6e-11	1.71e-08	0.36	0.3	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
HNSC	cis	rs2115630	0.645	rs3825877	ENSG00000229212.6	RP11-561C5.4	6.83	2.61e-11	1.71e-08	0.35	0.3	P wave terminal force;	chr15:84631400	chr15:85205440~85234795:-
HNSC	cis	rs2115630	0.645	rs3825878	ENSG00000229212.6	RP11-561C5.4	6.83	2.61e-11	1.71e-08	0.35	0.3	P wave terminal force;	chr15:84631524	chr15:85205440~85234795:-
HNSC	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	6.83	2.61e-11	1.71e-08	0.36	0.3	Depression;	chr6:28428413	chr6:28176188~28176674:+
HNSC	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-6.83	2.62e-11	1.71e-08	-0.48	-0.3	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
HNSC	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-6.83	2.62e-11	1.72e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
HNSC	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	6.83	2.62e-11	1.72e-08	0.4	0.3	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
HNSC	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	6.83	2.63e-11	1.72e-08	0.36	0.3	Depression;	chr6:28323463	chr6:28943877~28944537:+
HNSC	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	6.83	2.64e-11	1.73e-08	0.28	0.3	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
HNSC	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
HNSC	cis	rs394563	0.591	rs237012	ENSG00000231760.4	RP11-350J20.5	6.83	2.65e-11	1.74e-08	0.37	0.3	Dupuytren's disease;	chr6:149408062	chr6:149796151~149826294:-
HNSC	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	6.83	2.66e-11	1.74e-08	0.34	0.3	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	6.83	2.66e-11	1.74e-08	0.34	0.3	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
HNSC	cis	rs394563	0.589	rs1900300	ENSG00000231760.4	RP11-350J20.5	-6.83	2.66e-11	1.74e-08	-0.38	-0.3	Dupuytren's disease;	chr6:149320491	chr6:149796151~149826294:-
HNSC	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-6.83	2.66e-11	1.74e-08	-0.36	-0.3	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
HNSC	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	6.83	2.66e-11	1.74e-08	0.36	0.3	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
HNSC	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-6.83	2.67e-11	1.75e-08	-0.34	-0.3	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
HNSC	cis	rs2286503	0.901	rs10950922	ENSG00000221740.1	SNORD93	6.83	2.67e-11	1.75e-08	0.32	0.3	Fibrinogen;	chr7:22814387	chr7:22856613~22856686:+
HNSC	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	6.83	2.68e-11	1.75e-08	0.36	0.3	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
HNSC	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-6.83	2.68e-11	1.75e-08	-0.45	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
HNSC	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-6.83	2.68e-11	1.76e-08	-0.39	-0.3	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
HNSC	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.83	2.69e-11	1.76e-08	-0.38	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
HNSC	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	6.83	2.69e-11	1.76e-08	0.38	0.3	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
HNSC	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-6.83	2.69e-11	1.76e-08	-0.25	-0.3	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-6.83	2.69e-11	1.76e-08	-0.25	-0.3	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
HNSC	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	6.83	2.7e-11	1.76e-08	0.38	0.3	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
HNSC	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	6.83	2.7e-11	1.76e-08	0.36	0.3	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-6.83	2.71e-11	1.77e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
HNSC	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	6.83	2.71e-11	1.77e-08	0.42	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
HNSC	cis	rs9326248	0.53	rs1242229	ENSG00000280143.1	AP000892.6	6.83	2.71e-11	1.77e-08	0.47	0.3	Blood protein levels;	chr11:117191654	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	6.83	2.72e-11	1.77e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
HNSC	cis	rs2579103	0.63	rs825975	ENSG00000258183.4	RP11-753N8.1	6.83	2.72e-11	1.77e-08	0.41	0.3	Body mass index;	chr12:90314725	chr12:90280894~90300340:+
HNSC	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	6.83	2.72e-11	1.78e-08	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	6.83	2.72e-11	1.78e-08	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
HNSC	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-6.83	2.72e-11	1.78e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
HNSC	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-6.83	2.74e-11	1.79e-08	-0.34	-0.3	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
HNSC	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-6.83	2.74e-11	1.79e-08	-0.48	-0.3	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
HNSC	cis	rs9326248	0.53	rs2000614	ENSG00000280143.1	AP000892.6	6.82	2.74e-11	1.79e-08	0.44	0.3	Blood protein levels;	chr11:117045026	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs2000616	ENSG00000280143.1	AP000892.6	6.82	2.74e-11	1.79e-08	0.44	0.3	Blood protein levels;	chr11:117045813	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs10750100	ENSG00000280143.1	AP000892.6	6.82	2.74e-11	1.79e-08	0.44	0.3	Blood protein levels;	chr11:117046528	chr11:117204967~117210292:+
HNSC	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-6.82	2.74e-11	1.79e-08	-0.31	-0.3	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
HNSC	cis	rs1799949	1	rs2271573	ENSG00000267151.3	RP11-100E5.2	6.82	2.74e-11	1.79e-08	0.4	0.3	Menopause (age at onset);	chr17:43175604	chr17:43444707~43451200:+
HNSC	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	6.82	2.75e-11	1.79e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
HNSC	cis	rs7083	1	rs588763	ENSG00000254851.1	RP11-109L13.1	6.82	2.75e-11	1.79e-08	0.39	0.3	Blood protein levels;	chr11:117246065	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-6.82	2.75e-11	1.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-6.82	2.75e-11	1.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-6.82	2.75e-11	1.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	6.82	2.75e-11	1.79e-08	0.21	0.3	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
HNSC	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	6.82	2.76e-11	1.8e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	6.82	2.76e-11	1.8e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	6.82	2.76e-11	1.8e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
HNSC	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-6.82	2.76e-11	1.8e-08	-0.32	-0.3	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
HNSC	cis	rs1799949	1	rs11652332	ENSG00000267151.3	RP11-100E5.2	6.82	2.77e-11	1.81e-08	0.39	0.3	Menopause (age at onset);	chr17:43143472	chr17:43444707~43451200:+
HNSC	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	6.82	2.77e-11	1.81e-08	0.27	0.3	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	6.82	2.77e-11	1.81e-08	0.21	0.3	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
HNSC	cis	rs7083	0.935	rs523366	ENSG00000254851.1	RP11-109L13.1	6.82	2.78e-11	1.81e-08	0.39	0.3	Blood protein levels;	chr11:117248836	chr11:117135528~117138582:+
HNSC	cis	rs6951245	0.744	rs10275401	ENSG00000224079.1	AC091729.7	-6.82	2.78e-11	1.81e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1074450~1078036:+
HNSC	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	6.82	2.79e-11	1.82e-08	0.38	0.3	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
HNSC	cis	rs1799810	0.739	rs13030284	ENSG00000236682.1	AC068282.3	6.82	2.79e-11	1.82e-08	0.37	0.3	Self-rated health;	chr2:127401143	chr2:127389130~127400580:+
HNSC	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	6.82	2.79e-11	1.82e-08	0.39	0.3	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
HNSC	cis	rs7048146	0.51	rs2210159	ENSG00000213539.4	YBX1P6	-6.82	2.8e-11	1.82e-08	-0.34	-0.3	Vascular brain injury;	chr9:109526297	chr9:109532830~109534332:-
HNSC	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-6.82	2.8e-11	1.82e-08	-0.32	-0.3	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
HNSC	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-6.82	2.8e-11	1.83e-08	-0.35	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
HNSC	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-6.82	2.81e-11	1.83e-08	-0.44	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
HNSC	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.81e-11	1.83e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
HNSC	cis	rs6504622	0.791	rs61671555	ENSG00000262879.4	RP11-156P1.3	6.82	2.81e-11	1.83e-08	0.31	0.3	Orofacial clefts;	chr17:46960491	chr17:46984045~47100323:-
HNSC	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-6.82	2.82e-11	1.84e-08	-0.35	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
HNSC	cis	rs4218	0.608	rs34859729	ENSG00000259732.1	RP11-59H7.3	-6.82	2.82e-11	1.84e-08	-0.43	-0.3	Social communication problems;	chr15:59070117	chr15:59121034~59133250:+
HNSC	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-6.82	2.82e-11	1.84e-08	-0.48	-0.3	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
HNSC	cis	rs6867032	0.876	rs1552435	ENSG00000249731.1	RP11-259O2.3	6.82	2.83e-11	1.84e-08	0.37	0.3	Gut microbiome composition (winter);	chr5:2018264	chr5:1968094~1969013:+
HNSC	cis	rs17270561	0.609	rs1317817	ENSG00000272462.2	U91328.19	-6.82	2.83e-11	1.85e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25765149	chr6:25992662~26001775:+
HNSC	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	6.82	2.84e-11	1.85e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	6.82	2.84e-11	1.85e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	6.82	2.84e-11	1.85e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
HNSC	cis	rs7615952	0.8	rs35390120	ENSG00000248787.1	RP11-666A20.4	-6.82	2.85e-11	1.85e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125880966	chr3:125908005~125910272:-
HNSC	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.85e-11	1.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.85e-11	1.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.85e-11	1.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
HNSC	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-6.82	2.86e-11	1.86e-08	-0.41	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
HNSC	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	6.82	2.86e-11	1.86e-08	0.35	0.3	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
HNSC	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-6.82	2.86e-11	1.86e-08	-0.37	-0.3	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
HNSC	cis	rs7048146	0.51	rs4978821	ENSG00000213539.4	YBX1P6	-6.82	2.87e-11	1.87e-08	-0.34	-0.3	Vascular brain injury;	chr9:109525661	chr9:109532830~109534332:-
HNSC	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-6.82	2.87e-11	1.87e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
HNSC	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-6.82	2.87e-11	1.87e-08	-0.37	-0.3	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-6.82	2.87e-11	1.87e-08	-0.37	-0.3	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
HNSC	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	6.82	2.88e-11	1.88e-08	0.31	0.3	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	6.82	2.88e-11	1.88e-08	0.31	0.3	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
HNSC	cis	rs2579103	0.66	rs1438995	ENSG00000258183.4	RP11-753N8.1	6.82	2.89e-11	1.88e-08	0.33	0.3	Body mass index;	chr12:90262833	chr12:90280894~90300340:+
HNSC	cis	rs11089937	0.597	rs6001072	ENSG00000211638.2	IGLV8-61	-6.82	2.89e-11	1.88e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22098700~22099212:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	6.82	2.9e-11	1.89e-08	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
HNSC	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-6.82	2.91e-11	1.89e-08	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
HNSC	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	6.82	2.91e-11	1.89e-08	0.43	0.3	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
HNSC	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	6.82	2.91e-11	1.89e-08	0.28	0.3	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
HNSC	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-6.82	2.91e-11	1.89e-08	-0.37	-0.3	Migraine;	chr4:56851192	chr4:56960927~56961373:-
HNSC	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-6.82	2.91e-11	1.89e-08	-0.37	-0.3	Migraine;	chr4:56852087	chr4:56960927~56961373:-
HNSC	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-6.82	2.91e-11	1.89e-08	-0.37	-0.3	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
HNSC	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-6.82	2.91e-11	1.89e-08	-0.32	-0.3	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
HNSC	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	-6.82	2.92e-11	1.9e-08	-0.33	-0.3	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
HNSC	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	6.81	2.93e-11	1.9e-08	0.29	0.3	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
HNSC	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-6.81	2.93e-11	1.91e-08	-0.38	-0.3	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000173295.6	FAM86B3P	-6.81	2.94e-11	1.91e-08	-0.34	-0.3	Mood instability;	chr8:8937291	chr8:8228595~8244865:+
HNSC	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-6.81	2.94e-11	1.91e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
HNSC	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-6.81	2.95e-11	1.92e-08	-0.36	-0.3	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
HNSC	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-6.81	2.95e-11	1.92e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-6.81	2.95e-11	1.92e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
HNSC	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.81	2.96e-11	1.92e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.81	2.96e-11	1.92e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
HNSC	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	6.81	2.96e-11	1.93e-08	0.33	0.3	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
HNSC	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-6.81	2.96e-11	1.93e-08	-0.38	-0.3	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
HNSC	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-6.81	2.96e-11	1.93e-08	-0.38	-0.3	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
HNSC	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	6.81	2.97e-11	1.93e-08	0.27	0.3	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
HNSC	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	6.81	2.97e-11	1.93e-08	0.38	0.3	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
HNSC	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-6.81	2.97e-11	1.93e-08	-0.36	-0.3	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
HNSC	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	6.81	2.97e-11	1.93e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
HNSC	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	6.81	2.97e-11	1.93e-08	0.42	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
HNSC	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	6.81	2.97e-11	1.93e-08	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
HNSC	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-6.81	2.98e-11	1.93e-08	-0.38	-0.3	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-6.81	2.98e-11	1.93e-08	-0.38	-0.3	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-6.81	2.98e-11	1.93e-08	-0.38	-0.3	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
HNSC	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-6.81	2.98e-11	1.93e-08	-0.37	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000173295.6	FAM86B3P	6.81	2.98e-11	1.93e-08	0.34	0.3	Joint mobility (Beighton score);	chr8:9003384	chr8:8228595~8244865:+
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000254340.1	RP11-10A14.3	-6.81	2.99e-11	1.94e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9015783	chr8:9141424~9145435:+
HNSC	cis	rs2579103	0.767	rs1347845	ENSG00000258183.4	RP11-753N8.1	-6.81	3e-11	1.95e-08	-0.39	-0.3	Body mass index;	chr12:90269234	chr12:90280894~90300340:+
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000254340.1	RP11-10A14.3	-6.81	3e-11	1.95e-08	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9226611	chr8:9141424~9145435:+
HNSC	cis	rs5753618	0.504	rs9606847	ENSG00000236132.1	CTA-440B3.1	-6.81	3e-11	1.95e-08	-0.38	-0.3	Colorectal cancer;	chr22:31505803	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.504	rs9606848	ENSG00000236132.1	CTA-440B3.1	-6.81	3e-11	1.95e-08	-0.38	-0.3	Colorectal cancer;	chr22:31505881	chr22:31816379~31817491:-
HNSC	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	6.81	3e-11	1.95e-08	0.4	0.3	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
HNSC	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	6.81	3.01e-11	1.96e-08	0.42	0.3	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	6.81	3.01e-11	1.96e-08	0.21	0.3	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	6.81	3.01e-11	1.96e-08	0.21	0.3	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
HNSC	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	6.81	3.02e-11	1.96e-08	0.44	0.3	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	6.81	3.02e-11	1.96e-08	0.44	0.3	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-6.81	3.02e-11	1.96e-08	-0.44	-0.3	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
HNSC	cis	rs8177876	0.658	rs11150337	ENSG00000261061.1	RP11-303E16.2	-6.81	3.02e-11	1.96e-08	-0.49	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81030770~81031485:+
HNSC	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	6.81	3.03e-11	1.96e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
HNSC	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-6.81	3.03e-11	1.97e-08	-0.39	-0.3	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
HNSC	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	6.81	3.04e-11	1.97e-08	0.33	0.3	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
HNSC	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	6.81	3.05e-11	1.98e-08	0.31	0.3	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
HNSC	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	6.81	3.05e-11	1.98e-08	0.29	0.3	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
HNSC	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-6.81	3.06e-11	1.98e-08	-0.39	-0.3	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
HNSC	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-6.81	3.07e-11	1.99e-08	-0.36	-0.3	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
HNSC	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-6.81	3.07e-11	1.99e-08	-0.25	-0.3	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
HNSC	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
HNSC	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-6.81	3.09e-11	2e-08	-0.37	-0.3	Migraine;	chr4:56853383	chr4:56960927~56961373:-
HNSC	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-6.81	3.09e-11	2e-08	-0.32	-0.3	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
HNSC	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	6.81	3.1e-11	2.01e-08	0.44	0.3	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
HNSC	cis	rs7615952	0.599	rs6766327	ENSG00000241288.6	RP11-379B18.5	-6.81	3.1e-11	2.01e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126004834	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs12491577	ENSG00000241288.6	RP11-379B18.5	-6.81	3.1e-11	2.01e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126012288	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs1875683	ENSG00000241288.6	RP11-379B18.5	-6.81	3.1e-11	2.01e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126013638	chr3:125827238~125916384:-
HNSC	cis	rs453301	0.686	rs11785819	ENSG00000254340.1	RP11-10A14.3	-6.81	3.11e-11	2.01e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9012868	chr8:9141424~9145435:+
HNSC	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-6.81	3.11e-11	2.01e-08	-0.28	-0.3	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000254340.1	RP11-10A14.3	-6.8	3.12e-11	2.02e-08	-0.36	-0.3	Mood instability;	chr8:8939545	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000254340.1	RP11-10A14.3	-6.8	3.12e-11	2.02e-08	-0.36	-0.3	Mood instability;	chr8:8939563	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000254340.1	RP11-10A14.3	-6.8	3.12e-11	2.02e-08	-0.36	-0.3	Mood instability;	chr8:8939568	chr8:9141424~9145435:+
HNSC	cis	rs6951245	0.554	rs4724294	ENSG00000224079.1	AC091729.7	-6.8	3.12e-11	2.02e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1074450~1078036:+
HNSC	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-6.8	3.12e-11	2.02e-08	-0.28	-0.3	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
HNSC	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	6.8	3.12e-11	2.02e-08	0.37	0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
HNSC	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-6.8	3.12e-11	2.02e-08	-0.41	-0.3	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
HNSC	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	6.8	3.13e-11	2.02e-08	0.3	0.3	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
HNSC	cis	rs6951245	0.554	rs11544331	ENSG00000224079.1	AC091729.7	-6.8	3.14e-11	2.03e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1074450~1078036:+
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	6.8	3.14e-11	2.03e-08	0.23	0.3	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
HNSC	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-6.8	3.14e-11	2.03e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.673	rs34209763	ENSG00000248787.1	RP11-666A20.4	-6.8	3.15e-11	2.04e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125880752	chr3:125908005~125910272:-
HNSC	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	6.8	3.15e-11	2.04e-08	0.37	0.3	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
HNSC	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-6.8	3.15e-11	2.04e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-6.8	3.15e-11	2.04e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
HNSC	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	6.8	3.15e-11	2.04e-08	0.43	0.3	Height;	chr6:109403951	chr6:109382795~109383666:+
HNSC	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-6.8	3.16e-11	2.04e-08	-0.48	-0.3	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
HNSC	cis	rs1799949	1	rs2037075	ENSG00000267151.3	RP11-100E5.2	6.8	3.16e-11	2.05e-08	0.39	0.3	Menopause (age at onset);	chr17:43153809	chr17:43444707~43451200:+
HNSC	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	6.8	3.16e-11	2.05e-08	0.32	0.3	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
HNSC	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-6.8	3.16e-11	2.05e-08	-0.3	-0.3	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
HNSC	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-6.8	3.17e-11	2.05e-08	-0.38	-0.3	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
HNSC	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	6.8	3.17e-11	2.05e-08	0.78	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	6.8	3.17e-11	2.05e-08	0.78	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
HNSC	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-6.8	3.17e-11	2.05e-08	-0.31	-0.3	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
HNSC	cis	rs7819412	0.745	rs4841498	ENSG00000269918.1	AF131215.9	-6.8	3.18e-11	2.05e-08	-0.29	-0.3	Triglycerides;	chr8:11127922	chr8:11104691~11106704:-
HNSC	cis	rs6471393	0.964	rs56282609	ENSG00000253848.1	RP11-10N23.5	6.8	3.18e-11	2.06e-08	0.38	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737852	chr8:93741193~93744534:+
HNSC	cis	rs394563	0.726	rs6942381	ENSG00000231760.4	RP11-350J20.5	-6.8	3.18e-11	2.06e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149341855	chr6:149796151~149826294:-
HNSC	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-6.8	3.18e-11	2.06e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	6.8	3.18e-11	2.06e-08	0.21	0.3	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
HNSC	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-6.8	3.18e-11	2.06e-08	-0.48	-0.3	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-6.8	3.18e-11	2.06e-08	-0.48	-0.3	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-6.8	3.18e-11	2.06e-08	-0.48	-0.3	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
HNSC	cis	rs2404602	0.692	rs34181263	ENSG00000259422.1	RP11-593F23.1	6.8	3.19e-11	2.06e-08	0.34	0.3	Blood metabolite levels;	chr15:76773047	chr15:76174891~76181486:-
HNSC	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-6.8	3.19e-11	2.06e-08	-0.35	-0.3	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
HNSC	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	6.8	3.2e-11	2.07e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
HNSC	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	6.8	3.2e-11	2.07e-08	0.47	0.3	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
HNSC	cis	rs12439619	0.774	rs2867649	ENSG00000276710.3	CSPG4P8	-6.8	3.2e-11	2.07e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82459472~82477258:+
HNSC	cis	rs12439619	0.846	rs28697264	ENSG00000276710.3	CSPG4P8	-6.8	3.2e-11	2.07e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82459472~82477258:+
HNSC	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	6.8	3.21e-11	2.07e-08	0.59	0.3	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
HNSC	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-6.8	3.22e-11	2.08e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs11657835	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43139936	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1135214	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43140306	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793212	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43150733	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34534709	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43150923	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34059614	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43151054	chr17:43444707~43451200:+
HNSC	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-6.8	3.22e-11	2.08e-08	-0.36	-0.3	Migraine;	chr4:56850720	chr4:56960927~56961373:-
HNSC	cis	rs11089937	0.626	rs9619811	ENSG00000211638.2	IGLV8-61	-6.8	3.23e-11	2.09e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22098700~22099212:+
HNSC	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	6.8	3.23e-11	2.09e-08	0.34	0.3	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	6.8	3.23e-11	2.09e-08	0.34	0.3	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	6.8	3.23e-11	2.09e-08	0.34	0.3	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	6.8	3.25e-11	2.1e-08	0.36	0.3	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
HNSC	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
HNSC	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-6.8	3.25e-11	2.1e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
HNSC	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-6.8	3.26e-11	2.1e-08	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
HNSC	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.8	3.26e-11	2.1e-08	0.3	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
HNSC	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	6.8	3.27e-11	2.11e-08	0.37	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
HNSC	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	6.8	3.28e-11	2.11e-08	0.38	0.3	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
HNSC	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	6.8	3.28e-11	2.12e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
HNSC	cis	rs17270561	0.609	rs1892248	ENSG00000272462.2	U91328.19	-6.8	3.28e-11	2.12e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25768686	chr6:25992662~26001775:+
HNSC	cis	rs6951245	0.554	rs75075857	ENSG00000224079.1	AC091729.7	-6.8	3.29e-11	2.12e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	6.8	3.29e-11	2.12e-08	0.37	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
HNSC	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	6.8	3.3e-11	2.13e-08	0.34	0.3	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
HNSC	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	6.8	3.3e-11	2.13e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
HNSC	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	6.8	3.3e-11	2.13e-08	0.39	0.3	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
HNSC	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-6.8	3.31e-11	2.13e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
HNSC	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	6.8	3.31e-11	2.13e-08	0.55	0.3	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
HNSC	cis	rs35955747	0.934	rs5994397	ENSG00000236132.1	CTA-440B3.1	6.79	3.32e-11	2.14e-08	0.32	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31430164	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	6.79	3.32e-11	2.14e-08	0.22	0.3	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
HNSC	cis	rs673078	0.66	rs17440315	ENSG00000275409.1	RP11-131L12.4	-6.79	3.32e-11	2.14e-08	-0.49	-0.3	Glucose homeostasis traits;	chr12:118158819	chr12:118430147~118430699:+
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000173295.6	FAM86B3P	6.79	3.33e-11	2.14e-08	0.34	0.3	Systolic blood pressure;	chr8:8488264	chr8:8228595~8244865:+
HNSC	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	6.79	3.34e-11	2.15e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
HNSC	cis	rs453301	0.571	rs2929305	ENSG00000173295.6	FAM86B3P	-6.79	3.35e-11	2.16e-08	-0.33	-0.3	Joint mobility (Beighton score);	chr8:9227707	chr8:8228595~8244865:+
HNSC	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	6.79	3.35e-11	2.16e-08	0.35	0.3	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
HNSC	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	6.79	3.35e-11	2.16e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
HNSC	cis	rs4218	0.597	rs10431762	ENSG00000259732.1	RP11-59H7.3	-6.79	3.35e-11	2.16e-08	-0.43	-0.3	Social communication problems;	chr15:59066330	chr15:59121034~59133250:+
HNSC	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-6.79	3.36e-11	2.16e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
HNSC	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-6.79	3.37e-11	2.17e-08	-0.31	-0.3	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
HNSC	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	6.79	3.37e-11	2.17e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
HNSC	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	6.79	3.37e-11	2.17e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	6.79	3.37e-11	2.17e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000254340.1	RP11-10A14.3	-6.79	3.38e-11	2.17e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9053494	chr8:9141424~9145435:+
HNSC	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	6.79	3.38e-11	2.18e-08	0.54	0.3	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
HNSC	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	6.79	3.38e-11	2.18e-08	0.41	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
HNSC	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-6.79	3.39e-11	2.18e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
HNSC	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.79	3.41e-11	2.19e-08	-0.35	-0.3	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
HNSC	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-6.79	3.41e-11	2.19e-08	-0.27	-0.3	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.571	rs2929452	ENSG00000173295.6	FAM86B3P	-6.79	3.41e-11	2.19e-08	-0.33	-0.3	Joint mobility (Beighton score);	chr8:9226955	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-6.79	3.42e-11	2.2e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
HNSC	cis	rs4218	0.543	rs35658945	ENSG00000259732.1	RP11-59H7.3	-6.79	3.42e-11	2.2e-08	-0.4	-0.3	Social communication problems;	chr15:59018053	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.543	rs12050865	ENSG00000259732.1	RP11-59H7.3	-6.79	3.42e-11	2.2e-08	-0.4	-0.3	Social communication problems;	chr15:59020689	chr15:59121034~59133250:+
HNSC	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	6.79	3.42e-11	2.2e-08	0.32	0.3	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
HNSC	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-6.79	3.43e-11	2.2e-08	-0.34	-0.3	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
HNSC	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	6.79	3.44e-11	2.21e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
HNSC	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-6.79	3.46e-11	2.22e-08	-0.33	-0.3	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
HNSC	cis	rs889014	1	rs12517986	ENSG00000253768.1	CTB-33O18.1	-6.79	3.46e-11	2.22e-08	-0.32	-0.3	Height;	chr5:173568157	chr5:173562478~173573199:+
HNSC	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-6.79	3.46e-11	2.22e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
HNSC	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	6.79	3.47e-11	2.23e-08	0.46	0.3	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
HNSC	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	6.79	3.48e-11	2.23e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
HNSC	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-6.79	3.48e-11	2.23e-08	-0.56	-0.3	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
HNSC	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-6.79	3.48e-11	2.24e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-6.79	3.48e-11	2.24e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
HNSC	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-6.79	3.49e-11	2.24e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	6.79	3.5e-11	2.25e-08	0.47	0.3	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
HNSC	cis	rs1021993	0.545	rs77070927	ENSG00000231648.1	RP11-372M18.2	-6.79	3.52e-11	2.26e-08	-0.52	-0.3	Gut microbiome composition (winter);	chr1:209356960	chr1:209367662~209379690:+
HNSC	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	6.78	3.53e-11	2.27e-08	0.27	0.3	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	6.78	3.54e-11	2.27e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
HNSC	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-6.78	3.55e-11	2.28e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-6.78	3.55e-11	2.28e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
HNSC	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	6.78	3.55e-11	2.28e-08	0.33	0.3	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
HNSC	cis	rs2337406	0.85	rs11849578	ENSG00000211974.3	IGHV2-70	-6.78	3.55e-11	2.28e-08	-0.39	-0.3	Alzheimer's disease (late onset);	chr14:106670302	chr14:106723574~106724093:-
HNSC	cis	rs7048146	0.899	rs10979957	ENSG00000213539.4	YBX1P6	6.78	3.57e-11	2.29e-08	0.35	0.3	Vascular brain injury;	chr9:109594413	chr9:109532830~109534332:-
HNSC	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.57e-11	2.29e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
HNSC	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-6.78	3.58e-11	2.29e-08	-0.58	-0.3	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
HNSC	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-6.78	3.58e-11	2.3e-08	-0.3	-0.3	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	6.78	3.58e-11	2.3e-08	0.34	0.3	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-6.78	3.6e-11	2.31e-08	-0.27	-0.3	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
HNSC	cis	rs1659258	0.772	rs1659256	ENSG00000232508.1	MRPL45P1	6.78	3.6e-11	2.31e-08	0.57	0.3	Visceral fat;	chr2:88358967	chr2:88364695~88365608:-
HNSC	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	6.78	3.6e-11	2.31e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
HNSC	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-6.78	3.6e-11	2.31e-08	-0.34	-0.3	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
HNSC	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-6.78	3.61e-11	2.31e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
HNSC	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-6.78	3.61e-11	2.31e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
HNSC	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-6.78	3.61e-11	2.31e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
HNSC	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	6.78	3.61e-11	2.31e-08	0.36	0.3	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
HNSC	cis	rs17270561	0.609	rs4712964	ENSG00000272462.2	U91328.19	-6.78	3.61e-11	2.31e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25740594	chr6:25992662~26001775:+
HNSC	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	6.78	3.61e-11	2.32e-08	0.37	0.3	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
HNSC	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-6.78	3.62e-11	2.32e-08	-0.3	-0.3	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
HNSC	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	6.78	3.62e-11	2.32e-08	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	6.78	3.63e-11	2.32e-08	0.21	0.3	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
HNSC	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	6.78	3.63e-11	2.32e-08	0.27	0.3	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-6.78	3.64e-11	2.33e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
HNSC	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	6.78	3.66e-11	2.34e-08	0.27	0.3	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-6.78	3.66e-11	2.34e-08	-0.39	-0.3	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
HNSC	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	6.78	3.66e-11	2.34e-08	0.43	0.3	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
HNSC	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-6.78	3.66e-11	2.35e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	6.78	3.67e-11	2.35e-08	0.33	0.3	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.673	rs16834637	ENSG00000248787.1	RP11-666A20.4	-6.78	3.67e-11	2.35e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125886628	chr3:125908005~125910272:-
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	6.78	3.68e-11	2.35e-08	0.21	0.3	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
HNSC	cis	rs7615952	0.599	rs60847438	ENSG00000241288.6	RP11-379B18.5	-6.78	3.68e-11	2.35e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126027162	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.534	rs1503072	ENSG00000241288.6	RP11-379B18.5	-6.78	3.68e-11	2.35e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126035848	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs7631268	ENSG00000241288.6	RP11-379B18.5	-6.78	3.68e-11	2.35e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126036821	chr3:125827238~125916384:-
HNSC	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	6.78	3.68e-11	2.35e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
HNSC	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-6.78	3.69e-11	2.36e-08	-0.49	-0.3	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
HNSC	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-6.78	3.69e-11	2.36e-08	-0.35	-0.3	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
HNSC	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	6.78	3.69e-11	2.36e-08	0.36	0.3	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
HNSC	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	6.78	3.7e-11	2.37e-08	0.38	0.3	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
HNSC	cis	rs6951245	0.507	rs11976805	ENSG00000224079.1	AC091729.7	-6.78	3.7e-11	2.37e-08	-0.39	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1074450~1078036:+
HNSC	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.72e-11	2.38e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
HNSC	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	6.78	3.75e-11	2.4e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
HNSC	cis	rs6504622	0.902	rs1052586	ENSG00000262879.4	RP11-156P1.3	-6.77	3.76e-11	2.4e-08	-0.32	-0.3	Orofacial clefts;	chr17:46941097	chr17:46984045~47100323:-
HNSC	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	6.77	3.77e-11	2.41e-08	0.42	0.3	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
HNSC	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-6.77	3.78e-11	2.41e-08	-0.32	-0.3	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
HNSC	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-6.77	3.79e-11	2.42e-08	-0.33	-0.3	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
HNSC	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-6.77	3.79e-11	2.42e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
HNSC	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	6.77	3.8e-11	2.43e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	6.77	3.81e-11	2.43e-08	0.27	0.3	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
HNSC	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-6.77	3.81e-11	2.43e-08	-0.38	-0.3	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
HNSC	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-6.77	3.82e-11	2.44e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
HNSC	cis	rs11089937	0.926	rs5750601	ENSG00000211638.2	IGLV8-61	-6.77	3.82e-11	2.44e-08	-0.26	-0.3	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22098700~22099212:+
HNSC	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-6.77	3.82e-11	2.44e-08	-0.36	-0.3	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	6.77	3.82e-11	2.44e-08	0.44	0.3	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
HNSC	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	6.77	3.83e-11	2.44e-08	0.43	0.3	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
HNSC	cis	rs1021993	0.545	rs7548184	ENSG00000231648.1	RP11-372M18.2	-6.77	3.83e-11	2.44e-08	-0.53	-0.3	Gut microbiome composition (winter);	chr1:209358255	chr1:209367662~209379690:+
HNSC	cis	rs1075265	0.518	rs13414393	ENSG00000233266.1	HMGB1P31	6.77	3.83e-11	2.44e-08	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54051334~54051760:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-6.77	3.83e-11	2.45e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
HNSC	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	6.77	3.84e-11	2.45e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	6.77	3.84e-11	2.45e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
HNSC	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-6.77	3.87e-11	2.47e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
HNSC	cis	rs1799949	0.965	rs33961729	ENSG00000267151.3	RP11-100E5.2	6.77	3.88e-11	2.47e-08	0.39	0.3	Menopause (age at onset);	chr17:43135907	chr17:43444707~43451200:+
HNSC	cis	rs2286503	1	rs2286499	ENSG00000221740.1	SNORD93	6.77	3.89e-11	2.48e-08	0.32	0.3	Fibrinogen;	chr7:22817858	chr7:22856613~22856686:+
HNSC	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	6.77	3.89e-11	2.48e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
HNSC	cis	rs36405	0.5	rs2109273	ENSG00000266869.1	RP6-114E22.1	-6.77	3.89e-11	2.48e-08	-0.38	-0.3	Yang-deficiency constitution;	chr14:71894247	chr14:71848606~71908430:+
HNSC	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-6.77	3.9e-11	2.49e-08	-0.33	-0.3	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
HNSC	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	6.77	3.91e-11	2.49e-08	0.38	0.3	Height;	chr6:109421257	chr6:109382795~109383666:+
HNSC	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	6.77	3.91e-11	2.49e-08	0.29	0.3	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
HNSC	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	6.77	3.91e-11	2.49e-08	0.43	0.3	Height;	chr6:109441837	chr6:109382795~109383666:+
HNSC	cis	rs11089937	0.568	rs6001078	ENSG00000211638.2	IGLV8-61	-6.77	3.93e-11	2.5e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs5757005	ENSG00000211638.2	IGLV8-61	-6.77	3.93e-11	2.5e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22098700~22099212:+
HNSC	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-6.77	3.94e-11	2.51e-08	-0.48	-0.3	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
HNSC	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	6.77	3.94e-11	2.51e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
HNSC	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-6.77	3.94e-11	2.51e-08	-0.37	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
HNSC	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-6.77	3.95e-11	2.51e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-6.77	3.95e-11	2.51e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
HNSC	cis	rs71327718	1	rs71327718	ENSG00000241288.6	RP11-379B18.5	-6.77	3.95e-11	2.51e-08	-0.51	-0.3	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125827238~125916384:-
HNSC	cis	rs36405	0.5	rs2013781	ENSG00000266869.1	RP6-114E22.1	-6.77	3.96e-11	2.52e-08	-0.38	-0.3	Yang-deficiency constitution;	chr14:71890603	chr14:71848606~71908430:+
HNSC	cis	rs4218	0.648	rs34407560	ENSG00000259732.1	RP11-59H7.3	-6.77	3.96e-11	2.52e-08	-0.43	-0.3	Social communication problems;	chr15:59073397	chr15:59121034~59133250:+
HNSC	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-6.77	3.97e-11	2.53e-08	-0.3	-0.3	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
HNSC	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	6.77	3.97e-11	2.53e-08	0.4	0.3	Height;	chr6:109382524	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-6.77	3.97e-11	2.53e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
HNSC	cis	rs12682352	0.652	rs3789843	ENSG00000173295.6	FAM86B3P	6.77	3.98e-11	2.53e-08	0.33	0.3	Neuroticism;	chr8:8866747	chr8:8228595~8244865:+
HNSC	cis	rs12682352	0.652	rs3827806	ENSG00000173295.6	FAM86B3P	6.77	3.98e-11	2.53e-08	0.33	0.3	Neuroticism;	chr8:8866766	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000254340.1	RP11-10A14.3	-6.77	3.98e-11	2.54e-08	-0.36	-0.3	Mood instability;	chr8:8939092	chr8:9141424~9145435:+
HNSC	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	6.77	3.99e-11	2.54e-08	0.33	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-6.76	4e-11	2.55e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-6.76	4e-11	2.55e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
HNSC	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-6.76	4.01e-11	2.55e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	6.76	4.02e-11	2.56e-08	0.27	0.3	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-6.76	4.02e-11	2.56e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
HNSC	cis	rs453301	0.571	rs2929453	ENSG00000173295.6	FAM86B3P	-6.76	4.03e-11	2.56e-08	-0.32	-0.3	Joint mobility (Beighton score);	chr8:9226831	chr8:8228595~8244865:+
HNSC	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	6.76	4.03e-11	2.56e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	6.76	4.03e-11	2.56e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000254153.1	CTA-398F10.2	6.76	4.03e-11	2.56e-08	0.32	0.3	Mood instability;	chr8:8462594	chr8:8456909~8461337:-
HNSC	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	6.76	4.04e-11	2.57e-08	0.3	0.3	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
HNSC	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-6.76	4.04e-11	2.57e-08	-0.36	-0.3	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
HNSC	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	6.76	4.05e-11	2.58e-08	0.37	0.3	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
HNSC	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	6.76	4.07e-11	2.59e-08	0.45	0.3	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
HNSC	cis	rs1021993	0.597	rs10494921	ENSG00000231648.1	RP11-372M18.2	-6.76	4.07e-11	2.59e-08	-0.51	-0.3	Gut microbiome composition (winter);	chr1:209340156	chr1:209367662~209379690:+
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000173295.6	FAM86B3P	6.76	4.07e-11	2.59e-08	0.34	0.3	Neuroticism;	chr8:8287918	chr8:8228595~8244865:+
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000254340.1	RP11-10A14.3	6.76	4.08e-11	2.59e-08	0.36	0.3	Joint mobility (Beighton score);	chr8:9051726	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	6.76	4.08e-11	2.59e-08	0.4	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
HNSC	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	6.76	4.08e-11	2.59e-08	0.71	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
HNSC	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-6.76	4.08e-11	2.6e-08	-0.35	-0.3	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
HNSC	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-6.76	4.09e-11	2.6e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-6.76	4.09e-11	2.6e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-6.76	4.09e-11	2.6e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
HNSC	cis	rs1799949	0.965	rs9646413	ENSG00000267151.3	RP11-100E5.2	6.76	4.09e-11	2.6e-08	0.38	0.3	Menopause (age at onset);	chr17:43348789	chr17:43444707~43451200:+
HNSC	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	6.76	4.1e-11	2.6e-08	0.37	0.3	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
HNSC	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	6.76	4.1e-11	2.6e-08	0.37	0.3	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
HNSC	cis	rs9326246	0.556	rs662799	ENSG00000254851.1	RP11-109L13.1	-6.76	4.1e-11	2.61e-08	-0.73	-0.3	Coronary artery disease;	chr11:116792991	chr11:117135528~117138582:+
HNSC	cis	rs6951245	0.935	rs79067319	ENSG00000225146.1	AC073957.15	-6.76	4.11e-11	2.61e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025912	chr7:1029025~1043891:+
HNSC	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-6.76	4.11e-11	2.61e-08	-0.37	-0.3	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
HNSC	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	6.76	4.12e-11	2.62e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
HNSC	cis	rs673078	0.66	rs61943524	ENSG00000275409.1	RP11-131L12.4	-6.76	4.13e-11	2.62e-08	-0.49	-0.3	Glucose homeostasis traits;	chr12:118151530	chr12:118430147~118430699:+
HNSC	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	6.76	4.13e-11	2.62e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	6.76	4.13e-11	2.62e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	6.76	4.13e-11	2.62e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-6.76	4.13e-11	2.62e-08	-0.36	-0.3	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	6.76	4.14e-11	2.63e-08	0.23	0.3	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
HNSC	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	6.76	4.15e-11	2.63e-08	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
HNSC	cis	rs17270561	0.609	rs1892246	ENSG00000272462.2	U91328.19	-6.76	4.15e-11	2.63e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25764180	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	6.76	4.15e-11	2.64e-08	0.42	0.3	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000254340.1	RP11-10A14.3	-6.76	4.16e-11	2.64e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9053798	chr8:9141424~9145435:+
HNSC	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-6.76	4.16e-11	2.64e-08	-0.43	-0.3	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	6.76	4.16e-11	2.64e-08	0.42	0.3	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-6.76	4.16e-11	2.64e-08	-0.26	-0.3	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
HNSC	cis	rs6951245	0.529	rs10262070	ENSG00000224079.1	AC091729.7	-6.76	4.17e-11	2.64e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1074450~1078036:+
HNSC	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	6.76	4.17e-11	2.65e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
HNSC	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-6.76	4.17e-11	2.65e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
HNSC	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-6.76	4.17e-11	2.65e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
HNSC	cis	rs36405	0.5	rs17178883	ENSG00000266869.1	RP6-114E22.1	6.76	4.18e-11	2.65e-08	0.38	0.3	Yang-deficiency constitution;	chr14:71888874	chr14:71848606~71908430:+
HNSC	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-6.76	4.19e-11	2.66e-08	-0.33	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
HNSC	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
HNSC	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-6.76	4.2e-11	2.66e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	6.76	4.2e-11	2.66e-08	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
HNSC	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-6.76	4.2e-11	2.66e-08	-0.34	-0.3	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
HNSC	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-6.76	4.21e-11	2.67e-08	-0.27	-0.3	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
HNSC	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-6.76	4.21e-11	2.67e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
HNSC	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	6.76	4.21e-11	2.67e-08	0.28	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
HNSC	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	6.76	4.22e-11	2.67e-08	0.71	0.3	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	6.76	4.22e-11	2.67e-08	0.71	0.3	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
HNSC	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-6.76	4.23e-11	2.68e-08	-0.35	-0.3	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
HNSC	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-6.76	4.23e-11	2.68e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
HNSC	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-6.76	4.23e-11	2.68e-08	-0.35	-0.3	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
HNSC	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-6.76	4.23e-11	2.69e-08	-0.36	-0.3	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
HNSC	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-6.76	4.24e-11	2.69e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
HNSC	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	6.76	4.25e-11	2.7e-08	0.27	0.3	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
HNSC	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	6.76	4.25e-11	2.7e-08	0.43	0.3	Height;	chr6:109382480	chr6:109382795~109383666:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-6.76	4.26e-11	2.7e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
HNSC	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-6.76	4.26e-11	2.7e-08	-0.32	-0.3	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
HNSC	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	6.76	4.26e-11	2.7e-08	0.26	0.3	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	6.76	4.26e-11	2.7e-08	0.26	0.3	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
HNSC	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	6.75	4.27e-11	2.71e-08	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
HNSC	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-6.75	4.28e-11	2.71e-08	-0.36	-0.3	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
HNSC	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-6.75	4.28e-11	2.71e-08	-0.42	-0.3	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000254340.1	RP11-10A14.3	-6.75	4.29e-11	2.72e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9017276	chr8:9141424~9145435:+
HNSC	cis	rs4218	0.517	rs71480503	ENSG00000259732.1	RP11-59H7.3	-6.75	4.29e-11	2.72e-08	-0.43	-0.3	Social communication problems;	chr15:59098246	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000254340.1	RP11-10A14.3	-6.75	4.29e-11	2.72e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9050725	chr8:9141424~9145435:+
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	6.75	4.3e-11	2.72e-08	0.21	0.3	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
HNSC	cis	rs4218	0.648	rs1074702	ENSG00000259732.1	RP11-59H7.3	-6.75	4.31e-11	2.73e-08	-0.43	-0.3	Social communication problems;	chr15:59073900	chr15:59121034~59133250:+
HNSC	cis	rs35955747	0.934	rs131200	ENSG00000236132.1	CTA-440B3.1	-6.75	4.32e-11	2.73e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31307286	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-6.75	4.33e-11	2.74e-08	-0.2	-0.3	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
HNSC	cis	rs7048146	0.51	rs1109477	ENSG00000213539.4	YBX1P6	-6.75	4.33e-11	2.74e-08	-0.34	-0.3	Vascular brain injury;	chr9:109519571	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.51	rs1109478	ENSG00000213539.4	YBX1P6	-6.75	4.33e-11	2.74e-08	-0.34	-0.3	Vascular brain injury;	chr9:109519583	chr9:109532830~109534332:-
HNSC	cis	rs17270561	0.609	rs4712963	ENSG00000272462.2	U91328.19	-6.75	4.34e-11	2.75e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25740274	chr6:25992662~26001775:+
HNSC	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	6.75	4.36e-11	2.76e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000254340.1	RP11-10A14.3	-6.75	4.36e-11	2.76e-08	-0.36	-0.3	Mood instability;	chr8:8937520	chr8:9141424~9145435:+
HNSC	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.37e-11	2.77e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
HNSC	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	6.75	4.38e-11	2.77e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
HNSC	cis	rs35955747	0.838	rs28716	ENSG00000236132.1	CTA-440B3.1	-6.75	4.38e-11	2.77e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334203	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs131209	ENSG00000236132.1	CTA-440B3.1	-6.75	4.38e-11	2.77e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31336475	chr22:31816379~31817491:-
HNSC	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-6.75	4.38e-11	2.77e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-6.75	4.38e-11	2.77e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000254340.1	RP11-10A14.3	-6.75	4.39e-11	2.77e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9050721	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-6.75	4.41e-11	2.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
HNSC	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-6.75	4.42e-11	2.8e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
HNSC	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	6.75	4.44e-11	2.8e-08	0.33	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
HNSC	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	6.75	4.44e-11	2.8e-08	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000254340.1	RP11-10A14.3	-6.75	4.44e-11	2.8e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9016136	chr8:9141424~9145435:+
HNSC	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	6.75	4.44e-11	2.81e-08	0.4	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
HNSC	cis	rs394563	0.726	rs6922130	ENSG00000231760.4	RP11-350J20.5	-6.75	4.45e-11	2.81e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149351239	chr6:149796151~149826294:-
HNSC	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-6.75	4.45e-11	2.81e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
HNSC	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
HNSC	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	6.75	4.45e-11	2.81e-08	0.26	0.3	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	6.75	4.45e-11	2.81e-08	0.26	0.3	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
HNSC	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-6.75	4.46e-11	2.82e-08	-0.29	-0.3	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
HNSC	cis	rs6504622	0.905	rs9889741	ENSG00000262879.4	RP11-156P1.3	6.75	4.46e-11	2.82e-08	0.31	0.3	Orofacial clefts;	chr17:46948967	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-6.75	4.46e-11	2.82e-08	-0.32	-0.3	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	6.75	4.47e-11	2.82e-08	0.21	0.3	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	6.75	4.47e-11	2.82e-08	0.21	0.3	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
HNSC	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	6.75	4.48e-11	2.83e-08	0.32	0.3	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	6.75	4.48e-11	2.83e-08	0.26	0.3	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
HNSC	cis	rs7404843	0.789	rs222909	ENSG00000263065.1	AF001548.6	6.75	4.48e-11	2.83e-08	0.5	0.3	Testicular germ cell tumor;	chr16:15405432	chr16:15741151~15741791:+
HNSC	cis	rs7083	1	rs655023	ENSG00000254851.1	RP11-109L13.1	6.75	4.49e-11	2.83e-08	0.38	0.3	Blood protein levels;	chr11:117256904	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs505045	ENSG00000254851.1	RP11-109L13.1	6.75	4.49e-11	2.83e-08	0.38	0.3	Blood protein levels;	chr11:117281824	chr11:117135528~117138582:+
HNSC	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	6.75	4.49e-11	2.84e-08	0.37	0.3	Height;	chr3:53072864	chr3:53064283~53065091:-
HNSC	cis	rs7615952	0.611	rs35321002	ENSG00000248787.1	RP11-666A20.4	-6.75	4.5e-11	2.84e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125893222	chr3:125908005~125910272:-
HNSC	cis	rs7083	0.905	rs11216338	ENSG00000254851.1	RP11-109L13.1	6.75	4.52e-11	2.85e-08	0.38	0.3	Blood protein levels;	chr11:117261003	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs619772	ENSG00000254851.1	RP11-109L13.1	6.75	4.52e-11	2.85e-08	0.38	0.3	Blood protein levels;	chr11:117268120	chr11:117135528~117138582:+
HNSC	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-6.75	4.52e-11	2.85e-08	-0.44	-0.3	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
HNSC	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	6.75	4.52e-11	2.85e-08	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-6.75	4.52e-11	2.85e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
HNSC	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-6.75	4.53e-11	2.86e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
HNSC	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.54e-11	2.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.54e-11	2.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.54e-11	2.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
HNSC	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-6.74	4.55e-11	2.87e-08	-0.46	-0.3	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
HNSC	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	6.74	4.55e-11	2.87e-08	0.43	0.3	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
HNSC	cis	rs667920	0.573	rs9682783	ENSG00000273486.1	RP11-731C17.2	6.74	4.55e-11	2.87e-08	0.29	0.3	Coronary artery disease;	chr3:136820847	chr3:136837338~136839021:-
HNSC	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	6.74	4.56e-11	2.87e-08	0.35	0.3	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
HNSC	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	6.74	4.63e-11	2.92e-08	0.29	0.3	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
HNSC	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-6.74	4.63e-11	2.92e-08	-0.35	-0.3	Migraine;	chr4:56881195	chr4:56960927~56961373:-
HNSC	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	6.74	4.66e-11	2.94e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000254340.1	RP11-10A14.3	-6.74	4.67e-11	2.94e-08	-0.36	-0.3	Mood instability;	chr8:8939009	chr8:9141424~9145435:+
HNSC	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	6.74	4.67e-11	2.94e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
HNSC	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-6.74	4.68e-11	2.94e-08	-0.37	-0.3	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
HNSC	cis	rs4218	0.648	rs12441973	ENSG00000259732.1	RP11-59H7.3	-6.74	4.68e-11	2.95e-08	-0.42	-0.3	Social communication problems;	chr15:59057016	chr15:59121034~59133250:+
HNSC	cis	rs5753618	0.504	rs5753669	ENSG00000236132.1	CTA-440B3.1	-6.74	4.69e-11	2.95e-08	-0.37	-0.3	Colorectal cancer;	chr22:31509833	chr22:31816379~31817491:-
HNSC	cis	rs7083	1	rs493139	ENSG00000254851.1	RP11-109L13.1	6.74	4.7e-11	2.96e-08	0.38	0.3	Blood protein levels;	chr11:117275233	chr11:117135528~117138582:+
HNSC	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-6.74	4.7e-11	2.96e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
HNSC	cis	rs5753618	0.539	rs737888	ENSG00000236132.1	CTA-440B3.1	6.74	4.7e-11	2.96e-08	0.37	0.3	Colorectal cancer;	chr22:31215563	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.539	rs1034588	ENSG00000236132.1	CTA-440B3.1	6.74	4.7e-11	2.96e-08	0.37	0.3	Colorectal cancer;	chr22:31220315	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs5753521	ENSG00000236132.1	CTA-440B3.1	6.74	4.7e-11	2.96e-08	0.37	0.3	Colorectal cancer;	chr22:31242041	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	6.74	4.71e-11	2.96e-08	0.43	0.3	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
HNSC	cis	rs6951245	0.58	rs78894484	ENSG00000224079.1	AC091729.7	-6.74	4.71e-11	2.97e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1074450~1078036:+
HNSC	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	6.74	4.72e-11	2.97e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	6.74	4.72e-11	2.97e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
HNSC	cis	rs4218	0.648	rs10851642	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59077909	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.608	rs59282449	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59078881	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.648	rs60285686	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59079829	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.648	rs60741546	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59079831	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000254340.1	RP11-10A14.3	-6.74	4.73e-11	2.97e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9047129	chr8:9141424~9145435:+
HNSC	cis	rs394563	0.591	rs11155641	ENSG00000231760.4	RP11-350J20.5	-6.74	4.73e-11	2.98e-08	-0.38	-0.3	Dupuytren's disease;	chr6:149327459	chr6:149796151~149826294:-
HNSC	cis	rs9341808	0.539	rs2490253	ENSG00000272129.1	RP11-250B2.6	6.74	4.74e-11	2.98e-08	0.35	0.3	Sitting height ratio;	chr6:80186153	chr6:80355424~80356859:+
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000179406.6	LINC00174	6.74	4.74e-11	2.98e-08	0.38	0.3	Calcium levels;	chr7:66026136	chr7:66376044~66401338:-
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-6.74	4.74e-11	2.98e-08	-0.19	-0.3	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-6.74	4.75e-11	2.99e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	6.74	4.75e-11	2.99e-08	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
HNSC	cis	rs10504130	0.696	rs17284746	ENSG00000272024.1	RP11-546K22.3	-6.74	4.76e-11	2.99e-08	-0.43	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51930320	chr8:51950284~51950690:+
HNSC	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	6.74	4.77e-11	3e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
HNSC	cis	rs11089937	0.963	rs2226943	ENSG00000211638.2	IGLV8-61	-6.74	4.77e-11	3e-08	-0.26	-0.3	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22098700~22099212:+
HNSC	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-6.74	4.78e-11	3e-08	-0.34	-0.3	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
HNSC	cis	rs5769707	0.681	rs6009803	ENSG00000188511.11	C22orf34	6.74	4.81e-11	3.02e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49414524~49657542:-
HNSC	cis	rs6951245	0.554	rs58210047	ENSG00000224079.1	AC091729.7	-6.74	4.81e-11	3.02e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1074450~1078036:+
HNSC	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-6.74	4.81e-11	3.02e-08	-0.37	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
HNSC	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-6.74	4.81e-11	3.02e-08	-0.45	-0.3	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
HNSC	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-6.74	4.81e-11	3.02e-08	-0.29	-0.3	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
HNSC	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	6.74	4.82e-11	3.03e-08	0.4	0.3	Height;	chr6:109387685	chr6:109382795~109383666:+
HNSC	cis	rs5753618	0.504	rs8138525	ENSG00000236132.1	CTA-440B3.1	6.74	4.82e-11	3.03e-08	0.38	0.3	Colorectal cancer;	chr22:31615943	chr22:31816379~31817491:-
HNSC	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	6.74	4.83e-11	3.03e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-6.73	4.84e-11	3.04e-08	-0.29	-0.3	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
HNSC	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	6.73	4.85e-11	3.04e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
HNSC	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-6.73	4.85e-11	3.05e-08	-0.35	-0.3	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000254340.1	RP11-10A14.3	-6.73	4.86e-11	3.05e-08	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9225906	chr8:9141424~9145435:+
HNSC	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-6.73	4.87e-11	3.06e-08	-0.36	-0.3	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-6.73	4.87e-11	3.06e-08	-0.36	-0.3	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-6.73	4.87e-11	3.06e-08	-0.36	-0.3	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
HNSC	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-6.73	4.87e-11	3.06e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	6.73	4.88e-11	3.06e-08	0.27	0.3	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
HNSC	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-6.73	4.88e-11	3.06e-08	-0.36	-0.3	Height;	chr3:52949886	chr3:53064283~53065091:-
HNSC	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	6.73	4.88e-11	3.06e-08	0.31	0.3	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
HNSC	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-6.73	4.9e-11	3.07e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
HNSC	cis	rs5769707	0.605	rs2071900	ENSG00000188511.11	C22orf34	6.73	4.92e-11	3.08e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49658527	chr22:49414524~49657542:-
HNSC	cis	rs451417	0.818	rs236117	ENSG00000275632.1	RP5-967N21.11	6.73	4.92e-11	3.09e-08	0.38	0.3	Menopause (age at onset);	chr20:5956529	chr20:6000418~6000941:+
HNSC	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-6.73	4.92e-11	3.09e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
HNSC	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	6.73	4.92e-11	3.09e-08	0.37	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	6.73	4.93e-11	3.09e-08	0.27	0.3	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
HNSC	cis	rs77204473	0.744	rs74882651	ENSG00000254851.1	RP11-109L13.1	6.73	4.93e-11	3.09e-08	0.83	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117114475	chr11:117135528~117138582:+
HNSC	cis	rs6471393	0.964	rs2914959	ENSG00000253848.1	RP11-10N23.5	6.73	4.93e-11	3.09e-08	0.4	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93727117	chr8:93741193~93744534:+
HNSC	cis	rs394563	0.591	rs11964335	ENSG00000231760.4	RP11-350J20.5	-6.73	4.94e-11	3.09e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149336965	chr6:149796151~149826294:-
HNSC	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-6.73	4.94e-11	3.1e-08	-0.29	-0.3	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-6.73	4.94e-11	3.1e-08	-0.29	-0.3	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
HNSC	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-6.73	4.95e-11	3.1e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
HNSC	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-6.73	4.95e-11	3.1e-08	-0.36	-0.3	Height;	chr3:52967831	chr3:53064283~53065091:-
HNSC	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	6.73	4.96e-11	3.11e-08	0.35	0.3	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
HNSC	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-6.73	4.96e-11	3.11e-08	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
HNSC	cis	rs17270561	0.636	rs6923839	ENSG00000272462.2	U91328.19	-6.73	4.96e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745625	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs2000351	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25759555	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712968	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25760116	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7769908	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25760311	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7770037	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25760363	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9348695	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25762782	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs2000350	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25762926	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1318016	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25764476	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1892245	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25764605	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1317816	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25765162	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.583	rs6937800	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25765715	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs3778272	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25767433	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs2275905	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25767878	chr6:25992662~26001775:+
HNSC	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-6.73	4.97e-11	3.11e-08	-0.28	-0.3	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-6.73	4.97e-11	3.11e-08	-0.28	-0.3	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	6.73	4.97e-11	3.11e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
HNSC	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-6.73	4.98e-11	3.12e-08	-0.3	-0.3	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000173295.6	FAM86B3P	6.73	5e-11	3.13e-08	0.35	0.3	Joint mobility (Beighton score);	chr8:8995760	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	6.73	5e-11	3.13e-08	0.35	0.3	Depression;	chr6:28391932	chr6:28176188~28176674:+
HNSC	cis	rs2404602	0.655	rs8028294	ENSG00000259422.1	RP11-593F23.1	6.73	5e-11	3.13e-08	0.34	0.3	Blood metabolite levels;	chr15:76792536	chr15:76174891~76181486:-
HNSC	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-6.73	5.02e-11	3.14e-08	-0.3	-0.3	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
HNSC	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	6.73	5.02e-11	3.15e-08	0.35	0.3	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.626	rs5757013	ENSG00000211638.2	IGLV8-61	-6.73	5.03e-11	3.15e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs5757014	ENSG00000211638.2	IGLV8-61	-6.73	5.03e-11	3.15e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22098700~22099212:+
HNSC	cis	rs7615952	0.599	rs2279821	ENSG00000241288.6	RP11-379B18.5	-6.73	5.03e-11	3.15e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126015465	chr3:125827238~125916384:-
HNSC	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	6.73	5.05e-11	3.16e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000254340.1	RP11-10A14.3	-6.73	5.06e-11	3.16e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9047352	chr8:9141424~9145435:+
HNSC	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	6.73	5.06e-11	3.16e-08	0.26	0.3	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
HNSC	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	6.73	5.08e-11	3.18e-08	0.36	0.3	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
HNSC	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-6.73	5.09e-11	3.18e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
HNSC	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-6.73	5.09e-11	3.18e-08	-0.39	-0.3	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
HNSC	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	6.73	5.09e-11	3.18e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
HNSC	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-6.73	5.1e-11	3.19e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
HNSC	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-6.73	5.11e-11	3.19e-08	-0.31	-0.3	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
HNSC	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-6.73	5.11e-11	3.2e-08	-0.29	-0.3	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
HNSC	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	6.73	5.12e-11	3.2e-08	0.35	0.3	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000254340.1	RP11-10A14.3	-6.73	5.13e-11	3.21e-08	-0.38	-0.3	Mean corpuscular volume;	chr8:8993123	chr8:9141424~9145435:+
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-6.73	5.14e-11	3.21e-08	-0.35	-0.3	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
HNSC	cis	rs1021993	0.545	rs58017268	ENSG00000231648.1	RP11-372M18.2	-6.72	5.16e-11	3.22e-08	-0.53	-0.3	Gut microbiome composition (winter);	chr1:209366729	chr1:209367662~209379690:+
HNSC	cis	rs6951245	0.882	rs56048221	ENSG00000224079.1	AC091729.7	-6.72	5.16e-11	3.22e-08	-0.47	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052897	chr7:1074450~1078036:+
HNSC	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	6.72	5.18e-11	3.24e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
HNSC	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	6.72	5.18e-11	3.24e-08	0.36	0.3	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
HNSC	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-6.72	5.19e-11	3.24e-08	-0.29	-0.3	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
HNSC	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-6.72	5.19e-11	3.24e-08	-0.36	-0.3	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
HNSC	cis	rs1355223	0.837	rs11600402	ENSG00000271369.1	RP11-350D17.3	-6.72	5.21e-11	3.25e-08	-0.34	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670204	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-6.72	5.21e-11	3.26e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
HNSC	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	6.72	5.22e-11	3.26e-08	0.43	0.3	Height;	chr6:109436760	chr6:109382795~109383666:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000254340.1	RP11-10A14.3	-6.72	5.22e-11	3.26e-08	-0.36	-0.3	Mood instability;	chr8:8937937	chr8:9141424~9145435:+
HNSC	cis	rs67180937	0.677	rs17011666	ENSG00000272750.1	RP11-378J18.8	-6.72	5.23e-11	3.26e-08	-0.36	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222625623	chr1:222658867~222661512:-
HNSC	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	6.72	5.23e-11	3.26e-08	0.36	0.3	Depression;	chr6:28240757	chr6:28943877~28944537:+
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-6.72	5.24e-11	3.27e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
HNSC	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-6.72	5.26e-11	3.28e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
HNSC	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-6.72	5.28e-11	3.3e-08	-0.41	-0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
HNSC	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	6.72	5.28e-11	3.3e-08	0.56	0.3	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
HNSC	cis	rs7000734	0.637	rs2599706	ENSG00000245080.5	RP11-320N21.1	-6.72	5.3e-11	3.31e-08	-0.42	-0.3	Radiation response;	chr8:95074797	chr8:95066808~95073182:-
HNSC	cis	rs9326246	0.643	rs651821	ENSG00000254851.1	RP11-109L13.1	-6.72	5.3e-11	3.31e-08	-0.68	-0.3	Coronary artery disease;	chr11:116791863	chr11:117135528~117138582:+
HNSC	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-6.72	5.3e-11	3.31e-08	-0.37	-0.3	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-6.72	5.3e-11	3.31e-08	-0.37	-0.3	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000254153.1	CTA-398F10.2	6.72	5.31e-11	3.31e-08	0.32	0.3	Mood instability;	chr8:8461157	chr8:8456909~8461337:-
HNSC	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-6.72	5.31e-11	3.32e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
HNSC	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-6.72	5.31e-11	3.32e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
HNSC	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-6.72	5.34e-11	3.33e-08	-0.29	-0.3	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
HNSC	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-6.72	5.34e-11	3.33e-08	-0.35	-0.3	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
HNSC	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-6.72	5.34e-11	3.33e-08	-0.36	-0.3	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
HNSC	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-6.72	5.35e-11	3.34e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
HNSC	cis	rs17270561	0.636	rs6923367	ENSG00000272462.2	U91328.19	-6.72	5.37e-11	3.35e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745624	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs4145218	ENSG00000272462.2	U91328.19	-6.72	5.37e-11	3.35e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745855	chr6:25992662~26001775:+
HNSC	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-6.72	5.39e-11	3.36e-08	-0.35	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
HNSC	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-6.72	5.39e-11	3.36e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
HNSC	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	6.72	5.39e-11	3.36e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	6.72	5.39e-11	3.36e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	6.72	5.4e-11	3.37e-08	0.35	0.3	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	6.72	5.4e-11	3.37e-08	0.35	0.3	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
HNSC	cis	rs4218	0.813	rs8036907	ENSG00000259732.1	RP11-59H7.3	-6.72	5.4e-11	3.37e-08	-0.4	-0.3	Social communication problems;	chr15:59121144	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.724	rs35168204	ENSG00000259732.1	RP11-59H7.3	-6.72	5.4e-11	3.37e-08	-0.4	-0.3	Social communication problems;	chr15:59121354	chr15:59121034~59133250:+
HNSC	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	6.72	5.42e-11	3.37e-08	0.44	0.3	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
HNSC	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	6.72	5.42e-11	3.38e-08	0.71	0.3	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
HNSC	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	6.72	5.43e-11	3.38e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	6.72	5.43e-11	3.38e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	6.72	5.43e-11	3.38e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
HNSC	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	6.72	5.43e-11	3.38e-08	0.37	0.3	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
HNSC	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	6.72	5.44e-11	3.39e-08	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
HNSC	cis	rs1355223	0.902	rs865070	ENSG00000271369.1	RP11-350D17.3	-6.72	5.44e-11	3.39e-08	-0.33	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34720950	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1361645	ENSG00000271369.1	RP11-350D17.3	-6.72	5.44e-11	3.39e-08	-0.33	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724838	chr11:34709600~34710161:+
HNSC	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	6.72	5.46e-11	3.4e-08	0.4	0.3	Height;	chr6:109384228	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	6.72	5.46e-11	3.4e-08	0.4	0.3	Height;	chr6:109385087	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	6.72	5.46e-11	3.4e-08	0.4	0.3	Height;	chr6:109388256	chr6:109382795~109383666:+
HNSC	cis	rs1355223	0.867	rs7943363	ENSG00000271369.1	RP11-350D17.3	-6.72	5.47e-11	3.4e-08	-0.34	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669587	chr11:34709600~34710161:+
HNSC	cis	rs17270561	0.666	rs9356988	ENSG00000272462.2	U91328.19	-6.71	5.48e-11	3.41e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25777253	chr6:25992662~26001775:+
HNSC	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	6.71	5.48e-11	3.41e-08	0.32	0.3	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
HNSC	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	6.71	5.49e-11	3.41e-08	0.58	0.3	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
HNSC	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-6.71	5.49e-11	3.42e-08	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
HNSC	cis	rs6951245	0.554	rs35126802	ENSG00000224079.1	AC091729.7	-6.71	5.5e-11	3.42e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1074450~1078036:+
HNSC	cis	rs2337406	1	rs17113331	ENSG00000211974.3	IGHV2-70	-6.71	5.5e-11	3.42e-08	-0.36	-0.3	Alzheimer's disease (late onset);	chr14:106703843	chr14:106723574~106724093:-
HNSC	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-6.71	5.5e-11	3.42e-08	-0.36	-0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
HNSC	cis	rs1865760	0.519	rs4360119	ENSG00000272462.2	U91328.19	-6.71	5.51e-11	3.43e-08	-0.31	-0.3	Height;	chr6:25814846	chr6:25992662~26001775:+
HNSC	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	6.71	5.51e-11	3.43e-08	0.57	0.3	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
HNSC	cis	rs6951245	0.554	rs78999139	ENSG00000224079.1	AC091729.7	-6.71	5.51e-11	3.43e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1074450~1078036:+
HNSC	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	6.71	5.53e-11	3.44e-08	0.41	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
HNSC	cis	rs2115630	0.645	rs2292463	ENSG00000229212.6	RP11-561C5.4	6.71	5.54e-11	3.44e-08	0.35	0.3	P wave terminal force;	chr15:84632519	chr15:85205440~85234795:-
HNSC	cis	rs34375054	0.573	rs12823172	ENSG00000279233.1	RP11-158L12.4	6.71	5.55e-11	3.45e-08	0.4	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125161737	chr12:125138245~125141711:+
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000254340.1	RP11-10A14.3	-6.71	5.55e-11	3.45e-08	-0.36	-0.3	Mood instability;	chr8:8936683	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000254340.1	RP11-10A14.3	-6.71	5.55e-11	3.45e-08	-0.36	-0.3	Mood instability;	chr8:8936944	chr8:9141424~9145435:+
HNSC	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	6.71	5.56e-11	3.46e-08	0.56	0.3	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
HNSC	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	6.71	5.56e-11	3.46e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.692	rs3110382	ENSG00000259422.1	RP11-593F23.1	-6.71	5.56e-11	3.46e-08	-0.34	-0.3	Blood metabolite levels;	chr15:76856347	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000173295.6	FAM86B3P	6.71	5.57e-11	3.46e-08	0.33	0.3	Mood instability;	chr8:8788736	chr8:8228595~8244865:+
HNSC	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-6.71	5.57e-11	3.46e-08	-0.38	-0.3	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
HNSC	cis	rs2579103	0.63	rs10506985	ENSG00000258183.4	RP11-753N8.1	-6.71	5.57e-11	3.46e-08	-0.42	-0.3	Body mass index;	chr12:90318265	chr12:90280894~90300340:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-6.71	5.57e-11	3.46e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
HNSC	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	6.71	5.58e-11	3.47e-08	0.71	0.3	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
HNSC	cis	rs6991838	0.806	rs11781358	ENSG00000200714.1	Y_RNA	6.71	5.6e-11	3.48e-08	0.34	0.3	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65592731~65592820:+
HNSC	cis	rs11089937	0.626	rs5757051	ENSG00000211638.2	IGLV8-61	6.71	5.6e-11	3.48e-08	0.28	0.3	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22098700~22099212:+
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	6.71	5.62e-11	3.49e-08	0.23	0.3	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
HNSC	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	6.71	5.63e-11	3.5e-08	0.42	0.3	Height;	chr6:109427303	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	6.71	5.63e-11	3.5e-08	0.34	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
HNSC	cis	rs11089937	0.597	rs5750579	ENSG00000211638.2	IGLV8-61	-6.71	5.63e-11	3.5e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs11089925	ENSG00000211638.2	IGLV8-61	-6.71	5.63e-11	3.5e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22098700~22099212:+
HNSC	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	6.71	5.64e-11	3.51e-08	0.35	0.3	Height;	chr3:53091453	chr3:53064283~53065091:-
HNSC	cis	rs11089937	0.626	rs5757017	ENSG00000211638.2	IGLV8-61	-6.71	5.65e-11	3.51e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs59356111	ENSG00000211638.2	IGLV8-61	-6.71	5.65e-11	3.51e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs5757019	ENSG00000211638.2	IGLV8-61	-6.71	5.65e-11	3.51e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22098700~22099212:+
HNSC	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-6.71	5.65e-11	3.51e-08	-0.19	-0.3	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
HNSC	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-6.71	5.65e-11	3.51e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
HNSC	cis	rs1021993	0.545	rs4844815	ENSG00000231648.1	RP11-372M18.2	-6.71	5.66e-11	3.52e-08	-0.48	-0.3	Gut microbiome composition (winter);	chr1:209356309	chr1:209367662~209379690:+
HNSC	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	6.71	5.71e-11	3.54e-08	0.27	0.3	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
HNSC	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	6.71	5.72e-11	3.55e-08	0.71	0.3	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
HNSC	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
HNSC	cis	rs7615952	0.611	rs2971298	ENSG00000248787.1	RP11-666A20.4	-6.71	5.72e-11	3.55e-08	-0.49	-0.3	Blood pressure (smoking interaction);	chr3:125883870	chr3:125908005~125910272:-
HNSC	cis	rs2235642	0.893	rs2076445	ENSG00000280231.1	LA16c-380F5.3	-6.71	5.72e-11	3.55e-08	-0.36	-0.3	Coronary artery disease;	chr16:1542265	chr16:1553655~1554130:-
HNSC	cis	rs1355223	0.902	rs7102625	ENSG00000271369.1	RP11-350D17.3	6.71	5.73e-11	3.55e-08	0.33	0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34718170	chr11:34709600~34710161:+
HNSC	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	6.71	5.74e-11	3.56e-08	0.36	0.3	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
HNSC	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-6.71	5.74e-11	3.56e-08	-0.33	-0.3	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
HNSC	cis	rs2579103	0.683	rs10777234	ENSG00000258183.4	RP11-753N8.1	-6.71	5.75e-11	3.57e-08	-0.33	-0.3	Body mass index;	chr12:90213380	chr12:90280894~90300340:+
HNSC	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-6.71	5.76e-11	3.57e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-6.71	5.76e-11	3.57e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
HNSC	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	6.71	5.77e-11	3.58e-08	0.47	0.3	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
HNSC	cis	rs12439619	0.768	rs28694364	ENSG00000276710.3	CSPG4P8	-6.71	5.78e-11	3.58e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82459472~82477258:+
HNSC	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	6.71	5.79e-11	3.59e-08	0.44	0.3	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	6.71	5.79e-11	3.59e-08	0.44	0.3	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	6.71	5.8e-11	3.59e-08	0.33	0.3	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
HNSC	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	6.71	5.8e-11	3.59e-08	0.4	0.3	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
HNSC	cis	rs2404602	0.669	rs1875884	ENSG00000259422.1	RP11-593F23.1	6.71	5.8e-11	3.6e-08	0.34	0.3	Blood metabolite levels;	chr15:76345820	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-6.71	5.83e-11	3.61e-08	-0.31	-0.3	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
HNSC	cis	rs1075265	0.564	rs2111851	ENSG00000233266.1	HMGB1P31	6.7	5.84e-11	3.62e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53655030	chr2:54051334~54051760:+
HNSC	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-6.7	5.85e-11	3.62e-08	-0.34	-0.3	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
HNSC	cis	rs2297363	1	rs16888669	ENSG00000213073.4	RP11-288H12.3	-6.7	5.86e-11	3.63e-08	-0.41	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160082862	chr6:160093082~160096212:+
HNSC	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-6.7	5.86e-11	3.63e-08	-0.35	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
HNSC	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-6.7	5.87e-11	3.64e-08	-0.38	-0.3	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
HNSC	cis	rs947583	0.545	rs9494364	ENSG00000217482.2	HMGB1P17	6.7	5.88e-11	3.64e-08	0.34	0.3	Phosphorus levels;	chr6:135759549	chr6:135636086~135636713:-
HNSC	cis	rs7301826	0.504	rs11061164	ENSG00000256250.1	RP11-989F5.1	-6.7	5.88e-11	3.64e-08	-0.32	-0.3	Plasma plasminogen activator levels;	chr12:130839724	chr12:130810606~130812438:+
HNSC	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-6.7	5.9e-11	3.65e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
HNSC	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	6.7	5.91e-11	3.66e-08	0.37	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
HNSC	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-6.7	5.93e-11	3.67e-08	-0.31	-0.3	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
HNSC	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	6.7	5.94e-11	3.68e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
HNSC	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
HNSC	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-6.7	6e-11	3.71e-08	-0.36	-0.3	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
HNSC	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	6.7	6e-11	3.71e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
HNSC	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	6.7	6.02e-11	3.72e-08	0.36	0.3	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000235689.1	AP000351.13	6.7	6.04e-11	3.73e-08	0.31	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:24006305~24008258:-
HNSC	cis	rs11992162	0.636	rs11250182	ENSG00000206014.6	OR7E161P	6.7	6.04e-11	3.73e-08	0.32	0.3	Monocyte count;	chr8:11950067	chr8:11928597~11929563:-
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000173295.6	FAM86B3P	6.7	6.04e-11	3.73e-08	0.33	0.3	Joint mobility (Beighton score);	chr8:9044861	chr8:8228595~8244865:+
HNSC	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-6.7	6.05e-11	3.74e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
HNSC	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-6.7	6.05e-11	3.74e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
HNSC	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	6.7	6.06e-11	3.74e-08	0.38	0.3	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
HNSC	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	6.7	6.06e-11	3.74e-08	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
HNSC	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-6.7	6.07e-11	3.75e-08	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
HNSC	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-6.7	6.08e-11	3.75e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
HNSC	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-6.7	6.08e-11	3.76e-08	-0.4	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	6.7	6.11e-11	3.77e-08	0.43	0.3	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.692	rs12910382	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76761101	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs12911902	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76761234	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs4383105	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76763169	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs7174673	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76779657	chr15:76174891~76181486:-
HNSC	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-6.7	6.12e-11	3.78e-08	-0.29	-0.3	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
HNSC	cis	rs9326248	0.53	rs2155583	ENSG00000280143.1	AP000892.6	6.7	6.13e-11	3.78e-08	0.45	0.3	Blood protein levels;	chr11:117044501	chr11:117204967~117210292:+
HNSC	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	6.7	6.14e-11	3.79e-08	0.54	0.3	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
HNSC	cis	rs11089937	0.597	rs5757024	ENSG00000211638.2	IGLV8-61	-6.7	6.17e-11	3.8e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22098700~22099212:+
HNSC	cis	rs7615952	0.641	rs4490307	ENSG00000241288.6	RP11-379B18.5	-6.7	6.18e-11	3.81e-08	-0.38	-0.3	Blood pressure (smoking interaction);	chr3:125993833	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	6.7	6.2e-11	3.82e-08	0.4	0.3	Height;	chr6:109446728	chr6:109382795~109383666:+
HNSC	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-6.7	6.2e-11	3.82e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
HNSC	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	6.69	6.22e-11	3.83e-08	0.36	0.3	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
HNSC	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-6.69	6.22e-11	3.84e-08	-0.24	-0.3	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
HNSC	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-6.69	6.24e-11	3.84e-08	-0.5	-0.3	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
HNSC	cis	rs5753618	0.504	rs5753661	ENSG00000236132.1	CTA-440B3.1	-6.69	6.24e-11	3.85e-08	-0.37	-0.3	Colorectal cancer;	chr22:31503811	chr22:31816379~31817491:-
HNSC	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	6.69	6.25e-11	3.85e-08	0.31	0.3	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
HNSC	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	6.69	6.26e-11	3.86e-08	0.41	0.3	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
HNSC	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	6.69	6.28e-11	3.87e-08	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
HNSC	cis	rs394563	0.726	rs366905	ENSG00000231760.4	RP11-350J20.5	6.69	6.28e-11	3.87e-08	0.37	0.3	Dupuytren's disease;	chr6:149413961	chr6:149796151~149826294:-
HNSC	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	6.69	6.28e-11	3.87e-08	0.29	0.3	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
HNSC	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-6.69	6.3e-11	3.88e-08	-0.31	-0.3	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
HNSC	cis	rs2579103	0.708	rs825964	ENSG00000258183.4	RP11-753N8.1	6.69	6.32e-11	3.89e-08	0.41	0.3	Body mass index;	chr12:90306962	chr12:90280894~90300340:+
HNSC	cis	rs4141404	0.673	rs1968023	ENSG00000236132.1	CTA-440B3.1	6.69	6.34e-11	3.91e-08	0.41	0.3	Paclitaxel-induced neuropathy;	chr22:31546784	chr22:31816379~31817491:-
HNSC	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-6.69	6.35e-11	3.91e-08	-0.43	-0.3	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
HNSC	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.36e-11	3.92e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
HNSC	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-6.69	6.37e-11	3.92e-08	-0.35	-0.3	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
HNSC	cis	rs11089937	0.597	rs5757007	ENSG00000211638.2	IGLV8-61	-6.69	6.38e-11	3.93e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22098700~22099212:+
HNSC	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-6.69	6.39e-11	3.93e-08	-0.24	-0.3	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
HNSC	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
HNSC	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
HNSC	cis	rs6951245	0.638	rs4720486	ENSG00000224079.1	AC091729.7	-6.69	6.4e-11	3.94e-08	-0.39	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1074450~1078036:+
HNSC	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	6.69	6.41e-11	3.94e-08	0.37	0.3	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
HNSC	cis	rs2286503	1	rs1029740	ENSG00000221740.1	SNORD93	6.69	6.42e-11	3.95e-08	0.31	0.3	Fibrinogen;	chr7:22833967	chr7:22856613~22856686:+
HNSC	cis	rs4218	0.543	rs2414618	ENSG00000259732.1	RP11-59H7.3	-6.69	6.42e-11	3.95e-08	-0.4	-0.3	Social communication problems;	chr15:59019684	chr15:59121034~59133250:+
HNSC	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	6.69	6.42e-11	3.95e-08	0.44	0.3	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
HNSC	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
HNSC	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	6.69	6.43e-11	3.96e-08	0.77	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
HNSC	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.45e-11	3.96e-08	-0.29	-0.3	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-6.69	6.45e-11	3.96e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
HNSC	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-6.69	6.45e-11	3.97e-08	-0.41	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
HNSC	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-6.69	6.46e-11	3.97e-08	-0.39	-0.3	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
HNSC	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	6.69	6.46e-11	3.97e-08	0.32	0.3	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-6.69	6.47e-11	3.98e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-6.69	6.47e-11	3.98e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-6.69	6.47e-11	3.98e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
HNSC	cis	rs9341808	0.667	rs2505929	ENSG00000272129.1	RP11-250B2.6	6.69	6.5e-11	3.99e-08	0.34	0.3	Sitting height ratio;	chr6:80124491	chr6:80355424~80356859:+
HNSC	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	6.69	6.5e-11	4e-08	0.36	0.3	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
HNSC	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-6.69	6.51e-11	4e-08	-0.32	-0.3	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
HNSC	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	6.69	6.51e-11	4e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
HNSC	cis	rs9402743	0.709	rs9373136	ENSG00000217482.2	HMGB1P17	6.69	6.51e-11	4e-08	0.33	0.3	Systemic lupus erythematosus;	chr6:135617531	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.678	rs965191	ENSG00000217482.2	HMGB1P17	6.69	6.51e-11	4e-08	0.33	0.3	Systemic lupus erythematosus;	chr6:135618363	chr6:135636086~135636713:-
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-6.69	6.51e-11	4e-08	-0.41	-0.3	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
HNSC	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	6.69	6.52e-11	4e-08	0.35	0.3	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
HNSC	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	6.69	6.52e-11	4.01e-08	0.32	0.3	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
HNSC	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-6.69	6.53e-11	4.01e-08	-0.36	-0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
HNSC	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
HNSC	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
HNSC	cis	rs9907295	0.591	rs8080959	ENSG00000270977.1	AC015849.16	-6.69	6.58e-11	4.04e-08	-0.34	-0.3	Fibroblast growth factor basic levels;	chr17:35813450	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.636	rs4251724	ENSG00000270977.1	AC015849.16	-6.69	6.58e-11	4.04e-08	-0.34	-0.3	Fibroblast growth factor basic levels;	chr17:35816641	chr17:35893707~35911023:-
HNSC	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-6.69	6.59e-11	4.04e-08	-0.31	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
HNSC	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-6.69	6.59e-11	4.05e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
HNSC	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-6.69	6.6e-11	4.05e-08	-0.37	-0.3	Height;	chr3:52992698	chr3:53064283~53065091:-
HNSC	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-6.68	6.61e-11	4.05e-08	-0.37	-0.3	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
HNSC	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	6.68	6.61e-11	4.06e-08	0.35	0.3	Height;	chr4:55387515	chr4:55363971~55395847:-
HNSC	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-6.68	6.61e-11	4.06e-08	-0.24	-0.3	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
HNSC	cis	rs10504130	0.696	rs75833886	ENSG00000272024.1	RP11-546K22.3	-6.68	6.64e-11	4.07e-08	-0.42	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51929844	chr8:51950284~51950690:+
HNSC	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-6.68	6.65e-11	4.08e-08	-0.36	-0.3	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
HNSC	cis	rs9341808	0.935	rs942381	ENSG00000272129.1	RP11-250B2.6	6.68	6.66e-11	4.08e-08	0.35	0.3	Sitting height ratio;	chr6:80170433	chr6:80355424~80356859:+
HNSC	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	6.68	6.67e-11	4.09e-08	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	6.68	6.67e-11	4.09e-08	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	6.68	6.67e-11	4.09e-08	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
HNSC	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	6.68	6.68e-11	4.09e-08	0.29	0.3	Height;	chr2:231516534	chr2:231508426~231514339:-
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000254340.1	RP11-10A14.3	-6.68	6.68e-11	4.09e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9025061	chr8:9141424~9145435:+
HNSC	cis	rs11089937	0.626	rs9622968	ENSG00000211638.2	IGLV8-61	-6.68	6.7e-11	4.11e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22098700~22099212:+
HNSC	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	6.68	6.71e-11	4.11e-08	0.31	0.3	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
HNSC	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-6.68	6.72e-11	4.12e-08	-0.37	-0.3	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
HNSC	cis	rs35955747	0.902	rs5997938	ENSG00000236132.1	CTA-440B3.1	6.68	6.72e-11	4.12e-08	0.32	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31281006	chr22:31816379~31817491:-
HNSC	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	6.68	6.73e-11	4.12e-08	0.31	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
HNSC	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	6.68	6.73e-11	4.13e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
HNSC	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-6.68	6.76e-11	4.14e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
HNSC	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	6.68	6.76e-11	4.14e-08	0.71	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
HNSC	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	6.68	6.78e-11	4.15e-08	0.34	0.3	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
HNSC	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-6.68	6.78e-11	4.15e-08	-0.34	-0.3	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
HNSC	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	6.68	6.81e-11	4.17e-08	0.28	0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
HNSC	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	6.68	6.81e-11	4.17e-08	0.4	0.3	Height;	chr6:109438349	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	6.68	6.81e-11	4.17e-08	0.4	0.3	Height;	chr6:109441033	chr6:109382795~109383666:+
HNSC	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-6.68	6.81e-11	4.17e-08	-0.36	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
HNSC	cis	rs7615952	0.599	rs2333408	ENSG00000241288.6	RP11-379B18.5	-6.68	6.84e-11	4.19e-08	-0.38	-0.3	Blood pressure (smoking interaction);	chr3:126013255	chr3:125827238~125916384:-
HNSC	cis	rs451417	0.818	rs236113	ENSG00000275632.1	RP5-967N21.11	6.68	6.85e-11	4.19e-08	0.37	0.3	Menopause (age at onset);	chr20:5953920	chr20:6000418~6000941:+
HNSC	cis	rs9341808	0.667	rs3805919	ENSG00000272129.1	RP11-250B2.6	6.68	6.85e-11	4.19e-08	0.34	0.3	Sitting height ratio;	chr6:80197092	chr6:80355424~80356859:+
HNSC	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-6.68	6.85e-11	4.19e-08	-0.33	-0.3	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	6.68	6.85e-11	4.2e-08	0.33	0.3	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
HNSC	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	6.68	6.9e-11	4.22e-08	0.7	0.3	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
HNSC	cis	rs34526934	0.566	rs1374325	ENSG00000226363.3	HAGLROS	6.68	6.9e-11	4.22e-08	0.4	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179243	chr2:176177717~176179008:+
HNSC	cis	rs8054556	0.692	rs12716973	ENSG00000183604.13	SMG1P5	-6.68	6.9e-11	4.22e-08	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr16:29926331	chr16:30267553~30335374:-
HNSC	cis	rs6504622	0.905	rs2317997	ENSG00000262879.4	RP11-156P1.3	6.68	6.9e-11	4.22e-08	0.31	0.3	Orofacial clefts;	chr17:46950282	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.905	rs3809854	ENSG00000262879.4	RP11-156P1.3	6.68	6.9e-11	4.22e-08	0.31	0.3	Orofacial clefts;	chr17:46951928	chr17:46984045~47100323:-
HNSC	cis	rs17270561	0.609	rs1408271	ENSG00000272462.2	U91328.19	-6.68	6.91e-11	4.23e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25859393	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-6.68	6.91e-11	4.23e-08	-0.46	-0.3	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
HNSC	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-6.68	6.95e-11	4.25e-08	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
HNSC	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-6.68	6.95e-11	4.25e-08	-0.36	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
HNSC	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	6.68	6.97e-11	4.26e-08	0.34	0.3	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
HNSC	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	6.68	6.98e-11	4.26e-08	0.44	0.3	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
HNSC	cis	rs7083	0.935	rs529470	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117262092	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs529471	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117262093	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs7111678	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117265090	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs2509210	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117265354	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs507880	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117266539	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs2509211	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117266917	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs524085	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117266931	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.967	rs558590	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117268405	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs673738	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117272865	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs495438	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117274011	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs492151	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117275099	chr11:117135528~117138582:+
HNSC	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	6.68	6.98e-11	4.27e-08	0.34	0.3	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
HNSC	cis	rs8012947	1	rs10145481	ENSG00000279636.2	LINC00216	-6.68	7.02e-11	4.29e-08	-0.35	-0.3	Alcohol consumption in current drinkers;	chr14:58303671	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs1951204	ENSG00000279636.2	LINC00216	-6.68	7.02e-11	4.29e-08	-0.35	-0.3	Alcohol consumption in current drinkers;	chr14:58303983	chr14:58288033~58289158:+
HNSC	cis	rs12439619	0.81	rs28876157	ENSG00000276710.3	CSPG4P8	-6.67	7.04e-11	4.3e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82459472~82477258:+
HNSC	cis	rs2579103	0.708	rs2579105	ENSG00000258183.4	RP11-753N8.1	-6.67	7.04e-11	4.3e-08	-0.39	-0.3	Body mass index;	chr12:90290980	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.708	rs2579104	ENSG00000258183.4	RP11-753N8.1	-6.67	7.04e-11	4.3e-08	-0.39	-0.3	Body mass index;	chr12:90291037	chr12:90280894~90300340:+
HNSC	cis	rs2442825	0.54	rs35728233	ENSG00000206573.7	THUMPD3-AS1	-6.67	7.05e-11	4.31e-08	-0.26	-0.3	Cerebrospinal fluid clusterin levels;	chr3:9387510	chr3:9349689~9398579:-
HNSC	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	6.67	7.06e-11	4.31e-08	0.23	0.3	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
HNSC	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	6.67	7.06e-11	4.31e-08	0.33	0.3	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.655	rs34748201	ENSG00000259422.1	RP11-593F23.1	6.67	7.07e-11	4.32e-08	0.35	0.3	Blood metabolite levels;	chr15:76929189	chr15:76174891~76181486:-
HNSC	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-6.67	7.1e-11	4.34e-08	-0.39	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-6.67	7.1e-11	4.34e-08	-0.39	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
HNSC	cis	rs6951245	0.505	rs56117635	ENSG00000224079.1	AC091729.7	-6.67	7.1e-11	4.34e-08	-0.58	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:990398	chr7:1074450~1078036:+
HNSC	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	6.67	7.11e-11	4.34e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	6.67	7.11e-11	4.34e-08	0.35	0.3	Depression;	chr6:28399886	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	6.67	7.11e-11	4.34e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
HNSC	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	6.67	7.12e-11	4.34e-08	0.43	0.3	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
HNSC	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-6.67	7.12e-11	4.35e-08	-0.36	-0.3	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
HNSC	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-6.67	7.15e-11	4.36e-08	-0.36	-0.3	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
HNSC	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	6.67	7.15e-11	4.36e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
HNSC	cis	rs11089937	0.597	rs4145535	ENSG00000211638.2	IGLV8-61	-6.67	7.16e-11	4.37e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22098700~22099212:+
HNSC	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-6.67	7.17e-11	4.37e-08	-0.4	-0.29	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
HNSC	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	6.67	7.17e-11	4.37e-08	0.38	0.29	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
HNSC	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-6.67	7.18e-11	4.38e-08	-0.31	-0.29	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
HNSC	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-6.67	7.18e-11	4.38e-08	-0.28	-0.29	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
HNSC	cis	rs11089937	0.626	rs5757028	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs2213156	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs2213157	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs9622955	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs4821781	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22098700~22099212:+
HNSC	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-6.67	7.22e-11	4.4e-08	-0.27	-0.29	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	6.67	7.22e-11	4.4e-08	0.43	0.29	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
HNSC	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	6.67	7.24e-11	4.41e-08	0.33	0.29	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
HNSC	cis	rs10504130	0.696	rs79069311	ENSG00000272024.1	RP11-546K22.3	-6.67	7.25e-11	4.42e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51950284~51950690:+
HNSC	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	6.67	7.26e-11	4.43e-08	0.37	0.29	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
HNSC	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-6.67	7.32e-11	4.46e-08	-0.4	-0.29	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
HNSC	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-6.67	7.33e-11	4.46e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
HNSC	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-6.67	7.34e-11	4.47e-08	-0.48	-0.29	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
HNSC	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	6.67	7.39e-11	4.5e-08	0.56	0.29	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
HNSC	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-6.67	7.39e-11	4.5e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
HNSC	cis	rs7048146	0.51	rs10759347	ENSG00000213539.4	YBX1P6	-6.67	7.39e-11	4.5e-08	-0.33	-0.29	Vascular brain injury;	chr9:109521455	chr9:109532830~109534332:-
HNSC	cis	rs7615952	0.599	rs67566088	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126050130	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs12495947	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126052855	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs6805074	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126053431	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs4422257	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126055520	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs66520539	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126061531	chr3:125827238~125916384:-
HNSC	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	6.67	7.42e-11	4.52e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
HNSC	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-6.67	7.43e-11	4.52e-08	-0.29	-0.29	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
HNSC	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	6.67	7.43e-11	4.52e-08	0.37	0.29	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
HNSC	cis	rs17270561	0.609	rs9393655	ENSG00000272462.2	U91328.19	-6.67	7.44e-11	4.53e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25711110	chr6:25992662~26001775:+
HNSC	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	6.67	7.44e-11	4.53e-08	0.42	0.29	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	6.67	7.44e-11	4.53e-08	0.42	0.29	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
HNSC	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-6.67	7.45e-11	4.53e-08	-0.34	-0.29	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
HNSC	cis	rs2842992	0.672	rs7738253	ENSG00000237927.1	RP3-393E18.2	-6.67	7.45e-11	4.53e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159772885	chr6:159586955~159589169:-
HNSC	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-6.67	7.46e-11	4.54e-08	-0.35	-0.29	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000254340.1	RP11-10A14.3	-6.67	7.47e-11	4.54e-08	-0.35	-0.29	Mood instability;	chr8:8934916	chr8:9141424~9145435:+
HNSC	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-6.67	7.47e-11	4.55e-08	-0.31	-0.29	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
HNSC	cis	rs1799949	0.93	rs34210004	ENSG00000267151.3	RP11-100E5.2	6.67	7.48e-11	4.55e-08	0.38	0.29	Menopause (age at onset);	chr17:43218318	chr17:43444707~43451200:+
HNSC	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	6.67	7.48e-11	4.55e-08	0.39	0.29	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
HNSC	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-6.67	7.48e-11	4.55e-08	-0.36	-0.29	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
HNSC	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	6.66	7.48e-11	4.55e-08	0.41	0.29	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
HNSC	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.5e-11	4.56e-08	-0.36	-0.29	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
HNSC	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-6.66	7.51e-11	4.57e-08	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
HNSC	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-6.66	7.53e-11	4.58e-08	-0.28	-0.29	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
HNSC	cis	rs2235642	0.893	rs2076442	ENSG00000280231.1	LA16c-380F5.3	-6.66	7.53e-11	4.58e-08	-0.36	-0.29	Coronary artery disease;	chr16:1541111	chr16:1553655~1554130:-
HNSC	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	6.66	7.54e-11	4.58e-08	0.42	0.29	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
HNSC	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	6.66	7.54e-11	4.58e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
HNSC	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-6.66	7.54e-11	4.58e-08	-0.53	-0.29	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
HNSC	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-6.66	7.55e-11	4.59e-08	-0.42	-0.29	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
HNSC	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-6.66	7.58e-11	4.61e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
HNSC	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	6.66	7.61e-11	4.62e-08	0.34	0.29	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
HNSC	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-6.66	7.61e-11	4.62e-08	-0.35	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
HNSC	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	6.66	7.61e-11	4.62e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000173295.6	FAM86B3P	6.66	7.61e-11	4.63e-08	0.34	0.29	Mood instability;	chr8:8846820	chr8:8228595~8244865:+
HNSC	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-6.66	7.62e-11	4.63e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
HNSC	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	6.66	7.63e-11	4.63e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	6.66	7.63e-11	4.63e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	6.66	7.63e-11	4.63e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000173295.6	FAM86B3P	6.66	7.63e-11	4.64e-08	0.35	0.29	Mean corpuscular volume;	chr8:8994371	chr8:8228595~8244865:+
HNSC	cis	rs8012947	1	rs10147580	ENSG00000279636.2	LINC00216	-6.66	7.63e-11	4.64e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58247422	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.958	rs7158746	ENSG00000279636.2	LINC00216	-6.66	7.63e-11	4.64e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58254081	chr14:58288033~58289158:+
HNSC	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	6.66	7.64e-11	4.64e-08	0.46	0.29	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
HNSC	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-6.66	7.65e-11	4.65e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
HNSC	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	6.66	7.7e-11	4.68e-08	0.27	0.29	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
HNSC	cis	rs11089937	0.926	rs5750601	ENSG00000211639.2	IGLV4-60	6.66	7.7e-11	4.68e-08	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22162199~22162681:+
HNSC	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-6.66	7.72e-11	4.68e-08	-0.29	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
HNSC	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-6.66	7.74e-11	4.69e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-6.66	7.74e-11	4.69e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-6.66	7.74e-11	4.69e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
HNSC	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	6.66	7.74e-11	4.69e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	6.66	7.74e-11	4.69e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
HNSC	cis	rs2404602	0.655	rs3829489	ENSG00000259422.1	RP11-593F23.1	6.66	7.75e-11	4.7e-08	0.35	0.29	Blood metabolite levels;	chr15:76930915	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-6.66	7.78e-11	4.72e-08	-0.35	-0.29	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
HNSC	cis	rs4141404	0.651	rs5753723	ENSG00000236132.1	CTA-440B3.1	6.66	7.78e-11	4.72e-08	0.43	0.29	Paclitaxel-induced neuropathy;	chr22:31606308	chr22:31816379~31817491:-
HNSC	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
HNSC	cis	rs7083	1	rs7083	ENSG00000254851.1	RP11-109L13.1	6.66	7.79e-11	4.72e-08	0.38	0.29	Blood protein levels;	chr11:117285836	chr11:117135528~117138582:+
HNSC	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.8e-11	4.73e-08	-0.36	-0.29	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	6.66	7.8e-11	4.73e-08	0.3	0.29	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
HNSC	cis	rs7615952	0.688	rs17334074	ENSG00000248787.1	RP11-666A20.4	6.66	7.82e-11	4.74e-08	0.43	0.29	Blood pressure (smoking interaction);	chr3:125821617	chr3:125908005~125910272:-
HNSC	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
HNSC	cis	rs2337406	1	rs75651733	ENSG00000211974.3	IGHV2-70	-6.66	7.84e-11	4.75e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106701309	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.925	rs873534	ENSG00000211974.3	IGHV2-70	-6.66	7.85e-11	4.76e-08	-0.38	-0.29	Alzheimer's disease (late onset);	chr14:106667423	chr14:106723574~106724093:-
HNSC	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	6.66	7.85e-11	4.76e-08	0.37	0.29	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
HNSC	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-6.66	7.86e-11	4.76e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
HNSC	cis	rs11089937	0.597	rs11704434	ENSG00000211638.2	IGLV8-61	-6.66	7.87e-11	4.77e-08	-0.3	-0.29	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22098700~22099212:+
HNSC	cis	rs4141404	0.64	rs9606854	ENSG00000236132.1	CTA-440B3.1	-6.66	7.9e-11	4.78e-08	-0.41	-0.29	Paclitaxel-induced neuropathy;	chr22:31534581	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	6.66	7.9e-11	4.79e-08	0.47	0.29	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
HNSC	cis	rs4218	0.648	rs12442134	ENSG00000259732.1	RP11-59H7.3	-6.66	7.9e-11	4.79e-08	-0.43	-0.29	Social communication problems;	chr15:59074478	chr15:59121034~59133250:+
HNSC	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	6.66	7.93e-11	4.81e-08	0.29	0.29	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
HNSC	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	6.66	7.94e-11	4.81e-08	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
HNSC	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-6.65	7.96e-11	4.82e-08	-0.29	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
HNSC	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	6.65	7.97e-11	4.83e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-6.65	7.97e-11	4.83e-08	-0.29	-0.29	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
HNSC	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-6.65	7.97e-11	4.83e-08	-0.28	-0.29	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
HNSC	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-6.65	7.98e-11	4.83e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
HNSC	cis	rs4218	0.597	rs62002543	ENSG00000259732.1	RP11-59H7.3	-6.65	7.99e-11	4.84e-08	-0.42	-0.29	Social communication problems;	chr15:59066646	chr15:59121034~59133250:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	6.65	7.99e-11	4.84e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
HNSC	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	6.65	8e-11	4.84e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	6.65	8e-11	4.84e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
HNSC	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-6.65	8.02e-11	4.85e-08	-0.37	-0.29	Height;	chr3:52989412	chr3:53064283~53065091:-
HNSC	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	6.65	8.02e-11	4.85e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
HNSC	cis	rs2404602	0.632	rs34338978	ENSG00000259422.1	RP11-593F23.1	6.65	8.03e-11	4.86e-08	0.35	0.29	Blood metabolite levels;	chr15:76934464	chr15:76174891~76181486:-
HNSC	cis	rs35955747	0.902	rs2413048	ENSG00000236132.1	CTA-440B3.1	6.65	8.04e-11	4.87e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31290116	chr22:31816379~31817491:-
HNSC	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-6.65	8.05e-11	4.87e-08	-0.46	-0.29	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
HNSC	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-6.65	8.06e-11	4.88e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
HNSC	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	6.65	8.06e-11	4.88e-08	0.32	0.29	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
HNSC	cis	rs8012947	1	rs10145280	ENSG00000279636.2	LINC00216	-6.65	8.07e-11	4.88e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58303337	chr14:58288033~58289158:+
HNSC	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-6.65	8.07e-11	4.88e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
HNSC	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-6.65	8.12e-11	4.91e-08	-0.38	-0.29	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
HNSC	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	6.65	8.12e-11	4.91e-08	0.35	0.29	Depression;	chr6:28379133	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	6.65	8.12e-11	4.91e-08	0.35	0.29	Depression;	chr6:28379168	chr6:28176188~28176674:+
HNSC	cis	rs8012947	1	rs4595719	ENSG00000279636.2	LINC00216	-6.65	8.15e-11	4.92e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58302084	chr14:58288033~58289158:+
HNSC	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	6.65	8.15e-11	4.93e-08	0.33	0.29	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	6.65	8.15e-11	4.93e-08	0.33	0.29	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	6.65	8.15e-11	4.93e-08	0.33	0.29	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
HNSC	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-6.65	8.16e-11	4.93e-08	-0.57	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
HNSC	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	6.65	8.19e-11	4.95e-08	0.35	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
HNSC	cis	rs35955747	0.838	rs5997887	ENSG00000236132.1	CTA-440B3.1	6.65	8.19e-11	4.95e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31147211	chr22:31816379~31817491:-
HNSC	cis	rs6471393	0.893	rs2976350	ENSG00000253848.1	RP11-10N23.5	-6.65	8.2e-11	4.95e-08	-0.36	-0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716818	chr8:93741193~93744534:+
HNSC	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	6.65	8.2e-11	4.96e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
HNSC	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-6.65	8.21e-11	4.96e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
HNSC	cis	rs1659258	0.541	rs1270162	ENSG00000232508.1	MRPL45P1	-6.65	8.21e-11	4.96e-08	-0.61	-0.29	Visceral fat;	chr2:88351914	chr2:88364695~88365608:-
HNSC	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	6.65	8.21e-11	4.96e-08	0.29	0.29	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
HNSC	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	6.65	8.24e-11	4.98e-08	0.42	0.29	Height;	chr6:109415050	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	6.65	8.24e-11	4.98e-08	0.42	0.29	Height;	chr6:109416945	chr6:109382795~109383666:+
HNSC	cis	rs453301	0.686	rs28482034	ENSG00000254340.1	RP11-10A14.3	-6.65	8.25e-11	4.98e-08	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9012154	chr8:9141424~9145435:+
HNSC	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-6.65	8.27e-11	4.99e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
HNSC	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-6.65	8.27e-11	4.99e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
HNSC	cis	rs7115242	0.669	rs1241658	ENSG00000280143.1	AP000892.6	6.65	8.28e-11	5e-08	0.44	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs511676	ENSG00000280143.1	AP000892.6	6.65	8.28e-11	5e-08	0.44	0.29	Blood protein levels;	chr11:116954168	chr11:117204967~117210292:+
HNSC	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	6.65	8.3e-11	5.01e-08	0.35	0.29	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
HNSC	cis	rs394563	0.559	rs7753269	ENSG00000231760.4	RP11-350J20.5	-6.65	8.3e-11	5.01e-08	-0.36	-0.29	Dupuytren's disease;	chr6:149350224	chr6:149796151~149826294:-
HNSC	cis	rs947583	0.588	rs981580	ENSG00000217482.2	HMGB1P17	6.65	8.34e-11	5.04e-08	0.34	0.29	Phosphorus levels;	chr6:135786492	chr6:135636086~135636713:-
HNSC	cis	rs11089937	0.626	rs5750589	ENSG00000211638.2	IGLV8-61	-6.65	8.35e-11	5.04e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs5757038	ENSG00000211638.2	IGLV8-61	-6.65	8.35e-11	5.04e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22098700~22099212:+
HNSC	cis	rs9341808	0.935	rs2322633	ENSG00000272129.1	RP11-250B2.6	-6.65	8.36e-11	5.05e-08	-0.34	-0.29	Sitting height ratio;	chr6:80136272	chr6:80355424~80356859:+
HNSC	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	6.65	8.36e-11	5.05e-08	0.35	0.29	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
HNSC	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
HNSC	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-6.65	8.37e-11	5.05e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-6.65	8.37e-11	5.05e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
HNSC	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	6.65	8.37e-11	5.05e-08	0.35	0.29	Depression;	chr6:28386473	chr6:28176188~28176674:+
HNSC	cis	rs2880765	0.835	rs6496027	ENSG00000259295.5	CSPG4P12	6.65	8.38e-11	5.06e-08	0.34	0.29	Coronary artery disease;	chr15:85506757	chr15:85191438~85213905:+
HNSC	cis	rs9341808	0.69	rs2505932	ENSG00000272129.1	RP11-250B2.6	6.65	8.39e-11	5.06e-08	0.34	0.29	Sitting height ratio;	chr6:80129535	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.667	rs2322632	ENSG00000272129.1	RP11-250B2.6	6.65	8.39e-11	5.06e-08	0.34	0.29	Sitting height ratio;	chr6:80135891	chr6:80355424~80356859:+
HNSC	cis	rs11089937	0.825	rs5757012	ENSG00000211638.2	IGLV8-61	-6.65	8.39e-11	5.06e-08	-0.25	-0.29	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22098700~22099212:+
HNSC	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	6.65	8.39e-11	5.06e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
HNSC	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	6.65	8.4e-11	5.07e-08	0.27	0.29	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
HNSC	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	6.65	8.4e-11	5.07e-08	0.31	0.29	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
HNSC	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
HNSC	cis	rs1799949	0.931	rs34410138	ENSG00000267151.3	RP11-100E5.2	6.65	8.42e-11	5.08e-08	0.38	0.29	Menopause (age at onset);	chr17:43127753	chr17:43444707~43451200:+
HNSC	cis	rs8012947	0.877	rs10136481	ENSG00000279636.2	LINC00216	-6.65	8.43e-11	5.08e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58302690	chr14:58288033~58289158:+
HNSC	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-6.65	8.43e-11	5.08e-08	-0.35	-0.29	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
HNSC	cis	rs9326248	0.53	rs2513095	ENSG00000280143.1	AP000892.6	6.65	8.44e-11	5.08e-08	0.44	0.29	Blood protein levels;	chr11:116935553	chr11:117204967~117210292:+
HNSC	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-6.65	8.44e-11	5.09e-08	-0.36	-0.29	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
HNSC	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-6.65	8.45e-11	5.09e-08	-0.37	-0.29	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
HNSC	cis	rs860295	1	rs6427287	ENSG00000203761.5	MSTO2P	-6.65	8.45e-11	5.09e-08	-0.21	-0.29	Body mass index;	chr1:155753629	chr1:155745829~155750137:+
HNSC	cis	rs7829975	0.807	rs519019	ENSG00000173295.6	FAM86B3P	-6.65	8.46e-11	5.1e-08	-0.34	-0.29	Mood instability;	chr8:8737594	chr8:8228595~8244865:+
HNSC	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-6.65	8.46e-11	5.1e-08	-0.37	-0.29	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
HNSC	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	6.65	8.47e-11	5.1e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
HNSC	cis	rs9402743	0.634	rs9494306	ENSG00000217482.2	HMGB1P17	6.64	8.47e-11	5.11e-08	0.32	0.29	Systemic lupus erythematosus;	chr6:135622823	chr6:135636086~135636713:-
HNSC	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-6.64	8.48e-11	5.11e-08	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
HNSC	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	6.64	8.49e-11	5.11e-08	0.34	0.29	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-6.64	8.49e-11	5.12e-08	-0.19	-0.29	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
HNSC	cis	rs6471393	0.895	rs58103546	ENSG00000253848.1	RP11-10N23.5	6.64	8.5e-11	5.12e-08	0.37	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749483	chr8:93741193~93744534:+
HNSC	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	6.64	8.51e-11	5.13e-08	0.35	0.29	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
HNSC	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	6.64	8.53e-11	5.14e-08	0.4	0.29	Height;	chr6:109407148	chr6:109382795~109383666:+
HNSC	cis	rs4218	0.573	rs4775115	ENSG00000259732.1	RP11-59H7.3	-6.64	8.54e-11	5.14e-08	-0.4	-0.29	Social communication problems;	chr15:59076311	chr15:59121034~59133250:+
HNSC	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-6.64	8.54e-11	5.14e-08	-0.34	-0.29	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
HNSC	cis	rs11089937	0.626	rs5757056	ENSG00000211638.2	IGLV8-61	-6.64	8.58e-11	5.17e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22098700~22099212:+
HNSC	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	6.64	8.58e-11	5.17e-08	0.31	0.29	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
HNSC	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	6.64	8.59e-11	5.17e-08	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
HNSC	cis	rs9402743	0.67	rs7769840	ENSG00000217482.2	HMGB1P17	-6.64	8.59e-11	5.17e-08	-0.33	-0.29	Systemic lupus erythematosus;	chr6:135605412	chr6:135636086~135636713:-
HNSC	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-6.64	8.62e-11	5.19e-08	-0.35	-0.29	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
HNSC	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	6.64	8.63e-11	5.19e-08	0.34	0.29	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
HNSC	cis	rs6081541	0.689	rs6081546	ENSG00000179447.2	RP5-1027G4.3	-6.64	8.65e-11	5.2e-08	-0.36	-0.29	Psychosis (atypical);	chr20:19240785	chr20:19242302~19284596:-
HNSC	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-6.64	8.65e-11	5.2e-08	-0.31	-0.29	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-6.64	8.65e-11	5.2e-08	-0.31	-0.29	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-6.64	8.65e-11	5.2e-08	-0.31	-0.29	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
HNSC	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	6.64	8.66e-11	5.21e-08	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
HNSC	cis	rs2579103	0.63	rs862233	ENSG00000258183.4	RP11-753N8.1	-6.64	8.66e-11	5.21e-08	-0.39	-0.29	Body mass index;	chr12:90312060	chr12:90280894~90300340:+
HNSC	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	6.64	8.67e-11	5.21e-08	0.33	0.29	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
HNSC	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.67e-11	5.22e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.67e-11	5.22e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
HNSC	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-6.64	8.67e-11	5.22e-08	-0.33	-0.29	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
HNSC	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	6.64	8.7e-11	5.23e-08	0.48	0.29	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
HNSC	cis	rs2404602	0.692	rs12910734	ENSG00000259422.1	RP11-593F23.1	6.64	8.7e-11	5.23e-08	0.34	0.29	Blood metabolite levels;	chr15:76857590	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs12911174	ENSG00000259422.1	RP11-593F23.1	6.64	8.7e-11	5.23e-08	0.34	0.29	Blood metabolite levels;	chr15:76857602	chr15:76174891~76181486:-
HNSC	cis	rs1355223	0.902	rs1258464	ENSG00000271369.1	RP11-350D17.3	-6.64	8.71e-11	5.23e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709949	chr11:34709600~34710161:+
HNSC	cis	rs1075265	0.564	rs2160930	ENSG00000233266.1	HMGB1P31	6.64	8.71e-11	5.24e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53655390	chr2:54051334~54051760:+
HNSC	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	6.64	8.73e-11	5.25e-08	0.27	0.29	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
HNSC	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	6.64	8.73e-11	5.25e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
HNSC	cis	rs1355223	0.872	rs7116409	ENSG00000271369.1	RP11-350D17.3	-6.64	8.73e-11	5.25e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729460	chr11:34709600~34710161:+
HNSC	cis	rs35955747	0.902	rs12166373	ENSG00000236132.1	CTA-440B3.1	6.64	8.74e-11	5.25e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31304522	chr22:31816379~31817491:-
HNSC	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-6.64	8.74e-11	5.25e-08	-0.32	-0.29	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
HNSC	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-6.64	8.74e-11	5.25e-08	-0.37	-0.29	QT interval;	chr16:28824579	chr16:28700294~28701540:-
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000173295.6	FAM86B3P	6.64	8.75e-11	5.26e-08	0.33	0.29	Mood instability;	chr8:8460105	chr8:8228595~8244865:+
HNSC	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-6.64	8.78e-11	5.27e-08	-0.36	-0.29	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
HNSC	cis	rs7615952	0.611	rs2947646	ENSG00000248787.1	RP11-666A20.4	6.64	8.78e-11	5.27e-08	0.5	0.29	Blood pressure (smoking interaction);	chr3:125874759	chr3:125908005~125910272:-
HNSC	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	6.64	8.78e-11	5.28e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	6.64	8.78e-11	5.28e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
HNSC	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	6.64	8.79e-11	5.28e-08	0.33	0.29	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
HNSC	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-6.64	8.8e-11	5.29e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
HNSC	cis	rs667920	0.512	rs13069695	ENSG00000239213.4	NCK1-AS1	-6.64	8.81e-11	5.29e-08	-0.39	-0.29	Coronary artery disease;	chr3:136572720	chr3:136841726~136862054:-
HNSC	cis	rs6471393	0.964	rs1051914	ENSG00000253848.1	RP11-10N23.5	6.64	8.81e-11	5.29e-08	0.37	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93728838	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.964	rs2914952	ENSG00000253848.1	RP11-10N23.5	6.64	8.81e-11	5.29e-08	0.37	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93729524	chr8:93741193~93744534:+
HNSC	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.82e-11	5.3e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.82e-11	5.3e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
HNSC	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-6.64	8.82e-11	5.3e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-6.64	8.82e-11	5.3e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-6.64	8.82e-11	5.3e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
HNSC	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-6.64	8.82e-11	5.3e-08	-0.37	-0.29	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
HNSC	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
HNSC	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	6.64	8.85e-11	5.31e-08	0.45	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
HNSC	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-6.64	8.86e-11	5.32e-08	-0.37	-0.29	Height;	chr3:52989619	chr3:53064283~53065091:-
HNSC	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-6.64	8.87e-11	5.32e-08	-0.32	-0.29	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
HNSC	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	6.64	8.87e-11	5.32e-08	0.36	0.29	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
HNSC	cis	rs17270561	0.609	rs1317510	ENSG00000272462.2	U91328.19	-6.64	8.87e-11	5.32e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25778696	chr6:25992662~26001775:+
HNSC	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	6.64	8.87e-11	5.32e-08	0.29	0.29	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
HNSC	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
HNSC	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-6.64	8.89e-11	5.33e-08	-0.36	-0.29	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
HNSC	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-6.64	8.89e-11	5.34e-08	-0.31	-0.29	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
HNSC	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-6.64	8.9e-11	5.34e-08	-0.39	-0.29	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
HNSC	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	6.64	8.9e-11	5.34e-08	0.31	0.29	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	-6.64	8.92e-11	5.35e-08	-0.33	-0.29	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
HNSC	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	6.64	8.94e-11	5.36e-08	0.33	0.29	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000254340.1	RP11-10A14.3	6.64	8.96e-11	5.37e-08	0.35	0.29	Joint mobility (Beighton score);	chr8:9044861	chr8:9141424~9145435:+
HNSC	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-6.64	8.97e-11	5.38e-08	-0.35	-0.29	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
HNSC	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
HNSC	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	6.64	8.99e-11	5.39e-08	0.59	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
HNSC	cis	rs7615952	0.673	rs115942855	ENSG00000241288.6	RP11-379B18.5	-6.64	9e-11	5.4e-08	-0.51	-0.29	Blood pressure (smoking interaction);	chr3:125883117	chr3:125827238~125916384:-
HNSC	cis	rs9326248	0.53	rs510988	ENSG00000280143.1	AP000892.6	6.63	9.01e-11	5.4e-08	0.44	0.29	Blood protein levels;	chr11:116943088	chr11:117204967~117210292:+
HNSC	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	6.63	9.02e-11	5.41e-08	0.38	0.29	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
HNSC	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-6.63	9.02e-11	5.41e-08	-0.37	-0.29	QT interval;	chr16:28857143	chr16:28700294~28701540:-
HNSC	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-6.63	9.03e-11	5.41e-08	-0.31	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
HNSC	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	6.63	9.04e-11	5.42e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
HNSC	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	6.63	9.04e-11	5.42e-08	0.33	0.29	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
HNSC	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-6.63	9.06e-11	5.43e-08	-0.36	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
HNSC	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	6.63	9.06e-11	5.43e-08	0.33	0.29	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
HNSC	cis	rs5753618	0.561	rs2283879	ENSG00000236132.1	CTA-440B3.1	6.63	9.1e-11	5.45e-08	0.36	0.29	Colorectal cancer;	chr22:31242462	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2283881	ENSG00000236132.1	CTA-440B3.1	6.63	9.1e-11	5.45e-08	0.36	0.29	Colorectal cancer;	chr22:31242946	chr22:31816379~31817491:-
HNSC	cis	rs2985684	0.948	rs2883437	ENSG00000258568.1	RHOQP1	6.63	9.13e-11	5.47e-08	0.3	0.29	Carotid intima media thickness;	chr14:49564948	chr14:49599994~49600572:+
HNSC	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	6.63	9.13e-11	5.47e-08	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
HNSC	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-6.63	9.14e-11	5.47e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-6.63	9.15e-11	5.48e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
HNSC	cis	rs10504130	0.696	rs77958054	ENSG00000272024.1	RP11-546K22.3	-6.63	9.15e-11	5.48e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51926157	chr8:51950284~51950690:+
HNSC	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-6.63	9.18e-11	5.5e-08	-0.73	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
HNSC	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-6.63	9.18e-11	5.5e-08	-0.35	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
HNSC	cis	rs9326248	0.861	rs11216172	ENSG00000280143.1	AP000892.6	6.63	9.18e-11	5.5e-08	0.35	0.29	Blood protein levels;	chr11:116879162	chr11:117204967~117210292:+
HNSC	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.84	rs555617	ENSG00000173295.6	FAM86B3P	-6.63	9.19e-11	5.5e-08	-0.34	-0.29	Mood instability;	chr8:8735335	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.576	rs66671308	ENSG00000241288.6	RP11-379B18.5	-6.63	9.2e-11	5.51e-08	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:126074683	chr3:125827238~125916384:-
HNSC	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	6.63	9.2e-11	5.51e-08	0.28	0.29	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
HNSC	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-6.63	9.21e-11	5.51e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
HNSC	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-6.63	9.22e-11	5.52e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
HNSC	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-6.63	9.23e-11	5.52e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
HNSC	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	6.63	9.23e-11	5.52e-08	0.35	0.29	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
HNSC	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-6.63	9.24e-11	5.53e-08	-0.28	-0.29	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
HNSC	cis	rs17270561	0.609	rs2154218	ENSG00000272462.2	U91328.19	-6.63	9.28e-11	5.55e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25776062	chr6:25992662~26001775:+
HNSC	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-6.63	9.3e-11	5.56e-08	-0.28	-0.29	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
HNSC	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-6.63	9.31e-11	5.57e-08	-0.31	-0.29	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
HNSC	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	6.63	9.32e-11	5.57e-08	0.39	0.29	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
HNSC	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-6.63	9.34e-11	5.58e-08	-0.35	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
HNSC	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-6.63	9.35e-11	5.59e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
HNSC	cis	rs1021993	0.545	rs1507331	ENSG00000231648.1	RP11-372M18.2	-6.63	9.35e-11	5.59e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209343552	chr1:209367662~209379690:+
HNSC	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	6.63	9.37e-11	5.6e-08	0.39	0.29	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
HNSC	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-6.63	9.39e-11	5.61e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
HNSC	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-6.63	9.41e-11	5.62e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
HNSC	cis	rs12439619	0.846	rs7496227	ENSG00000276710.3	CSPG4P8	-6.63	9.41e-11	5.62e-08	-0.38	-0.29	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82459472~82477258:+
HNSC	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-6.63	9.41e-11	5.62e-08	-0.37	-0.29	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.692	rs60658665	ENSG00000259422.1	RP11-593F23.1	6.63	9.43e-11	5.63e-08	0.34	0.29	Blood metabolite levels;	chr15:76750167	chr15:76174891~76181486:-
HNSC	cis	rs7615952	0.599	rs6438955	ENSG00000241288.6	RP11-379B18.5	-6.63	9.45e-11	5.65e-08	-0.38	-0.29	Blood pressure (smoking interaction);	chr3:126011490	chr3:125827238~125916384:-
HNSC	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-6.63	9.46e-11	5.65e-08	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
HNSC	cis	rs1021993	0.597	rs17014323	ENSG00000231648.1	RP11-372M18.2	-6.63	9.48e-11	5.66e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209340507	chr1:209367662~209379690:+
HNSC	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-6.63	9.49e-11	5.67e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
HNSC	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	6.63	9.49e-11	5.67e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	6.63	9.51e-11	5.68e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
HNSC	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	6.63	9.52e-11	5.69e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	6.63	9.52e-11	5.69e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	6.63	9.52e-11	5.69e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
HNSC	cis	rs35955747	0.869	rs7286648	ENSG00000236132.1	CTA-440B3.1	-6.63	9.54e-11	5.7e-08	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31143628	chr22:31816379~31817491:-
HNSC	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	6.63	9.54e-11	5.7e-08	0.28	0.29	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
HNSC	cis	rs453301	0.686	rs28665409	ENSG00000254340.1	RP11-10A14.3	-6.63	9.55e-11	5.7e-08	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9011767	chr8:9141424~9145435:+
HNSC	cis	rs2404602	0.669	rs1875885	ENSG00000259422.1	RP11-593F23.1	6.63	9.55e-11	5.7e-08	0.34	0.29	Blood metabolite levels;	chr15:76345740	chr15:76174891~76181486:-
HNSC	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	6.63	9.56e-11	5.71e-08	0.36	0.29	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
HNSC	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	6.63	9.57e-11	5.71e-08	0.46	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
HNSC	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-6.63	9.58e-11	5.72e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
HNSC	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	6.62	9.6e-11	5.73e-08	0.35	0.29	Depression;	chr6:28317705	chr6:28943877~28944537:+
HNSC	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	6.62	9.61e-11	5.73e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	6.62	9.61e-11	5.73e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
HNSC	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-6.62	9.61e-11	5.74e-08	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
HNSC	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	6.62	9.61e-11	5.74e-08	0.33	0.29	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-6.62	9.62e-11	5.74e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-6.62	9.62e-11	5.74e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
HNSC	cis	rs11089937	0.626	rs9619800	ENSG00000211638.2	IGLV8-61	-6.62	9.62e-11	5.74e-08	-0.29	-0.29	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22098700~22099212:+
HNSC	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-6.62	9.63e-11	5.75e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
HNSC	cis	rs17270561	0.636	rs12194699	ENSG00000272462.2	U91328.19	-6.62	9.64e-11	5.75e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25729001	chr6:25992662~26001775:+
HNSC	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-6.62	9.65e-11	5.75e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
HNSC	cis	rs13113518	0.683	rs9761521	ENSG00000273257.1	RP11-177J6.1	6.62	9.65e-11	5.76e-08	0.36	0.29	Height;	chr4:55363436	chr4:55387949~55388271:+
HNSC	cis	rs9341808	0.667	rs6938280	ENSG00000272129.1	RP11-250B2.6	6.62	9.66e-11	5.76e-08	0.34	0.29	Sitting height ratio;	chr6:80188065	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000173295.6	FAM86B3P	-6.62	9.71e-11	5.79e-08	-0.32	-0.29	Joint mobility (Beighton score);	chr8:9226261	chr8:8228595~8244865:+
HNSC	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	6.62	9.75e-11	5.81e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-6.62	9.76e-11	5.82e-08	-0.39	-0.29	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
HNSC	cis	rs17270561	0.609	rs9379786	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25730027	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs12203927	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25732462	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs12192077	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25732566	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711098	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25734111	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs4360128	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25734330	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs3922699	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25734741	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs6924782	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25735588	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs6924794	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25735646	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs3922842	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25736336	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358876	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738728	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.583	rs9393661	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738852	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9356986	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738891	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358877	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25739000	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs12663099	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25739290	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9393662	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25739442	chr6:25992662~26001775:+
HNSC	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	6.62	9.77e-11	5.82e-08	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
HNSC	cis	rs35955747	0.84	rs9621221	ENSG00000236132.1	CTA-440B3.1	6.62	9.77e-11	5.82e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31220183	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs5997919	ENSG00000236132.1	CTA-440B3.1	6.62	9.77e-11	5.82e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31227456	chr22:31816379~31817491:-
HNSC	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	6.62	9.77e-11	5.82e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
HNSC	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-6.62	9.81e-11	5.84e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
HNSC	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-6.62	9.81e-11	5.84e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
HNSC	cis	rs453301	0.682	rs2929451	ENSG00000254340.1	RP11-10A14.3	6.62	9.82e-11	5.85e-08	0.34	0.29	Joint mobility (Beighton score);	chr8:9227785	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	6.62	9.83e-11	5.85e-08	0.38	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
HNSC	cis	rs17270561	0.609	rs9393658	ENSG00000272462.2	U91328.19	-6.62	9.85e-11	5.86e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25730210	chr6:25992662~26001775:+
HNSC	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-6.62	9.85e-11	5.87e-08	-0.36	-0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
HNSC	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-6.62	9.87e-11	5.88e-08	-0.29	-0.29	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
HNSC	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-6.62	9.87e-11	5.88e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
HNSC	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.87e-11	5.88e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.597	rs5750582	ENSG00000211638.2	IGLV8-61	-6.62	9.92e-11	5.91e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22098700~22099212:+
HNSC	cis	rs4938303	0.756	rs4938301	ENSG00000254851.1	RP11-109L13.1	6.62	9.94e-11	5.91e-08	0.46	0.29	Triglycerides;	chr11:116704757	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-6.62	9.94e-11	5.91e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	6.62	9.99e-11	5.94e-08	0.33	0.29	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
HNSC	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	6.62	1e-10	5.95e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.692	rs4886503	ENSG00000259422.1	RP11-593F23.1	-6.62	1e-10	5.95e-08	-0.34	-0.29	Blood metabolite levels;	chr15:76816533	chr15:76174891~76181486:-
HNSC	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-6.62	1e-10	5.96e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
HNSC	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
HNSC	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-6.62	1e-10	5.96e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
HNSC	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
HNSC	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	6.62	1.01e-10	5.99e-08	0.42	0.29	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	6.62	1.01e-10	5.99e-08	0.42	0.29	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
HNSC	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-6.62	1.01e-10	6e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-6.62	1.01e-10	6e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
HNSC	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	6.62	1.01e-10	6e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	6.62	1.01e-10	6e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
HNSC	cis	rs8012947	1	rs12323535	ENSG00000279636.2	LINC00216	-6.62	1.01e-10	6e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58303137	chr14:58288033~58289158:+
HNSC	cis	rs757110	0.77	rs1557765	ENSG00000260196.1	RP1-239B22.5	6.62	1.01e-10	6.01e-08	0.33	0.29	Type 2 diabetes;	chr11:17382092	chr11:17380649~17383531:+
HNSC	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-6.62	1.01e-10	6.01e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
HNSC	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-6.62	1.01e-10	6.02e-08	-0.45	-0.29	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
HNSC	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	6.62	1.01e-10	6.03e-08	0.34	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
HNSC	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-6.62	1.02e-10	6.04e-08	-0.33	-0.29	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-6.62	1.02e-10	6.04e-08	-0.33	-0.29	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
HNSC	cis	rs6504622	0.935	rs740617	ENSG00000262879.4	RP11-156P1.3	6.62	1.02e-10	6.05e-08	0.31	0.29	Orofacial clefts;	chr17:46950635	chr17:46984045~47100323:-
HNSC	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-6.62	1.02e-10	6.05e-08	-0.36	-0.29	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-6.62	1.02e-10	6.05e-08	-0.36	-0.29	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
HNSC	cis	rs10504130	0.696	rs12676835	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs12677407	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs59602923	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs113096282	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.735	rs77362085	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.735	rs12681203	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.735	rs12679287	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51950284~51950690:+
HNSC	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	6.61	1.02e-10	6.07e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
HNSC	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	6.61	1.02e-10	6.08e-08	0.27	0.29	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
HNSC	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	6.61	1.02e-10	6.08e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
HNSC	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-6.61	1.03e-10	6.09e-08	-0.28	-0.29	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
HNSC	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
HNSC	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
HNSC	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	6.61	1.03e-10	6.09e-08	0.33	0.29	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
HNSC	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	6.61	1.03e-10	6.09e-08	0.31	0.29	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000254340.1	RP11-10A14.3	-6.61	1.03e-10	6.11e-08	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9226344	chr8:9141424~9145435:+
HNSC	cis	rs4218	0.648	rs877269	ENSG00000259732.1	RP11-59H7.3	-6.61	1.03e-10	6.11e-08	-0.42	-0.29	Social communication problems;	chr15:59081595	chr15:59121034~59133250:+
HNSC	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-6.61	1.03e-10	6.11e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
HNSC	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	6.61	1.03e-10	6.11e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	6.61	1.03e-10	6.12e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
HNSC	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	6.61	1.03e-10	6.12e-08	0.32	0.29	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
HNSC	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-6.61	1.03e-10	6.13e-08	-0.31	-0.29	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
HNSC	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	6.61	1.03e-10	6.13e-08	0.29	0.29	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
HNSC	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-6.61	1.04e-10	6.14e-08	-0.37	-0.29	Height;	chr3:52991821	chr3:53064283~53065091:-
HNSC	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-6.61	1.04e-10	6.14e-08	-0.49	-0.29	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-6.61	1.04e-10	6.15e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
HNSC	cis	rs2404602	0.669	rs12441484	ENSG00000259422.1	RP11-593F23.1	6.61	1.04e-10	6.16e-08	0.34	0.29	Blood metabolite levels;	chr15:76817534	chr15:76174891~76181486:-
HNSC	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-6.61	1.04e-10	6.16e-08	-0.31	-0.29	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
HNSC	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	6.61	1.04e-10	6.17e-08	0.26	0.29	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	6.61	1.04e-10	6.18e-08	0.26	0.29	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
HNSC	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-6.61	1.04e-10	6.18e-08	-0.31	-0.29	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000254340.1	RP11-10A14.3	6.61	1.04e-10	6.18e-08	0.36	0.29	Joint mobility (Beighton score);	chr8:9003384	chr8:9141424~9145435:+
HNSC	cis	rs189798	1	rs189798	ENSG00000173295.6	FAM86B3P	-6.61	1.04e-10	6.18e-08	-0.34	-0.29	Myopia (pathological);	chr8:9133067	chr8:8228595~8244865:+
HNSC	cis	rs440932	0.887	rs398801	ENSG00000173295.6	FAM86B3P	-6.61	1.04e-10	6.19e-08	-0.36	-0.29	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8228595~8244865:+
HNSC	cis	rs9341808	0.667	rs2490241	ENSG00000272129.1	RP11-250B2.6	6.61	1.04e-10	6.19e-08	0.34	0.29	Sitting height ratio;	chr6:80136625	chr6:80355424~80356859:+
HNSC	cis	rs6504622	0.905	rs9898981	ENSG00000262879.4	RP11-156P1.3	6.61	1.04e-10	6.19e-08	0.31	0.29	Orofacial clefts;	chr17:46949349	chr17:46984045~47100323:-
HNSC	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
HNSC	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
HNSC	cis	rs867371	0.519	rs1566560	ENSG00000276710.3	CSPG4P8	-6.61	1.05e-10	6.2e-08	-0.32	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82459472~82477258:+
HNSC	cis	rs867371	0.519	rs1566559	ENSG00000276710.3	CSPG4P8	-6.61	1.05e-10	6.2e-08	-0.32	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82459472~82477258:+
HNSC	cis	rs11089937	0.609	rs2213158	ENSG00000211638.2	IGLV8-61	-6.61	1.05e-10	6.2e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.637	rs2213159	ENSG00000211638.2	IGLV8-61	-6.61	1.05e-10	6.2e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22098700~22099212:+
HNSC	cis	rs673078	0.66	rs61943525	ENSG00000275409.1	RP11-131L12.4	-6.61	1.05e-10	6.21e-08	-0.5	-0.29	Glucose homeostasis traits;	chr12:118152927	chr12:118430147~118430699:+
HNSC	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-6.61	1.05e-10	6.22e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-6.61	1.05e-10	6.22e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-6.61	1.05e-10	6.22e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	6.61	1.05e-10	6.22e-08	0.35	0.29	Depression;	chr6:28303421	chr6:28943877~28944537:+
HNSC	cis	rs2579103	0.708	rs1470032	ENSG00000258183.4	RP11-753N8.1	-6.61	1.05e-10	6.22e-08	-0.39	-0.29	Body mass index;	chr12:90277350	chr12:90280894~90300340:+
HNSC	cis	rs75422866	0.85	rs73111226	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47582204	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.702	rs12426387	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47582915	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.85	rs12423789	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47583112	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.702	rs73111229	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47583333	chr12:47731908~47732351:+
HNSC	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	6.61	1.05e-10	6.23e-08	0.51	0.29	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
HNSC	cis	rs8177876	0.57	rs11863158	ENSG00000261061.1	RP11-303E16.2	-6.61	1.05e-10	6.23e-08	-0.48	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81030770~81031485:+
HNSC	cis	rs7000734	0.598	rs2678841	ENSG00000245080.5	RP11-320N21.1	-6.61	1.05e-10	6.23e-08	-0.43	-0.29	Radiation response;	chr8:95076287	chr8:95066808~95073182:-
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000173295.6	FAM86B3P	6.61	1.05e-10	6.24e-08	0.33	0.29	Mood instability;	chr8:8795379	chr8:8228595~8244865:+
HNSC	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-6.61	1.06e-10	6.28e-08	-0.37	-0.29	Height;	chr3:53093751	chr3:53064283~53065091:-
HNSC	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	6.61	1.06e-10	6.28e-08	0.31	0.29	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
HNSC	cis	rs7674212	0.865	rs1481279	ENSG00000246560.2	RP11-10L12.4	-6.61	1.06e-10	6.28e-08	-0.33	-0.29	Type 2 diabetes;	chr4:103056781	chr4:102828055~102844075:+
HNSC	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	6.61	1.06e-10	6.29e-08	0.32	0.29	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	6.61	1.06e-10	6.29e-08	0.26	0.29	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
HNSC	cis	rs11089937	0.626	rs11704092	ENSG00000211638.2	IGLV8-61	-6.61	1.06e-10	6.3e-08	-0.29	-0.29	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22098700~22099212:+
HNSC	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-6.61	1.06e-10	6.3e-08	-0.37	-0.29	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000254340.1	RP11-10A14.3	-6.61	1.07e-10	6.31e-08	-0.36	-0.29	Mood instability;	chr8:8938391	chr8:9141424~9145435:+
HNSC	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	6.61	1.07e-10	6.31e-08	0.31	0.29	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
HNSC	cis	rs2337406	0.929	rs11847182	ENSG00000211974.3	IGHV2-70	-6.61	1.07e-10	6.31e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106697724	chr14:106723574~106724093:-
HNSC	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	6.61	1.07e-10	6.32e-08	0.31	0.29	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
HNSC	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-6.61	1.07e-10	6.32e-08	-0.35	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
HNSC	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-6.61	1.07e-10	6.32e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
HNSC	cis	rs1355223	0.872	rs12802798	ENSG00000271369.1	RP11-350D17.3	-6.61	1.07e-10	6.32e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725887	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	6.61	1.07e-10	6.32e-08	0.35	0.29	Depression;	chr6:28364057	chr6:28176188~28176674:+
HNSC	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	6.61	1.07e-10	6.34e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
HNSC	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	6.61	1.07e-10	6.35e-08	0.35	0.29	Height;	chr4:55577294	chr4:55363971~55395847:-
HNSC	cis	rs6951245	1	rs78896566	ENSG00000225146.1	AC073957.15	-6.61	1.08e-10	6.38e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79422648	ENSG00000225146.1	AC073957.15	-6.61	1.08e-10	6.38e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs113119264	ENSG00000225146.1	AC073957.15	-6.61	1.08e-10	6.38e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1029025~1043891:+
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-6.61	1.08e-10	6.38e-08	-0.19	-0.29	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
HNSC	cis	rs394563	0.559	rs13219868	ENSG00000231760.4	RP11-350J20.5	-6.61	1.08e-10	6.39e-08	-0.36	-0.29	Dupuytren's disease;	chr6:149365382	chr6:149796151~149826294:-
HNSC	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	6.61	1.08e-10	6.39e-08	0.4	0.29	Height;	chr6:109452743	chr6:109382795~109383666:+
HNSC	cis	rs6504622	0.935	rs17608961	ENSG00000262879.4	RP11-156P1.3	-6.61	1.08e-10	6.41e-08	-0.31	-0.29	Orofacial clefts;	chr17:46952302	chr17:46984045~47100323:-
HNSC	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-6.6	1.08e-10	6.41e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
HNSC	cis	rs2579103	0.708	rs2579102	ENSG00000258183.4	RP11-753N8.1	-6.6	1.09e-10	6.42e-08	-0.39	-0.29	Body mass index;	chr12:90291557	chr12:90280894~90300340:+
HNSC	cis	rs17270561	0.609	rs4464787	ENSG00000272462.2	U91328.19	-6.6	1.09e-10	6.43e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25733330	chr6:25992662~26001775:+
HNSC	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	6.6	1.09e-10	6.43e-08	0.27	0.29	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
HNSC	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-6.6	1.09e-10	6.44e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
HNSC	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	6.6	1.1e-10	6.48e-08	0.59	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
HNSC	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	6.6	1.1e-10	6.48e-08	0.59	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
HNSC	cis	rs451417	1	rs384578	ENSG00000275632.1	RP5-967N21.11	-6.6	1.1e-10	6.48e-08	-0.35	-0.29	Menopause (age at onset);	chr20:6000830	chr20:6000418~6000941:+
HNSC	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-6.6	1.1e-10	6.48e-08	-0.31	-0.29	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
HNSC	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-6.6	1.1e-10	6.5e-08	-0.35	-0.29	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
HNSC	cis	rs10504130	0.696	rs76522329	ENSG00000272024.1	RP11-546K22.3	-6.6	1.1e-10	6.51e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51950284~51950690:+
HNSC	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000254340.1	RP11-10A14.3	-6.6	1.11e-10	6.55e-08	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9036071	chr8:9141424~9145435:+
HNSC	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-6.6	1.11e-10	6.55e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
HNSC	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-6.6	1.11e-10	6.55e-08	-0.29	-0.29	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-6.6	1.11e-10	6.58e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-6.6	1.11e-10	6.58e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
HNSC	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	6.6	1.12e-10	6.59e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	6.6	1.12e-10	6.59e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
HNSC	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	6.6	1.12e-10	6.59e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	6.6	1.12e-10	6.59e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	6.6	1.12e-10	6.59e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
HNSC	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	6.6	1.12e-10	6.59e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
HNSC	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	6.6	1.12e-10	6.6e-08	0.7	0.29	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
HNSC	cis	rs35955747	0.902	rs7288735	ENSG00000236132.1	CTA-440B3.1	6.6	1.12e-10	6.61e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283560	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs7288643	ENSG00000236132.1	CTA-440B3.1	6.6	1.12e-10	6.61e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283683	chr22:31816379~31817491:-
HNSC	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	6.6	1.12e-10	6.61e-08	0.52	0.29	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
HNSC	cis	rs5753618	0.509	rs2079431	ENSG00000236132.1	CTA-440B3.1	6.6	1.12e-10	6.61e-08	0.36	0.29	Colorectal cancer;	chr22:31168348	chr22:31816379~31817491:-
HNSC	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	6.6	1.12e-10	6.62e-08	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
HNSC	cis	rs11089937	0.597	rs5757026	ENSG00000211638.2	IGLV8-61	-6.6	1.12e-10	6.62e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22098700~22099212:+
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000254340.1	RP11-10A14.3	-6.6	1.12e-10	6.62e-08	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9035094	chr8:9141424~9145435:+
HNSC	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-6.6	1.13e-10	6.64e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
HNSC	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
HNSC	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	6.6	1.13e-10	6.65e-08	0.41	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-6.6	1.13e-10	6.65e-08	-0.35	-0.29	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
HNSC	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	6.6	1.13e-10	6.66e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
HNSC	cis	rs77204473	0.744	rs12421425	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117131244	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
HNSC	cis	rs4218	0.648	rs8042896	ENSG00000259732.1	RP11-59H7.3	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Social communication problems;	chr15:59067727	chr15:59121034~59133250:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
HNSC	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	6.6	1.14e-10	6.69e-08	0.43	0.29	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	6.6	1.14e-10	6.69e-08	0.43	0.29	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	6.6	1.14e-10	6.69e-08	0.43	0.29	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
HNSC	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	6.6	1.14e-10	6.69e-08	0.35	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
HNSC	cis	rs9326248	0.53	rs562179	ENSG00000280143.1	AP000892.6	6.6	1.14e-10	6.7e-08	0.43	0.29	Blood protein levels;	chr11:116934488	chr11:117204967~117210292:+
HNSC	cis	rs2579103	0.631	rs2579113	ENSG00000258183.4	RP11-753N8.1	-6.6	1.14e-10	6.7e-08	-0.39	-0.29	Body mass index;	chr12:90288844	chr12:90280894~90300340:+
HNSC	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-6.6	1.14e-10	6.71e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
HNSC	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-6.6	1.14e-10	6.71e-08	-0.36	-0.29	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
HNSC	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-6.6	1.14e-10	6.72e-08	-0.35	-0.29	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
HNSC	cis	rs17270561	0.609	rs12529272	ENSG00000272462.2	U91328.19	-6.6	1.15e-10	6.74e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25731114	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9393659	ENSG00000272462.2	U91328.19	-6.6	1.15e-10	6.74e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25731130	chr6:25992662~26001775:+
HNSC	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	6.6	1.15e-10	6.76e-08	0.35	0.29	Height;	chr3:53073584	chr3:53064283~53065091:-
HNSC	cis	rs7615952	0.609	rs13088451	ENSG00000248787.1	RP11-666A20.4	-6.6	1.15e-10	6.76e-08	-0.42	-0.29	Blood pressure (smoking interaction);	chr3:125834656	chr3:125908005~125910272:-
HNSC	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-6.6	1.15e-10	6.77e-08	-0.37	-0.29	Height;	chr3:53094335	chr3:53064283~53065091:-
HNSC	cis	rs2579103	0.767	rs2579096	ENSG00000258183.4	RP11-753N8.1	-6.6	1.15e-10	6.78e-08	-0.36	-0.29	Body mass index;	chr12:90268478	chr12:90280894~90300340:+
HNSC	cis	rs5753618	0.555	rs5749286	ENSG00000236132.1	CTA-440B3.1	-6.59	1.16e-10	6.79e-08	-0.37	-0.29	Colorectal cancer;	chr22:31504373	chr22:31816379~31817491:-
HNSC	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	6.59	1.16e-10	6.8e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	6.59	1.16e-10	6.8e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
HNSC	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	6.59	1.16e-10	6.8e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
HNSC	cis	rs8012947	1	rs11158203	ENSG00000279636.2	LINC00216	-6.59	1.16e-10	6.81e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58303305	chr14:58288033~58289158:+
HNSC	cis	rs10504130	0.696	rs60796336	ENSG00000272024.1	RP11-546K22.3	-6.59	1.16e-10	6.81e-08	-0.41	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51950284~51950690:+
HNSC	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	6.59	1.16e-10	6.82e-08	0.27	0.29	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
HNSC	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
HNSC	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	6.59	1.16e-10	6.83e-08	0.32	0.29	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
HNSC	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.16e-10	6.84e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
HNSC	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
HNSC	cis	rs9341808	0.628	rs1892475	ENSG00000272129.1	RP11-250B2.6	6.59	1.17e-10	6.86e-08	0.34	0.29	Sitting height ratio;	chr6:80152496	chr6:80355424~80356859:+
HNSC	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	6.59	1.17e-10	6.87e-08	0.39	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
HNSC	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-6.59	1.17e-10	6.87e-08	-0.41	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
HNSC	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	6.59	1.17e-10	6.87e-08	0.33	0.29	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	6.59	1.17e-10	6.87e-08	0.33	0.29	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	6.59	1.17e-10	6.87e-08	0.33	0.29	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
HNSC	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	6.59	1.17e-10	6.87e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	6.59	1.17e-10	6.87e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
HNSC	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-6.59	1.17e-10	6.88e-08	-0.43	-0.29	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
HNSC	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.17e-10	6.89e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
HNSC	cis	rs2579103	0.708	rs2731254	ENSG00000258183.4	RP11-753N8.1	-6.59	1.17e-10	6.9e-08	-0.39	-0.29	Body mass index;	chr12:90289830	chr12:90280894~90300340:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	6.59	1.18e-10	6.91e-08	0.34	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
HNSC	cis	rs4218	0.689	rs60262196	ENSG00000259732.1	RP11-59H7.3	-6.59	1.18e-10	6.91e-08	-0.42	-0.29	Social communication problems;	chr15:59088853	chr15:59121034~59133250:+
HNSC	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-6.59	1.18e-10	6.91e-08	-0.42	-0.29	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
HNSC	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	6.59	1.18e-10	6.92e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
HNSC	cis	rs17270561	0.666	rs12209856	ENSG00000272462.2	U91328.19	-6.59	1.18e-10	6.93e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25793445	chr6:25992662~26001775:+
HNSC	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	6.59	1.18e-10	6.93e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
HNSC	cis	rs35955747	0.871	rs2013254	ENSG00000236132.1	CTA-440B3.1	6.59	1.18e-10	6.94e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31294817	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	6.59	1.18e-10	6.94e-08	0.33	0.29	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
HNSC	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	6.59	1.18e-10	6.94e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
HNSC	cis	rs11089937	0.597	rs5757027	ENSG00000211638.2	IGLV8-61	-6.59	1.18e-10	6.95e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22098700~22099212:+
HNSC	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	6.59	1.18e-10	6.95e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
HNSC	cis	rs4218	0.648	rs12442086	ENSG00000259732.1	RP11-59H7.3	-6.59	1.19e-10	6.97e-08	-0.42	-0.29	Social communication problems;	chr15:59074364	chr15:59121034~59133250:+
HNSC	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-6.59	1.19e-10	6.97e-08	-0.3	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
HNSC	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-6.59	1.19e-10	6.97e-08	-0.3	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
HNSC	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	6.59	1.19e-10	6.97e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
HNSC	cis	rs35955747	0.902	rs5997932	ENSG00000236132.1	CTA-440B3.1	6.59	1.19e-10	6.99e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31272168	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	6.59	1.19e-10	6.99e-08	0.29	0.29	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
HNSC	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	6.59	1.19e-10	7e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
HNSC	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-6.59	1.19e-10	7e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
HNSC	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.19e-10	7e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
HNSC	cis	rs2404602	0.692	rs34272342	ENSG00000259422.1	RP11-593F23.1	6.59	1.19e-10	7e-08	0.34	0.29	Blood metabolite levels;	chr15:76719935	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs67570291	ENSG00000259422.1	RP11-593F23.1	6.59	1.19e-10	7e-08	0.34	0.29	Blood metabolite levels;	chr15:76728161	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	6.59	1.19e-10	7.01e-08	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
HNSC	cis	rs35955747	0.869	rs131213	ENSG00000236132.1	CTA-440B3.1	-6.59	1.2e-10	7.01e-08	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31357863	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs12167361	ENSG00000236132.1	CTA-440B3.1	6.59	1.2e-10	7.02e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31300292	chr22:31816379~31817491:-
HNSC	cis	rs9341808	0.652	rs2505940	ENSG00000272129.1	RP11-250B2.6	6.59	1.2e-10	7.04e-08	0.34	0.29	Sitting height ratio;	chr6:80141474	chr6:80355424~80356859:+
HNSC	cis	rs2404602	0.716	rs4886813	ENSG00000259422.1	RP11-593F23.1	-6.59	1.2e-10	7.05e-08	-0.33	-0.29	Blood metabolite levels;	chr15:76545880	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.2e-10	7.05e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.2e-10	7.05e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.2e-10	7.05e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
HNSC	cis	rs1021993	1	rs1395747	ENSG00000231648.1	RP11-372M18.2	-6.59	1.21e-10	7.07e-08	-0.4	-0.29	Gut microbiome composition (winter);	chr1:209315219	chr1:209367662~209379690:+
HNSC	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-6.59	1.21e-10	7.07e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
HNSC	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-6.59	1.21e-10	7.07e-08	-0.36	-0.29	Height;	chr3:53064759	chr3:53064283~53065091:-
HNSC	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-6.59	1.21e-10	7.08e-08	-0.38	-0.29	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
HNSC	cis	rs7819412	0.775	rs2001329	ENSG00000269918.1	AF131215.9	-6.59	1.21e-10	7.08e-08	-0.29	-0.29	Triglycerides;	chr8:11129349	chr8:11104691~11106704:-
HNSC	cis	rs8054556	0.765	rs11150574	ENSG00000183604.13	SMG1P5	-6.59	1.21e-10	7.1e-08	-0.29	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29923498	chr16:30267553~30335374:-
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-6.59	1.21e-10	7.11e-08	-0.42	-0.29	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000254340.1	RP11-10A14.3	-6.59	1.21e-10	7.11e-08	-0.35	-0.29	Mood instability;	chr8:8934707	chr8:9141424~9145435:+
HNSC	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	6.59	1.22e-10	7.12e-08	0.37	0.29	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	6.59	1.22e-10	7.12e-08	0.37	0.29	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	6.59	1.22e-10	7.12e-08	0.37	0.29	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	6.59	1.22e-10	7.12e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
HNSC	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-6.59	1.22e-10	7.13e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
HNSC	cis	rs2404602	0.692	rs2137307	ENSG00000259422.1	RP11-593F23.1	6.59	1.22e-10	7.13e-08	0.34	0.29	Blood metabolite levels;	chr15:76856679	chr15:76174891~76181486:-
HNSC	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	6.59	1.22e-10	7.16e-08	0.7	0.29	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	6.59	1.22e-10	7.16e-08	0.7	0.29	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
HNSC	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	6.59	1.22e-10	7.16e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
HNSC	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.22e-10	7.16e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.22e-10	7.16e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
HNSC	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-6.59	1.22e-10	7.17e-08	-0.36	-0.29	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-6.58	1.23e-10	7.19e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-6.58	1.23e-10	7.2e-08	-0.27	-0.29	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-6.58	1.23e-10	7.2e-08	-0.27	-0.29	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
HNSC	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
HNSC	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-6.58	1.23e-10	7.23e-08	-0.33	-0.29	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
HNSC	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	6.58	1.24e-10	7.23e-08	0.33	0.29	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
HNSC	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	6.58	1.24e-10	7.25e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
HNSC	cis	rs1355223	0.902	rs1588353	ENSG00000271369.1	RP11-350D17.3	-6.58	1.24e-10	7.25e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709267	chr11:34709600~34710161:+
HNSC	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-6.58	1.24e-10	7.25e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-6.58	1.24e-10	7.25e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
HNSC	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-6.58	1.24e-10	7.26e-08	-0.37	-0.29	Height;	chr3:53007328	chr3:53064283~53065091:-
HNSC	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	6.58	1.24e-10	7.26e-08	0.39	0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
HNSC	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-6.58	1.25e-10	7.29e-08	-0.36	-0.29	Height;	chr3:53052712	chr3:53064283~53065091:-
HNSC	cis	rs9326248	0.648	rs11216257	ENSG00000280143.1	AP000892.6	6.58	1.25e-10	7.29e-08	0.34	0.29	Blood protein levels;	chr11:117061845	chr11:117204967~117210292:+
HNSC	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	6.58	1.25e-10	7.29e-08	0.4	0.29	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
HNSC	cis	rs2404602	0.692	rs1471780	ENSG00000259422.1	RP11-593F23.1	6.58	1.25e-10	7.29e-08	0.34	0.29	Blood metabolite levels;	chr15:76734185	chr15:76174891~76181486:-
HNSC	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-6.58	1.25e-10	7.3e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
HNSC	cis	rs12439619	0.846	rs62012003	ENSG00000276710.3	CSPG4P8	-6.58	1.25e-10	7.33e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82459472~82477258:+
HNSC	cis	rs17270561	0.609	rs4131670	ENSG00000272462.2	U91328.19	-6.58	1.25e-10	7.34e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738391	chr6:25992662~26001775:+
HNSC	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	6.58	1.26e-10	7.34e-08	0.43	0.29	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-6.58	1.26e-10	7.34e-08	-0.43	-0.29	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
HNSC	cis	rs2579103	0.668	rs1909552	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90282067	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.708	rs2731261	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90283399	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.668	rs2253621	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90283940	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.668	rs2253289	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90286943	chr12:90280894~90300340:+
HNSC	cis	rs9402743	0.851	rs4896167	ENSG00000217482.2	HMGB1P17	6.58	1.26e-10	7.36e-08	0.32	0.29	Systemic lupus erythematosus;	chr6:135693164	chr6:135636086~135636713:-
HNSC	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	6.58	1.26e-10	7.36e-08	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
HNSC	cis	rs394563	0.619	rs4895787	ENSG00000231760.4	RP11-350J20.5	-6.58	1.26e-10	7.37e-08	-0.37	-0.29	Dupuytren's disease;	chr6:149325364	chr6:149796151~149826294:-
HNSC	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-6.58	1.26e-10	7.37e-08	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
HNSC	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
HNSC	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	6.58	1.27e-10	7.4e-08	0.33	0.29	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
HNSC	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-6.58	1.27e-10	7.4e-08	-0.36	-0.29	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	6.58	1.27e-10	7.41e-08	0.33	0.29	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-6.58	1.27e-10	7.41e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
HNSC	cis	rs12682352	0.652	rs1567398	ENSG00000173295.6	FAM86B3P	-6.58	1.27e-10	7.42e-08	-0.32	-0.29	Neuroticism;	chr8:8869294	chr8:8228595~8244865:+
HNSC	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	6.58	1.27e-10	7.45e-08	0.29	0.29	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
HNSC	cis	rs10504130	0.696	rs79740712	ENSG00000272024.1	RP11-546K22.3	-6.58	1.28e-10	7.47e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51950284~51950690:+
HNSC	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-6.58	1.28e-10	7.48e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
HNSC	cis	rs6951245	0.872	rs74360401	ENSG00000225146.1	AC073957.15	-6.58	1.28e-10	7.48e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1027767	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs118132455	ENSG00000225146.1	AC073957.15	-6.58	1.28e-10	7.48e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028596	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78628466	ENSG00000225146.1	AC073957.15	-6.58	1.28e-10	7.48e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028817	chr7:1029025~1043891:+
HNSC	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	6.58	1.28e-10	7.48e-08	0.57	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
HNSC	cis	rs35955747	0.87	rs7289189	ENSG00000236132.1	CTA-440B3.1	6.58	1.28e-10	7.48e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31261196	chr22:31816379~31817491:-
HNSC	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	6.58	1.29e-10	7.5e-08	0.7	0.29	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
HNSC	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-6.58	1.29e-10	7.52e-08	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
HNSC	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	6.58	1.29e-10	7.52e-08	0.43	0.29	Depression;	chr6:28253486	chr6:28115628~28116551:+
HNSC	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.29e-10	7.53e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
HNSC	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	6.58	1.29e-10	7.55e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
HNSC	cis	rs12550612	0.83	rs10111172	ENSG00000253616.4	RP11-875O11.3	-6.58	1.29e-10	7.55e-08	-0.42	-0.29	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23111578	chr8:23071377~23074488:-
HNSC	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-6.58	1.3e-10	7.55e-08	-0.4	-0.29	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
HNSC	cis	rs5753618	0.504	rs5753671	ENSG00000236132.1	CTA-440B3.1	-6.58	1.3e-10	7.57e-08	-0.37	-0.29	Colorectal cancer;	chr22:31514748	chr22:31816379~31817491:-
HNSC	cis	rs2286503	0.966	rs6949233	ENSG00000221740.1	SNORD93	6.58	1.3e-10	7.57e-08	0.31	0.29	Fibrinogen;	chr7:22818572	chr7:22856613~22856686:+
HNSC	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	6.58	1.3e-10	7.57e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
HNSC	cis	rs1799949	0.965	rs799917	ENSG00000267151.3	RP11-100E5.2	6.58	1.3e-10	7.58e-08	0.37	0.29	Menopause (age at onset);	chr17:43092919	chr17:43444707~43451200:+
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-6.58	1.3e-10	7.58e-08	-0.35	-0.29	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
HNSC	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-6.58	1.3e-10	7.58e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
HNSC	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	6.58	1.3e-10	7.58e-08	0.27	0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	6.58	1.3e-10	7.59e-08	0.26	0.29	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
HNSC	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.3e-10	7.59e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.3e-10	7.59e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
HNSC	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
HNSC	cis	rs9402743	0.634	rs4896156	ENSG00000217482.2	HMGB1P17	6.58	1.3e-10	7.6e-08	0.32	0.29	Systemic lupus erythematosus;	chr6:135605725	chr6:135636086~135636713:-
HNSC	cis	rs75422866	0.85	rs73111231	ENSG00000274902.1	RP1-197B17.4	6.58	1.3e-10	7.6e-08	0.77	0.29	Pneumonia;	chr12:47584539	chr12:47731908~47732351:+
HNSC	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
HNSC	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	6.57	1.31e-10	7.6e-08	0.39	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
HNSC	cis	rs1021993	0.597	rs17014320	ENSG00000231648.1	RP11-372M18.2	-6.57	1.31e-10	7.65e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209338828	chr1:209367662~209379690:+
HNSC	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-6.57	1.32e-10	7.66e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-6.57	1.32e-10	7.66e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-6.57	1.32e-10	7.66e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
HNSC	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	6.57	1.32e-10	7.67e-08	0.33	0.29	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
HNSC	cis	rs9341808	0.667	rs3828753	ENSG00000272129.1	RP11-250B2.6	6.57	1.32e-10	7.68e-08	0.34	0.29	Sitting height ratio;	chr6:80203029	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.591	rs7741013	ENSG00000272129.1	RP11-250B2.6	6.57	1.32e-10	7.68e-08	0.34	0.29	Sitting height ratio;	chr6:80206613	chr6:80355424~80356859:+
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	6.57	1.32e-10	7.68e-08	0.22	0.29	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
HNSC	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	6.57	1.32e-10	7.69e-08	0.42	0.29	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
HNSC	cis	rs453301	0.658	rs9650616	ENSG00000254340.1	RP11-10A14.3	-6.57	1.32e-10	7.7e-08	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9011689	chr8:9141424~9145435:+
HNSC	cis	rs5753618	0.583	rs5749279	ENSG00000236132.1	CTA-440B3.1	-6.57	1.32e-10	7.7e-08	-0.33	-0.29	Colorectal cancer;	chr22:31458223	chr22:31816379~31817491:-
HNSC	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	6.57	1.33e-10	7.73e-08	0.33	0.29	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	6.57	1.33e-10	7.73e-08	0.33	0.29	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
HNSC	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	6.57	1.33e-10	7.73e-08	0.46	0.29	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
HNSC	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	6.57	1.33e-10	7.74e-08	0.34	0.29	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
HNSC	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	6.57	1.33e-10	7.75e-08	0.33	0.29	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
HNSC	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-6.57	1.34e-10	7.78e-08	-0.41	-0.29	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
HNSC	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-6.57	1.34e-10	7.8e-08	-0.29	-0.29	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
HNSC	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-6.57	1.34e-10	7.81e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
HNSC	cis	rs4218	0.648	rs35769647	ENSG00000259732.1	RP11-59H7.3	-6.57	1.34e-10	7.81e-08	-0.42	-0.29	Social communication problems;	chr15:59081670	chr15:59121034~59133250:+
HNSC	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	7.85e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
HNSC	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	6.57	1.35e-10	7.85e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-6.57	1.35e-10	7.86e-08	-0.22	-0.29	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
HNSC	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-6.57	1.36e-10	7.88e-08	-0.29	-0.29	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-6.57	1.36e-10	7.88e-08	-0.29	-0.29	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
HNSC	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	6.57	1.36e-10	7.88e-08	0.3	0.29	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
HNSC	cis	rs6951245	1	rs74785791	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs74366004	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77702926	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs78573577	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs76129108	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78523927	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1029025~1043891:+
HNSC	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-6.57	1.36e-10	7.9e-08	-0.37	-0.29	Height;	chr3:53015087	chr3:53064283~53065091:-
HNSC	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-6.57	1.36e-10	7.9e-08	-0.36	-0.29	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
HNSC	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-6.57	1.36e-10	7.91e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
HNSC	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	6.57	1.36e-10	7.92e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
HNSC	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-6.57	1.36e-10	7.93e-08	-0.36	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
HNSC	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	6.57	1.37e-10	7.95e-08	0.33	0.29	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
HNSC	cis	rs4218	0.648	rs2289895	ENSG00000259732.1	RP11-59H7.3	-6.57	1.37e-10	7.96e-08	-0.41	-0.29	Social communication problems;	chr15:59089570	chr15:59121034~59133250:+
HNSC	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-6.57	1.37e-10	7.98e-08	-0.37	-0.29	Height;	chr3:53009621	chr3:53064283~53065091:-
HNSC	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-6.57	1.38e-10	7.99e-08	-0.38	-0.29	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
HNSC	cis	rs1355223	0.902	rs34875830	ENSG00000271369.1	RP11-350D17.3	-6.57	1.38e-10	8e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34700658	chr11:34709600~34710161:+
HNSC	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-6.57	1.38e-10	8.01e-08	-0.28	-0.29	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-6.57	1.38e-10	8.01e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-6.57	1.38e-10	8.01e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-6.57	1.38e-10	8.01e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
HNSC	cis	rs35955747	0.838	rs7285171	ENSG00000236132.1	CTA-440B3.1	6.57	1.38e-10	8.01e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31202381	chr22:31816379~31817491:-
HNSC	cis	rs17270561	0.609	rs1165181	ENSG00000272462.2	U91328.19	-6.57	1.38e-10	8.01e-08	-0.29	-0.29	Iron status biomarkers;	chr6:25825162	chr6:25992662~26001775:+
HNSC	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	6.57	1.38e-10	8.03e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
HNSC	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-6.56	1.39e-10	8.06e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-6.56	1.39e-10	8.06e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
HNSC	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	6.56	1.39e-10	8.06e-08	0.38	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
HNSC	cis	rs6504622	0.818	rs3851784	ENSG00000262879.4	RP11-156P1.3	6.56	1.39e-10	8.06e-08	0.3	0.29	Orofacial clefts;	chr17:46962751	chr17:46984045~47100323:-
HNSC	cis	rs1799949	0.965	rs8071278	ENSG00000267151.3	RP11-100E5.2	6.56	1.39e-10	8.06e-08	0.38	0.29	Menopause (age at onset);	chr17:43041893	chr17:43444707~43451200:+
HNSC	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-6.56	1.39e-10	8.07e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
HNSC	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-6.56	1.39e-10	8.07e-08	-0.56	-0.29	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
HNSC	cis	rs9341808	0.667	rs1575541	ENSG00000272129.1	RP11-250B2.6	6.56	1.39e-10	8.08e-08	0.34	0.29	Sitting height ratio;	chr6:80207768	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-6.56	1.39e-10	8.08e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
HNSC	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-6.56	1.4e-10	8.1e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-6.56	1.4e-10	8.1e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000173295.6	FAM86B3P	6.56	1.4e-10	8.1e-08	0.33	0.29	Joint mobility (Beighton score);	chr8:8970227	chr8:8228595~8244865:+
HNSC	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	6.56	1.4e-10	8.14e-08	0.35	0.29	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
HNSC	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
HNSC	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	6.56	1.41e-10	8.17e-08	0.46	0.29	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-6.56	1.41e-10	8.18e-08	-0.36	-0.29	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
HNSC	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-6.56	1.41e-10	8.18e-08	-0.48	-0.29	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
HNSC	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-6.56	1.41e-10	8.19e-08	-0.29	-0.29	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
HNSC	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	6.56	1.42e-10	8.2e-08	0.42	0.29	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
HNSC	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	6.56	1.42e-10	8.21e-08	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
HNSC	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	6.56	1.42e-10	8.23e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
HNSC	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	6.56	1.42e-10	8.24e-08	0.28	0.29	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
HNSC	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	6.56	1.42e-10	8.24e-08	0.39	0.29	Height;	chr6:109428824	chr6:109382795~109383666:+
HNSC	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-6.56	1.43e-10	8.27e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
HNSC	cis	rs12439619	0.846	rs28470877	ENSG00000276710.3	CSPG4P8	-6.56	1.43e-10	8.27e-08	-0.38	-0.29	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82459472~82477258:+
HNSC	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-6.56	1.43e-10	8.3e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000173295.6	FAM86B3P	6.56	1.44e-10	8.31e-08	0.33	0.29	Mood instability;	chr8:8821020	chr8:8228595~8244865:+
HNSC	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	6.56	1.44e-10	8.31e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	6.56	1.44e-10	8.31e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
HNSC	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-6.56	1.44e-10	8.33e-08	-0.39	-0.29	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
HNSC	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-6.56	1.44e-10	8.34e-08	-0.57	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
HNSC	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-6.56	1.44e-10	8.35e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
HNSC	cis	rs17270561	0.666	rs9356987	ENSG00000272462.2	U91328.19	-6.56	1.44e-10	8.35e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738959	chr6:25992662~26001775:+
HNSC	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-6.56	1.44e-10	8.35e-08	-0.33	-0.29	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
HNSC	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-6.56	1.44e-10	8.35e-08	-0.35	-0.29	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
HNSC	cis	rs7615952	0.641	rs12487875	ENSG00000241288.6	RP11-379B18.5	-6.56	1.45e-10	8.37e-08	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:126068381	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	6.56	1.45e-10	8.38e-08	0.41	0.29	Height;	chr6:109773423	chr6:109382795~109383666:+
HNSC	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-6.56	1.45e-10	8.38e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
HNSC	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	6.56	1.45e-10	8.39e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
HNSC	cis	rs6951245	1	rs113575110	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs1881123	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs77569514	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11770909	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1029025~1043891:+
HNSC	cis	rs451417	0.73	rs236128	ENSG00000275632.1	RP5-967N21.11	-6.56	1.45e-10	8.4e-08	-0.37	-0.29	Menopause (age at onset);	chr20:5999007	chr20:6000418~6000941:+
HNSC	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-6.56	1.45e-10	8.41e-08	-0.37	-0.29	Height;	chr3:53027969	chr3:53064283~53065091:-
HNSC	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-6.56	1.46e-10	8.43e-08	-0.35	-0.29	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
HNSC	cis	rs2286503	1	rs2286503	ENSG00000221740.1	SNORD93	6.56	1.46e-10	8.43e-08	0.31	0.29	Fibrinogen;	chr7:22816987	chr7:22856613~22856686:+
HNSC	cis	rs2286503	1	rs2286501	ENSG00000221740.1	SNORD93	6.56	1.46e-10	8.43e-08	0.31	0.29	Fibrinogen;	chr7:22817166	chr7:22856613~22856686:+
HNSC	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	6.56	1.46e-10	8.43e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
HNSC	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-6.56	1.46e-10	8.43e-08	-0.35	-0.29	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	6.56	1.46e-10	8.43e-08	0.26	0.29	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	6.56	1.46e-10	8.43e-08	0.26	0.29	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
HNSC	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-6.56	1.46e-10	8.44e-08	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
HNSC	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-6.56	1.46e-10	8.44e-08	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
HNSC	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	6.56	1.47e-10	8.47e-08	0.41	0.29	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
HNSC	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-6.56	1.47e-10	8.47e-08	-0.37	-0.29	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
HNSC	cis	rs2286503	0.65	rs1990279	ENSG00000221740.1	SNORD93	6.56	1.47e-10	8.47e-08	0.32	0.29	Fibrinogen;	chr7:22851123	chr7:22856613~22856686:+
HNSC	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.555	rs5749291	ENSG00000236132.1	CTA-440B3.1	-6.56	1.47e-10	8.49e-08	-0.37	-0.29	Colorectal cancer;	chr22:31511537	chr22:31816379~31817491:-
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-6.56	1.47e-10	8.5e-08	-0.35	-0.29	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
HNSC	cis	rs7617773	0.539	rs6779517	ENSG00000228638.1	FCF1P2	-6.55	1.48e-10	8.54e-08	-0.26	-0.29	Coronary artery disease;	chr3:48342898	chr3:48290793~48291375:-
HNSC	cis	rs17270561	0.636	rs1185977	ENSG00000272462.2	U91328.19	-6.55	1.48e-10	8.55e-08	-0.29	-0.29	Iron status biomarkers;	chr6:25828826	chr6:25992662~26001775:+
HNSC	cis	rs11089937	0.857	rs5750578	ENSG00000211638.2	IGLV8-61	-6.55	1.48e-10	8.55e-08	-0.25	-0.29	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22098700~22099212:+
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	6.55	1.48e-10	8.55e-08	0.22	0.29	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
HNSC	cis	rs1021993	0.597	rs79455200	ENSG00000231648.1	RP11-372M18.2	-6.55	1.48e-10	8.56e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209334422	chr1:209367662~209379690:+
HNSC	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	6.55	1.48e-10	8.56e-08	0.35	0.29	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
HNSC	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-6.55	1.49e-10	8.58e-08	-0.37	-0.29	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
HNSC	cis	rs7942368	0.941	rs12290350	ENSG00000255100.1	RP11-21L23.3	-6.55	1.49e-10	8.59e-08	-0.38	-0.29	Endometriosis;	chr11:76769211	chr11:76782581~76783062:-
HNSC	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-6.55	1.49e-10	8.6e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
HNSC	cis	rs10504130	0.696	rs76717135	ENSG00000272024.1	RP11-546K22.3	-6.55	1.49e-10	8.6e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs17212256	ENSG00000272024.1	RP11-546K22.3	-6.55	1.49e-10	8.6e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs12676780	ENSG00000272024.1	RP11-546K22.3	-6.55	1.49e-10	8.6e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51950284~51950690:+
HNSC	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	6.55	1.49e-10	8.61e-08	0.39	0.29	Height;	chr6:109429207	chr6:109382795~109383666:+
HNSC	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	6.55	1.5e-10	8.64e-08	0.39	0.29	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
HNSC	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-6.55	1.5e-10	8.65e-08	-0.33	-0.29	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
HNSC	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-6.55	1.5e-10	8.65e-08	-0.41	-0.29	Gout;	chr7:66715944	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-6.55	1.5e-10	8.65e-08	-0.41	-0.29	Gout;	chr7:66721259	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-6.55	1.5e-10	8.65e-08	-0.41	-0.29	Gout;	chr7:66732812	chr7:66902857~66906297:+
HNSC	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	6.55	1.5e-10	8.66e-08	0.33	0.29	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
HNSC	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-6.55	1.5e-10	8.67e-08	-0.36	-0.29	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
HNSC	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	6.55	1.5e-10	8.67e-08	0.28	0.29	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
HNSC	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-6.55	1.51e-10	8.68e-08	-0.35	-0.29	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
HNSC	cis	rs35955747	0.902	rs131202	ENSG00000236132.1	CTA-440B3.1	-6.55	1.51e-10	8.68e-08	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31313323	chr22:31816379~31817491:-
HNSC	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
HNSC	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-6.55	1.51e-10	8.72e-08	-0.32	-0.29	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
HNSC	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	6.55	1.51e-10	8.72e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
HNSC	cis	rs75422866	0.85	rs73111220	ENSG00000274902.1	RP1-197B17.4	6.55	1.51e-10	8.73e-08	0.78	0.29	Pneumonia;	chr12:47578764	chr12:47731908~47732351:+
HNSC	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	6.55	1.52e-10	8.73e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000254340.1	RP11-10A14.3	6.55	1.52e-10	8.74e-08	0.35	0.29	Mood instability;	chr8:8788736	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.965	rs9897425	ENSG00000267151.3	RP11-100E5.2	6.55	1.52e-10	8.77e-08	0.37	0.29	Menopause (age at onset);	chr17:43352811	chr17:43444707~43451200:+
HNSC	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-6.55	1.52e-10	8.78e-08	-0.35	-0.29	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-6.55	1.52e-10	8.78e-08	-0.35	-0.29	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
HNSC	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-6.55	1.53e-10	8.82e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
HNSC	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-6.55	1.53e-10	8.82e-08	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
HNSC	cis	rs6951245	1	rs78158942	ENSG00000225146.1	AC073957.15	-6.55	1.54e-10	8.86e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1029025~1043891:+
HNSC	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	6.55	1.54e-10	8.87e-08	0.35	0.29	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
HNSC	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	6.55	1.54e-10	8.87e-08	0.58	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
HNSC	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-6.55	1.55e-10	8.89e-08	-0.33	-0.29	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
HNSC	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-6.55	1.55e-10	8.9e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
HNSC	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	6.55	1.55e-10	8.91e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
HNSC	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	6.55	1.55e-10	8.92e-08	0.41	0.29	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
HNSC	cis	rs6951245	1	rs1997243	ENSG00000225146.1	AC073957.15	-6.55	1.55e-10	8.92e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77760339	ENSG00000225146.1	AC073957.15	-6.55	1.55e-10	8.92e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1029025~1043891:+
HNSC	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-6.55	1.55e-10	8.93e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	6.55	1.55e-10	8.93e-08	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-6.55	1.55e-10	8.94e-08	-0.35	-0.29	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
HNSC	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	6.55	1.56e-10	8.95e-08	0.33	0.29	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
HNSC	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-6.55	1.56e-10	8.97e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
HNSC	cis	rs4141404	0.818	rs6518737	ENSG00000236132.1	CTA-440B3.1	6.55	1.56e-10	8.99e-08	0.31	0.29	Paclitaxel-induced neuropathy;	chr22:31186676	chr22:31816379~31817491:-
HNSC	cis	rs4141404	0.787	rs11913992	ENSG00000236132.1	CTA-440B3.1	6.55	1.56e-10	8.99e-08	0.31	0.29	Paclitaxel-induced neuropathy;	chr22:31189234	chr22:31816379~31817491:-
HNSC	cis	rs6504622	0.934	rs3760377	ENSG00000262879.4	RP11-156P1.3	-6.55	1.56e-10	8.99e-08	-0.31	-0.29	Orofacial clefts;	chr17:46964713	chr17:46984045~47100323:-
HNSC	cis	rs6504622	1	rs11079745	ENSG00000262879.4	RP11-156P1.3	-6.55	1.56e-10	8.99e-08	-0.31	-0.29	Orofacial clefts;	chr17:46966781	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.818	rs28451958	ENSG00000262879.4	RP11-156P1.3	6.55	1.56e-10	8.99e-08	0.31	0.29	Orofacial clefts;	chr17:46968528	chr17:46984045~47100323:-
HNSC	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	6.54	1.57e-10	9.04e-08	0.3	0.29	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
HNSC	cis	rs2337406	1	rs11850600	ENSG00000211974.3	IGHV2-70	-6.54	1.58e-10	9.05e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106670765	chr14:106723574~106724093:-
HNSC	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-6.54	1.58e-10	9.06e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
HNSC	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-6.54	1.58e-10	9.07e-08	-0.35	-0.29	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
HNSC	cis	rs7587476	0.601	rs6715570	ENSG00000229267.2	AC072062.1	6.54	1.58e-10	9.08e-08	0.36	0.29	Neuroblastoma;	chr2:214808716	chr2:214810229~214963274:+
HNSC	cis	rs7083	1	rs644215	ENSG00000254851.1	RP11-109L13.1	6.54	1.58e-10	9.09e-08	0.37	0.29	Blood protein levels;	chr11:117275202	chr11:117135528~117138582:+
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-6.54	1.59e-10	9.1e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
HNSC	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
HNSC	cis	rs6951245	1	rs76804143	ENSG00000225146.1	AC073957.15	-6.54	1.59e-10	9.12e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1029025~1043891:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	6.54	1.59e-10	9.12e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
HNSC	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	6.54	1.59e-10	9.12e-08	0.27	0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
HNSC	cis	rs2985684	0.74	rs2883438	ENSG00000258568.1	RHOQP1	6.54	1.59e-10	9.12e-08	0.3	0.29	Carotid intima media thickness;	chr14:49577674	chr14:49599994~49600572:+
HNSC	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.59e-10	9.14e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.59e-10	9.14e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
HNSC	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-6.54	1.59e-10	9.14e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
HNSC	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	6.54	1.59e-10	9.14e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
HNSC	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.54	1.6e-10	9.16e-08	0.34	0.29	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
HNSC	cis	rs6951245	0.938	rs11764937	ENSG00000225146.1	AC073957.15	-6.54	1.6e-10	9.17e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1029025~1043891:+
HNSC	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	6.54	1.6e-10	9.17e-08	0.22	0.29	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
HNSC	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-6.54	1.6e-10	9.17e-08	-0.35	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
HNSC	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-6.54	1.6e-10	9.19e-08	-0.51	-0.29	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
HNSC	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	6.54	1.61e-10	9.23e-08	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
HNSC	cis	rs1021993	0.597	rs4844807	ENSG00000231648.1	RP11-372M18.2	-6.54	1.61e-10	9.23e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209337769	chr1:209367662~209379690:+
HNSC	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
HNSC	cis	rs8177876	0.822	rs4324141	ENSG00000261061.1	RP11-303E16.2	6.54	1.61e-10	9.25e-08	0.47	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81030770~81031485:+
HNSC	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	6.54	1.61e-10	9.26e-08	0.39	0.29	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	6.54	1.61e-10	9.26e-08	0.39	0.29	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	6.54	1.61e-10	9.26e-08	0.39	0.29	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
HNSC	cis	rs8177876	0.749	rs935942	ENSG00000261061.1	RP11-303E16.2	6.54	1.62e-10	9.27e-08	0.45	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81030770~81031485:+
HNSC	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	6.54	1.62e-10	9.28e-08	0.31	0.29	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
HNSC	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	6.54	1.62e-10	9.28e-08	0.43	0.29	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
HNSC	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	6.54	1.62e-10	9.28e-08	0.43	0.29	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
HNSC	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	6.54	1.62e-10	9.29e-08	0.33	0.29	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	6.54	1.62e-10	9.29e-08	0.33	0.29	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	6.54	1.62e-10	9.31e-08	0.33	0.29	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
HNSC	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-6.54	1.63e-10	9.31e-08	-0.43	-0.29	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
HNSC	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	6.54	1.63e-10	9.34e-08	0.32	0.29	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
HNSC	cis	rs8012947	1	rs7154076	ENSG00000279636.2	LINC00216	-6.54	1.63e-10	9.35e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295564	chr14:58288033~58289158:+
HNSC	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-6.54	1.63e-10	9.36e-08	-0.41	-0.29	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
HNSC	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	6.54	1.63e-10	9.36e-08	0.29	0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
HNSC	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	6.54	1.64e-10	9.38e-08	0.33	0.29	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
HNSC	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-6.54	1.64e-10	9.39e-08	-0.35	-0.29	Height;	chr3:52971094	chr3:53064283~53065091:-
HNSC	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-6.54	1.64e-10	9.4e-08	-0.28	-0.29	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
HNSC	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
HNSC	cis	rs783540	0.542	rs62009945	ENSG00000276710.3	CSPG4P8	6.54	1.64e-10	9.41e-08	0.36	0.29	Schizophrenia;	chr15:82631205	chr15:82459472~82477258:+
HNSC	cis	rs1799949	0.859	rs11657004	ENSG00000267151.3	RP11-100E5.2	6.54	1.65e-10	9.42e-08	0.37	0.29	Menopause (age at onset);	chr17:43365383	chr17:43444707~43451200:+
HNSC	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-6.54	1.65e-10	9.42e-08	-0.36	-0.29	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
HNSC	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-6.54	1.65e-10	9.43e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
HNSC	cis	rs8054556	0.74	rs12716975	ENSG00000183604.13	SMG1P5	-6.54	1.65e-10	9.43e-08	-0.29	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30267553~30335374:-
HNSC	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-6.54	1.65e-10	9.44e-08	-0.34	-0.29	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
HNSC	cis	rs8059260	0.673	rs8056854	ENSG00000274038.1	RP11-66H6.4	-6.54	1.65e-10	9.44e-08	-0.56	-0.29	Alcohol consumption over the past year;	chr16:10947858	chr16:11056556~11057034:+
HNSC	cis	rs6951245	1	rs11768761	ENSG00000225146.1	AC073957.15	-6.54	1.65e-10	9.44e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030171	chr7:1029025~1043891:+
HNSC	cis	rs2579103	0.767	rs1347844	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90269439	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs1371085	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90271728	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs2118804	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90272189	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs1438992	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90275756	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.728	rs2731270	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90275906	chr12:90280894~90300340:+
HNSC	cis	rs35955747	0.869	rs5753576	ENSG00000236132.1	CTA-440B3.1	-6.54	1.65e-10	9.46e-08	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31361749	chr22:31816379~31817491:-
HNSC	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	6.54	1.65e-10	9.46e-08	0.45	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
HNSC	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	6.54	1.66e-10	9.49e-08	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
HNSC	cis	rs9341808	0.935	rs4706113	ENSG00000272129.1	RP11-250B2.6	6.54	1.66e-10	9.5e-08	0.34	0.29	Sitting height ratio;	chr6:80129598	chr6:80355424~80356859:+
HNSC	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	6.54	1.66e-10	9.51e-08	0.34	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	6.54	1.66e-10	9.51e-08	0.34	0.29	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
HNSC	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	6.54	1.66e-10	9.51e-08	0.34	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
HNSC	cis	rs1799949	0.965	rs4239149	ENSG00000267151.3	RP11-100E5.2	-6.54	1.66e-10	9.52e-08	-0.37	-0.29	Menopause (age at onset);	chr17:43176078	chr17:43444707~43451200:+
HNSC	cis	rs9890032	1	rs3764419	ENSG00000263531.1	RP13-753N3.1	6.54	1.66e-10	9.52e-08	0.35	0.29	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30863921~30864940:-
HNSC	cis	rs9890032	0.967	rs7342976	ENSG00000263531.1	RP13-753N3.1	6.54	1.66e-10	9.52e-08	0.35	0.29	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30863921~30864940:-
HNSC	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-6.54	1.67e-10	9.53e-08	-0.48	-0.29	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
HNSC	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-6.54	1.67e-10	9.53e-08	-0.52	-0.29	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
HNSC	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-6.54	1.67e-10	9.53e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
HNSC	cis	rs4141404	0.818	rs5997897	ENSG00000236132.1	CTA-440B3.1	6.53	1.67e-10	9.54e-08	0.31	0.29	Paclitaxel-induced neuropathy;	chr22:31174450	chr22:31816379~31817491:-
HNSC	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-6.53	1.67e-10	9.54e-08	-0.28	-0.29	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
HNSC	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	6.53	1.67e-10	9.55e-08	0.57	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
HNSC	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-6.53	1.67e-10	9.57e-08	-0.3	-0.29	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
HNSC	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	6.53	1.67e-10	9.57e-08	0.33	0.29	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.963	rs5757098	ENSG00000211638.2	IGLV8-61	6.53	1.68e-10	9.59e-08	0.25	0.29	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22098700~22099212:+
HNSC	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
HNSC	cis	rs2337406	1	rs17112416	ENSG00000211974.3	IGHV2-70	6.53	1.68e-10	9.59e-08	0.36	0.29	Alzheimer's disease (late onset);	chr14:106686773	chr14:106723574~106724093:-
HNSC	cis	rs2337406	1	rs7145172	ENSG00000211974.3	IGHV2-70	-6.53	1.68e-10	9.61e-08	-0.34	-0.29	Alzheimer's disease (late onset);	chr14:106704924	chr14:106723574~106724093:-
HNSC	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-6.53	1.69e-10	9.63e-08	-0.37	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
HNSC	cis	rs8012947	1	rs7154212	ENSG00000279636.2	LINC00216	-6.53	1.69e-10	9.64e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295491	chr14:58288033~58289158:+
HNSC	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-6.53	1.69e-10	9.65e-08	-0.28	-0.29	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-6.53	1.69e-10	9.67e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-6.53	1.69e-10	9.67e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
HNSC	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	6.53	1.69e-10	9.67e-08	0.33	0.29	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
HNSC	cis	rs35955747	0.934	rs4820045	ENSG00000236132.1	CTA-440B3.1	6.53	1.69e-10	9.67e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31389983	chr22:31816379~31817491:-
HNSC	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	6.53	1.7e-10	9.68e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	6.53	1.7e-10	9.68e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
HNSC	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-6.53	1.7e-10	9.7e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-6.53	1.7e-10	9.71e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
HNSC	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	6.53	1.7e-10	9.71e-08	0.55	0.29	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
HNSC	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-6.53	1.7e-10	9.72e-08	-0.3	-0.29	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
HNSC	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-6.53	1.71e-10	9.75e-08	-0.37	-0.29	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-6.53	1.71e-10	9.75e-08	-0.37	-0.29	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-6.53	1.71e-10	9.75e-08	-0.37	-0.29	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
HNSC	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-6.53	1.71e-10	9.75e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
HNSC	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-6.53	1.71e-10	9.76e-08	-0.29	-0.29	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
HNSC	cis	rs4273100	1	rs4924986	ENSG00000265185.4	SNORD3B-1	-6.53	1.71e-10	9.76e-08	-0.44	-0.29	Schizophrenia;	chr17:19339154	chr17:19061912~19062669:+
HNSC	cis	rs8054556	0.513	rs12596042	ENSG00000183604.13	SMG1P5	-6.53	1.71e-10	9.77e-08	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29923433	chr16:30267553~30335374:-
HNSC	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	6.53	1.71e-10	9.77e-08	0.23	0.29	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
HNSC	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-6.53	1.72e-10	9.8e-08	-0.27	-0.29	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
HNSC	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-6.53	1.72e-10	9.8e-08	-0.36	-0.29	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
HNSC	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.81e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.81e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
HNSC	cis	rs853679	1	rs2799077	ENSG00000219392.1	RP1-265C24.5	-6.53	1.72e-10	9.82e-08	-0.43	-0.29	Depression;	chr6:28266819	chr6:28115628~28116551:+
HNSC	cis	rs8177876	0.658	rs77874075	ENSG00000261061.1	RP11-303E16.2	-6.53	1.72e-10	9.83e-08	-0.53	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81030770~81031485:+
HNSC	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-6.53	1.72e-10	9.83e-08	-0.45	-0.29	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-6.53	1.73e-10	9.84e-08	-0.33	-0.29	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
HNSC	cis	rs860295	0.729	rs11264369	ENSG00000203761.5	MSTO2P	6.53	1.73e-10	9.85e-08	0.22	0.29	Body mass index;	chr1:155390039	chr1:155745829~155750137:+
HNSC	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	6.53	1.73e-10	9.86e-08	0.34	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
HNSC	cis	rs9890032	1	rs9890032	ENSG00000263531.1	RP13-753N3.1	-6.53	1.73e-10	9.87e-08	-0.34	-0.29	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30863921~30864940:-
HNSC	cis	rs2337406	1	rs78631692	ENSG00000211974.3	IGHV2-70	-6.53	1.73e-10	9.89e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106709371	chr14:106723574~106724093:-
HNSC	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	6.53	1.74e-10	9.91e-08	0.34	0.29	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
HNSC	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	6.53	1.74e-10	9.92e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
HNSC	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-6.53	1.74e-10	9.92e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-6.53	1.74e-10	9.92e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
HNSC	cis	rs11089937	0.667	rs78549985	ENSG00000211638.2	IGLV8-61	-6.53	1.74e-10	9.93e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22098700~22099212:+
HNSC	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-6.53	1.74e-10	9.93e-08	-0.35	-0.29	Height;	chr3:52972039	chr3:53064283~53065091:-
HNSC	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-6.53	1.74e-10	9.94e-08	-0.39	-0.29	Height;	chr6:109444615	chr6:109382795~109383666:+
HNSC	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	6.53	1.75e-10	9.95e-08	0.41	0.29	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-6.53	1.75e-10	9.97e-08	-0.19	-0.29	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-6.53	1.75e-10	9.98e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-6.53	1.75e-10	9.99e-08	-0.25	-0.29	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-6.53	1.75e-10	9.99e-08	-0.25	-0.29	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
HNSC	cis	rs860295	1	rs708611	ENSG00000203761.5	MSTO2P	6.53	1.76e-10	1e-07	0.21	0.29	Body mass index;	chr1:155773519	chr1:155745829~155750137:+
HNSC	cis	rs9341808	0.667	rs2490251	ENSG00000272129.1	RP11-250B2.6	6.53	1.76e-10	1e-07	0.34	0.29	Sitting height ratio;	chr6:80185447	chr6:80355424~80356859:+
HNSC	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	6.53	1.76e-10	1e-07	0.39	0.29	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
HNSC	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-6.53	1.76e-10	1e-07	-0.45	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
HNSC	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-6.53	1.76e-10	1e-07	-0.38	-0.29	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
HNSC	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-6.53	1.77e-10	1.01e-07	-0.29	-0.29	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
HNSC	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-6.52	1.77e-10	1.01e-07	-0.32	-0.29	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
HNSC	cis	rs4218	0.648	rs12915899	ENSG00000259732.1	RP11-59H7.3	-6.52	1.77e-10	1.01e-07	-0.41	-0.29	Social communication problems;	chr15:59084332	chr15:59121034~59133250:+
HNSC	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-6.52	1.78e-10	1.01e-07	-0.35	-0.29	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
HNSC	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	6.52	1.78e-10	1.01e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000173295.6	FAM86B3P	-6.52	1.78e-10	1.01e-07	-0.32	-0.29	Mood instability;	chr8:8936683	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000173295.6	FAM86B3P	-6.52	1.78e-10	1.01e-07	-0.32	-0.29	Mood instability;	chr8:8936944	chr8:8228595~8244865:+
HNSC	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-6.52	1.78e-10	1.01e-07	-0.35	-0.29	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
HNSC	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-6.52	1.79e-10	1.02e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	6.52	1.79e-10	1.02e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
HNSC	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-6.52	1.79e-10	1.02e-07	-0.43	-0.29	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-6.52	1.79e-10	1.02e-07	-0.32	-0.29	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
HNSC	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-6.52	1.79e-10	1.02e-07	-0.37	-0.29	Height;	chr3:53034139	chr3:53064283~53065091:-
HNSC	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-6.52	1.79e-10	1.02e-07	-0.36	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
HNSC	cis	rs8012947	0.959	rs2233752	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58288762	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs10132929	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58292289	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs7146801	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58292769	chr14:58288033~58289158:+
HNSC	cis	rs6951245	1	rs74369356	ENSG00000225146.1	AC073957.15	-6.52	1.79e-10	1.02e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032075	chr7:1029025~1043891:+
HNSC	cis	rs9341808	0.667	rs2505944	ENSG00000272129.1	RP11-250B2.6	6.52	1.79e-10	1.02e-07	0.34	0.29	Sitting height ratio;	chr6:80178693	chr6:80355424~80356859:+
HNSC	cis	rs8012947	1	rs1885134	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58270812	chr14:58288033~58289158:+
HNSC	cis	rs8012947	1	rs2180871	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58272819	chr14:58288033~58289158:+
HNSC	cis	rs2579103	0.625	rs1726065	ENSG00000258183.4	RP11-753N8.1	-6.52	1.8e-10	1.02e-07	-0.41	-0.29	Body mass index;	chr12:90319369	chr12:90280894~90300340:+
HNSC	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-6.52	1.8e-10	1.02e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
HNSC	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-6.52	1.8e-10	1.03e-07	-0.36	-0.29	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
HNSC	cis	rs6951245	1	rs28528096	ENSG00000225146.1	AC073957.15	-6.52	1.8e-10	1.03e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031276	chr7:1029025~1043891:+
HNSC	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	6.52	1.81e-10	1.03e-07	0.33	0.29	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	6.52	1.81e-10	1.03e-07	0.33	0.29	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	6.52	1.81e-10	1.03e-07	0.33	0.29	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
HNSC	cis	rs6951245	0.554	rs10270249	ENSG00000224079.1	AC091729.7	-6.52	1.81e-10	1.03e-07	-0.38	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1074450~1078036:+
HNSC	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	6.52	1.81e-10	1.03e-07	0.34	0.29	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
HNSC	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-6.52	1.82e-10	1.03e-07	-0.26	-0.29	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
HNSC	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-6.52	1.82e-10	1.03e-07	-0.37	-0.29	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
HNSC	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-6.52	1.82e-10	1.03e-07	-0.35	-0.29	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
HNSC	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	6.52	1.82e-10	1.03e-07	0.34	0.29	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
HNSC	cis	rs11089937	0.963	rs5757078	ENSG00000211638.2	IGLV8-61	-6.52	1.82e-10	1.03e-07	-0.25	-0.29	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22098700~22099212:+
HNSC	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-6.52	1.82e-10	1.03e-07	-0.38	-0.29	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
HNSC	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	6.52	1.82e-10	1.04e-07	0.37	0.29	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
HNSC	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-6.52	1.82e-10	1.04e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
HNSC	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-6.52	1.83e-10	1.04e-07	-0.35	-0.29	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
HNSC	cis	rs6918586	0.658	rs1572982	ENSG00000272462.2	U91328.19	6.52	1.83e-10	1.04e-07	0.27	0.29	Schizophrenia;	chr6:26094139	chr6:25992662~26001775:+
HNSC	cis	rs8012947	1	rs8012947	ENSG00000279636.2	LINC00216	-6.52	1.83e-10	1.04e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58317737	chr14:58288033~58289158:+
HNSC	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	6.52	1.83e-10	1.04e-07	0.27	0.29	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
HNSC	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66679692	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	6.52	1.83e-10	1.04e-07	0.41	0.29	Gout;	chr7:66682070	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	6.52	1.83e-10	1.04e-07	0.41	0.29	Gout;	chr7:66682162	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66692349	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66693433	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66694214	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66701371	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66702658	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66706390	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66710076	chr7:66902857~66906297:+
HNSC	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-6.52	1.83e-10	1.04e-07	-0.34	-0.29	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
HNSC	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	6.52	1.84e-10	1.04e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
HNSC	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	6.52	1.84e-10	1.04e-07	0.34	0.29	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
HNSC	cis	rs6504622	0.935	rs62075889	ENSG00000262879.4	RP11-156P1.3	-6.52	1.84e-10	1.04e-07	-0.31	-0.29	Orofacial clefts;	chr17:46950671	chr17:46984045~47100323:-
HNSC	cis	rs6504622	1	rs12940071	ENSG00000262879.4	RP11-156P1.3	-6.52	1.84e-10	1.04e-07	-0.31	-0.29	Orofacial clefts;	chr17:46950686	chr17:46984045~47100323:-
HNSC	cis	rs13113518	0.678	rs7663650	ENSG00000273257.1	RP11-177J6.1	-6.52	1.84e-10	1.04e-07	-0.35	-0.29	Height;	chr4:55364952	chr4:55387949~55388271:+
HNSC	cis	rs2404602	0.692	rs72738889	ENSG00000259422.1	RP11-593F23.1	6.52	1.84e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76699722	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs3816266	ENSG00000259422.1	RP11-593F23.1	6.52	1.84e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76701494	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs2304920	ENSG00000259422.1	RP11-593F23.1	6.52	1.84e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76701526	chr15:76174891~76181486:-
HNSC	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	6.52	1.84e-10	1.05e-07	0.42	0.29	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	6.52	1.85e-10	1.05e-07	0.19	0.29	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
HNSC	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-6.52	1.85e-10	1.05e-07	-0.37	-0.29	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
HNSC	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-6.52	1.85e-10	1.05e-07	-0.29	-0.29	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
HNSC	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	6.52	1.85e-10	1.05e-07	0.34	0.29	Depression;	chr6:28301886	chr6:28943877~28944537:+
HNSC	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	6.52	1.85e-10	1.05e-07	0.42	0.29	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	6.52	1.85e-10	1.05e-07	0.42	0.29	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
HNSC	cis	rs2404602	0.692	rs66866130	ENSG00000259422.1	RP11-593F23.1	6.52	1.85e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76836233	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs35170561	ENSG00000259422.1	RP11-593F23.1	6.52	1.85e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76838354	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-6.52	1.85e-10	1.05e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
HNSC	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	6.52	1.86e-10	1.05e-07	0.44	0.29	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
HNSC	cis	rs8012947	1	rs10133305	ENSG00000279636.2	LINC00216	-6.52	1.86e-10	1.05e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58294411	chr14:58288033~58289158:+
HNSC	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-6.52	1.86e-10	1.05e-07	-0.36	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
HNSC	cis	rs7819412	0.594	rs7460507	ENSG00000269918.1	AF131215.9	-6.52	1.86e-10	1.06e-07	-0.29	-0.29	Triglycerides;	chr8:11111565	chr8:11104691~11106704:-
HNSC	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	6.52	1.87e-10	1.06e-07	0.32	0.29	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
HNSC	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	6.52	1.87e-10	1.06e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
HNSC	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	6.52	1.87e-10	1.06e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
HNSC	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	6.52	1.87e-10	1.06e-07	0.33	0.29	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	6.52	1.87e-10	1.06e-07	0.33	0.29	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-6.52	1.88e-10	1.06e-07	-0.34	-0.29	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
HNSC	cis	rs783540	0.5	rs783541	ENSG00000276710.3	CSPG4P8	6.52	1.88e-10	1.06e-07	0.36	0.29	Schizophrenia;	chr15:82586310	chr15:82459472~82477258:+
HNSC	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	6.52	1.88e-10	1.06e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
HNSC	cis	rs2235642	0.893	rs2076439	ENSG00000280231.1	LA16c-380F5.3	-6.52	1.88e-10	1.07e-07	-0.35	-0.29	Coronary artery disease;	chr16:1537276	chr16:1553655~1554130:-
HNSC	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-6.52	1.88e-10	1.07e-07	-0.23	-0.29	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
HNSC	cis	rs2919917	1	rs4739134	ENSG00000254352.1	RP11-578O24.2	6.52	1.88e-10	1.07e-07	0.36	0.29	Lymphocyte counts;	chr8:78643913	chr8:78723796~78724136:-
HNSC	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	6.51	1.89e-10	1.07e-07	0.36	0.29	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
HNSC	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	6.51	1.89e-10	1.07e-07	0.33	0.29	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
HNSC	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	6.51	1.89e-10	1.07e-07	0.34	0.29	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	6.51	1.89e-10	1.07e-07	0.34	0.29	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
HNSC	cis	rs860295	1	rs6427286	ENSG00000203761.5	MSTO2P	-6.51	1.89e-10	1.07e-07	-0.21	-0.29	Body mass index;	chr1:155753506	chr1:155745829~155750137:+
HNSC	cis	rs860295	1	rs7541060	ENSG00000203761.5	MSTO2P	-6.51	1.89e-10	1.07e-07	-0.21	-0.29	Body mass index;	chr1:155758297	chr1:155745829~155750137:+
HNSC	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	6.51	1.9e-10	1.08e-07	0.42	0.29	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
HNSC	cis	rs2404602	0.619	rs7342603	ENSG00000259422.1	RP11-593F23.1	6.51	1.91e-10	1.08e-07	0.33	0.29	Blood metabolite levels;	chr15:76690284	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs7350777	ENSG00000259422.1	RP11-593F23.1	6.51	1.91e-10	1.08e-07	0.33	0.29	Blood metabolite levels;	chr15:76693100	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs35395069	ENSG00000259422.1	RP11-593F23.1	6.51	1.91e-10	1.08e-07	0.33	0.29	Blood metabolite levels;	chr15:76693993	chr15:76174891~76181486:-
HNSC	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
HNSC	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	6.51	1.91e-10	1.08e-07	0.41	0.29	Height;	chr6:109373851	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	6.51	1.91e-10	1.08e-07	0.41	0.29	Height;	chr6:109375848	chr6:109382795~109383666:+
HNSC	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
HNSC	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	6.51	1.91e-10	1.08e-07	0.34	0.29	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
HNSC	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-6.51	1.92e-10	1.08e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-6.51	1.92e-10	1.08e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-6.51	1.92e-10	1.09e-07	-0.33	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	6.51	1.92e-10	1.09e-07	0.46	0.29	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
HNSC	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	6.51	1.92e-10	1.09e-07	0.78	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
HNSC	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-6.51	1.92e-10	1.09e-07	-0.36	-0.29	QT interval;	chr16:28877088	chr16:28700294~28701540:-
HNSC	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	6.51	1.93e-10	1.09e-07	0.43	0.29	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
HNSC	cis	rs4853012	0.887	rs7570950	ENSG00000257800.1	FNBP1P1	6.51	1.93e-10	1.09e-07	0.33	0.29	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74120680~74123218:+
HNSC	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	6.51	1.93e-10	1.09e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	6.51	1.93e-10	1.09e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	6.51	1.93e-10	1.09e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
HNSC	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	6.51	1.93e-10	1.09e-07	0.29	0.29	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
HNSC	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-6.51	1.93e-10	1.09e-07	-0.35	-0.29	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
HNSC	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-6.51	1.93e-10	1.09e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
HNSC	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	6.51	1.93e-10	1.09e-07	0.36	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
HNSC	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	6.51	1.94e-10	1.09e-07	0.34	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
HNSC	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-6.51	1.94e-10	1.09e-07	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
HNSC	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-6.51	1.94e-10	1.09e-07	-0.52	-0.29	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
HNSC	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-6.51	1.94e-10	1.09e-07	-0.37	-0.29	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
HNSC	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	6.51	1.94e-10	1.09e-07	0.57	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
HNSC	cis	rs7309	0.622	rs4664395	ENSG00000227403.1	AC009299.3	-6.51	1.94e-10	1.1e-07	-0.39	-0.29	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161044790	chr2:161244739~161249050:+
HNSC	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	6.51	1.95e-10	1.1e-07	0.35	0.29	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
HNSC	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-6.51	1.95e-10	1.1e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
HNSC	cis	rs9402743	1	rs9402743	ENSG00000217482.2	HMGB1P17	6.51	1.95e-10	1.1e-07	0.31	0.29	Systemic lupus erythematosus;	chr6:135679896	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.816	rs7757431	ENSG00000217482.2	HMGB1P17	6.51	1.95e-10	1.1e-07	0.31	0.29	Systemic lupus erythematosus;	chr6:135680422	chr6:135636086~135636713:-
HNSC	cis	rs2579103	0.728	rs1371088	ENSG00000258183.4	RP11-753N8.1	-6.51	1.95e-10	1.1e-07	-0.36	-0.29	Body mass index;	chr12:90266956	chr12:90280894~90300340:+
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000173295.6	FAM86B3P	6.51	1.96e-10	1.1e-07	0.33	0.29	Neuroticism;	chr8:8866905	chr8:8228595~8244865:+
HNSC	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	6.51	1.96e-10	1.11e-07	0.32	0.29	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
HNSC	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-6.51	1.96e-10	1.11e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
HNSC	cis	rs35955747	0.902	rs11703927	ENSG00000236132.1	CTA-440B3.1	6.51	1.96e-10	1.11e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31248978	chr22:31816379~31817491:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	6.51	1.96e-10	1.11e-07	0.29	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
HNSC	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-6.51	1.96e-10	1.11e-07	-0.34	-0.29	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
HNSC	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-6.51	1.97e-10	1.11e-07	-0.42	-0.29	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
HNSC	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	6.51	1.97e-10	1.11e-07	0.33	0.29	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.692	rs58973160	ENSG00000259422.1	RP11-593F23.1	6.51	1.97e-10	1.11e-07	0.33	0.29	Blood metabolite levels;	chr15:76708001	chr15:76174891~76181486:-
HNSC	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	6.51	1.97e-10	1.11e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	6.51	1.97e-10	1.11e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
HNSC	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-6.51	1.97e-10	1.11e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
HNSC	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	6.51	1.97e-10	1.11e-07	0.34	0.29	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
HNSC	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-6.51	1.98e-10	1.12e-07	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-6.51	1.98e-10	1.12e-07	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-6.51	1.98e-10	1.12e-07	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
HNSC	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	6.51	1.98e-10	1.12e-07	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
HNSC	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	6.51	1.98e-10	1.12e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
HNSC	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-6.51	1.99e-10	1.12e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
HNSC	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-6.51	1.99e-10	1.12e-07	-0.54	-0.29	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
HNSC	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	6.51	2e-10	1.12e-07	0.33	0.29	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.963	rs5757078	ENSG00000211639.2	IGLV4-60	6.51	2e-10	1.13e-07	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22162199~22162681:+
HNSC	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	6.51	2e-10	1.13e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
HNSC	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-6.5	2e-10	1.13e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
HNSC	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-6.5	2.01e-10	1.13e-07	-0.32	-0.29	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
HNSC	cis	rs860295	1	rs822478	ENSG00000203761.5	MSTO2P	6.5	2.02e-10	1.14e-07	0.21	0.29	Body mass index;	chr1:155824178	chr1:155745829~155750137:+
HNSC	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	6.5	2.02e-10	1.14e-07	0.26	0.29	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
HNSC	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	6.5	2.02e-10	1.14e-07	0.45	0.29	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000267151.3	RP11-100E5.2	6.5	2.02e-10	1.14e-07	0.37	0.29	Menopause (age at onset);	chr17:43105117	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	6.5	2.02e-10	1.14e-07	0.22	0.29	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
HNSC	cis	rs2579103	0.767	rs2247166	ENSG00000258183.4	RP11-753N8.1	-6.5	2.03e-10	1.14e-07	-0.36	-0.29	Body mass index;	chr12:90267489	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs1595601	ENSG00000258183.4	RP11-753N8.1	-6.5	2.03e-10	1.14e-07	-0.36	-0.29	Body mass index;	chr12:90267591	chr12:90280894~90300340:+
HNSC	cis	rs6471393	0.798	rs62525169	ENSG00000253848.1	RP11-10N23.5	6.5	2.03e-10	1.14e-07	0.39	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93804169	chr8:93741193~93744534:+
HNSC	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	6.5	2.03e-10	1.14e-07	0.46	0.29	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
HNSC	cis	rs8054556	0.74	rs9936474	ENSG00000183604.13	SMG1P5	-6.5	2.03e-10	1.14e-07	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29921370	chr16:30267553~30335374:-
HNSC	cis	rs526231	0.726	rs35800	ENSG00000175749.11	EIF3KP1	6.5	2.03e-10	1.14e-07	0.39	0.29	Primary biliary cholangitis;	chr5:103272980	chr5:103032376~103033031:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-6.5	2.03e-10	1.14e-07	-0.19	-0.29	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
HNSC	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	6.5	2.03e-10	1.14e-07	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
HNSC	cis	rs8012947	0.959	rs7147470	ENSG00000279636.2	LINC00216	-6.5	2.03e-10	1.14e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58292948	chr14:58288033~58289158:+
HNSC	cis	rs6951245	1	rs76833820	ENSG00000225146.1	AC073957.15	-6.5	2.03e-10	1.14e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030642	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs28379681	ENSG00000225146.1	AC073957.15	-6.5	2.03e-10	1.14e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030903	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs28399710	ENSG00000225146.1	AC073957.15	-6.5	2.03e-10	1.14e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030995	chr7:1029025~1043891:+
HNSC	cis	rs35955747	0.902	rs140074	ENSG00000236132.1	CTA-440B3.1	-6.5	2.03e-10	1.15e-07	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31329648	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-6.5	2.04e-10	1.15e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
HNSC	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	6.5	2.04e-10	1.15e-07	0.34	0.29	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
HNSC	cis	rs853679	1	rs1778511	ENSG00000219392.1	RP1-265C24.5	6.5	2.04e-10	1.15e-07	0.43	0.29	Depression;	chr6:28261633	chr6:28115628~28116551:+
HNSC	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-6.5	2.04e-10	1.15e-07	-0.36	-0.29	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
HNSC	cis	rs7587476	0.505	rs6435862	ENSG00000229267.2	AC072062.1	6.5	2.05e-10	1.15e-07	0.37	0.29	Neuroblastoma;	chr2:214807822	chr2:214810229~214963274:+
HNSC	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.529	rs5749298	ENSG00000236132.1	CTA-440B3.1	-6.5	2.05e-10	1.15e-07	-0.37	-0.29	Colorectal cancer;	chr22:31545046	chr22:31816379~31817491:-
HNSC	cis	rs1799949	0.965	rs8176310	ENSG00000267151.3	RP11-100E5.2	6.5	2.05e-10	1.15e-07	0.37	0.29	Menopause (age at onset);	chr17:43047896	chr17:43444707~43451200:+
HNSC	cis	rs1355223	0.902	rs1901831	ENSG00000271369.1	RP11-350D17.3	-6.5	2.05e-10	1.15e-07	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703628	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs34610590	ENSG00000271369.1	RP11-350D17.3	-6.5	2.05e-10	1.15e-07	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703893	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs4465347	ENSG00000271369.1	RP11-350D17.3	-6.5	2.05e-10	1.15e-07	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705786	chr11:34709600~34710161:+
HNSC	cis	rs17507216	0.628	rs28607761	ENSG00000255769.6	GOLGA2P10	-6.5	2.06e-10	1.16e-07	-0.44	-0.29	Excessive daytime sleepiness;	chr15:82715317	chr15:82472993~82513950:-
HNSC	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-6.5	2.06e-10	1.16e-07	-0.28	-0.29	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
HNSC	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-6.5	2.07e-10	1.16e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
HNSC	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-6.5	2.07e-10	1.16e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
HNSC	cis	rs8012947	0.92	rs7154498	ENSG00000279636.2	LINC00216	-6.5	2.07e-10	1.16e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295814	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.92	rs7155825	ENSG00000279636.2	LINC00216	-6.5	2.07e-10	1.16e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295819	chr14:58288033~58289158:+
HNSC	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-6.5	2.07e-10	1.16e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
HNSC	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	6.5	2.07e-10	1.16e-07	0.35	0.29	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
HNSC	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	6.5	2.07e-10	1.16e-07	0.34	0.29	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
HNSC	cis	rs12439619	0.846	rs62013464	ENSG00000276710.3	CSPG4P8	-6.5	2.07e-10	1.16e-07	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82459472~82477258:+
HNSC	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-6.5	2.07e-10	1.17e-07	-0.34	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
HNSC	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
HNSC	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-6.5	2.08e-10	1.17e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
HNSC	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-6.5	2.08e-10	1.17e-07	-0.41	-0.29	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
HNSC	cis	rs2404602	0.716	rs1874944	ENSG00000259422.1	RP11-593F23.1	6.5	2.08e-10	1.17e-07	0.33	0.29	Blood metabolite levels;	chr15:76571587	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
HNSC	cis	rs5753618	0.504	rs7284622	ENSG00000236132.1	CTA-440B3.1	-6.5	2.08e-10	1.17e-07	-0.36	-0.29	Colorectal cancer;	chr22:31511999	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-6.5	2.09e-10	1.17e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-6.5	2.09e-10	1.17e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-6.5	2.09e-10	1.17e-07	-0.33	-0.29	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
HNSC	cis	rs35955747	0.902	rs739427	ENSG00000236132.1	CTA-440B3.1	-6.5	2.09e-10	1.17e-07	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31263115	chr22:31816379~31817491:-
HNSC	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	6.5	2.09e-10	1.17e-07	0.38	0.29	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
HNSC	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-6.5	2.09e-10	1.17e-07	-0.32	-0.29	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
HNSC	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-6.5	2.09e-10	1.17e-07	-0.32	-0.29	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
HNSC	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	6.5	2.09e-10	1.17e-07	0.34	0.29	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
HNSC	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	6.5	2.09e-10	1.17e-07	0.42	0.29	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	6.5	2.09e-10	1.17e-07	0.42	0.29	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	6.5	2.09e-10	1.17e-07	0.42	0.29	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
HNSC	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-6.5	2.09e-10	1.17e-07	-0.37	-0.29	Height;	chr3:53029908	chr3:53064283~53065091:-
HNSC	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	6.5	2.09e-10	1.18e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
HNSC	cis	rs2337406	0.778	rs58113768	ENSG00000274576.2	IGHV2-70	-6.5	2.09e-10	1.18e-07	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106700213	chr14:106770577~106771020:-
HNSC	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	6.5	2.09e-10	1.18e-07	0.39	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
HNSC	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-6.5	2.1e-10	1.18e-07	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
HNSC	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	6.5	2.1e-10	1.18e-07	0.41	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
HNSC	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	6.5	2.1e-10	1.18e-07	0.44	0.29	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
HNSC	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	6.5	2.1e-10	1.18e-07	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
HNSC	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	6.5	2.11e-10	1.18e-07	0.32	0.29	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	6.5	2.11e-10	1.18e-07	0.35	0.29	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
HNSC	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-6.5	2.11e-10	1.19e-07	-0.36	-0.29	Height;	chr3:52975027	chr3:53064283~53065091:-
HNSC	cis	rs5753618	0.509	rs5997902	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31187021	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs4820951	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31190262	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs5749229	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31191232	chr22:31816379~31817491:-
HNSC	cis	rs4141404	0.787	rs4820042	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Paclitaxel-induced neuropathy;	chr22:31193070	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs5997912	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31197875	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs5997913	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31197973	chr22:31816379~31817491:-
HNSC	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-10	1.19e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
HNSC	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.12e-10	1.19e-07	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
HNSC	cis	rs8177876	0.658	rs16954505	ENSG00000261061.1	RP11-303E16.2	-6.5	2.13e-10	1.19e-07	-0.5	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr16:81030770~81031485:+
HNSC	cis	rs4218	0.648	rs57361749	ENSG00000259732.1	RP11-59H7.3	-6.5	2.13e-10	1.19e-07	-0.4	-0.29	Social communication problems;	chr15:59091352	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.608	rs16941014	ENSG00000259732.1	RP11-59H7.3	-6.5	2.13e-10	1.19e-07	-0.4	-0.29	Social communication problems;	chr15:59091503	chr15:59121034~59133250:+
HNSC	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	6.49	2.13e-10	1.19e-07	0.69	0.29	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
HNSC	cis	rs4273100	1	rs16960499	ENSG00000265185.4	SNORD3B-1	6.49	2.13e-10	1.2e-07	0.44	0.29	Schizophrenia;	chr17:19299719	chr17:19061912~19062669:+
HNSC	cis	rs7615952	0.641	rs7632497	ENSG00000241288.6	RP11-379B18.5	-6.49	2.13e-10	1.2e-07	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:126064243	chr3:125827238~125916384:-
HNSC	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-6.49	2.13e-10	1.2e-07	-0.27	-0.29	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	6.49	2.13e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	6.49	2.13e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	6.49	2.13e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-6.49	2.13e-10	1.2e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
HNSC	cis	rs947583	0.588	rs9494360	ENSG00000217482.2	HMGB1P17	6.49	2.14e-10	1.2e-07	0.33	0.29	Phosphorus levels;	chr6:135755906	chr6:135636086~135636713:-
HNSC	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-6.49	2.14e-10	1.2e-07	-0.37	-0.29	Height;	chr3:53097932	chr3:53064283~53065091:-
HNSC	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-6.49	2.14e-10	1.2e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
HNSC	cis	rs5753618	0.509	rs2413033	ENSG00000236132.1	CTA-440B3.1	6.49	2.14e-10	1.2e-07	0.35	0.29	Colorectal cancer;	chr22:31178227	chr22:31816379~31817491:-
HNSC	cis	rs2404602	0.716	rs67204011	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76554214	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12902174	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76571199	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12438077	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76571260	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12441550	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76571341	chr15:76174891~76181486:-
HNSC	cis	rs2579103	0.66	rs3860258	ENSG00000258183.4	RP11-753N8.1	-6.49	2.15e-10	1.2e-07	-0.38	-0.29	Body mass index;	chr12:90316847	chr12:90280894~90300340:+
HNSC	cis	rs2235642	0.893	rs2076440	ENSG00000280231.1	LA16c-380F5.3	-6.49	2.15e-10	1.2e-07	-0.35	-0.29	Coronary artery disease;	chr16:1537321	chr16:1553655~1554130:-
HNSC	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	6.49	2.15e-10	1.21e-07	0.42	0.29	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
HNSC	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	6.49	2.16e-10	1.21e-07	0.38	0.29	Height;	chr6:109430398	chr6:109382795~109383666:+
HNSC	cis	rs1799949	0.965	rs799916	ENSG00000267151.3	RP11-100E5.2	-6.49	2.17e-10	1.21e-07	-0.36	-0.29	Menopause (age at onset);	chr17:43091173	chr17:43444707~43451200:+
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000253893.2	FAM85B	-6.49	2.17e-10	1.22e-07	-0.35	-0.29	Neuroticism;	chr8:8241055	chr8:8167819~8226614:-
HNSC	cis	rs860295	1	rs860295	ENSG00000203761.5	MSTO2P	6.49	2.18e-10	1.22e-07	0.21	0.29	Body mass index;	chr1:155797917	chr1:155745829~155750137:+
HNSC	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-6.49	2.18e-10	1.22e-07	-0.42	-0.29	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-6.49	2.18e-10	1.22e-07	-0.42	-0.29	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
HNSC	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-6.49	2.19e-10	1.22e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-6.49	2.19e-10	1.22e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
HNSC	cis	rs7615952	1	rs9289275	ENSG00000248787.1	RP11-666A20.4	-6.49	2.19e-10	1.22e-07	-0.43	-0.29	Blood pressure (smoking interaction);	chr3:125929816	chr3:125908005~125910272:-
HNSC	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	6.49	2.2e-10	1.23e-07	0.4	0.29	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
HNSC	cis	rs451417	0.818	rs236111	ENSG00000275632.1	RP5-967N21.11	6.49	2.2e-10	1.23e-07	0.39	0.29	Menopause (age at onset);	chr20:5952889	chr20:6000418~6000941:+
HNSC	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-6.49	2.2e-10	1.23e-07	-0.31	-0.29	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
HNSC	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	6.49	2.21e-10	1.23e-07	0.41	0.29	Height;	chr6:109769861	chr6:109382795~109383666:+
HNSC	cis	rs860295	1	rs822527	ENSG00000203761.5	MSTO2P	6.49	2.21e-10	1.23e-07	0.21	0.29	Body mass index;	chr1:155768262	chr1:155745829~155750137:+
HNSC	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-6.49	2.21e-10	1.24e-07	-0.54	-0.29	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
HNSC	cis	rs860295	1	rs10908482	ENSG00000203761.5	MSTO2P	-6.49	2.21e-10	1.24e-07	-0.21	-0.29	Body mass index;	chr1:155744082	chr1:155745829~155750137:+
HNSC	cis	rs4218	0.648	rs58087223	ENSG00000259732.1	RP11-59H7.3	-6.49	2.21e-10	1.24e-07	-0.42	-0.29	Social communication problems;	chr15:59075132	chr15:59121034~59133250:+
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000280411.1	IGHV1-69-2	-6.49	2.22e-10	1.24e-07	-0.19	-0.29	Kawasaki disease;	chr14:106767802	chr14:106762092~106762588:-
HNSC	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	6.49	2.22e-10	1.24e-07	0.29	0.29	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-6.49	2.22e-10	1.24e-07	-0.34	-0.29	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
HNSC	cis	rs2579103	0.767	rs1347842	ENSG00000258183.4	RP11-753N8.1	-6.49	2.22e-10	1.24e-07	-0.38	-0.29	Body mass index;	chr12:90270298	chr12:90280894~90300340:+
HNSC	cis	rs8012947	1	rs1984549	ENSG00000279636.2	LINC00216	-6.49	2.23e-10	1.24e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58322121	chr14:58288033~58289158:+
HNSC	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	6.49	2.23e-10	1.24e-07	0.32	0.29	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
HNSC	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-6.49	2.23e-10	1.25e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
HNSC	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	6.49	2.24e-10	1.25e-07	0.27	0.29	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.692	rs12913810	ENSG00000259422.1	RP11-593F23.1	6.49	2.24e-10	1.25e-07	0.33	0.29	Blood metabolite levels;	chr15:76874334	chr15:76174891~76181486:-
HNSC	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	6.49	2.25e-10	1.26e-07	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
HNSC	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-6.49	2.26e-10	1.26e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
HNSC	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	6.49	2.26e-10	1.26e-07	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	6.49	2.26e-10	1.26e-07	0.22	0.29	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
HNSC	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	6.48	2.26e-10	1.26e-07	0.32	0.29	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
HNSC	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	6.48	2.27e-10	1.27e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
HNSC	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
HNSC	cis	rs5753618	0.539	rs2106294	ENSG00000236132.1	CTA-440B3.1	6.48	2.27e-10	1.27e-07	0.35	0.29	Colorectal cancer;	chr22:31249773	chr22:31816379~31817491:-
HNSC	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-6.48	2.27e-10	1.27e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
HNSC	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-6.48	2.28e-10	1.27e-07	-0.33	-0.29	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
HNSC	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	6.48	2.28e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	6.48	2.28e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
HNSC	cis	rs75422866	0.867	rs73104163	ENSG00000274902.1	RP1-197B17.4	6.48	2.28e-10	1.28e-07	0.71	0.29	Pneumonia;	chr12:47706187	chr12:47731908~47732351:+
HNSC	cis	rs75422866	1	rs12423045	ENSG00000274902.1	RP1-197B17.4	6.48	2.28e-10	1.28e-07	0.71	0.29	Pneumonia;	chr12:47706275	chr12:47731908~47732351:+
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000254340.1	RP11-10A14.3	-6.48	2.28e-10	1.28e-07	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9035087	chr8:9141424~9145435:+
HNSC	cis	rs6951245	1	rs74652290	ENSG00000225146.1	AC073957.15	-6.48	2.29e-10	1.28e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1029025~1043891:+
HNSC	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-6.48	2.29e-10	1.28e-07	-0.37	-0.29	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
HNSC	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-6.48	2.29e-10	1.28e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
HNSC	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-6.48	2.29e-10	1.28e-07	-0.38	-0.29	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
HNSC	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	6.48	2.3e-10	1.28e-07	0.46	0.29	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
HNSC	cis	rs2235642	0.826	rs8048410	ENSG00000280231.1	LA16c-380F5.3	-6.48	2.3e-10	1.28e-07	-0.36	-0.29	Coronary artery disease;	chr16:1564096	chr16:1553655~1554130:-
HNSC	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-6.48	2.3e-10	1.28e-07	-0.45	-0.29	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	6.48	2.31e-10	1.29e-07	0.33	0.29	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
HNSC	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	6.48	2.31e-10	1.29e-07	0.27	0.29	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
HNSC	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	6.48	2.31e-10	1.29e-07	0.3	0.29	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
HNSC	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-6.48	2.31e-10	1.29e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
HNSC	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-6.48	2.31e-10	1.29e-07	-0.37	-0.29	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
HNSC	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.31e-10	1.29e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
HNSC	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	6.48	2.31e-10	1.29e-07	0.28	0.29	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	6.48	2.31e-10	1.29e-07	0.28	0.29	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
HNSC	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-6.48	2.32e-10	1.29e-07	-0.42	-0.29	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
HNSC	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-6.48	2.32e-10	1.29e-07	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
HNSC	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.32e-10	1.29e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.54	rs2329931	ENSG00000211638.2	IGLV8-61	-6.48	2.32e-10	1.29e-07	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs2876996	ENSG00000211638.2	IGLV8-61	-6.48	2.32e-10	1.29e-07	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22098700~22099212:+
HNSC	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-6.48	2.32e-10	1.29e-07	-0.34	-0.29	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
HNSC	cis	rs11992162	0.636	rs4841642	ENSG00000206014.6	OR7E161P	-6.48	2.33e-10	1.3e-07	-0.31	-0.29	Monocyte count;	chr8:11940825	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.636	rs4841646	ENSG00000206014.6	OR7E161P	-6.48	2.33e-10	1.3e-07	-0.31	-0.29	Monocyte count;	chr8:11941198	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.613	rs6998690	ENSG00000206014.6	OR7E161P	-6.48	2.33e-10	1.3e-07	-0.31	-0.29	Monocyte count;	chr8:11941287	chr8:11928597~11929563:-
HNSC	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-6.48	2.33e-10	1.3e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
HNSC	cis	rs2404602	0.692	rs35138393	ENSG00000259422.1	RP11-593F23.1	6.48	2.33e-10	1.3e-07	0.33	0.29	Blood metabolite levels;	chr15:76685276	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.669	rs12595313	ENSG00000259422.1	RP11-593F23.1	6.48	2.33e-10	1.3e-07	0.33	0.29	Blood metabolite levels;	chr15:76686029	chr15:76174891~76181486:-
HNSC	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	6.48	2.34e-10	1.3e-07	0.48	0.29	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
HNSC	cis	rs11992162	0.569	rs11786149	ENSG00000206014.6	OR7E161P	6.48	2.34e-10	1.3e-07	0.31	0.29	Monocyte count;	chr8:11943309	chr8:11928597~11929563:-
HNSC	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-6.48	2.34e-10	1.3e-07	-0.29	-0.29	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
HNSC	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	6.48	2.34e-10	1.31e-07	0.39	0.29	Height;	chr6:109423238	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	6.48	2.34e-10	1.31e-07	0.41	0.29	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
HNSC	cis	rs394563	0.726	rs6906384	ENSG00000231760.4	RP11-350J20.5	-6.48	2.34e-10	1.31e-07	-0.36	-0.29	Dupuytren's disease;	chr6:149343404	chr6:149796151~149826294:-
HNSC	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-6.48	2.34e-10	1.31e-07	-0.33	-0.29	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
HNSC	cis	rs6471393	0.862	rs11994625	ENSG00000253848.1	RP11-10N23.5	6.48	2.35e-10	1.31e-07	0.36	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93760149	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.83	rs6981752	ENSG00000253848.1	RP11-10N23.5	6.48	2.35e-10	1.31e-07	0.36	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761046	chr8:93741193~93744534:+
HNSC	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-6.48	2.35e-10	1.31e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
HNSC	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-6.48	2.35e-10	1.31e-07	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
HNSC	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	6.48	2.36e-10	1.31e-07	0.35	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
HNSC	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	6.48	2.38e-10	1.32e-07	0.34	0.29	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
HNSC	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	6.48	2.38e-10	1.32e-07	0.42	0.29	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
HNSC	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-6.48	2.39e-10	1.33e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
HNSC	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	6.48	2.39e-10	1.33e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
HNSC	cis	rs9402743	0.702	rs9399150	ENSG00000217482.2	HMGB1P17	6.48	2.39e-10	1.33e-07	0.32	0.29	Systemic lupus erythematosus;	chr6:135599752	chr6:135636086~135636713:-
HNSC	cis	rs7621025	0.69	rs11715257	ENSG00000273486.1	RP11-731C17.2	6.48	2.39e-10	1.33e-07	0.26	0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136837338~136839021:-
HNSC	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	6.48	2.39e-10	1.33e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
HNSC	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-6.48	2.39e-10	1.33e-07	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-6.48	2.39e-10	1.33e-07	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
HNSC	cis	rs9341808	0.667	rs7745301	ENSG00000272129.1	RP11-250B2.6	6.48	2.4e-10	1.33e-07	0.34	0.29	Sitting height ratio;	chr6:80212844	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-6.48	2.4e-10	1.33e-07	-0.53	-0.29	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-6.48	2.4e-10	1.33e-07	-0.53	-0.29	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
HNSC	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	6.48	2.4e-10	1.33e-07	0.33	0.29	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
HNSC	cis	rs2404602	0.655	rs4886824	ENSG00000259422.1	RP11-593F23.1	6.48	2.4e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76676915	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs58361452	ENSG00000259422.1	RP11-593F23.1	6.48	2.4e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76681031	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs8043474	ENSG00000259422.1	RP11-593F23.1	6.48	2.4e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76682382	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-6.48	2.4e-10	1.34e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
HNSC	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-6.48	2.4e-10	1.34e-07	-0.37	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
HNSC	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	6.47	2.41e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-6.47	2.42e-10	1.34e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
HNSC	cis	rs8177876	0.822	rs7203546	ENSG00000261061.1	RP11-303E16.2	6.47	2.43e-10	1.35e-07	0.44	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81030770~81031485:+
HNSC	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	6.47	2.43e-10	1.35e-07	0.37	0.29	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
HNSC	cis	rs4273100	0.526	rs2074280	ENSG00000265185.4	SNORD3B-1	6.47	2.43e-10	1.35e-07	0.37	0.29	Schizophrenia;	chr17:19014602	chr17:19061912~19062669:+
HNSC	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	6.47	2.43e-10	1.35e-07	0.45	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-6.47	2.43e-10	1.35e-07	-0.25	-0.29	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
HNSC	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-6.47	2.44e-10	1.35e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
HNSC	cis	rs7083	0.967	rs477269	ENSG00000254851.1	RP11-109L13.1	6.47	2.44e-10	1.35e-07	0.37	0.29	Blood protein levels;	chr11:117267575	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-6.47	2.44e-10	1.36e-07	-0.36	-0.29	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
HNSC	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	6.47	2.44e-10	1.36e-07	0.33	0.29	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.36e-07	0.25	0.29	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.36e-07	0.25	0.29	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
HNSC	cis	rs6951245	1	rs77083167	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032187	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs74347384	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032804	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78308415	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032998	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs75493422	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs118059236	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033566	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs113858334	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033840	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79765398	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79443843	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1029025~1043891:+
HNSC	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-6.47	2.46e-10	1.36e-07	-0.46	-0.29	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
HNSC	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-6.47	2.46e-10	1.36e-07	-0.44	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
HNSC	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.36e-07	-0.47	-0.29	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.36e-07	-0.47	-0.29	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
HNSC	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-6.47	2.46e-10	1.37e-07	-0.32	-0.29	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
HNSC	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.37e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.37e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.37e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
HNSC	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.46e-10	1.37e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.46e-10	1.37e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
HNSC	cis	rs10791097	0.935	rs4601795	ENSG00000254842.5	RP11-890B15.2	-6.47	2.46e-10	1.37e-07	-0.25	-0.29	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130859535	chr11:130844191~130865561:-
HNSC	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-6.47	2.47e-10	1.37e-07	-0.35	-0.29	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
HNSC	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	6.47	2.47e-10	1.37e-07	0.34	0.29	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
HNSC	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-6.47	2.47e-10	1.37e-07	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
HNSC	cis	rs7811142	0.72	rs112622797	ENSG00000078319.8	PMS2P1	-6.47	2.48e-10	1.37e-07	-0.4	-0.29	Platelet count;	chr7:100319793	chr7:100320992~100341908:-
HNSC	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-6.47	2.48e-10	1.38e-07	-0.32	-0.29	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
HNSC	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-6.47	2.48e-10	1.38e-07	-0.33	-0.29	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-6.47	2.48e-10	1.38e-07	-0.33	-0.29	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
HNSC	cis	rs9402743	0.671	rs2327650	ENSG00000217482.2	HMGB1P17	6.47	2.48e-10	1.38e-07	0.32	0.29	Systemic lupus erythematosus;	chr6:135630279	chr6:135636086~135636713:-
HNSC	cis	rs2579103	0.595	rs3849229	ENSG00000258183.4	RP11-753N8.1	-6.47	2.49e-10	1.38e-07	-0.37	-0.29	Body mass index;	chr12:90317586	chr12:90280894~90300340:+
HNSC	cis	rs1799949	0.536	rs4793227	ENSG00000267151.3	RP11-100E5.2	6.47	2.49e-10	1.38e-07	0.37	0.29	Menopause (age at onset);	chr17:43334882	chr17:43444707~43451200:+
HNSC	cis	rs17270561	0.636	rs2070642	ENSG00000272462.2	U91328.19	-6.47	2.49e-10	1.38e-07	-0.29	-0.29	Iron status biomarkers;	chr6:25830984	chr6:25992662~26001775:+
HNSC	cis	rs75422866	0.764	rs73104177	ENSG00000274902.1	RP1-197B17.4	6.47	2.49e-10	1.38e-07	0.71	0.29	Pneumonia;	chr12:47713550	chr12:47731908~47732351:+
HNSC	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	6.47	2.5e-10	1.38e-07	0.31	0.29	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
HNSC	cis	rs9341808	0.905	rs3805903	ENSG00000272129.1	RP11-250B2.6	6.47	2.51e-10	1.39e-07	0.34	0.29	Sitting height ratio;	chr6:80266112	chr6:80355424~80356859:+
HNSC	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.54e-10	1.4e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
HNSC	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-6.47	2.54e-10	1.41e-07	-0.29	-0.29	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-6.47	2.54e-10	1.41e-07	-0.29	-0.29	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
HNSC	cis	rs2404602	0.74	rs34924128	ENSG00000259422.1	RP11-593F23.1	6.47	2.54e-10	1.41e-07	0.33	0.29	Blood metabolite levels;	chr15:76672828	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs67010831	ENSG00000259422.1	RP11-593F23.1	6.47	2.54e-10	1.41e-07	0.33	0.29	Blood metabolite levels;	chr15:76672967	chr15:76174891~76181486:-
HNSC	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-6.47	2.54e-10	1.41e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
HNSC	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	6.47	2.55e-10	1.41e-07	0.42	0.29	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
HNSC	cis	rs7674212	0.772	rs13113099	ENSG00000246560.2	RP11-10L12.4	6.47	2.55e-10	1.41e-07	0.32	0.29	Type 2 diabetes;	chr4:103052965	chr4:102828055~102844075:+
HNSC	cis	rs75422866	0.764	rs73104184	ENSG00000274902.1	RP1-197B17.4	6.46	2.56e-10	1.42e-07	0.71	0.29	Pneumonia;	chr12:47715623	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.764	rs73104188	ENSG00000274902.1	RP1-197B17.4	6.46	2.56e-10	1.42e-07	0.71	0.29	Pneumonia;	chr12:47715885	chr12:47731908~47732351:+
HNSC	cis	rs11971779	0.68	rs10242419	ENSG00000273391.1	RP11-634H22.1	-6.46	2.57e-10	1.42e-07	-0.3	-0.29	Diisocyanate-induced asthma;	chr7:139404634	chr7:139359032~139359566:-
HNSC	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-6.46	2.57e-10	1.42e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
HNSC	cis	rs11992162	0.636	rs4841644	ENSG00000206014.6	OR7E161P	-6.46	2.57e-10	1.42e-07	-0.31	-0.29	Monocyte count;	chr8:11940924	chr8:11928597~11929563:-
HNSC	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
HNSC	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	6.46	2.58e-10	1.43e-07	0.29	0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
HNSC	cis	rs7587476	0.601	rs17489231	ENSG00000229267.2	AC072062.1	6.46	2.58e-10	1.43e-07	0.36	0.29	Neuroblastoma;	chr2:214809015	chr2:214810229~214963274:+
HNSC	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-6.46	2.58e-10	1.43e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-6.46	2.58e-10	1.43e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
HNSC	cis	rs783540	0.542	rs62009945	ENSG00000255769.6	GOLGA2P10	6.46	2.58e-10	1.43e-07	0.4	0.29	Schizophrenia;	chr15:82631205	chr15:82472993~82513950:-
HNSC	cis	rs2404602	0.692	rs59088060	ENSG00000259422.1	RP11-593F23.1	6.46	2.58e-10	1.43e-07	0.33	0.29	Blood metabolite levels;	chr15:76567633	chr15:76174891~76181486:-
HNSC	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	6.46	2.58e-10	1.43e-07	0.28	0.29	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	6.46	2.58e-10	1.43e-07	0.28	0.29	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
HNSC	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-6.46	2.59e-10	1.43e-07	-0.32	-0.29	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
HNSC	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
HNSC	cis	rs9326248	0.53	rs17120139	ENSG00000280143.1	AP000892.6	-6.46	2.59e-10	1.43e-07	-0.45	-0.29	Blood protein levels;	chr11:116903485	chr11:117204967~117210292:+
HNSC	cis	rs6951245	0.554	rs11761322	ENSG00000224079.1	AC091729.7	-6.46	2.59e-10	1.43e-07	-0.38	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
HNSC	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	6.46	2.59e-10	1.43e-07	0.3	0.29	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
HNSC	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
HNSC	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	6.46	2.59e-10	1.43e-07	0.39	0.29	Height;	chr6:109380457	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	6.46	2.59e-10	1.43e-07	0.39	0.29	Height;	chr6:109380990	chr6:109382795~109383666:+
HNSC	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	6.46	2.6e-10	1.44e-07	0.36	0.29	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
HNSC	cis	rs6951245	1	rs2363286	ENSG00000225146.1	AC073957.15	-6.46	2.6e-10	1.44e-07	-0.48	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1029025~1043891:+
HNSC	cis	rs35955747	0.902	rs5997929	ENSG00000236132.1	CTA-440B3.1	6.46	2.6e-10	1.44e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31268046	chr22:31816379~31817491:-
HNSC	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-6.46	2.6e-10	1.44e-07	-0.39	-0.29	Height;	chr6:109380015	chr6:109382795~109383666:+
HNSC	cis	rs6928977	0.896	rs2246943	ENSG00000234084.1	RP3-388E23.2	6.46	2.61e-10	1.44e-07	0.29	0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370378	chr6:135301568~135307158:+
HNSC	cis	rs9341808	0.667	rs742833	ENSG00000272129.1	RP11-250B2.6	6.46	2.61e-10	1.44e-07	0.33	0.29	Sitting height ratio;	chr6:80211729	chr6:80355424~80356859:+
HNSC	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-6.46	2.61e-10	1.44e-07	-0.41	-0.29	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
HNSC	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-6.46	2.61e-10	1.44e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
HNSC	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	6.46	2.61e-10	1.44e-07	0.32	0.29	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
HNSC	cis	rs17270561	0.609	rs4711094	ENSG00000272462.2	U91328.19	-6.46	2.62e-10	1.45e-07	-0.29	-0.29	Iron status biomarkers;	chr6:25705946	chr6:25992662~26001775:+
HNSC	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-6.46	2.62e-10	1.45e-07	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
HNSC	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	6.46	2.63e-10	1.45e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
HNSC	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	6.46	2.64e-10	1.45e-07	0.33	0.29	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
HNSC	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
HNSC	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	6.46	2.64e-10	1.46e-07	0.26	0.29	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-6.46	2.64e-10	1.46e-07	-0.31	-0.29	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
HNSC	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	6.46	2.64e-10	1.46e-07	0.27	0.29	Asthma;	chr2:102440033	chr2:102438713~102440475:+
HNSC	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	6.46	2.65e-10	1.46e-07	0.34	0.29	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
HNSC	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	6.46	2.65e-10	1.46e-07	0.38	0.29	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	6.46	2.65e-10	1.46e-07	0.38	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
HNSC	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	6.46	2.65e-10	1.46e-07	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.692	rs4442773	ENSG00000259422.1	RP11-593F23.1	6.46	2.66e-10	1.47e-07	0.33	0.29	Blood metabolite levels;	chr15:76739292	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-6.46	2.67e-10	1.47e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	6.46	2.67e-10	1.47e-07	0.48	0.29	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
HNSC	cis	rs8012947	0.959	rs4520767	ENSG00000279636.2	LINC00216	-6.46	2.67e-10	1.47e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58302220	chr14:58288033~58289158:+
HNSC	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-6.46	2.67e-10	1.47e-07	-0.32	-0.29	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
HNSC	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	6.46	2.67e-10	1.47e-07	0.36	0.29	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
HNSC	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	6.46	2.68e-10	1.48e-07	0.31	0.29	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
HNSC	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	6.46	2.68e-10	1.48e-07	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
HNSC	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	6.46	2.68e-10	1.48e-07	0.36	0.29	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
HNSC	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-6.46	2.68e-10	1.48e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
HNSC	cis	rs11089937	0.626	rs5757011	ENSG00000211638.2	IGLV8-61	-6.46	2.69e-10	1.48e-07	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22098700~22099212:+
HNSC	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-6.46	2.69e-10	1.48e-07	-0.38	-0.29	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
HNSC	cis	rs35955747	0.902	rs713947	ENSG00000236132.1	CTA-440B3.1	6.46	2.69e-10	1.48e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31243523	chr22:31816379~31817491:-
HNSC	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-6.46	2.7e-10	1.49e-07	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
HNSC	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-6.46	2.7e-10	1.49e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-6.46	2.7e-10	1.49e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
HNSC	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-6.46	2.71e-10	1.49e-07	-0.41	-0.29	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
HNSC	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	6.46	2.71e-10	1.49e-07	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
HNSC	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-6.46	2.71e-10	1.49e-07	-0.36	-0.29	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
HNSC	cis	rs3743266	0.507	rs56261931	ENSG00000245534.5	RORA-AS1	-6.46	2.71e-10	1.5e-07	-0.44	-0.29	Menarche (age at onset);	chr15:60439419	chr15:60479178~60630637:+
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000173295.6	FAM86B3P	-6.46	2.71e-10	1.5e-07	-0.33	-0.29	Joint mobility (Beighton score);	chr8:9053494	chr8:8228595~8244865:+
HNSC	cis	rs2235642	0.821	rs8051895	ENSG00000280231.1	LA16c-380F5.3	-6.45	2.72e-10	1.5e-07	-0.35	-0.29	Coronary artery disease;	chr16:1552810	chr16:1553655~1554130:-
HNSC	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	6.45	2.72e-10	1.5e-07	0.34	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
HNSC	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-6.45	2.72e-10	1.5e-07	-0.37	-0.29	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
HNSC	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-6.45	2.73e-10	1.5e-07	-0.29	-0.29	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
HNSC	cis	rs2337406	0.704	rs1858679	ENSG00000211974.3	IGHV2-70	-6.45	2.73e-10	1.51e-07	-0.35	-0.29	Alzheimer's disease (late onset);	chr14:106706726	chr14:106723574~106724093:-
HNSC	cis	rs2404602	0.692	rs12904198	ENSG00000259422.1	RP11-593F23.1	6.45	2.74e-10	1.51e-07	0.33	0.29	Blood metabolite levels;	chr15:76854637	chr15:76174891~76181486:-
HNSC	cis	rs6496044	0.547	rs1564719	ENSG00000259295.5	CSPG4P12	6.45	2.74e-10	1.51e-07	0.34	0.29	Interstitial lung disease;	chr15:85511035	chr15:85191438~85213905:+
HNSC	cis	rs4639966	0.836	rs4499035	ENSG00000255422.1	AP002954.4	6.45	2.75e-10	1.51e-07	0.4	0.29	Systemic lupus erythematosus;	chr11:118739754	chr11:118704607~118750263:+
HNSC	cis	rs4639966	0.836	rs1893029	ENSG00000255422.1	AP002954.4	6.45	2.75e-10	1.51e-07	0.4	0.29	Systemic lupus erythematosus;	chr11:118740117	chr11:118704607~118750263:+
HNSC	cis	rs8012947	0.959	rs10137327	ENSG00000279636.2	LINC00216	-6.45	2.75e-10	1.51e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58287183	chr14:58288033~58289158:+
HNSC	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-6.45	2.76e-10	1.52e-07	-0.3	-0.29	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
HNSC	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
HNSC	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-6.45	2.76e-10	1.52e-07	-0.54	-0.29	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
HNSC	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-6.45	2.76e-10	1.52e-07	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
HNSC	cis	rs4218	0.681	rs34977427	ENSG00000259732.1	RP11-59H7.3	-6.45	2.77e-10	1.52e-07	-0.4	-0.29	Social communication problems;	chr15:59098172	chr15:59121034~59133250:+
HNSC	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	6.45	2.77e-10	1.52e-07	0.38	0.29	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
HNSC	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-6.45	2.77e-10	1.52e-07	-0.31	-0.29	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
HNSC	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-6.45	2.77e-10	1.52e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-6.45	2.77e-10	1.52e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-6.45	2.77e-10	1.52e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
HNSC	cis	rs4218	0.648	rs17236453	ENSG00000259732.1	RP11-59H7.3	-6.45	2.77e-10	1.52e-07	-0.4	-0.29	Social communication problems;	chr15:59092156	chr15:59121034~59133250:+
HNSC	cis	rs7615952	0.641	rs7618515	ENSG00000241288.6	RP11-379B18.5	-6.45	2.78e-10	1.53e-07	-0.38	-0.29	Blood pressure (smoking interaction);	chr3:126071735	chr3:125827238~125916384:-
HNSC	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	6.45	2.78e-10	1.53e-07	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
HNSC	cis	rs9402743	1	rs6570026	ENSG00000217482.2	HMGB1P17	6.45	2.79e-10	1.53e-07	0.31	0.29	Systemic lupus erythematosus;	chr6:135670039	chr6:135636086~135636713:-
HNSC	cis	rs4218	0.648	rs12910987	ENSG00000259732.1	RP11-59H7.3	-6.45	2.79e-10	1.53e-07	-0.4	-0.29	Social communication problems;	chr15:59092782	chr15:59121034~59133250:+
HNSC	cis	rs801193	0.613	rs2016325	ENSG00000179406.6	LINC00174	6.45	2.79e-10	1.53e-07	0.37	0.29	Aortic root size;	chr7:66858513	chr7:66376044~66401338:-
HNSC	cis	rs2985684	0.894	rs6572586	ENSG00000258568.1	RHOQP1	6.45	2.79e-10	1.53e-07	0.29	0.29	Carotid intima media thickness;	chr14:49555223	chr14:49599994~49600572:+
HNSC	cis	rs2404602	0.692	rs55864032	ENSG00000259422.1	RP11-593F23.1	6.45	2.79e-10	1.53e-07	0.33	0.29	Blood metabolite levels;	chr15:76830207	chr15:76174891~76181486:-
HNSC	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-6.45	2.79e-10	1.53e-07	-0.27	-0.29	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
HNSC	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-6.45	2.8e-10	1.54e-07	-0.34	-0.29	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
HNSC	cis	rs6471393	0.792	rs7839522	ENSG00000253848.1	RP11-10N23.5	-6.45	2.81e-10	1.54e-07	-0.38	-0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93827906	chr8:93741193~93744534:+
HNSC	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-6.45	2.81e-10	1.54e-07	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
HNSC	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-6.45	2.81e-10	1.54e-07	-0.44	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
HNSC	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-6.45	2.81e-10	1.54e-07	-0.44	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
HNSC	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-6.45	2.81e-10	1.54e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-6.45	2.82e-10	1.55e-07	-0.33	-0.29	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
HNSC	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	6.45	2.82e-10	1.55e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	6.45	2.82e-10	1.55e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
HNSC	cis	rs2115630	0.645	rs6496284	ENSG00000229212.6	RP11-561C5.4	6.45	2.82e-10	1.55e-07	0.34	0.29	P wave terminal force;	chr15:84635039	chr15:85205440~85234795:-
HNSC	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	6.45	2.83e-10	1.55e-07	0.38	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
HNSC	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	6.45	2.83e-10	1.55e-07	0.34	0.29	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
HNSC	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	6.45	2.83e-10	1.55e-07	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
HNSC	cis	rs67180937	0.631	rs1909195	ENSG00000272750.1	RP11-378J18.8	-6.45	2.83e-10	1.55e-07	-0.35	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623985	chr1:222658867~222661512:-
HNSC	cis	rs13113518	0.513	rs13147861	ENSG00000273257.1	RP11-177J6.1	6.45	2.83e-10	1.55e-07	0.36	0.29	Height;	chr4:55611014	chr4:55387949~55388271:+
HNSC	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-6.45	2.84e-10	1.56e-07	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
HNSC	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.84e-10	1.56e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.84e-10	1.56e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.84e-10	1.56e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
HNSC	cis	rs5753618	0.509	rs5753500	ENSG00000236132.1	CTA-440B3.1	6.45	2.84e-10	1.56e-07	0.35	0.29	Colorectal cancer;	chr22:31182893	chr22:31816379~31817491:-
HNSC	cis	rs9341808	0.667	rs12209624	ENSG00000272129.1	RP11-250B2.6	6.45	2.84e-10	1.56e-07	0.33	0.29	Sitting height ratio;	chr6:80209416	chr6:80355424~80356859:+
HNSC	cis	rs2842992	0.747	rs4709378	ENSG00000237927.1	RP3-393E18.2	-6.45	2.84e-10	1.56e-07	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159806403	chr6:159586955~159589169:-
HNSC	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-6.45	2.84e-10	1.56e-07	-0.26	-0.29	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
HNSC	cis	rs8054556	0.74	rs8052502	ENSG00000183604.13	SMG1P5	-6.45	2.85e-10	1.56e-07	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29918407	chr16:30267553~30335374:-
HNSC	cis	rs2985684	0.894	rs4900928	ENSG00000258568.1	RHOQP1	6.45	2.85e-10	1.56e-07	0.29	0.29	Carotid intima media thickness;	chr14:49554099	chr14:49599994~49600572:+
HNSC	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	6.45	2.85e-10	1.56e-07	0.3	0.29	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	6.45	2.85e-10	1.56e-07	0.42	0.29	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
HNSC	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	6.45	2.86e-10	1.57e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
HNSC	cis	rs453301	0.571	rs330057	ENSG00000254340.1	RP11-10A14.3	-6.45	2.87e-10	1.58e-07	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9232283	chr8:9141424~9145435:+
HNSC	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-6.45	2.88e-10	1.58e-07	-0.31	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
HNSC	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-6.45	2.88e-10	1.58e-07	-0.36	-0.29	Height;	chr3:53047596	chr3:53064283~53065091:-
HNSC	cis	rs2834288	0.535	rs881229	ENSG00000237945.6	LINC00649	6.45	2.88e-10	1.58e-07	0.35	0.29	Gut microbiota (bacterial taxa);	chr21:33950417	chr21:33915534~33977691:+
HNSC	cis	rs10129255	0.642	rs11624918	ENSG00000224373.3	IGHV4-59	6.45	2.88e-10	1.58e-07	0.19	0.29	Kawasaki disease;	chr14:106664672	chr14:106627249~106627825:-
HNSC	cis	rs757110	0.745	rs10734252	ENSG00000260196.1	RP1-239B22.5	6.45	2.88e-10	1.58e-07	0.32	0.29	Type 2 diabetes;	chr11:17383292	chr11:17380649~17383531:+
HNSC	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	6.45	2.88e-10	1.58e-07	0.42	0.29	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
HNSC	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	6.44	2.88e-10	1.58e-07	0.35	0.29	QT interval;	chr16:28860645	chr16:28700294~28701540:-
HNSC	cis	rs2286503	0.966	rs2286507	ENSG00000221740.1	SNORD93	6.44	2.89e-10	1.58e-07	0.3	0.29	Fibrinogen;	chr7:22815141	chr7:22856613~22856686:+
HNSC	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-6.44	2.89e-10	1.58e-07	-0.27	-0.29	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-6.44	2.89e-10	1.58e-07	-0.19	-0.29	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
HNSC	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	6.44	2.89e-10	1.59e-07	0.7	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
HNSC	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	6.44	2.9e-10	1.59e-07	0.31	0.29	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
HNSC	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-6.44	2.91e-10	1.59e-07	-0.4	-0.29	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000254153.1	CTA-398F10.2	6.44	2.91e-10	1.6e-07	0.31	0.29	Joint mobility (Beighton score);	chr8:9001207	chr8:8456909~8461337:-
HNSC	cis	rs34526934	0.608	rs34720456	ENSG00000226363.3	HAGLROS	6.44	2.92e-10	1.6e-07	0.38	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176162564	chr2:176177717~176179008:+
HNSC	cis	rs34526934	0.608	rs7591820	ENSG00000226363.3	HAGLROS	6.44	2.92e-10	1.6e-07	0.38	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163416	chr2:176177717~176179008:+
HNSC	cis	rs34526934	0.608	rs7606110	ENSG00000226363.3	HAGLROS	6.44	2.92e-10	1.6e-07	0.38	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163823	chr2:176177717~176179008:+
HNSC	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-6.44	2.92e-10	1.6e-07	-0.39	-0.29	Height;	chr6:109405874	chr6:109382795~109383666:+
HNSC	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-6.44	2.93e-10	1.6e-07	-0.36	-0.29	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
HNSC	cis	rs8054556	0.716	rs11642933	ENSG00000183604.13	SMG1P5	-6.44	2.93e-10	1.61e-07	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30267553~30335374:-
HNSC	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-6.44	2.93e-10	1.61e-07	-0.32	-0.29	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
HNSC	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
HNSC	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	6.44	2.94e-10	1.61e-07	0.36	0.29	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
HNSC	cis	rs394563	0.559	rs7752555	ENSG00000231760.4	RP11-350J20.5	-6.44	2.94e-10	1.61e-07	-0.35	-0.29	Dupuytren's disease;	chr6:149349980	chr6:149796151~149826294:-
HNSC	cis	rs2337406	1	rs11845269	ENSG00000211974.3	IGHV2-70	-6.44	2.95e-10	1.61e-07	-0.35	-0.29	Alzheimer's disease (late onset);	chr14:106683851	chr14:106723574~106724093:-
HNSC	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	6.44	2.95e-10	1.62e-07	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
HNSC	cis	rs2921073	0.605	rs2976933	ENSG00000173295.6	FAM86B3P	6.44	2.96e-10	1.62e-07	0.32	0.29	Parkinson's disease;	chr8:8397365	chr8:8228595~8244865:+
HNSC	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-6.44	2.96e-10	1.62e-07	-0.4	-0.29	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-6.44	2.96e-10	1.62e-07	-0.36	-0.29	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
HNSC	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-6.44	2.96e-10	1.62e-07	-0.35	-0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
HNSC	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-6.44	2.96e-10	1.62e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
HNSC	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	6.44	2.97e-10	1.62e-07	0.42	0.29	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
HNSC	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	6.44	2.97e-10	1.62e-07	0.42	0.29	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
HNSC	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-6.44	2.97e-10	1.62e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
HNSC	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.44	2.97e-10	1.63e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
HNSC	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	6.44	2.98e-10	1.63e-07	0.4	0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-6.44	2.98e-10	1.63e-07	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
HNSC	cis	rs17507216	0.628	rs28371837	ENSG00000255769.6	GOLGA2P10	-6.44	2.98e-10	1.63e-07	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82714435	chr15:82472993~82513950:-
HNSC	cis	rs453301	0.571	rs2929453	ENSG00000254340.1	RP11-10A14.3	-6.44	2.98e-10	1.63e-07	-0.33	-0.29	Joint mobility (Beighton score);	chr8:9226831	chr8:9141424~9145435:+
HNSC	cis	rs1355223	0.902	rs1597962	ENSG00000271369.1	RP11-350D17.3	-6.44	2.98e-10	1.63e-07	-0.32	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705625	chr11:34709600~34710161:+
HNSC	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-6.44	2.98e-10	1.63e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
HNSC	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	6.44	2.99e-10	1.64e-07	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
HNSC	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-6.44	2.99e-10	1.64e-07	-0.38	-0.29	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
HNSC	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-6.44	2.99e-10	1.64e-07	-0.3	-0.29	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
HNSC	cis	rs6951245	0.58	rs10257426	ENSG00000224079.1	AC091729.7	-6.44	3e-10	1.64e-07	-0.46	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1074450~1078036:+
HNSC	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-6.44	3e-10	1.64e-07	-0.36	-0.29	QT interval;	chr16:28884339	chr16:28700294~28701540:-
HNSC	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	6.44	3e-10	1.64e-07	0.37	0.29	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
HNSC	cis	rs7829975	0.774	rs1039915	ENSG00000173295.6	FAM86B3P	6.44	3e-10	1.64e-07	0.32	0.29	Mood instability;	chr8:8822104	chr8:8228595~8244865:+
HNSC	cis	rs5753618	0.561	rs4141404	ENSG00000236132.1	CTA-440B3.1	6.44	3.01e-10	1.64e-07	0.35	0.29	Colorectal cancer;	chr22:31279199	chr22:31816379~31817491:-
HNSC	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	6.44	3.01e-10	1.65e-07	0.34	0.29	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
HNSC	cis	rs7829975	0.774	rs57312668	ENSG00000173295.6	FAM86B3P	6.44	3.02e-10	1.65e-07	0.32	0.29	Mood instability;	chr8:8822967	chr8:8228595~8244865:+
HNSC	cis	rs5753618	0.504	rs9609329	ENSG00000236132.1	CTA-440B3.1	-6.44	3.02e-10	1.65e-07	-0.36	-0.29	Colorectal cancer;	chr22:31570327	chr22:31816379~31817491:-
HNSC	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-6.44	3.02e-10	1.65e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
HNSC	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-6.44	3.02e-10	1.65e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
HNSC	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	6.44	3.02e-10	1.65e-07	0.34	0.29	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
HNSC	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-6.44	3.03e-10	1.65e-07	-0.31	-0.29	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
HNSC	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-6.44	3.03e-10	1.65e-07	-0.41	-0.29	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
HNSC	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-6.44	3.03e-10	1.66e-07	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
HNSC	cis	rs17507216	0.718	rs4779033	ENSG00000255769.6	GOLGA2P10	6.44	3.03e-10	1.66e-07	0.44	0.29	Excessive daytime sleepiness;	chr15:82576634	chr15:82472993~82513950:-
HNSC	cis	rs2404602	0.679	rs12908421	ENSG00000259422.1	RP11-593F23.1	6.44	3.04e-10	1.66e-07	0.33	0.29	Blood metabolite levels;	chr15:76589453	chr15:76174891~76181486:-
HNSC	cis	rs7591472	1	rs7591472	ENSG00000183308.6	AC005037.3	6.44	3.04e-10	1.66e-07	0.44	0.29	Triptolide cytotoxicity;	chr2:201025028	chr2:200963263~201009102:+
HNSC	cis	rs2235642	0.893	rs8051295	ENSG00000280231.1	LA16c-380F5.3	-6.44	3.04e-10	1.66e-07	-0.35	-0.29	Coronary artery disease;	chr16:1538086	chr16:1553655~1554130:-
HNSC	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-6.44	3.04e-10	1.66e-07	-0.27	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
HNSC	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-6.44	3.04e-10	1.66e-07	-0.36	-0.29	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
HNSC	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	6.44	3.05e-10	1.66e-07	0.38	0.29	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
HNSC	cis	rs853679	1	rs1679709	ENSG00000219392.1	RP1-265C24.5	6.44	3.05e-10	1.67e-07	0.43	0.29	Depression;	chr6:28260564	chr6:28115628~28116551:+
HNSC	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	6.43	3.07e-10	1.67e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
HNSC	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	6.43	3.07e-10	1.68e-07	0.39	0.29	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
HNSC	cis	rs8177876	0.749	rs2278025	ENSG00000261061.1	RP11-303E16.2	6.43	3.08e-10	1.68e-07	0.46	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045636	chr16:81030770~81031485:+
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-6.43	3.08e-10	1.68e-07	-0.19	-0.29	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
HNSC	cis	rs7115242	0.8	rs6589597	ENSG00000280143.1	AP000892.6	-6.43	3.08e-10	1.68e-07	-0.43	-0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	6.43	3.09e-10	1.68e-07	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
HNSC	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-6.43	3.09e-10	1.68e-07	-0.35	-0.29	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
HNSC	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-6.43	3.09e-10	1.68e-07	-0.41	-0.29	Gout;	chr7:66671562	chr7:66902857~66906297:+
HNSC	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-6.43	3.09e-10	1.68e-07	-0.37	-0.29	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
HNSC	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-6.43	3.09e-10	1.69e-07	-0.53	-0.29	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
HNSC	cis	rs8012947	1	rs10151828	ENSG00000279636.2	LINC00216	-6.43	3.09e-10	1.69e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58282711	chr14:58288033~58289158:+
HNSC	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-6.43	3.1e-10	1.69e-07	-0.34	-0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
HNSC	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-6.43	3.11e-10	1.69e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
HNSC	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	6.43	3.11e-10	1.69e-07	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
HNSC	cis	rs853679	1	rs853685	ENSG00000219392.1	RP1-265C24.5	-6.43	3.11e-10	1.7e-07	-0.42	-0.29	Depression;	chr6:28321008	chr6:28115628~28116551:+
HNSC	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-6.43	3.12e-10	1.7e-07	-0.3	-0.29	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
HNSC	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	6.43	3.12e-10	1.7e-07	0.31	0.29	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	6.43	3.12e-10	1.7e-07	0.31	0.29	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
HNSC	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	6.43	3.12e-10	1.7e-07	0.43	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
HNSC	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.12e-10	1.7e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
HNSC	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	6.43	3.13e-10	1.71e-07	0.34	0.29	Height;	chr4:55578154	chr4:55363971~55395847:-
HNSC	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
HNSC	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-6.43	3.15e-10	1.72e-07	-0.35	-0.29	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
HNSC	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	6.43	3.16e-10	1.72e-07	0.25	0.29	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
HNSC	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-6.43	3.16e-10	1.72e-07	-0.35	-0.29	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.882	rs2743555	ENSG00000219392.1	RP1-265C24.5	-6.43	3.16e-10	1.72e-07	-0.43	-0.29	Depression;	chr6:28273304	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs1419183	ENSG00000219392.1	RP1-265C24.5	-6.43	3.16e-10	1.72e-07	-0.43	-0.29	Depression;	chr6:28275017	chr6:28115628~28116551:+
HNSC	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-6.43	3.16e-10	1.72e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
HNSC	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-6.43	3.16e-10	1.72e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
HNSC	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-6.43	3.17e-10	1.73e-07	-0.34	-0.29	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
HNSC	cis	rs2985684	0.625	rs4900931	ENSG00000258568.1	RHOQP1	6.43	3.17e-10	1.73e-07	0.29	0.29	Carotid intima media thickness;	chr14:49556075	chr14:49599994~49600572:+
HNSC	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	6.43	3.17e-10	1.73e-07	0.36	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
HNSC	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
HNSC	cis	rs2235642	0.592	rs743963	ENSG00000280231.1	LA16c-380F5.3	-6.43	3.18e-10	1.73e-07	-0.36	-0.29	Coronary artery disease;	chr16:1607349	chr16:1553655~1554130:-
HNSC	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-6.43	3.19e-10	1.73e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-6.43	3.19e-10	1.73e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-6.43	3.19e-10	1.73e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
HNSC	cis	rs757110	0.77	rs11024271	ENSG00000260196.1	RP1-239B22.5	6.43	3.19e-10	1.73e-07	0.32	0.29	Type 2 diabetes;	chr11:17373993	chr11:17380649~17383531:+
HNSC	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
HNSC	cis	rs7804306	0.826	rs77672302	ENSG00000233264.2	AC006042.8	6.43	3.19e-10	1.74e-07	0.64	0.29	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8048681	chr7:7980312~7982228:+
HNSC	cis	rs2985684	0.894	rs8005990	ENSG00000258568.1	RHOQP1	6.43	3.2e-10	1.74e-07	0.29	0.29	Carotid intima media thickness;	chr14:49555530	chr14:49599994~49600572:+
HNSC	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	6.43	3.21e-10	1.74e-07	0.39	0.29	Height;	chr6:109414295	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	6.43	3.21e-10	1.74e-07	0.39	0.29	Height;	chr6:109416225	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	6.43	3.21e-10	1.75e-07	0.33	0.29	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
HNSC	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-6.43	3.21e-10	1.75e-07	-0.28	-0.29	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
HNSC	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	6.43	3.22e-10	1.75e-07	0.44	0.29	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-6.43	3.22e-10	1.75e-07	-0.4	-0.29	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000173295.6	FAM86B3P	6.43	3.22e-10	1.75e-07	0.31	0.29	Mood instability;	chr8:8933634	chr8:8228595~8244865:+
HNSC	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	6.43	3.22e-10	1.75e-07	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
HNSC	cis	rs35955747	0.838	rs5997900	ENSG00000236132.1	CTA-440B3.1	6.43	3.22e-10	1.75e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31184360	chr22:31816379~31817491:-
HNSC	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-6.43	3.22e-10	1.75e-07	-0.3	-0.29	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
HNSC	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	6.43	3.22e-10	1.75e-07	0.28	0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
HNSC	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-6.43	3.22e-10	1.75e-07	-0.35	-0.29	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
HNSC	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	6.43	3.23e-10	1.75e-07	0.33	0.29	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
HNSC	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-6.43	3.23e-10	1.75e-07	-0.28	-0.29	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
HNSC	cis	rs4713118	0.513	rs156738	ENSG00000204709.4	LINC01556	6.43	3.23e-10	1.76e-07	0.37	0.29	Parkinson's disease;	chr6:28046247	chr6:28943877~28944537:+
HNSC	cis	rs12439619	0.846	rs62012056	ENSG00000276710.3	CSPG4P8	-6.43	3.24e-10	1.76e-07	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82459472~82477258:+
HNSC	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-6.43	3.24e-10	1.76e-07	-0.26	-0.29	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
HNSC	cis	rs2985684	0.841	rs12894785	ENSG00000258568.1	RHOQP1	6.43	3.24e-10	1.76e-07	0.29	0.29	Carotid intima media thickness;	chr14:49583037	chr14:49599994~49600572:+
HNSC	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-6.43	3.24e-10	1.76e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.43	3.24e-10	1.76e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-6.43	3.24e-10	1.76e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000223648.3	IGHV3-64	6.42	3.26e-10	1.77e-07	0.23	0.28	Kawasaki disease;	chr14:106799309	chr14:106643132~106658258:-
HNSC	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-6.42	3.26e-10	1.77e-07	-0.38	-0.28	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
HNSC	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	6.42	3.26e-10	1.77e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
HNSC	cis	rs1799949	0.965	rs9911630	ENSG00000267151.3	RP11-100E5.2	6.42	3.27e-10	1.77e-07	0.37	0.28	Menopause (age at onset);	chr17:43036325	chr17:43444707~43451200:+
HNSC	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	6.42	3.27e-10	1.78e-07	0.29	0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
HNSC	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	6.42	3.28e-10	1.78e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
HNSC	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	6.42	3.29e-10	1.78e-07	0.29	0.28	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
HNSC	cis	rs6951245	0.554	rs76243429	ENSG00000224079.1	AC091729.7	-6.42	3.29e-10	1.79e-07	-0.38	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1074450~1078036:+
HNSC	cis	rs6471393	1	rs6997642	ENSG00000253848.1	RP11-10N23.5	-6.42	3.3e-10	1.79e-07	-0.36	-0.28	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703737	chr8:93741193~93744534:+
HNSC	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	6.42	3.3e-10	1.79e-07	0.29	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
HNSC	cis	rs7621025	0.5	rs16844241	ENSG00000273486.1	RP11-731C17.2	-6.42	3.3e-10	1.79e-07	-0.27	-0.28	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136837338~136839021:-
HNSC	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	6.42	3.3e-10	1.79e-07	0.36	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	6.42	3.3e-10	1.79e-07	0.36	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.716	rs67920045	ENSG00000259422.1	RP11-593F23.1	6.42	3.3e-10	1.79e-07	0.33	0.28	Blood metabolite levels;	chr15:76507743	chr15:76174891~76181486:-
HNSC	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	6.42	3.31e-10	1.79e-07	0.34	0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
HNSC	cis	rs35955747	0.902	rs7287402	ENSG00000236132.1	CTA-440B3.1	-6.42	3.31e-10	1.79e-07	-0.3	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31258837	chr22:31816379~31817491:-
HNSC	cis	rs12439619	0.739	rs62012046	ENSG00000276710.3	CSPG4P8	-6.42	3.31e-10	1.8e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82459472~82477258:+
HNSC	cis	rs12439619	0.774	rs62012047	ENSG00000276710.3	CSPG4P8	-6.42	3.31e-10	1.8e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82459472~82477258:+
HNSC	cis	rs12439619	0.81	rs62012049	ENSG00000276710.3	CSPG4P8	-6.42	3.31e-10	1.8e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82459472~82477258:+
HNSC	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-6.42	3.31e-10	1.8e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
HNSC	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	6.42	3.31e-10	1.8e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	6.42	3.31e-10	1.8e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	6.42	3.31e-10	1.8e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
HNSC	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-6.42	3.31e-10	1.8e-07	-0.34	-0.28	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
HNSC	cis	rs4713118	0.513	rs149958	ENSG00000204709.4	LINC01556	6.42	3.32e-10	1.8e-07	0.37	0.28	Parkinson's disease;	chr6:28045839	chr6:28943877~28944537:+
HNSC	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-6.42	3.32e-10	1.8e-07	-0.36	-0.28	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
HNSC	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-6.42	3.32e-10	1.8e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
HNSC	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-6.42	3.32e-10	1.8e-07	-0.41	-0.28	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-6.42	3.32e-10	1.8e-07	-0.41	-0.28	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-6.42	3.32e-10	1.8e-07	-0.41	-0.28	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-6.42	3.33e-10	1.81e-07	-0.41	-0.28	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
HNSC	cis	rs2286503	0.901	rs2286505	ENSG00000221740.1	SNORD93	6.42	3.33e-10	1.81e-07	0.3	0.28	Fibrinogen;	chr7:22815221	chr7:22856613~22856686:+
HNSC	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	6.42	3.34e-10	1.81e-07	0.3	0.28	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000173295.6	FAM86B3P	-6.42	3.34e-10	1.81e-07	-0.32	-0.28	Mood instability;	chr8:8937520	chr8:8228595~8244865:+
HNSC	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	6.42	3.34e-10	1.81e-07	0.34	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-6.42	3.34e-10	1.81e-07	-0.28	-0.28	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
HNSC	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	6.42	3.36e-10	1.82e-07	0.36	0.28	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
HNSC	cis	rs757110	0.705	rs10832778	ENSG00000260196.1	RP1-239B22.5	6.42	3.36e-10	1.82e-07	0.32	0.28	Type 2 diabetes;	chr11:17372526	chr11:17380649~17383531:+
HNSC	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-6.42	3.36e-10	1.82e-07	-0.38	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
HNSC	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-6.42	3.36e-10	1.82e-07	-0.34	-0.28	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
HNSC	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-6.42	3.37e-10	1.82e-07	-0.32	-0.28	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
HNSC	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-6.42	3.37e-10	1.83e-07	-0.36	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
HNSC	cis	rs8012947	0.727	rs10135729	ENSG00000279636.2	LINC00216	-6.42	3.37e-10	1.83e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58277859	chr14:58288033~58289158:+
HNSC	cis	rs17270561	0.609	rs7772382	ENSG00000272462.2	U91328.19	-6.42	3.37e-10	1.83e-07	-0.29	-0.28	Iron status biomarkers;	chr6:25707888	chr6:25992662~26001775:+
HNSC	cis	rs2985684	0.894	rs4900932	ENSG00000258568.1	RHOQP1	6.42	3.38e-10	1.83e-07	0.29	0.28	Carotid intima media thickness;	chr14:49556210	chr14:49599994~49600572:+
HNSC	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	6.42	3.38e-10	1.83e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000211974.3	IGHV2-70	-6.42	3.38e-10	1.83e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106700837	chr14:106723574~106724093:-
HNSC	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	6.42	3.38e-10	1.83e-07	0.33	0.28	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
HNSC	cis	rs35955747	0.869	rs34873968	ENSG00000236132.1	CTA-440B3.1	6.42	3.39e-10	1.83e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31185787	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.869	rs8143002	ENSG00000236132.1	CTA-440B3.1	6.42	3.39e-10	1.83e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191205	chr22:31816379~31817491:-
HNSC	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	6.42	3.39e-10	1.84e-07	0.31	0.28	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
HNSC	cis	rs1355223	0.902	rs2185700	ENSG00000271369.1	RP11-350D17.3	-6.42	3.39e-10	1.84e-07	-0.32	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702657	chr11:34709600~34710161:+
HNSC	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-6.42	3.39e-10	1.84e-07	-0.36	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
HNSC	cis	rs9402743	1	rs9389318	ENSG00000217482.2	HMGB1P17	6.42	3.39e-10	1.84e-07	0.31	0.28	Systemic lupus erythematosus;	chr6:135692396	chr6:135636086~135636713:-
HNSC	cis	rs8177876	0.658	rs2278022	ENSG00000261061.1	RP11-303E16.2	-6.42	3.39e-10	1.84e-07	-0.53	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81030770~81031485:+
HNSC	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	6.42	3.4e-10	1.84e-07	0.22	0.28	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
HNSC	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	6.42	3.41e-10	1.85e-07	0.34	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
HNSC	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	6.42	3.41e-10	1.85e-07	0.34	0.28	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
HNSC	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	6.42	3.43e-10	1.85e-07	0.75	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
HNSC	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-6.42	3.43e-10	1.86e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
HNSC	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-6.42	3.43e-10	1.86e-07	-0.44	-0.28	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
HNSC	cis	rs8031584	0.651	rs28664821	ENSG00000260382.1	RP11-540B6.2	-6.42	3.43e-10	1.86e-07	-0.34	-0.28	Huntington's disease progression;	chr15:30880120	chr15:30882267~30883231:-
HNSC	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-6.42	3.43e-10	1.86e-07	-0.38	-0.28	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
HNSC	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	6.42	3.43e-10	1.86e-07	0.27	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
HNSC	cis	rs4639966	0.836	rs10892282	ENSG00000255422.1	AP002954.4	-6.42	3.43e-10	1.86e-07	-0.39	-0.28	Systemic lupus erythematosus;	chr11:118757069	chr11:118704607~118750263:+
HNSC	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	6.42	3.44e-10	1.86e-07	0.34	0.28	Height;	chr4:55587104	chr4:55363971~55395847:-
HNSC	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-6.42	3.44e-10	1.86e-07	-0.39	-0.28	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000173295.6	FAM86B3P	-6.42	3.46e-10	1.87e-07	-0.32	-0.28	Mood instability;	chr8:8939092	chr8:8228595~8244865:+
HNSC	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	6.41	3.47e-10	1.87e-07	0.27	0.28	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
HNSC	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.87e-07	-0.38	-0.28	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
HNSC	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	6.41	3.47e-10	1.88e-07	0.29	0.28	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
HNSC	cis	rs1799949	0.965	rs8070179	ENSG00000267151.3	RP11-100E5.2	6.41	3.48e-10	1.88e-07	0.36	0.28	Menopause (age at onset);	chr17:43050671	chr17:43444707~43451200:+
HNSC	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	6.41	3.48e-10	1.88e-07	0.33	0.28	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
HNSC	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-6.41	3.48e-10	1.88e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
HNSC	cis	rs12439619	0.846	rs62012059	ENSG00000276710.3	CSPG4P8	-6.41	3.48e-10	1.88e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82459472~82477258:+
HNSC	cis	rs17507216	0.718	rs4779034	ENSG00000255769.6	GOLGA2P10	-6.41	3.48e-10	1.88e-07	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82576799	chr15:82472993~82513950:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	6.41	3.48e-10	1.88e-07	0.32	0.28	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
HNSC	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	6.41	3.48e-10	1.88e-07	0.37	0.28	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
HNSC	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-6.41	3.49e-10	1.89e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
HNSC	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-6.41	3.49e-10	1.89e-07	-0.39	-0.28	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
HNSC	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-6.41	3.49e-10	1.89e-07	-0.26	-0.28	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
HNSC	cis	rs9907295	0.584	rs7215845	ENSG00000270977.1	AC015849.16	-6.41	3.5e-10	1.89e-07	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35894698	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.591	rs4796128	ENSG00000270977.1	AC015849.16	-6.41	3.5e-10	1.89e-07	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35899268	chr17:35893707~35911023:-
HNSC	cis	rs1021993	0.645	rs11586524	ENSG00000231648.1	RP11-372M18.2	6.41	3.5e-10	1.89e-07	0.36	0.28	Gut microbiome composition (winter);	chr1:209323188	chr1:209367662~209379690:+
HNSC	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	6.41	3.5e-10	1.89e-07	0.28	0.28	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
HNSC	cis	rs2790457	0.792	rs1265845	ENSG00000254635.4	WAC-AS1	-6.41	3.5e-10	1.89e-07	-0.32	-0.28	Multiple myeloma;	chr10:28638294	chr10:28522652~28532743:-
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000254153.1	CTA-398F10.2	6.41	3.5e-10	1.89e-07	0.3	0.28	Systolic blood pressure;	chr8:8462519	chr8:8456909~8461337:-
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-6.41	3.51e-10	1.9e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
HNSC	cis	rs4987094	0.505	rs4938011	ENSG00000270179.1	RP11-159N11.4	6.41	3.51e-10	1.9e-07	0.5	0.28	Schizophrenia;	chr11:113376510	chr11:113368478~113369117:+
HNSC	cis	rs11992162	0.56	rs13276386	ENSG00000206014.6	OR7E161P	-6.41	3.52e-10	1.9e-07	-0.31	-0.28	Monocyte count;	chr8:11939912	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.621	rs13268810	ENSG00000206014.6	OR7E161P	-6.41	3.52e-10	1.9e-07	-0.31	-0.28	Monocyte count;	chr8:11939921	chr8:11928597~11929563:-
HNSC	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-6.41	3.52e-10	1.9e-07	-0.35	-0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
HNSC	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.509	rs5749224	ENSG00000236132.1	CTA-440B3.1	6.41	3.53e-10	1.9e-07	0.35	0.28	Colorectal cancer;	chr22:31162563	chr22:31816379~31817491:-
HNSC	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	6.41	3.53e-10	1.91e-07	0.42	0.28	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
HNSC	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	6.41	3.54e-10	1.91e-07	0.29	0.28	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
HNSC	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-6.41	3.55e-10	1.91e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-6.41	3.55e-10	1.91e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-6.41	3.55e-10	1.91e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
HNSC	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	6.41	3.55e-10	1.91e-07	0.32	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
HNSC	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	6.41	3.55e-10	1.92e-07	0.42	0.28	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
HNSC	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	6.41	3.56e-10	1.92e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
HNSC	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	6.41	3.56e-10	1.92e-07	0.33	0.28	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
HNSC	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	6.41	3.57e-10	1.92e-07	0.5	0.28	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
HNSC	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-6.41	3.57e-10	1.93e-07	-0.38	-0.28	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
HNSC	cis	rs4218	0.638	rs8042516	ENSG00000259732.1	RP11-59H7.3	-6.41	3.58e-10	1.93e-07	-0.4	-0.28	Social communication problems;	chr15:59067525	chr15:59121034~59133250:+
HNSC	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	6.41	3.58e-10	1.93e-07	0.33	0.28	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-6.41	3.58e-10	1.93e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-6.41	3.58e-10	1.93e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
HNSC	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-6.41	3.58e-10	1.93e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
HNSC	cis	rs8054556	0.73	rs4788190	ENSG00000183604.13	SMG1P5	-6.41	3.58e-10	1.93e-07	-0.28	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30267553~30335374:-
HNSC	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	6.41	3.59e-10	1.94e-07	0.34	0.28	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
HNSC	cis	rs2235642	0.821	rs2281234	ENSG00000280231.1	LA16c-380F5.3	-6.41	3.6e-10	1.94e-07	-0.35	-0.28	Coronary artery disease;	chr16:1552937	chr16:1553655~1554130:-
HNSC	cis	rs7615952	0.611	rs7632305	ENSG00000241288.6	RP11-379B18.5	-6.41	3.61e-10	1.95e-07	-0.48	-0.28	Blood pressure (smoking interaction);	chr3:125915924	chr3:125827238~125916384:-
HNSC	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	6.41	3.62e-10	1.95e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
HNSC	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	6.41	3.63e-10	1.95e-07	0.41	0.28	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
HNSC	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-6.41	3.63e-10	1.96e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-6.41	3.63e-10	1.96e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
HNSC	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-6.41	3.63e-10	1.96e-07	-0.35	-0.28	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
HNSC	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	6.41	3.63e-10	1.96e-07	0.39	0.28	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
HNSC	cis	rs6504622	0.905	rs736603	ENSG00000262879.4	RP11-156P1.3	6.41	3.64e-10	1.96e-07	0.3	0.28	Orofacial clefts;	chr17:46947379	chr17:46984045~47100323:-
HNSC	cis	rs7615952	0.576	rs2276726	ENSG00000241288.6	RP11-379B18.5	-6.41	3.66e-10	1.97e-07	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:126107444	chr3:125827238~125916384:-
HNSC	cis	rs6951245	1	rs78185558	ENSG00000225146.1	AC073957.15	-6.41	3.66e-10	1.97e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1029025~1043891:+
HNSC	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	6.4	3.67e-10	1.98e-07	0.32	0.28	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
HNSC	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-6.4	3.68e-10	1.98e-07	-0.34	-0.28	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000173295.6	FAM86B3P	-6.4	3.68e-10	1.98e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9047352	chr8:8228595~8244865:+
HNSC	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	6.4	3.69e-10	1.99e-07	0.38	0.28	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
HNSC	cis	rs2790457	0.833	rs1265846	ENSG00000254635.4	WAC-AS1	-6.4	3.69e-10	1.99e-07	-0.32	-0.28	Multiple myeloma;	chr10:28640168	chr10:28522652~28532743:-
HNSC	cis	rs2235642	0.787	rs2235646	ENSG00000280231.1	LA16c-380F5.3	-6.4	3.69e-10	1.99e-07	-0.35	-0.28	Coronary artery disease;	chr16:1551286	chr16:1553655~1554130:-
HNSC	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-6.4	3.69e-10	1.99e-07	-0.35	-0.28	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	6.4	3.69e-10	1.99e-07	0.33	0.28	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
HNSC	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
HNSC	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-6.4	3.7e-10	1.99e-07	-0.35	-0.28	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-6.4	3.7e-10	1.99e-07	-0.35	-0.28	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
HNSC	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-6.4	3.72e-10	2e-07	-0.53	-0.28	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
HNSC	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-6.4	3.73e-10	2e-07	-0.38	-0.28	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
HNSC	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-6.4	3.73e-10	2e-07	-0.38	-0.28	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
HNSC	cis	rs2235642	0.701	rs2281230	ENSG00000280231.1	LA16c-380F5.3	-6.4	3.73e-10	2e-07	-0.36	-0.28	Coronary artery disease;	chr16:1551766	chr16:1553655~1554130:-
HNSC	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-6.4	3.73e-10	2.01e-07	-0.35	-0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
HNSC	cis	rs6081541	0.689	rs723768	ENSG00000179447.2	RP5-1027G4.3	-6.4	3.73e-10	2.01e-07	-0.35	-0.28	Psychosis (atypical);	chr20:19234998	chr20:19242302~19284596:-
HNSC	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-6.4	3.75e-10	2.01e-07	-0.35	-0.28	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
HNSC	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-6.4	3.75e-10	2.02e-07	-0.35	-0.28	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-6.4	3.75e-10	2.02e-07	-0.35	-0.28	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-6.4	3.75e-10	2.02e-07	-0.41	-0.28	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000173295.6	FAM86B3P	-6.4	3.76e-10	2.02e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9047129	chr8:8228595~8244865:+
HNSC	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	6.4	3.76e-10	2.02e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
HNSC	cis	rs11971779	0.616	rs6967932	ENSG00000273391.1	RP11-634H22.1	6.4	3.76e-10	2.02e-07	0.31	0.28	Diisocyanate-induced asthma;	chr7:139337635	chr7:139359032~139359566:-
HNSC	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	6.4	3.76e-10	2.02e-07	0.78	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-6.4	3.77e-10	2.03e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-6.4	3.78e-10	2.03e-07	-0.34	-0.28	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
HNSC	cis	rs4841097	0.806	rs6992247	ENSG00000173295.6	FAM86B3P	6.4	3.78e-10	2.03e-07	0.32	0.28	Platelet distribution width;	chr8:9090959	chr8:8228595~8244865:+
HNSC	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-6.4	3.78e-10	2.03e-07	-0.36	-0.28	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
HNSC	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	6.4	3.79e-10	2.04e-07	0.24	0.28	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
HNSC	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	6.4	3.79e-10	2.04e-07	0.4	0.28	Height;	chr6:109775693	chr6:109382795~109383666:+
HNSC	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-6.4	3.79e-10	2.04e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-6.4	3.8e-10	2.04e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
HNSC	cis	rs2579103	0.708	rs2731266	ENSG00000258183.4	RP11-753N8.1	6.4	3.81e-10	2.05e-07	0.38	0.28	Body mass index;	chr12:90278930	chr12:90280894~90300340:+
HNSC	cis	rs8177876	0.749	rs2287995	ENSG00000261061.1	RP11-303E16.2	-6.4	3.81e-10	2.05e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81030770~81031485:+
HNSC	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	6.4	3.81e-10	2.05e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
HNSC	cis	rs2834288	0.535	rs881228	ENSG00000237945.6	LINC00649	6.4	3.82e-10	2.05e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33915534~33977691:+
HNSC	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	6.4	3.82e-10	2.05e-07	0.31	0.28	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
HNSC	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	6.4	3.82e-10	2.05e-07	0.41	0.28	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000173295.6	FAM86B3P	-6.4	3.82e-10	2.05e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9037242	chr8:8228595~8244865:+
HNSC	cis	rs11992162	0.636	rs13265816	ENSG00000206014.6	OR7E161P	-6.4	3.83e-10	2.05e-07	-0.31	-0.28	Monocyte count;	chr8:11939976	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000254153.1	CTA-398F10.2	6.4	3.87e-10	2.08e-07	0.31	0.28	Mood instability;	chr8:8465578	chr8:8456909~8461337:-
HNSC	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-6.4	3.88e-10	2.08e-07	-0.35	-0.28	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
HNSC	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-6.4	3.88e-10	2.08e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
HNSC	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-6.4	3.89e-10	2.08e-07	-0.35	-0.28	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
HNSC	cis	rs12935418	0.55	rs35595567	ENSG00000261061.1	RP11-303E16.2	-6.4	3.89e-10	2.08e-07	-0.37	-0.28	Mean corpuscular volume;	chr16:80999761	chr16:81030770~81031485:+
HNSC	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	6.4	3.89e-10	2.09e-07	0.36	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
HNSC	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-6.4	3.89e-10	2.09e-07	-0.24	-0.28	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
HNSC	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	6.4	3.9e-10	2.09e-07	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	6.4	3.9e-10	2.09e-07	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
HNSC	cis	rs2337406	0.866	rs2301536	ENSG00000211974.3	IGHV2-70	-6.4	3.9e-10	2.09e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106790636	chr14:106723574~106724093:-
HNSC	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	6.39	3.91e-10	2.1e-07	0.45	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
HNSC	cis	rs9326248	0.53	rs9919599	ENSG00000280143.1	AP000892.6	6.39	3.92e-10	2.1e-07	0.44	0.28	Blood protein levels;	chr11:116874768	chr11:117204967~117210292:+
HNSC	cis	rs2337406	0.85	rs1858678	ENSG00000211974.3	IGHV2-70	-6.39	3.92e-10	2.1e-07	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106706790	chr14:106723574~106724093:-
HNSC	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	6.39	3.93e-10	2.11e-07	0.33	0.28	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.39	3.93e-10	2.11e-07	0.38	0.28	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
HNSC	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	6.39	3.93e-10	2.11e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
HNSC	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-6.39	3.93e-10	2.11e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
HNSC	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	-6.39	3.94e-10	2.11e-07	-0.32	-0.28	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
HNSC	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-6.39	3.94e-10	2.11e-07	-0.4	-0.28	Gout;	chr7:66693028	chr7:66902857~66906297:+
HNSC	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	6.39	3.94e-10	2.11e-07	0.27	0.28	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
HNSC	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-6.39	3.95e-10	2.12e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
HNSC	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	6.39	3.95e-10	2.12e-07	0.4	0.28	Height;	chr6:109359125	chr6:109382795~109383666:+
HNSC	cis	rs8054556	0.74	rs10083738	ENSG00000183604.13	SMG1P5	-6.39	3.96e-10	2.12e-07	-0.28	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29916381	chr16:30267553~30335374:-
HNSC	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-6.39	3.96e-10	2.12e-07	-0.33	-0.28	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
HNSC	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-6.39	3.96e-10	2.12e-07	-0.28	-0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
HNSC	cis	rs2985684	0.894	rs4581611	ENSG00000258568.1	RHOQP1	6.39	3.97e-10	2.12e-07	0.29	0.28	Carotid intima media thickness;	chr14:49576802	chr14:49599994~49600572:+
HNSC	cis	rs860295	0.966	rs821551	ENSG00000203761.5	MSTO2P	-6.39	3.97e-10	2.13e-07	-0.21	-0.28	Body mass index;	chr1:155718789	chr1:155745829~155750137:+
HNSC	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	6.39	3.97e-10	2.13e-07	0.34	0.28	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
HNSC	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-6.39	3.97e-10	2.13e-07	-0.39	-0.28	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
HNSC	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	6.39	3.97e-10	2.13e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
HNSC	cis	rs4852324	0.541	rs7568898	ENSG00000217702.2	RP11-287D1.4	6.39	3.98e-10	2.13e-07	0.51	0.28	Systemic lupus erythematosus;	chr2:74044450	chr2:74130583~74135395:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-6.39	3.98e-10	2.13e-07	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
HNSC	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-6.39	3.98e-10	2.13e-07	-0.25	-0.28	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
HNSC	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-6.39	3.98e-10	2.13e-07	-0.31	-0.28	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
HNSC	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-6.39	3.98e-10	2.13e-07	-0.53	-0.28	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
HNSC	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	6.39	3.98e-10	2.13e-07	0.33	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
HNSC	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	6.39	3.98e-10	2.13e-07	0.27	0.28	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
HNSC	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	6.39	4.01e-10	2.15e-07	0.25	0.28	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
HNSC	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	6.39	4.01e-10	2.15e-07	0.56	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
HNSC	cis	rs453301	0.624	rs330060	ENSG00000254340.1	RP11-10A14.3	-6.39	4.01e-10	2.15e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9233392	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.624	rs330056	ENSG00000254340.1	RP11-10A14.3	-6.39	4.02e-10	2.15e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9232185	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.624	rs330058	ENSG00000254340.1	RP11-10A14.3	-6.39	4.02e-10	2.15e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9232299	chr8:9141424~9145435:+
HNSC	cis	rs172166	0.694	rs203884	ENSG00000204709.4	LINC01556	6.39	4.03e-10	2.16e-07	0.36	0.28	Cardiac Troponin-T levels;	chr6:28109596	chr6:28943877~28944537:+
HNSC	cis	rs2235642	0.826	rs8053605	ENSG00000280231.1	LA16c-380F5.3	-6.39	4.03e-10	2.16e-07	-0.35	-0.28	Coronary artery disease;	chr16:1544157	chr16:1553655~1554130:-
HNSC	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-6.39	4.05e-10	2.17e-07	-0.35	-0.28	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.561	rs9606831	ENSG00000236132.1	CTA-440B3.1	-6.39	4.05e-10	2.17e-07	-0.35	-0.28	Colorectal cancer;	chr22:31336526	chr22:31816379~31817491:-
HNSC	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	6.39	4.05e-10	2.17e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	6.39	4.05e-10	2.17e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
HNSC	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-6.39	4.06e-10	2.17e-07	-0.35	-0.28	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-6.39	4.06e-10	2.17e-07	-0.35	-0.28	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
HNSC	cis	rs5753618	0.561	rs714909	ENSG00000236132.1	CTA-440B3.1	-6.39	4.06e-10	2.17e-07	-0.35	-0.28	Colorectal cancer;	chr22:31345081	chr22:31816379~31817491:-
HNSC	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	6.39	4.06e-10	2.17e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
HNSC	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-6.39	4.07e-10	2.17e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-6.39	4.07e-10	2.18e-07	-0.19	-0.28	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-6.39	4.07e-10	2.18e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
HNSC	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-6.39	4.07e-10	2.18e-07	-0.37	-0.28	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
HNSC	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-6.39	4.07e-10	2.18e-07	-0.52	-0.28	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
HNSC	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	6.39	4.07e-10	2.18e-07	0.39	0.28	Height;	chr6:109449796	chr6:109382795~109383666:+
HNSC	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-6.39	4.08e-10	2.18e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
HNSC	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.08e-10	2.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.08e-10	2.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.08e-10	2.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
HNSC	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	6.39	4.08e-10	2.18e-07	0.33	0.28	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
HNSC	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-6.39	4.1e-10	2.19e-07	-0.35	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
HNSC	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-6.39	4.1e-10	2.19e-07	-0.35	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
HNSC	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	6.39	4.1e-10	2.19e-07	0.4	0.28	Height;	chr6:109372084	chr6:109382795~109383666:+
HNSC	cis	rs7396835	0.866	rs6589571	ENSG00000280143.1	AP000892.6	6.39	4.1e-10	2.19e-07	0.41	0.28	Quantitative traits;	chr11:116809702	chr11:117204967~117210292:+
HNSC	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	6.39	4.11e-10	2.2e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000211972.2	IGHV3-66	6.39	4.12e-10	2.2e-07	0.22	0.28	Kawasaki disease;	chr14:106711377	chr14:106675017~106675544:-
HNSC	cis	rs1021993	0.672	rs2660641	ENSG00000231648.1	RP11-372M18.2	6.39	4.13e-10	2.21e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209336539	chr1:209367662~209379690:+
HNSC	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-6.39	4.13e-10	2.21e-07	-0.69	-0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
HNSC	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-6.39	4.13e-10	2.21e-07	-0.54	-0.28	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
HNSC	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-6.39	4.14e-10	2.21e-07	-0.31	-0.28	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
HNSC	cis	rs11089937	0.857	rs5750580	ENSG00000211638.2	IGLV8-61	-6.38	4.15e-10	2.22e-07	-0.24	-0.28	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22098700~22099212:+
HNSC	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-6.38	4.15e-10	2.22e-07	-0.29	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
HNSC	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	6.38	4.15e-10	2.22e-07	0.32	0.28	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-6.38	4.17e-10	2.23e-07	-0.35	-0.28	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-6.38	4.17e-10	2.23e-07	-0.35	-0.28	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
HNSC	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-6.38	4.17e-10	2.23e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-6.38	4.17e-10	2.23e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
HNSC	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	6.38	4.17e-10	2.23e-07	0.28	0.28	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
HNSC	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-6.38	4.18e-10	2.23e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
HNSC	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	6.38	4.18e-10	2.23e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	6.38	4.18e-10	2.23e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
HNSC	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	6.38	4.18e-10	2.23e-07	0.29	0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	6.38	4.19e-10	2.23e-07	0.18	0.28	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
HNSC	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	6.38	4.19e-10	2.24e-07	0.45	0.28	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
HNSC	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	6.38	4.19e-10	2.24e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
HNSC	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-6.38	4.19e-10	2.24e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
HNSC	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-6.38	4.19e-10	2.24e-07	-0.37	-0.28	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
HNSC	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-6.38	4.2e-10	2.24e-07	-0.33	-0.28	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-6.38	4.2e-10	2.24e-07	-0.25	-0.28	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
HNSC	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-6.38	4.2e-10	2.24e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
HNSC	cis	rs8054556	0.733	rs35467921	ENSG00000183604.13	SMG1P5	-6.38	4.21e-10	2.24e-07	-0.29	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30037232	chr16:30267553~30335374:-
HNSC	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	6.38	4.21e-10	2.24e-07	0.33	0.28	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
HNSC	cis	rs860295	0.775	rs822505	ENSG00000203761.5	MSTO2P	6.38	4.22e-10	2.25e-07	0.21	0.28	Body mass index;	chr1:155876737	chr1:155745829~155750137:+
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-6.38	4.22e-10	2.25e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-6.38	4.22e-10	2.25e-07	-0.34	-0.28	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
HNSC	cis	rs17270561	0.666	rs1937129	ENSG00000272462.2	U91328.19	-6.38	4.23e-10	2.26e-07	-0.28	-0.28	Iron status biomarkers;	chr6:25788904	chr6:25992662~26001775:+
HNSC	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	6.38	4.23e-10	2.26e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
HNSC	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-6.38	4.24e-10	2.26e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
HNSC	cis	rs2337406	0.866	rs7153964	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106790480	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs7144369	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106793065	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs78525520	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106795643	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs7140974	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106795976	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Kawasaki disease;	chr14:106799309	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs76871148	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106799722	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs61521632	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106801091	chr14:106723574~106724093:-
HNSC	cis	rs4273100	1	rs868698	ENSG00000265185.4	SNORD3B-1	6.38	4.25e-10	2.26e-07	0.42	0.28	Schizophrenia;	chr17:19281898	chr17:19061912~19062669:+
HNSC	cis	rs12439619	0.846	rs62011975	ENSG00000276710.3	CSPG4P8	-6.38	4.25e-10	2.27e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82459472~82477258:+
HNSC	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-6.38	4.26e-10	2.27e-07	-0.32	-0.28	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
HNSC	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-6.38	4.26e-10	2.27e-07	-0.41	-0.28	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-6.38	4.26e-10	2.27e-07	-0.41	-0.28	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
HNSC	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	6.38	4.26e-10	2.27e-07	0.28	0.28	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	6.38	4.26e-10	2.27e-07	0.28	0.28	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
HNSC	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-6.38	4.27e-10	2.27e-07	-0.32	-0.28	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
HNSC	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	6.38	4.27e-10	2.27e-07	0.44	0.28	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
HNSC	cis	rs6435862	0.844	rs6720708	ENSG00000229267.2	AC072062.1	6.38	4.27e-10	2.28e-07	0.37	0.28	Neuroblastoma (high-risk);	chr2:214806593	chr2:214810229~214963274:+
HNSC	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	6.38	4.27e-10	2.28e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
HNSC	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	6.38	4.27e-10	2.28e-07	0.4	0.28	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
HNSC	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	6.38	4.27e-10	2.28e-07	0.46	0.28	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
HNSC	cis	rs7615952	0.576	rs2276729	ENSG00000241288.6	RP11-379B18.5	-6.38	4.28e-10	2.28e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126107371	chr3:125827238~125916384:-
HNSC	cis	rs2404602	0.716	rs4886817	ENSG00000259422.1	RP11-593F23.1	6.38	4.28e-10	2.28e-07	0.33	0.28	Blood metabolite levels;	chr15:76585361	chr15:76174891~76181486:-
HNSC	cis	rs5753618	0.561	rs1858821	ENSG00000236132.1	CTA-440B3.1	6.38	4.28e-10	2.28e-07	0.35	0.28	Colorectal cancer;	chr22:31280468	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.519	rs5997939	ENSG00000236132.1	CTA-440B3.1	6.38	4.28e-10	2.28e-07	0.35	0.28	Colorectal cancer;	chr22:31281144	chr22:31816379~31817491:-
HNSC	cis	rs2790457	0.833	rs1265843	ENSG00000254635.4	WAC-AS1	-6.38	4.29e-10	2.28e-07	-0.32	-0.28	Multiple myeloma;	chr10:28636088	chr10:28522652~28532743:-
HNSC	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-6.38	4.29e-10	2.29e-07	-0.36	-0.28	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
HNSC	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-6.38	4.29e-10	2.29e-07	-0.34	-0.28	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
HNSC	cis	rs6951245	0.554	rs79367977	ENSG00000224079.1	AC091729.7	-6.38	4.29e-10	2.29e-07	-0.37	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1074450~1078036:+
HNSC	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	6.38	4.29e-10	2.29e-07	0.35	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	6.38	4.3e-10	2.29e-07	0.32	0.28	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
HNSC	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	6.38	4.31e-10	2.29e-07	0.22	0.28	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
HNSC	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-6.38	4.31e-10	2.3e-07	-0.4	-0.28	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
HNSC	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	6.38	4.31e-10	2.3e-07	0.33	0.28	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
HNSC	cis	rs8177876	0.749	rs2278024	ENSG00000261061.1	RP11-303E16.2	-6.38	4.32e-10	2.3e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81030770~81031485:+
HNSC	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	6.38	4.32e-10	2.3e-07	0.37	0.28	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
HNSC	cis	rs2337406	0.706	rs74090742	ENSG00000211974.3	IGHV2-70	-6.38	4.32e-10	2.3e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106696601	chr14:106723574~106724093:-
HNSC	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-6.38	4.32e-10	2.3e-07	-0.29	-0.28	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
HNSC	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	6.38	4.33e-10	2.31e-07	0.37	0.28	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
HNSC	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-6.38	4.34e-10	2.31e-07	-0.3	-0.28	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
HNSC	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	6.38	4.34e-10	2.31e-07	0.27	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
HNSC	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-6.38	4.34e-10	2.31e-07	-0.32	-0.28	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
HNSC	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-6.38	4.35e-10	2.31e-07	-0.37	-0.28	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
HNSC	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	6.38	4.35e-10	2.31e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
HNSC	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-6.38	4.35e-10	2.31e-07	-0.36	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
HNSC	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-6.38	4.36e-10	2.32e-07	-0.32	-0.28	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
HNSC	cis	rs9890032	0.934	rs7225461	ENSG00000263531.1	RP13-753N3.1	6.38	4.36e-10	2.32e-07	0.34	0.28	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30863921~30864940:-
HNSC	cis	rs4141404	0.828	rs2413043	ENSG00000236132.1	CTA-440B3.1	6.38	4.37e-10	2.33e-07	0.35	0.28	Paclitaxel-induced neuropathy;	chr22:31252590	chr22:31816379~31817491:-
HNSC	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-6.38	4.38e-10	2.33e-07	-0.32	-0.28	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
HNSC	cis	rs6496044	0.547	rs7173125	ENSG00000259295.5	CSPG4P12	-6.38	4.39e-10	2.34e-07	-0.34	-0.28	Interstitial lung disease;	chr15:85512214	chr15:85191438~85213905:+
HNSC	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	6.38	4.4e-10	2.34e-07	0.28	0.28	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
HNSC	cis	rs35955747	0.811	rs9606835	ENSG00000236132.1	CTA-440B3.1	-6.38	4.4e-10	2.34e-07	-0.3	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31370974	chr22:31816379~31817491:-
HNSC	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-6.37	4.4e-10	2.34e-07	-0.4	-0.28	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
HNSC	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	6.37	4.4e-10	2.34e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
HNSC	cis	rs7615952	0.576	rs1127717	ENSG00000241288.6	RP11-379B18.5	-6.37	4.41e-10	2.34e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126107216	chr3:125827238~125916384:-
HNSC	cis	rs8012947	0.959	rs6573196	ENSG00000279636.2	LINC00216	-6.37	4.42e-10	2.35e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58255821	chr14:58288033~58289158:+
HNSC	cis	rs858239	0.863	rs274054	ENSG00000226816.2	AC005082.12	6.37	4.42e-10	2.35e-07	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23206013~23208045:+
HNSC	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-6.37	4.43e-10	2.36e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
HNSC	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	6.37	4.44e-10	2.36e-07	0.46	0.28	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
HNSC	cis	rs7615952	0.611	rs9681518	ENSG00000241288.6	RP11-379B18.5	-6.37	4.44e-10	2.36e-07	-0.47	-0.28	Blood pressure (smoking interaction);	chr3:125896287	chr3:125827238~125916384:-
HNSC	cis	rs1799949	0.827	rs74252763	ENSG00000267681.1	CTD-3199J23.6	-6.37	4.45e-10	2.37e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43324652	chr17:43144956~43145255:+
HNSC	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	6.37	4.45e-10	2.37e-07	0.4	0.28	Height;	chr6:109360679	chr6:109382795~109383666:+
HNSC	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-6.37	4.47e-10	2.37e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
HNSC	cis	rs1355223	0.902	rs1578622	ENSG00000271369.1	RP11-350D17.3	-6.37	4.47e-10	2.37e-07	-0.32	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34704368	chr11:34709600~34710161:+
HNSC	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	6.37	4.47e-10	2.38e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
HNSC	cis	rs2985684	0.894	rs2281837	ENSG00000258568.1	RHOQP1	6.37	4.47e-10	2.38e-07	0.29	0.28	Carotid intima media thickness;	chr14:49598641	chr14:49599994~49600572:+
HNSC	cis	rs8177876	0.822	rs4306521	ENSG00000261061.1	RP11-303E16.2	-6.37	4.47e-10	2.38e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs4324142	ENSG00000261061.1	RP11-303E16.2	-6.37	4.47e-10	2.38e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs4324143	ENSG00000261061.1	RP11-303E16.2	-6.37	4.47e-10	2.38e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81030770~81031485:+
HNSC	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-6.37	4.48e-10	2.38e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
HNSC	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	6.37	4.48e-10	2.38e-07	0.33	0.28	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
HNSC	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-6.37	4.48e-10	2.38e-07	-0.35	-0.28	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-6.37	4.48e-10	2.38e-07	-0.35	-0.28	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	6.37	4.48e-10	2.38e-07	0.31	0.28	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
HNSC	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-6.37	4.49e-10	2.38e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.66	rs61943362	ENSG00000275409.1	RP11-131L12.4	-6.37	4.49e-10	2.39e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118322042	chr12:118430147~118430699:+
HNSC	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	6.37	4.5e-10	2.39e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
HNSC	cis	rs6504622	0.791	rs758392	ENSG00000262879.4	RP11-156P1.3	-6.37	4.5e-10	2.39e-07	-0.29	-0.28	Orofacial clefts;	chr17:46940493	chr17:46984045~47100323:-
HNSC	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	6.37	4.5e-10	2.39e-07	0.32	0.28	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000254340.1	RP11-10A14.3	-6.37	4.5e-10	2.39e-07	-0.34	-0.28	Mood instability;	chr8:8933743	chr8:9141424~9145435:+
HNSC	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	6.37	4.5e-10	2.39e-07	0.42	0.28	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
HNSC	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-6.37	4.5e-10	2.39e-07	-0.35	-0.28	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
HNSC	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	6.37	4.51e-10	2.39e-07	0.35	0.28	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000173295.6	FAM86B3P	-6.37	4.51e-10	2.39e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9044411	chr8:8228595~8244865:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-6.37	4.51e-10	2.39e-07	-0.27	-0.28	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
HNSC	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	6.37	4.51e-10	2.39e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
HNSC	cis	rs853679	1	rs853679	ENSG00000219392.1	RP1-265C24.5	-6.37	4.51e-10	2.39e-07	-0.42	-0.28	Depression;	chr6:28329086	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs853678	ENSG00000219392.1	RP1-265C24.5	-6.37	4.51e-10	2.39e-07	-0.42	-0.28	Depression;	chr6:28329536	chr6:28115628~28116551:+
HNSC	cis	rs17507216	0.628	rs4513065	ENSG00000255769.6	GOLGA2P10	-6.37	4.51e-10	2.4e-07	-0.44	-0.28	Excessive daytime sleepiness;	chr15:82712096	chr15:82472993~82513950:-
HNSC	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-6.37	4.52e-10	2.4e-07	-0.36	-0.28	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
HNSC	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	6.37	4.52e-10	2.4e-07	0.39	0.28	Height;	chr6:109395761	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-6.37	4.52e-10	2.4e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
HNSC	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	6.37	4.53e-10	2.4e-07	0.28	0.28	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
HNSC	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	6.37	4.55e-10	2.41e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
HNSC	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	6.37	4.55e-10	2.42e-07	0.44	0.28	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
HNSC	cis	rs8054556	0.74	rs11649612	ENSG00000183604.13	SMG1P5	-6.37	4.59e-10	2.43e-07	-0.28	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30267553~30335374:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-6.37	4.59e-10	2.44e-07	-0.18	-0.28	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
HNSC	cis	rs11089937	0.864	rs5757041	ENSG00000211638.2	IGLV8-61	-6.37	4.6e-10	2.44e-07	-0.24	-0.28	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22098700~22099212:+
HNSC	cis	rs2337406	0.866	rs8016203	ENSG00000211974.3	IGHV2-70	-6.37	4.61e-10	2.45e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106780575	chr14:106723574~106724093:-
HNSC	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-6.37	4.61e-10	2.45e-07	-0.36	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
HNSC	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-6.37	4.62e-10	2.45e-07	-0.35	-0.28	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
HNSC	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-6.37	4.62e-10	2.45e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-6.37	4.62e-10	2.45e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
HNSC	cis	rs393155	0.517	rs330050	ENSG00000254340.1	RP11-10A14.3	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Neuroticism;	chr8:9230169	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.571	rs330054	ENSG00000254340.1	RP11-10A14.3	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9230781	chr8:9141424~9145435:+
HNSC	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
HNSC	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-6.37	4.63e-10	2.45e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
HNSC	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	6.37	4.64e-10	2.46e-07	0.33	0.28	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
HNSC	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	6.37	4.64e-10	2.46e-07	0.32	0.28	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	6.37	4.64e-10	2.46e-07	0.32	0.28	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	6.37	4.64e-10	2.46e-07	0.32	0.28	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
HNSC	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-6.37	4.64e-10	2.46e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-6.37	4.64e-10	2.46e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
HNSC	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	6.37	4.65e-10	2.47e-07	0.41	0.28	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
HNSC	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-6.37	4.65e-10	2.47e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
HNSC	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	6.37	4.66e-10	2.47e-07	0.28	0.28	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
HNSC	cis	rs17270561	0.583	rs6908713	ENSG00000272462.2	U91328.19	6.37	4.66e-10	2.47e-07	0.29	0.28	Iron status biomarkers;	chr6:25703383	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.583	rs6908407	ENSG00000272462.2	U91328.19	6.37	4.66e-10	2.47e-07	0.29	0.28	Iron status biomarkers;	chr6:25703428	chr6:25992662~26001775:+
HNSC	cis	rs2985684	0.841	rs7158577	ENSG00000258568.1	RHOQP1	6.36	4.67e-10	2.47e-07	0.29	0.28	Carotid intima media thickness;	chr14:49591915	chr14:49599994~49600572:+
HNSC	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-6.36	4.69e-10	2.48e-07	-0.4	-0.28	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-6.36	4.69e-10	2.48e-07	-0.4	-0.28	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
HNSC	cis	rs2404602	0.692	rs4641709	ENSG00000259422.1	RP11-593F23.1	-6.36	4.7e-10	2.49e-07	-0.33	-0.28	Blood metabolite levels;	chr15:76755395	chr15:76174891~76181486:-
HNSC	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	6.36	4.71e-10	2.49e-07	0.31	0.28	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	6.36	4.71e-10	2.49e-07	0.45	0.28	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
HNSC	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	6.36	4.72e-10	2.5e-07	0.27	0.28	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
HNSC	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	6.36	4.72e-10	2.5e-07	0.33	0.28	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
HNSC	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-6.36	4.73e-10	2.5e-07	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
HNSC	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-6.36	4.73e-10	2.5e-07	-0.31	-0.28	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
HNSC	cis	rs8177876	0.822	rs4889225	ENSG00000261061.1	RP11-303E16.2	6.36	4.74e-10	2.51e-07	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81030770~81031485:+
HNSC	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-6.36	4.75e-10	2.51e-07	-0.53	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
HNSC	cis	rs11089937	0.667	rs5757081	ENSG00000211638.2	IGLV8-61	-6.36	4.75e-10	2.51e-07	-0.27	-0.28	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22098700~22099212:+
HNSC	cis	rs8054556	0.787	rs12921753	ENSG00000183604.13	SMG1P5	-6.36	4.76e-10	2.52e-07	-0.29	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30007399	chr16:30267553~30335374:-
HNSC	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-6.36	4.77e-10	2.52e-07	-0.4	-0.28	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-6.36	4.77e-10	2.52e-07	-0.4	-0.28	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-6.36	4.77e-10	2.52e-07	-0.4	-0.28	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
HNSC	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-6.36	4.77e-10	2.52e-07	-0.24	-0.28	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
HNSC	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	6.36	4.77e-10	2.53e-07	0.39	0.28	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.36	4.78e-10	2.53e-07	-0.38	-0.28	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
HNSC	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	6.36	4.78e-10	2.53e-07	0.33	0.28	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
HNSC	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-6.36	4.8e-10	2.54e-07	-0.4	-0.28	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-6.36	4.81e-10	2.54e-07	-0.26	-0.28	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
HNSC	cis	rs8012947	1	rs1957038	ENSG00000279636.2	LINC00216	-6.36	4.83e-10	2.55e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58299899	chr14:58288033~58289158:+
HNSC	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-6.36	4.83e-10	2.56e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
HNSC	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	6.36	4.84e-10	2.56e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
HNSC	cis	rs1021993	0.729	rs2456809	ENSG00000231648.1	RP11-372M18.2	6.36	4.85e-10	2.56e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209314622	chr1:209367662~209379690:+
HNSC	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	6.36	4.85e-10	2.56e-07	0.41	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
HNSC	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	6.36	4.86e-10	2.57e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
HNSC	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-6.36	4.87e-10	2.57e-07	-0.26	-0.28	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
HNSC	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	6.36	4.87e-10	2.57e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	6.36	4.87e-10	2.57e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
HNSC	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	6.36	4.88e-10	2.58e-07	0.33	0.28	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
HNSC	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-6.36	4.88e-10	2.58e-07	-0.34	-0.28	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
HNSC	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	6.36	4.89e-10	2.58e-07	0.45	0.28	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
HNSC	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	6.36	4.89e-10	2.58e-07	0.31	0.28	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
HNSC	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-6.36	4.9e-10	2.59e-07	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
HNSC	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	6.36	4.9e-10	2.59e-07	0.37	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
HNSC	cis	rs858239	0.863	rs274058	ENSG00000226816.2	AC005082.12	6.36	4.9e-10	2.59e-07	0.35	0.28	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23206013~23208045:+
HNSC	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	6.36	4.9e-10	2.59e-07	0.38	0.28	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
HNSC	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-6.36	4.9e-10	2.59e-07	-0.35	-0.28	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
HNSC	cis	rs8177876	0.822	rs7206814	ENSG00000261061.1	RP11-303E16.2	6.36	4.9e-10	2.59e-07	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81030770~81031485:+
HNSC	cis	rs13113518	0.513	rs13132085	ENSG00000273257.1	RP11-177J6.1	-6.36	4.91e-10	2.59e-07	-0.36	-0.28	Height;	chr4:55593918	chr4:55387949~55388271:+
HNSC	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-6.36	4.91e-10	2.59e-07	-0.24	-0.28	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
HNSC	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	6.36	4.91e-10	2.59e-07	0.35	0.28	Depression;	chr6:28391932	chr6:28943877~28944537:+
HNSC	cis	rs9890032	1	rs28539246	ENSG00000263531.1	RP13-753N3.1	6.36	4.91e-10	2.59e-07	0.34	0.28	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30863921~30864940:-
HNSC	cis	rs9890032	0.967	rs9897628	ENSG00000263531.1	RP13-753N3.1	6.36	4.91e-10	2.59e-07	0.34	0.28	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30863921~30864940:-
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-6.36	4.92e-10	2.59e-07	-0.4	-0.28	Gout;	chr7:66654674	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-6.36	4.92e-10	2.59e-07	-0.4	-0.28	Gout;	chr7:66661502	chr7:66902857~66906297:+
HNSC	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	6.36	4.92e-10	2.6e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
HNSC	cis	rs1021993	0.672	rs2800929	ENSG00000231648.1	RP11-372M18.2	6.36	4.92e-10	2.6e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209318623	chr1:209367662~209379690:+
HNSC	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	6.36	4.93e-10	2.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
HNSC	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	6.36	4.93e-10	2.6e-07	0.66	0.28	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
HNSC	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-6.36	4.94e-10	2.6e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
HNSC	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	6.36	4.94e-10	2.61e-07	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
HNSC	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	6.36	4.95e-10	2.61e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
HNSC	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-6.36	4.95e-10	2.61e-07	-0.35	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
HNSC	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-6.36	4.96e-10	2.62e-07	-0.35	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
HNSC	cis	rs7819412	0.745	rs4841498	ENSG00000255310.2	AF131215.2	-6.35	4.96e-10	2.62e-07	-0.27	-0.28	Triglycerides;	chr8:11127922	chr8:11107788~11109726:-
HNSC	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
HNSC	cis	rs2834288	0.535	rs8132681	ENSG00000237945.6	LINC00649	6.35	4.96e-10	2.62e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33950035	chr21:33915534~33977691:+
HNSC	cis	rs8012947	1	rs10142973	ENSG00000279636.2	LINC00216	-6.35	4.98e-10	2.63e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58332400	chr14:58288033~58289158:+
HNSC	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-6.35	4.99e-10	2.63e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
HNSC	cis	rs2404602	0.716	rs7174953	ENSG00000259422.1	RP11-593F23.1	6.35	4.99e-10	2.63e-07	0.33	0.28	Blood metabolite levels;	chr15:76614506	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.679	rs12900494	ENSG00000259422.1	RP11-593F23.1	6.35	4.99e-10	2.63e-07	0.33	0.28	Blood metabolite levels;	chr15:76620163	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs7169394	ENSG00000259422.1	RP11-593F23.1	6.35	4.99e-10	2.63e-07	0.33	0.28	Blood metabolite levels;	chr15:76620933	chr15:76174891~76181486:-
HNSC	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	6.35	4.99e-10	2.63e-07	0.35	0.28	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
HNSC	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	6.35	5e-10	2.63e-07	0.33	0.28	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
HNSC	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	6.35	5e-10	2.63e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	6.35	5e-10	2.63e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
HNSC	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	6.35	5e-10	2.63e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
HNSC	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-6.35	5e-10	2.64e-07	-0.32	-0.28	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
HNSC	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	6.35	5e-10	2.64e-07	0.32	0.28	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
HNSC	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-6.35	5.01e-10	2.64e-07	-0.37	-0.28	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
HNSC	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	6.35	5.01e-10	2.64e-07	0.27	0.28	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
HNSC	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	6.35	5.02e-10	2.64e-07	0.39	0.28	Height;	chr6:109454855	chr6:109382795~109383666:+
HNSC	cis	rs9300255	0.739	rs4759415	ENSG00000280120.1	RP11-546D6.3	-6.35	5.02e-10	2.65e-07	-0.25	-0.28	Neutrophil percentage of white cells;	chr12:123259127	chr12:123152324~123153377:-
HNSC	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	6.35	5.03e-10	2.65e-07	0.24	0.28	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.773	rs9389263	ENSG00000232876.1	CTA-212D2.2	-6.35	5.03e-10	2.65e-07	-0.34	-0.28	Red blood cell count;	chr6:135079427	chr6:135055033~135060550:+
HNSC	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	6.35	5.03e-10	2.65e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
HNSC	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-6.35	5.04e-10	2.66e-07	-0.34	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
HNSC	cis	rs9907295	0.818	rs7211393	ENSG00000270977.1	AC015849.16	-6.35	5.04e-10	2.66e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35885124	chr17:35893707~35911023:-
HNSC	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-6.35	5.05e-10	2.66e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
HNSC	cis	rs7587476	0.765	rs2121284	ENSG00000229267.2	AC072062.1	6.35	5.05e-10	2.66e-07	0.36	0.28	Neuroblastoma;	chr2:214791536	chr2:214810229~214963274:+
HNSC	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-6.35	5.05e-10	2.66e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
HNSC	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	6.35	5.08e-10	2.67e-07	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	6.35	5.08e-10	2.67e-07	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
HNSC	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	6.35	5.08e-10	2.67e-07	0.45	0.28	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
HNSC	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	6.35	5.08e-10	2.68e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
HNSC	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	6.35	5.09e-10	2.68e-07	0.34	0.28	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
HNSC	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	6.35	5.09e-10	2.68e-07	0.34	0.28	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-6.35	5.09e-10	2.68e-07	-0.4	-0.28	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
HNSC	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-6.35	5.09e-10	2.68e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
HNSC	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-6.35	5.1e-10	2.68e-07	-0.33	-0.28	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
HNSC	cis	rs17270561	0.609	rs1185976	ENSG00000272462.2	U91328.19	6.35	5.1e-10	2.68e-07	0.28	0.28	Iron status biomarkers;	chr6:25822135	chr6:25992662~26001775:+
HNSC	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	6.35	5.1e-10	2.68e-07	0.4	0.28	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
HNSC	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	6.35	5.12e-10	2.7e-07	0.37	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
HNSC	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	6.35	5.13e-10	2.7e-07	0.37	0.28	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
HNSC	cis	rs4639966	0.836	rs7943039	ENSG00000255422.1	AP002954.4	6.35	5.13e-10	2.7e-07	0.39	0.28	Systemic lupus erythematosus;	chr11:118732321	chr11:118704607~118750263:+
HNSC	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	6.35	5.14e-10	2.7e-07	0.32	0.28	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
HNSC	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-6.35	5.14e-10	2.7e-07	-0.4	-0.28	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
HNSC	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	6.35	5.16e-10	2.71e-07	0.26	0.28	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	6.35	5.16e-10	2.71e-07	0.26	0.28	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
HNSC	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	6.35	5.16e-10	2.72e-07	0.27	0.28	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000223648.3	IGHV3-64	6.35	5.17e-10	2.72e-07	0.23	0.28	Kawasaki disease;	chr14:106777570	chr14:106643132~106658258:-
HNSC	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-6.35	5.19e-10	2.73e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
HNSC	cis	rs2235642	0.691	rs2281235	ENSG00000280231.1	LA16c-380F5.3	-6.35	5.19e-10	2.73e-07	-0.34	-0.28	Coronary artery disease;	chr16:1553534	chr16:1553655~1554130:-
HNSC	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	6.35	5.2e-10	2.73e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
HNSC	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-6.35	5.2e-10	2.74e-07	-0.31	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
HNSC	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	6.35	5.21e-10	2.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
HNSC	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-6.35	5.22e-10	2.74e-07	-0.41	-0.28	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-6.35	5.22e-10	2.75e-07	-0.33	-0.28	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
HNSC	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	6.35	5.22e-10	2.75e-07	0.27	0.28	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	6.35	5.22e-10	2.75e-07	0.27	0.28	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	6.35	5.22e-10	2.75e-07	0.27	0.28	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
HNSC	cis	rs2579103	0.708	rs2250237	ENSG00000258183.4	RP11-753N8.1	-6.35	5.23e-10	2.75e-07	-0.38	-0.28	Body mass index;	chr12:90289234	chr12:90280894~90300340:+
HNSC	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-6.35	5.24e-10	2.75e-07	-0.33	-0.28	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
HNSC	cis	rs451417	0.722	rs236189	ENSG00000275632.1	RP5-967N21.11	6.35	5.24e-10	2.76e-07	0.31	0.28	Menopause (age at onset);	chr20:5951544	chr20:6000418~6000941:+
HNSC	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	6.35	5.24e-10	2.76e-07	0.32	0.28	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	6.35	5.24e-10	2.76e-07	0.32	0.28	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	6.35	5.24e-10	2.76e-07	0.32	0.28	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
HNSC	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-6.35	5.26e-10	2.76e-07	-0.3	-0.28	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
HNSC	cis	rs964184	0.507	rs6589565	ENSG00000254851.1	RP11-109L13.1	-6.35	5.26e-10	2.77e-07	-0.69	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116769521	chr11:117135528~117138582:+
HNSC	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-6.34	5.27e-10	2.77e-07	-0.28	-0.28	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
HNSC	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	6.34	5.27e-10	2.77e-07	0.31	0.28	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	6.34	5.27e-10	2.77e-07	0.31	0.28	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
HNSC	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	6.34	5.27e-10	2.77e-07	0.4	0.28	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
HNSC	cis	rs2404602	0.692	rs57178708	ENSG00000259422.1	RP11-593F23.1	6.34	5.27e-10	2.77e-07	0.33	0.28	Blood metabolite levels;	chr15:76611728	chr15:76174891~76181486:-
HNSC	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-6.34	5.28e-10	2.77e-07	-0.34	-0.28	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
HNSC	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-6.34	5.28e-10	2.78e-07	-0.36	-0.28	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-6.34	5.28e-10	2.78e-07	-0.36	-0.28	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
HNSC	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-6.34	5.29e-10	2.78e-07	-0.38	-0.28	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
HNSC	cis	rs1021993	0.672	rs2254757	ENSG00000231648.1	RP11-372M18.2	6.34	5.29e-10	2.78e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209318648	chr1:209367662~209379690:+
HNSC	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	6.34	5.3e-10	2.78e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	6.34	5.3e-10	2.78e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
HNSC	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	6.34	5.31e-10	2.79e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
HNSC	cis	rs5753618	0.539	rs2228619	ENSG00000236132.1	CTA-440B3.1	6.34	5.31e-10	2.79e-07	0.35	0.28	Colorectal cancer;	chr22:31267856	chr22:31816379~31817491:-
HNSC	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-6.34	5.31e-10	2.79e-07	-0.36	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
HNSC	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	6.34	5.33e-10	2.8e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
HNSC	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-6.34	5.34e-10	2.8e-07	-0.31	-0.28	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
HNSC	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	6.34	5.35e-10	2.81e-07	0.32	0.28	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
HNSC	cis	rs2239557	0.885	rs4899502	ENSG00000259065.1	RP5-1021I20.1	6.34	5.36e-10	2.81e-07	0.34	0.28	Common traits (Other);	chr14:74203190	chr14:73787360~73803270:+
HNSC	cis	rs2985684	0.789	rs1957979	ENSG00000258568.1	RHOQP1	6.34	5.36e-10	2.81e-07	0.29	0.28	Carotid intima media thickness;	chr14:49596614	chr14:49599994~49600572:+
HNSC	cis	rs2985684	0.789	rs7161649	ENSG00000258568.1	RHOQP1	6.34	5.36e-10	2.81e-07	0.29	0.28	Carotid intima media thickness;	chr14:49597310	chr14:49599994~49600572:+
HNSC	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.38e-10	2.82e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	6.34	5.39e-10	2.83e-07	0.32	0.28	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
HNSC	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-6.34	5.39e-10	2.83e-07	-0.29	-0.28	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
HNSC	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-6.34	5.39e-10	2.83e-07	-0.39	-0.28	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
HNSC	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-6.34	5.39e-10	2.83e-07	-0.39	-0.28	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
HNSC	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-6.34	5.39e-10	2.83e-07	-0.41	-0.28	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
HNSC	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-6.34	5.4e-10	2.83e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
HNSC	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-6.34	5.4e-10	2.83e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
HNSC	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	6.34	5.4e-10	2.83e-07	0.33	0.28	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
HNSC	cis	rs8177876	0.731	rs76093926	ENSG00000261061.1	RP11-303E16.2	-6.34	5.4e-10	2.83e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs10514512	ENSG00000261061.1	RP11-303E16.2	-6.34	5.4e-10	2.83e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81030770~81031485:+
HNSC	cis	rs7615952	0.576	rs4646759	ENSG00000241288.6	RP11-379B18.5	-6.34	5.4e-10	2.83e-07	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:126104103	chr3:125827238~125916384:-
HNSC	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	6.34	5.41e-10	2.83e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
HNSC	cis	rs4141404	0.74	rs9609301	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Paclitaxel-induced neuropathy;	chr22:31499954	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.555	rs9609302	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31500001	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.504	rs9609303	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31500323	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.504	rs9606846	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31501585	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.555	rs9609304	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31501809	chr22:31816379~31817491:-
HNSC	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	6.34	5.42e-10	2.84e-07	0.33	0.28	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	6.34	5.42e-10	2.84e-07	0.33	0.28	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	6.34	5.42e-10	2.84e-07	0.33	0.28	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
HNSC	cis	rs5753618	0.561	rs2078803	ENSG00000236132.1	CTA-440B3.1	6.34	5.42e-10	2.84e-07	0.34	0.28	Colorectal cancer;	chr22:31256866	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2073857	ENSG00000236132.1	CTA-440B3.1	6.34	5.42e-10	2.84e-07	0.34	0.28	Colorectal cancer;	chr22:31262295	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs737684	ENSG00000236132.1	CTA-440B3.1	6.34	5.42e-10	2.84e-07	0.34	0.28	Colorectal cancer;	chr22:31263841	chr22:31816379~31817491:-
HNSC	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	6.34	5.42e-10	2.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	6.34	5.42e-10	2.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	6.34	5.42e-10	2.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
HNSC	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
HNSC	cis	rs7250849	0.79	rs73052830	ENSG00000273837.1	LLNLR-470E3.1	-6.34	5.42e-10	2.84e-07	-0.46	-0.28	Blood protein levels;	chr19:51657512	chr19:51639478~51639931:-
HNSC	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	6.34	5.42e-10	2.84e-07	0.31	0.28	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
HNSC	cis	rs2404602	0.716	rs2404737	ENSG00000259422.1	RP11-593F23.1	6.34	5.43e-10	2.84e-07	0.32	0.28	Blood metabolite levels;	chr15:76579876	chr15:76174891~76181486:-
HNSC	cis	rs2235642	0.75	rs763152	ENSG00000280231.1	LA16c-380F5.3	-6.34	5.43e-10	2.85e-07	-0.35	-0.28	Coronary artery disease;	chr16:1608055	chr16:1553655~1554130:-
HNSC	cis	rs2235642	0.717	rs9937922	ENSG00000280231.1	LA16c-380F5.3	-6.34	5.43e-10	2.85e-07	-0.35	-0.28	Coronary artery disease;	chr16:1608153	chr16:1553655~1554130:-
HNSC	cis	rs9326248	0.53	rs6589576	ENSG00000280143.1	AP000892.6	-6.34	5.43e-10	2.85e-07	-0.42	-0.28	Blood protein levels;	chr11:116865072	chr11:117204967~117210292:+
HNSC	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-6.34	5.44e-10	2.85e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
HNSC	cis	rs189798	0.807	rs330909	ENSG00000173295.6	FAM86B3P	6.34	5.44e-10	2.85e-07	0.34	0.28	Myopia (pathological);	chr8:9137877	chr8:8228595~8244865:+
HNSC	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	6.34	5.45e-10	2.85e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-6.34	5.46e-10	2.86e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
HNSC	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-6.34	5.46e-10	2.86e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-6.34	5.46e-10	2.86e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-6.34	5.46e-10	2.86e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
HNSC	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-6.34	5.47e-10	2.87e-07	-0.36	-0.28	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-6.34	5.48e-10	2.87e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
HNSC	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.34	5.48e-10	2.87e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
HNSC	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	6.34	5.49e-10	2.87e-07	0.27	0.28	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
HNSC	cis	rs860295	1	rs822490	ENSG00000203761.5	MSTO2P	-6.34	5.49e-10	2.87e-07	-0.21	-0.28	Body mass index;	chr1:155853180	chr1:155745829~155750137:+
HNSC	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
HNSC	cis	rs5769707	0.681	rs916360	ENSG00000188511.11	C22orf34	6.34	5.49e-10	2.88e-07	0.37	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	6.34	5.5e-10	2.88e-07	0.32	0.28	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
HNSC	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-6.34	5.51e-10	2.88e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
HNSC	cis	rs2337406	0.866	rs78462736	ENSG00000211974.3	IGHV2-70	-6.34	5.51e-10	2.88e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106779942	chr14:106723574~106724093:-
HNSC	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	6.34	5.51e-10	2.88e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
HNSC	cis	rs17270561	0.609	rs9467572	ENSG00000272462.2	U91328.19	6.34	5.52e-10	2.89e-07	0.29	0.28	Iron status biomarkers;	chr6:25703898	chr6:25992662~26001775:+
HNSC	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-6.34	5.53e-10	2.89e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-6.34	5.53e-10	2.89e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
HNSC	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
HNSC	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-6.34	5.56e-10	2.9e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
HNSC	cis	rs6951245	0.529	rs76001997	ENSG00000224079.1	AC091729.7	-6.34	5.56e-10	2.91e-07	-0.37	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1074450~1078036:+
HNSC	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-6.34	5.56e-10	2.91e-07	-0.43	-0.28	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
HNSC	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	6.34	5.56e-10	2.91e-07	0.36	0.28	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
HNSC	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	6.34	5.56e-10	2.91e-07	0.26	0.28	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
HNSC	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	6.34	5.56e-10	2.91e-07	0.32	0.28	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
HNSC	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.58e-10	2.91e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.58e-10	2.91e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.58e-10	2.91e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	6.34	5.58e-10	2.92e-07	0.23	0.28	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
HNSC	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-6.33	5.6e-10	2.93e-07	-0.4	-0.28	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000254153.1	CTA-398F10.2	6.33	5.6e-10	2.93e-07	0.3	0.28	Mood instability;	chr8:8462781	chr8:8456909~8461337:-
HNSC	cis	rs783540	0.521	rs28719490	ENSG00000276710.3	CSPG4P8	-6.33	5.6e-10	2.93e-07	-0.35	-0.28	Schizophrenia;	chr15:82720688	chr15:82459472~82477258:+
HNSC	cis	rs13113518	0.678	rs13149568	ENSG00000273257.1	RP11-177J6.1	6.33	5.61e-10	2.93e-07	0.34	0.28	Height;	chr4:55370412	chr4:55387949~55388271:+
HNSC	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
HNSC	cis	rs7615952	0.736	rs9862893	ENSG00000241288.6	RP11-379B18.5	-6.33	5.61e-10	2.93e-07	-0.44	-0.28	Blood pressure (smoking interaction);	chr3:125968131	chr3:125827238~125916384:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	6.33	5.62e-10	2.94e-07	0.3	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
HNSC	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	6.33	5.62e-10	2.94e-07	0.32	0.28	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	6.33	5.63e-10	2.94e-07	0.34	0.28	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
HNSC	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	6.33	5.64e-10	2.94e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
HNSC	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	6.33	5.64e-10	2.94e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
HNSC	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	6.33	5.65e-10	2.95e-07	0.25	0.28	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-6.33	5.65e-10	2.95e-07	-0.25	-0.28	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
HNSC	cis	rs7615952	0.512	rs4234285	ENSG00000241288.6	RP11-379B18.5	-6.33	5.65e-10	2.95e-07	-0.35	-0.28	Blood pressure (smoking interaction);	chr3:125685633	chr3:125827238~125916384:-
HNSC	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	6.33	5.65e-10	2.95e-07	0.28	0.28	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
HNSC	cis	rs440932	0.565	rs19334	ENSG00000173295.6	FAM86B3P	6.33	5.68e-10	2.97e-07	0.31	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8228595~8244865:+
HNSC	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-6.33	5.7e-10	2.97e-07	-0.34	-0.28	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
HNSC	cis	rs8012947	0.92	rs2348071	ENSG00000279636.2	LINC00216	-6.33	5.71e-10	2.98e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58263908	chr14:58288033~58289158:+
HNSC	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-6.33	5.71e-10	2.98e-07	-0.33	-0.28	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
HNSC	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-6.33	5.72e-10	2.98e-07	-0.4	-0.28	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
HNSC	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-6.33	5.74e-10	2.99e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
HNSC	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-6.33	5.74e-10	2.99e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
HNSC	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	6.33	5.74e-10	3e-07	0.27	0.28	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
HNSC	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	6.33	5.75e-10	3e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
HNSC	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-6.33	5.75e-10	3e-07	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
HNSC	cis	rs6504622	0.905	rs736604	ENSG00000262879.4	RP11-156P1.3	6.33	5.76e-10	3e-07	0.3	0.28	Orofacial clefts;	chr17:46947443	chr17:46984045~47100323:-
HNSC	cis	rs2239557	0.845	rs11622838	ENSG00000259065.1	RP5-1021I20.1	6.33	5.78e-10	3.02e-07	0.34	0.28	Common traits (Other);	chr14:74202656	chr14:73787360~73803270:+
HNSC	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-6.33	5.78e-10	3.02e-07	-0.35	-0.28	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
HNSC	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-6.33	5.79e-10	3.02e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.86	rs1858692	ENSG00000211974.3	IGHV2-70	6.33	5.79e-10	3.02e-07	0.33	0.28	Rheumatic heart disease;	chr14:106622776	chr14:106723574~106724093:-
HNSC	cis	rs2235642	0.601	rs2235647	ENSG00000280231.1	LA16c-380F5.3	-6.33	5.79e-10	3.02e-07	-0.36	-0.28	Coronary artery disease;	chr16:1551330	chr16:1553655~1554130:-
HNSC	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	6.33	5.79e-10	3.02e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
HNSC	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-6.33	5.8e-10	3.02e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
HNSC	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	6.33	5.8e-10	3.03e-07	0.34	0.28	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
HNSC	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-6.33	5.82e-10	3.04e-07	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
HNSC	cis	rs783540	0.5	rs783541	ENSG00000255769.6	GOLGA2P10	6.33	5.82e-10	3.04e-07	0.4	0.28	Schizophrenia;	chr15:82586310	chr15:82472993~82513950:-
HNSC	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	6.33	5.84e-10	3.04e-07	0.37	0.28	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
HNSC	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-6.33	5.84e-10	3.04e-07	-0.26	-0.28	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
HNSC	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-6.33	5.85e-10	3.05e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
HNSC	cis	rs2243480	0.706	rs34466769	ENSG00000179406.6	LINC00174	-6.33	5.86e-10	3.05e-07	-0.51	-0.28	Diabetic kidney disease;	chr7:65988305	chr7:66376044~66401338:-
HNSC	cis	rs8177876	0.822	rs9923732	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9925940	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9925943	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9933184	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9926174	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs8052490	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8056972	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs74437879	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs76948085	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs80315956	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs16954572	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9929586	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9938965	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs7204040	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs7188508	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs28672349	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.818	rs59177227	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs59685942	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs10514515	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs1410	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs1412	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs1414	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8177950	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs8177948	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8177940	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.73	rs76656387	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-6.33	5.86e-10	3.05e-07	-0.34	-0.28	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
HNSC	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-6.33	5.87e-10	3.06e-07	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
HNSC	cis	rs1799949	0.931	rs34474989	ENSG00000267151.3	RP11-100E5.2	6.33	5.88e-10	3.06e-07	0.35	0.28	Menopause (age at onset);	chr17:43368042	chr17:43444707~43451200:+
HNSC	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	6.33	5.88e-10	3.06e-07	0.36	0.28	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
HNSC	cis	rs11992162	0.591	rs34123222	ENSG00000206014.6	OR7E161P	6.33	5.88e-10	3.06e-07	0.31	0.28	Monocyte count;	chr8:11937840	chr8:11928597~11929563:-
HNSC	cis	rs4141404	0.851	rs5749222	ENSG00000236132.1	CTA-440B3.1	6.33	5.9e-10	3.07e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31160773	chr22:31816379~31817491:-
HNSC	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-6.33	5.9e-10	3.07e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-6.33	5.9e-10	3.07e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-6.33	5.9e-10	3.07e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
HNSC	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-6.33	5.91e-10	3.07e-07	-0.36	-0.28	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
HNSC	cis	rs2006771	0.818	rs8142376	ENSG00000236132.1	CTA-440B3.1	6.33	5.91e-10	3.08e-07	0.31	0.28	Nonsyndromic cleft lip with cleft palate;	chr22:31605051	chr22:31816379~31817491:-
HNSC	cis	rs4218	0.528	rs57557135	ENSG00000259732.1	RP11-59H7.3	-6.33	5.92e-10	3.08e-07	-0.37	-0.28	Social communication problems;	chr15:59054018	chr15:59121034~59133250:+
HNSC	cis	rs8054556	0.74	rs4407079	ENSG00000183604.13	SMG1P5	-6.33	5.92e-10	3.08e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30267553~30335374:-
HNSC	cis	rs853679	0.628	rs9368560	ENSG00000204709.4	LINC01556	6.33	5.93e-10	3.08e-07	0.39	0.28	Depression;	chr6:28192182	chr6:28943877~28944537:+
HNSC	cis	rs10504130	0.696	rs11785805	ENSG00000272024.1	RP11-546K22.3	-6.33	5.93e-10	3.08e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51950284~51950690:+
HNSC	cis	rs7804306	0.826	rs73050951	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8032762	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050956	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036076	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050958	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036162	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050959	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037069	chr7:7980312~7982228:+
HNSC	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-6.32	5.94e-10	3.09e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
HNSC	cis	rs5753618	0.561	rs9606830	ENSG00000236132.1	CTA-440B3.1	-6.32	5.94e-10	3.09e-07	-0.34	-0.28	Colorectal cancer;	chr22:31321813	chr22:31816379~31817491:-
HNSC	cis	rs2404602	0.716	rs1125932	ENSG00000259422.1	RP11-593F23.1	6.32	5.94e-10	3.09e-07	0.33	0.28	Blood metabolite levels;	chr15:76528199	chr15:76174891~76181486:-
HNSC	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-6.32	5.94e-10	3.09e-07	-0.34	-0.28	Height;	chr3:53069965	chr3:53064283~53065091:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000235689.1	AP000351.13	6.32	5.94e-10	3.09e-07	0.3	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:24006305~24008258:-
HNSC	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	6.32	5.95e-10	3.09e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-6.32	5.96e-10	3.1e-07	-0.22	-0.28	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
HNSC	cis	rs8012947	1	rs6573197	ENSG00000279636.2	LINC00216	-6.32	5.96e-10	3.1e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58257490	chr14:58288033~58289158:+
HNSC	cis	rs4218	0.689	rs34338282	ENSG00000259732.1	RP11-59H7.3	-6.32	5.97e-10	3.1e-07	-0.4	-0.28	Social communication problems;	chr15:59096897	chr15:59121034~59133250:+
HNSC	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	6.32	5.97e-10	3.11e-07	0.38	0.28	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
HNSC	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-6.32	5.98e-10	3.11e-07	-0.28	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
HNSC	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	6.32	6e-10	3.12e-07	0.35	0.28	Depression;	chr6:28430971	chr6:28943877~28944537:+
HNSC	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	6.32	6e-10	3.12e-07	0.31	0.28	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
HNSC	cis	rs6951245	0.745	rs79788515	ENSG00000225146.1	AC073957.15	-6.32	6e-10	3.12e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1029025~1043891:+
HNSC	cis	rs2235642	0.821	rs2281236	ENSG00000280231.1	LA16c-380F5.3	-6.32	6.01e-10	3.13e-07	-0.34	-0.28	Coronary artery disease;	chr16:1553575	chr16:1553655~1554130:-
HNSC	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	6.32	6.02e-10	3.13e-07	0.27	0.28	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
HNSC	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	6.32	6.04e-10	3.14e-07	0.35	0.28	Height;	chr4:55457922	chr4:55363971~55395847:-
HNSC	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-6.32	6.04e-10	3.14e-07	-0.34	-0.28	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
HNSC	cis	rs1021993	0.672	rs2495295	ENSG00000231648.1	RP11-372M18.2	6.32	6.04e-10	3.14e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209316343	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.672	rs1395752	ENSG00000231648.1	RP11-372M18.2	6.32	6.04e-10	3.14e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209317090	chr1:209367662~209379690:+
HNSC	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-6.32	6.06e-10	3.15e-07	-0.33	-0.28	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
HNSC	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-6.32	6.06e-10	3.15e-07	-0.18	-0.28	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
HNSC	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	6.32	6.06e-10	3.15e-07	0.33	0.28	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	6.32	6.06e-10	3.15e-07	0.33	0.28	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
HNSC	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	6.32	6.06e-10	3.15e-07	0.65	0.28	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	6.32	6.06e-10	3.15e-07	0.65	0.28	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
HNSC	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	6.32	6.07e-10	3.15e-07	0.32	0.28	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
HNSC	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-6.32	6.07e-10	3.15e-07	-0.34	-0.28	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
HNSC	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	6.32	6.07e-10	3.15e-07	0.35	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
HNSC	cis	rs853679	0.55	rs1237875	ENSG00000204709.4	LINC01556	-6.32	6.08e-10	3.16e-07	-0.37	-0.28	Depression;	chr6:28205232	chr6:28943877~28944537:+
HNSC	cis	rs1799949	0.931	rs9912203	ENSG00000267151.3	RP11-100E5.2	-6.32	6.08e-10	3.16e-07	-0.36	-0.28	Menopause (age at onset);	chr17:43367777	chr17:43444707~43451200:+
HNSC	cis	rs5753618	0.554	rs5753648	ENSG00000236132.1	CTA-440B3.1	-6.32	6.08e-10	3.16e-07	-0.37	-0.28	Colorectal cancer;	chr22:31483479	chr22:31816379~31817491:-
HNSC	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	6.32	6.09e-10	3.16e-07	0.25	0.28	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
HNSC	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-6.32	6.11e-10	3.17e-07	-0.27	-0.28	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
HNSC	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-6.32	6.12e-10	3.18e-07	-0.51	-0.28	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
HNSC	cis	rs8012947	1	rs8011191	ENSG00000279636.2	LINC00216	-6.32	6.12e-10	3.18e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58250295	chr14:58288033~58289158:+
HNSC	cis	rs8012947	1	rs7155580	ENSG00000279636.2	LINC00216	-6.32	6.13e-10	3.18e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58304914	chr14:58288033~58289158:+
HNSC	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-6.32	6.13e-10	3.18e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
HNSC	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.13e-10	3.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.13e-10	3.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.13e-10	3.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
HNSC	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-6.32	6.13e-10	3.18e-07	-0.32	-0.28	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
HNSC	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-6.32	6.13e-10	3.18e-07	-0.32	-0.28	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
HNSC	cis	rs11992162	0.636	rs4841645	ENSG00000206014.6	OR7E161P	6.32	6.14e-10	3.18e-07	0.31	0.28	Monocyte count;	chr8:11941175	chr8:11928597~11929563:-
HNSC	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-6.32	6.14e-10	3.19e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
HNSC	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	6.32	6.15e-10	3.19e-07	0.33	0.28	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
HNSC	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	6.32	6.15e-10	3.19e-07	0.28	0.28	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
HNSC	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	6.32	6.16e-10	3.2e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
HNSC	cis	rs2442825	0.508	rs2648545	ENSG00000206573.7	THUMPD3-AS1	-6.32	6.16e-10	3.2e-07	-0.24	-0.28	Cerebrospinal fluid clusterin levels;	chr3:9347539	chr3:9349689~9398579:-
HNSC	cis	rs7404843	0.789	rs222907	ENSG00000263065.1	AF001548.6	6.32	6.17e-10	3.2e-07	0.45	0.28	Testicular germ cell tumor;	chr16:15404950	chr16:15741151~15741791:+
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-6.32	6.19e-10	3.21e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
HNSC	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-6.32	6.19e-10	3.21e-07	-0.43	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
HNSC	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	6.32	6.2e-10	3.22e-07	0.4	0.28	Height;	chr6:109365409	chr6:109382795~109383666:+
HNSC	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	6.32	6.21e-10	3.22e-07	0.32	0.28	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
HNSC	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-6.32	6.21e-10	3.22e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
HNSC	cis	rs2579103	0.767	rs2731268	ENSG00000258183.4	RP11-753N8.1	-6.32	6.21e-10	3.22e-07	-0.35	-0.28	Body mass index;	chr12:90276679	chr12:90280894~90300340:+
HNSC	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	6.32	6.21e-10	3.22e-07	0.33	0.28	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
HNSC	cis	rs757110	0.77	rs4439492	ENSG00000260196.1	RP1-239B22.5	6.32	6.21e-10	3.22e-07	0.32	0.28	Type 2 diabetes;	chr11:17365186	chr11:17380649~17383531:+
HNSC	cis	rs757110	0.77	rs2051772	ENSG00000260196.1	RP1-239B22.5	6.32	6.21e-10	3.22e-07	0.32	0.28	Type 2 diabetes;	chr11:17368303	chr11:17380649~17383531:+
HNSC	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	6.32	6.22e-10	3.23e-07	0.44	0.28	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000173295.6	FAM86B3P	6.32	6.22e-10	3.23e-07	0.32	0.28	Joint mobility (Beighton score);	chr8:8967994	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000173295.6	FAM86B3P	6.32	6.22e-10	3.23e-07	0.32	0.28	Mood instability;	chr8:8968365	chr8:8228595~8244865:+
HNSC	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	6.32	6.22e-10	3.23e-07	0.31	0.28	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
HNSC	cis	rs17507216	0.671	rs28582623	ENSG00000255769.6	GOLGA2P10	-6.32	6.23e-10	3.23e-07	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82577381	chr15:82472993~82513950:-
HNSC	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-6.32	6.24e-10	3.23e-07	-0.29	-0.28	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
HNSC	cis	rs1799949	0.965	rs6503727	ENSG00000267151.3	RP11-100E5.2	6.32	6.24e-10	3.23e-07	0.36	0.28	Menopause (age at onset);	chr17:43160842	chr17:43444707~43451200:+
HNSC	cis	rs2836974	0.604	rs2854727	ENSG00000255568.3	BRWD1-AS2	6.32	6.24e-10	3.23e-07	0.23	0.28	Cognitive function;	chr21:39341861	chr21:39313935~39314962:+
HNSC	cis	rs440932	1	rs378974	ENSG00000173295.6	FAM86B3P	6.32	6.24e-10	3.23e-07	0.34	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8228595~8244865:+
HNSC	cis	rs9341808	0.667	rs7746917	ENSG00000272129.1	RP11-250B2.6	6.32	6.25e-10	3.24e-07	0.33	0.28	Sitting height ratio;	chr6:80221786	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-6.32	6.25e-10	3.24e-07	-0.46	-0.28	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
HNSC	cis	rs4639966	0.836	rs7124498	ENSG00000255422.1	AP002954.4	6.32	6.25e-10	3.24e-07	0.39	0.28	Systemic lupus erythematosus;	chr11:118745544	chr11:118704607~118750263:+
HNSC	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-6.32	6.26e-10	3.24e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
HNSC	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	6.32	6.26e-10	3.24e-07	0.42	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
HNSC	cis	rs947583	0.955	rs7760254	ENSG00000217482.2	HMGB1P17	-6.32	6.26e-10	3.24e-07	-0.3	-0.28	Phosphorus levels;	chr6:135811157	chr6:135636086~135636713:-
HNSC	cis	rs757110	0.74	rs10832776	ENSG00000260196.1	RP1-239B22.5	6.32	6.27e-10	3.25e-07	0.32	0.28	Type 2 diabetes;	chr11:17363677	chr11:17380649~17383531:+
HNSC	cis	rs61160187	0.582	rs17444495	ENSG00000215032.2	GNL3LP1	6.32	6.27e-10	3.25e-07	0.32	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60891935~60893577:-
HNSC	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.29e-10	3.26e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.29e-10	3.26e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
HNSC	cis	rs8177876	0.822	rs1563075	ENSG00000261061.1	RP11-303E16.2	-6.32	6.3e-10	3.26e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81030770~81031485:+
HNSC	cis	rs1865760	0.613	rs9358894	ENSG00000272462.2	U91328.19	-6.31	6.3e-10	3.26e-07	-0.27	-0.28	Height;	chr6:25923087	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.513	rs149959	ENSG00000204709.4	LINC01556	6.31	6.31e-10	3.27e-07	0.37	0.28	Parkinson's disease;	chr6:28046076	chr6:28943877~28944537:+
HNSC	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	6.31	6.31e-10	3.27e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
HNSC	cis	rs8054556	0.76	rs11642740	ENSG00000183604.13	SMG1P5	6.31	6.31e-10	3.27e-07	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr16:30049334	chr16:30267553~30335374:-
HNSC	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	6.31	6.32e-10	3.27e-07	0.45	0.28	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
HNSC	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	6.31	6.34e-10	3.28e-07	0.27	0.28	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
HNSC	cis	rs9907295	0.591	rs4325615	ENSG00000270977.1	AC015849.16	-6.31	6.34e-10	3.28e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35826379	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.551	rs28595279	ENSG00000270977.1	AC015849.16	-6.31	6.34e-10	3.28e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35826416	chr17:35893707~35911023:-
HNSC	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-6.31	6.35e-10	3.28e-07	-0.35	-0.28	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
HNSC	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-6.31	6.35e-10	3.29e-07	-0.31	-0.28	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000211972.2	IGHV3-66	6.31	6.35e-10	3.29e-07	0.22	0.28	Kawasaki disease;	chr14:106785589	chr14:106675017~106675544:-
HNSC	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-6.31	6.35e-10	3.29e-07	-0.24	-0.28	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
HNSC	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-6.31	6.36e-10	3.29e-07	-0.33	-0.28	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
HNSC	cis	rs4218	0.597	rs4775114	ENSG00000259732.1	RP11-59H7.3	-6.31	6.37e-10	3.3e-07	-0.39	-0.28	Social communication problems;	chr15:59059635	chr15:59121034~59133250:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	6.31	6.39e-10	3.31e-07	0.34	0.28	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
HNSC	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	6.31	6.39e-10	3.31e-07	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
HNSC	cis	rs8177876	0.822	rs10514514	ENSG00000261061.1	RP11-303E16.2	-6.31	6.4e-10	3.31e-07	-0.44	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81030770~81031485:+
HNSC	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	6.31	6.4e-10	3.31e-07	0.34	0.28	Height;	chr4:55575856	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-6.31	6.4e-10	3.31e-07	-0.41	-0.28	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
HNSC	cis	rs2834288	0.535	rs7278341	ENSG00000237945.6	LINC00649	6.31	6.42e-10	3.32e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.535	rs7279183	ENSG00000237945.6	LINC00649	6.31	6.42e-10	3.32e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33915534~33977691:+
HNSC	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-6.31	6.42e-10	3.32e-07	-0.3	-0.28	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
HNSC	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-6.31	6.43e-10	3.33e-07	-0.37	-0.28	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
HNSC	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-6.31	6.45e-10	3.33e-07	-0.38	-0.28	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
HNSC	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-6.31	6.46e-10	3.34e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
HNSC	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-6.31	6.46e-10	3.34e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
HNSC	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	6.31	6.48e-10	3.35e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
HNSC	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	6.31	6.51e-10	3.36e-07	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
HNSC	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-6.31	6.53e-10	3.37e-07	-0.35	-0.28	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
HNSC	cis	rs1355223	0.867	rs1377495	ENSG00000271369.1	RP11-350D17.3	6.31	6.53e-10	3.37e-07	0.33	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34661415	chr11:34709600~34710161:+
HNSC	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	6.31	6.54e-10	3.38e-07	0.33	0.28	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
HNSC	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	6.31	6.54e-10	3.38e-07	0.37	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
HNSC	cis	rs2834288	0.535	rs9982605	ENSG00000237945.6	LINC00649	6.31	6.54e-10	3.38e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33915534~33977691:+
HNSC	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	6.31	6.56e-10	3.39e-07	0.33	0.28	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
HNSC	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	6.31	6.56e-10	3.39e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
HNSC	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-6.31	6.57e-10	3.39e-07	-0.3	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
HNSC	cis	rs8012947	1	rs56208804	ENSG00000279636.2	LINC00216	-6.31	6.58e-10	3.4e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58313408	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs3945957	ENSG00000279636.2	LINC00216	-6.31	6.58e-10	3.4e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58316335	chr14:58288033~58289158:+
HNSC	cis	rs8012947	1	rs6573199	ENSG00000279636.2	LINC00216	-6.31	6.58e-10	3.4e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58318063	chr14:58288033~58289158:+
HNSC	cis	rs9650657	0.53	rs6982381	ENSG00000269918.1	AF131215.9	-6.31	6.59e-10	3.4e-07	-0.28	-0.28	Neuroticism;	chr8:11094990	chr8:11104691~11106704:-
HNSC	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.33	0.28	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
HNSC	cis	rs1021993	0.545	rs4844809	ENSG00000231648.1	RP11-372M18.2	-6.31	6.6e-10	3.41e-07	-0.46	-0.28	Gut microbiome composition (winter);	chr1:209346427	chr1:209367662~209379690:+
HNSC	cis	rs17507216	0.628	rs4627310	ENSG00000255769.6	GOLGA2P10	-6.31	6.6e-10	3.41e-07	-0.44	-0.28	Excessive daytime sleepiness;	chr15:82708330	chr15:82472993~82513950:-
HNSC	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-6.31	6.61e-10	3.41e-07	-0.38	-0.28	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
HNSC	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-6.31	6.61e-10	3.41e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
HNSC	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	6.31	6.63e-10	3.42e-07	0.66	0.28	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
HNSC	cis	rs757110	0.648	rs12146443	ENSG00000260196.1	RP1-239B22.5	6.31	6.63e-10	3.42e-07	0.32	0.28	Type 2 diabetes;	chr11:17362951	chr11:17380649~17383531:+
HNSC	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	6.31	6.64e-10	3.43e-07	0.35	0.28	Depression;	chr6:28432562	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	6.31	6.65e-10	3.43e-07	0.35	0.28	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
HNSC	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	6.31	6.65e-10	3.43e-07	0.36	0.28	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
HNSC	cis	rs8177876	0.731	rs74882687	ENSG00000261061.1	RP11-303E16.2	-6.31	6.66e-10	3.44e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs76909932	ENSG00000261061.1	RP11-303E16.2	-6.31	6.66e-10	3.44e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8177939	ENSG00000261061.1	RP11-303E16.2	-6.31	6.66e-10	3.44e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81030770~81031485:+
HNSC	cis	rs4141404	0.851	rs8135417	ENSG00000236132.1	CTA-440B3.1	6.31	6.68e-10	3.45e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31163269	chr22:31816379~31817491:-
HNSC	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	6.3	6.69e-10	3.45e-07	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
HNSC	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	6.3	6.69e-10	3.45e-07	0.42	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
HNSC	cis	rs2404602	0.692	rs1838048	ENSG00000259422.1	RP11-593F23.1	6.3	6.69e-10	3.45e-07	0.32	0.28	Blood metabolite levels;	chr15:76639338	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs56193230	ENSG00000259422.1	RP11-593F23.1	6.3	6.69e-10	3.45e-07	0.32	0.28	Blood metabolite levels;	chr15:76642131	chr15:76174891~76181486:-
HNSC	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	6.3	6.7e-10	3.46e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
HNSC	cis	rs67180937	0.55	rs9441926	ENSG00000272750.1	RP11-378J18.8	-6.3	6.71e-10	3.46e-07	-0.34	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622822	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.589	rs9441835	ENSG00000272750.1	RP11-378J18.8	-6.3	6.71e-10	3.46e-07	-0.34	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622827	chr1:222658867~222661512:-
HNSC	cis	rs9326248	0.53	rs72645460	ENSG00000280143.1	AP000892.6	-6.3	6.71e-10	3.46e-07	-0.44	-0.28	Blood protein levels;	chr11:116900659	chr11:117204967~117210292:+
HNSC	cis	rs7615952	0.546	rs2976733	ENSG00000241288.6	RP11-379B18.5	-6.3	6.73e-10	3.47e-07	-0.35	-0.28	Blood pressure (smoking interaction);	chr3:125695294	chr3:125827238~125916384:-
HNSC	cis	rs2404602	0.692	rs35498563	ENSG00000259422.1	RP11-593F23.1	6.3	6.73e-10	3.47e-07	0.32	0.28	Blood metabolite levels;	chr15:76666527	chr15:76174891~76181486:-
HNSC	cis	rs8177876	0.749	rs754429	ENSG00000261061.1	RP11-303E16.2	-6.3	6.73e-10	3.47e-07	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81030770~81031485:+
HNSC	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	6.3	6.74e-10	3.47e-07	0.41	0.28	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
HNSC	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-6.3	6.75e-10	3.48e-07	-0.38	-0.28	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
HNSC	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-6.3	6.75e-10	3.48e-07	-0.3	-0.28	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
HNSC	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-6.3	6.76e-10	3.48e-07	-0.34	-0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
HNSC	cis	rs7615952	0.558	rs7641353	ENSG00000241288.6	RP11-379B18.5	-6.3	6.76e-10	3.48e-07	-0.35	-0.28	Blood pressure (smoking interaction);	chr3:125621035	chr3:125827238~125916384:-
HNSC	cis	rs2337406	0.81	rs7161739	ENSG00000211974.3	IGHV2-70	-6.3	6.76e-10	3.48e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106776118	chr14:106723574~106724093:-
HNSC	cis	rs757110	0.77	rs11024268	ENSG00000260196.1	RP1-239B22.5	6.3	6.76e-10	3.48e-07	0.32	0.28	Type 2 diabetes;	chr11:17366435	chr11:17380649~17383531:+
HNSC	cis	rs2337406	0.778	rs58113768	ENSG00000211974.3	IGHV2-70	-6.3	6.76e-10	3.49e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106700213	chr14:106723574~106724093:-
HNSC	cis	rs8054556	0.692	rs12716972	ENSG00000183604.13	SMG1P5	-6.3	6.77e-10	3.49e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29925333	chr16:30267553~30335374:-
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000254153.1	CTA-398F10.2	6.3	6.77e-10	3.49e-07	0.3	0.28	Mood instability;	chr8:8460105	chr8:8456909~8461337:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
HNSC	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-6.3	6.77e-10	3.49e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
HNSC	cis	rs853679	1	rs11965538	ENSG00000219392.1	RP1-265C24.5	-6.3	6.78e-10	3.49e-07	-0.42	-0.28	Depression;	chr6:28272137	chr6:28115628~28116551:+
HNSC	cis	rs2235642	0.75	rs1894649	ENSG00000280231.1	LA16c-380F5.3	-6.3	6.78e-10	3.49e-07	-0.34	-0.28	Coronary artery disease;	chr16:1607283	chr16:1553655~1554130:-
HNSC	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	6.3	6.79e-10	3.5e-07	0.42	0.28	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
HNSC	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	6.3	6.8e-10	3.5e-07	0.32	0.28	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
HNSC	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	6.3	6.81e-10	3.51e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
HNSC	cis	rs8177876	0.642	rs56032321	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs56119129	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs77145371	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.908	rs80187824	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81030770~81031485:+
HNSC	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	6.3	6.83e-10	3.52e-07	0.36	0.28	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
HNSC	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	6.3	6.84e-10	3.52e-07	0.66	0.28	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
HNSC	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	6.3	6.84e-10	3.52e-07	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
HNSC	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	6.3	6.84e-10	3.52e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
HNSC	cis	rs4141404	0.851	rs5997893	ENSG00000236132.1	CTA-440B3.1	6.3	6.84e-10	3.52e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31160117	chr22:31816379~31817491:-
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-6.3	6.87e-10	3.53e-07	-0.33	-0.28	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.571	rs2929305	ENSG00000254340.1	RP11-10A14.3	-6.3	6.88e-10	3.54e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9227707	chr8:9141424~9145435:+
HNSC	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-6.3	6.88e-10	3.54e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
HNSC	cis	rs4713118	0.513	rs1225591	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.54e-07	0.36	0.28	Parkinson's disease;	chr6:28180974	chr6:28943877~28944537:+
HNSC	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	6.3	6.89e-10	3.54e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
HNSC	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-6.3	6.89e-10	3.54e-07	-0.29	-0.28	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
HNSC	cis	rs11992162	0.613	rs56094399	ENSG00000206014.6	OR7E161P	6.3	6.9e-10	3.55e-07	0.31	0.28	Monocyte count;	chr8:11939961	chr8:11928597~11929563:-
HNSC	cis	rs5753618	0.504	rs8142121	ENSG00000236132.1	CTA-440B3.1	-6.3	6.9e-10	3.55e-07	-0.37	-0.28	Colorectal cancer;	chr22:31486799	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs13054220	ENSG00000236132.1	CTA-440B3.1	-6.3	6.9e-10	3.55e-07	-0.34	-0.28	Colorectal cancer;	chr22:31308506	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs9609254	ENSG00000236132.1	CTA-440B3.1	-6.3	6.9e-10	3.55e-07	-0.34	-0.28	Colorectal cancer;	chr22:31309956	chr22:31816379~31817491:-
HNSC	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.9e-10	3.55e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
HNSC	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	6.3	6.91e-10	3.55e-07	0.38	0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
HNSC	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-6.3	6.91e-10	3.55e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
HNSC	cis	rs2286503	1	rs2286498	ENSG00000221740.1	SNORD93	-6.3	6.91e-10	3.55e-07	-0.29	-0.28	Fibrinogen;	chr7:22817885	chr7:22856613~22856686:+
HNSC	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	6.3	6.93e-10	3.56e-07	0.32	0.28	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
HNSC	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	6.3	6.93e-10	3.56e-07	0.32	0.28	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
HNSC	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	6.3	6.94e-10	3.56e-07	0.66	0.28	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	6.3	6.94e-10	3.57e-07	0.45	0.28	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
HNSC	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	6.3	6.95e-10	3.57e-07	0.31	0.28	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
HNSC	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	6.3	6.95e-10	3.57e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
HNSC	cis	rs9341808	0.935	rs9343974	ENSG00000272129.1	RP11-250B2.6	6.3	6.95e-10	3.57e-07	0.33	0.28	Sitting height ratio;	chr6:80214928	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000173295.6	FAM86B3P	-6.3	6.95e-10	3.57e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9036071	chr8:8228595~8244865:+
HNSC	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	6.3	6.95e-10	3.57e-07	0.24	0.28	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	6.3	6.95e-10	3.57e-07	0.24	0.28	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-6.3	6.95e-10	3.57e-07	-0.24	-0.28	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-6.3	6.95e-10	3.57e-07	-0.24	-0.28	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-6.3	6.95e-10	3.57e-07	-0.24	-0.28	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
HNSC	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	6.3	6.96e-10	3.57e-07	0.35	0.28	Depression;	chr6:28379133	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	6.3	6.96e-10	3.57e-07	0.35	0.28	Depression;	chr6:28379168	chr6:28943877~28944537:+
HNSC	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-6.3	6.98e-10	3.58e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-6.3	6.98e-10	3.58e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
HNSC	cis	rs2404602	0.692	rs35077207	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76642965	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs35195096	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76646106	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs34287706	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76650061	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.669	rs12438540	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76650872	chr15:76174891~76181486:-
HNSC	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	6.3	7e-10	3.59e-07	0.32	0.28	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
HNSC	cis	rs12439619	0.846	rs62012004	ENSG00000276710.3	CSPG4P8	-6.3	7e-10	3.59e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82459472~82477258:+
HNSC	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	6.3	7e-10	3.59e-07	0.39	0.28	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
HNSC	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	6.3	7e-10	3.59e-07	0.31	0.28	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	6.3	7e-10	3.59e-07	0.31	0.28	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
HNSC	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	6.3	7e-10	3.6e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
HNSC	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-6.3	7.02e-10	3.6e-07	-0.35	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-6.3	7.02e-10	3.6e-07	-0.33	-0.28	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
HNSC	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	6.3	7.02e-10	3.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	6.3	7.02e-10	3.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	6.3	7.02e-10	3.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
HNSC	cis	rs2404602	0.692	rs8037005	ENSG00000259422.1	RP11-593F23.1	6.3	7.02e-10	3.6e-07	0.32	0.28	Blood metabolite levels;	chr15:76658768	chr15:76174891~76181486:-
HNSC	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	6.3	7.03e-10	3.61e-07	0.32	0.28	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
HNSC	cis	rs6471393	1	rs6471393	ENSG00000253848.1	RP11-10N23.5	-6.3	7.04e-10	3.61e-07	-0.35	-0.28	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703063	chr8:93741193~93744534:+
HNSC	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-6.3	7.05e-10	3.62e-07	-0.28	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
HNSC	cis	rs453301	0.571	rs2929452	ENSG00000254340.1	RP11-10A14.3	-6.3	7.05e-10	3.62e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9226955	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-6.3	7.06e-10	3.62e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
HNSC	cis	rs7617773	0.817	rs11130163	ENSG00000228638.1	FCF1P2	-6.3	7.07e-10	3.63e-07	-0.25	-0.28	Coronary artery disease;	chr3:48271168	chr3:48290793~48291375:-
HNSC	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-6.3	7.07e-10	3.63e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-6.3	7.07e-10	3.63e-07	-0.32	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
HNSC	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	6.3	7.08e-10	3.63e-07	0.39	0.28	Height;	chr6:109465229	chr6:109382795~109383666:+
HNSC	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000173295.6	FAM86B3P	-6.3	7.08e-10	3.63e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9009151	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.744	rs2409092	ENSG00000173295.6	FAM86B3P	6.29	7.1e-10	3.64e-07	0.32	0.28	Mood instability;	chr8:8824682	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	6.29	7.11e-10	3.64e-07	0.4	0.28	Height;	chr6:109351533	chr6:109382795~109383666:+
HNSC	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	6.29	7.11e-10	3.64e-07	0.4	0.28	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
HNSC	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	6.29	7.11e-10	3.65e-07	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
HNSC	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	6.29	7.12e-10	3.65e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
HNSC	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	6.29	7.12e-10	3.65e-07	0.36	0.28	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
HNSC	cis	rs8054556	0.656	rs4420550	ENSG00000183604.13	SMG1P5	-6.29	7.15e-10	3.67e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29927499	chr16:30267553~30335374:-
HNSC	cis	rs1355223	0.844	rs12809046	ENSG00000271369.1	RP11-350D17.3	-6.29	7.15e-10	3.67e-07	-0.33	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726714	chr11:34709600~34710161:+
HNSC	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-6.29	7.16e-10	3.67e-07	-0.52	-0.28	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
HNSC	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	6.29	7.16e-10	3.67e-07	0.31	0.28	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
HNSC	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-6.29	7.17e-10	3.68e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
HNSC	cis	rs4639966	0.836	rs73001486	ENSG00000255422.1	AP002954.4	6.29	7.18e-10	3.68e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118758655	chr11:118704607~118750263:+
HNSC	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-6.29	7.19e-10	3.68e-07	-0.31	-0.28	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-6.29	7.19e-10	3.68e-07	-0.31	-0.28	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
HNSC	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	6.29	7.19e-10	3.69e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
HNSC	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	6.29	7.19e-10	3.69e-07	0.52	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
HNSC	cis	rs9341808	0.935	rs9448894	ENSG00000272129.1	RP11-250B2.6	6.29	7.2e-10	3.69e-07	0.33	0.28	Sitting height ratio;	chr6:80127536	chr6:80355424~80356859:+
HNSC	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-6.29	7.2e-10	3.69e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
HNSC	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	6.29	7.21e-10	3.69e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
HNSC	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	6.29	7.21e-10	3.7e-07	0.31	0.28	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	6.29	7.21e-10	3.7e-07	0.31	0.28	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	6.29	7.21e-10	3.7e-07	0.31	0.28	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
HNSC	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	6.29	7.23e-10	3.7e-07	0.33	0.28	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	6.29	7.23e-10	3.7e-07	0.33	0.28	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	6.29	7.23e-10	3.7e-07	0.33	0.28	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
HNSC	cis	rs4218	0.573	rs16940998	ENSG00000259732.1	RP11-59H7.3	6.29	7.24e-10	3.71e-07	0.37	0.28	Social communication problems;	chr15:59086095	chr15:59121034~59133250:+
HNSC	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-6.29	7.25e-10	3.71e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
HNSC	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-6.29	7.25e-10	3.72e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
HNSC	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-6.29	7.26e-10	3.72e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
HNSC	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	6.29	7.26e-10	3.72e-07	0.34	0.28	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
HNSC	cis	rs947583	0.866	rs7759326	ENSG00000217482.2	HMGB1P17	6.29	7.27e-10	3.72e-07	0.31	0.28	Phosphorus levels;	chr6:135816421	chr6:135636086~135636713:-
HNSC	cis	rs4948102	0.642	rs6593297	ENSG00000226278.1	PSPHP1	6.29	7.28e-10	3.73e-07	0.3	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55764797~55773288:+
HNSC	cis	rs2790457	0.833	rs1265847	ENSG00000254635.4	WAC-AS1	-6.29	7.3e-10	3.74e-07	-0.31	-0.28	Multiple myeloma;	chr10:28640757	chr10:28522652~28532743:-
HNSC	cis	rs8177876	0.822	rs8177959	ENSG00000261061.1	RP11-303E16.2	-6.29	7.31e-10	3.74e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81030770~81031485:+
HNSC	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	6.29	7.31e-10	3.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	6.29	7.31e-10	3.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	6.29	7.31e-10	3.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
HNSC	cis	rs9840812	0.567	rs2655008	ENSG00000273486.1	RP11-731C17.2	6.29	7.31e-10	3.74e-07	0.24	0.28	Fibrinogen levels;	chr3:136404933	chr3:136837338~136839021:-
HNSC	cis	rs7819412	0.775	rs2001329	ENSG00000255310.2	AF131215.2	-6.29	7.31e-10	3.74e-07	-0.27	-0.28	Triglycerides;	chr8:11129349	chr8:11107788~11109726:-
HNSC	cis	rs860295	0.775	rs822509	ENSG00000203761.5	MSTO2P	6.29	7.33e-10	3.75e-07	0.2	0.28	Body mass index;	chr1:155881020	chr1:155745829~155750137:+
HNSC	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	6.29	7.33e-10	3.75e-07	0.27	0.28	Asthma;	chr2:102446466	chr2:102438713~102440475:+
HNSC	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	6.29	7.33e-10	3.75e-07	0.32	0.28	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	6.29	7.33e-10	3.75e-07	0.32	0.28	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
HNSC	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-6.29	7.34e-10	3.75e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
HNSC	cis	rs11089937	0.929	rs2236727	ENSG00000211638.2	IGLV8-61	-6.29	7.35e-10	3.76e-07	-0.24	-0.28	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22098700~22099212:+
HNSC	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	6.29	7.37e-10	3.77e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
HNSC	cis	rs8177876	0.749	rs10459871	ENSG00000261061.1	RP11-303E16.2	-6.29	7.39e-10	3.78e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81030770~81031485:+
HNSC	cis	rs8054556	0.74	rs4609871	ENSG00000183604.13	SMG1P5	6.29	7.39e-10	3.78e-07	0.26	0.28	Autism spectrum disorder or schizophrenia;	chr16:29920743	chr16:30267553~30335374:-
HNSC	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-6.29	7.39e-10	3.78e-07	-0.31	-0.28	Monocyte count;	chr11:307036	chr11:318640~325631:+
HNSC	cis	rs34526934	0.566	rs9141	ENSG00000226363.3	HAGLROS	6.29	7.41e-10	3.79e-07	0.37	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176173242	chr2:176177717~176179008:+
HNSC	cis	rs7615952	0.576	rs4646763	ENSG00000241288.6	RP11-379B18.5	-6.29	7.41e-10	3.79e-07	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:126103286	chr3:125827238~125916384:-
HNSC	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	6.29	7.41e-10	3.79e-07	0.32	0.28	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
HNSC	cis	rs4639966	0.836	rs11217016	ENSG00000255422.1	AP002954.4	6.29	7.42e-10	3.79e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118756440	chr11:118704607~118750263:+
HNSC	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	6.29	7.42e-10	3.79e-07	0.36	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
HNSC	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	6.29	7.44e-10	3.8e-07	0.27	0.28	Asthma;	chr2:102437614	chr2:102438713~102440475:+
HNSC	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-6.29	7.44e-10	3.8e-07	-0.26	-0.28	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
HNSC	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
HNSC	cis	rs7246657	0.943	rs10404945	ENSG00000276846.1	CTD-3220F14.3	6.29	7.45e-10	3.81e-07	0.38	0.28	Coronary artery calcification;	chr19:37531456	chr19:37314868~37315620:-
HNSC	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-6.29	7.46e-10	3.81e-07	-0.33	-0.28	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
HNSC	cis	rs947583	0.517	rs4896181	ENSG00000217482.2	HMGB1P17	6.29	7.46e-10	3.81e-07	0.29	0.28	Phosphorus levels;	chr6:135788742	chr6:135636086~135636713:-
HNSC	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-6.29	7.47e-10	3.82e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
HNSC	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	6.29	7.48e-10	3.82e-07	0.32	0.28	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
HNSC	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	6.29	7.48e-10	3.82e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
HNSC	cis	rs13056815	1	rs13056815	ENSG00000236132.1	CTA-440B3.1	6.29	7.49e-10	3.82e-07	0.3	0.28	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr22:31272264	chr22:31816379~31817491:-
HNSC	cis	rs11846409	0.789	rs34917868	ENSG00000211974.3	IGHV2-70	-6.29	7.49e-10	3.83e-07	-0.33	-0.28	Rheumatic heart disease;	chr14:106618321	chr14:106723574~106724093:-
HNSC	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-6.29	7.49e-10	3.83e-07	-0.36	-0.28	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	6.29	7.49e-10	3.83e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	6.29	7.49e-10	3.83e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
HNSC	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	6.29	7.5e-10	3.83e-07	0.3	0.28	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
HNSC	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-6.29	7.5e-10	3.83e-07	-0.33	-0.28	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	6.28	7.53e-10	3.84e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
HNSC	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	6.28	7.53e-10	3.84e-07	0.28	0.28	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
HNSC	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
HNSC	cis	rs453301	0.571	rs330048	ENSG00000254340.1	RP11-10A14.3	-6.28	7.54e-10	3.85e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9229768	chr8:9141424~9145435:+
HNSC	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-6.28	7.55e-10	3.85e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
HNSC	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	6.28	7.56e-10	3.86e-07	0.36	0.28	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
HNSC	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
HNSC	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	6.28	7.56e-10	3.86e-07	0.35	0.28	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
HNSC	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.57e-10	3.86e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-6.28	7.58e-10	3.86e-07	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
HNSC	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-6.28	7.58e-10	3.87e-07	-0.37	-0.28	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
HNSC	cis	rs2404602	0.692	rs35557205	ENSG00000259422.1	RP11-593F23.1	6.28	7.59e-10	3.87e-07	0.33	0.28	Blood metabolite levels;	chr15:76838370	chr15:76174891~76181486:-
HNSC	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	6.28	7.59e-10	3.87e-07	0.28	0.28	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
HNSC	cis	rs9341808	0.667	rs10943698	ENSG00000272129.1	RP11-250B2.6	6.28	7.59e-10	3.87e-07	0.32	0.28	Sitting height ratio;	chr6:80224584	chr6:80355424~80356859:+
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-6.28	7.61e-10	3.88e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
HNSC	cis	rs2337406	1	rs1961901	ENSG00000211974.3	IGHV2-70	-6.28	7.62e-10	3.88e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106680856	chr14:106723574~106724093:-
HNSC	cis	rs2337406	1	rs4774172	ENSG00000211974.3	IGHV2-70	-6.28	7.62e-10	3.88e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106681320	chr14:106723574~106724093:-
HNSC	cis	rs2337406	1	rs4774173	ENSG00000211974.3	IGHV2-70	-6.28	7.62e-10	3.88e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106682029	chr14:106723574~106724093:-
HNSC	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.62e-10	3.89e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
HNSC	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	6.28	7.63e-10	3.89e-07	0.35	0.28	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
HNSC	cis	rs8012947	0.883	rs8005100	ENSG00000279636.2	LINC00216	-6.28	7.63e-10	3.89e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58271048	chr14:58288033~58289158:+
HNSC	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-6.28	7.64e-10	3.89e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
HNSC	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-6.28	7.65e-10	3.9e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
HNSC	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-6.28	7.67e-10	3.91e-07	-0.32	-0.28	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000173295.6	FAM86B3P	-6.28	7.67e-10	3.91e-07	-0.31	-0.28	Joint mobility (Beighton score);	chr8:9035094	chr8:8228595~8244865:+
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000173295.6	FAM86B3P	-6.28	7.67e-10	3.91e-07	-0.33	-0.28	Mean corpuscular volume;	chr8:8993123	chr8:8228595~8244865:+
HNSC	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-6.28	7.68e-10	3.91e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
HNSC	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	6.28	7.69e-10	3.92e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	6.28	7.69e-10	3.92e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	6.28	7.69e-10	3.92e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
HNSC	cis	rs860295	0.775	rs1749410	ENSG00000203761.5	MSTO2P	6.28	7.69e-10	3.92e-07	0.21	0.28	Body mass index;	chr1:155874274	chr1:155745829~155750137:+
HNSC	cis	rs4141404	0.923	rs2413046	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Paclitaxel-induced neuropathy;	chr22:31269923	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2413047	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Colorectal cancer;	chr22:31270040	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.539	rs8135344	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Colorectal cancer;	chr22:31275946	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.539	rs5997933	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Colorectal cancer;	chr22:31276766	chr22:31816379~31817491:-
HNSC	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	6.28	7.74e-10	3.94e-07	0.29	0.28	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
HNSC	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-6.28	7.74e-10	3.94e-07	-0.29	-0.28	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
HNSC	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-6.28	7.77e-10	3.95e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-6.28	7.77e-10	3.95e-07	-0.34	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
HNSC	cis	rs8177876	0.822	rs79926943	ENSG00000261061.1	RP11-303E16.2	-6.28	7.77e-10	3.96e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81030770~81031485:+
HNSC	cis	rs8012947	1	rs9743908	ENSG00000279636.2	LINC00216	-6.28	7.77e-10	3.96e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58256828	chr14:58288033~58289158:+
HNSC	cis	rs8059260	0.541	rs12917947	ENSG00000274038.1	RP11-66H6.4	-6.28	7.78e-10	3.96e-07	-0.54	-0.28	Alcohol consumption over the past year;	chr16:11116386	chr16:11056556~11057034:+
HNSC	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	6.28	7.78e-10	3.96e-07	0.33	0.28	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	6.28	7.78e-10	3.96e-07	0.33	0.28	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
HNSC	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	6.28	7.78e-10	3.96e-07	0.27	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-6.28	7.78e-10	3.96e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
HNSC	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-6.28	7.79e-10	3.96e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-6.28	7.79e-10	3.96e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
HNSC	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	6.28	7.79e-10	3.97e-07	0.45	0.28	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
HNSC	cis	rs783540	0.521	rs28719490	ENSG00000255769.6	GOLGA2P10	-6.28	7.8e-10	3.97e-07	-0.39	-0.28	Schizophrenia;	chr15:82720688	chr15:82472993~82513950:-
HNSC	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	6.28	7.8e-10	3.97e-07	0.39	0.28	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
HNSC	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-6.28	7.81e-10	3.97e-07	-0.33	-0.28	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
HNSC	cis	rs4218	0.513	rs17302142	ENSG00000259732.1	RP11-59H7.3	-6.28	7.81e-10	3.97e-07	-0.37	-0.28	Social communication problems;	chr15:59053813	chr15:59121034~59133250:+
HNSC	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	6.28	7.81e-10	3.97e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	6.28	7.81e-10	3.97e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	6.28	7.81e-10	3.97e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000211970.3	IGHV4-61	-6.28	7.81e-10	3.97e-07	-0.18	-0.28	Kawasaki disease;	chr14:106716993	chr14:106639119~106639657:-
HNSC	cis	rs947583	0.517	rs9402757	ENSG00000217482.2	HMGB1P17	-6.28	7.82e-10	3.98e-07	-0.29	-0.28	Phosphorus levels;	chr6:135799947	chr6:135636086~135636713:-
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.84e-10	3.99e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
HNSC	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-6.28	7.86e-10	4e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-6.28	7.86e-10	4e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
HNSC	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-6.28	7.86e-10	4e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
HNSC	cis	rs4713118	0.513	rs149955	ENSG00000204709.4	LINC01556	6.28	7.86e-10	4e-07	0.36	0.28	Parkinson's disease;	chr6:28068447	chr6:28943877~28944537:+
HNSC	cis	rs6918586	0.636	rs198857	ENSG00000272462.2	U91328.19	-6.28	7.87e-10	4e-07	-0.26	-0.28	Schizophrenia;	chr6:26102189	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198856	ENSG00000272462.2	U91328.19	-6.28	7.87e-10	4e-07	-0.26	-0.28	Schizophrenia;	chr6:26102480	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198854	ENSG00000272462.2	U91328.19	-6.28	7.87e-10	4e-07	-0.26	-0.28	Schizophrenia;	chr6:26103829	chr6:25992662~26001775:+
HNSC	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-6.28	7.88e-10	4.01e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
HNSC	cis	rs2790457	0.795	rs7903703	ENSG00000254635.4	WAC-AS1	-6.28	7.91e-10	4.02e-07	-0.32	-0.28	Multiple myeloma;	chr10:28646220	chr10:28522652~28532743:-
HNSC	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
HNSC	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-6.28	7.92e-10	4.02e-07	-0.39	-0.28	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
HNSC	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-6.28	7.93e-10	4.03e-07	-0.38	-0.28	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-6.28	7.93e-10	4.03e-07	-0.38	-0.28	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-6.28	7.93e-10	4.03e-07	-0.38	-0.28	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
HNSC	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	6.28	7.94e-10	4.03e-07	0.33	0.28	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	6.28	7.94e-10	4.03e-07	0.33	0.28	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	6.28	7.94e-10	4.03e-07	0.33	0.28	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
HNSC	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-6.28	7.94e-10	4.03e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
HNSC	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	6.28	7.94e-10	4.03e-07	0.32	0.28	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
HNSC	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-6.28	7.94e-10	4.04e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
HNSC	cis	rs453301	0.507	rs2929306	ENSG00000254340.1	RP11-10A14.3	-6.28	7.95e-10	4.04e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9227399	chr8:9141424~9145435:+
HNSC	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	6.28	7.95e-10	4.04e-07	0.28	0.28	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
HNSC	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
HNSC	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	6.28	7.96e-10	4.04e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
HNSC	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	6.28	7.97e-10	4.05e-07	0.35	0.28	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
HNSC	cis	rs2337406	1	rs61268362	ENSG00000211974.3	IGHV2-70	-6.28	7.98e-10	4.05e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106697010	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.85	rs8014460	ENSG00000211974.3	IGHV2-70	-6.28	7.98e-10	4.05e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106697140	chr14:106723574~106724093:-
HNSC	cis	rs9907295	0.591	rs78655848	ENSG00000270977.1	AC015849.16	-6.28	7.98e-10	4.05e-07	-0.32	-0.28	Fibroblast growth factor basic levels;	chr17:35856952	chr17:35893707~35911023:-
HNSC	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-6.27	8e-10	4.06e-07	-0.37	-0.28	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
HNSC	cis	rs2239557	0.961	rs8003212	ENSG00000259065.1	RP5-1021I20.1	6.27	8e-10	4.06e-07	0.33	0.28	Common traits (Other);	chr14:74158260	chr14:73787360~73803270:+
HNSC	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
HNSC	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	6.27	8.03e-10	4.08e-07	0.33	0.28	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
HNSC	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	6.27	8.04e-10	4.08e-07	0.39	0.28	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
HNSC	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	6.27	8.05e-10	4.08e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
HNSC	cis	rs2404602	0.692	rs4360890	ENSG00000259422.1	RP11-593F23.1	6.27	8.05e-10	4.08e-07	0.32	0.28	Blood metabolite levels;	chr15:76880954	chr15:76174891~76181486:-
HNSC	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-6.27	8.08e-10	4.1e-07	-0.33	-0.28	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
HNSC	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	6.27	8.11e-10	4.11e-07	0.66	0.28	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	6.27	8.11e-10	4.11e-07	0.66	0.28	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
HNSC	cis	rs526231	0.963	rs12187443	ENSG00000175749.11	EIF3KP1	6.27	8.12e-10	4.12e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103324699	chr5:103032376~103033031:+
HNSC	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	6.27	8.15e-10	4.13e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
HNSC	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	6.27	8.16e-10	4.14e-07	0.31	0.28	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
HNSC	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-6.27	8.16e-10	4.14e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000173295.6	FAM86B3P	6.27	8.17e-10	4.14e-07	0.32	0.28	Mood instability;	chr8:8865165	chr8:8228595~8244865:+
HNSC	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	6.27	8.17e-10	4.14e-07	0.32	0.28	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
HNSC	cis	rs17270561	0.666	rs1141034	ENSG00000272462.2	U91328.19	-6.27	8.17e-10	4.14e-07	-0.29	-0.28	Iron status biomarkers;	chr6:25780104	chr6:25992662~26001775:+
HNSC	cis	rs8177876	0.749	rs10459872	ENSG00000261061.1	RP11-303E16.2	6.27	8.18e-10	4.14e-07	0.47	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81030770~81031485:+
HNSC	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-6.27	8.19e-10	4.15e-07	-0.37	-0.28	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
HNSC	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	6.27	8.2e-10	4.16e-07	0.36	0.28	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
HNSC	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	6.27	8.21e-10	4.16e-07	0.38	0.28	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
HNSC	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	6.27	8.22e-10	4.16e-07	0.24	0.28	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
HNSC	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	6.27	8.22e-10	4.16e-07	0.57	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
HNSC	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-6.27	8.24e-10	4.17e-07	-0.35	-0.28	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000179406.6	LINC00174	-6.27	8.24e-10	4.17e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66474549	chr7:66376044~66401338:-
HNSC	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-6.27	8.25e-10	4.18e-07	-0.33	-0.28	Height;	chr4:55514317	chr4:55363971~55395847:-
HNSC	cis	rs2985684	0.846	rs10150624	ENSG00000258568.1	RHOQP1	6.27	8.25e-10	4.18e-07	0.29	0.28	Carotid intima media thickness;	chr14:49584847	chr14:49599994~49600572:+
HNSC	cis	rs2985684	0.802	rs10150823	ENSG00000258568.1	RHOQP1	6.27	8.25e-10	4.18e-07	0.29	0.28	Carotid intima media thickness;	chr14:49585033	chr14:49599994~49600572:+
HNSC	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	6.27	8.25e-10	4.18e-07	0.66	0.28	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
HNSC	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	6.27	8.25e-10	4.18e-07	0.28	0.28	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
HNSC	cis	rs867371	0.826	rs2047678	ENSG00000255769.6	GOLGA2P10	-6.27	8.27e-10	4.19e-07	-0.36	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472993~82513950:-
HNSC	cis	rs10504130	0.696	rs111926180	ENSG00000272024.1	RP11-546K22.3	-6.27	8.27e-10	4.19e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51950284~51950690:+
HNSC	cis	rs6657613	0.628	rs761423	ENSG00000186715.9	MST1L	6.27	8.28e-10	4.19e-07	0.22	0.28	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16754910~16770237:-
HNSC	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	6.27	8.28e-10	4.19e-07	0.32	0.28	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
HNSC	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	6.27	8.29e-10	4.2e-07	0.26	0.28	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
HNSC	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-6.27	8.3e-10	4.2e-07	-0.28	-0.28	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
HNSC	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	6.27	8.31e-10	4.21e-07	0.29	0.28	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
HNSC	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	6.27	8.33e-10	4.21e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	6.27	8.33e-10	4.21e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
HNSC	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-6.27	8.33e-10	4.22e-07	-0.36	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
HNSC	cis	rs853679	1	rs853694	ENSG00000219392.1	RP1-265C24.5	-6.27	8.34e-10	4.22e-07	-0.41	-0.28	Depression;	chr6:28311323	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-6.27	8.34e-10	4.22e-07	-0.31	-0.28	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
HNSC	cis	rs4218	0.689	rs12902628	ENSG00000259732.1	RP11-59H7.3	-6.27	8.35e-10	4.22e-07	-0.39	-0.28	Social communication problems;	chr15:59100193	chr15:59121034~59133250:+
HNSC	cis	rs2404602	0.692	rs12594556	ENSG00000259422.1	RP11-593F23.1	6.27	8.35e-10	4.23e-07	0.32	0.28	Blood metabolite levels;	chr15:76873022	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.669	rs12916324	ENSG00000259422.1	RP11-593F23.1	6.27	8.35e-10	4.23e-07	0.32	0.28	Blood metabolite levels;	chr15:76887262	chr15:76174891~76181486:-
HNSC	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-6.27	8.35e-10	4.23e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
HNSC	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-6.27	8.36e-10	4.23e-07	-0.18	-0.28	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
HNSC	cis	rs8054556	0.74	rs12716974	ENSG00000183604.13	SMG1P5	-6.27	8.37e-10	4.24e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30267553~30335374:-
HNSC	cis	rs34526934	0.608	rs72927183	ENSG00000226363.3	HAGLROS	6.27	8.37e-10	4.24e-07	0.37	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176169051	chr2:176177717~176179008:+
HNSC	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	6.27	8.39e-10	4.24e-07	0.21	0.28	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
HNSC	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	6.27	8.39e-10	4.24e-07	0.38	0.28	Height;	chr6:109375003	chr6:109382795~109383666:+
HNSC	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	6.27	8.41e-10	4.25e-07	0.28	0.28	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
HNSC	cis	rs6951245	1	rs77868187	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs75016635	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs113066613	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11763793	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11763835	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78861357	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs76713558	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.748	rs79658522	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs76525951	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79683221	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78185801	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs80031817	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78143408	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1029025~1043891:+
HNSC	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	6.27	8.45e-10	4.27e-07	0.31	0.28	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	6.27	8.45e-10	4.27e-07	0.31	0.28	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
HNSC	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	6.27	8.46e-10	4.28e-07	0.35	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
HNSC	cis	rs9907295	0.591	rs8069014	ENSG00000270977.1	AC015849.16	-6.27	8.47e-10	4.28e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35872994	chr17:35893707~35911023:-
HNSC	cis	rs8062405	0.54	rs193628	ENSG00000259982.1	CDC37P1	-6.27	8.47e-10	4.28e-07	-0.3	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28570821	chr16:28700294~28701540:-
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-6.26	8.49e-10	4.29e-07	-0.34	-0.28	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
HNSC	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-6.26	8.5e-10	4.29e-07	-0.34	-0.28	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
HNSC	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	6.26	8.5e-10	4.29e-07	0.27	0.28	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
HNSC	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-6.26	8.53e-10	4.31e-07	-0.26	-0.28	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
HNSC	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-6.26	8.53e-10	4.31e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
HNSC	cis	rs9890032	0.934	rs3760318	ENSG00000263531.1	RP13-753N3.1	6.26	8.53e-10	4.31e-07	0.33	0.28	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30863921~30864940:-
HNSC	cis	rs7176527	0.796	rs1057946	ENSG00000229212.6	RP11-561C5.4	6.26	8.53e-10	4.31e-07	0.45	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85205440~85234795:-
HNSC	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000179406.6	LINC00174	-6.26	8.55e-10	4.32e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66433290	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs67536397	ENSG00000179406.6	LINC00174	-6.26	8.55e-10	4.32e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66482930	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs58669269	ENSG00000179406.6	LINC00174	-6.26	8.55e-10	4.32e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66486966	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.527	rs9461443	ENSG00000204709.4	LINC01556	6.26	8.56e-10	4.32e-07	0.37	0.28	Depression;	chr6:28226851	chr6:28943877~28944537:+
HNSC	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	6.26	8.57e-10	4.33e-07	0.29	0.28	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
HNSC	cis	rs4388249	0.687	rs10038829	ENSG00000271849.1	CTC-332L22.1	6.26	8.57e-10	4.33e-07	0.37	0.28	Schizophrenia;	chr5:109769002	chr5:109687802~109688329:-
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	6.26	8.58e-10	4.33e-07	0.22	0.28	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
HNSC	cis	rs6951245	0.938	rs112425403	ENSG00000225146.1	AC073957.15	-6.26	8.58e-10	4.33e-07	-0.46	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031895	chr7:1029025~1043891:+
HNSC	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	6.26	8.58e-10	4.33e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
HNSC	cis	rs4218	0.689	rs73418863	ENSG00000259732.1	RP11-59H7.3	-6.26	8.59e-10	4.34e-07	-0.39	-0.28	Social communication problems;	chr15:59098923	chr15:59121034~59133250:+
HNSC	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	6.26	8.6e-10	4.34e-07	0.66	0.28	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
HNSC	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	6.26	8.61e-10	4.35e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
HNSC	cis	rs9329221	0.592	rs7832708	ENSG00000269918.1	AF131215.9	6.26	8.61e-10	4.35e-07	0.26	0.28	Neuroticism;	chr8:10332530	chr8:11104691~11106704:-
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
HNSC	cis	rs2235642	0.891	rs2281231	ENSG00000280231.1	LA16c-380F5.3	-6.26	8.64e-10	4.36e-07	-0.34	-0.28	Coronary artery disease;	chr16:1551878	chr16:1553655~1554130:-
HNSC	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	6.26	8.64e-10	4.36e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
HNSC	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-6.26	8.65e-10	4.36e-07	-0.34	-0.28	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
HNSC	cis	rs7829975	0.774	rs11775523	ENSG00000173295.6	FAM86B3P	6.26	8.66e-10	4.36e-07	0.31	0.28	Mood instability;	chr8:8821666	chr8:8228595~8244865:+
HNSC	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	6.26	8.66e-10	4.37e-07	0.65	0.28	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
HNSC	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-6.26	8.67e-10	4.37e-07	-0.19	-0.28	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
HNSC	cis	rs34375054	0.573	rs35698828	ENSG00000279233.1	RP11-158L12.4	6.26	8.67e-10	4.37e-07	0.37	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125174057	chr12:125138245~125141711:+
HNSC	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	6.26	8.67e-10	4.37e-07	0.27	0.28	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
HNSC	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	6.26	8.68e-10	4.37e-07	0.28	0.28	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
HNSC	cis	rs757110	0.69	rs35271178	ENSG00000260196.1	RP1-239B22.5	6.26	8.68e-10	4.38e-07	0.31	0.28	Type 2 diabetes;	chr11:17389473	chr11:17380649~17383531:+
HNSC	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	6.26	8.69e-10	4.38e-07	0.28	0.28	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
HNSC	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-6.26	8.69e-10	4.38e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
HNSC	cis	rs9402743	0.641	rs6906211	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Systemic lupus erythematosus;	chr6:135778283	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6906845	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135778363	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.64	rs9494384	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Systemic lupus erythematosus;	chr6:135779072	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6570041	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135780515	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6923513	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135780784	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs4895457	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135783172	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs7764412	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135787214	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.667	rs4896179	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Systemic lupus erythematosus;	chr6:135788352	chr6:135636086~135636713:-
HNSC	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	6.26	8.7e-10	4.38e-07	0.39	0.28	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
HNSC	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	6.26	8.7e-10	4.38e-07	0.32	0.28	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
HNSC	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	6.26	8.7e-10	4.39e-07	0.33	0.28	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	6.26	8.7e-10	4.39e-07	0.33	0.28	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
HNSC	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
HNSC	cis	rs4266144	0.581	rs1806867	ENSG00000244515.1	KRT18P34	-6.26	8.73e-10	4.4e-07	-0.29	-0.28	Coronary artery disease;	chr3:157110513	chr3:157162663~157163932:-
HNSC	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	6.26	8.74e-10	4.4e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
HNSC	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	6.26	8.74e-10	4.4e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
HNSC	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-6.26	8.75e-10	4.41e-07	-0.44	-0.28	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
HNSC	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-6.26	8.78e-10	4.42e-07	-0.34	-0.28	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
HNSC	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	6.26	8.8e-10	4.43e-07	0.24	0.28	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
HNSC	cis	rs9326248	0.53	rs7121347	ENSG00000280143.1	AP000892.6	6.26	8.8e-10	4.43e-07	0.42	0.28	Blood protein levels;	chr11:116996493	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs7114963	ENSG00000280143.1	AP000892.6	6.26	8.8e-10	4.43e-07	0.42	0.28	Blood protein levels;	chr11:117005267	chr11:117204967~117210292:+
HNSC	cis	rs7115242	0.72	rs10790169	ENSG00000280143.1	AP000892.6	6.26	8.8e-10	4.43e-07	0.42	0.28	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117204967~117210292:+
HNSC	cis	rs4273100	0.834	rs59415593	ENSG00000265185.4	SNORD3B-1	6.26	8.81e-10	4.43e-07	0.42	0.28	Schizophrenia;	chr17:19319911	chr17:19061912~19062669:+
HNSC	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-6.26	8.81e-10	4.44e-07	-0.31	-0.28	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-6.26	8.83e-10	4.44e-07	-0.18	-0.28	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
HNSC	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	6.26	8.83e-10	4.45e-07	0.3	0.28	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
HNSC	cis	rs2239557	0.961	rs4903200	ENSG00000259065.1	RP5-1021I20.1	6.26	8.84e-10	4.45e-07	0.33	0.28	Common traits (Other);	chr14:74192934	chr14:73787360~73803270:+
HNSC	cis	rs947583	1	rs6570043	ENSG00000217482.2	HMGB1P17	6.26	8.84e-10	4.45e-07	0.31	0.28	Phosphorus levels;	chr6:135812960	chr6:135636086~135636713:-
HNSC	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	6.26	8.84e-10	4.45e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
HNSC	cis	rs4218	0.681	rs35204615	ENSG00000259732.1	RP11-59H7.3	-6.26	8.84e-10	4.45e-07	-0.39	-0.28	Social communication problems;	chr15:59099637	chr15:59121034~59133250:+
HNSC	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	6.26	8.85e-10	4.45e-07	0.32	0.28	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-6.26	8.85e-10	4.45e-07	-0.36	-0.28	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
HNSC	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	6.26	8.85e-10	4.46e-07	0.3	0.28	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
HNSC	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	6.26	8.86e-10	4.46e-07	0.7	0.28	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
HNSC	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	6.26	8.88e-10	4.47e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
HNSC	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	6.26	8.9e-10	4.48e-07	0.29	0.28	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
HNSC	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-6.26	8.9e-10	4.48e-07	-0.27	-0.28	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
HNSC	cis	rs35955747	0.871	rs5994392	ENSG00000236132.1	CTA-440B3.1	6.26	8.91e-10	4.48e-07	0.3	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31387920	chr22:31816379~31817491:-
HNSC	cis	rs860295	0.775	rs729022	ENSG00000203761.5	MSTO2P	6.26	8.93e-10	4.49e-07	0.21	0.28	Body mass index;	chr1:155882332	chr1:155745829~155750137:+
HNSC	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	6.26	8.93e-10	4.49e-07	0.38	0.28	Height;	chr6:109480428	chr6:109382795~109383666:+
HNSC	cis	rs4239252	0.929	rs4796116	ENSG00000270977.1	AC015849.16	-6.26	8.94e-10	4.5e-07	-0.32	-0.28	Blood protein levels;	chr17:35841496	chr17:35893707~35911023:-
HNSC	cis	rs4239252	0.929	rs4251791	ENSG00000270977.1	AC015849.16	-6.26	8.94e-10	4.5e-07	-0.32	-0.28	Blood protein levels;	chr17:35845711	chr17:35893707~35911023:-
HNSC	cis	rs858239	0.704	rs466240	ENSG00000226816.2	AC005082.12	-6.26	8.94e-10	4.5e-07	-0.34	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23206013~23208045:+
HNSC	cis	rs7615952	0.604	rs9837847	ENSG00000248787.1	RP11-666A20.4	-6.26	8.94e-10	4.5e-07	-0.49	-0.28	Blood pressure (smoking interaction);	chr3:125905076	chr3:125908005~125910272:-
HNSC	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-6.26	8.97e-10	4.51e-07	-0.35	-0.28	Height;	chr3:52977358	chr3:53064283~53065091:-
HNSC	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-6.26	8.99e-10	4.52e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
HNSC	cis	rs853679	1	rs1936365	ENSG00000219392.1	RP1-265C24.5	6.25	9e-10	4.53e-07	0.4	0.28	Depression;	chr6:28300675	chr6:28115628~28116551:+
HNSC	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	6.25	9.01e-10	4.53e-07	0.32	0.28	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
HNSC	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-6.25	9.03e-10	4.54e-07	-0.28	-0.28	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
HNSC	cis	rs9326248	0.53	rs10790172	ENSG00000280143.1	AP000892.6	6.25	9.03e-10	4.54e-07	0.42	0.28	Blood protein levels;	chr11:117057024	chr11:117204967~117210292:+
HNSC	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-6.25	9.04e-10	4.54e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000254153.1	CTA-398F10.2	6.25	9.04e-10	4.54e-07	0.31	0.28	Systolic blood pressure;	chr8:8487658	chr8:8456909~8461337:-
HNSC	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	6.25	9.05e-10	4.55e-07	0.33	0.28	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
HNSC	cis	rs1665050	0.571	rs1446238	ENSG00000259732.1	RP11-59H7.3	-6.25	9.05e-10	4.55e-07	-0.37	-0.28	Atopic dermatitis;	chr15:59055558	chr15:59121034~59133250:+
HNSC	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
HNSC	cis	rs6951245	1	rs75488469	ENSG00000225146.1	AC073957.15	-6.25	9.06e-10	4.55e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1029025~1043891:+
HNSC	cis	rs7176527	1	rs3762168	ENSG00000229212.6	RP11-561C5.4	6.25	9.06e-10	4.55e-07	0.44	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85205440~85234795:-
HNSC	cis	rs8054556	0.74	rs8059619	ENSG00000183604.13	SMG1P5	-6.25	9.07e-10	4.56e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29914124	chr16:30267553~30335374:-
HNSC	cis	rs2404602	0.967	rs7167613	ENSG00000259422.1	RP11-593F23.1	6.25	9.07e-10	4.56e-07	0.32	0.28	Blood metabolite levels;	chr15:76748851	chr15:76174891~76181486:-
HNSC	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-6.25	9.09e-10	4.57e-07	-0.35	-0.28	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
HNSC	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-6.25	9.09e-10	4.57e-07	-0.32	-0.28	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
HNSC	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	6.25	9.1e-10	4.57e-07	0.28	0.28	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
HNSC	cis	rs7615952	0.576	rs6780025	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126096781	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.576	rs6804482	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126096919	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.576	rs12497295	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126099807	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs4646765	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126101864	chr3:125827238~125916384:-
HNSC	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-6.25	9.11e-10	4.57e-07	-0.37	-0.28	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
HNSC	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	6.25	9.12e-10	4.58e-07	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
HNSC	cis	rs889014	1	rs13183901	ENSG00000253768.1	CTB-33O18.1	6.25	9.12e-10	4.58e-07	0.3	0.28	Height;	chr5:173563489	chr5:173562478~173573199:+
HNSC	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	6.25	9.13e-10	4.58e-07	0.32	0.28	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
HNSC	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-6.25	9.13e-10	4.58e-07	-0.28	-0.28	Height;	chr2:231490121	chr2:231508426~231514339:-
HNSC	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-6.25	9.14e-10	4.59e-07	-0.32	-0.28	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
HNSC	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-6.25	9.17e-10	4.61e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
HNSC	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-6.25	9.18e-10	4.61e-07	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
HNSC	cis	rs2235642	0.75	rs2859310	ENSG00000280231.1	LA16c-380F5.3	6.25	9.18e-10	4.61e-07	0.34	0.28	Coronary artery disease;	chr16:1606764	chr16:1553655~1554130:-
HNSC	cis	rs8012947	1	rs8009579	ENSG00000279636.2	LINC00216	-6.25	9.21e-10	4.62e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58246841	chr14:58288033~58289158:+
HNSC	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	6.25	9.22e-10	4.63e-07	0.34	0.28	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
HNSC	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-6.25	9.25e-10	4.64e-07	-0.29	-0.28	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
HNSC	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	6.25	9.26e-10	4.65e-07	0.34	0.28	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
HNSC	cis	rs10435719	0.58	rs13260712	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.551	rs13268217	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	Monocyte count;	chr8:11925100	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.573	rs13264994	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	Monocyte count;	chr8:11925250	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.573	rs13275808	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	Monocyte count;	chr8:11925306	chr8:11928597~11929563:-
HNSC	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	6.25	9.29e-10	4.66e-07	0.27	0.28	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	6.25	9.3e-10	4.66e-07	0.32	0.28	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
HNSC	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-6.25	9.3e-10	4.67e-07	-0.32	-0.28	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	6.25	9.31e-10	4.67e-07	0.22	0.28	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	6.25	9.31e-10	4.67e-07	0.22	0.28	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
HNSC	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	6.25	9.32e-10	4.68e-07	0.29	0.28	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
HNSC	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	6.25	9.32e-10	4.68e-07	0.31	0.28	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
HNSC	cis	rs9341808	0.714	rs4256394	ENSG00000272129.1	RP11-250B2.6	6.25	9.35e-10	4.69e-07	0.32	0.28	Sitting height ratio;	chr6:80172425	chr6:80355424~80356859:+
HNSC	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-6.25	9.35e-10	4.69e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
HNSC	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	6.25	9.35e-10	4.69e-07	0.64	0.28	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
HNSC	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-6.25	9.36e-10	4.69e-07	-0.32	-0.28	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
HNSC	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	6.25	9.36e-10	4.69e-07	0.28	0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
HNSC	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.37e-10	4.7e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
HNSC	cis	rs11992162	0.573	rs61468577	ENSG00000206014.6	OR7E161P	6.25	9.37e-10	4.7e-07	0.3	0.28	Monocyte count;	chr8:11927416	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.507	rs60902764	ENSG00000206014.6	OR7E161P	6.25	9.37e-10	4.7e-07	0.3	0.28	Monocyte count;	chr8:11927482	chr8:11928597~11929563:-
HNSC	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	6.25	9.38e-10	4.71e-07	0.35	0.28	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
HNSC	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	6.25	9.39e-10	4.71e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-6.25	9.39e-10	4.71e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
HNSC	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	6.25	9.4e-10	4.71e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
HNSC	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	6.25	9.4e-10	4.72e-07	0.45	0.28	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
HNSC	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	6.25	9.41e-10	4.72e-07	0.3	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
HNSC	cis	rs10504130	0.696	rs113323463	ENSG00000272024.1	RP11-546K22.3	-6.25	9.41e-10	4.72e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs78238505	ENSG00000272024.1	RP11-546K22.3	-6.25	9.41e-10	4.72e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51950284~51950690:+
HNSC	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-6.25	9.41e-10	4.72e-07	-0.24	-0.28	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
HNSC	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	6.25	9.43e-10	4.73e-07	0.32	0.28	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
HNSC	cis	rs8177876	0.749	rs75923695	ENSG00000261061.1	RP11-303E16.2	-6.25	9.44e-10	4.73e-07	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81030770~81031485:+
HNSC	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-6.25	9.44e-10	4.73e-07	-0.24	-0.28	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
HNSC	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.44e-10	4.73e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
HNSC	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.44e-10	4.73e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
HNSC	cis	rs7176527	0.8	rs56747535	ENSG00000229212.6	RP11-561C5.4	6.25	9.44e-10	4.73e-07	0.45	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85205440~85234795:-
HNSC	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
HNSC	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.46e-10	4.74e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
HNSC	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-6.25	9.46e-10	4.74e-07	-0.24	-0.28	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
HNSC	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.48e-10	4.75e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	6.25	9.5e-10	4.76e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
HNSC	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	6.25	9.52e-10	4.77e-07	0.4	0.28	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
HNSC	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-6.25	9.53e-10	4.77e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
HNSC	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-6.25	9.54e-10	4.78e-07	-0.28	-0.28	Height;	chr2:231559006	chr2:231508426~231514339:-
HNSC	cis	rs4218	0.689	rs12907187	ENSG00000259732.1	RP11-59H7.3	-6.24	9.54e-10	4.78e-07	-0.39	-0.28	Social communication problems;	chr15:59100607	chr15:59121034~59133250:+
HNSC	cis	rs1799949	0.929	rs799905	ENSG00000267151.3	RP11-100E5.2	6.24	9.54e-10	4.78e-07	0.36	0.28	Menopause (age at onset);	chr17:43125170	chr17:43444707~43451200:+
HNSC	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-6.24	9.55e-10	4.78e-07	-0.47	-0.28	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-6.24	9.55e-10	4.78e-07	-0.47	-0.28	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
HNSC	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	6.24	9.55e-10	4.78e-07	0.36	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
HNSC	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	6.24	9.56e-10	4.79e-07	0.44	0.28	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
HNSC	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	6.24	9.56e-10	4.79e-07	0.33	0.28	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
HNSC	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	6.24	9.61e-10	4.81e-07	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
HNSC	cis	rs2404602	0.716	rs66754747	ENSG00000259422.1	RP11-593F23.1	6.24	9.64e-10	4.82e-07	0.32	0.28	Blood metabolite levels;	chr15:76536227	chr15:76174891~76181486:-
HNSC	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-6.24	9.64e-10	4.83e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
HNSC	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	6.24	9.65e-10	4.83e-07	0.42	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	6.24	9.66e-10	4.84e-07	0.19	0.28	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
HNSC	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-6.24	9.67e-10	4.84e-07	-0.33	-0.28	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
HNSC	cis	rs440932	0.747	rs330946	ENSG00000173295.6	FAM86B3P	6.24	9.67e-10	4.84e-07	0.32	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8228595~8244865:+
HNSC	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-6.24	9.71e-10	4.86e-07	-0.29	-0.28	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
HNSC	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-6.24	9.71e-10	4.86e-07	-0.43	-0.28	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
HNSC	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	6.24	9.75e-10	4.88e-07	0.38	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
HNSC	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-6.24	9.78e-10	4.89e-07	-0.42	-0.28	Depression;	chr6:28283207	chr6:28115628~28116551:+
HNSC	cis	rs7201929	0.959	rs35725751	ENSG00000259982.1	CDC37P1	-6.24	9.79e-10	4.89e-07	-0.36	-0.28	QT interval;	chr16:28834263	chr16:28700294~28701540:-
HNSC	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	6.24	9.79e-10	4.9e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
HNSC	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-6.24	9.79e-10	4.9e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
HNSC	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-6.24	9.8e-10	4.9e-07	-0.32	-0.28	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
HNSC	cis	rs853679	1	rs853676	ENSG00000219392.1	RP1-265C24.5	-6.24	9.81e-10	4.9e-07	-0.41	-0.28	Depression;	chr6:28331910	chr6:28115628~28116551:+
HNSC	cis	rs35955747	0.869	rs131219	ENSG00000236132.1	CTA-440B3.1	-6.24	9.81e-10	4.91e-07	-0.29	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31364264	chr22:31816379~31817491:-
HNSC	cis	rs4713118	0.513	rs149962	ENSG00000204709.4	LINC01556	6.24	9.82e-10	4.91e-07	0.36	0.28	Parkinson's disease;	chr6:28048140	chr6:28943877~28944537:+
HNSC	cis	rs2985684	0.948	rs4900925	ENSG00000258568.1	RHOQP1	-6.24	9.82e-10	4.91e-07	-0.29	-0.28	Carotid intima media thickness;	chr14:49545607	chr14:49599994~49600572:+
HNSC	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	6.24	9.82e-10	4.91e-07	0.65	0.28	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
HNSC	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-6.24	9.82e-10	4.91e-07	-0.33	-0.28	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
HNSC	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	6.24	9.83e-10	4.91e-07	0.25	0.28	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	6.24	9.83e-10	4.92e-07	0.44	0.28	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	6.24	9.83e-10	4.92e-07	0.44	0.28	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
HNSC	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	6.24	9.84e-10	4.92e-07	0.42	0.28	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
HNSC	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	6.24	9.84e-10	4.92e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
HNSC	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	6.24	9.86e-10	4.93e-07	0.26	0.28	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
HNSC	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-6.24	9.86e-10	4.93e-07	-0.34	-0.28	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
HNSC	cis	rs12439619	0.846	rs62010071	ENSG00000276710.3	CSPG4P8	-6.24	9.89e-10	4.94e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82459472~82477258:+
HNSC	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-6.24	9.92e-10	4.96e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-6.24	9.93e-10	4.96e-07	-0.18	-0.28	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-6.24	9.93e-10	4.96e-07	-0.19	-0.28	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
HNSC	cis	rs7567389	0.568	rs7568070	ENSG00000236682.1	AC068282.3	-6.24	9.94e-10	4.97e-07	-0.37	-0.28	Self-rated health;	chr2:127195478	chr2:127389130~127400580:+
HNSC	cis	rs947583	0.517	rs6570039	ENSG00000217482.2	HMGB1P17	6.24	9.95e-10	4.97e-07	0.29	0.28	Phosphorus levels;	chr6:135775602	chr6:135636086~135636713:-
HNSC	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	6.24	9.96e-10	4.97e-07	0.38	0.28	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
HNSC	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-6.24	9.97e-10	4.98e-07	-0.29	-0.28	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
HNSC	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	6.24	9.98e-10	4.98e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
HNSC	cis	rs2337406	0.925	rs873533	ENSG00000211974.3	IGHV2-70	-6.24	1e-09	5e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106667442	chr14:106723574~106724093:-
HNSC	cis	rs2834288	0.535	rs7275560	ENSG00000237945.6	LINC00649	-6.24	1e-09	5e-07	-0.34	-0.28	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.535	rs2834306	ENSG00000237945.6	LINC00649	-6.24	1e-09	5e-07	-0.34	-0.28	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33915534~33977691:+
HNSC	cis	rs2337406	1	rs17113257	ENSG00000211974.3	IGHV2-70	-6.24	1e-09	5.01e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106679574	chr14:106723574~106724093:-
HNSC	cis	rs6471393	0.964	rs10504930	ENSG00000253848.1	RP11-10N23.5	-6.24	1e-09	5.01e-07	-0.33	-0.28	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732585	chr8:93741193~93744534:+
HNSC	cis	rs2880765	0.743	rs7168345	ENSG00000259295.5	CSPG4P12	-6.24	1e-09	5.01e-07	-0.32	-0.28	Coronary artery disease;	chr15:85470370	chr15:85191438~85213905:+
HNSC	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	6.24	1e-09	5.01e-07	0.78	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
HNSC	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	6.24	1.01e-09	5.02e-07	0.39	0.28	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
HNSC	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-6.24	1.01e-09	5.02e-07	-0.33	-0.28	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
HNSC	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	6.24	1.01e-09	5.02e-07	0.37	0.28	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
HNSC	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	6.24	1.01e-09	5.03e-07	0.43	0.28	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
HNSC	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-6.24	1.01e-09	5.03e-07	-0.37	-0.28	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
HNSC	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	6.24	1.01e-09	5.04e-07	0.36	0.28	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
HNSC	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	6.24	1.01e-09	5.04e-07	0.34	0.28	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
HNSC	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-6.24	1.01e-09	5.04e-07	-0.32	-0.28	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
HNSC	cis	rs2985684	0.846	rs11157693	ENSG00000258568.1	RHOQP1	6.24	1.01e-09	5.05e-07	0.28	0.28	Carotid intima media thickness;	chr14:49581708	chr14:49599994~49600572:+
HNSC	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	6.23	1.01e-09	5.05e-07	0.34	0.28	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
HNSC	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	6.23	1.01e-09	5.05e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
HNSC	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	6.23	1.01e-09	5.06e-07	0.33	0.28	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
HNSC	cis	rs1865760	0.613	rs9379805	ENSG00000272462.2	U91328.19	-6.23	1.02e-09	5.07e-07	-0.26	-0.28	Height;	chr6:25938536	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	6.23	1.02e-09	5.08e-07	0.37	0.28	Height;	chr6:109486036	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-6.23	1.02e-09	5.08e-07	-0.35	-0.28	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
HNSC	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
HNSC	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	6.23	1.02e-09	5.09e-07	0.31	0.28	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000173295.6	FAM86B3P	-6.23	1.02e-09	5.09e-07	-0.31	-0.28	Mood instability;	chr8:8933743	chr8:8228595~8244865:+
HNSC	cis	rs61160187	0.582	rs62372103	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60891935~60893577:-
HNSC	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	6.23	1.02e-09	5.09e-07	0.32	0.28	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
HNSC	cis	rs9907295	0.591	rs4251749	ENSG00000270977.1	AC015849.16	-6.23	1.02e-09	5.1e-07	-0.32	-0.28	Fibroblast growth factor basic levels;	chr17:35823421	chr17:35893707~35911023:-
HNSC	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-6.23	1.02e-09	5.1e-07	-0.27	-0.28	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-6.23	1.02e-09	5.11e-07	-0.36	-0.28	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	6.23	1.02e-09	5.11e-07	0.22	0.28	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
HNSC	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	6.23	1.02e-09	5.11e-07	0.47	0.28	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
HNSC	cis	rs10504130	0.696	rs76649327	ENSG00000272024.1	RP11-546K22.3	-6.23	1.03e-09	5.12e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51950284~51950690:+
HNSC	cis	rs5753618	0.504	rs9609296	ENSG00000236132.1	CTA-440B3.1	-6.23	1.03e-09	5.12e-07	-0.36	-0.28	Colorectal cancer;	chr22:31495798	chr22:31816379~31817491:-
HNSC	cis	rs2834288	0.535	rs4816469	ENSG00000237945.6	LINC00649	6.23	1.03e-09	5.12e-07	0.34	0.28	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33915534~33977691:+
HNSC	cis	rs12935418	0.83	rs7188549	ENSG00000261061.1	RP11-303E16.2	-6.23	1.03e-09	5.12e-07	-0.38	-0.28	Mean corpuscular volume;	chr16:81016371	chr16:81030770~81031485:+
HNSC	cis	rs4639966	0.836	rs7130875	ENSG00000255422.1	AP002954.4	6.23	1.03e-09	5.13e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118742965	chr11:118704607~118750263:+
HNSC	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-6.23	1.03e-09	5.13e-07	-0.29	-0.28	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
HNSC	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-6.23	1.03e-09	5.13e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-6.23	1.03e-09	5.13e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
HNSC	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
HNSC	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-6.23	1.03e-09	5.14e-07	-0.26	-0.28	Asthma;	chr2:102438096	chr2:102438713~102440475:+
HNSC	cis	rs8012947	1	rs10145437	ENSG00000279636.2	LINC00216	-6.23	1.03e-09	5.15e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58294485	chr14:58288033~58289158:+
HNSC	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-6.23	1.03e-09	5.15e-07	-0.39	-0.28	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
HNSC	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	6.23	1.03e-09	5.15e-07	0.33	0.28	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
HNSC	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-6.23	1.04e-09	5.15e-07	-0.29	-0.28	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
HNSC	cis	rs7048146	0.668	rs2150260	ENSG00000213539.4	YBX1P6	6.23	1.04e-09	5.16e-07	0.31	0.28	Vascular brain injury;	chr9:109511914	chr9:109532830~109534332:-
HNSC	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-6.23	1.04e-09	5.16e-07	-0.32	-0.28	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
HNSC	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-6.23	1.04e-09	5.18e-07	-0.33	-0.28	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000254153.1	CTA-398F10.2	6.23	1.04e-09	5.19e-07	0.29	0.28	Neuroticism;	chr8:8461340	chr8:8456909~8461337:-
HNSC	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-6.23	1.04e-09	5.19e-07	-0.32	-0.28	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-6.23	1.04e-09	5.19e-07	-0.32	-0.28	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
HNSC	cis	rs6951245	0.935	rs61753396	ENSG00000225146.1	AC073957.15	-6.23	1.04e-09	5.19e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.938	rs113642700	ENSG00000225146.1	AC073957.15	-6.23	1.04e-09	5.19e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1029025~1043891:+
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000254153.1	CTA-398F10.2	6.23	1.04e-09	5.19e-07	0.29	0.28	Neuroticism;	chr8:8461672	chr8:8456909~8461337:-
HNSC	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	6.23	1.05e-09	5.2e-07	0.4	0.28	Height;	chr6:109762861	chr6:109382795~109383666:+
HNSC	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	6.23	1.05e-09	5.2e-07	0.33	0.28	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
HNSC	cis	rs1355223	0.902	rs12801509	ENSG00000271369.1	RP11-350D17.3	-6.23	1.05e-09	5.21e-07	-0.32	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725789	chr11:34709600~34710161:+
HNSC	cis	rs5753618	0.561	rs4603880	ENSG00000236132.1	CTA-440B3.1	-6.23	1.05e-09	5.21e-07	-0.34	-0.28	Colorectal cancer;	chr22:31348735	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs9609264	ENSG00000236132.1	CTA-440B3.1	-6.23	1.05e-09	5.21e-07	-0.34	-0.28	Colorectal cancer;	chr22:31350733	chr22:31816379~31817491:-
HNSC	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-6.23	1.05e-09	5.21e-07	-0.24	-0.28	Height;	chr11:118703185	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-6.23	1.05e-09	5.21e-07	-0.24	-0.28	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
HNSC	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	6.23	1.05e-09	5.21e-07	0.38	0.28	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
HNSC	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-6.23	1.05e-09	5.21e-07	-0.43	-0.28	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
HNSC	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-6.23	1.05e-09	5.22e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
HNSC	cis	rs2108622	0.64	rs58858790	ENSG00000267453.5	AC004791.2	-6.23	1.05e-09	5.22e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15863463	chr19:15851993~15864904:-
HNSC	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
HNSC	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	6.23	1.05e-09	5.23e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
HNSC	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
HNSC	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	6.23	1.05e-09	5.24e-07	0.36	0.28	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	6.23	1.05e-09	5.24e-07	0.36	0.28	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
HNSC	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-6.23	1.05e-09	5.25e-07	-0.31	-0.28	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
HNSC	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-6.23	1.06e-09	5.25e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
HNSC	cis	rs9840812	0.637	rs698270	ENSG00000273486.1	RP11-731C17.2	6.23	1.06e-09	5.25e-07	0.25	0.28	Fibrinogen levels;	chr3:136390670	chr3:136837338~136839021:-
HNSC	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-6.23	1.06e-09	5.27e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-6.23	1.06e-09	5.27e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
HNSC	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	6.23	1.06e-09	5.27e-07	0.33	0.28	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
HNSC	cis	rs4218	0.517	rs2899640	ENSG00000259732.1	RP11-59H7.3	-6.23	1.07e-09	5.31e-07	-0.38	-0.28	Social communication problems;	chr15:59060281	chr15:59121034~59133250:+
HNSC	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	6.23	1.07e-09	5.31e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000173295.6	FAM86B3P	-6.23	1.07e-09	5.31e-07	-0.31	-0.28	Joint mobility (Beighton score);	chr8:9050721	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	6.23	1.07e-09	5.31e-07	0.35	0.28	Depression;	chr6:28386473	chr6:28943877~28944537:+
HNSC	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	6.23	1.07e-09	5.31e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
HNSC	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	6.23	1.07e-09	5.32e-07	0.36	0.28	Height;	chr6:109415411	chr6:109382795~109383666:+
HNSC	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.07e-09	5.32e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
HNSC	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-6.23	1.07e-09	5.32e-07	-0.34	-0.28	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
HNSC	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-6.23	1.07e-09	5.32e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-6.23	1.07e-09	5.32e-07	-0.4	-0.28	Gout;	chr7:66642037	chr7:66902857~66906297:+
HNSC	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-6.23	1.07e-09	5.33e-07	-0.4	-0.28	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
HNSC	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	6.23	1.07e-09	5.33e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	6.22	1.07e-09	5.33e-07	0.21	0.28	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
HNSC	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	6.22	1.08e-09	5.34e-07	0.45	0.28	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
HNSC	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	6.22	1.08e-09	5.35e-07	0.33	0.28	Height;	chr4:55573424	chr4:55363971~55395847:-
HNSC	cis	rs2834288	0.535	rs4816468	ENSG00000237945.6	LINC00649	6.22	1.08e-09	5.35e-07	0.34	0.28	Gut microbiota (bacterial taxa);	chr21:33952235	chr21:33915534~33977691:+
HNSC	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	6.22	1.08e-09	5.35e-07	0.27	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
HNSC	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	6.22	1.08e-09	5.36e-07	0.28	0.28	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
HNSC	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
HNSC	cis	rs4639966	0.836	rs3825057	ENSG00000255422.1	AP002954.4	6.22	1.08e-09	5.37e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118752276	chr11:118704607~118750263:+
HNSC	cis	rs4639966	0.836	rs11217014	ENSG00000255422.1	AP002954.4	6.22	1.08e-09	5.37e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118755577	chr11:118704607~118750263:+
HNSC	cis	rs5753618	0.561	rs2040533	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31283124	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs5753543	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31289472	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2413049	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31290158	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs715510	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31294542	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs737887	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31300629	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs4820963	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31302180	chr22:31816379~31817491:-
HNSC	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	6.22	1.08e-09	5.38e-07	0.28	0.28	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
HNSC	cis	rs11992162	0.56	rs7846248	ENSG00000206014.6	OR7E161P	-6.22	1.08e-09	5.38e-07	-0.3	-0.28	Monocyte count;	chr8:11936540	chr8:11928597~11929563:-
HNSC	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	6.22	1.08e-09	5.38e-07	0.37	0.28	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
HNSC	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	6.22	1.09e-09	5.39e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	6.22	1.09e-09	5.39e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
HNSC	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	6.22	1.09e-09	5.39e-07	0.3	0.28	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
HNSC	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-6.22	1.09e-09	5.39e-07	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
HNSC	cis	rs2404602	0.655	rs4886507	ENSG00000259422.1	RP11-593F23.1	6.22	1.09e-09	5.39e-07	0.32	0.28	Blood metabolite levels;	chr15:76917353	chr15:76174891~76181486:-
HNSC	cis	rs6951245	0.935	rs61910751	ENSG00000225146.1	AC073957.15	-6.22	1.09e-09	5.4e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs77434655	ENSG00000225146.1	AC073957.15	-6.22	1.09e-09	5.4e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs75398423	ENSG00000225146.1	AC073957.15	-6.22	1.09e-09	5.4e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1029025~1043891:+
HNSC	cis	rs7829975	0.774	rs1703982	ENSG00000173295.6	FAM86B3P	-6.22	1.09e-09	5.4e-07	-0.32	-0.28	Mood instability;	chr8:8740878	chr8:8228595~8244865:+
HNSC	cis	rs9901225	1	rs9901225	ENSG00000108785.7	HSD17B1P1	-6.22	1.09e-09	5.4e-07	-0.28	-0.28	Colorectal or endometrial cancer;	chr17:42603793	chr17:42546764~42548706:+
HNSC	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	6.22	1.09e-09	5.42e-07	0.3	0.28	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
HNSC	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-6.22	1.09e-09	5.42e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
HNSC	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	6.22	1.09e-09	5.42e-07	0.26	0.28	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
HNSC	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	6.22	1.1e-09	5.43e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
HNSC	cis	rs2985684	0.802	rs8015368	ENSG00000258568.1	RHOQP1	6.22	1.1e-09	5.43e-07	0.28	0.28	Carotid intima media thickness;	chr14:49553792	chr14:49599994~49600572:+
HNSC	cis	rs8177876	0.658	rs75422577	ENSG00000261061.1	RP11-303E16.2	-6.22	1.1e-09	5.43e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.749	rs76892049	ENSG00000261061.1	RP11-303E16.2	-6.22	1.1e-09	5.43e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81030770~81031485:+
HNSC	cis	rs2834288	0.535	rs8129694	ENSG00000237945.6	LINC00649	-6.22	1.1e-09	5.44e-07	-0.34	-0.28	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33915534~33977691:+
HNSC	cis	rs7617773	0.925	rs35942721	ENSG00000228638.1	FCF1P2	-6.22	1.1e-09	5.44e-07	-0.3	-0.28	Coronary artery disease;	chr3:48131579	chr3:48290793~48291375:-
HNSC	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	6.22	1.1e-09	5.44e-07	0.33	0.28	Height;	chr4:55570843	chr4:55363971~55395847:-
HNSC	cis	rs9907295	0.591	rs11650668	ENSG00000270977.1	AC015849.16	-6.22	1.1e-09	5.45e-07	-0.32	-0.28	Fibroblast growth factor basic levels;	chr17:35822045	chr17:35893707~35911023:-
HNSC	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	6.22	1.1e-09	5.46e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
HNSC	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	6.22	1.1e-09	5.47e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
HNSC	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	6.22	1.1e-09	5.47e-07	0.55	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
HNSC	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-6.22	1.1e-09	5.47e-07	-0.31	-0.28	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
HNSC	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	6.22	1.1e-09	5.47e-07	0.35	0.28	Height;	chr4:55482360	chr4:55363971~55395847:-
HNSC	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-6.22	1.11e-09	5.48e-07	-0.31	-0.28	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-6.22	1.11e-09	5.48e-07	-0.31	-0.28	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
HNSC	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-6.22	1.11e-09	5.48e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
HNSC	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	6.22	1.11e-09	5.48e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
HNSC	cis	rs2239557	1	rs4903201	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74192987	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs10140433	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74193286	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs4903202	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74193599	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs4903203	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74193805	chr14:73787360~73803270:+
HNSC	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-6.22	1.11e-09	5.48e-07	-0.24	-0.28	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
HNSC	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-6.22	1.11e-09	5.48e-07	-0.24	-0.28	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
HNSC	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	6.22	1.11e-09	5.48e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
HNSC	cis	rs7048146	0.668	rs6477708	ENSG00000213539.4	YBX1P6	6.22	1.11e-09	5.49e-07	0.31	0.28	Vascular brain injury;	chr9:109513462	chr9:109532830~109534332:-
HNSC	cis	rs172166	0.694	rs203877	ENSG00000204709.4	LINC01556	6.22	1.11e-09	5.49e-07	0.35	0.28	Cardiac Troponin-T levels;	chr6:28080846	chr6:28943877~28944537:+
HNSC	cis	rs2276314	0.512	rs1789515	ENSG00000278986.1	RP11-723J4.3	6.22	1.11e-09	5.49e-07	0.3	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36055930	chr18:35972151~35973916:+
HNSC	cis	rs4218	0.689	rs35555888	ENSG00000259732.1	RP11-59H7.3	-6.22	1.11e-09	5.49e-07	-0.39	-0.28	Social communication problems;	chr15:59093935	chr15:59121034~59133250:+
HNSC	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	6.22	1.11e-09	5.49e-07	0.24	0.28	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
HNSC	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
HNSC	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	6.22	1.11e-09	5.49e-07	0.41	0.28	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
HNSC	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-6.22	1.11e-09	5.5e-07	-0.22	-0.28	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
HNSC	cis	rs757110	0.834	rs1002226	ENSG00000260196.1	RP1-239B22.5	6.22	1.11e-09	5.51e-07	0.31	0.28	Type 2 diabetes;	chr11:17384070	chr11:17380649~17383531:+
HNSC	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	6.22	1.11e-09	5.51e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	6.22	1.11e-09	5.51e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
HNSC	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-6.22	1.12e-09	5.52e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
HNSC	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	6.22	1.12e-09	5.52e-07	0.31	0.28	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.512	rs1077621	ENSG00000241288.6	RP11-379B18.5	-6.22	1.12e-09	5.53e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126100956	chr3:125827238~125916384:-
HNSC	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-6.22	1.12e-09	5.53e-07	-0.25	-0.28	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
HNSC	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	6.22	1.12e-09	5.53e-07	0.31	0.28	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	6.22	1.12e-09	5.53e-07	0.31	0.28	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
HNSC	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	6.22	1.12e-09	5.54e-07	0.36	0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
HNSC	cis	rs61160187	0.549	rs12518404	ENSG00000215032.2	GNL3LP1	6.22	1.12e-09	5.54e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60891935~60893577:-
HNSC	cis	rs2286503	0.839	rs2240728	ENSG00000221740.1	SNORD93	6.22	1.12e-09	5.54e-07	0.3	0.28	Fibrinogen;	chr7:22812880	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs1054471	ENSG00000221740.1	SNORD93	6.22	1.12e-09	5.54e-07	0.3	0.28	Fibrinogen;	chr7:22813024	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2240726	ENSG00000221740.1	SNORD93	6.22	1.12e-09	5.54e-07	0.3	0.28	Fibrinogen;	chr7:22813516	chr7:22856613~22856686:+
HNSC	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-6.22	1.12e-09	5.54e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-6.22	1.12e-09	5.54e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
HNSC	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	6.22	1.12e-09	5.54e-07	0.26	0.28	Asthma;	chr2:102446780	chr2:102438713~102440475:+
HNSC	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	6.22	1.12e-09	5.55e-07	0.3	0.28	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
HNSC	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	6.22	1.12e-09	5.55e-07	0.3	0.28	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
HNSC	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
HNSC	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	6.22	1.12e-09	5.56e-07	0.31	0.28	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
HNSC	cis	rs35955747	0.902	rs4820961	ENSG00000236132.1	CTA-440B3.1	6.22	1.12e-09	5.56e-07	0.3	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283463	chr22:31816379~31817491:-
HNSC	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-6.22	1.13e-09	5.57e-07	-0.28	-0.28	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-6.22	1.13e-09	5.57e-07	-0.28	-0.28	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
HNSC	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-6.22	1.13e-09	5.58e-07	-0.33	-0.28	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
HNSC	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
HNSC	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-6.22	1.13e-09	5.58e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
HNSC	cis	rs4938303	0.756	rs12802944	ENSG00000254851.1	RP11-109L13.1	6.22	1.13e-09	5.58e-07	0.47	0.28	Triglycerides;	chr11:116705684	chr11:117135528~117138582:+
HNSC	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	6.22	1.13e-09	5.58e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	6.22	1.13e-09	5.58e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
HNSC	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-6.22	1.13e-09	5.58e-07	-0.52	-0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
HNSC	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-6.22	1.13e-09	5.58e-07	-0.32	-0.28	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
HNSC	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
HNSC	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	6.22	1.13e-09	5.59e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
HNSC	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-6.22	1.13e-09	5.59e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-6.22	1.13e-09	5.59e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
HNSC	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-6.22	1.13e-09	5.59e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
HNSC	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	6.22	1.13e-09	5.59e-07	0.33	0.28	Height;	chr4:55440988	chr4:55363971~55395847:-
HNSC	cis	rs6951245	1	rs884977	ENSG00000224079.1	AC091729.7	-6.22	1.14e-09	5.61e-07	-0.43	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1026774	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
HNSC	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	6.22	1.14e-09	5.61e-07	0.38	0.28	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
HNSC	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	6.22	1.14e-09	5.61e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
HNSC	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	6.22	1.14e-09	5.61e-07	0.38	0.28	Height;	chr6:109479396	chr6:109382795~109383666:+
HNSC	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	6.22	1.14e-09	5.62e-07	0.34	0.28	Depression;	chr6:28428413	chr6:28943877~28944537:+
HNSC	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-6.22	1.14e-09	5.62e-07	-0.39	-0.28	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
HNSC	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-6.21	1.14e-09	5.63e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
HNSC	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-6.21	1.14e-09	5.63e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
HNSC	cis	rs7567389	0.812	rs6710496	ENSG00000236682.1	AC068282.3	6.21	1.14e-09	5.63e-07	0.34	0.28	Self-rated health;	chr2:127218798	chr2:127389130~127400580:+
HNSC	cis	rs2834288	0.535	rs13049489	ENSG00000237945.6	LINC00649	6.21	1.14e-09	5.64e-07	0.34	0.28	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33915534~33977691:+
HNSC	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-6.21	1.14e-09	5.64e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	6.21	1.14e-09	5.65e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
HNSC	cis	rs7048146	0.668	rs1411682	ENSG00000213539.4	YBX1P6	6.21	1.14e-09	5.65e-07	0.31	0.28	Vascular brain injury;	chr9:109514077	chr9:109532830~109534332:-
HNSC	cis	rs2235642	0.928	rs56289115	ENSG00000280231.1	LA16c-380F5.3	-6.21	1.15e-09	5.66e-07	-0.34	-0.28	Coronary artery disease;	chr16:1558933	chr16:1553655~1554130:-
HNSC	cis	rs6951245	0.872	rs112309216	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs76161580	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs76388414	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77305932	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs11768486	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11766526	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs76214082	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs113146460	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1029025~1043891:+
HNSC	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
HNSC	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-6.21	1.15e-09	5.66e-07	-0.28	-0.28	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000173295.6	FAM86B3P	-6.21	1.15e-09	5.67e-07	-0.31	-0.28	Joint mobility (Beighton score);	chr8:9050725	chr8:8228595~8244865:+
HNSC	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-6.21	1.15e-09	5.67e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
HNSC	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	6.21	1.15e-09	5.67e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
HNSC	cis	rs2243480	1	rs160655	ENSG00000179406.6	LINC00174	-6.21	1.15e-09	5.68e-07	-0.58	-0.28	Diabetic kidney disease;	chr7:66068227	chr7:66376044~66401338:-
HNSC	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	6.21	1.15e-09	5.69e-07	0.32	0.28	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
HNSC	cis	rs526231	0.819	rs2288788	ENSG00000175749.11	EIF3KP1	6.21	1.16e-09	5.7e-07	0.4	0.28	Primary biliary cholangitis;	chr5:103264868	chr5:103032376~103033031:+
HNSC	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	6.21	1.16e-09	5.71e-07	0.31	0.28	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
HNSC	cis	rs4713118	0.513	rs149954	ENSG00000204709.4	LINC01556	6.21	1.16e-09	5.74e-07	0.36	0.28	Parkinson's disease;	chr6:28067468	chr6:28943877~28944537:+
HNSC	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-6.21	1.17e-09	5.74e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
HNSC	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-6.21	1.17e-09	5.75e-07	-0.35	-0.28	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
HNSC	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	6.21	1.17e-09	5.75e-07	0.44	0.28	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
HNSC	cis	rs4239252	0.929	rs4251787	ENSG00000270977.1	AC015849.16	-6.21	1.17e-09	5.75e-07	-0.32	-0.28	Blood protein levels;	chr17:35845577	chr17:35893707~35911023:-
HNSC	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-6.21	1.17e-09	5.75e-07	-0.32	-0.28	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000173295.6	FAM86B3P	-6.21	1.17e-09	5.77e-07	-0.31	-0.28	Mood instability;	chr8:8937937	chr8:8228595~8244865:+
HNSC	cis	rs6504622	0.905	rs197926	ENSG00000262879.4	RP11-156P1.3	6.21	1.17e-09	5.77e-07	0.29	0.28	Orofacial clefts;	chr17:46934721	chr17:46984045~47100323:-
HNSC	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
HNSC	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-6.21	1.17e-09	5.78e-07	-0.4	-0.28	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
HNSC	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-6.21	1.17e-09	5.78e-07	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
HNSC	cis	rs2880765	0.743	rs8028240	ENSG00000259295.5	CSPG4P12	6.21	1.18e-09	5.79e-07	0.32	0.28	Coronary artery disease;	chr15:85470017	chr15:85191438~85213905:+
HNSC	cis	rs4657482	0.572	rs4656466	ENSG00000236364.3	RP11-525G13.2	6.21	1.18e-09	5.8e-07	0.29	0.28	Testicular germ cell tumor;	chr1:165900130	chr1:165890795~165900683:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000211970.3	IGHV4-61	-6.21	1.18e-09	5.81e-07	-0.18	-0.28	Kawasaki disease;	chr14:106799309	chr14:106639119~106639657:-
HNSC	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-6.21	1.18e-09	5.82e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
HNSC	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	6.21	1.18e-09	5.83e-07	0.31	0.28	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	6.21	1.18e-09	5.83e-07	0.31	0.28	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
HNSC	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	6.21	1.18e-09	5.83e-07	0.3	0.28	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
HNSC	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-6.21	1.19e-09	5.84e-07	-0.34	-0.28	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
HNSC	cis	rs4218	0.701	rs56375269	ENSG00000259732.1	RP11-59H7.3	-6.21	1.19e-09	5.84e-07	-0.38	-0.28	Social communication problems;	chr15:59137741	chr15:59121034~59133250:+
HNSC	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	6.21	1.19e-09	5.84e-07	0.32	0.28	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
HNSC	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	6.21	1.19e-09	5.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
HNSC	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	6.21	1.19e-09	5.86e-07	0.36	0.28	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	6.21	1.19e-09	5.86e-07	0.36	0.28	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	6.21	1.19e-09	5.86e-07	0.36	0.28	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
HNSC	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-6.21	1.19e-09	5.86e-07	-0.18	-0.28	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
HNSC	cis	rs7615952	0.673	rs9821905	ENSG00000241288.6	RP11-379B18.5	6.21	1.19e-09	5.87e-07	0.43	0.28	Blood pressure (smoking interaction);	chr3:125902007	chr3:125827238~125916384:-
HNSC	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-6.21	1.19e-09	5.87e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
HNSC	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-6.21	1.19e-09	5.87e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000211972.2	IGHV3-66	6.21	1.19e-09	5.88e-07	0.21	0.28	Kawasaki disease;	chr14:106779660	chr14:106675017~106675544:-
HNSC	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	6.21	1.2e-09	5.88e-07	0.34	0.28	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
HNSC	cis	rs7615952	0.641	rs61048217	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089062	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs60839048	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089095	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs7640158	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089168	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs2365019	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089292	chr3:125827238~125916384:-
HNSC	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	6.21	1.2e-09	5.89e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
HNSC	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-6.21	1.2e-09	5.9e-07	-0.4	-0.28	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
HNSC	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	6.21	1.2e-09	5.9e-07	0.39	0.28	Height;	chr6:109573151	chr6:109382795~109383666:+
HNSC	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	6.21	1.2e-09	5.9e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
HNSC	cis	rs7804306	0.826	rs17566854	ENSG00000233264.2	AC006042.8	6.21	1.2e-09	5.9e-07	0.59	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7993887	chr7:7980312~7982228:+
HNSC	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	6.21	1.2e-09	5.9e-07	0.33	0.28	Height;	chr4:55540928	chr4:55363971~55395847:-
HNSC	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
HNSC	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	6.21	1.2e-09	5.91e-07	0.3	0.28	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
HNSC	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	6.21	1.2e-09	5.92e-07	0.33	0.28	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	6.21	1.2e-09	5.92e-07	0.33	0.28	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
HNSC	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-6.21	1.2e-09	5.92e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-6.21	1.2e-09	5.92e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
HNSC	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-6.21	1.21e-09	5.93e-07	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
HNSC	cis	rs8177876	0.822	rs77475047	ENSG00000261061.1	RP11-303E16.2	-6.21	1.21e-09	5.93e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs55939311	ENSG00000261061.1	RP11-303E16.2	-6.21	1.21e-09	5.93e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs12444137	ENSG00000261061.1	RP11-303E16.2	-6.21	1.21e-09	5.93e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81030770~81031485:+
HNSC	cis	rs172166	0.694	rs203876	ENSG00000204709.4	LINC01556	6.21	1.21e-09	5.93e-07	0.35	0.28	Cardiac Troponin-T levels;	chr6:28078895	chr6:28943877~28944537:+
HNSC	cis	rs947583	0.517	rs9376147	ENSG00000217482.2	HMGB1P17	6.2	1.21e-09	5.93e-07	0.29	0.28	Phosphorus levels;	chr6:135774774	chr6:135636086~135636713:-
HNSC	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-6.2	1.21e-09	5.94e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000254340.1	RP11-10A14.3	-6.2	1.21e-09	5.94e-07	-0.32	-0.28	Mood instability;	chr8:8967348	chr8:9141424~9145435:+
HNSC	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	6.2	1.21e-09	5.95e-07	0.38	0.28	Height;	chr6:109469907	chr6:109382795~109383666:+
HNSC	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	6.2	1.21e-09	5.95e-07	0.36	0.28	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
HNSC	cis	rs4713118	0.513	rs156739	ENSG00000204709.4	LINC01556	6.2	1.21e-09	5.95e-07	0.36	0.28	Parkinson's disease;	chr6:28045632	chr6:28943877~28944537:+
HNSC	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-6.2	1.21e-09	5.95e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
HNSC	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-6.2	1.21e-09	5.96e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
HNSC	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-6.2	1.21e-09	5.96e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
HNSC	cis	rs9548119	0.941	rs9576404	ENSG00000223685.4	LINC00571	-6.2	1.21e-09	5.96e-07	-0.45	-0.28	Self-rated health;	chr13:37953276	chr13:38050817~38143232:-
HNSC	cis	rs2115630	0.645	rs1107179	ENSG00000229212.6	RP11-561C5.4	-6.2	1.21e-09	5.97e-07	-0.32	-0.28	P wave terminal force;	chr15:84655131	chr15:85205440~85234795:-
HNSC	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-6.2	1.22e-09	5.97e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000254153.1	CTA-398F10.2	6.2	1.22e-09	5.97e-07	0.3	0.28	Mood instability;	chr8:8520592	chr8:8456909~8461337:-
HNSC	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-6.2	1.22e-09	5.97e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
HNSC	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-6.2	1.22e-09	5.97e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
HNSC	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-6.2	1.22e-09	5.97e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
HNSC	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-6.2	1.22e-09	5.98e-07	-0.54	-0.28	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000254153.1	CTA-398F10.2	6.2	1.22e-09	5.98e-07	0.29	0.28	Systolic blood pressure;	chr8:8461832	chr8:8456909~8461337:-
HNSC	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
HNSC	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-6.2	1.22e-09	5.99e-07	-0.36	-0.28	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
HNSC	cis	rs2880765	0.805	rs34598679	ENSG00000259295.5	CSPG4P12	6.2	1.22e-09	5.99e-07	0.31	0.28	Coronary artery disease;	chr15:85498974	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs4344688	ENSG00000259295.5	CSPG4P12	6.2	1.22e-09	5.99e-07	0.31	0.28	Coronary artery disease;	chr15:85499776	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs4280192	ENSG00000259295.5	CSPG4P12	6.2	1.22e-09	5.99e-07	0.31	0.28	Coronary artery disease;	chr15:85499789	chr15:85191438~85213905:+
HNSC	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-6.2	1.22e-09	6e-07	-0.33	-0.28	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
HNSC	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
HNSC	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
HNSC	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-6.2	1.23e-09	6.02e-07	-0.3	-0.28	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
HNSC	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	6.2	1.23e-09	6.03e-07	0.29	0.28	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
HNSC	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-6.2	1.23e-09	6.04e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
HNSC	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	6.2	1.23e-09	6.04e-07	0.27	0.28	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
HNSC	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	6.2	1.23e-09	6.04e-07	0.69	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	6.2	1.23e-09	6.04e-07	0.69	0.28	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
HNSC	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	6.2	1.23e-09	6.04e-07	0.33	0.28	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	6.2	1.23e-09	6.04e-07	0.33	0.28	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	6.2	1.23e-09	6.04e-07	0.33	0.28	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
HNSC	cis	rs8177876	0.822	rs1563077	ENSG00000261061.1	RP11-303E16.2	-6.2	1.23e-09	6.05e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.692	rs55676827	ENSG00000259422.1	RP11-593F23.1	6.2	1.24e-09	6.06e-07	0.32	0.28	Blood metabolite levels;	chr15:76669375	chr15:76174891~76181486:-
HNSC	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-6.2	1.24e-09	6.06e-07	-0.29	-0.28	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
HNSC	cis	rs7617773	0.746	rs4130995	ENSG00000228638.1	FCF1P2	-6.2	1.24e-09	6.06e-07	-0.25	-0.28	Coronary artery disease;	chr3:48316765	chr3:48290793~48291375:-
HNSC	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-6.2	1.24e-09	6.07e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-6.2	1.24e-09	6.07e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
HNSC	cis	rs2235642	0.928	rs2076435	ENSG00000280231.1	LA16c-380F5.3	-6.2	1.24e-09	6.07e-07	-0.34	-0.28	Coronary artery disease;	chr16:1557573	chr16:1553655~1554130:-
HNSC	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.2	1.24e-09	6.08e-07	-0.37	-0.28	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-6.2	1.24e-09	6.08e-07	-0.37	-0.28	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-6.2	1.24e-09	6.08e-07	-0.37	-0.28	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
HNSC	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-6.2	1.24e-09	6.08e-07	-0.22	-0.28	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
HNSC	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	6.2	1.24e-09	6.09e-07	0.38	0.28	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
HNSC	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	6.2	1.25e-09	6.12e-07	0.31	0.28	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
HNSC	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	6.2	1.25e-09	6.12e-07	0.31	0.28	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
HNSC	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-6.2	1.25e-09	6.13e-07	-0.39	-0.28	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
HNSC	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-6.2	1.25e-09	6.13e-07	-0.34	-0.28	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
HNSC	cis	rs1198872	0.558	rs10929699	ENSG00000272275.1	RP11-791G15.2	-6.2	1.25e-09	6.13e-07	-0.36	-0.28	Cardiac Troponin-T levels;	chr2:10778083	chr2:10767875~10770058:-
HNSC	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-6.2	1.25e-09	6.13e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-6.2	1.25e-09	6.14e-07	-0.33	-0.28	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
HNSC	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	6.2	1.25e-09	6.15e-07	0.34	0.28	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
HNSC	cis	rs8054556	0.74	rs12444978	ENSG00000183604.13	SMG1P5	-6.2	1.26e-09	6.15e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29913101	chr16:30267553~30335374:-
HNSC	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-6.2	1.26e-09	6.15e-07	-0.29	-0.28	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
HNSC	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	6.2	1.26e-09	6.16e-07	0.36	0.28	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
HNSC	cis	rs2985684	0.948	rs6572592	ENSG00000258568.1	RHOQP1	6.2	1.26e-09	6.17e-07	0.28	0.28	Carotid intima media thickness;	chr14:49614153	chr14:49599994~49600572:+
HNSC	cis	rs2337406	1	rs10459466	ENSG00000211974.3	IGHV2-70	-6.2	1.26e-09	6.18e-07	-0.37	-0.28	Alzheimer's disease (late onset);	chr14:106689255	chr14:106723574~106724093:-
HNSC	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	6.2	1.26e-09	6.18e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
HNSC	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-6.2	1.26e-09	6.19e-07	-0.33	-0.28	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
HNSC	cis	rs9840812	0.596	rs571513	ENSG00000273486.1	RP11-731C17.2	6.2	1.27e-09	6.21e-07	0.24	0.28	Fibrinogen levels;	chr3:136376193	chr3:136837338~136839021:-
HNSC	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-6.2	1.27e-09	6.23e-07	-0.35	-0.28	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
HNSC	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	6.2	1.27e-09	6.23e-07	0.33	0.28	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
HNSC	cis	rs11992162	0.613	rs6601634	ENSG00000206014.6	OR7E161P	6.2	1.27e-09	6.23e-07	0.3	0.28	Monocyte count;	chr8:11948947	chr8:11928597~11929563:-
HNSC	cis	rs1659258	0.803	rs1258412	ENSG00000232508.1	MRPL45P1	-6.19	1.28e-09	6.27e-07	-0.54	-0.28	Visceral fat;	chr2:88318068	chr2:88364695~88365608:-
HNSC	cis	rs7811142	1	rs2406253	ENSG00000078319.8	PMS2P1	-6.19	1.28e-09	6.28e-07	-0.34	-0.28	Platelet count;	chr7:100479650	chr7:100320992~100341908:-
HNSC	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	6.19	1.28e-09	6.28e-07	0.39	0.28	Height;	chr6:109339681	chr6:109382795~109383666:+
HNSC	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-6.19	1.28e-09	6.28e-07	-0.26	-0.28	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
HNSC	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	6.19	1.29e-09	6.31e-07	0.3	0.28	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	6.19	1.29e-09	6.31e-07	0.3	0.28	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
HNSC	cis	rs4639966	0.836	rs7110526	ENSG00000255422.1	AP002954.4	6.19	1.29e-09	6.31e-07	0.37	0.28	Systemic lupus erythematosus;	chr11:118762824	chr11:118704607~118750263:+
HNSC	cis	rs4639966	0.797	rs11217021	ENSG00000255422.1	AP002954.4	6.19	1.29e-09	6.31e-07	0.37	0.28	Systemic lupus erythematosus;	chr11:118770119	chr11:118704607~118750263:+
HNSC	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-6.19	1.29e-09	6.32e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
HNSC	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-6.19	1.29e-09	6.32e-07	-0.28	-0.28	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
HNSC	cis	rs8012947	0.916	rs28411823	ENSG00000279636.2	LINC00216	-6.19	1.29e-09	6.32e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58239891	chr14:58288033~58289158:+
HNSC	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	6.19	1.29e-09	6.33e-07	0.34	0.28	Depression;	chr6:28431469	chr6:28943877~28944537:+
HNSC	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-6.19	1.3e-09	6.33e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-6.19	1.3e-09	6.33e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
HNSC	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	6.19	1.3e-09	6.33e-07	0.36	0.28	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
HNSC	cis	rs61542988	0.532	rs12673996	ENSG00000228649.7	AC005682.5	6.19	1.3e-09	6.33e-07	0.34	0.28	Fibrinogen levels;	chr7:22793781	chr7:22854178~22861579:+
HNSC	cis	rs2404602	0.692	rs10444858	ENSG00000259422.1	RP11-593F23.1	6.19	1.3e-09	6.34e-07	0.32	0.28	Blood metabolite levels;	chr15:76670163	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.34e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.34e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
HNSC	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	6.19	1.3e-09	6.34e-07	0.38	0.28	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	6.19	1.3e-09	6.34e-07	0.34	0.28	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
HNSC	cis	rs71327718	1	rs71327718	ENSG00000248787.1	RP11-666A20.4	-6.19	1.3e-09	6.35e-07	-0.5	-0.28	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125908005~125910272:-
HNSC	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.35e-07	-0.29	-0.28	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
HNSC	cis	rs7615952	0.576	rs4646748	ENSG00000241288.6	RP11-379B18.5	-6.19	1.3e-09	6.35e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126107486	chr3:125827238~125916384:-
HNSC	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.35e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
HNSC	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-6.19	1.3e-09	6.35e-07	-0.33	-0.28	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
HNSC	cis	rs5753618	0.561	rs4820043	ENSG00000236132.1	CTA-440B3.1	6.19	1.3e-09	6.36e-07	0.34	0.28	Colorectal cancer;	chr22:31251108	chr22:31816379~31817491:-
HNSC	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
HNSC	cis	rs2337406	1	rs3858878	ENSG00000211974.3	IGHV2-70	-6.19	1.3e-09	6.36e-07	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106688061	chr14:106723574~106724093:-
HNSC	cis	rs2836950	0.545	rs11700813	ENSG00000255568.3	BRWD1-AS2	-6.19	1.31e-09	6.38e-07	-0.22	-0.28	Menarche (age at onset);	chr21:39145543	chr21:39313935~39314962:+
HNSC	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	6.19	1.31e-09	6.38e-07	0.36	0.28	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
HNSC	cis	rs9840812	0.522	rs711976	ENSG00000273486.1	RP11-731C17.2	6.19	1.31e-09	6.38e-07	0.25	0.28	Fibrinogen levels;	chr3:136510180	chr3:136837338~136839021:-
HNSC	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-6.19	1.31e-09	6.39e-07	-0.28	-0.28	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
HNSC	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
HNSC	cis	rs4713118	0.513	rs149950	ENSG00000204709.4	LINC01556	6.19	1.31e-09	6.39e-07	0.36	0.28	Parkinson's disease;	chr6:28065261	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149951	ENSG00000204709.4	LINC01556	6.19	1.31e-09	6.39e-07	0.36	0.28	Parkinson's disease;	chr6:28065309	chr6:28943877~28944537:+
HNSC	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-6.19	1.31e-09	6.4e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
HNSC	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	6.19	1.31e-09	6.4e-07	0.43	0.28	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
HNSC	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
HNSC	cis	rs853679	1	rs7740487	ENSG00000219392.1	RP1-265C24.5	-6.19	1.31e-09	6.4e-07	-0.41	-0.28	Depression;	chr6:28248708	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs68141011	ENSG00000219392.1	RP1-265C24.5	-6.19	1.31e-09	6.4e-07	-0.41	-0.28	Depression;	chr6:28250019	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs13200462	ENSG00000219392.1	RP1-265C24.5	-6.19	1.31e-09	6.4e-07	-0.41	-0.28	Depression;	chr6:28250421	chr6:28115628~28116551:+
HNSC	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	6.19	1.31e-09	6.4e-07	0.49	0.28	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
HNSC	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-6.19	1.31e-09	6.4e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
HNSC	cis	rs7621025	0.5	rs4678275	ENSG00000273486.1	RP11-731C17.2	6.19	1.31e-09	6.41e-07	0.25	0.28	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136837338~136839021:-
HNSC	cis	rs2880765	0.743	rs6497194	ENSG00000259295.5	CSPG4P12	6.19	1.31e-09	6.41e-07	0.32	0.28	Coronary artery disease;	chr15:85470885	chr15:85191438~85213905:+
HNSC	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-6.19	1.31e-09	6.41e-07	-0.26	-0.28	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
HNSC	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-6.19	1.31e-09	6.41e-07	-0.38	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
HNSC	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-6.19	1.31e-09	6.41e-07	-0.38	-0.28	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
HNSC	cis	rs7819412	0.594	rs7460507	ENSG00000255310.2	AF131215.2	-6.19	1.32e-09	6.42e-07	-0.27	-0.28	Triglycerides;	chr8:11111565	chr8:11107788~11109726:-
HNSC	cis	rs2985684	0.894	rs7152110	ENSG00000258568.1	RHOQP1	6.19	1.32e-09	6.42e-07	0.28	0.28	Carotid intima media thickness;	chr14:49551500	chr14:49599994~49600572:+
HNSC	cis	rs453301	0.653	rs7853	ENSG00000254153.1	CTA-398F10.2	6.19	1.32e-09	6.43e-07	0.31	0.28	Joint mobility (Beighton score);	chr8:9033304	chr8:8456909~8461337:-
HNSC	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-6.19	1.32e-09	6.43e-07	-0.34	-0.28	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
HNSC	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	6.19	1.32e-09	6.44e-07	0.26	0.28	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
HNSC	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	6.19	1.32e-09	6.44e-07	0.29	0.28	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
HNSC	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-6.19	1.32e-09	6.44e-07	-0.29	-0.28	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
HNSC	cis	rs9326248	0.53	rs6589589	ENSG00000280143.1	AP000892.6	6.19	1.32e-09	6.44e-07	0.42	0.28	Blood protein levels;	chr11:117061712	chr11:117204967~117210292:+
HNSC	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	6.19	1.32e-09	6.44e-07	0.3	0.28	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
HNSC	cis	rs9907295	0.591	rs6505496	ENSG00000270977.1	AC015849.16	-6.19	1.32e-09	6.45e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35802063	chr17:35893707~35911023:-
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000211972.2	IGHV3-66	-6.19	1.33e-09	6.47e-07	-0.21	-0.28	Kawasaki disease;	chr14:106779223	chr14:106675017~106675544:-
HNSC	cis	rs8012947	1	rs1885133	ENSG00000279636.2	LINC00216	-6.19	1.33e-09	6.48e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58270684	chr14:58288033~58289158:+
HNSC	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
HNSC	cis	rs11089937	0.626	rs737840	ENSG00000211638.2	IGLV8-61	-6.19	1.33e-09	6.5e-07	-0.28	-0.28	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22098700~22099212:+
HNSC	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	6.19	1.34e-09	6.51e-07	0.32	0.28	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	6.19	1.34e-09	6.51e-07	0.34	0.28	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
HNSC	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	6.19	1.34e-09	6.51e-07	0.27	0.28	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
HNSC	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	6.19	1.34e-09	6.51e-07	0.27	0.28	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
HNSC	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-6.19	1.34e-09	6.52e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
HNSC	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-6.19	1.34e-09	6.53e-07	-0.33	-0.28	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
HNSC	cis	rs6951245	0.938	rs78351779	ENSG00000225146.1	AC073957.15	-6.19	1.34e-09	6.53e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11761941	ENSG00000225146.1	AC073957.15	-6.19	1.34e-09	6.53e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11767527	ENSG00000225146.1	AC073957.15	-6.19	1.34e-09	6.53e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1029025~1043891:+
HNSC	cis	rs2579103	0.809	rs34691361	ENSG00000258183.4	RP11-753N8.1	-6.19	1.34e-09	6.53e-07	-0.33	-0.28	Body mass index;	chr12:90202116	chr12:90280894~90300340:+
HNSC	cis	rs8012947	1	rs7149735	ENSG00000279636.2	LINC00216	-6.19	1.34e-09	6.54e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58289703	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs6573198	ENSG00000279636.2	LINC00216	-6.19	1.34e-09	6.54e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58293044	chr14:58288033~58289158:+
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000254340.1	RP11-10A14.3	-6.19	1.35e-09	6.56e-07	-0.34	-0.28	Joint mobility (Beighton score);	chr8:9018719	chr8:9141424~9145435:+
HNSC	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	6.19	1.35e-09	6.56e-07	0.38	0.28	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
HNSC	cis	rs4141404	0.757	rs5749272	ENSG00000236132.1	CTA-440B3.1	6.19	1.35e-09	6.56e-07	0.3	0.28	Paclitaxel-induced neuropathy;	chr22:31434365	chr22:31816379~31817491:-
HNSC	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-6.19	1.35e-09	6.57e-07	-0.37	-0.28	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	6.19	1.35e-09	6.58e-07	0.32	0.28	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
HNSC	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	6.19	1.35e-09	6.59e-07	0.42	0.28	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
HNSC	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	6.19	1.35e-09	6.59e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
HNSC	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
HNSC	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	6.19	1.35e-09	6.59e-07	0.3	0.28	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
HNSC	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	6.19	1.36e-09	6.6e-07	0.3	0.28	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	6.19	1.36e-09	6.6e-07	0.3	0.28	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
HNSC	cis	rs2404602	0.692	rs34478400	ENSG00000259422.1	RP11-593F23.1	6.18	1.36e-09	6.61e-07	0.32	0.28	Blood metabolite levels;	chr15:76631169	chr15:76174891~76181486:-
HNSC	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	6.18	1.36e-09	6.61e-07	0.41	0.28	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.626	rs737841	ENSG00000211638.2	IGLV8-61	-6.18	1.36e-09	6.62e-07	-0.27	-0.28	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22098700~22099212:+
HNSC	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-6.18	1.36e-09	6.62e-07	-0.68	-0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.513	rs149972	ENSG00000204709.4	LINC01556	6.18	1.36e-09	6.62e-07	0.35	0.28	Parkinson's disease;	chr6:28015449	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149975	ENSG00000204709.4	LINC01556	6.18	1.36e-09	6.62e-07	0.35	0.28	Parkinson's disease;	chr6:28018562	chr6:28943877~28944537:+
HNSC	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-6.18	1.36e-09	6.62e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.545	rs3167757	ENSG00000255568.3	BRWD1-AS2	6.18	1.36e-09	6.63e-07	0.23	0.28	Cognitive function;	chr21:39342552	chr21:39313935~39314962:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	6.18	1.36e-09	6.64e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	6.18	1.36e-09	6.64e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
HNSC	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	6.18	1.37e-09	6.64e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
HNSC	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-6.18	1.37e-09	6.64e-07	-0.29	-0.28	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
HNSC	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
HNSC	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-6.18	1.37e-09	6.65e-07	-0.34	-0.28	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	6.18	1.37e-09	6.65e-07	0.32	0.28	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
HNSC	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-6.18	1.37e-09	6.66e-07	-0.24	-0.28	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
HNSC	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	6.18	1.37e-09	6.66e-07	0.33	0.28	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
HNSC	cis	rs2337406	1	rs17113276	ENSG00000211974.3	IGHV2-70	6.18	1.37e-09	6.67e-07	0.33	0.28	Alzheimer's disease (late onset);	chr14:106683485	chr14:106723574~106724093:-
HNSC	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-6.18	1.37e-09	6.67e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
HNSC	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	6.18	1.38e-09	6.69e-07	0.26	0.28	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
HNSC	cis	rs17507216	0.628	rs28737193	ENSG00000255769.6	GOLGA2P10	-6.18	1.38e-09	6.69e-07	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82701318	chr15:82472993~82513950:-
HNSC	cis	rs2337406	1	rs1858677	ENSG00000211974.3	IGHV2-70	-6.18	1.38e-09	6.69e-07	-0.33	-0.28	Alzheimer's disease (late onset);	chr14:106706828	chr14:106723574~106724093:-
HNSC	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-6.18	1.38e-09	6.69e-07	-0.26	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
HNSC	cis	rs2337406	1	rs11849532	ENSG00000211974.3	IGHV2-70	-6.18	1.38e-09	6.7e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106669877	chr14:106723574~106724093:-
HNSC	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-6.18	1.38e-09	6.7e-07	-0.3	-0.28	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
HNSC	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-6.18	1.38e-09	6.7e-07	-0.31	-0.28	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
HNSC	cis	rs4639966	0.758	rs11217013	ENSG00000255422.1	AP002954.4	6.18	1.38e-09	6.71e-07	0.37	0.28	Systemic lupus erythematosus;	chr11:118754210	chr11:118704607~118750263:+
HNSC	cis	rs7824557	0.547	rs4512344	ENSG00000269918.1	AF131215.9	-6.18	1.38e-09	6.71e-07	-0.27	-0.28	Retinal vascular caliber;	chr8:11221272	chr8:11104691~11106704:-
HNSC	cis	rs7404843	0.789	rs222909	ENSG00000263335.1	AF001548.5	6.18	1.38e-09	6.71e-07	0.5	0.28	Testicular germ cell tumor;	chr16:15405432	chr16:15726674~15732993:+
HNSC	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-6.18	1.38e-09	6.71e-07	-0.26	-0.28	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
HNSC	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-6.18	1.38e-09	6.71e-07	-0.29	-0.28	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-6.18	1.38e-09	6.71e-07	-0.29	-0.28	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
HNSC	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	6.18	1.38e-09	6.72e-07	0.31	0.28	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
HNSC	cis	rs4657482	0.606	rs3790665	ENSG00000236364.3	RP11-525G13.2	6.18	1.38e-09	6.72e-07	0.29	0.28	Testicular germ cell tumor;	chr1:165900834	chr1:165890795~165900683:-
HNSC	cis	rs1021993	0.597	rs1395753	ENSG00000231648.1	RP11-372M18.2	-6.18	1.38e-09	6.72e-07	-0.46	-0.28	Gut microbiome composition (winter);	chr1:209317182	chr1:209367662~209379690:+
HNSC	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	6.18	1.39e-09	6.75e-07	0.3	0.27	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
HNSC	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
HNSC	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-6.18	1.39e-09	6.76e-07	-0.35	-0.27	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
HNSC	cis	rs4657482	0.607	rs473222	ENSG00000236364.3	RP11-525G13.2	-6.18	1.39e-09	6.76e-07	-0.28	-0.27	Testicular germ cell tumor;	chr1:165907341	chr1:165890795~165900683:-
HNSC	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	6.18	1.39e-09	6.77e-07	0.37	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	6.18	1.39e-09	6.77e-07	0.37	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
HNSC	cis	rs4218	0.597	rs12438208	ENSG00000259732.1	RP11-59H7.3	-6.18	1.4e-09	6.78e-07	-0.39	-0.27	Social communication problems;	chr15:59057715	chr15:59121034~59133250:+
HNSC	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-6.18	1.4e-09	6.78e-07	-0.37	-0.27	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-6.18	1.4e-09	6.78e-07	-0.37	-0.27	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
HNSC	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	1.4e-09	6.78e-07	-0.3	-0.27	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
HNSC	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	1.4e-09	6.78e-07	-0.3	-0.27	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
HNSC	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-6.18	1.4e-09	6.78e-07	-0.39	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-6.18	1.4e-09	6.78e-07	-0.39	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
HNSC	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	6.18	1.4e-09	6.79e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
HNSC	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-6.18	1.4e-09	6.8e-07	-0.4	-0.27	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
HNSC	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	6.18	1.4e-09	6.8e-07	0.36	0.27	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
HNSC	cis	rs9813712	0.953	rs7619208	ENSG00000249846.5	RP11-77P16.4	-6.18	1.4e-09	6.82e-07	-0.33	-0.27	Response to amphetamines;	chr3:130258163	chr3:130112550~130120579:+
HNSC	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	6.18	1.41e-09	6.82e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
HNSC	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-6.18	1.41e-09	6.82e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
HNSC	cis	rs6471393	0.83	rs57803852	ENSG00000253848.1	RP11-10N23.5	6.18	1.41e-09	6.83e-07	0.33	0.27	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761156	chr8:93741193~93744534:+
HNSC	cis	rs4713118	0.513	rs9368547	ENSG00000204709.4	LINC01556	6.18	1.41e-09	6.84e-07	0.36	0.27	Parkinson's disease;	chr6:28060289	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs183244	ENSG00000204709.4	LINC01556	6.18	1.41e-09	6.84e-07	0.36	0.27	Parkinson's disease;	chr6:28064060	chr6:28943877~28944537:+
HNSC	cis	rs5753618	0.583	rs71324184	ENSG00000236132.1	CTA-440B3.1	-6.18	1.41e-09	6.85e-07	-0.32	-0.27	Colorectal cancer;	chr22:31356075	chr22:31816379~31817491:-
HNSC	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-6.18	1.41e-09	6.86e-07	-0.39	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
HNSC	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-6.18	1.41e-09	6.86e-07	-0.3	-0.27	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
HNSC	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	6.18	1.42e-09	6.86e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	6.18	1.42e-09	6.86e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	6.18	1.42e-09	6.86e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
HNSC	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	6.18	1.42e-09	6.86e-07	0.25	0.27	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
HNSC	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-6.18	1.42e-09	6.86e-07	-0.24	-0.27	Height;	chr11:118703207	chr11:118791254~118793137:+
HNSC	cis	rs4657482	0.607	rs3790671	ENSG00000236364.3	RP11-525G13.2	6.18	1.42e-09	6.87e-07	0.29	0.27	Testicular germ cell tumor;	chr1:165904085	chr1:165890795~165900683:-
HNSC	cis	rs4657482	0.607	rs3790672	ENSG00000236364.3	RP11-525G13.2	-6.18	1.42e-09	6.87e-07	-0.29	-0.27	Testicular germ cell tumor;	chr1:165904155	chr1:165890795~165900683:-
HNSC	cis	rs853679	0.55	rs34477097	ENSG00000204709.4	LINC01556	6.18	1.42e-09	6.87e-07	0.37	0.27	Depression;	chr6:28229408	chr6:28943877~28944537:+
HNSC	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-6.18	1.42e-09	6.89e-07	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
HNSC	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
HNSC	cis	rs8012947	0.877	rs12879675	ENSG00000279636.2	LINC00216	-6.18	1.43e-09	6.93e-07	-0.34	-0.27	Alcohol consumption in current drinkers;	chr14:58240535	chr14:58288033~58289158:+
HNSC	cis	rs2070074	0.591	rs3739882	ENSG00000230074.1	RP11-195F19.9	6.18	1.43e-09	6.93e-07	0.61	0.27	CTACK levels;	chr9:34653112	chr9:34665665~34681298:+
HNSC	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-6.18	1.43e-09	6.93e-07	-0.33	-0.27	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
HNSC	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-6.18	1.43e-09	6.94e-07	-0.26	-0.27	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-6.18	1.43e-09	6.94e-07	-0.26	-0.27	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
HNSC	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-6.18	1.43e-09	6.95e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
HNSC	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	6.18	1.43e-09	6.95e-07	0.31	0.27	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	6.18	1.43e-09	6.95e-07	0.31	0.27	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
HNSC	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-6.18	1.44e-09	6.96e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
HNSC	cis	rs6951245	1	rs80212261	ENSG00000225146.1	AC073957.15	-6.17	1.44e-09	6.97e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77346188	ENSG00000225146.1	AC073957.15	-6.17	1.44e-09	6.97e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1029025~1043891:+
HNSC	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	6.17	1.44e-09	6.97e-07	0.33	0.27	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
HNSC	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	6.17	1.44e-09	6.98e-07	0.36	0.27	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
HNSC	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	6.17	1.44e-09	6.98e-07	0.33	0.27	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
HNSC	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	6.17	1.44e-09	6.99e-07	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
HNSC	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-6.17	1.45e-09	7.01e-07	-0.39	-0.27	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
HNSC	cis	rs2115630	0.645	rs4842978	ENSG00000229212.6	RP11-561C5.4	6.17	1.45e-09	7.01e-07	0.32	0.27	P wave terminal force;	chr15:84654022	chr15:85205440~85234795:-
HNSC	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	6.17	1.45e-09	7.01e-07	0.26	0.27	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	6.17	1.45e-09	7.01e-07	0.22	0.27	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
HNSC	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	6.17	1.45e-09	7.03e-07	0.37	0.27	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
HNSC	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	6.17	1.45e-09	7.03e-07	0.36	0.27	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
HNSC	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	6.17	1.45e-09	7.03e-07	0.46	0.27	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
HNSC	cis	rs7615952	0.673	rs35955861	ENSG00000248787.1	RP11-666A20.4	-6.17	1.45e-09	7.03e-07	-0.49	-0.27	Blood pressure (smoking interaction);	chr3:125907358	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.673	rs35001498	ENSG00000248787.1	RP11-666A20.4	-6.17	1.45e-09	7.03e-07	-0.49	-0.27	Blood pressure (smoking interaction);	chr3:125909801	chr3:125908005~125910272:-
HNSC	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	6.17	1.45e-09	7.03e-07	0.46	0.27	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
HNSC	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-6.17	1.45e-09	7.03e-07	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
HNSC	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	6.17	1.45e-09	7.04e-07	0.3	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
HNSC	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-6.17	1.46e-09	7.07e-07	-0.33	-0.27	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
HNSC	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-6.17	1.46e-09	7.08e-07	-0.31	-0.27	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
HNSC	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-6.17	1.47e-09	7.09e-07	-0.32	-0.27	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
HNSC	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	6.17	1.47e-09	7.11e-07	0.34	0.27	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
HNSC	cis	rs35955747	0.869	rs5997909	ENSG00000236132.1	CTA-440B3.1	6.17	1.47e-09	7.11e-07	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31195242	chr22:31816379~31817491:-
HNSC	cis	rs4218	0.689	rs12900369	ENSG00000259732.1	RP11-59H7.3	-6.17	1.47e-09	7.12e-07	-0.39	-0.27	Social communication problems;	chr15:59099254	chr15:59121034~59133250:+
HNSC	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-6.17	1.47e-09	7.12e-07	-0.29	-0.27	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
HNSC	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	6.17	1.47e-09	7.12e-07	0.32	0.27	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
HNSC	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-6.17	1.48e-09	7.14e-07	-0.25	-0.27	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
HNSC	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	6.17	1.48e-09	7.14e-07	0.3	0.27	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
HNSC	cis	rs8054556	0.76	rs12598856	ENSG00000183604.13	SMG1P5	-6.17	1.48e-09	7.15e-07	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30018227	chr16:30267553~30335374:-
HNSC	cis	rs853679	1	rs9986596	ENSG00000219392.1	RP1-265C24.5	-6.17	1.48e-09	7.16e-07	-0.41	-0.27	Depression;	chr6:28251883	chr6:28115628~28116551:+
HNSC	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	6.17	1.48e-09	7.16e-07	0.29	0.27	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
HNSC	cis	rs11992162	0.597	rs6996342	ENSG00000206014.6	OR7E161P	6.17	1.48e-09	7.16e-07	0.3	0.27	Monocyte count;	chr8:11927032	chr8:11928597~11929563:-
HNSC	cis	rs9326248	0.53	rs2000615	ENSG00000280143.1	AP000892.6	6.17	1.48e-09	7.17e-07	0.42	0.27	Blood protein levels;	chr11:117045103	chr11:117204967~117210292:+
HNSC	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-6.17	1.48e-09	7.17e-07	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-6.17	1.48e-09	7.17e-07	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
HNSC	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-6.17	1.48e-09	7.18e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-6.17	1.48e-09	7.18e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
HNSC	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	6.17	1.48e-09	7.18e-07	0.27	0.27	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
HNSC	cis	rs2404602	0.692	rs8024476	ENSG00000259422.1	RP11-593F23.1	6.17	1.49e-09	7.18e-07	0.31	0.27	Blood metabolite levels;	chr15:76691613	chr15:76174891~76181486:-
HNSC	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.17	1.49e-09	7.18e-07	0.28	0.27	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
HNSC	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-6.17	1.49e-09	7.18e-07	-0.32	-0.27	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
HNSC	cis	rs7674212	0.541	rs2720471	ENSG00000246560.2	RP11-10L12.4	6.17	1.49e-09	7.19e-07	0.31	0.27	Type 2 diabetes;	chr4:103102683	chr4:102828055~102844075:+
HNSC	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-6.17	1.49e-09	7.19e-07	-0.3	-0.27	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
HNSC	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	6.17	1.49e-09	7.2e-07	0.36	0.27	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000173295.6	FAM86B3P	-6.17	1.49e-09	7.21e-07	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9015783	chr8:8228595~8244865:+
HNSC	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-6.17	1.49e-09	7.21e-07	-0.3	-0.27	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
HNSC	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	6.17	1.49e-09	7.22e-07	0.27	0.27	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
HNSC	cis	rs9341808	0.667	rs2490244	ENSG00000272129.1	RP11-250B2.6	6.17	1.49e-09	7.22e-07	0.32	0.27	Sitting height ratio;	chr6:80181395	chr6:80355424~80356859:+
HNSC	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	6.17	1.49e-09	7.22e-07	0.25	0.27	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
HNSC	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-6.17	1.5e-09	7.22e-07	-0.32	-0.27	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
HNSC	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
HNSC	cis	rs440932	1	rs440932	ENSG00000173295.6	FAM86B3P	6.17	1.5e-09	7.26e-07	0.33	0.27	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8228595~8244865:+
HNSC	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	6.17	1.51e-09	7.27e-07	0.36	0.27	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	6.17	1.51e-09	7.27e-07	0.36	0.27	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
HNSC	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-6.17	1.51e-09	7.28e-07	-0.37	-0.27	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
HNSC	cis	rs9329221	0.682	rs6982308	ENSG00000269918.1	AF131215.9	-6.17	1.51e-09	7.28e-07	-0.27	-0.27	Neuroticism;	chr8:10336262	chr8:11104691~11106704:-
HNSC	cis	rs7209700	0.662	rs8066295	ENSG00000228782.6	CTD-2026D20.3	6.17	1.51e-09	7.28e-07	0.29	0.27	IgG glycosylation;	chr17:47270837	chr17:47450568~47492492:-
HNSC	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-6.17	1.51e-09	7.29e-07	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
HNSC	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-6.17	1.51e-09	7.29e-07	-0.29	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
HNSC	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-6.17	1.51e-09	7.29e-07	-0.29	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-6.17	1.52e-09	7.31e-07	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
HNSC	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	6.17	1.52e-09	7.32e-07	0.27	0.27	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
HNSC	cis	rs6928977	0.675	rs11154803	ENSG00000234084.1	RP3-388E23.2	-6.17	1.52e-09	7.32e-07	-0.28	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135301568~135307158:+
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000254340.1	RP11-10A14.3	-6.17	1.52e-09	7.32e-07	-0.34	-0.27	Mood instability;	chr8:8828136	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	6.17	1.52e-09	7.32e-07	0.37	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
HNSC	cis	rs9402743	0.666	rs9385737	ENSG00000217482.2	HMGB1P17	6.17	1.52e-09	7.33e-07	0.29	0.27	Systemic lupus erythematosus;	chr6:135759379	chr6:135636086~135636713:-
HNSC	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	6.17	1.52e-09	7.33e-07	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
HNSC	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	6.17	1.52e-09	7.33e-07	0.38	0.27	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
HNSC	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
HNSC	cis	rs11992162	0.591	rs35657308	ENSG00000206014.6	OR7E161P	6.17	1.52e-09	7.34e-07	0.29	0.27	Monocyte count;	chr8:11946893	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	6.17	1.52e-09	7.35e-07	0.33	0.27	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
HNSC	cis	rs7826238	0.623	rs2976893	ENSG00000254153.1	CTA-398F10.2	-6.17	1.53e-09	7.36e-07	-0.3	-0.27	Systolic blood pressure;	chr8:8480709	chr8:8456909~8461337:-
HNSC	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-6.16	1.53e-09	7.37e-07	-0.29	-0.27	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
HNSC	cis	rs8054556	0.787	rs12325400	ENSG00000183604.13	SMG1P5	-6.16	1.53e-09	7.37e-07	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30267553~30335374:-
HNSC	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-6.16	1.53e-09	7.37e-07	-0.27	-0.27	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.673	rs9841194	ENSG00000241288.6	RP11-379B18.5	-6.16	1.53e-09	7.37e-07	-0.47	-0.27	Blood pressure (smoking interaction);	chr3:125916896	chr3:125827238~125916384:-
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	6.16	1.53e-09	7.38e-07	0.31	0.27	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
HNSC	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	6.16	1.53e-09	7.38e-07	0.32	0.27	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	6.16	1.53e-09	7.38e-07	0.21	0.27	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
HNSC	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	6.16	1.53e-09	7.39e-07	0.32	0.27	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
HNSC	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-6.16	1.53e-09	7.39e-07	-0.38	-0.27	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
HNSC	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-6.16	1.53e-09	7.39e-07	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-6.16	1.53e-09	7.39e-07	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
HNSC	cis	rs116095464	1	rs62331562	ENSG00000277812.1	AC021087.1	6.16	1.54e-09	7.42e-07	0.68	0.27	Breast cancer;	chr5:349183	chr5:262769~262881:+
HNSC	cis	rs6951245	1	rs884977	ENSG00000225146.1	AC073957.15	-6.16	1.54e-09	7.43e-07	-0.42	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1026774	chr7:1029025~1043891:+
HNSC	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	6.16	1.54e-09	7.43e-07	0.41	0.27	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
HNSC	cis	rs2235642	0.505	rs56359342	ENSG00000280231.1	LA16c-380F5.3	-6.16	1.54e-09	7.43e-07	-0.34	-0.27	Coronary artery disease;	chr16:1604947	chr16:1553655~1554130:-
HNSC	cis	rs7824557	0.547	rs2409749	ENSG00000269918.1	AF131215.9	-6.16	1.54e-09	7.44e-07	-0.27	-0.27	Retinal vascular caliber;	chr8:11221440	chr8:11104691~11106704:-
HNSC	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	6.16	1.55e-09	7.44e-07	0.36	0.27	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	6.16	1.55e-09	7.44e-07	0.36	0.27	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
HNSC	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-6.16	1.55e-09	7.47e-07	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-6.16	1.55e-09	7.47e-07	-0.37	-0.27	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-6.16	1.55e-09	7.47e-07	-0.37	-0.27	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-6.16	1.55e-09	7.47e-07	-0.37	-0.27	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
HNSC	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	6.16	1.56e-09	7.49e-07	0.63	0.27	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
HNSC	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-6.16	1.56e-09	7.52e-07	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
HNSC	cis	rs11089937	0.637	rs988200	ENSG00000211638.2	IGLV8-61	-6.16	1.56e-09	7.52e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22098700~22099212:+
HNSC	cis	rs9611519	0.78	rs3171692	ENSG00000235513.1	RP4-756G23.5	6.16	1.56e-09	7.53e-07	0.29	0.27	Neuroticism;	chr22:41246208	chr22:41209122~41217627:-
HNSC	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	6.16	1.56e-09	7.53e-07	0.26	0.27	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
HNSC	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	6.16	1.57e-09	7.54e-07	0.31	0.27	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.539	rs12486944	ENSG00000228638.1	FCF1P2	-6.16	1.57e-09	7.55e-07	-0.24	-0.27	Coronary artery disease;	chr3:48348526	chr3:48290793~48291375:-
HNSC	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	6.16	1.57e-09	7.55e-07	0.34	0.27	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
HNSC	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	6.16	1.57e-09	7.55e-07	0.26	0.27	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
HNSC	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	6.16	1.57e-09	7.56e-07	0.32	0.27	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
HNSC	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-6.16	1.57e-09	7.57e-07	-0.36	-0.27	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
HNSC	cis	rs1799949	0.965	rs799910	ENSG00000267151.3	RP11-100E5.2	6.16	1.57e-09	7.57e-07	0.35	0.27	Menopause (age at onset);	chr17:43127544	chr17:43444707~43451200:+
HNSC	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	6.16	1.57e-09	7.57e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
HNSC	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	6.16	1.57e-09	7.57e-07	0.36	0.27	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	6.16	1.57e-09	7.58e-07	0.38	0.27	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
HNSC	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-6.16	1.58e-09	7.58e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-6.16	1.58e-09	7.58e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
HNSC	cis	rs2337406	1	rs7145100	ENSG00000211974.3	IGHV2-70	-6.16	1.58e-09	7.59e-07	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106704673	chr14:106723574~106724093:-
HNSC	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	6.16	1.58e-09	7.6e-07	0.31	0.27	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
HNSC	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-6.16	1.58e-09	7.6e-07	-0.33	-0.27	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-6.16	1.58e-09	7.6e-07	-0.33	-0.27	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
HNSC	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	6.16	1.58e-09	7.6e-07	0.31	0.27	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
HNSC	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	6.16	1.58e-09	7.61e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	6.16	1.58e-09	7.61e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
HNSC	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-6.16	1.58e-09	7.61e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
HNSC	cis	rs17270561	0.636	rs9348696	ENSG00000272462.2	U91328.19	-6.16	1.58e-09	7.61e-07	-0.28	-0.27	Iron status biomarkers;	chr6:25781710	chr6:25992662~26001775:+
HNSC	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	6.16	1.58e-09	7.61e-07	0.36	0.27	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
HNSC	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	6.16	1.59e-09	7.62e-07	0.31	0.27	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
HNSC	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	6.16	1.59e-09	7.63e-07	0.28	0.27	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
HNSC	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.59e-09	7.64e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
HNSC	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	6.16	1.59e-09	7.64e-07	0.32	0.27	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
HNSC	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	6.16	1.59e-09	7.65e-07	0.32	0.27	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
HNSC	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-6.16	1.59e-09	7.65e-07	-0.32	-0.27	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	6.16	1.59e-09	7.65e-07	0.49	0.27	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
HNSC	cis	rs9326248	0.53	rs7950364	ENSG00000280143.1	AP000892.6	6.16	1.59e-09	7.65e-07	0.41	0.27	Blood protein levels;	chr11:117028170	chr11:117204967~117210292:+
HNSC	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-6.16	1.59e-09	7.65e-07	-0.46	-0.27	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
HNSC	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-6.16	1.59e-09	7.66e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
HNSC	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	6.16	1.59e-09	7.66e-07	0.26	0.27	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000254153.1	CTA-398F10.2	-6.16	1.6e-09	7.7e-07	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9037960	chr8:8456909~8461337:-
HNSC	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	6.16	1.6e-09	7.7e-07	0.27	0.27	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
HNSC	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-6.16	1.6e-09	7.71e-07	-0.36	-0.27	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
HNSC	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	6.16	1.6e-09	7.71e-07	0.37	0.27	Height;	chr6:109357908	chr6:109382795~109383666:+
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-6.16	1.6e-09	7.71e-07	-0.18	-0.27	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	6.16	1.61e-09	7.72e-07	0.24	0.27	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	6.16	1.61e-09	7.73e-07	0.22	0.27	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
HNSC	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-6.16	1.61e-09	7.75e-07	-0.46	-0.27	Depression;	chr6:28124907	chr6:28115628~28116551:+
HNSC	cis	rs35955747	0.869	rs9621216	ENSG00000236132.1	CTA-440B3.1	6.16	1.61e-09	7.75e-07	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31194222	chr22:31816379~31817491:-
HNSC	cis	rs11648785	0.777	rs12932473	ENSG00000222019.6	URAHP	6.16	1.61e-09	7.75e-07	0.28	0.27	Tanning;	chr16:90033981	chr16:90039761~90047773:-
HNSC	cis	rs867371	0.82	rs7164362	ENSG00000255769.6	GOLGA2P10	-6.16	1.62e-09	7.76e-07	-0.36	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472993~82513950:-
HNSC	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-6.16	1.62e-09	7.76e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
HNSC	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-6.15	1.62e-09	7.77e-07	-0.33	-0.27	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
HNSC	cis	rs9525927	0.57	rs7400099	ENSG00000227258.4	SMIM2-AS1	-6.15	1.62e-09	7.77e-07	-0.37	-0.27	Dupuytren's disease;	chr13:44230344	chr13:44110451~44240517:+
HNSC	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	6.15	1.62e-09	7.79e-07	0.3	0.27	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
HNSC	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	6.15	1.62e-09	7.79e-07	0.27	0.27	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	6.15	1.62e-09	7.8e-07	0.31	0.27	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
HNSC	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	6.15	1.62e-09	7.8e-07	0.36	0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
HNSC	cis	rs2985684	0.894	rs6572585	ENSG00000258568.1	RHOQP1	6.15	1.63e-09	7.81e-07	0.28	0.27	Carotid intima media thickness;	chr14:49554357	chr14:49599994~49600572:+
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000254153.1	CTA-398F10.2	6.15	1.63e-09	7.82e-07	0.3	0.27	Mood instability;	chr8:8521596	chr8:8456909~8461337:-
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000254153.1	CTA-398F10.2	6.15	1.63e-09	7.82e-07	0.3	0.27	Mood instability;	chr8:8521597	chr8:8456909~8461337:-
HNSC	cis	rs7615952	0.673	rs9289270	ENSG00000241288.6	RP11-379B18.5	-6.15	1.63e-09	7.83e-07	-0.47	-0.27	Blood pressure (smoking interaction);	chr3:125918136	chr3:125827238~125916384:-
HNSC	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	6.15	1.64e-09	7.85e-07	0.37	0.27	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
HNSC	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	6.15	1.64e-09	7.85e-07	0.31	0.27	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
HNSC	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	6.15	1.64e-09	7.86e-07	0.3	0.27	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
HNSC	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-6.15	1.64e-09	7.88e-07	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
HNSC	cis	rs8177876	0.749	rs79834398	ENSG00000261061.1	RP11-303E16.2	-6.15	1.64e-09	7.88e-07	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81030770~81031485:+
HNSC	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	6.15	1.64e-09	7.88e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	6.15	1.64e-09	7.88e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
HNSC	cis	rs9907295	0.591	rs3817655	ENSG00000270977.1	AC015849.16	6.15	1.64e-09	7.89e-07	0.33	0.27	Fibroblast growth factor basic levels;	chr17:35872637	chr17:35893707~35911023:-
HNSC	cis	rs453301	0.624	rs330049	ENSG00000254340.1	RP11-10A14.3	6.15	1.65e-09	7.9e-07	0.32	0.27	Joint mobility (Beighton score);	chr8:9229789	chr8:9141424~9145435:+
HNSC	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-6.15	1.65e-09	7.91e-07	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
HNSC	cis	rs4657482	0.639	rs12045367	ENSG00000236364.3	RP11-525G13.2	6.15	1.65e-09	7.91e-07	0.28	0.27	Testicular germ cell tumor;	chr1:165906735	chr1:165890795~165900683:-
HNSC	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	6.15	1.65e-09	7.91e-07	0.28	0.27	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
HNSC	cis	rs4218	0.597	rs12438962	ENSG00000277144.1	RP11-59H7.4	-6.15	1.65e-09	7.92e-07	-0.37	-0.27	Social communication problems;	chr15:59065694	chr15:59115547~59116089:-
HNSC	cis	rs11089937	0.626	rs2213161	ENSG00000211638.2	IGLV8-61	-6.15	1.65e-09	7.92e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22098700~22099212:+
HNSC	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	6.15	1.65e-09	7.92e-07	0.34	0.27	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
HNSC	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-6.15	1.66e-09	7.94e-07	-0.35	-0.27	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
HNSC	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	6.15	1.66e-09	7.94e-07	0.28	0.27	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
HNSC	cis	rs2985684	0.895	rs4900940	ENSG00000258568.1	RHOQP1	6.15	1.66e-09	7.95e-07	0.28	0.27	Carotid intima media thickness;	chr14:49608592	chr14:49599994~49600572:+
HNSC	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	6.15	1.66e-09	7.96e-07	0.33	0.27	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	6.15	1.66e-09	7.96e-07	0.38	0.27	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	6.15	1.66e-09	7.96e-07	0.38	0.27	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
HNSC	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	6.15	1.66e-09	7.97e-07	0.31	0.27	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
HNSC	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	6.15	1.66e-09	7.97e-07	0.33	0.27	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
HNSC	cis	rs7804306	1	rs73050915	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8010614	chr7:7980312~7982228:+
HNSC	cis	rs7804306	1	rs73050929	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8019638	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050940	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027882	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs56142807	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8028562	chr7:7980312~7982228:+
HNSC	cis	rs11992162	0.551	rs35010200	ENSG00000206014.6	OR7E161P	6.15	1.67e-09	7.99e-07	0.3	0.27	Monocyte count;	chr8:11928146	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000233609.3	RP11-62H7.2	-6.15	1.67e-09	8e-07	-0.26	-0.27	Mood instability;	chr8:8939092	chr8:8961200~8979025:+
HNSC	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-6.15	1.67e-09	8e-07	-0.3	-0.27	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
HNSC	cis	rs12691307	1	rs12691307	ENSG00000183604.13	SMG1P5	-6.15	1.67e-09	8.01e-07	-0.26	-0.27	Schizophrenia;	chr16:29928556	chr16:30267553~30335374:-
HNSC	cis	rs8177876	0.642	rs12445303	ENSG00000261061.1	RP11-303E16.2	6.15	1.67e-09	8.01e-07	0.44	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81030770~81031485:+
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000254153.1	CTA-398F10.2	6.15	1.67e-09	8.02e-07	0.3	0.27	Mood instability;	chr8:8521482	chr8:8456909~8461337:-
HNSC	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	6.15	1.68e-09	8.03e-07	0.31	0.27	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	6.15	1.68e-09	8.03e-07	0.31	0.27	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	6.15	1.68e-09	8.03e-07	0.31	0.27	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
HNSC	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-6.15	1.68e-09	8.03e-07	-0.33	-0.27	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
HNSC	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-6.15	1.68e-09	8.04e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
HNSC	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	6.15	1.69e-09	8.08e-07	0.28	0.27	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
HNSC	cis	rs7048146	0.668	rs7341726	ENSG00000213539.4	YBX1P6	6.15	1.69e-09	8.09e-07	0.31	0.27	Vascular brain injury;	chr9:109513495	chr9:109532830~109534332:-
HNSC	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-6.15	1.69e-09	8.09e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
HNSC	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-6.15	1.69e-09	8.1e-07	-0.44	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
HNSC	cis	rs4639966	0.836	rs11217018	ENSG00000255422.1	AP002954.4	6.15	1.69e-09	8.1e-07	0.37	0.27	Systemic lupus erythematosus;	chr11:118764656	chr11:118704607~118750263:+
HNSC	cis	rs2337406	0.85	rs75196489	ENSG00000211974.3	IGHV2-70	-6.15	1.69e-09	8.1e-07	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106699438	chr14:106723574~106724093:-
HNSC	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-6.15	1.69e-09	8.11e-07	-0.28	-0.27	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
HNSC	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-6.15	1.69e-09	8.11e-07	-0.33	-0.27	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
HNSC	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	6.15	1.69e-09	8.11e-07	0.31	0.27	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
HNSC	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-6.15	1.7e-09	8.12e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-6.15	1.7e-09	8.12e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000173295.6	FAM86B3P	-6.15	1.7e-09	8.12e-07	-0.31	-0.27	Mood instability;	chr8:8939009	chr8:8228595~8244865:+
HNSC	cis	rs17270561	0.609	rs1937127	ENSG00000272462.2	U91328.19	6.15	1.7e-09	8.13e-07	0.28	0.27	Iron status biomarkers;	chr6:25769644	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-6.15	1.7e-09	8.14e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-6.15	1.7e-09	8.14e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
HNSC	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	6.15	1.7e-09	8.14e-07	0.56	0.27	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
HNSC	cis	rs2239557	1	rs2239557	ENSG00000259065.1	RP5-1021I20.1	-6.15	1.7e-09	8.14e-07	-0.32	-0.27	Common traits (Other);	chr14:74085267	chr14:73787360~73803270:+
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-6.15	1.7e-09	8.16e-07	-0.33	-0.27	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
HNSC	cis	rs7621025	0.505	rs61789642	ENSG00000239213.4	NCK1-AS1	-6.15	1.71e-09	8.17e-07	-0.36	-0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390854	chr3:136841726~136862054:-
HNSC	cis	rs7621025	0.505	rs61789643	ENSG00000239213.4	NCK1-AS1	-6.15	1.71e-09	8.17e-07	-0.36	-0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390910	chr3:136841726~136862054:-
HNSC	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	6.15	1.71e-09	8.17e-07	0.37	0.27	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-6.15	1.71e-09	8.17e-07	-0.18	-0.27	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
HNSC	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-6.15	1.71e-09	8.18e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000233609.3	RP11-62H7.2	-6.15	1.71e-09	8.2e-07	-0.26	-0.27	Mood instability;	chr8:8937520	chr8:8961200~8979025:+
HNSC	cis	rs9341808	0.667	rs2490239	ENSG00000272129.1	RP11-250B2.6	6.14	1.71e-09	8.21e-07	0.32	0.27	Sitting height ratio;	chr6:80116572	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.746	rs7619865	ENSG00000228638.1	FCF1P2	-6.14	1.72e-09	8.21e-07	-0.25	-0.27	Coronary artery disease;	chr3:48329090	chr3:48290793~48291375:-
HNSC	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	6.14	1.72e-09	8.22e-07	0.22	0.27	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
HNSC	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	6.14	1.72e-09	8.22e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
HNSC	cis	rs11089937	0.597	rs9619812	ENSG00000211638.2	IGLV8-61	-6.14	1.72e-09	8.22e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22098700~22099212:+
HNSC	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-6.14	1.72e-09	8.23e-07	-0.37	-0.27	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
HNSC	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	6.14	1.72e-09	8.23e-07	0.69	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
HNSC	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-6.14	1.72e-09	8.23e-07	-0.34	-0.27	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
HNSC	cis	rs9300255	0.739	rs1402275	ENSG00000280120.1	RP11-546D6.3	6.14	1.72e-09	8.23e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123266348	chr12:123152324~123153377:-
HNSC	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
HNSC	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	6.14	1.72e-09	8.24e-07	0.28	0.27	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	6.14	1.72e-09	8.25e-07	0.22	0.27	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
HNSC	cis	rs34526934	0.565	rs34729309	ENSG00000226363.3	HAGLROS	6.14	1.72e-09	8.25e-07	0.36	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176169393	chr2:176177717~176179008:+
HNSC	cis	rs6928977	0.832	rs2614286	ENSG00000234084.1	RP3-388E23.2	-6.14	1.72e-09	8.25e-07	-0.27	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371533	chr6:135301568~135307158:+
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-6.14	1.73e-09	8.26e-07	-0.18	-0.27	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
HNSC	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	6.14	1.73e-09	8.26e-07	0.32	0.27	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
HNSC	cis	rs8031584	0.678	rs798086	ENSG00000260382.1	RP11-540B6.2	-6.14	1.73e-09	8.27e-07	-0.35	-0.27	Huntington's disease progression;	chr15:30837008	chr15:30882267~30883231:-
HNSC	cis	rs6951245	1	rs79327308	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.938	rs117729148	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79617366	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs111899361	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1029025~1043891:+
HNSC	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-6.14	1.73e-09	8.28e-07	-0.4	-0.27	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
HNSC	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	6.14	1.73e-09	8.29e-07	0.29	0.27	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
HNSC	cis	rs2836950	0.501	rs2070865	ENSG00000255568.3	BRWD1-AS2	-6.14	1.73e-09	8.29e-07	-0.23	-0.27	Menarche (age at onset);	chr21:39343593	chr21:39313935~39314962:+
HNSC	cis	rs2404602	0.692	rs7169663	ENSG00000259422.1	RP11-593F23.1	6.14	1.73e-09	8.29e-07	0.32	0.27	Blood metabolite levels;	chr15:76900502	chr15:76174891~76181486:-
HNSC	cis	rs8012947	1	rs8009527	ENSG00000279636.2	LINC00216	-6.14	1.74e-09	8.3e-07	-0.33	-0.27	Alcohol consumption in current drinkers;	chr14:58285394	chr14:58288033~58289158:+
HNSC	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	6.14	1.74e-09	8.3e-07	0.35	0.27	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
HNSC	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-6.14	1.74e-09	8.3e-07	-0.27	-0.27	Height;	chr2:231539118	chr2:231508426~231514339:-
HNSC	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-6.14	1.74e-09	8.3e-07	-0.38	-0.27	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
HNSC	cis	rs35955747	0.869	rs28715	ENSG00000236132.1	CTA-440B3.1	-6.14	1.74e-09	8.31e-07	-0.29	-0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334183	chr22:31816379~31817491:-
HNSC	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	6.14	1.74e-09	8.31e-07	0.37	0.27	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
HNSC	cis	rs7621025	0.617	rs12637102	ENSG00000273486.1	RP11-731C17.2	6.14	1.74e-09	8.32e-07	0.25	0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136837338~136839021:-
HNSC	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-6.14	1.74e-09	8.32e-07	-0.36	-0.27	Height;	chr6:109485060	chr6:109382795~109383666:+
HNSC	cis	rs17507216	0.588	rs28864981	ENSG00000255769.6	GOLGA2P10	-6.14	1.74e-09	8.33e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82695420	chr15:82472993~82513950:-
HNSC	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	6.14	1.74e-09	8.33e-07	0.18	0.27	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
HNSC	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-6.14	1.74e-09	8.34e-07	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
HNSC	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-6.14	1.75e-09	8.35e-07	-0.28	-0.27	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
HNSC	cis	rs2404602	0.669	rs17367297	ENSG00000259422.1	RP11-593F23.1	6.14	1.75e-09	8.36e-07	0.32	0.27	Blood metabolite levels;	chr15:76865685	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-6.14	1.75e-09	8.36e-07	-0.24	-0.27	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	6.14	1.75e-09	8.36e-07	0.22	0.27	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	6.14	1.75e-09	8.36e-07	0.22	0.27	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
HNSC	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-6.14	1.75e-09	8.37e-07	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
HNSC	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	6.14	1.76e-09	8.39e-07	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	6.14	1.76e-09	8.39e-07	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
HNSC	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	6.14	1.76e-09	8.39e-07	0.3	0.27	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
HNSC	cis	rs7804306	0.826	rs73049290	ENSG00000233264.2	AC006042.8	6.14	1.76e-09	8.4e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7992584	chr7:7980312~7982228:+
HNSC	cis	rs10129255	1	rs10137758	ENSG00000211972.2	IGHV3-66	6.14	1.76e-09	8.4e-07	0.21	0.27	Kawasaki disease;	chr14:106697673	chr14:106675017~106675544:-
HNSC	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-6.14	1.76e-09	8.41e-07	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
HNSC	cis	rs2235642	0.859	rs12599207	ENSG00000280231.1	LA16c-380F5.3	-6.14	1.77e-09	8.44e-07	-0.34	-0.27	Coronary artery disease;	chr16:1556444	chr16:1553655~1554130:-
HNSC	cis	rs8177876	0.822	rs4889231	ENSG00000261061.1	RP11-303E16.2	6.14	1.77e-09	8.44e-07	0.43	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81030770~81031485:+
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000233609.3	RP11-62H7.2	6.14	1.77e-09	8.45e-07	0.26	0.27	Joint mobility (Beighton score);	chr8:8967994	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000233609.3	RP11-62H7.2	6.14	1.77e-09	8.45e-07	0.26	0.27	Mood instability;	chr8:8968365	chr8:8961200~8979025:+
HNSC	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-6.14	1.77e-09	8.45e-07	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
HNSC	cis	rs2239557	1	rs2358633	ENSG00000259065.1	RP5-1021I20.1	6.14	1.77e-09	8.46e-07	0.32	0.27	Common traits (Other);	chr14:74180715	chr14:73787360~73803270:+
HNSC	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	6.14	1.78e-09	8.49e-07	0.33	0.27	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
HNSC	cis	rs1799949	0.965	rs2236762	ENSG00000267151.3	RP11-100E5.2	6.14	1.78e-09	8.5e-07	0.35	0.27	Menopause (age at onset);	chr17:43074658	chr17:43444707~43451200:+
HNSC	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	6.14	1.78e-09	8.51e-07	0.33	0.27	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-6.14	1.78e-09	8.51e-07	-0.21	-0.27	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
HNSC	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	6.14	1.78e-09	8.51e-07	0.34	0.27	Depression;	chr6:28399846	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	6.14	1.79e-09	8.52e-07	0.41	0.27	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
HNSC	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-6.14	1.79e-09	8.52e-07	-0.3	-0.27	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
HNSC	cis	rs2985684	0.894	rs10147029	ENSG00000258568.1	RHOQP1	-6.14	1.79e-09	8.55e-07	-0.27	-0.27	Carotid intima media thickness;	chr14:49553514	chr14:49599994~49600572:+
HNSC	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	6.14	1.79e-09	8.55e-07	0.27	0.27	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
HNSC	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-6.14	1.8e-09	8.56e-07	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
HNSC	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	6.14	1.8e-09	8.56e-07	0.3	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
HNSC	cis	rs2404602	0.692	rs12595586	ENSG00000259422.1	RP11-593F23.1	6.14	1.8e-09	8.56e-07	0.32	0.27	Blood metabolite levels;	chr15:76879869	chr15:76174891~76181486:-
HNSC	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-6.14	1.8e-09	8.57e-07	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
HNSC	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	6.14	1.8e-09	8.58e-07	0.34	0.27	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
HNSC	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	6.14	1.8e-09	8.59e-07	0.31	0.27	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
HNSC	cis	rs860295	0.836	rs35615695	ENSG00000203761.5	MSTO2P	6.14	1.8e-09	8.59e-07	0.2	0.27	Body mass index;	chr1:155531223	chr1:155745829~155750137:+
HNSC	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	6.14	1.8e-09	8.6e-07	0.36	0.27	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
HNSC	cis	rs889014	1	rs889014	ENSG00000253768.1	CTB-33O18.1	6.14	1.81e-09	8.62e-07	0.29	0.27	Height;	chr5:173557111	chr5:173562478~173573199:+
HNSC	cis	rs11089937	1	rs6001121	ENSG00000211639.2	IGLV4-60	6.14	1.81e-09	8.63e-07	0.25	0.27	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22162199~22162681:+
HNSC	cis	rs8177876	0.822	rs804902	ENSG00000261061.1	RP11-303E16.2	-6.14	1.81e-09	8.63e-07	-0.42	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.692	rs35999717	ENSG00000259422.1	RP11-593F23.1	6.14	1.81e-09	8.64e-07	0.32	0.27	Blood metabolite levels;	chr15:76901026	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs58889902	ENSG00000259422.1	RP11-593F23.1	6.14	1.81e-09	8.64e-07	0.32	0.27	Blood metabolite levels;	chr15:76880729	chr15:76174891~76181486:-
HNSC	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-6.14	1.82e-09	8.66e-07	-0.34	-0.27	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
HNSC	cis	rs860295	0.871	rs11582072	ENSG00000203761.5	MSTO2P	6.14	1.82e-09	8.66e-07	0.2	0.27	Body mass index;	chr1:155507779	chr1:155745829~155750137:+
HNSC	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	6.13	1.82e-09	8.67e-07	0.37	0.27	Height;	chr6:109359747	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	6.13	1.82e-09	8.67e-07	0.37	0.27	Height;	chr6:109361318	chr6:109382795~109383666:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	6.13	1.82e-09	8.68e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
HNSC	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	6.13	1.82e-09	8.69e-07	0.34	0.27	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
HNSC	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	6.13	1.82e-09	8.69e-07	0.34	0.27	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
HNSC	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	6.13	1.82e-09	8.69e-07	0.34	0.27	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
HNSC	cis	rs2239557	1	rs2072293	ENSG00000259065.1	RP5-1021I20.1	-6.13	1.82e-09	8.69e-07	-0.32	-0.27	Common traits (Other);	chr14:74071182	chr14:73787360~73803270:+
HNSC	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	6.13	1.83e-09	8.71e-07	0.37	0.27	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
HNSC	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-6.13	1.83e-09	8.71e-07	-0.33	-0.27	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
HNSC	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	6.13	1.83e-09	8.71e-07	0.35	0.27	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
HNSC	cis	rs947583	0.588	rs9321532	ENSG00000217482.2	HMGB1P17	-6.13	1.83e-09	8.72e-07	-0.3	-0.27	Phosphorus levels;	chr6:135791078	chr6:135636086~135636713:-
HNSC	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-6.13	1.83e-09	8.73e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
HNSC	cis	rs1021993	0.672	rs2843173	ENSG00000231648.1	RP11-372M18.2	6.13	1.83e-09	8.73e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209313696	chr1:209367662~209379690:+
HNSC	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-6.13	1.83e-09	8.73e-07	-0.27	-0.27	Height;	chr2:231543307	chr2:231508426~231514339:-
HNSC	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-6.13	1.84e-09	8.74e-07	-0.46	-0.27	Depression;	chr6:28119105	chr6:28115628~28116551:+
HNSC	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-6.13	1.84e-09	8.76e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
HNSC	cis	rs2337406	1	rs78857163	ENSG00000211974.3	IGHV2-70	-6.13	1.84e-09	8.76e-07	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106707435	chr14:106723574~106724093:-
HNSC	cis	rs8012947	1	rs2348072	ENSG00000279636.2	LINC00216	-6.13	1.85e-09	8.78e-07	-0.33	-0.27	Alcohol consumption in current drinkers;	chr14:58277034	chr14:58288033~58289158:+
HNSC	cis	rs4218	0.689	rs28391430	ENSG00000259732.1	RP11-59H7.3	-6.13	1.85e-09	8.78e-07	-0.38	-0.27	Social communication problems;	chr15:59100318	chr15:59121034~59133250:+
HNSC	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	6.13	1.85e-09	8.78e-07	0.32	0.27	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
HNSC	cis	rs867371	0.896	rs8033831	ENSG00000276710.3	CSPG4P8	-6.13	1.85e-09	8.79e-07	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82459472~82477258:+
HNSC	cis	rs6951245	0.572	rs11559183	ENSG00000224079.1	AC091729.7	-6.13	1.85e-09	8.79e-07	-0.58	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:997389	chr7:1074450~1078036:+
HNSC	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	6.13	1.85e-09	8.79e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
HNSC	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	6.13	1.85e-09	8.79e-07	0.34	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
HNSC	cis	rs4218	0.689	rs28514475	ENSG00000259732.1	RP11-59H7.3	-6.13	1.85e-09	8.8e-07	-0.38	-0.27	Social communication problems;	chr15:59099896	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.689	rs28610479	ENSG00000259732.1	RP11-59H7.3	-6.13	1.85e-09	8.8e-07	-0.38	-0.27	Social communication problems;	chr15:59099906	chr15:59121034~59133250:+
HNSC	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-6.13	1.85e-09	8.8e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
HNSC	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
HNSC	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-6.13	1.85e-09	8.81e-07	-0.33	-0.27	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
HNSC	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	6.13	1.86e-09	8.82e-07	0.26	0.27	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
HNSC	cis	rs9300255	0.739	rs1969354	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123257229	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs1533703	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123257546	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs4759371	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123258016	chr12:123152324~123153377:-
HNSC	cis	rs63406760	1	rs63406760	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Allergic disease (asthma, hay fever or eczema);	chr12:123258146	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs2337934	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123260812	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.698	rs4759416	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123261810	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs4759417	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123261963	chr12:123152324~123153377:-
HNSC	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-6.13	1.86e-09	8.82e-07	-0.35	-0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
HNSC	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
HNSC	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	6.13	1.86e-09	8.83e-07	0.36	0.27	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
HNSC	cis	rs6951245	1	rs80094748	ENSG00000225146.1	AC073957.15	-6.13	1.86e-09	8.83e-07	-0.46	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1029025~1043891:+
HNSC	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-6.13	1.86e-09	8.84e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
HNSC	cis	rs8177876	0.642	rs10514513	ENSG00000261061.1	RP11-303E16.2	-6.13	1.86e-09	8.84e-07	-0.44	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81030770~81031485:+
HNSC	cis	rs9481169	0.557	rs34896684	ENSG00000255389.1	C6orf3	-6.13	1.86e-09	8.85e-07	-0.51	-0.27	Inflammatory skin disease;	chr6:111572034	chr6:111599875~111602295:+
HNSC	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-6.13	1.87e-09	8.86e-07	-0.27	-0.27	Height;	chr2:231556448	chr2:231508426~231514339:-
HNSC	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-6.13	1.87e-09	8.86e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
HNSC	cis	rs6951245	0.935	rs79143504	ENSG00000225146.1	AC073957.15	-6.13	1.87e-09	8.87e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1029025~1043891:+
HNSC	cis	rs17270561	0.636	rs9393671	ENSG00000272462.2	U91328.19	6.13	1.87e-09	8.87e-07	0.27	0.27	Iron status biomarkers;	chr6:25788961	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1179086	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25791517	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs1165157	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25792022	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1165156	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25792750	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1165155	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25795349	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs1165216	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25797743	chr6:25992662~26001775:+
HNSC	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	6.13	1.87e-09	8.88e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
HNSC	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-6.13	1.87e-09	8.89e-07	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-6.13	1.87e-09	8.89e-07	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
HNSC	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-6.13	1.87e-09	8.89e-07	-0.37	-0.27	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
HNSC	cis	rs14027	0.883	rs10087723	ENSG00000279347.1	RP11-85I17.2	-6.13	1.88e-09	8.91e-07	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119838736~119840385:-
HNSC	cis	rs2790457	0.958	rs2532741	ENSG00000254635.4	WAC-AS1	-6.13	1.88e-09	8.91e-07	-0.32	-0.27	Multiple myeloma;	chr10:28574879	chr10:28522652~28532743:-
HNSC	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-6.13	1.88e-09	8.91e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
HNSC	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-6.13	1.88e-09	8.93e-07	-0.32	-0.27	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-6.13	1.88e-09	8.93e-07	-0.32	-0.27	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
HNSC	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	6.13	1.88e-09	8.94e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
HNSC	cis	rs3743266	0.507	rs34092508	ENSG00000245534.5	RORA-AS1	-6.13	1.88e-09	8.94e-07	-0.43	-0.27	Menarche (age at onset);	chr15:60430780	chr15:60479178~60630637:+
HNSC	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-6.13	1.89e-09	8.96e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
HNSC	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-6.13	1.89e-09	8.96e-07	-0.3	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
HNSC	cis	rs988913	1	rs960834	ENSG00000224984.1	RP11-524H19.2	6.13	1.89e-09	8.97e-07	0.31	0.27	Menarche (age at onset);	chr6:54958633	chr6:54840118~54840855:-
HNSC	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	6.13	1.89e-09	8.97e-07	0.31	0.27	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
HNSC	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-6.13	1.89e-09	8.98e-07	-0.32	-0.27	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
HNSC	cis	rs8054556	0.787	rs11649274	ENSG00000183604.13	SMG1P5	-6.13	1.89e-09	8.98e-07	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30267553~30335374:-
HNSC	cis	rs7804306	0.826	rs56017154	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7995282	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049293	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999017	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049297	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999429	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049300	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8002315	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs58348680	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8005655	chr7:7980312~7982228:+
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	6.13	1.89e-09	8.99e-07	0.43	0.27	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-6.13	1.89e-09	8.99e-07	-0.18	-0.27	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
HNSC	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-6.13	1.89e-09	8.99e-07	-0.37	-0.27	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
HNSC	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-6.13	1.9e-09	8.99e-07	-0.32	-0.27	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.871	rs7829826	ENSG00000173295.6	FAM86B3P	-6.13	1.9e-09	8.99e-07	-0.31	-0.27	Mood instability;	chr8:8720610	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.692	rs36070630	ENSG00000259422.1	RP11-593F23.1	6.13	1.9e-09	9e-07	0.32	0.27	Blood metabolite levels;	chr15:76656918	chr15:76174891~76181486:-
HNSC	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-6.13	1.9e-09	9.01e-07	-0.32	-0.27	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
HNSC	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-6.13	1.9e-09	9.01e-07	-0.44	-0.27	Depression;	chr6:28129415	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
HNSC	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	6.13	1.9e-09	9.01e-07	0.59	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
HNSC	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	6.13	1.9e-09	9.01e-07	0.3	0.27	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	6.13	1.9e-09	9.01e-07	0.3	0.27	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
HNSC	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	6.13	1.91e-09	9.04e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
HNSC	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	6.13	1.91e-09	9.04e-07	0.33	0.27	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
HNSC	cis	rs2115630	0.653	rs61394864	ENSG00000229212.6	RP11-561C5.4	6.13	1.91e-09	9.05e-07	0.31	0.27	P wave terminal force;	chr15:84626943	chr15:85205440~85234795:-
HNSC	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	6.13	1.91e-09	9.05e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	6.13	1.91e-09	9.05e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
HNSC	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	6.13	1.91e-09	9.05e-07	0.35	0.27	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	6.13	1.91e-09	9.05e-07	0.32	0.27	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
HNSC	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-6.13	1.91e-09	9.06e-07	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-6.13	1.91e-09	9.06e-07	-0.34	-0.27	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
HNSC	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	6.13	1.92e-09	9.08e-07	0.63	0.27	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	6.13	1.92e-09	9.08e-07	0.63	0.27	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	6.13	1.92e-09	9.08e-07	0.63	0.27	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
HNSC	cis	rs17507216	0.718	rs7161977	ENSG00000255769.6	GOLGA2P10	-6.13	1.92e-09	9.09e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82646782	chr15:82472993~82513950:-
HNSC	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-6.13	1.92e-09	9.09e-07	-0.34	-0.27	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
HNSC	cis	rs1865760	0.613	rs9379801	ENSG00000272462.2	U91328.19	-6.13	1.92e-09	9.09e-07	-0.25	-0.27	Height;	chr6:25901483	chr6:25992662~26001775:+
HNSC	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	6.13	1.92e-09	9.1e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	6.13	1.92e-09	9.1e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
HNSC	cis	rs11846409	0.86	rs4774167	ENSG00000211974.3	IGHV2-70	-6.13	1.92e-09	9.11e-07	-0.31	-0.27	Rheumatic heart disease;	chr14:106619987	chr14:106723574~106724093:-
HNSC	cis	rs667920	0.512	rs13065626	ENSG00000239213.4	NCK1-AS1	-6.13	1.92e-09	9.11e-07	-0.34	-0.27	Coronary artery disease;	chr3:136575915	chr3:136841726~136862054:-
HNSC	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	6.13	1.93e-09	9.12e-07	0.3	0.27	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
HNSC	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	6.13	1.93e-09	9.12e-07	0.32	0.27	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
HNSC	cis	rs6081541	0.622	rs6035257	ENSG00000179447.2	RP5-1027G4.3	6.12	1.93e-09	9.13e-07	0.34	0.27	Psychosis (atypical);	chr20:19224067	chr20:19242302~19284596:-
HNSC	cis	rs6081541	0.622	rs6035259	ENSG00000179447.2	RP5-1027G4.3	6.12	1.93e-09	9.13e-07	0.34	0.27	Psychosis (atypical);	chr20:19225349	chr20:19242302~19284596:-
HNSC	cis	rs950776	0.695	rs1878399	ENSG00000261762.1	RP11-650L12.2	-6.12	1.93e-09	9.13e-07	-0.32	-0.27	Sudden cardiac arrest;	chr15:78619661	chr15:78589123~78591276:-
HNSC	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-6.12	1.93e-09	9.14e-07	-0.4	-0.27	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
HNSC	cis	rs17507216	0.628	rs8032321	ENSG00000255769.6	GOLGA2P10	-6.12	1.93e-09	9.14e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82698956	chr15:82472993~82513950:-
HNSC	cis	rs17507216	0.628	rs8040488	ENSG00000255769.6	GOLGA2P10	-6.12	1.93e-09	9.14e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82699081	chr15:82472993~82513950:-
HNSC	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	6.12	1.93e-09	9.15e-07	0.31	0.27	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
HNSC	cis	rs4218	0.648	rs35460138	ENSG00000259732.1	RP11-59H7.3	-6.12	1.94e-09	9.16e-07	-0.38	-0.27	Social communication problems;	chr15:59093200	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000254153.1	CTA-398F10.2	6.12	1.94e-09	9.18e-07	0.31	0.27	Joint mobility (Beighton score);	chr8:9034711	chr8:8456909~8461337:-
HNSC	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-6.12	1.94e-09	9.18e-07	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
HNSC	cis	rs2235642	0.928	rs9932984	ENSG00000280231.1	LA16c-380F5.3	-6.12	1.94e-09	9.19e-07	-0.33	-0.27	Coronary artery disease;	chr16:1555050	chr16:1553655~1554130:-
HNSC	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	6.12	1.94e-09	9.19e-07	0.36	0.27	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
HNSC	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-6.12	1.94e-09	9.19e-07	-0.29	-0.27	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
HNSC	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	6.12	1.95e-09	9.21e-07	0.29	0.27	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
HNSC	cis	rs947583	0.955	rs927330	ENSG00000217482.2	HMGB1P17	-6.12	1.95e-09	9.21e-07	-0.3	-0.27	Phosphorus levels;	chr6:135810618	chr6:135636086~135636713:-
HNSC	cis	rs4852324	0.536	rs17009553	ENSG00000217702.2	RP11-287D1.4	-6.12	1.95e-09	9.21e-07	-0.68	-0.27	Systemic lupus erythematosus;	chr2:73992908	chr2:74130583~74135395:+
HNSC	cis	rs8012947	1	rs7153897	ENSG00000279636.2	LINC00216	-6.12	1.95e-09	9.21e-07	-0.31	-0.27	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58288033~58289158:+
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000173295.6	FAM86B3P	6.12	1.95e-09	9.24e-07	0.31	0.27	Mood instability;	chr8:8797017	chr8:8228595~8244865:+
HNSC	cis	rs2243480	1	rs4149468	ENSG00000179406.6	LINC00174	-6.12	1.96e-09	9.25e-07	-0.57	-0.27	Diabetic kidney disease;	chr7:66360703	chr7:66376044~66401338:-
HNSC	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	6.12	1.96e-09	9.25e-07	0.34	0.27	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	6.12	1.96e-09	9.25e-07	0.34	0.27	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
HNSC	cis	rs11992162	0.55	rs61426048	ENSG00000206014.6	OR7E161P	6.12	1.96e-09	9.26e-07	0.3	0.27	Monocyte count;	chr8:11927447	chr8:11928597~11929563:-
HNSC	cis	rs11089937	0.626	rs4821784	ENSG00000211638.2	IGLV8-61	-6.12	1.96e-09	9.27e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22098700~22099212:+
HNSC	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	6.12	1.96e-09	9.27e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
HNSC	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-6.12	1.96e-09	9.27e-07	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
HNSC	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-6.12	1.97e-09	9.29e-07	-0.3	-0.27	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
HNSC	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-6.12	1.97e-09	9.3e-07	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
HNSC	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	6.12	1.97e-09	9.3e-07	0.43	0.27	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	6.12	1.97e-09	9.3e-07	0.32	0.27	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-6.12	1.97e-09	9.31e-07	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
HNSC	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-6.12	1.97e-09	9.32e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
HNSC	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-6.12	1.97e-09	9.32e-07	-0.22	-0.27	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
HNSC	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	6.12	1.97e-09	9.33e-07	0.33	0.27	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
HNSC	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	6.12	1.98e-09	9.33e-07	0.24	0.27	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
HNSC	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.33e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-6.12	1.98e-09	9.35e-07	-0.34	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
HNSC	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
HNSC	cis	rs6928977	0.66	rs9321508	ENSG00000217482.2	HMGB1P17	-6.12	1.98e-09	9.37e-07	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135556839	chr6:135636086~135636713:-
HNSC	cis	rs34526934	0.608	rs13017511	ENSG00000226363.3	HAGLROS	6.12	1.98e-09	9.37e-07	0.36	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176170667	chr2:176177717~176179008:+
HNSC	cis	rs947583	0.617	rs56048607	ENSG00000217482.2	HMGB1P17	6.12	1.98e-09	9.37e-07	0.3	0.27	Phosphorus levels;	chr6:135699171	chr6:135636086~135636713:-
HNSC	cis	rs2221433	1	rs2354423	ENSG00000260310.1	RP11-27M24.2	6.12	1.99e-09	9.38e-07	0.34	0.27	Eating disorders;	chr16:10578271	chr16:10576499~10578183:-
HNSC	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-6.12	1.99e-09	9.38e-07	-0.32	-0.27	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
HNSC	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-6.12	1.99e-09	9.38e-07	-0.28	-0.27	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-6.12	1.99e-09	9.41e-07	-0.32	-0.27	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
HNSC	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	6.12	1.99e-09	9.41e-07	0.31	0.27	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
HNSC	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-6.12	2e-09	9.42e-07	-0.33	-0.27	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
HNSC	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	6.12	2e-09	9.43e-07	0.34	0.27	Depression;	chr6:28402301	chr6:28943877~28944537:+
HNSC	cis	rs11846409	0.818	rs2516909	ENSG00000211974.3	IGHV2-70	6.12	2e-09	9.44e-07	0.31	0.27	Rheumatic heart disease;	chr14:106630317	chr14:106723574~106724093:-
HNSC	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	6.12	2e-09	9.45e-07	0.33	0.27	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	6.12	2e-09	9.45e-07	0.33	0.27	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	6.12	2e-09	9.45e-07	0.33	0.27	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
HNSC	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-6.12	2.01e-09	9.47e-07	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
HNSC	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-6.12	2.01e-09	9.48e-07	-0.3	-0.27	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
HNSC	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
HNSC	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	6.12	2.01e-09	9.48e-07	0.3	0.27	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000173295.6	FAM86B3P	-6.12	2.01e-09	9.49e-07	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9041808	chr8:8228595~8244865:+
HNSC	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	6.12	2.02e-09	9.5e-07	0.37	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
HNSC	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	6.12	2.02e-09	9.52e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
HNSC	cis	rs453301	0.631	rs28572014	ENSG00000254340.1	RP11-10A14.3	-6.12	2.02e-09	9.52e-07	-0.33	-0.27	Joint mobility (Beighton score);	chr8:8936097	chr8:9141424~9145435:+
HNSC	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	6.12	2.02e-09	9.53e-07	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	6.12	2.02e-09	9.53e-07	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
HNSC	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	6.12	2.02e-09	9.53e-07	0.29	0.27	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
HNSC	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-6.12	2.03e-09	9.55e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
HNSC	cis	rs35955747	0.778	rs9609263	ENSG00000236132.1	CTA-440B3.1	6.12	2.03e-09	9.55e-07	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31349288	chr22:31816379~31817491:-
HNSC	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-6.12	2.03e-09	9.55e-07	-0.31	-0.27	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
HNSC	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
HNSC	cis	rs7819412	0.745	rs2898260	ENSG00000269918.1	AF131215.9	-6.12	2.03e-09	9.57e-07	-0.27	-0.27	Triglycerides;	chr8:11081980	chr8:11104691~11106704:-
HNSC	cis	rs638893	0.673	rs538645	ENSG00000255422.1	AP002954.4	6.12	2.04e-09	9.59e-07	0.38	0.27	Vitiligo;	chr11:118840360	chr11:118704607~118750263:+
HNSC	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	6.12	2.04e-09	9.6e-07	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
HNSC	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-6.12	2.04e-09	9.6e-07	-0.32	-0.27	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
HNSC	cis	rs11089937	1	rs11089937	ENSG00000211638.2	IGLV8-61	-6.12	2.04e-09	9.6e-07	-0.24	-0.27	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22098700~22099212:+
HNSC	cis	rs17772222	0.651	rs12586714	ENSG00000258789.1	RP11-507K2.3	-6.12	2.04e-09	9.6e-07	-0.3	-0.27	Coronary artery calcification;	chr14:88360497	chr14:88551597~88552493:+
HNSC	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	6.12	2.04e-09	9.61e-07	0.64	0.27	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	6.12	2.04e-09	9.61e-07	0.64	0.27	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	6.12	2.04e-09	9.61e-07	0.64	0.27	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
HNSC	cis	rs4141404	0.706	rs5753698	ENSG00000236132.1	CTA-440B3.1	-6.11	2.04e-09	9.62e-07	-0.35	-0.27	Paclitaxel-induced neuropathy;	chr22:31574068	chr22:31816379~31817491:-
HNSC	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	6.11	2.04e-09	9.62e-07	0.36	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
HNSC	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	6.11	2.05e-09	9.63e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	6.11	2.05e-09	9.63e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
HNSC	cis	rs1021993	0.672	rs2247066	ENSG00000231648.1	RP11-372M18.2	6.11	2.05e-09	9.63e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209300349	chr1:209367662~209379690:+
HNSC	cis	rs17507216	0.681	rs28877110	ENSG00000255769.6	GOLGA2P10	-6.11	2.05e-09	9.65e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82672111	chr15:82472993~82513950:-
HNSC	cis	rs6991838	0.725	rs6995134	ENSG00000200714.1	Y_RNA	6.11	2.05e-09	9.65e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65592731~65592820:+
HNSC	cis	rs1021993	0.672	rs2660634	ENSG00000231648.1	RP11-372M18.2	6.11	2.05e-09	9.66e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209309668	chr1:209367662~209379690:+
HNSC	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-6.11	2.05e-09	9.66e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
HNSC	cis	rs1021993	0.672	rs2660633	ENSG00000231648.1	RP11-372M18.2	6.11	2.06e-09	9.68e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209313307	chr1:209367662~209379690:+
HNSC	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	6.11	2.06e-09	9.7e-07	0.3	0.27	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
HNSC	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	6.11	2.06e-09	9.7e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
HNSC	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-6.11	2.06e-09	9.71e-07	-0.32	-0.27	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-6.11	2.06e-09	9.71e-07	-0.32	-0.27	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
HNSC	cis	rs3743266	0.507	rs62003261	ENSG00000245534.5	RORA-AS1	-6.11	2.07e-09	9.72e-07	-0.44	-0.27	Menarche (age at onset);	chr15:60469290	chr15:60479178~60630637:+
HNSC	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-6.11	2.07e-09	9.73e-07	-0.38	-0.27	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
HNSC	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	6.11	2.07e-09	9.73e-07	0.29	0.27	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
HNSC	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.74e-07	0.37	0.27	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	6.11	2.07e-09	9.75e-07	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
HNSC	cis	rs6951245	0.935	rs113365567	ENSG00000225146.1	AC073957.15	-6.11	2.07e-09	9.75e-07	-0.46	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1029025~1043891:+
HNSC	cis	rs9525927	0.57	rs9316074	ENSG00000227258.4	SMIM2-AS1	6.11	2.07e-09	9.75e-07	0.39	0.27	Dupuytren's disease;	chr13:44229045	chr13:44110451~44240517:+
HNSC	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-6.11	2.07e-09	9.75e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
HNSC	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	6.11	2.07e-09	9.75e-07	0.3	0.27	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
HNSC	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
HNSC	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	6.11	2.07e-09	9.75e-07	0.3	0.27	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
HNSC	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-6.11	2.08e-09	9.77e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	6.11	2.09e-09	9.8e-07	0.36	0.27	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.09e-09	9.81e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
HNSC	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	6.11	2.09e-09	9.81e-07	0.33	0.27	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
HNSC	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-6.11	2.09e-09	9.82e-07	-0.36	-0.27	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
HNSC	cis	rs2115630	0.691	rs61322921	ENSG00000229212.6	RP11-561C5.4	6.11	2.09e-09	9.83e-07	0.31	0.27	P wave terminal force;	chr15:84620407	chr15:85205440~85234795:-
HNSC	cis	rs2404602	0.692	rs12437733	ENSG00000259422.1	RP11-593F23.1	6.11	2.09e-09	9.83e-07	0.32	0.27	Blood metabolite levels;	chr15:76863221	chr15:76174891~76181486:-
HNSC	cis	rs17772222	0.651	rs1950280	ENSG00000258789.1	RP11-507K2.3	6.11	2.09e-09	9.84e-07	0.3	0.27	Coronary artery calcification;	chr14:88366259	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	6.11	2.09e-09	9.84e-07	0.3	0.27	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	6.11	2.09e-09	9.84e-07	0.3	0.27	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
HNSC	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	6.11	2.09e-09	9.84e-07	0.26	0.27	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
HNSC	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.1e-09	9.85e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.1e-09	9.85e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
HNSC	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-6.11	2.1e-09	9.86e-07	-0.33	-0.27	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
HNSC	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	6.11	2.1e-09	9.86e-07	0.34	0.27	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
HNSC	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	6.11	2.1e-09	9.87e-07	0.47	0.27	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
HNSC	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	6.11	2.1e-09	9.88e-07	0.26	0.27	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000254153.1	CTA-398F10.2	6.11	2.1e-09	9.88e-07	0.3	0.27	Systolic blood pressure;	chr8:8488071	chr8:8456909~8461337:-
HNSC	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	6.11	2.1e-09	9.88e-07	0.37	0.27	Height;	chr6:109482392	chr6:109382795~109383666:+
HNSC	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-6.11	2.11e-09	9.89e-07	-0.32	-0.27	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
HNSC	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	6.11	2.11e-09	9.89e-07	0.36	0.27	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
HNSC	cis	rs1865760	0.613	rs9295674	ENSG00000272462.2	U91328.19	-6.11	2.11e-09	9.9e-07	-0.25	-0.27	Height;	chr6:25912114	chr6:25992662~26001775:+
HNSC	cis	rs17214007	0.627	rs28593034	ENSG00000263335.1	AF001548.5	-6.11	2.11e-09	9.91e-07	-0.43	-0.27	Cognitive function;	chr16:15597329	chr16:15726674~15732993:+
HNSC	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-6.11	2.11e-09	9.92e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
HNSC	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-6.11	2.11e-09	9.93e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
HNSC	cis	rs2980439	0.525	rs2980508	ENSG00000173295.6	FAM86B3P	6.11	2.11e-09	9.93e-07	0.29	0.27	Neuroticism;	chr8:8314210	chr8:8228595~8244865:+
HNSC	cis	rs11969893	0.85	rs12664068	ENSG00000270987.1	RP3-467N11.2	6.11	2.12e-09	9.93e-07	0.74	0.27	Economic and political preferences (immigration/crime);	chr6:100914222	chr6:100889603~100890338:+
HNSC	cis	rs8012947	0.848	rs1190982	ENSG00000279636.2	LINC00216	-6.11	2.12e-09	9.95e-07	-0.31	-0.27	Alcohol consumption in current drinkers;	chr14:58349121	chr14:58288033~58289158:+
HNSC	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	6.11	2.12e-09	9.96e-07	0.36	0.27	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
HNSC	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	6.11	2.12e-09	9.97e-07	0.3	0.27	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
HNSC	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	6.11	2.13e-09	9.98e-07	0.34	0.27	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
HNSC	cis	rs9611519	0.78	rs5751072	ENSG00000235513.1	RP4-756G23.5	6.11	2.13e-09	9.98e-07	0.28	0.27	Neuroticism;	chr22:41260505	chr22:41209122~41217627:-
HNSC	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	6.11	2.13e-09	1e-06	0.35	0.27	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000254153.1	CTA-398F10.2	-6.11	2.13e-09	1e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9032588	chr8:8456909~8461337:-
HNSC	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	6.11	2.13e-09	1e-06	0.55	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000211972.2	IGHV3-66	6.11	2.14e-09	1e-06	0.21	0.27	Kawasaki disease;	chr14:106711838	chr14:106675017~106675544:-
HNSC	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-6.11	2.14e-09	1.01e-06	-0.37	-0.27	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
HNSC	cis	rs12439619	0.705	rs4778665	ENSG00000276710.3	CSPG4P8	-6.11	2.14e-09	1.01e-06	-0.36	-0.27	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82459472~82477258:+
HNSC	cis	rs2235642	0.533	rs2667679	ENSG00000280231.1	LA16c-380F5.3	-6.11	2.15e-09	1.01e-06	-0.34	-0.27	Coronary artery disease;	chr16:1604945	chr16:1553655~1554130:-
HNSC	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.15e-09	1.01e-06	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
HNSC	cis	rs12922040	1	rs12922040	ENSG00000263065.1	AF001548.6	-6.11	2.15e-09	1.01e-06	-0.32	-0.27	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15741151~15741791:+
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000173295.6	FAM86B3P	-6.11	2.15e-09	1.01e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9032531	chr8:8228595~8244865:+
HNSC	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-6.11	2.15e-09	1.01e-06	-0.2	-0.27	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
HNSC	cis	rs8054556	0.692	rs4424923	ENSG00000183604.13	SMG1P5	-6.11	2.15e-09	1.01e-06	-0.26	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29927972	chr16:30267553~30335374:-
HNSC	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	6.11	2.16e-09	1.01e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
HNSC	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-6.11	2.16e-09	1.01e-06	-0.43	-0.27	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
HNSC	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-6.11	2.16e-09	1.01e-06	-0.29	-0.27	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
HNSC	cis	rs2239557	0.961	rs11159061	ENSG00000259065.1	RP5-1021I20.1	-6.11	2.16e-09	1.01e-06	-0.32	-0.27	Common traits (Other);	chr14:74089560	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs17096228	ENSG00000259065.1	RP5-1021I20.1	-6.11	2.16e-09	1.01e-06	-0.32	-0.27	Common traits (Other);	chr14:74091966	chr14:73787360~73803270:+
HNSC	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	6.11	2.16e-09	1.01e-06	0.35	0.27	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
HNSC	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	6.11	2.16e-09	1.01e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
HNSC	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	6.1	2.16e-09	1.01e-06	0.25	0.27	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.515	rs2003208	ENSG00000272462.2	U91328.19	-6.1	2.17e-09	1.01e-06	-0.25	-0.27	Height;	chr6:25940491	chr6:25992662~26001775:+
HNSC	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-6.1	2.17e-09	1.01e-06	-0.27	-0.27	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
HNSC	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-6.1	2.17e-09	1.01e-06	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
HNSC	cis	rs2404602	0.669	rs12148877	ENSG00000259422.1	RP11-593F23.1	6.1	2.17e-09	1.02e-06	0.32	0.27	Blood metabolite levels;	chr15:76627618	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs12902452	ENSG00000259422.1	RP11-593F23.1	6.1	2.17e-09	1.02e-06	0.32	0.27	Blood metabolite levels;	chr15:76629124	chr15:76174891~76181486:-
HNSC	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	6.1	2.17e-09	1.02e-06	0.27	0.27	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
HNSC	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-6.1	2.17e-09	1.02e-06	-0.32	-0.27	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
HNSC	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	6.1	2.17e-09	1.02e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
HNSC	cis	rs6928977	0.66	rs12214269	ENSG00000217482.2	HMGB1P17	-6.1	2.18e-09	1.02e-06	-0.3	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135525380	chr6:135636086~135636713:-
HNSC	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	6.1	2.18e-09	1.02e-06	0.38	0.27	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
HNSC	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-6.1	2.18e-09	1.02e-06	-0.42	-0.27	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
HNSC	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	6.1	2.19e-09	1.02e-06	0.26	0.27	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
HNSC	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-6.1	2.19e-09	1.02e-06	-0.3	-0.27	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
HNSC	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	6.1	2.19e-09	1.02e-06	0.26	0.27	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
HNSC	cis	rs2337406	1	rs11850709	ENSG00000211974.3	IGHV2-70	-6.1	2.19e-09	1.03e-06	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106670844	chr14:106723574~106724093:-
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.1	2.19e-09	1.03e-06	0.3	0.27	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
HNSC	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	6.1	2.19e-09	1.03e-06	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
HNSC	cis	rs2836974	0.583	rs2735307	ENSG00000255568.3	BRWD1-AS2	6.1	2.19e-09	1.03e-06	0.23	0.27	Cognitive function;	chr21:39341432	chr21:39313935~39314962:+
HNSC	cis	rs7396835	0.866	rs7927820	ENSG00000280143.1	AP000892.6	6.1	2.2e-09	1.03e-06	0.38	0.27	Quantitative traits;	chr11:116811440	chr11:117204967~117210292:+
HNSC	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	6.1	2.2e-09	1.03e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
HNSC	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-6.1	2.2e-09	1.03e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
HNSC	cis	rs9341808	0.667	rs2476826	ENSG00000272129.1	RP11-250B2.6	6.1	2.2e-09	1.03e-06	0.32	0.27	Sitting height ratio;	chr6:80166347	chr6:80355424~80356859:+
HNSC	cis	rs925255	0.81	rs1396733	ENSG00000270210.1	RP11-373D23.3	-6.1	2.2e-09	1.03e-06	-0.3	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28419880	chr2:28425945~28426719:+
HNSC	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-6.1	2.2e-09	1.03e-06	-0.31	-0.27	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-6.1	2.2e-09	1.03e-06	-0.31	-0.27	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
HNSC	cis	rs2286503	0.839	rs4722189	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22820855	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.809	rs4719716	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22821750	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2270108	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22822512	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2270107	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22822564	chr7:22856613~22856686:+
HNSC	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-6.1	2.2e-09	1.03e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
HNSC	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	6.1	2.21e-09	1.03e-06	0.33	0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
HNSC	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-6.1	2.21e-09	1.03e-06	-0.4	-0.27	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
HNSC	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	6.1	2.21e-09	1.03e-06	0.33	0.27	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
HNSC	cis	rs13113518	0.812	rs12649507	ENSG00000273257.1	RP11-177J6.1	-6.1	2.21e-09	1.03e-06	-0.33	-0.27	Height;	chr4:55514317	chr4:55387949~55388271:+
HNSC	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	6.1	2.21e-09	1.03e-06	0.25	0.27	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000179406.6	LINC00174	-6.1	2.22e-09	1.04e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66078212	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160648	ENSG00000179406.6	LINC00174	-6.1	2.22e-09	1.04e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66078397	chr7:66376044~66401338:-
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000254340.1	RP11-10A14.3	-6.1	2.22e-09	1.04e-06	-0.33	-0.27	Mood instability;	chr8:8932549	chr8:9141424~9145435:+
HNSC	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	6.1	2.22e-09	1.04e-06	0.33	0.27	Height;	chr4:55548666	chr4:55363971~55395847:-
HNSC	cis	rs5753618	0.539	rs5753596	ENSG00000236132.1	CTA-440B3.1	6.1	2.22e-09	1.04e-06	0.31	0.27	Colorectal cancer;	chr22:31391486	chr22:31816379~31817491:-
HNSC	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-6.1	2.22e-09	1.04e-06	-0.31	-0.27	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
HNSC	cis	rs6991838	0.778	rs11782837	ENSG00000200714.1	Y_RNA	6.1	2.22e-09	1.04e-06	0.31	0.27	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65592731~65592820:+
HNSC	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-6.1	2.22e-09	1.04e-06	-0.32	-0.27	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
HNSC	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	6.1	2.23e-09	1.04e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
HNSC	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-6.1	2.23e-09	1.04e-06	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
HNSC	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.837	rs4331474	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615457	chr2:10589166~10604830:+
HNSC	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-6.1	2.23e-09	1.04e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
HNSC	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	6.1	2.23e-09	1.04e-06	0.25	0.27	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	6.1	2.23e-09	1.04e-06	0.25	0.27	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
HNSC	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	6.1	2.23e-09	1.04e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
HNSC	cis	rs2235642	0.717	rs2236269	ENSG00000280231.1	LA16c-380F5.3	-6.1	2.23e-09	1.04e-06	-0.33	-0.27	Coronary artery disease;	chr16:1602613	chr16:1553655~1554130:-
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000179406.6	LINC00174	6.1	2.24e-09	1.05e-06	0.35	0.27	Calcium levels;	chr7:66040056	chr7:66376044~66401338:-
HNSC	cis	rs9300255	0.739	rs10846491	ENSG00000280120.1	RP11-546D6.3	6.1	2.24e-09	1.05e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123268945	chr12:123152324~123153377:-
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-6.1	2.24e-09	1.05e-06	-0.18	-0.27	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
HNSC	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	6.1	2.24e-09	1.05e-06	0.34	0.27	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
HNSC	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-6.1	2.24e-09	1.05e-06	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
HNSC	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-6.1	2.24e-09	1.05e-06	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
HNSC	cis	rs9611519	0.78	rs5751071	ENSG00000235513.1	RP4-756G23.5	6.1	2.25e-09	1.05e-06	0.28	0.27	Neuroticism;	chr22:41260328	chr22:41209122~41217627:-
HNSC	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	6.1	2.25e-09	1.05e-06	0.3	0.27	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
HNSC	cis	rs5753618	0.509	rs1034589	ENSG00000236132.1	CTA-440B3.1	6.1	2.25e-09	1.05e-06	0.33	0.27	Colorectal cancer;	chr22:31183247	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-6.1	2.25e-09	1.05e-06	-0.29	-0.27	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	6.1	2.25e-09	1.05e-06	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
HNSC	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-6.1	2.25e-09	1.05e-06	-0.33	-0.27	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
HNSC	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-6.1	2.25e-09	1.05e-06	-0.34	-0.27	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-6.1	2.25e-09	1.05e-06	-0.34	-0.27	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000211972.2	IGHV3-66	6.1	2.25e-09	1.05e-06	0.21	0.27	Kawasaki disease;	chr14:106779116	chr14:106675017~106675544:-
HNSC	cis	rs2579103	0.624	rs1371081	ENSG00000258183.4	RP11-753N8.1	-6.1	2.26e-09	1.05e-06	-0.4	-0.27	Body mass index;	chr12:90288436	chr12:90280894~90300340:+
HNSC	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	6.1	2.26e-09	1.05e-06	0.36	0.27	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	6.1	2.26e-09	1.05e-06	0.36	0.27	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-6.1	2.26e-09	1.05e-06	-0.33	-0.27	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
HNSC	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	6.1	2.26e-09	1.05e-06	0.27	0.27	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000211972.2	IGHV3-66	6.1	2.26e-09	1.06e-06	0.21	0.27	Kawasaki disease;	chr14:106815190	chr14:106675017~106675544:-
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-6.1	2.26e-09	1.06e-06	-0.31	-0.27	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
HNSC	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-6.1	2.26e-09	1.06e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-6.1	2.27e-09	1.06e-06	-0.31	-0.27	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
HNSC	cis	rs6604026	0.555	rs1415296	ENSG00000223787.2	RP4-593M8.1	-6.1	2.27e-09	1.06e-06	-0.37	-0.27	Multiple sclerosis;	chr1:92624919	chr1:92580476~92580821:-
HNSC	cis	rs9481169	0.557	rs2179070	ENSG00000255389.1	C6orf3	-6.1	2.27e-09	1.06e-06	-0.49	-0.27	Inflammatory skin disease;	chr6:111564549	chr6:111599875~111602295:+
HNSC	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	6.1	2.27e-09	1.06e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
HNSC	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	6.1	2.27e-09	1.06e-06	0.39	0.27	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
HNSC	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	6.1	2.27e-09	1.06e-06	0.36	0.27	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
HNSC	cis	rs860295	0.775	rs822508	ENSG00000203761.5	MSTO2P	-6.1	2.27e-09	1.06e-06	-0.2	-0.27	Body mass index;	chr1:155880767	chr1:155745829~155750137:+
HNSC	cis	rs7826238	0.502	rs10503377	ENSG00000173295.6	FAM86B3P	6.1	2.28e-09	1.06e-06	0.34	0.27	Systolic blood pressure;	chr8:8520912	chr8:8228595~8244865:+
HNSC	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	6.1	2.28e-09	1.07e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
HNSC	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	6.1	2.28e-09	1.07e-06	0.31	0.27	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	6.1	2.28e-09	1.07e-06	0.31	0.27	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	6.1	2.28e-09	1.07e-06	0.31	0.27	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-6.1	2.29e-09	1.07e-06	-0.31	-0.27	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-6.1	2.29e-09	1.07e-06	-0.18	-0.27	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
HNSC	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	6.1	2.29e-09	1.07e-06	0.28	0.27	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6.1	2.29e-09	1.07e-06	0.28	0.27	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6.1	2.29e-09	1.07e-06	0.28	0.27	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
HNSC	cis	rs4657482	0.607	rs10494449	ENSG00000236364.3	RP11-525G13.2	6.1	2.29e-09	1.07e-06	0.28	0.27	Testicular germ cell tumor;	chr1:165914066	chr1:165890795~165900683:-
HNSC	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-6.1	2.29e-09	1.07e-06	-0.53	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
HNSC	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	6.1	2.29e-09	1.07e-06	0.3	0.27	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
HNSC	cis	rs2235642	0.525	rs2667688	ENSG00000280231.1	LA16c-380F5.3	-6.1	2.29e-09	1.07e-06	-0.38	-0.27	Coronary artery disease;	chr16:1511445	chr16:1553655~1554130:-
HNSC	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-6.1	2.29e-09	1.07e-06	-0.33	-0.27	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-6.1	2.29e-09	1.07e-06	-0.33	-0.27	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-6.1	2.29e-09	1.07e-06	-0.33	-0.27	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-6.09	2.29e-09	1.07e-06	-0.39	-0.27	Gout;	chr7:66645053	chr7:66902857~66906297:+
HNSC	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-6.09	2.29e-09	1.07e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
HNSC	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-6.09	2.3e-09	1.07e-06	-0.31	-0.27	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
HNSC	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	6.09	2.3e-09	1.07e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
HNSC	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-6.09	2.3e-09	1.07e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
HNSC	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-6.09	2.3e-09	1.07e-06	-0.34	-0.27	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
HNSC	cis	rs1355223	0.902	rs11607035	ENSG00000271369.1	RP11-350D17.3	-6.09	2.3e-09	1.07e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34697364	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-6.09	2.3e-09	1.07e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
HNSC	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.09	2.3e-09	1.07e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.09	2.3e-09	1.07e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.09	2.3e-09	1.07e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-6.09	2.3e-09	1.07e-06	-0.32	-0.27	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
HNSC	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-6.09	2.31e-09	1.08e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
HNSC	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	6.09	2.31e-09	1.08e-06	0.3	0.27	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
HNSC	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-6.09	2.31e-09	1.08e-06	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
HNSC	cis	rs5753618	0.583	rs5753632	ENSG00000236132.1	CTA-440B3.1	-6.09	2.31e-09	1.08e-06	-0.32	-0.27	Colorectal cancer;	chr22:31467111	chr22:31816379~31817491:-
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-6.09	2.31e-09	1.08e-06	-0.32	-0.27	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
HNSC	cis	rs2836974	0.583	rs2776306	ENSG00000255568.3	BRWD1-AS2	6.09	2.31e-09	1.08e-06	0.23	0.27	Cognitive function;	chr21:39341828	chr21:39313935~39314962:+
HNSC	cis	rs603446	1	rs603446	ENSG00000254851.1	RP11-109L13.1	-6.09	2.31e-09	1.08e-06	-0.35	-0.27	Triglycerides;	chr11:116783719	chr11:117135528~117138582:+
HNSC	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	1.08e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
HNSC	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	6.09	2.32e-09	1.08e-06	0.3	0.27	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
HNSC	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	6.09	2.32e-09	1.08e-06	0.25	0.27	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
HNSC	cis	rs8177876	0.597	rs1048194	ENSG00000261061.1	RP11-303E16.2	6.09	2.32e-09	1.08e-06	0.48	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81030770~81031485:+
HNSC	cis	rs6928977	0.675	rs12206850	ENSG00000217482.2	HMGB1P17	6.09	2.32e-09	1.08e-06	0.3	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135476670	chr6:135636086~135636713:-
HNSC	cis	rs9611519	0.78	rs1983631	ENSG00000235513.1	RP4-756G23.5	6.09	2.32e-09	1.08e-06	0.29	0.27	Neuroticism;	chr22:41248070	chr22:41209122~41217627:-
HNSC	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-6.09	2.32e-09	1.08e-06	-0.37	-0.27	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
HNSC	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	6.09	2.32e-09	1.08e-06	0.3	0.27	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
HNSC	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-6.09	2.33e-09	1.08e-06	-0.32	-0.27	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-6.09	2.33e-09	1.08e-06	-0.32	-0.27	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-6.09	2.33e-09	1.08e-06	-0.32	-0.27	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
HNSC	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-6.09	2.33e-09	1.08e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
HNSC	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	6.09	2.33e-09	1.08e-06	0.3	0.27	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
HNSC	cis	rs9840812	0.535	rs695983	ENSG00000273486.1	RP11-731C17.2	6.09	2.33e-09	1.08e-06	0.22	0.27	Fibrinogen levels;	chr3:136345705	chr3:136837338~136839021:-
HNSC	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-6.09	2.33e-09	1.09e-06	-0.4	-0.27	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
HNSC	cis	rs7396835	0.741	rs7396851	ENSG00000280143.1	AP000892.6	-6.09	2.33e-09	1.09e-06	-0.36	-0.27	Quantitative traits;	chr11:116813448	chr11:117204967~117210292:+
HNSC	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
HNSC	cis	rs11969893	0.85	rs9791284	ENSG00000270987.1	RP3-467N11.2	6.09	2.34e-09	1.09e-06	0.74	0.27	Economic and political preferences (immigration/crime);	chr6:100906010	chr6:100889603~100890338:+
HNSC	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	6.09	2.34e-09	1.09e-06	0.42	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
HNSC	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	6.09	2.34e-09	1.09e-06	0.32	0.27	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
HNSC	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	6.09	2.35e-09	1.09e-06	0.33	0.27	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
HNSC	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-6.09	2.35e-09	1.09e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-6.09	2.35e-09	1.09e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
HNSC	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-6.09	2.35e-09	1.09e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
HNSC	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-6.09	2.35e-09	1.09e-06	-0.34	-0.27	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
HNSC	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-6.09	2.35e-09	1.09e-06	-0.34	-0.27	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
HNSC	cis	rs1799949	0.894	rs36062488	ENSG00000267151.3	RP11-100E5.2	-6.09	2.35e-09	1.09e-06	-0.35	-0.27	Menopause (age at onset);	chr17:43185455	chr17:43444707~43451200:+
HNSC	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-6.09	2.35e-09	1.09e-06	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
HNSC	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	6.09	2.35e-09	1.09e-06	0.39	0.27	Height;	chr6:109764163	chr6:109382795~109383666:+
HNSC	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	6.09	2.35e-09	1.09e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
HNSC	cis	rs2579103	0.651	rs865438	ENSG00000258183.4	RP11-753N8.1	-6.09	2.35e-09	1.1e-06	-0.4	-0.27	Body mass index;	chr12:90309334	chr12:90280894~90300340:+
HNSC	cis	rs1355223	0.902	rs61881050	ENSG00000271369.1	RP11-350D17.3	-6.09	2.35e-09	1.1e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34698202	chr11:34709600~34710161:+
HNSC	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-6.09	2.35e-09	1.1e-06	-0.33	-0.27	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
HNSC	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-6.09	2.36e-09	1.1e-06	-0.37	-0.27	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
HNSC	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
HNSC	cis	rs6918586	0.658	rs198838	ENSG00000272462.2	U91328.19	6.09	2.36e-09	1.1e-06	0.25	0.27	Schizophrenia;	chr6:26113112	chr6:25992662~26001775:+
HNSC	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-6.09	2.36e-09	1.1e-06	-0.3	-0.27	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
HNSC	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	6.09	2.37e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	6.09	2.37e-09	1.1e-06	0.21	0.27	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
HNSC	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	6.09	2.37e-09	1.1e-06	0.37	0.27	Height;	chr6:109354040	chr6:109382795~109383666:+
HNSC	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	6.09	2.37e-09	1.1e-06	0.54	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
HNSC	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-6.09	2.37e-09	1.1e-06	-0.28	-0.27	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
HNSC	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	6.09	2.37e-09	1.1e-06	0.29	0.27	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
HNSC	cis	rs8012947	1	rs12878264	ENSG00000279636.2	LINC00216	-6.09	2.37e-09	1.1e-06	-0.32	-0.27	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58288033~58289158:+
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000254153.1	CTA-398F10.2	6.09	2.38e-09	1.1e-06	0.3	0.27	Mood instability;	chr8:8522961	chr8:8456909~8461337:-
HNSC	cis	rs3758785	0.565	rs598645	ENSG00000255893.1	RP11-685N10.1	6.09	2.38e-09	1.11e-06	0.32	0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94338579	chr11:94472908~94473570:-
HNSC	cis	rs2880765	0.835	rs4842886	ENSG00000259295.5	CSPG4P12	6.09	2.38e-09	1.11e-06	0.31	0.27	Coronary artery disease;	chr15:85492542	chr15:85191438~85213905:+
HNSC	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	6.09	2.38e-09	1.11e-06	0.3	0.27	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
HNSC	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-6.09	2.39e-09	1.11e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
HNSC	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-6.09	2.39e-09	1.11e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000211972.2	IGHV3-66	6.09	2.39e-09	1.11e-06	0.21	0.27	Kawasaki disease;	chr14:106775695	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000211972.2	IGHV3-66	6.09	2.39e-09	1.11e-06	0.21	0.27	Kawasaki disease;	chr14:106775735	chr14:106675017~106675544:-
HNSC	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	6.09	2.39e-09	1.11e-06	0.26	0.27	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	6.09	2.39e-09	1.11e-06	0.33	0.27	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
HNSC	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-6.09	2.39e-09	1.11e-06	-0.3	-0.27	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
HNSC	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	6.09	2.39e-09	1.11e-06	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
HNSC	cis	rs4218	0.681	rs58335303	ENSG00000259732.1	RP11-59H7.3	-6.09	2.39e-09	1.11e-06	-0.38	-0.27	Social communication problems;	chr15:59073206	chr15:59121034~59133250:+
HNSC	cis	rs61160187	0.582	rs976630	ENSG00000215032.2	GNL3LP1	6.09	2.4e-09	1.11e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60891935~60893577:-
HNSC	cis	rs2880765	0.835	rs900573	ENSG00000259295.5	CSPG4P12	-6.09	2.4e-09	1.11e-06	-0.3	-0.27	Coronary artery disease;	chr15:85494762	chr15:85191438~85213905:+
HNSC	cis	rs3743266	0.507	rs11637887	ENSG00000245534.5	RORA-AS1	-6.09	2.4e-09	1.11e-06	-0.44	-0.27	Menarche (age at onset);	chr15:60473017	chr15:60479178~60630637:+
HNSC	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	6.09	2.4e-09	1.11e-06	0.34	0.27	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
HNSC	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	6.09	2.4e-09	1.12e-06	0.3	0.27	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
HNSC	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-6.09	2.4e-09	1.12e-06	-0.33	-0.27	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
HNSC	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	6.09	2.4e-09	1.12e-06	0.42	0.27	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
HNSC	cis	rs1355223	1	rs1355222	ENSG00000271369.1	RP11-350D17.3	-6.09	2.4e-09	1.12e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737169	chr11:34709600~34710161:+
HNSC	cis	rs2286503	0.839	rs2270105	ENSG00000221740.1	SNORD93	6.09	2.41e-09	1.12e-06	0.3	0.27	Fibrinogen;	chr7:22822848	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2270103	ENSG00000221740.1	SNORD93	6.09	2.41e-09	1.12e-06	0.3	0.27	Fibrinogen;	chr7:22823103	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs10276099	ENSG00000221740.1	SNORD93	6.09	2.41e-09	1.12e-06	0.3	0.27	Fibrinogen;	chr7:22823331	chr7:22856613~22856686:+
HNSC	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	6.09	2.41e-09	1.12e-06	0.28	0.27	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
HNSC	cis	rs2842992	0.747	rs4709379	ENSG00000237927.1	RP3-393E18.2	-6.09	2.41e-09	1.12e-06	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159806498	chr6:159586955~159589169:-
HNSC	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	6.09	2.41e-09	1.12e-06	0.24	0.27	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
HNSC	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-6.09	2.41e-09	1.12e-06	-0.34	-0.27	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
HNSC	cis	rs172166	0.611	rs203883	ENSG00000204709.4	LINC01556	6.09	2.41e-09	1.12e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28110578	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	6.09	2.41e-09	1.12e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	6.09	2.41e-09	1.12e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
HNSC	cis	rs1865760	0.593	rs2097273	ENSG00000272462.2	U91328.19	-6.09	2.42e-09	1.12e-06	-0.25	-0.27	Height;	chr6:25941082	chr6:25992662~26001775:+
HNSC	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-6.09	2.42e-09	1.12e-06	-0.28	-0.27	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
HNSC	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-6.09	2.42e-09	1.12e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
HNSC	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	6.09	2.42e-09	1.13e-06	0.27	0.27	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
HNSC	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	6.09	2.43e-09	1.13e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	6.08	2.43e-09	1.13e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
HNSC	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	6.08	2.43e-09	1.13e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	6.08	2.43e-09	1.13e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
HNSC	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-6.08	2.43e-09	1.13e-06	-0.31	-0.27	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-6.08	2.43e-09	1.13e-06	-0.31	-0.27	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	6.08	2.44e-09	1.13e-06	0.34	0.27	Depression;	chr6:28364057	chr6:28943877~28944537:+
HNSC	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	6.08	2.44e-09	1.13e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
HNSC	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-6.08	2.44e-09	1.13e-06	-0.36	-0.27	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
HNSC	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-6.08	2.44e-09	1.13e-06	-0.39	-0.27	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
HNSC	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-6.08	2.45e-09	1.13e-06	-0.31	-0.27	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	6.08	2.45e-09	1.13e-06	0.24	0.27	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	6.08	2.45e-09	1.13e-06	0.24	0.27	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
HNSC	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-6.08	2.45e-09	1.14e-06	-0.54	-0.27	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
HNSC	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	6.08	2.45e-09	1.14e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-6.08	2.45e-09	1.14e-06	-0.18	-0.27	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
HNSC	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	6.08	2.46e-09	1.14e-06	0.32	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
HNSC	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	6.08	2.46e-09	1.14e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000254153.1	CTA-398F10.2	6.08	2.47e-09	1.15e-06	0.3	0.27	Mood instability;	chr8:8522714	chr8:8456909~8461337:-
HNSC	cis	rs1355223	1	rs1396883	ENSG00000271369.1	RP11-350D17.3	-6.08	2.47e-09	1.15e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34735900	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.506	rs1150693	ENSG00000204709.4	LINC01556	6.08	2.47e-09	1.15e-06	0.37	0.27	Depression;	chr6:28206812	chr6:28943877~28944537:+
HNSC	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-6.08	2.47e-09	1.15e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-6.08	2.47e-09	1.15e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-6.08	2.47e-09	1.15e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-6.08	2.48e-09	1.15e-06	-0.29	-0.27	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
HNSC	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-6.08	2.48e-09	1.15e-06	-0.32	-0.27	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-6.08	2.48e-09	1.15e-06	-0.32	-0.27	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
HNSC	cis	rs9907295	0.591	rs2291299	ENSG00000270977.1	AC015849.16	-6.08	2.48e-09	1.15e-06	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35864402	chr17:35893707~35911023:-
HNSC	cis	rs7615952	0.576	rs2276727	ENSG00000241288.6	RP11-379B18.5	-6.08	2.48e-09	1.15e-06	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:126107400	chr3:125827238~125916384:-
HNSC	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	6.08	2.48e-09	1.15e-06	0.33	0.27	Height;	chr4:55544621	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
HNSC	cis	rs947583	0.588	rs9321530	ENSG00000217482.2	HMGB1P17	6.08	2.49e-09	1.15e-06	0.3	0.27	Phosphorus levels;	chr6:135790941	chr6:135636086~135636713:-
HNSC	cis	rs4803480	0.678	rs3745936	ENSG00000270164.1	LINC01480	-6.08	2.5e-09	1.16e-06	-0.23	-0.27	Schizophrenia;	chr19:41586462	chr19:41535183~41536904:+
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-6.08	2.5e-09	1.16e-06	-0.26	-0.27	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-6.08	2.5e-09	1.16e-06	-0.26	-0.27	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
HNSC	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-6.08	2.5e-09	1.16e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
HNSC	cis	rs9611565	0.506	rs7364221	ENSG00000235513.1	RP4-756G23.5	6.08	2.51e-09	1.16e-06	0.28	0.27	Vitiligo;	chr22:41254186	chr22:41209122~41217627:-
HNSC	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-6.08	2.51e-09	1.16e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-6.08	2.51e-09	1.16e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-6.08	2.51e-09	1.16e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
HNSC	cis	rs6928977	0.932	rs6914831	ENSG00000234084.1	RP3-388E23.2	6.08	2.51e-09	1.16e-06	0.28	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135318506	chr6:135301568~135307158:+
HNSC	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	6.08	2.51e-09	1.16e-06	0.48	0.27	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
HNSC	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	6.08	2.51e-09	1.16e-06	0.33	0.27	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
HNSC	cis	rs172166	0.769	rs149965	ENSG00000204709.4	LINC01556	6.08	2.51e-09	1.16e-06	0.36	0.27	Cardiac Troponin-T levels;	chr6:28050911	chr6:28943877~28944537:+
HNSC	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-6.08	2.52e-09	1.16e-06	-0.24	-0.27	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000211972.2	IGHV3-66	6.08	2.52e-09	1.17e-06	0.21	0.27	Kawasaki disease;	chr14:106777528	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-6.08	2.52e-09	1.17e-06	-0.32	-0.27	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
HNSC	cis	rs6928977	0.714	rs11154801	ENSG00000217482.2	HMGB1P17	6.08	2.52e-09	1.17e-06	0.31	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135418217	chr6:135636086~135636713:-
HNSC	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	6.08	2.52e-09	1.17e-06	0.34	0.27	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
HNSC	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
HNSC	cis	rs4713118	0.513	rs202908	ENSG00000204709.4	LINC01556	6.08	2.54e-09	1.17e-06	0.35	0.27	Parkinson's disease;	chr6:28043773	chr6:28943877~28944537:+
HNSC	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	6.08	2.54e-09	1.17e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
HNSC	cis	rs2880765	0.835	rs7168860	ENSG00000259295.5	CSPG4P12	6.08	2.54e-09	1.18e-06	0.31	0.27	Coronary artery disease;	chr15:85493799	chr15:85191438~85213905:+
HNSC	cis	rs4657482	0.606	rs4657490	ENSG00000236364.3	RP11-525G13.2	6.08	2.55e-09	1.18e-06	0.28	0.27	Testicular germ cell tumor;	chr1:165900453	chr1:165890795~165900683:-
HNSC	cis	rs7630852	1	rs7626440	ENSG00000272359.1	U4	-6.08	2.55e-09	1.18e-06	-0.29	-0.27	Eosinophil counts;	chr3:196778019	chr3:196747192~196747324:-
HNSC	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000173295.6	FAM86B3P	-6.08	2.55e-09	1.18e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9053798	chr8:8228595~8244865:+
HNSC	cis	rs4218	0.608	rs34859729	ENSG00000277144.1	RP11-59H7.4	-6.08	2.56e-09	1.18e-06	-0.37	-0.27	Social communication problems;	chr15:59070117	chr15:59115547~59116089:-
HNSC	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-6.08	2.56e-09	1.18e-06	-0.34	-0.27	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
HNSC	cis	rs4218	0.587	rs1446237	ENSG00000259732.1	RP11-59H7.3	-6.08	2.56e-09	1.18e-06	-0.36	-0.27	Social communication problems;	chr15:59052603	chr15:59121034~59133250:+
HNSC	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-6.08	2.56e-09	1.18e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
HNSC	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	6.08	2.56e-09	1.18e-06	0.35	0.27	Height;	chr6:109415123	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	6.08	2.56e-09	1.18e-06	0.35	0.27	Height;	chr6:109416903	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	6.08	2.56e-09	1.18e-06	0.35	0.27	Height;	chr6:109417941	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.866	rs4774019	ENSG00000211974.3	IGHV2-70	-6.08	2.57e-09	1.19e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106805386	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs58850145	ENSG00000211974.3	IGHV2-70	-6.08	2.57e-09	1.19e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106806185	chr14:106723574~106724093:-
HNSC	cis	rs17507216	0.628	rs8028130	ENSG00000276710.3	CSPG4P8	-6.08	2.57e-09	1.19e-06	-0.38	-0.27	Excessive daytime sleepiness;	chr15:82734974	chr15:82459472~82477258:+
HNSC	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	6.08	2.57e-09	1.19e-06	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
HNSC	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
HNSC	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-6.07	2.58e-09	1.19e-06	-0.31	-0.27	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
HNSC	cis	rs8031584	0.736	rs11635775	ENSG00000260382.1	RP11-540B6.2	6.07	2.58e-09	1.19e-06	0.35	0.27	Huntington's disease progression;	chr15:30868437	chr15:30882267~30883231:-
HNSC	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-6.07	2.59e-09	1.19e-06	-0.32	-0.27	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
HNSC	cis	rs2239557	1	rs75824542	ENSG00000259065.1	RP5-1021I20.1	-6.07	2.59e-09	1.2e-06	-0.32	-0.27	Common traits (Other);	chr14:74056344	chr14:73787360~73803270:+
HNSC	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-6.07	2.59e-09	1.2e-06	-0.25	-0.27	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
HNSC	cis	rs9907295	0.591	rs6505498	ENSG00000270977.1	AC015849.16	-6.07	2.59e-09	1.2e-06	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35803047	chr17:35893707~35911023:-
HNSC	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-6.07	2.59e-09	1.2e-06	-0.32	-0.27	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
HNSC	cis	rs7617773	0.78	rs9846818	ENSG00000228638.1	FCF1P2	-6.07	2.6e-09	1.2e-06	-0.25	-0.27	Coronary artery disease;	chr3:48334195	chr3:48290793~48291375:-
HNSC	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	6.07	2.6e-09	1.2e-06	0.34	0.27	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
HNSC	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-6.07	2.6e-09	1.2e-06	-0.41	-0.27	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.692	rs1116535	ENSG00000259422.1	RP11-593F23.1	-6.07	2.6e-09	1.2e-06	-0.31	-0.27	Blood metabolite levels;	chr15:76717173	chr15:76174891~76181486:-
HNSC	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	6.07	2.6e-09	1.2e-06	0.33	0.27	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
HNSC	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-6.07	2.6e-09	1.2e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-6.07	2.6e-09	1.2e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-6.07	2.6e-09	1.2e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
HNSC	cis	rs2404602	0.669	rs9788684	ENSG00000259422.1	RP11-593F23.1	6.07	2.6e-09	1.2e-06	0.31	0.27	Blood metabolite levels;	chr15:76902497	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	6.07	2.6e-09	1.2e-06	0.37	0.27	Height;	chr6:109352730	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	6.07	2.6e-09	1.2e-06	0.37	0.27	Height;	chr6:109353355	chr6:109382795~109383666:+
HNSC	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	6.07	2.6e-09	1.2e-06	0.32	0.27	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
HNSC	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	6.07	2.6e-09	1.2e-06	0.32	0.27	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
HNSC	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	6.07	2.6e-09	1.2e-06	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
HNSC	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-6.07	2.6e-09	1.2e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	6.07	2.6e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
HNSC	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	6.07	2.6e-09	1.2e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	6.07	2.6e-09	1.2e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	6.07	2.6e-09	1.2e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
HNSC	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	6.07	2.6e-09	1.2e-06	0.64	0.27	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
HNSC	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	6.07	2.6e-09	1.2e-06	0.36	0.27	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
HNSC	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-6.07	2.61e-09	1.2e-06	-0.3	-0.27	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
HNSC	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
HNSC	cis	rs2337406	0.866	rs2301535	ENSG00000211974.3	IGHV2-70	-6.07	2.61e-09	1.2e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106790663	chr14:106723574~106724093:-
HNSC	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	6.07	2.61e-09	1.21e-06	0.3	0.27	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
HNSC	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-6.07	2.62e-09	1.21e-06	-0.34	-0.27	Depression;	chr6:28422360	chr6:28943877~28944537:+
HNSC	cis	rs2243480	1	rs709607	ENSG00000179406.6	LINC00174	6.07	2.62e-09	1.21e-06	0.51	0.27	Diabetic kidney disease;	chr7:65984554	chr7:66376044~66401338:-
HNSC	cis	rs1021993	0.621	rs2246571	ENSG00000231648.1	RP11-372M18.2	6.07	2.62e-09	1.21e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209296326	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.553	rs5008730	ENSG00000231648.1	RP11-372M18.2	6.07	2.62e-09	1.21e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209296662	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.645	rs5008731	ENSG00000231648.1	RP11-372M18.2	6.07	2.62e-09	1.21e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209296665	chr1:209367662~209379690:+
HNSC	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-6.07	2.62e-09	1.21e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
HNSC	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-6.07	2.63e-09	1.21e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
HNSC	cis	rs2404602	0.692	rs2120108	ENSG00000259422.1	RP11-593F23.1	-6.07	2.63e-09	1.21e-06	-0.31	-0.27	Blood metabolite levels;	chr15:76577588	chr15:76174891~76181486:-
HNSC	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-6.07	2.63e-09	1.21e-06	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-6.07	2.63e-09	1.21e-06	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
HNSC	cis	rs7927592	0.83	rs11228240	ENSG00000212093.1	AP000807.1	6.07	2.63e-09	1.21e-06	0.33	0.27	Total body bone mineral density;	chr11:68450822	chr11:68506083~68506166:-
HNSC	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	6.07	2.63e-09	1.21e-06	0.3	0.27	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
HNSC	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	6.07	2.63e-09	1.21e-06	0.42	0.27	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
HNSC	cis	rs6928977	0.675	rs9399148	ENSG00000217482.2	HMGB1P17	-6.07	2.63e-09	1.21e-06	-0.3	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135636086~135636713:-
HNSC	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-6.07	2.63e-09	1.21e-06	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
HNSC	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	6.07	2.63e-09	1.21e-06	0.34	0.27	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
HNSC	cis	rs7811142	1	rs11559117	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100478991	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs4463351	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100480603	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs60844404	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100482851	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11763511	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100484321	chr7:100320992~100341908:-
HNSC	cis	rs6504622	0.818	rs758391	ENSG00000262879.4	RP11-156P1.3	6.07	2.64e-09	1.21e-06	0.29	0.27	Orofacial clefts;	chr17:46939875	chr17:46984045~47100323:-
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	6.07	2.64e-09	1.21e-06	0.3	0.27	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	6.07	2.64e-09	1.22e-06	0.37	0.27	Height;	chr6:109366911	chr6:109382795~109383666:+
HNSC	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-6.07	2.65e-09	1.22e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
HNSC	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
HNSC	cis	rs2985684	0.894	rs2354439	ENSG00000258568.1	RHOQP1	6.07	2.65e-09	1.22e-06	0.27	0.27	Carotid intima media thickness;	chr14:49552699	chr14:49599994~49600572:+
HNSC	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	6.07	2.66e-09	1.22e-06	0.35	0.27	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
HNSC	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-6.07	2.66e-09	1.22e-06	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-6.07	2.66e-09	1.22e-06	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
HNSC	cis	rs7819412	0.775	rs6601564	ENSG00000269918.1	AF131215.9	-6.07	2.66e-09	1.22e-06	-0.27	-0.27	Triglycerides;	chr8:11124541	chr8:11104691~11106704:-
HNSC	cis	rs2985684	0.841	rs2281836	ENSG00000258568.1	RHOQP1	6.07	2.66e-09	1.23e-06	0.28	0.27	Carotid intima media thickness;	chr14:49598999	chr14:49599994~49600572:+
HNSC	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	6.07	2.66e-09	1.23e-06	0.36	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
HNSC	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	6.07	2.66e-09	1.23e-06	0.37	0.27	Height;	chr6:109347085	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	6.07	2.66e-09	1.23e-06	0.37	0.27	Height;	chr6:109347277	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.667	rs1408292	ENSG00000272129.1	RP11-250B2.6	6.07	2.67e-09	1.23e-06	0.32	0.27	Sitting height ratio;	chr6:80174189	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.628	rs2490245	ENSG00000272129.1	RP11-250B2.6	6.07	2.67e-09	1.23e-06	0.32	0.27	Sitting height ratio;	chr6:80182710	chr6:80355424~80356859:+
HNSC	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	6.07	2.67e-09	1.23e-06	0.37	0.27	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
HNSC	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	6.07	2.67e-09	1.23e-06	0.33	0.27	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
HNSC	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	6.07	2.67e-09	1.23e-06	0.26	0.27	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
HNSC	cis	rs4713118	0.513	rs149989	ENSG00000204709.4	LINC01556	6.07	2.68e-09	1.23e-06	0.35	0.27	Parkinson's disease;	chr6:28030406	chr6:28943877~28944537:+
HNSC	cis	rs7209700	0.778	rs3851807	ENSG00000228782.6	CTD-2026D20.3	-6.07	2.68e-09	1.23e-06	-0.27	-0.27	IgG glycosylation;	chr17:47274153	chr17:47450568~47492492:-
HNSC	cis	rs9481169	0.557	rs13190932	ENSG00000255389.1	C6orf3	-6.07	2.68e-09	1.23e-06	-0.55	-0.27	Inflammatory skin disease;	chr6:111591867	chr6:111599875~111602295:+
HNSC	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-6.07	2.68e-09	1.24e-06	-0.23	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
HNSC	cis	rs11846409	0.652	rs10143549	ENSG00000211974.3	IGHV2-70	-6.07	2.68e-09	1.24e-06	-0.3	-0.27	Rheumatic heart disease;	chr14:106644643	chr14:106723574~106724093:-
HNSC	cis	rs1799949	0.965	rs6503726	ENSG00000267151.3	RP11-100E5.2	6.07	2.69e-09	1.24e-06	0.35	0.27	Menopause (age at onset);	chr17:43132725	chr17:43444707~43451200:+
HNSC	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-6.07	2.69e-09	1.24e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	6.07	2.7e-09	1.24e-06	0.33	0.27	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	6.07	2.7e-09	1.24e-06	0.35	0.27	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	6.07	2.7e-09	1.24e-06	0.35	0.27	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
HNSC	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109420812	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109422189	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109423330	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109423487	chr6:109382795~109383666:+
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000254153.1	CTA-398F10.2	6.07	2.7e-09	1.24e-06	0.29	0.27	Joint mobility (Beighton score);	chr8:8979093	chr8:8456909~8461337:-
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000179406.6	LINC00174	-6.07	2.71e-09	1.24e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66500146	chr7:66376044~66401338:-
HNSC	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000211972.2	IGHV3-66	6.07	2.71e-09	1.25e-06	0.21	0.27	Kawasaki disease;	chr14:106777570	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-6.07	2.71e-09	1.25e-06	-0.32	-0.27	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
HNSC	cis	rs7617773	0.539	rs13069884	ENSG00000228638.1	FCF1P2	-6.07	2.72e-09	1.25e-06	-0.24	-0.27	Coronary artery disease;	chr3:48339658	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs2017859	ENSG00000228638.1	FCF1P2	-6.07	2.72e-09	1.25e-06	-0.24	-0.27	Coronary artery disease;	chr3:48340771	chr3:48290793~48291375:-
HNSC	cis	rs7309	0.622	rs4664396	ENSG00000235724.7	AC009299.2	6.07	2.72e-09	1.25e-06	0.32	0.27	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161222785~161308303:-
HNSC	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-6.07	2.72e-09	1.25e-06	-0.28	-0.27	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
HNSC	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-6.07	2.72e-09	1.25e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
HNSC	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-6.07	2.72e-09	1.25e-06	-0.37	-0.27	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
HNSC	cis	rs4218	0.689	rs2121237	ENSG00000259732.1	RP11-59H7.3	-6.06	2.73e-09	1.25e-06	-0.38	-0.27	Social communication problems;	chr15:59091888	chr15:59121034~59133250:+
HNSC	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-6.06	2.73e-09	1.26e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000233609.3	RP11-62H7.2	-6.06	2.73e-09	1.26e-06	-0.25	-0.27	Mood instability;	chr8:8967348	chr8:8961200~8979025:+
HNSC	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-6.06	2.74e-09	1.26e-06	-0.32	-0.27	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
HNSC	cis	rs9402743	0.598	rs2327654	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135758303	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.703	rs6933668	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135760013	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.703	rs7756751	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135761314	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.703	rs6570030	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135761688	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6909996	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Phosphorus levels;	chr6:135763365	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs9399164	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Phosphorus levels;	chr6:135765408	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs4385331	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Phosphorus levels;	chr6:135772025	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.641	rs9402752	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135772549	chr6:135636086~135636713:-
HNSC	cis	rs9611519	0.78	rs9611528	ENSG00000235513.1	RP4-756G23.5	6.06	2.74e-09	1.26e-06	0.28	0.27	Neuroticism;	chr22:41252498	chr22:41209122~41217627:-
HNSC	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-6.06	2.74e-09	1.26e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
HNSC	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	6.06	2.74e-09	1.26e-06	0.32	0.27	Height;	chr4:55532542	chr4:55363971~55395847:-
HNSC	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-6.06	2.75e-09	1.26e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000173295.6	FAM86B3P	6.06	2.75e-09	1.26e-06	0.31	0.27	Mood instability;	chr8:8786764	chr8:8228595~8244865:+
HNSC	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-6.06	2.75e-09	1.26e-06	-0.34	-0.27	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-6.06	2.75e-09	1.26e-06	-0.34	-0.27	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
HNSC	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	6.06	2.75e-09	1.26e-06	0.23	0.27	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
HNSC	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	6.06	2.76e-09	1.27e-06	0.3	0.27	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
HNSC	cis	rs853679	0.55	rs1233704	ENSG00000204709.4	LINC01556	-6.06	2.76e-09	1.27e-06	-0.36	-0.27	Depression;	chr6:28199145	chr6:28943877~28944537:+
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	6.06	2.76e-09	1.27e-06	0.18	0.27	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
HNSC	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	6.06	2.76e-09	1.27e-06	0.37	0.27	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
HNSC	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	6.06	2.76e-09	1.27e-06	0.26	0.27	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
HNSC	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	6.06	2.77e-09	1.27e-06	0.29	0.27	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
HNSC	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-6.06	2.77e-09	1.27e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-6.06	2.77e-09	1.27e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	6.06	2.77e-09	1.27e-06	0.18	0.27	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
HNSC	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	6.06	2.77e-09	1.27e-06	0.33	0.27	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
HNSC	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-6.06	2.78e-09	1.27e-06	-0.3	-0.27	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
HNSC	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	6.06	2.78e-09	1.28e-06	0.3	0.27	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
HNSC	cis	rs8177876	0.749	rs78707250	ENSG00000261061.1	RP11-303E16.2	-6.06	2.78e-09	1.28e-06	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81030770~81031485:+
HNSC	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-6.06	2.78e-09	1.28e-06	-0.31	-0.27	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
HNSC	cis	rs1355223	0.902	rs11605785	ENSG00000271369.1	RP11-350D17.3	-6.06	2.78e-09	1.28e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729840	chr11:34709600~34710161:+
HNSC	cis	rs6928977	0.675	rs7759971	ENSG00000217482.2	HMGB1P17	6.06	2.78e-09	1.28e-06	0.3	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135425746	chr6:135636086~135636713:-
HNSC	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	6.06	2.78e-09	1.28e-06	0.27	0.27	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
HNSC	cis	rs947583	0.517	rs7756915	ENSG00000217482.2	HMGB1P17	6.06	2.78e-09	1.28e-06	0.28	0.27	Phosphorus levels;	chr6:135798177	chr6:135636086~135636713:-
HNSC	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-6.06	2.79e-09	1.28e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-6.06	2.79e-09	1.28e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000173295.6	FAM86B3P	-6.06	2.79e-09	1.28e-06	-0.3	-0.27	Mood instability;	chr8:8939545	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	-6.06	2.79e-09	1.28e-06	-0.3	-0.27	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000173295.6	FAM86B3P	-6.06	2.79e-09	1.28e-06	-0.3	-0.27	Mood instability;	chr8:8939568	chr8:8228595~8244865:+
HNSC	cis	rs17270561	0.609	rs7746502	ENSG00000272462.2	U91328.19	6.06	2.79e-09	1.28e-06	0.27	0.27	Iron status biomarkers;	chr6:25718534	chr6:25992662~26001775:+
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000211972.2	IGHV3-66	6.06	2.79e-09	1.28e-06	0.21	0.27	Kawasaki disease;	chr14:106668657	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-6.06	2.79e-09	1.28e-06	-0.32	-0.27	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
HNSC	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-6.06	2.8e-09	1.29e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
HNSC	cis	rs7819412	0.538	rs4523214	ENSG00000269918.1	AF131215.9	-6.06	2.8e-09	1.29e-06	-0.27	-0.27	Triglycerides;	chr8:11113263	chr8:11104691~11106704:-
HNSC	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	6.06	2.81e-09	1.29e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
HNSC	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-6.06	2.81e-09	1.29e-06	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
HNSC	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	6.06	2.81e-09	1.29e-06	0.3	0.27	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
HNSC	cis	rs11648785	0.747	rs3743826	ENSG00000222019.6	URAHP	6.06	2.81e-09	1.29e-06	0.28	0.27	Tanning;	chr16:90027806	chr16:90039761~90047773:-
HNSC	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	6.06	2.81e-09	1.29e-06	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
HNSC	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-6.06	2.81e-09	1.29e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-6.06	2.81e-09	1.29e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
HNSC	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-6.06	2.82e-09	1.29e-06	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
HNSC	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	6.06	2.82e-09	1.29e-06	0.26	0.27	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
HNSC	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-6.06	2.83e-09	1.29e-06	-0.35	-0.27	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
HNSC	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-6.06	2.83e-09	1.3e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
HNSC	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
HNSC	cis	rs6928977	0.675	rs58761508	ENSG00000217482.2	HMGB1P17	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.631	rs9385726	ENSG00000217482.2	HMGB1P17	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.637	rs9647635	ENSG00000217482.2	HMGB1P17	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135636086~135636713:-
HNSC	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
HNSC	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	6.06	2.84e-09	1.3e-06	0.31	0.27	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
HNSC	cis	rs8054556	0.692	rs7201384	ENSG00000183604.13	SMG1P5	-6.06	2.84e-09	1.3e-06	-0.26	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29913584	chr16:30267553~30335374:-
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000179406.6	LINC00174	-6.06	2.84e-09	1.3e-06	-0.56	-0.27	Diabetic kidney disease;	chr7:66357373	chr7:66376044~66401338:-
HNSC	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-6.06	2.85e-09	1.3e-06	-0.32	-0.27	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
HNSC	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	6.06	2.85e-09	1.3e-06	0.37	0.27	Height;	chr6:109371573	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-6.06	2.85e-09	1.31e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
HNSC	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	6.06	2.85e-09	1.31e-06	0.36	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
HNSC	cis	rs9300255	0.602	rs1790095	ENSG00000280120.1	RP11-546D6.3	6.06	2.85e-09	1.31e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123196675	chr12:123152324~123153377:-
HNSC	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-6.06	2.86e-09	1.31e-06	-0.39	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
HNSC	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-6.06	2.86e-09	1.31e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-6.06	2.86e-09	1.31e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-6.06	2.86e-09	1.31e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
HNSC	cis	rs526231	0.764	rs2569014	ENSG00000175749.11	EIF3KP1	6.06	2.86e-09	1.31e-06	0.35	0.27	Primary biliary cholangitis;	chr5:103302398	chr5:103032376~103033031:+
HNSC	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-6.06	2.86e-09	1.31e-06	-0.32	-0.27	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
HNSC	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	6.06	2.86e-09	1.31e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
HNSC	cis	rs4657482	0.607	rs10918309	ENSG00000236364.3	RP11-525G13.2	6.06	2.87e-09	1.31e-06	0.28	0.27	Testicular germ cell tumor;	chr1:165904791	chr1:165890795~165900683:-
HNSC	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
HNSC	cis	rs75920871	0.512	rs6589583	ENSG00000254851.1	RP11-109L13.1	6.06	2.87e-09	1.31e-06	0.38	0.27	Subjective well-being;	chr11:116993050	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs7930264	ENSG00000254851.1	RP11-109L13.1	6.06	2.87e-09	1.31e-06	0.38	0.27	Subjective well-being;	chr11:117000050	chr11:117135528~117138582:+
HNSC	cis	rs7396835	0.8	rs6589572	ENSG00000280143.1	AP000892.6	6.06	2.87e-09	1.31e-06	0.38	0.27	Quantitative traits;	chr11:116810847	chr11:117204967~117210292:+
HNSC	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-6.06	2.87e-09	1.31e-06	-0.31	-0.27	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
HNSC	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	6.06	2.88e-09	1.32e-06	0.26	0.27	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
HNSC	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	6.06	2.88e-09	1.32e-06	0.22	0.27	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
HNSC	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	6.06	2.88e-09	1.32e-06	0.31	0.27	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
HNSC	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-6.06	2.88e-09	1.32e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
HNSC	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	6.06	2.89e-09	1.32e-06	0.36	0.27	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
HNSC	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	6.05	2.89e-09	1.32e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	6.05	2.89e-09	1.32e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-6.05	2.89e-09	1.32e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-6.05	2.89e-09	1.32e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-6.05	2.89e-09	1.32e-06	-0.35	-0.27	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-6.05	2.9e-09	1.32e-06	-0.35	-0.27	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-6.05	2.9e-09	1.32e-06	-0.35	-0.27	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
HNSC	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	6.05	2.9e-09	1.33e-06	0.28	0.27	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-6.05	2.91e-09	1.33e-06	-0.25	-0.27	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
HNSC	cis	rs853679	1	rs10456362	ENSG00000219392.1	RP1-265C24.5	6.05	2.91e-09	1.33e-06	0.39	0.27	Depression;	chr6:28254038	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-6.05	2.91e-09	1.33e-06	-0.17	-0.27	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
HNSC	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	6.05	2.91e-09	1.33e-06	0.45	0.27	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
HNSC	cis	rs2834288	0.536	rs8129513	ENSG00000237945.6	LINC00649	6.05	2.91e-09	1.33e-06	0.33	0.27	Gut microbiota (bacterial taxa);	chr21:33952615	chr21:33915534~33977691:+
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	6.05	2.91e-09	1.33e-06	0.22	0.27	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
HNSC	cis	rs6504622	1	rs1047779	ENSG00000262879.4	RP11-156P1.3	-6.05	2.92e-09	1.33e-06	-0.29	-0.27	Orofacial clefts;	chr17:46941877	chr17:46984045~47100323:-
HNSC	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-6.05	2.92e-09	1.33e-06	-0.33	-0.27	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-6.05	2.92e-09	1.33e-06	-0.32	-0.27	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
HNSC	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	6.05	2.92e-09	1.33e-06	0.32	0.27	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
HNSC	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	6.05	2.92e-09	1.33e-06	0.36	0.27	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
HNSC	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	6.05	2.92e-09	1.34e-06	0.39	0.27	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
HNSC	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.94e-09	1.34e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
HNSC	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-6.05	2.94e-09	1.34e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-6.05	2.94e-09	1.34e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
HNSC	cis	rs6604026	0.555	rs11805007	ENSG00000223787.2	RP4-593M8.1	6.05	2.94e-09	1.34e-06	0.37	0.27	Multiple sclerosis;	chr1:92616633	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs56044027	ENSG00000223787.2	RP4-593M8.1	6.05	2.94e-09	1.34e-06	0.37	0.27	Multiple sclerosis;	chr1:92617137	chr1:92580476~92580821:-
HNSC	cis	rs6928977	0.896	rs2614285	ENSG00000234084.1	RP3-388E23.2	6.05	2.94e-09	1.34e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371480	chr6:135301568~135307158:+
HNSC	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-6.05	2.94e-09	1.34e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-6.05	2.94e-09	1.34e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
HNSC	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	6.05	2.94e-09	1.34e-06	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
HNSC	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	6.05	2.95e-09	1.35e-06	0.31	0.27	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
HNSC	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
HNSC	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-6.05	2.95e-09	1.35e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
HNSC	cis	rs9840812	0.637	rs698270	ENSG00000239213.4	NCK1-AS1	6.05	2.95e-09	1.35e-06	0.26	0.27	Fibrinogen levels;	chr3:136390670	chr3:136841726~136862054:-
HNSC	cis	rs7811142	0.945	rs6955362	ENSG00000078319.8	PMS2P1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Platelet count;	chr7:100458543	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs6975514	ENSG00000078319.8	PMS2P1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Platelet count;	chr7:100458597	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs7811142	ENSG00000078319.8	PMS2P1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Platelet count;	chr7:100467820	chr7:100320992~100341908:-
HNSC	cis	rs17270561	0.583	rs7765833	ENSG00000272462.2	U91328.19	-6.05	2.95e-09	1.35e-06	-0.27	-0.27	Iron status biomarkers;	chr6:25712205	chr6:25992662~26001775:+
HNSC	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	6.05	2.96e-09	1.35e-06	0.37	0.27	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
HNSC	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-6.05	2.96e-09	1.35e-06	-0.29	-0.27	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
HNSC	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	6.05	2.96e-09	1.35e-06	0.27	0.27	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
HNSC	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	6.05	2.96e-09	1.35e-06	0.25	0.27	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	6.05	2.96e-09	1.35e-06	0.25	0.27	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
HNSC	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	6.05	2.96e-09	1.35e-06	0.33	0.27	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
HNSC	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	6.05	2.96e-09	1.35e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
HNSC	cis	rs17507216	0.718	rs72751675	ENSG00000255769.6	GOLGA2P10	-6.05	2.97e-09	1.35e-06	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82630452	chr15:82472993~82513950:-
HNSC	cis	rs67981189	0.529	rs8181986	ENSG00000274818.1	RP1-292L20.3	6.05	2.97e-09	1.36e-06	0.33	0.27	Schizophrenia;	chr14:71115527	chr14:70906657~70907111:-
HNSC	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-6.05	2.97e-09	1.36e-06	-0.33	-0.27	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
HNSC	cis	rs6051080	1	rs6051080	ENSG00000204556.4	CTD-2514C3.1	-6.05	2.98e-09	1.36e-06	-0.34	-0.27	Colorectal or endometrial cancer;	chr20:25995038	chr20:26018832~26020684:+
HNSC	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	6.05	2.98e-09	1.36e-06	0.26	0.27	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
HNSC	cis	rs7980687	0.574	rs10744149	ENSG00000280120.1	RP11-546D6.3	6.05	2.98e-09	1.36e-06	0.24	0.27	Head circumference (infant);Educational attainment;Height;	chr12:123223943	chr12:123152324~123153377:-
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000173295.6	FAM86B3P	6.05	2.98e-09	1.36e-06	0.31	0.27	Systolic blood pressure;	chr8:8486617	chr8:8228595~8244865:+
HNSC	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-6.05	2.98e-09	1.36e-06	-0.29	-0.27	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
HNSC	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-6.05	2.98e-09	1.36e-06	-0.35	-0.27	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
HNSC	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-6.05	2.98e-09	1.36e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
HNSC	cis	rs14027	0.883	rs13272852	ENSG00000279347.1	RP11-85I17.2	-6.05	2.99e-09	1.36e-06	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.883	rs28486074	ENSG00000279347.1	RP11-85I17.2	-6.05	2.99e-09	1.36e-06	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.842	rs28634937	ENSG00000279347.1	RP11-85I17.2	-6.05	2.99e-09	1.36e-06	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119838736~119840385:-
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-6.05	2.99e-09	1.36e-06	-0.32	-0.27	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
HNSC	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	6.05	2.99e-09	1.36e-06	0.31	0.27	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	6.05	2.99e-09	1.36e-06	0.31	0.27	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
HNSC	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	6.05	2.99e-09	1.36e-06	0.51	0.27	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	6.05	2.99e-09	1.36e-06	0.51	0.27	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
HNSC	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.99e-09	1.36e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
HNSC	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	6.05	2.99e-09	1.36e-06	0.5	0.27	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
HNSC	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	6.05	2.99e-09	1.36e-06	0.21	0.27	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
HNSC	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-6.05	2.99e-09	1.37e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
HNSC	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	6.05	3e-09	1.37e-06	0.3	0.27	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
HNSC	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-6.05	3e-09	1.37e-06	-0.28	-0.27	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
HNSC	cis	rs12550612	0.83	rs9918919	ENSG00000253616.4	RP11-875O11.3	6.05	3e-09	1.37e-06	0.4	0.27	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109777	chr8:23071377~23074488:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000173295.6	FAM86B3P	-6.05	3.01e-09	1.37e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9033292	chr8:8228595~8244865:+
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000173295.6	FAM86B3P	-6.05	3.01e-09	1.37e-06	-0.3	-0.27	Myopia (pathological);Myopia;	chr8:9033866	chr8:8228595~8244865:+
HNSC	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-6.05	3.01e-09	1.37e-06	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
HNSC	cis	rs947583	0.517	rs9376144	ENSG00000217482.2	HMGB1P17	6.05	3.01e-09	1.37e-06	0.28	0.27	Phosphorus levels;	chr6:135756247	chr6:135636086~135636713:-
HNSC	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-6.05	3.01e-09	1.37e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
HNSC	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-6.05	3.01e-09	1.37e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
HNSC	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	6.05	3.02e-09	1.38e-06	0.25	0.27	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
HNSC	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-6.05	3.02e-09	1.38e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
HNSC	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.05	3.02e-09	1.38e-06	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
HNSC	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-6.05	3.02e-09	1.38e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
HNSC	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	6.05	3.03e-09	1.38e-06	0.32	0.27	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
HNSC	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-6.05	3.03e-09	1.38e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-6.05	3.03e-09	1.38e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
HNSC	cis	rs8012947	1	rs11628909	ENSG00000279636.2	LINC00216	6.05	3.03e-09	1.38e-06	0.33	0.27	Alcohol consumption in current drinkers;	chr14:58352508	chr14:58288033~58289158:+
HNSC	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-6.05	3.03e-09	1.38e-06	-0.46	-0.27	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000254340.1	RP11-10A14.3	6.05	3.03e-09	1.38e-06	0.33	0.27	Mood instability;	chr8:8795379	chr8:9141424~9145435:+
HNSC	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-6.05	3.04e-09	1.38e-06	-0.32	-0.27	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
HNSC	cis	rs6951245	1	rs74887741	ENSG00000225146.1	AC073957.15	-6.05	3.04e-09	1.38e-06	-0.46	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1029025~1043891:+
HNSC	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-6.05	3.04e-09	1.39e-06	-0.28	-0.27	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
HNSC	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-6.05	3.04e-09	1.39e-06	-0.38	-0.27	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
HNSC	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	6.05	3.04e-09	1.39e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
HNSC	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-6.05	3.04e-09	1.39e-06	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
HNSC	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-6.05	3.05e-09	1.39e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
HNSC	cis	rs6928977	0.538	rs17064702	ENSG00000217482.2	HMGB1P17	6.05	3.05e-09	1.39e-06	0.31	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135636086~135636713:-
HNSC	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	6.05	3.05e-09	1.39e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	6.05	3.05e-09	1.39e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	6.05	3.05e-09	1.39e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
HNSC	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	6.05	3.05e-09	1.39e-06	0.36	0.27	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
HNSC	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	6.05	3.05e-09	1.39e-06	0.37	0.27	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	6.05	3.05e-09	1.39e-06	0.37	0.27	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
HNSC	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	6.05	3.06e-09	1.39e-06	0.31	0.27	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
HNSC	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-6.05	3.06e-09	1.39e-06	-0.36	-0.27	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
HNSC	cis	rs2985684	0.948	rs11623263	ENSG00000258568.1	RHOQP1	6.04	3.06e-09	1.39e-06	0.28	0.27	Carotid intima media thickness;	chr14:49616577	chr14:49599994~49600572:+
HNSC	cis	rs17270561	0.583	rs12662869	ENSG00000272462.2	U91328.19	6.04	3.06e-09	1.39e-06	0.27	0.27	Iron status biomarkers;	chr6:25784253	chr6:25992662~26001775:+
HNSC	cis	rs947583	0.517	rs9494390	ENSG00000217482.2	HMGB1P17	6.04	3.06e-09	1.39e-06	0.28	0.27	Phosphorus levels;	chr6:135794875	chr6:135636086~135636713:-
HNSC	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	6.04	3.06e-09	1.39e-06	0.41	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
HNSC	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-6.04	3.07e-09	1.4e-06	-0.4	-0.27	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
HNSC	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	6.04	3.07e-09	1.4e-06	0.35	0.27	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
HNSC	cis	rs7048146	0.668	rs10124300	ENSG00000213539.4	YBX1P6	-6.04	3.07e-09	1.4e-06	-0.29	-0.27	Vascular brain injury;	chr9:109515460	chr9:109532830~109534332:-
HNSC	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
HNSC	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	6.04	3.07e-09	1.4e-06	0.36	0.27	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
HNSC	cis	rs9907295	0.591	rs3760327	ENSG00000270977.1	AC015849.16	-6.04	3.08e-09	1.4e-06	-0.31	-0.27	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35893707~35911023:-
HNSC	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-6.04	3.08e-09	1.4e-06	-0.3	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
HNSC	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-6.04	3.08e-09	1.4e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-6.04	3.08e-09	1.4e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
HNSC	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	6.04	3.08e-09	1.4e-06	0.33	0.27	Height;	chr4:55542243	chr4:55363971~55395847:-
HNSC	cis	rs2985684	0.846	rs4476096	ENSG00000258568.1	RHOQP1	6.04	3.09e-09	1.41e-06	0.27	0.27	Carotid intima media thickness;	chr14:49552673	chr14:49599994~49600572:+
HNSC	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-6.04	3.09e-09	1.41e-06	-0.36	-0.27	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
HNSC	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-6.04	3.1e-09	1.41e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
HNSC	cis	rs9300255	0.602	rs1790126	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123199016	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs1716182	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123201580	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1402274	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123201677	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs11057192	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123208873	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs2682434	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123210177	chr12:123152324~123153377:-
HNSC	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	6.04	3.1e-09	1.41e-06	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
HNSC	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	6.04	3.1e-09	1.41e-06	0.37	0.27	Height;	chr6:109352852	chr6:109382795~109383666:+
HNSC	cis	rs2790457	0.792	rs1265830	ENSG00000254635.4	WAC-AS1	6.04	3.11e-09	1.41e-06	0.3	0.27	Multiple myeloma;	chr10:28623294	chr10:28522652~28532743:-
HNSC	cis	rs17507216	0.718	rs28587782	ENSG00000255769.6	GOLGA2P10	-6.04	3.11e-09	1.41e-06	-0.42	-0.27	Excessive daytime sleepiness;	chr15:82576881	chr15:82472993~82513950:-
HNSC	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	6.04	3.11e-09	1.41e-06	0.31	0.27	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
HNSC	cis	rs6928977	0.896	rs2614287	ENSG00000234084.1	RP3-388E23.2	6.04	3.11e-09	1.41e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135301568~135307158:+
HNSC	cis	rs2834288	0.5	rs7283594	ENSG00000237945.6	LINC00649	-6.04	3.11e-09	1.41e-06	-0.33	-0.27	Gut microbiota (bacterial taxa);	chr21:33962798	chr21:33915534~33977691:+
HNSC	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	6.04	3.12e-09	1.42e-06	0.34	0.27	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
HNSC	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
HNSC	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-6.04	3.12e-09	1.42e-06	-0.34	-0.27	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
HNSC	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-6.04	3.13e-09	1.42e-06	-0.36	-0.27	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000179406.6	LINC00174	-6.04	3.13e-09	1.42e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66500834	chr7:66376044~66401338:-
HNSC	cis	rs7209700	0.662	rs8080254	ENSG00000228782.6	CTD-2026D20.3	6.04	3.13e-09	1.42e-06	0.29	0.27	IgG glycosylation;	chr17:47270526	chr17:47450568~47492492:-
HNSC	cis	rs8054556	0.787	rs1140239	ENSG00000183604.13	SMG1P5	-6.04	3.13e-09	1.42e-06	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30267553~30335374:-
HNSC	cis	rs5753618	0.539	rs695438	ENSG00000236132.1	CTA-440B3.1	-6.04	3.14e-09	1.42e-06	-0.31	-0.27	Colorectal cancer;	chr22:31415890	chr22:31816379~31817491:-
HNSC	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	6.04	3.14e-09	1.43e-06	0.34	0.27	Depression;	chr6:28407125	chr6:28943877~28944537:+
HNSC	cis	rs5753618	0.539	rs4820962	ENSG00000236132.1	CTA-440B3.1	6.04	3.14e-09	1.43e-06	0.33	0.27	Colorectal cancer;	chr22:31293965	chr22:31816379~31817491:-
HNSC	cis	rs7811142	1	rs67471932	ENSG00000078319.8	PMS2P1	-6.04	3.14e-09	1.43e-06	-0.34	-0.27	Platelet count;	chr7:100412362	chr7:100320992~100341908:-
HNSC	cis	rs17270561	0.636	rs1575535	ENSG00000272462.2	U91328.19	-6.04	3.14e-09	1.43e-06	-0.27	-0.27	Iron status biomarkers;	chr6:25809681	chr6:25992662~26001775:+
HNSC	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	6.04	3.15e-09	1.43e-06	0.31	0.27	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	6.04	3.15e-09	1.43e-06	0.31	0.27	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
HNSC	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	6.04	3.15e-09	1.43e-06	0.32	0.27	Height;	chr4:55490176	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	6.04	3.15e-09	1.43e-06	0.32	0.27	Height;	chr4:55490228	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	6.04	3.15e-09	1.43e-06	0.32	0.27	Height;	chr4:55491150	chr4:55363971~55395847:-
HNSC	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-6.04	3.16e-09	1.43e-06	-0.38	-0.27	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
HNSC	cis	rs7209700	0.662	rs8074094	ENSG00000228782.6	CTD-2026D20.3	-6.04	3.16e-09	1.43e-06	-0.29	-0.27	IgG glycosylation;	chr17:47270655	chr17:47450568~47492492:-
HNSC	cis	rs947583	0.573	rs12191817	ENSG00000217482.2	HMGB1P17	6.04	3.16e-09	1.43e-06	0.3	0.27	Phosphorus levels;	chr6:135702608	chr6:135636086~135636713:-
HNSC	cis	rs2134046	0.555	rs11854483	ENSG00000255769.6	GOLGA2P10	-6.04	3.17e-09	1.44e-06	-0.32	-0.27	Cognitive ability;	chr15:82267217	chr15:82472993~82513950:-
HNSC	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-6.04	3.17e-09	1.44e-06	-0.33	-0.27	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
HNSC	cis	rs9840812	0.522	rs699165	ENSG00000273486.1	RP11-731C17.2	6.04	3.17e-09	1.44e-06	0.24	0.27	Fibrinogen levels;	chr3:136505855	chr3:136837338~136839021:-
HNSC	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-6.04	3.17e-09	1.44e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
HNSC	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	6.04	3.17e-09	1.44e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
HNSC	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	6.04	3.18e-09	1.44e-06	0.36	0.27	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
HNSC	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	6.04	3.18e-09	1.44e-06	0.32	0.27	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
HNSC	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	6.04	3.18e-09	1.44e-06	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
HNSC	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	6.04	3.18e-09	1.44e-06	0.34	0.27	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
HNSC	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	6.04	3.18e-09	1.44e-06	0.33	0.27	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	6.04	3.18e-09	1.44e-06	0.33	0.27	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
HNSC	cis	rs11648785	0.735	rs868372	ENSG00000222019.6	URAHP	6.04	3.19e-09	1.45e-06	0.27	0.27	Tanning;	chr16:90031587	chr16:90039761~90047773:-
HNSC	cis	rs11846409	0.629	rs76295389	ENSG00000274576.2	IGHV2-70	6.04	3.19e-09	1.45e-06	0.28	0.27	Rheumatic heart disease;	chr14:106650437	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.698	rs71419854	ENSG00000274576.2	IGHV2-70	6.04	3.19e-09	1.45e-06	0.28	0.27	Rheumatic heart disease;	chr14:106650440	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.5	rs71419855	ENSG00000274576.2	IGHV2-70	6.04	3.19e-09	1.45e-06	0.28	0.27	Alzheimer's disease (late onset);	chr14:106650444	chr14:106770577~106771020:-
HNSC	cis	rs867371	0.929	rs1045508	ENSG00000276710.3	CSPG4P8	6.04	3.19e-09	1.45e-06	0.3	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82459472~82477258:+
HNSC	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	6.04	3.19e-09	1.45e-06	0.3	0.27	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
HNSC	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	6.04	3.19e-09	1.45e-06	0.31	0.27	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
HNSC	cis	rs947583	0.588	rs2208574	ENSG00000217482.2	HMGB1P17	6.04	3.2e-09	1.45e-06	0.3	0.27	Phosphorus levels;	chr6:135754479	chr6:135636086~135636713:-
HNSC	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-6.04	3.2e-09	1.45e-06	-0.32	-0.27	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
HNSC	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-6.04	3.2e-09	1.45e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
HNSC	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-6.04	3.2e-09	1.45e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
HNSC	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-6.04	3.2e-09	1.45e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-6.04	3.2e-09	1.45e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-6.04	3.2e-09	1.45e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
HNSC	cis	rs2286503	0.839	rs4722188	ENSG00000221740.1	SNORD93	6.04	3.2e-09	1.45e-06	0.3	0.27	Fibrinogen;	chr7:22820592	chr7:22856613~22856686:+
HNSC	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	6.04	3.2e-09	1.45e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	6.04	3.2e-09	1.45e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
HNSC	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	6.04	3.21e-09	1.46e-06	0.27	0.27	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
HNSC	cis	rs67981189	0.529	rs2810097	ENSG00000274818.1	RP1-292L20.3	-6.04	3.21e-09	1.46e-06	-0.32	-0.27	Schizophrenia;	chr14:70967397	chr14:70906657~70907111:-
HNSC	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
HNSC	cis	rs1355223	1	rs11602909	ENSG00000271369.1	RP11-350D17.3	-6.04	3.22e-09	1.46e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746456	chr11:34709600~34710161:+
HNSC	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	6.04	3.22e-09	1.46e-06	0.32	0.27	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
HNSC	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
HNSC	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
HNSC	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	6.04	3.22e-09	1.46e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	6.04	3.22e-09	1.46e-06	0.35	0.27	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
HNSC	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-6.04	3.23e-09	1.46e-06	-0.43	-0.27	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
HNSC	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	6.04	3.23e-09	1.47e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
HNSC	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
HNSC	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	6.03	3.25e-09	1.47e-06	0.32	0.27	Height;	chr4:55528801	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	6.03	3.25e-09	1.47e-06	0.32	0.27	Height;	chr4:55529387	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	6.03	3.25e-09	1.47e-06	0.32	0.27	Height;	chr4:55529786	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-6.03	3.25e-09	1.47e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
HNSC	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-6.03	3.25e-09	1.47e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-6.03	3.25e-09	1.47e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-6.03	3.25e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
HNSC	cis	rs67180937	0.583	rs2936054	ENSG00000272750.1	RP11-378J18.8	6.03	3.25e-09	1.47e-06	0.35	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222627290	chr1:222658867~222661512:-
HNSC	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-6.03	3.26e-09	1.47e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
HNSC	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	6.03	3.26e-09	1.47e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
HNSC	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-6.03	3.26e-09	1.48e-06	-0.31	-0.27	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
HNSC	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
HNSC	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	6.03	3.27e-09	1.48e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
HNSC	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-6.03	3.27e-09	1.48e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
HNSC	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	6.03	3.28e-09	1.48e-06	0.34	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	6.03	3.28e-09	1.48e-06	0.34	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
HNSC	cis	rs73198271	0.751	rs617813	ENSG00000253893.2	FAM85B	6.03	3.28e-09	1.48e-06	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.866	rs2027901	ENSG00000211974.3	IGHV2-70	-6.03	3.28e-09	1.49e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106807164	chr14:106723574~106724093:-
HNSC	cis	rs7819412	0.668	rs920047	ENSG00000269918.1	AF131215.9	-6.03	3.29e-09	1.49e-06	-0.27	-0.27	Triglycerides;	chr8:11229966	chr8:11104691~11106704:-
HNSC	cis	rs11648785	0.777	rs4433810	ENSG00000222019.6	URAHP	6.03	3.29e-09	1.49e-06	0.28	0.27	Tanning;	chr16:90032058	chr16:90039761~90047773:-
HNSC	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	6.03	3.29e-09	1.49e-06	0.3	0.27	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
HNSC	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-6.03	3.3e-09	1.49e-06	-0.37	-0.27	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
HNSC	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.03	3.3e-09	1.49e-06	-0.51	-0.27	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	6.03	3.3e-09	1.49e-06	0.37	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
HNSC	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-6.03	3.3e-09	1.49e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
HNSC	cis	rs2239557	0.961	rs10133356	ENSG00000259065.1	RP5-1021I20.1	6.03	3.3e-09	1.49e-06	0.32	0.27	Common traits (Other);	chr14:74181056	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs10144220	ENSG00000259065.1	RP5-1021I20.1	6.03	3.3e-09	1.49e-06	0.32	0.27	Common traits (Other);	chr14:74181201	chr14:73787360~73803270:+
HNSC	cis	rs2239557	0.961	rs10135858	ENSG00000259065.1	RP5-1021I20.1	6.03	3.3e-09	1.49e-06	0.32	0.27	Common traits (Other);	chr14:74181259	chr14:73787360~73803270:+
HNSC	cis	rs61160187	0.582	rs1526896	ENSG00000215032.2	GNL3LP1	6.03	3.31e-09	1.5e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60891935~60893577:-
HNSC	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	6.03	3.32e-09	1.5e-06	0.42	0.27	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
HNSC	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	6.03	3.32e-09	1.5e-06	0.3	0.27	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
HNSC	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
HNSC	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
HNSC	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-6.03	3.32e-09	1.5e-06	-0.33	-0.27	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-6.03	3.32e-09	1.5e-06	-0.33	-0.27	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
HNSC	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	6.03	3.33e-09	1.5e-06	0.32	0.27	Height;	chr4:55465165	chr4:55363971~55395847:-
HNSC	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	6.03	3.33e-09	1.5e-06	0.33	0.27	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
HNSC	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-6.03	3.33e-09	1.5e-06	-0.32	-0.27	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
HNSC	cis	rs7209700	0.632	rs11657963	ENSG00000228782.6	CTD-2026D20.3	-6.03	3.33e-09	1.5e-06	-0.28	-0.27	IgG glycosylation;	chr17:47270167	chr17:47450568~47492492:-
HNSC	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-6.03	3.33e-09	1.51e-06	-0.32	-0.27	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
HNSC	cis	rs9907295	0.591	rs9908928	ENSG00000270977.1	AC015849.16	-6.03	3.34e-09	1.51e-06	-0.31	-0.27	Fibroblast growth factor basic levels;	chr17:35862013	chr17:35893707~35911023:-
HNSC	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-6.03	3.34e-09	1.51e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-6.03	3.34e-09	1.51e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
HNSC	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	6.03	3.34e-09	1.51e-06	0.41	0.27	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	6.03	3.34e-09	1.51e-06	0.41	0.27	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	6.03	3.34e-09	1.51e-06	0.41	0.27	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
HNSC	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-6.03	3.35e-09	1.51e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
HNSC	cis	rs7811142	1	rs113738841	ENSG00000078319.8	PMS2P1	-6.03	3.35e-09	1.51e-06	-0.34	-0.27	Platelet count;	chr7:100483683	chr7:100320992~100341908:-
HNSC	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	6.03	3.35e-09	1.51e-06	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
HNSC	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	6.03	3.35e-09	1.51e-06	0.33	0.27	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
HNSC	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
HNSC	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-6.03	3.37e-09	1.52e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-6.03	3.37e-09	1.52e-06	-0.32	-0.27	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-6.03	3.37e-09	1.52e-06	-0.32	-0.27	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
HNSC	cis	rs9300255	0.596	rs10773002	ENSG00000280120.1	RP11-546D6.3	-6.03	3.38e-09	1.52e-06	-0.23	-0.27	Neutrophil percentage of white cells;	chr12:123262414	chr12:123152324~123153377:-
HNSC	cis	rs17214007	0.518	rs8047940	ENSG00000263335.1	AF001548.5	-6.03	3.38e-09	1.52e-06	-0.4	-0.27	Cognitive function;	chr16:15691787	chr16:15726674~15732993:+
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000173295.6	FAM86B3P	-6.03	3.38e-09	1.53e-06	-0.3	-0.27	Mood instability;	chr8:8934707	chr8:8228595~8244865:+
HNSC	cis	rs2235642	0.928	rs1057610	ENSG00000280231.1	LA16c-380F5.3	-6.03	3.38e-09	1.53e-06	-0.33	-0.27	Coronary artery disease;	chr16:1555536	chr16:1553655~1554130:-
HNSC	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-6.03	3.38e-09	1.53e-06	-0.34	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000224373.3	IGHV4-59	6.03	3.39e-09	1.53e-06	0.17	0.27	Kawasaki disease;	chr14:106656426	chr14:106627249~106627825:-
HNSC	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-6.03	3.39e-09	1.53e-06	-0.23	-0.27	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
HNSC	cis	rs673078	0.66	rs61943365	ENSG00000275409.1	RP11-131L12.4	-6.03	3.39e-09	1.53e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118339166	chr12:118430147~118430699:+
HNSC	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-6.03	3.39e-09	1.53e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
HNSC	cis	rs1012068	0.686	rs5998176	ENSG00000236132.1	CTA-440B3.1	-6.03	3.4e-09	1.53e-06	-0.31	-0.27	Chronic hepatitis C infection;	chr22:31922107	chr22:31816379~31817491:-
HNSC	cis	rs453301	0.597	rs7001187	ENSG00000254340.1	RP11-10A14.3	-6.03	3.4e-09	1.53e-06	-0.33	-0.27	Joint mobility (Beighton score);	chr8:8935272	chr8:9141424~9145435:+
HNSC	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	6.03	3.4e-09	1.53e-06	0.25	0.27	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
HNSC	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	6.03	3.41e-09	1.54e-06	0.22	0.27	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
HNSC	cis	rs35955747	0.869	rs8141987	ENSG00000236132.1	CTA-440B3.1	6.03	3.42e-09	1.54e-06	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191169	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.869	rs8142988	ENSG00000236132.1	CTA-440B3.1	6.03	3.42e-09	1.54e-06	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191172	chr22:31816379~31817491:-
HNSC	cis	rs172166	0.652	rs476167	ENSG00000204709.4	LINC01556	6.03	3.42e-09	1.54e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28098110	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.694	rs203892	ENSG00000204709.4	LINC01556	6.03	3.42e-09	1.54e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28099418	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	6.03	3.42e-09	1.54e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
HNSC	cis	rs75920871	0.528	rs7935913	ENSG00000254851.1	RP11-109L13.1	-6.03	3.42e-09	1.54e-06	-0.37	-0.27	Subjective well-being;	chr11:117073632	chr11:117135528~117138582:+
HNSC	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-6.03	3.43e-09	1.55e-06	-0.37	-0.27	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
HNSC	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-6.03	3.43e-09	1.55e-06	-0.33	-0.27	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
HNSC	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	6.03	3.43e-09	1.55e-06	0.34	0.27	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000173295.6	FAM86B3P	-6.03	3.43e-09	1.55e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9017276	chr8:8228595~8244865:+
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000254153.1	CTA-398F10.2	6.03	3.43e-09	1.55e-06	0.28	0.27	Neuroticism;	chr8:8460377	chr8:8456909~8461337:-
HNSC	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-6.02	3.44e-09	1.55e-06	-0.31	-0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
HNSC	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-6.02	3.44e-09	1.55e-06	-0.41	-0.27	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	6.02	3.44e-09	1.55e-06	0.33	0.27	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
HNSC	cis	rs2985684	1	rs8014170	ENSG00000258568.1	RHOQP1	6.02	3.44e-09	1.55e-06	0.28	0.27	Carotid intima media thickness;	chr14:49604976	chr14:49599994~49600572:+
HNSC	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	6.02	3.45e-09	1.55e-06	0.25	0.27	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
HNSC	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	6.02	3.45e-09	1.56e-06	0.21	0.27	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
HNSC	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-6.02	3.46e-09	1.56e-06	-0.32	-0.27	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000173295.6	FAM86B3P	-6.02	3.46e-09	1.56e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9016136	chr8:8228595~8244865:+
HNSC	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-6.02	3.46e-09	1.56e-06	-0.33	-0.27	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
HNSC	cis	rs7811142	1	rs74460138	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100429716	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs6975729	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100430564	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs1073	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100433989	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs4989959	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100434665	chr7:100320992~100341908:-
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	6.02	3.47e-09	1.56e-06	0.21	0.27	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
HNSC	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-6.02	3.48e-09	1.57e-06	-0.28	-0.27	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000233609.3	RP11-62H7.2	-6.02	3.48e-09	1.57e-06	-0.26	-0.27	Mood instability;	chr8:8939545	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000233609.3	RP11-62H7.2	-6.02	3.48e-09	1.57e-06	-0.26	-0.27	Mood instability;	chr8:8939563	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000233609.3	RP11-62H7.2	-6.02	3.48e-09	1.57e-06	-0.26	-0.27	Mood instability;	chr8:8939568	chr8:8961200~8979025:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	6.02	3.49e-09	1.57e-06	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-6.02	3.5e-09	1.57e-06	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
HNSC	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-6.02	3.5e-09	1.57e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
HNSC	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-6.02	3.5e-09	1.58e-06	-0.24	-0.27	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
HNSC	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	6.02	3.5e-09	1.58e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
HNSC	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
HNSC	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-6.02	3.51e-09	1.58e-06	-0.36	-0.27	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
HNSC	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.51e-09	1.58e-06	-0.35	-0.27	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
HNSC	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-6.02	3.51e-09	1.58e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
HNSC	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	6.02	3.52e-09	1.58e-06	0.37	0.27	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000173295.6	FAM86B3P	6.02	3.52e-09	1.58e-06	0.3	0.27	Neuroticism;	chr8:8866141	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	6.02	3.52e-09	1.58e-06	0.33	0.27	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
HNSC	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-6.02	3.52e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-6.02	3.52e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-6.02	3.52e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
HNSC	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-6.02	3.53e-09	1.59e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000211972.2	IGHV3-66	6.02	3.53e-09	1.59e-06	0.21	0.27	Kawasaki disease;	chr14:106816039	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-6.02	3.54e-09	1.59e-06	-0.32	-0.27	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-6.02	3.54e-09	1.59e-06	-0.32	-0.27	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-6.02	3.54e-09	1.59e-06	-0.18	-0.27	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
HNSC	cis	rs8177876	0.731	rs4889227	ENSG00000261061.1	RP11-303E16.2	6.02	3.54e-09	1.59e-06	0.42	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81030770~81031485:+
HNSC	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	6.02	3.54e-09	1.59e-06	0.25	0.27	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	6.02	3.54e-09	1.59e-06	0.25	0.27	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	6.02	3.54e-09	1.59e-06	0.25	0.27	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
HNSC	cis	rs8177876	0.658	rs12444747	ENSG00000261061.1	RP11-303E16.2	-6.02	3.55e-09	1.6e-06	-0.5	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041299	chr16:81030770~81031485:+
HNSC	cis	rs1355223	0.902	rs34751755	ENSG00000271369.1	RP11-350D17.3	-6.02	3.56e-09	1.6e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34672696	chr11:34709600~34710161:+
HNSC	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-6.02	3.56e-09	1.6e-06	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	6.02	3.56e-09	1.6e-06	0.35	0.27	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	6.02	3.56e-09	1.6e-06	0.35	0.27	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
HNSC	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-6.02	3.56e-09	1.6e-06	-0.31	-0.27	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-6.02	3.56e-09	1.6e-06	-0.31	-0.27	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
HNSC	cis	rs8012947	1	rs941752	ENSG00000279636.2	LINC00216	-6.02	3.56e-09	1.6e-06	-0.33	-0.27	Alcohol consumption in current drinkers;	chr14:58332643	chr14:58288033~58289158:+
HNSC	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-6.02	3.57e-09	1.6e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
HNSC	cis	rs853679	0.55	rs9295762	ENSG00000204709.4	LINC01556	-6.02	3.58e-09	1.61e-06	-0.35	-0.27	Depression;	chr6:28187640	chr6:28943877~28944537:+
HNSC	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	6.02	3.58e-09	1.61e-06	0.3	0.27	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	6.02	3.58e-09	1.61e-06	0.3	0.27	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
HNSC	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	6.02	3.58e-09	1.61e-06	0.3	0.27	Depression;	chr6:28273214	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	6.02	3.58e-09	1.61e-06	0.3	0.27	Depression;	chr6:28273215	chr6:28176188~28176674:+
HNSC	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.02	3.58e-09	1.61e-06	0.39	0.27	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
HNSC	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-6.02	3.59e-09	1.61e-06	-0.32	-0.27	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000280411.1	IGHV1-69-2	-6.02	3.59e-09	1.61e-06	-0.18	-0.27	Kawasaki disease;	chr14:106686149	chr14:106762092~106762588:-
HNSC	cis	rs2880765	0.743	rs8032488	ENSG00000259295.5	CSPG4P12	6.02	3.6e-09	1.62e-06	0.31	0.27	Coronary artery disease;	chr15:85469537	chr15:85191438~85213905:+
HNSC	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	6.02	3.6e-09	1.62e-06	0.38	0.27	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-6.02	3.6e-09	1.62e-06	-0.17	-0.27	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	6.02	3.61e-09	1.62e-06	0.32	0.27	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
HNSC	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
HNSC	cis	rs189798	0.807	rs12785	ENSG00000173295.6	FAM86B3P	6.02	3.61e-09	1.62e-06	0.33	0.27	Myopia (pathological);	chr8:9137426	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-6.02	3.61e-09	1.62e-06	-0.32	-0.27	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
HNSC	cis	rs4713118	0.513	rs149941	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28033255	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149942	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28033832	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149944	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28035040	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149945	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28035075	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000233609.3	RP11-62H7.2	-6.02	3.62e-09	1.62e-06	-0.25	-0.27	Mood instability;	chr8:8939009	chr8:8961200~8979025:+
HNSC	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.62e-09	1.63e-06	-0.34	-0.27	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
HNSC	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	6.02	3.62e-09	1.63e-06	0.3	0.27	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
HNSC	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-6.02	3.62e-09	1.63e-06	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
HNSC	cis	rs440932	1	rs365309	ENSG00000173295.6	FAM86B3P	-6.02	3.63e-09	1.63e-06	-0.32	-0.27	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8228595~8244865:+
HNSC	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	6.02	3.63e-09	1.63e-06	0.39	0.27	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
HNSC	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-6.02	3.63e-09	1.63e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
HNSC	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-6.01	3.64e-09	1.63e-06	-0.38	-0.27	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.846	rs7005216	ENSG00000173295.6	FAM86B3P	-6.01	3.65e-09	1.64e-06	-0.31	-0.27	Mood instability;	chr8:8689600	chr8:8228595~8244865:+
HNSC	cis	rs831571	0.649	rs831556	ENSG00000280620.1	SCAANT1	-6.01	3.65e-09	1.64e-06	-0.37	-0.27	Type 2 diabetes;	chr3:64036017	chr3:63911518~63911772:-
HNSC	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-6.01	3.65e-09	1.64e-06	-0.33	-0.27	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
HNSC	cis	rs867371	0.614	rs1814739	ENSG00000255769.6	GOLGA2P10	-6.01	3.65e-09	1.64e-06	-0.37	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82472993~82513950:-
HNSC	cis	rs6918586	0.658	rs198840	ENSG00000272462.2	U91328.19	-6.01	3.65e-09	1.64e-06	-0.25	-0.27	Schizophrenia;	chr6:26111936	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-6.01	3.66e-09	1.64e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
HNSC	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-6.01	3.66e-09	1.64e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
HNSC	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-6.01	3.66e-09	1.64e-06	-0.3	-0.27	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
HNSC	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	6.01	3.66e-09	1.64e-06	0.32	0.27	Height;	chr4:55460485	chr4:55363971~55395847:-
HNSC	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	6.01	3.67e-09	1.65e-06	0.25	0.27	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	6.01	3.67e-09	1.65e-06	0.25	0.27	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
HNSC	cis	rs8059260	0.736	rs79361721	ENSG00000274038.1	RP11-66H6.4	-6.01	3.67e-09	1.65e-06	-0.52	-0.27	Alcohol consumption over the past year;	chr16:10968082	chr16:11056556~11057034:+
HNSC	cis	rs9611519	0.78	rs2235849	ENSG00000235513.1	RP4-756G23.5	6.01	3.68e-09	1.65e-06	0.28	0.27	Neuroticism;	chr22:41257536	chr22:41209122~41217627:-
HNSC	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	6.01	3.68e-09	1.65e-06	0.3	0.27	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-6.01	3.69e-09	1.65e-06	-0.18	-0.27	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-6.01	3.69e-09	1.65e-06	-0.18	-0.27	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
HNSC	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-6.01	3.69e-09	1.66e-06	-0.32	-0.27	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
HNSC	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-6.01	3.69e-09	1.66e-06	-0.34	-0.27	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
HNSC	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-6.01	3.7e-09	1.66e-06	-0.31	-0.27	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	6.01	3.7e-09	1.66e-06	0.18	0.27	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
HNSC	cis	rs673078	0.66	rs73205551	ENSG00000275409.1	RP11-131L12.4	-6.01	3.7e-09	1.66e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118330808	chr12:118430147~118430699:+
HNSC	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-6.01	3.71e-09	1.66e-06	-0.39	-0.27	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
HNSC	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.66e-06	0.36	0.27	Depression;	chr6:28193021	chr6:28943877~28944537:+
HNSC	cis	rs6918586	0.658	rs198843	ENSG00000272462.2	U91328.19	-6.01	3.72e-09	1.67e-06	-0.25	-0.27	Schizophrenia;	chr6:26110086	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.594	rs198842	ENSG00000272462.2	U91328.19	-6.01	3.72e-09	1.67e-06	-0.25	-0.27	Schizophrenia;	chr6:26111220	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7746609	ENSG00000272462.2	U91328.19	6.01	3.72e-09	1.67e-06	0.27	0.27	Iron status biomarkers;	chr6:25727768	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-6.01	3.72e-09	1.67e-06	-0.36	-0.27	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
HNSC	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-6.01	3.73e-09	1.67e-06	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
HNSC	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	6.01	3.74e-09	1.67e-06	0.3	0.27	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
HNSC	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	6.01	3.74e-09	1.67e-06	0.33	0.27	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
HNSC	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-6.01	3.74e-09	1.67e-06	-0.39	-0.27	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
HNSC	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-6.01	3.74e-09	1.68e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
HNSC	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-6.01	3.74e-09	1.68e-06	-0.39	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
HNSC	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-6.01	3.75e-09	1.68e-06	-0.4	-0.27	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
HNSC	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-6.01	3.75e-09	1.68e-06	-0.29	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
HNSC	cis	rs8054556	0.787	rs12935701	ENSG00000183604.13	SMG1P5	-6.01	3.75e-09	1.68e-06	-0.27	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30267553~30335374:-
HNSC	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-6.01	3.75e-09	1.68e-06	-0.22	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
HNSC	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-6.01	3.75e-09	1.68e-06	-0.22	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
HNSC	cis	rs7674212	0.57	rs6841136	ENSG00000246560.2	RP11-10L12.4	6.01	3.76e-09	1.68e-06	0.3	0.27	Type 2 diabetes;	chr4:103182352	chr4:102828055~102844075:+
HNSC	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	6.01	3.76e-09	1.68e-06	0.36	0.27	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
HNSC	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	6.01	3.76e-09	1.68e-06	0.32	0.27	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
HNSC	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-6.01	3.76e-09	1.69e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000254340.1	RP11-10A14.3	-6.01	3.78e-09	1.69e-06	-0.32	-0.27	Joint mobility (Beighton score);	chr8:9225923	chr8:9141424~9145435:+
HNSC	cis	rs2337406	1	rs74090714	ENSG00000211974.3	IGHV2-70	-6.01	3.78e-09	1.69e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106691225	chr14:106723574~106724093:-
HNSC	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-6.01	3.78e-09	1.69e-06	-0.3	-0.27	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
HNSC	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	6.01	3.78e-09	1.69e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
HNSC	cis	rs17507216	0.609	rs1431716	ENSG00000255769.6	GOLGA2P10	-6.01	3.78e-09	1.69e-06	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82676180	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	6.01	3.79e-09	1.7e-06	0.35	0.27	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
HNSC	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	6.01	3.79e-09	1.7e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
HNSC	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	6.01	3.79e-09	1.7e-06	0.37	0.27	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
HNSC	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-6.01	3.79e-09	1.7e-06	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
HNSC	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	6.01	3.8e-09	1.7e-06	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
HNSC	cis	rs4218	0.543	rs4775110	ENSG00000259732.1	RP11-59H7.3	-6.01	3.8e-09	1.7e-06	-0.35	-0.27	Social communication problems;	chr15:59023685	chr15:59121034~59133250:+
HNSC	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	6.01	3.8e-09	1.7e-06	0.3	0.27	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	6.01	3.8e-09	1.7e-06	0.3	0.27	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
HNSC	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	6.01	3.8e-09	1.7e-06	0.36	0.27	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	6.01	3.8e-09	1.7e-06	0.36	0.27	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	6.01	3.8e-09	1.7e-06	0.36	0.27	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
HNSC	cis	rs7674212	0.57	rs1031804	ENSG00000246560.2	RP11-10L12.4	6.01	3.8e-09	1.7e-06	0.3	0.27	Type 2 diabetes;	chr4:103144892	chr4:102828055~102844075:+
HNSC	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	6.01	3.8e-09	1.7e-06	0.35	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
HNSC	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	6.01	3.8e-09	1.7e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
HNSC	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	6.01	3.8e-09	1.7e-06	0.3	0.27	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
HNSC	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	6.01	3.8e-09	1.7e-06	0.37	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
HNSC	cis	rs9341808	0.714	rs9448911	ENSG00000272129.1	RP11-250B2.6	6.01	3.81e-09	1.7e-06	0.31	0.27	Sitting height ratio;	chr6:80204142	chr6:80355424~80356859:+
HNSC	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	6.01	3.81e-09	1.7e-06	0.38	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
HNSC	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-6.01	3.81e-09	1.7e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	6.01	3.81e-09	1.7e-06	0.21	0.27	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
HNSC	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	6.01	3.81e-09	1.7e-06	0.34	0.27	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
HNSC	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-6.01	3.81e-09	1.71e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
HNSC	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	6.01	3.81e-09	1.71e-06	0.2	0.27	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
HNSC	cis	rs6918586	0.658	rs198809	ENSG00000272462.2	U91328.19	-6.01	3.82e-09	1.71e-06	-0.25	-0.27	Schizophrenia;	chr6:26128538	chr6:25992662~26001775:+
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-6.01	3.82e-09	1.71e-06	-0.32	-0.27	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
HNSC	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	6.01	3.82e-09	1.71e-06	0.34	0.27	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
HNSC	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	6.01	3.82e-09	1.71e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
HNSC	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-6.01	3.82e-09	1.71e-06	-0.4	-0.27	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
HNSC	cis	rs9341808	0.591	rs6454147	ENSG00000272129.1	RP11-250B2.6	6.01	3.82e-09	1.71e-06	0.31	0.27	Sitting height ratio;	chr6:80206611	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.628	rs9294172	ENSG00000272129.1	RP11-250B2.6	6.01	3.82e-09	1.71e-06	0.31	0.27	Sitting height ratio;	chr6:80208844	chr6:80355424~80356859:+
HNSC	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-6.01	3.82e-09	1.71e-06	-0.31	-0.27	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
HNSC	cis	rs8177876	0.554	rs56286107	ENSG00000261061.1	RP11-303E16.2	-6.01	3.83e-09	1.71e-06	-0.5	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81030770~81031485:+
HNSC	cis	rs1823913	1	rs13019004	ENSG00000280083.1	RP11-317J9.1	-6.01	3.83e-09	1.71e-06	-0.33	-0.27	Obesity-related traits;	chr2:191245493	chr2:191154118~191156070:-
HNSC	cis	rs7811142	1	rs60257855	ENSG00000078319.8	PMS2P1	-6.01	3.83e-09	1.71e-06	-0.34	-0.27	Platelet count;	chr7:100429157	chr7:100320992~100341908:-
HNSC	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-6.01	3.83e-09	1.71e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
HNSC	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-6.01	3.84e-09	1.71e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
HNSC	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	6.01	3.85e-09	1.72e-06	0.29	0.27	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
HNSC	cis	rs11846409	0.587	rs1806881	ENSG00000211974.3	IGHV2-70	6	3.85e-09	1.72e-06	0.31	0.27	Rheumatic heart disease;	chr14:106650770	chr14:106723574~106724093:-
HNSC	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-6	3.85e-09	1.72e-06	-0.37	-0.27	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
HNSC	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-6	3.85e-09	1.72e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	6	3.86e-09	1.72e-06	0.21	0.27	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
HNSC	cis	rs75920871	0.528	rs2513094	ENSG00000254851.1	RP11-109L13.1	6	3.86e-09	1.73e-06	0.38	0.27	Subjective well-being;	chr11:116935696	chr11:117135528~117138582:+
HNSC	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	6	3.87e-09	1.73e-06	0.36	0.27	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
HNSC	cis	rs4639966	0.723	rs11217022	ENSG00000255422.1	AP002954.4	6	3.87e-09	1.73e-06	0.37	0.27	Systemic lupus erythematosus;	chr11:118770897	chr11:118704607~118750263:+
HNSC	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-6	3.87e-09	1.73e-06	-0.25	-0.27	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
HNSC	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-6	3.87e-09	1.73e-06	-0.32	-0.27	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
HNSC	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	6	3.88e-09	1.73e-06	0.35	0.27	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
HNSC	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	6	3.89e-09	1.74e-06	0.3	0.27	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	6	3.89e-09	1.74e-06	0.3	0.27	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	6	3.89e-09	1.74e-06	0.3	0.27	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
HNSC	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	6	3.89e-09	1.74e-06	0.33	0.27	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
HNSC	cis	rs6928977	0.675	rs6908428	ENSG00000217482.2	HMGB1P17	6	3.9e-09	1.74e-06	0.3	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135636086~135636713:-
HNSC	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	6	3.9e-09	1.74e-06	0.37	0.27	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
HNSC	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	6	3.91e-09	1.74e-06	0.31	0.27	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
HNSC	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	6	3.91e-09	1.74e-06	0.27	0.27	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
HNSC	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-6	3.91e-09	1.75e-06	-0.51	-0.27	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
HNSC	cis	rs2337406	0.539	rs2583290	ENSG00000211974.3	IGHV2-70	6	3.91e-09	1.75e-06	0.31	0.27	Alzheimer's disease (late onset);	chr14:106650277	chr14:106723574~106724093:-
HNSC	cis	rs6928977	0.896	rs2746429	ENSG00000234084.1	RP3-388E23.2	6	3.91e-09	1.75e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352146	chr6:135301568~135307158:+
HNSC	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	6	3.92e-09	1.75e-06	0.32	0.27	Height;	chr4:55527164	chr4:55363971~55395847:-
HNSC	cis	rs7615952	0.673	rs115942855	ENSG00000248787.1	RP11-666A20.4	-6	3.92e-09	1.75e-06	-0.49	-0.27	Blood pressure (smoking interaction);	chr3:125883117	chr3:125908005~125910272:-
HNSC	cis	rs4218	0.551	rs12906212	ENSG00000277144.1	RP11-59H7.4	-6	3.92e-09	1.75e-06	-0.37	-0.27	Social communication problems;	chr15:59070556	chr15:59115547~59116089:-
HNSC	cis	rs6604026	0.555	rs3790450	ENSG00000223787.2	RP4-593M8.1	6	3.93e-09	1.75e-06	0.36	0.27	Multiple sclerosis;	chr1:92625508	chr1:92580476~92580821:-
HNSC	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-6	3.93e-09	1.75e-06	-0.4	-0.27	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
HNSC	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	6	3.93e-09	1.75e-06	0.25	0.27	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
HNSC	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	6	3.94e-09	1.76e-06	0.3	0.27	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
HNSC	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	6	3.94e-09	1.76e-06	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
HNSC	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	6	3.94e-09	1.76e-06	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
HNSC	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	6	3.95e-09	1.76e-06	0.27	0.27	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
HNSC	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-6	3.95e-09	1.76e-06	-0.38	-0.27	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
HNSC	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-6	3.95e-09	1.76e-06	-0.33	-0.27	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
HNSC	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-6	3.95e-09	1.76e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-6	3.95e-09	1.76e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-6	3.95e-09	1.76e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
HNSC	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	6	3.96e-09	1.77e-06	0.33	0.27	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
HNSC	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-6	3.96e-09	1.77e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
HNSC	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	6	3.98e-09	1.77e-06	0.31	0.27	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
HNSC	cis	rs6918586	0.658	rs198844	ENSG00000272462.2	U91328.19	-6	3.98e-09	1.78e-06	-0.25	-0.27	Schizophrenia;	chr6:26108054	chr6:25992662~26001775:+
HNSC	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-6	3.98e-09	1.78e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
HNSC	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-6	3.98e-09	1.78e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
HNSC	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-6	3.98e-09	1.78e-06	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-6	3.99e-09	1.78e-06	-0.32	-0.27	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
HNSC	cis	rs13113518	0.756	rs11939652	ENSG00000273257.1	RP11-177J6.1	6	3.99e-09	1.78e-06	0.33	0.27	Height;	chr4:55532542	chr4:55387949~55388271:+
HNSC	cis	rs1355223	1	rs11604069	ENSG00000271369.1	RP11-350D17.3	-6	4e-09	1.78e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742704	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-6	4e-09	1.78e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
HNSC	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-6	4e-09	1.78e-06	-0.35	-0.27	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
HNSC	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	6	4e-09	1.78e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
HNSC	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-6	4e-09	1.78e-06	-0.26	-0.27	Height;	chr2:231541633	chr2:231508426~231514339:-
HNSC	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	6	4.01e-09	1.79e-06	0.35	0.27	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
HNSC	cis	rs1799949	0.894	rs71367985	ENSG00000267151.3	RP11-100E5.2	6	4.02e-09	1.79e-06	0.34	0.27	Menopause (age at onset);	chr17:43222443	chr17:43444707~43451200:+
HNSC	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	6	4.03e-09	1.8e-06	0.2	0.27	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
HNSC	cis	rs7811142	0.887	rs4074838	ENSG00000078319.8	PMS2P1	-6	4.03e-09	1.8e-06	-0.34	-0.27	Platelet count;	chr7:100435042	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11764818	ENSG00000078319.8	PMS2P1	-6	4.03e-09	1.8e-06	-0.34	-0.27	Platelet count;	chr7:100445432	chr7:100320992~100341908:-
HNSC	cis	rs17270561	0.609	rs1165211	ENSG00000272462.2	U91328.19	-6	4.04e-09	1.8e-06	-0.26	-0.27	Iron status biomarkers;	chr6:25800694	chr6:25992662~26001775:+
HNSC	cis	rs1021993	0.672	rs2843167	ENSG00000231648.1	RP11-372M18.2	-6	4.04e-09	1.8e-06	-0.33	-0.27	Gut microbiome composition (winter);	chr1:209339552	chr1:209367662~209379690:+
HNSC	cis	rs9907295	0.636	rs4251703	ENSG00000270977.1	AC015849.16	-6	4.04e-09	1.8e-06	-0.31	-0.27	Fibroblast growth factor basic levels;	chr17:35807954	chr17:35893707~35911023:-
HNSC	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-6	4.04e-09	1.8e-06	-0.41	-0.27	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
HNSC	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-6	4.05e-09	1.8e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
HNSC	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-6	4.05e-09	1.8e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
HNSC	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-6	4.05e-09	1.8e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
HNSC	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-6	4.05e-09	1.8e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
HNSC	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-6	4.05e-09	1.8e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
HNSC	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	6	4.05e-09	1.8e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	6	4.05e-09	1.8e-06	0.21	0.27	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-6	4.05e-09	1.8e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000235689.1	AP000351.13	6	4.05e-09	1.81e-06	0.27	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:24006305~24008258:-
HNSC	cis	rs858239	0.669	rs1618339	ENSG00000226816.2	AC005082.12	6	4.05e-09	1.81e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23206013~23208045:+
HNSC	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	6	4.06e-09	1.81e-06	0.25	0.27	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	6	4.07e-09	1.81e-06	0.25	0.27	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	6	4.07e-09	1.81e-06	0.25	0.27	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
HNSC	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-5.99	4.08e-09	1.81e-06	-0.41	-0.27	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
HNSC	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	5.99	4.08e-09	1.82e-06	0.36	0.27	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	5.99	4.08e-09	1.82e-06	0.36	0.27	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
HNSC	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-5.99	4.08e-09	1.82e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000254340.1	RP11-10A14.3	5.99	4.08e-09	1.82e-06	0.33	0.27	Mood instability;	chr8:8828344	chr8:9141424~9145435:+
HNSC	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	5.99	4.08e-09	1.82e-06	0.3	0.27	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-5.99	4.08e-09	1.82e-06	-0.39	-0.27	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
HNSC	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	5.99	4.09e-09	1.82e-06	0.3	0.27	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
HNSC	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	5.99	4.09e-09	1.82e-06	0.35	0.27	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-5.99	4.09e-09	1.82e-06	-0.31	-0.27	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
HNSC	cis	rs6928977	0.675	rs7750586	ENSG00000234084.1	RP3-388E23.2	5.99	4.09e-09	1.82e-06	0.28	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135301568~135307158:+
HNSC	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-5.99	4.09e-09	1.82e-06	-0.39	-0.27	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-5.99	4.09e-09	1.82e-06	-0.32	-0.27	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	5.99	4.1e-09	1.82e-06	0.21	0.27	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	5.99	4.1e-09	1.82e-06	0.21	0.27	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
HNSC	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-5.99	4.1e-09	1.82e-06	-0.34	-0.27	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
HNSC	cis	rs7617773	0.501	rs12185901	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48341429	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs13082217	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48341774	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs11706939	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48342502	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs11130165	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48343231	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs1471217	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48343405	chr3:48290793~48291375:-
HNSC	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-5.99	4.1e-09	1.83e-06	-0.32	-0.27	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
HNSC	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	5.99	4.11e-09	1.83e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	5.99	4.11e-09	1.83e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	5.99	4.11e-09	1.83e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
HNSC	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-5.99	4.11e-09	1.83e-06	-0.48	-0.27	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
HNSC	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-5.99	4.11e-09	1.83e-06	-0.32	-0.27	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	5.99	4.11e-09	1.83e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
HNSC	cis	rs2115630	1	rs2115630	ENSG00000229212.6	RP11-561C5.4	5.99	4.11e-09	1.83e-06	0.31	0.27	P wave terminal force;	chr15:84821285	chr15:85205440~85234795:-
HNSC	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
HNSC	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	5.99	4.11e-09	1.83e-06	0.37	0.27	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
HNSC	cis	rs6928977	0.896	rs2614259	ENSG00000234084.1	RP3-388E23.2	5.99	4.11e-09	1.83e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356114	chr6:135301568~135307158:+
HNSC	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	5.99	4.12e-09	1.83e-06	0.31	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
HNSC	cis	rs11992162	0.551	rs59191504	ENSG00000206014.6	OR7E161P	5.99	4.12e-09	1.83e-06	0.29	0.27	Monocyte count;	chr8:11927572	chr8:11928597~11929563:-
HNSC	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-5.99	4.12e-09	1.83e-06	-0.23	-0.27	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
HNSC	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
HNSC	cis	rs6751744	0.513	rs7563368	ENSG00000226266.5	AC009961.3	5.99	4.12e-09	1.83e-06	0.29	0.27	Dysphagia;	chr2:159600564	chr2:159670708~159712435:-
HNSC	cis	rs11992162	0.56	rs13256329	ENSG00000206014.6	OR7E161P	5.99	4.13e-09	1.83e-06	0.29	0.27	Monocyte count;	chr8:11924705	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.638	rs67146188	ENSG00000206014.6	OR7E161P	5.99	4.13e-09	1.83e-06	0.29	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11928597~11929563:-
HNSC	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	5.99	4.13e-09	1.84e-06	0.3	0.27	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	5.99	4.13e-09	1.84e-06	0.43	0.27	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
HNSC	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	5.99	4.13e-09	1.84e-06	0.32	0.27	Height;	chr4:55493557	chr4:55363971~55395847:-
HNSC	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-5.99	4.14e-09	1.84e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
HNSC	cis	rs1799949	0.965	rs7223952	ENSG00000267151.3	RP11-100E5.2	5.99	4.14e-09	1.84e-06	0.35	0.27	Menopause (age at onset);	chr17:43042868	chr17:43444707~43451200:+
HNSC	cis	rs853679	1	rs6905391	ENSG00000219392.1	RP1-265C24.5	-5.99	4.14e-09	1.84e-06	-0.4	-0.27	Depression;	chr6:28294909	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.896	rs9321501	ENSG00000234084.1	RP3-388E23.2	5.99	4.15e-09	1.84e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320279	chr6:135301568~135307158:+
HNSC	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-5.99	4.15e-09	1.84e-06	-0.32	-0.27	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
HNSC	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-5.99	4.15e-09	1.84e-06	-0.33	-0.27	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
HNSC	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	5.99	4.15e-09	1.85e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
HNSC	cis	rs453301	0.686	rs11785819	ENSG00000173295.6	FAM86B3P	-5.99	4.16e-09	1.85e-06	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9012868	chr8:8228595~8244865:+
HNSC	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-5.99	4.16e-09	1.85e-06	-0.47	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
HNSC	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	5.99	4.16e-09	1.85e-06	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
HNSC	cis	rs4803480	0.543	rs7257282	ENSG00000270164.1	LINC01480	-5.99	4.16e-09	1.85e-06	-0.25	-0.27	Schizophrenia;	chr19:41536585	chr19:41535183~41536904:+
HNSC	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-5.99	4.17e-09	1.85e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-5.99	4.17e-09	1.85e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
HNSC	cis	rs2235642	0.653	rs7197288	ENSG00000280231.1	LA16c-380F5.3	-5.99	4.17e-09	1.85e-06	-0.33	-0.27	Coronary artery disease;	chr16:1604752	chr16:1553655~1554130:-
HNSC	cis	rs11992162	0.508	rs7003792	ENSG00000206014.6	OR7E161P	5.99	4.17e-09	1.85e-06	0.29	0.27	Monocyte count;	chr8:11923955	chr8:11928597~11929563:-
HNSC	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.85e-06	0.36	0.27	Depression;	chr6:28205175	chr6:28943877~28944537:+
HNSC	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-5.99	4.18e-09	1.86e-06	-0.38	-0.27	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
HNSC	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	5.99	4.18e-09	1.86e-06	0.34	0.27	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
HNSC	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	5.99	4.18e-09	1.86e-06	0.27	0.27	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
HNSC	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	5.99	4.19e-09	1.86e-06	0.3	0.27	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
HNSC	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	5.99	4.19e-09	1.86e-06	0.32	0.27	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
HNSC	cis	rs4218	0.597	rs12438111	ENSG00000259732.1	RP11-59H7.3	-5.99	4.2e-09	1.86e-06	-0.37	-0.27	Social communication problems;	chr15:59057540	chr15:59121034~59133250:+
HNSC	cis	rs2115630	1	rs2879828	ENSG00000229212.6	RP11-561C5.4	5.99	4.22e-09	1.87e-06	0.31	0.27	P wave terminal force;	chr15:84818746	chr15:85205440~85234795:-
HNSC	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	5.99	4.22e-09	1.87e-06	0.3	0.27	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
HNSC	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-5.99	4.22e-09	1.87e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-5.99	4.22e-09	1.87e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
HNSC	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	5.99	4.22e-09	1.87e-06	0.41	0.27	Height;	chr6:109409645	chr6:109382795~109383666:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000254153.1	CTA-398F10.2	-5.99	4.23e-09	1.87e-06	-0.29	-0.27	Mood instability;	chr8:8523020	chr8:8456909~8461337:-
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-5.99	4.23e-09	1.87e-06	-0.32	-0.27	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
HNSC	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	5.99	4.23e-09	1.88e-06	0.36	0.27	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
HNSC	cis	rs6928977	0.896	rs2064431	ENSG00000234084.1	RP3-388E23.2	5.99	4.23e-09	1.88e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324065	chr6:135301568~135307158:+
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-5.99	4.24e-09	1.88e-06	-0.31	-0.27	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
HNSC	cis	rs4639966	0.684	rs487177	ENSG00000255422.1	AP002954.4	5.99	4.24e-09	1.88e-06	0.37	0.27	Systemic lupus erythematosus;	chr11:118786588	chr11:118704607~118750263:+
HNSC	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	5.99	4.24e-09	1.88e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
HNSC	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-5.99	4.24e-09	1.88e-06	-0.39	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
HNSC	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-5.99	4.25e-09	1.88e-06	-0.32	-0.27	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-5.99	4.25e-09	1.88e-06	-0.32	-0.27	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
HNSC	cis	rs9300255	0.568	rs3018098	ENSG00000280120.1	RP11-546D6.3	5.99	4.25e-09	1.88e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123170265	chr12:123152324~123153377:-
HNSC	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-5.99	4.25e-09	1.88e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
HNSC	cis	rs17772222	0.675	rs845758	ENSG00000258789.1	RP11-507K2.3	5.99	4.25e-09	1.88e-06	0.3	0.27	Coronary artery calcification;	chr14:88433746	chr14:88551597~88552493:+
HNSC	cis	rs6928977	0.675	rs12206850	ENSG00000234084.1	RP3-388E23.2	-5.99	4.25e-09	1.88e-06	-0.28	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135476670	chr6:135301568~135307158:+
HNSC	cis	rs465969	0.744	rs34659678	ENSG00000255389.1	C6orf3	-5.99	4.26e-09	1.88e-06	-0.5	-0.27	Psoriasis;	chr6:111567337	chr6:111599875~111602295:+
HNSC	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-5.99	4.26e-09	1.89e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-5.99	4.26e-09	1.89e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
HNSC	cis	rs6918586	0.658	rs198803	ENSG00000272462.2	U91328.19	-5.99	4.26e-09	1.89e-06	-0.25	-0.27	Schizophrenia;	chr6:26134824	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	5.99	4.26e-09	1.89e-06	0.36	0.27	Depression;	chr6:28197321	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	5.99	4.26e-09	1.89e-06	0.36	0.27	Depression;	chr6:28197412	chr6:28943877~28944537:+
HNSC	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-5.99	4.26e-09	1.89e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
HNSC	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-5.99	4.26e-09	1.89e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
HNSC	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	5.99	4.26e-09	1.89e-06	0.36	0.27	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
HNSC	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-5.99	4.27e-09	1.89e-06	-0.38	-0.27	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
HNSC	cis	rs2985684	0.948	rs12897941	ENSG00000258568.1	RHOQP1	5.99	4.28e-09	1.9e-06	0.27	0.27	Carotid intima media thickness;	chr14:49549983	chr14:49599994~49600572:+
HNSC	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-5.99	4.28e-09	1.9e-06	-0.33	-0.27	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-5.99	4.28e-09	1.9e-06	-0.33	-0.27	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
HNSC	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	5.99	4.28e-09	1.9e-06	0.28	0.27	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
HNSC	cis	rs35955747	0.777	rs5997895	ENSG00000236132.1	CTA-440B3.1	5.99	4.29e-09	1.9e-06	0.28	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31170187	chr22:31816379~31817491:-
HNSC	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-5.99	4.3e-09	1.9e-06	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
HNSC	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-5.99	4.3e-09	1.9e-06	-0.47	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
HNSC	cis	rs11846409	1	rs11846409	ENSG00000211974.3	IGHV2-70	-5.99	4.3e-09	1.9e-06	-0.31	-0.27	Rheumatic heart disease;	chr14:106645692	chr14:106723574~106724093:-
HNSC	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	5.99	4.31e-09	1.91e-06	0.37	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	5.99	4.31e-09	1.91e-06	0.37	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
HNSC	cis	rs6471393	0.861	rs2976372	ENSG00000253848.1	RP11-10N23.5	-5.99	4.31e-09	1.91e-06	-0.34	-0.27	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93690797	chr8:93741193~93744534:+
HNSC	cis	rs9300255	0.602	rs1727306	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123181148	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.512	rs2851436	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123182807	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.544	rs1716157	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123185926	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.544	rs10772995	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123187214	chr12:123152324~123153377:-
HNSC	cis	rs4218	0.619	rs10851643	ENSG00000259732.1	RP11-59H7.3	-5.99	4.31e-09	1.91e-06	-0.35	-0.27	Social communication problems;	chr15:59102985	chr15:59121034~59133250:+
HNSC	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	5.98	4.32e-09	1.91e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000173295.6	FAM86B3P	-5.98	4.32e-09	1.91e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9035087	chr8:8228595~8244865:+
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-5.98	4.32e-09	1.91e-06	-0.31	-0.27	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
HNSC	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	5.98	4.33e-09	1.91e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
HNSC	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	5.98	4.33e-09	1.92e-06	0.34	0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
HNSC	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	5.98	4.33e-09	1.92e-06	0.36	0.27	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	5.98	4.34e-09	1.92e-06	0.32	0.27	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
HNSC	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	5.98	4.34e-09	1.92e-06	0.38	0.27	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
HNSC	cis	rs7209700	0.662	rs11656865	ENSG00000228782.6	CTD-2026D20.3	-5.98	4.34e-09	1.92e-06	-0.28	-0.27	IgG glycosylation;	chr17:47269123	chr17:47450568~47492492:-
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	5.98	4.34e-09	1.92e-06	0.3	0.27	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
HNSC	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-5.98	4.34e-09	1.92e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
HNSC	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	5.98	4.34e-09	1.92e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000254340.1	RP11-10A14.3	-5.98	4.35e-09	1.92e-06	-0.32	-0.27	Joint mobility (Beighton score);	chr8:9226261	chr8:9141424~9145435:+
HNSC	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-5.98	4.36e-09	1.93e-06	-0.39	-0.27	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
HNSC	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-5.98	4.36e-09	1.93e-06	-0.33	-0.27	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
HNSC	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-5.98	4.36e-09	1.93e-06	-0.32	-0.27	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
HNSC	cis	rs2880765	0.835	rs7169429	ENSG00000259295.5	CSPG4P12	5.98	4.37e-09	1.93e-06	0.3	0.27	Coronary artery disease;	chr15:85493417	chr15:85191438~85213905:+
HNSC	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	5.98	4.37e-09	1.93e-06	0.31	0.27	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
HNSC	cis	rs1865760	0.593	rs3903852	ENSG00000272462.2	U91328.19	-5.98	4.38e-09	1.94e-06	-0.25	-0.27	Height;	chr6:25914919	chr6:25992662~26001775:+
HNSC	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	5.98	4.38e-09	1.94e-06	0.34	0.27	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
HNSC	cis	rs11846409	0.86	rs73378154	ENSG00000211974.3	IGHV2-70	-5.98	4.39e-09	1.94e-06	-0.3	-0.27	Rheumatic heart disease;	chr14:106637687	chr14:106723574~106724093:-
HNSC	cis	rs11154801	0.696	rs4432992	ENSG00000217482.2	HMGB1P17	5.98	4.39e-09	1.94e-06	0.31	0.27	Multiple sclerosis;	chr6:135612356	chr6:135636086~135636713:-
HNSC	cis	rs13113518	1	rs13132420	ENSG00000273257.1	RP11-177J6.1	-5.98	4.39e-09	1.94e-06	-0.32	-0.27	Height;	chr4:55526646	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.738	rs6849883	ENSG00000273257.1	RP11-177J6.1	5.98	4.4e-09	1.94e-06	0.32	0.27	Height;	chr4:55387515	chr4:55387949~55388271:+
HNSC	cis	rs7674212	0.537	rs2623060	ENSG00000246560.2	RP11-10L12.4	5.98	4.4e-09	1.94e-06	0.3	0.27	Type 2 diabetes;	chr4:103126347	chr4:102828055~102844075:+
HNSC	cis	rs831571	0.915	rs6797912	ENSG00000280620.1	SCAANT1	-5.98	4.4e-09	1.94e-06	-0.38	-0.27	Type 2 diabetes;	chr3:64072564	chr3:63911518~63911772:-
HNSC	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-5.98	4.41e-09	1.95e-06	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
HNSC	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	5.98	4.41e-09	1.95e-06	0.39	0.27	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
HNSC	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	5.98	4.41e-09	1.95e-06	0.39	0.27	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
HNSC	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-5.98	4.41e-09	1.95e-06	-0.33	-0.27	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
HNSC	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-5.98	4.41e-09	1.95e-06	-0.33	-0.27	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
HNSC	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-5.98	4.41e-09	1.95e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
HNSC	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-5.98	4.42e-09	1.95e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-5.98	4.42e-09	1.95e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
HNSC	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	5.98	4.42e-09	1.95e-06	0.38	0.27	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
HNSC	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-5.98	4.42e-09	1.95e-06	-0.32	-0.27	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
HNSC	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-5.98	4.43e-09	1.95e-06	-0.38	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
HNSC	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-5.98	4.43e-09	1.95e-06	-0.38	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
HNSC	cis	rs7402982	0.625	rs4966009	ENSG00000278022.1	RP11-35O15.2	-5.98	4.43e-09	1.96e-06	-0.31	-0.27	Birth weight;	chr15:98660267	chr15:98660210~98660668:+
HNSC	cis	rs8031584	0.678	rs798127	ENSG00000260382.1	RP11-540B6.2	-5.98	4.43e-09	1.96e-06	-0.34	-0.27	Huntington's disease progression;	chr15:30825200	chr15:30882267~30883231:-
HNSC	cis	rs17270561	0.583	rs7749149	ENSG00000272462.2	U91328.19	-5.98	4.43e-09	1.96e-06	-0.27	-0.27	Iron status biomarkers;	chr6:25780911	chr6:25992662~26001775:+
HNSC	cis	rs8177876	0.749	rs12444969	ENSG00000261061.1	RP11-303E16.2	-5.98	4.44e-09	1.96e-06	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81030770~81031485:+
HNSC	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	5.98	4.45e-09	1.96e-06	0.41	0.27	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
HNSC	cis	rs13126694	0.744	rs10005901	ENSG00000248429.4	RP11-597D13.9	5.98	4.45e-09	1.96e-06	0.3	0.27	Blood osmolality (transformed sodium);	chr4:158041750	chr4:158170752~158202877:+
HNSC	cis	rs860295	0.871	rs6688636	ENSG00000203761.5	MSTO2P	5.98	4.45e-09	1.97e-06	0.2	0.27	Body mass index;	chr1:155509106	chr1:155745829~155750137:+
HNSC	cis	rs4639966	0.756	rs61219050	ENSG00000255422.1	AP002954.4	5.98	4.46e-09	1.97e-06	0.37	0.27	Systemic lupus erythematosus;	chr11:118777915	chr11:118704607~118750263:+
HNSC	cis	rs453301	0.686	rs28482034	ENSG00000173295.6	FAM86B3P	-5.98	4.47e-09	1.97e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9012154	chr8:8228595~8244865:+
HNSC	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-5.98	4.48e-09	1.98e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
HNSC	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	5.98	4.48e-09	1.98e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
HNSC	cis	rs2337406	0.866	rs11488879	ENSG00000211974.3	IGHV2-70	-5.98	4.49e-09	1.98e-06	-0.32	-0.27	Alzheimer's disease (late onset);	chr14:106786097	chr14:106723574~106724093:-
HNSC	cis	rs947583	0.588	rs6925090	ENSG00000217482.2	HMGB1P17	5.98	4.49e-09	1.98e-06	0.29	0.27	Phosphorus levels;	chr6:135795339	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	5.98	4.49e-09	1.98e-06	0.33	0.27	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-5.98	4.5e-09	1.98e-06	-0.21	-0.27	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
HNSC	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	5.98	4.5e-09	1.98e-06	0.29	0.27	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
HNSC	cis	rs2286503	0.78	rs981792	ENSG00000221740.1	SNORD93	5.98	4.5e-09	1.98e-06	0.29	0.27	Fibrinogen;	chr7:22822020	chr7:22856613~22856686:+
HNSC	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-5.98	4.5e-09	1.99e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
HNSC	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	5.98	4.51e-09	1.99e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.669	rs6461688	ENSG00000226816.2	AC005082.12	5.98	4.51e-09	1.99e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23206013~23208045:+
HNSC	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-5.98	4.51e-09	1.99e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
HNSC	cis	rs2880765	0.835	rs7180213	ENSG00000259295.5	CSPG4P12	5.98	4.51e-09	1.99e-06	0.3	0.27	Coronary artery disease;	chr15:85477956	chr15:85191438~85213905:+
HNSC	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-5.98	4.51e-09	1.99e-06	-0.33	-0.27	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
HNSC	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-5.98	4.52e-09	1.99e-06	-0.32	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
HNSC	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	5.98	4.52e-09	1.99e-06	0.29	0.27	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
HNSC	cis	rs2880765	0.835	rs4360875	ENSG00000259295.5	CSPG4P12	5.98	4.53e-09	2e-06	0.3	0.27	Coronary artery disease;	chr15:85497163	chr15:85191438~85213905:+
HNSC	cis	rs9326248	0.53	rs10732856	ENSG00000280143.1	AP000892.6	5.98	4.54e-09	2e-06	0.4	0.27	Blood protein levels;	chr11:117036397	chr11:117204967~117210292:+
HNSC	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	5.98	4.54e-09	2e-06	0.35	0.27	Height;	chr6:109350642	chr6:109382795~109383666:+
HNSC	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	5.98	4.54e-09	2e-06	0.28	0.27	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	5.98	4.55e-09	2e-06	0.21	0.27	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
HNSC	cis	rs17270561	0.609	rs1165208	ENSG00000272462.2	U91328.19	-5.98	4.55e-09	2.01e-06	-0.26	-0.27	Iron status biomarkers;	chr6:25803676	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-5.98	4.56e-09	2.01e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-5.98	4.56e-09	2.01e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
HNSC	cis	rs13113518	0.812	rs2035692	ENSG00000273257.1	RP11-177J6.1	5.98	4.56e-09	2.01e-06	0.33	0.27	Height;	chr4:55528801	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs4507426	ENSG00000273257.1	RP11-177J6.1	5.98	4.56e-09	2.01e-06	0.33	0.27	Height;	chr4:55529387	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs2035691	ENSG00000273257.1	RP11-177J6.1	5.98	4.56e-09	2.01e-06	0.33	0.27	Height;	chr4:55529786	chr4:55387949~55388271:+
HNSC	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-5.98	4.56e-09	2.01e-06	-0.36	-0.27	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
HNSC	cis	rs9525927	0.625	rs9533801	ENSG00000227258.4	SMIM2-AS1	5.98	4.56e-09	2.01e-06	0.4	0.27	Dupuytren's disease;	chr13:44242433	chr13:44110451~44240517:+
HNSC	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-5.97	4.57e-09	2.01e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
HNSC	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	5.97	4.57e-09	2.02e-06	0.27	0.27	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000211972.2	IGHV3-66	5.97	4.57e-09	2.02e-06	0.21	0.27	Kawasaki disease;	chr14:106716993	chr14:106675017~106675544:-
HNSC	cis	rs6504622	1	rs4968286	ENSG00000262879.4	RP11-156P1.3	-5.97	4.58e-09	2.02e-06	-0.29	-0.27	Orofacial clefts;	chr17:46940279	chr17:46984045~47100323:-
HNSC	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	5.97	4.58e-09	2.02e-06	0.33	0.27	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	5.97	4.58e-09	2.02e-06	0.33	0.27	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
HNSC	cis	rs6951245	0.572	rs75818004	ENSG00000224079.1	AC091729.7	-5.97	4.59e-09	2.02e-06	-0.57	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1007936	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.572	rs75083636	ENSG00000224079.1	AC091729.7	-5.97	4.59e-09	2.02e-06	-0.57	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1011164	chr7:1074450~1078036:+
HNSC	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	5.97	4.59e-09	2.02e-06	0.43	0.27	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
HNSC	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	5.97	4.59e-09	2.02e-06	0.3	0.27	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
HNSC	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	5.97	4.59e-09	2.02e-06	0.27	0.27	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
HNSC	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.59e-09	2.02e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
HNSC	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	5.97	4.59e-09	2.02e-06	0.3	0.27	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
HNSC	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-5.97	4.6e-09	2.02e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
HNSC	cis	rs6928977	0.896	rs1012645	ENSG00000234084.1	RP3-388E23.2	5.97	4.6e-09	2.02e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324309	chr6:135301568~135307158:+
HNSC	cis	rs4834770	1	rs4336213	ENSG00000249244.1	RP11-548H18.2	5.97	4.6e-09	2.02e-06	0.29	0.27	Blood protein levels;	chr4:119315314	chr4:119391831~119395335:-
HNSC	cis	rs7819412	0.811	rs2409691	ENSG00000269918.1	AF131215.9	-5.97	4.61e-09	2.03e-06	-0.26	-0.27	Triglycerides;	chr8:11085766	chr8:11104691~11106704:-
HNSC	cis	rs9341808	0.558	rs3805911	ENSG00000272129.1	RP11-250B2.6	5.97	4.61e-09	2.03e-06	0.31	0.27	Sitting height ratio;	chr6:80224279	chr6:80355424~80356859:+
HNSC	cis	rs2239557	1	rs10150201	ENSG00000259065.1	RP5-1021I20.1	5.97	4.61e-09	2.03e-06	0.32	0.27	Common traits (Other);	chr14:74182454	chr14:73787360~73803270:+
HNSC	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	5.97	4.62e-09	2.03e-06	0.28	0.27	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
HNSC	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	5.97	4.63e-09	2.04e-06	0.28	0.27	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
HNSC	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	5.97	4.65e-09	2.04e-06	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
HNSC	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	5.97	4.65e-09	2.05e-06	0.28	0.27	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
HNSC	cis	rs2834288	0.7	rs2834298	ENSG00000237945.6	LINC00649	-5.97	4.65e-09	2.05e-06	-0.34	-0.27	Gut microbiota (bacterial taxa);	chr21:33911251	chr21:33915534~33977691:+
HNSC	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	5.97	4.66e-09	2.05e-06	0.34	0.27	Height;	chr4:55566291	chr4:55363971~55395847:-
HNSC	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-5.97	4.66e-09	2.05e-06	-0.32	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
HNSC	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
HNSC	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	5.97	4.67e-09	2.05e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
HNSC	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	5.97	4.67e-09	2.05e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
HNSC	cis	rs2985684	0.948	rs12886130	ENSG00000258568.1	RHOQP1	5.97	4.67e-09	2.05e-06	0.28	0.27	Carotid intima media thickness;	chr14:49616035	chr14:49599994~49600572:+
HNSC	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-5.97	4.68e-09	2.06e-06	-0.36	-0.27	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
HNSC	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	5.97	4.68e-09	2.06e-06	0.32	0.27	Height;	chr4:55561053	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	5.97	4.68e-09	2.06e-06	0.32	0.27	Height;	chr4:55564241	chr4:55363971~55395847:-
HNSC	cis	rs4948102	0.642	rs766333	ENSG00000226278.1	PSPHP1	-5.97	4.68e-09	2.06e-06	-0.29	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55764797~55773288:+
HNSC	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	5.97	4.68e-09	2.06e-06	0.32	0.27	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	5.97	4.68e-09	2.06e-06	0.32	0.27	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
HNSC	cis	rs1799949	1	rs35070007	ENSG00000267151.3	RP11-100E5.2	-5.97	4.68e-09	2.06e-06	-0.34	-0.27	Menopause (age at onset);	chr17:43164730	chr17:43444707~43451200:+
HNSC	cis	rs710913	0.966	rs3738676	ENSG00000182109.6	RP11-69E11.4	5.97	4.68e-09	2.06e-06	0.26	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39525916	chr1:39522280~39546187:-
HNSC	cis	rs4218	0.635	rs10431792	ENSG00000259732.1	RP11-59H7.3	-5.97	4.68e-09	2.06e-06	-0.37	-0.27	Social communication problems;	chr15:59066181	chr15:59121034~59133250:+
HNSC	cis	rs9341808	0.667	rs3805913	ENSG00000272129.1	RP11-250B2.6	5.97	4.69e-09	2.06e-06	0.31	0.27	Sitting height ratio;	chr6:80217605	chr6:80355424~80356859:+
HNSC	cis	rs7674212	0.541	rs4699051	ENSG00000246560.2	RP11-10L12.4	5.97	4.69e-09	2.06e-06	0.3	0.27	Type 2 diabetes;	chr4:103193237	chr4:102828055~102844075:+
HNSC	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	5.97	4.69e-09	2.06e-06	0.29	0.27	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
HNSC	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-5.97	4.69e-09	2.06e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
HNSC	cis	rs11992162	0.967	rs10088415	ENSG00000206014.6	OR7E161P	5.97	4.7e-09	2.06e-06	0.28	0.27	Monocyte count;	chr8:11973316	chr8:11928597~11929563:-
HNSC	cis	rs7804306	0.826	rs73049252	ENSG00000233264.2	AC006042.8	5.97	4.7e-09	2.06e-06	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7976971	chr7:7980312~7982228:+
HNSC	cis	rs9910055	0.762	rs227579	ENSG00000267080.4	ASB16-AS1	5.97	4.7e-09	2.07e-06	0.21	0.27	Total body bone mineral density;	chr17:44145766	chr17:44175973~44186717:-
HNSC	cis	rs11098499	0.644	rs2389880	ENSG00000249244.1	RP11-548H18.2	5.97	4.7e-09	2.07e-06	0.34	0.27	Corneal astigmatism;	chr4:119638715	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	5.97	4.71e-09	2.07e-06	0.41	0.27	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
HNSC	cis	rs1865760	0.593	rs9393676	ENSG00000272462.2	U91328.19	-5.97	4.71e-09	2.07e-06	-0.25	-0.27	Height;	chr6:25936716	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.593	rs9295678	ENSG00000272462.2	U91328.19	-5.97	4.71e-09	2.07e-06	-0.25	-0.27	Height;	chr6:25936805	chr6:25992662~26001775:+
HNSC	cis	rs17772222	0.606	rs449338	ENSG00000258789.1	RP11-507K2.3	5.97	4.72e-09	2.07e-06	0.3	0.27	Coronary artery calcification;	chr14:88411690	chr14:88551597~88552493:+
HNSC	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-5.97	4.72e-09	2.07e-06	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
HNSC	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-5.97	4.72e-09	2.07e-06	-0.31	-0.27	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
HNSC	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	5.97	4.72e-09	2.07e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
HNSC	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-5.97	4.73e-09	2.08e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-5.97	4.73e-09	2.08e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-5.97	4.73e-09	2.08e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
HNSC	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	5.97	4.73e-09	2.08e-06	0.35	0.27	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
HNSC	cis	rs8031584	0.678	rs798125	ENSG00000260382.1	RP11-540B6.2	-5.97	4.73e-09	2.08e-06	-0.34	-0.27	Huntington's disease progression;	chr15:30824597	chr15:30882267~30883231:-
HNSC	cis	rs2239557	1	rs7153587	ENSG00000259065.1	RP5-1021I20.1	-5.97	4.73e-09	2.08e-06	-0.31	-0.27	Common traits (Other);	chr14:74042957	chr14:73787360~73803270:+
HNSC	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-5.97	4.73e-09	2.08e-06	-0.37	-0.27	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
HNSC	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	5.97	4.74e-09	2.08e-06	0.35	0.27	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
HNSC	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	5.97	4.75e-09	2.08e-06	0.31	0.27	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
HNSC	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	5.97	4.75e-09	2.08e-06	0.31	0.27	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
HNSC	cis	rs1021993	0.672	rs1876409	ENSG00000231648.1	RP11-372M18.2	5.97	4.75e-09	2.09e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209307758	chr1:209367662~209379690:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-5.97	4.75e-09	2.09e-06	-0.29	-0.27	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
HNSC	cis	rs1012068	0.686	rs5753818	ENSG00000236132.1	CTA-440B3.1	5.97	4.76e-09	2.09e-06	0.3	0.27	Chronic hepatitis C infection;	chr22:31917947	chr22:31816379~31817491:-
HNSC	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	5.97	4.76e-09	2.09e-06	0.24	0.27	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
HNSC	cis	rs6951245	0.572	rs79396168	ENSG00000224079.1	AC091729.7	-5.97	4.76e-09	2.09e-06	-0.56	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1009292	chr7:1074450~1078036:+
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000254340.1	RP11-10A14.3	5.97	4.77e-09	2.09e-06	0.33	0.27	Mood instability;	chr8:8846820	chr8:9141424~9145435:+
HNSC	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	5.97	4.77e-09	2.09e-06	0.31	0.27	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
HNSC	cis	rs2836974	0.544	rs8128919	ENSG00000255568.3	BRWD1-AS2	5.97	4.77e-09	2.09e-06	0.22	0.27	Cognitive function;	chr21:39339936	chr21:39313935~39314962:+
HNSC	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	5.97	4.78e-09	2.1e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
HNSC	cis	rs17772222	0.582	rs11625009	ENSG00000258789.1	RP11-507K2.3	5.97	4.78e-09	2.1e-06	0.3	0.27	Coronary artery calcification;	chr14:88521018	chr14:88551597~88552493:+
HNSC	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	5.97	4.79e-09	2.1e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
HNSC	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	5.97	4.81e-09	2.11e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-5.97	4.81e-09	2.11e-06	-0.32	-0.27	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
HNSC	cis	rs867371	0.502	rs28610286	ENSG00000276710.3	CSPG4P8	-5.97	4.82e-09	2.11e-06	-0.28	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000211970.3	IGHV4-61	-5.97	4.83e-09	2.12e-06	-0.18	-0.27	Kawasaki disease;	chr14:106711838	chr14:106639119~106639657:-
HNSC	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	5.97	4.83e-09	2.12e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
HNSC	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-5.97	4.83e-09	2.12e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
HNSC	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	5.96	4.84e-09	2.12e-06	0.32	0.27	Height;	chr4:55489895	chr4:55363971~55395847:-
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-5.96	4.84e-09	2.12e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
HNSC	cis	rs9326248	0.569	rs11216161	ENSG00000280143.1	AP000892.6	5.96	4.85e-09	2.12e-06	0.37	0.27	Blood protein levels;	chr11:116850485	chr11:117204967~117210292:+
HNSC	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	5.96	4.85e-09	2.13e-06	0.31	0.27	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
HNSC	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-5.96	4.85e-09	2.13e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-5.96	4.85e-09	2.13e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
HNSC	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	5.96	4.85e-09	2.13e-06	0.35	0.27	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
HNSC	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-5.96	4.85e-09	2.13e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-5.96	4.85e-09	2.13e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-5.96	4.85e-09	2.13e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
HNSC	cis	rs2286503	0.78	rs1304431	ENSG00000221740.1	SNORD93	5.96	4.85e-09	2.13e-06	0.29	0.27	Fibrinogen;	chr7:22825793	chr7:22856613~22856686:+
HNSC	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	5.96	4.86e-09	2.13e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
HNSC	cis	rs111315781	1	rs111315781	ENSG00000183308.6	AC005037.3	5.96	4.86e-09	2.13e-06	0.45	0.27	Triptolide cytotoxicity;	chr2:200874001	chr2:200963263~201009102:+
HNSC	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-5.96	4.86e-09	2.13e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
HNSC	cis	rs2235642	0.685	rs2667681	ENSG00000280231.1	LA16c-380F5.3	-5.96	4.87e-09	2.13e-06	-0.33	-0.27	Coronary artery disease;	chr16:1603205	chr16:1553655~1554130:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	5.96	4.87e-09	2.13e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
HNSC	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-5.96	4.87e-09	2.13e-06	-0.36	-0.27	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	5.96	4.88e-09	2.14e-06	0.21	0.27	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
HNSC	cis	rs6928977	0.932	rs6931735	ENSG00000234084.1	RP3-388E23.2	-5.96	4.88e-09	2.14e-06	-0.27	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135303673	chr6:135301568~135307158:+
HNSC	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	5.96	4.88e-09	2.14e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	5.96	4.88e-09	2.14e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
HNSC	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-5.96	4.9e-09	2.15e-06	-0.33	-0.27	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-5.96	4.9e-09	2.15e-06	-0.33	-0.27	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
HNSC	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	5.96	4.9e-09	2.15e-06	0.23	0.27	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
HNSC	cis	rs7824557	0.524	rs7835318	ENSG00000269918.1	AF131215.9	-5.96	4.91e-09	2.15e-06	-0.26	-0.27	Retinal vascular caliber;	chr8:11096364	chr8:11104691~11106704:-
HNSC	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	5.96	4.92e-09	2.15e-06	0.33	0.27	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
HNSC	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-5.96	4.92e-09	2.16e-06	-0.37	-0.27	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.675	rs6908428	ENSG00000234084.1	RP3-388E23.2	-5.96	4.92e-09	2.16e-06	-0.27	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135301568~135307158:+
HNSC	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	5.96	4.93e-09	2.16e-06	0.33	0.27	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
HNSC	cis	rs116095464	1	rs3777237	ENSG00000277812.1	AC021087.1	5.96	4.93e-09	2.16e-06	0.63	0.27	Breast cancer;	chr5:307526	chr5:262769~262881:+
HNSC	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-5.96	4.94e-09	2.16e-06	-0.34	-0.27	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
HNSC	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-5.96	4.94e-09	2.16e-06	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000173295.6	FAM86B3P	5.96	4.94e-09	2.16e-06	0.3	0.27	Mood instability;	chr8:8872978	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	5.96	4.94e-09	2.16e-06	0.33	0.27	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
HNSC	cis	rs2880765	0.743	rs11630410	ENSG00000259295.5	CSPG4P12	5.96	4.95e-09	2.16e-06	0.31	0.27	Coronary artery disease;	chr15:85461510	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.71	rs11630457	ENSG00000259295.5	CSPG4P12	5.96	4.95e-09	2.16e-06	0.31	0.27	Coronary artery disease;	chr15:85461570	chr15:85191438~85213905:+
HNSC	cis	rs7824557	0.505	rs2736313	ENSG00000269918.1	AF131215.9	5.96	4.95e-09	2.17e-06	0.26	0.27	Retinal vascular caliber;	chr8:11229433	chr8:11104691~11106704:-
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	5.96	4.95e-09	2.17e-06	0.3	0.27	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
HNSC	cis	rs1479119	0.78	rs7971776	ENSG00000180861.8	LINC01559	5.96	4.95e-09	2.17e-06	0.36	0.27	Intelligence (multi-trait analysis);	chr12:13347962	chr12:13371089~13387167:-
HNSC	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-5.96	4.96e-09	2.17e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
HNSC	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-5.96	4.96e-09	2.17e-06	-0.24	-0.27	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
HNSC	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-5.96	4.96e-09	2.17e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-5.96	4.96e-09	2.17e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
HNSC	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	5.96	4.96e-09	2.17e-06	0.3	0.27	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
HNSC	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-5.96	4.96e-09	2.17e-06	-0.35	-0.27	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-5.96	4.96e-09	2.17e-06	-0.35	-0.27	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
HNSC	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-5.96	4.96e-09	2.17e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
HNSC	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	5.96	4.98e-09	2.18e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	5.96	4.98e-09	2.18e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
HNSC	cis	rs1021993	0.62	rs1395748	ENSG00000231648.1	RP11-372M18.2	5.96	4.98e-09	2.18e-06	0.33	0.27	Gut microbiome composition (winter);	chr1:209302600	chr1:209367662~209379690:+
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000173295.6	FAM86B3P	-5.96	4.98e-09	2.18e-06	-0.3	-0.27	Mood instability;	chr8:8726362	chr8:8228595~8244865:+
HNSC	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	5.96	4.99e-09	2.18e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
HNSC	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	5.96	4.99e-09	2.18e-06	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
HNSC	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-5.96	5.03e-09	2.2e-06	-0.39	-0.27	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
HNSC	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-5.96	5.03e-09	2.2e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
HNSC	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-5.96	5.03e-09	2.2e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-5.96	5.03e-09	2.2e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
HNSC	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	5.96	5.03e-09	2.2e-06	0.27	0.27	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
HNSC	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	5.96	5.03e-09	2.2e-06	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
HNSC	cis	rs2579103	0.767	rs1545179	ENSG00000258183.4	RP11-753N8.1	-5.96	5.04e-09	2.2e-06	-0.37	-0.27	Body mass index;	chr12:90273213	chr12:90280894~90300340:+
HNSC	cis	rs11089937	0.667	rs10483108	ENSG00000211638.2	IGLV8-61	-5.96	5.06e-09	2.21e-06	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22098700~22099212:+
HNSC	cis	rs9300255	0.544	rs2049114	ENSG00000280120.1	RP11-546D6.3	5.96	5.06e-09	2.21e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123172791	chr12:123152324~123153377:-
HNSC	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-5.96	5.06e-09	2.21e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
HNSC	cis	rs6918586	0.658	rs198837	ENSG00000272462.2	U91328.19	5.96	5.07e-09	2.21e-06	0.25	0.27	Schizophrenia;	chr6:26113170	chr6:25992662~26001775:+
HNSC	cis	rs1021993	1	rs1021993	ENSG00000231648.1	RP11-372M18.2	-5.96	5.07e-09	2.21e-06	-0.37	-0.27	Gut microbiome composition (winter);	chr1:209339028	chr1:209367662~209379690:+
HNSC	cis	rs2834288	0.7	rs2834299	ENSG00000237945.6	LINC00649	-5.96	5.07e-09	2.22e-06	-0.36	-0.27	Gut microbiota (bacterial taxa);	chr21:33912198	chr21:33915534~33977691:+
HNSC	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-5.96	5.08e-09	2.22e-06	-0.38	-0.27	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
HNSC	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-5.96	5.08e-09	2.22e-06	-0.33	-0.27	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
HNSC	cis	rs7402982	0.647	rs34038360	ENSG00000278022.1	RP11-35O15.2	-5.96	5.08e-09	2.22e-06	-0.31	-0.27	Birth weight;	chr15:98658344	chr15:98660210~98660668:+
HNSC	cis	rs9987353	0.518	rs4841110	ENSG00000173295.6	FAM86B3P	5.96	5.08e-09	2.22e-06	0.31	0.27	Recombination measurement;	chr8:9228513	chr8:8228595~8244865:+
HNSC	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	5.96	5.1e-09	2.23e-06	0.33	0.27	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
HNSC	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	5.96	5.1e-09	2.23e-06	0.33	0.27	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
HNSC	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55486718	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55495262	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55502504	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55508982	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55509442	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55510177	chr4:55363971~55395847:-
HNSC	cis	rs2108622	0.545	rs59140933	ENSG00000267453.5	AC004791.2	-5.96	5.1e-09	2.23e-06	-0.33	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15851993~15864904:-
HNSC	cis	rs61160187	0.548	rs68104763	ENSG00000215032.2	GNL3LP1	5.96	5.1e-09	2.23e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60891935~60893577:-
HNSC	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	5.96	5.11e-09	2.23e-06	0.32	0.27	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
HNSC	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-5.96	5.11e-09	2.23e-06	-0.33	-0.27	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-5.96	5.11e-09	2.23e-06	-0.18	-0.27	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
HNSC	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	5.95	5.12e-09	2.24e-06	0.34	0.27	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
HNSC	cis	rs6604026	0.624	rs11800409	ENSG00000223787.2	RP4-593M8.1	5.95	5.12e-09	2.24e-06	0.37	0.27	Multiple sclerosis;	chr1:92715456	chr1:92580476~92580821:-
HNSC	cis	rs7811142	1	rs73161759	ENSG00000078319.8	PMS2P1	-5.95	5.13e-09	2.24e-06	-0.33	-0.27	Platelet count;	chr7:100412371	chr7:100320992~100341908:-
HNSC	cis	rs947583	0.517	rs9376148	ENSG00000217482.2	HMGB1P17	5.95	5.14e-09	2.24e-06	0.28	0.27	Phosphorus levels;	chr6:135777362	chr6:135636086~135636713:-
HNSC	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-5.95	5.15e-09	2.25e-06	-0.27	-0.27	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-5.95	5.15e-09	2.25e-06	-0.32	-0.27	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
HNSC	cis	rs526231	0.857	rs2569013	ENSG00000175749.11	EIF3KP1	5.95	5.15e-09	2.25e-06	0.35	0.27	Primary biliary cholangitis;	chr5:103305870	chr5:103032376~103033031:+
HNSC	cis	rs6969780	1	rs6976129	ENSG00000233429.8	HOTAIRM1	5.95	5.15e-09	2.25e-06	0.49	0.27	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27138127	chr7:27095647~27100265:+
HNSC	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	5.95	5.15e-09	2.25e-06	0.34	0.27	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000173295.6	FAM86B3P	5.95	5.16e-09	2.25e-06	0.3	0.27	Mood instability;	chr8:8314761	chr8:8228595~8244865:+
HNSC	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	5.95	5.16e-09	2.25e-06	0.26	0.27	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
HNSC	cis	rs2834288	0.5	rs2834304	ENSG00000273102.1	AP000569.9	5.95	5.17e-09	2.25e-06	0.28	0.27	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33967101~33968573:-
HNSC	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	5.95	5.17e-09	2.25e-06	0.32	0.27	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
HNSC	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-5.95	5.17e-09	2.26e-06	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
HNSC	cis	rs9300255	0.602	rs1716172	ENSG00000280120.1	RP11-546D6.3	5.95	5.18e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123228165	chr12:123152324~123153377:-
HNSC	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-5.95	5.19e-09	2.26e-06	-0.32	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
HNSC	cis	rs9300255	0.602	rs4372492	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123212810	chr12:123152324~123153377:-
HNSC	cis	rs7980687	0.627	rs1727325	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Head circumference (infant);Educational attainment;Height;	chr12:123213785	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.51	rs1727323	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123214243	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1716160	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123215678	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.569	rs1727320	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123215929	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1790131	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123216463	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.544	rs1790130	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123216723	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs2682431	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123218679	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs2851450	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123218954	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs1790101	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123220297	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1790102	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123220343	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1626899	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123223516	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs10846486	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123225380	chr12:123152324~123153377:-
HNSC	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	5.95	5.19e-09	2.26e-06	0.36	0.27	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
HNSC	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-5.95	5.2e-09	2.26e-06	-0.33	-0.27	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
HNSC	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	5.95	5.2e-09	2.27e-06	0.34	0.27	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
HNSC	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	5.95	5.2e-09	2.27e-06	0.36	0.27	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	5.95	5.2e-09	2.27e-06	0.36	0.27	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	5.95	5.2e-09	2.27e-06	0.36	0.27	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
HNSC	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	5.95	5.2e-09	2.27e-06	0.31	0.27	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
HNSC	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-5.95	5.2e-09	2.27e-06	-0.33	-0.27	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
HNSC	cis	rs189798	0.807	rs330905	ENSG00000173295.6	FAM86B3P	5.95	5.21e-09	2.27e-06	0.31	0.27	Myopia (pathological);	chr8:9136041	chr8:8228595~8244865:+
HNSC	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	5.95	5.22e-09	2.27e-06	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
HNSC	cis	rs2834288	0.7	rs2834292	ENSG00000237945.6	LINC00649	-5.95	5.22e-09	2.27e-06	-0.35	-0.27	Gut microbiota (bacterial taxa);	chr21:33901909	chr21:33915534~33977691:+
HNSC	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-5.95	5.22e-09	2.28e-06	-0.32	-0.27	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
HNSC	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55514802	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55516548	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55516744	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55517185	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55522229	chr4:55363971~55395847:-
HNSC	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	5.95	5.22e-09	2.28e-06	0.3	0.27	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
HNSC	cis	rs757110	0.868	rs5219	ENSG00000260196.1	RP1-239B22.5	5.95	5.22e-09	2.28e-06	0.31	0.27	Type 2 diabetes;	chr11:17388025	chr11:17380649~17383531:+
HNSC	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	5.95	5.23e-09	2.28e-06	0.4	0.27	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
HNSC	cis	rs2880765	0.835	rs4360874	ENSG00000259295.5	CSPG4P12	5.95	5.24e-09	2.28e-06	0.3	0.27	Coronary artery disease;	chr15:85497589	chr15:85191438~85213905:+
HNSC	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	5.95	5.24e-09	2.28e-06	0.3	0.27	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-5.95	5.24e-09	2.28e-06	-0.32	-0.27	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
HNSC	cis	rs6479901	0.841	rs10995453	ENSG00000232075.1	MRPL35P2	-5.95	5.24e-09	2.28e-06	-0.36	-0.27	Intelligence (multi-trait analysis);	chr10:63174571	chr10:63634317~63634827:-
HNSC	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	5.95	5.25e-09	2.29e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	5.95	5.25e-09	2.29e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
HNSC	cis	rs4713118	0.513	rs149897	ENSG00000204709.4	LINC01556	5.95	5.25e-09	2.29e-06	0.34	0.27	Parkinson's disease;	chr6:28038872	chr6:28943877~28944537:+
HNSC	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	5.95	5.26e-09	2.29e-06	0.2	0.27	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
HNSC	cis	rs9300255	0.602	rs1716164	ENSG00000280120.1	RP11-546D6.3	5.95	5.27e-09	2.29e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123179113	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1727300	ENSG00000280120.1	RP11-546D6.3	5.95	5.27e-09	2.29e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123179658	chr12:123152324~123153377:-
HNSC	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-5.95	5.27e-09	2.29e-06	-0.37	-0.27	Depression;	chr6:27871968	chr6:28115628~28116551:+
HNSC	cis	rs9914544	1	rs7223231	ENSG00000264885.1	RP11-815I9.4	-5.95	5.27e-09	2.29e-06	-0.28	-0.27	Educational attainment (years of education);	chr17:18908533	chr17:18667629~18669461:-
HNSC	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
HNSC	cis	rs2985684	0.894	rs4900927	ENSG00000258568.1	RHOQP1	5.95	5.28e-09	2.3e-06	0.27	0.27	Carotid intima media thickness;	chr14:49552023	chr14:49599994~49600572:+
HNSC	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	5.95	5.3e-09	2.31e-06	0.3	0.27	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
HNSC	cis	rs4713118	0.513	rs156734	ENSG00000204709.4	LINC01556	5.95	5.31e-09	2.31e-06	0.34	0.27	Parkinson's disease;	chr6:28039579	chr6:28943877~28944537:+
HNSC	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	5.95	5.31e-09	2.31e-06	0.29	0.27	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	5.95	5.31e-09	2.31e-06	0.29	0.27	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
HNSC	cis	rs7811142	1	rs66632384	ENSG00000078319.8	PMS2P1	-5.95	5.32e-09	2.32e-06	-0.33	-0.27	Platelet count;	chr7:100421281	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs73403312	ENSG00000078319.8	PMS2P1	-5.95	5.32e-09	2.32e-06	-0.33	-0.27	Platelet count;	chr7:100426530	chr7:100320992~100341908:-
HNSC	cis	rs7674212	0.57	rs2126470	ENSG00000246560.2	RP11-10L12.4	5.95	5.32e-09	2.32e-06	0.3	0.27	Type 2 diabetes;	chr4:103140605	chr4:102828055~102844075:+
HNSC	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	5.95	5.33e-09	2.32e-06	0.3	0.27	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
HNSC	cis	rs8177876	1	rs8177876	ENSG00000261061.1	RP11-303E16.2	-5.95	5.33e-09	2.32e-06	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81030770~81031485:+
HNSC	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-5.95	5.33e-09	2.32e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
HNSC	cis	rs7674212	0.57	rs2711898	ENSG00000246560.2	RP11-10L12.4	5.95	5.34e-09	2.32e-06	0.3	0.27	Type 2 diabetes;	chr4:103141914	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	5.95	5.34e-09	2.32e-06	0.35	0.27	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	5.95	5.34e-09	2.32e-06	0.23	0.27	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
HNSC	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-5.95	5.34e-09	2.32e-06	-0.31	-0.27	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
HNSC	cis	rs3738814	0.529	rs761422	ENSG00000186715.9	MST1L	-5.95	5.34e-09	2.33e-06	-0.22	-0.27	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Height;	chr1:16975285	chr1:16754910~16770237:-
HNSC	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-5.95	5.35e-09	2.33e-06	-0.27	-0.27	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
HNSC	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-5.95	5.35e-09	2.33e-06	-0.32	-0.27	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
HNSC	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	5.95	5.36e-09	2.33e-06	0.32	0.27	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
HNSC	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	5.95	5.36e-09	2.33e-06	0.26	0.27	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
HNSC	cis	rs11089937	0.929	rs5750624	ENSG00000211638.2	IGLV8-61	-5.95	5.36e-09	2.33e-06	-0.23	-0.27	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22098700~22099212:+
HNSC	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	5.95	5.36e-09	2.33e-06	0.28	0.27	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
HNSC	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	5.95	5.36e-09	2.33e-06	0.32	0.27	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
HNSC	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-5.95	5.36e-09	2.33e-06	-0.36	-0.27	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-5.95	5.36e-09	2.33e-06	-0.36	-0.27	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
HNSC	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	5.95	5.37e-09	2.33e-06	0.27	0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-5.95	5.38e-09	2.34e-06	-0.17	-0.27	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
HNSC	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
HNSC	cis	rs13126694	0.744	rs10027000	ENSG00000248429.4	RP11-597D13.9	5.95	5.38e-09	2.34e-06	0.3	0.27	Blood osmolality (transformed sodium);	chr4:158053401	chr4:158170752~158202877:+
HNSC	cis	rs7083	1	rs678837	ENSG00000254851.1	RP11-109L13.1	5.95	5.38e-09	2.34e-06	0.35	0.27	Blood protein levels;	chr11:117238554	chr11:117135528~117138582:+
HNSC	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	5.95	5.38e-09	2.34e-06	0.3	0.27	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
HNSC	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	5.95	5.38e-09	2.34e-06	0.33	0.27	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
HNSC	cis	rs12682352	0.652	rs3789843	ENSG00000253893.2	FAM85B	-5.95	5.39e-09	2.34e-06	-0.31	-0.27	Neuroticism;	chr8:8866747	chr8:8167819~8226614:-
HNSC	cis	rs12682352	0.652	rs3827806	ENSG00000253893.2	FAM85B	-5.95	5.39e-09	2.34e-06	-0.31	-0.27	Neuroticism;	chr8:8866766	chr8:8167819~8226614:-
HNSC	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	5.95	5.39e-09	2.34e-06	0.32	0.27	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
HNSC	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-5.95	5.39e-09	2.34e-06	-0.32	-0.27	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.55	rs1233699	ENSG00000204709.4	LINC01556	5.95	5.39e-09	2.34e-06	0.35	0.27	Depression;	chr6:28201380	chr6:28943877~28944537:+
HNSC	cis	rs2579103	0.838	rs2579115	ENSG00000258183.4	RP11-753N8.1	-5.95	5.4e-09	2.35e-06	-0.33	-0.27	Body mass index;	chr12:90214973	chr12:90280894~90300340:+
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-5.95	5.4e-09	2.35e-06	-0.17	-0.27	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-5.95	5.4e-09	2.35e-06	-0.17	-0.27	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
HNSC	cis	rs2071303	0.836	rs198835	ENSG00000272462.2	U91328.19	-5.95	5.41e-09	2.35e-06	-0.25	-0.27	Intelligence (multi-trait analysis);	chr6:26113766	chr6:25992662~26001775:+
HNSC	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-5.95	5.41e-09	2.35e-06	-0.33	-0.27	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
HNSC	cis	rs454422	0.857	rs236106	ENSG00000275632.1	RP5-967N21.11	5.95	5.41e-09	2.35e-06	0.27	0.27	HIV-1 viral setpoint;	chr20:5980045	chr20:6000418~6000941:+
HNSC	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	5.95	5.42e-09	2.35e-06	0.54	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
HNSC	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-5.94	5.42e-09	2.36e-06	-0.33	-0.27	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
HNSC	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	5.94	5.44e-09	2.36e-06	0.33	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
HNSC	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	5.94	5.44e-09	2.36e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	5.94	5.44e-09	2.36e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
HNSC	cis	rs11089937	0.667	rs10483107	ENSG00000211638.2	IGLV8-61	-5.94	5.45e-09	2.37e-06	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22098700~22099212:+
HNSC	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-5.94	5.45e-09	2.37e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-5.94	5.45e-09	2.37e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
HNSC	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	5.94	5.47e-09	2.37e-06	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
HNSC	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	5.94	5.47e-09	2.37e-06	0.36	0.27	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	5.94	5.47e-09	2.37e-06	0.36	0.27	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
HNSC	cis	rs4218	0.648	rs877269	ENSG00000277144.1	RP11-59H7.4	-5.94	5.47e-09	2.38e-06	-0.36	-0.27	Social communication problems;	chr15:59081595	chr15:59115547~59116089:-
HNSC	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-5.94	5.47e-09	2.38e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
HNSC	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.49e-09	2.38e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
HNSC	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-5.94	5.49e-09	2.38e-06	-0.35	-0.27	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-5.94	5.49e-09	2.38e-06	-0.35	-0.27	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.55	rs6901017	ENSG00000204709.4	LINC01556	5.94	5.49e-09	2.39e-06	0.36	0.27	Depression;	chr6:28184805	chr6:28943877~28944537:+
HNSC	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	5.94	5.5e-09	2.39e-06	0.2	0.27	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
HNSC	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-5.94	5.51e-09	2.39e-06	-0.36	-0.27	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
HNSC	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-5.94	5.52e-09	2.39e-06	-0.31	-0.27	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
HNSC	cis	rs11976180	0.517	rs6949375	ENSG00000244479.5	OR2A1-AS1	5.94	5.52e-09	2.4e-06	0.4	0.27	Obesity-related traits;	chr7:144076758	chr7:144251264~144356181:-
HNSC	cis	rs6969780	1	rs73071548	ENSG00000233429.8	HOTAIRM1	5.94	5.52e-09	2.4e-06	0.49	0.27	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27107811	chr7:27095647~27100265:+
HNSC	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	5.94	5.53e-09	2.4e-06	0.33	0.27	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000173295.6	FAM86B3P	-5.94	5.53e-09	2.4e-06	-0.3	-0.27	Mood instability;	chr8:8812572	chr8:8228595~8244865:+
HNSC	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-5.94	5.53e-09	2.4e-06	-0.35	-0.27	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
HNSC	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-5.94	5.53e-09	2.4e-06	-0.29	-0.27	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
HNSC	cis	rs1799949	0.683	rs55737636	ENSG00000267151.3	RP11-100E5.2	5.94	5.53e-09	2.4e-06	0.34	0.27	Menopause (age at onset);	chr17:43112722	chr17:43444707~43451200:+
HNSC	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	5.94	5.54e-09	2.4e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	5.94	5.54e-09	2.41e-06	0.33	0.27	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
HNSC	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-5.94	5.56e-09	2.41e-06	-0.25	-0.27	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-5.94	5.56e-09	2.41e-06	-0.18	-0.27	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-5.94	5.56e-09	2.41e-06	-0.18	-0.27	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
HNSC	cis	rs2115630	0.691	rs8040066	ENSG00000229212.6	RP11-561C5.4	5.94	5.58e-09	2.42e-06	0.3	0.27	P wave terminal force;	chr15:84633234	chr15:85205440~85234795:-
HNSC	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	5.94	5.58e-09	2.42e-06	0.42	0.27	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
HNSC	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-5.94	5.59e-09	2.42e-06	-0.24	-0.27	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
HNSC	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	5.94	5.59e-09	2.42e-06	0.32	0.27	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
HNSC	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	5.94	5.59e-09	2.42e-06	0.32	0.27	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
HNSC	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-5.94	5.59e-09	2.42e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
HNSC	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-5.94	5.59e-09	2.42e-06	-0.31	-0.27	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
HNSC	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-5.94	5.59e-09	2.42e-06	-0.34	-0.27	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
HNSC	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-5.94	5.61e-09	2.43e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-5.94	5.63e-09	2.44e-06	-0.31	-0.26	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-5.94	5.63e-09	2.44e-06	-0.31	-0.26	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-5.94	5.64e-09	2.44e-06	-0.17	-0.26	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
HNSC	cis	rs13113518	0.783	rs11943206	ENSG00000273257.1	RP11-177J6.1	5.94	5.64e-09	2.44e-06	0.33	0.26	Height;	chr4:55570843	chr4:55387949~55388271:+
HNSC	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-5.94	5.64e-09	2.44e-06	-0.31	-0.26	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
HNSC	cis	rs9840812	0.592	rs12489577	ENSG00000273486.1	RP11-731C17.2	5.94	5.64e-09	2.44e-06	0.23	0.26	Fibrinogen levels;	chr3:136494303	chr3:136837338~136839021:-
HNSC	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	5.94	5.64e-09	2.44e-06	0.32	0.26	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
HNSC	cis	rs1355223	0.934	rs5010670	ENSG00000271369.1	RP11-350D17.3	-5.94	5.65e-09	2.45e-06	-0.31	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745102	chr11:34709600~34710161:+
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-5.94	5.65e-09	2.45e-06	-0.17	-0.26	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
HNSC	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	5.94	5.66e-09	2.45e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
HNSC	cis	rs35306767	0.953	rs11253509	ENSG00000229869.1	RP11-363N22.2	-5.94	5.66e-09	2.45e-06	-0.35	-0.26	Eosinophil percentage of granulocytes;	chr10:918366	chr10:933026~942743:+
HNSC	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-5.94	5.66e-09	2.45e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-5.94	5.66e-09	2.45e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
HNSC	cis	rs2239557	1	rs11628710	ENSG00000259065.1	RP5-1021I20.1	-5.94	5.66e-09	2.45e-06	-0.31	-0.26	Common traits (Other);	chr14:74182577	chr14:73787360~73803270:+
HNSC	cis	rs1479119	0.78	rs1479114	ENSG00000180861.8	LINC01559	-5.94	5.66e-09	2.45e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr12:13347305	chr12:13371089~13387167:-
HNSC	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-5.94	5.67e-09	2.45e-06	-0.25	-0.26	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
HNSC	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-5.94	5.67e-09	2.45e-06	-0.37	-0.26	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
HNSC	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-5.94	5.67e-09	2.45e-06	-0.37	-0.26	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
HNSC	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.94	5.67e-09	2.46e-06	-0.28	-0.26	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
HNSC	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	5.94	5.67e-09	2.46e-06	0.4	0.26	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
HNSC	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	5.94	5.68e-09	2.46e-06	0.29	0.26	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
HNSC	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	5.94	5.68e-09	2.46e-06	0.2	0.26	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
HNSC	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-5.94	5.69e-09	2.46e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000179406.6	LINC00174	-5.94	5.69e-09	2.46e-06	-0.57	-0.26	Diabetic kidney disease;	chr7:66591724	chr7:66376044~66401338:-
HNSC	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	5.94	5.7e-09	2.47e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
HNSC	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-5.94	5.71e-09	2.47e-06	-0.36	-0.26	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
HNSC	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	5.94	5.71e-09	2.47e-06	0.29	0.26	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
HNSC	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-5.94	5.71e-09	2.47e-06	-0.32	-0.26	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
HNSC	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	5.94	5.72e-09	2.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	5.94	5.72e-09	2.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	5.94	5.72e-09	2.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
HNSC	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	5.94	5.72e-09	2.48e-06	0.3	0.26	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000179406.6	LINC00174	5.94	5.73e-09	2.48e-06	0.34	0.26	Calcium levels;	chr7:66045710	chr7:66376044~66401338:-
HNSC	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	5.94	5.73e-09	2.48e-06	0.3	0.26	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
HNSC	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	5.94	5.73e-09	2.48e-06	0.3	0.26	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
HNSC	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	5.94	5.73e-09	2.48e-06	0.36	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	5.94	5.73e-09	2.48e-06	0.36	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
HNSC	cis	rs2286503	0.78	rs2240727	ENSG00000221740.1	SNORD93	5.93	5.73e-09	2.48e-06	0.29	0.26	Fibrinogen;	chr7:22812893	chr7:22856613~22856686:+
HNSC	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-5.93	5.74e-09	2.48e-06	-0.26	-0.26	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
HNSC	cis	rs12935418	0.83	rs7195459	ENSG00000261061.1	RP11-303E16.2	-5.93	5.74e-09	2.49e-06	-0.37	-0.26	Mean corpuscular volume;	chr16:81016376	chr16:81030770~81031485:+
HNSC	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-5.93	5.75e-09	2.49e-06	-0.43	-0.26	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
HNSC	cis	rs783540	0.5	rs7178459	ENSG00000276710.3	CSPG4P8	-5.93	5.75e-09	2.49e-06	-0.33	-0.26	Schizophrenia;	chr15:82729632	chr15:82459472~82477258:+
HNSC	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
HNSC	cis	rs6604026	0.555	rs34812295	ENSG00000223787.2	RP4-593M8.1	5.93	5.77e-09	2.49e-06	0.36	0.26	Multiple sclerosis;	chr1:92606712	chr1:92580476~92580821:-
HNSC	cis	rs7674212	0.57	rs12501621	ENSG00000246560.2	RP11-10L12.4	5.93	5.79e-09	2.5e-06	0.3	0.26	Type 2 diabetes;	chr4:103174348	chr4:102828055~102844075:+
HNSC	cis	rs35306767	0.903	rs12761424	ENSG00000229869.1	RP11-363N22.2	-5.93	5.79e-09	2.5e-06	-0.35	-0.26	Eosinophil percentage of granulocytes;	chr10:921355	chr10:933026~942743:+
HNSC	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-5.93	5.79e-09	2.5e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000211972.2	IGHV3-66	5.93	5.79e-09	2.5e-06	0.2	0.26	Kawasaki disease;	chr14:106781682	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000211972.2	IGHV3-66	5.93	5.79e-09	2.5e-06	0.2	0.26	Kawasaki disease;	chr14:106781820	chr14:106675017~106675544:-
HNSC	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-5.93	5.79e-09	2.5e-06	-0.23	-0.26	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
HNSC	cis	rs6504622	0.967	rs11869840	ENSG00000262879.4	RP11-156P1.3	-5.93	5.8e-09	2.51e-06	-0.29	-0.26	Orofacial clefts;	chr17:46918734	chr17:46984045~47100323:-
HNSC	cis	rs12550612	1	rs12550612	ENSG00000253616.4	RP11-875O11.3	5.93	5.81e-09	2.51e-06	0.4	0.26	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109256	chr8:23071377~23074488:-
HNSC	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-5.93	5.81e-09	2.51e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
HNSC	cis	rs76934034	0.522	rs117488236	ENSG00000237840.5	FAM21FP	-5.93	5.82e-09	2.51e-06	-0.44	-0.26	Prostate cancer;	chr10:45546587	chr10:45706431~45727231:-
HNSC	cis	rs1799949	0.965	rs7212284	ENSG00000267151.3	RP11-100E5.2	5.93	5.82e-09	2.52e-06	0.34	0.26	Menopause (age at onset);	chr17:43053924	chr17:43444707~43451200:+
HNSC	cis	rs4218	0.648	rs35769647	ENSG00000277144.1	RP11-59H7.4	-5.93	5.83e-09	2.52e-06	-0.36	-0.26	Social communication problems;	chr15:59081670	chr15:59115547~59116089:-
HNSC	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	5.93	5.83e-09	2.52e-06	0.3	0.26	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
HNSC	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	5.93	5.83e-09	2.52e-06	0.28	0.26	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
HNSC	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	5.93	5.83e-09	2.52e-06	0.29	0.26	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
HNSC	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	5.93	5.84e-09	2.52e-06	0.33	0.26	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
HNSC	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	5.93	5.84e-09	2.52e-06	0.27	0.26	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
HNSC	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	5.93	5.85e-09	2.53e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
HNSC	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-5.93	5.85e-09	2.53e-06	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	5.93	5.85e-09	2.53e-06	0.35	0.26	Depression;	chr6:28198669	chr6:28943877~28944537:+
HNSC	cis	rs155076	0.666	rs2015241	ENSG00000233325.3	MIPEPP3	-5.93	5.85e-09	2.53e-06	-0.43	-0.26	White matter hyperintensity burden;	chr13:21314115	chr13:21298139~21306373:+
HNSC	cis	rs13113518	0.783	rs1586555	ENSG00000273257.1	RP11-177J6.1	5.93	5.85e-09	2.53e-06	0.33	0.26	Height;	chr4:55587104	chr4:55387949~55388271:+
HNSC	cis	rs2235642	0.525	rs8048290	ENSG00000280231.1	LA16c-380F5.3	-5.93	5.86e-09	2.53e-06	-0.37	-0.26	Coronary artery disease;	chr16:1512025	chr16:1553655~1554130:-
HNSC	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-5.93	5.86e-09	2.53e-06	-0.31	-0.26	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
HNSC	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
HNSC	cis	rs7804306	0.826	rs73049270	ENSG00000233264.2	AC006042.8	5.93	5.87e-09	2.53e-06	0.59	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982015	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049276	ENSG00000233264.2	AC006042.8	5.93	5.87e-09	2.53e-06	0.59	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982385	chr7:7980312~7982228:+
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	5.93	5.87e-09	2.53e-06	0.21	0.26	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
HNSC	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	5.93	5.87e-09	2.53e-06	0.29	0.26	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
HNSC	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	5.93	5.87e-09	2.54e-06	0.23	0.26	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
HNSC	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-5.93	5.88e-09	2.54e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
HNSC	cis	rs947583	0.573	rs12202212	ENSG00000217482.2	HMGB1P17	5.93	5.88e-09	2.54e-06	0.3	0.26	Phosphorus levels;	chr6:135698009	chr6:135636086~135636713:-
HNSC	cis	rs4218	0.648	rs12441973	ENSG00000277144.1	RP11-59H7.4	-5.93	5.88e-09	2.54e-06	-0.35	-0.26	Social communication problems;	chr15:59057016	chr15:59115547~59116089:-
HNSC	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	5.93	5.88e-09	2.54e-06	0.3	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000219392.1	RP1-265C24.5	-5.93	5.89e-09	2.54e-06	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28200255	chr6:28115628~28116551:+
HNSC	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-5.93	5.89e-09	2.54e-06	-0.31	-0.26	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
HNSC	cis	rs860295	0.871	rs6696888	ENSG00000203761.5	MSTO2P	5.93	5.89e-09	2.54e-06	0.2	0.26	Body mass index;	chr1:155539091	chr1:155745829~155750137:+
HNSC	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	5.93	5.9e-09	2.54e-06	0.34	0.26	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
HNSC	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	5.93	5.9e-09	2.54e-06	0.36	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
HNSC	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	5.93	5.9e-09	2.55e-06	0.32	0.26	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
HNSC	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	5.93	5.9e-09	2.55e-06	0.33	0.26	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs8077486	ENSG00000267151.3	RP11-100E5.2	5.93	5.9e-09	2.55e-06	0.34	0.26	Menopause (age at onset);	chr17:43060788	chr17:43444707~43451200:+
HNSC	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-5.93	5.9e-09	2.55e-06	-0.32	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
HNSC	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	5.93	5.9e-09	2.55e-06	0.23	0.26	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
HNSC	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	5.93	5.9e-09	2.55e-06	0.3	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000254340.1	RP11-10A14.3	-5.93	5.91e-09	2.55e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:9009151	chr8:9141424~9145435:+
HNSC	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	5.93	5.91e-09	2.55e-06	0.24	0.26	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-5.93	5.91e-09	2.55e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-5.93	5.91e-09	2.55e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
HNSC	cis	rs36405	0.5	rs8003168	ENSG00000266869.1	RP6-114E22.1	-5.93	5.91e-09	2.55e-06	-0.33	-0.26	Yang-deficiency constitution;	chr14:71896671	chr14:71848606~71908430:+
HNSC	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	5.93	5.93e-09	2.56e-06	0.35	0.26	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
HNSC	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-5.93	5.93e-09	2.56e-06	-0.31	-0.26	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
HNSC	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	5.93	5.94e-09	2.56e-06	0.37	0.26	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
HNSC	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	5.93	5.94e-09	2.56e-06	0.31	0.26	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
HNSC	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	5.93	5.95e-09	2.56e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
HNSC	cis	rs7811142	1	rs67315960	ENSG00000078319.8	PMS2P1	-5.93	5.95e-09	2.57e-06	-0.33	-0.26	Platelet count;	chr7:100417501	chr7:100320992~100341908:-
HNSC	cis	rs6918586	0.658	rs13161	ENSG00000272462.2	U91328.19	-5.93	5.95e-09	2.57e-06	-0.25	-0.26	Schizophrenia;	chr6:26114474	chr6:25992662~26001775:+
HNSC	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	5.93	5.96e-09	2.57e-06	0.38	0.26	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
HNSC	cis	rs1021993	0.672	rs906353	ENSG00000231648.1	RP11-372M18.2	5.93	5.96e-09	2.57e-06	0.33	0.26	Gut microbiome composition (winter);	chr1:209294177	chr1:209367662~209379690:+
HNSC	cis	rs6918586	0.658	rs198814	ENSG00000272462.2	U91328.19	-5.93	5.96e-09	2.57e-06	-0.25	-0.26	Schizophrenia;	chr6:26127531	chr6:25992662~26001775:+
HNSC	cis	rs453301	0.686	rs28665409	ENSG00000173295.6	FAM86B3P	-5.93	5.96e-09	2.57e-06	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9011767	chr8:8228595~8244865:+
HNSC	cis	rs189798	0.738	rs330908	ENSG00000173295.6	FAM86B3P	5.93	5.97e-09	2.58e-06	0.31	0.26	Myopia (pathological);	chr8:9137656	chr8:8228595~8244865:+
HNSC	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-5.93	5.98e-09	2.58e-06	-0.36	-0.26	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
HNSC	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	5.93	5.98e-09	2.58e-06	0.27	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
HNSC	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	5.93	5.99e-09	2.58e-06	0.38	0.26	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
HNSC	cis	rs2834288	0.666	rs2834293	ENSG00000237945.6	LINC00649	-5.93	6e-09	2.59e-06	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr21:33903905	chr21:33915534~33977691:+
HNSC	cis	rs4388249	0.696	rs31600	ENSG00000271849.1	CTC-332L22.1	5.93	6.01e-09	2.59e-06	0.37	0.26	Schizophrenia;	chr5:109670675	chr5:109687802~109688329:-
HNSC	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-5.93	6.01e-09	2.59e-06	-0.27	-0.26	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
HNSC	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	5.93	6.01e-09	2.59e-06	0.35	0.26	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
HNSC	cis	rs7811142	1	rs11773661	ENSG00000078319.8	PMS2P1	-5.93	6.02e-09	2.6e-06	-0.34	-0.26	Platelet count;	chr7:100475446	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs66958101	ENSG00000078319.8	PMS2P1	-5.93	6.02e-09	2.6e-06	-0.34	-0.26	Platelet count;	chr7:100476397	chr7:100320992~100341908:-
HNSC	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
HNSC	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	5.93	6.05e-09	2.61e-06	0.29	0.26	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
HNSC	cis	rs7617773	0.539	rs2017858	ENSG00000228638.1	FCF1P2	-5.93	6.05e-09	2.61e-06	-0.24	-0.26	Coronary artery disease;	chr3:48340792	chr3:48290793~48291375:-
HNSC	cis	rs2006771	0.74	rs8140312	ENSG00000236132.1	CTA-440B3.1	-5.93	6.05e-09	2.61e-06	-0.29	-0.26	Nonsyndromic cleft lip with cleft palate;	chr22:31609608	chr22:31816379~31817491:-
HNSC	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-5.93	6.05e-09	2.61e-06	-0.29	-0.26	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
HNSC	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-5.93	6.06e-09	2.61e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
HNSC	cis	rs6918586	0.616	rs198836	ENSG00000272462.2	U91328.19	-5.93	6.06e-09	2.61e-06	-0.25	-0.26	Schizophrenia;	chr6:26113388	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.616	rs1056314	ENSG00000272462.2	U91328.19	5.93	6.06e-09	2.61e-06	0.25	0.26	Schizophrenia;	chr6:26114425	chr6:25992662~26001775:+
HNSC	cis	rs4218	0.648	rs10851642	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59077909	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.608	rs59282449	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59078881	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.648	rs60285686	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59079829	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.648	rs60741546	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59079831	chr15:59115547~59116089:-
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	5.92	6.07e-09	2.62e-06	0.26	0.26	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	5.92	6.07e-09	2.62e-06	0.26	0.26	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
HNSC	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	5.92	6.08e-09	2.62e-06	0.33	0.26	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
HNSC	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-5.92	6.11e-09	2.63e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
HNSC	cis	rs10435719	0.746	rs58007588	ENSG00000206014.6	OR7E161P	-5.92	6.11e-09	2.63e-06	-0.29	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:11928597~11929563:-
HNSC	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-5.92	6.12e-09	2.63e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
HNSC	cis	rs8177876	0.822	rs56198248	ENSG00000261061.1	RP11-303E16.2	-5.92	6.12e-09	2.63e-06	-0.49	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81030770~81031485:+
HNSC	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-5.92	6.12e-09	2.63e-06	-0.44	-0.26	Depression;	chr6:28139579	chr6:28115628~28116551:+
HNSC	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-5.92	6.12e-09	2.64e-06	-0.52	-0.26	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
HNSC	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	5.92	6.12e-09	2.64e-06	0.29	0.26	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
HNSC	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-5.92	6.13e-09	2.64e-06	-0.31	-0.26	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-5.92	6.13e-09	2.64e-06	-0.31	-0.26	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	5.92	6.14e-09	2.64e-06	0.31	0.26	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
HNSC	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	5.92	6.14e-09	2.64e-06	0.41	0.26	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
HNSC	cis	rs4218	0.597	rs4775114	ENSG00000277144.1	RP11-59H7.4	-5.92	6.15e-09	2.65e-06	-0.35	-0.26	Social communication problems;	chr15:59059635	chr15:59115547~59116089:-
HNSC	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	5.92	6.15e-09	2.65e-06	0.35	0.26	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	5.92	6.16e-09	2.65e-06	0.29	0.26	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	5.92	6.16e-09	2.65e-06	0.29	0.26	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
HNSC	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-5.92	6.16e-09	2.65e-06	-0.31	-0.26	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
HNSC	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	5.92	6.16e-09	2.65e-06	0.25	0.26	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
HNSC	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-5.92	6.16e-09	2.65e-06	-0.36	-0.26	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-5.92	6.17e-09	2.65e-06	-0.28	-0.26	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
HNSC	cis	rs11098499	0.73	rs12505735	ENSG00000249244.1	RP11-548H18.2	5.92	6.18e-09	2.66e-06	0.32	0.26	Corneal astigmatism;	chr4:119611801	chr4:119391831~119395335:-
HNSC	cis	rs7811142	1	rs11763414	ENSG00000078319.8	PMS2P1	-5.92	6.19e-09	2.66e-06	-0.33	-0.26	Platelet count;	chr7:100419221	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs67163493	ENSG00000078319.8	PMS2P1	-5.92	6.19e-09	2.66e-06	-0.33	-0.26	Platelet count;	chr7:100426215	chr7:100320992~100341908:-
HNSC	cis	rs11089937	0.667	rs11704024	ENSG00000211638.2	IGLV8-61	-5.92	6.19e-09	2.66e-06	-0.27	-0.26	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22098700~22099212:+
HNSC	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-5.92	6.19e-09	2.66e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
HNSC	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	5.92	6.21e-09	2.67e-06	0.35	0.26	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	5.92	6.21e-09	2.67e-06	0.35	0.26	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
HNSC	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	5.92	6.21e-09	2.67e-06	0.36	0.26	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-5.92	6.23e-09	2.68e-06	-0.37	-0.26	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
HNSC	cis	rs2836950	0.501	rs1474490	ENSG00000255568.3	BRWD1-AS2	-5.92	6.24e-09	2.68e-06	-0.22	-0.26	Menarche (age at onset);	chr21:39344210	chr21:39313935~39314962:+
HNSC	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	5.92	6.24e-09	2.68e-06	0.28	0.26	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
HNSC	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-5.92	6.24e-09	2.68e-06	-0.39	-0.26	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
HNSC	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	5.92	6.25e-09	2.69e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
HNSC	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-5.92	6.26e-09	2.69e-06	-0.31	-0.26	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-5.92	6.26e-09	2.69e-06	-0.31	-0.26	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.717	rs9806227	ENSG00000205771.5	CATSPER2P1	-5.92	6.26e-09	2.69e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43387917	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs12323999	ENSG00000205771.5	CATSPER2P1	-5.92	6.26e-09	2.69e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43390917	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2584702	ENSG00000205771.5	CATSPER2P1	-5.92	6.26e-09	2.69e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43392716	chr15:43726918~43747094:-
HNSC	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-5.92	6.26e-09	2.69e-06	-0.31	-0.26	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
HNSC	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-5.92	6.27e-09	2.69e-06	-0.32	-0.26	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
HNSC	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	5.92	6.27e-09	2.69e-06	0.36	0.26	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
HNSC	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	5.92	6.27e-09	2.7e-06	0.32	0.26	Height;	chr4:55483718	chr4:55363971~55395847:-
HNSC	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-5.92	6.27e-09	2.7e-06	-0.35	-0.26	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
HNSC	cis	rs4948102	0.667	rs7811270	ENSG00000226278.1	PSPHP1	-5.92	6.28e-09	2.7e-06	-0.29	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55764797~55773288:+
HNSC	cis	rs526231	0.725	rs487937	ENSG00000175749.11	EIF3KP1	5.92	6.29e-09	2.7e-06	0.34	0.26	Primary biliary cholangitis;	chr5:103302541	chr5:103032376~103033031:+
HNSC	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	5.92	6.29e-09	2.7e-06	0.3	0.26	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
HNSC	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-5.92	6.29e-09	2.7e-06	-0.3	-0.26	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
HNSC	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-5.92	6.3e-09	2.71e-06	-0.32	-0.26	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
HNSC	cis	rs9300255	0.544	rs1790100	ENSG00000280120.1	RP11-546D6.3	5.92	6.31e-09	2.71e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123172178	chr12:123152324~123153377:-
HNSC	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	5.92	6.31e-09	2.71e-06	0.29	0.26	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
HNSC	cis	rs17507216	0.671	rs4779035	ENSG00000255769.6	GOLGA2P10	-5.92	6.31e-09	2.71e-06	-0.42	-0.26	Excessive daytime sleepiness;	chr15:82591686	chr15:82472993~82513950:-
HNSC	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.92	6.32e-09	2.71e-06	0.36	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
HNSC	cis	rs6472866	0.679	rs1425771	ENSG00000254349.4	FLJ39080	-5.92	6.33e-09	2.72e-06	-0.28	-0.26	Protein quantitative trait loci;	chr8:74593494	chr8:74599775~74823313:+
HNSC	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-5.92	6.33e-09	2.72e-06	-0.3	-0.26	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-5.92	6.34e-09	2.72e-06	-0.35	-0.26	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-5.92	6.34e-09	2.72e-06	-0.35	-0.26	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-5.92	6.34e-09	2.72e-06	-0.35	-0.26	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
HNSC	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-5.92	6.35e-09	2.73e-06	-0.31	-0.26	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
HNSC	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-5.92	6.35e-09	2.73e-06	-0.23	-0.26	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
HNSC	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	5.92	6.35e-09	2.73e-06	0.41	0.26	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000173295.6	FAM86B3P	-5.92	6.36e-09	2.73e-06	-0.3	-0.26	Mood instability;	chr8:8932549	chr8:8228595~8244865:+
HNSC	cis	rs172166	0.694	rs203893	ENSG00000204709.4	LINC01556	5.92	6.37e-09	2.73e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28094288	chr6:28943877~28944537:+
HNSC	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	5.92	6.37e-09	2.73e-06	0.26	0.26	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
HNSC	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-5.92	6.37e-09	2.73e-06	-0.31	-0.26	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
HNSC	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-5.92	6.38e-09	2.74e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
HNSC	cis	rs8177876	0.822	rs16954582	ENSG00000261061.1	RP11-303E16.2	-5.92	6.39e-09	2.74e-06	-0.43	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.716	rs2404736	ENSG00000259422.1	RP11-593F23.1	5.92	6.39e-09	2.74e-06	0.3	0.26	Blood metabolite levels;	chr15:76583602	chr15:76174891~76181486:-
HNSC	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	5.92	6.4e-09	2.75e-06	0.29	0.26	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
HNSC	cis	rs2880765	0.546	rs8042776	ENSG00000259295.5	CSPG4P12	5.92	6.4e-09	2.75e-06	0.32	0.26	Coronary artery disease;	chr15:85512398	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	5.92	6.4e-09	2.75e-06	0.33	0.26	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
HNSC	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	5.92	6.41e-09	2.75e-06	0.32	0.26	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
HNSC	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-5.92	6.42e-09	2.75e-06	-0.28	-0.26	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
HNSC	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-5.91	6.42e-09	2.76e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-5.91	6.42e-09	2.76e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-5.91	6.43e-09	2.76e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
HNSC	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	5.91	6.43e-09	2.76e-06	0.32	0.26	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	5.91	6.44e-09	2.76e-06	0.3	0.26	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
HNSC	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	5.91	6.44e-09	2.76e-06	0.55	0.26	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
HNSC	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-5.91	6.45e-09	2.76e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
HNSC	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	5.91	6.45e-09	2.77e-06	0.26	0.26	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
HNSC	cis	rs7615952	0.611	rs7632305	ENSG00000248787.1	RP11-666A20.4	-5.91	6.45e-09	2.77e-06	-0.48	-0.26	Blood pressure (smoking interaction);	chr3:125915924	chr3:125908005~125910272:-
HNSC	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	5.91	6.45e-09	2.77e-06	0.34	0.26	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
HNSC	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-5.91	6.46e-09	2.77e-06	-0.32	-0.26	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
HNSC	cis	rs9300255	0.596	rs1727331	ENSG00000280120.1	RP11-546D6.3	-5.91	6.46e-09	2.77e-06	-0.23	-0.26	Neutrophil percentage of white cells;	chr12:123234332	chr12:123152324~123153377:-
HNSC	cis	rs8177876	0.915	rs12444974	ENSG00000261061.1	RP11-303E16.2	-5.91	6.46e-09	2.77e-06	-0.46	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094625	chr16:81030770~81031485:+
HNSC	cis	rs13113518	1	rs11133388	ENSG00000249700.7	SRD5A3-AS1	-5.91	6.47e-09	2.77e-06	-0.31	-0.26	Height;	chr4:55477866	chr4:55363971~55395847:-
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000211972.2	IGHV3-66	5.91	6.47e-09	2.77e-06	0.21	0.26	Kawasaki disease;	chr14:106787730	chr14:106675017~106675544:-
HNSC	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-5.91	6.47e-09	2.78e-06	-0.37	-0.26	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-5.91	6.47e-09	2.78e-06	-0.37	-0.26	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000254153.1	CTA-398F10.2	5.91	6.47e-09	2.78e-06	0.3	0.26	Joint mobility (Beighton score);	chr8:9045624	chr8:8456909~8461337:-
HNSC	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	5.91	6.49e-09	2.78e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
HNSC	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-5.91	6.49e-09	2.78e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
HNSC	cis	rs73186030	1	rs73186030	ENSG00000272758.4	RP11-299J3.8	5.91	6.49e-09	2.78e-06	0.39	0.26	Serum parathyroid hormone levels;	chr3:122294618	chr3:122416207~122443180:+
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000211972.2	IGHV3-66	5.91	6.49e-09	2.78e-06	0.2	0.26	Kawasaki disease;	chr14:106782206	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000211972.2	IGHV3-66	5.91	6.49e-09	2.78e-06	0.2	0.26	Kawasaki disease;	chr14:106782238	chr14:106675017~106675544:-
HNSC	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-5.91	6.5e-09	2.78e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-5.91	6.5e-09	2.78e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000211972.2	IGHV3-66	5.91	6.5e-09	2.79e-06	0.2	0.26	Kawasaki disease;	chr14:106780451	chr14:106675017~106675544:-
HNSC	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	5.91	6.5e-09	2.79e-06	0.29	0.26	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
HNSC	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	5.91	6.5e-09	2.79e-06	0.32	0.26	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
HNSC	cis	rs8031584	0.697	rs798080	ENSG00000260382.1	RP11-540B6.2	-5.91	6.52e-09	2.79e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30829966	chr15:30882267~30883231:-
HNSC	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-5.91	6.52e-09	2.8e-06	-0.3	-0.26	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
HNSC	cis	rs9611519	0.78	rs9611527	ENSG00000235513.1	RP4-756G23.5	5.91	6.53e-09	2.8e-06	0.28	0.26	Neuroticism;	chr22:41248424	chr22:41209122~41217627:-
HNSC	cis	rs189798	0.807	rs330912	ENSG00000173295.6	FAM86B3P	5.91	6.53e-09	2.8e-06	0.33	0.26	Myopia (pathological);	chr8:9138784	chr8:8228595~8244865:+
HNSC	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	5.91	6.53e-09	2.8e-06	0.24	0.26	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-5.91	6.53e-09	2.8e-06	-0.31	-0.26	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
HNSC	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	5.91	6.53e-09	2.8e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
HNSC	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-5.91	6.54e-09	2.8e-06	-0.33	-0.26	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	5.91	6.55e-09	2.81e-06	0.41	0.26	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000173295.6	FAM86B3P	-5.91	6.56e-09	2.81e-06	-0.29	-0.26	Mood instability;	chr8:8934916	chr8:8228595~8244865:+
HNSC	cis	rs75920871	0.528	rs10082609	ENSG00000254851.1	RP11-109L13.1	5.91	6.56e-09	2.81e-06	0.36	0.26	Subjective well-being;	chr11:117078358	chr11:117135528~117138582:+
HNSC	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-5.91	6.57e-09	2.81e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
HNSC	cis	rs11089937	0.559	rs2330014	ENSG00000211638.2	IGLV8-61	-5.91	6.57e-09	2.81e-06	-0.24	-0.26	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22098700~22099212:+
HNSC	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	5.91	6.57e-09	2.82e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
HNSC	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	5.91	6.58e-09	2.82e-06	0.31	0.26	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
HNSC	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
HNSC	cis	rs2235642	0.75	rs2755185	ENSG00000280231.1	LA16c-380F5.3	-5.91	6.59e-09	2.82e-06	-0.32	-0.26	Coronary artery disease;	chr16:1595826	chr16:1553655~1554130:-
HNSC	cis	rs13113518	0.812	rs56055342	ENSG00000273257.1	RP11-177J6.1	5.91	6.59e-09	2.82e-06	0.33	0.26	Height;	chr4:55540928	chr4:55387949~55388271:+
HNSC	cis	rs7617773	0.539	rs12486935	ENSG00000228638.1	FCF1P2	-5.91	6.59e-09	2.82e-06	-0.23	-0.26	Coronary artery disease;	chr3:48348674	chr3:48290793~48291375:-
HNSC	cis	rs8031584	0.678	rs8035703	ENSG00000260382.1	RP11-540B6.2	5.91	6.59e-09	2.82e-06	0.33	0.26	Huntington's disease progression;	chr15:30876269	chr15:30882267~30883231:-
HNSC	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-5.91	6.6e-09	2.82e-06	-0.31	-0.26	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
HNSC	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	-5.91	6.6e-09	2.83e-06	-0.3	-0.26	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
HNSC	cis	rs7804306	0.826	rs113537684	ENSG00000233264.2	AC006042.8	5.91	6.61e-09	2.83e-06	0.58	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7985192	chr7:7980312~7982228:+
HNSC	cis	rs6969780	1	rs1801085	ENSG00000233429.8	HOTAIRM1	5.91	6.61e-09	2.83e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27128971	chr7:27095647~27100265:+
HNSC	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.91	6.61e-09	2.83e-06	0.35	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
HNSC	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-5.91	6.62e-09	2.83e-06	-0.35	-0.26	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
HNSC	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	5.91	6.62e-09	2.83e-06	0.3	0.26	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
HNSC	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	5.91	6.62e-09	2.83e-06	0.34	0.26	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
HNSC	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-5.91	6.62e-09	2.83e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-5.91	6.63e-09	2.84e-06	-0.31	-0.26	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
HNSC	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	5.91	6.63e-09	2.84e-06	0.32	0.26	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
HNSC	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-5.91	6.63e-09	2.84e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
HNSC	cis	rs9300255	0.544	rs1716175	ENSG00000280120.1	RP11-546D6.3	5.91	6.64e-09	2.84e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123173841	chr12:123152324~123153377:-
HNSC	cis	rs11089937	0.609	rs9622980	ENSG00000211638.2	IGLV8-61	-5.91	6.65e-09	2.84e-06	-0.27	-0.26	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22098700~22099212:+
HNSC	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	5.91	6.65e-09	2.84e-06	0.32	0.26	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
HNSC	cis	rs9840812	0.637	rs667920	ENSG00000273486.1	RP11-731C17.2	5.91	6.65e-09	2.84e-06	0.24	0.26	Fibrinogen levels;	chr3:136350630	chr3:136837338~136839021:-
HNSC	cis	rs60617249	0.507	rs34591416	ENSG00000228204.2	RP4-724E13.2	5.91	6.65e-09	2.84e-06	0.33	0.26	Major depression and alcohol dependence;	chr7:50872830	chr7:50866747~51022990:+
HNSC	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	5.91	6.65e-09	2.84e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
HNSC	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	5.91	6.65e-09	2.85e-06	0.24	0.26	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
HNSC	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	5.91	6.66e-09	2.85e-06	0.37	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
HNSC	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-5.91	6.67e-09	2.85e-06	-0.37	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
HNSC	cis	rs9840812	0.623	rs4678433	ENSG00000273486.1	RP11-731C17.2	5.91	6.67e-09	2.85e-06	0.23	0.26	Fibrinogen levels;	chr3:136546840	chr3:136837338~136839021:-
HNSC	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	5.91	6.67e-09	2.85e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
HNSC	cis	rs6604026	0.557	rs72724515	ENSG00000223787.2	RP4-593M8.1	5.91	6.68e-09	2.86e-06	0.36	0.26	Multiple sclerosis;	chr1:92585519	chr1:92580476~92580821:-
HNSC	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	5.91	6.68e-09	2.86e-06	0.31	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
HNSC	cis	rs2286503	0.752	rs6461669	ENSG00000221740.1	SNORD93	5.91	6.68e-09	2.86e-06	0.29	0.26	Fibrinogen;	chr7:22818447	chr7:22856613~22856686:+
HNSC	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-5.91	6.68e-09	2.86e-06	-0.31	-0.26	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-5.91	6.68e-09	2.86e-06	-0.31	-0.26	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-5.91	6.68e-09	2.86e-06	-0.31	-0.26	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	5.91	6.69e-09	2.86e-06	0.25	0.26	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
HNSC	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	5.91	6.69e-09	2.86e-06	0.35	0.26	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	5.91	6.71e-09	2.87e-06	0.3	0.26	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
HNSC	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-5.91	6.71e-09	2.87e-06	-0.33	-0.26	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-5.91	6.71e-09	2.87e-06	-0.33	-0.26	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
HNSC	cis	rs6969780	0.778	rs61384251	ENSG00000233429.8	HOTAIRM1	5.91	6.71e-09	2.87e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106583	chr7:27095647~27100265:+
HNSC	cis	rs2880765	0.743	rs4551990	ENSG00000259295.5	CSPG4P12	5.91	6.72e-09	2.87e-06	0.31	0.26	Coronary artery disease;	chr15:85472056	chr15:85191438~85213905:+
HNSC	cis	rs7615952	0.512	rs2979351	ENSG00000241288.6	RP11-379B18.5	-5.91	6.72e-09	2.87e-06	-0.33	-0.26	Blood pressure (smoking interaction);	chr3:125644755	chr3:125827238~125916384:-
HNSC	cis	rs9291683	0.552	rs3796832	ENSG00000250413.1	RP11-448G15.1	-5.91	6.72e-09	2.87e-06	-0.33	-0.26	Bone mineral density;	chr4:10014241	chr4:10006482~10009725:+
HNSC	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-5.91	6.72e-09	2.87e-06	-0.24	-0.26	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
HNSC	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	5.91	6.74e-09	2.88e-06	0.47	0.26	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
HNSC	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	5.91	6.74e-09	2.88e-06	0.36	0.26	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
HNSC	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-5.91	6.74e-09	2.88e-06	-0.31	-0.26	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
HNSC	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
HNSC	cis	rs13113518	0.841	rs11133400	ENSG00000249700.7	SRD5A3-AS1	5.91	6.76e-09	2.89e-06	0.31	0.26	Height;	chr4:55578787	chr4:55363971~55395847:-
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000254153.1	CTA-398F10.2	5.91	6.76e-09	2.89e-06	0.29	0.26	Systolic blood pressure;	chr8:8486617	chr8:8456909~8461337:-
HNSC	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-5.91	6.76e-09	2.89e-06	-0.23	-0.26	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
HNSC	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-5.91	6.77e-09	2.89e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
HNSC	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	5.91	6.77e-09	2.89e-06	0.49	0.26	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
HNSC	cis	rs526231	0.756	rs556560	ENSG00000175749.11	EIF3KP1	-5.91	6.77e-09	2.89e-06	-0.32	-0.26	Primary biliary cholangitis;	chr5:103288223	chr5:103032376~103033031:+
HNSC	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	5.91	6.78e-09	2.89e-06	0.28	0.26	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	5.91	6.78e-09	2.89e-06	0.28	0.26	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
HNSC	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-5.91	6.79e-09	2.9e-06	-0.31	-0.26	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
HNSC	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-5.91	6.79e-09	2.9e-06	-0.34	-0.26	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
HNSC	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	5.9	6.8e-09	2.9e-06	0.23	0.26	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
HNSC	cis	rs17507216	0.718	rs17158403	ENSG00000255769.6	GOLGA2P10	-5.9	6.8e-09	2.9e-06	-0.41	-0.26	Excessive daytime sleepiness;	chr15:82572478	chr15:82472993~82513950:-
HNSC	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	5.9	6.8e-09	2.9e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	5.9	6.8e-09	2.9e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
HNSC	cis	rs6928977	0.932	rs6935146	ENSG00000234084.1	RP3-388E23.2	-5.9	6.81e-09	2.91e-06	-0.26	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306231	chr6:135301568~135307158:+
HNSC	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.81e-09	2.91e-06	-0.32	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
HNSC	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	5.9	6.82e-09	2.91e-06	0.27	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
HNSC	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-5.9	6.82e-09	2.91e-06	-0.32	-0.26	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
HNSC	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	5.9	6.82e-09	2.91e-06	0.29	0.26	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-5.9	6.82e-09	2.91e-06	-0.17	-0.26	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
HNSC	cis	rs2115630	1	rs6496452	ENSG00000229212.6	RP11-561C5.4	5.9	6.83e-09	2.91e-06	0.3	0.26	P wave terminal force;	chr15:84829414	chr15:85205440~85234795:-
HNSC	cis	rs9914544	0.932	rs11870265	ENSG00000264885.1	RP11-815I9.4	-5.9	6.83e-09	2.92e-06	-0.28	-0.26	Educational attainment (years of education);	chr17:18917672	chr17:18667629~18669461:-
HNSC	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	5.9	6.85e-09	2.92e-06	0.42	0.26	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
HNSC	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-5.9	6.85e-09	2.92e-06	-0.37	-0.26	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
HNSC	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-5.9	6.86e-09	2.93e-06	-0.31	-0.26	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
HNSC	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-5.9	6.86e-09	2.93e-06	-0.26	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
HNSC	cis	rs56080343	0.748	rs56190986	ENSG00000275759.1	RP11-131L12.3	-5.9	6.86e-09	2.93e-06	-0.53	-0.26	Neuroticism;	chr12:118408458	chr12:118428281~118428870:+
HNSC	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	5.9	6.87e-09	2.93e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
HNSC	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	5.9	6.87e-09	2.93e-06	0.36	0.26	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
HNSC	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-5.9	6.87e-09	2.93e-06	-0.29	-0.26	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-5.9	6.87e-09	2.93e-06	-0.17	-0.26	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
HNSC	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	5.9	6.88e-09	2.93e-06	0.34	0.26	Height;	chr4:55501955	chr4:55363971~55395847:-
HNSC	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	5.9	6.89e-09	2.94e-06	0.32	0.26	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
HNSC	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-5.9	6.89e-09	2.94e-06	-0.34	-0.26	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
HNSC	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-5.9	6.89e-09	2.94e-06	-0.2	-0.26	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
HNSC	cis	rs9300255	0.62	rs1716173	ENSG00000280120.1	RP11-546D6.3	5.9	6.89e-09	2.94e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123176174	chr12:123152324~123153377:-
HNSC	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-5.9	6.9e-09	2.94e-06	-0.31	-0.26	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
HNSC	cis	rs13113518	0.783	rs13111128	ENSG00000273257.1	RP11-177J6.1	5.9	6.91e-09	2.95e-06	0.33	0.26	Height;	chr4:55578154	chr4:55387949~55388271:+
HNSC	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-5.9	6.91e-09	2.95e-06	-0.4	-0.26	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
HNSC	cis	rs6918586	0.615	rs198841	ENSG00000272462.2	U91328.19	-5.9	6.92e-09	2.95e-06	-0.25	-0.26	Schizophrenia;	chr6:26111443	chr6:25992662~26001775:+
HNSC	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-5.9	6.92e-09	2.95e-06	-0.3	-0.26	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
HNSC	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-5.9	6.93e-09	2.95e-06	-0.38	-0.26	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
HNSC	cis	rs2880765	0.835	rs6497202	ENSG00000259295.5	CSPG4P12	5.9	6.94e-09	2.96e-06	0.3	0.26	Coronary artery disease;	chr15:85478144	chr15:85191438~85213905:+
HNSC	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	5.9	6.95e-09	2.96e-06	0.31	0.26	Height;	chr4:55409063	chr4:55363971~55395847:-
HNSC	cis	rs9611519	0.754	rs4820435	ENSG00000235513.1	RP4-756G23.5	5.9	6.95e-09	2.96e-06	0.28	0.26	Neuroticism;	chr22:41256842	chr22:41209122~41217627:-
HNSC	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	5.9	6.96e-09	2.97e-06	0.36	0.26	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000211972.2	IGHV3-66	5.9	6.96e-09	2.97e-06	0.2	0.26	Kawasaki disease;	chr14:106767996	chr14:106675017~106675544:-
HNSC	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-5.9	6.96e-09	2.97e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
HNSC	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-5.9	6.97e-09	2.97e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.524	rs2877021	ENSG00000211638.2	IGLV8-61	-5.9	6.97e-09	2.97e-06	-0.24	-0.26	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22098700~22099212:+
HNSC	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	5.9	6.97e-09	2.97e-06	0.25	0.26	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
HNSC	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	5.9	6.98e-09	2.97e-06	0.4	0.26	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
HNSC	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-5.9	6.98e-09	2.97e-06	-0.34	-0.26	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
HNSC	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-5.9	6.98e-09	2.97e-06	-0.2	-0.26	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
HNSC	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	5.9	6.98e-09	2.97e-06	0.38	0.26	Height;	chr6:109732047	chr6:109382795~109383666:+
HNSC	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
HNSC	cis	rs6928977	0.675	rs7750586	ENSG00000217482.2	HMGB1P17	-5.9	6.98e-09	2.98e-06	-0.29	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135636086~135636713:-
HNSC	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-5.9	6.99e-09	2.98e-06	-0.33	-0.26	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
HNSC	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
HNSC	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-5.9	7e-09	2.98e-06	-0.32	-0.26	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-5.9	7e-09	2.98e-06	-0.21	-0.26	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
HNSC	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	5.9	7.03e-09	2.99e-06	0.32	0.26	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
HNSC	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-5.9	7.03e-09	2.99e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-5.9	7.03e-09	2.99e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
HNSC	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	5.9	7.03e-09	2.99e-06	0.33	0.26	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
HNSC	cis	rs8054556	0.74	rs3924855	ENSG00000183604.13	SMG1P5	-5.9	7.04e-09	3e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30267553~30335374:-
HNSC	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	5.9	7.04e-09	3e-06	0.25	0.26	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-5.9	7.05e-09	3e-06	-0.31	-0.26	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
HNSC	cis	rs7674212	0.54	rs2711897	ENSG00000246560.2	RP11-10L12.4	5.9	7.05e-09	3e-06	0.3	0.26	Type 2 diabetes;	chr4:103102410	chr4:102828055~102844075:+
HNSC	cis	rs2255336	0.873	rs11053806	ENSG00000245648.1	RP11-277P12.20	-5.9	7.06e-09	3e-06	-0.43	-0.26	Blood protein levels;	chr12:10455822	chr12:10363769~10398506:+
HNSC	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	5.9	7.06e-09	3.01e-06	0.3	0.26	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
HNSC	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-5.9	7.06e-09	3.01e-06	-0.31	-0.26	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
HNSC	cis	rs11098499	0.644	rs10009566	ENSG00000249244.1	RP11-548H18.2	5.9	7.06e-09	3.01e-06	0.32	0.26	Corneal astigmatism;	chr4:119637453	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	5.9	7.07e-09	3.01e-06	0.34	0.26	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
HNSC	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	5.9	7.07e-09	3.01e-06	0.36	0.26	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
HNSC	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-5.9	7.07e-09	3.01e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
HNSC	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-5.9	7.08e-09	3.01e-06	-0.26	-0.26	Height;	chr2:231549981	chr2:231508426~231514339:-
HNSC	cis	rs2790457	0.76	rs1265834	ENSG00000254635.4	WAC-AS1	5.9	7.08e-09	3.01e-06	0.29	0.26	Multiple myeloma;	chr10:28652932	chr10:28522652~28532743:-
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	5.9	7.09e-09	3.01e-06	0.29	0.26	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
HNSC	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	5.9	7.09e-09	3.02e-06	0.31	0.26	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000254153.1	CTA-398F10.2	5.9	7.09e-09	3.02e-06	0.29	0.26	Joint mobility (Beighton score);	chr8:9002766	chr8:8456909~8461337:-
HNSC	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
HNSC	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	5.9	7.1e-09	3.02e-06	0.41	0.26	Height;	chr6:109455700	chr6:109382795~109383666:+
HNSC	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-5.9	7.11e-09	3.02e-06	-0.31	-0.26	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
HNSC	cis	rs6918586	0.636	rs198817	ENSG00000272462.2	U91328.19	-5.9	7.11e-09	3.02e-06	-0.25	-0.26	Schizophrenia;	chr6:26126296	chr6:25992662~26001775:+
HNSC	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-5.9	7.12e-09	3.03e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
HNSC	cis	rs2980436	1	rs2980436	ENSG00000254153.1	CTA-398F10.2	-5.9	7.12e-09	3.03e-06	-0.29	-0.26	Schizophrenia;	chr8:8234503	chr8:8456909~8461337:-
HNSC	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	5.9	7.12e-09	3.03e-06	0.27	0.26	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
HNSC	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	5.9	7.15e-09	3.04e-06	0.3	0.26	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
HNSC	cis	rs11992162	0.967	rs4841661	ENSG00000206014.6	OR7E161P	-5.9	7.15e-09	3.04e-06	-0.28	-0.26	Monocyte count;	chr8:11975260	chr8:11928597~11929563:-
HNSC	cis	rs6867032	0.527	rs13190594	ENSG00000249731.1	RP11-259O2.3	5.9	7.16e-09	3.04e-06	0.29	0.26	Gut microbiome composition (winter);	chr5:2012360	chr5:1968094~1969013:+
HNSC	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-5.9	7.16e-09	3.04e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-5.9	7.16e-09	3.04e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-5.9	7.16e-09	3.04e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
HNSC	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	5.9	7.16e-09	3.04e-06	0.35	0.26	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	5.9	7.16e-09	3.04e-06	0.35	0.26	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
HNSC	cis	rs2439831	1	rs2254321	ENSG00000205771.5	CATSPER2P1	-5.9	7.17e-09	3.05e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43415344	chr15:43726918~43747094:-
HNSC	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-5.9	7.18e-09	3.05e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
HNSC	cis	rs7587476	0.906	rs62201985	ENSG00000229267.2	AC072062.1	-5.9	7.18e-09	3.05e-06	-0.39	-0.26	Neuroblastoma;	chr2:214793914	chr2:214810229~214963274:+
HNSC	cis	rs8012947	1	rs61450169	ENSG00000279636.2	LINC00216	5.9	7.18e-09	3.05e-06	0.32	0.26	Alcohol consumption in current drinkers;	chr14:58246142	chr14:58288033~58289158:+
HNSC	cis	rs2337406	0.925	rs4774188	ENSG00000211974.3	IGHV2-70	-5.89	7.19e-09	3.06e-06	-0.34	-0.26	Alzheimer's disease (late onset);	chr14:106767918	chr14:106723574~106724093:-
HNSC	cis	rs2976388	0.647	rs13272904	ENSG00000253741.1	CTD-2292P10.4	-5.89	7.2e-09	3.06e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142701196	chr8:142702252~142726973:-
HNSC	cis	rs8031584	0.723	rs711224	ENSG00000260382.1	RP11-540B6.2	-5.89	7.2e-09	3.06e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30835718	chr15:30882267~30883231:-
HNSC	cis	rs867371	0.502	rs1846908	ENSG00000276710.3	CSPG4P8	-5.89	7.2e-09	3.06e-06	-0.28	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82459472~82477258:+
HNSC	cis	rs2665103	0.655	rs1501367	ENSG00000276710.3	CSPG4P8	-5.89	7.2e-09	3.06e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82459472~82477258:+
HNSC	cis	rs11846409	0.799	rs10467899	ENSG00000211974.3	IGHV2-70	-5.89	7.21e-09	3.06e-06	-0.3	-0.26	Rheumatic heart disease;	chr14:106644012	chr14:106723574~106724093:-
HNSC	cis	rs13113518	1	rs4864542	ENSG00000249700.7	SRD5A3-AS1	-5.89	7.22e-09	3.07e-06	-0.31	-0.26	Height;	chr4:55487920	chr4:55363971~55395847:-
HNSC	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-5.89	7.22e-09	3.07e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000254153.1	CTA-398F10.2	5.89	7.22e-09	3.07e-06	0.29	0.26	Joint mobility (Beighton score);	chr8:9005011	chr8:8456909~8461337:-
HNSC	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-5.89	7.23e-09	3.07e-06	-0.36	-0.26	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
HNSC	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-5.89	7.23e-09	3.07e-06	-0.36	-0.26	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
HNSC	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	5.89	7.23e-09	3.07e-06	0.24	0.26	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
HNSC	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	5.89	7.23e-09	3.07e-06	0.28	0.26	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
HNSC	cis	rs1012068	1	rs1012068	ENSG00000236132.1	CTA-440B3.1	-5.89	7.24e-09	3.07e-06	-0.31	-0.26	Chronic hepatitis C infection;	chr22:31869917	chr22:31816379~31817491:-
HNSC	cis	rs7115242	0.844	rs645258	ENSG00000280143.1	AP000892.6	5.89	7.24e-09	3.07e-06	0.49	0.26	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117204967~117210292:+
HNSC	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-5.89	7.24e-09	3.08e-06	-0.34	-0.26	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
HNSC	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-5.89	7.26e-09	3.08e-06	-0.35	-0.26	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	5.89	7.27e-09	3.09e-06	0.29	0.26	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000173295.6	FAM86B3P	-5.89	7.27e-09	3.09e-06	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9018719	chr8:8228595~8244865:+
HNSC	cis	rs2880765	0.743	rs16940052	ENSG00000259295.5	CSPG4P12	5.89	7.27e-09	3.09e-06	0.3	0.26	Coronary artery disease;	chr15:85463443	chr15:85191438~85213905:+
HNSC	cis	rs7819412	0.805	rs2409710	ENSG00000269918.1	AF131215.9	-5.89	7.28e-09	3.09e-06	-0.26	-0.26	Triglycerides;	chr8:11122311	chr8:11104691~11106704:-
HNSC	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	5.89	7.28e-09	3.09e-06	0.4	0.26	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	5.89	7.28e-09	3.09e-06	0.4	0.26	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
HNSC	cis	rs2404602	0.669	rs8036703	ENSG00000259422.1	RP11-593F23.1	5.89	7.29e-09	3.09e-06	0.3	0.26	Blood metabolite levels;	chr15:76658699	chr15:76174891~76181486:-
HNSC	cis	rs2134046	0.587	rs11854289	ENSG00000255769.6	GOLGA2P10	5.89	7.3e-09	3.1e-06	0.31	0.26	Cognitive ability;	chr15:82266461	chr15:82472993~82513950:-
HNSC	cis	rs7617773	0.539	rs17593974	ENSG00000228638.1	FCF1P2	-5.89	7.31e-09	3.1e-06	-0.23	-0.26	Coronary artery disease;	chr3:48345844	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.514	rs11130166	ENSG00000228638.1	FCF1P2	-5.89	7.31e-09	3.1e-06	-0.23	-0.26	Coronary artery disease;	chr3:48346566	chr3:48290793~48291375:-
HNSC	cis	rs13113518	1	rs4864546	ENSG00000249700.7	SRD5A3-AS1	5.89	7.31e-09	3.1e-06	0.31	0.26	Height;	chr4:55537960	chr4:55363971~55395847:-
HNSC	cis	rs988913	0.957	rs1910350	ENSG00000224984.1	RP11-524H19.2	5.89	7.33e-09	3.11e-06	0.3	0.26	Menarche (age at onset);	chr6:54987664	chr6:54840118~54840855:-
HNSC	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-5.89	7.34e-09	3.11e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
HNSC	cis	rs2880765	0.835	rs4514633	ENSG00000259295.5	CSPG4P12	5.89	7.34e-09	3.11e-06	0.3	0.26	Coronary artery disease;	chr15:85497786	chr15:85191438~85213905:+
HNSC	cis	rs2404602	0.692	rs7163397	ENSG00000259422.1	RP11-593F23.1	5.89	7.36e-09	3.12e-06	0.3	0.26	Blood metabolite levels;	chr15:76647974	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	5.89	7.36e-09	3.12e-06	0.36	0.26	Height;	chr6:109582583	chr6:109382795~109383666:+
HNSC	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	5.89	7.36e-09	3.12e-06	0.31	0.26	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	5.89	7.36e-09	3.12e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
HNSC	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-5.89	7.36e-09	3.12e-06	-0.34	-0.26	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
HNSC	cis	rs950169	0.526	rs698620	ENSG00000229212.6	RP11-561C5.4	5.89	7.37e-09	3.12e-06	0.3	0.26	Schizophrenia;	chr15:84633977	chr15:85205440~85234795:-
HNSC	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-5.89	7.38e-09	3.13e-06	-0.29	-0.26	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
HNSC	cis	rs7819412	0.749	rs11991118	ENSG00000269918.1	AF131215.9	5.89	7.38e-09	3.13e-06	0.26	0.26	Triglycerides;	chr8:11081763	chr8:11104691~11106704:-
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-5.89	7.38e-09	3.13e-06	-0.29	-0.26	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
HNSC	cis	rs7824557	0.547	rs6601570	ENSG00000269918.1	AF131215.9	-5.89	7.39e-09	3.13e-06	-0.26	-0.26	Retinal vascular caliber;	chr8:11221858	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	5.89	7.39e-09	3.13e-06	0.32	0.26	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
HNSC	cis	rs9907295	0.688	rs2735475	ENSG00000270977.1	AC015849.16	-5.89	7.39e-09	3.13e-06	-0.35	-0.26	Fibroblast growth factor basic levels;	chr17:35931003	chr17:35893707~35911023:-
HNSC	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	-5.89	7.4e-09	3.14e-06	-0.3	-0.26	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
HNSC	cis	rs853679	0.55	rs1233701	ENSG00000204709.4	LINC01556	-5.89	7.4e-09	3.14e-06	-0.35	-0.26	Depression;	chr6:28200948	chr6:28943877~28944537:+
HNSC	cis	rs2834288	0.5	rs881231	ENSG00000273102.1	AP000569.9	5.89	7.41e-09	3.14e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33967101~33968573:-
HNSC	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	5.89	7.41e-09	3.14e-06	0.32	0.26	Height;	chr4:55436423	chr4:55363971~55395847:-
HNSC	cis	rs75422866	0.51	rs73104197	ENSG00000276691.1	RP5-1057I20.5	5.89	7.41e-09	3.14e-06	0.47	0.26	Pneumonia;	chr12:47717273	chr12:47788426~47788971:+
HNSC	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	5.89	7.43e-09	3.15e-06	0.4	0.26	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
HNSC	cis	rs6969780	1	rs6969780	ENSG00000233429.8	HOTAIRM1	5.89	7.43e-09	3.15e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119517	chr7:27095647~27100265:+
HNSC	cis	rs2834288	0.5	rs766425	ENSG00000273102.1	AP000569.9	5.89	7.43e-09	3.15e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33967101~33968573:-
HNSC	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-5.89	7.43e-09	3.15e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
HNSC	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-5.89	7.44e-09	3.15e-06	-0.31	-0.26	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
HNSC	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	5.89	7.45e-09	3.16e-06	0.25	0.26	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
HNSC	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-5.89	7.45e-09	3.16e-06	-0.35	-0.26	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
HNSC	cis	rs6951245	0.872	rs11768895	ENSG00000225146.1	AC073957.15	-5.89	7.46e-09	3.16e-06	-0.41	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024055	chr7:1029025~1043891:+
HNSC	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-5.89	7.46e-09	3.16e-06	-0.3	-0.26	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
HNSC	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-5.89	7.47e-09	3.17e-06	-0.27	-0.26	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
HNSC	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	5.89	7.5e-09	3.18e-06	0.34	0.26	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
HNSC	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	5.89	7.5e-09	3.18e-06	0.3	0.26	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
HNSC	cis	rs9300255	0.537	rs1727334	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123229689	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.639	rs941306	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123230566	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs941305	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123230719	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.639	rs1716171	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123231829	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.569	rs1716170	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123231966	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.679	rs4759409	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123235038	chr12:123152324~123153377:-
HNSC	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-5.89	7.51e-09	3.18e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
HNSC	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-5.89	7.52e-09	3.18e-06	-0.31	-0.26	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
HNSC	cis	rs6918586	0.636	rs198816	ENSG00000272462.2	U91328.19	-5.89	7.54e-09	3.19e-06	-0.25	-0.26	Schizophrenia;	chr6:26126956	chr6:25992662~26001775:+
HNSC	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-5.89	7.54e-09	3.19e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-5.89	7.55e-09	3.19e-06	-0.41	-0.26	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
HNSC	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-5.89	7.55e-09	3.2e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
HNSC	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	5.89	7.55e-09	3.2e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	5.89	7.55e-09	3.2e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	5.89	7.55e-09	3.2e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
HNSC	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-5.89	7.56e-09	3.2e-06	-0.38	-0.26	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
HNSC	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-5.89	7.56e-09	3.2e-06	-0.31	-0.26	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
HNSC	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	5.89	7.56e-09	3.2e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000254340.1	RP11-10A14.3	5.89	7.57e-09	3.2e-06	0.33	0.26	Mood instability;	chr8:8786764	chr8:9141424~9145435:+
HNSC	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-5.89	7.57e-09	3.2e-06	-0.34	-0.26	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
HNSC	cis	rs889014	0.751	rs11742399	ENSG00000253768.1	CTB-33O18.1	5.89	7.57e-09	3.2e-06	0.29	0.26	Height;	chr5:173551352	chr5:173562478~173573199:+
HNSC	cis	rs8177876	0.841	rs117310590	ENSG00000261061.1	RP11-303E16.2	-5.89	7.58e-09	3.21e-06	-0.48	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81030770~81031485:+
HNSC	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	5.89	7.6e-09	3.21e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
HNSC	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	5.89	7.6e-09	3.22e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-5.89	7.6e-09	3.22e-06	-0.29	-0.26	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
HNSC	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-5.88	7.61e-09	3.22e-06	-0.44	-0.26	Depression;	chr6:28076050	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-5.88	7.61e-09	3.22e-06	-0.44	-0.26	Depression;	chr6:28085045	chr6:28115628~28116551:+
HNSC	cis	rs673078	0.562	rs61944672	ENSG00000275409.1	RP11-131L12.4	-5.88	7.62e-09	3.22e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118450123	chr12:118430147~118430699:+
HNSC	cis	rs7615952	0.641	rs12488180	ENSG00000241288.6	RP11-379B18.5	-5.88	7.63e-09	3.23e-06	-0.34	-0.26	Blood pressure (smoking interaction);	chr3:126063393	chr3:125827238~125916384:-
HNSC	cis	rs7617773	0.925	rs34513961	ENSG00000228638.1	FCF1P2	-5.88	7.63e-09	3.23e-06	-0.28	-0.26	Coronary artery disease;	chr3:48132163	chr3:48290793~48291375:-
HNSC	cis	rs3743266	0.507	rs9630426	ENSG00000245534.5	RORA-AS1	-5.88	7.63e-09	3.23e-06	-0.42	-0.26	Menarche (age at onset);	chr15:60446854	chr15:60479178~60630637:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000233609.3	RP11-62H7.2	-5.88	7.64e-09	3.23e-06	-0.25	-0.26	Mood instability;	chr8:8934916	chr8:8961200~8979025:+
HNSC	cis	rs13113518	0.812	rs13140173	ENSG00000273257.1	RP11-177J6.1	5.88	7.65e-09	3.23e-06	0.32	0.26	Height;	chr4:55527164	chr4:55387949~55388271:+
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000211972.2	IGHV3-66	-5.88	7.65e-09	3.23e-06	-0.2	-0.26	Kawasaki disease;	chr14:106775945	chr14:106675017~106675544:-
HNSC	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	5.88	7.66e-09	3.24e-06	0.28	0.26	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
HNSC	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-5.88	7.66e-09	3.24e-06	-0.36	-0.26	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
HNSC	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-5.88	7.66e-09	3.24e-06	-0.32	-0.26	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-5.88	7.68e-09	3.25e-06	-0.31	-0.26	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000228039.3	KB-1125A3.10	5.88	7.69e-09	3.25e-06	0.33	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23963780~23964374:+
HNSC	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-5.88	7.69e-09	3.25e-06	-0.31	-0.26	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
HNSC	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	5.88	7.69e-09	3.25e-06	0.32	0.26	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
HNSC	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-5.88	7.69e-09	3.25e-06	-0.34	-0.26	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
HNSC	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	5.88	7.69e-09	3.25e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
HNSC	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	5.88	7.69e-09	3.25e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	5.88	7.69e-09	3.25e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	5.88	7.7e-09	3.25e-06	0.4	0.26	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
HNSC	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-5.88	7.7e-09	3.26e-06	-0.44	-0.26	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000179406.6	LINC00174	-5.88	7.7e-09	3.26e-06	-0.57	-0.26	Diabetic kidney disease;	chr7:66528779	chr7:66376044~66401338:-
HNSC	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	5.88	7.71e-09	3.26e-06	0.36	0.26	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	5.88	7.71e-09	3.26e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
HNSC	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-5.88	7.71e-09	3.26e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
HNSC	cis	rs17214007	0.597	rs4781677	ENSG00000263335.1	AF001548.5	-5.88	7.72e-09	3.26e-06	-0.41	-0.26	Cognitive function;	chr16:15636388	chr16:15726674~15732993:+
HNSC	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.55	rs1150692	ENSG00000204709.4	LINC01556	5.88	7.73e-09	3.26e-06	0.36	0.26	Depression;	chr6:28206179	chr6:28943877~28944537:+
HNSC	cis	rs75422866	0.558	rs73104190	ENSG00000276691.1	RP5-1057I20.5	5.88	7.73e-09	3.26e-06	0.47	0.26	Pneumonia;	chr12:47716040	chr12:47788426~47788971:+
HNSC	cis	rs13113518	0.595	rs13120635	ENSG00000273257.1	RP11-177J6.1	5.88	7.74e-09	3.27e-06	0.34	0.26	Height;	chr4:55361200	chr4:55387949~55388271:+
HNSC	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	5.88	7.74e-09	3.27e-06	0.36	0.26	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
HNSC	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	5.88	7.74e-09	3.27e-06	0.24	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
HNSC	cis	rs13113518	0.783	rs34534635	ENSG00000273257.1	RP11-177J6.1	5.88	7.74e-09	3.27e-06	0.33	0.26	Height;	chr4:55573424	chr4:55387949~55388271:+
HNSC	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-5.88	7.76e-09	3.28e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
HNSC	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	5.88	7.77e-09	3.28e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
HNSC	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	5.88	7.77e-09	3.28e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
HNSC	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	5.88	7.77e-09	3.28e-06	0.29	0.26	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
HNSC	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	5.88	7.77e-09	3.28e-06	0.35	0.26	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
HNSC	cis	rs9840812	0.691	rs1070232	ENSG00000273486.1	RP11-731C17.2	5.88	7.77e-09	3.28e-06	0.23	0.26	Fibrinogen levels;	chr3:136529245	chr3:136837338~136839021:-
HNSC	cis	rs17507216	1	rs3850610	ENSG00000276710.3	CSPG4P8	5.88	7.79e-09	3.29e-06	0.32	0.26	Excessive daytime sleepiness;	chr15:82552642	chr15:82459472~82477258:+
HNSC	cis	rs889014	1	rs6885032	ENSG00000253768.1	CTB-33O18.1	5.88	7.8e-09	3.29e-06	0.28	0.26	Height;	chr5:173556276	chr5:173562478~173573199:+
HNSC	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-5.88	7.8e-09	3.29e-06	-0.31	-0.26	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
HNSC	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-5.88	7.8e-09	3.29e-06	-0.37	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
HNSC	cis	rs11098499	0.644	rs28787668	ENSG00000249244.1	RP11-548H18.2	5.88	7.82e-09	3.3e-06	0.33	0.26	Corneal astigmatism;	chr4:119633532	chr4:119391831~119395335:-
HNSC	cis	rs11846409	0.521	rs10143547	ENSG00000211974.3	IGHV2-70	-5.88	7.83e-09	3.3e-06	-0.3	-0.26	Rheumatic heart disease;	chr14:106644638	chr14:106723574~106724093:-
HNSC	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-5.88	7.83e-09	3.3e-06	-0.17	-0.26	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
HNSC	cis	rs7674212	0.54	rs2720469	ENSG00000246560.2	RP11-10L12.4	5.88	7.83e-09	3.31e-06	0.3	0.26	Type 2 diabetes;	chr4:103165327	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.57	rs6810571	ENSG00000246560.2	RP11-10L12.4	5.88	7.83e-09	3.31e-06	0.3	0.26	Type 2 diabetes;	chr4:103165630	chr4:102828055~102844075:+
HNSC	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	5.88	7.84e-09	3.31e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
HNSC	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	5.88	7.84e-09	3.31e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
HNSC	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	5.88	7.84e-09	3.31e-06	0.33	0.26	Height;	chr6:109355573	chr6:109382795~109383666:+
HNSC	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	5.88	7.85e-09	3.31e-06	0.35	0.26	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
HNSC	cis	rs1799949	0.929	rs799906	ENSG00000267151.3	RP11-100E5.2	5.88	7.85e-09	3.31e-06	0.34	0.26	Menopause (age at onset);	chr17:43126099	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs799908	ENSG00000267151.3	RP11-100E5.2	5.88	7.85e-09	3.31e-06	0.34	0.26	Menopause (age at onset);	chr17:43126899	chr17:43444707~43451200:+
HNSC	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	5.88	7.86e-09	3.31e-06	0.35	0.26	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000254153.1	CTA-398F10.2	-5.88	7.87e-09	3.32e-06	-0.29	-0.26	Mood instability;	chr8:8460307	chr8:8456909~8461337:-
HNSC	cis	rs8031584	0.678	rs4779496	ENSG00000260382.1	RP11-540B6.2	5.88	7.89e-09	3.32e-06	0.33	0.26	Huntington's disease progression;	chr15:30858851	chr15:30882267~30883231:-
HNSC	cis	rs4218	0.597	rs12442301	ENSG00000277144.1	RP11-59H7.4	-5.88	7.89e-09	3.33e-06	-0.35	-0.26	Social communication problems;	chr15:59065968	chr15:59115547~59116089:-
HNSC	cis	rs947583	0.517	rs6935371	ENSG00000217482.2	HMGB1P17	5.88	7.89e-09	3.33e-06	0.28	0.26	Phosphorus levels;	chr6:135779380	chr6:135636086~135636713:-
HNSC	cis	rs9693857	1	rs9693857	ENSG00000254340.1	RP11-10A14.3	-5.88	7.89e-09	3.33e-06	-0.32	-0.26	Systolic blood pressure;	chr8:9409607	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs778729	ENSG00000179406.6	LINC00174	-5.88	7.9e-09	3.33e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66359432	chr7:66376044~66401338:-
HNSC	cis	rs6918586	0.658	rs198819	ENSG00000272462.2	U91328.19	-5.88	7.9e-09	3.33e-06	-0.25	-0.26	Schizophrenia;	chr6:26124202	chr6:25992662~26001775:+
HNSC	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-5.88	7.91e-09	3.33e-06	-0.31	-0.26	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-5.88	7.91e-09	3.33e-06	-0.31	-0.26	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
HNSC	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	5.88	7.91e-09	3.34e-06	0.32	0.26	Height;	chr4:55561218	chr4:55363971~55395847:-
HNSC	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	5.88	7.92e-09	3.34e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
HNSC	cis	rs11089937	0.589	rs4239891	ENSG00000211638.2	IGLV8-61	-5.88	7.92e-09	3.34e-06	-0.24	-0.26	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22098700~22099212:+
HNSC	cis	rs2337406	0.539	rs2583290	ENSG00000274576.2	IGHV2-70	5.88	7.92e-09	3.34e-06	0.26	0.26	Alzheimer's disease (late onset);	chr14:106650277	chr14:106770577~106771020:-
HNSC	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	5.88	7.93e-09	3.34e-06	0.36	0.26	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000253893.2	FAM85B	-5.88	7.93e-09	3.34e-06	-0.31	-0.26	Mood instability;	chr8:8283379	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	5.88	7.94e-09	3.35e-06	0.23	0.26	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
HNSC	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
HNSC	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	5.88	7.95e-09	3.35e-06	0.32	0.26	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
HNSC	cis	rs7309	0.622	rs4664395	ENSG00000235724.7	AC009299.2	-5.88	7.95e-09	3.35e-06	-0.32	-0.26	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161044790	chr2:161222785~161308303:-
HNSC	cis	rs7674212	0.541	rs2251322	ENSG00000246560.2	RP11-10L12.4	5.88	7.96e-09	3.35e-06	0.3	0.26	Type 2 diabetes;	chr4:103158267	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.541	rs2615539	ENSG00000246560.2	RP11-10L12.4	5.88	7.96e-09	3.35e-06	0.3	0.26	Type 2 diabetes;	chr4:103159949	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.57	rs2251634	ENSG00000246560.2	RP11-10L12.4	5.88	7.96e-09	3.35e-06	0.3	0.26	Type 2 diabetes;	chr4:103161192	chr4:102828055~102844075:+
HNSC	cis	rs6918586	0.658	rs198813	ENSG00000272462.2	U91328.19	-5.88	7.96e-09	3.35e-06	-0.25	-0.26	Schizophrenia;	chr6:26127998	chr6:25992662~26001775:+
HNSC	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	5.88	7.96e-09	3.35e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	5.88	7.96e-09	3.35e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
HNSC	cis	rs9300255	0.51	rs1790133	ENSG00000280120.1	RP11-546D6.3	5.88	7.96e-09	3.35e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123213971	chr12:123152324~123153377:-
HNSC	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-5.88	7.96e-09	3.35e-06	-0.3	-0.26	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
HNSC	cis	rs4218	0.597	rs10431762	ENSG00000277144.1	RP11-59H7.4	-5.88	7.96e-09	3.35e-06	-0.36	-0.26	Social communication problems;	chr15:59066330	chr15:59115547~59116089:-
HNSC	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	5.88	7.97e-09	3.36e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
HNSC	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-5.88	7.97e-09	3.36e-06	-0.29	-0.26	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
HNSC	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	5.88	7.98e-09	3.36e-06	0.31	0.26	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
HNSC	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-5.88	7.98e-09	3.36e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000233609.3	RP11-62H7.2	-5.88	7.99e-09	3.37e-06	-0.25	-0.26	Mood instability;	chr8:8934707	chr8:8961200~8979025:+
HNSC	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-5.88	8e-09	3.37e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
HNSC	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-5.88	8e-09	3.37e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
HNSC	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-5.88	8e-09	3.37e-06	-0.31	-0.26	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-5.88	8e-09	3.37e-06	-0.17	-0.26	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
HNSC	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-5.88	8.01e-09	3.37e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
HNSC	cis	rs2834288	0.7	rs731061	ENSG00000237945.6	LINC00649	-5.88	8.01e-09	3.37e-06	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr21:33902937	chr21:33915534~33977691:+
HNSC	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-5.88	8.02e-09	3.38e-06	-0.23	-0.26	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
HNSC	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	5.88	8.02e-09	3.38e-06	0.26	0.26	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
HNSC	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
HNSC	cis	rs67981189	0.501	rs2810104	ENSG00000274818.1	RP1-292L20.3	5.87	8.05e-09	3.39e-06	0.31	0.26	Schizophrenia;	chr14:70958096	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	5.87	8.06e-09	3.39e-06	0.32	0.26	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
HNSC	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	5.87	8.06e-09	3.39e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
HNSC	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-5.87	8.06e-09	3.39e-06	-0.3	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
HNSC	cis	rs7567389	0.889	rs1504136	ENSG00000236682.1	AC068282.3	5.87	8.06e-09	3.39e-06	0.32	0.26	Self-rated health;	chr2:127219542	chr2:127389130~127400580:+
HNSC	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-5.87	8.06e-09	3.39e-06	-0.31	-0.26	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
HNSC	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-5.87	8.07e-09	3.4e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	5.87	8.08e-09	3.4e-06	0.33	0.26	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	5.87	8.08e-09	3.4e-06	0.32	0.26	Depression;	chr6:28086929	chr6:28161781~28169594:+
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000179406.6	LINC00174	-5.87	8.09e-09	3.4e-06	-0.35	-0.26	Calcium levels;	chr7:65806798	chr7:66376044~66401338:-
HNSC	cis	rs526231	0.756	rs35804	ENSG00000175749.11	EIF3KP1	5.87	8.09e-09	3.4e-06	0.33	0.26	Primary biliary cholangitis;	chr5:103289634	chr5:103032376~103033031:+
HNSC	cis	rs6969780	1	rs929249	ENSG00000233429.8	HOTAIRM1	5.87	8.09e-09	3.4e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127918	chr7:27095647~27100265:+
HNSC	cis	rs860295	0.676	rs2666826	ENSG00000203761.5	MSTO2P	-5.87	8.09e-09	3.4e-06	-0.19	-0.26	Body mass index;	chr1:155688294	chr1:155745829~155750137:+
HNSC	cis	rs6504622	1	rs4968285	ENSG00000262879.4	RP11-156P1.3	-5.87	8.1e-09	3.41e-06	-0.28	-0.26	Orofacial clefts;	chr17:46938266	chr17:46984045~47100323:-
HNSC	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	5.87	8.1e-09	3.41e-06	0.32	0.26	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	5.87	8.1e-09	3.41e-06	0.33	0.26	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
HNSC	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	5.87	8.11e-09	3.41e-06	0.32	0.26	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
HNSC	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-5.87	8.11e-09	3.41e-06	-0.35	-0.26	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
HNSC	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-5.87	8.11e-09	3.41e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
HNSC	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	5.87	8.12e-09	3.41e-06	0.36	0.26	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
HNSC	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
HNSC	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-5.87	8.12e-09	3.41e-06	-0.38	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	5.87	8.14e-09	3.42e-06	0.29	0.26	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
HNSC	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	5.87	8.15e-09	3.43e-06	0.25	0.26	Asthma;	chr2:102410644	chr2:102438713~102440475:+
HNSC	cis	rs667920	0.575	rs9861150	ENSG00000273486.1	RP11-731C17.2	5.87	8.16e-09	3.43e-06	0.26	0.26	Coronary artery disease;	chr3:136464478	chr3:136837338~136839021:-
HNSC	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	5.87	8.18e-09	3.44e-06	0.33	0.26	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	5.87	8.18e-09	3.44e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
HNSC	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-5.87	8.19e-09	3.44e-06	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
HNSC	cis	rs2834288	0.7	rs6517196	ENSG00000237945.6	LINC00649	-5.87	8.2e-09	3.44e-06	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr21:33905116	chr21:33915534~33977691:+
HNSC	cis	rs5753618	0.504	rs5753659	ENSG00000236132.1	CTA-440B3.1	-5.87	8.2e-09	3.44e-06	-0.34	-0.26	Colorectal cancer;	chr22:31497627	chr22:31816379~31817491:-
HNSC	cis	rs8031584	0.678	rs4779790	ENSG00000260382.1	RP11-540B6.2	5.87	8.2e-09	3.45e-06	0.33	0.26	Huntington's disease progression;	chr15:30872392	chr15:30882267~30883231:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	5.87	8.21e-09	3.45e-06	0.21	0.26	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
HNSC	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-5.87	8.22e-09	3.45e-06	-0.31	-0.26	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-5.87	8.22e-09	3.45e-06	-0.31	-0.26	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
HNSC	cis	rs4938330	0.739	rs11216266	ENSG00000254851.1	RP11-109L13.1	5.87	8.22e-09	3.45e-06	0.36	0.26	Blood protein levels;	chr11:117079434	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.748	rs7106662	ENSG00000254851.1	RP11-109L13.1	5.87	8.22e-09	3.45e-06	0.36	0.26	Subjective well-being;	chr11:117080669	chr11:117135528~117138582:+
HNSC	cis	rs6604026	0.522	rs12756786	ENSG00000223787.2	RP4-593M8.1	5.87	8.23e-09	3.45e-06	0.36	0.26	Multiple sclerosis;	chr1:92579398	chr1:92580476~92580821:-
HNSC	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-5.87	8.24e-09	3.46e-06	-0.31	-0.26	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
HNSC	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-5.87	8.25e-09	3.46e-06	-0.38	-0.26	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-5.87	8.26e-09	3.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
HNSC	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.26e-09	3.47e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
HNSC	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-5.87	8.26e-09	3.47e-06	-0.29	-0.26	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
HNSC	cis	rs925255	0.682	rs7590263	ENSG00000270210.1	RP11-373D23.3	5.87	8.27e-09	3.47e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr2:28422935	chr2:28425945~28426719:+
HNSC	cis	rs2834288	0.5	rs881230	ENSG00000273102.1	AP000569.9	5.87	8.28e-09	3.47e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33967101~33968573:-
HNSC	cis	rs860295	0.836	rs1360554	ENSG00000203761.5	MSTO2P	5.87	8.28e-09	3.47e-06	0.19	0.26	Body mass index;	chr1:155503565	chr1:155745829~155750137:+
HNSC	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	5.87	8.28e-09	3.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-5.87	8.31e-09	3.48e-06	-0.32	-0.26	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-5.87	8.31e-09	3.48e-06	-0.32	-0.26	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-5.87	8.31e-09	3.48e-06	-0.32	-0.26	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
HNSC	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	5.87	8.31e-09	3.49e-06	0.3	0.26	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
HNSC	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-5.87	8.32e-09	3.49e-06	-0.36	-0.26	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
HNSC	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-5.87	8.32e-09	3.49e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
HNSC	cis	rs9329221	0.967	rs7005363	ENSG00000269918.1	AF131215.9	-5.87	8.33e-09	3.49e-06	-0.26	-0.26	Neuroticism;	chr8:10426238	chr8:11104691~11106704:-
HNSC	cis	rs9840812	0.592	rs1711161	ENSG00000273486.1	RP11-731C17.2	5.87	8.33e-09	3.49e-06	0.23	0.26	Fibrinogen levels;	chr3:136361695	chr3:136837338~136839021:-
HNSC	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	5.87	8.34e-09	3.49e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
HNSC	cis	rs6928977	0.675	rs11154803	ENSG00000217482.2	HMGB1P17	5.87	8.34e-09	3.5e-06	0.29	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135636086~135636713:-
HNSC	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	5.87	8.35e-09	3.5e-06	0.23	0.26	Height;	chr11:118758322	chr11:118791254~118793137:+
HNSC	cis	rs9300255	0.679	rs10772998	ENSG00000280120.1	RP11-546D6.3	5.87	8.35e-09	3.5e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123236630	chr12:123152324~123153377:-
HNSC	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	5.87	8.35e-09	3.5e-06	0.29	0.26	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
HNSC	cis	rs2337406	0.925	rs11851094	ENSG00000211974.3	IGHV2-70	-5.87	8.35e-09	3.5e-06	-0.32	-0.26	Alzheimer's disease (late onset);	chr14:106688967	chr14:106723574~106724093:-
HNSC	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	5.87	8.35e-09	3.5e-06	0.35	0.26	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
HNSC	cis	rs6928977	0.863	rs2223803	ENSG00000234084.1	RP3-388E23.2	5.87	8.35e-09	3.5e-06	0.26	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366924	chr6:135301568~135307158:+
HNSC	cis	rs67981189	0.529	rs2158996	ENSG00000274818.1	RP1-292L20.3	5.87	8.37e-09	3.51e-06	0.32	0.26	Schizophrenia;	chr14:71062882	chr14:70906657~70907111:-
HNSC	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	5.87	8.37e-09	3.51e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	5.87	8.37e-09	3.51e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	5.87	8.37e-09	3.51e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
HNSC	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-5.87	8.38e-09	3.51e-06	-0.38	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
HNSC	cis	rs7819412	0.838	rs3021494	ENSG00000269918.1	AF131215.9	-5.87	8.39e-09	3.51e-06	-0.26	-0.26	Triglycerides;	chr8:11126024	chr8:11104691~11106704:-
HNSC	cis	rs11992162	0.548	rs4841631	ENSG00000206014.6	OR7E161P	5.87	8.4e-09	3.52e-06	0.28	0.26	Monocyte count;	chr8:11924159	chr8:11928597~11929563:-
HNSC	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-5.87	8.4e-09	3.52e-06	-0.25	-0.26	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-5.87	8.4e-09	3.52e-06	-0.25	-0.26	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
HNSC	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-5.87	8.41e-09	3.52e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
HNSC	cis	rs860295	0.702	rs1325908	ENSG00000203761.5	MSTO2P	-5.87	8.41e-09	3.52e-06	-0.2	-0.26	Body mass index;	chr1:155443513	chr1:155745829~155750137:+
HNSC	cis	rs13113518	0.812	rs4865001	ENSG00000273257.1	RP11-177J6.1	5.87	8.42e-09	3.52e-06	0.32	0.26	Height;	chr4:55490176	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs4864543	ENSG00000273257.1	RP11-177J6.1	5.87	8.42e-09	3.52e-06	0.32	0.26	Height;	chr4:55490228	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs6825774	ENSG00000273257.1	RP11-177J6.1	5.87	8.42e-09	3.52e-06	0.32	0.26	Height;	chr4:55491150	chr4:55387949~55388271:+
HNSC	cis	rs6928977	0.675	rs58761508	ENSG00000234084.1	RP3-388E23.2	5.87	8.42e-09	3.52e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.631	rs9385726	ENSG00000234084.1	RP3-388E23.2	5.87	8.42e-09	3.52e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.637	rs9647635	ENSG00000234084.1	RP3-388E23.2	5.87	8.42e-09	3.52e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135301568~135307158:+
HNSC	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-5.87	8.42e-09	3.52e-06	-0.31	-0.26	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
HNSC	cis	rs10435719	0.867	rs62493601	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.753	rs9694940	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.78	rs9692662	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.899	rs9693925	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:11928597~11929563:-
HNSC	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	5.87	8.42e-09	3.53e-06	0.35	0.26	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
HNSC	cis	rs6867032	0.527	rs9312971	ENSG00000249731.1	RP11-259O2.3	5.87	8.42e-09	3.53e-06	0.29	0.26	Gut microbiome composition (winter);	chr5:2012774	chr5:1968094~1969013:+
HNSC	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	5.87	8.45e-09	3.54e-06	0.5	0.26	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
HNSC	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-5.87	8.45e-09	3.54e-06	-0.37	-0.26	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
HNSC	cis	rs9914544	0.966	rs9906795	ENSG00000264885.1	RP11-815I9.4	-5.87	8.46e-09	3.54e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18913427	chr17:18667629~18669461:-
HNSC	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-5.87	8.46e-09	3.54e-06	-0.31	-0.26	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
HNSC	cis	rs17270561	0.583	rs6926425	ENSG00000272462.2	U91328.19	-5.87	8.46e-09	3.54e-06	-0.26	-0.26	Iron status biomarkers;	chr6:25785076	chr6:25992662~26001775:+
HNSC	cis	rs61160187	0.582	rs3797559	ENSG00000215032.2	GNL3LP1	5.87	8.46e-09	3.54e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60891935~60893577:-
HNSC	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	5.87	8.47e-09	3.54e-06	0.4	0.26	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
HNSC	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-5.87	8.47e-09	3.55e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
HNSC	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	5.87	8.49e-09	3.55e-06	0.36	0.26	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	5.87	8.49e-09	3.55e-06	0.36	0.26	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
HNSC	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-5.87	8.49e-09	3.55e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
HNSC	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	5.87	8.49e-09	3.55e-06	0.36	0.26	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
HNSC	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-5.87	8.51e-09	3.56e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
HNSC	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
HNSC	cis	rs867371	0.656	rs2665103	ENSG00000255769.6	GOLGA2P10	5.86	8.52e-09	3.56e-06	0.31	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472993~82513950:-
HNSC	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	5.86	8.52e-09	3.56e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
HNSC	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	5.86	8.52e-09	3.56e-06	0.3	0.26	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
HNSC	cis	rs6928977	0.896	rs2614284	ENSG00000234084.1	RP3-388E23.2	5.86	8.52e-09	3.56e-06	0.26	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135368697	chr6:135301568~135307158:+
HNSC	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	5.86	8.53e-09	3.57e-06	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	5.86	8.53e-09	3.57e-06	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
HNSC	cis	rs804280	0.543	rs13261205	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	Myopia (pathological);	chr8:11933707	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.867	rs34465618	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.867	rs34583868	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:11928597~11929563:-
HNSC	cis	rs804280	0.518	rs34266352	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	Myopia (pathological);	chr8:11933953	chr8:11928597~11929563:-
HNSC	cis	rs804280	0.542	rs36100659	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934144	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-5.86	8.56e-09	3.58e-06	-0.31	-0.26	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-5.86	8.56e-09	3.58e-06	-0.31	-0.26	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
HNSC	cis	rs4657482	0.606	rs2241965	ENSG00000236364.3	RP11-525G13.2	5.86	8.56e-09	3.58e-06	0.26	0.26	Testicular germ cell tumor;	chr1:165896457	chr1:165890795~165900683:-
HNSC	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	5.86	8.57e-09	3.58e-06	0.36	0.26	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-5.86	8.57e-09	3.58e-06	-0.3	-0.26	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
HNSC	cis	rs7811142	1	rs11771241	ENSG00000078319.8	PMS2P1	-5.86	8.58e-09	3.59e-06	-0.33	-0.26	Platelet count;	chr7:100397162	chr7:100320992~100341908:-
HNSC	cis	rs9341808	0.6	rs2505930	ENSG00000272129.1	RP11-250B2.6	5.86	8.58e-09	3.59e-06	0.31	0.26	Sitting height ratio;	chr6:80127341	chr6:80355424~80356859:+
HNSC	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-5.86	8.59e-09	3.59e-06	-0.3	-0.26	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
HNSC	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	5.86	8.63e-09	3.61e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
HNSC	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	5.86	8.63e-09	3.61e-06	0.32	0.26	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	5.86	8.63e-09	3.61e-06	0.32	0.26	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
HNSC	cis	rs2579103	0.809	rs1978864	ENSG00000258183.4	RP11-753N8.1	-5.86	8.63e-09	3.61e-06	-0.32	-0.26	Body mass index;	chr12:90232279	chr12:90280894~90300340:+
HNSC	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	5.86	8.64e-09	3.61e-06	0.31	0.26	Height;	chr4:55452921	chr4:55363971~55395847:-
HNSC	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-5.86	8.65e-09	3.62e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-5.86	8.66e-09	3.62e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
HNSC	cis	rs60617249	0.507	rs34790261	ENSG00000228204.2	RP4-724E13.2	5.86	8.66e-09	3.62e-06	0.33	0.26	Major depression and alcohol dependence;	chr7:50880125	chr7:50866747~51022990:+
HNSC	cis	rs2665103	0.632	rs3902959	ENSG00000276710.3	CSPG4P8	-5.86	8.67e-09	3.62e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82459472~82477258:+
HNSC	cis	rs4218	0.517	rs71480503	ENSG00000277144.1	RP11-59H7.4	-5.86	8.67e-09	3.62e-06	-0.36	-0.26	Social communication problems;	chr15:59098246	chr15:59115547~59116089:-
HNSC	cis	rs2439831	0.867	rs2243434	ENSG00000205771.5	CATSPER2P1	-5.86	8.68e-09	3.62e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43397669	chr15:43726918~43747094:-
HNSC	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	5.86	8.68e-09	3.62e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
HNSC	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-5.86	8.68e-09	3.63e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
HNSC	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-5.86	8.68e-09	3.63e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
HNSC	cis	rs2579103	0.965	rs2579106	ENSG00000258183.4	RP11-753N8.1	-5.86	8.69e-09	3.63e-06	-0.35	-0.26	Body mass index;	chr12:90234453	chr12:90280894~90300340:+
HNSC	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-5.86	8.7e-09	3.63e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
HNSC	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	5.86	8.7e-09	3.63e-06	0.34	0.26	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
HNSC	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	5.86	8.71e-09	3.64e-06	0.3	0.26	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
HNSC	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	5.86	8.72e-09	3.64e-06	0.2	0.26	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
HNSC	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
HNSC	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	5.86	8.73e-09	3.64e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
HNSC	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-5.86	8.73e-09	3.64e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
HNSC	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	5.86	8.74e-09	3.65e-06	0.31	0.26	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	5.86	8.74e-09	3.65e-06	0.31	0.26	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
HNSC	cis	rs4218	0.597	rs62002544	ENSG00000277144.1	RP11-59H7.4	-5.86	8.74e-09	3.65e-06	-0.36	-0.26	Social communication problems;	chr15:59066663	chr15:59115547~59116089:-
HNSC	cis	rs9300255	0.739	rs11057210	ENSG00000280120.1	RP11-546D6.3	5.86	8.74e-09	3.65e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123249252	chr12:123152324~123153377:-
HNSC	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	5.86	8.75e-09	3.65e-06	0.37	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
HNSC	cis	rs453301	0.631	rs17700611	ENSG00000254340.1	RP11-10A14.3	-5.86	8.75e-09	3.65e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:8936144	chr8:9141424~9145435:+
HNSC	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-5.86	8.76e-09	3.65e-06	-0.29	-0.26	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
HNSC	cis	rs804280	0.542	rs35647515	ENSG00000206014.6	OR7E161P	-5.86	8.76e-09	3.65e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934120	chr8:11928597~11929563:-
HNSC	cis	rs2337406	0.587	rs11624678	ENSG00000274576.2	IGHV2-70	5.86	8.76e-09	3.66e-06	0.27	0.26	Alzheimer's disease (late onset);	chr14:106650408	chr14:106770577~106771020:-
HNSC	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	5.86	8.77e-09	3.66e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
HNSC	cis	rs1012068	0.686	rs5994451	ENSG00000236132.1	CTA-440B3.1	-5.86	8.77e-09	3.66e-06	-0.3	-0.26	Chronic hepatitis C infection;	chr22:31927525	chr22:31816379~31817491:-
HNSC	cis	rs453301	0.658	rs9650616	ENSG00000173295.6	FAM86B3P	-5.86	8.78e-09	3.66e-06	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9011689	chr8:8228595~8244865:+
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66521515	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs13237037	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66532895	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66557269	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1796228	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66568097	chr7:66376044~66401338:-
HNSC	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-5.86	8.79e-09	3.67e-06	-0.24	-0.26	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
HNSC	cis	rs17214007	0.518	rs35694612	ENSG00000263335.1	AF001548.5	-5.86	8.8e-09	3.67e-06	-0.39	-0.26	Cognitive function;	chr16:15674392	chr16:15726674~15732993:+
HNSC	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-5.86	8.8e-09	3.67e-06	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
HNSC	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-5.86	8.8e-09	3.67e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
HNSC	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-5.86	8.81e-09	3.67e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
HNSC	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	5.86	8.83e-09	3.68e-06	0.5	0.26	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	5.86	8.83e-09	3.68e-06	0.29	0.26	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
HNSC	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-5.86	8.84e-09	3.69e-06	-0.35	-0.26	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
HNSC	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	5.86	8.86e-09	3.69e-06	0.2	0.26	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
HNSC	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-5.86	8.87e-09	3.7e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
HNSC	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-5.86	8.87e-09	3.7e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
HNSC	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	5.86	8.88e-09	3.7e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
HNSC	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-5.86	8.88e-09	3.7e-06	-0.3	-0.26	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
HNSC	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-5.86	8.89e-09	3.7e-06	-0.22	-0.26	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-5.86	8.89e-09	3.7e-06	-0.22	-0.26	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
HNSC	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-5.86	8.89e-09	3.7e-06	-0.31	-0.26	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-5.86	8.89e-09	3.7e-06	-0.31	-0.26	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-5.86	8.89e-09	3.7e-06	-0.31	-0.26	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
HNSC	cis	rs9910055	0.762	rs2526020	ENSG00000267080.4	ASB16-AS1	-5.86	8.91e-09	3.71e-06	-0.21	-0.26	Total body bone mineral density;	chr17:44139220	chr17:44175973~44186717:-
HNSC	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-5.86	8.92e-09	3.72e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
HNSC	cis	rs8031584	0.672	rs17227989	ENSG00000260382.1	RP11-540B6.2	5.86	8.94e-09	3.72e-06	0.38	0.26	Huntington's disease progression;	chr15:31001571	chr15:30882267~30883231:-
HNSC	cis	rs4803480	0.542	rs7255742	ENSG00000270164.1	LINC01480	-5.86	8.95e-09	3.73e-06	-0.23	-0.26	Schizophrenia;	chr19:41543459	chr19:41535183~41536904:+
HNSC	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-5.86	8.96e-09	3.73e-06	-0.25	-0.26	Asthma;	chr2:102399682	chr2:102438713~102440475:+
HNSC	cis	rs13113518	0.783	rs7690837	ENSG00000273257.1	RP11-177J6.1	5.86	8.96e-09	3.73e-06	0.32	0.26	Height;	chr4:55575856	chr4:55387949~55388271:+
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	5.86	8.96e-09	3.73e-06	0.21	0.26	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
HNSC	cis	rs6928977	0.675	rs7759971	ENSG00000234084.1	RP3-388E23.2	-5.86	8.96e-09	3.73e-06	-0.27	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135425746	chr6:135301568~135307158:+
HNSC	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-5.86	8.97e-09	3.74e-06	-0.31	-0.26	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-5.86	8.97e-09	3.74e-06	-0.31	-0.26	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-5.86	8.97e-09	3.74e-06	-0.31	-0.26	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66370832	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs778679	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66375924	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs778704	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66398480	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66407358	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs778691	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66408105	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs13235972	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66418618	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34192067	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66422670	chr7:66376044~66401338:-
HNSC	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	5.86	8.98e-09	3.74e-06	0.3	0.26	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
HNSC	cis	rs7811142	0.943	rs10241492	ENSG00000078319.8	PMS2P1	-5.86	8.99e-09	3.74e-06	-0.33	-0.26	Platelet count;	chr7:100397190	chr7:100320992~100341908:-
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000211972.2	IGHV3-66	5.86	9e-09	3.75e-06	0.2	0.26	Kawasaki disease;	chr14:106776558	chr14:106675017~106675544:-
HNSC	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-5.85	9.01e-09	3.75e-06	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
HNSC	cis	rs67981189	0.529	rs17093738	ENSG00000274818.1	RP1-292L20.3	5.85	9.01e-09	3.75e-06	0.32	0.26	Schizophrenia;	chr14:71119931	chr14:70906657~70907111:-
HNSC	cis	rs947583	0.573	rs9494336	ENSG00000217482.2	HMGB1P17	5.85	9.02e-09	3.75e-06	0.3	0.26	Phosphorus levels;	chr6:135694749	chr6:135636086~135636713:-
HNSC	cis	rs7209700	0.547	rs11657517	ENSG00000228782.6	CTD-2026D20.3	-5.85	9.02e-09	3.75e-06	-0.28	-0.26	IgG glycosylation;	chr17:47266347	chr17:47450568~47492492:-
HNSC	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	5.85	9.02e-09	3.75e-06	0.19	0.26	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	5.85	9.02e-09	3.75e-06	0.19	0.26	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	5.85	9.02e-09	3.75e-06	0.19	0.26	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
HNSC	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-5.85	9.02e-09	3.76e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
HNSC	cis	rs740698	0.522	rs1024653	ENSG00000265702.1	RP11-156L14.1	-5.85	9.03e-09	3.76e-06	-0.32	-0.26	Pulse pressure;	chr17:62714457	chr17:62699244~62737922:+
HNSC	cis	rs860295	0.841	rs7556102	ENSG00000203761.5	MSTO2P	5.85	9.04e-09	3.76e-06	0.19	0.26	Body mass index;	chr1:155398412	chr1:155745829~155750137:+
HNSC	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	5.85	9.05e-09	3.77e-06	0.32	0.26	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
HNSC	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-5.85	9.06e-09	3.77e-06	-0.29	-0.26	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
HNSC	cis	rs1355223	0.902	rs35032224	ENSG00000271369.1	RP11-350D17.3	-5.85	9.06e-09	3.77e-06	-0.3	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676607	chr11:34709600~34710161:+
HNSC	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	5.85	9.06e-09	3.77e-06	0.32	0.26	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
HNSC	cis	rs7819412	0.745	rs2898260	ENSG00000255310.2	AF131215.2	-5.85	9.07e-09	3.78e-06	-0.25	-0.26	Triglycerides;	chr8:11081980	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	5.85	9.08e-09	3.78e-06	0.32	0.26	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	5.85	9.09e-09	3.78e-06	0.35	0.26	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
HNSC	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	5.85	9.09e-09	3.78e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
HNSC	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	5.85	9.09e-09	3.78e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
HNSC	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.09e-09	3.78e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.09e-09	3.78e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
HNSC	cis	rs9341808	0.538	rs615585	ENSG00000272129.1	RP11-250B2.6	-5.85	9.09e-09	3.78e-06	-0.31	-0.26	Sitting height ratio;	chr6:80276436	chr6:80355424~80356859:+
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	5.85	9.11e-09	3.79e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	5.85	9.11e-09	3.79e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
HNSC	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
HNSC	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-5.85	9.12e-09	3.79e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	5.85	9.13e-09	3.79e-06	0.31	0.26	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
HNSC	cis	rs9326248	0.569	rs10047459	ENSG00000280143.1	AP000892.6	5.85	9.14e-09	3.8e-06	0.36	0.26	Blood protein levels;	chr11:116851110	chr11:117204967~117210292:+
HNSC	cis	rs2337406	0.778	rs56965016	ENSG00000274576.2	IGHV2-70	-5.85	9.14e-09	3.8e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106656649	chr14:106770577~106771020:-
HNSC	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-5.85	9.14e-09	3.8e-06	-0.26	-0.26	Height;	chr2:231551270	chr2:231508426~231514339:-
HNSC	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-5.85	9.14e-09	3.8e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-5.85	9.14e-09	3.8e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-5.85	9.14e-09	3.8e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
HNSC	cis	rs8177876	0.749	rs11537	ENSG00000261061.1	RP11-303E16.2	-5.85	9.14e-09	3.8e-06	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81030770~81031485:+
HNSC	cis	rs2235642	0.75	rs2974845	ENSG00000280231.1	LA16c-380F5.3	-5.85	9.16e-09	3.81e-06	-0.32	-0.26	Coronary artery disease;	chr16:1598161	chr16:1553655~1554130:-
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000254340.1	RP11-10A14.3	5.85	9.18e-09	3.82e-06	0.32	0.26	Mood instability;	chr8:8797017	chr8:9141424~9145435:+
HNSC	cis	rs2579103	0.898	rs1583700	ENSG00000258183.4	RP11-753N8.1	-5.85	9.19e-09	3.82e-06	-0.32	-0.26	Body mass index;	chr12:90206076	chr12:90280894~90300340:+
HNSC	cis	rs6604026	0.695	rs11164801	ENSG00000223787.2	RP4-593M8.1	5.85	9.19e-09	3.82e-06	0.34	0.26	Multiple sclerosis;	chr1:92737621	chr1:92580476~92580821:-
HNSC	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
HNSC	cis	rs9840812	0.623	rs1394092	ENSG00000273486.1	RP11-731C17.2	5.85	9.22e-09	3.83e-06	0.22	0.26	Fibrinogen levels;	chr3:136477229	chr3:136837338~136839021:-
HNSC	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-5.85	9.23e-09	3.84e-06	-0.24	-0.26	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
HNSC	cis	rs7829975	0.811	rs7011229	ENSG00000173295.6	FAM86B3P	-5.85	9.23e-09	3.84e-06	-0.3	-0.26	Mood instability;	chr8:8685814	chr8:8228595~8244865:+
HNSC	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-5.85	9.23e-09	3.84e-06	-0.35	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
HNSC	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.23e-09	3.84e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
HNSC	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	5.85	9.25e-09	3.84e-06	0.32	0.26	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
HNSC	cis	rs860295	0.65	rs28662267	ENSG00000203761.5	MSTO2P	-5.85	9.25e-09	3.84e-06	-0.2	-0.26	Body mass index;	chr1:155710658	chr1:155745829~155750137:+
HNSC	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	5.85	9.26e-09	3.85e-06	0.28	0.26	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
HNSC	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-5.85	9.26e-09	3.85e-06	-0.36	-0.26	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	-5.85	9.26e-09	3.85e-06	-0.3	-0.26	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
HNSC	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	5.85	9.27e-09	3.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	5.85	9.27e-09	3.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	5.85	9.27e-09	3.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
HNSC	cis	rs1799949	0.93	rs1554063	ENSG00000267151.3	RP11-100E5.2	5.85	9.29e-09	3.86e-06	0.33	0.26	Menopause (age at onset);	chr17:43135128	chr17:43444707~43451200:+
HNSC	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	5.85	9.29e-09	3.86e-06	0.36	0.26	Height;	chr6:109655182	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	5.85	9.29e-09	3.86e-06	0.36	0.26	Height;	chr6:109656105	chr6:109382795~109383666:+
HNSC	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	5.85	9.29e-09	3.86e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	5.85	9.29e-09	3.86e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
HNSC	cis	rs783540	0.5	rs7178459	ENSG00000255769.6	GOLGA2P10	-5.85	9.3e-09	3.86e-06	-0.36	-0.26	Schizophrenia;	chr15:82729632	chr15:82472993~82513950:-
HNSC	cis	rs4218	0.813	rs8036907	ENSG00000277144.1	RP11-59H7.4	-5.85	9.31e-09	3.86e-06	-0.34	-0.26	Social communication problems;	chr15:59121144	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.724	rs35168204	ENSG00000277144.1	RP11-59H7.4	-5.85	9.31e-09	3.86e-06	-0.34	-0.26	Social communication problems;	chr15:59121354	chr15:59115547~59116089:-
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	5.85	9.31e-09	3.87e-06	0.29	0.26	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
HNSC	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	5.85	9.32e-09	3.87e-06	0.37	0.26	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
HNSC	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-5.85	9.32e-09	3.87e-06	-0.33	-0.26	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	5.85	9.34e-09	3.88e-06	0.33	0.26	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
HNSC	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-5.85	9.34e-09	3.88e-06	-0.31	-0.26	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
HNSC	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	5.85	9.35e-09	3.88e-06	0.27	0.26	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
HNSC	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	5.85	9.35e-09	3.88e-06	0.36	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
HNSC	cis	rs603446	0.678	rs664059	ENSG00000254851.1	RP11-109L13.1	-5.85	9.36e-09	3.88e-06	-0.33	-0.26	Triglycerides;	chr11:116771421	chr11:117135528~117138582:+
HNSC	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	5.85	9.36e-09	3.88e-06	0.29	0.26	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	5.85	9.36e-09	3.89e-06	0.31	0.26	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
HNSC	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-5.85	9.36e-09	3.89e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
HNSC	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.38e-09	3.89e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
HNSC	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	5.85	9.38e-09	3.89e-06	0.32	0.26	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
HNSC	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-5.85	9.38e-09	3.89e-06	-0.38	-0.26	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
HNSC	cis	rs526231	0.756	rs2561479	ENSG00000175749.11	EIF3KP1	5.85	9.38e-09	3.89e-06	0.33	0.26	Primary biliary cholangitis;	chr5:103286176	chr5:103032376~103033031:+
HNSC	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-5.85	9.39e-09	3.89e-06	-0.41	-0.26	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
HNSC	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	5.85	9.39e-09	3.89e-06	0.36	0.26	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	5.85	9.39e-09	3.89e-06	0.33	0.26	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	5.85	9.39e-09	3.9e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	5.85	9.39e-09	3.9e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
HNSC	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	5.85	9.4e-09	3.9e-06	0.36	0.26	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
HNSC	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-5.85	9.4e-09	3.9e-06	-0.33	-0.26	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
HNSC	cis	rs2337406	0.778	rs56658355	ENSG00000274576.2	IGHV2-70	-5.85	9.4e-09	3.9e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106662151	chr14:106770577~106771020:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000179406.6	LINC00174	-5.85	9.4e-09	3.9e-06	-0.56	-0.26	Gout;	chr7:66645053	chr7:66376044~66401338:-
HNSC	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	5.85	9.41e-09	3.9e-06	0.32	0.26	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
HNSC	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-5.85	9.41e-09	3.9e-06	-0.31	-0.26	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-5.85	9.41e-09	3.9e-06	-0.31	-0.26	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
HNSC	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	5.85	9.42e-09	3.9e-06	0.19	0.26	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
HNSC	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-5.85	9.44e-09	3.91e-06	-0.31	-0.26	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-5.85	9.44e-09	3.91e-06	-0.31	-0.26	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
HNSC	cis	rs757110	0.866	rs5215	ENSG00000260196.1	RP1-239B22.5	5.85	9.44e-09	3.91e-06	0.29	0.26	Type 2 diabetes;	chr11:17387083	chr11:17380649~17383531:+
HNSC	cis	rs858239	0.863	rs466225	ENSG00000226816.2	AC005082.12	5.85	9.44e-09	3.91e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23206013~23208045:+
HNSC	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	5.85	9.44e-09	3.91e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	5.85	9.44e-09	3.91e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
HNSC	cis	rs10435719	0.805	rs13269417	ENSG00000206014.6	OR7E161P	-5.85	9.45e-09	3.92e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:11928597~11929563:-
HNSC	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	5.85	9.45e-09	3.92e-06	0.29	0.26	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
HNSC	cis	rs454422	1	rs236104	ENSG00000275632.1	RP5-967N21.11	5.85	9.46e-09	3.92e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5978314	chr20:6000418~6000941:+
HNSC	cis	rs8040855	0.559	rs6496801	ENSG00000259774.1	RP11-182J1.13	-5.85	9.46e-09	3.92e-06	-0.33	-0.26	Bulimia nervosa;	chr15:85185168	chr15:84422618~84425882:+
HNSC	cis	rs8031584	0.678	rs4779497	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30859162	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.678	rs8028173	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30863546	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.706	rs2177670	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30865548	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.678	rs36047941	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30867032	chr15:30882267~30883231:-
HNSC	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-5.85	9.47e-09	3.92e-06	-0.32	-0.26	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
HNSC	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	5.85	9.48e-09	3.93e-06	0.43	0.26	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
HNSC	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	5.85	9.49e-09	3.93e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
HNSC	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	5.85	9.51e-09	3.94e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
HNSC	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	5.85	9.51e-09	3.94e-06	0.3	0.26	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000235689.1	AP000351.13	-5.84	9.52e-09	3.94e-06	-0.27	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:24006305~24008258:-
HNSC	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	5.84	9.53e-09	3.95e-06	0.32	0.26	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
HNSC	cis	rs10504130	0.66	rs6473666	ENSG00000272024.1	RP11-546K22.3	-5.84	9.53e-09	3.95e-06	-0.34	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51950284~51950690:+
HNSC	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-5.84	9.55e-09	3.95e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
HNSC	cis	rs508487	0.537	rs5072	ENSG00000280143.1	AP000892.6	5.84	9.55e-09	3.95e-06	0.47	0.26	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117204967~117210292:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	5.84	9.55e-09	3.95e-06	0.29	0.26	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
HNSC	cis	rs13113518	1	rs11133388	ENSG00000273257.1	RP11-177J6.1	-5.84	9.55e-09	3.96e-06	-0.32	-0.26	Height;	chr4:55477866	chr4:55387949~55388271:+
HNSC	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	5.84	9.56e-09	3.96e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	5.84	9.56e-09	3.96e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
HNSC	cis	rs526231	0.67	rs421946	ENSG00000175749.11	EIF3KP1	5.84	9.56e-09	3.96e-06	0.33	0.26	Primary biliary cholangitis;	chr5:103286340	chr5:103032376~103033031:+
HNSC	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-5.84	9.56e-09	3.96e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
HNSC	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	5.84	9.57e-09	3.96e-06	0.19	0.26	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
HNSC	cis	rs2579103	0.867	rs10745527	ENSG00000258183.4	RP11-753N8.1	-5.84	9.57e-09	3.96e-06	-0.32	-0.26	Body mass index;	chr12:90215240	chr12:90280894~90300340:+
HNSC	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	5.84	9.58e-09	3.97e-06	0.31	0.26	Depression;	chr6:28314871	chr6:28943877~28944537:+
HNSC	cis	rs6479901	0.501	rs7084396	ENSG00000232075.1	MRPL35P2	-5.84	9.59e-09	3.97e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr10:63116965	chr10:63634317~63634827:-
HNSC	cis	rs13113518	0.783	rs12510400	ENSG00000273257.1	RP11-177J6.1	5.84	9.59e-09	3.97e-06	0.33	0.26	Height;	chr4:55577294	chr4:55387949~55388271:+
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	5.84	9.59e-09	3.97e-06	0.28	0.26	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
HNSC	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	5.84	9.6e-09	3.97e-06	0.29	0.26	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000179406.6	LINC00174	-5.84	9.6e-09	3.97e-06	-0.34	-0.26	Calcium levels;	chr7:65977808	chr7:66376044~66401338:-
HNSC	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-5.84	9.6e-09	3.97e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-5.84	9.6e-09	3.97e-06	-0.32	-0.26	Depression;	chr6:28079011	chr6:28161781~28169594:+
HNSC	cis	rs12220777	1	rs72644211	ENSG00000230091.5	TMEM254-AS1	5.84	9.6e-09	3.97e-06	0.55	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021939	chr10:80046860~80078912:-
HNSC	cis	rs3743266	0.507	rs10162677	ENSG00000245534.5	RORA-AS1	-5.84	9.61e-09	3.98e-06	-0.42	-0.26	Menarche (age at onset);	chr15:60456369	chr15:60479178~60630637:+
HNSC	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
HNSC	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-5.84	9.63e-09	3.98e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
HNSC	cis	rs858239	0.712	rs199650	ENSG00000226816.2	AC005082.12	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23206013~23208045:+
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-5.84	9.64e-09	3.99e-06	-0.3	-0.26	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
HNSC	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	5.84	9.64e-09	3.99e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
HNSC	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-5.84	9.65e-09	3.99e-06	-0.35	-0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
HNSC	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-5.84	9.65e-09	3.99e-06	-0.37	-0.26	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
HNSC	cis	rs2439831	1	rs537115	ENSG00000205771.5	CATSPER2P1	-5.84	9.67e-09	4e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43437750	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2245908	ENSG00000205771.5	CATSPER2P1	-5.84	9.67e-09	4e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43439256	chr15:43726918~43747094:-
HNSC	cis	rs12922040	1	rs2075516	ENSG00000263065.1	AF001548.6	5.84	9.67e-09	4e-06	0.31	0.26	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15741151~15741791:+
HNSC	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-5.84	9.68e-09	4e-06	-0.34	-0.26	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
HNSC	cis	rs10506328	0.689	rs4759348	ENSG00000248265.1	FLJ12825	5.84	9.69e-09	4.01e-06	0.33	0.26	Mean platelet volume;	chr12:54236733	chr12:54058254~54122234:+
HNSC	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-5.84	9.7e-09	4.01e-06	-0.38	-0.26	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
HNSC	cis	rs13113518	0.966	rs11942472	ENSG00000249700.7	SRD5A3-AS1	5.84	9.7e-09	4.01e-06	0.31	0.26	Height;	chr4:55574959	chr4:55363971~55395847:-
HNSC	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-5.84	9.7e-09	4.01e-06	-0.33	-0.26	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
HNSC	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	5.84	9.71e-09	4.01e-06	0.34	0.26	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
HNSC	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-5.84	9.71e-09	4.01e-06	-0.35	-0.26	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
HNSC	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-5.84	9.71e-09	4.01e-06	-0.35	-0.26	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
HNSC	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-5.84	9.72e-09	4.02e-06	-0.27	-0.26	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
HNSC	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-5.84	9.72e-09	4.02e-06	-0.23	-0.26	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
HNSC	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-5.84	9.72e-09	4.02e-06	-0.31	-0.26	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-5.84	9.72e-09	4.02e-06	-0.31	-0.26	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-5.84	9.72e-09	4.02e-06	-0.31	-0.26	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
HNSC	cis	rs17507216	1	rs17507216	ENSG00000276710.3	CSPG4P8	5.84	9.73e-09	4.02e-06	0.34	0.26	Excessive daytime sleepiness;	chr15:82558175	chr15:82459472~82477258:+
HNSC	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-5.84	9.73e-09	4.02e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000254153.1	CTA-398F10.2	5.84	9.74e-09	4.02e-06	0.29	0.26	Mood instability;	chr8:8482967	chr8:8456909~8461337:-
HNSC	cis	rs2834288	0.666	rs762188	ENSG00000237945.6	LINC00649	-5.84	9.74e-09	4.03e-06	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr21:33902206	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.7	rs731059	ENSG00000237945.6	LINC00649	-5.84	9.74e-09	4.03e-06	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr21:33902813	chr21:33915534~33977691:+
HNSC	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	5.84	9.75e-09	4.03e-06	0.3	0.26	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
HNSC	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
HNSC	cis	rs947583	0.913	rs2027516	ENSG00000217482.2	HMGB1P17	5.84	9.75e-09	4.03e-06	0.29	0.26	Phosphorus levels;	chr6:135810750	chr6:135636086~135636713:-
HNSC	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	5.84	9.75e-09	4.03e-06	0.2	0.26	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
HNSC	cis	rs75920871	0.528	rs7109649	ENSG00000254851.1	RP11-109L13.1	5.84	9.75e-09	4.03e-06	0.35	0.26	Subjective well-being;	chr11:117072828	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs1531706	ENSG00000254851.1	RP11-109L13.1	5.84	9.75e-09	4.03e-06	0.35	0.26	Subjective well-being;	chr11:117073236	chr11:117135528~117138582:+
HNSC	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-5.84	9.75e-09	4.03e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
HNSC	cis	rs14027	0.883	rs1469755	ENSG00000279347.1	RP11-85I17.2	-5.84	9.77e-09	4.03e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119838736~119840385:-
HNSC	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	5.84	9.77e-09	4.03e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
HNSC	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	5.84	9.78e-09	4.04e-06	0.32	0.26	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000173295.6	FAM86B3P	-5.84	9.78e-09	4.04e-06	-0.29	-0.26	Joint mobility (Beighton score);	chr8:9028444	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-5.84	9.78e-09	4.04e-06	-0.31	-0.26	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
HNSC	cis	rs2286503	0.78	rs12113458	ENSG00000221740.1	SNORD93	5.84	9.78e-09	4.04e-06	0.29	0.26	Fibrinogen;	chr7:22816009	chr7:22856613~22856686:+
HNSC	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-5.84	9.79e-09	4.04e-06	-0.23	-0.26	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
HNSC	cis	rs2834288	0.5	rs4817602	ENSG00000273102.1	AP000569.9	5.84	9.79e-09	4.04e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.5	rs7280837	ENSG00000273102.1	AP000569.9	5.84	9.79e-09	4.04e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33967101~33968573:-
HNSC	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	5.84	9.8e-09	4.05e-06	0.27	0.26	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000179406.6	LINC00174	-5.84	9.81e-09	4.05e-06	-0.56	-0.26	Gout;	chr7:66654674	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000179406.6	LINC00174	-5.84	9.81e-09	4.05e-06	-0.56	-0.26	Gout;	chr7:66661502	chr7:66376044~66401338:-
HNSC	cis	rs8031584	0.652	rs2691683	ENSG00000260382.1	RP11-540B6.2	-5.84	9.81e-09	4.05e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30842857	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.578	rs1088473	ENSG00000260382.1	RP11-540B6.2	-5.84	9.81e-09	4.05e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30847095	chr15:30882267~30883231:-
HNSC	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-5.84	9.82e-09	4.05e-06	-0.33	-0.26	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
HNSC	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-5.84	9.82e-09	4.05e-06	-0.41	-0.26	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
HNSC	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-5.84	9.82e-09	4.05e-06	-0.31	-0.26	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-5.84	9.82e-09	4.05e-06	-0.31	-0.26	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-5.84	9.82e-09	4.05e-06	-0.31	-0.26	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-5.84	9.83e-09	4.06e-06	-0.31	-0.26	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
HNSC	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-5.84	9.83e-09	4.06e-06	-0.41	-0.26	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
HNSC	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-5.84	9.83e-09	4.06e-06	-0.33	-0.26	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-5.84	9.83e-09	4.06e-06	-0.33	-0.26	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-5.84	9.83e-09	4.06e-06	-0.33	-0.26	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
HNSC	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-5.84	9.84e-09	4.06e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
HNSC	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-5.84	9.86e-09	4.07e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
HNSC	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-5.84	9.86e-09	4.07e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-5.84	9.86e-09	4.07e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
HNSC	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	5.84	9.87e-09	4.07e-06	0.27	0.26	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
HNSC	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	5.84	9.88e-09	4.08e-06	0.36	0.26	Height;	chr6:109613205	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	5.84	9.88e-09	4.08e-06	0.36	0.26	Height;	chr6:109617741	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	5.84	9.88e-09	4.08e-06	0.36	0.26	Height;	chr6:109619295	chr6:109382795~109383666:+
HNSC	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-5.84	9.88e-09	4.08e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-5.84	9.88e-09	4.08e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
HNSC	cis	rs10129255	1	rs10134517	ENSG00000211972.2	IGHV3-66	5.84	9.88e-09	4.08e-06	0.2	0.26	Kawasaki disease;	chr14:106718498	chr14:106675017~106675544:-
HNSC	cis	rs6969780	0.778	rs2465276	ENSG00000233429.8	HOTAIRM1	5.84	9.88e-09	4.08e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106098	chr7:27095647~27100265:+
HNSC	cis	rs673078	0.607	rs7294498	ENSG00000275409.1	RP11-131L12.4	-5.84	9.89e-09	4.08e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118321680	chr12:118430147~118430699:+
HNSC	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	5.84	9.89e-09	4.08e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	5.84	9.9e-09	4.08e-06	0.28	0.26	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
HNSC	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	5.84	9.9e-09	4.08e-06	0.29	0.26	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
HNSC	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-5.84	9.9e-09	4.08e-06	-0.43	-0.26	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
HNSC	cis	rs8177876	0.658	rs16954513	ENSG00000261061.1	RP11-303E16.2	-5.84	9.91e-09	4.09e-06	-0.48	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81030770~81031485:+
HNSC	cis	rs6928977	0.675	rs9399148	ENSG00000234084.1	RP3-388E23.2	5.84	9.91e-09	4.09e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135301568~135307158:+
HNSC	cis	rs4218	0.648	rs34407560	ENSG00000277144.1	RP11-59H7.4	-5.84	9.91e-09	4.09e-06	-0.36	-0.26	Social communication problems;	chr15:59073397	chr15:59115547~59116089:-
HNSC	cis	rs947583	0.588	rs9494389	ENSG00000217482.2	HMGB1P17	5.84	9.93e-09	4.1e-06	0.29	0.26	Phosphorus levels;	chr6:135794369	chr6:135636086~135636713:-
HNSC	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-5.84	9.94e-09	4.1e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
HNSC	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	5.84	9.94e-09	4.1e-06	0.28	0.26	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
HNSC	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-5.84	9.95e-09	4.1e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000233609.3	RP11-62H7.2	-5.84	9.95e-09	4.1e-06	-0.25	-0.26	Mood instability;	chr8:8937937	chr8:8961200~8979025:+
HNSC	cis	rs453301	0.631	rs13250781	ENSG00000254340.1	RP11-10A14.3	-5.84	9.95e-09	4.1e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:8935833	chr8:9141424~9145435:+
HNSC	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-5.84	9.96e-09	4.11e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
HNSC	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-5.84	9.96e-09	4.11e-06	-0.3	-0.26	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
HNSC	cis	rs4218	0.597	rs62002543	ENSG00000277144.1	RP11-59H7.4	-5.84	9.97e-09	4.11e-06	-0.35	-0.26	Social communication problems;	chr15:59066646	chr15:59115547~59116089:-
HNSC	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	5.84	9.97e-09	4.11e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	5.84	9.97e-09	4.11e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	5.84	9.97e-09	4.11e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
HNSC	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	5.84	9.98e-09	4.12e-06	0.3	0.26	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
HNSC	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	5.84	9.98e-09	4.12e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
HNSC	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	5.84	9.99e-09	4.12e-06	0.34	0.26	Height;	chr6:109478720	chr6:109382795~109383666:+
HNSC	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55452295	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55454900	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55454938	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55455102	chr4:55363971~55395847:-
HNSC	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	5.84	1e-08	4.12e-06	0.41	0.26	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
HNSC	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-5.84	1e-08	4.12e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-5.84	1e-08	4.12e-06	-0.41	-0.26	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
HNSC	cis	rs2880765	0.805	rs11858817	ENSG00000259295.5	CSPG4P12	5.84	1e-08	4.12e-06	0.3	0.26	Coronary artery disease;	chr15:85488029	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs28874135	ENSG00000259295.5	CSPG4P12	5.84	1e-08	4.12e-06	0.3	0.26	Coronary artery disease;	chr15:85488272	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs11633604	ENSG00000259295.5	CSPG4P12	5.84	1e-08	4.12e-06	0.3	0.26	Coronary artery disease;	chr15:85488348	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	5.84	1e-08	4.13e-06	0.33	0.26	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	5.84	1e-08	4.14e-06	0.34	0.26	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
HNSC	cis	rs7811142	0.83	rs28495773	ENSG00000078319.8	PMS2P1	-5.84	1e-08	4.14e-06	-0.35	-0.26	Platelet count;	chr7:100345960	chr7:100320992~100341908:-
HNSC	cis	rs2337406	0.925	rs10131226	ENSG00000274576.2	IGHV2-70	-5.84	1e-08	4.14e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106665764	chr14:106770577~106771020:-
HNSC	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-5.84	1.01e-08	4.14e-06	-0.33	-0.26	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
HNSC	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	5.84	1.01e-08	4.14e-06	0.31	0.26	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
HNSC	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-5.84	1.01e-08	4.14e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
HNSC	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	5.84	1.01e-08	4.14e-06	0.3	0.26	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
HNSC	cis	rs4218	0.648	rs2289895	ENSG00000277144.1	RP11-59H7.4	-5.83	1.01e-08	4.15e-06	-0.35	-0.26	Social communication problems;	chr15:59089570	chr15:59115547~59116089:-
HNSC	cis	rs11089937	0.626	rs11089933	ENSG00000211638.2	IGLV8-61	-5.83	1.01e-08	4.15e-06	-0.26	-0.26	Periodontitis (PAL4Q3);	chr22:22145708	chr22:22098700~22099212:+
HNSC	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	5.83	1.01e-08	4.15e-06	0.25	0.26	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
HNSC	cis	rs2439831	0.867	rs3213991	ENSG00000205771.5	CATSPER2P1	-5.83	1.01e-08	4.16e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43378082	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7163245	ENSG00000205771.5	CATSPER2P1	-5.83	1.01e-08	4.16e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43379096	chr15:43726918~43747094:-
HNSC	cis	rs13113518	0.812	rs11133385	ENSG00000273257.1	RP11-177J6.1	5.83	1.01e-08	4.16e-06	0.32	0.26	Height;	chr4:55460485	chr4:55387949~55388271:+
HNSC	cis	rs2439831	1	rs690263	ENSG00000205771.5	CATSPER2P1	-5.83	1.01e-08	4.17e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43412267	chr15:43726918~43747094:-
HNSC	cis	rs4218	0.648	rs1074702	ENSG00000277144.1	RP11-59H7.4	-5.83	1.01e-08	4.17e-06	-0.36	-0.26	Social communication problems;	chr15:59073900	chr15:59115547~59116089:-
HNSC	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-5.83	1.01e-08	4.18e-06	-0.34	-0.26	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
HNSC	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	5.83	1.02e-08	4.18e-06	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
HNSC	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-5.83	1.02e-08	4.19e-06	-0.26	-0.26	Height;	chr2:231553603	chr2:231508426~231514339:-
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000254340.1	RP11-10A14.3	-5.83	1.02e-08	4.19e-06	-0.32	-0.26	Mood instability;	chr8:8804024	chr8:9141424~9145435:+
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-5.83	1.02e-08	4.2e-06	-0.17	-0.26	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
HNSC	cis	rs75920871	0.528	rs7950093	ENSG00000254851.1	RP11-109L13.1	5.83	1.02e-08	4.2e-06	0.36	0.26	Subjective well-being;	chr11:117092803	chr11:117135528~117138582:+
HNSC	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	5.83	1.02e-08	4.2e-06	0.29	0.26	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
HNSC	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-5.83	1.02e-08	4.2e-06	-0.4	-0.26	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
HNSC	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	5.83	1.02e-08	4.2e-06	0.32	0.26	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	5.83	1.02e-08	4.2e-06	0.29	0.26	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
HNSC	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-5.83	1.02e-08	4.2e-06	-0.24	-0.26	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
HNSC	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	5.83	1.02e-08	4.2e-06	0.34	0.26	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
HNSC	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-5.83	1.02e-08	4.2e-06	-0.36	-0.26	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
HNSC	cis	rs1355223	0.872	rs12785367	ENSG00000271369.1	RP11-350D17.3	-5.83	1.02e-08	4.21e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34693722	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs11819839	ENSG00000271369.1	RP11-350D17.3	-5.83	1.02e-08	4.21e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34694231	chr11:34709600~34710161:+
HNSC	cis	rs8059260	0.736	rs77334546	ENSG00000274038.1	RP11-66H6.4	-5.83	1.02e-08	4.21e-06	-0.52	-0.26	Alcohol consumption over the past year;	chr16:10970061	chr16:11056556~11057034:+
HNSC	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	5.83	1.02e-08	4.22e-06	0.34	0.26	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
HNSC	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	5.83	1.03e-08	4.23e-06	0.27	0.26	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
HNSC	cis	rs9402743	0.632	rs7773035	ENSG00000217482.2	HMGB1P17	5.83	1.03e-08	4.23e-06	0.28	0.26	Systemic lupus erythematosus;	chr6:135784743	chr6:135636086~135636713:-
HNSC	cis	rs6604026	0.555	rs67646822	ENSG00000223787.2	RP4-593M8.1	5.83	1.03e-08	4.23e-06	0.36	0.26	Multiple sclerosis;	chr1:92643406	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.661	rs72724555	ENSG00000223787.2	RP4-593M8.1	5.83	1.03e-08	4.23e-06	0.36	0.26	Multiple sclerosis;	chr1:92645318	chr1:92580476~92580821:-
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000254340.1	RP11-10A14.3	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:8935355	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000173295.6	FAM86B3P	-5.83	1.03e-08	4.24e-06	-0.29	-0.26	Joint mobility (Beighton score);	chr8:9026993	chr8:8228595~8244865:+
HNSC	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
HNSC	cis	rs13113518	0.934	rs10866425	ENSG00000249700.7	SRD5A3-AS1	5.83	1.03e-08	4.24e-06	0.31	0.26	Height;	chr4:55582068	chr4:55363971~55395847:-
HNSC	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	5.83	1.03e-08	4.24e-06	0.35	0.26	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
HNSC	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28082231	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28082261	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28082984	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28083994	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28084025	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28085319	chr6:28161781~28169594:+
HNSC	cis	rs189798	0.807	rs9949	ENSG00000173295.6	FAM86B3P	5.83	1.03e-08	4.24e-06	0.34	0.26	Myopia (pathological);	chr8:9137002	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000235689.1	AP000351.13	-5.83	1.03e-08	4.24e-06	-0.27	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:24006305~24008258:-
HNSC	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	5.83	1.03e-08	4.25e-06	0.34	0.26	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
HNSC	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	5.83	1.04e-08	4.26e-06	0.28	0.26	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
HNSC	cis	rs9914544	1	rs1737944	ENSG00000264885.1	RP11-815I9.4	-5.83	1.04e-08	4.26e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18937120	chr17:18667629~18669461:-
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-5.83	1.04e-08	4.26e-06	-0.4	-0.26	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
HNSC	cis	rs6918586	0.658	rs198830	ENSG00000272462.2	U91328.19	-5.83	1.04e-08	4.26e-06	-0.25	-0.26	Schizophrenia;	chr6:26118018	chr6:25992662~26001775:+
HNSC	cis	rs13113518	0.812	rs3805153	ENSG00000273257.1	RP11-177J6.1	5.83	1.04e-08	4.27e-06	0.32	0.26	Height;	chr4:55493557	chr4:55387949~55388271:+
HNSC	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	5.83	1.04e-08	4.27e-06	0.34	0.26	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
HNSC	cis	rs6928977	0.66	rs9389301	ENSG00000217482.2	HMGB1P17	-5.83	1.04e-08	4.27e-06	-0.29	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135549844	chr6:135636086~135636713:-
HNSC	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-5.83	1.04e-08	4.27e-06	-0.32	-0.26	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
HNSC	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	5.83	1.04e-08	4.27e-06	0.34	0.26	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
HNSC	cis	rs7587476	0.906	rs2734674	ENSG00000229267.2	AC072062.1	5.83	1.04e-08	4.28e-06	0.36	0.26	Neuroblastoma;	chr2:214794171	chr2:214810229~214963274:+
HNSC	cis	rs2115630	1	rs7183401	ENSG00000229212.6	RP11-561C5.4	5.83	1.04e-08	4.28e-06	0.29	0.26	P wave terminal force;	chr15:84828713	chr15:85205440~85234795:-
HNSC	cis	rs8059260	0.736	rs113433437	ENSG00000274038.1	RP11-66H6.4	-5.83	1.04e-08	4.28e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10959438	chr16:11056556~11057034:+
HNSC	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	5.83	1.04e-08	4.28e-06	0.27	0.26	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-5.83	1.04e-08	4.29e-06	-0.37	-0.26	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
HNSC	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	5.83	1.04e-08	4.29e-06	0.36	0.26	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
HNSC	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-5.83	1.04e-08	4.29e-06	-0.47	-0.26	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	5.83	1.04e-08	4.29e-06	0.29	0.26	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	5.83	1.04e-08	4.29e-06	0.29	0.26	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
HNSC	cis	rs61542988	0.57	rs62448267	ENSG00000228649.7	AC005682.5	5.83	1.05e-08	4.29e-06	0.33	0.26	Fibrinogen levels;	chr7:22782882	chr7:22854178~22861579:+
HNSC	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-5.83	1.05e-08	4.29e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
HNSC	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	5.83	1.05e-08	4.29e-06	0.32	0.26	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
HNSC	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	5.83	1.05e-08	4.3e-06	0.3	0.26	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
HNSC	cis	rs7674212	0.57	rs2069274	ENSG00000246560.2	RP11-10L12.4	5.83	1.05e-08	4.3e-06	0.29	0.26	Type 2 diabetes;	chr4:103099624	chr4:102828055~102844075:+
HNSC	cis	rs7819412	0.745	rs28464654	ENSG00000269918.1	AF131215.9	-5.83	1.05e-08	4.3e-06	-0.26	-0.26	Triglycerides;	chr8:11223156	chr8:11104691~11106704:-
HNSC	cis	rs7819412	0.745	rs28591576	ENSG00000269918.1	AF131215.9	-5.83	1.05e-08	4.3e-06	-0.26	-0.26	Triglycerides;	chr8:11223166	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	5.83	1.05e-08	4.3e-06	0.32	0.26	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
HNSC	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	5.83	1.05e-08	4.3e-06	0.19	0.26	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
HNSC	cis	rs35955747	0.749	rs2027982	ENSG00000236132.1	CTA-440B3.1	5.83	1.05e-08	4.31e-06	0.29	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31197449	chr22:31816379~31817491:-
HNSC	cis	rs4218	0.648	rs12910987	ENSG00000277144.1	RP11-59H7.4	-5.83	1.05e-08	4.31e-06	-0.35	-0.26	Social communication problems;	chr15:59092782	chr15:59115547~59116089:-
HNSC	cis	rs8059260	0.736	rs77599345	ENSG00000274038.1	RP11-66H6.4	-5.83	1.05e-08	4.32e-06	-0.51	-0.26	Alcohol consumption over the past year;	chr16:10964707	chr16:11056556~11057034:+
HNSC	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	5.83	1.05e-08	4.32e-06	0.32	0.26	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
HNSC	cis	rs9487094	1	rs17070580	ENSG00000260273.1	RP11-425D10.10	-5.83	1.06e-08	4.33e-06	-0.33	-0.26	Height;	chr6:109417511	chr6:109382795~109383666:+
HNSC	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-5.83	1.06e-08	4.33e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
HNSC	cis	rs526231	0.756	rs448086	ENSG00000175749.11	EIF3KP1	5.83	1.06e-08	4.33e-06	0.32	0.26	Primary biliary cholangitis;	chr5:103287880	chr5:103032376~103033031:+
HNSC	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-5.83	1.06e-08	4.34e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
HNSC	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	5.83	1.06e-08	4.34e-06	0.33	0.26	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
HNSC	cis	rs6969780	1	rs739734	ENSG00000233429.8	HOTAIRM1	5.83	1.06e-08	4.34e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119786	chr7:27095647~27100265:+
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000173295.6	FAM86B3P	-5.83	1.06e-08	4.34e-06	-0.29	-0.26	Mood instability;	chr8:8938391	chr8:8228595~8244865:+
HNSC	cis	rs11846409	0.86	rs61686131	ENSG00000211974.3	IGHV2-70	-5.83	1.06e-08	4.34e-06	-0.29	-0.26	Rheumatic heart disease;	chr14:106631568	chr14:106723574~106724093:-
HNSC	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	5.83	1.06e-08	4.34e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	5.83	1.06e-08	4.34e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	5.83	1.06e-08	4.34e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
HNSC	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	5.83	1.06e-08	4.34e-06	0.37	0.26	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
HNSC	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	5.83	1.06e-08	4.35e-06	0.3	0.26	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
HNSC	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	5.83	1.06e-08	4.35e-06	0.23	0.26	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
HNSC	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-5.83	1.06e-08	4.35e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
HNSC	cis	rs4218	0.543	rs8027536	ENSG00000259732.1	RP11-59H7.3	-5.83	1.06e-08	4.35e-06	-0.33	-0.26	Social communication problems;	chr15:59022364	chr15:59121034~59133250:+
HNSC	cis	rs2243480	1	rs1638734	ENSG00000179406.6	LINC00174	-5.83	1.06e-08	4.35e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66632552	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs1267818	ENSG00000179406.6	LINC00174	-5.83	1.06e-08	4.35e-06	-0.56	-0.26	Gout;	chr7:66642037	chr7:66376044~66401338:-
HNSC	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-5.83	1.06e-08	4.35e-06	-0.29	-0.26	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
HNSC	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-5.83	1.06e-08	4.35e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
HNSC	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.83	1.06e-08	4.35e-06	-0.34	-0.26	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
HNSC	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-5.83	1.06e-08	4.36e-06	-0.23	-0.26	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
HNSC	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-5.83	1.06e-08	4.36e-06	-0.37	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000233609.3	RP11-62H7.2	-5.83	1.06e-08	4.36e-06	-0.25	-0.26	Mood instability;	chr8:8937291	chr8:8961200~8979025:+
HNSC	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	5.83	1.06e-08	4.36e-06	0.32	0.26	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
HNSC	cis	rs13113518	0.812	rs7667741	ENSG00000273257.1	RP11-177J6.1	5.83	1.06e-08	4.36e-06	0.32	0.26	Height;	chr4:55544621	chr4:55387949~55388271:+
HNSC	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-5.83	1.06e-08	4.36e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
HNSC	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	5.83	1.06e-08	4.36e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
HNSC	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	5.82	1.07e-08	4.37e-06	0.33	0.26	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
HNSC	cis	rs988913	1	rs6902422	ENSG00000224984.1	RP11-524H19.2	-5.82	1.07e-08	4.37e-06	-0.29	-0.26	Menarche (age at onset);	chr6:54946412	chr6:54840118~54840855:-
HNSC	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	5.82	1.07e-08	4.37e-06	0.49	0.26	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
HNSC	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	5.82	1.07e-08	4.37e-06	0.36	0.26	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	5.82	1.07e-08	4.37e-06	0.36	0.26	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
HNSC	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	5.82	1.07e-08	4.37e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
HNSC	cis	rs4218	0.689	rs12440692	ENSG00000259732.1	RP11-59H7.3	-5.82	1.07e-08	4.38e-06	-0.36	-0.26	Social communication problems;	chr15:59090671	chr15:59121034~59133250:+
HNSC	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	5.82	1.07e-08	4.38e-06	0.27	0.26	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
HNSC	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-5.82	1.07e-08	4.38e-06	-0.22	-0.26	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
HNSC	cis	rs2337406	0.587	rs10150642	ENSG00000211974.3	IGHV2-70	5.82	1.07e-08	4.38e-06	0.29	0.26	Alzheimer's disease (late onset);	chr14:106647269	chr14:106723574~106724093:-
HNSC	cis	rs13113518	1	rs1056545	ENSG00000249700.7	SRD5A3-AS1	5.82	1.07e-08	4.39e-06	0.31	0.26	Height;	chr4:55430730	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs5863	ENSG00000249700.7	SRD5A3-AS1	5.82	1.07e-08	4.39e-06	0.31	0.26	Height;	chr4:55430740	chr4:55363971~55395847:-
HNSC	cis	rs2337406	1	rs11849532	ENSG00000274576.2	IGHV2-70	-5.82	1.07e-08	4.39e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr14:106669877	chr14:106770577~106771020:-
HNSC	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-5.82	1.07e-08	4.39e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
HNSC	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	-5.82	1.07e-08	4.39e-06	-0.32	-0.26	Depression;	chr6:28126588	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	-5.82	1.07e-08	4.39e-06	-0.32	-0.26	Depression;	chr6:28126953	chr6:28161781~28169594:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000235689.1	AP000351.13	5.82	1.07e-08	4.39e-06	0.27	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:24006305~24008258:-
HNSC	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	5.82	1.07e-08	4.4e-06	0.35	0.26	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000173295.6	FAM86B3P	5.82	1.07e-08	4.4e-06	0.3	0.26	Mood instability;	chr8:8828344	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	5.82	1.08e-08	4.41e-06	0.31	0.26	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
HNSC	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-5.82	1.08e-08	4.41e-06	-0.39	-0.26	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
HNSC	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-5.82	1.08e-08	4.41e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
HNSC	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	5.82	1.08e-08	4.42e-06	0.32	0.26	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
HNSC	cis	rs13043901	0.539	rs6097480	ENSG00000197670.6	RP4-724E16.2	-5.82	1.08e-08	4.42e-06	-0.25	-0.26	Type 2 diabetes (age of onset);	chr20:53560021	chr20:53552770~53575863:+
HNSC	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-5.82	1.08e-08	4.42e-06	-0.32	-0.26	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
HNSC	cis	rs6604026	0.555	rs11589122	ENSG00000223787.2	RP4-593M8.1	5.82	1.08e-08	4.43e-06	0.36	0.26	Multiple sclerosis;	chr1:92618346	chr1:92580476~92580821:-
HNSC	cis	rs11098499	0.644	rs34835603	ENSG00000249244.1	RP11-548H18.2	5.82	1.08e-08	4.43e-06	0.32	0.26	Corneal astigmatism;	chr4:119632273	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.615	rs28850368	ENSG00000249244.1	RP11-548H18.2	5.82	1.08e-08	4.43e-06	0.32	0.26	Corneal astigmatism;	chr4:119633158	chr4:119391831~119395335:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	5.82	1.08e-08	4.43e-06	0.23	0.26	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
HNSC	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-5.82	1.08e-08	4.43e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
HNSC	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	5.82	1.08e-08	4.44e-06	0.29	0.26	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000211972.2	IGHV3-66	5.82	1.08e-08	4.44e-06	0.2	0.26	Kawasaki disease;	chr14:106813798	chr14:106675017~106675544:-
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	5.82	1.08e-08	4.44e-06	0.29	0.26	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
HNSC	cis	rs13113518	1	rs13133579	ENSG00000249700.7	SRD5A3-AS1	5.82	1.08e-08	4.44e-06	0.31	0.26	Height;	chr4:55459921	chr4:55363971~55395847:-
HNSC	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-5.82	1.08e-08	4.44e-06	-0.32	-0.26	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
HNSC	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-5.82	1.08e-08	4.44e-06	-0.31	-0.26	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-5.82	1.08e-08	4.44e-06	-0.31	-0.26	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
HNSC	cis	rs1355223	1	rs11601923	ENSG00000271369.1	RP11-350D17.3	-5.82	1.09e-08	4.45e-06	-0.3	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742807	chr11:34709600~34710161:+
HNSC	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
HNSC	cis	rs2243480	1	rs1267820	ENSG00000179406.6	LINC00174	-5.82	1.09e-08	4.45e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66585308	chr7:66376044~66401338:-
HNSC	cis	rs3206736	0.548	rs1649221	ENSG00000197085.10	NPSR1-AS1	-5.82	1.09e-08	4.45e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34948146	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.529	rs1649225	ENSG00000197085.10	NPSR1-AS1	-5.82	1.09e-08	4.45e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34952064	chr7:34346512~34871582:-
HNSC	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-5.82	1.09e-08	4.45e-06	-0.32	-0.26	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
HNSC	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-5.82	1.09e-08	4.46e-06	-0.26	-0.26	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
HNSC	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-5.82	1.09e-08	4.46e-06	-0.26	-0.26	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
HNSC	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	5.82	1.09e-08	4.46e-06	0.67	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
HNSC	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	5.82	1.09e-08	4.47e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
HNSC	cis	rs5753618	0.583	rs5753639	ENSG00000236132.1	CTA-440B3.1	5.82	1.09e-08	4.47e-06	0.31	0.26	Colorectal cancer;	chr22:31474414	chr22:31816379~31817491:-
HNSC	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	5.82	1.09e-08	4.48e-06	0.33	0.26	Height;	chr4:55415153	chr4:55363971~55395847:-
HNSC	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	5.82	1.09e-08	4.48e-06	0.34	0.26	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
HNSC	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-5.82	1.09e-08	4.48e-06	-0.32	-0.26	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
HNSC	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	5.82	1.09e-08	4.48e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
HNSC	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	5.82	1.1e-08	4.48e-06	0.31	0.26	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
HNSC	cis	rs1865760	0.613	rs7749342	ENSG00000272462.2	U91328.19	-5.82	1.1e-08	4.48e-06	-0.25	-0.26	Height;	chr6:25920037	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	5.82	1.1e-08	4.49e-06	0.29	0.26	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
HNSC	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	5.82	1.1e-08	4.49e-06	0.4	0.26	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
HNSC	cis	rs1865760	0.573	rs7450342	ENSG00000272462.2	U91328.19	-5.82	1.1e-08	4.49e-06	-0.25	-0.26	Height;	chr6:25919252	chr6:25992662~26001775:+
HNSC	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	5.82	1.1e-08	4.5e-06	0.36	0.26	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
HNSC	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	5.82	1.1e-08	4.5e-06	0.32	0.26	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
HNSC	cis	rs4218	0.648	rs57361749	ENSG00000277144.1	RP11-59H7.4	-5.82	1.1e-08	4.5e-06	-0.35	-0.26	Social communication problems;	chr15:59091352	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.608	rs16941014	ENSG00000277144.1	RP11-59H7.4	-5.82	1.1e-08	4.5e-06	-0.35	-0.26	Social communication problems;	chr15:59091503	chr15:59115547~59116089:-
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	5.82	1.1e-08	4.5e-06	0.4	0.26	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
HNSC	cis	rs1800562	1	rs1800562	ENSG00000272462.2	U91328.19	-5.82	1.1e-08	4.5e-06	-0.49	-0.26	Hematology traits;Iron status biomarkers (transferrin levels);Iron status biomarkers;Red blood cell count;Red blood cell traits;Mean corpuscular volume;Iron status biomarkers (ferritin levels);Iron status biomarkers (transferrin saturation);Diastolic blood pressure;Cholesterol, total;Cardiovascular disease risk factors;Hematocrit;Alcohol consumption (transferrin glycosylation);Hemoglobin;Iron status biomarkers (iron levels);Hematological parameters;LDL cholesterol;Mean corpuscular hemoglobin;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hepcidin levels;	chr6:26092913	chr6:25992662~26001775:+
HNSC	cis	rs8054556	0.751	rs11642430	ENSG00000183604.13	SMG1P5	-5.82	1.1e-08	4.51e-06	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30267553~30335374:-
HNSC	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	5.82	1.1e-08	4.51e-06	0.23	0.26	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
HNSC	cis	rs7811142	1	rs11771419	ENSG00000078319.8	PMS2P1	-5.82	1.1e-08	4.51e-06	-0.32	-0.26	Platelet count;	chr7:100390780	chr7:100320992~100341908:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000254153.1	CTA-398F10.2	5.82	1.1e-08	4.52e-06	0.29	0.26	Mood instability;	chr8:8483595	chr8:8456909~8461337:-
HNSC	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	5.82	1.11e-08	4.52e-06	0.32	0.26	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
HNSC	cis	rs4218	0.648	rs17236453	ENSG00000277144.1	RP11-59H7.4	-5.82	1.11e-08	4.52e-06	-0.35	-0.26	Social communication problems;	chr15:59092156	chr15:59115547~59116089:-
HNSC	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	5.82	1.11e-08	4.52e-06	0.28	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
HNSC	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	5.82	1.11e-08	4.53e-06	0.31	0.26	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
HNSC	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	5.82	1.11e-08	4.53e-06	0.55	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
HNSC	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	5.82	1.11e-08	4.53e-06	0.23	0.26	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
HNSC	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-5.82	1.11e-08	4.53e-06	-0.23	-0.26	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
HNSC	cis	rs13113518	1	rs11133381	ENSG00000249700.7	SRD5A3-AS1	5.82	1.11e-08	4.54e-06	0.31	0.26	Height;	chr4:55450812	chr4:55363971~55395847:-
HNSC	cis	rs1021993	0.857	rs1395756	ENSG00000231648.1	RP11-372M18.2	5.82	1.11e-08	4.54e-06	0.36	0.26	Gut microbiome composition (winter);	chr1:209290352	chr1:209367662~209379690:+
HNSC	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	5.82	1.11e-08	4.54e-06	0.37	0.26	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
HNSC	cis	rs2286503	0.78	rs929464	ENSG00000221740.1	SNORD93	5.82	1.11e-08	4.54e-06	0.29	0.26	Fibrinogen;	chr7:22835151	chr7:22856613~22856686:+
HNSC	cis	rs7615952	0.512	rs2979336	ENSG00000241288.6	RP11-379B18.5	-5.82	1.11e-08	4.54e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125638626	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	5.82	1.11e-08	4.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
HNSC	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-5.82	1.11e-08	4.55e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
HNSC	cis	rs2439831	0.717	rs10518820	ENSG00000205771.5	CATSPER2P1	-5.82	1.11e-08	4.55e-06	-0.49	-0.26	Lung cancer in ever smokers;	chr15:43596778	chr15:43726918~43747094:-
HNSC	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-5.82	1.11e-08	4.55e-06	-0.36	-0.26	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
HNSC	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	5.82	1.11e-08	4.55e-06	0.31	0.26	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
HNSC	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-5.82	1.11e-08	4.55e-06	-0.21	-0.26	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
HNSC	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-5.82	1.11e-08	4.55e-06	-0.26	-0.26	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	5.82	1.11e-08	4.55e-06	0.25	0.26	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
HNSC	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-5.82	1.12e-08	4.55e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-5.82	1.12e-08	4.56e-06	-0.17	-0.26	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
HNSC	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	5.82	1.12e-08	4.56e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
HNSC	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-5.82	1.12e-08	4.56e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
HNSC	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.56e-06	0.34	0.26	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
HNSC	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-5.82	1.12e-08	4.56e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
HNSC	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	5.82	1.12e-08	4.56e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
HNSC	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.56e-06	0.35	0.26	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
HNSC	cis	rs78773383	0.505	rs10033019	ENSG00000249207.1	RP11-360F5.1	5.82	1.12e-08	4.57e-06	0.3	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39390320	chr4:39112677~39126818:-
HNSC	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-5.82	1.12e-08	4.57e-06	-0.34	-0.26	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
HNSC	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	5.82	1.12e-08	4.57e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000179406.6	LINC00174	-5.82	1.12e-08	4.57e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66358338	chr7:66376044~66401338:-
HNSC	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	5.82	1.12e-08	4.57e-06	0.35	0.26	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	5.82	1.12e-08	4.57e-06	0.35	0.26	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	5.82	1.12e-08	4.57e-06	0.35	0.26	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
HNSC	cis	rs6928977	0.66	rs2614263	ENSG00000217482.2	HMGB1P17	-5.82	1.12e-08	4.57e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135459579	chr6:135636086~135636713:-
HNSC	cis	rs2439831	0.85	rs558656	ENSG00000205771.5	CATSPER2P1	-5.82	1.12e-08	4.58e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43431316	chr15:43726918~43747094:-
HNSC	cis	rs9341808	0.905	rs9343977	ENSG00000272129.1	RP11-250B2.6	5.82	1.12e-08	4.58e-06	0.31	0.26	Sitting height ratio;	chr6:80257284	chr6:80355424~80356859:+
HNSC	cis	rs6928977	0.66	rs2614267	ENSG00000217482.2	HMGB1P17	-5.82	1.12e-08	4.58e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135455340	chr6:135636086~135636713:-
HNSC	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.59e-06	0.35	0.26	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.59e-06	0.35	0.26	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-5.82	1.12e-08	4.59e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
HNSC	cis	rs6928977	0.66	rs2757647	ENSG00000217482.2	HMGB1P17	-5.82	1.12e-08	4.59e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135446416	chr6:135636086~135636713:-
HNSC	cis	rs9341808	0.519	rs4446525	ENSG00000272129.1	RP11-250B2.6	-5.82	1.12e-08	4.59e-06	-0.31	-0.26	Sitting height ratio;	chr6:80314336	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.538	rs613588	ENSG00000272129.1	RP11-250B2.6	-5.82	1.13e-08	4.59e-06	-0.31	-0.26	Sitting height ratio;	chr6:80269211	chr6:80355424~80356859:+
HNSC	cis	rs7615952	0.512	rs4679430	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125639049	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs34651730	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125639796	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs2979334	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125639980	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs11929125	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125640599	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs11921452	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125640906	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs2922175	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125642516	chr3:125827238~125916384:-
HNSC	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-5.82	1.13e-08	4.59e-06	-0.31	-0.26	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
HNSC	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-5.81	1.13e-08	4.59e-06	-0.29	-0.26	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
HNSC	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-5.81	1.13e-08	4.59e-06	-0.29	-0.26	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
HNSC	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-5.81	1.13e-08	4.6e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
HNSC	cis	rs6928977	0.66	rs9373131	ENSG00000217482.2	HMGB1P17	-5.81	1.13e-08	4.6e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135636086~135636713:-
HNSC	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-5.81	1.13e-08	4.6e-06	-0.31	-0.26	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
HNSC	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-5.81	1.13e-08	4.6e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
HNSC	cis	rs13113518	0.902	rs11133386	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55461320	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs4340844	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55462689	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs1522112	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55463606	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4864997	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55466010	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs960152	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55467308	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs12644948	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55470266	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805151	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55470874	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13118237	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55474259	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs11133387	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55475130	chr4:55363971~55395847:-
HNSC	cis	rs6928977	0.714	rs11154801	ENSG00000234084.1	RP3-388E23.2	-5.81	1.13e-08	4.61e-06	-0.27	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135418217	chr6:135301568~135307158:+
HNSC	cis	rs330048	0.51	rs11784654	ENSG00000254340.1	RP11-10A14.3	-5.81	1.13e-08	4.61e-06	-0.31	-0.26	Systemic lupus erythematosus;	chr8:9112101	chr8:9141424~9145435:+
HNSC	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-5.81	1.13e-08	4.61e-06	-0.31	-0.26	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
HNSC	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	5.81	1.13e-08	4.61e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106783079	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106783685	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106784199	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106784709	chr14:106675017~106675544:-
HNSC	cis	rs75920871	0.528	rs682048	ENSG00000254851.1	RP11-109L13.1	5.81	1.13e-08	4.62e-06	0.36	0.26	Subjective well-being;	chr11:116957604	chr11:117135528~117138582:+
HNSC	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.63e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
HNSC	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-5.81	1.14e-08	4.63e-06	-0.37	-0.26	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	5.81	1.14e-08	4.63e-06	0.3	0.26	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
HNSC	cis	rs7617773	0.539	rs13094496	ENSG00000228638.1	FCF1P2	-5.81	1.14e-08	4.63e-06	-0.23	-0.26	Coronary artery disease;	chr3:48345560	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	5.81	1.14e-08	4.63e-06	0.17	0.26	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000211972.2	IGHV3-66	5.81	1.14e-08	4.64e-06	0.2	0.26	Kawasaki disease;	chr14:106779068	chr14:106675017~106675544:-
HNSC	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	5.81	1.14e-08	4.65e-06	0.34	0.26	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	5.81	1.14e-08	4.65e-06	0.34	0.26	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
HNSC	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
HNSC	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-5.81	1.14e-08	4.65e-06	-0.46	-0.26	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
HNSC	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
HNSC	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	5.81	1.14e-08	4.65e-06	0.32	0.26	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
HNSC	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	5.81	1.14e-08	4.66e-06	0.19	0.26	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
HNSC	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-5.81	1.14e-08	4.66e-06	-0.36	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-5.81	1.15e-08	4.66e-06	-0.34	-0.26	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-5.81	1.15e-08	4.66e-06	-0.34	-0.26	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
HNSC	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	5.81	1.15e-08	4.66e-06	0.29	0.26	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
HNSC	cis	rs6928977	0.826	rs9321502	ENSG00000234084.1	RP3-388E23.2	5.81	1.15e-08	4.67e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135335114	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.538	rs9494290	ENSG00000217482.2	HMGB1P17	5.81	1.15e-08	4.67e-06	0.3	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135596407	chr6:135636086~135636713:-
HNSC	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-5.81	1.15e-08	4.67e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
HNSC	cis	rs7806994	1	rs7806994	ENSG00000226278.1	PSPHP1	-5.81	1.15e-08	4.67e-06	-0.36	-0.26	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55764797~55773288:+
HNSC	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	5.81	1.15e-08	4.67e-06	0.24	0.26	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
HNSC	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-5.81	1.15e-08	4.67e-06	-0.41	-0.26	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-5.81	1.15e-08	4.67e-06	-0.41	-0.26	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
HNSC	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-5.81	1.15e-08	4.67e-06	-0.41	-0.26	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
HNSC	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-5.81	1.15e-08	4.67e-06	-0.47	-0.26	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-5.81	1.15e-08	4.67e-06	-0.47	-0.26	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	5.81	1.15e-08	4.68e-06	0.28	0.26	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
HNSC	cis	rs2933343	0.649	rs728839	ENSG00000261159.1	RP11-723O4.9	5.81	1.15e-08	4.68e-06	0.25	0.26	IgG glycosylation;	chr3:128870516	chr3:128859716~128860526:-
HNSC	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	5.81	1.15e-08	4.68e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
HNSC	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-5.81	1.15e-08	4.68e-06	-0.29	-0.26	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
HNSC	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-5.81	1.15e-08	4.69e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
HNSC	cis	rs11992162	0.591	rs4240678	ENSG00000206014.6	OR7E161P	5.81	1.15e-08	4.69e-06	0.28	0.26	Monocyte count;	chr8:11944917	chr8:11928597~11929563:-
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-5.81	1.15e-08	4.69e-06	-0.17	-0.26	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
HNSC	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-5.81	1.15e-08	4.69e-06	-0.23	-0.26	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000211972.2	IGHV3-66	5.81	1.15e-08	4.69e-06	0.2	0.26	Kawasaki disease;	chr14:106777611	chr14:106675017~106675544:-
HNSC	cis	rs1355223	0.902	rs1539250	ENSG00000271369.1	RP11-350D17.3	-5.81	1.15e-08	4.69e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721228	chr11:34709600~34710161:+
HNSC	cis	rs6951245	0.572	rs73259905	ENSG00000224079.1	AC091729.7	-5.81	1.15e-08	4.69e-06	-0.53	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:983728	chr7:1074450~1078036:+
HNSC	cis	rs2579103	0.898	rs1371089	ENSG00000258183.4	RP11-753N8.1	-5.81	1.16e-08	4.7e-06	-0.32	-0.26	Body mass index;	chr12:90214751	chr12:90280894~90300340:+
HNSC	cis	rs5753618	0.504	rs9609297	ENSG00000236132.1	CTA-440B3.1	-5.81	1.16e-08	4.7e-06	-0.35	-0.26	Colorectal cancer;	chr22:31497745	chr22:31816379~31817491:-
HNSC	cis	rs440932	0.798	rs330942	ENSG00000173295.6	FAM86B3P	5.81	1.16e-08	4.7e-06	0.29	0.26	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8228595~8244865:+
HNSC	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-5.81	1.16e-08	4.71e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
HNSC	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	5.81	1.16e-08	4.71e-06	0.32	0.26	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	5.81	1.16e-08	4.71e-06	0.32	0.26	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
HNSC	cis	rs75422866	0.51	rs73105819	ENSG00000276691.1	RP5-1057I20.5	5.81	1.16e-08	4.71e-06	0.45	0.26	Pneumonia;	chr12:47727190	chr12:47788426~47788971:+
HNSC	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	5.81	1.16e-08	4.71e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
HNSC	cis	rs9914544	1	rs8066385	ENSG00000264885.1	RP11-815I9.4	-5.81	1.16e-08	4.71e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18857820	chr17:18667629~18669461:-
HNSC	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-5.81	1.16e-08	4.71e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000254153.1	CTA-398F10.2	5.81	1.16e-08	4.71e-06	0.29	0.26	Joint mobility (Beighton score);	chr8:9043712	chr8:8456909~8461337:-
HNSC	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-5.81	1.16e-08	4.71e-06	-0.37	-0.26	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
HNSC	cis	rs13113518	0.812	rs11945371	ENSG00000273257.1	RP11-177J6.1	5.81	1.16e-08	4.71e-06	0.32	0.26	Height;	chr4:55409063	chr4:55387949~55388271:+
HNSC	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	5.81	1.16e-08	4.72e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
HNSC	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
HNSC	cis	rs35963943	0.625	rs11713263	ENSG00000228956.7	SATB1-AS1	-5.81	1.16e-08	4.72e-06	-0.32	-0.26	Lymphocyte counts;	chr3:18678418	chr3:18445024~18920401:+
HNSC	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-5.81	1.16e-08	4.73e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
HNSC	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-5.81	1.16e-08	4.73e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
HNSC	cis	rs11098499	0.675	rs11098534	ENSG00000249244.1	RP11-548H18.2	5.81	1.16e-08	4.73e-06	0.32	0.26	Corneal astigmatism;	chr4:119635617	chr4:119391831~119395335:-
HNSC	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-5.81	1.17e-08	4.74e-06	-0.38	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
HNSC	cis	rs5753618	0.607	rs5753621	ENSG00000236132.1	CTA-440B3.1	-5.81	1.17e-08	4.74e-06	-0.32	-0.26	Colorectal cancer;	chr22:31451661	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	5.81	1.17e-08	4.74e-06	0.28	0.26	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
HNSC	cis	rs867371	0.929	rs1501371	ENSG00000276710.3	CSPG4P8	-5.81	1.17e-08	4.74e-06	-0.3	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82459472~82477258:+
HNSC	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.17e-08	4.75e-06	-0.26	-0.26	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
HNSC	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.17e-08	4.75e-06	-0.26	-0.26	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
HNSC	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-5.81	1.17e-08	4.75e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-5.81	1.17e-08	4.75e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-5.81	1.17e-08	4.75e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
HNSC	cis	rs8059260	0.736	rs76818150	ENSG00000274038.1	RP11-66H6.4	-5.81	1.17e-08	4.75e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10955006	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-5.81	1.17e-08	4.75e-06	-0.34	-0.26	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
HNSC	cis	rs9300255	0.602	rs1716177	ENSG00000280120.1	RP11-546D6.3	5.81	1.17e-08	4.76e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123170910	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.508	rs1716176	ENSG00000280120.1	RP11-546D6.3	5.81	1.17e-08	4.76e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123170920	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1790098	ENSG00000280120.1	RP11-546D6.3	5.81	1.17e-08	4.76e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123170934	chr12:123152324~123153377:-
HNSC	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	5.81	1.17e-08	4.76e-06	0.33	0.26	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
HNSC	cis	rs12030196	0.536	rs2716130	ENSG00000230812.4	LINC01358	5.81	1.17e-08	4.76e-06	0.25	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59021456	chr1:59020387~59044614:+
HNSC	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-5.81	1.17e-08	4.76e-06	-0.74	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
HNSC	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.17e-08	4.76e-06	-0.26	-0.26	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-5.81	1.17e-08	4.76e-06	-0.31	-0.26	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
HNSC	cis	rs1355223	0.902	rs704744	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715014	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs836466	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715819	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1773910	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34719706	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1539251	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721225	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs836462	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721716	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1773908	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721833	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs860712	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721947	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs2226113	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724742	chr11:34709600~34710161:+
HNSC	cis	rs1355223	1	rs11601205	ENSG00000271369.1	RP11-350D17.3	-5.81	1.18e-08	4.77e-06	-0.3	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746932	chr11:34709600~34710161:+
HNSC	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	5.81	1.18e-08	4.78e-06	0.34	0.26	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
HNSC	cis	rs155076	0.711	rs9550724	ENSG00000233325.3	MIPEPP3	-5.81	1.18e-08	4.78e-06	-0.42	-0.26	White matter hyperintensity burden;	chr13:21310891	chr13:21298139~21306373:+
HNSC	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-5.81	1.18e-08	4.78e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
HNSC	cis	rs2933343	0.679	rs789221	ENSG00000261159.1	RP11-723O4.9	5.81	1.18e-08	4.78e-06	0.25	0.26	IgG glycosylation;	chr3:128872782	chr3:128859716~128860526:-
HNSC	cis	rs7402982	0.625	rs7179841	ENSG00000278022.1	RP11-35O15.2	-5.81	1.18e-08	4.78e-06	-0.31	-0.26	Birth weight;	chr15:98661423	chr15:98660210~98660668:+
HNSC	cis	rs1355223	0.902	rs11603774	ENSG00000271369.1	RP11-350D17.3	-5.81	1.18e-08	4.79e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34711344	chr11:34709600~34710161:+
HNSC	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	5.81	1.18e-08	4.8e-06	0.27	0.26	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
HNSC	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.18e-08	4.8e-06	-0.26	-0.26	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
HNSC	cis	rs11089937	0.929	rs5757155	ENSG00000211638.2	IGLV8-61	-5.81	1.18e-08	4.8e-06	-0.23	-0.26	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22098700~22099212:+
HNSC	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	5.81	1.18e-08	4.81e-06	0.35	0.26	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
HNSC	cis	rs13113518	0.783	rs6843722	ENSG00000273257.1	RP11-177J6.1	5.81	1.18e-08	4.81e-06	0.32	0.26	Height;	chr4:55465165	chr4:55387949~55388271:+
HNSC	cis	rs9907295	0.748	rs2526328	ENSG00000270977.1	AC015849.16	-5.81	1.19e-08	4.81e-06	-0.35	-0.26	Fibroblast growth factor basic levels;	chr17:35932348	chr17:35893707~35911023:-
HNSC	cis	rs1012068	0.662	rs11703779	ENSG00000236132.1	CTA-440B3.1	-5.81	1.19e-08	4.81e-06	-0.3	-0.26	Chronic hepatitis C infection;	chr22:31926398	chr22:31816379~31817491:-
HNSC	cis	rs10435719	0.867	rs35778860	ENSG00000206014.6	OR7E161P	-5.81	1.19e-08	4.81e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:11928597~11929563:-
HNSC	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-5.81	1.19e-08	4.82e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-5.81	1.19e-08	4.82e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
HNSC	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	5.81	1.19e-08	4.82e-06	0.38	0.26	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
HNSC	cis	rs13113518	0.812	rs1522114	ENSG00000273257.1	RP11-177J6.1	5.8	1.19e-08	4.83e-06	0.32	0.26	Height;	chr4:55489895	chr4:55387949~55388271:+
HNSC	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-5.8	1.19e-08	4.83e-06	-0.25	-0.26	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
HNSC	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	5.8	1.19e-08	4.83e-06	0.34	0.26	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
HNSC	cis	rs11089937	0.667	rs9622981	ENSG00000211638.2	IGLV8-61	-5.8	1.19e-08	4.83e-06	-0.26	-0.26	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22098700~22099212:+
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	5.8	1.19e-08	4.84e-06	0.28	0.26	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
HNSC	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-5.8	1.19e-08	4.84e-06	-0.31	-0.26	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
HNSC	cis	rs35306767	0.953	rs35693858	ENSG00000229869.1	RP11-363N22.2	-5.8	1.19e-08	4.84e-06	-0.35	-0.26	Eosinophil percentage of granulocytes;	chr10:933873	chr10:933026~942743:+
HNSC	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	5.8	1.19e-08	4.84e-06	0.34	0.26	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
HNSC	cis	rs2762353	0.526	rs12215823	ENSG00000272462.2	U91328.19	-5.8	1.2e-08	4.85e-06	-0.25	-0.26	Blood metabolite levels;	chr6:25725846	chr6:25992662~26001775:+
HNSC	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	5.8	1.2e-08	4.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
HNSC	cis	rs13113518	1	rs4864999	ENSG00000249700.7	SRD5A3-AS1	5.8	1.2e-08	4.85e-06	0.31	0.26	Height;	chr4:55476736	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12506788	ENSG00000249700.7	SRD5A3-AS1	5.8	1.2e-08	4.85e-06	0.31	0.26	Height;	chr4:55477426	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs10517344	ENSG00000249700.7	SRD5A3-AS1	5.8	1.2e-08	4.85e-06	0.31	0.26	Height;	chr4:55477545	chr4:55363971~55395847:-
HNSC	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	5.8	1.2e-08	4.85e-06	0.31	0.26	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
HNSC	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-5.8	1.2e-08	4.86e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
HNSC	cis	rs2742234	0.541	rs10793426	ENSG00000273008.1	RP11-351D16.3	5.8	1.2e-08	4.86e-06	0.36	0.26	Hirschsprung disease;	chr10:43249832	chr10:43136824~43138334:-
HNSC	cis	rs13113518	0.783	rs11133389	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55486718	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.756	rs7658446	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55495262	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.776	rs13124436	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55502504	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.783	rs6843997	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55508982	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.783	rs12508367	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55509442	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs2272073	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55510177	chr4:55387949~55388271:+
HNSC	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-5.8	1.2e-08	4.87e-06	-0.34	-0.26	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
HNSC	cis	rs13113518	0.812	rs13140590	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.87e-06	0.32	0.26	Height;	chr4:55548666	chr4:55387949~55388271:+
HNSC	cis	rs75422866	0.51	rs73105818	ENSG00000276691.1	RP5-1057I20.5	5.8	1.2e-08	4.87e-06	0.45	0.26	Pneumonia;	chr12:47726538	chr12:47788426~47788971:+
HNSC	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	5.8	1.2e-08	4.87e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
HNSC	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	5.8	1.2e-08	4.88e-06	0.32	0.26	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
HNSC	cis	rs6918586	0.658	rs198825	ENSG00000272462.2	U91328.19	-5.8	1.21e-08	4.88e-06	-0.24	-0.26	Schizophrenia;	chr6:26122274	chr6:25992662~26001775:+
HNSC	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	5.8	1.21e-08	4.88e-06	0.27	0.26	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
HNSC	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-5.8	1.21e-08	4.89e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
HNSC	cis	rs13113518	1	rs13116194	ENSG00000249700.7	SRD5A3-AS1	5.8	1.21e-08	4.89e-06	0.31	0.26	Height;	chr4:55531150	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13117836	ENSG00000249700.7	SRD5A3-AS1	5.8	1.21e-08	4.89e-06	0.31	0.26	Height;	chr4:55531218	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs7668429	ENSG00000249700.7	SRD5A3-AS1	5.8	1.21e-08	4.89e-06	0.31	0.26	Height;	chr4:55531811	chr4:55363971~55395847:-
HNSC	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-5.8	1.21e-08	4.9e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-5.8	1.21e-08	4.9e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
HNSC	cis	rs9300255	0.739	rs1980252	ENSG00000280120.1	RP11-546D6.3	5.8	1.21e-08	4.91e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123260631	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1716167	ENSG00000280120.1	RP11-546D6.3	-5.8	1.21e-08	4.91e-06	-0.24	-0.26	Neutrophil percentage of white cells;	chr12:123166615	chr12:123152324~123153377:-
HNSC	cis	rs11098499	0.644	rs10050092	ENSG00000249244.1	RP11-548H18.2	5.8	1.21e-08	4.92e-06	0.32	0.26	Corneal astigmatism;	chr4:119610930	chr4:119391831~119395335:-
HNSC	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-5.8	1.22e-08	4.93e-06	-0.68	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
HNSC	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	5.8	1.22e-08	4.93e-06	0.27	0.26	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
HNSC	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-5.8	1.22e-08	4.93e-06	-0.29	-0.26	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
HNSC	cis	rs2439831	0.867	rs486301	ENSG00000205771.5	CATSPER2P1	-5.8	1.22e-08	4.93e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43544751	chr15:43726918~43747094:-
HNSC	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-5.8	1.22e-08	4.93e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
HNSC	cis	rs7630852	1	rs9852432	ENSG00000272359.1	U4	-5.8	1.22e-08	4.94e-06	-0.28	-0.26	Eosinophil counts;	chr3:196780210	chr3:196747192~196747324:-
HNSC	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-5.8	1.22e-08	4.94e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-5.8	1.22e-08	4.94e-06	-0.3	-0.26	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
HNSC	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	5.8	1.22e-08	4.94e-06	0.25	0.26	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
HNSC	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-5.8	1.22e-08	4.94e-06	-0.33	-0.26	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
HNSC	cis	rs867371	0.502	rs8025964	ENSG00000276710.3	CSPG4P8	-5.8	1.22e-08	4.94e-06	-0.28	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	5.8	1.22e-08	4.94e-06	0.4	0.26	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
HNSC	cis	rs3206736	0.548	rs328902	ENSG00000197085.10	NPSR1-AS1	-5.8	1.22e-08	4.94e-06	-0.33	-0.26	Diastolic blood pressure;	chr7:34981231	chr7:34346512~34871582:-
HNSC	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-5.8	1.22e-08	4.94e-06	-0.36	-0.26	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
HNSC	cis	rs2579103	1	rs2731277	ENSG00000258183.4	RP11-753N8.1	-5.8	1.22e-08	4.94e-06	-0.34	-0.26	Body mass index;	chr12:90230184	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2579103	ENSG00000258183.4	RP11-753N8.1	-5.8	1.22e-08	4.94e-06	-0.34	-0.26	Body mass index;	chr12:90239730	chr12:90280894~90300340:+
HNSC	cis	rs13126694	0.901	rs4691460	ENSG00000248429.4	RP11-597D13.9	-5.8	1.22e-08	4.95e-06	-0.29	-0.26	Blood osmolality (transformed sodium);	chr4:158138279	chr4:158170752~158202877:+
HNSC	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs13116194	ENSG00000273257.1	RP11-177J6.1	5.8	1.22e-08	4.95e-06	0.32	0.26	Height;	chr4:55531150	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13117836	ENSG00000273257.1	RP11-177J6.1	5.8	1.22e-08	4.95e-06	0.32	0.26	Height;	chr4:55531218	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs7668429	ENSG00000273257.1	RP11-177J6.1	5.8	1.22e-08	4.95e-06	0.32	0.26	Height;	chr4:55531811	chr4:55387949~55388271:+
HNSC	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-5.8	1.22e-08	4.95e-06	-0.35	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
HNSC	cis	rs13113518	0.902	rs12642716	ENSG00000249700.7	SRD5A3-AS1	5.8	1.22e-08	4.95e-06	0.3	0.26	Height;	chr4:55479996	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12501636	ENSG00000249700.7	SRD5A3-AS1	5.8	1.22e-08	4.95e-06	0.3	0.26	Height;	chr4:55482317	chr4:55363971~55395847:-
HNSC	cis	rs75920871	0.528	rs7128772	ENSG00000254851.1	RP11-109L13.1	5.8	1.23e-08	4.96e-06	0.37	0.26	Subjective well-being;	chr11:117018695	chr11:117135528~117138582:+
HNSC	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-5.8	1.23e-08	4.97e-06	-0.31	-0.26	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
HNSC	cis	rs9914544	1	rs28436199	ENSG00000264885.1	RP11-815I9.4	-5.8	1.23e-08	4.97e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18848417	chr17:18667629~18669461:-
HNSC	cis	rs4834770	1	rs878374	ENSG00000249244.1	RP11-548H18.2	5.8	1.23e-08	4.97e-06	0.29	0.26	Blood protein levels;	chr4:119316409	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	5.8	1.23e-08	4.98e-06	0.34	0.26	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
HNSC	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-5.8	1.23e-08	4.98e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
HNSC	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-5.8	1.23e-08	4.98e-06	-0.37	-0.26	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
HNSC	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-5.8	1.23e-08	4.98e-06	-0.42	-0.26	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-5.8	1.23e-08	4.98e-06	-0.37	-0.26	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
HNSC	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	5.8	1.24e-08	4.99e-06	0.32	0.26	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
HNSC	cis	rs10504130	0.569	rs11775611	ENSG00000272024.1	RP11-546K22.3	-5.8	1.24e-08	4.99e-06	-0.36	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51950284~51950690:+
HNSC	cis	rs2439831	0.867	rs2255440	ENSG00000205771.5	CATSPER2P1	-5.8	1.24e-08	4.99e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43538269	chr15:43726918~43747094:-
HNSC	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	5.8	1.24e-08	4.99e-06	0.33	0.26	Height;	chr4:55401306	chr4:55363971~55395847:-
HNSC	cis	rs75422866	0.85	rs73111210	ENSG00000257433.4	RP1-197B17.3	5.8	1.24e-08	5e-06	0.66	0.26	Pneumonia;	chr12:47576949	chr12:47706085~47742294:+
HNSC	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-5.8	1.24e-08	5e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
HNSC	cis	rs62344088	1	rs7710931	ENSG00000277812.1	AC021087.1	5.8	1.24e-08	5.01e-06	0.72	0.26	Asthma (childhood onset);	chr5:152171	chr5:262769~262881:+
HNSC	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	5.8	1.24e-08	5.01e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	5.8	1.24e-08	5.01e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
HNSC	cis	rs9840812	0.623	rs9854084	ENSG00000273486.1	RP11-731C17.2	5.8	1.24e-08	5.01e-06	0.23	0.26	Fibrinogen levels;	chr3:136475901	chr3:136837338~136839021:-
HNSC	cis	rs950776	0.518	rs4887063	ENSG00000261762.1	RP11-650L12.2	-5.8	1.24e-08	5.01e-06	-0.3	-0.26	Sudden cardiac arrest;	chr15:78547373	chr15:78589123~78591276:-
HNSC	cis	rs9907295	0.591	rs2107538	ENSG00000270977.1	AC015849.16	-5.8	1.24e-08	5.01e-06	-0.3	-0.26	Fibroblast growth factor basic levels;	chr17:35880776	chr17:35893707~35911023:-
HNSC	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	5.8	1.24e-08	5.02e-06	0.31	0.26	Height;	chr4:55437438	chr4:55363971~55395847:-
HNSC	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	5.8	1.24e-08	5.02e-06	0.35	0.26	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
HNSC	cis	rs5753618	0.583	rs9606843	ENSG00000236132.1	CTA-440B3.1	-5.8	1.25e-08	5.03e-06	-0.33	-0.26	Colorectal cancer;	chr22:31457385	chr22:31816379~31817491:-
HNSC	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.25e-08	5.03e-06	-0.32	-0.26	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
HNSC	cis	rs2745572	0.557	rs2816299	ENSG00000272279.1	RP11-157J24.2	-5.8	1.25e-08	5.03e-06	-0.32	-0.26	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548451	chr6:1528364~1528911:-
HNSC	cis	rs988913	1	rs1393776	ENSG00000224984.1	RP11-524H19.2	-5.8	1.25e-08	5.03e-06	-0.29	-0.26	Menarche (age at onset);	chr6:54898220	chr6:54840118~54840855:-
HNSC	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	5.8	1.25e-08	5.03e-06	0.33	0.26	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000179406.6	LINC00174	-5.8	1.25e-08	5.03e-06	-0.34	-0.26	Calcium levels;	chr7:65800652	chr7:66376044~66401338:-
HNSC	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	5.8	1.25e-08	5.03e-06	0.31	0.26	Height;	chr4:55407965	chr4:55363971~55395847:-
HNSC	cis	rs9300255	0.699	rs11057204	ENSG00000280120.1	RP11-546D6.3	5.8	1.25e-08	5.03e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123241280	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.62	rs7313483	ENSG00000280120.1	RP11-546D6.3	5.8	1.25e-08	5.03e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123242287	chr12:123152324~123153377:-
HNSC	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	5.8	1.25e-08	5.04e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
HNSC	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	5.8	1.25e-08	5.04e-06	0.31	0.26	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
HNSC	cis	rs9840812	0.623	rs6794351	ENSG00000273486.1	RP11-731C17.2	5.8	1.25e-08	5.05e-06	0.22	0.26	Fibrinogen levels;	chr3:136573437	chr3:136837338~136839021:-
HNSC	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	5.8	1.25e-08	5.05e-06	0.34	0.26	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
HNSC	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	5.8	1.25e-08	5.05e-06	0.24	0.26	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
HNSC	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.25e-08	5.05e-06	-0.32	-0.26	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
HNSC	cis	rs4218	0.517	rs2899640	ENSG00000277144.1	RP11-59H7.4	-5.8	1.25e-08	5.06e-06	-0.34	-0.26	Social communication problems;	chr15:59060281	chr15:59115547~59116089:-
HNSC	cis	rs9840812	0.728	rs12630999	ENSG00000273486.1	RP11-731C17.2	5.8	1.26e-08	5.06e-06	0.22	0.26	Fibrinogen levels;	chr3:136582085	chr3:136837338~136839021:-
HNSC	cis	rs757110	0.866	rs5213	ENSG00000260196.1	RP1-239B22.5	5.8	1.26e-08	5.06e-06	0.3	0.26	Type 2 diabetes;	chr11:17386857	chr11:17380649~17383531:+
HNSC	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.26e-08	5.06e-06	-0.32	-0.26	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
HNSC	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	5.8	1.26e-08	5.06e-06	0.33	0.26	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
HNSC	cis	rs9341808	0.538	rs667097	ENSG00000272129.1	RP11-250B2.6	-5.8	1.26e-08	5.07e-06	-0.31	-0.26	Sitting height ratio;	chr6:80269226	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-5.8	1.26e-08	5.07e-06	-0.31	-0.26	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
HNSC	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-5.8	1.26e-08	5.07e-06	-0.36	-0.26	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-5.8	1.26e-08	5.07e-06	-0.36	-0.26	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
HNSC	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-5.79	1.26e-08	5.07e-06	-0.35	-0.26	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
HNSC	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	5.79	1.26e-08	5.07e-06	0.33	0.26	Height;	chr6:109350188	chr6:109382795~109383666:+
HNSC	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-5.79	1.26e-08	5.08e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
HNSC	cis	rs13113518	1	rs10462032	ENSG00000249700.7	SRD5A3-AS1	5.79	1.26e-08	5.1e-06	0.3	0.26	Height;	chr4:55479069	chr4:55363971~55395847:-
HNSC	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	5.79	1.27e-08	5.1e-06	0.35	0.26	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
HNSC	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-5.79	1.27e-08	5.11e-06	-0.49	-0.26	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
HNSC	cis	rs4852324	0.536	rs13387174	ENSG00000217702.2	RP11-287D1.4	5.79	1.27e-08	5.11e-06	0.63	0.26	Systemic lupus erythematosus;	chr2:73979558	chr2:74130583~74135395:+
HNSC	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	5.79	1.27e-08	5.12e-06	0.35	0.26	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
HNSC	cis	rs454422	1	rs2326680	ENSG00000275632.1	RP5-967N21.11	5.79	1.27e-08	5.12e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5962309	chr20:6000418~6000941:+
HNSC	cis	rs454422	1	rs409035	ENSG00000275632.1	RP5-967N21.11	5.79	1.27e-08	5.12e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5963003	chr20:6000418~6000941:+
HNSC	cis	rs454422	1	rs454422	ENSG00000275632.1	RP5-967N21.11	5.79	1.27e-08	5.12e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5963047	chr20:6000418~6000941:+
HNSC	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	5.79	1.27e-08	5.12e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	5.79	1.27e-08	5.12e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	5.79	1.27e-08	5.12e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
HNSC	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-5.79	1.27e-08	5.12e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
HNSC	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-5.79	1.27e-08	5.13e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
HNSC	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	-5.79	1.27e-08	5.13e-06	-0.3	-0.26	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
HNSC	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	5.79	1.27e-08	5.13e-06	0.3	0.26	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
HNSC	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-5.79	1.27e-08	5.13e-06	-0.29	-0.26	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
HNSC	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	5.79	1.28e-08	5.13e-06	0.34	0.26	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
HNSC	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	5.79	1.28e-08	5.14e-06	0.36	0.26	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	5.79	1.28e-08	5.14e-06	0.21	0.26	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
HNSC	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	5.79	1.28e-08	5.14e-06	0.3	0.26	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
HNSC	cis	rs7674212	0.51	rs55715738	ENSG00000246560.2	RP11-10L12.4	5.79	1.28e-08	5.14e-06	0.29	0.26	Type 2 diabetes;	chr4:103209032	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.736	rs8046423	ENSG00000274038.1	RP11-66H6.4	-5.79	1.28e-08	5.16e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10964016	chr16:11056556~11057034:+
HNSC	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
HNSC	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	5.79	1.28e-08	5.16e-06	0.32	0.26	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000254340.1	RP11-10A14.3	5.79	1.28e-08	5.17e-06	0.31	0.26	Mood instability;	chr8:8816091	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	5.79	1.29e-08	5.17e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
HNSC	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	5.79	1.29e-08	5.17e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
HNSC	cis	rs12439619	1	rs35152457	ENSG00000276710.3	CSPG4P8	-5.79	1.29e-08	5.18e-06	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82459472~82477258:+
HNSC	cis	rs2985684	1	rs3007030	ENSG00000258568.1	RHOQP1	5.79	1.29e-08	5.18e-06	0.27	0.26	Carotid intima media thickness;	chr14:49619845	chr14:49599994~49600572:+
HNSC	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-5.79	1.29e-08	5.19e-06	-0.33	-0.26	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-5.79	1.29e-08	5.19e-06	-0.33	-0.26	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
HNSC	cis	rs9300255	0.602	rs1716168	ENSG00000280120.1	RP11-546D6.3	-5.79	1.29e-08	5.19e-06	-0.23	-0.26	Neutrophil percentage of white cells;	chr12:123167419	chr12:123152324~123153377:-
HNSC	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	5.79	1.29e-08	5.19e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
HNSC	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	5.79	1.29e-08	5.19e-06	0.34	0.26	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	5.79	1.29e-08	5.19e-06	0.34	0.26	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	5.79	1.29e-08	5.19e-06	0.34	0.26	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-5.79	1.29e-08	5.19e-06	-0.34	-0.26	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-5.79	1.29e-08	5.19e-06	-0.34	-0.26	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-5.79	1.29e-08	5.19e-06	-0.34	-0.26	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.644	rs10012252	ENSG00000249244.1	RP11-548H18.2	5.79	1.29e-08	5.19e-06	0.32	0.26	Corneal astigmatism;	chr4:119637984	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.644	rs3806808	ENSG00000249244.1	RP11-548H18.2	5.79	1.29e-08	5.2e-06	0.32	0.26	Corneal astigmatism;	chr4:119629930	chr4:119391831~119395335:-
HNSC	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
HNSC	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
HNSC	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	5.79	1.29e-08	5.2e-06	0.25	0.26	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-5.79	1.3e-08	5.21e-06	-0.3	-0.26	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-5.79	1.3e-08	5.21e-06	-0.3	-0.26	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-5.79	1.3e-08	5.21e-06	-0.3	-0.26	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
HNSC	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-5.79	1.3e-08	5.21e-06	-0.39	-0.26	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
HNSC	cis	rs2483058	0.767	rs11579993	ENSG00000261000.1	RP11-534L20.5	5.79	1.3e-08	5.22e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206445529	chr1:206503948~206504456:+
HNSC	cis	rs2762353	0.526	rs3936052	ENSG00000272462.2	U91328.19	-5.79	1.3e-08	5.22e-06	-0.25	-0.26	Blood metabolite levels;	chr6:25715306	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-5.79	1.3e-08	5.22e-06	-0.32	-0.26	Depression;	chr6:28133900	chr6:28161781~28169594:+
HNSC	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-5.79	1.3e-08	5.22e-06	-0.34	-0.26	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
HNSC	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
HNSC	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-5.79	1.3e-08	5.23e-06	-0.34	-0.26	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
HNSC	cis	rs61542988	0.57	rs62448268	ENSG00000228649.7	AC005682.5	5.79	1.3e-08	5.23e-06	0.34	0.26	Fibrinogen levels;	chr7:22789845	chr7:22854178~22861579:+
HNSC	cis	rs7587476	0.638	rs34358404	ENSG00000229267.2	AC072062.1	-5.79	1.3e-08	5.23e-06	-0.38	-0.26	Neuroblastoma;	chr2:214794730	chr2:214810229~214963274:+
HNSC	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-5.79	1.3e-08	5.23e-06	-0.28	-0.26	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
HNSC	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-5.79	1.3e-08	5.23e-06	-0.27	-0.26	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-5.79	1.3e-08	5.23e-06	-0.27	-0.26	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
HNSC	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	5.79	1.3e-08	5.23e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
HNSC	cis	rs9650657	0.53	rs6982381	ENSG00000255310.2	AF131215.2	-5.79	1.31e-08	5.25e-06	-0.25	-0.26	Neuroticism;	chr8:11094990	chr8:11107788~11109726:-
HNSC	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	5.79	1.31e-08	5.25e-06	0.34	0.26	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
HNSC	cis	rs9341808	0.538	rs9443742	ENSG00000272129.1	RP11-250B2.6	-5.79	1.31e-08	5.25e-06	-0.3	-0.26	Sitting height ratio;	chr6:80307212	chr6:80355424~80356859:+
HNSC	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-5.79	1.31e-08	5.26e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
HNSC	cis	rs4141404	0.851	rs9606833	ENSG00000236132.1	CTA-440B3.1	-5.79	1.31e-08	5.26e-06	-0.36	-0.26	Paclitaxel-induced neuropathy;	chr22:31354027	chr22:31816379~31817491:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000235689.1	AP000351.13	5.79	1.31e-08	5.27e-06	0.26	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:24006305~24008258:-
HNSC	cis	rs9640161	0.783	rs35435439	ENSG00000261305.1	RP4-584D14.7	5.79	1.31e-08	5.28e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150366445	chr7:150341771~150342607:+
HNSC	cis	rs9840812	0.691	rs833752	ENSG00000273486.1	RP11-731C17.2	5.79	1.32e-08	5.29e-06	0.23	0.26	Fibrinogen levels;	chr3:136536327	chr3:136837338~136839021:-
HNSC	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-5.79	1.32e-08	5.29e-06	-0.27	-0.26	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
HNSC	cis	rs11992162	0.529	rs6995037	ENSG00000206014.6	OR7E161P	5.79	1.32e-08	5.29e-06	0.28	0.26	Monocyte count;	chr8:11923378	chr8:11928597~11929563:-
HNSC	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	5.79	1.32e-08	5.31e-06	0.28	0.26	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
HNSC	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	5.79	1.32e-08	5.31e-06	0.33	0.26	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
HNSC	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	5.79	1.32e-08	5.31e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
HNSC	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	5.79	1.32e-08	5.31e-06	0.41	0.26	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
HNSC	cis	rs3206736	0.548	rs167893	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35003121	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.52	rs328934	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35004114	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328936	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35007967	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.521	rs329232	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35015339	chr7:34346512~34871582:-
HNSC	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-5.79	1.33e-08	5.32e-06	-0.37	-0.26	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
HNSC	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	5.79	1.33e-08	5.32e-06	0.34	0.26	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	5.79	1.33e-08	5.32e-06	0.34	0.26	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
HNSC	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	5.79	1.33e-08	5.33e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
HNSC	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	5.79	1.33e-08	5.33e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
HNSC	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	5.79	1.33e-08	5.33e-06	0.29	0.26	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
HNSC	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	5.79	1.33e-08	5.33e-06	0.29	0.26	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
HNSC	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-5.79	1.33e-08	5.33e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
HNSC	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	5.79	1.33e-08	5.33e-06	0.25	0.26	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
HNSC	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-5.78	1.33e-08	5.34e-06	-0.3	-0.26	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-5.78	1.33e-08	5.34e-06	-0.3	-0.26	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-5.78	1.33e-08	5.34e-06	-0.3	-0.26	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
HNSC	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	5.78	1.33e-08	5.34e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
HNSC	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	5.78	1.33e-08	5.34e-06	0.28	0.26	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
HNSC	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	5.78	1.33e-08	5.34e-06	0.33	0.26	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
HNSC	cis	rs2976388	0.507	rs7813604	ENSG00000253741.1	CTD-2292P10.4	-5.78	1.33e-08	5.34e-06	-0.26	-0.26	Urinary tract infection frequency;	chr8:142756644	chr8:142702252~142726973:-
HNSC	cis	rs61542988	0.532	rs10240168	ENSG00000228649.7	AC005682.5	5.78	1.33e-08	5.35e-06	0.31	0.26	Fibrinogen levels;	chr7:22779715	chr7:22854178~22861579:+
HNSC	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	5.78	1.33e-08	5.35e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
HNSC	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	5.78	1.34e-08	5.36e-06	0.34	0.26	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
HNSC	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-5.78	1.34e-08	5.37e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
HNSC	cis	rs1021993	0.857	rs1553622	ENSG00000231648.1	RP11-372M18.2	-5.78	1.34e-08	5.37e-06	-0.35	-0.26	Gut microbiome composition (winter);	chr1:209290515	chr1:209367662~209379690:+
HNSC	cis	rs6504622	0.875	rs3785888	ENSG00000262879.4	RP11-156P1.3	-5.78	1.34e-08	5.37e-06	-0.28	-0.26	Orofacial clefts;	chr17:46928337	chr17:46984045~47100323:-
HNSC	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	5.78	1.34e-08	5.37e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
HNSC	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-5.78	1.34e-08	5.38e-06	-0.3	-0.26	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
HNSC	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-5.78	1.35e-08	5.4e-06	-0.36	-0.26	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
HNSC	cis	rs673078	0.66	rs11068910	ENSG00000275409.1	RP11-131L12.4	-5.78	1.35e-08	5.4e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118336076	chr12:118430147~118430699:+
HNSC	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-5.78	1.35e-08	5.4e-06	-0.39	-0.26	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
HNSC	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-5.78	1.35e-08	5.4e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
HNSC	cis	rs783540	0.5	rs7163840	ENSG00000276710.3	CSPG4P8	5.78	1.35e-08	5.41e-06	0.31	0.26	Schizophrenia;	chr15:82729551	chr15:82459472~82477258:+
HNSC	cis	rs2439831	1	rs565007	ENSG00000205771.5	CATSPER2P1	-5.78	1.35e-08	5.41e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43424443	chr15:43726918~43747094:-
HNSC	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	5.78	1.35e-08	5.41e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	5.78	1.35e-08	5.42e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
HNSC	cis	rs6604026	0.555	rs34734076	ENSG00000223787.2	RP4-593M8.1	5.78	1.35e-08	5.42e-06	0.36	0.26	Multiple sclerosis;	chr1:92613901	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs11807962	ENSG00000223787.2	RP4-593M8.1	5.78	1.35e-08	5.42e-06	0.36	0.26	Multiple sclerosis;	chr1:92614721	chr1:92580476~92580821:-
HNSC	cis	rs75920871	0.528	rs10466590	ENSG00000254851.1	RP11-109L13.1	5.78	1.36e-08	5.43e-06	0.36	0.26	Subjective well-being;	chr11:117023697	chr11:117135528~117138582:+
HNSC	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-5.78	1.36e-08	5.44e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
HNSC	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-5.78	1.36e-08	5.44e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	5.45e-06	-0.31	-0.26	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
HNSC	cis	rs6969780	1	rs73071550	ENSG00000233429.8	HOTAIRM1	5.78	1.36e-08	5.45e-06	0.47	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109480	chr7:27095647~27100265:+
HNSC	cis	rs6969780	1	rs6461985	ENSG00000233429.8	HOTAIRM1	5.78	1.36e-08	5.45e-06	0.47	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111015	chr7:27095647~27100265:+
HNSC	cis	rs61542988	0.535	rs10807813	ENSG00000228649.7	AC005682.5	5.78	1.36e-08	5.45e-06	0.34	0.26	Fibrinogen levels;	chr7:22790342	chr7:22854178~22861579:+
HNSC	cis	rs2179367	0.632	rs10155766	ENSG00000216906.2	RP11-350J20.9	5.78	1.36e-08	5.45e-06	0.38	0.26	Dupuytren's disease;	chr6:149364577	chr6:149904243~149906418:+
HNSC	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	5.78	1.36e-08	5.45e-06	0.34	0.26	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
HNSC	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-5.78	1.36e-08	5.46e-06	-0.44	-0.26	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
HNSC	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	5.78	1.36e-08	5.46e-06	0.21	0.26	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
HNSC	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-5.78	1.36e-08	5.46e-06	-0.22	-0.26	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
HNSC	cis	rs75422866	0.85	rs73111212	ENSG00000257433.4	RP1-197B17.3	5.78	1.36e-08	5.46e-06	0.66	0.26	Pneumonia;	chr12:47577638	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.85	rs73111216	ENSG00000257433.4	RP1-197B17.3	5.78	1.36e-08	5.46e-06	0.66	0.26	Pneumonia;	chr12:47577671	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.85	rs73111217	ENSG00000257433.4	RP1-197B17.3	5.78	1.36e-08	5.46e-06	0.66	0.26	Pneumonia;	chr12:47577693	chr12:47706085~47742294:+
HNSC	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	5.78	1.36e-08	5.46e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
HNSC	cis	rs2579103	0.898	rs2263480	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90222950	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2731251	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90227881	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2731278	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90230046	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs1371086	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90231669	chr12:90280894~90300340:+
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-5.78	1.37e-08	5.47e-06	-0.4	-0.26	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
HNSC	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-5.78	1.37e-08	5.47e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
HNSC	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.47e-06	0.32	0.26	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	5.78	1.37e-08	5.48e-06	0.4	0.26	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
HNSC	cis	rs889014	0.751	rs4867720	ENSG00000253768.1	CTB-33O18.1	5.78	1.37e-08	5.48e-06	0.29	0.26	Height;	chr5:173552560	chr5:173562478~173573199:+
HNSC	cis	rs13113518	0.812	rs4865003	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55514802	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.756	rs12510275	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55516548	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs12510327	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55516744	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs11939580	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55517185	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs6830409	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55522229	chr4:55387949~55388271:+
HNSC	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-5.78	1.37e-08	5.49e-06	-0.23	-0.26	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
HNSC	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-5.78	1.37e-08	5.49e-06	-0.26	-0.26	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
HNSC	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
HNSC	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	5.78	1.37e-08	5.49e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
HNSC	cis	rs1799949	0.773	rs2137990	ENSG00000267151.3	RP11-100E5.2	-5.78	1.37e-08	5.49e-06	-0.33	-0.26	Menopause (age at onset);	chr17:43165879	chr17:43444707~43451200:+
HNSC	cis	rs2179367	0.632	rs9498325	ENSG00000216906.2	RP11-350J20.9	5.78	1.37e-08	5.49e-06	0.38	0.26	Dupuytren's disease;	chr6:149345993	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498326	ENSG00000216906.2	RP11-350J20.9	5.78	1.37e-08	5.49e-06	0.38	0.26	Dupuytren's disease;	chr6:149346112	chr6:149904243~149906418:+
HNSC	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	5.78	1.37e-08	5.5e-06	0.29	0.26	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-5.78	1.37e-08	5.5e-06	-0.4	-0.26	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
HNSC	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.5e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.5e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
HNSC	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	5.78	1.38e-08	5.5e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
HNSC	cis	rs2579103	1	rs1579669	ENSG00000258183.4	RP11-753N8.1	-5.78	1.38e-08	5.5e-06	-0.34	-0.26	Body mass index;	chr12:90216068	chr12:90280894~90300340:+
HNSC	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-5.78	1.38e-08	5.5e-06	-0.31	-0.26	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
HNSC	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-5.78	1.38e-08	5.5e-06	-0.33	-0.26	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
HNSC	cis	rs17507216	0.718	rs72751657	ENSG00000255769.6	GOLGA2P10	-5.78	1.38e-08	5.51e-06	-0.42	-0.26	Excessive daytime sleepiness;	chr15:82581259	chr15:82472993~82513950:-
HNSC	cis	rs4218	0.648	rs12442134	ENSG00000277144.1	RP11-59H7.4	-5.78	1.38e-08	5.51e-06	-0.36	-0.26	Social communication problems;	chr15:59074478	chr15:59115547~59116089:-
HNSC	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-5.78	1.38e-08	5.51e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
HNSC	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	5.78	1.38e-08	5.51e-06	0.32	0.26	Depression;	chr6:28142370	chr6:28161781~28169594:+
HNSC	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	5.78	1.38e-08	5.51e-06	0.32	0.26	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	5.78	1.38e-08	5.51e-06	0.32	0.26	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
HNSC	cis	rs1355223	0.902	rs10501134	ENSG00000271369.1	RP11-350D17.3	-5.78	1.38e-08	5.51e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34727590	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs7130325	ENSG00000271369.1	RP11-350D17.3	-5.78	1.38e-08	5.51e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729412	chr11:34709600~34710161:+
HNSC	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.52e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.52e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
HNSC	cis	rs11846409	1	rs11846409	ENSG00000274576.2	IGHV2-70	-5.78	1.38e-08	5.52e-06	-0.26	-0.26	Rheumatic heart disease;	chr14:106645692	chr14:106770577~106771020:-
HNSC	cis	rs7587476	1	rs2121285	ENSG00000229267.2	AC072062.1	5.78	1.38e-08	5.52e-06	0.35	0.26	Neuroblastoma;	chr2:214791444	chr2:214810229~214963274:+
HNSC	cis	rs17507216	1	rs17158413	ENSG00000276710.3	CSPG4P8	-5.78	1.38e-08	5.52e-06	-0.33	-0.26	Excessive daytime sleepiness;	chr15:82566658	chr15:82459472~82477258:+
HNSC	cis	rs13113518	1	rs4864993	ENSG00000249700.7	SRD5A3-AS1	5.78	1.38e-08	5.53e-06	0.31	0.26	Height;	chr4:55450662	chr4:55363971~55395847:-
HNSC	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-5.78	1.38e-08	5.53e-06	-0.36	-0.26	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
HNSC	cis	rs2976388	0.507	rs13259549	ENSG00000253741.1	CTD-2292P10.4	-5.78	1.38e-08	5.53e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142757101	chr8:142702252~142726973:-
HNSC	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-5.78	1.39e-08	5.55e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
HNSC	cis	rs75920871	0.528	rs1531707	ENSG00000254851.1	RP11-109L13.1	5.78	1.39e-08	5.55e-06	0.35	0.26	Subjective well-being;	chr11:117073996	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs7484045	ENSG00000254851.1	RP11-109L13.1	5.78	1.39e-08	5.55e-06	0.35	0.26	Subjective well-being;	chr11:117076174	chr11:117135528~117138582:+
HNSC	cis	rs2115630	1	rs4633690	ENSG00000229212.6	RP11-561C5.4	5.78	1.39e-08	5.56e-06	0.3	0.26	P wave terminal force;	chr15:84818729	chr15:85205440~85234795:-
HNSC	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-5.78	1.39e-08	5.56e-06	-0.31	-0.26	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106776528	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106776695	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106778202	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106778401	chr14:106675017~106675544:-
HNSC	cis	rs4699052	1	rs6533059	ENSG00000246560.2	RP11-10L12.4	5.78	1.39e-08	5.56e-06	0.3	0.26	Testicular germ cell tumor;	chr4:103212219	chr4:102828055~102844075:+
HNSC	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-5.78	1.39e-08	5.57e-06	-0.36	-0.26	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-5.78	1.39e-08	5.57e-06	-0.36	-0.26	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
HNSC	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-5.78	1.4e-08	5.57e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
HNSC	cis	rs1864400	0.645	rs10899787	ENSG00000273008.1	RP11-351D16.3	5.78	1.4e-08	5.57e-06	0.36	0.26	Hirschsprung disease;	chr10:43254696	chr10:43136824~43138334:-
HNSC	cis	rs1021993	0.953	rs925077	ENSG00000231648.1	RP11-372M18.2	5.78	1.4e-08	5.57e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209335907	chr1:209367662~209379690:+
HNSC	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	5.78	1.4e-08	5.57e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	5.78	1.4e-08	5.57e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	5.78	1.4e-08	5.57e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
HNSC	cis	rs9329221	0.592	rs7832708	ENSG00000255310.2	AF131215.2	5.78	1.4e-08	5.58e-06	0.24	0.26	Neuroticism;	chr8:10332530	chr8:11107788~11109726:-
HNSC	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-5.78	1.4e-08	5.58e-06	-0.26	-0.26	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
HNSC	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	5.78	1.4e-08	5.58e-06	0.32	0.26	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs9312661	ENSG00000249700.7	SRD5A3-AS1	5.78	1.4e-08	5.58e-06	0.3	0.26	Height;	chr4:55476159	chr4:55363971~55395847:-
HNSC	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-5.78	1.4e-08	5.58e-06	-0.21	-0.26	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
HNSC	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	5.78	1.4e-08	5.59e-06	0.33	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-5.78	1.4e-08	5.59e-06	-0.17	-0.26	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
HNSC	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-5.78	1.4e-08	5.6e-06	-0.34	-0.26	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
HNSC	cis	rs14027	0.883	rs1433953	ENSG00000279347.1	RP11-85I17.2	-5.78	1.4e-08	5.6e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119838736~119840385:-
HNSC	cis	rs3206736	0.548	rs1637675	ENSG00000197085.10	NPSR1-AS1	-5.78	1.4e-08	5.6e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34960880	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs1637676	ENSG00000197085.10	NPSR1-AS1	-5.78	1.4e-08	5.6e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34960947	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.514	rs1637679	ENSG00000197085.10	NPSR1-AS1	-5.78	1.4e-08	5.6e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34961410	chr7:34346512~34871582:-
HNSC	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	5.78	1.4e-08	5.6e-06	0.35	0.26	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
HNSC	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-5.78	1.4e-08	5.6e-06	-0.3	-0.26	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
HNSC	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	5.78	1.4e-08	5.6e-06	0.31	0.26	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
HNSC	cis	rs9341808	0.519	rs676311	ENSG00000272129.1	RP11-250B2.6	-5.78	1.4e-08	5.61e-06	-0.31	-0.26	Sitting height ratio;	chr6:80280033	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	5.78	1.4e-08	5.61e-06	0.32	0.26	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
HNSC	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	5.78	1.41e-08	5.61e-06	0.3	0.26	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
HNSC	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	5.78	1.41e-08	5.61e-06	0.31	0.26	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
HNSC	cis	rs7615952	0.673	rs9841194	ENSG00000248787.1	RP11-666A20.4	-5.78	1.41e-08	5.61e-06	-0.47	-0.26	Blood pressure (smoking interaction);	chr3:125916896	chr3:125908005~125910272:-
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	5.77	1.41e-08	5.61e-06	0.28	0.26	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
HNSC	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.77	1.41e-08	5.61e-06	0.35	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
HNSC	cis	rs4218	0.593	rs8040456	ENSG00000259732.1	RP11-59H7.3	-5.77	1.41e-08	5.62e-06	-0.35	-0.26	Social communication problems;	chr15:59063904	chr15:59121034~59133250:+
HNSC	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	5.77	1.41e-08	5.62e-06	0.25	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
HNSC	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	5.77	1.41e-08	5.63e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
HNSC	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
HNSC	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28074687	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28076559	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28076704	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28078391	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28080757	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28080760	chr6:28161781~28169594:+
HNSC	cis	rs8054556	0.787	rs12444108	ENSG00000183604.13	SMG1P5	-5.77	1.41e-08	5.64e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30267553~30335374:-
HNSC	cis	rs60617249	0.507	rs71540279	ENSG00000228204.2	RP4-724E13.2	5.77	1.42e-08	5.65e-06	0.32	0.26	Major depression and alcohol dependence;	chr7:50909215	chr7:50866747~51022990:+
HNSC	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	5.77	1.42e-08	5.65e-06	0.34	0.26	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
HNSC	cis	rs7402982	0.625	rs4966011	ENSG00000278022.1	RP11-35O15.2	-5.77	1.42e-08	5.65e-06	-0.3	-0.26	Birth weight;	chr15:98660777	chr15:98660210~98660668:+
HNSC	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	5.77	1.42e-08	5.65e-06	0.32	0.26	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
HNSC	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-5.77	1.42e-08	5.65e-06	-0.28	-0.26	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-5.77	1.42e-08	5.66e-06	-0.31	-0.26	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
HNSC	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	5.77	1.42e-08	5.67e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
HNSC	cis	rs4948102	0.642	rs4948104	ENSG00000226278.1	PSPHP1	-5.77	1.42e-08	5.67e-06	-0.29	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55764797~55773288:+
HNSC	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-5.77	1.42e-08	5.67e-06	-0.31	-0.26	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-5.77	1.42e-08	5.67e-06	-0.31	-0.26	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-5.77	1.43e-08	5.69e-06	-0.31	-0.26	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
HNSC	cis	rs597539	0.727	rs632984	ENSG00000250508.1	RP11-757G1.6	-5.77	1.43e-08	5.69e-06	-0.37	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68852803	chr11:68870664~68874542:+
HNSC	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-5.77	1.43e-08	5.69e-06	-0.35	-0.26	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
HNSC	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-5.77	1.43e-08	5.69e-06	-0.34	-0.26	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
HNSC	cis	rs17507216	0.718	rs72751662	ENSG00000255769.6	GOLGA2P10	-5.77	1.43e-08	5.71e-06	-0.42	-0.26	Excessive daytime sleepiness;	chr15:82594705	chr15:82472993~82513950:-
HNSC	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	5.77	1.43e-08	5.71e-06	0.29	0.26	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
HNSC	cis	rs10446497	0.585	rs13074050	ENSG00000272359.1	U4	5.77	1.43e-08	5.71e-06	0.31	0.26	Schizophrenia;	chr3:196816270	chr3:196747192~196747324:-
HNSC	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	5.77	1.43e-08	5.71e-06	0.32	0.26	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
HNSC	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.43e-08	5.72e-06	-0.32	-0.26	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	5.77	1.43e-08	5.72e-06	0.32	0.26	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
HNSC	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	5.77	1.44e-08	5.72e-06	0.28	0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
HNSC	cis	rs7819412	0.805	rs4333549	ENSG00000269918.1	AF131215.9	-5.77	1.44e-08	5.72e-06	-0.26	-0.26	Triglycerides;	chr8:11122051	chr8:11104691~11106704:-
HNSC	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.44e-08	5.73e-06	-0.32	-0.26	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.44e-08	5.73e-06	-0.32	-0.26	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.44e-08	5.73e-06	-0.32	-0.26	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
HNSC	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-5.77	1.44e-08	5.73e-06	-0.37	-0.26	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
HNSC	cis	rs7630852	1	rs7630852	ENSG00000272359.1	U4	-5.77	1.44e-08	5.74e-06	-0.28	-0.26	Eosinophil counts;	chr3:196781680	chr3:196747192~196747324:-
HNSC	cis	rs11846409	0.655	rs79296226	ENSG00000211974.3	IGHV2-70	5.77	1.44e-08	5.74e-06	0.3	0.26	Rheumatic heart disease;	chr14:106650436	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.587	rs11624678	ENSG00000211974.3	IGHV2-70	5.77	1.44e-08	5.74e-06	0.31	0.26	Alzheimer's disease (late onset);	chr14:106650408	chr14:106723574~106724093:-
HNSC	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-5.77	1.44e-08	5.74e-06	-0.37	-0.26	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
HNSC	cis	rs2880765	0.714	rs6497187	ENSG00000259295.5	CSPG4P12	5.77	1.44e-08	5.75e-06	0.3	0.26	Coronary artery disease;	chr15:85468119	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs6497191	ENSG00000259295.5	CSPG4P12	5.77	1.44e-08	5.75e-06	0.3	0.26	Coronary artery disease;	chr15:85468270	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs6416598	ENSG00000259295.5	CSPG4P12	5.77	1.44e-08	5.75e-06	0.3	0.26	Coronary artery disease;	chr15:85468617	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
HNSC	cis	rs75422866	0.85	rs73111220	ENSG00000257433.4	RP1-197B17.3	5.77	1.44e-08	5.75e-06	0.68	0.26	Pneumonia;	chr12:47578764	chr12:47706085~47742294:+
HNSC	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	5.77	1.45e-08	5.76e-06	0.33	0.26	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
HNSC	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	5.77	1.45e-08	5.76e-06	0.32	0.26	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
HNSC	cis	rs1021993	1	rs2660642	ENSG00000231648.1	RP11-372M18.2	5.77	1.45e-08	5.76e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209321498	chr1:209367662~209379690:+
HNSC	cis	rs1021993	1	rs1027823	ENSG00000231648.1	RP11-372M18.2	5.77	1.45e-08	5.76e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209338109	chr1:209367662~209379690:+
HNSC	cis	rs1021993	1	rs1027821	ENSG00000231648.1	RP11-372M18.2	5.77	1.45e-08	5.76e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209338541	chr1:209367662~209379690:+
HNSC	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	5.77	1.45e-08	5.76e-06	0.39	0.26	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
HNSC	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	5.77	1.45e-08	5.76e-06	0.31	0.26	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
HNSC	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	5.77	1.45e-08	5.77e-06	0.29	0.26	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000254340.1	RP11-10A14.3	5.77	1.45e-08	5.77e-06	0.32	0.26	Mood instability;	chr8:8865165	chr8:9141424~9145435:+
HNSC	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	5.77	1.45e-08	5.78e-06	0.36	0.26	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
HNSC	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	5.77	1.45e-08	5.78e-06	0.26	0.26	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
HNSC	cis	rs13113518	1	rs13122619	ENSG00000249700.7	SRD5A3-AS1	5.77	1.45e-08	5.78e-06	0.3	0.26	Height;	chr4:55479339	chr4:55363971~55395847:-
HNSC	cis	rs7617773	0.563	rs62263035	ENSG00000228638.1	FCF1P2	-5.77	1.45e-08	5.78e-06	-0.23	-0.26	Coronary artery disease;	chr3:48350079	chr3:48290793~48291375:-
HNSC	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-5.77	1.45e-08	5.78e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-5.77	1.45e-08	5.78e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
HNSC	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	5.77	1.45e-08	5.78e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	5.77	1.45e-08	5.78e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	5.77	1.45e-08	5.78e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
HNSC	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-5.77	1.45e-08	5.79e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
HNSC	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	5.77	1.46e-08	5.8e-06	0.32	0.26	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
HNSC	cis	rs13113518	1	rs55699500	ENSG00000249700.7	SRD5A3-AS1	5.77	1.46e-08	5.8e-06	0.31	0.26	Height;	chr4:55540912	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs56362210	ENSG00000249700.7	SRD5A3-AS1	5.77	1.46e-08	5.8e-06	0.31	0.26	Height;	chr4:55540972	chr4:55363971~55395847:-
HNSC	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	5.77	1.46e-08	5.81e-06	0.24	0.26	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
HNSC	cis	rs67180937	0.535	rs3008615	ENSG00000272750.1	RP11-378J18.8	5.77	1.46e-08	5.81e-06	0.34	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623242	chr1:222658867~222661512:-
HNSC	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-5.77	1.46e-08	5.81e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
HNSC	cis	rs454422	1	rs6053816	ENSG00000275632.1	RP5-967N21.11	5.77	1.46e-08	5.82e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5990104	chr20:6000418~6000941:+
HNSC	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	5.77	1.46e-08	5.82e-06	0.33	0.26	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
HNSC	cis	rs2286503	0.78	rs2286506	ENSG00000221740.1	SNORD93	5.77	1.46e-08	5.83e-06	0.29	0.26	Fibrinogen;	chr7:22815196	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.752	rs2286504	ENSG00000221740.1	SNORD93	5.77	1.46e-08	5.83e-06	0.29	0.26	Fibrinogen;	chr7:22815228	chr7:22856613~22856686:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000235689.1	AP000351.13	5.77	1.47e-08	5.83e-06	0.26	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:24006305~24008258:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000235689.1	AP000351.13	5.77	1.47e-08	5.83e-06	0.26	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:24006305~24008258:-
HNSC	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-5.77	1.47e-08	5.83e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
HNSC	cis	rs6504622	0.967	rs9889762	ENSG00000262879.4	RP11-156P1.3	5.77	1.47e-08	5.83e-06	0.27	0.26	Orofacial clefts;	chr17:46949000	chr17:46984045~47100323:-
HNSC	cis	rs2483058	0.767	rs61817176	ENSG00000261000.1	RP11-534L20.5	5.77	1.47e-08	5.84e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206447682	chr1:206503948~206504456:+
HNSC	cis	rs13113518	0.812	rs13107810	ENSG00000273257.1	RP11-177J6.1	5.77	1.47e-08	5.84e-06	0.32	0.26	Height;	chr4:55542243	chr4:55387949~55388271:+
HNSC	cis	rs1799949	0.827	rs74252763	ENSG00000267151.3	RP11-100E5.2	5.77	1.47e-08	5.85e-06	0.34	0.26	Menopause (age at onset);	chr17:43324652	chr17:43444707~43451200:+
HNSC	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	5.77	1.47e-08	5.85e-06	0.25	0.26	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
HNSC	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	5.77	1.47e-08	5.85e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	5.77	1.47e-08	5.85e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
HNSC	cis	rs67981189	0.558	rs56043821	ENSG00000274818.1	RP1-292L20.3	5.77	1.47e-08	5.85e-06	0.32	0.26	Schizophrenia;	chr14:71103835	chr14:70906657~70907111:-
HNSC	cis	rs2108622	0.628	rs11086005	ENSG00000267453.5	AC004791.2	-5.77	1.47e-08	5.85e-06	-0.32	-0.26	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864286	chr19:15851993~15864904:-
HNSC	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.47e-08	5.85e-06	-0.32	-0.26	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
HNSC	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-5.77	1.47e-08	5.86e-06	-0.42	-0.26	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
HNSC	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-5.77	1.47e-08	5.86e-06	-0.33	-0.26	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
HNSC	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-5.77	1.47e-08	5.86e-06	-0.29	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
HNSC	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	5.77	1.47e-08	5.86e-06	0.31	0.26	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
HNSC	cis	rs6951245	1	rs11764748	ENSG00000225146.1	AC073957.15	-5.77	1.48e-08	5.87e-06	-0.42	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1029025~1043891:+
HNSC	cis	rs2842992	0.692	rs9347342	ENSG00000237927.1	RP3-393E18.2	-5.77	1.48e-08	5.87e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159586955~159589169:-
HNSC	cis	rs867371	0.929	rs7173852	ENSG00000276710.3	CSPG4P8	-5.77	1.48e-08	5.87e-06	-0.29	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82459472~82477258:+
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000254340.1	RP11-10A14.3	5.77	1.48e-08	5.88e-06	0.31	0.26	Mood instability;	chr8:8933634	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	5.77	1.48e-08	5.88e-06	0.28	0.26	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
HNSC	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	5.77	1.48e-08	5.89e-06	0.32	0.26	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
HNSC	cis	rs853679	0.769	rs17720293	ENSG00000219392.1	RP1-265C24.5	-5.77	1.48e-08	5.89e-06	-0.45	-0.26	Depression;	chr6:28246920	chr6:28115628~28116551:+
HNSC	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	5.77	1.48e-08	5.9e-06	0.34	0.26	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
HNSC	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-5.77	1.48e-08	5.9e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
HNSC	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-5.77	1.48e-08	5.9e-06	-0.35	-0.26	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
HNSC	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	5.76	1.49e-08	5.91e-06	0.33	0.26	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
HNSC	cis	rs10435719	0.764	rs10103485	ENSG00000206014.6	OR7E161P	-5.76	1.49e-08	5.92e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:11928597~11929563:-
HNSC	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	5.76	1.49e-08	5.92e-06	0.27	0.26	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
HNSC	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	5.76	1.49e-08	5.92e-06	0.63	0.26	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
HNSC	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	5.76	1.49e-08	5.92e-06	0.63	0.26	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
HNSC	cis	rs13113518	1	rs10462032	ENSG00000273257.1	RP11-177J6.1	5.76	1.49e-08	5.93e-06	0.31	0.26	Height;	chr4:55479069	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	5.76	1.49e-08	5.93e-06	0.32	0.26	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
HNSC	cis	rs75422866	0.51	rs35784744	ENSG00000276691.1	RP5-1057I20.5	5.76	1.49e-08	5.93e-06	0.45	0.26	Pneumonia;	chr12:47729646	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.541	rs12425816	ENSG00000276691.1	RP5-1057I20.5	5.76	1.49e-08	5.93e-06	0.45	0.26	Pneumonia;	chr12:47731419	chr12:47788426~47788971:+
HNSC	cis	rs2579103	0.867	rs10735280	ENSG00000258183.4	RP11-753N8.1	-5.76	1.49e-08	5.93e-06	-0.31	-0.26	Body mass index;	chr12:90248932	chr12:90280894~90300340:+
HNSC	cis	rs9840812	0.861	rs645040	ENSG00000239213.4	NCK1-AS1	-5.76	1.49e-08	5.93e-06	-0.24	-0.26	Fibrinogen levels;	chr3:136207780	chr3:136841726~136862054:-
HNSC	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-5.76	1.49e-08	5.94e-06	-0.41	-0.26	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
HNSC	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102426252	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102427407	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102427715	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102431747	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102432120	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102432614	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102433405	chr2:102438713~102440475:+
HNSC	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	5.76	1.5e-08	5.94e-06	0.35	0.26	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
HNSC	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	5.76	1.5e-08	5.95e-06	0.29	0.26	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
HNSC	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	5.76	1.5e-08	5.95e-06	0.36	0.26	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
HNSC	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	5.76	1.5e-08	5.95e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	5.76	1.5e-08	5.95e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
HNSC	cis	rs804280	0.542	rs34117651	ENSG00000206014.6	OR7E161P	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934108	chr8:11928597~11929563:-
HNSC	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
HNSC	cis	rs2439831	0.867	rs28729853	ENSG00000205771.5	CATSPER2P1	-5.76	1.5e-08	5.96e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43381482	chr15:43726918~43747094:-
HNSC	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
HNSC	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	5.76	1.5e-08	5.96e-06	0.32	0.26	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	5.76	1.5e-08	5.96e-06	0.32	0.26	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	5.76	1.5e-08	5.97e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
HNSC	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-5.76	1.5e-08	5.97e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
HNSC	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-5.76	1.5e-08	5.97e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
HNSC	cis	rs2976388	0.507	rs2572874	ENSG00000253741.1	CTD-2292P10.4	-5.76	1.51e-08	5.98e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142755801	chr8:142702252~142726973:-
HNSC	cis	rs3206736	0.548	rs328939	ENSG00000197085.10	NPSR1-AS1	-5.76	1.51e-08	5.98e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35010615	chr7:34346512~34871582:-
HNSC	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	5.76	1.51e-08	5.98e-06	0.47	0.26	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
HNSC	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-5.76	1.51e-08	5.98e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
HNSC	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	5.76	1.51e-08	5.98e-06	0.37	0.26	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	5.76	1.51e-08	5.98e-06	0.28	0.26	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
HNSC	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-5.76	1.51e-08	5.98e-06	-0.35	-0.26	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
HNSC	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-5.76	1.51e-08	5.99e-06	-0.29	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
HNSC	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-5.76	1.51e-08	5.99e-06	-0.33	-0.26	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
HNSC	cis	rs9341808	0.538	rs623048	ENSG00000272129.1	RP11-250B2.6	-5.76	1.51e-08	6e-06	-0.3	-0.26	Sitting height ratio;	chr6:80272199	chr6:80355424~80356859:+
HNSC	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-5.76	1.51e-08	6e-06	-0.44	-0.26	Depression;	chr6:28159062	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.932	rs6931735	ENSG00000231028.7	LINC00271	-5.76	1.52e-08	6.01e-06	-0.3	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135303673	chr6:135497801~135716055:+
HNSC	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	5.76	1.52e-08	6.02e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
HNSC	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	5.76	1.52e-08	6.03e-06	0.31	0.26	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
HNSC	cis	rs5753618	0.561	rs5753609	ENSG00000236132.1	CTA-440B3.1	-5.76	1.52e-08	6.03e-06	-0.3	-0.26	Colorectal cancer;	chr22:31423226	chr22:31816379~31817491:-
HNSC	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-5.76	1.52e-08	6.03e-06	-0.36	-0.26	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
HNSC	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-5.76	1.52e-08	6.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	5.76	1.52e-08	6.03e-06	0.32	0.26	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	5.76	1.52e-08	6.03e-06	0.32	0.26	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
HNSC	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-5.76	1.52e-08	6.04e-06	-0.35	-0.26	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
HNSC	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	5.76	1.52e-08	6.04e-06	0.37	0.26	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
HNSC	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-5.76	1.53e-08	6.05e-06	-0.33	-0.26	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
HNSC	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	5.76	1.53e-08	6.05e-06	0.33	0.26	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
HNSC	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-5.76	1.53e-08	6.05e-06	-0.29	-0.26	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
HNSC	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-5.76	1.53e-08	6.05e-06	-0.33	-0.26	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
HNSC	cis	rs7615952	0.673	rs9289270	ENSG00000248787.1	RP11-666A20.4	-5.76	1.53e-08	6.05e-06	-0.47	-0.26	Blood pressure (smoking interaction);	chr3:125918136	chr3:125908005~125910272:-
HNSC	cis	rs526231	0.718	rs402962	ENSG00000175749.11	EIF3KP1	5.76	1.53e-08	6.06e-06	0.32	0.26	Primary biliary cholangitis;	chr5:103288307	chr5:103032376~103033031:+
HNSC	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	5.76	1.53e-08	6.07e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
HNSC	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	5.76	1.54e-08	6.08e-06	0.31	0.26	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
HNSC	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	5.76	1.54e-08	6.08e-06	0.4	0.26	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
HNSC	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	5.76	1.54e-08	6.09e-06	0.3	0.26	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
HNSC	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-5.76	1.54e-08	6.09e-06	-0.3	-0.26	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
HNSC	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	5.76	1.54e-08	6.09e-06	0.27	0.26	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
HNSC	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	5.76	1.54e-08	6.09e-06	0.47	0.26	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
HNSC	cis	rs8054556	0.787	rs11642612	ENSG00000183604.13	SMG1P5	-5.76	1.54e-08	6.09e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30267553~30335374:-
HNSC	cis	rs8054556	0.787	rs11150581	ENSG00000183604.13	SMG1P5	-5.76	1.54e-08	6.09e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30267553~30335374:-
HNSC	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	5.76	1.54e-08	6.1e-06	0.28	0.26	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	5.76	1.54e-08	6.1e-06	0.28	0.26	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	5.76	1.54e-08	6.1e-06	0.28	0.26	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
HNSC	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	5.76	1.54e-08	6.11e-06	0.34	0.26	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	5.76	1.54e-08	6.11e-06	0.34	0.26	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
HNSC	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	5.76	1.54e-08	6.11e-06	0.35	0.26	Height;	chr6:109530435	chr6:109382795~109383666:+
HNSC	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-5.76	1.54e-08	6.11e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
HNSC	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	5.76	1.55e-08	6.12e-06	0.26	0.26	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	5.76	1.55e-08	6.12e-06	0.26	0.26	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
HNSC	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-5.76	1.55e-08	6.12e-06	-0.34	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
HNSC	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	5.76	1.55e-08	6.12e-06	0.3	0.26	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	5.76	1.55e-08	6.12e-06	0.3	0.26	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
HNSC	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	5.76	1.55e-08	6.13e-06	0.28	0.26	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
HNSC	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-5.76	1.55e-08	6.13e-06	-0.23	-0.26	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
HNSC	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-5.76	1.55e-08	6.13e-06	-0.37	-0.26	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
HNSC	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	5.76	1.55e-08	6.14e-06	0.33	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
HNSC	cis	rs4218	0.689	rs60262196	ENSG00000277144.1	RP11-59H7.4	-5.76	1.55e-08	6.15e-06	-0.36	-0.26	Social communication problems;	chr15:59088853	chr15:59115547~59116089:-
HNSC	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-5.76	1.55e-08	6.15e-06	-0.3	-0.26	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
HNSC	cis	rs35306767	0.953	rs12354639	ENSG00000229869.1	RP11-363N22.2	-5.76	1.55e-08	6.15e-06	-0.34	-0.26	Eosinophil percentage of granulocytes;	chr10:917741	chr10:933026~942743:+
HNSC	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-5.76	1.55e-08	6.15e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
HNSC	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-5.76	1.56e-08	6.16e-06	-0.23	-0.26	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
HNSC	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-5.76	1.56e-08	6.16e-06	-0.36	-0.26	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
HNSC	cis	rs2243480	1	rs1618893	ENSG00000179406.6	LINC00174	-5.76	1.56e-08	6.16e-06	-0.5	-0.26	Diabetic kidney disease;	chr7:66631132	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28123153	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28124529	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28127577	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28131566	chr6:28161781~28169594:+
HNSC	cis	rs7630852	0.965	rs4256169	ENSG00000272359.1	U4	-5.76	1.56e-08	6.16e-06	-0.28	-0.26	Eosinophil counts;	chr3:196785852	chr3:196747192~196747324:-
HNSC	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-5.76	1.56e-08	6.17e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
HNSC	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	5.76	1.56e-08	6.17e-06	0.26	0.26	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
HNSC	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-5.76	1.56e-08	6.17e-06	-0.32	-0.26	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-5.76	1.56e-08	6.17e-06	-0.4	-0.26	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-5.76	1.56e-08	6.17e-06	-0.4	-0.26	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-5.76	1.56e-08	6.17e-06	-0.4	-0.26	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
HNSC	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-5.76	1.56e-08	6.17e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
HNSC	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-5.76	1.56e-08	6.18e-06	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
HNSC	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	5.76	1.56e-08	6.18e-06	0.36	0.26	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
HNSC	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-5.76	1.56e-08	6.18e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
HNSC	cis	rs4218	0.543	rs11852461	ENSG00000259732.1	RP11-59H7.3	-5.76	1.56e-08	6.18e-06	-0.33	-0.26	Social communication problems;	chr15:59021728	chr15:59121034~59133250:+
HNSC	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-5.76	1.56e-08	6.18e-06	-0.37	-0.26	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
HNSC	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-5.76	1.57e-08	6.19e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000254340.1	RP11-10A14.3	5.76	1.57e-08	6.19e-06	0.31	0.26	Mood instability;	chr8:8783635	chr8:9141424~9145435:+
HNSC	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	5.76	1.57e-08	6.19e-06	0.3	0.26	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
HNSC	cis	rs2006771	0.765	rs6518752	ENSG00000236132.1	CTA-440B3.1	-5.76	1.57e-08	6.2e-06	-0.28	-0.26	Nonsyndromic cleft lip with cleft palate;	chr22:31603141	chr22:31816379~31817491:-
HNSC	cis	rs2337406	0.587	rs916547	ENSG00000211974.3	IGHV2-70	-5.76	1.57e-08	6.2e-06	-0.3	-0.26	Alzheimer's disease (late onset);	chr14:106646735	chr14:106723574~106724093:-
HNSC	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-5.76	1.57e-08	6.21e-06	-0.3	-0.26	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
HNSC	cis	rs6604026	0.555	rs11591094	ENSG00000223787.2	RP4-593M8.1	5.75	1.57e-08	6.21e-06	0.36	0.26	Multiple sclerosis;	chr1:92649899	chr1:92580476~92580821:-
HNSC	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	5.75	1.57e-08	6.22e-06	0.27	0.26	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
HNSC	cis	rs8054556	0.708	rs2278557	ENSG00000183604.13	SMG1P5	-5.75	1.57e-08	6.22e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30082458	chr16:30267553~30335374:-
HNSC	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-5.75	1.58e-08	6.22e-06	-0.3	-0.26	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
HNSC	cis	rs75920871	0.528	rs1241655	ENSG00000254851.1	RP11-109L13.1	5.75	1.58e-08	6.23e-06	0.36	0.26	Subjective well-being;	chr11:116967092	chr11:117135528~117138582:+
HNSC	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	5.75	1.58e-08	6.23e-06	0.31	0.26	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
HNSC	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	5.75	1.58e-08	6.25e-06	0.39	0.26	Height;	chr6:109479488	chr6:109382795~109383666:+
HNSC	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-5.75	1.58e-08	6.25e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-5.75	1.58e-08	6.25e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-5.75	1.58e-08	6.25e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
HNSC	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-5.75	1.58e-08	6.26e-06	-0.34	-0.26	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
HNSC	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	5.75	1.59e-08	6.26e-06	0.34	0.26	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
HNSC	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-5.75	1.59e-08	6.26e-06	-0.32	-0.26	Depression;	chr6:28096077	chr6:28161781~28169594:+
HNSC	cis	rs2898681	0.618	rs7677726	ENSG00000248375.1	RP11-177B4.1	5.75	1.59e-08	6.26e-06	0.48	0.26	Optic nerve measurement (cup area);	chr4:52873095	chr4:52720081~52720831:-
HNSC	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-5.75	1.59e-08	6.26e-06	-0.3	-0.26	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
HNSC	cis	rs867371	0.502	rs7176926	ENSG00000276710.3	CSPG4P8	-5.75	1.59e-08	6.27e-06	-0.27	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82459472~82477258:+
HNSC	cis	rs2243480	1	rs4718334	ENSG00000179406.6	LINC00174	5.75	1.59e-08	6.27e-06	0.54	0.26	Diabetic kidney disease;	chr7:66324467	chr7:66376044~66401338:-
HNSC	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	5.75	1.59e-08	6.27e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	5.75	1.59e-08	6.27e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
HNSC	cis	rs7819412	0.775	rs34094119	ENSG00000269918.1	AF131215.9	-5.75	1.59e-08	6.27e-06	-0.25	-0.26	Triglycerides;	chr8:11078388	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	5.75	1.59e-08	6.28e-06	0.32	0.26	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
HNSC	cis	rs6951245	0.572	rs80133931	ENSG00000224079.1	AC091729.7	-5.75	1.59e-08	6.28e-06	-0.56	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:987650	chr7:1074450~1078036:+
HNSC	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	5.75	1.59e-08	6.28e-06	0.35	0.26	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	5.75	1.59e-08	6.28e-06	0.21	0.26	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
HNSC	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	5.75	1.59e-08	6.28e-06	0.32	0.26	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
HNSC	cis	rs35955747	0.722	rs5997898	ENSG00000236132.1	CTA-440B3.1	5.75	1.59e-08	6.29e-06	0.28	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31176977	chr22:31816379~31817491:-
HNSC	cis	rs73198271	0.737	rs506960	ENSG00000253893.2	FAM85B	5.75	1.59e-08	6.29e-06	0.34	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8167819~8226614:-
HNSC	cis	rs4141404	0.816	rs5749227	ENSG00000236132.1	CTA-440B3.1	5.75	1.6e-08	6.3e-06	0.36	0.26	Paclitaxel-induced neuropathy;	chr22:31185180	chr22:31816379~31817491:-
HNSC	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	5.75	1.6e-08	6.3e-06	0.35	0.26	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
HNSC	cis	rs4218	0.648	rs12915899	ENSG00000277144.1	RP11-59H7.4	-5.75	1.6e-08	6.31e-06	-0.35	-0.26	Social communication problems;	chr15:59084332	chr15:59115547~59116089:-
HNSC	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	5.75	1.6e-08	6.31e-06	0.34	0.26	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
HNSC	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-5.75	1.6e-08	6.31e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000233609.3	RP11-62H7.2	5.75	1.6e-08	6.31e-06	0.25	0.26	Joint mobility (Beighton score);	chr8:8970227	chr8:8961200~8979025:+
HNSC	cis	rs2483058	0.796	rs11120291	ENSG00000261000.1	RP11-534L20.5	5.75	1.6e-08	6.31e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206442751	chr1:206503948~206504456:+
HNSC	cis	rs75920871	0.528	rs11216240	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117028532	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs11216241	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117028533	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs11600552	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117030231	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs7941428	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117032668	chr11:117135528~117138582:+
HNSC	cis	rs35306767	0.953	rs34405399	ENSG00000229869.1	RP11-363N22.2	-5.75	1.6e-08	6.32e-06	-0.34	-0.26	Eosinophil percentage of granulocytes;	chr10:935075	chr10:933026~942743:+
HNSC	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-5.75	1.6e-08	6.33e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
HNSC	cis	rs7819412	0.775	rs4841489	ENSG00000269918.1	AF131215.9	-5.75	1.6e-08	6.33e-06	-0.25	-0.26	Triglycerides;	chr8:11079301	chr8:11104691~11106704:-
HNSC	cis	rs7819412	0.775	rs4841490	ENSG00000269918.1	AF131215.9	-5.75	1.6e-08	6.33e-06	-0.25	-0.26	Triglycerides;	chr8:11079381	chr8:11104691~11106704:-
HNSC	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-5.75	1.61e-08	6.34e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
HNSC	cis	rs2985684	1	rs2985696	ENSG00000258568.1	RHOQP1	5.75	1.61e-08	6.34e-06	0.27	0.26	Carotid intima media thickness;	chr14:49628195	chr14:49599994~49600572:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	5.75	1.61e-08	6.34e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-5.75	1.61e-08	6.34e-06	-0.28	-0.26	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
HNSC	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-5.75	1.61e-08	6.35e-06	-0.37	-0.26	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
HNSC	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	5.75	1.61e-08	6.35e-06	0.31	0.26	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
HNSC	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-5.75	1.61e-08	6.36e-06	-0.36	-0.26	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
HNSC	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
HNSC	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
HNSC	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-5.75	1.62e-08	6.37e-06	-0.29	-0.26	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
HNSC	cis	rs14027	0.883	rs13255850	ENSG00000279347.1	RP11-85I17.2	-5.75	1.62e-08	6.38e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119838736~119840385:-
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-5.75	1.62e-08	6.38e-06	-0.31	-0.26	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
HNSC	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	5.75	1.62e-08	6.39e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
HNSC	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-5.75	1.62e-08	6.39e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
HNSC	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	5.75	1.62e-08	6.4e-06	0.23	0.26	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
HNSC	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	5.75	1.62e-08	6.4e-06	0.35	0.26	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
HNSC	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	5.75	1.62e-08	6.4e-06	0.34	0.26	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
HNSC	cis	rs9987353	0.518	rs4841110	ENSG00000254340.1	RP11-10A14.3	5.75	1.63e-08	6.4e-06	0.33	0.26	Recombination measurement;	chr8:9228513	chr8:9141424~9145435:+
HNSC	cis	rs2179367	0.632	rs9498324	ENSG00000216906.2	RP11-350J20.9	5.75	1.63e-08	6.4e-06	0.38	0.26	Dupuytren's disease;	chr6:149338973	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs55826712	ENSG00000216906.2	RP11-350J20.9	5.75	1.63e-08	6.4e-06	0.38	0.26	Dupuytren's disease;	chr6:149344716	chr6:149904243~149906418:+
HNSC	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	5.75	1.63e-08	6.41e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	5.75	1.63e-08	6.41e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
HNSC	cis	rs4140799	0.78	rs10137642	ENSG00000266869.1	RP6-114E22.1	-5.75	1.63e-08	6.42e-06	-0.31	-0.26	Neuroticism;	chr14:71738604	chr14:71848606~71908430:+
HNSC	cis	rs4218	0.541	rs1374155	ENSG00000259732.1	RP11-59H7.3	-5.75	1.63e-08	6.43e-06	-0.34	-0.26	Social communication problems;	chr15:59030630	chr15:59121034~59133250:+
HNSC	cis	rs6951245	0.572	rs74791540	ENSG00000224079.1	AC091729.7	-5.75	1.63e-08	6.43e-06	-0.54	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1022277	chr7:1074450~1078036:+
HNSC	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-5.75	1.63e-08	6.43e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
HNSC	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-5.75	1.64e-08	6.44e-06	-0.26	-0.26	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
HNSC	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-5.75	1.64e-08	6.44e-06	-0.48	-0.26	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
HNSC	cis	rs2919917	0.628	rs11776243	ENSG00000254352.1	RP11-578O24.2	5.75	1.64e-08	6.45e-06	0.35	0.26	Lymphocyte counts;	chr8:78648848	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs10110524	ENSG00000254352.1	RP11-578O24.2	5.75	1.64e-08	6.45e-06	0.35	0.26	Lymphocyte counts;	chr8:78648871	chr8:78723796~78724136:-
HNSC	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	5.75	1.64e-08	6.45e-06	0.35	0.26	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	5.75	1.64e-08	6.45e-06	0.35	0.26	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
HNSC	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-5.75	1.64e-08	6.45e-06	-0.27	-0.26	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000211972.2	IGHV3-66	5.75	1.64e-08	6.45e-06	0.21	0.26	Kawasaki disease;	chr14:106803901	chr14:106675017~106675544:-
HNSC	cis	rs17507216	0.591	rs7163848	ENSG00000276710.3	CSPG4P8	-5.75	1.64e-08	6.45e-06	-0.36	-0.26	Excessive daytime sleepiness;	chr15:82729563	chr15:82459472~82477258:+
HNSC	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-5.75	1.64e-08	6.46e-06	-0.33	-0.26	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-5.75	1.64e-08	6.47e-06	-0.31	-0.26	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
HNSC	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-5.75	1.64e-08	6.47e-06	-0.3	-0.26	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-5.75	1.64e-08	6.47e-06	-0.3	-0.26	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-5.75	1.64e-08	6.47e-06	-0.32	-0.26	Depression;	chr6:28071808	chr6:28161781~28169594:+
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-5.75	1.65e-08	6.48e-06	-0.31	-0.26	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-5.75	1.65e-08	6.48e-06	-0.31	-0.26	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
HNSC	cis	rs9914544	1	rs9916245	ENSG00000264885.1	RP11-815I9.4	-5.75	1.65e-08	6.49e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18863512	chr17:18667629~18669461:-
HNSC	cis	rs11089937	1	rs6001121	ENSG00000211638.2	IGLV8-61	-5.75	1.65e-08	6.49e-06	-0.22	-0.26	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22098700~22099212:+
HNSC	cis	rs9341808	0.6	rs668329	ENSG00000272129.1	RP11-250B2.6	-5.75	1.65e-08	6.5e-06	-0.31	-0.26	Sitting height ratio;	chr6:80258861	chr6:80355424~80356859:+
HNSC	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	5.75	1.65e-08	6.51e-06	0.31	0.26	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
HNSC	cis	rs9840812	0.655	rs696516	ENSG00000273486.1	RP11-731C17.2	5.75	1.65e-08	6.51e-06	0.22	0.26	Fibrinogen levels;	chr3:136348936	chr3:136837338~136839021:-
HNSC	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-5.75	1.66e-08	6.51e-06	-0.25	-0.26	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
HNSC	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-5.75	1.66e-08	6.52e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
HNSC	cis	rs3206736	0.548	rs1637673	ENSG00000197085.10	NPSR1-AS1	-5.74	1.66e-08	6.55e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34958238	chr7:34346512~34871582:-
HNSC	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	5.74	1.67e-08	6.55e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	5.74	1.67e-08	6.55e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
HNSC	cis	rs2243480	1	rs2707844	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66594522	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1796220	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66597113	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2707831	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66597524	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs1638731	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66679692	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs1882655	ENSG00000179406.6	LINC00174	5.74	1.67e-08	6.55e-06	0.55	0.26	Gout;	chr7:66682070	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000179406.6	LINC00174	5.74	1.67e-08	6.55e-06	0.55	0.26	Gout;	chr7:66682162	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2659913	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66692349	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2659911	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66693433	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2707838	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66694214	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs60326618	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66701371	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2707830	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66702658	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2707828	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66706390	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66710076	chr7:66376044~66401338:-
HNSC	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-5.74	1.67e-08	6.55e-06	-0.3	-0.26	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-5.74	1.67e-08	6.55e-06	-0.3	-0.26	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-5.74	1.67e-08	6.55e-06	-0.3	-0.26	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
HNSC	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	5.74	1.67e-08	6.56e-06	0.27	0.26	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
HNSC	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	5.74	1.67e-08	6.56e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
HNSC	cis	rs75920871	0.528	rs12274388	ENSG00000254851.1	RP11-109L13.1	5.74	1.67e-08	6.57e-06	0.35	0.26	Subjective well-being;	chr11:117075522	chr11:117135528~117138582:+
HNSC	cis	rs1355223	0.816	rs2136506	ENSG00000271369.1	RP11-350D17.3	-5.74	1.67e-08	6.57e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726713	chr11:34709600~34710161:+
HNSC	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-5.74	1.67e-08	6.57e-06	-0.37	-0.26	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
HNSC	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-5.74	1.67e-08	6.58e-06	-0.32	-0.26	Depression;	chr6:28091242	chr6:28161781~28169594:+
HNSC	cis	rs2235642	0.785	rs1057983	ENSG00000280231.1	LA16c-380F5.3	-5.74	1.68e-08	6.58e-06	-0.31	-0.26	Coronary artery disease;	chr16:1610273	chr16:1553655~1554130:-
HNSC	cis	rs6928977	0.86	rs2746432	ENSG00000234084.1	RP3-388E23.2	5.74	1.68e-08	6.59e-06	0.26	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135375459	chr6:135301568~135307158:+
HNSC	cis	rs9329221	0.617	rs483916	ENSG00000254340.1	RP11-10A14.3	-5.74	1.68e-08	6.59e-06	-0.29	-0.26	Neuroticism;	chr8:9936091	chr8:9141424~9145435:+
HNSC	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-5.74	1.68e-08	6.6e-06	-0.31	-0.26	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
HNSC	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-5.74	1.68e-08	6.62e-06	-0.35	-0.26	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
HNSC	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	5.74	1.69e-08	6.62e-06	0.38	0.26	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-5.74	1.69e-08	6.62e-06	-0.15	-0.26	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
HNSC	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	5.74	1.69e-08	6.62e-06	0.29	0.26	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
HNSC	cis	rs11532322	1	rs11532322	ENSG00000280120.1	RP11-546D6.3	5.74	1.69e-08	6.63e-06	0.22	0.26	Schizophrenia;	chr12:123246876	chr12:123152324~123153377:-
HNSC	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-5.74	1.69e-08	6.63e-06	-0.23	-0.26	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
HNSC	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	5.74	1.69e-08	6.63e-06	0.28	0.26	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
HNSC	cis	rs6604026	0.589	rs67026262	ENSG00000223787.2	RP4-593M8.1	5.74	1.69e-08	6.63e-06	0.36	0.26	Multiple sclerosis;	chr1:92646070	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.589	rs67876779	ENSG00000223787.2	RP4-593M8.1	5.74	1.69e-08	6.63e-06	0.36	0.26	Multiple sclerosis;	chr1:92646308	chr1:92580476~92580821:-
HNSC	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-5.74	1.69e-08	6.63e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-5.74	1.69e-08	6.63e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-5.74	1.69e-08	6.63e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
HNSC	cis	rs13113518	1	rs4865004	ENSG00000249700.7	SRD5A3-AS1	5.74	1.69e-08	6.64e-06	0.3	0.26	Height;	chr4:55515118	chr4:55363971~55395847:-
HNSC	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-5.74	1.69e-08	6.65e-06	-0.51	-0.26	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
HNSC	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-5.74	1.69e-08	6.65e-06	-0.41	-0.26	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
HNSC	cis	rs13113518	1	rs13114841	ENSG00000249700.7	SRD5A3-AS1	5.74	1.69e-08	6.65e-06	0.3	0.26	Height;	chr4:55485974	chr4:55363971~55395847:-
HNSC	cis	rs1355223	0.902	rs12802120	ENSG00000271369.1	RP11-350D17.3	-5.74	1.7e-08	6.66e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726103	chr11:34709600~34710161:+
HNSC	cis	rs1908814	0.516	rs13275143	ENSG00000206014.6	OR7E161P	-5.74	1.7e-08	6.68e-06	-0.28	-0.26	Neuroticism;	chr8:11939481	chr8:11928597~11929563:-
HNSC	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	5.74	1.7e-08	6.68e-06	0.35	0.26	Height;	chr6:109581800	chr6:109382795~109383666:+
HNSC	cis	rs6604026	0.778	rs11164820	ENSG00000223787.2	RP4-593M8.1	-5.74	1.7e-08	6.69e-06	-0.36	-0.26	Multiple sclerosis;	chr1:92815231	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-5.74	1.7e-08	6.69e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-5.74	1.7e-08	6.69e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
HNSC	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.74	1.7e-08	6.69e-06	0.28	0.26	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
HNSC	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	-5.74	1.71e-08	6.69e-06	-0.29	-0.26	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
HNSC	cis	rs75422866	0.51	rs73105829	ENSG00000276691.1	RP5-1057I20.5	5.74	1.71e-08	6.69e-06	0.45	0.26	Pneumonia;	chr12:47734162	chr12:47788426~47788971:+
HNSC	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	5.74	1.71e-08	6.7e-06	0.32	0.26	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
HNSC	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	5.74	1.71e-08	6.71e-06	0.37	0.26	Height;	chr6:109737797	chr6:109382795~109383666:+
HNSC	cis	rs2483058	0.767	rs2336938	ENSG00000261000.1	RP11-534L20.5	5.74	1.71e-08	6.71e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206445453	chr1:206503948~206504456:+
HNSC	cis	rs1012068	0.686	rs4820996	ENSG00000236132.1	CTA-440B3.1	-5.74	1.71e-08	6.72e-06	-0.3	-0.26	Chronic hepatitis C infection;	chr22:31928044	chr22:31816379~31817491:-
HNSC	cis	rs2179367	0.586	rs62426088	ENSG00000216906.2	RP11-350J20.9	5.74	1.72e-08	6.73e-06	0.38	0.26	Dupuytren's disease;	chr6:149339301	chr6:149904243~149906418:+
HNSC	cis	rs2579103	0.898	rs2579119	ENSG00000258183.4	RP11-753N8.1	-5.74	1.72e-08	6.73e-06	-0.31	-0.26	Body mass index;	chr12:90212163	chr12:90280894~90300340:+
HNSC	cis	rs9813712	0.953	rs6782280	ENSG00000249846.5	RP11-77P16.4	5.74	1.72e-08	6.73e-06	0.31	0.26	Response to amphetamines;	chr3:130245370	chr3:130112550~130120579:+
HNSC	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	5.74	1.72e-08	6.74e-06	0.28	0.26	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
HNSC	cis	rs858239	0.669	rs1990365	ENSG00000226816.2	AC005082.12	5.74	1.72e-08	6.75e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23206013~23208045:+
HNSC	cis	rs4664293	0.764	rs1425044	ENSG00000226266.5	AC009961.3	-5.74	1.72e-08	6.75e-06	-0.27	-0.26	Monocyte percentage of white cells;	chr2:159618426	chr2:159670708~159712435:-
HNSC	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-5.74	1.72e-08	6.75e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
HNSC	cis	rs1021993	0.556	rs2153043	ENSG00000231648.1	RP11-372M18.2	5.74	1.72e-08	6.75e-06	0.36	0.26	Gut microbiome composition (winter);	chr1:209252959	chr1:209367662~209379690:+
HNSC	cis	rs9341808	0.519	rs3805878	ENSG00000272129.1	RP11-250B2.6	5.74	1.72e-08	6.76e-06	0.3	0.26	Sitting height ratio;	chr6:80304138	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000233609.3	RP11-62H7.2	-5.74	1.72e-08	6.76e-06	-0.25	-0.26	Mood instability;	chr8:8938391	chr8:8961200~8979025:+
HNSC	cis	rs13113518	1	rs1047354	ENSG00000249700.7	SRD5A3-AS1	5.74	1.72e-08	6.76e-06	0.3	0.26	Height;	chr4:55429416	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs1056547	ENSG00000249700.7	SRD5A3-AS1	5.74	1.72e-08	6.76e-06	0.3	0.26	Height;	chr4:55430596	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs6828570	ENSG00000249700.7	SRD5A3-AS1	5.74	1.72e-08	6.76e-06	0.3	0.26	Height;	chr4:55431595	chr4:55363971~55395847:-
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000179406.6	LINC00174	-5.74	1.72e-08	6.76e-06	-0.34	-0.26	Calcium levels;	chr7:65829754	chr7:66376044~66401338:-
HNSC	cis	rs62344088	1	rs7715867	ENSG00000277812.1	AC021087.1	5.74	1.72e-08	6.76e-06	0.71	0.26	Asthma (childhood onset);	chr5:128944	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs73022563	ENSG00000277812.1	AC021087.1	5.74	1.72e-08	6.76e-06	0.71	0.26	Asthma (childhood onset);	chr5:140698	chr5:262769~262881:+
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	5.74	1.73e-08	6.77e-06	0.23	0.26	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
HNSC	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	5.74	1.73e-08	6.77e-06	0.24	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
HNSC	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	5.74	1.73e-08	6.78e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
HNSC	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	5.74	1.73e-08	6.78e-06	0.3	0.26	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000254340.1	RP11-10A14.3	5.74	1.73e-08	6.78e-06	0.31	0.26	Mood instability;	chr8:8803028	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-5.74	1.73e-08	6.78e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
HNSC	cis	rs1964356	0.524	rs7839585	ENSG00000254340.1	RP11-10A14.3	-5.74	1.73e-08	6.79e-06	-0.31	-0.26	Mean corpuscular volume;	chr8:8996725	chr8:9141424~9145435:+
HNSC	cis	rs4141404	0.923	rs2413035	ENSG00000236132.1	CTA-440B3.1	5.74	1.74e-08	6.8e-06	0.32	0.26	Paclitaxel-induced neuropathy;	chr22:31204474	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	5.74	1.74e-08	6.8e-06	0.32	0.26	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	5.74	1.74e-08	6.8e-06	0.32	0.26	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000254340.1	RP11-10A14.3	5.74	1.74e-08	6.8e-06	0.32	0.26	Mood instability;	chr8:8786428	chr8:9141424~9145435:+
HNSC	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-5.74	1.74e-08	6.8e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
HNSC	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-5.74	1.74e-08	6.8e-06	-0.22	-0.26	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
HNSC	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-5.74	1.74e-08	6.8e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
HNSC	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	5.74	1.74e-08	6.81e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	5.74	1.74e-08	6.81e-06	0.28	0.26	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-5.74	1.74e-08	6.81e-06	-0.17	-0.26	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
HNSC	cis	rs867371	1	rs8042464	ENSG00000259429.4	UBE2Q2P2	-5.74	1.74e-08	6.81e-06	-0.25	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82355142~82420075:+
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	5.74	1.74e-08	6.81e-06	0.23	0.26	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
HNSC	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-5.74	1.74e-08	6.82e-06	-0.29	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
HNSC	cis	rs9525927	0.625	rs4941488	ENSG00000227258.4	SMIM2-AS1	5.74	1.74e-08	6.82e-06	0.37	0.26	Dupuytren's disease;	chr13:44243622	chr13:44110451~44240517:+
HNSC	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28096855	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28099759	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28100648	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28104824	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28107222	chr6:28161781~28169594:+
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	5.74	1.74e-08	6.83e-06	0.31	0.26	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
HNSC	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-5.74	1.74e-08	6.83e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
HNSC	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	5.74	1.75e-08	6.83e-06	0.29	0.26	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
HNSC	cis	rs9341808	1	rs1359239	ENSG00000272129.1	RP11-250B2.6	5.74	1.75e-08	6.84e-06	0.31	0.26	Sitting height ratio;	chr6:80246429	chr6:80355424~80356859:+
HNSC	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-5.74	1.75e-08	6.84e-06	-0.33	-0.26	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
HNSC	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	5.74	1.75e-08	6.84e-06	0.29	0.26	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	5.74	1.75e-08	6.84e-06	0.29	0.26	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	5.74	1.75e-08	6.84e-06	0.29	0.26	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
HNSC	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-5.74	1.75e-08	6.84e-06	-0.36	-0.26	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
HNSC	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-5.74	1.75e-08	6.85e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
HNSC	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-5.74	1.75e-08	6.85e-06	-0.37	-0.26	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
HNSC	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	5.74	1.75e-08	6.85e-06	0.28	0.26	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	5.74	1.75e-08	6.85e-06	0.28	0.26	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	5.74	1.75e-08	6.85e-06	0.28	0.26	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
HNSC	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-5.74	1.75e-08	6.85e-06	-0.22	-0.26	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	5.74	1.75e-08	6.85e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
HNSC	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	5.74	1.75e-08	6.85e-06	0.46	0.26	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
HNSC	cis	rs7811142	0.887	rs35111986	ENSG00000078319.8	PMS2P1	-5.74	1.75e-08	6.86e-06	-0.34	-0.26	Platelet count;	chr7:100402651	chr7:100320992~100341908:-
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-5.73	1.75e-08	6.87e-06	-0.17	-0.26	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
HNSC	cis	rs9341808	0.622	rs682482	ENSG00000272129.1	RP11-250B2.6	-5.73	1.75e-08	6.87e-06	-0.31	-0.26	Sitting height ratio;	chr6:80251422	chr6:80355424~80356859:+
HNSC	cis	rs2579103	0.898	rs2731224	ENSG00000258183.4	RP11-753N8.1	-5.73	1.76e-08	6.87e-06	-0.32	-0.26	Body mass index;	chr12:90202115	chr12:90280894~90300340:+
HNSC	cis	rs6918586	0.615	rs198824	ENSG00000272462.2	U91328.19	-5.73	1.76e-08	6.87e-06	-0.24	-0.26	Schizophrenia;	chr6:26122555	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198821	ENSG00000272462.2	U91328.19	-5.73	1.76e-08	6.87e-06	-0.24	-0.26	Schizophrenia;	chr6:26123401	chr6:25992662~26001775:+
HNSC	cis	rs13113518	1	rs939823	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55487368	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6838882	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55489310	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13146987	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55491628	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs7677085	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55495801	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12510681	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55496737	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12500162	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55496933	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs3805155	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55497842	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs7686261	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55500224	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11729220	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55501629	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133390	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55501726	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133391	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55501788	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs13133484	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55504176	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs13127906	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55504201	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6849433	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55506498	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12501327	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55507248	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133392	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55507729	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6838305	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55508587	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.902	rs12503578	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55509367	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs3828480	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55510352	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	5.73	1.76e-08	6.87e-06	0.27	0.26	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	5.73	1.76e-08	6.88e-06	0.25	0.26	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
HNSC	cis	rs7819412	0.807	rs4840542	ENSG00000269918.1	AF131215.9	-5.73	1.76e-08	6.89e-06	-0.25	-0.26	Triglycerides;	chr8:11087299	chr8:11104691~11106704:-
HNSC	cis	rs75920871	0.528	rs3886960	ENSG00000254851.1	RP11-109L13.1	5.73	1.76e-08	6.89e-06	0.36	0.26	Subjective well-being;	chr11:117054274	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs723955	ENSG00000254851.1	RP11-109L13.1	5.73	1.76e-08	6.89e-06	0.36	0.26	Subjective well-being;	chr11:117054326	chr11:117135528~117138582:+
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000173295.6	FAM86B3P	5.73	1.76e-08	6.9e-06	0.29	0.26	Mood instability;	chr8:8786428	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	5.73	1.76e-08	6.9e-06	0.32	0.26	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	5.73	1.76e-08	6.9e-06	0.32	0.26	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	5.73	1.76e-08	6.9e-06	0.32	0.26	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
HNSC	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-5.73	1.77e-08	6.9e-06	-0.22	-0.26	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
HNSC	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	5.73	1.77e-08	6.91e-06	0.31	0.26	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	5.73	1.77e-08	6.91e-06	0.31	0.26	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
HNSC	cis	rs13113518	1	rs11724094	ENSG00000249700.7	SRD5A3-AS1	5.73	1.77e-08	6.91e-06	0.3	0.26	Height;	chr4:55501479	chr4:55363971~55395847:-
HNSC	cis	rs189798	0.738	rs330911	ENSG00000173295.6	FAM86B3P	5.73	1.77e-08	6.91e-06	0.31	0.26	Myopia (pathological);	chr8:9138763	chr8:8228595~8244865:+
HNSC	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	5.73	1.77e-08	6.92e-06	0.34	0.26	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
HNSC	cis	rs9640161	0.783	rs1132261	ENSG00000261305.1	RP4-584D14.7	5.73	1.77e-08	6.93e-06	0.34	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150362898	chr7:150341771~150342607:+
HNSC	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-5.73	1.78e-08	6.94e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	5.73	1.78e-08	6.94e-06	0.27	0.26	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
HNSC	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-5.73	1.78e-08	6.94e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
HNSC	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	5.73	1.78e-08	6.94e-06	0.32	0.26	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
HNSC	cis	rs673078	0.562	rs61944668	ENSG00000275409.1	RP11-131L12.4	-5.73	1.78e-08	6.95e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118448446	chr12:118430147~118430699:+
HNSC	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-5.73	1.78e-08	6.95e-06	-0.27	-0.26	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
HNSC	cis	rs2834288	0.7	rs2409502	ENSG00000237945.6	LINC00649	-5.73	1.78e-08	6.95e-06	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr21:33902431	chr21:33915534~33977691:+
HNSC	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-5.73	1.78e-08	6.95e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
HNSC	cis	rs1865760	0.534	rs1541988	ENSG00000272462.2	U91328.19	-5.73	1.78e-08	6.95e-06	-0.24	-0.26	Height;	chr6:25950576	chr6:25992662~26001775:+
HNSC	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-5.73	1.78e-08	6.95e-06	-0.36	-0.26	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
HNSC	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	5.73	1.78e-08	6.96e-06	0.27	0.26	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
HNSC	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-5.73	1.79e-08	6.98e-06	-0.32	-0.26	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-5.73	1.79e-08	6.99e-06	-0.18	-0.26	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
HNSC	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-5.73	1.79e-08	7e-06	-0.29	-0.26	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
HNSC	cis	rs67180937	0.583	rs3008614	ENSG00000272750.1	RP11-378J18.8	5.73	1.79e-08	7e-06	0.34	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622794	chr1:222658867~222661512:-
HNSC	cis	rs13113518	0.902	rs12642716	ENSG00000273257.1	RP11-177J6.1	5.73	1.79e-08	7.01e-06	0.31	0.26	Height;	chr4:55479996	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12501636	ENSG00000273257.1	RP11-177J6.1	5.73	1.79e-08	7.01e-06	0.31	0.26	Height;	chr4:55482317	chr4:55387949~55388271:+
HNSC	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	5.73	1.79e-08	7.01e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
HNSC	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
HNSC	cis	rs14027	0.921	rs2289011	ENSG00000279347.1	RP11-85I17.2	5.73	1.8e-08	7.02e-06	0.24	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119838736~119840385:-
HNSC	cis	rs2439831	0.85	rs3097773	ENSG00000205771.5	CATSPER2P1	5.73	1.8e-08	7.02e-06	0.46	0.26	Lung cancer in ever smokers;	chr15:43600874	chr15:43726918~43747094:-
HNSC	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-5.73	1.8e-08	7.02e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
HNSC	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-5.73	1.8e-08	7.02e-06	-0.28	-0.26	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
HNSC	cis	rs7674212	0.512	rs2720462	ENSG00000246560.2	RP11-10L12.4	5.73	1.8e-08	7.03e-06	0.29	0.26	Type 2 diabetes;	chr4:103135053	chr4:102828055~102844075:+
HNSC	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	5.73	1.81e-08	7.05e-06	0.25	0.26	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
HNSC	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-5.73	1.81e-08	7.05e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
HNSC	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-5.73	1.81e-08	7.06e-06	-0.3	-0.26	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
HNSC	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-5.73	1.81e-08	7.06e-06	-0.35	-0.26	Depression;	chr6:28230678	chr6:28115628~28116551:+
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	5.73	1.81e-08	7.06e-06	0.28	0.26	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
HNSC	cis	rs13113518	1	rs13133579	ENSG00000273257.1	RP11-177J6.1	5.73	1.81e-08	7.06e-06	0.31	0.26	Height;	chr4:55459921	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	5.73	1.81e-08	7.06e-06	0.32	0.26	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	5.73	1.81e-08	7.07e-06	0.3	0.26	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
HNSC	cis	rs755249	0.565	rs2695324	ENSG00000182109.6	RP11-69E11.4	5.73	1.81e-08	7.08e-06	0.25	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39522280~39546187:-
HNSC	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	5.73	1.82e-08	7.09e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
HNSC	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	5.73	1.82e-08	7.09e-06	0.27	0.26	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
HNSC	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-5.73	1.82e-08	7.09e-06	-0.34	-0.26	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
HNSC	cis	rs6604026	0.589	rs12738833	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92653561	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.589	rs11578098	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92653853	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.589	rs11800771	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92661552	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs68160001	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92668018	chr1:92580476~92580821:-
HNSC	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-5.73	1.82e-08	7.09e-06	-0.32	-0.26	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
HNSC	cis	rs13113518	0.841	rs7699867	ENSG00000273257.1	RP11-177J6.1	5.73	1.82e-08	7.1e-06	0.32	0.26	Height;	chr4:55483718	chr4:55387949~55388271:+
HNSC	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-5.73	1.82e-08	7.1e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-5.73	1.82e-08	7.1e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
HNSC	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	5.73	1.82e-08	7.11e-06	0.28	0.26	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
HNSC	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-5.73	1.83e-08	7.12e-06	-0.22	-0.26	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
HNSC	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-5.73	1.83e-08	7.12e-06	-0.35	-0.26	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
HNSC	cis	rs9341808	0.667	rs806783	ENSG00000272129.1	RP11-250B2.6	-5.73	1.83e-08	7.13e-06	-0.31	-0.26	Sitting height ratio;	chr6:80233226	chr6:80355424~80356859:+
HNSC	cis	rs4218	0.701	rs7174277	ENSG00000259732.1	RP11-59H7.3	-5.73	1.83e-08	7.13e-06	-0.32	-0.26	Social communication problems;	chr15:59150390	chr15:59121034~59133250:+
HNSC	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	5.73	1.83e-08	7.14e-06	0.28	0.26	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	5.73	1.83e-08	7.14e-06	0.28	0.26	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	5.73	1.83e-08	7.14e-06	0.28	0.26	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
HNSC	cis	rs8054556	0.787	rs35105141	ENSG00000183604.13	SMG1P5	-5.73	1.83e-08	7.14e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30045827	chr16:30267553~30335374:-
HNSC	cis	rs454422	1	rs236121	ENSG00000275632.1	RP5-967N21.11	5.73	1.83e-08	7.14e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5991948	chr20:6000418~6000941:+
HNSC	cis	rs4803480	0.935	rs758349	ENSG00000270164.1	LINC01480	-5.73	1.83e-08	7.14e-06	-0.23	-0.26	Schizophrenia;	chr19:41578753	chr19:41535183~41536904:+
HNSC	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-5.73	1.83e-08	7.15e-06	-0.33	-0.26	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
HNSC	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	5.73	1.84e-08	7.15e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
HNSC	cis	rs4723738	1	rs7795499	ENSG00000227191.5	TRGC2	-5.73	1.84e-08	7.15e-06	-0.2	-0.26	Treatment response for severe sepsis;	chr7:38228794	chr7:38239580~38368091:-
HNSC	cis	rs9302065	0.529	rs2992904	ENSG00000223298.1	RNY3P8	5.73	1.84e-08	7.16e-06	0.26	0.26	Blood metabolite levels;	chr13:95305919	chr13:95310830~95310955:-
HNSC	cis	rs9302065	0.529	rs2993582	ENSG00000223298.1	RNY3P8	5.73	1.84e-08	7.16e-06	0.26	0.26	Blood metabolite levels;	chr13:95305927	chr13:95310830~95310955:-
HNSC	cis	rs9302065	0.565	rs2992905	ENSG00000223298.1	RNY3P8	5.73	1.84e-08	7.16e-06	0.26	0.26	Blood metabolite levels;	chr13:95305936	chr13:95310830~95310955:-
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-5.73	1.84e-08	7.16e-06	-0.15	-0.26	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
HNSC	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	5.73	1.84e-08	7.17e-06	0.31	0.26	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
HNSC	cis	rs1021993	1	rs2174775	ENSG00000231648.1	RP11-372M18.2	5.73	1.84e-08	7.17e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209311422	chr1:209367662~209379690:+
HNSC	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	5.73	1.84e-08	7.18e-06	0.34	0.26	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
HNSC	cis	rs2880765	0.743	rs12906308	ENSG00000259295.5	CSPG4P12	-5.73	1.84e-08	7.18e-06	-0.3	-0.26	Coronary artery disease;	chr15:85464828	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs8039049	ENSG00000259295.5	CSPG4P12	5.73	1.84e-08	7.18e-06	0.3	0.26	Coronary artery disease;	chr15:85464398	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs8039631	ENSG00000259295.5	CSPG4P12	5.73	1.84e-08	7.18e-06	0.3	0.26	Coronary artery disease;	chr15:85464700	chr15:85191438~85213905:+
HNSC	cis	rs757110	0.745	rs2074311	ENSG00000260196.1	RP1-239B22.5	5.73	1.84e-08	7.18e-06	0.29	0.26	Type 2 diabetes;	chr11:17400313	chr11:17380649~17383531:+
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000254153.1	CTA-398F10.2	5.73	1.84e-08	7.18e-06	0.29	0.26	Neuroticism;	chr8:8241055	chr8:8456909~8461337:-
HNSC	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	5.73	1.84e-08	7.18e-06	0.66	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
HNSC	cis	rs13113518	1	rs4865004	ENSG00000273257.1	RP11-177J6.1	5.73	1.84e-08	7.18e-06	0.31	0.26	Height;	chr4:55515118	chr4:55387949~55388271:+
HNSC	cis	rs9402743	0.632	rs6570040	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135779557	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs7754830	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135779904	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs2104133	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135781149	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.597	rs9483880	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135781474	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4895458	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135783235	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896178	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135783957	chr6:135636086~135636713:-
HNSC	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	5.73	1.85e-08	7.19e-06	0.37	0.26	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	5.73	1.85e-08	7.19e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
HNSC	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-5.73	1.85e-08	7.19e-06	-0.31	-0.26	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-5.73	1.85e-08	7.19e-06	-0.31	-0.26	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
HNSC	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	5.73	1.85e-08	7.19e-06	0.32	0.26	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-5.73	1.85e-08	7.19e-06	-0.17	-0.26	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
HNSC	cis	rs6991838	0.751	rs35553155	ENSG00000200714.1	Y_RNA	5.73	1.85e-08	7.2e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.806	rs35024820	ENSG00000200714.1	Y_RNA	5.73	1.85e-08	7.2e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65592731~65592820:+
HNSC	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	5.73	1.85e-08	7.21e-06	0.62	0.26	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
HNSC	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	5.72	1.86e-08	7.22e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	5.72	1.86e-08	7.22e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
HNSC	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-5.72	1.86e-08	7.23e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
HNSC	cis	rs6951245	0.572	rs79396675	ENSG00000224079.1	AC091729.7	-5.72	1.86e-08	7.23e-06	-0.54	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1015411	chr7:1074450~1078036:+
HNSC	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-5.72	1.86e-08	7.23e-06	-0.36	-0.26	Depression;	chr6:28231053	chr6:28115628~28116551:+
HNSC	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	5.72	1.86e-08	7.23e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
HNSC	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-5.72	1.87e-08	7.26e-06	-0.27	-0.26	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
HNSC	cis	rs6604026	0.59	rs35612297	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92688538	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs2051841	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92690638	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs72724574	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92692547	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs11577426	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92694681	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs12756698	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92697243	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-5.72	1.87e-08	7.26e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-5.72	1.87e-08	7.26e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
HNSC	cis	rs13113518	1	rs3762837	ENSG00000249700.7	SRD5A3-AS1	5.72	1.87e-08	7.27e-06	0.3	0.26	Height;	chr4:55511198	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13108499	ENSG00000249700.7	SRD5A3-AS1	5.72	1.87e-08	7.27e-06	0.3	0.26	Height;	chr4:55526514	chr4:55363971~55395847:-
HNSC	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-5.72	1.87e-08	7.27e-06	-0.17	-0.26	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
HNSC	cis	rs11992162	1	rs11994417	ENSG00000206014.6	OR7E161P	-5.72	1.87e-08	7.28e-06	-0.28	-0.26	Monocyte count;	chr8:11975753	chr8:11928597~11929563:-
HNSC	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-5.72	1.87e-08	7.29e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
HNSC	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	5.72	1.87e-08	7.29e-06	0.36	0.26	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
HNSC	cis	rs10129255	1	rs10129255	ENSG00000211972.2	IGHV3-66	-5.72	1.88e-08	7.29e-06	-0.19	-0.26	Kawasaki disease;	chr14:106767970	chr14:106675017~106675544:-
HNSC	cis	rs2985684	1	rs2985697	ENSG00000258568.1	RHOQP1	5.72	1.88e-08	7.3e-06	0.27	0.26	Carotid intima media thickness;	chr14:49626184	chr14:49599994~49600572:+
HNSC	cis	rs13113518	1	rs4864542	ENSG00000273257.1	RP11-177J6.1	-5.72	1.88e-08	7.3e-06	-0.31	-0.26	Height;	chr4:55487920	chr4:55387949~55388271:+
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	5.72	1.88e-08	7.3e-06	0.17	0.26	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
HNSC	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	5.72	1.88e-08	7.3e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	5.72	1.88e-08	7.3e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
HNSC	cis	rs11846409	0.655	rs79296226	ENSG00000274576.2	IGHV2-70	5.72	1.88e-08	7.3e-06	0.26	0.26	Rheumatic heart disease;	chr14:106650436	chr14:106770577~106771020:-
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-5.72	1.88e-08	7.3e-06	-0.3	-0.26	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
HNSC	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	5.72	1.88e-08	7.3e-06	0.29	0.26	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
HNSC	cis	rs755249	0.565	rs7539261	ENSG00000182109.6	RP11-69E11.4	-5.72	1.88e-08	7.31e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39522280~39546187:-
HNSC	cis	rs2933343	0.649	rs2638845	ENSG00000261159.1	RP11-723O4.9	5.72	1.88e-08	7.32e-06	0.25	0.26	IgG glycosylation;	chr3:128868526	chr3:128859716~128860526:-
HNSC	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-5.72	1.88e-08	7.32e-06	-0.55	-0.26	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
HNSC	cis	rs62344088	1	rs10037843	ENSG00000277812.1	AC021087.1	5.72	1.89e-08	7.34e-06	0.71	0.26	Asthma (childhood onset);	chr5:119963	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs13436694	ENSG00000277812.1	AC021087.1	5.72	1.89e-08	7.34e-06	0.71	0.26	Asthma (childhood onset);	chr5:122767	chr5:262769~262881:+
HNSC	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
HNSC	cis	rs3002131	0.522	rs2378583	ENSG00000225265.1	TAF1A-AS1	-5.72	1.89e-08	7.35e-06	-0.37	-0.26	Interleukin-10 levels;	chr1:222565958	chr1:222589825~222593032:+
HNSC	cis	rs13113518	0.966	rs4864544	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55515292	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6847529	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55518776	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6822740	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55518922	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs13108409	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55520278	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11726198	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55523835	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs11133396	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55524246	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs7675109	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55525589	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4865005	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55525781	chr4:55363971~55395847:-
HNSC	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	5.72	1.89e-08	7.36e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
HNSC	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-5.72	1.9e-08	7.36e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
HNSC	cis	rs783540	0.5	rs7163840	ENSG00000255769.6	GOLGA2P10	5.72	1.9e-08	7.37e-06	0.35	0.26	Schizophrenia;	chr15:82729551	chr15:82472993~82513950:-
HNSC	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	5.72	1.9e-08	7.37e-06	0.34	0.26	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
HNSC	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.37e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.37e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.37e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
HNSC	cis	rs9813712	0.953	rs9847910	ENSG00000249846.5	RP11-77P16.4	5.72	1.9e-08	7.37e-06	0.31	0.26	Response to amphetamines;	chr3:130248174	chr3:130112550~130120579:+
HNSC	cis	rs2579103	0.782	rs2579132	ENSG00000258183.4	RP11-753N8.1	-5.72	1.9e-08	7.38e-06	-0.32	-0.26	Body mass index;	chr12:90201954	chr12:90280894~90300340:+
HNSC	cis	rs1355223	0.966	rs11602318	ENSG00000271369.1	RP11-350D17.3	5.72	1.9e-08	7.38e-06	0.3	0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745436	chr11:34709600~34710161:+
HNSC	cis	rs2337406	0.778	rs56965016	ENSG00000211974.3	IGHV2-70	-5.72	1.9e-08	7.38e-06	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106656649	chr14:106723574~106724093:-
HNSC	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.38e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
HNSC	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-5.72	1.9e-08	7.39e-06	-0.28	-0.26	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
HNSC	cis	rs2243480	1	rs4718317	ENSG00000179406.6	LINC00174	5.72	1.9e-08	7.39e-06	0.53	0.26	Diabetic kidney disease;	chr7:66183914	chr7:66376044~66401338:-
HNSC	cis	rs9840812	0.906	rs61791757	ENSG00000239213.4	NCK1-AS1	-5.72	1.9e-08	7.39e-06	-0.25	-0.26	Fibrinogen levels;	chr3:136186483	chr3:136841726~136862054:-
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	5.72	1.91e-08	7.4e-06	0.2	0.26	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
HNSC	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	5.72	1.91e-08	7.41e-06	0.24	0.26	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	5.72	1.91e-08	7.41e-06	0.24	0.26	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
HNSC	cis	rs5753618	0.583	rs2273249	ENSG00000236132.1	CTA-440B3.1	-5.72	1.91e-08	7.41e-06	-0.32	-0.26	Colorectal cancer;	chr22:31440500	chr22:31816379~31817491:-
HNSC	cis	rs7819412	0.745	rs7017567	ENSG00000269918.1	AF131215.9	-5.72	1.91e-08	7.43e-06	-0.25	-0.26	Triglycerides;	chr8:11076189	chr8:11104691~11106704:-
HNSC	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	5.72	1.91e-08	7.43e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
HNSC	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-5.72	1.91e-08	7.43e-06	-0.39	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	5.72	1.91e-08	7.43e-06	0.32	0.26	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
HNSC	cis	rs1908814	0.504	rs7830734	ENSG00000206014.6	OR7E161P	-5.72	1.92e-08	7.44e-06	-0.28	-0.26	Neuroticism;	chr8:11938130	chr8:11928597~11929563:-
HNSC	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	5.72	1.92e-08	7.44e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
HNSC	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
HNSC	cis	rs860295	0.557	rs348196	ENSG00000203761.5	MSTO2P	-5.72	1.92e-08	7.44e-06	-0.2	-0.26	Body mass index;	chr1:155697170	chr1:155745829~155750137:+
HNSC	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-5.72	1.92e-08	7.45e-06	-0.31	-0.26	Depression;	chr6:28070115	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-5.72	1.92e-08	7.45e-06	-0.31	-0.26	Depression;	chr6:28071237	chr6:28161781~28169594:+
HNSC	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-5.72	1.92e-08	7.45e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
HNSC	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	5.72	1.92e-08	7.46e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	5.72	1.92e-08	7.46e-06	0.23	0.26	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
HNSC	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-5.72	1.92e-08	7.47e-06	-0.41	-0.26	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
HNSC	cis	rs9840812	0.655	rs4452981	ENSG00000273486.1	RP11-731C17.2	5.72	1.93e-08	7.47e-06	0.22	0.26	Fibrinogen levels;	chr3:136588925	chr3:136837338~136839021:-
HNSC	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	5.72	1.93e-08	7.48e-06	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
HNSC	cis	rs6918586	0.658	rs198829	ENSG00000272462.2	U91328.19	-5.72	1.93e-08	7.48e-06	-0.24	-0.26	Schizophrenia;	chr6:26118665	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198828	ENSG00000272462.2	U91328.19	-5.72	1.93e-08	7.48e-06	-0.24	-0.26	Schizophrenia;	chr6:26119231	chr6:25992662~26001775:+
HNSC	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	5.72	1.93e-08	7.48e-06	0.46	0.26	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	5.72	1.93e-08	7.48e-06	0.46	0.26	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
HNSC	cis	rs2933343	0.621	rs728838	ENSG00000261159.1	RP11-723O4.9	5.72	1.93e-08	7.48e-06	0.24	0.26	IgG glycosylation;	chr3:128870170	chr3:128859716~128860526:-
HNSC	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-5.72	1.93e-08	7.49e-06	-0.32	-0.26	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-5.72	1.93e-08	7.49e-06	-0.32	-0.26	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-5.72	1.93e-08	7.49e-06	-0.31	-0.26	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
HNSC	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-5.72	1.93e-08	7.49e-06	-0.27	-0.26	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
HNSC	cis	rs454422	0.767	rs236119	ENSG00000275632.1	RP5-967N21.11	5.72	1.93e-08	7.49e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5958008	chr20:6000418~6000941:+
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	5.72	1.93e-08	7.49e-06	0.27	0.26	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
HNSC	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	5.72	1.93e-08	7.5e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
HNSC	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	5.72	1.93e-08	7.5e-06	0.23	0.26	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-5.72	1.93e-08	7.5e-06	-0.18	-0.26	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
HNSC	cis	rs75920871	0.528	rs2513097	ENSG00000254851.1	RP11-109L13.1	5.72	1.94e-08	7.51e-06	0.36	0.26	Subjective well-being;	chr11:116965496	chr11:117135528~117138582:+
HNSC	cis	rs1499614	1	rs2659903	ENSG00000179406.6	LINC00174	-5.72	1.94e-08	7.51e-06	-0.55	-0.26	Gout;	chr7:66715944	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2141924	ENSG00000179406.6	LINC00174	-5.72	1.94e-08	7.51e-06	-0.55	-0.26	Gout;	chr7:66721259	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000179406.6	LINC00174	-5.72	1.94e-08	7.51e-06	-0.55	-0.26	Gout;	chr7:66732812	chr7:66376044~66401338:-
HNSC	cis	rs2579103	0.898	rs1583699	ENSG00000258183.4	RP11-753N8.1	-5.72	1.94e-08	7.51e-06	-0.31	-0.26	Body mass index;	chr12:90206198	chr12:90280894~90300340:+
HNSC	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	5.72	1.94e-08	7.53e-06	0.2	0.26	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	5.72	1.95e-08	7.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	5.72	1.95e-08	7.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	5.72	1.95e-08	7.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	5.72	1.95e-08	7.54e-06	0.27	0.26	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
HNSC	cis	rs2179367	0.632	rs10872636	ENSG00000216906.2	RP11-350J20.9	5.72	1.95e-08	7.54e-06	0.38	0.26	Dupuytren's disease;	chr6:149353678	chr6:149904243~149906418:+
HNSC	cis	rs6918586	0.658	rs198826	ENSG00000272462.2	U91328.19	5.72	1.95e-08	7.54e-06	0.24	0.26	Schizophrenia;	chr6:26120925	chr6:25992662~26001775:+
HNSC	cis	rs3206736	0.548	rs1186721	ENSG00000197085.10	NPSR1-AS1	-5.72	1.95e-08	7.55e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34934990	chr7:34346512~34871582:-
HNSC	cis	rs10504130	0.542	rs1589079	ENSG00000272024.1	RP11-546K22.3	-5.72	1.95e-08	7.55e-06	-0.33	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51923739	chr8:51950284~51950690:+
HNSC	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-5.72	1.95e-08	7.56e-06	-0.25	-0.26	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
HNSC	cis	rs2579103	0.617	rs61924675	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90208613	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.867	rs2118805	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90209168	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.838	rs2043850	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90209938	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.898	rs2731229	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90211096	chr12:90280894~90300340:+
HNSC	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	5.72	1.95e-08	7.57e-06	0.34	0.26	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
HNSC	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	5.72	1.95e-08	7.57e-06	0.34	0.26	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
HNSC	cis	rs6604026	0.624	rs12731107	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92701772	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11803097	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92705932	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs12749786	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92706367	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs72724586	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92707620	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs72724587	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92707653	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs34305407	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92708658	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs35311203	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92712910	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs12749480	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92714968	chr1:92580476~92580821:-
HNSC	cis	rs35306767	0.904	rs10904584	ENSG00000229869.1	RP11-363N22.2	-5.72	1.96e-08	7.58e-06	-0.34	-0.26	Eosinophil percentage of granulocytes;	chr10:937807	chr10:933026~942743:+
HNSC	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
HNSC	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	5.72	1.96e-08	7.58e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
HNSC	cis	rs9341808	0.558	rs2490234	ENSG00000272129.1	RP11-250B2.6	5.71	1.96e-08	7.58e-06	0.3	0.26	Sitting height ratio;	chr6:80107249	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-5.71	1.96e-08	7.59e-06	-0.31	-0.26	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	5.71	1.96e-08	7.6e-06	0.32	0.26	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
HNSC	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-5.71	1.96e-08	7.6e-06	-0.31	-0.26	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
HNSC	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	5.71	1.96e-08	7.6e-06	0.31	0.26	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
HNSC	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-5.71	1.97e-08	7.62e-06	-0.26	-0.26	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
HNSC	cis	rs6604026	0.624	rs11578004	ENSG00000223787.2	RP4-593M8.1	5.71	1.97e-08	7.62e-06	0.35	0.26	Multiple sclerosis;	chr1:92726707	chr1:92580476~92580821:-
HNSC	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
HNSC	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	5.71	1.97e-08	7.62e-06	0.3	0.26	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000211970.3	IGHV4-61	-5.71	1.97e-08	7.62e-06	-0.17	-0.26	Kawasaki disease;	chr14:106716897	chr14:106639119~106639657:-
HNSC	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-5.71	1.97e-08	7.62e-06	-0.33	-0.26	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
HNSC	cis	rs11089937	0.864	rs5757041	ENSG00000211639.2	IGLV4-60	5.71	1.97e-08	7.62e-06	0.23	0.26	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22162199~22162681:+
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000253893.2	FAM85B	5.71	1.97e-08	7.62e-06	0.32	0.26	Mean corpuscular volume;	chr8:8993123	chr8:8167819~8226614:-
HNSC	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-5.71	1.97e-08	7.62e-06	-0.29	-0.26	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
HNSC	cis	rs11648785	0.59	rs10431948	ENSG00000222019.6	URAHP	-5.71	1.97e-08	7.63e-06	-0.24	-0.26	Tanning;	chr16:90033163	chr16:90039761~90047773:-
HNSC	cis	rs4948102	0.597	rs12669623	ENSG00000226278.1	PSPHP1	-5.71	1.97e-08	7.63e-06	-0.28	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55764797~55773288:+
HNSC	cis	rs1355223	0.902	rs1258470	ENSG00000271369.1	RP11-350D17.3	5.71	1.97e-08	7.64e-06	0.29	0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34707718	chr11:34709600~34710161:+
HNSC	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-5.71	1.98e-08	7.64e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
HNSC	cis	rs3206736	0.556	rs1649235	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.64e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34964270	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.514	rs1649236	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.64e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34964522	chr7:34346512~34871582:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	5.71	1.98e-08	7.64e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
HNSC	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-5.71	1.98e-08	7.65e-06	-0.3	-0.26	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
HNSC	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-5.71	1.98e-08	7.66e-06	-0.33	-0.26	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-5.71	1.98e-08	7.66e-06	-0.33	-0.26	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
HNSC	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-5.71	1.98e-08	7.66e-06	-0.3	-0.26	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
HNSC	cis	rs11846409	0.872	rs2956482	ENSG00000211974.3	IGHV2-70	5.71	1.98e-08	7.67e-06	0.29	0.26	Rheumatic heart disease;	chr14:106630013	chr14:106723574~106724093:-
HNSC	cis	rs3206736	0.556	rs328924	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.67e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34996092	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328925	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.67e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34997715	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328929	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.67e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35000426	chr7:34346512~34871582:-
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	5.71	1.99e-08	7.68e-06	0.27	0.26	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
HNSC	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	5.71	1.99e-08	7.7e-06	0.28	0.26	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
HNSC	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	5.71	2e-08	7.72e-06	0.32	0.26	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
HNSC	cis	rs6918586	0.658	rs198822	ENSG00000272462.2	U91328.19	-5.71	2e-08	7.72e-06	-0.24	-0.26	Schizophrenia;	chr6:26123311	chr6:25992662~26001775:+
HNSC	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-5.71	2e-08	7.73e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
HNSC	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	5.71	2e-08	7.73e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	5.71	2e-08	7.73e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	5.71	2e-08	7.73e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
HNSC	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	5.71	2.01e-08	7.77e-06	0.33	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
HNSC	cis	rs804280	0.509	rs13268030	ENSG00000206014.6	OR7E161P	-5.71	2.01e-08	7.77e-06	-0.27	-0.26	Myopia (pathological);	chr8:11925564	chr8:11928597~11929563:-
HNSC	cis	rs950776	0.714	rs17408276	ENSG00000261762.1	RP11-650L12.2	5.71	2.01e-08	7.77e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78589276	chr15:78589123~78591276:-
HNSC	cis	rs13113518	1	rs4864999	ENSG00000273257.1	RP11-177J6.1	5.71	2.01e-08	7.77e-06	0.31	0.26	Height;	chr4:55476736	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12506788	ENSG00000273257.1	RP11-177J6.1	5.71	2.01e-08	7.77e-06	0.31	0.26	Height;	chr4:55477426	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs10517344	ENSG00000273257.1	RP11-177J6.1	5.71	2.01e-08	7.77e-06	0.31	0.26	Height;	chr4:55477545	chr4:55387949~55388271:+
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000233609.3	RP11-62H7.2	-5.71	2.01e-08	7.77e-06	-0.25	-0.26	Joint mobility (Beighton score);	chr8:8935355	chr8:8961200~8979025:+
HNSC	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-5.71	2.01e-08	7.78e-06	-0.43	-0.26	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
HNSC	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	5.71	2.02e-08	7.78e-06	0.34	0.26	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
HNSC	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	5.71	2.02e-08	7.78e-06	0.34	0.26	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	5.71	2.02e-08	7.78e-06	0.23	0.26	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	5.71	2.02e-08	7.79e-06	0.27	0.26	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
HNSC	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	5.71	2.02e-08	7.8e-06	0.34	0.26	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
HNSC	cis	rs4140799	0.839	rs8015004	ENSG00000266869.1	RP6-114E22.1	5.71	2.02e-08	7.8e-06	0.31	0.26	Neuroticism;	chr14:71706696	chr14:71848606~71908430:+
HNSC	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-5.71	2.02e-08	7.8e-06	-0.4	-0.26	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
HNSC	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	5.71	2.03e-08	7.82e-06	0.32	0.26	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	5.71	2.03e-08	7.82e-06	0.32	0.26	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
HNSC	cis	rs2834288	0.5	rs2834305	ENSG00000273102.1	AP000569.9	5.71	2.03e-08	7.82e-06	0.27	0.26	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.5	rs7277248	ENSG00000273102.1	AP000569.9	5.71	2.03e-08	7.82e-06	0.27	0.26	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33967101~33968573:-
HNSC	cis	rs9300255	0.568	rs1790108	ENSG00000280120.1	RP11-546D6.3	5.71	2.03e-08	7.83e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123152294	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.51	rs1790109	ENSG00000280120.1	RP11-546D6.3	5.71	2.03e-08	7.83e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123153205	chr12:123152324~123153377:-
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	5.71	2.03e-08	7.83e-06	0.32	0.26	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	5.71	2.03e-08	7.83e-06	0.32	0.26	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
HNSC	cis	rs9326248	0.53	rs718847	ENSG00000280143.1	AP000892.6	5.71	2.03e-08	7.83e-06	0.4	0.26	Blood protein levels;	chr11:116863430	chr11:117204967~117210292:+
HNSC	cis	rs13113518	1	rs6858803	ENSG00000249700.7	SRD5A3-AS1	5.71	2.03e-08	7.83e-06	0.3	0.26	Height;	chr4:55484534	chr4:55363971~55395847:-
HNSC	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-5.71	2.03e-08	7.84e-06	-0.32	-0.26	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-5.71	2.03e-08	7.84e-06	-0.32	-0.26	Depression;	chr6:28138981	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-5.71	2.03e-08	7.84e-06	-0.32	-0.26	Depression;	chr6:28139012	chr6:28161781~28169594:+
HNSC	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-5.71	2.03e-08	7.84e-06	-0.33	-0.26	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
HNSC	cis	rs11098499	0.644	rs7676296	ENSG00000249244.1	RP11-548H18.2	5.71	2.03e-08	7.84e-06	0.32	0.26	Corneal astigmatism;	chr4:119634532	chr4:119391831~119395335:-
HNSC	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	5.71	2.03e-08	7.84e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
HNSC	cis	rs603446	0.967	rs180375	ENSG00000254851.1	RP11-109L13.1	5.71	2.04e-08	7.86e-06	0.34	0.26	Triglycerides;	chr11:116720324	chr11:117135528~117138582:+
HNSC	cis	rs12439619	1	rs12439619	ENSG00000276710.3	CSPG4P8	-5.71	2.04e-08	7.86e-06	-0.3	-0.26	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82459472~82477258:+
HNSC	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	5.71	2.04e-08	7.86e-06	0.36	0.26	Height;	chr6:109333018	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.6	rs590641	ENSG00000272129.1	RP11-250B2.6	5.71	2.04e-08	7.87e-06	0.3	0.26	Sitting height ratio;	chr6:80256766	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	5.71	2.04e-08	7.87e-06	0.32	0.26	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
HNSC	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	5.71	2.05e-08	7.89e-06	0.33	0.26	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
HNSC	cis	rs7160336	0.641	rs17782448	ENSG00000259065.1	RP5-1021I20.1	-5.71	2.05e-08	7.89e-06	-0.3	-0.26	Blood protein levels;	chr14:74215998	chr14:73787360~73803270:+
HNSC	cis	rs7829975	0.774	rs35039922	ENSG00000173295.6	FAM86B3P	5.71	2.05e-08	7.89e-06	0.28	0.26	Mood instability;	chr8:8817815	chr8:8228595~8244865:+
HNSC	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-5.71	2.05e-08	7.89e-06	-0.39	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-5.71	2.05e-08	7.89e-06	-0.39	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
HNSC	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	5.71	2.05e-08	7.89e-06	0.29	0.26	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
HNSC	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	5.71	2.05e-08	7.9e-06	0.37	0.26	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
HNSC	cis	rs9302065	0.565	rs2992908	ENSG00000223298.1	RNY3P8	5.71	2.05e-08	7.9e-06	0.26	0.26	Blood metabolite levels;	chr13:95308346	chr13:95310830~95310955:-
HNSC	cis	rs75422866	0.51	rs73105845	ENSG00000276691.1	RP5-1057I20.5	5.71	2.05e-08	7.9e-06	0.46	0.26	Pneumonia;	chr12:47741824	chr12:47788426~47788971:+
HNSC	cis	rs8177876	0.731	rs74878296	ENSG00000261061.1	RP11-303E16.2	-5.71	2.05e-08	7.91e-06	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81030770~81031485:+
HNSC	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	5.71	2.05e-08	7.92e-06	0.27	0.26	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
HNSC	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	5.71	2.06e-08	7.92e-06	0.45	0.26	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
HNSC	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-5.71	2.06e-08	7.92e-06	-0.26	-0.26	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
HNSC	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	5.71	2.06e-08	7.92e-06	0.29	0.26	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
HNSC	cis	rs10504130	0.569	rs7820177	ENSG00000272024.1	RP11-546K22.3	-5.71	2.06e-08	7.93e-06	-0.33	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51924373	chr8:51950284~51950690:+
HNSC	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	5.71	2.06e-08	7.94e-06	0.32	0.26	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	5.71	2.06e-08	7.94e-06	0.27	0.26	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
HNSC	cis	rs13113518	0.902	rs11133386	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55461320	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs4340844	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55462689	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs1522112	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55463606	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4864997	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55466010	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs960152	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55467308	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs12644948	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55470266	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805151	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55470874	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13118237	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55474259	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs11133387	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55475130	chr4:55387949~55388271:+
HNSC	cis	rs1021993	0.674	rs937874	ENSG00000231648.1	RP11-372M18.2	5.71	2.07e-08	7.96e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209326036	chr1:209367662~209379690:+
HNSC	cis	rs7819412	0.594	rs17724226	ENSG00000269918.1	AF131215.9	-5.71	2.07e-08	7.96e-06	-0.26	-0.26	Triglycerides;	chr8:11111416	chr8:11104691~11106704:-
HNSC	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	5.7	2.07e-08	7.98e-06	0.34	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
HNSC	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-5.7	2.07e-08	7.98e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs9312661	ENSG00000273257.1	RP11-177J6.1	5.7	2.08e-08	8e-06	0.31	0.26	Height;	chr4:55476159	chr4:55387949~55388271:+
HNSC	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	5.7	2.08e-08	8e-06	0.25	0.26	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
HNSC	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	5.7	2.08e-08	8e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
HNSC	cis	rs9840812	0.592	rs900048	ENSG00000273486.1	RP11-731C17.2	5.7	2.08e-08	8e-06	0.22	0.26	Fibrinogen levels;	chr3:136500088	chr3:136837338~136839021:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-5.7	2.08e-08	8.01e-06	-0.17	-0.26	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
HNSC	cis	rs6951245	0.572	rs79489623	ENSG00000224079.1	AC091729.7	-5.7	2.08e-08	8.01e-06	-0.55	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1005996	chr7:1074450~1078036:+
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	5.7	2.08e-08	8.01e-06	0.27	0.26	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
HNSC	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-5.7	2.08e-08	8.02e-06	-0.33	-0.26	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
HNSC	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-5.7	2.08e-08	8.02e-06	-0.32	-0.26	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
HNSC	cis	rs13113518	0.934	rs11935823	ENSG00000273257.1	RP11-177J6.1	5.7	2.08e-08	8.02e-06	0.31	0.26	Height;	chr4:55589624	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	5.7	2.09e-08	8.02e-06	0.32	0.26	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
HNSC	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-5.7	2.09e-08	8.04e-06	-0.37	-0.26	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
HNSC	cis	rs4218	0.588	rs9788719	ENSG00000259732.1	RP11-59H7.3	-5.7	2.09e-08	8.04e-06	-0.33	-0.26	Social communication problems;	chr15:59028920	chr15:59121034~59133250:+
HNSC	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-5.7	2.09e-08	8.04e-06	-0.29	-0.26	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
HNSC	cis	rs4218	0.569	rs73418864	ENSG00000259732.1	RP11-59H7.3	-5.7	2.09e-08	8.05e-06	-0.35	-0.26	Social communication problems;	chr15:59098996	chr15:59121034~59133250:+
HNSC	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-5.7	2.09e-08	8.05e-06	-0.35	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
HNSC	cis	rs9341808	0.558	rs2322635	ENSG00000272129.1	RP11-250B2.6	5.7	2.09e-08	8.05e-06	0.3	0.26	Sitting height ratio;	chr6:80187493	chr6:80355424~80356859:+
HNSC	cis	rs13113518	1	rs13114841	ENSG00000273257.1	RP11-177J6.1	5.7	2.1e-08	8.06e-06	0.31	0.26	Height;	chr4:55485974	chr4:55387949~55388271:+
HNSC	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-5.7	2.1e-08	8.07e-06	-0.22	-0.26	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-5.7	2.1e-08	8.07e-06	-0.22	-0.26	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
HNSC	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-5.7	2.1e-08	8.07e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
HNSC	cis	rs67981189	0.529	rs61990387	ENSG00000274818.1	RP1-292L20.3	5.7	2.1e-08	8.07e-06	0.31	0.26	Schizophrenia;	chr14:71024850	chr14:70906657~70907111:-
HNSC	cis	rs7209700	0.547	rs7219925	ENSG00000228782.6	CTD-2026D20.3	-5.7	2.1e-08	8.07e-06	-0.27	-0.26	IgG glycosylation;	chr17:47264274	chr17:47450568~47492492:-
HNSC	cis	rs9300255	0.596	rs11057207	ENSG00000280120.1	RP11-546D6.3	5.7	2.1e-08	8.08e-06	0.22	0.26	Neutrophil percentage of white cells;	chr12:123246344	chr12:123152324~123153377:-
HNSC	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-5.7	2.1e-08	8.08e-06	-0.29	-0.26	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-5.7	2.1e-08	8.08e-06	-0.29	-0.26	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
HNSC	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	5.7	2.1e-08	8.09e-06	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
HNSC	cis	rs6969780	0.915	rs11983200	ENSG00000233429.8	HOTAIRM1	5.7	2.11e-08	8.1e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27146977	chr7:27095647~27100265:+
HNSC	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-5.7	2.11e-08	8.1e-06	-0.36	-0.26	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-5.7	2.11e-08	8.1e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000179406.6	LINC00174	-5.7	2.11e-08	8.11e-06	-0.54	-0.26	Diabetic kidney disease;	chr7:66105184	chr7:66376044~66401338:-
HNSC	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	5.7	2.11e-08	8.11e-06	0.34	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
HNSC	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-5.7	2.11e-08	8.12e-06	-0.31	-0.26	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	5.7	2.11e-08	8.12e-06	0.27	0.26	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
HNSC	cis	rs2115630	0.967	rs8028490	ENSG00000229212.6	RP11-561C5.4	5.7	2.11e-08	8.13e-06	0.29	0.26	P wave terminal force;	chr15:84734657	chr15:85205440~85234795:-
HNSC	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	5.7	2.12e-08	8.15e-06	0.27	0.26	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
HNSC	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-5.7	2.12e-08	8.16e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
HNSC	cis	rs2439831	0.867	rs8039638	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43342207	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs28415933	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43343602	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs12324572	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43344002	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2412780	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43363596	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2899082	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43363845	chr15:43726918~43747094:-
HNSC	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	5.7	2.13e-08	8.16e-06	0.29	0.26	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
HNSC	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	5.7	2.13e-08	8.16e-06	0.4	0.26	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	5.7	2.13e-08	8.16e-06	0.4	0.26	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	5.7	2.13e-08	8.16e-06	0.4	0.26	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
HNSC	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-5.7	2.13e-08	8.16e-06	-0.25	-0.26	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
HNSC	cis	rs804280	0.517	rs7815179	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934539	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.871	rs7815186	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs7833079	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	Neuroticism;	chr8:11934620	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.899	rs7815595	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:11928597~11929563:-
HNSC	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-5.7	2.13e-08	8.17e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	5.7	2.13e-08	8.17e-06	0.31	0.26	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
HNSC	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-5.7	2.13e-08	8.17e-06	-0.32	-0.26	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
HNSC	cis	rs710913	0.738	rs1180347	ENSG00000182109.6	RP11-69E11.4	-5.7	2.13e-08	8.18e-06	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39522280~39546187:-
HNSC	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-5.7	2.13e-08	8.18e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	5.7	2.13e-08	8.19e-06	0.32	0.26	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.624	rs34202284	ENSG00000223787.2	RP4-593M8.1	-5.7	2.13e-08	8.19e-06	-0.35	-0.26	Multiple sclerosis;	chr1:92694445	chr1:92580476~92580821:-
HNSC	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	-5.7	2.14e-08	8.2e-06	-0.32	-0.26	Depression;	chr6:28139049	chr6:28161781~28169594:+
HNSC	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-5.7	2.14e-08	8.21e-06	-0.26	-0.25	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
HNSC	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	5.7	2.14e-08	8.21e-06	0.25	0.25	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	5.7	2.14e-08	8.21e-06	0.25	0.25	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	5.7	2.14e-08	8.21e-06	0.25	0.25	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
HNSC	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-5.7	2.14e-08	8.21e-06	-0.28	-0.25	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
HNSC	cis	rs2742234	0.541	rs10793427	ENSG00000273008.1	RP11-351D16.3	5.7	2.14e-08	8.22e-06	0.35	0.25	Hirschsprung disease;	chr10:43251995	chr10:43136824~43138334:-
HNSC	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	5.7	2.14e-08	8.22e-06	0.32	0.25	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	5.7	2.14e-08	8.22e-06	0.32	0.25	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
HNSC	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-5.7	2.15e-08	8.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
HNSC	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	5.7	2.15e-08	8.25e-06	0.32	0.25	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	5.7	2.15e-08	8.25e-06	0.31	0.25	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000179406.6	LINC00174	-5.7	2.15e-08	8.25e-06	-0.33	-0.25	Calcium levels;	chr7:65751755	chr7:66376044~66401338:-
HNSC	cis	rs13113518	0.966	rs11942472	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55574959	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13115828	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55551447	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13136282	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55551845	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11934897	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55553396	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs11932293	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55554025	chr4:55387949~55388271:+
HNSC	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	5.7	2.15e-08	8.26e-06	0.62	0.25	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	5.7	2.15e-08	8.26e-06	0.62	0.25	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
HNSC	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-5.7	2.16e-08	8.27e-06	-0.33	-0.25	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
HNSC	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-5.7	2.16e-08	8.29e-06	-0.27	-0.25	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-5.7	2.16e-08	8.29e-06	-0.27	-0.25	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
HNSC	cis	rs11098499	0.644	rs7693919	ENSG00000249244.1	RP11-548H18.2	5.7	2.16e-08	8.29e-06	0.32	0.25	Corneal astigmatism;	chr4:119619416	chr4:119391831~119395335:-
HNSC	cis	rs4664293	1	rs4665083	ENSG00000226266.5	AC009961.3	5.7	2.17e-08	8.32e-06	0.27	0.25	Monocyte percentage of white cells;	chr2:159573616	chr2:159670708~159712435:-
HNSC	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-5.7	2.17e-08	8.32e-06	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-5.7	2.17e-08	8.32e-06	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
HNSC	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-5.7	2.17e-08	8.33e-06	-0.33	-0.25	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
HNSC	cis	rs35306767	0.953	rs7908138	ENSG00000229869.1	RP11-363N22.2	-5.7	2.17e-08	8.33e-06	-0.35	-0.25	Eosinophil percentage of granulocytes;	chr10:917038	chr10:933026~942743:+
HNSC	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-5.7	2.17e-08	8.34e-06	-0.25	-0.25	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
HNSC	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	5.7	2.18e-08	8.34e-06	0.3	0.25	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
HNSC	cis	rs11648785	0.777	rs3785183	ENSG00000222019.6	URAHP	5.7	2.18e-08	8.35e-06	0.25	0.25	Tanning;	chr16:90029153	chr16:90039761~90047773:-
HNSC	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	5.7	2.18e-08	8.35e-06	0.47	0.25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
HNSC	cis	rs72807246	1	rs72807246	ENSG00000228701.1	TNKS2-AS1	5.7	2.18e-08	8.35e-06	0.48	0.25	Breast cancer;	chr10:92172529	chr10:91782839~91798291:-
HNSC	cis	rs11098499	0.57	rs6832740	ENSG00000249244.1	RP11-548H18.2	5.7	2.18e-08	8.36e-06	0.32	0.25	Corneal astigmatism;	chr4:119624981	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.644	rs6855918	ENSG00000249244.1	RP11-548H18.2	5.7	2.18e-08	8.36e-06	0.32	0.25	Corneal astigmatism;	chr4:119625144	chr4:119391831~119395335:-
HNSC	cis	rs3747113	1	rs35303215	ENSG00000128262.7	POM121L9P	-5.7	2.18e-08	8.36e-06	-0.3	-0.25	Gut microbiome composition (summer);	chr22:24405567	chr22:24251828~24265525:+
HNSC	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-5.7	2.18e-08	8.36e-06	-0.27	-0.25	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
HNSC	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	5.7	2.18e-08	8.37e-06	0.37	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
HNSC	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	5.69	2.19e-08	8.38e-06	0.25	0.25	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
HNSC	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	5.69	2.19e-08	8.38e-06	0.25	0.25	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
HNSC	cis	rs2337406	0.587	rs10129888	ENSG00000211974.3	IGHV2-70	-5.69	2.19e-08	8.38e-06	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106647421	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.872	rs74091715	ENSG00000211974.3	IGHV2-70	-5.69	2.19e-08	8.38e-06	-0.29	-0.25	Rheumatic heart disease;	chr14:106637731	chr14:106723574~106724093:-
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	5.69	2.19e-08	8.39e-06	0.27	0.25	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
HNSC	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	5.69	2.19e-08	8.39e-06	0.33	0.25	Height;	chr4:55413708	chr4:55363971~55395847:-
HNSC	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	5.69	2.19e-08	8.39e-06	0.5	0.25	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
HNSC	cis	rs6951245	0.572	rs112072378	ENSG00000224079.1	AC091729.7	-5.69	2.19e-08	8.4e-06	-0.54	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:999764	chr7:1074450~1078036:+
HNSC	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	5.69	2.19e-08	8.41e-06	0.31	0.25	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
HNSC	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	5.69	2.2e-08	8.41e-06	0.25	0.25	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
HNSC	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	5.69	2.2e-08	8.42e-06	0.35	0.25	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	5.69	2.2e-08	8.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	5.69	2.2e-08	8.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	5.69	2.2e-08	8.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
HNSC	cis	rs13113518	0.966	rs7677952	ENSG00000249700.7	SRD5A3-AS1	5.69	2.2e-08	8.42e-06	0.3	0.25	Height;	chr4:55425312	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	5.69	2.2e-08	8.42e-06	0.28	0.25	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
HNSC	cis	rs4218	0.648	rs58087223	ENSG00000277144.1	RP11-59H7.4	-5.69	2.2e-08	8.43e-06	-0.35	-0.25	Social communication problems;	chr15:59075132	chr15:59115547~59116089:-
HNSC	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	5.69	2.2e-08	8.43e-06	0.32	0.25	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
HNSC	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	5.69	2.2e-08	8.44e-06	0.32	0.25	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
HNSC	cis	rs2579103	1	rs2918621	ENSG00000258183.4	RP11-753N8.1	-5.69	2.2e-08	8.44e-06	-0.33	-0.25	Body mass index;	chr12:90213775	chr12:90280894~90300340:+
HNSC	cis	rs13113518	0.934	rs11935823	ENSG00000249700.7	SRD5A3-AS1	5.69	2.2e-08	8.44e-06	0.3	0.25	Height;	chr4:55589624	chr4:55363971~55395847:-
HNSC	cis	rs6479901	0.793	rs10761725	ENSG00000232075.1	MRPL35P2	-5.69	2.21e-08	8.44e-06	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63634317~63634827:-
HNSC	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	5.69	2.21e-08	8.44e-06	0.29	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	5.69	2.21e-08	8.44e-06	0.29	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
HNSC	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	5.69	2.21e-08	8.45e-06	0.35	0.25	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
HNSC	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-5.69	2.21e-08	8.45e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-5.69	2.21e-08	8.45e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-5.69	2.21e-08	8.45e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
HNSC	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-5.69	2.21e-08	8.45e-06	-0.48	-0.25	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
HNSC	cis	rs11992162	0.967	rs10108320	ENSG00000206014.6	OR7E161P	5.69	2.21e-08	8.45e-06	0.26	0.25	Monocyte count;	chr8:11974754	chr8:11928597~11929563:-
HNSC	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	5.69	2.21e-08	8.46e-06	0.34	0.25	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
HNSC	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	5.69	2.21e-08	8.46e-06	0.35	0.25	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	5.69	2.21e-08	8.46e-06	0.27	0.25	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
HNSC	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	5.69	2.21e-08	8.47e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	5.69	2.21e-08	8.48e-06	0.27	0.25	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
HNSC	cis	rs13126694	0.744	rs10049927	ENSG00000248429.4	RP11-597D13.9	5.69	2.21e-08	8.48e-06	0.29	0.25	Blood osmolality (transformed sodium);	chr4:157998056	chr4:158170752~158202877:+
HNSC	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-5.69	2.22e-08	8.48e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	5.69	2.22e-08	8.48e-06	0.29	0.25	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
HNSC	cis	rs950776	0.79	rs2067808	ENSG00000261762.1	RP11-650L12.2	5.69	2.22e-08	8.49e-06	0.31	0.25	Sudden cardiac arrest;	chr15:78619438	chr15:78589123~78591276:-
HNSC	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	5.69	2.22e-08	8.49e-06	0.2	0.25	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
HNSC	cis	rs75422866	0.85	rs73111231	ENSG00000257433.4	RP1-197B17.3	5.69	2.22e-08	8.5e-06	0.67	0.25	Pneumonia;	chr12:47584539	chr12:47706085~47742294:+
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	5.69	2.22e-08	8.5e-06	0.27	0.25	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
HNSC	cis	rs6604026	0.555	rs34221961	ENSG00000223787.2	RP4-593M8.1	5.69	2.22e-08	8.51e-06	0.35	0.25	Multiple sclerosis;	chr1:92615337	chr1:92580476~92580821:-
HNSC	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-5.69	2.22e-08	8.51e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-5.69	2.22e-08	8.51e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
HNSC	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	5.69	2.23e-08	8.52e-06	0.34	0.25	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
HNSC	cis	rs7404843	0.733	rs153003	ENSG00000263065.1	AF001548.6	5.69	2.23e-08	8.52e-06	0.4	0.25	Testicular germ cell tumor;	chr16:15397543	chr16:15741151~15741791:+
HNSC	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	5.69	2.23e-08	8.53e-06	0.27	0.25	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
HNSC	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-5.69	2.23e-08	8.53e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000211972.2	IGHV3-66	5.69	2.23e-08	8.53e-06	0.2	0.25	Kawasaki disease;	chr14:106716897	chr14:106675017~106675544:-
HNSC	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-5.69	2.23e-08	8.54e-06	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
HNSC	cis	rs2579103	1	rs2043852	ENSG00000258183.4	RP11-753N8.1	-5.69	2.24e-08	8.55e-06	-0.34	-0.25	Body mass index;	chr12:90195659	chr12:90280894~90300340:+
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000254340.1	RP11-10A14.3	5.69	2.24e-08	8.56e-06	0.31	0.25	Mood instability;	chr8:8816226	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	5.69	2.24e-08	8.57e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	5.69	2.24e-08	8.57e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	5.69	2.24e-08	8.57e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
HNSC	cis	rs35306767	0.953	rs1106064	ENSG00000229869.1	RP11-363N22.2	-5.69	2.24e-08	8.57e-06	-0.35	-0.25	Eosinophil percentage of granulocytes;	chr10:911271	chr10:933026~942743:+
HNSC	cis	rs8054556	0.787	rs12325539	ENSG00000183604.13	SMG1P5	-5.69	2.24e-08	8.58e-06	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30267553~30335374:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000254153.1	CTA-398F10.2	5.69	2.24e-08	8.58e-06	0.28	0.25	Mood instability;	chr8:8484905	chr8:8456909~8461337:-
HNSC	cis	rs2810114	0.76	rs2810105	ENSG00000274818.1	RP1-292L20.3	-5.69	2.24e-08	8.58e-06	-0.31	-0.25	Alcohol dependence;	chr14:70957934	chr14:70906657~70907111:-
HNSC	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-5.69	2.25e-08	8.58e-06	-0.28	-0.25	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
HNSC	cis	rs9341808	0.519	rs607130	ENSG00000272129.1	RP11-250B2.6	-5.69	2.25e-08	8.59e-06	-0.3	-0.25	Sitting height ratio;	chr6:80289516	chr6:80355424~80356859:+
HNSC	cis	rs2337406	0.789	rs112027230	ENSG00000211974.3	IGHV2-70	-5.69	2.25e-08	8.6e-06	-0.32	-0.25	Alzheimer's disease (late onset);	chr14:106810329	chr14:106723574~106724093:-
HNSC	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-5.69	2.25e-08	8.6e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
HNSC	cis	rs13113518	0.934	rs11133397	ENSG00000273257.1	RP11-177J6.1	5.69	2.25e-08	8.6e-06	0.31	0.25	Height;	chr4:55534166	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs11133398	ENSG00000273257.1	RP11-177J6.1	5.69	2.25e-08	8.6e-06	0.31	0.25	Height;	chr4:55534180	chr4:55387949~55388271:+
HNSC	cis	rs2742234	0.541	rs11238490	ENSG00000273008.1	RP11-351D16.3	5.69	2.25e-08	8.62e-06	0.35	0.25	Hirschsprung disease;	chr10:43252150	chr10:43136824~43138334:-
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000254340.1	RP11-10A14.3	-5.69	2.26e-08	8.62e-06	-0.31	-0.25	Mood instability;	chr8:8812572	chr8:9141424~9145435:+
HNSC	cis	rs6969780	1	rs6948297	ENSG00000233429.8	HOTAIRM1	5.69	2.26e-08	8.63e-06	0.46	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109785	chr7:27095647~27100265:+
HNSC	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	5.69	2.26e-08	8.63e-06	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
HNSC	cis	rs4356203	0.933	rs12801545	ENSG00000260196.1	RP1-239B22.5	5.69	2.27e-08	8.66e-06	0.28	0.25	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17244629	chr11:17380649~17383531:+
HNSC	cis	rs11976180	0.569	rs12703565	ENSG00000244479.5	OR2A1-AS1	5.69	2.27e-08	8.66e-06	0.38	0.25	Obesity-related traits;	chr7:144057308	chr7:144251264~144356181:-
HNSC	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	5.69	2.27e-08	8.66e-06	0.32	0.25	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	5.69	2.27e-08	8.66e-06	0.32	0.25	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
HNSC	cis	rs9840812	0.691	rs7621025	ENSG00000273486.1	RP11-731C17.2	5.69	2.27e-08	8.66e-06	0.22	0.25	Fibrinogen levels;	chr3:136553404	chr3:136837338~136839021:-
HNSC	cis	rs9840812	0.728	rs6439646	ENSG00000273486.1	RP11-731C17.2	5.69	2.27e-08	8.66e-06	0.22	0.25	Fibrinogen levels;	chr3:136554721	chr3:136837338~136839021:-
HNSC	cis	rs2834288	0.575	rs2239564	ENSG00000237945.6	LINC00649	-5.69	2.27e-08	8.67e-06	-0.33	-0.25	Gut microbiota (bacterial taxa);	chr21:33908245	chr21:33915534~33977691:+
HNSC	cis	rs2483058	0.739	rs963893	ENSG00000261000.1	RP11-534L20.5	5.69	2.27e-08	8.67e-06	0.25	0.25	Cholesterol and Triglycerides;	chr1:206452351	chr1:206503948~206504456:+
HNSC	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	5.69	2.27e-08	8.68e-06	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
HNSC	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	5.69	2.27e-08	8.68e-06	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
HNSC	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-5.69	2.27e-08	8.68e-06	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
HNSC	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	5.69	2.28e-08	8.69e-06	0.35	0.25	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
HNSC	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	5.69	2.28e-08	8.69e-06	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
HNSC	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	5.69	2.28e-08	8.69e-06	0.28	0.25	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
HNSC	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	5.69	2.28e-08	8.7e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
HNSC	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-5.69	2.28e-08	8.7e-06	-0.26	-0.25	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
HNSC	cis	rs9402743	0.6	rs9376151	ENSG00000217482.2	HMGB1P17	5.69	2.28e-08	8.71e-06	0.27	0.25	Systemic lupus erythematosus;	chr6:135789599	chr6:135636086~135636713:-
HNSC	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-5.69	2.29e-08	8.72e-06	-0.31	-0.25	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
HNSC	cis	rs860295	0.871	rs12724079	ENSG00000203761.5	MSTO2P	5.69	2.29e-08	8.72e-06	0.19	0.25	Body mass index;	chr1:155464151	chr1:155745829~155750137:+
HNSC	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-5.69	2.29e-08	8.73e-06	-0.36	-0.25	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
HNSC	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-5.69	2.29e-08	8.74e-06	-0.33	-0.25	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
HNSC	cis	rs35306767	0.953	rs1539174	ENSG00000229869.1	RP11-363N22.2	-5.69	2.29e-08	8.75e-06	-0.34	-0.25	Eosinophil percentage of granulocytes;	chr10:928930	chr10:933026~942743:+
HNSC	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-5.69	2.3e-08	8.76e-06	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
HNSC	cis	rs6723108	0.517	rs1530557	ENSG00000224043.6	CCNT2-AS1	5.69	2.3e-08	8.77e-06	0.3	0.25	Type 2 diabetes;	chr2:134849309	chr2:134735464~134918710:-
HNSC	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-5.69	2.3e-08	8.77e-06	-0.41	-0.25	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
HNSC	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-5.69	2.3e-08	8.77e-06	-0.41	-0.25	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
HNSC	cis	rs13113518	1	rs4864546	ENSG00000273257.1	RP11-177J6.1	5.69	2.3e-08	8.77e-06	0.31	0.25	Height;	chr4:55537960	chr4:55387949~55388271:+
HNSC	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	5.69	2.3e-08	8.77e-06	0.25	0.25	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
HNSC	cis	rs2579103	0.782	rs1583701	ENSG00000258183.4	RP11-753N8.1	-5.69	2.3e-08	8.78e-06	-0.31	-0.25	Body mass index;	chr12:90205824	chr12:90280894~90300340:+
HNSC	cis	rs13113518	1	rs4865007	ENSG00000249700.7	SRD5A3-AS1	-5.69	2.3e-08	8.79e-06	-0.3	-0.25	Height;	chr4:55537550	chr4:55363971~55395847:-
HNSC	cis	rs2976388	0.647	rs2585174	ENSG00000253741.1	CTD-2292P10.4	-5.69	2.31e-08	8.79e-06	-0.24	-0.25	Urinary tract infection frequency;	chr8:142700626	chr8:142702252~142726973:-
HNSC	cis	rs2579103	0.898	rs35018904	ENSG00000258183.4	RP11-753N8.1	-5.69	2.31e-08	8.79e-06	-0.31	-0.25	Body mass index;	chr12:90202113	chr12:90280894~90300340:+
HNSC	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	5.69	2.31e-08	8.79e-06	0.26	0.25	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
HNSC	cis	rs2579103	0.898	rs10777237	ENSG00000258183.4	RP11-753N8.1	5.69	2.31e-08	8.79e-06	0.31	0.25	Body mass index;	chr12:90249747	chr12:90280894~90300340:+
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-5.69	2.31e-08	8.79e-06	-0.27	-0.25	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-5.69	2.31e-08	8.79e-06	-0.27	-0.25	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-5.69	2.31e-08	8.79e-06	-0.27	-0.25	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
HNSC	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-5.69	2.31e-08	8.8e-06	-0.28	-0.25	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
HNSC	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-5.68	2.31e-08	8.8e-06	-0.34	-0.25	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
HNSC	cis	rs4144743	0.641	rs67696888	ENSG00000228782.6	CTD-2026D20.3	-5.68	2.31e-08	8.8e-06	-0.33	-0.25	Body mass index;	chr17:47277750	chr17:47450568~47492492:-
HNSC	cis	rs9300255	0.55	rs10772997	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.8e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123235333	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs11057202	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.8e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123236228	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.566	rs10744150	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.8e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123237067	chr12:123152324~123153377:-
HNSC	cis	rs2919917	0.578	rs922928	ENSG00000254352.1	RP11-578O24.2	5.68	2.31e-08	8.81e-06	0.35	0.25	Lymphocyte counts;	chr8:78645085	chr8:78723796~78724136:-
HNSC	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	5.68	2.31e-08	8.81e-06	0.31	0.25	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
HNSC	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	5.68	2.31e-08	8.81e-06	0.25	0.25	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	5.68	2.31e-08	8.81e-06	0.25	0.25	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
HNSC	cis	rs9302065	0.565	rs2993585	ENSG00000223298.1	RNY3P8	5.68	2.31e-08	8.82e-06	0.26	0.25	Blood metabolite levels;	chr13:95309712	chr13:95310830~95310955:-
HNSC	cis	rs9300255	0.596	rs1568427	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123254131	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.539	rs1969355	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123257514	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs10734900	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123258898	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs10734901	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123258900	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs10732573	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123259336	chr12:123152324~123153377:-
HNSC	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-5.68	2.32e-08	8.83e-06	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
HNSC	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	5.68	2.32e-08	8.83e-06	0.26	0.25	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	5.68	2.32e-08	8.83e-06	0.26	0.25	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	5.68	2.32e-08	8.83e-06	0.26	0.25	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-5.68	2.32e-08	8.84e-06	-0.3	-0.25	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-5.68	2.33e-08	8.86e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
HNSC	cis	rs60617249	0.501	rs4446688	ENSG00000228204.2	RP4-724E13.2	5.68	2.33e-08	8.88e-06	0.32	0.25	Major depression and alcohol dependence;	chr7:50925780	chr7:50866747~51022990:+
HNSC	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	5.68	2.33e-08	8.88e-06	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
HNSC	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
HNSC	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-5.68	2.33e-08	8.89e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-5.68	2.33e-08	8.89e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	5.68	2.33e-08	8.89e-06	0.32	0.25	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
HNSC	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	5.68	2.34e-08	8.9e-06	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
HNSC	cis	rs8177876	0.915	rs4889233	ENSG00000261061.1	RP11-303E16.2	5.68	2.34e-08	8.9e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093378	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.915	rs11866124	ENSG00000261061.1	RP11-303E16.2	5.68	2.34e-08	8.9e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093866	chr16:81030770~81031485:+
HNSC	cis	rs3738443	0.672	rs6691539	ENSG00000259865.1	RP11-488L18.10	5.68	2.34e-08	8.91e-06	0.2	0.25	Alcohol dependence;	chr1:247209370	chr1:247187281~247188526:-
HNSC	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-5.68	2.34e-08	8.92e-06	-0.3	-0.25	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
HNSC	cis	rs11846409	0.652	rs10143549	ENSG00000274576.2	IGHV2-70	-5.68	2.34e-08	8.92e-06	-0.25	-0.25	Rheumatic heart disease;	chr14:106644643	chr14:106770577~106771020:-
HNSC	cis	rs10435719	0.718	rs7813935	ENSG00000206014.6	OR7E161P	-5.68	2.34e-08	8.92e-06	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11928597~11929563:-
HNSC	cis	rs10256972	0.967	rs7799110	ENSG00000225146.1	AC073957.15	5.68	2.34e-08	8.92e-06	0.3	0.25	Endometriosis;Longevity;	chr7:999429	chr7:1029025~1043891:+
HNSC	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-5.68	2.34e-08	8.92e-06	-0.39	-0.25	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
HNSC	cis	rs9300255	0.568	rs1627724	ENSG00000280120.1	RP11-546D6.3	5.68	2.35e-08	8.93e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123154033	chr12:123152324~123153377:-
HNSC	cis	rs7402982	0.625	rs4966008	ENSG00000278022.1	RP11-35O15.2	5.68	2.35e-08	8.93e-06	0.3	0.25	Birth weight;	chr15:98660216	chr15:98660210~98660668:+
HNSC	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	5.68	2.35e-08	8.93e-06	0.28	0.25	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
HNSC	cis	rs9611519	0.78	rs2235850	ENSG00000235513.1	RP4-756G23.5	5.68	2.35e-08	8.93e-06	0.26	0.25	Neuroticism;	chr22:41261622	chr22:41209122~41217627:-
HNSC	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	5.68	2.35e-08	8.94e-06	0.31	0.25	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
HNSC	cis	rs9302065	0.565	rs2993584	ENSG00000223298.1	RNY3P8	5.68	2.35e-08	8.94e-06	0.26	0.25	Blood metabolite levels;	chr13:95309424	chr13:95310830~95310955:-
HNSC	cis	rs1355223	0.902	rs12802323	ENSG00000271369.1	RP11-350D17.3	-5.68	2.35e-08	8.94e-06	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726192	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-5.68	2.35e-08	8.95e-06	-0.32	-0.25	Depression;	chr6:28139876	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-5.68	2.35e-08	8.95e-06	-0.32	-0.25	Depression;	chr6:28139998	chr6:28161781~28169594:+
HNSC	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	5.68	2.35e-08	8.95e-06	0.32	0.25	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
HNSC	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	5.68	2.35e-08	8.95e-06	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
HNSC	cis	rs11846409	0.932	rs74091721	ENSG00000211974.3	IGHV2-70	-5.68	2.35e-08	8.95e-06	-0.29	-0.25	Rheumatic heart disease;	chr14:106638262	chr14:106723574~106724093:-
HNSC	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-5.68	2.35e-08	8.95e-06	-0.24	-0.25	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
HNSC	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-5.68	2.35e-08	8.95e-06	-0.33	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
HNSC	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	5.68	2.35e-08	8.95e-06	0.33	0.25	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
HNSC	cis	rs9611519	1	rs5758267	ENSG00000235513.1	RP4-756G23.5	-5.68	2.36e-08	8.97e-06	-0.27	-0.25	Neuroticism;	chr22:41223346	chr22:41209122~41217627:-
HNSC	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.97e-06	0.31	0.25	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	5.68	2.36e-08	8.98e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	5.68	2.36e-08	8.98e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-5.68	2.36e-08	8.99e-06	-0.18	-0.25	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
HNSC	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-5.68	2.36e-08	8.99e-06	-0.31	-0.25	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
HNSC	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-5.68	2.37e-08	9e-06	-0.24	-0.25	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
HNSC	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	5.68	2.37e-08	9.01e-06	0.35	0.25	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000211972.2	IGHV3-66	5.68	2.37e-08	9.02e-06	0.2	0.25	Kawasaki disease;	chr14:106708947	chr14:106675017~106675544:-
HNSC	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-5.68	2.37e-08	9.02e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
HNSC	cis	rs2483058	0.767	rs10779631	ENSG00000261000.1	RP11-534L20.5	5.68	2.37e-08	9.02e-06	0.25	0.25	Cholesterol and Triglycerides;	chr1:206448943	chr1:206503948~206504456:+
HNSC	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	5.68	2.37e-08	9.02e-06	0.36	0.25	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
HNSC	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-5.68	2.37e-08	9.02e-06	-0.24	-0.25	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
HNSC	cis	rs2933343	0.679	rs789254	ENSG00000261159.1	RP11-723O4.9	5.68	2.37e-08	9.02e-06	0.25	0.25	IgG glycosylation;	chr3:128855750	chr3:128859716~128860526:-
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	5.68	2.38e-08	9.05e-06	0.26	0.25	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000211972.2	IGHV3-66	5.68	2.38e-08	9.05e-06	0.21	0.25	Kawasaki disease;	chr14:106805607	chr14:106675017~106675544:-
HNSC	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-5.68	2.38e-08	9.06e-06	-0.27	-0.25	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-5.68	2.38e-08	9.06e-06	-0.15	-0.25	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-5.68	2.38e-08	9.06e-06	-0.15	-0.25	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	5.68	2.38e-08	9.06e-06	0.27	0.25	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
HNSC	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	5.68	2.39e-08	9.07e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
HNSC	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-5.68	2.39e-08	9.08e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-5.68	2.39e-08	9.08e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-5.68	2.39e-08	9.08e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
HNSC	cis	rs9813712	0.904	rs6439223	ENSG00000249846.5	RP11-77P16.4	5.68	2.39e-08	9.08e-06	0.3	0.25	Response to amphetamines;	chr3:130256697	chr3:130112550~130120579:+
HNSC	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-5.68	2.39e-08	9.09e-06	-0.25	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
HNSC	cis	rs5753618	0.583	rs5753628	ENSG00000236132.1	CTA-440B3.1	-5.68	2.39e-08	9.1e-06	-0.33	-0.25	Colorectal cancer;	chr22:31464336	chr22:31816379~31817491:-
HNSC	cis	rs1908814	0.516	rs7825529	ENSG00000206014.6	OR7E161P	-5.68	2.4e-08	9.1e-06	-0.27	-0.25	Neuroticism;	chr8:11936935	chr8:11928597~11929563:-
HNSC	cis	rs8059260	0.877	rs6498146	ENSG00000274038.1	RP11-66H6.4	5.68	2.4e-08	9.1e-06	0.38	0.25	Alcohol consumption over the past year;	chr16:11012850	chr16:11056556~11057034:+
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-5.68	2.4e-08	9.1e-06	-0.17	-0.25	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
HNSC	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28136698	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28136856	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28137418	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28138363	chr6:28161781~28169594:+
HNSC	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-5.68	2.4e-08	9.11e-06	-0.23	-0.25	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
HNSC	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-5.68	2.4e-08	9.11e-06	-0.37	-0.25	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
HNSC	cis	rs9914544	0.966	rs1737943	ENSG00000264885.1	RP11-815I9.4	5.68	2.4e-08	9.11e-06	0.27	0.25	Educational attainment (years of education);	chr17:18938277	chr17:18667629~18669461:-
HNSC	cis	rs7567389	0.534	rs2069904	ENSG00000236682.1	AC068282.3	-5.68	2.4e-08	9.11e-06	-0.32	-0.25	Self-rated health;	chr2:127418203	chr2:127389130~127400580:+
HNSC	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-5.68	2.4e-08	9.11e-06	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
HNSC	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-5.68	2.4e-08	9.12e-06	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
HNSC	cis	rs8177876	0.686	rs804897	ENSG00000261061.1	RP11-303E16.2	5.68	2.4e-08	9.13e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067590	chr16:81030770~81031485:+
HNSC	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
HNSC	cis	rs13113518	0.812	rs12500456	ENSG00000273257.1	RP11-177J6.1	5.68	2.41e-08	9.14e-06	0.32	0.25	Height;	chr4:55561053	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.783	rs2171618	ENSG00000273257.1	RP11-177J6.1	5.68	2.41e-08	9.14e-06	0.32	0.25	Height;	chr4:55564241	chr4:55387949~55388271:+
HNSC	cis	rs12701220	0.901	rs12701708	ENSG00000229043.2	AC091729.9	-5.68	2.41e-08	9.14e-06	-0.35	-0.25	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1160374~1165267:+
HNSC	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-5.68	2.41e-08	9.15e-06	-0.32	-0.25	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
HNSC	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	5.68	2.41e-08	9.15e-06	0.24	0.25	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
HNSC	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	5.68	2.41e-08	9.16e-06	0.31	0.25	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	5.68	2.41e-08	9.16e-06	0.31	0.25	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
HNSC	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	5.68	2.41e-08	9.17e-06	0.29	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
HNSC	cis	rs4218	0.648	rs12442086	ENSG00000277144.1	RP11-59H7.4	-5.68	2.42e-08	9.17e-06	-0.35	-0.25	Social communication problems;	chr15:59074364	chr15:59115547~59116089:-
HNSC	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	5.68	2.42e-08	9.18e-06	0.27	0.25	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
HNSC	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	5.68	2.42e-08	9.18e-06	0.31	0.25	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
HNSC	cis	rs73186030	0.764	rs34408666	ENSG00000272758.4	RP11-299J3.8	5.68	2.42e-08	9.19e-06	0.36	0.25	Serum parathyroid hormone levels;	chr3:122262762	chr3:122416207~122443180:+
HNSC	cis	rs2579103	1	rs2408222	ENSG00000258183.4	RP11-753N8.1	-5.68	2.42e-08	9.19e-06	-0.33	-0.25	Body mass index;	chr12:90208355	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2731228	ENSG00000258183.4	RP11-753N8.1	-5.68	2.42e-08	9.19e-06	-0.33	-0.25	Body mass index;	chr12:90211011	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2579121	ENSG00000258183.4	RP11-753N8.1	-5.68	2.42e-08	9.19e-06	-0.33	-0.25	Body mass index;	chr12:90211227	chr12:90280894~90300340:+
HNSC	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	5.68	2.43e-08	9.21e-06	0.21	0.25	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
HNSC	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	5.68	2.43e-08	9.22e-06	0.31	0.25	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
HNSC	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	5.68	2.43e-08	9.22e-06	0.31	0.25	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
HNSC	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-5.68	2.43e-08	9.22e-06	-0.23	-0.25	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
HNSC	cis	rs13113518	1	rs11942279	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55439652	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805148	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55440643	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133380	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55441110	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12510110	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55441567	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12510990	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55441907	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805149	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55442184	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11945370	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55442875	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12647677	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55444253	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.902	rs3805150	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55446869	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4864990	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55447523	chr4:55363971~55395847:-
HNSC	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-5.68	2.43e-08	9.22e-06	-0.22	-0.25	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
HNSC	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-5.68	2.43e-08	9.22e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
HNSC	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-5.68	2.43e-08	9.22e-06	-0.24	-0.25	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
HNSC	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	5.67	2.44e-08	9.26e-06	0.35	0.25	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
HNSC	cis	rs2439831	0.681	rs11858152	ENSG00000205771.5	CATSPER2P1	-5.67	2.44e-08	9.26e-06	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43341998	chr15:43726918~43747094:-
HNSC	cis	rs8012947	0.916	rs11851552	ENSG00000279636.2	LINC00216	5.67	2.44e-08	9.27e-06	0.32	0.25	Alcohol consumption in current drinkers;	chr14:58240032	chr14:58288033~58289158:+
HNSC	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	5.67	2.44e-08	9.27e-06	0.31	0.25	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
HNSC	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-5.67	2.44e-08	9.27e-06	-0.32	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
HNSC	cis	rs8054556	1	rs11901	ENSG00000183604.13	SMG1P5	-5.67	2.45e-08	9.27e-06	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4318227	ENSG00000183604.13	SMG1P5	-5.67	2.45e-08	9.27e-06	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:30267553~30335374:-
HNSC	cis	rs7587476	1	rs1542173	ENSG00000229267.2	AC072062.1	5.67	2.45e-08	9.27e-06	0.35	0.25	Neuroblastoma;	chr2:214792836	chr2:214810229~214963274:+
HNSC	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-5.67	2.45e-08	9.28e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000211972.2	IGHV3-66	5.67	2.45e-08	9.29e-06	0.2	0.25	Kawasaki disease;	chr14:106705271	chr14:106675017~106675544:-
HNSC	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-5.67	2.45e-08	9.29e-06	-0.24	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
HNSC	cis	rs7621025	0.554	rs1471740	ENSG00000273486.1	RP11-731C17.2	5.67	2.45e-08	9.3e-06	0.22	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136609428	chr3:136837338~136839021:-
HNSC	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	5.67	2.45e-08	9.3e-06	0.32	0.25	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
HNSC	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	5.67	2.46e-08	9.31e-06	0.3	0.25	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28089816	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28090857	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28091439	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28091659	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28092227	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28093966	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28094014	chr6:28161781~28169594:+
HNSC	cis	rs13113518	1	rs4864549	ENSG00000273257.1	RP11-177J6.1	5.67	2.46e-08	9.31e-06	0.31	0.25	Height;	chr4:55554380	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4865011	ENSG00000273257.1	RP11-177J6.1	5.67	2.46e-08	9.31e-06	0.31	0.25	Height;	chr4:55554456	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4865013	ENSG00000273257.1	RP11-177J6.1	5.67	2.46e-08	9.31e-06	0.31	0.25	Height;	chr4:55559957	chr4:55387949~55388271:+
HNSC	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	5.67	2.46e-08	9.32e-06	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
HNSC	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-5.67	2.46e-08	9.32e-06	-0.36	-0.25	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
HNSC	cis	rs11992162	0.597	rs7011924	ENSG00000206014.6	OR7E161P	5.67	2.46e-08	9.33e-06	0.28	0.25	Monocyte count;	chr8:11923084	chr8:11928597~11929563:-
HNSC	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-5.67	2.46e-08	9.33e-06	-0.32	-0.25	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
HNSC	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-5.67	2.47e-08	9.36e-06	-0.24	-0.25	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
HNSC	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
HNSC	cis	rs6951245	0.572	rs60918895	ENSG00000224079.1	AC091729.7	-5.67	2.47e-08	9.37e-06	-0.51	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:999400	chr7:1074450~1078036:+
HNSC	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-5.67	2.47e-08	9.37e-06	-0.31	-0.25	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
HNSC	cis	rs667920	0.512	rs13065626	ENSG00000273486.1	RP11-731C17.2	-5.67	2.47e-08	9.37e-06	-0.3	-0.25	Coronary artery disease;	chr3:136575915	chr3:136837338~136839021:-
HNSC	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	5.67	2.47e-08	9.37e-06	0.35	0.25	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	5.67	2.47e-08	9.37e-06	0.35	0.25	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	5.67	2.47e-08	9.37e-06	0.35	0.25	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
HNSC	cis	rs904251	0.507	rs11756941	ENSG00000204110.6	RP1-153P14.8	-5.67	2.47e-08	9.37e-06	-0.31	-0.25	Cognitive performance;	chr6:37448443	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	5.67	2.48e-08	9.38e-06	0.31	0.25	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	5.67	2.48e-08	9.38e-06	0.31	0.25	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
HNSC	cis	rs155076	0.711	rs4770131	ENSG00000233325.3	MIPEPP3	-5.67	2.48e-08	9.38e-06	-0.41	-0.25	White matter hyperintensity burden;	chr13:21323329	chr13:21298139~21306373:+
HNSC	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-5.67	2.48e-08	9.38e-06	-0.22	-0.25	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-5.67	2.48e-08	9.38e-06	-0.22	-0.25	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
HNSC	cis	rs13113518	1	rs13152173	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55534788	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13141049	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55535489	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs12507722	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55536421	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs7696832	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55537080	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4864547	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55538228	chr4:55387949~55388271:+
HNSC	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-5.67	2.48e-08	9.39e-06	-0.39	-0.25	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
HNSC	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-5.67	2.48e-08	9.4e-06	-0.28	-0.25	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
HNSC	cis	rs13113518	0.934	rs11133397	ENSG00000249700.7	SRD5A3-AS1	5.67	2.49e-08	9.41e-06	0.3	0.25	Height;	chr4:55534166	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs11133398	ENSG00000249700.7	SRD5A3-AS1	5.67	2.49e-08	9.41e-06	0.3	0.25	Height;	chr4:55534180	chr4:55363971~55395847:-
HNSC	cis	rs9840812	0.861	rs687339	ENSG00000239213.4	NCK1-AS1	5.67	2.49e-08	9.41e-06	0.24	0.25	Fibrinogen levels;	chr3:136213517	chr3:136841726~136862054:-
HNSC	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	5.67	2.49e-08	9.42e-06	0.29	0.25	Migraine;	chr4:56861145	chr4:56960927~56961373:-
HNSC	cis	rs9326248	0.53	rs2075292	ENSG00000280143.1	AP000892.6	5.67	2.49e-08	9.42e-06	0.39	0.25	Blood protein levels;	chr11:116861796	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs6589575	ENSG00000280143.1	AP000892.6	5.67	2.49e-08	9.42e-06	0.39	0.25	Blood protein levels;	chr11:116862594	chr11:117204967~117210292:+
HNSC	cis	rs3206736	0.548	rs328896	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34977610	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328900	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34980668	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328901	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34980839	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328904	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34981564	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328908	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34986396	chr7:34346512~34871582:-
HNSC	cis	rs11098499	0.754	rs12711071	ENSG00000249244.1	RP11-548H18.2	5.67	2.49e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119319779	chr4:119391831~119395335:-
HNSC	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-5.67	2.49e-08	9.42e-06	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
HNSC	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-5.67	2.49e-08	9.42e-06	-0.3	-0.25	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
HNSC	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-5.67	2.49e-08	9.42e-06	-0.47	-0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
HNSC	cis	rs8054556	1	rs3814881	ENSG00000183604.13	SMG1P5	-5.67	2.5e-08	9.42e-06	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:30267553~30335374:-
HNSC	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
HNSC	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	5.67	2.5e-08	9.43e-06	0.45	0.25	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
HNSC	cis	rs6951245	0.935	rs112554101	ENSG00000225146.1	AC073957.15	-5.67	2.5e-08	9.43e-06	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1029025~1043891:+
HNSC	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.43e-06	0.31	0.25	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
HNSC	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.5e-08	9.43e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.5e-08	9.43e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
HNSC	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	5.67	2.5e-08	9.45e-06	0.36	0.25	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
HNSC	cis	rs9300255	0.602	rs2510885	ENSG00000280120.1	RP11-546D6.3	5.67	2.5e-08	9.46e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123130266	chr12:123152324~123153377:-
HNSC	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-5.67	2.51e-08	9.47e-06	-0.32	-0.25	Depression;	chr6:28108492	chr6:28161781~28169594:+
HNSC	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-5.67	2.51e-08	9.48e-06	-0.31	-0.25	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
HNSC	cis	rs75920871	0.528	rs12279066	ENSG00000254851.1	RP11-109L13.1	5.67	2.51e-08	9.48e-06	0.36	0.25	Subjective well-being;	chr11:117043193	chr11:117135528~117138582:+
HNSC	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-5.67	2.51e-08	9.49e-06	-0.29	-0.25	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
HNSC	cis	rs5753618	0.583	rs2273251	ENSG00000236132.1	CTA-440B3.1	-5.67	2.52e-08	9.5e-06	-0.32	-0.25	Colorectal cancer;	chr22:31447581	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.69	rs7674713	ENSG00000249244.1	RP11-548H18.2	5.67	2.52e-08	9.53e-06	0.31	0.25	Corneal astigmatism;	chr4:119401102	chr4:119391831~119395335:-
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	5.67	2.53e-08	9.53e-06	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
HNSC	cis	rs1355223	0.902	rs1258468	ENSG00000271369.1	RP11-350D17.3	-5.67	2.53e-08	9.54e-06	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708184	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.872	rs1258466	ENSG00000271369.1	RP11-350D17.3	-5.67	2.53e-08	9.54e-06	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708519	chr11:34709600~34710161:+
HNSC	cis	rs804280	0.509	rs13276433	ENSG00000206014.6	OR7E161P	-5.67	2.53e-08	9.54e-06	-0.27	-0.25	Myopia (pathological);	chr8:11925527	chr8:11928597~11929563:-
HNSC	cis	rs7209700	0.894	rs7212751	ENSG00000228782.6	CTD-2026D20.3	-5.67	2.53e-08	9.54e-06	-0.25	-0.25	IgG glycosylation;	chr17:47278133	chr17:47450568~47492492:-
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	5.67	2.53e-08	9.55e-06	0.29	0.25	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
HNSC	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	5.67	2.53e-08	9.55e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
HNSC	cis	rs13126694	0.744	rs7691516	ENSG00000248429.4	RP11-597D13.9	5.67	2.53e-08	9.56e-06	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158073326	chr4:158170752~158202877:+
HNSC	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-5.67	2.53e-08	9.56e-06	-0.23	-0.25	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
HNSC	cis	rs9341808	0.667	rs583426	ENSG00000272129.1	RP11-250B2.6	-5.67	2.53e-08	9.56e-06	-0.3	-0.25	Sitting height ratio;	chr6:80236970	chr6:80355424~80356859:+
HNSC	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-5.67	2.53e-08	9.56e-06	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
HNSC	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	5.67	2.54e-08	9.57e-06	0.3	0.25	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
HNSC	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	5.67	2.54e-08	9.57e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-5.67	2.54e-08	9.58e-06	-0.17	-0.25	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
HNSC	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	5.67	2.54e-08	9.58e-06	0.31	0.25	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
HNSC	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	5.67	2.54e-08	9.58e-06	0.26	0.25	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
HNSC	cis	rs13113518	1	rs4864548	ENSG00000249700.7	SRD5A3-AS1	-5.67	2.54e-08	9.59e-06	-0.3	-0.25	Height;	chr4:55547636	chr4:55363971~55395847:-
HNSC	cis	rs6928977	0.66	rs2757643	ENSG00000217482.2	HMGB1P17	5.67	2.54e-08	9.59e-06	0.27	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135440095	chr6:135636086~135636713:-
HNSC	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-5.67	2.54e-08	9.59e-06	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-5.67	2.54e-08	9.59e-06	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
HNSC	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	5.67	2.54e-08	9.59e-06	0.3	0.25	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
HNSC	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-5.67	2.54e-08	9.59e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
HNSC	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	5.67	2.55e-08	9.63e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
HNSC	cis	rs9300255	0.537	rs1618679	ENSG00000280120.1	RP11-546D6.3	5.67	2.55e-08	9.63e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123166167	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1621194	ENSG00000280120.1	RP11-546D6.3	5.67	2.55e-08	9.63e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123166471	chr12:123152324~123153377:-
HNSC	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	5.67	2.55e-08	9.64e-06	0.24	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
HNSC	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	5.67	2.55e-08	9.64e-06	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
HNSC	cis	rs947583	0.588	rs9494355	ENSG00000217482.2	HMGB1P17	5.67	2.56e-08	9.64e-06	0.29	0.25	Phosphorus levels;	chr6:135743579	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.588	rs12216021	ENSG00000217482.2	HMGB1P17	5.67	2.56e-08	9.64e-06	0.29	0.25	Phosphorus levels;	chr6:135752789	chr6:135636086~135636713:-
HNSC	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	5.67	2.56e-08	9.65e-06	0.21	0.25	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
HNSC	cis	rs8177876	0.915	rs6420421	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094601	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.749	rs5023849	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094694	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.841	rs5023850	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094755	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.915	rs5023852	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094800	chr16:81030770~81031485:+
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000211972.2	IGHV3-66	5.67	2.56e-08	9.65e-06	0.2	0.25	Kawasaki disease;	chr14:106799304	chr14:106675017~106675544:-
HNSC	cis	rs9300255	0.83	rs28413626	ENSG00000280120.1	RP11-546D6.3	-5.67	2.56e-08	9.66e-06	-0.23	-0.25	Neutrophil percentage of white cells;	chr12:123376905	chr12:123152324~123153377:-
HNSC	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-5.67	2.56e-08	9.66e-06	-0.32	-0.25	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
HNSC	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-5.67	2.57e-08	9.68e-06	-0.27	-0.25	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
HNSC	cis	rs1021993	1	rs2660643	ENSG00000231648.1	RP11-372M18.2	5.67	2.57e-08	9.68e-06	0.35	0.25	Gut microbiome composition (winter);	chr1:209299094	chr1:209367662~209379690:+
HNSC	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-5.67	2.57e-08	9.68e-06	-0.25	-0.25	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
HNSC	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	5.67	2.57e-08	9.69e-06	0.27	0.25	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
HNSC	cis	rs9813712	0.909	rs1453257	ENSG00000249846.5	RP11-77P16.4	-5.67	2.57e-08	9.69e-06	-0.3	-0.25	Response to amphetamines;	chr3:130258730	chr3:130112550~130120579:+
HNSC	cis	rs3738443	0.594	rs6664697	ENSG00000259865.1	RP11-488L18.10	-5.67	2.57e-08	9.7e-06	-0.2	-0.25	Alcohol dependence;	chr1:247217308	chr1:247187281~247188526:-
HNSC	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-5.67	2.57e-08	9.7e-06	-0.22	-0.25	Height;	chr11:118760944	chr11:118791254~118793137:+
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	5.67	2.57e-08	9.7e-06	0.31	0.25	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
HNSC	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-5.67	2.57e-08	9.7e-06	-0.2	-0.25	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
HNSC	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-5.66	2.57e-08	9.7e-06	-0.32	-0.25	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
HNSC	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-5.66	2.58e-08	9.71e-06	-0.31	-0.25	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
HNSC	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-5.66	2.58e-08	9.71e-06	-0.32	-0.25	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
HNSC	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-5.66	2.58e-08	9.71e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
HNSC	cis	rs10435719	0.902	rs4840599	ENSG00000206014.6	OR7E161P	5.66	2.58e-08	9.73e-06	0.27	0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000254340.1	RP11-10A14.3	5.66	2.58e-08	9.74e-06	0.3	0.25	Mood instability;	chr8:8863963	chr8:9141424~9145435:+
HNSC	cis	rs1933112	0.5	rs1998510	ENSG00000227777.1	RP4-738P11.3	-5.66	2.59e-08	9.74e-06	-0.35	-0.25	Blood protein levels;	chr1:168533924	chr1:168542737~168543354:+
HNSC	cis	rs1933112	0.5	rs4656599	ENSG00000227777.1	RP4-738P11.3	-5.66	2.59e-08	9.74e-06	-0.35	-0.25	Blood protein levels;	chr1:168534148	chr1:168542737~168543354:+
HNSC	cis	rs2810114	0.916	rs2810099	ENSG00000274818.1	RP1-292L20.3	-5.66	2.59e-08	9.77e-06	-0.31	-0.25	Alcohol dependence;	chr14:70965704	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.57	rs67188216	ENSG00000274818.1	RP1-292L20.3	5.66	2.59e-08	9.77e-06	0.31	0.25	Schizophrenia;	chr14:71042607	chr14:70906657~70907111:-
HNSC	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-5.66	2.59e-08	9.77e-06	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
HNSC	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-5.66	2.6e-08	9.78e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
HNSC	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	5.66	2.6e-08	9.78e-06	0.32	0.25	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	5.66	2.6e-08	9.78e-06	0.32	0.25	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
HNSC	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-5.66	2.6e-08	9.79e-06	-0.31	-0.25	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
HNSC	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	5.66	2.6e-08	9.8e-06	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
HNSC	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	5.66	2.6e-08	9.81e-06	0.36	0.25	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
HNSC	cis	rs13113518	1	rs3749474	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55434518	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs1474271	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55435912	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11937487	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55436576	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805146	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55436985	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133378	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55439472	chr4:55363971~55395847:-
HNSC	cis	rs858239	0.799	rs10279941	ENSG00000226816.2	AC005082.12	5.66	2.61e-08	9.81e-06	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23206013~23208045:+
HNSC	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	5.66	2.61e-08	9.81e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
HNSC	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	5.66	2.61e-08	9.82e-06	0.24	0.25	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
HNSC	cis	rs2579103	0.898	rs2118806	ENSG00000258183.4	RP11-753N8.1	-5.66	2.61e-08	9.83e-06	-0.31	-0.25	Body mass index;	chr12:90207532	chr12:90280894~90300340:+
HNSC	cis	rs8177876	0.749	rs58144189	ENSG00000261061.1	RP11-303E16.2	-5.66	2.61e-08	9.83e-06	-0.48	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.749	rs1035541	ENSG00000261061.1	RP11-303E16.2	-5.66	2.61e-08	9.83e-06	-0.48	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81030770~81031485:+
HNSC	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	5.66	2.61e-08	9.84e-06	0.66	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
HNSC	cis	rs4699052	0.787	rs2169508	ENSG00000246560.2	RP11-10L12.4	5.66	2.62e-08	9.86e-06	0.29	0.25	Testicular germ cell tumor;	chr4:103145733	chr4:102828055~102844075:+
HNSC	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	5.66	2.62e-08	9.87e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
HNSC	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	5.66	2.63e-08	9.88e-06	0.34	0.25	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
HNSC	cis	rs6928977	0.896	rs2064430	ENSG00000234084.1	RP3-388E23.2	-5.66	2.63e-08	9.89e-06	-0.25	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135321618	chr6:135301568~135307158:+
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	5.66	2.63e-08	9.9e-06	0.31	0.25	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
HNSC	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	5.66	2.63e-08	9.9e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
HNSC	cis	rs67981189	0.529	rs2810096	ENSG00000274818.1	RP1-292L20.3	-5.66	2.63e-08	9.9e-06	-0.31	-0.25	Schizophrenia;	chr14:70968583	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.529	rs17108808	ENSG00000274818.1	RP1-292L20.3	5.66	2.63e-08	9.9e-06	0.31	0.25	Schizophrenia;	chr14:70974835	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.501	rs3829954	ENSG00000274818.1	RP1-292L20.3	5.66	2.63e-08	9.9e-06	0.31	0.25	Schizophrenia;	chr14:70988823	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.529	rs17108862	ENSG00000274818.1	RP1-292L20.3	5.66	2.63e-08	9.9e-06	0.31	0.25	Schizophrenia;	chr14:70997949	chr14:70906657~70907111:-
HNSC	cis	rs4803480	1	rs11882144	ENSG00000270164.1	LINC01480	-5.66	2.63e-08	9.91e-06	-0.23	-0.25	Schizophrenia;	chr19:41566244	chr19:41535183~41536904:+
HNSC	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-5.66	2.64e-08	9.91e-06	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
HNSC	cis	rs2243480	1	rs464895	ENSG00000179406.6	LINC00174	-5.66	2.64e-08	9.91e-06	-0.55	-0.25	Diabetic kidney disease;	chr7:66062119	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160633	ENSG00000179406.6	LINC00174	-5.66	2.64e-08	9.91e-06	-0.55	-0.25	Diabetic kidney disease;	chr7:66063241	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	5.66	2.64e-08	9.92e-06	0.27	0.25	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
HNSC	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	5.66	2.64e-08	9.92e-06	0.3	0.25	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
HNSC	cis	rs7209700	0.745	rs8074348	ENSG00000228782.6	CTD-2026D20.3	-5.66	2.64e-08	9.92e-06	-0.25	-0.25	IgG glycosylation;	chr17:47276047	chr17:47450568~47492492:-
HNSC	cis	rs3096299	0.629	rs12929744	ENSG00000274627.1	RP11-104N10.2	5.66	2.64e-08	9.93e-06	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89427172	chr16:89516797~89522217:+
HNSC	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	5.66	2.64e-08	9.94e-06	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
HNSC	cis	rs7115242	0.8	rs1320668	ENSG00000280143.1	AP000892.6	5.66	2.65e-08	9.95e-06	0.38	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117204967~117210292:+
HNSC	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	5.66	2.65e-08	9.95e-06	0.27	0.25	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
HNSC	cis	rs867371	0.502	rs2047679	ENSG00000276710.3	CSPG4P8	-5.66	2.65e-08	9.95e-06	-0.27	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82459472~82477258:+
HNSC	cis	rs2898681	0.528	rs73814883	ENSG00000248375.1	RP11-177B4.1	-5.66	2.65e-08	9.95e-06	-0.49	-0.25	Optic nerve measurement (cup area);	chr4:52861887	chr4:52720081~52720831:-
HNSC	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	5.66	2.65e-08	9.96e-06	0.31	0.25	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-5.66	2.65e-08	9.97e-06	-0.39	-0.25	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
HNSC	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-5.66	2.66e-08	9.99e-06	-0.32	-0.25	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
HNSC	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-5.66	2.66e-08	9.99e-06	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
HNSC	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
HNSC	cis	rs13113518	1	rs3762837	ENSG00000273257.1	RP11-177J6.1	5.66	2.66e-08	1e-05	0.31	0.25	Height;	chr4:55511198	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13108499	ENSG00000273257.1	RP11-177J6.1	5.66	2.66e-08	1e-05	0.31	0.25	Height;	chr4:55526514	chr4:55387949~55388271:+
HNSC	cis	rs6928977	0.832	rs9402703	ENSG00000234084.1	RP3-388E23.2	5.66	2.66e-08	1e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135325097	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.597	rs9483879	ENSG00000217482.2	HMGB1P17	5.66	2.67e-08	1e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135778024	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs9494383	ENSG00000217482.2	HMGB1P17	5.66	2.67e-08	1e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135778026	chr6:135636086~135636713:-
HNSC	cis	rs9611565	0.506	rs1984839	ENSG00000235513.1	RP4-756G23.5	5.66	2.67e-08	1e-05	0.27	0.25	Vitiligo;	chr22:41289933	chr22:41209122~41217627:-
HNSC	cis	rs7980687	0.628	rs2102949	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123192216	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs4460848	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123193263	chr12:123152324~123153377:-
HNSC	cis	rs7980687	0.628	rs2851443	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123209703	chr12:123152324~123153377:-
HNSC	cis	rs7980687	0.596	rs1727319	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123216806	chr12:123152324~123153377:-
HNSC	cis	rs13113518	1	rs13115828	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55551447	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13136282	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55551845	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11934897	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55553396	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs11932293	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55554025	chr4:55363971~55395847:-
HNSC	cis	rs9611519	0.78	rs2284079	ENSG00000235513.1	RP4-756G23.5	5.66	2.67e-08	1e-05	0.26	0.25	Neuroticism;	chr22:41262628	chr22:41209122~41217627:-
HNSC	cis	rs2439831	0.867	rs2412779	ENSG00000205771.5	CATSPER2P1	-5.66	2.67e-08	1e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43363729	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-5.66	2.67e-08	1e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	5.66	2.67e-08	1e-05	0.27	0.25	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-5.66	2.68e-08	1e-05	-0.27	-0.25	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
HNSC	cis	rs6991838	0.806	rs35284121	ENSG00000200714.1	Y_RNA	5.66	2.68e-08	1.01e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65592731~65592820:+
HNSC	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	5.66	2.68e-08	1.01e-05	0.21	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
HNSC	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	5.66	2.68e-08	1.01e-05	0.35	0.25	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
HNSC	cis	rs13113518	1	rs939823	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55487368	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6838882	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55489310	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13146987	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55491628	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs7677085	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55495801	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12510681	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55496737	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12500162	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55496933	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs3805155	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55497842	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs7686261	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55500224	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11729220	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55501629	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133390	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55501726	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133391	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55501788	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs13133484	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55504176	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs13127906	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55504201	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6849433	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55506498	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12501327	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55507248	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133392	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55507729	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6838305	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55508587	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.902	rs12503578	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55509367	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs3828480	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55510352	chr4:55387949~55388271:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	5.66	2.68e-08	1.01e-05	0.27	0.25	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
HNSC	cis	rs8012947	0.917	rs2145600	ENSG00000279636.2	LINC00216	5.66	2.68e-08	1.01e-05	0.33	0.25	Alcohol consumption in current drinkers;	chr14:58284184	chr14:58288033~58289158:+
HNSC	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	5.66	2.68e-08	1.01e-05	0.27	0.25	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
HNSC	cis	rs11098499	0.691	rs9996644	ENSG00000249244.1	RP11-548H18.2	5.66	2.69e-08	1.01e-05	0.31	0.25	Corneal astigmatism;	chr4:119317722	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.691	rs9996494	ENSG00000249244.1	RP11-548H18.2	5.66	2.69e-08	1.01e-05	0.31	0.25	Corneal astigmatism;	chr4:119317725	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.589	rs11800848	ENSG00000223787.2	RP4-593M8.1	5.66	2.69e-08	1.01e-05	0.35	0.25	Multiple sclerosis;	chr1:92662370	chr1:92580476~92580821:-
HNSC	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	5.66	2.69e-08	1.01e-05	0.46	0.25	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
HNSC	cis	rs9300255	0.596	rs7304782	ENSG00000280120.1	RP11-546D6.3	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Neutrophil percentage of white cells;	chr12:123234897	chr12:123152324~123153377:-
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-5.66	2.7e-08	1.01e-05	-0.3	-0.25	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
HNSC	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	5.66	2.7e-08	1.01e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	5.66	2.7e-08	1.01e-05	0.27	0.25	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
HNSC	cis	rs2439831	0.681	rs528517	ENSG00000205771.5	CATSPER2P1	-5.66	2.7e-08	1.01e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43320727	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-5.66	2.7e-08	1.01e-05	-0.47	-0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
HNSC	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	5.66	2.7e-08	1.01e-05	0.4	0.25	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
HNSC	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-5.66	2.71e-08	1.02e-05	-0.31	-0.25	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
HNSC	cis	rs9813712	0.953	rs1453258	ENSG00000249846.5	RP11-77P16.4	5.66	2.71e-08	1.02e-05	0.3	0.25	Response to amphetamines;	chr3:130256454	chr3:130112550~130120579:+
HNSC	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	5.66	2.71e-08	1.02e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	5.66	2.71e-08	1.02e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
HNSC	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	5.66	2.71e-08	1.02e-05	0.37	0.25	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000211972.2	IGHV3-66	5.66	2.71e-08	1.02e-05	0.2	0.25	Kawasaki disease;	chr14:106779713	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-5.65	2.72e-08	1.02e-05	-0.3	-0.25	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-5.65	2.72e-08	1.02e-05	-0.3	-0.25	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-5.65	2.73e-08	1.02e-05	-0.17	-0.25	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
HNSC	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	5.65	2.73e-08	1.02e-05	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
HNSC	cis	rs988913	0.958	rs1503140	ENSG00000224984.1	RP11-524H19.2	5.65	2.73e-08	1.02e-05	0.29	0.25	Menarche (age at onset);	chr6:54945968	chr6:54840118~54840855:-
HNSC	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-5.65	2.73e-08	1.02e-05	-0.41	-0.25	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
HNSC	cis	rs61542988	0.57	rs10950919	ENSG00000228649.7	AC005682.5	5.65	2.73e-08	1.02e-05	0.32	0.25	Fibrinogen levels;	chr7:22794202	chr7:22854178~22861579:+
HNSC	cis	rs13113518	1	rs13152173	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55534788	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13141049	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55535489	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs12507722	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55536421	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs7696832	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55537080	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4864547	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55538228	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55451489	chr4:55363971~55395847:-
HNSC	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-5.65	2.75e-08	1.03e-05	-0.31	-0.25	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
HNSC	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	5.65	2.75e-08	1.03e-05	0.32	0.25	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
HNSC	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-5.65	2.75e-08	1.03e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
HNSC	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-5.65	2.76e-08	1.03e-05	-0.25	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
HNSC	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-5.65	2.76e-08	1.03e-05	-0.25	-0.25	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000253893.2	FAM85B	5.65	2.76e-08	1.03e-05	0.33	0.25	Neuroticism;	chr8:8504313	chr8:8167819~8226614:-
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	5.65	2.76e-08	1.03e-05	0.31	0.25	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-5.65	2.77e-08	1.04e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
HNSC	cis	rs4140799	0.789	rs1204988	ENSG00000266869.1	RP6-114E22.1	5.65	2.77e-08	1.04e-05	0.31	0.25	Neuroticism;	chr14:71745231	chr14:71848606~71908430:+
HNSC	cis	rs1355223	1	rs11607300	ENSG00000271369.1	RP11-350D17.3	-5.65	2.77e-08	1.04e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737772	chr11:34709600~34710161:+
HNSC	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	5.65	2.77e-08	1.04e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
HNSC	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-5.65	2.77e-08	1.04e-05	-0.27	-0.25	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
HNSC	cis	rs13126694	0.75	rs2346782	ENSG00000248429.4	RP11-597D13.9	5.65	2.77e-08	1.04e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158170752~158202877:+
HNSC	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	5.65	2.77e-08	1.04e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
HNSC	cis	rs14027	0.883	rs10102038	ENSG00000279347.1	RP11-85I17.2	-5.65	2.77e-08	1.04e-05	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.883	rs35660840	ENSG00000279347.1	RP11-85I17.2	-5.65	2.77e-08	1.04e-05	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119838736~119840385:-
HNSC	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	5.65	2.78e-08	1.04e-05	0.31	0.25	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
HNSC	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-5.65	2.78e-08	1.04e-05	-0.26	-0.25	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
HNSC	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-5.65	2.78e-08	1.04e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
HNSC	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	5.65	2.78e-08	1.04e-05	0.33	0.25	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	5.65	2.78e-08	1.04e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	5.65	2.78e-08	1.04e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	5.65	2.78e-08	1.04e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
HNSC	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	5.65	2.78e-08	1.04e-05	0.33	0.25	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-5.65	2.78e-08	1.04e-05	-0.27	-0.25	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
HNSC	cis	rs6928977	0.932	rs6914831	ENSG00000231028.7	LINC00271	5.65	2.79e-08	1.04e-05	0.3	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135318506	chr6:135497801~135716055:+
HNSC	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-5.65	2.79e-08	1.04e-05	-0.24	-0.25	Asthma;	chr2:102394777	chr2:102438713~102440475:+
HNSC	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-5.65	2.79e-08	1.04e-05	-0.29	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
HNSC	cis	rs2976388	0.525	rs2016749	ENSG00000253741.1	CTD-2292P10.4	5.65	2.79e-08	1.04e-05	0.25	0.25	Urinary tract infection frequency;	chr8:142754700	chr8:142702252~142726973:-
HNSC	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	5.65	2.8e-08	1.05e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
HNSC	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-5.65	2.8e-08	1.05e-05	-0.22	-0.25	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
HNSC	cis	rs10435719	0.834	rs11250176	ENSG00000206014.6	OR7E161P	-5.65	2.8e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:11928597~11929563:-
HNSC	cis	rs6928977	0.832	rs2327613	ENSG00000234084.1	RP3-388E23.2	5.65	2.8e-08	1.05e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341234	chr6:135301568~135307158:+
HNSC	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-5.65	2.8e-08	1.05e-05	-0.3	-0.25	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
HNSC	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	5.65	2.8e-08	1.05e-05	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
HNSC	cis	rs6061231	0.631	rs2427317	ENSG00000273619.1	RP5-908M14.9	-5.65	2.8e-08	1.05e-05	-0.22	-0.25	Colorectal cancer;	chr20:62400669	chr20:62386303~62386970:-
HNSC	cis	rs61542988	0.797	rs4329182	ENSG00000228649.7	AC005682.5	5.65	2.8e-08	1.05e-05	0.3	0.25	Fibrinogen levels;	chr7:22843002	chr7:22854178~22861579:+
HNSC	cis	rs61542988	0.756	rs5013587	ENSG00000228649.7	AC005682.5	5.65	2.8e-08	1.05e-05	0.3	0.25	Fibrinogen levels;	chr7:22843041	chr7:22854178~22861579:+
HNSC	cis	rs2579103	0.898	rs6538231	ENSG00000258183.4	RP11-753N8.1	-5.65	2.8e-08	1.05e-05	-0.31	-0.25	Body mass index;	chr12:90205038	chr12:90280894~90300340:+
HNSC	cis	rs9840812	0.592	rs35418151	ENSG00000273486.1	RP11-731C17.2	5.65	2.81e-08	1.05e-05	0.22	0.25	Fibrinogen levels;	chr3:136443779	chr3:136837338~136839021:-
HNSC	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-5.65	2.81e-08	1.05e-05	-0.36	-0.25	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-5.65	2.81e-08	1.05e-05	-0.36	-0.25	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
HNSC	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-5.65	2.81e-08	1.05e-05	-0.36	-0.25	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
HNSC	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	5.65	2.81e-08	1.05e-05	0.28	0.25	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-5.65	2.82e-08	1.05e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
HNSC	cis	rs10435719	0.647	rs10092605	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:11928597~11929563:-
HNSC	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-5.65	2.82e-08	1.05e-05	-0.32	-0.25	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
HNSC	cis	rs1908814	0.516	rs10113062	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11935740	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs10113145	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11935786	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs4367597	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11936020	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.899	rs9329251	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.773	rs7842810	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs7812563	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11936979	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13281077	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11937305	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13281315	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11937346	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs4840597	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11938559	chr8:11928597~11929563:-
HNSC	cis	rs804280	0.509	rs4841639	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Myopia (pathological);	chr8:11938584	chr8:11928597~11929563:-
HNSC	cis	rs13113518	1	rs34648901	ENSG00000273257.1	RP11-177J6.1	5.65	2.82e-08	1.05e-05	0.31	0.25	Height;	chr4:55541259	chr4:55387949~55388271:+
HNSC	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	5.65	2.82e-08	1.05e-05	0.24	0.25	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
HNSC	cis	rs638893	0.617	rs4938558	ENSG00000255422.1	AP002954.4	-5.65	2.82e-08	1.05e-05	-0.35	-0.25	Vitiligo;	chr11:118847220	chr11:118704607~118750263:+
HNSC	cis	rs6471393	0.861	rs2976374	ENSG00000253848.1	RP11-10N23.5	5.65	2.82e-08	1.05e-05	0.32	0.25	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93691945	chr8:93741193~93744534:+
HNSC	cis	rs2579103	0.867	rs11105539	ENSG00000258183.4	RP11-753N8.1	-5.65	2.82e-08	1.05e-05	-0.31	-0.25	Body mass index;	chr12:90208768	chr12:90280894~90300340:+
HNSC	cis	rs75920871	0.528	rs11216244	ENSG00000254851.1	RP11-109L13.1	5.65	2.82e-08	1.05e-05	0.35	0.25	Subjective well-being;	chr11:117042014	chr11:117135528~117138582:+
HNSC	cis	rs13113518	1	rs7662966	ENSG00000273257.1	RP11-177J6.1	5.65	2.83e-08	1.06e-05	0.31	0.25	Height;	chr4:55548261	chr4:55387949~55388271:+
HNSC	cis	rs889014	0.679	rs11742377	ENSG00000253768.1	CTB-33O18.1	5.65	2.83e-08	1.06e-05	0.28	0.25	Height;	chr5:173551281	chr5:173562478~173573199:+
HNSC	cis	rs11976180	1	rs11976037	ENSG00000273234.1	OR2A13P	-5.65	2.83e-08	1.06e-05	-0.29	-0.25	Obesity-related traits;	chr7:144043931	chr7:144142009~144142938:+
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-5.65	2.83e-08	1.06e-05	-0.16	-0.25	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-5.65	2.83e-08	1.06e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
HNSC	cis	rs10435719	0.902	rs7459545	ENSG00000206014.6	OR7E161P	-5.65	2.83e-08	1.06e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:11928597~11929563:-
HNSC	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-5.65	2.83e-08	1.06e-05	-0.27	-0.25	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
HNSC	cis	rs804280	0.509	rs35626932	ENSG00000206014.6	OR7E161P	-5.65	2.83e-08	1.06e-05	-0.27	-0.25	Myopia (pathological);	chr8:11929423	chr8:11928597~11929563:-
HNSC	cis	rs2337406	0.587	rs10139664	ENSG00000211974.3	IGHV2-70	-5.65	2.83e-08	1.06e-05	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106647254	chr14:106723574~106724093:-
HNSC	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	5.65	2.83e-08	1.06e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
HNSC	cis	rs889014	0.724	rs11745770	ENSG00000253768.1	CTB-33O18.1	5.65	2.83e-08	1.06e-05	0.28	0.25	Height;	chr5:173551101	chr5:173562478~173573199:+
HNSC	cis	rs11841001	0.556	rs12859043	ENSG00000261105.4	LMO7-AS1	-5.65	2.84e-08	1.06e-05	-0.34	-0.25	Corneal astigmatism;	chr13:75769362	chr13:75604700~75635994:-
HNSC	cis	rs2337406	0.925	rs10131226	ENSG00000211974.3	IGHV2-70	-5.65	2.84e-08	1.06e-05	-0.3	-0.25	Alzheimer's disease (late onset);	chr14:106665764	chr14:106723574~106724093:-
HNSC	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	5.65	2.84e-08	1.06e-05	0.3	0.25	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
HNSC	cis	rs1499614	1	rs2707840	ENSG00000179406.6	LINC00174	-5.65	2.84e-08	1.06e-05	-0.54	-0.25	Gout;	chr7:66693028	chr7:66376044~66401338:-
HNSC	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-5.65	2.85e-08	1.06e-05	-0.36	-0.25	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
HNSC	cis	rs9402743	0.632	rs9399167	ENSG00000217482.2	HMGB1P17	5.65	2.85e-08	1.06e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135792678	chr6:135636086~135636713:-
HNSC	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	5.65	2.85e-08	1.06e-05	0.28	0.25	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
HNSC	cis	rs804280	0.509	rs10109241	ENSG00000206014.6	OR7E161P	-5.65	2.85e-08	1.06e-05	-0.27	-0.25	Myopia (pathological);	chr8:11927476	chr8:11928597~11929563:-
HNSC	cis	rs7819412	0.775	rs11773990	ENSG00000269918.1	AF131215.9	-5.65	2.85e-08	1.07e-05	-0.25	-0.25	Triglycerides;	chr8:11077572	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000254153.1	CTA-398F10.2	-5.65	2.85e-08	1.07e-05	-0.28	-0.25	Joint mobility (Beighton score);	chr8:9044914	chr8:8456909~8461337:-
HNSC	cis	rs9300255	0.602	rs1727314	ENSG00000280120.1	RP11-546D6.3	5.65	2.86e-08	1.07e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123156117	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs2682429	ENSG00000280120.1	RP11-546D6.3	5.65	2.86e-08	1.07e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123158408	chr12:123152324~123153377:-
HNSC	cis	rs7819412	0.775	rs4545055	ENSG00000269918.1	AF131215.9	-5.65	2.86e-08	1.07e-05	-0.25	-0.25	Triglycerides;	chr8:11077856	chr8:11104691~11106704:-
HNSC	cis	rs7819412	0.775	rs2898257	ENSG00000269918.1	AF131215.9	-5.65	2.86e-08	1.07e-05	-0.25	-0.25	Triglycerides;	chr8:11077858	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-5.65	2.86e-08	1.07e-05	-0.31	-0.25	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
HNSC	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	5.65	2.86e-08	1.07e-05	0.35	0.25	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	5.65	2.86e-08	1.07e-05	0.35	0.25	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
HNSC	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	5.65	2.86e-08	1.07e-05	0.43	0.25	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
HNSC	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-5.65	2.86e-08	1.07e-05	-0.31	-0.25	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
HNSC	cis	rs13113518	1	rs55699500	ENSG00000273257.1	RP11-177J6.1	5.65	2.86e-08	1.07e-05	0.31	0.25	Height;	chr4:55540912	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs56362210	ENSG00000273257.1	RP11-177J6.1	5.65	2.86e-08	1.07e-05	0.31	0.25	Height;	chr4:55540972	chr4:55387949~55388271:+
HNSC	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-5.65	2.86e-08	1.07e-05	-0.32	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
HNSC	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-5.65	2.86e-08	1.07e-05	-0.32	-0.25	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
HNSC	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-5.64	2.87e-08	1.07e-05	-0.31	-0.25	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
HNSC	cis	rs6604026	0.555	rs1333743	ENSG00000223787.2	RP4-593M8.1	5.64	2.87e-08	1.07e-05	0.35	0.25	Multiple sclerosis;	chr1:92600617	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs11808092	ENSG00000223787.2	RP4-593M8.1	5.64	2.87e-08	1.07e-05	0.35	0.25	Multiple sclerosis;	chr1:92607671	chr1:92580476~92580821:-
HNSC	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-5.64	2.88e-08	1.07e-05	-0.28	-0.25	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	5.64	2.88e-08	1.07e-05	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-5.64	2.88e-08	1.07e-05	-0.16	-0.25	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
HNSC	cis	rs10791097	0.765	rs7943757	ENSG00000254842.5	RP11-890B15.2	-5.64	2.88e-08	1.07e-05	-0.22	-0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130846262	chr11:130844191~130865561:-
HNSC	cis	rs1012068	0.921	rs5994442	ENSG00000236132.1	CTA-440B3.1	-5.64	2.88e-08	1.08e-05	-0.3	-0.25	Chronic hepatitis C infection;	chr22:31875946	chr22:31816379~31817491:-
HNSC	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-5.64	2.89e-08	1.08e-05	-0.29	-0.25	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
HNSC	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	5.64	2.89e-08	1.08e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
HNSC	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	5.64	2.89e-08	1.08e-05	0.27	0.25	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
HNSC	cis	rs9300255	0.602	rs2851438	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123159142	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1047158	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123159509	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1051431	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123161256	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1727296	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123163178	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1716165	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123164334	chr12:123152324~123153377:-
HNSC	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-5.64	2.9e-08	1.08e-05	-0.24	-0.25	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
HNSC	cis	rs9341808	1	rs9341808	ENSG00000272129.1	RP11-250B2.6	5.64	2.9e-08	1.08e-05	0.3	0.25	Sitting height ratio;	chr6:80243540	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-5.64	2.9e-08	1.08e-05	-0.3	-0.25	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
HNSC	cis	rs7209700	0.547	rs10514919	ENSG00000228782.6	CTD-2026D20.3	-5.64	2.91e-08	1.08e-05	-0.27	-0.25	IgG glycosylation;	chr17:47264763	chr17:47450568~47492492:-
HNSC	cis	rs804280	0.509	rs9886639	ENSG00000206014.6	OR7E161P	-5.64	2.91e-08	1.09e-05	-0.27	-0.25	Myopia (pathological);	chr8:11927020	chr8:11928597~11929563:-
HNSC	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	5.64	2.91e-08	1.09e-05	0.28	0.25	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	5.64	2.91e-08	1.09e-05	0.23	0.25	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	5.64	2.92e-08	1.09e-05	0.31	0.25	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
HNSC	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-5.64	2.92e-08	1.09e-05	-0.24	-0.25	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
HNSC	cis	rs10446497	0.61	rs12497046	ENSG00000272359.1	U4	5.64	2.92e-08	1.09e-05	0.3	0.25	Schizophrenia;	chr3:196816775	chr3:196747192~196747324:-
HNSC	cis	rs6928977	0.514	rs2757635	ENSG00000217482.2	HMGB1P17	-5.64	2.92e-08	1.09e-05	-0.27	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135413172	chr6:135636086~135636713:-
HNSC	cis	rs3747113	0.913	rs34999116	ENSG00000128262.7	POM121L9P	-5.64	2.92e-08	1.09e-05	-0.3	-0.25	Gut microbiome composition (summer);	chr22:24418657	chr22:24251828~24265525:+
HNSC	cis	rs2115630	1	rs6496441	ENSG00000229212.6	RP11-561C5.4	5.64	2.93e-08	1.09e-05	0.29	0.25	P wave terminal force;	chr15:84820117	chr15:85205440~85234795:-
HNSC	cis	rs13113518	0.966	rs4864544	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55515292	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6847529	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55518776	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6822740	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55518922	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs13108409	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55520278	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11726198	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55523835	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs11133396	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55524246	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs7675109	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55525589	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4865005	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55525781	chr4:55387949~55388271:+
HNSC	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-5.64	2.93e-08	1.09e-05	-0.35	-0.25	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
HNSC	cis	rs2579103	0.898	rs1347850	ENSG00000258183.4	RP11-753N8.1	-5.64	2.93e-08	1.09e-05	-0.31	-0.25	Body mass index;	chr12:90211819	chr12:90280894~90300340:+
HNSC	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	5.64	2.93e-08	1.09e-05	0.26	0.25	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	5.64	2.94e-08	1.09e-05	0.23	0.25	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-5.64	2.94e-08	1.09e-05	-0.23	-0.25	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
HNSC	cis	rs867371	0.614	rs7183805	ENSG00000255769.6	GOLGA2P10	-5.64	2.94e-08	1.09e-05	-0.35	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82472993~82513950:-
HNSC	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	5.64	2.95e-08	1.1e-05	0.29	0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
HNSC	cis	rs10242455	0.702	rs41385645	ENSG00000078319.8	PMS2P1	-5.64	2.95e-08	1.1e-05	-0.47	-0.25	Blood metabolite levels;	chr7:99376415	chr7:100320992~100341908:-
HNSC	cis	rs2302464	1	rs6835705	ENSG00000214846.4	RP11-115L11.1	-5.64	2.95e-08	1.1e-05	-0.58	-0.25	Cerebrospinal fluid biomarker levels;	chr4:15736747	chr4:15730962~15731627:-
HNSC	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-5.64	2.96e-08	1.1e-05	-0.27	-0.25	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
HNSC	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-5.64	2.96e-08	1.1e-05	-0.42	-0.25	Depression;	chr6:28111963	chr6:28115628~28116551:+
HNSC	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	5.64	2.96e-08	1.1e-05	0.26	0.25	Height;	chr2:46624894	chr2:46668870~46670778:+
HNSC	cis	rs9813712	0.953	rs1453256	ENSG00000249846.5	RP11-77P16.4	-5.64	2.96e-08	1.1e-05	-0.3	-0.25	Response to amphetamines;	chr3:130258787	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.953	rs935916	ENSG00000249846.5	RP11-77P16.4	-5.64	2.96e-08	1.1e-05	-0.3	-0.25	Response to amphetamines;	chr3:130258931	chr3:130112550~130120579:+
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-5.64	2.96e-08	1.1e-05	-0.17	-0.25	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
HNSC	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	5.64	2.97e-08	1.11e-05	0.28	0.25	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	5.64	2.97e-08	1.11e-05	0.28	0.25	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
HNSC	cis	rs2145598	0.967	rs12892257	ENSG00000279636.2	LINC00216	-5.64	2.98e-08	1.11e-05	-0.28	-0.25	Coronary artery disease;	chr14:58266030	chr14:58288033~58289158:+
HNSC	cis	rs8177876	0.658	rs889516	ENSG00000261061.1	RP11-303E16.2	5.64	2.98e-08	1.11e-05	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034943	chr16:81030770~81031485:+
HNSC	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	5.64	2.98e-08	1.11e-05	0.3	0.25	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
HNSC	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-5.64	2.98e-08	1.11e-05	-0.43	-0.25	Depression;	chr6:28223052	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-5.64	2.98e-08	1.11e-05	-0.43	-0.25	Depression;	chr6:28223279	chr6:28115628~28116551:+
HNSC	cis	rs13113518	0.902	rs12505266	ENSG00000249700.7	SRD5A3-AS1	5.64	2.98e-08	1.11e-05	0.3	0.25	Height;	chr4:55546002	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs56154935	ENSG00000249700.7	SRD5A3-AS1	5.64	2.98e-08	1.11e-05	0.3	0.25	Height;	chr4:55546378	chr4:55363971~55395847:-
HNSC	cis	rs7657257	1	rs4321629	ENSG00000214846.4	RP11-115L11.1	5.64	2.98e-08	1.11e-05	0.62	0.25	Blood protein levels;	chr4:15730757	chr4:15730962~15731627:-
HNSC	cis	rs7657257	1	rs10516290	ENSG00000214846.4	RP11-115L11.1	5.64	2.98e-08	1.11e-05	0.62	0.25	Blood protein levels;	chr4:15730833	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs10516291	ENSG00000214846.4	RP11-115L11.1	5.64	2.98e-08	1.11e-05	0.62	0.25	Cerebrospinal fluid biomarker levels;	chr4:15731168	chr4:15730962~15731627:-
HNSC	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	5.64	2.98e-08	1.11e-05	0.34	0.25	Height;	chr6:109640682	chr6:109382795~109383666:+
HNSC	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
HNSC	cis	rs6604026	0.624	rs11164814	ENSG00000223787.2	RP4-593M8.1	5.64	2.99e-08	1.11e-05	0.35	0.25	Multiple sclerosis;	chr1:92795816	chr1:92580476~92580821:-
HNSC	cis	rs75422866	0.85	rs73111226	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47582204	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.702	rs12426387	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47582915	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.85	rs12423789	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47583112	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.702	rs73111229	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47583333	chr12:47706085~47742294:+
HNSC	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-5.64	2.99e-08	1.11e-05	-0.41	-0.25	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-5.64	2.99e-08	1.11e-05	-0.3	-0.25	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
HNSC	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	5.64	2.99e-08	1.11e-05	0.36	0.25	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
HNSC	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	5.64	2.99e-08	1.11e-05	0.29	0.25	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	5.64	2.99e-08	1.11e-05	0.29	0.25	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
HNSC	cis	rs6928977	0.932	rs11154799	ENSG00000234084.1	RP3-388E23.2	5.64	2.99e-08	1.11e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311511	chr6:135301568~135307158:+
HNSC	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	-5.64	3e-08	1.11e-05	-0.32	-0.25	Depression;	chr6:28140307	chr6:28161781~28169594:+
HNSC	cis	rs1355223	0.872	rs913204	ENSG00000271369.1	RP11-350D17.3	5.64	3e-08	1.11e-05	0.3	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34684677	chr11:34709600~34710161:+
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000223648.3	IGHV3-64	5.64	3e-08	1.12e-05	0.2	0.25	Kawasaki disease;	chr14:106813798	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	5.64	3e-08	1.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	5.64	3e-08	1.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	5.64	3e-08	1.12e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
HNSC	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102404807	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102407218	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
HNSC	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	5.64	3.01e-08	1.12e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	5.64	3.01e-08	1.12e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000211972.2	IGHV3-66	5.64	3.01e-08	1.12e-05	0.2	0.25	Kawasaki disease;	chr14:106705441	chr14:106675017~106675544:-
HNSC	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102374753	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102379885	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102381261	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102381819	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102382514	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102382943	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102394452	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102399227	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102402540	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102402571	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102403325	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102403679	chr2:102438713~102440475:+
HNSC	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	5.64	3.01e-08	1.12e-05	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	5.64	3.01e-08	1.12e-05	0.28	0.25	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
HNSC	cis	rs2145598	0.967	rs6573194	ENSG00000279636.2	LINC00216	-5.64	3.01e-08	1.12e-05	-0.28	-0.25	Coronary artery disease;	chr14:58246196	chr14:58288033~58289158:+
HNSC	cis	rs8177876	0.915	rs1563072	ENSG00000261061.1	RP11-303E16.2	5.64	3.01e-08	1.12e-05	0.44	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095811	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.841	rs874437	ENSG00000261061.1	RP11-303E16.2	5.64	3.01e-08	1.12e-05	0.44	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095890	chr16:81030770~81031485:+
HNSC	cis	rs10435719	0.902	rs12681142	ENSG00000206014.6	OR7E161P	-5.64	3.02e-08	1.12e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:11928597~11929563:-
HNSC	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-5.64	3.02e-08	1.12e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
HNSC	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	5.64	3.02e-08	1.12e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	5.64	3.02e-08	1.12e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000254153.1	CTA-398F10.2	5.64	3.02e-08	1.12e-05	0.27	0.25	Systolic blood pressure;	chr8:8462453	chr8:8456909~8461337:-
HNSC	cis	rs9341808	0.644	rs62408577	ENSG00000272129.1	RP11-250B2.6	-5.64	3.03e-08	1.12e-05	-0.3	-0.25	Sitting height ratio;	chr6:80232307	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.644	rs76102095	ENSG00000272129.1	RP11-250B2.6	-5.64	3.03e-08	1.12e-05	-0.3	-0.25	Sitting height ratio;	chr6:80232309	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.644	rs59371711	ENSG00000272129.1	RP11-250B2.6	-5.64	3.03e-08	1.12e-05	-0.3	-0.25	Sitting height ratio;	chr6:80232310	chr6:80355424~80356859:+
HNSC	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102388870	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102389644	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102389988	chr2:102438713~102440475:+
HNSC	cis	rs13113518	1	rs4864549	ENSG00000249700.7	SRD5A3-AS1	5.64	3.03e-08	1.12e-05	0.3	0.25	Height;	chr4:55554380	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4865011	ENSG00000249700.7	SRD5A3-AS1	5.64	3.03e-08	1.12e-05	0.3	0.25	Height;	chr4:55554456	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4865013	ENSG00000249700.7	SRD5A3-AS1	5.64	3.03e-08	1.12e-05	0.3	0.25	Height;	chr4:55559957	chr4:55363971~55395847:-
HNSC	cis	rs3206736	0.548	rs329236	ENSG00000197085.10	NPSR1-AS1	-5.64	3.03e-08	1.12e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35016654	chr7:34346512~34871582:-
HNSC	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-5.64	3.03e-08	1.13e-05	-0.27	-0.25	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
HNSC	cis	rs2179367	0.632	rs12211357	ENSG00000216906.2	RP11-350J20.9	5.63	3.04e-08	1.13e-05	0.37	0.25	Dupuytren's disease;	chr6:149331148	chr6:149904243~149906418:+
HNSC	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	5.63	3.04e-08	1.13e-05	0.31	0.25	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
HNSC	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-5.63	3.04e-08	1.13e-05	-0.29	-0.25	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
HNSC	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-5.63	3.05e-08	1.13e-05	-0.33	-0.25	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
HNSC	cis	rs2842992	0.724	rs2273827	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790307	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.662	rs2273825	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790392	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.768	rs2273824	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790413	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.724	rs2273823	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790453	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.692	rs1128661	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790522	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.724	rs1128670	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790604	chr6:159586955~159589169:-
HNSC	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	5.63	3.05e-08	1.13e-05	0.31	0.25	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	5.63	3.05e-08	1.13e-05	0.31	0.25	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.562	rs1038248	ENSG00000254340.1	RP11-10A14.3	-5.63	3.06e-08	1.13e-05	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9183348	chr8:9141424~9145435:+
HNSC	cis	rs1355223	0.902	rs7121272	ENSG00000271369.1	RP11-350D17.3	-5.63	3.06e-08	1.14e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34731015	chr11:34709600~34710161:+
HNSC	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	5.63	3.06e-08	1.14e-05	0.29	0.25	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
HNSC	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-5.63	3.06e-08	1.14e-05	-0.24	-0.25	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-5.63	3.06e-08	1.14e-05	-0.24	-0.25	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
HNSC	cis	rs67180937	0.583	rs3008616	ENSG00000272750.1	RP11-378J18.8	5.63	3.07e-08	1.14e-05	0.33	0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623831	chr1:222658867~222661512:-
HNSC	cis	rs889014	0.751	rs7712664	ENSG00000253768.1	CTB-33O18.1	5.63	3.07e-08	1.14e-05	0.28	0.25	Height;	chr5:173551663	chr5:173562478~173573199:+
HNSC	cis	rs1499614	1	rs2707832	ENSG00000179406.6	LINC00174	-5.63	3.07e-08	1.14e-05	-0.54	-0.25	Gout;	chr7:66671562	chr7:66376044~66401338:-
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000211972.2	IGHV3-66	5.63	3.07e-08	1.14e-05	0.2	0.25	Kawasaki disease;	chr14:106705382	chr14:106675017~106675544:-
HNSC	cis	rs7567389	0.504	rs41280570	ENSG00000236682.1	AC068282.3	-5.63	3.07e-08	1.14e-05	-0.32	-0.25	Self-rated health;	chr2:127418654	chr2:127389130~127400580:+
HNSC	cis	rs9402743	0.632	rs9399166	ENSG00000217482.2	HMGB1P17	5.63	3.07e-08	1.14e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135776762	chr6:135636086~135636713:-
HNSC	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	5.63	3.08e-08	1.14e-05	0.26	0.25	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	5.63	3.08e-08	1.14e-05	0.26	0.25	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
HNSC	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	5.63	3.08e-08	1.14e-05	0.32	0.25	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
HNSC	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	5.63	3.08e-08	1.14e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs6958420	ENSG00000179406.6	LINC00174	5.63	3.08e-08	1.14e-05	0.53	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	5.63	3.08e-08	1.14e-05	0.32	0.25	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
HNSC	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-5.63	3.08e-08	1.14e-05	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
HNSC	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-5.63	3.08e-08	1.14e-05	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
HNSC	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-5.63	3.08e-08	1.14e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	5.63	3.09e-08	1.14e-05	0.27	0.25	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
HNSC	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	5.63	3.09e-08	1.14e-05	0.34	0.25	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
HNSC	cis	rs2179367	0.586	rs9498341	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149379737	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498342	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149379806	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12191079	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149380333	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12204461	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149380399	chr6:149904243~149906418:+
HNSC	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-5.63	3.09e-08	1.15e-05	-0.27	-0.25	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
HNSC	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	5.63	3.09e-08	1.15e-05	0.29	0.25	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
HNSC	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	5.63	3.09e-08	1.15e-05	0.35	0.25	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
HNSC	cis	rs75422866	0.51	rs73105803	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47722135	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.51	rs73105812	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47724404	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.51	rs74733564	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47724644	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.51	rs73105814	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47725817	chr12:47788426~47788971:+
HNSC	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	5.63	3.1e-08	1.15e-05	0.31	0.25	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	5.63	3.1e-08	1.15e-05	0.32	0.25	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	5.63	3.1e-08	1.15e-05	0.32	0.25	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
HNSC	cis	rs13113518	0.812	rs13116035	ENSG00000273257.1	RP11-177J6.1	5.63	3.1e-08	1.15e-05	0.31	0.25	Height;	chr4:55561218	chr4:55387949~55388271:+
HNSC	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
HNSC	cis	rs925255	0.817	rs7606480	ENSG00000270210.1	RP11-373D23.3	-5.63	3.1e-08	1.15e-05	-0.28	-0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28409510	chr2:28425945~28426719:+
HNSC	cis	rs8177876	0.915	rs73597252	ENSG00000261061.1	RP11-303E16.2	-5.63	3.1e-08	1.15e-05	-0.45	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81030770~81031485:+
HNSC	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	5.63	3.1e-08	1.15e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	5.63	3.1e-08	1.15e-05	0.3	0.25	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
HNSC	cis	rs947583	1	rs7742626	ENSG00000217482.2	HMGB1P17	-5.63	3.11e-08	1.15e-05	-0.29	-0.25	Phosphorus levels;	chr6:135811358	chr6:135636086~135636713:-
HNSC	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	5.63	3.11e-08	1.15e-05	0.4	0.25	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
HNSC	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	5.63	3.11e-08	1.15e-05	0.31	0.25	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
HNSC	cis	rs6991838	0.806	rs13262793	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.778	rs13261559	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.778	rs7843697	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.778	rs7843724	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65592731~65592820:+
HNSC	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-5.63	3.12e-08	1.16e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
HNSC	cis	rs8012947	0.917	rs57044214	ENSG00000279636.2	LINC00216	5.63	3.12e-08	1.16e-05	0.31	0.25	Alcohol consumption in current drinkers;	chr14:58367191	chr14:58288033~58289158:+
HNSC	cis	rs6928977	0.733	rs9321500	ENSG00000234084.1	RP3-388E23.2	5.63	3.12e-08	1.16e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320231	chr6:135301568~135307158:+
HNSC	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	5.63	3.12e-08	1.16e-05	0.31	0.25	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
HNSC	cis	rs4803480	0.872	rs2058149	ENSG00000270164.1	LINC01480	-5.63	3.12e-08	1.16e-05	-0.23	-0.25	Schizophrenia;	chr19:41580312	chr19:41535183~41536904:+
HNSC	cis	rs6714900	0.588	rs11675048	ENSG00000234896.1	OR7E62P	-5.63	3.12e-08	1.16e-05	-0.31	-0.25	Blood protein levels;	chr2:71065534	chr2:71055527~71056003:+
HNSC	cis	rs13113518	1	rs6858803	ENSG00000273257.1	RP11-177J6.1	5.63	3.12e-08	1.16e-05	0.31	0.25	Height;	chr4:55484534	chr4:55387949~55388271:+
HNSC	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	5.63	3.12e-08	1.16e-05	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
HNSC	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-5.63	3.12e-08	1.16e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-5.63	3.12e-08	1.16e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
HNSC	cis	rs4140799	0.816	rs1204995	ENSG00000266869.1	RP6-114E22.1	5.63	3.13e-08	1.16e-05	0.31	0.25	Neuroticism;	chr14:71721133	chr14:71848606~71908430:+
HNSC	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-5.63	3.13e-08	1.16e-05	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
HNSC	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-5.63	3.13e-08	1.16e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
HNSC	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-5.63	3.13e-08	1.16e-05	-0.37	-0.25	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
HNSC	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	5.63	3.14e-08	1.16e-05	0.26	0.25	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
HNSC	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-5.63	3.14e-08	1.16e-05	-0.34	-0.25	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
HNSC	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-5.63	3.14e-08	1.16e-05	-0.31	-0.25	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-5.63	3.14e-08	1.16e-05	-0.31	-0.25	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
HNSC	cis	rs73186030	0.844	rs73186015	ENSG00000272758.4	RP11-299J3.8	5.63	3.14e-08	1.16e-05	0.36	0.25	Serum parathyroid hormone levels;	chr3:122272236	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs17251221	ENSG00000272758.4	RP11-299J3.8	5.63	3.14e-08	1.16e-05	0.36	0.25	Serum parathyroid hormone levels;	chr3:122274400	chr3:122416207~122443180:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000235689.1	AP000351.13	5.63	3.14e-08	1.16e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:24006305~24008258:-
HNSC	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-5.63	3.14e-08	1.16e-05	-0.26	-0.25	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
HNSC	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-5.63	3.14e-08	1.16e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
HNSC	cis	rs2985684	0.779	rs12160	ENSG00000258568.1	RHOQP1	5.63	3.14e-08	1.16e-05	0.26	0.25	Carotid intima media thickness;	chr14:49625214	chr14:49599994~49600572:+
HNSC	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-5.63	3.14e-08	1.16e-05	-0.27	-0.25	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-5.63	3.14e-08	1.16e-05	-0.27	-0.25	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
HNSC	cis	rs330048	0.545	rs11774353	ENSG00000254340.1	RP11-10A14.3	5.63	3.15e-08	1.17e-05	0.31	0.25	Systemic lupus erythematosus;	chr8:9295617	chr8:9141424~9145435:+
HNSC	cis	rs5758659	1	rs134900	ENSG00000227370.1	RP4-669P10.19	-5.63	3.15e-08	1.17e-05	-0.24	-0.25	Cognitive function;	chr22:42287337	chr22:42132543~42132998:+
HNSC	cis	rs2742234	0.541	rs61845684	ENSG00000273008.1	RP11-351D16.3	5.63	3.15e-08	1.17e-05	0.35	0.25	Hirschsprung disease;	chr10:43249535	chr10:43136824~43138334:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66226660	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7778911	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66229519	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1979823	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66239626	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs10807701	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66259699	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1499613	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66265873	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1553174	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66266207	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs10950032	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66273604	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1392104	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718333	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66307771	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7792391	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66308442	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs10247526	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66315709	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66333815	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	5.63	3.16e-08	1.17e-05	0.32	0.25	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
HNSC	cis	rs7980687	0.657	rs2851447	ENSG00000280120.1	RP11-546D6.3	5.63	3.16e-08	1.17e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123180566	chr12:123152324~123153377:-
HNSC	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-5.63	3.16e-08	1.17e-05	-0.32	-0.25	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
HNSC	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-5.63	3.16e-08	1.17e-05	-0.28	-0.25	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
HNSC	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	5.63	3.17e-08	1.17e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
HNSC	cis	rs7617773	0.925	rs7374376	ENSG00000228638.1	FCF1P2	5.63	3.17e-08	1.17e-05	0.24	0.25	Coronary artery disease;	chr3:48131197	chr3:48290793~48291375:-
HNSC	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	5.63	3.17e-08	1.17e-05	0.25	0.25	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
HNSC	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-5.63	3.17e-08	1.17e-05	-0.31	-0.25	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
HNSC	cis	rs67981189	0.529	rs2526857	ENSG00000274818.1	RP1-292L20.3	-5.63	3.17e-08	1.17e-05	-0.31	-0.25	Schizophrenia;	chr14:70945909	chr14:70906657~70907111:-
HNSC	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	5.63	3.17e-08	1.17e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	5.63	3.17e-08	1.17e-05	0.2	0.25	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
HNSC	cis	rs13113518	1	rs34648901	ENSG00000249700.7	SRD5A3-AS1	5.63	3.17e-08	1.17e-05	0.3	0.25	Height;	chr4:55541259	chr4:55363971~55395847:-
HNSC	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-5.63	3.18e-08	1.17e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
HNSC	cis	rs7396835	1	rs7396835	ENSG00000280143.1	AP000892.6	5.63	3.18e-08	1.17e-05	0.33	0.25	Quantitative traits;	chr11:116813312	chr11:117204967~117210292:+
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	5.63	3.18e-08	1.18e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
HNSC	cis	rs7819412	0.811	rs2409691	ENSG00000255310.2	AF131215.2	-5.63	3.18e-08	1.18e-05	-0.24	-0.25	Triglycerides;	chr8:11085766	chr8:11107788~11109726:-
HNSC	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	5.63	3.18e-08	1.18e-05	0.2	0.25	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	5.63	3.18e-08	1.18e-05	0.31	0.25	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
HNSC	cis	rs1012068	0.662	rs5753816	ENSG00000236132.1	CTA-440B3.1	-5.63	3.18e-08	1.18e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31916856	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-5.63	3.19e-08	1.18e-05	-0.15	-0.25	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-5.63	3.19e-08	1.18e-05	-0.15	-0.25	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
HNSC	cis	rs2439831	0.571	rs689883	ENSG00000205771.5	CATSPER2P1	-5.63	3.19e-08	1.18e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43520398	chr15:43726918~43747094:-
HNSC	cis	rs11648785	0.506	rs7191175	ENSG00000222019.6	URAHP	-5.63	3.19e-08	1.18e-05	-0.23	-0.25	Tanning;	chr16:90028869	chr16:90039761~90047773:-
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000211972.2	IGHV3-66	-5.63	3.19e-08	1.18e-05	-0.19	-0.25	Kawasaki disease;	chr14:106769752	chr14:106675017~106675544:-
HNSC	cis	rs13126694	0.839	rs66490968	ENSG00000248429.4	RP11-597D13.9	5.62	3.2e-08	1.18e-05	0.29	0.25	Blood osmolality (transformed sodium);	chr4:157994770	chr4:158170752~158202877:+
HNSC	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	5.62	3.2e-08	1.18e-05	0.27	0.25	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
HNSC	cis	rs7209700	0.862	rs2015729	ENSG00000228782.6	CTD-2026D20.3	-5.62	3.21e-08	1.19e-05	-0.25	-0.25	IgG glycosylation;	chr17:47277127	chr17:47450568~47492492:-
HNSC	cis	rs11648785	0.747	rs12920767	ENSG00000222019.6	URAHP	5.62	3.21e-08	1.19e-05	0.25	0.25	Tanning;	chr16:90028162	chr16:90039761~90047773:-
HNSC	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-5.62	3.21e-08	1.19e-05	-0.32	-0.25	Depression;	chr6:28135913	chr6:28161781~28169594:+
HNSC	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-5.62	3.21e-08	1.19e-05	-0.27	-0.25	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
HNSC	cis	rs13113518	0.934	rs10866425	ENSG00000273257.1	RP11-177J6.1	5.62	3.22e-08	1.19e-05	0.31	0.25	Height;	chr4:55582068	chr4:55387949~55388271:+
HNSC	cis	rs35306767	0.953	rs11253521	ENSG00000229869.1	RP11-363N22.2	-5.62	3.22e-08	1.19e-05	-0.32	-0.25	Eosinophil percentage of granulocytes;	chr10:930476	chr10:933026~942743:+
HNSC	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	5.62	3.22e-08	1.19e-05	0.34	0.25	Height;	chr6:109340338	chr6:109382795~109383666:+
HNSC	cis	rs61542988	0.606	rs4722185	ENSG00000228649.7	AC005682.5	5.62	3.22e-08	1.19e-05	0.33	0.25	Fibrinogen levels;	chr7:22793092	chr7:22854178~22861579:+
HNSC	cis	rs3206736	0.548	rs329240	ENSG00000197085.10	NPSR1-AS1	5.62	3.23e-08	1.19e-05	0.31	0.25	Diastolic blood pressure;	chr7:35018828	chr7:34346512~34871582:-
HNSC	cis	rs9611519	0.857	rs4820434	ENSG00000235513.1	RP4-756G23.5	5.62	3.23e-08	1.19e-05	0.28	0.25	Neuroticism;	chr22:41241115	chr22:41209122~41217627:-
HNSC	cis	rs1865760	0.555	rs2051541	ENSG00000272462.2	U91328.19	5.62	3.23e-08	1.19e-05	0.24	0.25	Height;	chr6:25944983	chr6:25992662~26001775:+
HNSC	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-5.62	3.23e-08	1.19e-05	-0.3	-0.25	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
HNSC	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-5.62	3.23e-08	1.19e-05	-0.3	-0.25	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.723	rs1736904	ENSG00000219392.1	RP1-265C24.5	-5.62	3.23e-08	1.19e-05	-0.31	-0.25	Depression;	chr6:28251492	chr6:28115628~28116551:+
HNSC	cis	rs9929218	0.52	rs1078621	ENSG00000260459.2	FTLP14	5.62	3.23e-08	1.19e-05	0.34	0.25	Colorectal cancer;	chr16:68745093	chr16:68822587~68823070:+
HNSC	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	5.62	3.23e-08	1.19e-05	0.36	0.25	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
HNSC	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	5.62	3.24e-08	1.19e-05	0.25	0.25	Height;	chr5:37025769	chr5:36666214~36725195:-
HNSC	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-5.62	3.24e-08	1.19e-05	-0.37	-0.25	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
HNSC	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-5.62	3.24e-08	1.2e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
HNSC	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-5.62	3.24e-08	1.2e-05	-0.29	-0.25	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
HNSC	cis	rs2898681	0.618	rs79471207	ENSG00000248375.1	RP11-177B4.1	-5.62	3.24e-08	1.2e-05	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52872357	chr4:52720081~52720831:-
HNSC	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	5.62	3.25e-08	1.2e-05	0.65	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	5.62	3.25e-08	1.2e-05	0.65	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	5.62	3.25e-08	1.2e-05	0.65	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
HNSC	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	5.62	3.25e-08	1.2e-05	0.24	0.25	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
HNSC	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	5.62	3.25e-08	1.2e-05	0.22	0.25	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
HNSC	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-5.62	3.25e-08	1.2e-05	-0.33	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
HNSC	cis	rs2115630	1	rs58581703	ENSG00000229212.6	RP11-561C5.4	5.62	3.26e-08	1.2e-05	0.29	0.25	P wave terminal force;	chr15:84733704	chr15:85205440~85234795:-
HNSC	cis	rs11992162	0.967	rs10112888	ENSG00000206014.6	OR7E161P	-5.62	3.26e-08	1.2e-05	-0.27	-0.25	Monocyte count;	chr8:11972699	chr8:11928597~11929563:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-5.62	3.26e-08	1.2e-05	-0.27	-0.25	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
HNSC	cis	rs4141404	0.851	rs5749248	ENSG00000236132.1	CTA-440B3.1	5.62	3.26e-08	1.2e-05	0.35	0.25	Paclitaxel-induced neuropathy;	chr22:31287725	chr22:31816379~31817491:-
HNSC	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-5.62	3.26e-08	1.2e-05	-0.37	-0.25	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
HNSC	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-5.62	3.26e-08	1.2e-05	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
HNSC	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
HNSC	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	5.62	3.27e-08	1.21e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	5.62	3.27e-08	1.21e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
HNSC	cis	rs2985684	0.948	rs4900925	ENSG00000278009.1	RP11-649E7.8	-5.62	3.27e-08	1.21e-05	-0.33	-0.25	Carotid intima media thickness;	chr14:49545607	chr14:49601011~49601124:-
HNSC	cis	rs9402743	0.634	rs9321512	ENSG00000217482.2	HMGB1P17	-5.62	3.27e-08	1.21e-05	-0.27	-0.25	Systemic lupus erythematosus;	chr6:135603299	chr6:135636086~135636713:-
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-5.62	3.27e-08	1.21e-05	-0.17	-0.25	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
HNSC	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
HNSC	cis	rs2337406	0.778	rs56658355	ENSG00000211974.3	IGHV2-70	-5.62	3.27e-08	1.21e-05	-0.3	-0.25	Alzheimer's disease (late onset);	chr14:106662151	chr14:106723574~106724093:-
HNSC	cis	rs2235642	0.859	rs9927529	ENSG00000280231.1	LA16c-380F5.3	-5.62	3.28e-08	1.21e-05	-0.31	-0.25	Coronary artery disease;	chr16:1569487	chr16:1553655~1554130:-
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	5.62	3.28e-08	1.21e-05	0.27	0.25	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
HNSC	cis	rs7615952	0.611	rs9681518	ENSG00000248787.1	RP11-666A20.4	-5.62	3.28e-08	1.21e-05	-0.44	-0.25	Blood pressure (smoking interaction);	chr3:125896287	chr3:125908005~125910272:-
HNSC	cis	rs5758659	1	rs134873	ENSG00000227370.1	RP4-669P10.19	-5.62	3.28e-08	1.21e-05	-0.24	-0.25	Cognitive function;	chr22:42261560	chr22:42132543~42132998:+
HNSC	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-5.62	3.29e-08	1.21e-05	-0.29	-0.25	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	5.62	3.29e-08	1.21e-05	0.27	0.25	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	5.62	3.29e-08	1.21e-05	0.27	0.25	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
HNSC	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	5.62	3.29e-08	1.21e-05	0.24	0.25	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
HNSC	cis	rs9611519	0.808	rs5751074	ENSG00000235513.1	RP4-756G23.5	5.62	3.29e-08	1.21e-05	0.26	0.25	Neuroticism;	chr22:41269718	chr22:41209122~41217627:-
HNSC	cis	rs4713118	0.662	rs149900	ENSG00000204709.4	LINC01556	5.62	3.29e-08	1.21e-05	0.35	0.25	Parkinson's disease;	chr6:28046819	chr6:28943877~28944537:+
HNSC	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-5.62	3.29e-08	1.21e-05	-0.43	-0.25	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
HNSC	cis	rs75920871	0.528	rs7124872	ENSG00000254851.1	RP11-109L13.1	-5.62	3.29e-08	1.21e-05	-0.35	-0.25	Subjective well-being;	chr11:117057235	chr11:117135528~117138582:+
HNSC	cis	rs4948102	0.551	rs4275190	ENSG00000226278.1	PSPHP1	-5.62	3.29e-08	1.21e-05	-0.28	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55764797~55773288:+
HNSC	cis	rs9341808	0.519	rs59232999	ENSG00000272129.1	RP11-250B2.6	-5.62	3.3e-08	1.21e-05	-0.3	-0.25	Sitting height ratio;	chr6:80309066	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-5.62	3.31e-08	1.22e-05	-0.3	-0.25	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
HNSC	cis	rs67981189	0.529	rs61990379	ENSG00000274818.1	RP1-292L20.3	5.62	3.31e-08	1.22e-05	0.3	0.25	Schizophrenia;	chr14:71000353	chr14:70906657~70907111:-
HNSC	cis	rs4925386	0.559	rs2427291	ENSG00000273619.1	RP5-908M14.9	-5.62	3.31e-08	1.22e-05	-0.28	-0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346268	chr20:62386303~62386970:-
HNSC	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	5.62	3.31e-08	1.22e-05	0.35	0.25	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	5.62	3.31e-08	1.22e-05	0.35	0.25	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
HNSC	cis	rs11154801	0.634	rs6941396	ENSG00000217482.2	HMGB1P17	5.62	3.32e-08	1.22e-05	0.3	0.25	Multiple sclerosis;	chr6:135606388	chr6:135636086~135636713:-
HNSC	cis	rs13113518	1	rs7662966	ENSG00000249700.7	SRD5A3-AS1	5.62	3.32e-08	1.22e-05	0.3	0.25	Height;	chr4:55548261	chr4:55363971~55395847:-
HNSC	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	5.62	3.32e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
HNSC	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-5.62	3.33e-08	1.22e-05	-0.3	-0.25	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
HNSC	cis	rs13113518	1	rs4864995	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55452853	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12651640	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55454154	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs1554483	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55455650	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs10517346	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55457027	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133384	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55457086	chr4:55363971~55395847:-
HNSC	cis	rs8177876	0.642	rs4454990	ENSG00000261061.1	RP11-303E16.2	5.62	3.33e-08	1.22e-05	0.4	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81030770~81031485:+
HNSC	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-5.62	3.33e-08	1.23e-05	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
HNSC	cis	rs2439831	1	rs2444029	ENSG00000205771.5	CATSPER2P1	-5.62	3.33e-08	1.23e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43445286	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	5.62	3.33e-08	1.23e-05	0.21	0.25	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
HNSC	cis	rs6969780	0.915	rs17471520	ENSG00000233429.8	HOTAIRM1	5.62	3.33e-08	1.23e-05	0.45	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27139171	chr7:27095647~27100265:+
HNSC	cis	rs7209700	0.547	rs16941776	ENSG00000228782.6	CTD-2026D20.3	-5.62	3.33e-08	1.23e-05	-0.27	-0.25	IgG glycosylation;	chr17:47265775	chr17:47450568~47492492:-
HNSC	cis	rs7209700	0.547	rs16941780	ENSG00000228782.6	CTD-2026D20.3	-5.62	3.33e-08	1.23e-05	-0.27	-0.25	IgG glycosylation;	chr17:47265817	chr17:47450568~47492492:-
HNSC	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-5.62	3.33e-08	1.23e-05	-0.24	-0.25	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
HNSC	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-5.62	3.33e-08	1.23e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
HNSC	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	5.62	3.34e-08	1.23e-05	0.32	0.25	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
HNSC	cis	rs2337406	0.866	rs8012619	ENSG00000211974.3	IGHV2-70	-5.62	3.34e-08	1.23e-05	-0.3	-0.25	Alzheimer's disease (late onset);	chr14:106793907	chr14:106723574~106724093:-
HNSC	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	5.62	3.35e-08	1.23e-05	0.32	0.25	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
HNSC	cis	rs330048	0.561	rs330088	ENSG00000254340.1	RP11-10A14.3	5.62	3.35e-08	1.23e-05	0.31	0.25	Systemic lupus erythematosus;	chr8:9292236	chr8:9141424~9145435:+
HNSC	cis	rs4763879	0.593	rs2080206	ENSG00000256673.1	RP11-599J14.2	5.62	3.35e-08	1.23e-05	0.24	0.25	Type 1 diabetes;	chr12:9715370	chr12:9398355~9414851:-
HNSC	cis	rs9402743	0.632	rs6570038	ENSG00000217482.2	HMGB1P17	5.62	3.35e-08	1.23e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135775465	chr6:135636086~135636713:-
HNSC	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	5.62	3.35e-08	1.23e-05	0.3	0.25	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
HNSC	cis	rs11846409	0.932	rs756588	ENSG00000211974.3	IGHV2-70	5.62	3.35e-08	1.23e-05	0.29	0.25	Rheumatic heart disease;	chr14:106632316	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.86	rs55745256	ENSG00000211974.3	IGHV2-70	-5.62	3.35e-08	1.23e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632365	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs731013	ENSG00000211974.3	IGHV2-70	-5.62	3.35e-08	1.23e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632481	chr14:106723574~106724093:-
HNSC	cis	rs1972460	0.506	rs62012050	ENSG00000276710.3	CSPG4P8	-5.62	3.35e-08	1.23e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82459472~82477258:+
HNSC	cis	rs60617249	0.507	rs12718990	ENSG00000228204.2	RP4-724E13.2	5.62	3.36e-08	1.24e-05	0.32	0.25	Major depression and alcohol dependence;	chr7:50906089	chr7:50866747~51022990:+
HNSC	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	5.62	3.36e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-5.62	3.37e-08	1.24e-05	-0.28	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
HNSC	cis	rs7824557	0.547	rs2409749	ENSG00000255310.2	AF131215.2	-5.62	3.38e-08	1.24e-05	-0.24	-0.25	Retinal vascular caliber;	chr8:11221440	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
HNSC	cis	rs2976388	0.647	rs1048831	ENSG00000253741.1	CTD-2292P10.4	-5.61	3.38e-08	1.24e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142700440	chr8:142702252~142726973:-
HNSC	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-5.61	3.38e-08	1.24e-05	-0.29	-0.25	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
HNSC	cis	rs9525927	0.521	rs4942298	ENSG00000227258.4	SMIM2-AS1	5.61	3.38e-08	1.24e-05	0.34	0.25	Dupuytren's disease;	chr13:44224486	chr13:44110451~44240517:+
HNSC	cis	rs6479891	0.63	rs4545434	ENSG00000232075.1	MRPL35P2	5.61	3.4e-08	1.25e-05	0.4	0.25	Arthritis (juvenile idiopathic);	chr10:63115985	chr10:63634317~63634827:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	5.61	3.4e-08	1.25e-05	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
HNSC	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-5.61	3.4e-08	1.25e-05	-0.37	-0.25	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
HNSC	cis	rs9291683	0.585	rs12648479	ENSG00000250413.1	RP11-448G15.1	5.61	3.4e-08	1.25e-05	0.31	0.25	Bone mineral density;	chr4:10102947	chr4:10006482~10009725:+
HNSC	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	5.61	3.4e-08	1.25e-05	0.29	0.25	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
HNSC	cis	rs9813712	0.571	rs9824426	ENSG00000249846.5	RP11-77P16.4	-5.61	3.41e-08	1.25e-05	-0.27	-0.25	Response to amphetamines;	chr3:130226115	chr3:130112550~130120579:+
HNSC	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	5.61	3.41e-08	1.25e-05	0.55	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
HNSC	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
HNSC	cis	rs4218	0.648	rs8042896	ENSG00000277144.1	RP11-59H7.4	-5.61	3.41e-08	1.25e-05	-0.34	-0.25	Social communication problems;	chr15:59067727	chr15:59115547~59116089:-
HNSC	cis	rs7980687	0.628	rs1727332	ENSG00000280120.1	RP11-546D6.3	5.61	3.41e-08	1.25e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123233754	chr12:123152324~123153377:-
HNSC	cis	rs6928977	0.5	rs12211833	ENSG00000217482.2	HMGB1P17	5.61	3.42e-08	1.26e-05	0.29	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	5.61	3.42e-08	1.26e-05	0.31	0.25	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
HNSC	cis	rs3206736	0.548	rs329229	ENSG00000197085.10	NPSR1-AS1	-5.61	3.42e-08	1.26e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35014417	chr7:34346512~34871582:-
HNSC	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-5.61	3.43e-08	1.26e-05	-0.3	-0.25	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	5.61	3.43e-08	1.26e-05	0.27	0.25	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
HNSC	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-5.61	3.43e-08	1.26e-05	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
HNSC	cis	rs4938303	0.589	rs11216100	ENSG00000254851.1	RP11-109L13.1	5.61	3.43e-08	1.26e-05	0.36	0.25	Triglycerides;	chr11:116701814	chr11:117135528~117138582:+
HNSC	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	5.61	3.43e-08	1.26e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
HNSC	cis	rs6951245	0.572	rs73264028	ENSG00000224079.1	AC091729.7	-5.61	3.44e-08	1.26e-05	-0.5	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1005819	chr7:1074450~1078036:+
HNSC	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-5.61	3.44e-08	1.26e-05	-0.27	-0.25	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
HNSC	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	5.61	3.45e-08	1.27e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
HNSC	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-5.61	3.45e-08	1.27e-05	-0.24	-0.25	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
HNSC	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-5.61	3.45e-08	1.27e-05	-0.36	-0.25	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
HNSC	cis	rs1355223	0.833	rs11032804	ENSG00000271369.1	RP11-350D17.3	-5.61	3.45e-08	1.27e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659051	chr11:34709600~34710161:+
HNSC	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	5.61	3.46e-08	1.27e-05	0.31	0.25	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	5.61	3.46e-08	1.27e-05	0.31	0.25	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
HNSC	cis	rs9813712	0.818	rs11718381	ENSG00000249846.5	RP11-77P16.4	5.61	3.46e-08	1.27e-05	0.3	0.25	Response to amphetamines;	chr3:130222660	chr3:130112550~130120579:+
HNSC	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.61	3.46e-08	1.27e-05	-0.2	-0.25	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
HNSC	cis	rs988913	1	rs6926997	ENSG00000224984.1	RP11-524H19.2	5.61	3.46e-08	1.27e-05	0.28	0.25	Menarche (age at onset);	chr6:54952528	chr6:54840118~54840855:-
HNSC	cis	rs4535700	0.501	rs57251705	ENSG00000226278.1	PSPHP1	5.61	3.47e-08	1.27e-05	0.3	0.25	Macular telangiectasia type 2;	chr7:55913390	chr7:55764797~55773288:+
HNSC	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	5.61	3.47e-08	1.27e-05	0.36	0.25	Height;	chr6:109712525	chr6:109382795~109383666:+
HNSC	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	5.61	3.47e-08	1.27e-05	0.24	0.25	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
HNSC	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	5.61	3.47e-08	1.27e-05	0.27	0.25	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
HNSC	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	5.61	3.47e-08	1.27e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
HNSC	cis	rs7674212	0.539	rs6854709	ENSG00000246560.2	RP11-10L12.4	5.61	3.47e-08	1.27e-05	0.29	0.25	Type 2 diabetes;	chr4:103208629	chr4:102828055~102844075:+
HNSC	cis	rs11846409	0.932	rs731012	ENSG00000211974.3	IGHV2-70	-5.61	3.47e-08	1.27e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632578	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs731011	ENSG00000211974.3	IGHV2-70	-5.61	3.47e-08	1.27e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632619	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs10138537	ENSG00000211974.3	IGHV2-70	-5.61	3.47e-08	1.27e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632778	chr14:106723574~106724093:-
HNSC	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	5.61	3.48e-08	1.28e-05	0.34	0.25	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
HNSC	cis	rs3738443	0.645	rs11811599	ENSG00000259865.1	RP11-488L18.10	5.61	3.48e-08	1.28e-05	0.2	0.25	Alcohol dependence;	chr1:247203133	chr1:247187281~247188526:-
HNSC	cis	rs1355223	0.902	rs286858	ENSG00000271369.1	RP11-350D17.3	5.61	3.48e-08	1.28e-05	0.29	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34695810	chr11:34709600~34710161:+
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	5.61	3.48e-08	1.28e-05	0.27	0.25	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
HNSC	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	5.61	3.48e-08	1.28e-05	0.26	0.25	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
HNSC	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	5.61	3.48e-08	1.28e-05	0.26	0.25	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
HNSC	cis	rs4657482	0.962	rs10800164	ENSG00000236364.3	RP11-525G13.2	-5.61	3.48e-08	1.28e-05	-0.25	-0.25	Testicular germ cell tumor;	chr1:165889117	chr1:165890795~165900683:-
HNSC	cis	rs8054556	1	rs4583255	ENSG00000183604.13	SMG1P5	-5.61	3.48e-08	1.28e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29977620	chr16:30267553~30335374:-
HNSC	cis	rs9341808	0.5	rs2322629	ENSG00000272129.1	RP11-250B2.6	5.61	3.48e-08	1.28e-05	0.3	0.25	Sitting height ratio;	chr6:80101823	chr6:80355424~80356859:+
HNSC	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-5.61	3.49e-08	1.28e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
HNSC	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	5.61	3.49e-08	1.28e-05	0.32	0.25	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000235689.1	AP000351.13	5.61	3.49e-08	1.28e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:24006305~24008258:-
HNSC	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	5.61	3.49e-08	1.28e-05	0.26	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
HNSC	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
HNSC	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-5.61	3.5e-08	1.28e-05	-0.24	-0.25	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
HNSC	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	5.61	3.5e-08	1.28e-05	0.29	0.25	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
HNSC	cis	rs7160336	0.738	rs11849883	ENSG00000259065.1	RP5-1021I20.1	5.61	3.5e-08	1.28e-05	0.29	0.25	Blood protein levels;	chr14:74010633	chr14:73787360~73803270:+
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	5.61	3.5e-08	1.28e-05	0.28	0.25	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
HNSC	cis	rs2179367	0.632	rs9498332	ENSG00000216906.2	RP11-350J20.9	5.61	3.5e-08	1.28e-05	0.37	0.25	Dupuytren's disease;	chr6:149367490	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498333	ENSG00000216906.2	RP11-350J20.9	5.61	3.5e-08	1.28e-05	0.37	0.25	Dupuytren's disease;	chr6:149368196	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498334	ENSG00000216906.2	RP11-350J20.9	5.61	3.5e-08	1.28e-05	0.37	0.25	Dupuytren's disease;	chr6:149370902	chr6:149904243~149906418:+
HNSC	cis	rs6604026	0.59	rs11810217	ENSG00000223787.2	RP4-593M8.1	5.61	3.51e-08	1.29e-05	0.35	0.25	Multiple sclerosis;	chr1:92682820	chr1:92580476~92580821:-
HNSC	cis	rs11810217	0.718	rs114225281	ENSG00000223787.2	RP4-593M8.1	5.61	3.51e-08	1.29e-05	0.35	0.25	Multiple sclerosis;	chr1:92685669	chr1:92580476~92580821:-
HNSC	cis	rs2179367	0.632	rs7349921	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149392727	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs60153446	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393186	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs61259243	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393457	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs62426115	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393718	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs68080376	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393873	chr6:149904243~149906418:+
HNSC	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	5.61	3.51e-08	1.29e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	5.61	3.51e-08	1.29e-05	0.31	0.25	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
HNSC	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-5.61	3.51e-08	1.29e-05	-0.35	-0.25	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-5.61	3.51e-08	1.29e-05	-0.35	-0.25	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
HNSC	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	5.61	3.51e-08	1.29e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
HNSC	cis	rs13113518	0.902	rs12505266	ENSG00000273257.1	RP11-177J6.1	5.61	3.52e-08	1.29e-05	0.31	0.25	Height;	chr4:55546002	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs56154935	ENSG00000273257.1	RP11-177J6.1	5.61	3.52e-08	1.29e-05	0.31	0.25	Height;	chr4:55546378	chr4:55387949~55388271:+
HNSC	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-5.61	3.52e-08	1.29e-05	-0.35	-0.25	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
HNSC	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	5.61	3.52e-08	1.29e-05	0.27	0.25	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
HNSC	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
HNSC	cis	rs9329221	0.935	rs3750310	ENSG00000269918.1	AF131215.9	-5.61	3.52e-08	1.29e-05	-0.24	-0.25	Neuroticism;	chr8:10425916	chr8:11104691~11106704:-
HNSC	cis	rs9402743	0.632	rs6900101	ENSG00000217482.2	HMGB1P17	5.61	3.52e-08	1.29e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135773766	chr6:135636086~135636713:-
HNSC	cis	rs6918586	0.681	rs198831	ENSG00000272462.2	U91328.19	-5.61	3.52e-08	1.29e-05	-0.24	-0.25	Schizophrenia;	chr6:26116768	chr6:25992662~26001775:+
HNSC	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	5.61	3.52e-08	1.29e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
HNSC	cis	rs4140799	0.78	rs1204992	ENSG00000266869.1	RP6-114E22.1	5.61	3.52e-08	1.29e-05	0.31	0.25	Neuroticism;	chr14:71731794	chr14:71848606~71908430:+
HNSC	cis	rs2579103	0.898	rs2165039	ENSG00000258183.4	RP11-753N8.1	5.61	3.53e-08	1.29e-05	0.31	0.25	Body mass index;	chr12:90207656	chr12:90280894~90300340:+
HNSC	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-5.61	3.53e-08	1.29e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
HNSC	cis	rs7980687	0.657	rs10744151	ENSG00000280120.1	RP11-546D6.3	5.61	3.53e-08	1.29e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123239188	chr12:123152324~123153377:-
HNSC	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-5.61	3.53e-08	1.29e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-5.61	3.53e-08	1.29e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-5.61	3.53e-08	1.29e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
HNSC	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	5.61	3.53e-08	1.29e-05	0.31	0.25	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
HNSC	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	5.61	3.54e-08	1.29e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	5.61	3.54e-08	1.3e-05	0.31	0.25	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
HNSC	cis	rs947583	0.588	rs11753333	ENSG00000217482.2	HMGB1P17	5.61	3.54e-08	1.3e-05	0.3	0.25	Phosphorus levels;	chr6:135715788	chr6:135636086~135636713:-
HNSC	cis	rs11089937	0.963	rs2073454	ENSG00000211638.2	IGLV8-61	-5.61	3.54e-08	1.3e-05	-0.22	-0.25	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22098700~22099212:+
HNSC	cis	rs1355223	0.867	rs3818514	ENSG00000271369.1	RP11-350D17.3	-5.61	3.55e-08	1.3e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34658506	chr11:34709600~34710161:+
HNSC	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	5.61	3.55e-08	1.3e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
HNSC	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	5.61	3.55e-08	1.3e-05	0.23	0.25	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
HNSC	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	5.61	3.56e-08	1.3e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
HNSC	cis	rs853679	1	rs735765	ENSG00000204709.4	LINC01556	5.61	3.56e-08	1.3e-05	0.42	0.25	Depression;	chr6:28202519	chr6:28943877~28944537:+
HNSC	cis	rs9813712	0.526	rs62281641	ENSG00000249846.5	RP11-77P16.4	-5.61	3.56e-08	1.3e-05	-0.27	-0.25	Response to amphetamines;	chr3:130235668	chr3:130112550~130120579:+
HNSC	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-5.61	3.56e-08	1.3e-05	-0.27	-0.25	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-5.61	3.56e-08	1.3e-05	-0.27	-0.25	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
HNSC	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	5.61	3.56e-08	1.3e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
HNSC	cis	rs35306767	0.807	rs11253513	ENSG00000229869.1	RP11-363N22.2	-5.61	3.57e-08	1.3e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:922510	chr10:933026~942743:+
HNSC	cis	rs35306767	0.953	rs12259338	ENSG00000229869.1	RP11-363N22.2	-5.61	3.57e-08	1.3e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:923437	chr10:933026~942743:+
HNSC	cis	rs947583	0.588	rs12201044	ENSG00000217482.2	HMGB1P17	5.6	3.57e-08	1.3e-05	0.29	0.25	Phosphorus levels;	chr6:135743303	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.588	rs7748386	ENSG00000217482.2	HMGB1P17	5.6	3.57e-08	1.3e-05	0.29	0.25	Phosphorus levels;	chr6:135750576	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.588	rs12202435	ENSG00000217482.2	HMGB1P17	5.6	3.57e-08	1.3e-05	0.29	0.25	Phosphorus levels;	chr6:135752622	chr6:135636086~135636713:-
HNSC	cis	rs9914544	1	rs6502677	ENSG00000264885.1	RP11-815I9.4	-5.6	3.57e-08	1.31e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18900345	chr17:18667629~18669461:-
HNSC	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.6	3.58e-08	1.31e-05	-0.37	-0.25	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
HNSC	cis	rs9291683	0.546	rs10939672	ENSG00000250413.1	RP11-448G15.1	-5.6	3.58e-08	1.31e-05	-0.31	-0.25	Bone mineral density;	chr4:10050512	chr4:10006482~10009725:+
HNSC	cis	rs2921036	0.529	rs2979192	ENSG00000254153.1	CTA-398F10.2	5.6	3.59e-08	1.31e-05	0.28	0.25	Neuroticism;	chr8:8480637	chr8:8456909~8461337:-
HNSC	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	5.6	3.59e-08	1.31e-05	0.35	0.25	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
HNSC	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	5.6	3.59e-08	1.31e-05	0.24	0.25	Height;	chr5:36887793	chr5:36666214~36725195:-
HNSC	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	5.6	3.59e-08	1.31e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
HNSC	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-5.6	3.59e-08	1.31e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-5.6	3.59e-08	1.31e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
HNSC	cis	rs1908814	0.516	rs35391955	ENSG00000206014.6	OR7E161P	-5.6	3.59e-08	1.31e-05	-0.27	-0.25	Neuroticism;	chr8:11939219	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs58869268	ENSG00000206014.6	OR7E161P	-5.6	3.59e-08	1.31e-05	-0.27	-0.25	Neuroticism;	chr8:11939586	chr8:11928597~11929563:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000235689.1	AP000351.13	5.6	3.59e-08	1.31e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:24006305~24008258:-
HNSC	cis	rs763567	1	rs763567	ENSG00000271811.1	RP1-79C4.4	-5.6	3.59e-08	1.31e-05	-0.28	-0.25	Tonsillectomy;	chr1:170596864	chr1:170667381~170669425:+
HNSC	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-5.6	3.59e-08	1.31e-05	-0.3	-0.25	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
HNSC	cis	rs9341808	0.538	rs9343980	ENSG00000272129.1	RP11-250B2.6	-5.6	3.6e-08	1.32e-05	-0.29	-0.25	Sitting height ratio;	chr6:80313715	chr6:80355424~80356859:+
HNSC	cis	rs5753618	0.583	rs7287267	ENSG00000236132.1	CTA-440B3.1	-5.6	3.6e-08	1.32e-05	-0.3	-0.25	Colorectal cancer;	chr22:31352429	chr22:31816379~31817491:-
HNSC	cis	rs11089937	0.825	rs5757012	ENSG00000211639.2	IGLV4-60	5.6	3.6e-08	1.32e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22162199~22162681:+
HNSC	cis	rs6951245	0.572	rs73264010	ENSG00000224079.1	AC091729.7	-5.6	3.6e-08	1.32e-05	-0.5	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1000841	chr7:1074450~1078036:+
HNSC	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	5.6	3.6e-08	1.32e-05	0.26	0.25	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
HNSC	cis	rs9341808	0.519	rs3805872	ENSG00000272129.1	RP11-250B2.6	-5.6	3.6e-08	1.32e-05	-0.3	-0.25	Sitting height ratio;	chr6:80325385	chr6:80355424~80356859:+
HNSC	cis	rs763567	0.585	rs553905	ENSG00000271811.1	RP1-79C4.4	-5.6	3.61e-08	1.32e-05	-0.27	-0.25	Tonsillectomy;	chr1:170611336	chr1:170667381~170669425:+
HNSC	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	5.6	3.61e-08	1.32e-05	0.3	0.25	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
HNSC	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-5.6	3.61e-08	1.32e-05	-0.37	-0.25	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
HNSC	cis	rs6928977	0.86	rs3827780	ENSG00000234084.1	RP3-388E23.2	5.6	3.62e-08	1.32e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135388622	chr6:135301568~135307158:+
HNSC	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	5.6	3.62e-08	1.32e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	5.6	3.62e-08	1.32e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
HNSC	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-5.6	3.62e-08	1.32e-05	-0.31	-0.25	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
HNSC	cis	rs9341808	0.538	rs7756067	ENSG00000272129.1	RP11-250B2.6	-5.6	3.62e-08	1.32e-05	-0.29	-0.25	Sitting height ratio;	chr6:80310077	chr6:80355424~80356859:+
HNSC	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-5.6	3.63e-08	1.33e-05	-0.31	-0.25	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
HNSC	cis	rs17772222	0.71	rs1028455	ENSG00000258789.1	RP11-507K2.3	-5.6	3.63e-08	1.33e-05	-0.28	-0.25	Coronary artery calcification;	chr14:88363631	chr14:88551597~88552493:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	5.6	3.63e-08	1.33e-05	0.2	0.25	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
HNSC	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-5.6	3.64e-08	1.33e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
HNSC	cis	rs8177876	0.915	rs8059692	ENSG00000261061.1	RP11-303E16.2	-5.6	3.64e-08	1.33e-05	-0.43	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81030770~81031485:+
HNSC	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.64e-08	1.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.64e-08	1.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.64e-08	1.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
HNSC	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-5.6	3.64e-08	1.33e-05	-0.27	-0.25	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
HNSC	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-5.6	3.65e-08	1.33e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
HNSC	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-5.6	3.65e-08	1.33e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
HNSC	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-5.6	3.65e-08	1.33e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
HNSC	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-5.6	3.65e-08	1.33e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
HNSC	cis	rs2033711	0.654	rs734380	ENSG00000269473.1	CTD-2619J13.19	5.6	3.65e-08	1.33e-05	0.31	0.25	Uric acid clearance;	chr19:58387596	chr19:58440448~58445849:+
HNSC	cis	rs4763879	0.54	rs741200	ENSG00000256673.1	RP11-599J14.2	5.6	3.65e-08	1.33e-05	0.24	0.25	Type 1 diabetes;	chr12:9717819	chr12:9398355~9414851:-
HNSC	cis	rs6928977	0.86	rs2757649	ENSG00000231028.7	LINC00271	-5.6	3.65e-08	1.33e-05	-0.29	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135405475	chr6:135497801~135716055:+
HNSC	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	5.6	3.65e-08	1.33e-05	0.29	0.25	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
HNSC	cis	rs7211079	0.719	rs2289535	ENSG00000279259.1	RP11-334C17.3	5.6	3.65e-08	1.33e-05	0.31	0.25	Myocardial infarction;	chr17:80137650	chr17:80147250~80148596:+
HNSC	cis	rs2842992	0.724	rs4709368	ENSG00000237927.1	RP3-393E18.2	5.6	3.66e-08	1.34e-05	0.36	0.25	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159586955~159589169:-
HNSC	cis	rs9611519	0.761	rs35445172	ENSG00000235513.1	RP4-756G23.5	5.6	3.66e-08	1.34e-05	0.26	0.25	Neuroticism;	chr22:41264297	chr22:41209122~41217627:-
HNSC	cis	rs860295	0.557	rs10796944	ENSG00000203761.5	MSTO2P	-5.6	3.66e-08	1.34e-05	-0.21	-0.25	Body mass index;	chr1:155446537	chr1:155745829~155750137:+
HNSC	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-5.6	3.67e-08	1.34e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
HNSC	cis	rs9341808	0.538	rs620147	ENSG00000272129.1	RP11-250B2.6	-5.6	3.67e-08	1.34e-05	-0.29	-0.25	Sitting height ratio;	chr6:80282373	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-5.6	3.67e-08	1.34e-05	-0.22	-0.25	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	5.6	3.67e-08	1.34e-05	0.31	0.25	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
HNSC	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-5.6	3.67e-08	1.34e-05	-0.32	-0.25	Depression;	chr6:28140454	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-5.6	3.67e-08	1.34e-05	-0.32	-0.25	Depression;	chr6:28141189	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-5.6	3.67e-08	1.34e-05	-0.32	-0.25	Depression;	chr6:28141484	chr6:28161781~28169594:+
HNSC	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
HNSC	cis	rs2933343	0.621	rs789249	ENSG00000261159.1	RP11-723O4.9	5.6	3.68e-08	1.34e-05	0.25	0.25	IgG glycosylation;	chr3:128859610	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.621	rs789241	ENSG00000261159.1	RP11-723O4.9	5.6	3.68e-08	1.34e-05	0.25	0.25	IgG glycosylation;	chr3:128866909	chr3:128859716~128860526:-
HNSC	cis	rs2842992	0.662	rs2273826	ENSG00000237927.1	RP3-393E18.2	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790389	chr6:159586955~159589169:-
HNSC	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	5.6	3.69e-08	1.34e-05	0.26	0.25	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	5.6	3.69e-08	1.35e-05	0.27	0.25	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
HNSC	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-5.6	3.69e-08	1.35e-05	-0.35	-0.25	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000254340.1	RP11-10A14.3	5.6	3.69e-08	1.35e-05	0.3	0.25	Mood instability;	chr8:8813089	chr8:9141424~9145435:+
HNSC	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-5.6	3.7e-08	1.35e-05	-0.35	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
HNSC	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-5.6	3.7e-08	1.35e-05	-0.2	-0.25	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
HNSC	cis	rs13113518	0.812	rs2048564	ENSG00000273257.1	RP11-177J6.1	5.6	3.7e-08	1.35e-05	0.31	0.25	Height;	chr4:55407965	chr4:55387949~55388271:+
HNSC	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-5.6	3.71e-08	1.35e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
HNSC	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-5.6	3.71e-08	1.35e-05	-0.32	-0.25	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
HNSC	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-5.6	3.71e-08	1.35e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
HNSC	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-5.6	3.71e-08	1.35e-05	-0.4	-0.25	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
HNSC	cis	rs13113518	1	rs1464490	ENSG00000249700.7	SRD5A3-AS1	5.6	3.71e-08	1.35e-05	0.29	0.25	Height;	chr4:55456620	chr4:55363971~55395847:-
HNSC	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	5.6	3.71e-08	1.35e-05	0.34	0.25	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	5.6	3.71e-08	1.35e-05	0.34	0.25	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	5.6	3.71e-08	1.35e-05	0.34	0.25	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	5.6	3.71e-08	1.35e-05	0.3	0.25	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
HNSC	cis	rs7209700	0.821	rs2292863	ENSG00000228782.6	CTD-2026D20.3	-5.6	3.71e-08	1.35e-05	-0.26	-0.25	IgG glycosylation;	chr17:47291764	chr17:47450568~47492492:-
HNSC	cis	rs7209700	0.821	rs4642	ENSG00000228782.6	CTD-2026D20.3	-5.6	3.71e-08	1.35e-05	-0.26	-0.25	IgG glycosylation;	chr17:47292411	chr17:47450568~47492492:-
HNSC	cis	rs7209700	0.821	rs4634	ENSG00000228782.6	CTD-2026D20.3	-5.6	3.71e-08	1.35e-05	-0.26	-0.25	IgG glycosylation;	chr17:47292423	chr17:47450568~47492492:-
HNSC	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	5.6	3.72e-08	1.35e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
HNSC	cis	rs3206736	0.548	rs1649238	ENSG00000197085.10	NPSR1-AS1	5.6	3.72e-08	1.36e-05	0.31	0.25	Diastolic blood pressure;	chr7:34964905	chr7:34346512~34871582:-
HNSC	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-5.6	3.72e-08	1.36e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
HNSC	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-5.6	3.72e-08	1.36e-05	-0.3	-0.25	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
HNSC	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	5.6	3.72e-08	1.36e-05	0.24	0.25	Asthma;	chr2:102423587	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	5.6	3.72e-08	1.36e-05	0.24	0.25	Asthma;	chr2:102423717	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	5.6	3.72e-08	1.36e-05	0.24	0.25	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
HNSC	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-5.6	3.73e-08	1.36e-05	-0.28	-0.25	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
HNSC	cis	rs75422866	0.51	rs75424057	ENSG00000276691.1	RP5-1057I20.5	5.6	3.73e-08	1.36e-05	0.44	0.25	Pneumonia;	chr12:47737294	chr12:47788426~47788971:+
HNSC	cis	rs11098499	0.663	rs9996501	ENSG00000249244.1	RP11-548H18.2	5.6	3.73e-08	1.36e-05	0.31	0.25	Corneal astigmatism;	chr4:119317763	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs28458294	ENSG00000249244.1	RP11-548H18.2	5.6	3.73e-08	1.36e-05	0.31	0.25	Corneal astigmatism;	chr4:119317769	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.663	rs28369503	ENSG00000249244.1	RP11-548H18.2	5.6	3.73e-08	1.36e-05	0.31	0.25	Corneal astigmatism;	chr4:119317770	chr4:119391831~119395335:-
HNSC	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-5.6	3.74e-08	1.36e-05	-0.27	-0.25	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
HNSC	cis	rs2268667	0.509	rs7521189	ENSG00000223653.4	RP11-131L23.1	-5.6	3.74e-08	1.36e-05	-0.32	-0.25	Asymmetrical dimethylarginine levels;	chr1:85423913	chr1:85276715~85448124:+
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-5.6	3.75e-08	1.37e-05	-0.17	-0.25	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
HNSC	cis	rs5758659	0.904	rs134877	ENSG00000227370.1	RP4-669P10.19	-5.6	3.75e-08	1.37e-05	-0.24	-0.25	Cognitive function;	chr22:42266365	chr22:42132543~42132998:+
HNSC	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-5.6	3.75e-08	1.37e-05	-0.3	-0.25	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
HNSC	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-5.6	3.75e-08	1.37e-05	-0.22	-0.25	Height;	chr11:118761813	chr11:118791254~118793137:+
HNSC	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-5.6	3.75e-08	1.37e-05	-0.2	-0.25	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
HNSC	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
HNSC	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-5.6	3.75e-08	1.37e-05	-0.29	-0.25	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
HNSC	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	5.6	3.76e-08	1.37e-05	0.22	0.25	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
HNSC	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.76e-08	1.37e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.76e-08	1.37e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
HNSC	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	5.6	3.76e-08	1.37e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
HNSC	cis	rs13113518	0.841	rs11133400	ENSG00000273257.1	RP11-177J6.1	5.59	3.77e-08	1.37e-05	0.31	0.25	Height;	chr4:55578787	chr4:55387949~55388271:+
HNSC	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-5.59	3.77e-08	1.37e-05	-0.3	-0.25	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
HNSC	cis	rs9287719	0.649	rs12617968	ENSG00000234818.1	AC092687.5	5.59	3.77e-08	1.37e-05	0.53	0.25	Prostate cancer;	chr2:10581819	chr2:10589166~10604830:+
HNSC	cis	rs60617249	0.55	rs13309489	ENSG00000228204.2	RP4-724E13.2	5.59	3.77e-08	1.37e-05	0.32	0.25	Major depression and alcohol dependence;	chr7:50943627	chr7:50866747~51022990:+
HNSC	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-5.59	3.77e-08	1.37e-05	-0.28	-0.25	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
HNSC	cis	rs503425	0.818	rs2508922	ENSG00000255422.1	AP002954.4	5.59	3.78e-08	1.38e-05	0.35	0.25	Systemic lupus erythematosus;	chr11:118810379	chr11:118704607~118750263:+
HNSC	cis	rs2439831	0.867	rs4583210	ENSG00000205771.5	CATSPER2P1	-5.59	3.78e-08	1.38e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43368727	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs28461955	ENSG00000205771.5	CATSPER2P1	-5.59	3.78e-08	1.38e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43369261	chr15:43726918~43747094:-
HNSC	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	5.59	3.78e-08	1.38e-05	0.31	0.25	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	5.59	3.78e-08	1.38e-05	0.31	0.25	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
HNSC	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-5.59	3.79e-08	1.38e-05	-0.31	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-5.59	3.79e-08	1.38e-05	-0.31	-0.25	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
HNSC	cis	rs11992162	0.597	rs7016320	ENSG00000206014.6	OR7E161P	5.59	3.79e-08	1.38e-05	0.27	0.25	Monocyte count;	chr8:11923543	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000254340.1	RP11-10A14.3	5.59	3.79e-08	1.38e-05	0.31	0.25	Mood instability;	chr8:8410553	chr8:9141424~9145435:+
HNSC	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
HNSC	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
HNSC	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	5.59	3.79e-08	1.38e-05	0.27	0.25	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
HNSC	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
HNSC	cis	rs7819412	0.634	rs6987767	ENSG00000269918.1	AF131215.9	5.59	3.79e-08	1.38e-05	0.25	0.25	Triglycerides;	chr8:11052556	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	5.59	3.79e-08	1.38e-05	0.2	0.25	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
HNSC	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	5.59	3.8e-08	1.38e-05	0.24	0.25	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
HNSC	cis	rs6604026	0.59	rs111807611	ENSG00000223787.2	RP4-593M8.1	5.59	3.8e-08	1.38e-05	0.35	0.25	Multiple sclerosis;	chr1:92687707	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-5.59	3.8e-08	1.38e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
HNSC	cis	rs10435719	0.902	rs6601633	ENSG00000206014.6	OR7E161P	5.59	3.8e-08	1.38e-05	0.27	0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11928597~11929563:-
HNSC	cis	rs2243480	1	rs313813	ENSG00000179406.6	LINC00174	-5.59	3.8e-08	1.38e-05	-0.54	-0.25	Diabetic kidney disease;	chr7:66038513	chr7:66376044~66401338:-
HNSC	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-5.59	3.81e-08	1.39e-05	-0.27	-0.25	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
HNSC	cis	rs1355223	1	rs2221720	ENSG00000271369.1	RP11-350D17.3	5.59	3.81e-08	1.39e-05	0.27	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34733374	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	5.59	3.81e-08	1.39e-05	0.27	0.25	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
HNSC	cis	rs11846409	0.872	rs2516914	ENSG00000211974.3	IGHV2-70	5.59	3.81e-08	1.39e-05	0.28	0.25	Rheumatic heart disease;	chr14:106629835	chr14:106723574~106724093:-
HNSC	cis	rs10435719	0.899	rs11250177	ENSG00000206014.6	OR7E161P	-5.59	3.82e-08	1.39e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11928597~11929563:-
HNSC	cis	rs503425	1	rs503425	ENSG00000255422.1	AP002954.4	-5.59	3.82e-08	1.39e-05	-0.35	-0.25	Systemic lupus erythematosus;	chr11:118822018	chr11:118704607~118750263:+
HNSC	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-5.59	3.82e-08	1.39e-05	-0.35	-0.25	Depression;	chr6:28231986	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-5.59	3.82e-08	1.39e-05	-0.35	-0.25	Depression;	chr6:28232159	chr6:28115628~28116551:+
HNSC	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	5.59	3.82e-08	1.39e-05	0.33	0.25	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
HNSC	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	5.59	3.82e-08	1.39e-05	0.34	0.25	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
HNSC	cis	rs7819412	0.538	rs4523214	ENSG00000255310.2	AF131215.2	-5.59	3.82e-08	1.39e-05	-0.24	-0.25	Triglycerides;	chr8:11113263	chr8:11107788~11109726:-
HNSC	cis	rs75422866	0.558	rs73104190	ENSG00000274902.1	RP1-197B17.4	5.59	3.83e-08	1.39e-05	0.57	0.25	Pneumonia;	chr12:47716040	chr12:47731908~47732351:+
HNSC	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	5.59	3.83e-08	1.39e-05	0.31	0.25	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
HNSC	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	5.59	3.83e-08	1.39e-05	0.3	0.25	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
HNSC	cis	rs2243480	1	rs2420171	ENSG00000179406.6	LINC00174	5.59	3.83e-08	1.39e-05	0.53	0.25	Diabetic kidney disease;	chr7:66172773	chr7:66376044~66401338:-
HNSC	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	5.59	3.84e-08	1.4e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	5.59	3.84e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-5.59	3.84e-08	1.4e-05	-0.16	-0.25	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-5.59	3.84e-08	1.4e-05	-0.16	-0.25	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
HNSC	cis	rs4803480	0.935	rs9304595	ENSG00000270164.1	LINC01480	5.59	3.84e-08	1.4e-05	0.23	0.25	Schizophrenia;	chr19:41571639	chr19:41535183~41536904:+
HNSC	cis	rs5753618	0.583	rs738657	ENSG00000236132.1	CTA-440B3.1	-5.59	3.85e-08	1.4e-05	-0.3	-0.25	Colorectal cancer;	chr22:31445763	chr22:31816379~31817491:-
HNSC	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-5.59	3.85e-08	1.4e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	5.59	3.85e-08	1.4e-05	0.3	0.25	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
HNSC	cis	rs7674212	0.57	rs2711899	ENSG00000246560.2	RP11-10L12.4	5.59	3.85e-08	1.4e-05	0.28	0.25	Type 2 diabetes;	chr4:103141257	chr4:102828055~102844075:+
HNSC	cis	rs10256972	0.967	rs4723338	ENSG00000225146.1	AC073957.15	5.59	3.85e-08	1.4e-05	0.29	0.25	Endometriosis;Longevity;	chr7:996605	chr7:1029025~1043891:+
HNSC	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	5.59	3.85e-08	1.4e-05	0.27	0.25	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
HNSC	cis	rs988913	1	rs9370342	ENSG00000224984.1	RP11-524H19.2	5.59	3.86e-08	1.4e-05	0.28	0.25	Menarche (age at onset);	chr6:54955872	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9370343	ENSG00000224984.1	RP11-524H19.2	5.59	3.86e-08	1.4e-05	0.28	0.25	Menarche (age at onset);	chr6:54955878	chr6:54840118~54840855:-
HNSC	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-5.59	3.86e-08	1.4e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
HNSC	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-5.59	3.86e-08	1.4e-05	-0.28	-0.25	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
HNSC	cis	rs9341808	0.622	rs684283	ENSG00000272129.1	RP11-250B2.6	-5.59	3.87e-08	1.4e-05	-0.3	-0.25	Sitting height ratio;	chr6:80257600	chr6:80355424~80356859:+
HNSC	cis	rs7665090	0.728	rs228628	ENSG00000246560.2	RP11-10L12.4	-5.59	3.87e-08	1.4e-05	-0.29	-0.25	Primary biliary cholangitis;	chr4:102652166	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.692	rs228629	ENSG00000246560.2	RP11-10L12.4	-5.59	3.87e-08	1.4e-05	-0.29	-0.25	Primary biliary cholangitis;	chr4:102652220	chr4:102828055~102844075:+
HNSC	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	5.59	3.87e-08	1.41e-05	0.26	0.25	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
HNSC	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-5.59	3.88e-08	1.41e-05	-0.32	-0.25	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
HNSC	cis	rs13113518	1	rs4865007	ENSG00000273257.1	RP11-177J6.1	-5.59	3.88e-08	1.41e-05	-0.3	-0.25	Height;	chr4:55537550	chr4:55387949~55388271:+
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000254153.1	CTA-398F10.2	5.59	3.88e-08	1.41e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9027656	chr8:8456909~8461337:-
HNSC	cis	rs9914544	1	rs67411574	ENSG00000264885.1	RP11-815I9.4	-5.59	3.89e-08	1.41e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18894024	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.966	rs7210746	ENSG00000264885.1	RP11-815I9.4	-5.59	3.89e-08	1.41e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18895280	chr17:18667629~18669461:-
HNSC	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	5.59	3.89e-08	1.41e-05	0.31	0.25	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	5.59	3.89e-08	1.41e-05	0.31	0.25	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000254153.1	CTA-398F10.2	-5.59	3.89e-08	1.41e-05	-0.27	-0.25	Neuroticism;	chr8:8237241	chr8:8456909~8461337:-
HNSC	cis	rs61160187	0.555	rs34608	ENSG00000215032.2	GNL3LP1	5.59	3.89e-08	1.41e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:60891935~60893577:-
HNSC	cis	rs7674212	0.541	rs2720448	ENSG00000246560.2	RP11-10L12.4	5.59	3.89e-08	1.41e-05	0.29	0.25	Type 2 diabetes;	chr4:103109432	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.541	rs2623064	ENSG00000246560.2	RP11-10L12.4	5.59	3.89e-08	1.41e-05	0.29	0.25	Type 2 diabetes;	chr4:103109635	chr4:102828055~102844075:+
HNSC	cis	rs1012068	0.662	rs4820994	ENSG00000236132.1	CTA-440B3.1	-5.59	3.89e-08	1.41e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31915633	chr22:31816379~31817491:-
HNSC	cis	rs526231	0.857	rs415657	ENSG00000175749.11	EIF3KP1	-5.59	3.89e-08	1.41e-05	-0.31	-0.25	Primary biliary cholangitis;	chr5:103329295	chr5:103032376~103033031:+
HNSC	cis	rs867371	0.502	rs3759800	ENSG00000276710.3	CSPG4P8	5.59	3.9e-08	1.41e-05	0.26	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82459472~82477258:+
HNSC	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-5.59	3.9e-08	1.41e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
HNSC	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-5.59	3.9e-08	1.42e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
HNSC	cis	rs60617249	0.602	rs34709117	ENSG00000228204.2	RP4-724E13.2	5.59	3.9e-08	1.42e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50930485	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.55	rs13235836	ENSG00000228204.2	RP4-724E13.2	5.59	3.9e-08	1.42e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50931626	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.55	rs71540281	ENSG00000228204.2	RP4-724E13.2	5.59	3.9e-08	1.42e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50936419	chr7:50866747~51022990:+
HNSC	cis	rs2834288	0.7	rs731060	ENSG00000237945.6	LINC00649	-5.59	3.91e-08	1.42e-05	-0.32	-0.25	Gut microbiota (bacterial taxa);	chr21:33902624	chr21:33915534~33977691:+
HNSC	cis	rs603446	0.967	rs180365	ENSG00000254851.1	RP11-109L13.1	-5.59	3.91e-08	1.42e-05	-0.33	-0.25	Triglycerides;	chr11:116725458	chr11:117135528~117138582:+
HNSC	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-5.59	3.91e-08	1.42e-05	-0.35	-0.25	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
HNSC	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	5.59	3.91e-08	1.42e-05	0.45	0.25	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	5.59	3.91e-08	1.42e-05	0.22	0.25	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
HNSC	cis	rs9840812	0.769	rs1711171	ENSG00000273486.1	RP11-731C17.2	5.59	3.92e-08	1.42e-05	0.22	0.25	Fibrinogen levels;	chr3:136301699	chr3:136837338~136839021:-
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000173295.6	FAM86B3P	-5.59	3.92e-08	1.42e-05	-0.28	-0.25	Joint mobility (Beighton score);	chr8:9025061	chr8:8228595~8244865:+
HNSC	cis	rs2115630	1	rs8037423	ENSG00000229212.6	RP11-561C5.4	5.59	3.92e-08	1.42e-05	0.29	0.25	P wave terminal force;	chr15:84812263	chr15:85205440~85234795:-
HNSC	cis	rs7160336	0.728	rs4899488	ENSG00000259065.1	RP5-1021I20.1	5.59	3.92e-08	1.42e-05	0.29	0.25	Blood protein levels;	chr14:74008147	chr14:73787360~73803270:+
HNSC	cis	rs75422866	0.51	rs73104197	ENSG00000274902.1	RP1-197B17.4	5.59	3.92e-08	1.42e-05	0.57	0.25	Pneumonia;	chr12:47717273	chr12:47731908~47732351:+
HNSC	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-5.59	3.92e-08	1.42e-05	-0.27	-0.25	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
HNSC	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	5.59	3.92e-08	1.42e-05	0.3	0.25	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
HNSC	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-5.59	3.93e-08	1.42e-05	-0.48	-0.25	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-5.59	3.93e-08	1.42e-05	-0.27	-0.25	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
HNSC	cis	rs2337406	0.539	rs2583292	ENSG00000211974.3	IGHV2-70	-5.59	3.93e-08	1.42e-05	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106649040	chr14:106723574~106724093:-
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	5.59	3.93e-08	1.42e-05	0.27	0.25	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
HNSC	cis	rs35306767	0.953	rs12762973	ENSG00000229869.1	RP11-363N22.2	-5.59	3.93e-08	1.43e-05	-0.35	-0.25	Eosinophil percentage of granulocytes;	chr10:914821	chr10:933026~942743:+
HNSC	cis	rs7811142	0.83	rs118119933	ENSG00000078319.8	PMS2P1	-5.59	3.93e-08	1.43e-05	-0.33	-0.25	Platelet count;	chr7:100341427	chr7:100320992~100341908:-
HNSC	cis	rs9992667	0.955	rs28560778	ENSG00000231160.8	KLF3-AS1	5.59	3.93e-08	1.43e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38609668	chr4:38612701~38664883:-
HNSC	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	5.59	3.93e-08	1.43e-05	0.26	0.25	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
HNSC	cis	rs8054556	1	rs6565173	ENSG00000183604.13	SMG1P5	-5.59	3.93e-08	1.43e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:30267553~30335374:-
HNSC	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	5.59	3.93e-08	1.43e-05	0.22	0.25	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
HNSC	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-5.59	3.94e-08	1.43e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	5.59	3.94e-08	1.43e-05	0.32	0.25	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	5.59	3.94e-08	1.43e-05	0.32	0.25	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	5.59	3.94e-08	1.43e-05	0.32	0.25	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
HNSC	cis	rs1355223	0.902	rs680727	ENSG00000271369.1	RP11-350D17.3	5.59	3.95e-08	1.43e-05	0.29	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682899	chr11:34709600~34710161:+
HNSC	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-5.59	3.95e-08	1.43e-05	-0.27	-0.25	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
HNSC	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-5.59	3.95e-08	1.43e-05	-0.27	-0.25	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
HNSC	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-5.59	3.95e-08	1.43e-05	-0.33	-0.25	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-5.59	3.95e-08	1.43e-05	-0.33	-0.25	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
HNSC	cis	rs10504130	0.569	rs16916966	ENSG00000272024.1	RP11-546K22.3	-5.59	3.95e-08	1.43e-05	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51930769	chr8:51950284~51950690:+
HNSC	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	5.59	3.95e-08	1.43e-05	0.31	0.25	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	5.59	3.95e-08	1.43e-05	0.31	0.25	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
HNSC	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-5.59	3.96e-08	1.43e-05	-0.45	-0.25	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000235689.1	AP000351.13	5.59	3.96e-08	1.44e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:24006305~24008258:-
HNSC	cis	rs10129255	1	rs10141557	ENSG00000211972.2	IGHV3-66	5.59	3.96e-08	1.44e-05	0.19	0.25	Kawasaki disease;	chr14:106767990	chr14:106675017~106675544:-
HNSC	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	5.59	3.96e-08	1.44e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	5.59	3.96e-08	1.44e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	5.59	3.96e-08	1.44e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-5.59	3.96e-08	1.44e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
HNSC	cis	rs6061231	0.631	rs2427318	ENSG00000273619.1	RP5-908M14.9	-5.59	3.96e-08	1.44e-05	-0.22	-0.25	Colorectal cancer;	chr20:62400671	chr20:62386303~62386970:-
HNSC	cis	rs77204473	0.744	rs12420725	ENSG00000254851.1	RP11-109L13.1	5.59	3.97e-08	1.44e-05	0.4	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117146814	chr11:117135528~117138582:+
HNSC	cis	rs988913	1	rs6922186	ENSG00000224984.1	RP11-524H19.2	5.59	3.97e-08	1.44e-05	0.28	0.25	Menarche (age at onset);	chr6:54946294	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs6929930	ENSG00000224984.1	RP11-524H19.2	5.59	3.97e-08	1.44e-05	0.28	0.25	Menarche (age at onset);	chr6:54947912	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs6902245	ENSG00000224984.1	RP11-524H19.2	5.59	3.97e-08	1.44e-05	0.28	0.25	Menarche (age at onset);	chr6:54948208	chr6:54840118~54840855:-
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	5.59	3.97e-08	1.44e-05	0.27	0.25	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
HNSC	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-5.59	3.97e-08	1.44e-05	-0.26	-0.25	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
HNSC	cis	rs2337406	0.587	rs2516889	ENSG00000211974.3	IGHV2-70	5.59	3.97e-08	1.44e-05	0.29	0.25	Alzheimer's disease (late onset);	chr14:106648903	chr14:106723574~106724093:-
HNSC	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-5.58	3.98e-08	1.44e-05	-0.22	-0.25	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
HNSC	cis	rs4535700	0.501	rs28828764	ENSG00000226278.1	PSPHP1	5.58	3.98e-08	1.44e-05	0.3	0.25	Macular telangiectasia type 2;	chr7:55920986	chr7:55764797~55773288:+
HNSC	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	5.58	3.98e-08	1.44e-05	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
HNSC	cis	rs7824557	0.547	rs4512344	ENSG00000255310.2	AF131215.2	-5.58	3.99e-08	1.44e-05	-0.24	-0.25	Retinal vascular caliber;	chr8:11221272	chr8:11107788~11109726:-
HNSC	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	5.58	3.99e-08	1.44e-05	0.22	0.25	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
HNSC	cis	rs67981189	0.529	rs2526858	ENSG00000274818.1	RP1-292L20.3	-5.58	3.99e-08	1.44e-05	-0.31	-0.25	Schizophrenia;	chr14:70945623	chr14:70906657~70907111:-
HNSC	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
HNSC	cis	rs12817211	0.536	rs3184122	ENSG00000272368.2	RP4-605O3.4	-5.58	4e-08	1.45e-05	-0.25	-0.25	Colorectal or endometrial cancer;	chr12:50176344	chr12:50112197~50165618:+
HNSC	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
HNSC	cis	rs73186030	0.925	rs1801725	ENSG00000272758.4	RP11-299J3.8	5.58	4e-08	1.45e-05	0.36	0.25	Serum parathyroid hormone levels;	chr3:122284910	chr3:122416207~122443180:+
HNSC	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	5.58	4e-08	1.45e-05	0.27	0.25	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
HNSC	cis	rs9329221	0.682	rs6982308	ENSG00000255310.2	AF131215.2	-5.58	4.01e-08	1.45e-05	-0.24	-0.25	Neuroticism;	chr8:10336262	chr8:11107788~11109726:-
HNSC	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-5.58	4.01e-08	1.45e-05	-0.27	-0.25	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
HNSC	cis	rs13126694	1	rs13126694	ENSG00000248429.4	RP11-597D13.9	-5.58	4.01e-08	1.45e-05	-0.28	-0.25	Blood osmolality (transformed sodium);	chr4:158177632	chr4:158170752~158202877:+
HNSC	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	5.58	4.01e-08	1.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs2279458	ENSG00000273257.1	RP11-177J6.1	5.58	4.02e-08	1.45e-05	0.31	0.25	Height;	chr4:55562653	chr4:55387949~55388271:+
HNSC	cis	rs3738443	0.52	rs1771932	ENSG00000259865.1	RP11-488L18.10	5.58	4.02e-08	1.45e-05	0.2	0.25	Alcohol dependence;	chr1:247218747	chr1:247187281~247188526:-
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-5.58	4.02e-08	1.46e-05	-0.3	-0.25	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
HNSC	cis	rs5753618	0.583	rs7285619	ENSG00000236132.1	CTA-440B3.1	-5.58	4.03e-08	1.46e-05	-0.31	-0.25	Colorectal cancer;	chr22:31446568	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-5.58	4.03e-08	1.46e-05	-0.17	-0.25	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
HNSC	cis	rs947583	0.588	rs721366	ENSG00000217482.2	HMGB1P17	5.58	4.03e-08	1.46e-05	0.3	0.25	Phosphorus levels;	chr6:135713061	chr6:135636086~135636713:-
HNSC	cis	rs67981189	0.529	rs8014273	ENSG00000274818.1	RP1-292L20.3	5.58	4.04e-08	1.46e-05	0.3	0.25	Schizophrenia;	chr14:71043113	chr14:70906657~70907111:-
HNSC	cis	rs8054556	1	rs4788200	ENSG00000183604.13	SMG1P5	-5.58	4.04e-08	1.46e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4788201	ENSG00000183604.13	SMG1P5	-5.58	4.04e-08	1.46e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:30267553~30335374:-
HNSC	cis	rs9329221	0.935	rs3750311	ENSG00000269918.1	AF131215.9	-5.58	4.04e-08	1.46e-05	-0.24	-0.25	Neuroticism;	chr8:10426092	chr8:11104691~11106704:-
HNSC	cis	rs12439619	0.739	rs4778988	ENSG00000276710.3	CSPG4P8	-5.58	4.04e-08	1.46e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82459472~82477258:+
HNSC	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	5.58	4.04e-08	1.46e-05	0.31	0.25	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
HNSC	cis	rs2904967	0.636	rs239253	ENSG00000254614.2	AP003068.23	-5.58	4.04e-08	1.46e-05	-0.36	-0.25	Mean corpuscular volume;	chr11:65217272	chr11:65177606~65181834:-
HNSC	cis	rs4140799	0.816	rs1204997	ENSG00000266869.1	RP6-114E22.1	5.58	4.04e-08	1.46e-05	0.3	0.25	Neuroticism;	chr14:71716592	chr14:71848606~71908430:+
HNSC	cis	rs17507216	0.718	rs72753931	ENSG00000255769.6	GOLGA2P10	-5.58	4.05e-08	1.46e-05	-0.41	-0.25	Excessive daytime sleepiness;	chr15:82721485	chr15:82472993~82513950:-
HNSC	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	5.58	4.05e-08	1.47e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
HNSC	cis	rs9611519	0.964	rs4820428	ENSG00000235513.1	RP4-756G23.5	-5.58	4.05e-08	1.47e-05	-0.27	-0.25	Neuroticism;	chr22:41141585	chr22:41209122~41217627:-
HNSC	cis	rs2439831	1	rs2467739	ENSG00000205771.5	CATSPER2P1	-5.58	4.05e-08	1.47e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43447998	chr15:43726918~43747094:-
HNSC	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	5.58	4.05e-08	1.47e-05	0.31	0.25	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
HNSC	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-5.58	4.06e-08	1.47e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-5.58	4.06e-08	1.47e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
HNSC	cis	rs2439831	1	rs690002	ENSG00000205771.5	CATSPER2P1	-5.58	4.06e-08	1.47e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43437151	chr15:43726918~43747094:-
HNSC	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-5.58	4.06e-08	1.47e-05	-0.29	-0.25	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
HNSC	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-5.58	4.06e-08	1.47e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
HNSC	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-5.58	4.06e-08	1.47e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
HNSC	cis	rs988913	1	rs9382402	ENSG00000224984.1	RP11-524H19.2	5.58	4.06e-08	1.47e-05	0.28	0.25	Menarche (age at onset);	chr6:54944695	chr6:54840118~54840855:-
HNSC	cis	rs2243480	1	rs12698509	ENSG00000179406.6	LINC00174	-5.58	4.07e-08	1.47e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:65953889	chr7:66376044~66401338:-
HNSC	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	5.58	4.07e-08	1.47e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
HNSC	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-5.58	4.07e-08	1.47e-05	-0.35	-0.25	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
HNSC	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	5.58	4.08e-08	1.47e-05	0.34	0.25	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
HNSC	cis	rs2243480	1	rs6964245	ENSG00000179406.6	LINC00174	5.58	4.08e-08	1.47e-05	0.53	0.25	Diabetic kidney disease;	chr7:66253730	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	5.58	4.08e-08	1.48e-05	0.22	0.25	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
HNSC	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	5.58	4.08e-08	1.48e-05	0.26	0.25	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
HNSC	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	5.58	4.09e-08	1.48e-05	0.31	0.25	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	5.58	4.09e-08	1.48e-05	0.31	0.25	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000254153.1	CTA-398F10.2	5.58	4.09e-08	1.48e-05	0.28	0.25	Neuroticism;	chr8:8287918	chr8:8456909~8461337:-
HNSC	cis	rs13113518	0.812	rs12500686	ENSG00000273257.1	RP11-177J6.1	5.58	4.09e-08	1.48e-05	0.32	0.25	Height;	chr4:55457922	chr4:55387949~55388271:+
HNSC	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	5.58	4.09e-08	1.48e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
HNSC	cis	rs4713118	0.662	rs9380045	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28057501	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.616	rs9348789	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28057708	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468274	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28058299	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468275	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28058358	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468276	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28059910	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468277	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28060612	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468278	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28060704	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs13218430	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28062059	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9380046	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28062721	chr6:28943877~28944537:+
HNSC	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-5.58	4.1e-08	1.48e-05	-0.43	-0.25	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
HNSC	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-5.58	4.1e-08	1.48e-05	-0.22	-0.25	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
HNSC	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	5.58	4.1e-08	1.48e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	5.58	4.1e-08	1.48e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
HNSC	cis	rs2243480	1	rs6964530	ENSG00000179406.6	LINC00174	5.58	4.1e-08	1.48e-05	0.53	0.25	Diabetic kidney disease;	chr7:66253864	chr7:66376044~66401338:-
HNSC	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	5.58	4.1e-08	1.48e-05	0.33	0.25	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
HNSC	cis	rs36093844	0.752	rs17744699	ENSG00000279742.1	RP11-700A24.1	-5.58	4.1e-08	1.48e-05	-0.35	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886120	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs17817343	ENSG00000279742.1	RP11-700A24.1	-5.58	4.1e-08	1.48e-05	-0.35	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85887269	chr11:85852557~85854943:-
HNSC	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	5.58	4.1e-08	1.48e-05	0.27	0.25	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
HNSC	cis	rs6981523	0.517	rs13251510	ENSG00000269918.1	AF131215.9	-5.58	4.11e-08	1.48e-05	-0.25	-0.25	Neuroticism;	chr8:11059464	chr8:11104691~11106704:-
HNSC	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma;	chr2:102419319	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma;	chr2:102419875	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
HNSC	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	5.58	4.11e-08	1.48e-05	0.23	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	5.58	4.11e-08	1.48e-05	0.23	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
HNSC	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-5.58	4.11e-08	1.48e-05	-0.3	-0.25	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
HNSC	cis	rs763567	1	rs1928715	ENSG00000271811.1	RP1-79C4.4	-5.58	4.12e-08	1.49e-05	-0.27	-0.25	Tonsillectomy;	chr1:170598296	chr1:170667381~170669425:+
HNSC	cis	rs2268667	0.565	rs6657732	ENSG00000223653.4	RP11-131L23.1	-5.58	4.12e-08	1.49e-05	-0.32	-0.25	Asymmetrical dimethylarginine levels;	chr1:85408812	chr1:85276715~85448124:+
HNSC	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-5.58	4.12e-08	1.49e-05	-0.21	-0.25	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000237310.1	GS1-124K5.4	5.58	4.12e-08	1.49e-05	0.23	0.25	Aortic root size;	chr7:66517181	chr7:66493706~66495474:+
HNSC	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-5.58	4.12e-08	1.49e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	5.58	4.12e-08	1.49e-05	0.2	0.25	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
HNSC	cis	rs783540	0.632	rs17356528	ENSG00000255769.6	GOLGA2P10	5.58	4.12e-08	1.49e-05	0.33	0.25	Schizophrenia;	chr15:82636799	chr15:82472993~82513950:-
HNSC	cis	rs2985684	0.947	rs1952013	ENSG00000258568.1	RHOQP1	5.58	4.13e-08	1.49e-05	0.26	0.25	Carotid intima media thickness;	chr14:49620639	chr14:49599994~49600572:+
HNSC	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	5.58	4.13e-08	1.49e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
HNSC	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-5.58	4.13e-08	1.49e-05	-0.3	-0.25	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
HNSC	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-5.58	4.14e-08	1.49e-05	-0.26	-0.25	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
HNSC	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-5.58	4.14e-08	1.49e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
HNSC	cis	rs889014	0.751	rs6891923	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552180	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.751	rs4868286	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552257	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.751	rs6892270	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552321	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.646	rs4867719	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552491	chr5:173562478~173573199:+
HNSC	cis	rs6472866	0.622	rs10957727	ENSG00000254349.4	FLJ39080	5.58	4.14e-08	1.5e-05	0.28	0.25	Protein quantitative trait loci;	chr8:74585958	chr8:74599775~74823313:+
HNSC	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-5.58	4.15e-08	1.5e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
HNSC	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-5.58	4.15e-08	1.5e-05	-0.3	-0.25	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
HNSC	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-5.58	4.15e-08	1.5e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
HNSC	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-5.58	4.16e-08	1.5e-05	-0.27	-0.25	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
HNSC	cis	rs9402743	0.634	rs6570018	ENSG00000217482.2	HMGB1P17	5.58	4.16e-08	1.5e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135602218	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.634	rs9494294	ENSG00000217482.2	HMGB1P17	5.58	4.16e-08	1.5e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135603460	chr6:135636086~135636713:-
HNSC	cis	rs9302065	0.565	rs2992910	ENSG00000223298.1	RNY3P8	5.58	4.16e-08	1.5e-05	0.26	0.25	Blood metabolite levels;	chr13:95309962	chr13:95310830~95310955:-
HNSC	cis	rs6951245	0.882	rs11764817	ENSG00000225146.1	AC073957.15	-5.58	4.16e-08	1.5e-05	-0.38	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024974	chr7:1029025~1043891:+
HNSC	cis	rs4699052	0.537	rs1580278	ENSG00000246560.2	RP11-10L12.4	-5.58	4.17e-08	1.5e-05	-0.29	-0.25	Testicular germ cell tumor;	chr4:103219691	chr4:102828055~102844075:+
HNSC	cis	rs2439831	1	rs2467743	ENSG00000205771.5	CATSPER2P1	-5.58	4.17e-08	1.5e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43458148	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2245176	ENSG00000205771.5	CATSPER2P1	-5.58	4.17e-08	1.5e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43458564	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2264876	ENSG00000205771.5	CATSPER2P1	-5.58	4.17e-08	1.5e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43465221	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	5.58	4.17e-08	1.51e-05	0.19	0.25	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
HNSC	cis	rs77204473	1	rs1135663	ENSG00000254851.1	RP11-109L13.1	5.58	4.17e-08	1.51e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116918121	chr11:117135528~117138582:+
HNSC	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-5.58	4.17e-08	1.51e-05	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
HNSC	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.18e-08	1.51e-05	-0.31	-0.25	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.18e-08	1.51e-05	-0.31	-0.25	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
HNSC	cis	rs6928977	0.896	rs2246943	ENSG00000231028.7	LINC00271	5.58	4.18e-08	1.51e-05	0.29	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370378	chr6:135497801~135716055:+
HNSC	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
HNSC	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	5.58	4.18e-08	1.51e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
HNSC	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	5.58	4.19e-08	1.51e-05	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
HNSC	cis	rs1908814	0.516	rs60176945	ENSG00000206014.6	OR7E161P	-5.58	4.19e-08	1.51e-05	-0.27	-0.25	Neuroticism;	chr8:11939165	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs56102998	ENSG00000206014.6	OR7E161P	-5.58	4.19e-08	1.51e-05	-0.27	-0.25	Neuroticism;	chr8:11939166	chr8:11928597~11929563:-
HNSC	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	5.58	4.19e-08	1.51e-05	0.28	0.25	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
HNSC	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	5.58	4.19e-08	1.51e-05	0.54	0.25	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	5.58	4.19e-08	1.51e-05	0.31	0.25	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
HNSC	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	5.58	4.19e-08	1.51e-05	0.31	0.25	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
HNSC	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-5.58	4.19e-08	1.51e-05	-0.32	-0.25	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
HNSC	cis	rs75920871	0.528	rs7108912	ENSG00000254851.1	RP11-109L13.1	5.57	4.19e-08	1.51e-05	0.35	0.25	Subjective well-being;	chr11:117055280	chr11:117135528~117138582:+
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	5.57	4.19e-08	1.51e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000233609.3	RP11-62H7.2	-5.57	4.2e-08	1.51e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9018719	chr8:8961200~8979025:+
HNSC	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.2e-08	1.51e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
HNSC	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-5.57	4.2e-08	1.52e-05	-0.3	-0.25	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
HNSC	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-5.57	4.21e-08	1.52e-05	-0.36	-0.25	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
HNSC	cis	rs1355223	1	rs12792532	ENSG00000271369.1	RP11-350D17.3	-5.57	4.21e-08	1.52e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34744235	chr11:34709600~34710161:+
HNSC	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	5.57	4.21e-08	1.52e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
HNSC	cis	rs2985684	0.894	rs6572585	ENSG00000278009.1	RP11-649E7.8	5.57	4.21e-08	1.52e-05	0.33	0.25	Carotid intima media thickness;	chr14:49554357	chr14:49601011~49601124:-
HNSC	cis	rs9300255	0.51	rs1790086	ENSG00000280120.1	RP11-546D6.3	5.57	4.22e-08	1.52e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123187971	chr12:123152324~123153377:-
HNSC	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	5.57	4.22e-08	1.52e-05	0.2	0.25	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
HNSC	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	5.57	4.23e-08	1.52e-05	0.29	0.25	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
HNSC	cis	rs1355223	1	rs1355223	ENSG00000271369.1	RP11-350D17.3	-5.57	4.23e-08	1.52e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742932	chr11:34709600~34710161:+
HNSC	cis	rs7674212	0.539	rs6821617	ENSG00000246560.2	RP11-10L12.4	5.57	4.23e-08	1.52e-05	0.28	0.25	Type 2 diabetes;	chr4:103207253	chr4:102828055~102844075:+
HNSC	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	5.57	4.23e-08	1.52e-05	0.28	0.25	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	5.57	4.23e-08	1.52e-05	0.28	0.25	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
HNSC	cis	rs526231	0.644	rs35797	ENSG00000175749.11	EIF3KP1	-5.57	4.23e-08	1.52e-05	-0.31	-0.25	Primary biliary cholangitis;	chr5:103278626	chr5:103032376~103033031:+
HNSC	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	5.57	4.23e-08	1.53e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
HNSC	cis	rs9611519	0.78	rs1535048	ENSG00000235513.1	RP4-756G23.5	5.57	4.24e-08	1.53e-05	0.27	0.25	Neuroticism;	chr22:41288089	chr22:41209122~41217627:-
HNSC	cis	rs4938330	0.68	rs4938329	ENSG00000254851.1	RP11-109L13.1	5.57	4.24e-08	1.53e-05	0.35	0.25	Blood protein levels;	chr11:117057396	chr11:117135528~117138582:+
HNSC	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-5.57	4.24e-08	1.53e-05	-0.35	-0.25	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
HNSC	cis	rs6993244	1	rs6993244	ENSG00000254153.1	CTA-398F10.2	5.57	4.24e-08	1.53e-05	0.28	0.25	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8456909~8461337:-
HNSC	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-5.57	4.24e-08	1.53e-05	-0.35	-0.25	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
HNSC	cis	rs9302065	0.565	rs2993586	ENSG00000223298.1	RNY3P8	5.57	4.24e-08	1.53e-05	0.26	0.25	Blood metabolite levels;	chr13:95310324	chr13:95310830~95310955:-
HNSC	cis	rs673078	1	rs673078	ENSG00000275409.1	RP11-131L12.4	5.57	4.25e-08	1.53e-05	0.36	0.25	Glucose homeostasis traits;	chr12:118353636	chr12:118430147~118430699:+
HNSC	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	5.57	4.25e-08	1.53e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	5.57	4.25e-08	1.53e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
HNSC	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-5.57	4.26e-08	1.53e-05	-0.35	-0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
HNSC	cis	rs7674212	0.541	rs11727498	ENSG00000246560.2	RP11-10L12.4	5.57	4.26e-08	1.53e-05	0.29	0.25	Type 2 diabetes;	chr4:103179830	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000223648.3	IGHV3-64	5.57	4.26e-08	1.53e-05	0.2	0.25	Kawasaki disease;	chr14:106711377	chr14:106643132~106658258:-
HNSC	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-5.57	4.26e-08	1.53e-05	-0.37	-0.25	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
HNSC	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	5.57	4.26e-08	1.53e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
HNSC	cis	rs3206736	0.548	rs329242	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35020055	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs329243	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35020104	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs7779894	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35021897	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs10243141	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35022954	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs57315957	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35023207	chr7:34346512~34871582:-
HNSC	cis	rs4218	0.597	rs12438208	ENSG00000277144.1	RP11-59H7.4	-5.57	4.27e-08	1.54e-05	-0.33	-0.25	Social communication problems;	chr15:59057715	chr15:59115547~59116089:-
HNSC	cis	rs13113518	0.702	rs78829811	ENSG00000273257.1	RP11-177J6.1	5.57	4.27e-08	1.54e-05	0.31	0.25	Height;	chr4:55558258	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.702	rs75801206	ENSG00000273257.1	RP11-177J6.1	5.57	4.27e-08	1.54e-05	0.31	0.25	Height;	chr4:55558259	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.702	rs34658078	ENSG00000273257.1	RP11-177J6.1	5.57	4.27e-08	1.54e-05	0.31	0.25	Height;	chr4:55558261	chr4:55387949~55388271:+
HNSC	cis	rs5753618	0.583	rs5753631	ENSG00000236132.1	CTA-440B3.1	-5.57	4.28e-08	1.54e-05	-0.32	-0.25	Colorectal cancer;	chr22:31467036	chr22:31816379~31817491:-
HNSC	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
HNSC	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	5.57	4.28e-08	1.54e-05	0.3	0.25	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
HNSC	cis	rs8177876	0.822	rs12443549	ENSG00000261061.1	RP11-303E16.2	5.57	4.28e-08	1.54e-05	0.4	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81030770~81031485:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	5.57	4.28e-08	1.54e-05	0.21	0.25	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
HNSC	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-5.57	4.29e-08	1.54e-05	-0.29	-0.25	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
HNSC	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	5.57	4.29e-08	1.54e-05	0.26	0.25	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
HNSC	cis	rs4657482	0.64	rs10918304	ENSG00000236364.3	RP11-525G13.2	5.57	4.29e-08	1.54e-05	0.25	0.25	Testicular germ cell tumor;	chr1:165895450	chr1:165890795~165900683:-
HNSC	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-5.57	4.29e-08	1.54e-05	-0.21	-0.25	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
HNSC	cis	rs9611519	1	rs5758264	ENSG00000235513.1	RP4-756G23.5	5.57	4.29e-08	1.55e-05	0.26	0.25	Neuroticism;	chr22:41220280	chr22:41209122~41217627:-
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000211970.3	IGHV4-61	-5.57	4.29e-08	1.55e-05	-0.16	-0.25	Kawasaki disease;	chr14:106711377	chr14:106639119~106639657:-
HNSC	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	5.57	4.3e-08	1.55e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
HNSC	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-5.57	4.3e-08	1.55e-05	-0.35	-0.25	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-5.57	4.3e-08	1.55e-05	-0.15	-0.25	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
HNSC	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-5.57	4.3e-08	1.55e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
HNSC	cis	rs6928977	0.896	rs2614257	ENSG00000234084.1	RP3-388E23.2	5.57	4.3e-08	1.55e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135355266	chr6:135301568~135307158:+
HNSC	cis	rs5753618	0.583	rs8138596	ENSG00000236132.1	CTA-440B3.1	-5.57	4.3e-08	1.55e-05	-0.31	-0.25	Colorectal cancer;	chr22:31390975	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	5.57	4.31e-08	1.55e-05	0.32	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
HNSC	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	5.57	4.31e-08	1.55e-05	0.3	0.25	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-5.57	4.32e-08	1.55e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-5.57	4.32e-08	1.55e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-5.57	4.32e-08	1.55e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	5.57	4.32e-08	1.55e-05	0.27	0.25	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
HNSC	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-5.57	4.32e-08	1.55e-05	-0.24	-0.25	Asthma;	chr2:102374909	chr2:102438713~102440475:+
HNSC	cis	rs9402743	0.634	rs2327646	ENSG00000217482.2	HMGB1P17	5.57	4.32e-08	1.55e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135597186	chr6:135636086~135636713:-
HNSC	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	5.57	4.32e-08	1.55e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	5.57	4.32e-08	1.55e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
HNSC	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-5.57	4.32e-08	1.55e-05	-0.29	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
HNSC	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	5.57	4.33e-08	1.55e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
HNSC	cis	rs2579103	0.651	rs2731275	ENSG00000258183.4	RP11-753N8.1	5.57	4.33e-08	1.56e-05	0.35	0.25	Body mass index;	chr12:90249822	chr12:90280894~90300340:+
HNSC	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	5.57	4.34e-08	1.56e-05	0.34	0.25	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
HNSC	cis	rs2115630	0.967	rs10438428	ENSG00000229212.6	RP11-561C5.4	5.57	4.34e-08	1.56e-05	0.29	0.25	P wave terminal force;	chr15:84787514	chr15:85205440~85234795:-
HNSC	cis	rs9611519	0.964	rs5995992	ENSG00000235513.1	RP4-756G23.5	5.57	4.34e-08	1.56e-05	0.28	0.25	Neuroticism;	chr22:41091214	chr22:41209122~41217627:-
HNSC	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	5.57	4.34e-08	1.56e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	5.57	4.34e-08	1.56e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	5.57	4.34e-08	1.56e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
HNSC	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	5.57	4.35e-08	1.56e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
HNSC	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	5.57	4.35e-08	1.56e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
HNSC	cis	rs9341808	0.935	rs1535825	ENSG00000272129.1	RP11-250B2.6	-5.57	4.35e-08	1.56e-05	-0.29	-0.25	Sitting height ratio;	chr6:80228869	chr6:80355424~80356859:+
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-5.57	4.35e-08	1.56e-05	-0.16	-0.25	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	5.57	4.35e-08	1.56e-05	0.22	0.25	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	5.57	4.36e-08	1.56e-05	0.27	0.25	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
HNSC	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-5.57	4.36e-08	1.57e-05	-0.33	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
HNSC	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-5.57	4.36e-08	1.57e-05	-0.24	-0.25	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
HNSC	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.36e-08	1.57e-05	-0.31	-0.25	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
HNSC	cis	rs988913	1	rs1503142	ENSG00000224984.1	RP11-524H19.2	5.57	4.37e-08	1.57e-05	0.28	0.25	Menarche (age at onset);	chr6:54954150	chr6:54840118~54840855:-
HNSC	cis	rs8032939	0.533	rs16967103	ENSG00000259747.1	RP11-275I4.2	-5.57	4.37e-08	1.57e-05	-0.31	-0.25	Rheumatoid arthritis;	chr15:38606989	chr15:38671847~38689191:+
HNSC	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-5.57	4.38e-08	1.57e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
HNSC	cis	rs7160336	0.604	rs10149539	ENSG00000259065.1	RP5-1021I20.1	-5.57	4.38e-08	1.57e-05	-0.3	-0.25	Blood protein levels;	chr14:74215524	chr14:73787360~73803270:+
HNSC	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-5.57	4.38e-08	1.57e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
HNSC	cis	rs35306767	0.953	rs10904581	ENSG00000229869.1	RP11-363N22.2	-5.57	4.38e-08	1.57e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:918745	chr10:933026~942743:+
HNSC	cis	rs13113518	0.966	rs13144598	ENSG00000249700.7	SRD5A3-AS1	5.57	4.39e-08	1.58e-05	0.3	0.25	Height;	chr4:55570311	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-5.57	4.39e-08	1.58e-05	-0.3	-0.25	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
HNSC	cis	rs6867032	0.527	rs13162781	ENSG00000249731.1	RP11-259O2.3	5.57	4.39e-08	1.58e-05	0.28	0.25	Gut microbiome composition (winter);	chr5:2012121	chr5:1968094~1969013:+
HNSC	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-5.57	4.39e-08	1.58e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-5.57	4.39e-08	1.58e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-5.57	4.39e-08	1.58e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	5.57	4.4e-08	1.58e-05	0.31	0.25	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
HNSC	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-5.57	4.4e-08	1.58e-05	-0.24	-0.25	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
HNSC	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-5.57	4.4e-08	1.58e-05	-0.31	-0.25	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
HNSC	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	5.57	4.4e-08	1.58e-05	0.31	0.25	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000254153.1	CTA-398F10.2	5.57	4.41e-08	1.58e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9003384	chr8:8456909~8461337:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	5.57	4.41e-08	1.58e-05	0.27	0.25	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
HNSC	cis	rs7617773	0.963	rs12495221	ENSG00000228638.1	FCF1P2	5.57	4.41e-08	1.58e-05	0.23	0.25	Coronary artery disease;	chr3:48137688	chr3:48290793~48291375:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-5.57	4.42e-08	1.59e-05	-0.31	-0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
HNSC	cis	rs4763879	0.739	rs2114871	ENSG00000256673.1	RP11-599J14.2	5.56	4.43e-08	1.59e-05	0.24	0.25	Type 1 diabetes;	chr12:9676842	chr12:9398355~9414851:-
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-5.56	4.43e-08	1.59e-05	-0.17	-0.25	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
HNSC	cis	rs2115630	0.691	rs2292462	ENSG00000229212.6	RP11-561C5.4	5.56	4.43e-08	1.59e-05	0.28	0.25	P wave terminal force;	chr15:84657523	chr15:85205440~85234795:-
HNSC	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	5.56	4.44e-08	1.59e-05	0.32	0.25	Height;	chr6:109403287	chr6:109382795~109383666:+
HNSC	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-5.56	4.44e-08	1.59e-05	-0.35	-0.25	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
HNSC	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	5.56	4.44e-08	1.59e-05	0.3	0.25	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	5.56	4.44e-08	1.59e-05	0.3	0.25	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	5.56	4.44e-08	1.59e-05	0.3	0.25	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.866	rs11488879	ENSG00000254174.1	IGHV1-12	5.56	4.44e-08	1.59e-05	0.21	0.25	Alzheimer's disease (late onset);	chr14:106786097	chr14:106122420~106122709:-
HNSC	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	5.56	4.44e-08	1.59e-05	0.36	0.25	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-5.56	4.45e-08	1.59e-05	-0.3	-0.25	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
HNSC	cis	rs6918586	0.557	rs198827	ENSG00000272462.2	U91328.19	-5.56	4.45e-08	1.6e-05	-0.23	-0.25	Schizophrenia;	chr6:26120774	chr6:25992662~26001775:+
HNSC	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	5.56	4.45e-08	1.6e-05	0.33	0.25	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	5.56	4.45e-08	1.6e-05	0.33	0.25	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	5.56	4.45e-08	1.6e-05	0.33	0.25	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
HNSC	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	5.56	4.45e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	5.56	4.45e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
HNSC	cis	rs10129255	1	rs10137758	ENSG00000223648.3	IGHV3-64	5.56	4.46e-08	1.6e-05	0.2	0.25	Kawasaki disease;	chr14:106697673	chr14:106643132~106658258:-
HNSC	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	5.56	4.46e-08	1.6e-05	0.29	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	5.56	4.46e-08	1.6e-05	0.27	0.25	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
HNSC	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	5.56	4.46e-08	1.6e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
HNSC	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-5.56	4.46e-08	1.6e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000223648.3	IGHV3-64	5.56	4.47e-08	1.6e-05	0.2	0.25	Kawasaki disease;	chr14:106716993	chr14:106643132~106658258:-
HNSC	cis	rs14027	0.883	rs16893025	ENSG00000279347.1	RP11-85I17.2	-5.56	4.47e-08	1.6e-05	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119838736~119840385:-
HNSC	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
HNSC	cis	rs9611565	0.506	rs2024566	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41301334	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.506	rs2024567	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41303202	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.506	rs4822020	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41304199	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.732	rs1883826	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Neuroticism;	chr22:41307424	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.525	rs9611549	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41309905	chr22:41209122~41217627:-
HNSC	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-5.56	4.48e-08	1.6e-05	-0.22	-0.25	Height;	chr11:118764443	chr11:118791254~118793137:+
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000179406.6	LINC00174	-5.56	4.48e-08	1.6e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66136229	chr7:66376044~66401338:-
HNSC	cis	rs2179367	0.632	rs9485389	ENSG00000216906.2	RP11-350J20.9	-5.56	4.49e-08	1.61e-05	-0.37	-0.25	Dupuytren's disease;	chr6:149420078	chr6:149904243~149906418:+
HNSC	cis	rs7209700	0.6	rs7218632	ENSG00000228782.6	CTD-2026D20.3	-5.56	4.5e-08	1.61e-05	-0.25	-0.25	IgG glycosylation;	chr17:47287787	chr17:47450568~47492492:-
HNSC	cis	rs2834288	0.613	rs2040113	ENSG00000273102.1	AP000569.9	5.56	4.5e-08	1.61e-05	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33967101~33968573:-
HNSC	cis	rs3206736	0.548	rs6963995	ENSG00000197085.10	NPSR1-AS1	-5.56	4.5e-08	1.61e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35018737	chr7:34346512~34871582:-
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-5.56	4.5e-08	1.61e-05	-0.16	-0.25	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
HNSC	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-5.56	4.5e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
HNSC	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	5.56	4.5e-08	1.61e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
HNSC	cis	rs1012068	0.624	rs4820997	ENSG00000236132.1	CTA-440B3.1	-5.56	4.5e-08	1.61e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31928154	chr22:31816379~31817491:-
HNSC	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-5.56	4.5e-08	1.61e-05	-0.32	-0.25	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
HNSC	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-5.56	4.5e-08	1.61e-05	-0.28	-0.25	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
HNSC	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	5.56	4.51e-08	1.61e-05	0.36	0.25	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
HNSC	cis	rs2115630	0.967	rs11073731	ENSG00000229212.6	RP11-561C5.4	5.56	4.52e-08	1.62e-05	0.29	0.25	P wave terminal force;	chr15:84811882	chr15:85205440~85234795:-
HNSC	cis	rs4218	0.638	rs8042516	ENSG00000277144.1	RP11-59H7.4	-5.56	4.52e-08	1.62e-05	-0.33	-0.25	Social communication problems;	chr15:59067525	chr15:59115547~59116089:-
HNSC	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-5.56	4.53e-08	1.62e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
HNSC	cis	rs13126694	0.744	rs7682867	ENSG00000248429.4	RP11-597D13.9	5.56	4.53e-08	1.62e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158026735	chr4:158170752~158202877:+
HNSC	cis	rs7819412	0.775	rs6601564	ENSG00000255310.2	AF131215.2	-5.56	4.53e-08	1.62e-05	-0.24	-0.25	Triglycerides;	chr8:11124541	chr8:11107788~11109726:-
HNSC	cis	rs11648785	0.526	rs4530137	ENSG00000222019.6	URAHP	5.56	4.54e-08	1.62e-05	0.23	0.25	Tanning;	chr16:90028093	chr16:90039761~90047773:-
HNSC	cis	rs2337406	0.587	rs2583291	ENSG00000211974.3	IGHV2-70	5.56	4.54e-08	1.62e-05	0.29	0.25	Alzheimer's disease (late onset);	chr14:106649293	chr14:106723574~106724093:-
HNSC	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-5.56	4.54e-08	1.62e-05	-0.28	-0.25	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
HNSC	cis	rs4699052	1	rs7661702	ENSG00000246560.2	RP11-10L12.4	5.56	4.55e-08	1.63e-05	0.28	0.25	Testicular germ cell tumor;	chr4:103218972	chr4:102828055~102844075:+
HNSC	cis	rs10129255	1	rs10137758	ENSG00000211970.3	IGHV4-61	-5.56	4.55e-08	1.63e-05	-0.16	-0.25	Kawasaki disease;	chr14:106697673	chr14:106639119~106639657:-
HNSC	cis	rs4834770	1	rs878375	ENSG00000249244.1	RP11-548H18.2	5.56	4.55e-08	1.63e-05	0.28	0.25	Blood protein levels;	chr4:119316419	chr4:119391831~119395335:-
HNSC	cis	rs9291683	0.655	rs55941493	ENSG00000250413.1	RP11-448G15.1	5.56	4.56e-08	1.63e-05	0.31	0.25	Bone mineral density;	chr4:10098717	chr4:10006482~10009725:+
HNSC	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	5.56	4.56e-08	1.63e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	5.56	4.56e-08	1.63e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	5.56	4.56e-08	1.63e-05	0.31	0.25	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
HNSC	cis	rs9300255	0.602	rs1790116	ENSG00000280120.1	RP11-546D6.3	5.56	4.56e-08	1.63e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123133997	chr12:123152324~123153377:-
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000254153.1	CTA-398F10.2	5.56	4.56e-08	1.63e-05	0.28	0.25	Mean corpuscular volume;	chr8:8994371	chr8:8456909~8461337:-
HNSC	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-5.56	4.57e-08	1.63e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
HNSC	cis	rs4713118	0.662	rs9357060	ENSG00000204709.4	LINC01556	5.56	4.57e-08	1.63e-05	0.34	0.25	Parkinson's disease;	chr6:28056708	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468271	ENSG00000204709.4	LINC01556	5.56	4.57e-08	1.63e-05	0.34	0.25	Parkinson's disease;	chr6:28056792	chr6:28943877~28944537:+
HNSC	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	5.56	4.57e-08	1.63e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
HNSC	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-5.56	4.58e-08	1.64e-05	-0.31	-0.25	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
HNSC	cis	rs2337406	0.866	rs4280141	ENSG00000211974.3	IGHV2-70	5.56	4.59e-08	1.64e-05	0.29	0.25	Alzheimer's disease (late onset);	chr14:106780476	chr14:106723574~106724093:-
HNSC	cis	rs7617773	0.963	rs9822496	ENSG00000228638.1	FCF1P2	-5.56	4.59e-08	1.64e-05	-0.23	-0.25	Coronary artery disease;	chr3:48139843	chr3:48290793~48291375:-
HNSC	cis	rs4218	0.541	rs8030323	ENSG00000259732.1	RP11-59H7.3	-5.56	4.59e-08	1.64e-05	-0.34	-0.25	Social communication problems;	chr15:59048048	chr15:59121034~59133250:+
HNSC	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
HNSC	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
HNSC	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	5.56	4.62e-08	1.65e-05	0.23	0.25	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
HNSC	cis	rs1355223	1	rs35365094	ENSG00000271369.1	RP11-350D17.3	-5.56	4.62e-08	1.65e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746243	chr11:34709600~34710161:+
HNSC	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	5.56	4.62e-08	1.65e-05	0.31	0.25	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
HNSC	cis	rs2033711	0.811	rs9304814	ENSG00000269473.1	CTD-2619J13.19	5.56	4.62e-08	1.65e-05	0.31	0.25	Uric acid clearance;	chr19:58440444	chr19:58440448~58445849:+
HNSC	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-5.56	4.63e-08	1.65e-05	-0.36	-0.25	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
HNSC	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-5.56	4.63e-08	1.65e-05	-0.24	-0.25	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
HNSC	cis	rs9402743	0.634	rs2327647	ENSG00000217482.2	HMGB1P17	-5.56	4.63e-08	1.65e-05	-0.27	-0.25	Systemic lupus erythematosus;	chr6:135597296	chr6:135636086~135636713:-
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	5.56	4.64e-08	1.65e-05	0.27	0.25	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
HNSC	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-5.56	4.65e-08	1.66e-05	-0.24	-0.25	Asthma;	chr2:102393077	chr2:102438713~102440475:+
HNSC	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	5.56	4.65e-08	1.66e-05	0.61	0.25	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	5.56	4.65e-08	1.66e-05	0.61	0.25	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
HNSC	cis	rs5753618	0.583	rs2899164	ENSG00000236132.1	CTA-440B3.1	-5.56	4.65e-08	1.66e-05	-0.31	-0.25	Colorectal cancer;	chr22:31394303	chr22:31816379~31817491:-
HNSC	cis	rs8054556	1	rs11150580	ENSG00000183604.13	SMG1P5	-5.56	4.66e-08	1.66e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:30267553~30335374:-
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	5.56	4.67e-08	1.66e-05	0.2	0.25	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
HNSC	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-5.56	4.67e-08	1.67e-05	-0.27	-0.25	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
HNSC	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-5.56	4.67e-08	1.67e-05	-0.24	-0.25	Asthma;	chr2:102377873	chr2:102438713~102440475:+
HNSC	cis	rs1012068	0.92	rs5994443	ENSG00000236132.1	CTA-440B3.1	-5.55	4.67e-08	1.67e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31879367	chr22:31816379~31817491:-
HNSC	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	5.55	4.67e-08	1.67e-05	0.61	0.25	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
HNSC	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	5.55	4.67e-08	1.67e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	5.55	4.67e-08	1.67e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	5.55	4.67e-08	1.67e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
HNSC	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-5.55	4.68e-08	1.67e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	5.55	4.68e-08	1.67e-05	0.16	0.25	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
HNSC	cis	rs2115630	0.905	rs1975277	ENSG00000229212.6	RP11-561C5.4	5.55	4.69e-08	1.67e-05	0.29	0.25	P wave terminal force;	chr15:84786327	chr15:85205440~85234795:-
HNSC	cis	rs72807246	0.54	rs72807258	ENSG00000228701.1	TNKS2-AS1	5.55	4.69e-08	1.67e-05	0.46	0.25	Breast cancer;	chr10:92209153	chr10:91782839~91798291:-
HNSC	cis	rs9813712	0.953	rs896822	ENSG00000249846.5	RP11-77P16.4	-5.55	4.69e-08	1.67e-05	-0.3	-0.25	Response to amphetamines;	chr3:130259987	chr3:130112550~130120579:+
HNSC	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	5.55	4.69e-08	1.67e-05	0.31	0.25	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
HNSC	cis	rs2255336	0.938	rs73070924	ENSG00000245648.1	RP11-277P12.20	-5.55	4.7e-08	1.67e-05	-0.4	-0.25	Blood protein levels;	chr12:10457386	chr12:10363769~10398506:+
HNSC	cis	rs4218	0.871	rs2414621	ENSG00000259732.1	RP11-59H7.3	-5.55	4.7e-08	1.68e-05	-0.32	-0.25	Social communication problems;	chr15:59142129	chr15:59121034~59133250:+
HNSC	cis	rs17428076	0.836	rs57718990	ENSG00000228389.1	AC068039.4	-5.55	4.7e-08	1.68e-05	-0.3	-0.25	Myopia;	chr2:171806104	chr2:171773482~171775844:+
HNSC	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	5.55	4.7e-08	1.68e-05	0.37	0.25	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
HNSC	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	5.55	4.7e-08	1.68e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	5.55	4.7e-08	1.68e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	5.55	4.7e-08	1.68e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
HNSC	cis	rs9341808	0.538	rs12176343	ENSG00000272129.1	RP11-250B2.6	-5.55	4.71e-08	1.68e-05	-0.3	-0.25	Sitting height ratio;	chr6:80317670	chr6:80355424~80356859:+
HNSC	cis	rs13126694	0.71	rs6847800	ENSG00000248429.4	RP11-597D13.9	5.55	4.71e-08	1.68e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158011724	chr4:158170752~158202877:+
HNSC	cis	rs9840812	0.728	rs12635723	ENSG00000273486.1	RP11-731C17.2	5.55	4.71e-08	1.68e-05	0.22	0.25	Fibrinogen levels;	chr3:136581890	chr3:136837338~136839021:-
HNSC	cis	rs1823913	0.614	rs1947457	ENSG00000227542.1	AC092614.2	5.55	4.71e-08	1.68e-05	0.49	0.25	Obesity-related traits;	chr2:191298970	chr2:191229165~191246172:-
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-5.55	4.71e-08	1.68e-05	-0.27	-0.25	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
HNSC	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-5.55	4.72e-08	1.68e-05	-0.28	-0.25	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
HNSC	cis	rs2115630	1	rs55646601	ENSG00000229212.6	RP11-561C5.4	5.55	4.72e-08	1.68e-05	0.29	0.25	P wave terminal force;	chr15:84780337	chr15:85205440~85234795:-
HNSC	cis	rs3733585	0.762	rs6449217	ENSG00000250413.1	RP11-448G15.1	-5.55	4.72e-08	1.68e-05	-0.31	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10007527	chr4:10006482~10009725:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	5.55	4.73e-08	1.69e-05	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
HNSC	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	5.55	4.74e-08	1.69e-05	0.31	0.25	Depression;	chr6:28109824	chr6:28161781~28169594:+
HNSC	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-5.55	4.74e-08	1.69e-05	-0.29	-0.25	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000179406.6	LINC00174	5.55	4.74e-08	1.69e-05	0.54	0.25	Diabetic kidney disease;	chr7:66170692	chr7:66376044~66401338:-
HNSC	cis	rs7829975	0.714	rs7823757	ENSG00000173295.6	FAM86B3P	5.55	4.74e-08	1.69e-05	0.27	0.25	Mood instability;	chr8:8812667	chr8:8228595~8244865:+
HNSC	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
HNSC	cis	rs7819412	0.749	rs11991118	ENSG00000255310.2	AF131215.2	5.55	4.75e-08	1.69e-05	0.24	0.25	Triglycerides;	chr8:11081763	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-5.55	4.75e-08	1.69e-05	-0.33	-0.25	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
HNSC	cis	rs9402743	0.634	rs9483853	ENSG00000217482.2	HMGB1P17	5.55	4.75e-08	1.69e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135595767	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.634	rs4394233	ENSG00000217482.2	HMGB1P17	5.55	4.75e-08	1.69e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135596752	chr6:135636086~135636713:-
HNSC	cis	rs9813712	1	rs57804141	ENSG00000249846.5	RP11-77P16.4	5.55	4.75e-08	1.69e-05	0.3	0.25	Response to amphetamines;	chr3:130243669	chr3:130112550~130120579:+
HNSC	cis	rs6928977	0.897	rs2246852	ENSG00000234084.1	RP3-388E23.2	5.55	4.75e-08	1.69e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370654	chr6:135301568~135307158:+
HNSC	cis	rs348196	0.672	rs670876	ENSG00000203761.5	MSTO2P	-5.55	4.76e-08	1.69e-05	-0.19	-0.25	Breast cancer;	chr1:155701887	chr1:155745829~155750137:+
HNSC	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-5.55	4.76e-08	1.7e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
HNSC	cis	rs2579103	0.898	rs1438993	ENSG00000258183.4	RP11-753N8.1	-5.55	4.77e-08	1.7e-05	-0.31	-0.25	Body mass index;	chr12:90203038	chr12:90280894~90300340:+
HNSC	cis	rs9813712	0.78	rs55929137	ENSG00000249846.5	RP11-77P16.4	5.55	4.77e-08	1.7e-05	0.3	0.25	Response to amphetamines;	chr3:130236002	chr3:130112550~130120579:+
HNSC	cis	rs7630852	0.841	rs9325377	ENSG00000272359.1	U4	-5.55	4.77e-08	1.7e-05	-0.27	-0.25	Eosinophil counts;	chr3:196779282	chr3:196747192~196747324:-
HNSC	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.55	4.78e-08	1.7e-05	-0.26	-0.25	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-5.55	4.78e-08	1.7e-05	-0.15	-0.25	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
HNSC	cis	rs4763879	0.739	rs12582584	ENSG00000256673.1	RP11-599J14.2	5.55	4.78e-08	1.7e-05	0.24	0.25	Type 1 diabetes;	chr12:9671542	chr12:9398355~9414851:-
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	5.55	4.78e-08	1.7e-05	0.27	0.25	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
HNSC	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	5.55	4.79e-08	1.7e-05	0.66	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
HNSC	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	5.55	4.79e-08	1.7e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
HNSC	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-5.55	4.79e-08	1.7e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
HNSC	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.71e-05	-0.43	-0.25	Depression;	chr6:28173682	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.71e-05	-0.43	-0.25	Depression;	chr6:28175340	chr6:28115628~28116551:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000228039.3	KB-1125A3.10	-5.55	4.8e-08	1.71e-05	-0.34	-0.25	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23963780~23964374:+
HNSC	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-5.55	4.8e-08	1.71e-05	-0.3	-0.25	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
HNSC	cis	rs7160336	0.568	rs10146294	ENSG00000259065.1	RP5-1021I20.1	-5.55	4.81e-08	1.71e-05	-0.29	-0.25	Blood protein levels;	chr14:74214679	chr14:73787360~73803270:+
HNSC	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-5.55	4.81e-08	1.71e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
HNSC	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-5.55	4.81e-08	1.71e-05	-0.4	-0.25	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
HNSC	cis	rs9611565	0.506	rs1883825	ENSG00000235513.1	RP4-756G23.5	5.55	4.81e-08	1.71e-05	0.26	0.25	Vitiligo;	chr22:41307404	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.525	rs1883827	ENSG00000235513.1	RP4-756G23.5	5.55	4.81e-08	1.71e-05	0.26	0.25	Vitiligo;	chr22:41307575	chr22:41209122~41217627:-
HNSC	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	5.55	4.82e-08	1.71e-05	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
HNSC	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	5.55	4.82e-08	1.71e-05	0.36	0.25	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
HNSC	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28111382	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28111650	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28112175	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28113851	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28114487	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28114933	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28115743	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28116411	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
HNSC	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-5.55	4.82e-08	1.71e-05	-0.29	-0.25	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	5.55	4.83e-08	1.71e-05	0.3	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
HNSC	cis	rs6604026	0.624	rs11164816	ENSG00000223787.2	RP4-593M8.1	5.55	4.83e-08	1.72e-05	0.35	0.25	Multiple sclerosis;	chr1:92795941	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11581705	ENSG00000223787.2	RP4-593M8.1	5.55	4.83e-08	1.72e-05	0.35	0.25	Multiple sclerosis;	chr1:92796459	chr1:92580476~92580821:-
HNSC	cis	rs12701220	0.744	rs2030958	ENSG00000229043.2	AC091729.9	-5.55	4.84e-08	1.72e-05	-0.37	-0.25	Bronchopulmonary dysplasia;	chr7:1036374	chr7:1160374~1165267:+
HNSC	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	-5.55	4.85e-08	1.72e-05	-0.29	-0.25	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
HNSC	cis	rs6604026	0.59	rs12743005	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92727181	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs35526187	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92732610	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11805698	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92737695	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs35241270	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92739957	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs12746893	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92745319	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11164803	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92746363	chr1:92580476~92580821:-
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000179406.6	LINC00174	5.55	4.85e-08	1.72e-05	0.53	0.25	Diabetic kidney disease;	chr7:66219914	chr7:66376044~66401338:-
HNSC	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-5.55	4.86e-08	1.72e-05	-0.36	-0.25	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
HNSC	cis	rs7115242	0.748	rs1035237	ENSG00000280143.1	AP000892.6	5.55	4.86e-08	1.73e-05	0.38	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	5.55	4.86e-08	1.73e-05	0.22	0.25	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
HNSC	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	5.55	4.87e-08	1.73e-05	0.28	0.25	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
HNSC	cis	rs2117029	0.898	rs10875914	ENSG00000258017.1	RP11-386G11.10	-5.55	4.87e-08	1.73e-05	-0.29	-0.25	Intelligence (multi-trait analysis);	chr12:49028311	chr12:49127782~49147869:+
HNSC	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-5.55	4.87e-08	1.73e-05	-0.28	-0.25	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-5.55	4.87e-08	1.73e-05	-0.28	-0.25	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
HNSC	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-5.55	4.87e-08	1.73e-05	-0.34	-0.25	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
HNSC	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-5.55	4.87e-08	1.73e-05	-0.36	-0.25	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
HNSC	cis	rs2985684	1	rs2147712	ENSG00000258568.1	RHOQP1	5.55	4.87e-08	1.73e-05	0.26	0.25	Carotid intima media thickness;	chr14:49624966	chr14:49599994~49600572:+
HNSC	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	5.55	4.87e-08	1.73e-05	0.24	0.25	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	5.55	4.88e-08	1.73e-05	0.31	0.25	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
HNSC	cis	rs7811142	1	rs7794485	ENSG00000078319.8	PMS2P1	-5.55	4.89e-08	1.74e-05	-0.34	-0.25	Platelet count;	chr7:100471313	chr7:100320992~100341908:-
HNSC	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	5.55	4.89e-08	1.74e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
HNSC	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-5.55	4.89e-08	1.74e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
HNSC	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	5.55	4.89e-08	1.74e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
HNSC	cis	rs7621025	0.69	rs11715257	ENSG00000239213.4	NCK1-AS1	5.55	4.9e-08	1.74e-05	0.23	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136841726~136862054:-
HNSC	cis	rs9840812	0.645	rs13068119	ENSG00000273486.1	RP11-731C17.2	-5.55	4.9e-08	1.74e-05	-0.23	-0.25	Fibrinogen levels;	chr3:136487527	chr3:136837338~136839021:-
HNSC	cis	rs4938303	0.633	rs35681250	ENSG00000254851.1	RP11-109L13.1	5.55	4.9e-08	1.74e-05	0.43	0.25	Triglycerides;	chr11:116684670	chr11:117135528~117138582:+
HNSC	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.55	4.9e-08	1.74e-05	0.29	0.25	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
HNSC	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	5.55	4.9e-08	1.74e-05	0.35	0.25	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
HNSC	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-5.55	4.9e-08	1.74e-05	-0.24	-0.25	Asthma;	chr2:102392894	chr2:102438713~102440475:+
HNSC	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-5.55	4.9e-08	1.74e-05	-0.36	-0.25	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
HNSC	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	5.55	4.9e-08	1.74e-05	0.22	0.25	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
HNSC	cis	rs1355223	0.902	rs286861	ENSG00000271369.1	RP11-350D17.3	-5.55	4.91e-08	1.74e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34696877	chr11:34709600~34710161:+
HNSC	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-5.55	4.91e-08	1.74e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
HNSC	cis	rs6751744	0.855	rs7585513	ENSG00000226266.5	AC009961.3	-5.55	4.92e-08	1.74e-05	-0.29	-0.25	Dysphagia;	chr2:159550379	chr2:159670708~159712435:-
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	5.55	4.92e-08	1.74e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	5.55	4.92e-08	1.74e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
HNSC	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-5.55	4.92e-08	1.74e-05	-0.49	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
HNSC	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	5.55	4.92e-08	1.74e-05	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
HNSC	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102418383	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102411180	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102411191	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102412435	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102412461	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102412524	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102415109	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102415289	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102417501	chr2:102438713~102440475:+
HNSC	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	5.55	4.92e-08	1.75e-05	0.3	0.25	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
HNSC	cis	rs4388249	0.687	rs10041575	ENSG00000271849.1	CTC-332L22.1	-5.55	4.92e-08	1.75e-05	-0.34	-0.25	Schizophrenia;	chr5:109768576	chr5:109687802~109688329:-
HNSC	cis	rs11098499	0.874	rs28452522	ENSG00000248280.1	RP11-33B1.2	5.54	4.93e-08	1.75e-05	0.3	0.25	Corneal astigmatism;	chr4:119189629	chr4:119440561~119450157:-
HNSC	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-5.54	4.93e-08	1.75e-05	-0.28	-0.25	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
HNSC	cis	rs2115630	0.755	rs7169629	ENSG00000229212.6	RP11-561C5.4	-5.54	4.93e-08	1.75e-05	-0.28	-0.25	P wave terminal force;	chr15:84648043	chr15:85205440~85234795:-
HNSC	cis	rs4218	0.871	rs2414621	ENSG00000277144.1	RP11-59H7.4	-5.54	4.94e-08	1.75e-05	-0.3	-0.25	Social communication problems;	chr15:59142129	chr15:59115547~59116089:-
HNSC	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
HNSC	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-5.54	4.94e-08	1.75e-05	-0.35	-0.25	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
HNSC	cis	rs9402743	0.597	rs9385729	ENSG00000217482.2	HMGB1P17	5.54	4.94e-08	1.75e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135600001	chr6:135636086~135636713:-
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-5.54	4.95e-08	1.75e-05	-0.17	-0.25	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000254153.1	CTA-398F10.2	5.54	4.95e-08	1.75e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:8995760	chr8:8456909~8461337:-
HNSC	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-5.54	4.95e-08	1.76e-05	-0.36	-0.25	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
HNSC	cis	rs11846409	0.818	rs2516909	ENSG00000274576.2	IGHV2-70	5.54	4.95e-08	1.76e-05	0.25	0.25	Rheumatic heart disease;	chr14:106630317	chr14:106770577~106771020:-
HNSC	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	5.54	4.96e-08	1.76e-05	0.33	0.25	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
HNSC	cis	rs9326248	0.603	rs7396061	ENSG00000280143.1	AP000892.6	5.54	4.96e-08	1.76e-05	0.25	0.25	Blood protein levels;	chr11:116880158	chr11:117204967~117210292:+
HNSC	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-5.54	4.96e-08	1.76e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
HNSC	cis	rs8035957	0.522	rs56083426	ENSG00000259747.1	RP11-275I4.2	-5.54	4.97e-08	1.76e-05	-0.31	-0.25	Type 1 diabetes;	chr15:38606558	chr15:38671847~38689191:+
HNSC	cis	rs2483058	0.767	rs4127124	ENSG00000261000.1	RP11-534L20.5	5.54	4.97e-08	1.76e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206451019	chr1:206503948~206504456:+
HNSC	cis	rs11846409	0.629	rs76295389	ENSG00000211974.3	IGHV2-70	5.54	4.97e-08	1.76e-05	0.3	0.25	Rheumatic heart disease;	chr14:106650437	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.698	rs71419854	ENSG00000211974.3	IGHV2-70	5.54	4.97e-08	1.76e-05	0.3	0.25	Rheumatic heart disease;	chr14:106650440	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.5	rs71419855	ENSG00000211974.3	IGHV2-70	5.54	4.97e-08	1.76e-05	0.3	0.25	Alzheimer's disease (late onset);	chr14:106650444	chr14:106723574~106724093:-
HNSC	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	5.54	4.97e-08	1.76e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
HNSC	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	5.54	4.97e-08	1.76e-05	0.33	0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
HNSC	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	5.54	4.97e-08	1.76e-05	0.33	0.25	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
HNSC	cis	rs11154801	0.732	rs13202115	ENSG00000217482.2	HMGB1P17	5.54	4.98e-08	1.76e-05	0.28	0.25	Multiple sclerosis;	chr6:135604386	chr6:135636086~135636713:-
HNSC	cis	rs67981189	0.519	rs2526879	ENSG00000274818.1	RP1-292L20.3	-5.54	4.98e-08	1.76e-05	-0.3	-0.25	Schizophrenia;	chr14:70910501	chr14:70906657~70907111:-
HNSC	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-5.54	4.99e-08	1.77e-05	-0.53	-0.25	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
HNSC	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-5.54	4.99e-08	1.77e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
HNSC	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-5.54	4.99e-08	1.77e-05	-0.36	-0.25	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
HNSC	cis	rs13113518	1	rs7691799	ENSG00000249700.7	SRD5A3-AS1	5.54	4.99e-08	1.77e-05	0.29	0.25	Height;	chr4:55545574	chr4:55363971~55395847:-
HNSC	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	5.54	4.99e-08	1.77e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
HNSC	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
HNSC	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-5.54	5e-08	1.77e-05	-0.29	-0.25	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
HNSC	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	5.54	5e-08	1.77e-05	0.62	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
HNSC	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	5.54	5e-08	1.77e-05	0.24	0.25	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
HNSC	cis	rs3738443	0.569	rs6704060	ENSG00000259865.1	RP11-488L18.10	5.54	5e-08	1.77e-05	0.2	0.25	Alcohol dependence;	chr1:247218222	chr1:247187281~247188526:-
HNSC	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-5.54	5.01e-08	1.77e-05	-0.27	-0.25	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	5.54	5.01e-08	1.77e-05	0.27	0.25	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
HNSC	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-5.54	5.03e-08	1.78e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
HNSC	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
HNSC	cis	rs6928977	0.86	rs2746438	ENSG00000234084.1	RP3-388E23.2	5.54	5.03e-08	1.78e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135396930	chr6:135301568~135307158:+
HNSC	cis	rs988913	0.958	rs9475078	ENSG00000224984.1	RP11-524H19.2	5.54	5.03e-08	1.78e-05	0.28	0.25	Menarche (age at onset);	chr6:54944791	chr6:54840118~54840855:-
HNSC	cis	rs2439831	0.681	rs2242067	ENSG00000205771.5	CATSPER2P1	-5.54	5.04e-08	1.78e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43407105	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-5.54	5.04e-08	1.78e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
HNSC	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	5.54	5.05e-08	1.79e-05	0.25	0.25	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
HNSC	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-5.54	5.05e-08	1.79e-05	-0.32	-0.25	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
HNSC	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	5.54	5.05e-08	1.79e-05	0.27	0.25	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
HNSC	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	5.54	5.05e-08	1.79e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
HNSC	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-5.54	5.06e-08	1.79e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
HNSC	cis	rs3206736	0.548	rs328937	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35009519	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328940	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35010752	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328942	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35012203	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs329233	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35016219	chr7:34346512~34871582:-
HNSC	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	5.54	5.07e-08	1.79e-05	0.32	0.25	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
HNSC	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	5.54	5.07e-08	1.79e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	5.54	5.07e-08	1.79e-05	0.31	0.25	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
HNSC	cis	rs2179367	0.632	rs763590	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149398831	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs17506789	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149399710	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.586	rs34097428	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149399822	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498344	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149401053	chr6:149904243~149906418:+
HNSC	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	5.54	5.08e-08	1.8e-05	0.25	0.25	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
HNSC	cis	rs34421088	0.576	rs2572437	ENSG00000255310.2	AF131215.2	-5.54	5.08e-08	1.8e-05	-0.26	-0.25	Neuroticism;	chr8:11240932	chr8:11107788~11109726:-
HNSC	cis	rs2524005	1	rs2524005	ENSG00000243753.4	HLA-L	-5.54	5.08e-08	1.8e-05	-0.36	-0.25	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30259584~30293014:+
HNSC	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	5.54	5.08e-08	1.8e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
HNSC	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-5.54	5.09e-08	1.8e-05	-0.35	-0.25	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	5.54	5.09e-08	1.8e-05	0.31	0.25	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	5.54	5.09e-08	1.8e-05	0.31	0.25	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
HNSC	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-5.54	5.09e-08	1.8e-05	-0.26	-0.25	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-5.54	5.09e-08	1.8e-05	-0.26	-0.25	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
HNSC	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-5.54	5.09e-08	1.8e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	5.54	5.09e-08	1.8e-05	0.31	0.25	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
HNSC	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-5.54	5.09e-08	1.8e-05	-0.24	-0.25	Asthma;	chr2:102374328	chr2:102438713~102440475:+
HNSC	cis	rs34245511	1	rs34245511	ENSG00000272368.2	RP4-605O3.4	-5.54	5.1e-08	1.8e-05	-0.24	-0.25	Colorectal cancer;	chr12:50179650	chr12:50112197~50165618:+
HNSC	cis	rs7819412	0.936	rs7814499	ENSG00000269918.1	AF131215.9	-5.54	5.1e-08	1.8e-05	-0.25	-0.25	Triglycerides;	chr8:11183138	chr8:11104691~11106704:-
HNSC	cis	rs6604026	0.589	rs34250288	ENSG00000223787.2	RP4-593M8.1	5.54	5.12e-08	1.81e-05	0.35	0.25	Multiple sclerosis;	chr1:92792062	chr1:92580476~92580821:-
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000254340.1	RP11-10A14.3	5.54	5.12e-08	1.81e-05	0.3	0.25	Mood instability;	chr8:8804171	chr8:9141424~9145435:+
HNSC	cis	rs75920871	0.502	rs7124996	ENSG00000254851.1	RP11-109L13.1	5.54	5.12e-08	1.81e-05	0.34	0.25	Subjective well-being;	chr11:117057290	chr11:117135528~117138582:+
HNSC	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-5.54	5.12e-08	1.81e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
HNSC	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	5.54	5.13e-08	1.81e-05	0.43	0.25	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
HNSC	cis	rs9992667	0.911	rs28360925	ENSG00000231160.8	KLF3-AS1	5.54	5.13e-08	1.81e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38615676	chr4:38612701~38664883:-
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-5.54	5.13e-08	1.81e-05	-0.29	-0.25	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
HNSC	cis	rs1355223	0.902	rs286862	ENSG00000271369.1	RP11-350D17.3	5.54	5.13e-08	1.81e-05	0.28	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34697232	chr11:34709600~34710161:+
HNSC	cis	rs9300255	0.602	rs1727294	ENSG00000280120.1	RP11-546D6.3	5.54	5.13e-08	1.81e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123131967	chr12:123152324~123153377:-
HNSC	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	5.54	5.13e-08	1.81e-05	0.61	0.25	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
HNSC	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	5.54	5.13e-08	1.81e-05	0.3	0.25	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
HNSC	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-5.54	5.13e-08	1.81e-05	-0.31	-0.25	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
HNSC	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	5.54	5.14e-08	1.82e-05	0.34	0.25	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	5.54	5.14e-08	1.82e-05	0.34	0.25	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
HNSC	cis	rs6928977	0.932	rs11154798	ENSG00000234084.1	RP3-388E23.2	-5.54	5.15e-08	1.82e-05	-0.25	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311487	chr6:135301568~135307158:+
HNSC	cis	rs2439831	1	rs690316	ENSG00000205771.5	CATSPER2P1	-5.54	5.15e-08	1.82e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43445682	chr15:43726918~43747094:-
HNSC	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	5.54	5.15e-08	1.82e-05	0.27	0.25	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
HNSC	cis	rs7804306	1	rs35143180	ENSG00000233264.2	AC006042.8	5.54	5.17e-08	1.83e-05	0.48	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8017141	chr7:7980312~7982228:+
HNSC	cis	rs4713118	0.629	rs203890	ENSG00000204709.4	LINC01556	5.54	5.17e-08	1.83e-05	0.34	0.25	Parkinson's disease;	chr6:28054470	chr6:28943877~28944537:+
HNSC	cis	rs822354	1	rs822354	ENSG00000226652.2	PSMD10P2	5.54	5.18e-08	1.83e-05	0.28	0.25	Adiponectin levels;	chr3:186762417	chr3:186760693~186762050:+
HNSC	cis	rs453301	0.686	rs13252797	ENSG00000233609.3	RP11-62H7.2	5.54	5.18e-08	1.83e-05	0.24	0.25	Joint mobility (Beighton score);	chr8:9003920	chr8:8961200~8979025:+
HNSC	cis	rs6604026	0.555	rs12743520	ENSG00000223787.2	RP4-593M8.1	5.54	5.19e-08	1.83e-05	0.35	0.25	Multiple sclerosis;	chr1:92571555	chr1:92580476~92580821:-
HNSC	cis	rs860295	0.812	rs2297775	ENSG00000203761.5	MSTO2P	5.54	5.19e-08	1.83e-05	0.19	0.25	Body mass index;	chr1:155765221	chr1:155745829~155750137:+
HNSC	cis	rs2179367	0.632	rs62426068	ENSG00000216906.2	RP11-350J20.9	5.54	5.19e-08	1.83e-05	0.36	0.25	Dupuytren's disease;	chr6:149325795	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs62426069	ENSG00000216906.2	RP11-350J20.9	5.54	5.19e-08	1.83e-05	0.36	0.25	Dupuytren's disease;	chr6:149325804	chr6:149904243~149906418:+
HNSC	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	5.54	5.19e-08	1.83e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
HNSC	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-5.53	5.2e-08	1.84e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
HNSC	cis	rs2483058	0.767	rs2336939	ENSG00000261000.1	RP11-534L20.5	5.53	5.21e-08	1.84e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206446827	chr1:206503948~206504456:+
HNSC	cis	rs8177876	0.749	rs12927239	ENSG00000261061.1	RP11-303E16.2	-5.53	5.21e-08	1.84e-05	-0.4	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81053883	chr16:81030770~81031485:+
HNSC	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-5.53	5.21e-08	1.84e-05	-0.32	-0.25	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
HNSC	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	5.53	5.22e-08	1.84e-05	0.33	0.25	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
HNSC	cis	rs889014	0.751	rs6891807	ENSG00000253768.1	CTB-33O18.1	5.53	5.23e-08	1.84e-05	0.27	0.25	Height;	chr5:173551858	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.751	rs34151159	ENSG00000253768.1	CTB-33O18.1	5.53	5.23e-08	1.84e-05	0.27	0.25	Height;	chr5:173551868	chr5:173562478~173573199:+
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000211972.2	IGHV3-66	5.53	5.23e-08	1.84e-05	0.19	0.25	Kawasaki disease;	chr14:106799309	chr14:106675017~106675544:-
HNSC	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-5.53	5.23e-08	1.85e-05	-0.31	-0.25	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
HNSC	cis	rs4803480	0.935	rs1476769	ENSG00000270164.1	LINC01480	-5.53	5.23e-08	1.85e-05	-0.23	-0.25	Schizophrenia;	chr19:41577925	chr19:41535183~41536904:+
HNSC	cis	rs4803480	0.873	rs1476770	ENSG00000270164.1	LINC01480	-5.53	5.23e-08	1.85e-05	-0.23	-0.25	Schizophrenia;	chr19:41578033	chr19:41535183~41536904:+
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000254340.1	RP11-10A14.3	-5.53	5.23e-08	1.85e-05	-0.3	-0.25	Mood instability;	chr8:8872251	chr8:9141424~9145435:+
HNSC	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	5.53	5.23e-08	1.85e-05	0.3	0.25	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	5.53	5.24e-08	1.85e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
HNSC	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	5.53	5.24e-08	1.85e-05	0.27	0.25	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
HNSC	cis	rs9987353	0.566	rs13260067	ENSG00000254340.1	RP11-10A14.3	-5.53	5.24e-08	1.85e-05	-0.31	-0.25	Recombination measurement;	chr8:9213523	chr8:9141424~9145435:+
HNSC	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-5.53	5.24e-08	1.85e-05	-0.22	-0.25	Height;	chr11:118747911	chr11:118791254~118793137:+
HNSC	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-5.53	5.25e-08	1.85e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
HNSC	cis	rs7048146	0.531	rs34302146	ENSG00000213539.4	YBX1P6	5.53	5.25e-08	1.85e-05	0.33	0.25	Vascular brain injury;	chr9:109521469	chr9:109532830~109534332:-
HNSC	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-5.53	5.25e-08	1.85e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
HNSC	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-5.53	5.26e-08	1.85e-05	-0.4	-0.25	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
HNSC	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-5.53	5.26e-08	1.85e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
HNSC	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	5.53	5.26e-08	1.85e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
HNSC	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	5.53	5.26e-08	1.86e-05	0.3	0.25	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
HNSC	cis	rs9525927	0.57	rs9533797	ENSG00000227258.4	SMIM2-AS1	5.53	5.26e-08	1.86e-05	0.33	0.25	Dupuytren's disease;	chr13:44225232	chr13:44110451~44240517:+
HNSC	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.53	5.26e-08	1.86e-05	-0.52	-0.25	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
HNSC	cis	rs60617249	0.507	rs10486745	ENSG00000228204.2	RP4-724E13.2	5.53	5.27e-08	1.86e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50914829	chr7:50866747~51022990:+
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	5.53	5.27e-08	1.86e-05	0.27	0.25	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
HNSC	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	5.53	5.28e-08	1.86e-05	0.35	0.25	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
HNSC	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	5.53	5.28e-08	1.86e-05	0.24	0.25	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
HNSC	cis	rs4978813	0.5	rs4978817	ENSG00000213539.4	YBX1P6	5.53	5.28e-08	1.86e-05	0.3	0.25	Plantar warts;	chr9:109509525	chr9:109532830~109534332:-
HNSC	cis	rs4978813	0.5	rs34590358	ENSG00000213539.4	YBX1P6	5.53	5.28e-08	1.86e-05	0.3	0.25	Plantar warts;	chr9:109510284	chr9:109532830~109534332:-
HNSC	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-5.53	5.28e-08	1.86e-05	-0.32	-0.25	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
HNSC	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-5.53	5.3e-08	1.87e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
HNSC	cis	rs860295	0.557	rs12091730	ENSG00000203761.5	MSTO2P	-5.53	5.3e-08	1.87e-05	-0.21	-0.25	Body mass index;	chr1:155587180	chr1:155745829~155750137:+
HNSC	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	5.53	5.3e-08	1.87e-05	0.26	0.25	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-5.53	5.3e-08	1.87e-05	-0.15	-0.25	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
HNSC	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	5.53	5.3e-08	1.87e-05	0.35	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
HNSC	cis	rs9402743	0.634	rs7765113	ENSG00000217482.2	HMGB1P17	5.53	5.3e-08	1.87e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135598935	chr6:135636086~135636713:-
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	5.53	5.3e-08	1.87e-05	0.28	0.25	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
HNSC	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	5.53	5.31e-08	1.87e-05	0.31	0.25	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
HNSC	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-5.53	5.31e-08	1.87e-05	-0.29	-0.25	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
HNSC	cis	rs6604026	0.778	rs11810111	ENSG00000223787.2	RP4-593M8.1	5.53	5.32e-08	1.87e-05	0.35	0.25	Multiple sclerosis;	chr1:92813212	chr1:92580476~92580821:-
HNSC	cis	rs1933112	0.5	rs7543171	ENSG00000227777.1	RP4-738P11.3	-5.53	5.32e-08	1.87e-05	-0.35	-0.25	Blood protein levels;	chr1:168535895	chr1:168542737~168543354:+
HNSC	cis	rs7000734	0.874	rs2599726	ENSG00000245080.5	RP11-320N21.1	-5.53	5.32e-08	1.88e-05	-0.35	-0.25	Radiation response;	chr8:95120544	chr8:95066808~95073182:-
HNSC	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	5.53	5.33e-08	1.88e-05	0.31	0.25	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
HNSC	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	5.53	5.33e-08	1.88e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	5.53	5.33e-08	1.88e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
HNSC	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-5.53	5.33e-08	1.88e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
HNSC	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-5.53	5.33e-08	1.88e-05	-0.34	-0.25	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
HNSC	cis	rs9402743	0.634	rs9494289	ENSG00000217482.2	HMGB1P17	5.53	5.33e-08	1.88e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135594751	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.863	rs7772681	ENSG00000234084.1	RP3-388E23.2	-5.53	5.33e-08	1.88e-05	-0.25	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135327875	chr6:135301568~135307158:+
HNSC	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	5.53	5.33e-08	1.88e-05	0.33	0.25	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
HNSC	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	5.53	5.35e-08	1.88e-05	0.27	0.25	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
HNSC	cis	rs9611519	0.964	rs2179744	ENSG00000235513.1	RP4-756G23.5	5.53	5.35e-08	1.88e-05	0.26	0.25	Neuroticism;	chr22:41225710	chr22:41209122~41217627:-
HNSC	cis	rs9611519	1	rs5758268	ENSG00000235513.1	RP4-756G23.5	5.53	5.35e-08	1.88e-05	0.26	0.25	Neuroticism;	chr22:41226415	chr22:41209122~41217627:-
HNSC	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	5.53	5.35e-08	1.88e-05	0.22	0.25	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
HNSC	cis	rs4657482	0.606	rs3790655	ENSG00000236364.3	RP11-525G13.2	5.53	5.36e-08	1.89e-05	0.25	0.25	Testicular germ cell tumor;	chr1:165893086	chr1:165890795~165900683:-
HNSC	cis	rs61542988	0.57	rs7781074	ENSG00000228649.7	AC005682.5	-5.53	5.36e-08	1.89e-05	-0.32	-0.25	Fibrinogen levels;	chr7:22786741	chr7:22854178~22861579:+
HNSC	cis	rs1021993	0.953	rs950890	ENSG00000231648.1	RP11-372M18.2	5.53	5.37e-08	1.89e-05	0.33	0.25	Gut microbiome composition (winter);	chr1:209309472	chr1:209367662~209379690:+
HNSC	cis	rs2834288	0.7	rs11088263	ENSG00000237945.6	LINC00649	-5.53	5.37e-08	1.89e-05	-0.32	-0.25	Gut microbiota (bacterial taxa);	chr21:33918486	chr21:33915534~33977691:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	5.53	5.37e-08	1.89e-05	0.27	0.25	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
HNSC	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	5.53	5.38e-08	1.89e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
HNSC	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-5.53	5.38e-08	1.9e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
HNSC	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	5.53	5.38e-08	1.9e-05	0.27	0.25	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
HNSC	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-5.53	5.39e-08	1.9e-05	-0.3	-0.25	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
HNSC	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	5.53	5.39e-08	1.9e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
HNSC	cis	rs10504130	0.569	rs11775587	ENSG00000272024.1	RP11-546K22.3	5.53	5.4e-08	1.9e-05	0.34	0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51907605	chr8:51950284~51950690:+
HNSC	cis	rs783540	0.632	rs17356528	ENSG00000276710.3	CSPG4P8	5.53	5.4e-08	1.9e-05	0.29	0.25	Schizophrenia;	chr15:82636799	chr15:82459472~82477258:+
HNSC	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-5.53	5.4e-08	1.9e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-5.53	5.4e-08	1.9e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
HNSC	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	5.53	5.41e-08	1.9e-05	0.31	0.25	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
HNSC	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-5.53	5.41e-08	1.91e-05	-0.39	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-5.53	5.41e-08	1.91e-05	-0.39	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-5.53	5.41e-08	1.91e-05	-0.39	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
HNSC	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
HNSC	cis	rs832187	0.776	rs854622	ENSG00000280620.1	SCAANT1	5.53	5.43e-08	1.91e-05	0.3	0.25	Schizophrenia;	chr3:63877166	chr3:63911518~63911772:-
HNSC	cis	rs783540	0.656	rs783524	ENSG00000276710.3	CSPG4P8	5.53	5.44e-08	1.91e-05	0.29	0.25	Schizophrenia;	chr15:82615393	chr15:82459472~82477258:+
HNSC	cis	rs783540	0.592	rs2567632	ENSG00000276710.3	CSPG4P8	5.53	5.44e-08	1.91e-05	0.29	0.25	Schizophrenia;	chr15:82616053	chr15:82459472~82477258:+
HNSC	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	5.53	5.44e-08	1.91e-05	0.25	0.25	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
HNSC	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
HNSC	cis	rs7829975	0.514	rs2979139	ENSG00000254340.1	RP11-10A14.3	5.53	5.44e-08	1.91e-05	0.3	0.25	Mood instability;	chr8:8410803	chr8:9141424~9145435:+
HNSC	cis	rs988913	0.957	rs2397177	ENSG00000224984.1	RP11-524H19.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Menarche (age at onset);	chr6:54969335	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9382404	ENSG00000224984.1	RP11-524H19.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Menarche (age at onset);	chr6:54970420	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7764641	ENSG00000224984.1	RP11-524H19.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Menarche (age at onset);	chr6:54970671	chr6:54840118~54840855:-
HNSC	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-5.53	5.46e-08	1.92e-05	-0.35	-0.25	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
HNSC	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-5.53	5.46e-08	1.92e-05	-0.35	-0.25	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	5.53	5.46e-08	1.92e-05	0.3	0.25	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
HNSC	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-5.53	5.46e-08	1.92e-05	-0.24	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
HNSC	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	5.53	5.47e-08	1.92e-05	0.35	0.25	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
HNSC	cis	rs7615952	0.673	rs9821905	ENSG00000248787.1	RP11-666A20.4	5.53	5.47e-08	1.92e-05	0.41	0.25	Blood pressure (smoking interaction);	chr3:125902007	chr3:125908005~125910272:-
HNSC	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	5.53	5.48e-08	1.93e-05	0.3	0.25	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	5.53	5.48e-08	1.93e-05	0.31	0.25	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
HNSC	cis	rs8031584	0.678	rs35098644	ENSG00000260382.1	RP11-540B6.2	5.52	5.49e-08	1.93e-05	0.31	0.25	Huntington's disease progression;	chr15:30853237	chr15:30882267~30883231:-
HNSC	cis	rs9987353	0.566	rs13260067	ENSG00000173295.6	FAM86B3P	-5.52	5.49e-08	1.93e-05	-0.29	-0.25	Recombination measurement;	chr8:9213523	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	5.52	5.5e-08	1.93e-05	0.3	0.25	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
HNSC	cis	rs732716	0.853	rs72990643	ENSG00000267980.1	AC007292.6	-5.52	5.5e-08	1.93e-05	-0.29	-0.25	Mean corpuscular volume;	chr19:4454739	chr19:4363789~4364640:+
HNSC	cis	rs13113518	1	rs11724094	ENSG00000273257.1	RP11-177J6.1	5.52	5.5e-08	1.93e-05	0.3	0.25	Height;	chr4:55501479	chr4:55387949~55388271:+
HNSC	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	5.52	5.5e-08	1.93e-05	0.55	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
HNSC	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	5.52	5.51e-08	1.94e-05	0.43	0.25	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	5.52	5.51e-08	1.94e-05	0.43	0.25	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	5.52	5.51e-08	1.94e-05	0.43	0.25	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
HNSC	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	5.52	5.51e-08	1.94e-05	0.35	0.25	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	5.52	5.51e-08	1.94e-05	0.35	0.25	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	5.52	5.51e-08	1.94e-05	0.35	0.25	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
HNSC	cis	rs7209700	0.788	rs12949936	ENSG00000228782.6	CTD-2026D20.3	-5.52	5.52e-08	1.94e-05	-0.26	-0.25	IgG glycosylation;	chr17:47295056	chr17:47450568~47492492:-
HNSC	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	5.52	5.52e-08	1.94e-05	0.63	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
HNSC	cis	rs11154801	0.589	rs6924066	ENSG00000217482.2	HMGB1P17	5.52	5.52e-08	1.94e-05	0.28	0.25	Multiple sclerosis;	chr6:135598006	chr6:135636086~135636713:-
HNSC	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-5.52	5.54e-08	1.95e-05	-0.31	-0.25	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
HNSC	cis	rs2243480	1	rs6460260	ENSG00000179406.6	LINC00174	5.52	5.55e-08	1.95e-05	0.53	0.25	Diabetic kidney disease;	chr7:65750468	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6460261	ENSG00000179406.6	LINC00174	5.52	5.55e-08	1.95e-05	0.53	0.25	Diabetic kidney disease;	chr7:65750593	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs4718273	ENSG00000179406.6	LINC00174	5.52	5.55e-08	1.95e-05	0.53	0.25	Diabetic kidney disease;	chr7:65751112	chr7:66376044~66401338:-
HNSC	cis	rs988913	1	rs9382408	ENSG00000224984.1	RP11-524H19.2	5.52	5.55e-08	1.95e-05	0.28	0.25	Menarche (age at onset);	chr6:54972186	chr6:54840118~54840855:-
HNSC	cis	rs10435719	0.902	rs7006538	ENSG00000206014.6	OR7E161P	-5.52	5.55e-08	1.95e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11928597~11929563:-
HNSC	cis	rs8054556	1	rs3935873	ENSG00000183604.13	SMG1P5	5.52	5.55e-08	1.95e-05	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr16:30007179	chr16:30267553~30335374:-
HNSC	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	5.52	5.56e-08	1.95e-05	0.25	0.25	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
HNSC	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	5.52	5.56e-08	1.95e-05	0.19	0.25	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
HNSC	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	5.52	5.57e-08	1.95e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	5.52	5.57e-08	1.95e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
HNSC	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	5.52	5.57e-08	1.96e-05	0.23	0.25	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
HNSC	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-5.52	5.58e-08	1.96e-05	-0.28	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
HNSC	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	5.52	5.58e-08	1.96e-05	0.3	0.25	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000233609.3	RP11-62H7.2	-5.52	5.58e-08	1.96e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9047352	chr8:8961200~8979025:+
HNSC	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-5.52	5.58e-08	1.96e-05	-0.33	-0.25	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
HNSC	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-5.52	5.59e-08	1.96e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
HNSC	cis	rs11648785	0.506	rs3743829	ENSG00000222019.6	URAHP	5.52	5.59e-08	1.96e-05	0.23	0.25	Tanning;	chr16:90027561	chr16:90039761~90047773:-
HNSC	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-5.52	5.6e-08	1.97e-05	-0.28	-0.25	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
HNSC	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
HNSC	cis	rs10435719	0.867	rs6999030	ENSG00000206014.6	OR7E161P	-5.52	5.61e-08	1.97e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.834	rs6985792	ENSG00000206014.6	OR7E161P	-5.52	5.61e-08	1.97e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:11928597~11929563:-
HNSC	cis	rs12439619	0.921	rs4778672	ENSG00000255769.6	GOLGA2P10	5.52	5.61e-08	1.97e-05	0.33	0.25	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472993~82513950:-
HNSC	cis	rs7209700	0.708	rs2292699	ENSG00000228782.6	CTD-2026D20.3	5.52	5.61e-08	1.97e-05	0.25	0.25	IgG glycosylation;	chr17:47284929	chr17:47450568~47492492:-
HNSC	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000233609.3	RP11-62H7.2	-5.52	5.62e-08	1.97e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9047129	chr8:8961200~8979025:+
HNSC	cis	rs72772090	0.634	rs17402639	ENSG00000248734.2	CTD-2260A17.1	-5.52	5.62e-08	1.97e-05	-0.38	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96771301	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.634	rs72773912	ENSG00000248734.2	CTD-2260A17.1	-5.52	5.62e-08	1.97e-05	-0.38	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96772097	chr5:96784777~96785999:+
HNSC	cis	rs947583	0.573	rs55789102	ENSG00000217482.2	HMGB1P17	5.52	5.63e-08	1.97e-05	0.27	0.25	Phosphorus levels;	chr6:135699954	chr6:135636086~135636713:-
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000254340.1	RP11-10A14.3	5.52	5.63e-08	1.97e-05	0.3	0.25	Joint mobility (Beighton score);	chr8:8970227	chr8:9141424~9145435:+
HNSC	cis	rs503425	0.546	rs540716	ENSG00000255422.1	AP002954.4	5.52	5.63e-08	1.97e-05	0.34	0.25	Systemic lupus erythematosus;	chr11:118814306	chr11:118704607~118750263:+
HNSC	cis	rs9650657	0.547	rs11250099	ENSG00000269918.1	AF131215.9	5.52	5.64e-08	1.98e-05	0.24	0.25	Neuroticism;	chr8:10961147	chr8:11104691~11106704:-
HNSC	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-5.52	5.64e-08	1.98e-05	-0.26	-0.25	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
HNSC	cis	rs2439831	1	rs550239	ENSG00000205771.5	CATSPER2P1	-5.52	5.64e-08	1.98e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43427999	chr15:43726918~43747094:-
HNSC	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	5.52	5.65e-08	1.98e-05	0.28	0.25	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
HNSC	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	5.52	5.65e-08	1.98e-05	0.38	0.25	Height;	chr6:109369898	chr6:109382795~109383666:+
HNSC	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-5.52	5.65e-08	1.98e-05	-0.23	-0.25	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-5.52	5.66e-08	1.98e-05	-0.16	-0.25	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
HNSC	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	5.52	5.66e-08	1.98e-05	0.33	0.25	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
HNSC	cis	rs2933343	0.7	rs1680778	ENSG00000261159.1	RP11-723O4.9	5.52	5.66e-08	1.98e-05	0.25	0.25	IgG glycosylation;	chr3:128895342	chr3:128859716~128860526:-
HNSC	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-5.52	5.66e-08	1.98e-05	-0.33	-0.25	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
HNSC	cis	rs603446	0.967	rs180361	ENSG00000254851.1	RP11-109L13.1	-5.52	5.66e-08	1.98e-05	-0.32	-0.25	Triglycerides;	chr11:116727933	chr11:117135528~117138582:+
HNSC	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	5.52	5.67e-08	1.99e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	5.52	5.67e-08	1.99e-05	0.3	0.25	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	5.52	5.67e-08	1.99e-05	0.3	0.25	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
HNSC	cis	rs831571	1	rs17069791	ENSG00000280620.1	SCAANT1	5.52	5.67e-08	1.99e-05	0.4	0.25	Type 2 diabetes;	chr3:64066603	chr3:63911518~63911772:-
HNSC	cis	rs2243480	1	rs1499614	ENSG00000179406.6	LINC00174	-5.52	5.67e-08	1.99e-05	-0.53	-0.25	Diabetic kidney disease;	chr7:66265811	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	5.52	5.68e-08	1.99e-05	0.27	0.25	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	5.52	5.69e-08	2e-05	0.27	0.25	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
HNSC	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-5.52	5.7e-08	2e-05	-0.3	-0.25	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
HNSC	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-5.52	5.7e-08	2e-05	-0.32	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
HNSC	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	5.52	5.7e-08	2e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
HNSC	cis	rs9291683	0.62	rs4444830	ENSG00000250413.1	RP11-448G15.1	5.52	5.7e-08	2e-05	0.32	0.25	Bone mineral density;	chr4:10123195	chr4:10006482~10009725:+
HNSC	cis	rs2243480	1	rs160652	ENSG00000179406.6	LINC00174	-5.52	5.7e-08	2e-05	-0.54	-0.25	Diabetic kidney disease;	chr7:66073444	chr7:66376044~66401338:-
HNSC	cis	rs11976180	1	rs11975942	ENSG00000273234.1	OR2A13P	-5.52	5.71e-08	2e-05	-0.28	-0.25	Obesity-related traits;	chr7:144043487	chr7:144142009~144142938:+
HNSC	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	5.52	5.71e-08	2e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
HNSC	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	5.52	5.71e-08	2e-05	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
HNSC	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	5.52	5.72e-08	2e-05	0.26	0.25	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
HNSC	cis	rs75920871	0.528	rs11216255	ENSG00000254851.1	RP11-109L13.1	5.52	5.72e-08	2e-05	0.34	0.25	Subjective well-being;	chr11:117059279	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	5.52	5.73e-08	2e-05	0.3	0.25	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
HNSC	cis	rs2483058	0.767	rs963894	ENSG00000261000.1	RP11-534L20.5	5.52	5.73e-08	2.01e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206452085	chr1:206503948~206504456:+
HNSC	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	5.52	5.73e-08	2.01e-05	0.37	0.25	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	5.52	5.73e-08	2.01e-05	0.37	0.25	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
HNSC	cis	rs5758511	0.689	rs45441993	ENSG00000226450.2	CYP2D8P	5.52	5.73e-08	2.01e-05	0.26	0.25	Birth weight;	chr22:42075734	chr22:42149886~42155001:-
HNSC	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	5.52	5.75e-08	2.01e-05	0.35	0.25	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
HNSC	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-5.52	5.75e-08	2.01e-05	-0.33	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
HNSC	cis	rs2337406	0.587	rs2516886	ENSG00000211974.3	IGHV2-70	5.52	5.76e-08	2.02e-05	0.28	0.25	Alzheimer's disease (late onset);	chr14:106649674	chr14:106723574~106724093:-
HNSC	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-5.52	5.76e-08	2.02e-05	-0.37	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
HNSC	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	5.52	5.76e-08	2.02e-05	0.3	0.25	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.624	rs111281067	ENSG00000223787.2	RP4-593M8.1	5.52	5.77e-08	2.02e-05	0.35	0.25	Multiple sclerosis;	chr1:92790096	chr1:92580476~92580821:-
HNSC	cis	rs67981189	0.519	rs2526853	ENSG00000274818.1	RP1-292L20.3	-5.52	5.77e-08	2.02e-05	-0.3	-0.25	Schizophrenia;	chr14:70949235	chr14:70906657~70907111:-
HNSC	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-5.52	5.77e-08	2.02e-05	-0.24	-0.25	Asthma;	chr2:102401592	chr2:102438713~102440475:+
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000254153.1	CTA-398F10.2	-5.52	5.77e-08	2.02e-05	-0.27	-0.25	Mood instability;	chr8:8516047	chr8:8456909~8461337:-
HNSC	cis	rs13126694	0.933	rs6830475	ENSG00000248429.4	RP11-597D13.9	5.52	5.78e-08	2.02e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158155527	chr4:158170752~158202877:+
HNSC	cis	rs9992667	0.955	rs6819274	ENSG00000231160.8	KLF3-AS1	5.51	5.79e-08	2.02e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38614306	chr4:38612701~38664883:-
HNSC	cis	rs9291683	0.62	rs717615	ENSG00000250413.1	RP11-448G15.1	-5.51	5.79e-08	2.03e-05	-0.3	-0.25	Bone mineral density;	chr4:10103046	chr4:10006482~10009725:+
HNSC	cis	rs763567	0.933	rs531007	ENSG00000271811.1	RP1-79C4.4	5.51	5.8e-08	2.03e-05	0.27	0.25	Tonsillectomy;	chr1:170649241	chr1:170667381~170669425:+
HNSC	cis	rs9402743	0.671	rs6901733	ENSG00000217482.2	HMGB1P17	5.51	5.8e-08	2.03e-05	0.28	0.25	Systemic lupus erythematosus;	chr6:135619407	chr6:135636086~135636713:-
HNSC	cis	rs13113518	1	rs13122619	ENSG00000273257.1	RP11-177J6.1	5.51	5.8e-08	2.03e-05	0.3	0.25	Height;	chr4:55479339	chr4:55387949~55388271:+
HNSC	cis	rs1908814	0.516	rs11996277	ENSG00000206014.6	OR7E161P	-5.51	5.8e-08	2.03e-05	-0.27	-0.25	Neuroticism;	chr8:11942522	chr8:11928597~11929563:-
HNSC	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	5.51	5.81e-08	2.03e-05	0.3	0.25	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
HNSC	cis	rs3002131	0.604	rs3008641	ENSG00000225265.1	TAF1A-AS1	-5.51	5.81e-08	2.03e-05	-0.33	-0.25	Interleukin-10 levels;	chr1:222566947	chr1:222589825~222593032:+
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000254153.1	CTA-398F10.2	5.51	5.81e-08	2.03e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9026395	chr8:8456909~8461337:-
HNSC	cis	rs2483058	0.739	rs3860302	ENSG00000261000.1	RP11-534L20.5	5.51	5.82e-08	2.04e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206451299	chr1:206503948~206504456:+
HNSC	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	5.51	5.82e-08	2.04e-05	0.33	0.25	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
HNSC	cis	rs9859260	0.744	rs3933	ENSG00000207650.1	MIR570	-5.51	5.83e-08	2.04e-05	-0.23	-0.25	Mean corpuscular volume;	chr3:196058126	chr3:195699401~195699497:+
HNSC	cis	rs13113518	1	rs13132420	ENSG00000249700.7	SRD5A3-AS1	-5.51	5.83e-08	2.04e-05	-0.29	-0.25	Height;	chr4:55526646	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	5.51	5.84e-08	2.04e-05	0.26	0.25	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
HNSC	cis	rs2179367	0.632	rs66672129	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149334387	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498322	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149335950	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498323	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149336077	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12204793	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149340102	chr6:149904243~149906418:+
HNSC	cis	rs2337406	0.539	rs2583292	ENSG00000254174.1	IGHV1-12	5.51	5.85e-08	2.04e-05	0.19	0.25	Alzheimer's disease (late onset);	chr14:106649040	chr14:106122420~106122709:-
HNSC	cis	rs6604026	0.624	rs59864761	ENSG00000223787.2	RP4-593M8.1	5.51	5.85e-08	2.04e-05	0.35	0.25	Multiple sclerosis;	chr1:92791656	chr1:92580476~92580821:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000235689.1	AP000351.13	5.51	5.85e-08	2.04e-05	0.25	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:24006305~24008258:-
HNSC	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
HNSC	cis	rs2115630	0.875	rs8039472	ENSG00000229212.6	RP11-561C5.4	5.51	5.85e-08	2.05e-05	0.29	0.25	P wave terminal force;	chr15:84818413	chr15:85205440~85234795:-
HNSC	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-5.51	5.86e-08	2.05e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
HNSC	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	5.51	5.86e-08	2.05e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	5.51	5.86e-08	2.05e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
HNSC	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-5.51	5.86e-08	2.05e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
HNSC	cis	rs35306767	0.953	rs35174953	ENSG00000229869.1	RP11-363N22.2	-5.51	5.86e-08	2.05e-05	-0.34	-0.25	Eosinophil percentage of granulocytes;	chr10:915251	chr10:933026~942743:+
HNSC	cis	rs1799949	0.965	rs4793237	ENSG00000267681.1	CTD-3199J23.6	-5.51	5.86e-08	2.05e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43359227	chr17:43144956~43145255:+
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66108952	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313820	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66109479	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160639	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66115000	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313824	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66116220	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs186378	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66117071	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160637	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66119331	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs466983	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.54	-0.25	Diabetic kidney disease;	chr7:66055509	chr7:66376044~66401338:-
HNSC	cis	rs7000734	0.916	rs172469	ENSG00000245080.5	RP11-320N21.1	-5.51	5.88e-08	2.05e-05	-0.35	-0.25	Radiation response;	chr8:95120167	chr8:95066808~95073182:-
HNSC	cis	rs36093844	0.8	rs17817326	ENSG00000279742.1	RP11-700A24.1	-5.51	5.89e-08	2.06e-05	-0.35	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884170	chr11:85852557~85854943:-
HNSC	cis	rs6604026	0.624	rs34761380	ENSG00000223787.2	RP4-593M8.1	5.51	5.89e-08	2.06e-05	0.34	0.25	Multiple sclerosis;	chr1:92731928	chr1:92580476~92580821:-
HNSC	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	5.51	5.9e-08	2.06e-05	0.32	0.25	Height;	chr6:109332622	chr6:109382795~109383666:+
HNSC	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-5.51	5.9e-08	2.06e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
HNSC	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-5.51	5.9e-08	2.06e-05	-0.33	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
HNSC	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	5.51	5.91e-08	2.06e-05	0.3	0.25	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
HNSC	cis	rs2933343	0.621	rs789242	ENSG00000261159.1	RP11-723O4.9	5.51	5.91e-08	2.06e-05	0.24	0.25	IgG glycosylation;	chr3:128866864	chr3:128859716~128860526:-
HNSC	cis	rs7160336	0.738	rs7145427	ENSG00000259065.1	RP5-1021I20.1	5.51	5.91e-08	2.06e-05	0.28	0.25	Blood protein levels;	chr14:74016745	chr14:73787360~73803270:+
HNSC	cis	rs9402743	0.634	rs6923032	ENSG00000217482.2	HMGB1P17	5.51	5.91e-08	2.06e-05	0.28	0.25	Systemic lupus erythematosus;	chr6:135597708	chr6:135636086~135636713:-
HNSC	cis	rs7777677	0.925	rs4726540	ENSG00000244273.1	PGBD4P1	-5.51	5.91e-08	2.07e-05	-0.26	-0.25	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142722358~142722764:+
HNSC	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-5.51	5.92e-08	2.07e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
HNSC	cis	rs13126694	0.71	rs13137826	ENSG00000248429.4	RP11-597D13.9	5.51	5.92e-08	2.07e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158001354	chr4:158170752~158202877:+
HNSC	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	5.51	5.92e-08	2.07e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
HNSC	cis	rs42490	0.625	rs425312	ENSG00000251136.7	RP11-37B2.1	-5.51	5.93e-08	2.07e-05	-0.21	-0.25	Leprosy;	chr8:89834127	chr8:89609409~89757727:-
HNSC	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	5.51	5.93e-08	2.07e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	5.51	5.93e-08	2.07e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
HNSC	cis	rs2439831	1	rs28666488	ENSG00000205771.5	CATSPER2P1	-5.51	5.93e-08	2.07e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43448892	chr15:43726918~43747094:-
HNSC	cis	rs5758659	1	rs134882	ENSG00000227370.1	RP4-669P10.19	-5.51	5.94e-08	2.07e-05	-0.24	-0.25	Cognitive function;	chr22:42274959	chr22:42132543~42132998:+
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000254340.1	RP11-10A14.3	5.51	5.94e-08	2.07e-05	0.3	0.25	Mood instability;	chr8:8872978	chr8:9141424~9145435:+
HNSC	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-5.51	5.94e-08	2.08e-05	-0.31	-0.25	Depression;	chr6:28113616	chr6:28161781~28169594:+
HNSC	cis	rs860295	0.871	rs34632540	ENSG00000203761.5	MSTO2P	5.51	5.94e-08	2.08e-05	0.18	0.25	Body mass index;	chr1:155642406	chr1:155745829~155750137:+
HNSC	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-5.51	5.95e-08	2.08e-05	-0.24	-0.25	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.882	rs9380069	ENSG00000219392.1	RP1-265C24.5	-5.51	5.95e-08	2.08e-05	-0.38	-0.25	Depression;	chr6:28235522	chr6:28115628~28116551:+
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	5.51	5.95e-08	2.08e-05	0.26	0.25	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs10278195	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35024847	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs17793874	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35025946	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs59505449	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35026240	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs73110554	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35026919	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs73110557	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35028445	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs17793929	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35029368	chr7:34346512~34871582:-
HNSC	cis	rs11846409	0.521	rs10143547	ENSG00000274576.2	IGHV2-70	-5.51	5.96e-08	2.08e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106644638	chr14:106770577~106771020:-
HNSC	cis	rs330048	0.525	rs10112237	ENSG00000254340.1	RP11-10A14.3	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Systemic lupus erythematosus;	chr8:9215219	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.83	rs17173702	ENSG00000261305.1	RP4-584D14.7	5.51	5.96e-08	2.08e-05	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150371516	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.83	rs17173703	ENSG00000261305.1	RP4-584D14.7	5.51	5.96e-08	2.08e-05	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150371531	chr7:150341771~150342607:+
HNSC	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-5.51	5.97e-08	2.08e-05	-0.29	-0.25	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
HNSC	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-5.51	5.97e-08	2.08e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
HNSC	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	5.51	5.97e-08	2.08e-05	0.27	0.25	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
HNSC	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-5.51	5.98e-08	2.09e-05	-0.24	-0.25	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-5.51	5.98e-08	2.09e-05	-0.24	-0.25	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
HNSC	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-5.51	5.98e-08	2.09e-05	-0.27	-0.25	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
HNSC	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	5.51	5.98e-08	2.09e-05	0.29	0.25	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
HNSC	cis	rs7615952	0.558	rs7641353	ENSG00000248787.1	RP11-666A20.4	-5.51	5.98e-08	2.09e-05	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125621035	chr3:125908005~125910272:-
HNSC	cis	rs9840812	0.906	rs61791757	ENSG00000273486.1	RP11-731C17.2	-5.51	5.98e-08	2.09e-05	-0.23	-0.25	Fibrinogen levels;	chr3:136186483	chr3:136837338~136839021:-
HNSC	cis	rs6991838	0.806	rs4285523	ENSG00000200714.1	Y_RNA	5.51	5.98e-08	2.09e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65592731~65592820:+
HNSC	cis	rs17507216	1	rs17356118	ENSG00000276710.3	CSPG4P8	-5.51	5.99e-08	2.09e-05	-0.32	-0.25	Excessive daytime sleepiness;	chr15:82569149	chr15:82459472~82477258:+
HNSC	cis	rs2179367	0.543	rs9498328	ENSG00000216906.2	RP11-350J20.9	5.51	5.99e-08	2.09e-05	0.36	0.25	Dupuytren's disease;	chr6:149348715	chr6:149904243~149906418:+
HNSC	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	5.51	5.99e-08	2.09e-05	0.35	0.25	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
HNSC	cis	rs5758511	0.508	rs2413667	ENSG00000226450.2	CYP2D8P	5.51	5.99e-08	2.09e-05	0.25	0.25	Birth weight;	chr22:42076233	chr22:42149886~42155001:-
HNSC	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-5.51	5.99e-08	2.09e-05	-0.28	-0.25	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
HNSC	cis	rs4141404	0.748	rs2232176	ENSG00000236132.1	CTA-440B3.1	5.51	6e-08	2.09e-05	0.3	0.25	Paclitaxel-induced neuropathy;	chr22:31140147	chr22:31816379~31817491:-
HNSC	cis	rs7811142	1	rs11761725	ENSG00000078319.8	PMS2P1	-5.51	6e-08	2.09e-05	-0.33	-0.25	Platelet count;	chr7:100442192	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs2406255	ENSG00000078319.8	PMS2P1	-5.51	6e-08	2.09e-05	-0.33	-0.25	Platelet count;	chr7:100456067	chr7:100320992~100341908:-
HNSC	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	5.51	6.01e-08	2.1e-05	0.26	0.25	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
HNSC	cis	rs35306767	0.953	rs12259801	ENSG00000229869.1	RP11-363N22.2	-5.51	6.02e-08	2.1e-05	-0.34	-0.25	Eosinophil percentage of granulocytes;	chr10:913366	chr10:933026~942743:+
HNSC	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-5.51	6.02e-08	2.1e-05	-0.33	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
HNSC	cis	rs9402743	0.717	rs6930773	ENSG00000217482.2	HMGB1P17	5.51	6.03e-08	2.1e-05	0.26	0.25	Systemic lupus erythematosus;	chr6:135694363	chr6:135636086~135636713:-
HNSC	cis	rs10256972	0.967	rs1881122	ENSG00000225146.1	AC073957.15	5.51	6.03e-08	2.1e-05	0.29	0.25	Endometriosis;Longevity;	chr7:1001310	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	5.51	6.03e-08	2.1e-05	0.31	0.25	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
HNSC	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-5.51	6.04e-08	2.11e-05	-0.33	-0.25	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
HNSC	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	5.51	6.04e-08	2.11e-05	0.35	0.25	Height;	chr6:109713188	chr6:109382795~109383666:+
HNSC	cis	rs9291683	0.704	rs11726271	ENSG00000250413.1	RP11-448G15.1	5.51	6.04e-08	2.11e-05	0.31	0.25	Bone mineral density;	chr4:10096568	chr4:10006482~10009725:+
HNSC	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-5.51	6.05e-08	2.11e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
HNSC	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-5.51	6.06e-08	2.11e-05	-0.4	-0.25	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
HNSC	cis	rs9300255	0.602	rs1727316	ENSG00000280120.1	RP11-546D6.3	5.51	6.06e-08	2.11e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123134056	chr12:123152324~123153377:-
HNSC	cis	rs2179367	0.632	rs6920383	ENSG00000216906.2	RP11-350J20.9	5.51	6.06e-08	2.11e-05	0.36	0.25	Dupuytren's disease;	chr6:149356361	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs11155645	ENSG00000216906.2	RP11-350J20.9	5.51	6.06e-08	2.11e-05	0.36	0.25	Dupuytren's disease;	chr6:149360056	chr6:149904243~149906418:+
HNSC	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-5.51	6.06e-08	2.11e-05	-0.2	-0.25	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
HNSC	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-5.51	6.07e-08	2.12e-05	-0.2	-0.25	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
HNSC	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-5.51	6.07e-08	2.12e-05	-0.2	-0.25	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
HNSC	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-5.51	6.07e-08	2.12e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
HNSC	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	5.51	6.07e-08	2.12e-05	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
HNSC	cis	rs7674212	0.57	rs6813563	ENSG00000246560.2	RP11-10L12.4	5.51	6.08e-08	2.12e-05	0.28	0.25	Type 2 diabetes;	chr4:103177953	chr4:102828055~102844075:+
HNSC	cis	rs7429990	0.965	rs7651237	ENSG00000228638.1	FCF1P2	5.51	6.08e-08	2.12e-05	0.23	0.25	Educational attainment (years of education);	chr3:48064038	chr3:48290793~48291375:-
HNSC	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-5.51	6.08e-08	2.12e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
HNSC	cis	rs6693567	0.565	rs11205355	ENSG00000228126.1	FALEC	-5.51	6.08e-08	2.12e-05	-0.3	-0.25	Migraine;	chr1:150279918	chr1:150515757~150518032:+
HNSC	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	5.5	6.1e-08	2.13e-05	0.26	0.25	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
HNSC	cis	rs2742234	0.504	rs7093409	ENSG00000273008.1	RP11-351D16.3	5.5	6.11e-08	2.13e-05	0.32	0.25	Hirschsprung disease;	chr10:43244619	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs1879310	ENSG00000273008.1	RP11-351D16.3	5.5	6.11e-08	2.13e-05	0.33	0.25	Hirschsprung disease;	chr10:43239327	chr10:43136824~43138334:-
HNSC	cis	rs7160336	0.738	rs35579176	ENSG00000259065.1	RP5-1021I20.1	5.5	6.11e-08	2.13e-05	0.28	0.25	Blood protein levels;	chr14:74013601	chr14:73787360~73803270:+
HNSC	cis	rs7777677	0.925	rs4726542	ENSG00000244273.1	PGBD4P1	-5.5	6.11e-08	2.13e-05	-0.26	-0.25	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142722358~142722764:+
HNSC	cis	rs67981189	0.529	rs2526868	ENSG00000274818.1	RP1-292L20.3	-5.5	6.12e-08	2.13e-05	-0.3	-0.25	Schizophrenia;	chr14:70923672	chr14:70906657~70907111:-
HNSC	cis	rs7829975	1	rs7829975	ENSG00000254153.1	CTA-398F10.2	-5.5	6.12e-08	2.13e-05	-0.28	-0.25	Mood instability;	chr8:8690607	chr8:8456909~8461337:-
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000254153.1	CTA-398F10.2	5.5	6.12e-08	2.13e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9014200	chr8:8456909~8461337:-
HNSC	cis	rs9840812	0.592	rs1711161	ENSG00000239213.4	NCK1-AS1	5.5	6.12e-08	2.13e-05	0.23	0.25	Fibrinogen levels;	chr3:136361695	chr3:136841726~136862054:-
HNSC	cis	rs10256972	0.9	rs7812072	ENSG00000225146.1	AC073957.15	5.5	6.13e-08	2.13e-05	0.29	0.25	Endometriosis;Longevity;	chr7:1014226	chr7:1029025~1043891:+
HNSC	cis	rs12701220	0.894	rs8591	ENSG00000229043.2	AC091729.9	-5.5	6.13e-08	2.13e-05	-0.35	-0.25	Bronchopulmonary dysplasia;	chr7:997163	chr7:1160374~1165267:+
HNSC	cis	rs4713118	0.662	rs149961	ENSG00000204709.4	LINC01556	5.5	6.13e-08	2.13e-05	0.34	0.25	Parkinson's disease;	chr6:28047791	chr6:28943877~28944537:+
HNSC	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	5.5	6.14e-08	2.14e-05	0.27	0.25	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
HNSC	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-5.5	6.15e-08	2.14e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-5.5	6.15e-08	2.14e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
HNSC	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-5.5	6.15e-08	2.14e-05	-0.35	-0.25	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-5.5	6.15e-08	2.14e-05	-0.35	-0.25	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-5.5	6.15e-08	2.14e-05	-0.35	-0.25	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
HNSC	cis	rs763567	0.605	rs647438	ENSG00000271811.1	RP1-79C4.4	-5.5	6.15e-08	2.14e-05	-0.26	-0.25	Tonsillectomy;	chr1:170608094	chr1:170667381~170669425:+
HNSC	cis	rs12468226	0.873	rs1474267	ENSG00000226261.1	AC064836.3	-5.5	6.16e-08	2.14e-05	-0.38	-0.25	Urate levels;	chr2:202178596	chr2:202336024~202336727:-
HNSC	cis	rs35306767	0.953	rs10904583	ENSG00000229869.1	RP11-363N22.2	-5.5	6.16e-08	2.14e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:937558	chr10:933026~942743:+
HNSC	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-5.5	6.16e-08	2.14e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
HNSC	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	5.5	6.16e-08	2.14e-05	0.33	0.25	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
HNSC	cis	rs6928977	0.932	rs11154798	ENSG00000231028.7	LINC00271	-5.5	6.16e-08	2.15e-05	-0.28	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311487	chr6:135497801~135716055:+
HNSC	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-5.5	6.16e-08	2.15e-05	-0.29	-0.25	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
HNSC	cis	rs8012947	0.565	rs4901852	ENSG00000279636.2	LINC00216	5.5	6.16e-08	2.15e-05	0.26	0.25	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58288033~58289158:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-5.5	6.17e-08	2.15e-05	-0.22	-0.25	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
HNSC	cis	rs1355223	0.768	rs11032806	ENSG00000271369.1	RP11-350D17.3	-5.5	6.17e-08	2.15e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670758	chr11:34709600~34710161:+
HNSC	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-5.5	6.17e-08	2.15e-05	-0.28	-0.25	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	5.5	6.17e-08	2.15e-05	0.26	0.25	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
HNSC	cis	rs2439831	0.681	rs498837	ENSG00000205771.5	CATSPER2P1	-5.5	6.18e-08	2.15e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43315826	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.681	rs1095386	ENSG00000205771.5	CATSPER2P1	-5.5	6.18e-08	2.15e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43317311	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-5.5	6.18e-08	2.15e-05	-0.22	-0.25	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
HNSC	cis	rs7048146	0.531	rs12554939	ENSG00000213539.4	YBX1P6	5.5	6.18e-08	2.15e-05	0.33	0.25	Vascular brain injury;	chr9:109529001	chr9:109532830~109534332:-
HNSC	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	5.5	6.19e-08	2.15e-05	0.29	0.25	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-5.5	6.19e-08	2.15e-05	-0.29	-0.25	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
HNSC	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	5.5	6.2e-08	2.16e-05	0.2	0.25	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
HNSC	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	5.5	6.2e-08	2.16e-05	0.3	0.25	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.5	rs7841082	ENSG00000173295.6	FAM86B3P	-5.5	6.2e-08	2.16e-05	-0.28	-0.25	Mood instability;	chr8:8311465	chr8:8228595~8244865:+
HNSC	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-5.5	6.2e-08	2.16e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
HNSC	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-5.5	6.2e-08	2.16e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
HNSC	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-5.5	6.2e-08	2.16e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	5.5	6.21e-08	2.16e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
HNSC	cis	rs4218	0.734	rs12912071	ENSG00000259732.1	RP11-59H7.3	-5.5	6.21e-08	2.16e-05	-0.31	-0.25	Social communication problems;	chr15:59150951	chr15:59121034~59133250:+
HNSC	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-5.5	6.21e-08	2.16e-05	-0.3	-0.25	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
HNSC	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-5.5	6.21e-08	2.16e-05	-0.22	-0.25	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
HNSC	cis	rs950776	0.695	rs8025188	ENSG00000261762.1	RP11-650L12.2	-5.5	6.22e-08	2.16e-05	-0.28	-0.25	Sudden cardiac arrest;	chr15:78619936	chr15:78589123~78591276:-
HNSC	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	5.5	6.23e-08	2.16e-05	0.27	0.25	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
HNSC	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-5.5	6.23e-08	2.16e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
HNSC	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	5.5	6.23e-08	2.17e-05	0.18	0.25	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
HNSC	cis	rs2255336	0.938	rs10161486	ENSG00000245648.1	RP11-277P12.20	-5.5	6.24e-08	2.17e-05	-0.4	-0.25	Blood protein levels;	chr12:10457167	chr12:10363769~10398506:+
HNSC	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	5.5	6.24e-08	2.17e-05	0.26	0.25	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
HNSC	cis	rs944990	0.576	rs3933795	ENSG00000227603.1	RP11-165J3.6	5.5	6.25e-08	2.17e-05	0.21	0.25	Body mass index;	chr9:93423391	chr9:93435332~93437121:-
HNSC	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	5.5	6.25e-08	2.17e-05	0.26	0.25	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
HNSC	cis	rs9987353	0.589	rs1053036	ENSG00000254340.1	RP11-10A14.3	-5.5	6.25e-08	2.17e-05	-0.31	-0.25	Recombination measurement;	chr8:9202567	chr8:9141424~9145435:+
HNSC	cis	rs2985684	0.625	rs4900931	ENSG00000278009.1	RP11-649E7.8	5.5	6.25e-08	2.17e-05	0.32	0.25	Carotid intima media thickness;	chr14:49556075	chr14:49601011~49601124:-
HNSC	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-5.5	6.25e-08	2.17e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-5.5	6.25e-08	2.17e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-5.5	6.26e-08	2.17e-05	-0.15	-0.25	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
HNSC	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	5.5	6.26e-08	2.17e-05	0.28	0.25	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
HNSC	cis	rs9311676	0.502	rs4681676	ENSG00000273493.1	RP11-80H18.4	-5.5	6.26e-08	2.18e-05	-0.31	-0.25	Systemic lupus erythematosus;	chr3:58314070	chr3:58329965~58330118:+
HNSC	cis	rs7610312	0.681	rs6445969	ENSG00000273493.1	RP11-80H18.4	-5.5	6.26e-08	2.18e-05	-0.31	-0.25	Red blood cell count;	chr3:58315609	chr3:58329965~58330118:+
HNSC	cis	rs7610312	0.681	rs4681677	ENSG00000273493.1	RP11-80H18.4	-5.5	6.26e-08	2.18e-05	-0.31	-0.25	Red blood cell count;	chr3:58316313	chr3:58329965~58330118:+
HNSC	cis	rs6928977	0.932	rs11154799	ENSG00000231028.7	LINC00271	5.5	6.26e-08	2.18e-05	0.29	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311511	chr6:135497801~135716055:+
HNSC	cis	rs13113518	1	rs4864994	ENSG00000249700.7	SRD5A3-AS1	5.5	6.26e-08	2.18e-05	0.29	0.25	Height;	chr4:55451955	chr4:55363971~55395847:-
HNSC	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	5.5	6.27e-08	2.18e-05	0.21	0.25	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
HNSC	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	5.5	6.27e-08	2.18e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
HNSC	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-5.5	6.27e-08	2.18e-05	-0.43	-0.25	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
HNSC	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	5.5	6.28e-08	2.18e-05	0.31	0.25	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
HNSC	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-5.5	6.28e-08	2.18e-05	-0.31	-0.25	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
HNSC	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	5.5	6.28e-08	2.18e-05	0.25	0.25	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
HNSC	cis	rs17428076	0.793	rs3765167	ENSG00000228389.1	AC068039.4	-5.5	6.28e-08	2.18e-05	-0.3	-0.25	Myopia;	chr2:171837434	chr2:171773482~171775844:+
HNSC	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	5.5	6.3e-08	2.19e-05	0.28	0.25	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
HNSC	cis	rs2439831	0.681	rs3742971	ENSG00000205771.5	CATSPER2P1	5.5	6.3e-08	2.19e-05	0.39	0.25	Lung cancer in ever smokers;	chr15:43330718	chr15:43726918~43747094:-
HNSC	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	5.5	6.3e-08	2.19e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
HNSC	cis	rs804280	0.509	rs12719915	ENSG00000206014.6	OR7E161P	5.5	6.31e-08	2.19e-05	0.26	0.25	Myopia (pathological);	chr8:11928746	chr8:11928597~11929563:-
HNSC	cis	rs9840812	0.637	rs667920	ENSG00000239213.4	NCK1-AS1	5.5	6.31e-08	2.19e-05	0.23	0.25	Fibrinogen levels;	chr3:136350630	chr3:136841726~136862054:-
HNSC	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	5.5	6.31e-08	2.19e-05	0.3	0.25	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	5.5	6.31e-08	2.19e-05	0.3	0.25	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	5.5	6.31e-08	2.19e-05	0.3	0.25	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	5.5	6.32e-08	2.19e-05	0.22	0.25	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
HNSC	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	5.5	6.33e-08	2.2e-05	0.49	0.25	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
HNSC	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-5.5	6.33e-08	2.2e-05	-0.36	-0.25	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
HNSC	cis	rs9992667	0.955	rs1962053	ENSG00000231160.8	KLF3-AS1	5.5	6.33e-08	2.2e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38610736	chr4:38612701~38664883:-
HNSC	cis	rs4535700	0.501	rs10245725	ENSG00000226278.1	PSPHP1	-5.5	6.33e-08	2.2e-05	-0.29	-0.25	Macular telangiectasia type 2;	chr7:55908855	chr7:55764797~55773288:+
HNSC	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	5.5	6.34e-08	2.2e-05	0.3	0.25	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
HNSC	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	5.5	6.34e-08	2.2e-05	0.35	0.25	Height;	chr6:109708527	chr6:109382795~109383666:+
HNSC	cis	rs2243480	1	rs383402	ENSG00000179406.6	LINC00174	5.5	6.35e-08	2.2e-05	0.51	0.25	Diabetic kidney disease;	chr7:66121666	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.515	rs7630575	ENSG00000241288.6	RP11-379B18.5	-5.5	6.36e-08	2.21e-05	-0.32	-0.25	Blood pressure (smoking interaction);	chr3:125963487	chr3:125827238~125916384:-
HNSC	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	5.5	6.36e-08	2.21e-05	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
HNSC	cis	rs10435719	0.744	rs11250175	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13279577	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	Neuroticism;	chr8:11935587	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs10112958	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	Neuroticism;	chr8:11935631	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs10113042	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	Neuroticism;	chr8:11935669	chr8:11928597~11929563:-
HNSC	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	5.5	6.36e-08	2.21e-05	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
HNSC	cis	rs9840812	0.598	rs33999043	ENSG00000273486.1	RP11-731C17.2	5.5	6.36e-08	2.21e-05	0.25	0.25	Fibrinogen levels;	chr3:136381198	chr3:136837338~136839021:-
HNSC	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-5.5	6.37e-08	2.21e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
HNSC	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-5.5	6.37e-08	2.21e-05	-0.33	-0.25	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
HNSC	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-5.5	6.38e-08	2.21e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
HNSC	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-5.5	6.38e-08	2.21e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
HNSC	cis	rs12817211	0.502	rs34167640	ENSG00000272368.2	RP4-605O3.4	-5.5	6.38e-08	2.21e-05	-0.24	-0.25	Colorectal or endometrial cancer;	chr12:50123208	chr12:50112197~50165618:+
HNSC	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	5.5	6.38e-08	2.21e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
HNSC	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	5.5	6.38e-08	2.21e-05	0.6	0.25	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	5.5	6.38e-08	2.21e-05	0.6	0.25	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
HNSC	cis	rs4713118	0.629	rs203889	ENSG00000204709.4	LINC01556	5.5	6.38e-08	2.21e-05	0.34	0.25	Parkinson's disease;	chr6:28053997	chr6:28943877~28944537:+
HNSC	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-5.5	6.38e-08	2.21e-05	-0.27	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
HNSC	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-5.5	6.39e-08	2.22e-05	-0.26	-0.25	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-5.5	6.39e-08	2.22e-05	-0.26	-0.25	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-5.5	6.39e-08	2.22e-05	-0.26	-0.25	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
HNSC	cis	rs889014	0.679	rs4868287	ENSG00000253768.1	CTB-33O18.1	5.5	6.39e-08	2.22e-05	0.27	0.25	Height;	chr5:173552624	chr5:173562478~173573199:+
HNSC	cis	rs4535700	0.501	rs9642405	ENSG00000226278.1	PSPHP1	5.5	6.39e-08	2.22e-05	0.29	0.25	Macular telangiectasia type 2;	chr7:55910473	chr7:55764797~55773288:+
HNSC	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	5.5	6.4e-08	2.22e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	5.5	6.4e-08	2.22e-05	0.27	0.25	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	5.5	6.4e-08	2.22e-05	0.27	0.25	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs1186716	ENSG00000197085.10	NPSR1-AS1	-5.5	6.4e-08	2.22e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:34931073	chr7:34346512~34871582:-
HNSC	cis	rs10504130	0.66	rs6473666	ENSG00000253844.1	RP11-546K22.1	-5.5	6.4e-08	2.22e-05	-0.34	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51961458~52022974:+
HNSC	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	5.5	6.41e-08	2.22e-05	0.33	0.25	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
HNSC	cis	rs2179367	0.632	rs11155640	ENSG00000216906.2	RP11-350J20.9	5.5	6.41e-08	2.22e-05	0.36	0.25	Dupuytren's disease;	chr6:149323648	chr6:149904243~149906418:+
HNSC	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	5.5	6.41e-08	2.22e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
HNSC	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	5.5	6.41e-08	2.22e-05	0.26	0.25	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
HNSC	cis	rs10463554	0.501	rs6860813	ENSG00000175749.11	EIF3KP1	5.5	6.41e-08	2.22e-05	0.31	0.25	Parkinson's disease;	chr5:103353125	chr5:103032376~103033031:+
HNSC	cis	rs2976388	0.625	rs2257840	ENSG00000253741.1	CTD-2292P10.4	-5.5	6.42e-08	2.23e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142727775	chr8:142702252~142726973:-
HNSC	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-5.5	6.42e-08	2.23e-05	-0.27	-0.25	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
HNSC	cis	rs17428076	0.793	rs3765166	ENSG00000228389.1	AC068039.4	-5.5	6.42e-08	2.23e-05	-0.3	-0.25	Myopia;	chr2:171837270	chr2:171773482~171775844:+
HNSC	cis	rs5753618	0.561	rs5749265	ENSG00000236132.1	CTA-440B3.1	-5.5	6.43e-08	2.23e-05	-0.31	-0.25	Colorectal cancer;	chr22:31400911	chr22:31816379~31817491:-
HNSC	cis	rs11648785	0.735	rs12926012	ENSG00000222019.6	URAHP	5.5	6.43e-08	2.23e-05	0.26	0.25	Tanning;	chr16:90029595	chr16:90039761~90047773:-
HNSC	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	5.5	6.43e-08	2.23e-05	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	5.5	6.43e-08	2.23e-05	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
HNSC	cis	rs3930017	0.513	rs3930018	ENSG00000242435.1	UPK3BP1	5.49	6.45e-08	2.23e-05	0.29	0.25	Body mass index;	chr7:77091318	chr7:77004662~77005774:+
HNSC	cis	rs13126694	0.744	rs28635553	ENSG00000248429.4	RP11-597D13.9	5.49	6.45e-08	2.24e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158010962	chr4:158170752~158202877:+
HNSC	cis	rs7811142	1	rs7803454	ENSG00000078319.8	PMS2P1	-5.49	6.46e-08	2.24e-05	-0.32	-0.25	Platelet count;	chr7:100393925	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs11769886	ENSG00000078319.8	PMS2P1	-5.49	6.46e-08	2.24e-05	-0.32	-0.25	Platelet count;	chr7:100400984	chr7:100320992~100341908:-
HNSC	cis	rs11098499	0.697	rs35280960	ENSG00000249244.1	RP11-548H18.2	5.49	6.46e-08	2.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119335904	chr4:119391831~119395335:-
HNSC	cis	rs925255	0.776	rs2279990	ENSG00000270210.1	RP11-373D23.3	5.49	6.47e-08	2.24e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28413873	chr2:28425945~28426719:+
HNSC	cis	rs2337406	0.538	rs2015470	ENSG00000211974.3	IGHV2-70	-5.49	6.47e-08	2.24e-05	-0.27	-0.25	Alzheimer's disease (late onset);	chr14:106631885	chr14:106723574~106724093:-
HNSC	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	5.49	6.48e-08	2.24e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
HNSC	cis	rs2235642	0.507	rs2235645	ENSG00000280231.1	LA16c-380F5.3	-5.49	6.48e-08	2.24e-05	-0.33	-0.25	Coronary artery disease;	chr16:1547923	chr16:1553655~1554130:-
HNSC	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	5.49	6.48e-08	2.24e-05	0.27	0.25	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
HNSC	cis	rs11089937	0.895	rs5756985	ENSG00000211639.2	IGLV4-60	5.49	6.48e-08	2.25e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22162199~22162681:+
HNSC	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-5.49	6.49e-08	2.25e-05	-0.35	-0.25	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
HNSC	cis	rs67981189	0.529	rs2526872	ENSG00000274818.1	RP1-292L20.3	-5.49	6.49e-08	2.25e-05	-0.3	-0.25	Schizophrenia;	chr14:70918168	chr14:70906657~70907111:-
HNSC	cis	rs1908814	0.516	rs13252853	ENSG00000206014.6	OR7E161P	-5.49	6.49e-08	2.25e-05	-0.27	-0.25	Neuroticism;	chr8:11935465	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13252854	ENSG00000206014.6	OR7E161P	-5.49	6.49e-08	2.25e-05	-0.27	-0.25	Neuroticism;	chr8:11935469	chr8:11928597~11929563:-
HNSC	cis	rs1021993	1	rs1507341	ENSG00000231648.1	RP11-372M18.2	5.49	6.49e-08	2.25e-05	0.34	0.25	Gut microbiome composition (winter);	chr1:209299505	chr1:209367662~209379690:+
HNSC	cis	rs526231	0.67	rs253756	ENSG00000175749.11	EIF3KP1	5.49	6.49e-08	2.25e-05	0.31	0.25	Primary biliary cholangitis;	chr5:103284771	chr5:103032376~103033031:+
HNSC	cis	rs9611519	0.78	rs9611542	ENSG00000235513.1	RP4-756G23.5	5.49	6.49e-08	2.25e-05	0.27	0.25	Neuroticism;	chr22:41281313	chr22:41209122~41217627:-
HNSC	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
HNSC	cis	rs1355223	0.867	rs7944030	ENSG00000271369.1	RP11-350D17.3	-5.49	6.51e-08	2.25e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670191	chr11:34709600~34710161:+
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-5.49	6.51e-08	2.25e-05	-0.17	-0.25	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-5.49	6.51e-08	2.25e-05	-0.17	-0.25	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
HNSC	cis	rs5753618	0.583	rs5749268	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.31	-0.25	Colorectal cancer;	chr22:31413166	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs34545960	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.31	-0.25	Colorectal cancer;	chr22:31416476	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs5749270	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.31	-0.25	Colorectal cancer;	chr22:31416867	chr22:31816379~31817491:-
HNSC	cis	rs1012068	0.581	rs5753817	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31917741	chr22:31816379~31817491:-
HNSC	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-5.49	6.51e-08	2.26e-05	-0.2	-0.25	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000254153.1	CTA-398F10.2	5.49	6.52e-08	2.26e-05	0.27	0.25	Neuroticism;	chr8:8237204	chr8:8456909~8461337:-
HNSC	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	5.49	6.52e-08	2.26e-05	0.26	0.25	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
HNSC	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	5.49	6.53e-08	2.26e-05	0.29	0.25	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	5.49	6.53e-08	2.26e-05	0.29	0.25	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
HNSC	cis	rs9813712	0.953	rs9871734	ENSG00000249846.5	RP11-77P16.4	5.49	6.53e-08	2.26e-05	0.28	0.25	Response to amphetamines;	chr3:130240756	chr3:130112550~130120579:+
HNSC	cis	rs2742234	0.541	rs10899779	ENSG00000273008.1	RP11-351D16.3	5.49	6.53e-08	2.26e-05	0.33	0.25	Hirschsprung disease;	chr10:43228528	chr10:43136824~43138334:-
HNSC	cis	rs13113518	0.783	rs12504300	ENSG00000273257.1	RP11-177J6.1	5.49	6.54e-08	2.26e-05	0.32	0.25	Height;	chr4:55482360	chr4:55387949~55388271:+
HNSC	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	5.49	6.54e-08	2.26e-05	0.28	0.25	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
HNSC	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-5.49	6.55e-08	2.27e-05	-0.28	-0.25	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
HNSC	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	5.49	6.55e-08	2.27e-05	0.3	0.25	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
HNSC	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-5.49	6.55e-08	2.27e-05	-0.28	-0.25	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
HNSC	cis	rs2810114	0.916	rs2526851	ENSG00000274818.1	RP1-292L20.3	-5.49	6.56e-08	2.27e-05	-0.3	-0.25	Alcohol dependence;	chr14:70949563	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.529	rs2526850	ENSG00000274818.1	RP1-292L20.3	-5.49	6.56e-08	2.27e-05	-0.3	-0.25	Schizophrenia;	chr14:70950532	chr14:70906657~70907111:-
HNSC	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-5.49	6.56e-08	2.27e-05	-0.29	-0.25	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
HNSC	cis	rs1908814	0.51	rs57655799	ENSG00000206014.6	OR7E161P	-5.49	6.57e-08	2.27e-05	-0.26	-0.25	Neuroticism;	chr8:11924908	chr8:11928597~11929563:-
HNSC	cis	rs36093844	0.747	rs17817314	ENSG00000279742.1	RP11-700A24.1	-5.49	6.57e-08	2.27e-05	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85883929	chr11:85852557~85854943:-
HNSC	cis	rs2579103	1	rs1438994	ENSG00000258183.4	RP11-753N8.1	-5.49	6.58e-08	2.28e-05	-0.33	-0.25	Body mass index;	chr12:90200612	chr12:90280894~90300340:+
HNSC	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	5.49	6.58e-08	2.28e-05	0.42	0.25	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
HNSC	cis	rs2834288	0.5	rs2051189	ENSG00000273102.1	AP000569.9	5.49	6.59e-08	2.28e-05	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33967101~33968573:-
HNSC	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-5.49	6.59e-08	2.28e-05	-0.32	-0.25	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-5.49	6.59e-08	2.28e-05	-0.32	-0.25	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
HNSC	cis	rs9525927	0.625	rs9567395	ENSG00000227258.4	SMIM2-AS1	5.49	6.6e-08	2.28e-05	0.38	0.25	Dupuytren's disease;	chr13:44249337	chr13:44110451~44240517:+
HNSC	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
HNSC	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
HNSC	cis	rs3738443	0.594	rs60050650	ENSG00000259865.1	RP11-488L18.10	5.49	6.6e-08	2.28e-05	0.2	0.25	Alcohol dependence;	chr1:247213474	chr1:247187281~247188526:-
HNSC	cis	rs9402743	0.632	rs9389329	ENSG00000217482.2	HMGB1P17	-5.49	6.61e-08	2.28e-05	-0.26	-0.25	Systemic lupus erythematosus;	chr6:135777966	chr6:135636086~135636713:-
HNSC	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-5.49	6.62e-08	2.29e-05	-0.31	-0.25	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
HNSC	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-5.49	6.62e-08	2.29e-05	-0.24	-0.25	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
HNSC	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	5.49	6.62e-08	2.29e-05	0.32	0.25	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
HNSC	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
HNSC	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-5.49	6.63e-08	2.29e-05	-0.29	-0.25	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
HNSC	cis	rs11723261	0.664	rs4627799	ENSG00000211553.1	AC253576.2	-5.49	6.63e-08	2.29e-05	-0.35	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:136461~136568:+
HNSC	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-5.49	6.63e-08	2.29e-05	-0.4	-0.25	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
HNSC	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	5.49	6.63e-08	2.29e-05	0.35	0.25	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
HNSC	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	5.49	6.64e-08	2.3e-05	0.36	0.25	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
HNSC	cis	rs867371	0.929	rs1045508	ENSG00000259429.4	UBE2Q2P2	5.49	6.65e-08	2.3e-05	0.23	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82355142~82420075:+
HNSC	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	5.49	6.66e-08	2.3e-05	0.33	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
HNSC	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-5.49	6.67e-08	2.3e-05	-0.31	-0.25	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
HNSC	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	5.49	6.67e-08	2.31e-05	0.24	0.25	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
HNSC	cis	rs11976020	1	rs11976020	ENSG00000225648.4	SBDSP1	-5.49	6.67e-08	2.31e-05	-0.29	-0.25	Educational attainment (years of education);	chr7:72782785	chr7:72829425~72836701:+
HNSC	cis	rs2243480	1	rs160646	ENSG00000179406.6	LINC00174	-5.49	6.67e-08	2.31e-05	-0.51	-0.25	Diabetic kidney disease;	chr7:66091293	chr7:66376044~66401338:-
HNSC	cis	rs13073817	0.563	rs949606	ENSG00000228956.7	SATB1-AS1	5.49	6.67e-08	2.31e-05	0.26	0.25	Crohn's disease;	chr3:18628685	chr3:18445024~18920401:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66189722	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2420170	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66191066	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6958289	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66192124	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7804223	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66199572	chr7:66376044~66401338:-
HNSC	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-5.49	6.68e-08	2.31e-05	-0.4	-0.25	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
HNSC	cis	rs9914544	1	rs1634409	ENSG00000264885.1	RP11-815I9.4	-5.49	6.69e-08	2.31e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18932864	chr17:18667629~18669461:-
HNSC	cis	rs11846409	0.86	rs73378154	ENSG00000274576.2	IGHV2-70	-5.49	6.69e-08	2.31e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106637687	chr14:106770577~106771020:-
HNSC	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-5.49	6.7e-08	2.31e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-5.49	6.7e-08	2.31e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
HNSC	cis	rs4968361	0.892	rs67028302	ENSG00000266992.1	DHX40P1	5.49	6.7e-08	2.31e-05	0.44	0.25	Schizophrenia;	chr17:59443342	chr17:59976009~60002384:-
HNSC	cis	rs860295	0.756	rs7546258	ENSG00000203761.5	MSTO2P	-5.49	6.7e-08	2.31e-05	-0.19	-0.25	Body mass index;	chr1:155728854	chr1:155745829~155750137:+
HNSC	cis	rs453301	0.597	rs7001187	ENSG00000233609.3	RP11-62H7.2	-5.49	6.7e-08	2.31e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:8935272	chr8:8961200~8979025:+
HNSC	cis	rs2834288	0.734	rs9984514	ENSG00000237945.6	LINC00649	5.49	6.7e-08	2.31e-05	0.31	0.25	Gut microbiota (bacterial taxa);	chr21:33892370	chr21:33915534~33977691:+
HNSC	cis	rs7819412	1	rs7819412	ENSG00000269918.1	AF131215.9	5.49	6.71e-08	2.32e-05	0.24	0.25	Triglycerides;	chr8:11187652	chr8:11104691~11106704:-
HNSC	cis	rs2439831	0.681	rs3742969	ENSG00000205771.5	CATSPER2P1	-5.49	6.71e-08	2.32e-05	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43329749	chr15:43726918~43747094:-
HNSC	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	5.49	6.71e-08	2.32e-05	0.29	0.25	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
HNSC	cis	rs71520386	0.607	rs4308627	ENSG00000221740.1	SNORD93	-5.49	6.71e-08	2.32e-05	-0.29	-0.25	Fibrinogen levels;	chr7:22840285	chr7:22856613~22856686:+
HNSC	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-5.49	6.71e-08	2.32e-05	-0.24	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
HNSC	cis	rs13126694	0.649	rs4615226	ENSG00000248429.4	RP11-597D13.9	5.49	6.72e-08	2.32e-05	0.27	0.25	Blood osmolality (transformed sodium);	chr4:157979297	chr4:158170752~158202877:+
HNSC	cis	rs5758659	0.935	rs134879	ENSG00000227370.1	RP4-669P10.19	-5.49	6.74e-08	2.33e-05	-0.24	-0.25	Cognitive function;	chr22:42268195	chr22:42132543~42132998:+
HNSC	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	5.49	6.74e-08	2.33e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
HNSC	cis	rs9329221	0.617	rs615632	ENSG00000254340.1	RP11-10A14.3	-5.49	6.74e-08	2.33e-05	-0.29	-0.25	Neuroticism;	chr8:9938811	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	5.49	6.74e-08	2.33e-05	0.31	0.25	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
HNSC	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-5.49	6.74e-08	2.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
HNSC	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-5.49	6.74e-08	2.33e-05	-0.31	-0.25	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
HNSC	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
HNSC	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	5.49	6.76e-08	2.33e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
HNSC	cis	rs61160187	0.582	rs4700407	ENSG00000215032.2	GNL3LP1	-5.49	6.76e-08	2.33e-05	-0.27	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60891935~60893577:-
HNSC	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-5.49	6.76e-08	2.33e-05	-0.21	-0.25	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
HNSC	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	5.49	6.76e-08	2.33e-05	0.33	0.25	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000223701.3	RAET1E-AS1	5.49	6.77e-08	2.33e-05	0.27	0.25	Lung cancer;	chr6:149863746	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	5.49	6.77e-08	2.33e-05	0.31	0.25	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	5.49	6.77e-08	2.33e-05	0.31	0.25	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
HNSC	cis	rs10027350	0.964	rs2302565	ENSG00000281501.1	SEPSECS-AS1	5.49	6.77e-08	2.34e-05	0.31	0.25	Childhood ear infection;	chr4:25144685	chr4:25160641~25201440:+
HNSC	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-5.49	6.77e-08	2.34e-05	-0.27	-0.25	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
HNSC	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-5.49	6.77e-08	2.34e-05	-0.31	-0.25	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
HNSC	cis	rs7615952	0.599	rs16834938	ENSG00000248787.1	RP11-666A20.4	-5.49	6.77e-08	2.34e-05	-0.34	-0.25	Blood pressure (smoking interaction);	chr3:125987203	chr3:125908005~125910272:-
HNSC	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-5.49	6.77e-08	2.34e-05	-0.26	-0.25	Height;	chr2:46629946	chr2:46668870~46670778:+
HNSC	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-5.49	6.77e-08	2.34e-05	-0.26	-0.25	Height;	chr2:46630262	chr2:46668870~46670778:+
HNSC	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-5.49	6.77e-08	2.34e-05	-0.26	-0.25	Height;	chr2:46631182	chr2:46668870~46670778:+
HNSC	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-5.49	6.78e-08	2.34e-05	-0.39	-0.25	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
HNSC	cis	rs7777677	0.925	rs6969951	ENSG00000244273.1	PGBD4P1	5.49	6.78e-08	2.34e-05	0.26	0.25	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142722358~142722764:+
HNSC	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	5.49	6.79e-08	2.34e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
HNSC	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	5.48	6.79e-08	2.34e-05	0.31	0.25	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
HNSC	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	5.48	6.79e-08	2.34e-05	0.25	0.25	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	5.48	6.79e-08	2.34e-05	0.25	0.25	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	5.48	6.8e-08	2.35e-05	0.22	0.25	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
HNSC	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-5.48	6.81e-08	2.35e-05	-0.29	-0.25	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
HNSC	cis	rs10028773	0.632	rs34481394	ENSG00000249244.1	RP11-548H18.2	5.48	6.81e-08	2.35e-05	0.31	0.25	Educational attainment;	chr4:119327219	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.666	rs35231872	ENSG00000249244.1	RP11-548H18.2	5.48	6.81e-08	2.35e-05	0.31	0.25	Educational attainment;	chr4:119327221	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.7	rs35653026	ENSG00000249244.1	RP11-548H18.2	5.48	6.81e-08	2.35e-05	0.31	0.25	Educational attainment;	chr4:119327223	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	5.48	6.82e-08	2.35e-05	0.33	0.25	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
HNSC	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-5.48	6.82e-08	2.35e-05	-0.26	-0.25	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
HNSC	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	5.48	6.82e-08	2.35e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
HNSC	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	5.48	6.83e-08	2.35e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
HNSC	cis	rs7824557	0.524	rs7835318	ENSG00000255310.2	AF131215.2	-5.48	6.83e-08	2.35e-05	-0.23	-0.25	Retinal vascular caliber;	chr8:11096364	chr8:11107788~11109726:-
HNSC	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	5.48	6.84e-08	2.36e-05	0.18	0.25	Breast size;	chr12:9232939	chr12:9277235~9313241:+
HNSC	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	6.84e-08	2.36e-05	-0.27	-0.25	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
HNSC	cis	rs9611519	0.78	rs9611546	ENSG00000235513.1	RP4-756G23.5	5.48	6.85e-08	2.36e-05	0.27	0.25	Neuroticism;	chr22:41302538	chr22:41209122~41217627:-
HNSC	cis	rs9326248	0.53	rs2471884	ENSG00000280143.1	AP000892.6	5.48	6.85e-08	2.36e-05	0.37	0.25	Blood protein levels;	chr11:117139604	chr11:117204967~117210292:+
HNSC	cis	rs2439831	1	rs2584726	ENSG00000205771.5	CATSPER2P1	-5.48	6.86e-08	2.36e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43423184	chr15:43726918~43747094:-
HNSC	cis	rs7824557	0.505	rs2736313	ENSG00000255310.2	AF131215.2	5.48	6.86e-08	2.36e-05	0.24	0.25	Retinal vascular caliber;	chr8:11229433	chr8:11107788~11109726:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	5.48	6.86e-08	2.36e-05	0.26	0.25	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
HNSC	cis	rs11969893	0.85	rs9485417	ENSG00000270987.1	RP3-467N11.2	-5.48	6.87e-08	2.37e-05	-0.62	-0.25	Economic and political preferences (immigration/crime);	chr6:100852162	chr6:100889603~100890338:+
HNSC	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	5.48	6.87e-08	2.37e-05	0.23	0.25	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
HNSC	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	5.48	6.87e-08	2.37e-05	0.28	0.25	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	5.48	6.87e-08	2.37e-05	0.28	0.25	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
HNSC	cis	rs9326248	0.569	rs4938315	ENSG00000280143.1	AP000892.6	5.48	6.87e-08	2.37e-05	0.38	0.25	Blood protein levels;	chr11:116860489	chr11:117204967~117210292:+
HNSC	cis	rs11992162	0.933	rs10108075	ENSG00000206014.6	OR7E161P	-5.48	6.88e-08	2.37e-05	-0.27	-0.25	Monocyte count;	chr8:11974570	chr8:11928597~11929563:-
HNSC	cis	rs9611519	1	rs2273085	ENSG00000235513.1	RP4-756G23.5	5.48	6.88e-08	2.37e-05	0.26	0.25	Neuroticism;	chr22:41219372	chr22:41209122~41217627:-
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	5.48	6.89e-08	2.37e-05	0.29	0.25	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
HNSC	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-5.48	6.89e-08	2.37e-05	-0.22	-0.25	Height;	chr11:118773873	chr11:118791254~118793137:+
HNSC	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	5.48	6.89e-08	2.37e-05	0.28	0.25	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
HNSC	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	5.48	6.89e-08	2.37e-05	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	5.48	6.89e-08	2.37e-05	0.3	0.25	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
HNSC	cis	rs9987353	0.566	rs6998368	ENSG00000173295.6	FAM86B3P	-5.48	6.89e-08	2.37e-05	-0.29	-0.25	Recombination measurement;	chr8:9212778	chr8:8228595~8244865:+
HNSC	cis	rs2179367	0.632	rs56924465	ENSG00000216906.2	RP11-350J20.9	5.48	6.89e-08	2.37e-05	0.36	0.25	Dupuytren's disease;	chr6:149350270	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.568	rs62426092	ENSG00000216906.2	RP11-350J20.9	5.48	6.89e-08	2.37e-05	0.36	0.25	Dupuytren's disease;	chr6:149352720	chr6:149904243~149906418:+
HNSC	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-5.48	6.9e-08	2.38e-05	-0.26	-0.25	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
HNSC	cis	rs526231	0.764	rs599447	ENSG00000175749.11	EIF3KP1	5.48	6.91e-08	2.38e-05	0.31	0.25	Primary biliary cholangitis;	chr5:103302154	chr5:103032376~103033031:+
HNSC	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-5.48	6.91e-08	2.38e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
HNSC	cis	rs9650657	0.529	rs10108618	ENSG00000269918.1	AF131215.9	-5.48	6.91e-08	2.38e-05	-0.24	-0.25	Neuroticism;	chr8:11095582	chr8:11104691~11106704:-
HNSC	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	5.48	6.92e-08	2.38e-05	0.26	0.25	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
HNSC	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-5.48	6.92e-08	2.38e-05	-0.32	-0.25	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
HNSC	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	5.48	6.92e-08	2.38e-05	0.21	0.25	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
HNSC	cis	rs7674212	0.539	rs6850461	ENSG00000246560.2	RP11-10L12.4	5.48	6.92e-08	2.38e-05	0.28	0.25	Type 2 diabetes;	chr4:103198884	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.539	rs6533056	ENSG00000246560.2	RP11-10L12.4	5.48	6.92e-08	2.38e-05	0.28	0.25	Type 2 diabetes;	chr4:103199840	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.539	rs2866635	ENSG00000246560.2	RP11-10L12.4	5.48	6.92e-08	2.38e-05	0.28	0.25	Type 2 diabetes;	chr4:103200419	chr4:102828055~102844075:+
HNSC	cis	rs947583	0.71	rs6570045	ENSG00000217482.2	HMGB1P17	5.48	6.94e-08	2.39e-05	0.27	0.25	Phosphorus levels;	chr6:135815734	chr6:135636086~135636713:-
HNSC	cis	rs4713118	0.629	rs149899	ENSG00000204709.4	LINC01556	5.48	6.94e-08	2.39e-05	0.34	0.25	Parkinson's disease;	chr6:28052201	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.629	rs172165	ENSG00000204709.4	LINC01556	5.48	6.94e-08	2.39e-05	0.34	0.25	Parkinson's disease;	chr6:28053036	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.597	rs172166	ENSG00000204709.4	LINC01556	5.48	6.94e-08	2.39e-05	0.34	0.25	Parkinson's disease;	chr6:28053042	chr6:28943877~28944537:+
HNSC	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	6.94e-08	2.39e-05	-0.27	-0.25	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
HNSC	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-5.48	6.95e-08	2.39e-05	-0.24	-0.25	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
HNSC	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-5.48	6.96e-08	2.39e-05	-0.26	-0.25	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	5.48	6.96e-08	2.39e-05	0.27	0.25	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	5.48	6.96e-08	2.4e-05	0.14	0.25	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
HNSC	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-5.48	6.97e-08	2.4e-05	-0.31	-0.25	Depression;	chr6:28110254	chr6:28161781~28169594:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000254153.1	CTA-398F10.2	5.48	6.98e-08	2.4e-05	0.27	0.25	Mood instability;	chr8:8515975	chr8:8456909~8461337:-
HNSC	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
HNSC	cis	rs667920	0.512	rs13069695	ENSG00000273486.1	RP11-731C17.2	-5.48	6.99e-08	2.4e-05	-0.31	-0.25	Coronary artery disease;	chr3:136572720	chr3:136837338~136839021:-
HNSC	cis	rs860295	0.812	rs10908481	ENSG00000203761.5	MSTO2P	-5.48	6.99e-08	2.41e-05	-0.19	-0.25	Body mass index;	chr1:155743859	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.812	rs4278368	ENSG00000203761.5	MSTO2P	-5.48	6.99e-08	2.41e-05	-0.19	-0.25	Body mass index;	chr1:155752766	chr1:155745829~155750137:+
HNSC	cis	rs17428076	0.831	rs3821093	ENSG00000228389.1	AC068039.4	-5.48	7.02e-08	2.41e-05	-0.3	-0.25	Myopia;	chr2:171838077	chr2:171773482~171775844:+
HNSC	cis	rs2439831	0.764	rs12324584	ENSG00000205771.5	CATSPER2P1	-5.48	7.02e-08	2.41e-05	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43391248	chr15:43726918~43747094:-
HNSC	cis	rs651386	0.529	rs2206063	ENSG00000271811.1	RP1-79C4.4	-5.48	7.02e-08	2.41e-05	-0.27	-0.25	Atrial fibrillation;	chr1:170615956	chr1:170667381~170669425:+
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-5.48	7.03e-08	2.42e-05	-0.16	-0.25	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
HNSC	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	5.48	7.03e-08	2.42e-05	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
HNSC	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	5.48	7.03e-08	2.42e-05	0.34	0.25	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	5.48	7.03e-08	2.42e-05	0.34	0.25	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-5.48	7.03e-08	2.42e-05	-0.34	-0.25	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-5.48	7.03e-08	2.42e-05	-0.34	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-5.48	7.03e-08	2.42e-05	-0.34	-0.25	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
HNSC	cis	rs860295	0.557	rs11264372	ENSG00000203761.5	MSTO2P	-5.48	7.04e-08	2.42e-05	-0.19	-0.25	Body mass index;	chr1:155443139	chr1:155745829~155750137:+
HNSC	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-5.48	7.04e-08	2.42e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
HNSC	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
HNSC	cis	rs9813712	0.597	rs11711883	ENSG00000249846.5	RP11-77P16.4	-5.48	7.05e-08	2.42e-05	-0.26	-0.25	Response to amphetamines;	chr3:130241367	chr3:130112550~130120579:+
HNSC	cis	rs4938303	0.589	rs11601584	ENSG00000254851.1	RP11-109L13.1	5.48	7.06e-08	2.43e-05	0.35	0.25	Triglycerides;	chr11:116700568	chr11:117135528~117138582:+
HNSC	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-5.48	7.06e-08	2.43e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
HNSC	cis	rs9525927	0.625	rs9533802	ENSG00000227258.4	SMIM2-AS1	5.48	7.07e-08	2.43e-05	0.36	0.25	Dupuytren's disease;	chr13:44245923	chr13:44110451~44240517:+
HNSC	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	5.48	7.07e-08	2.43e-05	0.28	0.25	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
HNSC	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-5.48	7.08e-08	2.43e-05	-0.23	-0.25	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
HNSC	cis	rs9611519	0.964	rs20551	ENSG00000235513.1	RP4-756G23.5	5.48	7.08e-08	2.43e-05	0.28	0.25	Neuroticism;	chr22:41152004	chr22:41209122~41217627:-
HNSC	cis	rs5758659	1	rs134869	ENSG00000227370.1	RP4-669P10.19	-5.48	7.09e-08	2.43e-05	-0.24	-0.25	Cognitive function;	chr22:42256068	chr22:42132543~42132998:+
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-5.48	7.09e-08	2.44e-05	-0.16	-0.25	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
HNSC	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-5.48	7.1e-08	2.44e-05	-0.29	-0.25	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	5.48	7.1e-08	2.44e-05	0.27	0.25	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
HNSC	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	5.48	7.1e-08	2.44e-05	0.35	0.25	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
HNSC	cis	rs9402743	0.634	rs66513771	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135603885	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.634	rs7774974	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135604248	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.538	rs6570019	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135604595	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.564	rs6570020	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135604607	chr6:135636086~135636713:-
HNSC	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-5.48	7.11e-08	2.44e-05	-0.3	-0.25	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
HNSC	cis	rs9402743	0.634	rs7767072	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135593899	chr6:135636086~135636713:-
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-5.48	7.12e-08	2.44e-05	-0.16	-0.25	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-5.48	7.12e-08	2.44e-05	-0.16	-0.25	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-5.48	7.12e-08	2.44e-05	-0.14	-0.25	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
HNSC	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	5.48	7.12e-08	2.44e-05	0.37	0.25	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	5.48	7.12e-08	2.44e-05	0.37	0.25	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
HNSC	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-5.48	7.12e-08	2.44e-05	-0.27	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
HNSC	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-5.48	7.12e-08	2.45e-05	-0.34	-0.25	Depression;	chr6:28240414	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-5.48	7.12e-08	2.45e-05	-0.34	-0.25	Depression;	chr6:28240780	chr6:28115628~28116551:+
HNSC	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	5.48	7.13e-08	2.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	5.48	7.15e-08	2.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
HNSC	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-5.48	7.16e-08	2.46e-05	-0.27	-0.25	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
HNSC	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	5.47	7.16e-08	2.46e-05	0.41	0.25	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
HNSC	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	5.47	7.16e-08	2.46e-05	0.3	0.25	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
HNSC	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	5.47	7.17e-08	2.46e-05	0.25	0.25	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
HNSC	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-5.47	7.17e-08	2.46e-05	-0.23	-0.25	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
HNSC	cis	rs62344088	1	rs10042022	ENSG00000277812.1	AC021087.1	5.47	7.17e-08	2.46e-05	0.71	0.25	Asthma (childhood onset);	chr5:113956	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs76792440	ENSG00000277812.1	AC021087.1	5.47	7.17e-08	2.46e-05	0.71	0.25	Asthma (childhood onset);	chr5:114459	chr5:262769~262881:+
HNSC	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-5.47	7.18e-08	2.46e-05	-0.27	-0.25	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
HNSC	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	5.47	7.19e-08	2.47e-05	0.55	0.25	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000253893.2	FAM85B	-5.47	7.19e-08	2.47e-05	-0.29	-0.25	Systolic blood pressure;	chr8:8488264	chr8:8167819~8226614:-
HNSC	cis	rs4535700	0.501	rs60517461	ENSG00000226278.1	PSPHP1	5.47	7.19e-08	2.47e-05	0.29	0.25	Macular telangiectasia type 2;	chr7:55949952	chr7:55764797~55773288:+
HNSC	cis	rs442309	0.553	rs7088592	ENSG00000238280.1	RP11-436D10.3	-5.47	7.2e-08	2.47e-05	-0.31	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62721530	chr10:62793562~62805887:-
HNSC	cis	rs34421088	0.576	rs2572437	ENSG00000269918.1	AF131215.9	-5.47	7.2e-08	2.47e-05	-0.26	-0.25	Neuroticism;	chr8:11240932	chr8:11104691~11106704:-
HNSC	cis	rs11976180	1	rs7777389	ENSG00000273234.1	OR2A13P	-5.47	7.21e-08	2.47e-05	-0.28	-0.25	Obesity-related traits;	chr7:144047709	chr7:144142009~144142938:+
HNSC	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	5.47	7.22e-08	2.47e-05	0.25	0.25	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
HNSC	cis	rs6604026	0.555	rs36114576	ENSG00000223787.2	RP4-593M8.1	5.47	7.22e-08	2.48e-05	0.35	0.25	Multiple sclerosis;	chr1:92671999	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs11809055	ENSG00000223787.2	RP4-593M8.1	5.47	7.22e-08	2.48e-05	0.35	0.25	Multiple sclerosis;	chr1:92675107	chr1:92580476~92580821:-
HNSC	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	5.47	7.22e-08	2.48e-05	0.29	0.25	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
HNSC	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-5.47	7.23e-08	2.48e-05	-0.31	-0.25	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
HNSC	cis	rs9840812	0.559	rs6439640	ENSG00000273486.1	RP11-731C17.2	5.47	7.23e-08	2.48e-05	0.25	0.25	Fibrinogen levels;	chr3:136466838	chr3:136837338~136839021:-
HNSC	cis	rs4763879	0.634	rs2098298	ENSG00000256673.1	RP11-599J14.2	5.47	7.23e-08	2.48e-05	0.23	0.25	Type 1 diabetes;	chr12:9707473	chr12:9398355~9414851:-
HNSC	cis	rs4763879	0.594	rs12427310	ENSG00000256673.1	RP11-599J14.2	5.47	7.23e-08	2.48e-05	0.23	0.25	Type 1 diabetes;	chr12:9707539	chr12:9398355~9414851:-
HNSC	cis	rs10462794	0.661	rs16873568	ENSG00000260763.1	RP11-445O3.3	5.47	7.23e-08	2.48e-05	0.36	0.25	DNA methylation (variation);	chr5:4523737	chr5:4436850~4440259:-
HNSC	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	5.47	7.23e-08	2.48e-05	0.3	0.25	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
HNSC	cis	rs2115630	0.967	rs12595786	ENSG00000229212.6	RP11-561C5.4	5.47	7.24e-08	2.48e-05	0.28	0.25	P wave terminal force;	chr15:84793439	chr15:85205440~85234795:-
HNSC	cis	rs67981189	0.529	rs8010063	ENSG00000274818.1	RP1-292L20.3	5.47	7.24e-08	2.48e-05	0.3	0.25	Schizophrenia;	chr14:71043408	chr14:70906657~70907111:-
HNSC	cis	rs9987353	0.544	rs2929469	ENSG00000254340.1	RP11-10A14.3	5.47	7.24e-08	2.48e-05	0.31	0.25	Recombination measurement;	chr8:9205146	chr8:9141424~9145435:+
HNSC	cis	rs9914544	1	rs1634411	ENSG00000264885.1	RP11-815I9.4	-5.47	7.24e-08	2.48e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18930497	chr17:18667629~18669461:-
HNSC	cis	rs2980439	0.525	rs2980508	ENSG00000254153.1	CTA-398F10.2	5.47	7.24e-08	2.48e-05	0.25	0.25	Neuroticism;	chr8:8314210	chr8:8456909~8461337:-
HNSC	cis	rs2337406	0.587	rs916547	ENSG00000254174.1	IGHV1-12	5.47	7.24e-08	2.48e-05	0.2	0.25	Alzheimer's disease (late onset);	chr14:106646735	chr14:106122420~106122709:-
HNSC	cis	rs7209700	0.547	rs61131650	ENSG00000228782.6	CTD-2026D20.3	-5.47	7.24e-08	2.48e-05	-0.27	-0.25	IgG glycosylation;	chr17:47266961	chr17:47450568~47492492:-
HNSC	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-5.47	7.25e-08	2.49e-05	-0.43	-0.25	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
HNSC	cis	rs9300255	0.568	rs1790090	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123148877	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs949142	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123149496	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs884548	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123149575	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs2695482	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123138627	chr12:123152324~123153377:-
HNSC	cis	rs603446	0.967	rs180350	ENSG00000254851.1	RP11-109L13.1	-5.47	7.26e-08	2.49e-05	-0.33	-0.25	Triglycerides;	chr11:116739332	chr11:117135528~117138582:+
HNSC	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	5.47	7.28e-08	2.5e-05	0.28	0.25	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
HNSC	cis	rs6604026	0.624	rs35038369	ENSG00000223787.2	RP4-593M8.1	5.47	7.28e-08	2.5e-05	0.34	0.25	Multiple sclerosis;	chr1:92765411	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11585590	ENSG00000223787.2	RP4-593M8.1	5.47	7.28e-08	2.5e-05	0.34	0.25	Multiple sclerosis;	chr1:92766823	chr1:92580476~92580821:-
HNSC	cis	rs7665090	0.87	rs228627	ENSG00000246560.2	RP11-10L12.4	-5.47	7.31e-08	2.5e-05	-0.28	-0.25	Primary biliary cholangitis;	chr4:102651925	chr4:102828055~102844075:+
HNSC	cis	rs13126694	0.744	rs4077776	ENSG00000248429.4	RP11-597D13.9	5.47	7.31e-08	2.5e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158008446	chr4:158170752~158202877:+
HNSC	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-5.47	7.32e-08	2.51e-05	-0.28	-0.25	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
HNSC	cis	rs7777677	0.925	rs73543808	ENSG00000244273.1	PGBD4P1	-5.47	7.32e-08	2.51e-05	-0.26	-0.25	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142722358~142722764:+
HNSC	cis	rs832187	0.629	rs7624403	ENSG00000280620.1	SCAANT1	5.47	7.33e-08	2.51e-05	0.3	0.25	Schizophrenia;	chr3:63984401	chr3:63911518~63911772:-
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000211972.2	IGHV3-66	5.47	7.33e-08	2.51e-05	0.18	0.25	Kawasaki disease;	chr14:106673171	chr14:106675017~106675544:-
HNSC	cis	rs1799949	0.587	rs1824890	ENSG00000267151.3	RP11-100E5.2	5.47	7.33e-08	2.51e-05	0.36	0.25	Menopause (age at onset);	chr17:43344536	chr17:43444707~43451200:+
HNSC	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-5.47	7.34e-08	2.51e-05	-0.29	-0.25	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
HNSC	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-5.47	7.34e-08	2.51e-05	-0.31	-0.25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
HNSC	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-5.47	7.34e-08	2.51e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
HNSC	cis	rs2985684	0.894	rs4900932	ENSG00000278009.1	RP11-649E7.8	5.47	7.35e-08	2.52e-05	0.32	0.25	Carotid intima media thickness;	chr14:49556210	chr14:49601011~49601124:-
HNSC	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-5.47	7.35e-08	2.52e-05	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
HNSC	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-5.47	7.35e-08	2.52e-05	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
HNSC	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-5.47	7.35e-08	2.52e-05	-0.31	-0.25	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
HNSC	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	5.47	7.36e-08	2.52e-05	0.36	0.25	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
HNSC	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
HNSC	cis	rs11846409	0.872	rs2516914	ENSG00000274576.2	IGHV2-70	5.47	7.38e-08	2.53e-05	0.24	0.25	Rheumatic heart disease;	chr14:106629835	chr14:106770577~106771020:-
HNSC	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	5.47	7.39e-08	2.53e-05	0.34	0.25	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
HNSC	cis	rs2742234	0.504	rs10899780	ENSG00000273008.1	RP11-351D16.3	5.47	7.4e-08	2.53e-05	0.33	0.25	Hirschsprung disease;	chr10:43230348	chr10:43136824~43138334:-
HNSC	cis	rs6928977	0.86	rs2614266	ENSG00000234084.1	RP3-388E23.2	5.47	7.4e-08	2.53e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135395394	chr6:135301568~135307158:+
HNSC	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	5.47	7.41e-08	2.53e-05	0.41	0.25	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
HNSC	cis	rs10466239	0.73	rs2460535	ENSG00000230555.2	RP11-517P14.2	5.47	7.41e-08	2.53e-05	0.32	0.25	Telomere length;	chr10:43325932	chr10:43420738~43422100:+
HNSC	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-5.47	7.41e-08	2.54e-05	-0.27	-0.25	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
HNSC	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	5.47	7.42e-08	2.54e-05	0.45	0.25	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
HNSC	cis	rs8040855	0.542	rs2342122	ENSG00000259774.1	RP11-182J1.13	-5.47	7.43e-08	2.54e-05	-0.31	-0.25	Bulimia nervosa;	chr15:85185304	chr15:84422618~84425882:+
HNSC	cis	rs8040855	0.644	rs2342120	ENSG00000259774.1	RP11-182J1.13	-5.47	7.43e-08	2.54e-05	-0.31	-0.25	Bulimia nervosa;	chr15:85185589	chr15:84422618~84425882:+
HNSC	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	5.47	7.43e-08	2.54e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
HNSC	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	5.47	7.43e-08	2.54e-05	0.31	0.25	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
HNSC	cis	rs7819412	0.668	rs920047	ENSG00000255310.2	AF131215.2	-5.47	7.43e-08	2.54e-05	-0.24	-0.25	Triglycerides;	chr8:11229966	chr8:11107788~11109726:-
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	5.47	7.44e-08	2.54e-05	0.22	0.25	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
HNSC	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
HNSC	cis	rs7617773	0.539	rs13087050	ENSG00000228638.1	FCF1P2	-5.47	7.44e-08	2.54e-05	-0.22	-0.25	Coronary artery disease;	chr3:48351310	chr3:48290793~48291375:-
HNSC	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-5.47	7.44e-08	2.54e-05	-0.2	-0.25	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
HNSC	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	5.47	7.44e-08	2.54e-05	0.3	0.25	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
HNSC	cis	rs3206736	0.548	rs73110562	ENSG00000197085.10	NPSR1-AS1	-5.47	7.45e-08	2.55e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35030311	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs10254796	ENSG00000197085.10	NPSR1-AS1	-5.47	7.45e-08	2.55e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35031323	chr7:34346512~34871582:-
HNSC	cis	rs1355223	0.902	rs1453387	ENSG00000271369.1	RP11-350D17.3	-5.47	7.45e-08	2.55e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34686351	chr11:34709600~34710161:+
HNSC	cis	rs2179367	0.632	rs12154153	ENSG00000216906.2	RP11-350J20.9	5.47	7.47e-08	2.55e-05	0.36	0.25	Dupuytren's disease;	chr6:149401686	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs55836833	ENSG00000216906.2	RP11-350J20.9	5.47	7.47e-08	2.55e-05	0.36	0.25	Dupuytren's disease;	chr6:149403736	chr6:149904243~149906418:+
HNSC	cis	rs10504130	0.569	rs34372756	ENSG00000272024.1	RP11-546K22.3	-5.47	7.48e-08	2.56e-05	-0.35	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51950284~51950690:+
HNSC	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-5.47	7.48e-08	2.56e-05	-0.32	-0.25	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-5.47	7.48e-08	2.56e-05	-0.32	-0.25	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-5.47	7.49e-08	2.56e-05	-0.28	-0.25	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-5.47	7.49e-08	2.56e-05	-0.28	-0.25	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-5.47	7.49e-08	2.56e-05	-0.28	-0.25	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
HNSC	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	5.47	7.49e-08	2.56e-05	0.18	0.25	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
HNSC	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-5.47	7.5e-08	2.56e-05	-0.28	-0.25	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
HNSC	cis	rs9987353	0.522	rs2929466	ENSG00000254340.1	RP11-10A14.3	-5.47	7.5e-08	2.56e-05	-0.3	-0.25	Recombination measurement;	chr8:9206389	chr8:9141424~9145435:+
HNSC	cis	rs11096990	0.891	rs61691409	ENSG00000249207.1	RP11-360F5.1	5.47	7.5e-08	2.56e-05	0.28	0.25	Cognitive function;	chr4:39243801	chr4:39112677~39126818:-
HNSC	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	5.47	7.5e-08	2.56e-05	0.24	0.25	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
HNSC	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-5.47	7.51e-08	2.56e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.66	rs9321508	ENSG00000234084.1	RP3-388E23.2	5.47	7.51e-08	2.57e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135556839	chr6:135301568~135307158:+
HNSC	cis	rs6714900	0.619	rs7580273	ENSG00000234896.1	OR7E62P	5.47	7.52e-08	2.57e-05	0.29	0.25	Blood protein levels;	chr2:71049568	chr2:71055527~71056003:+
HNSC	cis	rs11846409	0.86	rs61686131	ENSG00000274576.2	IGHV2-70	-5.47	7.52e-08	2.57e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106631568	chr14:106770577~106771020:-
HNSC	cis	rs8054556	0.787	rs3814877	ENSG00000183604.13	SMG1P5	-5.47	7.53e-08	2.57e-05	-0.24	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:30267553~30335374:-
HNSC	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	5.47	7.53e-08	2.57e-05	0.42	0.25	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
HNSC	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	5.47	7.54e-08	2.57e-05	0.3	0.25	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000179406.6	LINC00174	5.47	7.54e-08	2.58e-05	0.32	0.25	Calcium levels;	chr7:65733651	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	5.47	7.54e-08	2.58e-05	0.3	0.25	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
HNSC	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	5.47	7.54e-08	2.58e-05	0.3	0.25	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-5.47	7.55e-08	2.58e-05	-0.29	-0.25	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
HNSC	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	5.46	7.55e-08	2.58e-05	0.27	0.25	Height;	chr3:53073764	chr3:53064283~53065091:-
HNSC	cis	rs7674212	0.539	rs7676041	ENSG00000246560.2	RP11-10L12.4	5.46	7.55e-08	2.58e-05	0.28	0.25	Type 2 diabetes;	chr4:103205264	chr4:102828055~102844075:+
HNSC	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-5.46	7.55e-08	2.58e-05	-0.27	-0.25	Height;	chr3:53074760	chr3:53064283~53065091:-
HNSC	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	5.46	7.55e-08	2.58e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
HNSC	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
HNSC	cis	rs577676	0.533	rs10800529	ENSG00000271811.1	RP1-79C4.4	5.46	7.56e-08	2.58e-05	0.27	0.25	Prevalent atrial fibrillation;	chr1:170600902	chr1:170667381~170669425:+
HNSC	cis	rs4218	0.541	rs8030246	ENSG00000259732.1	RP11-59H7.3	-5.46	7.56e-08	2.58e-05	-0.33	-0.25	Social communication problems;	chr15:59049447	chr15:59121034~59133250:+
HNSC	cis	rs9611519	1	rs9611520	ENSG00000235513.1	RP4-756G23.5	5.46	7.56e-08	2.58e-05	0.27	0.25	Neuroticism;	chr22:41217299	chr22:41209122~41217627:-
HNSC	cis	rs442309	0.583	rs10995307	ENSG00000238280.1	RP11-436D10.3	5.46	7.58e-08	2.59e-05	0.28	0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62792482	chr10:62793562~62805887:-
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-5.46	7.58e-08	2.59e-05	-0.16	-0.25	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
HNSC	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-5.46	7.58e-08	2.59e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
HNSC	cis	rs4763879	0.778	rs9332411	ENSG00000256673.1	RP11-599J14.2	5.46	7.59e-08	2.59e-05	0.23	0.25	Type 1 diabetes;	chr12:9681749	chr12:9398355~9414851:-
HNSC	cis	rs9300255	0.602	rs1106241	ENSG00000280120.1	RP11-546D6.3	5.46	7.59e-08	2.59e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123142469	chr12:123152324~123153377:-
HNSC	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
HNSC	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	5.46	7.6e-08	2.59e-05	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
HNSC	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	5.46	7.61e-08	2.6e-05	0.28	0.25	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
HNSC	cis	rs71520386	0.607	rs11767419	ENSG00000221740.1	SNORD93	-5.46	7.61e-08	2.6e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22839364	chr7:22856613~22856686:+
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	5.46	7.61e-08	2.6e-05	0.27	0.25	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
HNSC	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-5.46	7.62e-08	2.6e-05	-0.34	-0.25	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
HNSC	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-5.46	7.62e-08	2.6e-05	-0.26	-0.25	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
HNSC	cis	rs520525	0.927	rs583006	ENSG00000271811.1	RP1-79C4.4	5.46	7.63e-08	2.6e-05	0.29	0.25	Atrial fibrillation;	chr1:170659247	chr1:170667381~170669425:+
HNSC	cis	rs3733585	0.699	rs4621431	ENSG00000250413.1	RP11-448G15.1	5.46	7.64e-08	2.61e-05	0.3	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9945966	chr4:10006482~10009725:+
HNSC	cis	rs4803480	0.578	rs7252454	ENSG00000270164.1	LINC01480	-5.46	7.64e-08	2.61e-05	-0.23	-0.25	Schizophrenia;	chr19:41527343	chr19:41535183~41536904:+
HNSC	cis	rs6928977	0.896	rs2614287	ENSG00000231028.7	LINC00271	5.46	7.65e-08	2.61e-05	0.28	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135497801~135716055:+
HNSC	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
HNSC	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
HNSC	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	5.46	7.65e-08	2.61e-05	0.35	0.25	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
HNSC	cis	rs4763879	0.778	rs7977940	ENSG00000256673.1	RP11-599J14.2	5.46	7.66e-08	2.61e-05	0.23	0.25	Type 1 diabetes;	chr12:9686320	chr12:9398355~9414851:-
HNSC	cis	rs3206736	0.593	rs328923	ENSG00000197085.10	NPSR1-AS1	-5.46	7.66e-08	2.61e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:34996083	chr7:34346512~34871582:-
HNSC	cis	rs6928977	0.932	rs6935146	ENSG00000231028.7	LINC00271	-5.46	7.66e-08	2.61e-05	-0.28	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306231	chr6:135497801~135716055:+
HNSC	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-5.46	7.67e-08	2.61e-05	-0.44	-0.25	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000254153.1	CTA-398F10.2	5.46	7.68e-08	2.62e-05	0.27	0.25	Mood instability;	chr8:8516446	chr8:8456909~8461337:-
HNSC	cis	rs7209700	0.644	rs7214468	ENSG00000228782.6	CTD-2026D20.3	-5.46	7.68e-08	2.62e-05	-0.24	-0.25	IgG glycosylation;	chr17:47293400	chr17:47450568~47492492:-
HNSC	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-5.46	7.69e-08	2.62e-05	-0.28	-0.25	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000254153.1	CTA-398F10.2	5.46	7.69e-08	2.62e-05	0.27	0.25	Mood instability;	chr8:8527137	chr8:8456909~8461337:-
HNSC	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.7e-08	2.62e-05	-0.3	-0.25	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.7e-08	2.62e-05	-0.3	-0.25	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.7e-08	2.62e-05	-0.3	-0.25	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
HNSC	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	5.46	7.7e-08	2.63e-05	0.29	0.25	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
HNSC	cis	rs14027	0.883	rs16893027	ENSG00000279347.1	RP11-85I17.2	-5.46	7.71e-08	2.63e-05	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701534	chr8:119838736~119840385:-
HNSC	cis	rs2439831	0.867	rs2278860	ENSG00000205771.5	CATSPER2P1	5.46	7.71e-08	2.63e-05	0.4	0.25	Lung cancer in ever smokers;	chr15:43366848	chr15:43726918~43747094:-
HNSC	cis	rs9813712	0.818	rs16845853	ENSG00000249846.5	RP11-77P16.4	5.46	7.71e-08	2.63e-05	0.28	0.24	Response to amphetamines;	chr3:130229587	chr3:130112550~130120579:+
HNSC	cis	rs7617773	0.563	rs13082269	ENSG00000228638.1	FCF1P2	-5.46	7.71e-08	2.63e-05	-0.22	-0.24	Coronary artery disease;	chr3:48350784	chr3:48290793~48291375:-
HNSC	cis	rs36093844	0.752	rs7121363	ENSG00000279742.1	RP11-700A24.1	-5.46	7.71e-08	2.63e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85864067	chr11:85852557~85854943:-
HNSC	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	5.46	7.72e-08	2.63e-05	0.3	0.24	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
HNSC	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	5.46	7.72e-08	2.63e-05	0.28	0.24	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
HNSC	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-5.46	7.74e-08	2.64e-05	-0.31	-0.24	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
HNSC	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-5.46	7.74e-08	2.64e-05	-0.39	-0.24	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
HNSC	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	5.46	7.75e-08	2.64e-05	0.3	0.24	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
HNSC	cis	rs526231	0.786	rs171695	ENSG00000175749.11	EIF3KP1	5.46	7.76e-08	2.64e-05	0.3	0.24	Primary biliary cholangitis;	chr5:103296339	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	5.46	7.76e-08	2.64e-05	0.28	0.24	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
HNSC	cis	rs4718428	1	rs4718428	ENSG00000179406.6	LINC00174	-5.46	7.77e-08	2.65e-05	-0.33	-0.24	Corneal structure;	chr7:66956459	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	5.46	7.77e-08	2.65e-05	0.3	0.24	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
HNSC	cis	rs7615952	0.515	rs4441610	ENSG00000241288.6	RP11-379B18.5	-5.46	7.77e-08	2.65e-05	-0.31	-0.24	Blood pressure (smoking interaction);	chr3:125962464	chr3:125827238~125916384:-
HNSC	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-5.46	7.78e-08	2.65e-05	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-5.46	7.78e-08	2.65e-05	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
HNSC	cis	rs9650657	0.589	rs6985109	ENSG00000269918.1	AF131215.9	5.46	7.78e-08	2.65e-05	0.24	0.24	Neuroticism;	chr8:10904075	chr8:11104691~11106704:-
HNSC	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-5.46	7.79e-08	2.65e-05	-0.4	-0.24	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
HNSC	cis	rs1908814	0.516	rs4841641	ENSG00000206014.6	OR7E161P	-5.46	7.79e-08	2.65e-05	-0.26	-0.24	Neuroticism;	chr8:11940718	chr8:11928597~11929563:-
HNSC	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	5.46	7.79e-08	2.65e-05	0.3	0.24	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
HNSC	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.46	7.79e-08	2.65e-05	-0.2	-0.24	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.46	7.79e-08	2.65e-05	-0.2	-0.24	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
HNSC	cis	rs2058059	0.636	rs2961005	ENSG00000225648.4	SBDSP1	5.46	7.8e-08	2.65e-05	0.33	0.24	Subcutaneous adipose tissue;	chr7:72675517	chr7:72829425~72836701:+
HNSC	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	5.46	7.8e-08	2.66e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
HNSC	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	5.46	7.82e-08	2.66e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
HNSC	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	5.46	7.83e-08	2.66e-05	0.28	0.24	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
HNSC	cis	rs3738443	0.645	rs55768801	ENSG00000259865.1	RP11-488L18.10	5.46	7.83e-08	2.66e-05	0.19	0.24	Alcohol dependence;	chr1:247199688	chr1:247187281~247188526:-
HNSC	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-5.46	7.83e-08	2.67e-05	-0.29	-0.24	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
HNSC	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-5.46	7.84e-08	2.67e-05	-0.28	-0.24	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-5.46	7.84e-08	2.67e-05	-0.28	-0.24	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
HNSC	cis	rs947583	1	rs947583	ENSG00000217482.2	HMGB1P17	5.46	7.84e-08	2.67e-05	0.29	0.24	Phosphorus levels;	chr6:135812521	chr6:135636086~135636713:-
HNSC	cis	rs5753618	0.583	rs5753601	ENSG00000236132.1	CTA-440B3.1	-5.46	7.85e-08	2.67e-05	-0.31	-0.24	Colorectal cancer;	chr22:31402273	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs5753612	ENSG00000236132.1	CTA-440B3.1	-5.46	7.85e-08	2.67e-05	-0.31	-0.24	Colorectal cancer;	chr22:31425493	chr22:31816379~31817491:-
HNSC	cis	rs2115630	1	rs56074163	ENSG00000229212.6	RP11-561C5.4	5.46	7.85e-08	2.67e-05	0.28	0.24	P wave terminal force;	chr15:84808101	chr15:85205440~85234795:-
HNSC	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-5.46	7.86e-08	2.68e-05	-0.31	-0.24	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
HNSC	cis	rs6928977	0.86	rs2746438	ENSG00000231028.7	LINC00271	5.46	7.86e-08	2.68e-05	0.29	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135396930	chr6:135497801~135716055:+
HNSC	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-5.46	7.86e-08	2.68e-05	-0.22	-0.24	Height;	chr11:118746590	chr11:118791254~118793137:+
HNSC	cis	rs988913	1	rs1393772	ENSG00000224984.1	RP11-524H19.2	5.46	7.87e-08	2.68e-05	0.28	0.24	Menarche (age at onset);	chr6:54973590	chr6:54840118~54840855:-
HNSC	cis	rs8054556	1	rs4788209	ENSG00000183604.13	SMG1P5	-5.46	7.88e-08	2.68e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4788210	ENSG00000183604.13	SMG1P5	-5.46	7.88e-08	2.68e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:30267553~30335374:-
HNSC	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	5.46	7.88e-08	2.68e-05	0.26	0.24	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
HNSC	cis	rs75920871	0.528	rs11216245	ENSG00000254851.1	RP11-109L13.1	5.46	7.88e-08	2.68e-05	0.34	0.24	Subjective well-being;	chr11:117042486	chr11:117135528~117138582:+
HNSC	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-5.46	7.89e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
HNSC	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-5.46	7.89e-08	2.68e-05	-0.24	-0.24	Height;	chr5:37005003	chr5:36666214~36725195:-
HNSC	cis	rs6928977	0.5	rs3734213	ENSG00000217482.2	HMGB1P17	5.46	7.9e-08	2.69e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135620170	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.5	rs6941629	ENSG00000217482.2	HMGB1P17	5.46	7.9e-08	2.69e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135621634	chr6:135636086~135636713:-
HNSC	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-5.46	7.9e-08	2.69e-05	-0.28	-0.24	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
HNSC	cis	rs2439831	1	rs28628574	ENSG00000205771.5	CATSPER2P1	-5.46	7.9e-08	2.69e-05	-0.49	-0.24	Lung cancer in ever smokers;	chr15:43509840	chr15:43726918~43747094:-
HNSC	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	5.46	7.9e-08	2.69e-05	0.27	0.24	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
HNSC	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-5.46	7.9e-08	2.69e-05	-0.3	-0.24	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
HNSC	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-5.46	7.9e-08	2.69e-05	-0.4	-0.24	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-5.46	7.91e-08	2.69e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-5.46	7.91e-08	2.69e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-5.46	7.91e-08	2.69e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
HNSC	cis	rs1799949	0.86	rs8176279	ENSG00000267151.3	RP11-100E5.2	5.46	7.91e-08	2.69e-05	0.31	0.24	Menopause (age at onset);	chr17:43058379	chr17:43444707~43451200:+
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	5.46	7.93e-08	2.7e-05	0.28	0.24	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
HNSC	cis	rs6931421	0.8	rs12662365	ENSG00000272129.1	RP11-250B2.6	5.46	7.93e-08	2.7e-05	0.32	0.24	Sitting height ratio;	chr6:80195672	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.927	rs56009503	ENSG00000249207.1	RP11-360F5.1	5.46	7.94e-08	2.7e-05	0.28	0.24	Cognitive function;	chr4:39242642	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.964	rs7687651	ENSG00000249207.1	RP11-360F5.1	5.46	7.94e-08	2.7e-05	0.28	0.24	Cognitive function;	chr4:39243072	chr4:39112677~39126818:-
HNSC	cis	rs988913	1	rs1503136	ENSG00000224984.1	RP11-524H19.2	5.46	7.94e-08	2.7e-05	0.28	0.24	Menarche (age at onset);	chr6:54987167	chr6:54840118~54840855:-
HNSC	cis	rs9402743	0.597	rs9399162	ENSG00000217482.2	HMGB1P17	5.46	7.95e-08	2.7e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135759368	chr6:135636086~135636713:-
HNSC	cis	rs4763879	0.634	rs7974396	ENSG00000256673.1	RP11-599J14.2	5.46	7.95e-08	2.7e-05	0.23	0.24	Type 1 diabetes;	chr12:9708101	chr12:9398355~9414851:-
HNSC	cis	rs2179367	0.632	rs9485384	ENSG00000216906.2	RP11-350J20.9	5.46	7.95e-08	2.7e-05	0.36	0.24	Dupuytren's disease;	chr6:149328808	chr6:149904243~149906418:+
HNSC	cis	rs2985684	1	rs1957977	ENSG00000258568.1	RHOQP1	5.46	7.95e-08	2.7e-05	0.25	0.24	Carotid intima media thickness;	chr14:49623885	chr14:49599994~49600572:+
HNSC	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-5.46	7.95e-08	2.7e-05	-0.33	-0.24	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	5.45	7.96e-08	2.71e-05	0.27	0.24	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	5.45	7.96e-08	2.71e-05	0.27	0.24	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
HNSC	cis	rs72615157	0.613	rs56089143	ENSG00000078319.8	PMS2P1	-5.45	7.96e-08	2.71e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr7:100222221	chr7:100320992~100341908:-
HNSC	cis	rs9840812	0.861	rs687339	ENSG00000273486.1	RP11-731C17.2	5.45	7.97e-08	2.71e-05	0.22	0.24	Fibrinogen levels;	chr3:136213517	chr3:136837338~136839021:-
HNSC	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-5.45	7.97e-08	2.71e-05	-0.28	-0.24	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
HNSC	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-5.45	7.97e-08	2.71e-05	-0.33	-0.24	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
HNSC	cis	rs4295623	0.553	rs11250163	ENSG00000269918.1	AF131215.9	5.45	7.97e-08	2.71e-05	0.24	0.24	Morning vs. evening chronotype;	chr8:11738928	chr8:11104691~11106704:-
HNSC	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	5.45	7.98e-08	2.71e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
HNSC	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-5.45	7.99e-08	2.71e-05	-0.32	-0.24	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
HNSC	cis	rs6693567	0.565	rs12739706	ENSG00000228126.1	FALEC	-5.45	7.99e-08	2.71e-05	-0.3	-0.24	Migraine;	chr1:150289240	chr1:150515757~150518032:+
HNSC	cis	rs3754214	0.823	rs10888579	ENSG00000228126.1	FALEC	-5.45	7.99e-08	2.71e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr1:150289512	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs7544900	ENSG00000228126.1	FALEC	-5.45	7.99e-08	2.71e-05	-0.3	-0.24	Migraine;	chr1:150289918	chr1:150515757~150518032:+
HNSC	cis	rs7674212	0.539	rs6815783	ENSG00000246560.2	RP11-10L12.4	5.45	8e-08	2.72e-05	0.28	0.24	Type 2 diabetes;	chr4:103200989	chr4:102828055~102844075:+
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	5.45	8e-08	2.72e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
HNSC	cis	rs13126694	0.682	rs6536288	ENSG00000248429.4	RP11-597D13.9	-5.45	8.01e-08	2.72e-05	-0.27	-0.24	Blood osmolality (transformed sodium);	chr4:157949748	chr4:158170752~158202877:+
HNSC	cis	rs1908814	0.503	rs34657250	ENSG00000206014.6	OR7E161P	5.45	8.02e-08	2.72e-05	0.27	0.24	Neuroticism;	chr8:11937864	chr8:11928597~11929563:-
HNSC	cis	rs12817211	0.536	rs9364	ENSG00000272368.2	RP4-605O3.4	5.45	8.03e-08	2.73e-05	0.24	0.24	Colorectal or endometrial cancer;	chr12:50176736	chr12:50112197~50165618:+
HNSC	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-5.45	8.04e-08	2.73e-05	-0.34	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
HNSC	cis	rs2404602	0.563	rs12914005	ENSG00000259422.1	RP11-593F23.1	5.45	8.04e-08	2.73e-05	0.28	0.24	Blood metabolite levels;	chr15:76473326	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.536	rs7163946	ENSG00000259422.1	RP11-593F23.1	5.45	8.04e-08	2.73e-05	0.28	0.24	Blood metabolite levels;	chr15:76473708	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.536	rs7165025	ENSG00000259422.1	RP11-593F23.1	5.45	8.04e-08	2.73e-05	0.28	0.24	Blood metabolite levels;	chr15:76474093	chr15:76174891~76181486:-
HNSC	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-5.45	8.05e-08	2.74e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-5.45	8.05e-08	2.74e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000254153.1	CTA-398F10.2	5.45	8.05e-08	2.74e-05	0.28	0.24	Joint mobility (Beighton score);	chr8:9012918	chr8:8456909~8461337:-
HNSC	cis	rs783540	0.656	rs783524	ENSG00000255769.6	GOLGA2P10	5.45	8.07e-08	2.74e-05	0.32	0.24	Schizophrenia;	chr15:82615393	chr15:82472993~82513950:-
HNSC	cis	rs783540	0.592	rs2567632	ENSG00000255769.6	GOLGA2P10	5.45	8.07e-08	2.74e-05	0.32	0.24	Schizophrenia;	chr15:82616053	chr15:82472993~82513950:-
HNSC	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-5.45	8.07e-08	2.74e-05	-0.38	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-5.45	8.08e-08	2.74e-05	-0.17	-0.24	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	5.45	8.08e-08	2.74e-05	0.3	0.24	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.802	rs2614276	ENSG00000234084.1	RP3-388E23.2	5.45	8.08e-08	2.74e-05	0.26	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135360566	chr6:135301568~135307158:+
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-5.45	8.08e-08	2.74e-05	-0.3	-0.24	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	5.45	8.09e-08	2.74e-05	0.27	0.24	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
HNSC	cis	rs6928977	0.869	rs6912933	ENSG00000234084.1	RP3-388E23.2	5.45	8.09e-08	2.74e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306396	chr6:135301568~135307158:+
HNSC	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	5.45	8.09e-08	2.75e-05	0.25	0.24	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-5.45	8.09e-08	2.75e-05	-0.15	-0.24	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	5.45	8.1e-08	2.75e-05	0.26	0.24	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-5.45	8.1e-08	2.75e-05	-0.16	-0.24	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
HNSC	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	5.45	8.1e-08	2.75e-05	0.3	0.24	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
HNSC	cis	rs4713118	0.5	rs9461434	ENSG00000226314.6	ZNF192P1	-5.45	8.11e-08	2.75e-05	-0.33	-0.24	Parkinson's disease;	chr6:28134687	chr6:28161781~28169594:+
HNSC	cis	rs8054556	0.647	rs8048433	ENSG00000183604.13	SMG1P5	-5.45	8.11e-08	2.75e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30267553~30335374:-
HNSC	cis	rs13113518	1	rs2279458	ENSG00000249700.7	SRD5A3-AS1	5.45	8.12e-08	2.76e-05	0.29	0.24	Height;	chr4:55562653	chr4:55363971~55395847:-
HNSC	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-5.45	8.12e-08	2.76e-05	-0.18	-0.24	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	5.45	8.13e-08	2.76e-05	0.32	0.24	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
HNSC	cis	rs10435719	0.902	rs11250179	ENSG00000206014.6	OR7E161P	-5.45	8.13e-08	2.76e-05	-0.26	-0.24	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11928597~11929563:-
HNSC	cis	rs9992667	0.955	rs9998440	ENSG00000231160.8	KLF3-AS1	-5.45	8.14e-08	2.76e-05	-0.28	-0.24	Eosinophil percentage of granulocytes;	chr4:38606180	chr4:38612701~38664883:-
HNSC	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	5.45	8.14e-08	2.76e-05	0.25	0.24	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
HNSC	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	8.15e-08	2.76e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
HNSC	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	5.45	8.16e-08	2.77e-05	0.29	0.24	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
HNSC	cis	rs6969780	1	rs6973182	ENSG00000233429.8	HOTAIRM1	5.45	8.16e-08	2.77e-05	0.44	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27095647~27100265:+
HNSC	cis	rs7811142	0.887	rs111972532	ENSG00000078319.8	PMS2P1	-5.45	8.17e-08	2.77e-05	-0.31	-0.24	Platelet count;	chr7:100471465	chr7:100320992~100341908:-
HNSC	cis	rs5758659	1	rs5758660	ENSG00000227370.1	RP4-669P10.19	-5.45	8.17e-08	2.77e-05	-0.24	-0.24	Cognitive function;	chr22:42227712	chr22:42132543~42132998:+
HNSC	cis	rs8054556	1	rs4787486	ENSG00000183604.13	SMG1P5	-5.45	8.17e-08	2.77e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29966241	chr16:30267553~30335374:-
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	5.45	8.19e-08	2.78e-05	0.26	0.24	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
HNSC	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	5.45	8.19e-08	2.78e-05	0.25	0.24	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
HNSC	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
HNSC	cis	rs4356203	1	rs4356203	ENSG00000260196.1	RP1-239B22.5	5.45	8.2e-08	2.78e-05	0.26	0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17138601	chr11:17380649~17383531:+
HNSC	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-5.45	8.2e-08	2.78e-05	-0.34	-0.24	Depression;	chr6:28241324	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-5.45	8.2e-08	2.78e-05	-0.34	-0.24	Depression;	chr6:28241753	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-5.45	8.2e-08	2.78e-05	-0.34	-0.24	Depression;	chr6:28242515	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.66	rs2757643	ENSG00000234084.1	RP3-388E23.2	-5.45	8.21e-08	2.78e-05	-0.24	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135440095	chr6:135301568~135307158:+
HNSC	cis	rs7773987	1	rs7773987	ENSG00000234084.1	RP3-388E23.2	5.45	8.21e-08	2.78e-05	0.25	0.24	Selective IgA deficiency;	chr6:135386348	chr6:135301568~135307158:+
HNSC	cis	rs2579103	0.867	rs2731222	ENSG00000258183.4	RP11-753N8.1	-5.45	8.22e-08	2.79e-05	-0.31	-0.24	Body mass index;	chr12:90201606	chr12:90280894~90300340:+
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-5.45	8.23e-08	2.79e-05	-0.27	-0.24	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
HNSC	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	5.45	8.23e-08	2.79e-05	0.28	0.24	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.514	rs2945873	ENSG00000254340.1	RP11-10A14.3	5.45	8.23e-08	2.79e-05	0.3	0.24	Mood instability;	chr8:8402935	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	5.45	8.24e-08	2.79e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
HNSC	cis	rs11976180	1	rs11976180	ENSG00000273234.1	OR2A13P	-5.45	8.25e-08	2.79e-05	-0.28	-0.24	Obesity-related traits;	chr7:144044487	chr7:144142009~144142938:+
HNSC	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	5.45	8.25e-08	2.8e-05	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
HNSC	cis	rs2179367	0.632	rs11155650	ENSG00000216906.2	RP11-350J20.9	5.45	8.26e-08	2.8e-05	0.36	0.24	Dupuytren's disease;	chr6:149407613	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs11155651	ENSG00000216906.2	RP11-350J20.9	5.45	8.26e-08	2.8e-05	0.36	0.24	Dupuytren's disease;	chr6:149408146	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs7896	ENSG00000216906.2	RP11-350J20.9	5.45	8.26e-08	2.8e-05	0.36	0.24	Dupuytren's disease;	chr6:149410340	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	5.45	8.27e-08	2.8e-05	0.28	0.24	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
HNSC	cis	rs4964805	0.657	rs11111783	ENSG00000257681.1	RP11-341G23.4	5.45	8.28e-08	2.8e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794745	chr12:103746315~103768858:-
HNSC	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	5.45	8.28e-08	2.81e-05	0.23	0.24	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
HNSC	cis	rs1933112	0.5	rs34328291	ENSG00000227777.1	RP4-738P11.3	-5.45	8.28e-08	2.81e-05	-0.34	-0.24	Blood protein levels;	chr1:168545108	chr1:168542737~168543354:+
HNSC	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	5.45	8.29e-08	2.81e-05	0.33	0.24	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
HNSC	cis	rs8054556	1	rs7204797	ENSG00000183604.13	SMG1P5	-5.45	8.31e-08	2.81e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29956694	chr16:30267553~30335374:-
HNSC	cis	rs1908814	0.541	rs7824267	ENSG00000206014.6	OR7E161P	-5.45	8.31e-08	2.81e-05	-0.27	-0.24	Neuroticism;	chr8:11936770	chr8:11928597~11929563:-
HNSC	cis	rs2985684	0.894	rs6572586	ENSG00000278009.1	RP11-649E7.8	5.45	8.31e-08	2.82e-05	0.32	0.24	Carotid intima media thickness;	chr14:49555223	chr14:49601011~49601124:-
HNSC	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	5.45	8.31e-08	2.82e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
HNSC	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	5.45	8.32e-08	2.82e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
HNSC	cis	rs6723108	0.517	rs6430543	ENSG00000224043.6	CCNT2-AS1	5.45	8.33e-08	2.82e-05	0.29	0.24	Type 2 diabetes;	chr2:134844839	chr2:134735464~134918710:-
HNSC	cis	rs2179367	0.632	rs9498329	ENSG00000216906.2	RP11-350J20.9	5.45	8.33e-08	2.82e-05	0.36	0.24	Dupuytren's disease;	chr6:149349941	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs59820585	ENSG00000216906.2	RP11-350J20.9	5.45	8.33e-08	2.82e-05	0.36	0.24	Dupuytren's disease;	chr6:149350249	chr6:149904243~149906418:+
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000233609.3	RP11-62H7.2	5.45	8.34e-08	2.82e-05	0.24	0.24	Joint mobility (Beighton score);	chr8:9003384	chr8:8961200~8979025:+
HNSC	cis	rs5753618	0.583	rs7293171	ENSG00000236132.1	CTA-440B3.1	-5.45	8.34e-08	2.82e-05	-0.31	-0.24	Colorectal cancer;	chr22:31406338	chr22:31816379~31817491:-
HNSC	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-5.45	8.34e-08	2.82e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
HNSC	cis	rs13113518	1	rs4864548	ENSG00000273257.1	RP11-177J6.1	-5.45	8.35e-08	2.83e-05	-0.3	-0.24	Height;	chr4:55547636	chr4:55387949~55388271:+
HNSC	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	5.45	8.35e-08	2.83e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
HNSC	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	5.45	8.35e-08	2.83e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
HNSC	cis	rs7819412	0.875	rs6981523	ENSG00000269918.1	AF131215.9	-5.45	8.37e-08	2.83e-05	-0.24	-0.24	Triglycerides;	chr8:11204283	chr8:11104691~11106704:-
HNSC	cis	rs7615952	0.599	rs6438953	ENSG00000248787.1	RP11-666A20.4	-5.45	8.37e-08	2.83e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:126006108	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs1044215	ENSG00000248787.1	RP11-666A20.4	-5.45	8.37e-08	2.83e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:126006716	chr3:125908005~125910272:-
HNSC	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-5.45	8.37e-08	2.83e-05	-0.22	-0.24	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
HNSC	cis	rs7176527	0.519	rs12148368	ENSG00000229212.6	RP11-561C5.4	5.45	8.37e-08	2.83e-05	0.33	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85205440~85234795:-
HNSC	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-5.44	8.39e-08	2.84e-05	-0.32	-0.24	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
HNSC	cis	rs1665050	0.545	rs59540276	ENSG00000259732.1	RP11-59H7.3	-5.44	8.39e-08	2.84e-05	-0.33	-0.24	Atopic dermatitis;	chr15:59037559	chr15:59121034~59133250:+
HNSC	cis	rs7674212	0.541	rs2720458	ENSG00000246560.2	RP11-10L12.4	5.44	8.4e-08	2.84e-05	0.28	0.24	Type 2 diabetes;	chr4:103131806	chr4:102828055~102844075:+
HNSC	cis	rs4535700	0.501	rs28678267	ENSG00000226278.1	PSPHP1	5.44	8.41e-08	2.84e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55941797	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.501	rs11765531	ENSG00000226278.1	PSPHP1	5.44	8.41e-08	2.84e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55942594	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.501	rs10227764	ENSG00000226278.1	PSPHP1	5.44	8.41e-08	2.84e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55944729	chr7:55764797~55773288:+
HNSC	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	5.44	8.41e-08	2.84e-05	0.29	0.24	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs1723267	ENSG00000179406.6	LINC00174	-5.44	8.41e-08	2.84e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66008327	chr7:66376044~66401338:-
HNSC	cis	rs2985684	0.894	rs8005990	ENSG00000278009.1	RP11-649E7.8	5.44	8.41e-08	2.84e-05	0.32	0.24	Carotid intima media thickness;	chr14:49555530	chr14:49601011~49601124:-
HNSC	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	5.44	8.41e-08	2.85e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
HNSC	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	5.44	8.41e-08	2.85e-05	0.3	0.24	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
HNSC	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	5.44	8.42e-08	2.85e-05	0.37	0.24	Height;	chr6:109352277	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.587	rs2516889	ENSG00000254174.1	IGHV1-12	-5.44	8.42e-08	2.85e-05	-0.2	-0.24	Alzheimer's disease (late onset);	chr14:106648903	chr14:106122420~106122709:-
HNSC	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	5.44	8.43e-08	2.85e-05	0.31	0.24	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
HNSC	cis	rs9611519	0.929	rs11090039	ENSG00000235513.1	RP4-756G23.5	5.44	8.43e-08	2.85e-05	0.28	0.24	Neuroticism;	chr22:41100796	chr22:41209122~41217627:-
HNSC	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	5.44	8.43e-08	2.85e-05	0.27	0.24	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	5.44	8.43e-08	2.85e-05	0.27	0.24	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
HNSC	cis	rs6479901	0.841	rs10761720	ENSG00000232075.1	MRPL35P2	-5.44	8.43e-08	2.85e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63634317~63634827:-
HNSC	cis	rs783540	0.609	rs803686	ENSG00000276710.3	CSPG4P8	5.44	8.44e-08	2.85e-05	0.29	0.24	Schizophrenia;	chr15:82550590	chr15:82459472~82477258:+
HNSC	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	5.44	8.45e-08	2.86e-05	0.23	0.24	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
HNSC	cis	rs13113518	1	rs1056545	ENSG00000273257.1	RP11-177J6.1	5.44	8.45e-08	2.86e-05	0.3	0.24	Height;	chr4:55430730	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs5863	ENSG00000273257.1	RP11-177J6.1	5.44	8.45e-08	2.86e-05	0.3	0.24	Height;	chr4:55430740	chr4:55387949~55388271:+
HNSC	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-5.44	8.46e-08	2.86e-05	-0.23	-0.24	Height;	chr5:36904297	chr5:36666214~36725195:-
HNSC	cis	rs3813579	1	rs3813579	ENSG00000261390.4	RP11-345M22.2	-5.44	8.46e-08	2.86e-05	-0.31	-0.24	Thyroid volume;	chr16:79715379	chr16:79715232~79770563:-
HNSC	cis	rs9291683	0.509	rs10939671	ENSG00000250413.1	RP11-448G15.1	-5.44	8.47e-08	2.86e-05	-0.3	-0.24	Bone mineral density;	chr4:10049191	chr4:10006482~10009725:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66121618	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316313	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66128561	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316312	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66131504	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs419603	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66132354	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs387676	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66133233	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs13310597	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66133553	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs431076	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66135333	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2257790	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66135463	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2460422	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66136518	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316334	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66137139	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316332	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66139312	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316330	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66140385	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316329	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66143429	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316326	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66144466	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316325	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66144531	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316321	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66146626	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316318	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66147917	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316317	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66148650	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316304	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66151907	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2465120	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66155987	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66157859	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66158142	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718309	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66162777	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6460274	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66163497	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7787230	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66164112	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66170354	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6974723	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66172952	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs9769882	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66177938	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6966322	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66181767	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4145008	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66182524	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718315	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66183554	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718316	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66183744	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1873494	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66184912	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6959002	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66185509	chr7:66376044~66401338:-
HNSC	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	5.44	8.47e-08	2.86e-05	0.35	0.24	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	5.44	8.47e-08	2.86e-05	0.35	0.24	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	5.44	8.47e-08	2.86e-05	0.35	0.24	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
HNSC	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	5.44	8.48e-08	2.86e-05	0.27	0.24	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
HNSC	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-5.44	8.48e-08	2.86e-05	-0.24	-0.24	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
HNSC	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-5.44	8.49e-08	2.87e-05	-0.22	-0.24	Height;	chr11:118791319	chr11:118791254~118793137:+
HNSC	cis	rs831571	0.876	rs56363381	ENSG00000280620.1	SCAANT1	5.44	8.5e-08	2.87e-05	0.4	0.24	Type 2 diabetes;	chr3:64071001	chr3:63911518~63911772:-
HNSC	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	5.44	8.5e-08	2.87e-05	0.31	0.24	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	5.44	8.5e-08	2.87e-05	0.31	0.24	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	5.44	8.5e-08	2.87e-05	0.31	0.24	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
HNSC	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	5.44	8.5e-08	2.87e-05	0.3	0.24	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
HNSC	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
HNSC	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	5.44	8.52e-08	2.88e-05	0.3	0.24	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
HNSC	cis	rs17428076	0.836	rs3770455	ENSG00000228389.1	AC068039.4	-5.44	8.52e-08	2.88e-05	-0.3	-0.24	Myopia;	chr2:171811385	chr2:171773482~171775844:+
HNSC	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	5.44	8.53e-08	2.88e-05	0.3	0.24	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
HNSC	cis	rs2337406	0.866	rs74092511	ENSG00000254174.1	IGHV1-12	5.44	8.54e-08	2.88e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779234	chr14:106122420~106122709:-
HNSC	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	5.44	8.55e-08	2.89e-05	0.31	0.24	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
HNSC	cis	rs526231	0.736	rs6886092	ENSG00000175749.11	EIF3KP1	5.44	8.55e-08	2.89e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103298328	chr5:103032376~103033031:+
HNSC	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-5.44	8.56e-08	2.89e-05	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
HNSC	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-5.44	8.56e-08	2.89e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
HNSC	cis	rs9859260	0.71	rs419068	ENSG00000207650.1	MIR570	-5.44	8.57e-08	2.89e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196055305	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.71	rs366268	ENSG00000207650.1	MIR570	-5.44	8.57e-08	2.89e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196055306	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.744	rs419059	ENSG00000207650.1	MIR570	-5.44	8.57e-08	2.89e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196055313	chr3:195699401~195699497:+
HNSC	cis	rs4648739	0.613	rs13303201	ENSG00000268575.1	RP1-283E3.8	5.44	8.57e-08	2.89e-05	0.24	0.24	Severe influenza A (H1N1) infection;	chr1:1972273	chr1:1702736~1737688:-
HNSC	cis	rs763567	0.967	rs7412231	ENSG00000271811.1	RP1-79C4.4	-5.44	8.57e-08	2.89e-05	-0.27	-0.24	Tonsillectomy;	chr1:170601358	chr1:170667381~170669425:+
HNSC	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	5.44	8.57e-08	2.89e-05	0.27	0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
HNSC	cis	rs4699052	0.928	rs2126473	ENSG00000246560.2	RP11-10L12.4	5.44	8.57e-08	2.89e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103220376	chr4:102828055~102844075:+
HNSC	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	5.44	8.58e-08	2.9e-05	0.27	0.24	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
HNSC	cis	rs3206736	0.548	rs328891	ENSG00000197085.10	NPSR1-AS1	-5.44	8.59e-08	2.9e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:34973905	chr7:34346512~34871582:-
HNSC	cis	rs732716	0.853	rs1127888	ENSG00000267980.1	AC007292.6	-5.44	8.59e-08	2.9e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4454086	chr19:4363789~4364640:+
HNSC	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	5.44	8.59e-08	2.9e-05	0.29	0.24	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
HNSC	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-5.44	8.61e-08	2.9e-05	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
HNSC	cis	rs155076	1	rs12870992	ENSG00000233325.3	MIPEPP3	-5.44	8.63e-08	2.91e-05	-0.43	-0.24	White matter hyperintensity burden;	chr13:21271880	chr13:21298139~21306373:+
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000254153.1	CTA-398F10.2	5.44	8.64e-08	2.91e-05	0.27	0.24	Neuroticism;	chr8:8240557	chr8:8456909~8461337:-
HNSC	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	5.44	8.65e-08	2.92e-05	0.27	0.24	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
HNSC	cis	rs763567	0.967	rs6690642	ENSG00000271811.1	RP1-79C4.4	-5.44	8.65e-08	2.92e-05	-0.26	-0.24	Tonsillectomy;	chr1:170614803	chr1:170667381~170669425:+
HNSC	cis	rs7819412	0.838	rs3021494	ENSG00000255310.2	AF131215.2	-5.44	8.65e-08	2.92e-05	-0.24	-0.24	Triglycerides;	chr8:11126024	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.662	rs9393881	ENSG00000204709.4	LINC01556	5.44	8.65e-08	2.92e-05	0.34	0.24	Parkinson's disease;	chr6:28055973	chr6:28943877~28944537:+
HNSC	cis	rs11969893	0.85	rs9386260	ENSG00000270987.1	RP3-467N11.2	5.44	8.66e-08	2.92e-05	0.62	0.24	Economic and political preferences (immigration/crime);	chr6:100881552	chr6:100889603~100890338:+
HNSC	cis	rs7160336	0.738	rs66941731	ENSG00000259065.1	RP5-1021I20.1	5.44	8.66e-08	2.92e-05	0.28	0.24	Blood protein levels;	chr14:74026538	chr14:73787360~73803270:+
HNSC	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	5.44	8.67e-08	2.92e-05	0.47	0.24	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
HNSC	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	5.44	8.67e-08	2.92e-05	0.28	0.24	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
HNSC	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	5.44	8.68e-08	2.93e-05	0.36	0.24	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	5.44	8.68e-08	2.93e-05	0.36	0.24	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	5.44	8.68e-08	2.93e-05	0.36	0.24	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
HNSC	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-5.44	8.7e-08	2.93e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
HNSC	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
HNSC	cis	rs9291683	0.546	rs4575994	ENSG00000250413.1	RP11-448G15.1	-5.44	8.7e-08	2.93e-05	-0.3	-0.24	Bone mineral density;	chr4:9996355	chr4:10006482~10009725:+
HNSC	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-5.44	8.71e-08	2.94e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
HNSC	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	5.44	8.73e-08	2.94e-05	0.29	0.24	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
HNSC	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	5.44	8.73e-08	2.94e-05	0.28	0.24	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
HNSC	cis	rs3806843	0.766	rs801399	ENSG00000202515.1	VTRNA1-3	5.44	8.74e-08	2.94e-05	0.27	0.24	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr5:140726158~140726246:+
HNSC	cis	rs7211079	0.917	rs4243251	ENSG00000279259.1	RP11-334C17.3	5.44	8.74e-08	2.94e-05	0.32	0.24	Myocardial infarction;	chr17:80138811	chr17:80147250~80148596:+
HNSC	cis	rs9840812	0.598	rs1145101	ENSG00000273486.1	RP11-731C17.2	5.44	8.74e-08	2.94e-05	0.25	0.24	Fibrinogen levels;	chr3:136350444	chr3:136837338~136839021:-
HNSC	cis	rs9611519	0.828	rs4822008	ENSG00000235513.1	RP4-756G23.5	5.44	8.74e-08	2.95e-05	0.27	0.24	Neuroticism;	chr22:41143202	chr22:41209122~41217627:-
HNSC	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-5.44	8.74e-08	2.95e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
HNSC	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-5.44	8.74e-08	2.95e-05	-0.27	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
HNSC	cis	rs2179367	0.632	rs12196750	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149413335	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.552	rs11155652	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149417849	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12209364	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149418062	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498348	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149418352	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9322179	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149418664	chr6:149904243~149906418:+
HNSC	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-5.44	8.75e-08	2.95e-05	-0.39	-0.24	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
HNSC	cis	rs17428076	0.793	rs7584258	ENSG00000228389.1	AC068039.4	-5.44	8.76e-08	2.95e-05	-0.3	-0.24	Myopia;	chr2:171803326	chr2:171773482~171775844:+
HNSC	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	5.44	8.76e-08	2.95e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-5.44	8.76e-08	2.95e-05	-0.14	-0.24	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-5.44	8.76e-08	2.95e-05	-0.26	-0.24	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
HNSC	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	5.44	8.77e-08	2.95e-05	0.59	0.24	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
HNSC	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-5.44	8.77e-08	2.95e-05	-0.27	-0.24	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
HNSC	cis	rs7804306	1	rs13225545	ENSG00000233264.2	AC006042.8	5.44	8.78e-08	2.96e-05	0.47	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027509	chr7:7980312~7982228:+
HNSC	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	5.44	8.78e-08	2.96e-05	0.33	0.24	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-5.44	8.78e-08	2.96e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
HNSC	cis	rs13113518	0.812	rs11932712	ENSG00000273257.1	RP11-177J6.1	5.44	8.79e-08	2.96e-05	0.3	0.24	Height;	chr4:55436423	chr4:55387949~55388271:+
HNSC	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	5.44	8.79e-08	2.96e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	5.44	8.79e-08	2.96e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
HNSC	cis	rs6604026	0.555	rs4642892	ENSG00000223787.2	RP4-593M8.1	5.44	8.8e-08	2.96e-05	0.35	0.24	Multiple sclerosis;	chr1:92628570	chr1:92580476~92580821:-
HNSC	cis	rs9300255	0.602	rs1616131	ENSG00000280120.1	RP11-546D6.3	5.44	8.8e-08	2.96e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135291	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1616181	ENSG00000280120.1	RP11-546D6.3	5.44	8.8e-08	2.96e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135309	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.569	rs1790115	ENSG00000280120.1	RP11-546D6.3	5.44	8.8e-08	2.96e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135723	chr12:123152324~123153377:-
HNSC	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	5.44	8.81e-08	2.97e-05	0.33	0.24	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
HNSC	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	5.44	8.81e-08	2.97e-05	0.29	0.24	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	5.44	8.82e-08	2.97e-05	0.2	0.24	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
HNSC	cis	rs6928977	0.896	rs2746425	ENSG00000234084.1	RP3-388E23.2	5.44	8.82e-08	2.97e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135343227	chr6:135301568~135307158:+
HNSC	cis	rs8059260	0.935	rs9928255	ENSG00000274038.1	RP11-66H6.4	-5.44	8.82e-08	2.97e-05	-0.36	-0.24	Alcohol consumption over the past year;	chr16:11027408	chr16:11056556~11057034:+
HNSC	cis	rs4938303	0.633	rs528806	ENSG00000254851.1	RP11-109L13.1	5.44	8.82e-08	2.97e-05	0.44	0.24	Triglycerides;	chr11:116659197	chr11:117135528~117138582:+
HNSC	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	5.44	8.82e-08	2.97e-05	0.36	0.24	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
HNSC	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	5.43	8.86e-08	2.98e-05	0.42	0.24	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
HNSC	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	5.43	8.86e-08	2.98e-05	0.42	0.24	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-5.43	8.86e-08	2.98e-05	-0.16	-0.24	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.514	rs2976926	ENSG00000254340.1	RP11-10A14.3	5.43	8.86e-08	2.98e-05	0.29	0.24	Mood instability;	chr8:8404114	chr8:9141424~9145435:+
HNSC	cis	rs8054556	1	rs3814880	ENSG00000183604.13	SMG1P5	-5.43	8.87e-08	2.98e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30006574	chr16:30267553~30335374:-
HNSC	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-5.43	8.88e-08	2.99e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
HNSC	cis	rs2337406	0.5	rs7152934	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778702	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.789	rs12050392	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779073	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092505	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779163	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.789	rs74092507	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779174	chr14:106122420~106122709:-
HNSC	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-5.43	8.89e-08	2.99e-05	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
HNSC	cis	rs4252134	0.551	rs6926947	ENSG00000231863.1	RP3-428L16.1	-5.43	8.89e-08	2.99e-05	-0.32	-0.24	Giant cell arteritis;	chr6:160851644	chr6:160931080~160969771:+
HNSC	cis	rs4699052	0.963	rs11943325	ENSG00000246560.2	RP11-10L12.4	5.43	8.9e-08	2.99e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103257236	chr4:102828055~102844075:+
HNSC	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	5.43	8.9e-08	2.99e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	5.43	8.9e-08	2.99e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
HNSC	cis	rs8054556	1	rs12921996	ENSG00000183604.13	SMG1P5	-5.43	8.91e-08	3e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30000297	chr16:30267553~30335374:-
HNSC	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-5.43	8.91e-08	3e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
HNSC	cis	rs9813712	0.574	rs62281647	ENSG00000249846.5	RP11-77P16.4	-5.43	8.91e-08	3e-05	-0.26	-0.24	Response to amphetamines;	chr3:130242670	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.597	rs62281648	ENSG00000249846.5	RP11-77P16.4	-5.43	8.91e-08	3e-05	-0.26	-0.24	Response to amphetamines;	chr3:130244794	chr3:130112550~130120579:+
HNSC	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	5.43	8.91e-08	3e-05	0.62	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	5.43	8.92e-08	3e-05	0.29	0.24	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
HNSC	cis	rs783540	0.681	rs1259178	ENSG00000276710.3	CSPG4P8	5.43	8.92e-08	3e-05	0.28	0.24	Schizophrenia;	chr15:82603127	chr15:82459472~82477258:+
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-5.43	8.93e-08	3e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
HNSC	cis	rs2579103	0.898	rs4842510	ENSG00000258183.4	RP11-753N8.1	-5.43	8.93e-08	3e-05	-0.3	-0.24	Body mass index;	chr12:90199640	chr12:90280894~90300340:+
HNSC	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	5.43	8.93e-08	3e-05	0.26	0.24	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
HNSC	cis	rs6928977	0.86	rs2746426	ENSG00000234084.1	RP3-388E23.2	5.43	8.93e-08	3e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135345294	chr6:135301568~135307158:+
HNSC	cis	rs2985684	0.901	rs7146248	ENSG00000258568.1	RHOQP1	5.43	8.94e-08	3.01e-05	0.25	0.24	Carotid intima media thickness;	chr14:49645349	chr14:49599994~49600572:+
HNSC	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	5.43	8.94e-08	3.01e-05	0.26	0.24	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
HNSC	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-5.43	8.95e-08	3.01e-05	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
HNSC	cis	rs6928977	0.832	rs2746427	ENSG00000234084.1	RP3-388E23.2	5.43	8.95e-08	3.01e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135347959	chr6:135301568~135307158:+
HNSC	cis	rs9813712	0.672	rs73210789	ENSG00000249846.5	RP11-77P16.4	5.43	8.95e-08	3.01e-05	0.29	0.24	Response to amphetamines;	chr3:130243418	chr3:130112550~130120579:+
HNSC	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-5.43	8.96e-08	3.01e-05	-0.29	-0.24	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
HNSC	cis	rs6928977	0.86	rs2746433	ENSG00000234084.1	RP3-388E23.2	5.43	8.96e-08	3.01e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135379567	chr6:135301568~135307158:+
HNSC	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-5.43	8.97e-08	3.01e-05	-0.35	-0.24	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
HNSC	cis	rs2179367	0.632	rs9498321	ENSG00000216906.2	RP11-350J20.9	5.43	8.97e-08	3.01e-05	0.35	0.24	Dupuytren's disease;	chr6:149322573	chr6:149904243~149906418:+
HNSC	cis	rs651386	0.506	rs12027180	ENSG00000271811.1	RP1-79C4.4	5.43	8.97e-08	3.02e-05	0.28	0.24	Atrial fibrillation;	chr1:170594064	chr1:170667381~170669425:+
HNSC	cis	rs2411233	0.967	rs11856829	ENSG00000259278.1	RP11-62C7.2	5.43	8.97e-08	3.02e-05	0.39	0.24	Platelet count;	chr15:38985580	chr15:39019233~39024918:+
HNSC	cis	rs603446	0.967	rs180346	ENSG00000254851.1	RP11-109L13.1	-5.43	8.97e-08	3.02e-05	-0.32	-0.24	Triglycerides;	chr11:116741943	chr11:117135528~117138582:+
HNSC	cis	rs4978813	0.5	rs11791965	ENSG00000213539.4	YBX1P6	5.43	8.98e-08	3.02e-05	0.29	0.24	Plantar warts;	chr9:109515083	chr9:109532830~109534332:-
HNSC	cis	rs2439831	1	rs2245790	ENSG00000205771.5	CATSPER2P1	-5.43	8.99e-08	3.02e-05	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43452259	chr15:43726918~43747094:-
HNSC	cis	rs2985684	0.748	rs2985686	ENSG00000258568.1	RHOQP1	5.43	8.99e-08	3.02e-05	0.25	0.24	Carotid intima media thickness;	chr14:49633965	chr14:49599994~49600572:+
HNSC	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	5.43	8.99e-08	3.02e-05	0.42	0.24	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
HNSC	cis	rs655720	1	rs655720	ENSG00000273486.1	RP11-731C17.2	5.43	8.99e-08	3.02e-05	0.2	0.24	Coronary artery disease;	chr3:136384425	chr3:136837338~136839021:-
HNSC	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-5.43	8.99e-08	3.02e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
HNSC	cis	rs13126694	0.71	rs4631100	ENSG00000248429.4	RP11-597D13.9	5.43	9e-08	3.02e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157991162	chr4:158170752~158202877:+
HNSC	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	5.43	9e-08	3.02e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
HNSC	cis	rs9650657	0.504	rs10093053	ENSG00000269918.1	AF131215.9	-5.43	9e-08	3.03e-05	-0.24	-0.24	Neuroticism;	chr8:11179678	chr8:11104691~11106704:-
HNSC	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-5.43	9.01e-08	3.03e-05	-0.38	-0.24	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
HNSC	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	5.43	9.01e-08	3.03e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	5.43	9.02e-08	3.03e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	5.43	9.02e-08	3.03e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
HNSC	cis	rs4218	0.573	rs4775115	ENSG00000277144.1	RP11-59H7.4	-5.43	9.02e-08	3.03e-05	-0.31	-0.24	Social communication problems;	chr15:59076311	chr15:59115547~59116089:-
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	5.43	9.03e-08	3.03e-05	0.26	0.24	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
HNSC	cis	rs13113518	1	rs13113518	ENSG00000273257.1	RP11-177J6.1	5.43	9.04e-08	3.04e-05	0.29	0.24	Height;	chr4:55533481	chr4:55387949~55388271:+
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000233609.3	RP11-62H7.2	5.43	9.04e-08	3.04e-05	0.24	0.24	Mean corpuscular volume;	chr8:8994371	chr8:8961200~8979025:+
HNSC	cis	rs925255	0.817	rs12624279	ENSG00000270210.1	RP11-373D23.3	-5.43	9.05e-08	3.04e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28411923	chr2:28425945~28426719:+
HNSC	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	5.43	9.06e-08	3.04e-05	0.25	0.24	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
HNSC	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	5.43	9.06e-08	3.04e-05	0.2	0.24	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
HNSC	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-5.43	9.06e-08	3.04e-05	-0.3	-0.24	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
HNSC	cis	rs783540	0.656	rs783538	ENSG00000276710.3	CSPG4P8	5.43	9.07e-08	3.05e-05	0.29	0.24	Schizophrenia;	chr15:82584394	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	5.43	9.07e-08	3.05e-05	0.26	0.24	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	5.43	9.07e-08	3.05e-05	0.26	0.24	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs328895	ENSG00000197085.10	NPSR1-AS1	-5.43	9.07e-08	3.05e-05	-0.31	-0.24	Diastolic blood pressure;	chr7:34976775	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs2021177	ENSG00000197085.10	NPSR1-AS1	-5.43	9.07e-08	3.05e-05	-0.31	-0.24	Diastolic blood pressure;	chr7:34980576	chr7:34346512~34871582:-
HNSC	cis	rs2404602	0.536	rs12915248	ENSG00000259422.1	RP11-593F23.1	5.43	9.07e-08	3.05e-05	0.27	0.24	Blood metabolite levels;	chr15:76473274	chr15:76174891~76181486:-
HNSC	cis	rs8177876	0.822	rs56166222	ENSG00000261061.1	RP11-303E16.2	-5.43	9.08e-08	3.05e-05	-0.46	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81030770~81031485:+
HNSC	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-5.43	9.08e-08	3.05e-05	-0.45	-0.24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
HNSC	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-5.43	9.09e-08	3.05e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
HNSC	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-5.43	9.1e-08	3.06e-05	-0.33	-0.24	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-5.43	9.1e-08	3.06e-05	-0.33	-0.24	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
HNSC	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	5.43	9.11e-08	3.06e-05	0.28	0.24	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
HNSC	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	5.43	9.11e-08	3.06e-05	0.27	0.24	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
HNSC	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-5.43	9.11e-08	3.06e-05	-0.38	-0.24	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
HNSC	cis	rs763567	1	rs12755237	ENSG00000271811.1	RP1-79C4.4	-5.43	9.12e-08	3.06e-05	-0.27	-0.24	Tonsillectomy;	chr1:170599573	chr1:170667381~170669425:+
HNSC	cis	rs763567	1	rs12742164	ENSG00000271811.1	RP1-79C4.4	-5.43	9.12e-08	3.06e-05	-0.27	-0.24	Tonsillectomy;	chr1:170599755	chr1:170667381~170669425:+
HNSC	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	5.43	9.12e-08	3.06e-05	0.3	0.24	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	5.43	9.12e-08	3.06e-05	0.3	0.24	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
HNSC	cis	rs4968361	0.892	rs68025251	ENSG00000266992.1	DHX40P1	5.43	9.13e-08	3.07e-05	0.44	0.24	Schizophrenia;	chr17:59442071	chr17:59976009~60002384:-
HNSC	cis	rs9914544	0.933	rs11871889	ENSG00000264885.1	RP11-815I9.4	-5.43	9.14e-08	3.07e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18868112	chr17:18667629~18669461:-
HNSC	cis	rs13113518	0.966	rs13144598	ENSG00000273257.1	RP11-177J6.1	5.43	9.14e-08	3.07e-05	0.3	0.24	Height;	chr4:55570311	chr4:55387949~55388271:+
HNSC	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	5.43	9.14e-08	3.07e-05	0.27	0.24	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
HNSC	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-5.43	9.15e-08	3.07e-05	-0.24	-0.24	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-5.43	9.15e-08	3.07e-05	-0.14	-0.24	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
HNSC	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	5.43	9.15e-08	3.07e-05	0.33	0.24	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000211972.2	IGHV3-66	5.43	9.16e-08	3.07e-05	0.19	0.24	Kawasaki disease;	chr14:106787630	chr14:106675017~106675544:-
HNSC	cis	rs7819412	0.634	rs4841485	ENSG00000269918.1	AF131215.9	5.43	9.16e-08	3.07e-05	0.25	0.24	Triglycerides;	chr8:11052426	chr8:11104691~11106704:-
HNSC	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	5.43	9.16e-08	3.07e-05	0.3	0.24	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	5.43	9.16e-08	3.07e-05	0.3	0.24	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
HNSC	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-5.43	9.16e-08	3.07e-05	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
HNSC	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	5.43	9.16e-08	3.08e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
HNSC	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-5.43	9.17e-08	3.08e-05	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000254153.1	CTA-398F10.2	-5.43	9.17e-08	3.08e-05	-0.27	-0.24	Mood instability;	chr8:8726362	chr8:8456909~8461337:-
HNSC	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-5.43	9.17e-08	3.08e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
HNSC	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-5.43	9.18e-08	3.08e-05	-0.27	-0.24	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
HNSC	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	5.43	9.19e-08	3.08e-05	0.31	0.24	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
HNSC	cis	rs6604026	0.624	rs35705463	ENSG00000223787.2	RP4-593M8.1	5.43	9.19e-08	3.08e-05	0.34	0.24	Multiple sclerosis;	chr1:92767766	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	5.43	9.19e-08	3.08e-05	0.34	0.24	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
HNSC	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-5.43	9.2e-08	3.09e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
HNSC	cis	rs950169	0.922	rs62028133	ENSG00000229212.6	RP11-561C5.4	-5.43	9.2e-08	3.09e-05	-0.35	-0.24	Schizophrenia;	chr15:84250623	chr15:85205440~85234795:-
HNSC	cis	rs2337406	0.81	rs7161739	ENSG00000254174.1	IGHV1-12	5.43	9.2e-08	3.09e-05	0.21	0.24	Alzheimer's disease (late onset);	chr14:106776118	chr14:106122420~106122709:-
HNSC	cis	rs8054556	1	rs11150579	ENSG00000183604.13	SMG1P5	-5.43	9.21e-08	3.09e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs9924686	ENSG00000183604.13	SMG1P5	-5.43	9.21e-08	3.09e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:30267553~30335374:-
HNSC	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	5.43	9.21e-08	3.09e-05	0.28	0.24	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
HNSC	cis	rs763567	1	rs61217505	ENSG00000271811.1	RP1-79C4.4	-5.43	9.22e-08	3.09e-05	-0.27	-0.24	Tonsillectomy;	chr1:170604117	chr1:170667381~170669425:+
HNSC	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-5.43	9.22e-08	3.09e-05	-0.26	-0.24	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
HNSC	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	5.43	9.22e-08	3.09e-05	0.34	0.24	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
HNSC	cis	rs4763879	0.634	rs11052582	ENSG00000256673.1	RP11-599J14.2	5.43	9.22e-08	3.09e-05	0.23	0.24	Type 1 diabetes;	chr12:9706714	chr12:9398355~9414851:-
HNSC	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	5.43	9.22e-08	3.09e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
HNSC	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	5.43	9.23e-08	3.09e-05	0.59	0.24	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
HNSC	cis	rs860295	0.812	rs12081192	ENSG00000203761.5	MSTO2P	-5.43	9.23e-08	3.1e-05	-0.19	-0.24	Body mass index;	chr1:155768253	chr1:155745829~155750137:+
HNSC	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	5.43	9.24e-08	3.1e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
HNSC	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-5.43	9.24e-08	3.1e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
HNSC	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-5.43	9.25e-08	3.1e-05	-0.3	-0.24	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
HNSC	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-5.43	9.25e-08	3.1e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-5.43	9.25e-08	3.1e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-5.43	9.25e-08	3.1e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
HNSC	cis	rs9650657	0.504	rs7813802	ENSG00000269918.1	AF131215.9	5.43	9.25e-08	3.1e-05	0.24	0.24	Neuroticism;	chr8:11176467	chr8:11104691~11106704:-
HNSC	cis	rs11846409	0.932	rs10151046	ENSG00000211974.3	IGHV2-70	-5.43	9.26e-08	3.1e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106633095	chr14:106723574~106724093:-
HNSC	cis	rs9611565	0.569	rs6002328	ENSG00000235513.1	RP4-756G23.5	5.43	9.26e-08	3.1e-05	0.26	0.24	Vitiligo;	chr22:41314030	chr22:41209122~41217627:-
HNSC	cis	rs2337406	0.789	rs112027230	ENSG00000254174.1	IGHV1-12	5.43	9.26e-08	3.1e-05	0.21	0.24	Alzheimer's disease (late onset);	chr14:106810329	chr14:106122420~106122709:-
HNSC	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	5.43	9.26e-08	3.1e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
HNSC	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	5.43	9.27e-08	3.11e-05	0.3	0.24	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
HNSC	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	5.43	9.27e-08	3.11e-05	0.27	0.24	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
HNSC	cis	rs442309	0.553	rs10995299	ENSG00000238280.1	RP11-436D10.3	-5.43	9.28e-08	3.11e-05	-0.31	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62744443	chr10:62793562~62805887:-
HNSC	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	5.43	9.29e-08	3.11e-05	0.28	0.24	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
HNSC	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-5.43	9.29e-08	3.11e-05	-0.23	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
HNSC	cis	rs3733585	0.736	rs4543113	ENSG00000250413.1	RP11-448G15.1	-5.43	9.29e-08	3.11e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10006681	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000254340.1	RP11-10A14.3	5.43	9.3e-08	3.12e-05	0.3	0.24	Mood instability;	chr8:8813226	chr8:9141424~9145435:+
HNSC	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-5.43	9.31e-08	3.12e-05	-0.34	-0.24	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
HNSC	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-5.43	9.31e-08	3.12e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
HNSC	cis	rs6430553	0.964	rs62168869	ENSG00000224043.6	CCNT2-AS1	-5.43	9.32e-08	3.12e-05	-0.29	-0.24	Blood metabolite levels;	chr2:134889209	chr2:134735464~134918710:-
HNSC	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28145952	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28147378	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28147406	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28148143	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28149979	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28151096	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28152885	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28153120	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28154567	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28156691	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28158424	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159056	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159666	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159843	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159925	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159932	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28161802	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28162053	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28162598	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28163375	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28163759	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28164580	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28164825	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28164948	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28165025	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28165528	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28168434	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169019	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169249	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169676	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169755	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169791	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28170075	chr6:28161781~28169594:+
HNSC	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	5.42	9.33e-08	3.12e-05	0.27	0.24	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
HNSC	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	5.42	9.33e-08	3.12e-05	0.32	0.24	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
HNSC	cis	rs9291683	0.679	rs2241483	ENSG00000250413.1	RP11-448G15.1	5.42	9.33e-08	3.13e-05	0.3	0.24	Bone mineral density;	chr4:10098207	chr4:10006482~10009725:+
HNSC	cis	rs763567	1	rs3903239	ENSG00000271811.1	RP1-79C4.4	-5.42	9.33e-08	3.13e-05	-0.27	-0.24	Tonsillectomy;	chr1:170600176	chr1:170667381~170669425:+
HNSC	cis	rs763567	1	rs12760630	ENSG00000271811.1	RP1-79C4.4	-5.42	9.33e-08	3.13e-05	-0.27	-0.24	Tonsillectomy;	chr1:170600548	chr1:170667381~170669425:+
HNSC	cis	rs9291683	0.546	rs13120348	ENSG00000250413.1	RP11-448G15.1	5.42	9.34e-08	3.13e-05	0.3	0.24	Bone mineral density;	chr4:10051531	chr4:10006482~10009725:+
HNSC	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	5.42	9.34e-08	3.13e-05	0.3	0.24	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	5.42	9.34e-08	3.13e-05	0.19	0.24	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
HNSC	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-5.42	9.35e-08	3.13e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
HNSC	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	5.42	9.35e-08	3.13e-05	0.33	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
HNSC	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	5.42	9.36e-08	3.13e-05	0.26	0.24	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
HNSC	cis	rs4699052	0.963	rs6533078	ENSG00000246560.2	RP11-10L12.4	5.42	9.36e-08	3.13e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103290999	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs7672802	ENSG00000246560.2	RP11-10L12.4	5.42	9.36e-08	3.13e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103291076	chr4:102828055~102844075:+
HNSC	cis	rs603446	0.967	rs3741301	ENSG00000254851.1	RP11-109L13.1	-5.42	9.37e-08	3.14e-05	-0.33	-0.24	Triglycerides;	chr11:116760675	chr11:117135528~117138582:+
HNSC	cis	rs4140799	0.816	rs1204996	ENSG00000266869.1	RP6-114E22.1	5.42	9.38e-08	3.14e-05	0.3	0.24	Neuroticism;	chr14:71719967	chr14:71848606~71908430:+
HNSC	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-5.42	9.38e-08	3.14e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-5.42	9.38e-08	3.14e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-5.42	9.38e-08	3.14e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
HNSC	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-5.42	9.38e-08	3.14e-05	-0.24	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
HNSC	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-5.42	9.39e-08	3.14e-05	-0.32	-0.24	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
HNSC	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-5.42	9.39e-08	3.14e-05	-0.28	-0.24	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
HNSC	cis	rs1355223	0.867	rs7943755	ENSG00000271369.1	RP11-350D17.3	-5.42	9.39e-08	3.14e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669904	chr11:34709600~34710161:+
HNSC	cis	rs6928977	0.896	rs2179779	ENSG00000234084.1	RP3-388E23.2	5.42	9.4e-08	3.15e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135328678	chr6:135301568~135307158:+
HNSC	cis	rs3754214	0.857	rs9126	ENSG00000228126.1	FALEC	-5.42	9.4e-08	3.15e-05	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr1:150286988	chr1:150515757~150518032:+
HNSC	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-5.42	9.4e-08	3.15e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-5.42	9.4e-08	3.15e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	5.42	9.4e-08	3.15e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	5.42	9.4e-08	3.15e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	5.42	9.4e-08	3.15e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	5.42	9.4e-08	3.15e-05	0.22	0.24	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
HNSC	cis	rs1355223	0.902	rs6484726	ENSG00000271369.1	RP11-350D17.3	-5.42	9.41e-08	3.15e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676011	chr11:34709600~34710161:+
HNSC	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	5.42	9.41e-08	3.15e-05	0.18	0.24	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	5.42	9.42e-08	3.15e-05	0.3	0.24	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
HNSC	cis	rs763567	1	rs10919437	ENSG00000271811.1	RP1-79C4.4	-5.42	9.43e-08	3.15e-05	-0.27	-0.24	Tonsillectomy;	chr1:170603805	chr1:170667381~170669425:+
HNSC	cis	rs763567	1	rs2206062	ENSG00000271811.1	RP1-79C4.4	-5.42	9.43e-08	3.15e-05	-0.27	-0.24	Tonsillectomy;	chr1:170606966	chr1:170667381~170669425:+
HNSC	cis	rs11098499	0.739	rs10031033	ENSG00000249244.1	RP11-548H18.2	5.42	9.43e-08	3.15e-05	0.28	0.24	Corneal astigmatism;	chr4:119230297	chr4:119391831~119395335:-
HNSC	cis	rs2742234	0.541	rs11238483	ENSG00000273008.1	RP11-351D16.3	5.42	9.43e-08	3.16e-05	0.33	0.24	Hirschsprung disease;	chr10:43233332	chr10:43136824~43138334:-
HNSC	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	5.42	9.44e-08	3.16e-05	0.29	0.24	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
HNSC	cis	rs11096990	0.964	rs11096987	ENSG00000249207.1	RP11-360F5.1	5.42	9.44e-08	3.16e-05	0.28	0.24	Cognitive function;	chr4:39257570	chr4:39112677~39126818:-
HNSC	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	5.42	9.44e-08	3.16e-05	0.25	0.24	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
HNSC	cis	rs9880211	0.613	rs6786582	ENSG00000273486.1	RP11-731C17.2	-5.42	9.46e-08	3.16e-05	-0.21	-0.24	Height;Body mass index;	chr3:136180142	chr3:136837338~136839021:-
HNSC	cis	rs9329221	0.507	rs12678938	ENSG00000269918.1	AF131215.9	-5.42	9.47e-08	3.17e-05	-0.24	-0.24	Neuroticism;	chr8:10159459	chr8:11104691~11106704:-
HNSC	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	5.42	9.47e-08	3.17e-05	0.33	0.24	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
HNSC	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-5.42	9.47e-08	3.17e-05	-0.28	-0.24	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
HNSC	cis	rs4218	0.648	rs35460138	ENSG00000277144.1	RP11-59H7.4	-5.42	9.47e-08	3.17e-05	-0.32	-0.24	Social communication problems;	chr15:59093200	chr15:59115547~59116089:-
HNSC	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	5.42	9.48e-08	3.17e-05	0.28	0.24	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
HNSC	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	5.42	9.49e-08	3.17e-05	0.28	0.24	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	5.42	9.49e-08	3.17e-05	0.28	0.24	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
HNSC	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-5.42	9.5e-08	3.18e-05	-0.26	-0.24	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
HNSC	cis	rs11846409	0.932	rs73378158	ENSG00000211974.3	IGHV2-70	-5.42	9.5e-08	3.18e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106638433	chr14:106723574~106724093:-
HNSC	cis	rs9611519	1	rs9611510	ENSG00000235513.1	RP4-756G23.5	5.42	9.51e-08	3.18e-05	0.27	0.24	Neuroticism;	chr22:41173120	chr22:41209122~41217627:-
HNSC	cis	rs7980687	0.527	rs1626703	ENSG00000280120.1	RP11-546D6.3	5.42	9.53e-08	3.18e-05	0.21	0.24	Head circumference (infant);Educational attainment;Height;	chr12:123226288	chr12:123152324~123153377:-
HNSC	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
HNSC	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	5.42	9.54e-08	3.19e-05	0.33	0.24	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
HNSC	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-5.42	9.55e-08	3.19e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000233609.3	RP11-62H7.2	-5.42	9.55e-08	3.19e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9044411	chr8:8961200~8979025:+
HNSC	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	5.42	9.56e-08	3.19e-05	0.31	0.24	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	5.42	9.56e-08	3.19e-05	0.31	0.24	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	5.42	9.56e-08	3.19e-05	0.31	0.24	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
HNSC	cis	rs2439831	0.681	rs511673	ENSG00000205771.5	CATSPER2P1	-5.42	9.57e-08	3.2e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43326665	chr15:43726918~43747094:-
HNSC	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	5.42	9.58e-08	3.2e-05	0.29	0.24	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
HNSC	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	5.42	9.58e-08	3.2e-05	0.24	0.24	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
HNSC	cis	rs950169	0.84	rs72748702	ENSG00000229212.6	RP11-561C5.4	-5.42	9.59e-08	3.2e-05	-0.34	-0.24	Schizophrenia;	chr15:84246494	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.922	rs4338765	ENSG00000229212.6	RP11-561C5.4	-5.42	9.59e-08	3.2e-05	-0.34	-0.24	Schizophrenia;	chr15:84248084	chr15:85205440~85234795:-
HNSC	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-5.42	9.6e-08	3.21e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-5.42	9.6e-08	3.21e-05	-0.2	-0.24	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
HNSC	cis	rs4927850	1	rs7614767	ENSG00000273009.1	RP11-352G9.1	-5.42	9.61e-08	3.21e-05	-0.28	-0.24	Pancreatic cancer;	chr3:196026580	chr3:195913078~195913683:-
HNSC	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	5.42	9.62e-08	3.21e-05	0.27	0.24	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
HNSC	cis	rs13113518	0.702	rs78829811	ENSG00000249700.7	SRD5A3-AS1	5.42	9.62e-08	3.21e-05	0.29	0.24	Height;	chr4:55558258	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.702	rs75801206	ENSG00000249700.7	SRD5A3-AS1	5.42	9.62e-08	3.21e-05	0.29	0.24	Height;	chr4:55558259	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.702	rs34658078	ENSG00000249700.7	SRD5A3-AS1	5.42	9.62e-08	3.21e-05	0.29	0.24	Height;	chr4:55558261	chr4:55363971~55395847:-
HNSC	cis	rs11648785	0.62	rs10153134	ENSG00000222019.6	URAHP	5.42	9.62e-08	3.21e-05	0.23	0.24	Tanning;	chr16:90024691	chr16:90039761~90047773:-
HNSC	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-5.42	9.62e-08	3.21e-05	-0.31	-0.24	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
HNSC	cis	rs8062405	0.54	rs151226	ENSG00000251417.2	RP11-1348G14.4	-5.42	9.63e-08	3.22e-05	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28802743~28817828:+
HNSC	cis	rs453301	0.631	rs13250781	ENSG00000233609.3	RP11-62H7.2	-5.42	9.64e-08	3.22e-05	-0.24	-0.24	Joint mobility (Beighton score);	chr8:8935833	chr8:8961200~8979025:+
HNSC	cis	rs4938303	0.633	rs1960036	ENSG00000254851.1	RP11-109L13.1	5.42	9.64e-08	3.22e-05	0.42	0.24	Triglycerides;	chr11:116676692	chr11:117135528~117138582:+
HNSC	cis	rs4938303	0.633	rs61906104	ENSG00000254851.1	RP11-109L13.1	5.42	9.64e-08	3.22e-05	0.42	0.24	Triglycerides;	chr11:116679398	chr11:117135528~117138582:+
HNSC	cis	rs4763879	0.634	rs61915472	ENSG00000256673.1	RP11-599J14.2	5.42	9.65e-08	3.22e-05	0.23	0.24	Type 1 diabetes;	chr12:9700995	chr12:9398355~9414851:-
HNSC	cis	rs7587476	0.861	rs17488049	ENSG00000229267.2	AC072062.1	-5.42	9.66e-08	3.22e-05	-0.37	-0.24	Neuroblastoma;	chr2:214787026	chr2:214810229~214963274:+
HNSC	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	5.42	9.68e-08	3.23e-05	0.36	0.24	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	5.42	9.68e-08	3.23e-05	0.22	0.24	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
HNSC	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	5.42	9.68e-08	3.23e-05	0.35	0.24	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	5.42	9.68e-08	3.23e-05	0.35	0.24	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
HNSC	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-5.42	9.69e-08	3.23e-05	-0.24	-0.24	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-5.42	9.69e-08	3.24e-05	-0.16	-0.24	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
HNSC	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	5.42	9.7e-08	3.24e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	5.42	9.7e-08	3.24e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
HNSC	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-5.42	9.7e-08	3.24e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
HNSC	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-5.42	9.7e-08	3.24e-05	-0.21	-0.24	Height;	chr11:118749988	chr11:118791254~118793137:+
HNSC	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-5.42	9.7e-08	3.24e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-5.42	9.7e-08	3.24e-05	-0.28	-0.24	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
HNSC	cis	rs656319	0.513	rs34990153	ENSG00000269918.1	AF131215.9	-5.42	9.71e-08	3.24e-05	-0.25	-0.24	Myopia (pathological);	chr8:10138879	chr8:11104691~11106704:-
HNSC	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	5.42	9.72e-08	3.24e-05	0.27	0.24	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	5.42	9.72e-08	3.24e-05	0.27	0.24	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	5.42	9.73e-08	3.24e-05	0.26	0.24	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
HNSC	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-5.42	9.73e-08	3.25e-05	-0.2	-0.24	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
HNSC	cis	rs3738443	0.52	rs6699577	ENSG00000259865.1	RP11-488L18.10	5.42	9.73e-08	3.25e-05	0.19	0.24	Alcohol dependence;	chr1:247224152	chr1:247187281~247188526:-
HNSC	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-5.42	9.75e-08	3.25e-05	-0.3	-0.24	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
HNSC	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	5.42	9.75e-08	3.25e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	5.42	9.75e-08	3.25e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
HNSC	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	5.42	9.76e-08	3.26e-05	0.3	0.24	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	5.42	9.76e-08	3.26e-05	0.19	0.24	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
HNSC	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-5.42	9.78e-08	3.26e-05	-0.3	-0.24	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
HNSC	cis	rs6714900	0.589	rs12993301	ENSG00000234896.1	OR7E62P	-5.42	9.78e-08	3.26e-05	-0.29	-0.24	Blood protein levels;	chr2:71055392	chr2:71055527~71056003:+
HNSC	cis	rs8054556	1	rs10871451	ENSG00000183604.13	SMG1P5	-5.42	9.78e-08	3.26e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29974884	chr16:30267553~30335374:-
HNSC	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-5.42	9.79e-08	3.26e-05	-0.3	-0.24	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
HNSC	cis	rs9611519	1	rs9611505	ENSG00000235513.1	RP4-756G23.5	5.42	9.8e-08	3.27e-05	0.27	0.24	Neuroticism;	chr22:41144275	chr22:41209122~41217627:-
HNSC	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-5.42	9.8e-08	3.27e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
HNSC	cis	rs2115630	0.967	rs11073702	ENSG00000229212.6	RP11-561C5.4	5.42	9.81e-08	3.27e-05	0.28	0.24	P wave terminal force;	chr15:84766840	chr15:85205440~85234795:-
HNSC	cis	rs1012068	0.581	rs5749339	ENSG00000236132.1	CTA-440B3.1	5.42	9.81e-08	3.27e-05	0.29	0.24	Chronic hepatitis C infection;	chr22:31919749	chr22:31816379~31817491:-
HNSC	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	5.42	9.81e-08	3.27e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
HNSC	cis	rs10504130	0.569	rs9650179	ENSG00000272024.1	RP11-546K22.3	-5.42	9.81e-08	3.27e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51950284~51950690:+
HNSC	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	5.42	9.82e-08	3.27e-05	0.3	0.24	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
HNSC	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-5.42	9.82e-08	3.27e-05	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
HNSC	cis	rs2404602	0.536	rs1587381	ENSG00000259422.1	RP11-593F23.1	5.41	9.83e-08	3.28e-05	0.28	0.24	Blood metabolite levels;	chr15:76477279	chr15:76174891~76181486:-
HNSC	cis	rs3806843	0.931	rs13168670	ENSG00000202515.1	VTRNA1-3	-5.41	9.85e-08	3.28e-05	-0.27	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr5:140726158~140726246:+
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	5.41	9.85e-08	3.28e-05	0.2	0.24	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
HNSC	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	5.41	9.85e-08	3.28e-05	0.35	0.24	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
HNSC	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	5.41	9.88e-08	3.29e-05	0.27	0.24	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
HNSC	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-5.41	9.88e-08	3.29e-05	-0.28	-0.24	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
HNSC	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	5.41	9.89e-08	3.29e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
HNSC	cis	rs4141404	0.748	rs2232170	ENSG00000236132.1	CTA-440B3.1	5.41	9.89e-08	3.3e-05	0.3	0.24	Paclitaxel-induced neuropathy;	chr22:31141136	chr22:31816379~31817491:-
HNSC	cis	rs9611519	1	rs4820433	ENSG00000235513.1	RP4-756G23.5	5.41	9.89e-08	3.3e-05	0.26	0.24	Neuroticism;	chr22:41211061	chr22:41209122~41217627:-
HNSC	cis	rs9611519	1	rs3818003	ENSG00000235513.1	RP4-756G23.5	5.41	9.89e-08	3.3e-05	0.26	0.24	Neuroticism;	chr22:41213686	chr22:41209122~41217627:-
HNSC	cis	rs2985684	0.894	rs4900928	ENSG00000278009.1	RP11-649E7.8	5.41	9.9e-08	3.3e-05	0.32	0.24	Carotid intima media thickness;	chr14:49554099	chr14:49601011~49601124:-
HNSC	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-5.41	9.91e-08	3.3e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
HNSC	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-5.41	9.91e-08	3.3e-05	-0.31	-0.24	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
HNSC	cis	rs10256972	1	rs10256972	ENSG00000225146.1	AC073957.15	-5.41	9.92e-08	3.3e-05	-0.28	-0.24	Endometriosis;Longevity;	chr7:999367	chr7:1029025~1043891:+
HNSC	cis	rs763567	0.967	rs10919444	ENSG00000271811.1	RP1-79C4.4	-5.41	9.93e-08	3.31e-05	-0.26	-0.24	Tonsillectomy;	chr1:170612493	chr1:170667381~170669425:+
HNSC	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	5.41	9.94e-08	3.31e-05	0.27	0.24	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
HNSC	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	5.41	9.94e-08	3.31e-05	0.59	0.24	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
HNSC	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	5.41	9.95e-08	3.31e-05	0.28	0.24	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
HNSC	cis	rs11971779	1	rs75919582	ENSG00000273391.1	RP11-634H22.1	5.41	9.95e-08	3.31e-05	0.32	0.24	Diisocyanate-induced asthma;	chr7:139370173	chr7:139359032~139359566:-
HNSC	cis	rs763567	0.967	rs1952675	ENSG00000271811.1	RP1-79C4.4	-5.41	9.96e-08	3.32e-05	-0.26	-0.24	Tonsillectomy;	chr1:170613434	chr1:170667381~170669425:+
HNSC	cis	rs8040855	0.644	rs4635318	ENSG00000259774.1	RP11-182J1.13	-5.41	9.96e-08	3.32e-05	-0.31	-0.24	Bulimia nervosa;	chr15:85183506	chr15:84422618~84425882:+
HNSC	cis	rs8032939	0.533	rs17574546	ENSG00000259747.1	RP11-275I4.2	5.41	9.96e-08	3.32e-05	0.31	0.24	Rheumatoid arthritis;	chr15:38610275	chr15:38671847~38689191:+
HNSC	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	5.41	9.97e-08	3.32e-05	0.3	0.24	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
HNSC	cis	rs2058059	0.551	rs13225871	ENSG00000225648.4	SBDSP1	-5.41	9.97e-08	3.32e-05	-0.35	-0.24	Subcutaneous adipose tissue;	chr7:72573203	chr7:72829425~72836701:+
HNSC	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-5.41	9.97e-08	3.32e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-5.41	9.97e-08	3.32e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	5.41	9.97e-08	3.32e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
HNSC	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-5.41	9.98e-08	3.32e-05	-0.28	-0.24	Height;	chr2:46617930	chr2:46668870~46670778:+
HNSC	cis	rs17428076	0.715	rs788164	ENSG00000228389.1	AC068039.4	5.41	9.98e-08	3.32e-05	0.29	0.24	Myopia;	chr2:172048662	chr2:171773482~171775844:+
HNSC	cis	rs72615157	0.612	rs7786505	ENSG00000078319.8	PMS2P1	-5.41	9.99e-08	3.33e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr7:100219962	chr7:100320992~100341908:-
HNSC	cis	rs72615157	0.664	rs6953580	ENSG00000078319.8	PMS2P1	-5.41	9.99e-08	3.33e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr7:100227652	chr7:100320992~100341908:-
HNSC	cis	rs8035957	0.564	rs17651741	ENSG00000259747.1	RP11-275I4.2	-5.41	1e-07	3.33e-05	-0.32	-0.24	Type 1 diabetes;	chr15:38577465	chr15:38671847~38689191:+
HNSC	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-5.41	1e-07	3.33e-05	-0.42	-0.24	Depression;	chr6:28200565	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.649	rs6722126	ENSG00000243819.4	RN7SL832P	5.41	1e-07	3.33e-05	0.25	0.24	Prostate cancer;	chr2:10581516	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	5.41	1e-07	3.33e-05	0.25	0.24	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
HNSC	cis	rs748404	0.534	rs489509	ENSG00000205771.5	CATSPER2P1	-5.41	1e-07	3.33e-05	-0.31	-0.24	Lung cancer;	chr15:43294709	chr15:43726918~43747094:-
HNSC	cis	rs4947019	0.688	rs9487119	ENSG00000260273.1	RP11-425D10.10	5.41	1e-07	3.34e-05	0.68	0.24	Hematological parameters;	chr6:109464954	chr6:109382795~109383666:+
HNSC	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	5.41	1e-07	3.34e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
HNSC	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-5.41	1e-07	3.34e-05	-0.23	-0.24	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
HNSC	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-5.41	1e-07	3.34e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	5.41	1.01e-07	3.35e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
HNSC	cis	rs11096990	0.964	rs16988409	ENSG00000249207.1	RP11-360F5.1	-5.41	1.01e-07	3.35e-05	-0.28	-0.24	Cognitive function;	chr4:39267730	chr4:39112677~39126818:-
HNSC	cis	rs2235642	0.621	rs2667665	ENSG00000280231.1	LA16c-380F5.3	-5.41	1.01e-07	3.35e-05	-0.32	-0.24	Coronary artery disease;	chr16:1519523	chr16:1553655~1554130:-
HNSC	cis	rs4947019	0.614	rs117663805	ENSG00000260273.1	RP11-425D10.10	5.41	1.01e-07	3.35e-05	0.68	0.24	Hematological parameters;	chr6:109455712	chr6:109382795~109383666:+
HNSC	cis	rs9859260	0.744	rs557527	ENSG00000207650.1	MIR570	-5.41	1.01e-07	3.35e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196053838	chr3:195699401~195699497:+
HNSC	cis	rs7580658	0.75	rs6761391	ENSG00000236682.1	AC068282.3	-5.41	1.01e-07	3.35e-05	-0.28	-0.24	Protein C levels;	chr2:127396708	chr2:127389130~127400580:+
HNSC	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-5.41	1.01e-07	3.35e-05	-0.22	-0.24	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
HNSC	cis	rs12701220	0.725	rs13242971	ENSG00000229043.2	AC091729.9	-5.41	1.01e-07	3.35e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1160374~1165267:+
HNSC	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	5.41	1.01e-07	3.35e-05	0.27	0.24	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
HNSC	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	5.41	1.01e-07	3.35e-05	0.27	0.24	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
HNSC	cis	rs4664293	0.867	rs3764968	ENSG00000226266.5	AC009961.3	-5.41	1.01e-07	3.35e-05	-0.27	-0.24	Monocyte percentage of white cells;	chr2:159790579	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	5.41	1.01e-07	3.36e-05	0.31	0.24	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
HNSC	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-5.41	1.01e-07	3.36e-05	-0.31	-0.24	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
HNSC	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	5.41	1.01e-07	3.36e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	5.41	1.01e-07	3.36e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
HNSC	cis	rs7674212	0.541	rs4699050	ENSG00000246560.2	RP11-10L12.4	5.41	1.01e-07	3.36e-05	0.28	0.24	Type 2 diabetes;	chr4:103193140	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.541	rs17217473	ENSG00000246560.2	RP11-10L12.4	5.41	1.01e-07	3.36e-05	0.28	0.24	Type 2 diabetes;	chr4:103193585	chr4:102828055~102844075:+
HNSC	cis	rs6928977	0.66	rs12214269	ENSG00000234084.1	RP3-388E23.2	5.41	1.01e-07	3.37e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135525380	chr6:135301568~135307158:+
HNSC	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
HNSC	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-5.41	1.01e-07	3.37e-05	-0.27	-0.24	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
HNSC	cis	rs4763879	0.739	rs2895988	ENSG00000256673.1	RP11-599J14.2	5.41	1.01e-07	3.37e-05	0.23	0.24	Type 1 diabetes;	chr12:9675831	chr12:9398355~9414851:-
HNSC	cis	rs6693567	0.565	rs10888578	ENSG00000228126.1	FALEC	-5.41	1.01e-07	3.37e-05	-0.29	-0.24	Migraine;	chr1:150288580	chr1:150515757~150518032:+
HNSC	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-5.41	1.02e-07	3.38e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
HNSC	cis	rs11096990	0.964	rs35494908	ENSG00000249207.1	RP11-360F5.1	5.41	1.02e-07	3.38e-05	0.28	0.24	Cognitive function;	chr4:39252574	chr4:39112677~39126818:-
HNSC	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-5.41	1.02e-07	3.38e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
HNSC	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	5.41	1.02e-07	3.38e-05	0.34	0.24	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
HNSC	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	5.41	1.02e-07	3.38e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
HNSC	cis	rs2115630	1	rs1030863	ENSG00000229212.6	RP11-561C5.4	5.41	1.02e-07	3.38e-05	0.28	0.24	P wave terminal force;	chr15:84739404	chr15:85205440~85234795:-
HNSC	cis	rs2898681	0.618	rs116241740	ENSG00000248375.1	RP11-177B4.1	-5.41	1.02e-07	3.38e-05	-0.46	-0.24	Optic nerve measurement (cup area);	chr4:52867356	chr4:52720081~52720831:-
HNSC	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	5.41	1.02e-07	3.38e-05	0.3	0.24	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	5.41	1.02e-07	3.38e-05	0.3	0.24	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	5.41	1.02e-07	3.38e-05	0.31	0.24	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
HNSC	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-5.41	1.02e-07	3.39e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-5.41	1.02e-07	3.39e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
HNSC	cis	rs61160187	0.582	rs17332824	ENSG00000215032.2	GNL3LP1	-5.41	1.02e-07	3.39e-05	-0.27	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60870360	chr5:60891935~60893577:-
HNSC	cis	rs1355223	0.752	rs17293467	ENSG00000271369.1	RP11-350D17.3	-5.41	1.02e-07	3.39e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34655813	chr11:34709600~34710161:+
HNSC	cis	rs9840812	0.773	rs1154988	ENSG00000239213.4	NCK1-AS1	-5.41	1.02e-07	3.39e-05	-0.23	-0.24	Fibrinogen levels;	chr3:136206349	chr3:136841726~136862054:-
HNSC	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	5.41	1.02e-07	3.39e-05	0.29	0.24	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
HNSC	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-5.41	1.02e-07	3.4e-05	-0.28	-0.24	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
HNSC	cis	rs116095464	1	rs7723693	ENSG00000277812.1	AC021087.1	5.41	1.02e-07	3.4e-05	0.52	0.24	Breast cancer;	chr5:305917	chr5:262769~262881:+
HNSC	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	5.41	1.02e-07	3.4e-05	0.3	0.24	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	5.41	1.02e-07	3.4e-05	0.26	0.24	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
HNSC	cis	rs9650657	0.504	rs2409724	ENSG00000269918.1	AF131215.9	-5.41	1.02e-07	3.4e-05	-0.25	-0.24	Neuroticism;	chr8:11184133	chr8:11104691~11106704:-
HNSC	cis	rs5753618	0.583	rs5753615	ENSG00000236132.1	CTA-440B3.1	-5.41	1.02e-07	3.4e-05	-0.3	-0.24	Colorectal cancer;	chr22:31432041	chr22:31816379~31817491:-
HNSC	cis	rs11992162	0.967	rs7461062	ENSG00000206014.6	OR7E161P	-5.41	1.02e-07	3.4e-05	-0.26	-0.24	Monocyte count;	chr8:11974439	chr8:11928597~11929563:-
HNSC	cis	rs9402743	0.631	rs9376112	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135606862	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.635	rs9373135	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135611101	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs2143681	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135611867	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.564	rs9376113	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135612254	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs6934482	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135612363	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9402724	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135614046	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.564	rs2327649	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615097	chr6:135636086~135636713:-
HNSC	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-5.41	1.03e-07	3.41e-05	-0.28	-0.24	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
HNSC	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-5.41	1.03e-07	3.41e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
HNSC	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	5.41	1.03e-07	3.41e-05	0.25	0.24	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
HNSC	cis	rs2439831	0.85	rs28509275	ENSG00000205771.5	CATSPER2P1	-5.41	1.03e-07	3.41e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43805907	chr15:43726918~43747094:-
HNSC	cis	rs9859260	0.744	rs406271	ENSG00000207650.1	MIR570	-5.41	1.03e-07	3.41e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196050105	chr3:195699401~195699497:+
HNSC	cis	rs8040855	0.644	rs7495437	ENSG00000259774.1	RP11-182J1.13	-5.41	1.03e-07	3.42e-05	-0.3	-0.24	Bulimia nervosa;	chr15:85183059	chr15:84422618~84425882:+
HNSC	cis	rs9813712	1	rs9864582	ENSG00000249846.5	RP11-77P16.4	5.41	1.03e-07	3.42e-05	0.29	0.24	Response to amphetamines;	chr3:130251619	chr3:130112550~130120579:+
HNSC	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-5.41	1.03e-07	3.42e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
HNSC	cis	rs7777677	0.925	rs4726546	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs6960743	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs6956756	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.889	rs6975391	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs9655661	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.888	rs9655574	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.963	rs4726550	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.963	rs7796324	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142722358~142722764:+
HNSC	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-5.41	1.03e-07	3.42e-05	-0.3	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
HNSC	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	5.41	1.03e-07	3.42e-05	0.28	0.24	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	5.41	1.03e-07	3.42e-05	0.26	0.24	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
HNSC	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	5.41	1.03e-07	3.43e-05	0.29	0.24	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	5.41	1.03e-07	3.43e-05	0.29	0.24	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	5.41	1.03e-07	3.43e-05	0.29	0.24	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
HNSC	cis	rs1008375	0.931	rs3775926	ENSG00000249502.1	AC006160.5	-5.41	1.03e-07	3.43e-05	-0.27	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17598214	chr4:17587467~17614571:-
HNSC	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-5.41	1.03e-07	3.43e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
HNSC	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	5.41	1.03e-07	3.43e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	5.41	1.03e-07	3.43e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	5.41	1.03e-07	3.43e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
HNSC	cis	rs4938330	0.723	rs7931398	ENSG00000254851.1	RP11-109L13.1	5.41	1.03e-07	3.43e-05	0.34	0.24	Blood protein levels;	chr11:117008960	chr11:117135528~117138582:+
HNSC	cis	rs3733585	0.781	rs13103879	ENSG00000250413.1	RP11-448G15.1	5.41	1.03e-07	3.43e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9971255	chr4:10006482~10009725:+
HNSC	cis	rs13113518	0.812	rs12501746	ENSG00000273257.1	RP11-177J6.1	5.41	1.03e-07	3.43e-05	0.3	0.24	Height;	chr4:55437438	chr4:55387949~55388271:+
HNSC	cis	rs9291683	0.546	rs6829727	ENSG00000250413.1	RP11-448G15.1	-5.41	1.03e-07	3.43e-05	-0.31	-0.24	Bone mineral density;	chr4:10050048	chr4:10006482~10009725:+
HNSC	cis	rs860818	0.793	rs10230879	ENSG00000226816.2	AC005082.12	-5.41	1.04e-07	3.43e-05	-0.65	-0.24	Initial pursuit acceleration;	chr7:23158939	chr7:23206013~23208045:+
HNSC	cis	rs6928977	0.863	rs2614255	ENSG00000234084.1	RP3-388E23.2	5.41	1.04e-07	3.43e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135342443	chr6:135301568~135307158:+
HNSC	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	5.41	1.04e-07	3.44e-05	0.33	0.24	Height;	chr6:109331033	chr6:109382795~109383666:+
HNSC	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-5.4	1.04e-07	3.44e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
HNSC	cis	rs6604026	0.885	rs12738964	ENSG00000223787.2	RP4-593M8.1	5.4	1.04e-07	3.44e-05	0.34	0.24	Multiple sclerosis;	chr1:92808893	chr1:92580476~92580821:-
HNSC	cis	rs9611519	0.894	rs9623320	ENSG00000235513.1	RP4-756G23.5	5.4	1.04e-07	3.44e-05	0.27	0.24	Neuroticism;	chr22:41082478	chr22:41209122~41217627:-
HNSC	cis	rs13126694	0.71	rs6848159	ENSG00000248429.4	RP11-597D13.9	-5.4	1.04e-07	3.44e-05	-0.27	-0.24	Blood osmolality (transformed sodium);	chr4:158051130	chr4:158170752~158202877:+
HNSC	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	5.4	1.04e-07	3.45e-05	0.27	0.24	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	5.4	1.04e-07	3.45e-05	0.27	0.24	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000254153.1	CTA-398F10.2	-5.4	1.04e-07	3.45e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9035087	chr8:8456909~8461337:-
HNSC	cis	rs8054556	1	rs11150577	ENSG00000183604.13	SMG1P5	-5.4	1.04e-07	3.45e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29975204	chr16:30267553~30335374:-
HNSC	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-5.4	1.04e-07	3.45e-05	-0.24	-0.24	Height;	chr5:37022673	chr5:36666214~36725195:-
HNSC	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	5.4	1.04e-07	3.45e-05	0.27	0.24	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-5.4	1.04e-07	3.45e-05	-0.22	-0.24	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
HNSC	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	5.4	1.04e-07	3.45e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
HNSC	cis	rs763121	0.776	rs4820346	ENSG00000273076.1	RP3-508I15.22	-5.4	1.04e-07	3.45e-05	-0.26	-0.24	Menopause (age at onset);	chr22:38729069	chr22:38743495~38743910:+
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
HNSC	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	5.4	1.04e-07	3.46e-05	0.23	0.24	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
HNSC	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-5.4	1.04e-07	3.46e-05	-0.22	-0.24	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
HNSC	cis	rs11841001	0.556	rs34083520	ENSG00000261105.4	LMO7-AS1	-5.4	1.04e-07	3.46e-05	-0.32	-0.24	Corneal astigmatism;	chr13:75775622	chr13:75604700~75635994:-
HNSC	cis	rs3806843	0.966	rs2563265	ENSG00000202515.1	VTRNA1-3	5.4	1.05e-07	3.46e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr5:140726158~140726246:+
HNSC	cis	rs1355223	0.902	rs7129089	ENSG00000271369.1	RP11-350D17.3	-5.4	1.05e-07	3.47e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34678152	chr11:34709600~34710161:+
HNSC	cis	rs950169	0.723	rs17589320	ENSG00000229212.6	RP11-561C5.4	-5.4	1.05e-07	3.47e-05	-0.34	-0.24	Schizophrenia;	chr15:84251244	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.845	rs4502182	ENSG00000229212.6	RP11-561C5.4	-5.4	1.05e-07	3.47e-05	-0.34	-0.24	Schizophrenia;	chr15:84254768	chr15:85205440~85234795:-
HNSC	cis	rs13113518	0.812	rs12505880	ENSG00000273257.1	RP11-177J6.1	5.4	1.05e-07	3.47e-05	0.3	0.24	Height;	chr4:55440988	chr4:55387949~55388271:+
HNSC	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-5.4	1.05e-07	3.47e-05	-0.24	-0.24	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
HNSC	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
HNSC	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-5.4	1.05e-07	3.48e-05	-0.22	-0.24	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
HNSC	cis	rs6928977	0.896	rs2746421	ENSG00000234084.1	RP3-388E23.2	5.4	1.05e-07	3.48e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135340491	chr6:135301568~135307158:+
HNSC	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-5.4	1.05e-07	3.49e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
HNSC	cis	rs6928977	0.863	rs2746430	ENSG00000234084.1	RP3-388E23.2	5.4	1.05e-07	3.49e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352154	chr6:135301568~135307158:+
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-5.4	1.05e-07	3.49e-05	-0.22	-0.24	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	5.4	1.05e-07	3.49e-05	0.26	0.24	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	5.4	1.05e-07	3.49e-05	0.26	0.24	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
HNSC	cis	rs1056107	0.966	rs4979094	ENSG00000225513.1	RP11-165N19.2	-5.4	1.05e-07	3.49e-05	-0.26	-0.24	Colorectal cancer;	chr9:112283837	chr9:112173522~112173971:-
HNSC	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-5.4	1.05e-07	3.49e-05	-0.29	-0.24	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
HNSC	cis	rs9287719	0.649	rs10929683	ENSG00000243819.4	RN7SL832P	-5.4	1.05e-07	3.49e-05	-0.25	-0.24	Prostate cancer;	chr2:10592082	chr2:10690344~10692099:+
HNSC	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	5.4	1.05e-07	3.49e-05	0.29	0.24	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
HNSC	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	5.4	1.05e-07	3.49e-05	0.3	0.24	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
HNSC	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	5.4	1.05e-07	3.49e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-5.4	1.05e-07	3.49e-05	-0.22	-0.24	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
HNSC	cis	rs2179367	0.632	rs9498335	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149372648	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498336	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149374208	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs1980774	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149375030	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498337	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149375970	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498338	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149376428	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12196656	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149383104	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12211570	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149383616	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.568	rs11155647	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149384499	chr6:149904243~149906418:+
HNSC	cis	rs6928977	0.86	rs2614266	ENSG00000231028.7	LINC00271	5.4	1.06e-07	3.49e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135395394	chr6:135497801~135716055:+
HNSC	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-5.4	1.06e-07	3.5e-05	-0.3	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
HNSC	cis	rs4713118	0.629	rs203888	ENSG00000204709.4	LINC01556	5.4	1.06e-07	3.5e-05	0.33	0.24	Parkinson's disease;	chr6:28053811	chr6:28943877~28944537:+
HNSC	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	5.4	1.06e-07	3.5e-05	0.34	0.24	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
HNSC	cis	rs860295	0.65	rs2993207	ENSG00000203761.5	MSTO2P	5.4	1.06e-07	3.5e-05	0.18	0.24	Body mass index;	chr1:155903523	chr1:155745829~155750137:+
HNSC	cis	rs6928977	0.827	rs2614265	ENSG00000234084.1	RP3-388E23.2	5.4	1.06e-07	3.5e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135394237	chr6:135301568~135307158:+
HNSC	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	5.4	1.06e-07	3.51e-05	0.35	0.24	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
HNSC	cis	rs6479901	0.793	rs4450077	ENSG00000232075.1	MRPL35P2	-5.4	1.06e-07	3.52e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63634317~63634827:-
HNSC	cis	rs17767294	0.612	rs12332927	ENSG00000219392.1	RP1-265C24.5	-5.4	1.06e-07	3.52e-05	-0.42	-0.24	Parkinson's disease;	chr6:27987337	chr6:28115628~28116551:+
HNSC	cis	rs17507216	0.958	rs28648832	ENSG00000276710.3	CSPG4P8	-5.4	1.06e-07	3.52e-05	-0.31	-0.24	Excessive daytime sleepiness;	chr15:82567642	chr15:82459472~82477258:+
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-5.4	1.06e-07	3.52e-05	-0.22	-0.24	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
HNSC	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-5.4	1.06e-07	3.52e-05	-0.28	-0.24	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
HNSC	cis	rs2243480	1	rs2462569	ENSG00000179406.6	LINC00174	5.4	1.06e-07	3.52e-05	0.5	0.24	Diabetic kidney disease;	chr7:66009859	chr7:66376044~66401338:-
HNSC	cis	rs73607972	0.778	rs55662133	ENSG00000275191.1	RP11-36I17.2	-5.4	1.06e-07	3.52e-05	-0.33	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612761	chr16:53628256~53628816:-
HNSC	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	5.4	1.07e-07	3.53e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-5.4	1.07e-07	3.53e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
HNSC	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	5.4	1.07e-07	3.53e-05	0.42	0.24	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
HNSC	cis	rs7824557	0.547	rs2409745	ENSG00000269918.1	AF131215.9	5.4	1.07e-07	3.53e-05	0.24	0.24	Retinal vascular caliber;	chr8:11219126	chr8:11104691~11106704:-
HNSC	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-5.4	1.07e-07	3.53e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	5.4	1.07e-07	3.53e-05	0.27	0.24	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
HNSC	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-5.4	1.07e-07	3.54e-05	-0.3	-0.24	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
HNSC	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-5.4	1.07e-07	3.54e-05	-0.31	-0.24	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
HNSC	cis	rs5758511	0.508	rs58099562	ENSG00000226450.2	CYP2D8P	5.4	1.07e-07	3.54e-05	0.25	0.24	Birth weight;	chr22:42057768	chr22:42149886~42155001:-
HNSC	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-5.4	1.07e-07	3.55e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
HNSC	cis	rs13113518	0.966	rs7677952	ENSG00000273257.1	RP11-177J6.1	5.4	1.07e-07	3.55e-05	0.29	0.24	Height;	chr4:55425312	chr4:55387949~55388271:+
HNSC	cis	rs8177876	0.731	rs79546329	ENSG00000261061.1	RP11-303E16.2	-5.4	1.07e-07	3.55e-05	-0.46	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103636	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs12448806	ENSG00000261061.1	RP11-303E16.2	-5.4	1.07e-07	3.55e-05	-0.46	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104597	chr16:81030770~81031485:+
HNSC	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-5.4	1.07e-07	3.55e-05	-0.28	-0.24	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
HNSC	cis	rs7819412	0.806	rs2409689	ENSG00000269918.1	AF131215.9	-5.4	1.07e-07	3.55e-05	-0.24	-0.24	Triglycerides;	chr8:11075358	chr8:11104691~11106704:-
HNSC	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	5.4	1.07e-07	3.55e-05	0.3	0.24	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
HNSC	cis	rs6928977	0.66	rs9373131	ENSG00000234084.1	RP3-388E23.2	5.4	1.07e-07	3.55e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135301568~135307158:+
HNSC	cis	rs2976388	0.647	rs2572898	ENSG00000253741.1	CTD-2292P10.4	-5.4	1.07e-07	3.55e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142700856	chr8:142702252~142726973:-
HNSC	cis	rs5758659	0.967	rs5751250	ENSG00000227370.1	RP4-669P10.19	-5.4	1.08e-07	3.56e-05	-0.23	-0.24	Cognitive function;	chr22:42243639	chr22:42132543~42132998:+
HNSC	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	5.4	1.08e-07	3.56e-05	0.18	0.24	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
HNSC	cis	rs10256972	0.678	rs6962989	ENSG00000225146.1	AC073957.15	-5.4	1.08e-07	3.56e-05	-0.43	-0.24	Endometriosis;Longevity;	chr7:977876	chr7:1029025~1043891:+
HNSC	cis	rs9287719	0.649	rs12473957	ENSG00000243819.4	RN7SL832P	-5.4	1.08e-07	3.56e-05	-0.24	-0.24	Prostate cancer;	chr2:10577588	chr2:10690344~10692099:+
HNSC	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	5.4	1.08e-07	3.57e-05	0.23	0.24	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
HNSC	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-5.4	1.08e-07	3.57e-05	-0.27	-0.24	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
HNSC	cis	rs4218	0.689	rs12902628	ENSG00000277144.1	RP11-59H7.4	-5.4	1.08e-07	3.57e-05	-0.32	-0.24	Social communication problems;	chr15:59100193	chr15:59115547~59116089:-
HNSC	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-5.4	1.08e-07	3.57e-05	-0.34	-0.24	Depression;	chr6:28242910	chr6:28115628~28116551:+
HNSC	cis	rs7160336	0.641	rs10136002	ENSG00000259065.1	RP5-1021I20.1	-5.4	1.08e-07	3.58e-05	-0.29	-0.24	Blood protein levels;	chr14:74215072	chr14:73787360~73803270:+
HNSC	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	5.4	1.08e-07	3.58e-05	0.3	0.24	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
HNSC	cis	rs4937076	0.51	rs13424	ENSG00000254967.5	RP11-680F20.6	-5.4	1.08e-07	3.58e-05	-0.27	-0.24	Primary tooth development (time to first tooth eruption);	chr11:125957058	chr11:125950116~125956319:+
HNSC	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-5.4	1.08e-07	3.58e-05	-0.27	-0.24	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000254153.1	CTA-398F10.2	5.4	1.08e-07	3.58e-05	0.27	0.24	Mood instability;	chr8:8525195	chr8:8456909~8461337:-
HNSC	cis	rs2439831	0.867	rs2242068	ENSG00000205771.5	CATSPER2P1	-5.4	1.08e-07	3.58e-05	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43407106	chr15:43726918~43747094:-
HNSC	cis	rs12817211	0.502	rs7135322	ENSG00000272368.2	RP4-605O3.4	-5.4	1.08e-07	3.58e-05	-0.23	-0.24	Colorectal or endometrial cancer;	chr12:50118065	chr12:50112197~50165618:+
HNSC	cis	rs12468226	1	rs7565875	ENSG00000226261.1	AC064836.3	5.4	1.09e-07	3.59e-05	0.35	0.24	Urate levels;	chr2:202516412	chr2:202336024~202336727:-
HNSC	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-5.4	1.09e-07	3.59e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
HNSC	cis	rs72727394	0.51	rs56165729	ENSG00000259747.1	RP11-275I4.2	-5.4	1.09e-07	3.59e-05	-0.33	-0.24	Crohn's disease;	chr15:38627978	chr15:38671847~38689191:+
HNSC	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	5.4	1.09e-07	3.59e-05	0.25	0.24	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
HNSC	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	5.4	1.09e-07	3.59e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	5.4	1.09e-07	3.59e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
HNSC	cis	rs6714900	0.588	rs2287331	ENSG00000234896.1	OR7E62P	-5.4	1.09e-07	3.59e-05	-0.29	-0.24	Blood protein levels;	chr2:71067422	chr2:71055527~71056003:+
HNSC	cis	rs10504130	0.569	rs9650305	ENSG00000272024.1	RP11-546K22.3	-5.4	1.09e-07	3.59e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs9650180	ENSG00000272024.1	RP11-546K22.3	-5.4	1.09e-07	3.59e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51950284~51950690:+
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	5.4	1.09e-07	3.59e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
HNSC	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	5.4	1.09e-07	3.6e-05	0.3	0.24	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
HNSC	cis	rs860295	0.812	rs12024257	ENSG00000203761.5	MSTO2P	-5.4	1.09e-07	3.6e-05	-0.19	-0.24	Body mass index;	chr1:155810745	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.812	rs6657670	ENSG00000203761.5	MSTO2P	-5.4	1.09e-07	3.6e-05	-0.19	-0.24	Body mass index;	chr1:155818076	chr1:155745829~155750137:+
HNSC	cis	rs8054556	1	rs9925915	ENSG00000183604.13	SMG1P5	-5.4	1.09e-07	3.6e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29982365	chr16:30267553~30335374:-
HNSC	cis	rs2579103	0.898	rs2118807	ENSG00000258183.4	RP11-753N8.1	-5.4	1.09e-07	3.6e-05	-0.3	-0.24	Body mass index;	chr12:90205569	chr12:90280894~90300340:+
HNSC	cis	rs4664293	0.867	rs6740910	ENSG00000226266.5	AC009961.3	-5.4	1.09e-07	3.6e-05	-0.27	-0.24	Monocyte percentage of white cells;	chr2:159792709	chr2:159670708~159712435:-
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000254153.1	CTA-398F10.2	5.39	1.09e-07	3.61e-05	0.26	0.24	Neuroticism;	chr8:8237439	chr8:8456909~8461337:-
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	5.39	1.09e-07	3.61e-05	0.26	0.24	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
HNSC	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-5.39	1.09e-07	3.61e-05	-0.23	-0.24	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000254153.1	CTA-398F10.2	-5.39	1.09e-07	3.61e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9037242	chr8:8456909~8461337:-
HNSC	cis	rs2810114	1	rs2810114	ENSG00000274818.1	RP1-292L20.3	-5.39	1.09e-07	3.61e-05	-0.3	-0.24	Alcohol dependence;	chr14:70928887	chr14:70906657~70907111:-
HNSC	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	5.39	1.09e-07	3.61e-05	0.28	0.24	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
HNSC	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-5.39	1.1e-07	3.61e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
HNSC	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	5.39	1.1e-07	3.62e-05	0.29	0.24	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
HNSC	cis	rs2032447	0.613	rs6456708	ENSG00000272462.2	U91328.19	-5.39	1.1e-07	3.62e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr6:26032619	chr6:25992662~26001775:+
HNSC	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	5.39	1.1e-07	3.62e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
HNSC	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	5.39	1.1e-07	3.63e-05	0.32	0.24	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
HNSC	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-5.39	1.1e-07	3.63e-05	-0.29	-0.24	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
HNSC	cis	rs7819412	0.806	rs6980856	ENSG00000269918.1	AF131215.9	5.39	1.1e-07	3.63e-05	0.24	0.24	Triglycerides;	chr8:11080750	chr8:11104691~11106704:-
HNSC	cis	rs17428076	0.836	rs12053046	ENSG00000228389.1	AC068039.4	-5.39	1.1e-07	3.64e-05	-0.29	-0.24	Myopia;	chr2:171816889	chr2:171773482~171775844:+
HNSC	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-5.39	1.1e-07	3.64e-05	-0.29	-0.24	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
HNSC	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	5.39	1.1e-07	3.64e-05	0.27	0.24	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
HNSC	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-5.39	1.1e-07	3.64e-05	-0.3	-0.24	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
HNSC	cis	rs10504130	0.569	rs35032384	ENSG00000272024.1	RP11-546K22.3	-5.39	1.1e-07	3.64e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51910524	chr8:51950284~51950690:+
HNSC	cis	rs2933343	0.7	rs1680779	ENSG00000261159.1	RP11-723O4.9	5.39	1.1e-07	3.64e-05	0.24	0.24	IgG glycosylation;	chr3:128895927	chr3:128859716~128860526:-
HNSC	cis	rs1707322	1	rs10890355	ENSG00000234329.1	RP11-767N6.2	5.39	1.1e-07	3.64e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211204	ENSG00000234329.1	RP11-767N6.2	5.39	1.1e-07	3.64e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45651039~45651826:-
HNSC	cis	rs42490	0.7	rs40250	ENSG00000251136.7	RP11-37B2.1	-5.39	1.1e-07	3.64e-05	-0.22	-0.24	Leprosy;	chr8:89828779	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.7	rs419890	ENSG00000251136.7	RP11-37B2.1	-5.39	1.1e-07	3.64e-05	-0.22	-0.24	Leprosy;	chr8:89829012	chr8:89609409~89757727:-
HNSC	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	5.39	1.1e-07	3.64e-05	0.24	0.24	Height;	chr5:36941665	chr5:36666214~36725195:-
HNSC	cis	rs6928977	0.863	rs2179780	ENSG00000234084.1	RP3-388E23.2	5.39	1.11e-07	3.65e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135329128	chr6:135301568~135307158:+
HNSC	cis	rs9300255	0.537	rs1619561	ENSG00000280120.1	RP11-546D6.3	5.39	1.11e-07	3.65e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135721	chr12:123152324~123153377:-
HNSC	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	5.39	1.11e-07	3.65e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
HNSC	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-5.39	1.11e-07	3.65e-05	-0.24	-0.24	Height;	chr5:37019252	chr5:36666214~36725195:-
HNSC	cis	rs7760535	0.656	rs7766190	ENSG00000255389.1	C6orf3	-5.39	1.11e-07	3.65e-05	-0.22	-0.24	Metabolic traits;	chr6:111583863	chr6:111599875~111602295:+
HNSC	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	5.39	1.11e-07	3.66e-05	0.3	0.24	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.636	rs74090069	ENSG00000254174.1	IGHV1-12	5.39	1.11e-07	3.66e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777532	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74090071	ENSG00000254174.1	IGHV1-12	5.39	1.11e-07	3.66e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777533	chr14:106122420~106122709:-
HNSC	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	5.39	1.11e-07	3.66e-05	0.3	0.24	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
HNSC	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	5.39	1.11e-07	3.66e-05	0.3	0.24	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs13113518	ENSG00000249700.7	SRD5A3-AS1	5.39	1.11e-07	3.66e-05	0.28	0.24	Height;	chr4:55533481	chr4:55363971~55395847:-
HNSC	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	5.39	1.11e-07	3.67e-05	0.3	0.24	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
HNSC	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
HNSC	cis	rs5758659	1	rs5751255	ENSG00000227370.1	RP4-669P10.19	-5.39	1.11e-07	3.67e-05	-0.23	-0.24	Cognitive function;	chr22:42252402	chr22:42132543~42132998:+
HNSC	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	5.39	1.11e-07	3.67e-05	0.25	0.24	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
HNSC	cis	rs11773103	0.881	rs11771569	ENSG00000224046.1	AC005076.5	5.39	1.12e-07	3.68e-05	0.45	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87208752	chr7:87151423~87152420:-
HNSC	cis	rs860295	0.627	rs11264410	ENSG00000203761.5	MSTO2P	-5.39	1.12e-07	3.68e-05	-0.19	-0.24	Body mass index;	chr1:155775558	chr1:155745829~155750137:+
HNSC	cis	rs2439831	0.867	rs3213990	ENSG00000205771.5	CATSPER2P1	-5.39	1.12e-07	3.68e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43378028	chr15:43726918~43747094:-
HNSC	cis	rs2483058	0.767	rs11809494	ENSG00000261000.1	RP11-534L20.5	5.39	1.12e-07	3.68e-05	0.23	0.24	Cholesterol and Triglycerides;	chr1:206450521	chr1:206503948~206504456:+
HNSC	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-5.39	1.12e-07	3.69e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-5.39	1.12e-07	3.69e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
HNSC	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-5.39	1.12e-07	3.69e-05	-0.28	-0.24	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
HNSC	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	5.39	1.12e-07	3.69e-05	0.39	0.24	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	5.39	1.12e-07	3.69e-05	0.39	0.24	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
HNSC	cis	rs12468226	0.938	rs10931993	ENSG00000226261.1	AC064836.3	5.39	1.12e-07	3.69e-05	0.34	0.24	Urate levels;	chr2:202243017	chr2:202336024~202336727:-
HNSC	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	5.39	1.12e-07	3.69e-05	0.27	0.24	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
HNSC	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-5.39	1.12e-07	3.69e-05	-0.24	-0.24	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
HNSC	cis	rs13126694	0.75	rs6833295	ENSG00000248429.4	RP11-597D13.9	5.39	1.12e-07	3.69e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158170752~158202877:+
HNSC	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	5.39	1.12e-07	3.69e-05	0.23	0.24	Asthma;	chr2:102418659	chr2:102438713~102440475:+
HNSC	cis	rs6928977	0.86	rs2757649	ENSG00000234084.1	RP3-388E23.2	-5.39	1.12e-07	3.69e-05	-0.25	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135405475	chr6:135301568~135307158:+
HNSC	cis	rs6714900	0.619	rs7593893	ENSG00000234896.1	OR7E62P	-5.39	1.12e-07	3.69e-05	-0.28	-0.24	Blood protein levels;	chr2:71049433	chr2:71055527~71056003:+
HNSC	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-5.39	1.12e-07	3.7e-05	-0.34	-0.24	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
HNSC	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-5.39	1.12e-07	3.7e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
HNSC	cis	rs3747113	0.732	rs11704465	ENSG00000128262.7	POM121L9P	-5.39	1.12e-07	3.7e-05	-0.28	-0.24	Gut microbiome composition (summer);	chr22:24466629	chr22:24251828~24265525:+
HNSC	cis	rs73198271	0.74	rs964771	ENSG00000173295.6	FAM86B3P	5.39	1.12e-07	3.7e-05	0.31	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8228595~8244865:+
HNSC	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-5.39	1.12e-07	3.7e-05	-0.3	-0.24	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000254153.1	CTA-398F10.2	-5.39	1.12e-07	3.7e-05	-0.26	-0.24	Mood instability;	chr8:8933743	chr8:8456909~8461337:-
HNSC	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-5.39	1.13e-07	3.71e-05	-0.34	-0.24	Depression;	chr6:28237724	chr6:28115628~28116551:+
HNSC	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	5.39	1.13e-07	3.71e-05	0.27	0.24	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
HNSC	cis	rs2337406	0.587	rs2516886	ENSG00000254174.1	IGHV1-12	-5.39	1.13e-07	3.71e-05	-0.19	-0.24	Alzheimer's disease (late onset);	chr14:106649674	chr14:106122420~106122709:-
HNSC	cis	rs73198271	0.694	rs73201840	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.694	rs113694763	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.694	rs115037021	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.694	rs114184516	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8167819~8226614:-
HNSC	cis	rs2302464	1	rs16892287	ENSG00000214846.4	RP11-115L11.1	5.39	1.13e-07	3.71e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15730570	chr4:15730962~15731627:-
HNSC	cis	rs651386	0.529	rs722597	ENSG00000271811.1	RP1-79C4.4	5.39	1.13e-07	3.72e-05	0.27	0.24	Atrial fibrillation;	chr1:170607914	chr1:170667381~170669425:+
HNSC	cis	rs9291683	0.668	rs2241474	ENSG00000250413.1	RP11-448G15.1	-5.39	1.13e-07	3.72e-05	-0.3	-0.24	Bone mineral density;	chr4:10084391	chr4:10006482~10009725:+
HNSC	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-5.39	1.13e-07	3.72e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
HNSC	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-5.39	1.13e-07	3.72e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	5.39	1.13e-07	3.72e-05	0.3	0.24	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	5.39	1.13e-07	3.72e-05	0.3	0.24	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	5.39	1.13e-07	3.72e-05	0.3	0.24	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
HNSC	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-5.39	1.13e-07	3.72e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-5.39	1.13e-07	3.72e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
HNSC	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	5.39	1.13e-07	3.72e-05	0.32	0.24	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
HNSC	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	5.39	1.13e-07	3.72e-05	0.58	0.24	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
HNSC	cis	rs7819412	0.66	rs7462931	ENSG00000269918.1	AF131215.9	-5.39	1.13e-07	3.73e-05	-0.25	-0.24	Triglycerides;	chr8:11052833	chr8:11104691~11106704:-
HNSC	cis	rs860295	0.702	rs11264381	ENSG00000203761.5	MSTO2P	5.39	1.13e-07	3.73e-05	0.19	0.24	Body mass index;	chr1:155552781	chr1:155745829~155750137:+
HNSC	cis	rs13113518	0.812	rs6849474	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55452295	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs2412648	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55454900	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs12512737	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55454938	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs13125984	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55455102	chr4:55387949~55388271:+
HNSC	cis	rs7621025	0.691	rs4678438	ENSG00000273486.1	RP11-731C17.2	5.39	1.13e-07	3.73e-05	0.2	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136626078	chr3:136837338~136839021:-
HNSC	cis	rs763567	1	rs6677540	ENSG00000271811.1	RP1-79C4.4	-5.39	1.13e-07	3.73e-05	-0.26	-0.24	Tonsillectomy;	chr1:170614370	chr1:170667381~170669425:+
HNSC	cis	rs9987353	0.519	rs11779181	ENSG00000254340.1	RP11-10A14.3	5.39	1.13e-07	3.73e-05	0.3	0.24	Recombination measurement;	chr8:9205517	chr8:9141424~9145435:+
HNSC	cis	rs17270561	0.541	rs17586946	ENSG00000272810.1	U91328.22	-5.39	1.13e-07	3.73e-05	-0.27	-0.24	Iron status biomarkers;	chr6:25938825	chr6:26013241~26013757:+
HNSC	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	5.39	1.13e-07	3.73e-05	0.3	0.24	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
HNSC	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-5.39	1.14e-07	3.74e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
HNSC	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-5.39	1.14e-07	3.74e-05	-0.2	-0.24	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
HNSC	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-5.39	1.14e-07	3.74e-05	-0.2	-0.24	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-5.39	1.14e-07	3.74e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
HNSC	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-5.39	1.14e-07	3.74e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
HNSC	cis	rs5758659	1	rs5758659	ENSG00000227370.1	RP4-669P10.19	-5.39	1.14e-07	3.75e-05	-0.23	-0.24	Cognitive function;	chr22:42225997	chr22:42132543~42132998:+
HNSC	cis	rs6928977	0.86	rs2614264	ENSG00000234084.1	RP3-388E23.2	-5.39	1.14e-07	3.75e-05	-0.24	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135301568~135307158:+
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	5.39	1.14e-07	3.75e-05	0.26	0.24	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
HNSC	cis	rs4699052	0.963	rs11097804	ENSG00000246560.2	RP11-10L12.4	5.39	1.14e-07	3.75e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103293980	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.928	rs4456958	ENSG00000246560.2	RP11-10L12.4	5.39	1.14e-07	3.75e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103294175	chr4:102828055~102844075:+
HNSC	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-5.39	1.14e-07	3.75e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
HNSC	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-5.39	1.14e-07	3.75e-05	-0.31	-0.24	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
HNSC	cis	rs7804306	0.655	rs34746652	ENSG00000233264.2	AC006042.8	5.39	1.14e-07	3.76e-05	0.46	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8012957	chr7:7980312~7982228:+
HNSC	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-5.39	1.14e-07	3.76e-05	-0.3	-0.24	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
HNSC	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-5.39	1.14e-07	3.76e-05	-0.23	-0.24	Breast cancer;	chr11:743813	chr11:781645~782105:+
HNSC	cis	rs60617249	0.519	rs2107695	ENSG00000228204.2	RP4-724E13.2	5.39	1.14e-07	3.76e-05	0.28	0.24	Major depression and alcohol dependence;	chr7:50882640	chr7:50866747~51022990:+
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	5.39	1.14e-07	3.76e-05	0.26	0.24	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
HNSC	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	5.39	1.14e-07	3.76e-05	0.3	0.24	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
HNSC	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-5.39	1.14e-07	3.76e-05	-0.35	-0.24	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
HNSC	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-5.39	1.14e-07	3.76e-05	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
HNSC	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	5.39	1.14e-07	3.77e-05	0.32	0.24	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
HNSC	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-5.39	1.15e-07	3.77e-05	-0.26	-0.24	Height;	chr2:46627225	chr2:46668870~46670778:+
HNSC	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	5.39	1.15e-07	3.77e-05	0.23	0.24	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
HNSC	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-5.39	1.15e-07	3.77e-05	-0.31	-0.24	Depression;	chr6:28173770	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-5.39	1.15e-07	3.77e-05	-0.31	-0.24	Depression;	chr6:28174809	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-5.39	1.15e-07	3.77e-05	-0.31	-0.24	Depression;	chr6:28175233	chr6:28161781~28169594:+
HNSC	cis	rs4699052	1	rs4699052	ENSG00000246560.2	RP11-10L12.4	5.39	1.15e-07	3.77e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103216633	chr4:102828055~102844075:+
HNSC	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-5.39	1.15e-07	3.77e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
HNSC	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-5.39	1.15e-07	3.77e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
HNSC	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	5.39	1.15e-07	3.77e-05	0.25	0.24	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
HNSC	cis	rs5742933	0.597	rs6756913	ENSG00000253559.1	OSGEPL1-AS1	5.39	1.15e-07	3.77e-05	0.27	0.24	Ferritin levels;	chr2:189641040	chr2:189762704~189765556:+
HNSC	cis	rs9914544	1	rs9914544	ENSG00000264885.1	RP11-815I9.4	-5.39	1.15e-07	3.77e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18884515	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.966	rs9915346	ENSG00000264885.1	RP11-815I9.4	-5.39	1.15e-07	3.77e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18884618	chr17:18667629~18669461:-
HNSC	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-5.39	1.15e-07	3.78e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
HNSC	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-5.39	1.15e-07	3.78e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
HNSC	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-5.39	1.15e-07	3.78e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
HNSC	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-5.39	1.15e-07	3.78e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-5.39	1.15e-07	3.78e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
HNSC	cis	rs656319	0.607	rs35437983	ENSG00000269918.1	AF131215.9	-5.39	1.15e-07	3.78e-05	-0.25	-0.24	Myopia (pathological);	chr8:10147543	chr8:11104691~11106704:-
HNSC	cis	rs42490	1	rs431264	ENSG00000251136.7	RP11-37B2.1	-5.39	1.15e-07	3.78e-05	-0.21	-0.24	Leprosy;	chr8:89765282	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs42490	ENSG00000251136.7	RP11-37B2.1	-5.39	1.15e-07	3.78e-05	-0.21	-0.24	Leprosy;	chr8:89766285	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs40544	ENSG00000251136.7	RP11-37B2.1	-5.39	1.15e-07	3.78e-05	-0.21	-0.24	Leprosy;	chr8:89768867	chr8:89609409~89757727:-
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-5.38	1.15e-07	3.78e-05	-0.15	-0.24	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
HNSC	cis	rs2243480	1	rs4718269	ENSG00000179406.6	LINC00174	5.38	1.15e-07	3.78e-05	0.51	0.24	Diabetic kidney disease;	chr7:65735810	chr7:66376044~66401338:-
HNSC	cis	rs860295	0.836	rs6684889	ENSG00000203761.5	MSTO2P	5.38	1.15e-07	3.79e-05	0.18	0.24	Body mass index;	chr1:155457271	chr1:155745829~155750137:+
HNSC	cis	rs1355223	0.902	rs448016	ENSG00000271369.1	RP11-350D17.3	5.38	1.15e-07	3.79e-05	0.28	0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34685046	chr11:34709600~34710161:+
HNSC	cis	rs889014	0.724	rs10062678	ENSG00000253768.1	CTB-33O18.1	5.38	1.15e-07	3.79e-05	0.27	0.24	Height;	chr5:173545046	chr5:173562478~173573199:+
HNSC	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	5.38	1.15e-07	3.79e-05	0.28	0.24	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
HNSC	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	5.38	1.15e-07	3.79e-05	0.31	0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
HNSC	cis	rs11648785	0.59	rs4324129	ENSG00000222019.6	URAHP	5.38	1.15e-07	3.79e-05	0.23	0.24	Tanning;	chr16:90032653	chr16:90039761~90047773:-
HNSC	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.38	1.15e-07	3.79e-05	0.24	0.24	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.8e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
HNSC	cis	rs1008375	0.966	rs3775927	ENSG00000249502.1	AC006160.5	-5.38	1.16e-07	3.8e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17598271	chr4:17587467~17614571:-
HNSC	cis	rs8054556	1	rs11642046	ENSG00000183604.13	SMG1P5	-5.38	1.16e-07	3.8e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:30267553~30335374:-
HNSC	cis	rs4763879	0.593	rs7960328	ENSG00000256673.1	RP11-599J14.2	5.38	1.16e-07	3.8e-05	0.23	0.24	Type 1 diabetes;	chr12:9699584	chr12:9398355~9414851:-
HNSC	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
HNSC	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.8e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.8e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
HNSC	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-5.38	1.16e-07	3.81e-05	-0.29	-0.24	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
HNSC	cis	rs10256972	0.605	rs10251094	ENSG00000224079.1	AC091729.7	-5.38	1.16e-07	3.82e-05	-0.45	-0.24	Endometriosis;Longevity;	chr7:977447	chr7:1074450~1078036:+
HNSC	cis	rs36093844	0.615	rs77258124	ENSG00000279742.1	RP11-700A24.1	-5.38	1.16e-07	3.82e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867038	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.8	rs76663264	ENSG00000279742.1	RP11-700A24.1	-5.38	1.16e-07	3.82e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867412	chr11:85852557~85854943:-
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.82e-05	0.26	0.24	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.82e-05	0.26	0.24	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
HNSC	cis	rs7567389	0.504	rs2069895	ENSG00000236682.1	AC068282.3	-5.38	1.16e-07	3.82e-05	-0.31	-0.24	Self-rated health;	chr2:127416492	chr2:127389130~127400580:+
HNSC	cis	rs7617773	0.539	rs35460860	ENSG00000228638.1	FCF1P2	-5.38	1.16e-07	3.82e-05	-0.22	-0.24	Coronary artery disease;	chr3:48350595	chr3:48290793~48291375:-
HNSC	cis	rs6951245	0.832	rs79808627	ENSG00000225146.1	AC073957.15	-5.38	1.17e-07	3.83e-05	-0.38	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052883	chr7:1029025~1043891:+
HNSC	cis	rs860818	1	rs858254	ENSG00000226816.2	AC005082.12	5.38	1.17e-07	3.83e-05	0.6	0.24	Initial pursuit acceleration;	chr7:23177584	chr7:23206013~23208045:+
HNSC	cis	rs9300255	0.602	rs1727315	ENSG00000280120.1	RP11-546D6.3	-5.38	1.17e-07	3.83e-05	-0.22	-0.24	Neutrophil percentage of white cells;	chr12:123154383	chr12:123152324~123153377:-
HNSC	cis	rs1355223	0.752	rs896856	ENSG00000271369.1	RP11-350D17.3	-5.38	1.17e-07	3.83e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34655295	chr11:34709600~34710161:+
HNSC	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	5.38	1.17e-07	3.83e-05	0.27	0.24	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
HNSC	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-5.38	1.17e-07	3.84e-05	-0.2	-0.24	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
HNSC	cis	rs783540	0.609	rs803686	ENSG00000255769.6	GOLGA2P10	5.38	1.17e-07	3.84e-05	0.32	0.24	Schizophrenia;	chr15:82550590	chr15:82472993~82513950:-
HNSC	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-5.38	1.17e-07	3.85e-05	-0.26	-0.24	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
HNSC	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-5.38	1.17e-07	3.85e-05	-0.22	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000223648.3	IGHV3-64	5.38	1.17e-07	3.85e-05	0.19	0.24	Kawasaki disease;	chr14:106708947	chr14:106643132~106658258:-
HNSC	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	5.38	1.17e-07	3.85e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
HNSC	cis	rs67981189	0.546	rs2810075	ENSG00000274818.1	RP1-292L20.3	-5.38	1.17e-07	3.85e-05	-0.3	-0.24	Schizophrenia;	chr14:70908363	chr14:70906657~70907111:-
HNSC	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-5.38	1.17e-07	3.85e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
HNSC	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	5.38	1.17e-07	3.85e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
HNSC	cis	rs2337406	0.866	rs111881598	ENSG00000211974.3	IGHV2-70	-5.38	1.18e-07	3.86e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783113	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs61164979	ENSG00000211974.3	IGHV2-70	-5.38	1.18e-07	3.86e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783133	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs61419485	ENSG00000211974.3	IGHV2-70	-5.38	1.18e-07	3.86e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783374	chr14:106723574~106724093:-
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	5.38	1.18e-07	3.86e-05	0.26	0.24	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	5.38	1.18e-07	3.86e-05	0.26	0.24	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
HNSC	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-5.38	1.18e-07	3.86e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
HNSC	cis	rs2337406	0.85	rs10131280	ENSG00000274576.2	IGHV2-70	-5.38	1.18e-07	3.87e-05	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106665591	chr14:106770577~106771020:-
HNSC	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-5.38	1.18e-07	3.87e-05	-0.39	-0.24	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
HNSC	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	5.38	1.18e-07	3.87e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
HNSC	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	5.38	1.18e-07	3.87e-05	0.21	0.24	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
HNSC	cis	rs180730	0.561	rs2892917	ENSG00000251609.2	SETP12	-5.38	1.18e-07	3.87e-05	-0.29	-0.24	Fasting plasma glucose;	chr4:120898600	chr4:120895494~120897083:-
HNSC	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-5.38	1.18e-07	3.87e-05	-0.23	-0.24	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
HNSC	cis	rs6964833	0.935	rs34630792	ENSG00000184616.8	AC004166.6	5.38	1.18e-07	3.87e-05	0.3	0.24	Menarche (age at onset);	chr7:74646869	chr7:74906673~74913256:-
HNSC	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	5.38	1.18e-07	3.88e-05	0.29	0.24	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
HNSC	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	5.38	1.18e-07	3.88e-05	0.27	0.24	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	5.38	1.18e-07	3.88e-05	0.27	0.24	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
HNSC	cis	rs4699052	1	rs6533060	ENSG00000246560.2	RP11-10L12.4	5.38	1.18e-07	3.88e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103218839	chr4:102828055~102844075:+
HNSC	cis	rs3806843	0.735	rs801183	ENSG00000202515.1	VTRNA1-3	-5.38	1.18e-07	3.88e-05	-0.27	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr5:140726158~140726246:+
HNSC	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-5.38	1.19e-07	3.89e-05	-0.22	-0.24	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-5.38	1.19e-07	3.89e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-5.38	1.19e-07	3.89e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
HNSC	cis	rs9291683	0.679	rs3756225	ENSG00000250413.1	RP11-448G15.1	5.38	1.19e-07	3.89e-05	0.3	0.24	Bone mineral density;	chr4:10092509	chr4:10006482~10009725:+
HNSC	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	5.38	1.19e-07	3.89e-05	0.29	0.24	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
HNSC	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-5.38	1.19e-07	3.9e-05	-0.2	-0.24	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
HNSC	cis	rs4699052	0.963	rs6816055	ENSG00000246560.2	RP11-10L12.4	5.38	1.19e-07	3.9e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103222003	chr4:102828055~102844075:+
HNSC	cis	rs950169	0.881	rs150965	ENSG00000229212.6	RP11-561C5.4	-5.38	1.19e-07	3.9e-05	-0.34	-0.24	Schizophrenia;	chr15:84537296	chr15:85205440~85234795:-
HNSC	cis	rs36093844	0.752	rs17817308	ENSG00000279742.1	RP11-700A24.1	-5.38	1.19e-07	3.9e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882486	chr11:85852557~85854943:-
HNSC	cis	rs60617249	0.507	rs12718991	ENSG00000228204.2	RP4-724E13.2	5.38	1.19e-07	3.9e-05	0.31	0.24	Major depression and alcohol dependence;	chr7:50917570	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.507	rs17725573	ENSG00000228204.2	RP4-724E13.2	5.38	1.19e-07	3.9e-05	0.31	0.24	Major depression and alcohol dependence;	chr7:50918320	chr7:50866747~51022990:+
HNSC	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-5.38	1.19e-07	3.91e-05	-0.31	-0.24	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
HNSC	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	5.38	1.19e-07	3.91e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
HNSC	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	5.38	1.19e-07	3.91e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	5.38	1.19e-07	3.91e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
HNSC	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	5.38	1.19e-07	3.91e-05	0.31	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
HNSC	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-5.38	1.19e-07	3.91e-05	-0.2	-0.24	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
HNSC	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	5.38	1.19e-07	3.91e-05	0.33	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
HNSC	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-5.38	1.19e-07	3.91e-05	-0.33	-0.24	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
HNSC	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-5.38	1.19e-07	3.91e-05	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
HNSC	cis	rs853679	0.723	rs9366718	ENSG00000204709.4	LINC01556	5.38	1.19e-07	3.91e-05	0.35	0.24	Depression;	chr6:28237724	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	5.38	1.2e-07	3.92e-05	0.26	0.24	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
HNSC	cis	rs13113518	1	rs1047354	ENSG00000273257.1	RP11-177J6.1	5.38	1.2e-07	3.92e-05	0.29	0.24	Height;	chr4:55429416	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs1056547	ENSG00000273257.1	RP11-177J6.1	5.38	1.2e-07	3.92e-05	0.29	0.24	Height;	chr4:55430596	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs6828570	ENSG00000273257.1	RP11-177J6.1	5.38	1.2e-07	3.92e-05	0.29	0.24	Height;	chr4:55431595	chr4:55387949~55388271:+
HNSC	cis	rs526231	0.824	rs253755	ENSG00000175749.11	EIF3KP1	5.38	1.2e-07	3.92e-05	0.3	0.24	Primary biliary cholangitis;	chr5:103295232	chr5:103032376~103033031:+
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000254153.1	CTA-398F10.2	5.38	1.2e-07	3.92e-05	0.26	0.24	Mood instability;	chr8:8726834	chr8:8456909~8461337:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	5.38	1.2e-07	3.93e-05	0.2	0.24	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	5.38	1.2e-07	3.93e-05	0.29	0.24	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
HNSC	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	5.38	1.2e-07	3.93e-05	0.32	0.24	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
HNSC	cis	rs11976180	1	rs13243677	ENSG00000273234.1	OR2A13P	-5.38	1.2e-07	3.93e-05	-0.27	-0.24	Obesity-related traits;	chr7:144049479	chr7:144142009~144142938:+
HNSC	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-5.38	1.2e-07	3.93e-05	-0.28	-0.24	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2167494	ENSG00000249207.1	RP11-360F5.1	5.38	1.2e-07	3.93e-05	0.29	0.24	Cognitive function;	chr4:39214601	chr4:39112677~39126818:-
HNSC	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-5.38	1.2e-07	3.93e-05	-0.31	-0.24	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
HNSC	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	5.38	1.2e-07	3.93e-05	0.36	0.24	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
HNSC	cis	rs3733585	0.673	rs6840802	ENSG00000250413.1	RP11-448G15.1	-5.38	1.2e-07	3.94e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9964009	chr4:10006482~10009725:+
HNSC	cis	rs860295	0.812	rs3820594	ENSG00000203761.5	MSTO2P	-5.38	1.2e-07	3.94e-05	-0.19	-0.24	Body mass index;	chr1:155859720	chr1:155745829~155750137:+
HNSC	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-5.38	1.2e-07	3.94e-05	-0.34	-0.24	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
HNSC	cis	rs9650657	0.537	rs4841457	ENSG00000269918.1	AF131215.9	-5.38	1.2e-07	3.94e-05	-0.24	-0.24	Neuroticism;	chr8:10916001	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000211972.2	IGHV3-66	5.38	1.21e-07	3.94e-05	0.19	0.24	Kawasaki disease;	chr14:106767441	chr14:106675017~106675544:-
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-5.38	1.21e-07	3.94e-05	-0.29	-0.24	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
HNSC	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	5.38	1.21e-07	3.94e-05	0.23	0.24	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-5.38	1.21e-07	3.95e-05	-0.14	-0.24	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000254153.1	CTA-398F10.2	-5.38	1.21e-07	3.95e-05	-0.27	-0.24	Mood instability;	chr8:8723898	chr8:8456909~8461337:-
HNSC	cis	rs3002131	0.604	rs1319392	ENSG00000225265.1	TAF1A-AS1	-5.38	1.21e-07	3.95e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222567271	chr1:222589825~222593032:+
HNSC	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-5.38	1.21e-07	3.95e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
HNSC	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-5.38	1.21e-07	3.95e-05	-0.31	-0.24	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-5.38	1.21e-07	3.95e-05	-0.31	-0.24	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
HNSC	cis	rs988913	1	rs6941796	ENSG00000224984.1	RP11-524H19.2	5.38	1.21e-07	3.96e-05	0.27	0.24	Menarche (age at onset);	chr6:54972823	chr6:54840118~54840855:-
HNSC	cis	rs2439831	0.85	rs2439832	ENSG00000205771.5	CATSPER2P1	-5.37	1.21e-07	3.97e-05	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43487488	chr15:43726918~43747094:-
HNSC	cis	rs5753618	0.583	rs8141150	ENSG00000236132.1	CTA-440B3.1	-5.37	1.21e-07	3.97e-05	-0.3	-0.24	Colorectal cancer;	chr22:31404350	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs9606839	ENSG00000236132.1	CTA-440B3.1	-5.37	1.21e-07	3.97e-05	-0.3	-0.24	Colorectal cancer;	chr22:31406724	chr22:31816379~31817491:-
HNSC	cis	rs7048146	0.509	rs7020545	ENSG00000213539.4	YBX1P6	5.37	1.21e-07	3.97e-05	0.34	0.24	Vascular brain injury;	chr9:109567309	chr9:109532830~109534332:-
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-5.37	1.21e-07	3.97e-05	-0.15	-0.24	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
HNSC	cis	rs35542019	1	rs35542019	ENSG00000273102.1	AP000569.9	5.37	1.21e-07	3.97e-05	0.26	0.24	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33967101~33968573:-
HNSC	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	5.37	1.21e-07	3.97e-05	0.3	0.24	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	5.37	1.21e-07	3.97e-05	0.26	0.24	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	5.37	1.22e-07	3.97e-05	0.26	0.24	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
HNSC	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-5.37	1.22e-07	3.98e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
HNSC	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-5.37	1.22e-07	3.98e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
HNSC	cis	rs11846409	0.932	rs731012	ENSG00000274576.2	IGHV2-70	-5.37	1.22e-07	3.98e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632578	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs731011	ENSG00000274576.2	IGHV2-70	-5.37	1.22e-07	3.98e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632619	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs10138537	ENSG00000274576.2	IGHV2-70	-5.37	1.22e-07	3.98e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632778	chr14:106770577~106771020:-
HNSC	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-5.37	1.22e-07	3.98e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
HNSC	cis	rs4535700	0.501	rs6943341	ENSG00000226278.1	PSPHP1	5.37	1.22e-07	3.98e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55907489	chr7:55764797~55773288:+
HNSC	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-5.37	1.22e-07	3.98e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
HNSC	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	5.37	1.22e-07	3.99e-05	0.21	0.24	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
HNSC	cis	rs9813712	0.855	rs6806152	ENSG00000249846.5	RP11-77P16.4	-5.37	1.22e-07	3.99e-05	-0.29	-0.24	Response to amphetamines;	chr3:130245358	chr3:130112550~130120579:+
HNSC	cis	rs36093844	0.752	rs17744675	ENSG00000279742.1	RP11-700A24.1	5.37	1.22e-07	3.99e-05	0.32	0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882863	chr11:85852557~85854943:-
HNSC	cis	rs526231	0.764	rs2116755	ENSG00000175749.11	EIF3KP1	5.37	1.22e-07	3.99e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103314187	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.764	rs372564	ENSG00000175749.11	EIF3KP1	5.37	1.22e-07	3.99e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103314823	chr5:103032376~103033031:+
HNSC	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-5.37	1.22e-07	3.99e-05	-0.23	-0.24	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
HNSC	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-5.37	1.22e-07	3.99e-05	-0.31	-0.24	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
HNSC	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-5.37	1.22e-07	4e-05	-0.3	-0.24	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
HNSC	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-5.37	1.22e-07	4e-05	-0.27	-0.24	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	5.37	1.23e-07	4.01e-05	0.26	0.24	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	5.37	1.23e-07	4.01e-05	0.26	0.24	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
HNSC	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	5.37	1.23e-07	4.01e-05	0.26	0.24	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
HNSC	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	5.37	1.23e-07	4.01e-05	0.3	0.24	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
HNSC	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-5.37	1.23e-07	4.01e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-5.37	1.23e-07	4.01e-05	-0.14	-0.24	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
HNSC	cis	rs4535700	0.501	rs2135116	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55923451	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.543	rs2174459	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55923600	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.504	rs66528253	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55929070	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.501	rs11765577	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55930245	chr7:55764797~55773288:+
HNSC	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-5.37	1.23e-07	4.02e-05	-0.3	-0.24	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-5.37	1.23e-07	4.02e-05	-0.16	-0.24	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
HNSC	cis	rs9859260	0.744	rs539816	ENSG00000207650.1	MIR570	-5.37	1.23e-07	4.02e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196057205	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.744	rs492349	ENSG00000207650.1	MIR570	-5.37	1.23e-07	4.02e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196057321	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.744	rs492288	ENSG00000207650.1	MIR570	-5.37	1.23e-07	4.02e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196057339	chr3:195699401~195699497:+
HNSC	cis	rs10435719	0.902	rs7459983	ENSG00000206014.6	OR7E161P	-5.37	1.23e-07	4.02e-05	-0.26	-0.24	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:11928597~11929563:-
HNSC	cis	rs2404602	0.536	rs11072599	ENSG00000259422.1	RP11-593F23.1	5.37	1.23e-07	4.02e-05	0.28	0.24	Blood metabolite levels;	chr15:76482167	chr15:76174891~76181486:-
HNSC	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	5.37	1.23e-07	4.03e-05	0.26	0.24	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
HNSC	cis	rs9992667	0.955	rs6855993	ENSG00000231160.8	KLF3-AS1	5.37	1.23e-07	4.03e-05	0.27	0.24	Eosinophil percentage of granulocytes;	chr4:38607291	chr4:38612701~38664883:-
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000211972.2	IGHV3-66	-5.37	1.23e-07	4.03e-05	-0.19	-0.24	Kawasaki disease;	chr14:106771605	chr14:106675017~106675544:-
HNSC	cis	rs2337406	0.789	rs9324095	ENSG00000254174.1	IGHV1-12	5.37	1.24e-07	4.03e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106795885	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs58154560	ENSG00000254174.1	IGHV1-12	5.37	1.24e-07	4.03e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106799601	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs756588	ENSG00000274576.2	IGHV2-70	5.37	1.24e-07	4.03e-05	0.24	0.24	Rheumatic heart disease;	chr14:106632316	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.86	rs55745256	ENSG00000274576.2	IGHV2-70	-5.37	1.24e-07	4.03e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632365	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs731013	ENSG00000274576.2	IGHV2-70	-5.37	1.24e-07	4.03e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632481	chr14:106770577~106771020:-
HNSC	cis	rs4140799	0.845	rs2286135	ENSG00000266869.1	RP6-114E22.1	5.37	1.24e-07	4.03e-05	0.3	0.24	Neuroticism;	chr14:71703041	chr14:71848606~71908430:+
HNSC	cis	rs3733585	0.638	rs28715627	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956516	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.664	rs17245436	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956545	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.638	rs17185835	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956556	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.664	rs17185870	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956590	chr4:10006482~10009725:+
HNSC	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	5.37	1.24e-07	4.04e-05	0.29	0.24	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-5.37	1.24e-07	4.04e-05	-0.15	-0.24	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
HNSC	cis	rs9402743	0.671	rs6925684	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615740	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs6905536	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615865	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs6905555	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615894	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9402725	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135616509	chr6:135636086~135636713:-
HNSC	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-5.37	1.24e-07	4.05e-05	-0.43	-0.24	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
HNSC	cis	rs7674212	0.541	rs2720464	ENSG00000246560.2	RP11-10L12.4	5.37	1.24e-07	4.05e-05	0.27	0.24	Type 2 diabetes;	chr4:103152044	chr4:102828055~102844075:+
HNSC	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	5.37	1.24e-07	4.05e-05	0.64	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
HNSC	cis	rs72949976	0.511	rs11903721	ENSG00000270659.1	RP11-105N14.1	5.37	1.24e-07	4.06e-05	0.24	0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213152028	chr2:213152970~213153659:+
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-5.37	1.25e-07	4.06e-05	-0.14	-0.24	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
HNSC	cis	rs7630852	0.965	rs6774504	ENSG00000272359.1	U4	5.37	1.25e-07	4.07e-05	0.26	0.24	Eosinophil counts;	chr3:196784021	chr3:196747192~196747324:-
HNSC	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-5.37	1.25e-07	4.07e-05	-0.2	-0.24	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
HNSC	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-5.37	1.25e-07	4.07e-05	-0.2	-0.24	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
HNSC	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-5.37	1.25e-07	4.07e-05	-0.2	-0.24	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
HNSC	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-5.37	1.25e-07	4.07e-05	-0.31	-0.24	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-5.37	1.25e-07	4.07e-05	-0.31	-0.24	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
HNSC	cis	rs116095464	1	rs2721025	ENSG00000277812.1	AC021087.1	5.37	1.25e-07	4.07e-05	0.55	0.24	Breast cancer;	chr5:347329	chr5:262769~262881:+
HNSC	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-5.37	1.25e-07	4.08e-05	-0.29	-0.24	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
HNSC	cis	rs13113518	0.812	rs4864996	ENSG00000273257.1	RP11-177J6.1	5.37	1.25e-07	4.08e-05	0.3	0.24	Height;	chr4:55452921	chr4:55387949~55388271:+
HNSC	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-5.37	1.25e-07	4.08e-05	-0.28	-0.24	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
HNSC	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	5.37	1.25e-07	4.08e-05	0.3	0.24	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
HNSC	cis	rs9890032	0.52	rs2321926	ENSG00000263531.1	RP13-753N3.1	5.37	1.25e-07	4.09e-05	0.29	0.24	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30863921~30864940:-
HNSC	cis	rs860295	0.812	rs11264413	ENSG00000203761.5	MSTO2P	-5.37	1.25e-07	4.09e-05	-0.19	-0.24	Body mass index;	chr1:155818865	chr1:155745829~155750137:+
HNSC	cis	rs6928977	0.863	rs9389286	ENSG00000234084.1	RP3-388E23.2	5.37	1.25e-07	4.09e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135319827	chr6:135301568~135307158:+
HNSC	cis	rs3733585	0.699	rs6449171	ENSG00000250413.1	RP11-448G15.1	-5.37	1.25e-07	4.09e-05	-0.29	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9964374	chr4:10006482~10009725:+
HNSC	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	5.37	1.25e-07	4.09e-05	0.29	0.24	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
HNSC	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	5.37	1.25e-07	4.09e-05	0.26	0.24	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
HNSC	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-5.37	1.26e-07	4.09e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
HNSC	cis	rs889014	0.751	rs11742164	ENSG00000253768.1	CTB-33O18.1	-5.37	1.26e-07	4.1e-05	-0.26	-0.24	Height;	chr5:173550708	chr5:173562478~173573199:+
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	5.37	1.26e-07	4.11e-05	0.26	0.24	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
HNSC	cis	rs7777677	1	rs7777677	ENSG00000244273.1	PGBD4P1	-5.37	1.26e-07	4.11e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142722358~142722764:+
HNSC	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	5.37	1.26e-07	4.11e-05	0.29	0.24	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
HNSC	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	5.37	1.26e-07	4.11e-05	0.3	0.24	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	5.37	1.26e-07	4.11e-05	0.26	0.24	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
HNSC	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	5.37	1.26e-07	4.11e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	5.37	1.26e-07	4.11e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
HNSC	cis	rs2439831	1	rs2467426	ENSG00000205771.5	CATSPER2P1	-5.37	1.26e-07	4.11e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43697320	chr15:43726918~43747094:-
HNSC	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-5.37	1.26e-07	4.12e-05	-0.27	-0.24	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
HNSC	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-5.37	1.26e-07	4.12e-05	-0.23	-0.24	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
HNSC	cis	rs822354	1	rs822355	ENSG00000226652.2	PSMD10P2	5.37	1.26e-07	4.12e-05	0.26	0.24	Adiponectin levels;	chr3:186762334	chr3:186760693~186762050:+
HNSC	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	5.37	1.27e-07	4.12e-05	0.27	0.24	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	5.37	1.27e-07	4.12e-05	0.27	0.24	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	5.37	1.27e-07	4.13e-05	0.29	0.24	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	5.37	1.27e-07	4.13e-05	0.27	0.24	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
HNSC	cis	rs11976180	1	rs6464573	ENSG00000273234.1	OR2A13P	5.37	1.27e-07	4.14e-05	0.27	0.24	Obesity-related traits;	chr7:144051005	chr7:144142009~144142938:+
HNSC	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.37	1.27e-07	4.14e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.37	1.27e-07	4.14e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
HNSC	cis	rs9880211	0.563	rs9848926	ENSG00000273486.1	RP11-731C17.2	5.37	1.27e-07	4.14e-05	0.21	0.24	Height;Body mass index;	chr3:136097460	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.66	rs10093926	ENSG00000173295.6	FAM86B3P	-5.37	1.27e-07	4.14e-05	-0.28	-0.24	Mood instability;	chr8:8691510	chr8:8228595~8244865:+
HNSC	cis	rs9813712	0.571	rs11715351	ENSG00000249846.5	RP11-77P16.4	-5.37	1.27e-07	4.14e-05	-0.26	-0.24	Response to amphetamines;	chr3:130214704	chr3:130112550~130120579:+
HNSC	cis	rs9840812	0.769	rs483465	ENSG00000273486.1	RP11-731C17.2	5.37	1.27e-07	4.15e-05	0.21	0.24	Fibrinogen levels;	chr3:136329135	chr3:136837338~136839021:-
HNSC	cis	rs3738443	0.545	rs12566906	ENSG00000259865.1	RP11-488L18.10	5.37	1.27e-07	4.15e-05	0.19	0.24	Alcohol dependence;	chr1:247224904	chr1:247187281~247188526:-
HNSC	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	5.37	1.27e-07	4.15e-05	0.33	0.24	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
HNSC	cis	rs11846409	0.932	rs60659763	ENSG00000211974.3	IGHV2-70	-5.37	1.28e-07	4.15e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634172	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs57080270	ENSG00000211974.3	IGHV2-70	-5.37	1.28e-07	4.15e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634215	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs60917084	ENSG00000211974.3	IGHV2-70	-5.37	1.28e-07	4.15e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634621	chr14:106723574~106724093:-
HNSC	cis	rs4252134	0.615	rs73029749	ENSG00000231863.1	RP3-428L16.1	-5.37	1.28e-07	4.16e-05	-0.32	-0.24	Giant cell arteritis;	chr6:160847379	chr6:160931080~160969771:+
HNSC	cis	rs2239557	1	rs11159067	ENSG00000259065.1	RP5-1021I20.1	-5.36	1.28e-07	4.16e-05	-0.27	-0.24	Common traits (Other);	chr14:74170741	chr14:73787360~73803270:+
HNSC	cis	rs2058059	0.511	rs66624667	ENSG00000225648.4	SBDSP1	-5.36	1.28e-07	4.16e-05	-0.35	-0.24	Subcutaneous adipose tissue;	chr7:72565634	chr7:72829425~72836701:+
HNSC	cis	rs2058059	0.551	rs58608277	ENSG00000225648.4	SBDSP1	-5.36	1.28e-07	4.16e-05	-0.35	-0.24	Subcutaneous adipose tissue;	chr7:72567083	chr7:72829425~72836701:+
HNSC	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	5.36	1.28e-07	4.16e-05	0.29	0.24	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	5.36	1.28e-07	4.17e-05	0.32	0.24	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
HNSC	cis	rs2243480	1	rs34703416	ENSG00000179406.6	LINC00174	-5.36	1.28e-07	4.17e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65835655	chr7:66376044~66401338:-
HNSC	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	5.36	1.28e-07	4.17e-05	0.36	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	5.36	1.28e-07	4.17e-05	0.29	0.24	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
HNSC	cis	rs6951245	0.572	rs74791540	ENSG00000225146.1	AC073957.15	-5.36	1.28e-07	4.17e-05	-0.5	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1022277	chr7:1029025~1043891:+
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	5.36	1.28e-07	4.17e-05	0.26	0.24	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
HNSC	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	5.36	1.28e-07	4.17e-05	0.28	0.24	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
HNSC	cis	rs9341808	0.519	rs660888	ENSG00000272129.1	RP11-250B2.6	5.36	1.28e-07	4.17e-05	0.28	0.24	Sitting height ratio;	chr6:80273495	chr6:80355424~80356859:+
HNSC	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-5.36	1.28e-07	4.18e-05	-0.26	-0.24	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
HNSC	cis	rs71520386	0.632	rs12535331	ENSG00000221740.1	SNORD93	5.36	1.28e-07	4.18e-05	0.28	0.24	Fibrinogen levels;	chr7:22838485	chr7:22856613~22856686:+
HNSC	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	5.36	1.29e-07	4.18e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
HNSC	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	5.36	1.29e-07	4.18e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
HNSC	cis	rs11846409	0.932	rs61233250	ENSG00000211974.3	IGHV2-70	-5.36	1.29e-07	4.19e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634072	chr14:106723574~106724093:-
HNSC	cis	rs4908760	0.783	rs301799	ENSG00000232912.4	RP5-1115A15.1	5.36	1.29e-07	4.19e-05	0.25	0.24	Vitiligo;	chr1:8429242	chr1:8424645~8434838:+
HNSC	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-5.36	1.29e-07	4.19e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
HNSC	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-5.36	1.29e-07	4.2e-05	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
HNSC	cis	rs988913	1	rs6941291	ENSG00000224984.1	RP11-524H19.2	5.36	1.29e-07	4.2e-05	0.27	0.24	Menarche (age at onset);	chr6:54972578	chr6:54840118~54840855:-
HNSC	cis	rs9402743	0.632	rs6570029	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135757894	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs9399161	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135759326	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.665	rs6933507	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135760018	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.665	rs4896172	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135760664	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs6570031	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762018	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896173	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762413	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896174	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762421	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896175	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762568	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs2093330	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135763534	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs9389324	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135765375	chr6:135636086~135636713:-
HNSC	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-5.36	1.29e-07	4.2e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
HNSC	cis	rs9611519	1	rs2057070	ENSG00000235513.1	RP4-756G23.5	5.36	1.29e-07	4.21e-05	0.27	0.24	Neuroticism;	chr22:41168283	chr22:41209122~41217627:-
HNSC	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	5.36	1.29e-07	4.21e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
HNSC	cis	rs9341808	0.5	rs806851	ENSG00000272129.1	RP11-250B2.6	-5.36	1.29e-07	4.21e-05	-0.28	-0.24	Sitting height ratio;	chr6:80321114	chr6:80355424~80356859:+
HNSC	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	5.36	1.3e-07	4.21e-05	0.29	0.24	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
HNSC	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	5.36	1.3e-07	4.21e-05	0.29	0.24	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
HNSC	cis	rs792448	0.501	rs2307128	ENSG00000226251.4	RP11-15I11.3	-5.36	1.3e-07	4.22e-05	-0.28	-0.24	White blood cell count (basophil);	chr1:212226474	chr1:212225278~212238977:-
HNSC	cis	rs9291683	0.53	rs17246501	ENSG00000250413.1	RP11-448G15.1	-5.36	1.3e-07	4.22e-05	-0.3	-0.24	Bone mineral density;	chr4:9984086	chr4:10006482~10009725:+
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-5.36	1.3e-07	4.22e-05	-0.14	-0.24	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-5.36	1.3e-07	4.22e-05	-0.14	-0.24	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-5.36	1.3e-07	4.22e-05	-0.14	-0.24	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
HNSC	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-5.36	1.3e-07	4.22e-05	-0.3	-0.24	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-5.36	1.3e-07	4.22e-05	-0.27	-0.24	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
HNSC	cis	rs9907295	0.892	rs55950249	ENSG00000270977.1	AC015849.16	-5.36	1.3e-07	4.22e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35903948	chr17:35893707~35911023:-
HNSC	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	5.36	1.3e-07	4.23e-05	0.26	0.24	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
HNSC	cis	rs520525	0.963	rs663887	ENSG00000271811.1	RP1-79C4.4	5.36	1.3e-07	4.23e-05	0.27	0.24	Atrial fibrillation;	chr1:170657812	chr1:170667381~170669425:+
HNSC	cis	rs860295	0.702	rs4971095	ENSG00000203761.5	MSTO2P	5.36	1.3e-07	4.23e-05	0.18	0.24	Body mass index;	chr1:155636433	chr1:155745829~155750137:+
HNSC	cis	rs2933343	0.601	rs1680759	ENSG00000261159.1	RP11-723O4.9	5.36	1.3e-07	4.23e-05	0.24	0.24	IgG glycosylation;	chr3:128876053	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.601	rs1680758	ENSG00000261159.1	RP11-723O4.9	5.36	1.3e-07	4.23e-05	0.24	0.24	IgG glycosylation;	chr3:128876054	chr3:128859716~128860526:-
HNSC	cis	rs2179367	0.632	rs11155649	ENSG00000216906.2	RP11-350J20.9	5.36	1.3e-07	4.24e-05	0.35	0.24	Dupuytren's disease;	chr6:149405830	chr6:149904243~149906418:+
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000233609.3	RP11-62H7.2	-5.36	1.3e-07	4.24e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9037242	chr8:8961200~8979025:+
HNSC	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	5.36	1.3e-07	4.24e-05	0.3	0.24	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
HNSC	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
HNSC	cis	rs6931421	1	rs6931421	ENSG00000272129.1	RP11-250B2.6	5.36	1.31e-07	4.24e-05	0.31	0.24	Sitting height ratio;	chr6:80170421	chr6:80355424~80356859:+
HNSC	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	5.36	1.31e-07	4.25e-05	0.36	0.24	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
HNSC	cis	rs4763879	0.729	rs10844472	ENSG00000256673.1	RP11-599J14.2	5.36	1.31e-07	4.25e-05	0.23	0.24	Type 1 diabetes;	chr12:9691137	chr12:9398355~9414851:-
HNSC	cis	rs860295	0.702	rs10908479	ENSG00000203761.5	MSTO2P	-5.36	1.31e-07	4.26e-05	-0.18	-0.24	Body mass index;	chr1:155673612	chr1:155745829~155750137:+
HNSC	cis	rs2337406	0.866	rs74092512	ENSG00000211974.3	IGHV2-70	-5.36	1.31e-07	4.26e-05	-0.29	-0.24	Alzheimer's disease (late onset);	chr14:106779306	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-5.36	1.31e-07	4.27e-05	-0.14	-0.24	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
HNSC	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-5.36	1.32e-07	4.28e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs7691799	ENSG00000273257.1	RP11-177J6.1	5.36	1.32e-07	4.29e-05	0.29	0.24	Height;	chr4:55545574	chr4:55387949~55388271:+
HNSC	cis	rs3733585	0.753	rs12500805	ENSG00000250413.1	RP11-448G15.1	-5.36	1.32e-07	4.29e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10016355	chr4:10006482~10009725:+
HNSC	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	5.36	1.32e-07	4.29e-05	0.35	0.24	Height;	chr6:109618283	chr6:109382795~109383666:+
HNSC	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	5.36	1.32e-07	4.3e-05	0.25	0.24	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
HNSC	cis	rs2008905	1	rs2008905	ENSG00000260196.1	RP1-239B22.5	5.36	1.32e-07	4.3e-05	0.26	0.24	Schizophrenia;	chr11:17163076	chr11:17380649~17383531:+
HNSC	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	5.36	1.32e-07	4.3e-05	0.27	0.24	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
HNSC	cis	rs2933343	0.649	rs789219	ENSG00000261159.1	RP11-723O4.9	5.36	1.32e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128873677	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.649	rs789214	ENSG00000261159.1	RP11-723O4.9	5.36	1.33e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128876152	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.729	rs789224	ENSG00000261159.1	RP11-723O4.9	5.36	1.33e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128879388	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.761	rs789225	ENSG00000261159.1	RP11-723O4.9	5.36	1.33e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128881386	chr3:128859716~128860526:-
HNSC	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-5.36	1.33e-07	4.3e-05	-0.24	-0.24	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
HNSC	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	5.36	1.33e-07	4.3e-05	0.29	0.24	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
HNSC	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-5.36	1.33e-07	4.3e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-5.36	1.33e-07	4.31e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
HNSC	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-5.36	1.33e-07	4.31e-05	-0.34	-0.24	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
HNSC	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	5.36	1.33e-07	4.31e-05	0.42	0.24	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
HNSC	cis	rs2834288	0.734	rs1557269	ENSG00000237945.6	LINC00649	-5.36	1.33e-07	4.31e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33894091	chr21:33915534~33977691:+
HNSC	cis	rs75422866	0.764	rs67408202	ENSG00000274902.1	RP1-197B17.4	5.36	1.33e-07	4.31e-05	0.57	0.24	Pneumonia;	chr12:47713564	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs57848393	ENSG00000274902.1	RP1-197B17.4	5.36	1.33e-07	4.31e-05	0.57	0.24	Pneumonia;	chr12:47714734	chr12:47731908~47732351:+
HNSC	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	5.36	1.33e-07	4.31e-05	0.2	0.24	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
HNSC	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	5.36	1.33e-07	4.31e-05	0.33	0.24	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
HNSC	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-5.36	1.33e-07	4.31e-05	-0.21	-0.24	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
HNSC	cis	rs4140799	0.874	rs10132111	ENSG00000266869.1	RP6-114E22.1	5.36	1.33e-07	4.31e-05	0.29	0.24	Neuroticism;	chr14:71705701	chr14:71848606~71908430:+
HNSC	cis	rs224090	0.523	rs12220700	ENSG00000238280.1	RP11-436D10.3	-5.36	1.33e-07	4.31e-05	-0.3	-0.24	Crohn's disease;	chr10:62801746	chr10:62793562~62805887:-
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000254153.1	CTA-398F10.2	5.36	1.33e-07	4.32e-05	0.26	0.24	Mood instability;	chr8:8237348	chr8:8456909~8461337:-
HNSC	cis	rs7819412	0.807	rs10105315	ENSG00000269918.1	AF131215.9	-5.36	1.33e-07	4.32e-05	-0.24	-0.24	Triglycerides;	chr8:11074693	chr8:11104691~11106704:-
HNSC	cis	rs9543976	0.614	rs4885308	ENSG00000261553.4	RP11-29G8.3	-5.36	1.33e-07	4.32e-05	-0.49	-0.24	Diabetic retinopathy;	chr13:75532357	chr13:75549773~75807120:+
HNSC	cis	rs783540	0.681	rs1259178	ENSG00000255769.6	GOLGA2P10	5.36	1.33e-07	4.33e-05	0.31	0.24	Schizophrenia;	chr15:82603127	chr15:82472993~82513950:-
HNSC	cis	rs860295	0.702	rs2175391	ENSG00000203761.5	MSTO2P	5.36	1.33e-07	4.33e-05	0.18	0.24	Body mass index;	chr1:155655811	chr1:155745829~155750137:+
HNSC	cis	rs7048146	0.509	rs10979937	ENSG00000213539.4	YBX1P6	5.36	1.33e-07	4.33e-05	0.34	0.24	Vascular brain injury;	chr9:109567759	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs72748673	ENSG00000213539.4	YBX1P6	5.36	1.33e-07	4.33e-05	0.34	0.24	Vascular brain injury;	chr9:109567809	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs72748674	ENSG00000213539.4	YBX1P6	5.36	1.33e-07	4.33e-05	0.34	0.24	Vascular brain injury;	chr9:109567816	chr9:109532830~109534332:-
HNSC	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	5.36	1.33e-07	4.33e-05	0.2	0.24	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
HNSC	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	5.36	1.34e-07	4.33e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	5.36	1.34e-07	4.33e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
HNSC	cis	rs9300255	0.507	rs1615350	ENSG00000280120.1	RP11-546D6.3	5.36	1.34e-07	4.33e-05	0.21	0.24	Neutrophil percentage of white cells;	chr12:123165788	chr12:123152324~123153377:-
HNSC	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	5.36	1.34e-07	4.33e-05	0.3	0.24	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
HNSC	cis	rs9840812	0.623	rs4678433	ENSG00000239213.4	NCK1-AS1	5.36	1.34e-07	4.33e-05	0.22	0.24	Fibrinogen levels;	chr3:136546840	chr3:136841726~136862054:-
HNSC	cis	rs6928977	0.796	rs2179781	ENSG00000234084.1	RP3-388E23.2	5.36	1.34e-07	4.33e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135398362	chr6:135301568~135307158:+
HNSC	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-5.36	1.34e-07	4.34e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-5.36	1.34e-07	4.34e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-5.36	1.34e-07	4.34e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
HNSC	cis	rs8054556	1	rs3814884	ENSG00000183604.13	SMG1P5	-5.36	1.34e-07	4.34e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29983415	chr16:30267553~30335374:-
HNSC	cis	rs4699052	1	rs7694190	ENSG00000246560.2	RP11-10L12.4	5.36	1.34e-07	4.34e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103246860	chr4:102828055~102844075:+
HNSC	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-5.36	1.34e-07	4.34e-05	-0.24	-0.24	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
HNSC	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	5.36	1.34e-07	4.35e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
HNSC	cis	rs9840812	0.61	rs34967300	ENSG00000273486.1	RP11-731C17.2	-5.36	1.34e-07	4.35e-05	-0.23	-0.24	Fibrinogen levels;	chr3:136549976	chr3:136837338~136839021:-
HNSC	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	5.36	1.34e-07	4.35e-05	0.36	0.24	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
HNSC	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-5.36	1.34e-07	4.35e-05	-0.31	-0.24	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
HNSC	cis	rs783540	0.656	rs783538	ENSG00000255769.6	GOLGA2P10	5.36	1.34e-07	4.35e-05	0.32	0.24	Schizophrenia;	chr15:82584394	chr15:82472993~82513950:-
HNSC	cis	rs10256972	0.869	rs4720158	ENSG00000225146.1	AC073957.15	5.36	1.34e-07	4.35e-05	0.28	0.24	Endometriosis;Longevity;	chr7:1000689	chr7:1029025~1043891:+
HNSC	cis	rs9402743	0.671	rs6901733	ENSG00000234084.1	RP3-388E23.2	-5.36	1.34e-07	4.36e-05	-0.25	-0.24	Systemic lupus erythematosus;	chr6:135619407	chr6:135301568~135307158:+
HNSC	cis	rs2790457	0.771	rs2800737	ENSG00000254635.4	WAC-AS1	-5.36	1.34e-07	4.36e-05	-0.26	-0.24	Multiple myeloma;	chr10:28654143	chr10:28522652~28532743:-
HNSC	cis	rs9907295	0.901	rs4795096	ENSG00000270977.1	AC015849.16	-5.36	1.34e-07	4.36e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35888821	chr17:35893707~35911023:-
HNSC	cis	rs2115630	1	rs10220733	ENSG00000229212.6	RP11-561C5.4	5.36	1.34e-07	4.36e-05	0.28	0.24	P wave terminal force;	chr15:84737633	chr15:85205440~85234795:-
HNSC	cis	rs1355223	0.833	rs286885	ENSG00000271369.1	RP11-350D17.3	5.36	1.34e-07	4.36e-05	0.27	0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34665799	chr11:34709600~34710161:+
HNSC	cis	rs7819412	0.805	rs2409710	ENSG00000255310.2	AF131215.2	-5.36	1.34e-07	4.36e-05	-0.23	-0.24	Triglycerides;	chr8:11122311	chr8:11107788~11109726:-
HNSC	cis	rs860295	0.702	rs12239100	ENSG00000203761.5	MSTO2P	-5.35	1.34e-07	4.36e-05	-0.19	-0.24	Body mass index;	chr1:155458685	chr1:155745829~155750137:+
HNSC	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	5.35	1.35e-07	4.36e-05	0.25	0.24	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	5.35	1.35e-07	4.36e-05	0.25	0.24	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
HNSC	cis	rs11976180	1	rs67239267	ENSG00000273234.1	OR2A13P	-5.35	1.35e-07	4.36e-05	-0.27	-0.24	Obesity-related traits;	chr7:144048023	chr7:144142009~144142938:+
HNSC	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	5.35	1.35e-07	4.36e-05	0.3	0.24	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
HNSC	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-5.35	1.35e-07	4.37e-05	-0.23	-0.24	Height;	chr5:37053874	chr5:36666214~36725195:-
HNSC	cis	rs9402743	0.632	rs2104132	ENSG00000217482.2	HMGB1P17	5.35	1.35e-07	4.37e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135763810	chr6:135636086~135636713:-
HNSC	cis	rs853679	0.76	rs967005	ENSG00000204709.4	LINC01556	5.35	1.35e-07	4.37e-05	0.35	0.24	Depression;	chr6:28242910	chr6:28943877~28944537:+
HNSC	cis	rs6693567	0.565	rs6685252	ENSG00000228126.1	FALEC	-5.35	1.35e-07	4.37e-05	-0.29	-0.24	Migraine;	chr1:150287533	chr1:150515757~150518032:+
HNSC	cis	rs2302464	1	rs12651052	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15726813	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs56381553	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15726824	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs12645513	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15727155	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs58335439	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15727183	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs73123625	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15727550	chr4:15730962~15731627:-
HNSC	cis	rs7657257	1	rs12643722	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Blood protein levels;	chr4:15728480	chr4:15730962~15731627:-
HNSC	cis	rs7657257	1	rs12640554	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Blood protein levels;	chr4:15728484	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs111541714	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15728782	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs73125993	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15728890	chr4:15730962~15731627:-
HNSC	cis	rs17428076	0.874	rs17581347	ENSG00000228389.1	AC068039.4	-5.35	1.35e-07	4.37e-05	-0.29	-0.24	Myopia;	chr2:171826091	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.874	rs17581361	ENSG00000228389.1	AC068039.4	-5.35	1.35e-07	4.37e-05	-0.29	-0.24	Myopia;	chr2:171826102	chr2:171773482~171775844:+
HNSC	cis	rs9611519	0.894	rs13053242	ENSG00000235513.1	RP4-756G23.5	5.35	1.35e-07	4.37e-05	0.27	0.24	Neuroticism;	chr22:41063482	chr22:41209122~41217627:-
HNSC	cis	rs9992667	0.955	rs28510735	ENSG00000231160.8	KLF3-AS1	5.35	1.35e-07	4.37e-05	0.27	0.24	Eosinophil percentage of granulocytes;	chr4:38612320	chr4:38612701~38664883:-
HNSC	cis	rs9859260	0.71	rs41298097	ENSG00000207650.1	MIR570	-5.35	1.35e-07	4.37e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196052284	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.71	rs34906439	ENSG00000207650.1	MIR570	-5.35	1.35e-07	4.37e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196052835	chr3:195699401~195699497:+
HNSC	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	5.35	1.35e-07	4.38e-05	0.28	0.24	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
HNSC	cis	rs2834288	0.613	rs2834297	ENSG00000273102.1	AP000569.9	-5.35	1.35e-07	4.38e-05	-0.25	-0.24	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33967101~33968573:-
HNSC	cis	rs6430553	0.964	rs1530556	ENSG00000224043.6	CCNT2-AS1	-5.35	1.35e-07	4.38e-05	-0.28	-0.24	Blood metabolite levels;	chr2:134842164	chr2:134735464~134918710:-
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	5.35	1.35e-07	4.38e-05	0.26	0.24	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	5.35	1.35e-07	4.38e-05	0.26	0.24	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
HNSC	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-5.35	1.35e-07	4.39e-05	-0.28	-0.24	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
HNSC	cis	rs2255336	0.938	rs17549004	ENSG00000245648.1	RP11-277P12.20	-5.35	1.36e-07	4.39e-05	-0.42	-0.24	Blood protein levels;	chr12:10410024	chr12:10363769~10398506:+
HNSC	cis	rs1008375	0.966	rs3796812	ENSG00000249502.1	AC006160.5	-5.35	1.36e-07	4.39e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17580428	chr4:17587467~17614571:-
HNSC	cis	rs75422866	0.764	rs67201012	ENSG00000274902.1	RP1-197B17.4	5.35	1.36e-07	4.39e-05	0.57	0.24	Pneumonia;	chr12:47715881	chr12:47731908~47732351:+
HNSC	cis	rs2933343	0.649	rs789216	ENSG00000261159.1	RP11-723O4.9	5.35	1.36e-07	4.4e-05	0.24	0.24	IgG glycosylation;	chr3:128875660	chr3:128859716~128860526:-
HNSC	cis	rs6928977	0.66	rs9389301	ENSG00000234084.1	RP3-388E23.2	5.35	1.36e-07	4.4e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135549844	chr6:135301568~135307158:+
HNSC	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	5.35	1.36e-07	4.41e-05	0.3	0.24	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	5.35	1.36e-07	4.41e-05	0.3	0.24	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
HNSC	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	5.35	1.36e-07	4.41e-05	0.29	0.24	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	5.35	1.36e-07	4.41e-05	0.29	0.24	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
HNSC	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-5.35	1.36e-07	4.42e-05	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	5.35	1.36e-07	4.42e-05	0.26	0.24	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs329235	ENSG00000197085.10	NPSR1-AS1	5.35	1.36e-07	4.42e-05	0.29	0.24	Diastolic blood pressure;	chr7:35016554	chr7:34346512~34871582:-
HNSC	cis	rs8054556	1	rs9932196	ENSG00000183604.13	SMG1P5	-5.35	1.37e-07	4.42e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29971798	chr16:30267553~30335374:-
HNSC	cis	rs11846409	0.932	rs73378155	ENSG00000211974.3	IGHV2-70	-5.35	1.37e-07	4.42e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106637840	chr14:106723574~106724093:-
HNSC	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	5.35	1.37e-07	4.43e-05	0.7	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
HNSC	cis	rs490608	0.628	rs678157	ENSG00000203761.5	MSTO2P	-5.35	1.37e-07	4.43e-05	-0.18	-0.24	Inflammatory bowel disease;	chr1:155688550	chr1:155745829~155750137:+
HNSC	cis	rs2976388	0.647	rs2585136	ENSG00000253741.1	CTD-2292P10.4	-5.35	1.37e-07	4.43e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142730723	chr8:142702252~142726973:-
HNSC	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-5.35	1.37e-07	4.43e-05	-0.3	-0.24	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
HNSC	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	5.35	1.37e-07	4.43e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
HNSC	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
HNSC	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	5.35	1.37e-07	4.44e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.44e-05	0.26	0.24	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.44e-05	0.26	0.24	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.44e-05	0.26	0.24	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
HNSC	cis	rs1008375	0.966	rs28441502	ENSG00000249502.1	AC006160.5	-5.35	1.37e-07	4.44e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17596761	chr4:17587467~17614571:-
HNSC	cis	rs12701220	0.894	rs10257744	ENSG00000229043.2	AC091729.9	-5.35	1.38e-07	4.45e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.847	rs10272002	ENSG00000229043.2	AC091729.9	-5.35	1.38e-07	4.45e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1160374~1165267:+
HNSC	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-5.35	1.38e-07	4.45e-05	-0.39	-0.24	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
HNSC	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-5.35	1.38e-07	4.46e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
HNSC	cis	rs2243480	1	rs937108	ENSG00000179406.6	LINC00174	-5.35	1.38e-07	4.46e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65963465	chr7:66376044~66401338:-
HNSC	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-5.35	1.38e-07	4.47e-05	-0.33	-0.24	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
HNSC	cis	rs9611519	0.929	rs9611509	ENSG00000235513.1	RP4-756G23.5	5.35	1.38e-07	4.47e-05	0.27	0.24	Neuroticism;	chr22:41169823	chr22:41209122~41217627:-
HNSC	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-5.35	1.38e-07	4.47e-05	-0.29	-0.24	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
HNSC	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-5.35	1.38e-07	4.47e-05	-0.24	-0.24	Height;	chr5:37023796	chr5:36666214~36725195:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	5.35	1.38e-07	4.47e-05	0.25	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
HNSC	cis	rs1012068	0.541	rs11703587	ENSG00000236132.1	CTA-440B3.1	-5.35	1.38e-07	4.47e-05	-0.29	-0.24	Chronic hepatitis C infection;	chr22:31926428	chr22:31816379~31817491:-
HNSC	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-5.35	1.38e-07	4.47e-05	-0.29	-0.24	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.582	rs11783950	ENSG00000173295.6	FAM86B3P	-5.35	1.38e-07	4.47e-05	-0.28	-0.24	Mood instability;	chr8:8740321	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	5.35	1.38e-07	4.48e-05	0.35	0.24	Height;	chr6:109564272	chr6:109382795~109383666:+
HNSC	cis	rs860295	0.702	rs12025532	ENSG00000203761.5	MSTO2P	-5.35	1.38e-07	4.48e-05	-0.19	-0.24	Body mass index;	chr1:155399511	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.678	rs12563627	ENSG00000203761.5	MSTO2P	5.35	1.38e-07	4.48e-05	0.18	0.24	Body mass index;	chr1:155893175	chr1:155745829~155750137:+
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	5.35	1.39e-07	4.48e-05	0.26	0.24	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	5.35	1.39e-07	4.48e-05	0.26	0.24	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
HNSC	cis	rs9611519	0.929	rs2064560	ENSG00000235513.1	RP4-756G23.5	5.35	1.39e-07	4.48e-05	0.27	0.24	Neuroticism;	chr22:41134036	chr22:41209122~41217627:-
HNSC	cis	rs3733585	0.781	rs13103690	ENSG00000250413.1	RP11-448G15.1	5.35	1.39e-07	4.48e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9971154	chr4:10006482~10009725:+
HNSC	cis	rs9611519	0.894	rs9611486	ENSG00000235513.1	RP4-756G23.5	5.35	1.39e-07	4.48e-05	0.27	0.24	Neuroticism;	chr22:41062780	chr22:41209122~41217627:-
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	5.35	1.39e-07	4.48e-05	0.26	0.24	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
HNSC	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-5.35	1.39e-07	4.48e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
HNSC	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-5.35	1.39e-07	4.48e-05	-0.23	-0.24	Height;	chr5:36925633	chr5:36666214~36725195:-
HNSC	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	5.35	1.39e-07	4.48e-05	0.31	0.24	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
HNSC	cis	rs13126694	0.682	rs4504305	ENSG00000248429.4	RP11-597D13.9	5.35	1.39e-07	4.48e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157982801	chr4:158170752~158202877:+
HNSC	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-5.35	1.39e-07	4.49e-05	-0.42	-0.24	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000254153.1	CTA-398F10.2	-5.35	1.39e-07	4.49e-05	-0.25	-0.24	Mood instability;	chr8:8967348	chr8:8456909~8461337:-
HNSC	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	5.35	1.39e-07	4.49e-05	0.3	0.24	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.932	rs4896143	ENSG00000231028.7	LINC00271	5.35	1.39e-07	4.49e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135313962	chr6:135497801~135716055:+
HNSC	cis	rs2337406	1	rs78857163	ENSG00000254174.1	IGHV1-12	5.35	1.39e-07	4.49e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106707435	chr14:106122420~106122709:-
HNSC	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	5.35	1.39e-07	4.49e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
HNSC	cis	rs7688540	0.8	rs10028482	ENSG00000211553.1	AC253576.2	-5.35	1.39e-07	4.5e-05	-0.3	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:136461~136568:+
HNSC	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	5.35	1.39e-07	4.5e-05	0.28	0.24	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
HNSC	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	5.35	1.39e-07	4.5e-05	0.3	0.24	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
HNSC	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-5.35	1.39e-07	4.5e-05	-0.21	-0.24	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	5.35	1.39e-07	4.5e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	5.35	1.39e-07	4.5e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	5.35	1.4e-07	4.51e-05	0.26	0.24	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
HNSC	cis	rs603446	0.935	rs180372	ENSG00000254851.1	RP11-109L13.1	-5.35	1.4e-07	4.51e-05	-0.31	-0.24	Triglycerides;	chr11:116721218	chr11:117135528~117138582:+
HNSC	cis	rs4723738	0.693	rs6462818	ENSG00000227191.5	TRGC2	-5.35	1.4e-07	4.51e-05	-0.18	-0.24	Treatment response for severe sepsis;	chr7:38211435	chr7:38239580~38368091:-
HNSC	cis	rs42490	0.59	rs39771	ENSG00000251136.7	RP11-37B2.1	-5.35	1.4e-07	4.51e-05	-0.21	-0.24	Leprosy;	chr8:89826378	chr8:89609409~89757727:-
HNSC	cis	rs7617773	0.925	rs6442105	ENSG00000228638.1	FCF1P2	5.35	1.4e-07	4.51e-05	0.23	0.24	Coronary artery disease;	chr3:48140836	chr3:48290793~48291375:-
HNSC	cis	rs4664293	0.669	rs35299907	ENSG00000226266.5	AC009961.3	5.35	1.4e-07	4.52e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159562142	chr2:159670708~159712435:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000179406.6	LINC00174	-5.35	1.4e-07	4.52e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66021736	chr7:66376044~66401338:-
HNSC	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	5.35	1.4e-07	4.52e-05	0.54	0.24	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
HNSC	cis	rs2762353	0.526	rs9461203	ENSG00000272462.2	U91328.19	5.35	1.4e-07	4.53e-05	0.23	0.24	Blood metabolite levels;	chr6:25710327	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.526	rs6912391	ENSG00000272462.2	U91328.19	5.35	1.4e-07	4.53e-05	0.23	0.24	Blood metabolite levels;	chr6:25710535	chr6:25992662~26001775:+
HNSC	cis	rs5758659	0.967	rs5758670	ENSG00000227370.1	RP4-669P10.19	-5.35	1.4e-07	4.53e-05	-0.23	-0.24	Cognitive function;	chr22:42240681	chr22:42132543~42132998:+
HNSC	cis	rs7819412	1	rs2409722	ENSG00000269918.1	AF131215.9	-5.35	1.4e-07	4.53e-05	-0.24	-0.24	Triglycerides;	chr8:11182307	chr8:11104691~11106704:-
HNSC	cis	rs2243480	1	rs34815098	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65827267	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7456042	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65834791	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35735127	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65835436	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs35256305	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65841418	chr7:66376044~66401338:-
HNSC	cis	rs2179367	0.632	rs12197598	ENSG00000216906.2	RP11-350J20.9	5.35	1.41e-07	4.54e-05	0.35	0.24	Dupuytren's disease;	chr6:149385418	chr6:149904243~149906418:+
HNSC	cis	rs2337406	0.866	rs79901786	ENSG00000254174.1	IGHV1-12	5.35	1.41e-07	4.54e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777623	chr14:106122420~106122709:-
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000233609.3	RP11-62H7.2	5.35	1.41e-07	4.54e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9044861	chr8:8961200~8979025:+
HNSC	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-5.35	1.41e-07	4.54e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
HNSC	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-5.35	1.41e-07	4.54e-05	-0.29	-0.24	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
HNSC	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	5.35	1.41e-07	4.55e-05	0.28	0.24	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
HNSC	cis	rs7621025	0.617	rs12637102	ENSG00000239213.4	NCK1-AS1	5.35	1.41e-07	4.55e-05	0.23	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136841726~136862054:-
HNSC	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	5.35	1.41e-07	4.55e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
HNSC	cis	rs11846409	0.932	rs74091728	ENSG00000211974.3	IGHV2-70	-5.35	1.41e-07	4.55e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106638762	chr14:106723574~106724093:-
HNSC	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-5.35	1.41e-07	4.55e-05	-0.23	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
HNSC	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-5.35	1.41e-07	4.56e-05	-0.21	-0.24	Height;	chr11:118737916	chr11:118791254~118793137:+
HNSC	cis	rs988913	1	rs2221334	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54969743	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs4715492	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54970380	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7765236	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54970769	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs1503134	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54971426	chr6:54840118~54840855:-
HNSC	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-5.35	1.41e-07	4.56e-05	-0.29	-0.24	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
HNSC	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-5.35	1.41e-07	4.56e-05	-0.29	-0.24	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
HNSC	cis	rs7176527	0.579	rs366717	ENSG00000229212.6	RP11-561C5.4	5.35	1.41e-07	4.56e-05	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85205440~85234795:-
HNSC	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	5.35	1.41e-07	4.56e-05	0.3	0.24	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	5.35	1.41e-07	4.56e-05	0.3	0.24	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
HNSC	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-5.35	1.42e-07	4.57e-05	-0.29	-0.24	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
HNSC	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-5.34	1.42e-07	4.57e-05	-0.31	-0.24	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-5.34	1.42e-07	4.57e-05	-0.31	-0.24	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
HNSC	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	5.34	1.42e-07	4.57e-05	0.33	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	5.34	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
HNSC	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-5.34	1.42e-07	4.58e-05	-0.25	-0.24	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
HNSC	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	5.34	1.42e-07	4.58e-05	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
HNSC	cis	rs12701220	0.894	rs13224488	ENSG00000229043.2	AC091729.9	-5.34	1.42e-07	4.58e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1160374~1165267:+
HNSC	cis	rs72772090	0.908	rs6864233	ENSG00000248734.2	CTD-2260A17.1	5.34	1.42e-07	4.59e-05	0.33	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96708977	chr5:96784777~96785999:+
HNSC	cis	rs6928977	0.5	rs9494308	ENSG00000217482.2	HMGB1P17	-5.34	1.42e-07	4.59e-05	-0.27	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135636086~135636713:-
HNSC	cis	rs17507216	0.628	rs28607761	ENSG00000276710.3	CSPG4P8	-5.34	1.43e-07	4.6e-05	-0.33	-0.24	Excessive daytime sleepiness;	chr15:82715317	chr15:82459472~82477258:+
HNSC	cis	rs889014	0.751	rs6891528	ENSG00000253768.1	CTB-33O18.1	-5.34	1.43e-07	4.6e-05	-0.26	-0.24	Height;	chr5:173551902	chr5:173562478~173573199:+
HNSC	cis	rs13126694	0.744	rs28477319	ENSG00000248429.4	RP11-597D13.9	5.34	1.43e-07	4.6e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:158095785	chr4:158170752~158202877:+
HNSC	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-5.34	1.43e-07	4.6e-05	-0.32	-0.24	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
HNSC	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	5.34	1.43e-07	4.61e-05	0.29	0.24	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
HNSC	cis	rs1665050	0.571	rs1446238	ENSG00000277144.1	RP11-59H7.4	-5.34	1.43e-07	4.61e-05	-0.3	-0.24	Atopic dermatitis;	chr15:59055558	chr15:59115547~59116089:-
HNSC	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	5.34	1.43e-07	4.61e-05	0.54	0.24	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
HNSC	cis	rs442309	0.553	rs10995281	ENSG00000238280.1	RP11-436D10.3	-5.34	1.43e-07	4.61e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62707416	chr10:62793562~62805887:-
HNSC	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-5.34	1.43e-07	4.61e-05	-0.39	-0.24	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
HNSC	cis	rs4713118	0.621	rs10484403	ENSG00000204709.4	LINC01556	5.34	1.43e-07	4.61e-05	0.34	0.24	Parkinson's disease;	chr6:28065745	chr6:28943877~28944537:+
HNSC	cis	rs4239252	0.725	rs1994182	ENSG00000270977.1	AC015849.16	5.34	1.43e-07	4.61e-05	0.28	0.24	Blood protein levels;	chr17:35760685	chr17:35893707~35911023:-
HNSC	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-5.34	1.43e-07	4.61e-05	-0.21	-0.24	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-5.34	1.43e-07	4.61e-05	-0.21	-0.24	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
HNSC	cis	rs4140799	0.845	rs2286136	ENSG00000266869.1	RP6-114E22.1	-5.34	1.43e-07	4.61e-05	-0.3	-0.24	Neuroticism;	chr14:71701978	chr14:71848606~71908430:+
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
HNSC	cis	rs1355223	0.872	rs7112608	ENSG00000271369.1	RP11-350D17.3	-5.34	1.43e-07	4.61e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677722	chr11:34709600~34710161:+
HNSC	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	5.34	1.43e-07	4.61e-05	0.31	0.24	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
HNSC	cis	rs7829975	0.714	rs7823757	ENSG00000254340.1	RP11-10A14.3	5.34	1.43e-07	4.62e-05	0.29	0.24	Mood instability;	chr8:8812667	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	5.34	1.43e-07	4.62e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
HNSC	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-5.34	1.43e-07	4.62e-05	-0.23	-0.24	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
HNSC	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	5.34	1.43e-07	4.62e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
HNSC	cis	rs2243480	1	rs781157	ENSG00000179406.6	LINC00174	-5.34	1.44e-07	4.62e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66013324	chr7:66376044~66401338:-
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000173295.6	FAM86B3P	-5.34	1.44e-07	4.63e-05	-0.3	-0.24	Neuroticism;	chr8:8504313	chr8:8228595~8244865:+
HNSC	cis	rs7824557	0.547	rs6601570	ENSG00000255310.2	AF131215.2	-5.34	1.44e-07	4.63e-05	-0.23	-0.24	Retinal vascular caliber;	chr8:11221858	chr8:11107788~11109726:-
HNSC	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-5.34	1.44e-07	4.63e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
HNSC	cis	rs988913	1	rs9382407	ENSG00000224984.1	RP11-524H19.2	5.34	1.44e-07	4.63e-05	0.27	0.24	Menarche (age at onset);	chr6:54971840	chr6:54840118~54840855:-
HNSC	cis	rs5742933	0.597	rs12471663	ENSG00000253559.1	OSGEPL1-AS1	5.34	1.44e-07	4.63e-05	0.27	0.24	Ferritin levels;	chr2:189642372	chr2:189762704~189765556:+
HNSC	cis	rs9611519	1	rs9611519	ENSG00000235513.1	RP4-756G23.5	5.34	1.44e-07	4.64e-05	0.27	0.24	Neuroticism;	chr22:41217184	chr22:41209122~41217627:-
HNSC	cis	rs2337406	0.866	rs8012619	ENSG00000254174.1	IGHV1-12	5.34	1.44e-07	4.64e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106793907	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74090151	ENSG00000211974.3	IGHV2-70	-5.34	1.44e-07	4.64e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106785377	chr14:106723574~106724093:-
HNSC	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	5.34	1.44e-07	4.64e-05	0.26	0.24	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
HNSC	cis	rs1008375	0.966	rs1860591	ENSG00000249502.1	AC006160.5	-5.34	1.44e-07	4.64e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575706	chr4:17587467~17614571:-
HNSC	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-5.34	1.44e-07	4.65e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
HNSC	cis	rs3733585	0.673	rs9994937	ENSG00000250413.1	RP11-448G15.1	5.34	1.44e-07	4.65e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9963175	chr4:10006482~10009725:+
HNSC	cis	rs2115630	0.905	rs6496401	ENSG00000229212.6	RP11-561C5.4	5.34	1.44e-07	4.65e-05	0.28	0.24	P wave terminal force;	chr15:84754562	chr15:85205440~85234795:-
HNSC	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-5.34	1.45e-07	4.65e-05	-0.33	-0.24	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
HNSC	cis	rs7688540	0.8	rs61794998	ENSG00000211553.1	AC253576.2	-5.34	1.45e-07	4.66e-05	-0.3	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:136461~136568:+
HNSC	cis	rs7621025	0.691	rs9845762	ENSG00000273486.1	RP11-731C17.2	5.34	1.45e-07	4.66e-05	0.2	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136637622	chr3:136837338~136839021:-
HNSC	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	5.34	1.45e-07	4.66e-05	0.38	0.24	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
HNSC	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	5.34	1.45e-07	4.66e-05	0.28	0.24	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
HNSC	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	5.34	1.45e-07	4.66e-05	0.18	0.24	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-5.34	1.45e-07	4.66e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
HNSC	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-5.34	1.45e-07	4.67e-05	-0.31	-0.24	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
HNSC	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	5.34	1.45e-07	4.67e-05	0.27	0.24	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
HNSC	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-5.34	1.45e-07	4.67e-05	-0.27	-0.24	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
HNSC	cis	rs6540731	0.967	rs2884512	ENSG00000226251.4	RP11-15I11.3	-5.34	1.45e-07	4.67e-05	-0.28	-0.24	Intelligence (childhood);	chr1:212229848	chr1:212225278~212238977:-
HNSC	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-5.34	1.45e-07	4.67e-05	-0.41	-0.24	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
HNSC	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	5.34	1.45e-07	4.68e-05	0.26	0.24	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
HNSC	cis	rs2834288	0.734	rs9984662	ENSG00000237945.6	LINC00649	5.34	1.45e-07	4.68e-05	0.3	0.24	Gut microbiota (bacterial taxa);	chr21:33892504	chr21:33915534~33977691:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000273009.1	RP11-352G9.1	-5.34	1.45e-07	4.68e-05	-0.28	-0.24	Pancreatic cancer;	chr3:196026895	chr3:195913078~195913683:-
HNSC	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	5.34	1.45e-07	4.68e-05	0.24	0.24	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
HNSC	cis	rs9907295	0.901	rs9909416	ENSG00000270977.1	AC015849.16	-5.34	1.45e-07	4.68e-05	-0.32	-0.24	Fibroblast growth factor basic levels;	chr17:35870979	chr17:35893707~35911023:-
HNSC	cis	rs792448	0.545	rs6679796	ENSG00000226251.4	RP11-15I11.3	-5.34	1.45e-07	4.68e-05	-0.27	-0.24	White blood cell count (basophil);	chr1:212229182	chr1:212225278~212238977:-
HNSC	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	5.34	1.45e-07	4.68e-05	0.3	0.24	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
HNSC	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-5.34	1.46e-07	4.68e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
HNSC	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	5.34	1.46e-07	4.68e-05	0.26	0.24	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	5.34	1.46e-07	4.68e-05	0.21	0.24	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
HNSC	cis	rs9329221	0.741	rs13264066	ENSG00000254340.1	RP11-10A14.3	-5.34	1.46e-07	4.7e-05	-0.29	-0.24	Neuroticism;	chr8:9946565	chr8:9141424~9145435:+
HNSC	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-5.34	1.46e-07	4.7e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
HNSC	cis	rs2243480	1	rs55895244	ENSG00000179406.6	LINC00174	-5.34	1.46e-07	4.7e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65922691	chr7:66376044~66401338:-
HNSC	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-5.34	1.46e-07	4.7e-05	-0.22	-0.24	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
HNSC	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	5.34	1.46e-07	4.7e-05	0.21	0.24	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
HNSC	cis	rs9329221	0.741	rs9650622	ENSG00000254340.1	RP11-10A14.3	-5.34	1.46e-07	4.7e-05	-0.29	-0.24	Neuroticism;	chr8:9946782	chr8:9141424~9145435:+
HNSC	cis	rs6928977	1	rs6928977	ENSG00000231028.7	LINC00271	5.34	1.46e-07	4.71e-05	0.29	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135305210	chr6:135497801~135716055:+
HNSC	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
HNSC	cis	rs17507216	0.628	rs28371837	ENSG00000276710.3	CSPG4P8	-5.34	1.47e-07	4.71e-05	-0.33	-0.24	Excessive daytime sleepiness;	chr15:82714435	chr15:82459472~82477258:+
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-5.34	1.47e-07	4.72e-05	-0.22	-0.24	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
HNSC	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-5.34	1.47e-07	4.72e-05	-0.23	-0.24	Height;	chr5:36941456	chr5:36666214~36725195:-
HNSC	cis	rs988913	1	rs6922438	ENSG00000224984.1	RP11-524H19.2	5.34	1.47e-07	4.73e-05	0.27	0.24	Menarche (age at onset);	chr6:54976585	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs1503135	ENSG00000224984.1	RP11-524H19.2	5.34	1.47e-07	4.73e-05	0.27	0.24	Menarche (age at onset);	chr6:54976874	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9349741	ENSG00000224984.1	RP11-524H19.2	5.34	1.47e-07	4.73e-05	0.27	0.24	Menarche (age at onset);	chr6:54976911	chr6:54840118~54840855:-
HNSC	cis	rs73198271	0.74	rs10094270	ENSG00000253893.2	FAM85B	5.34	1.47e-07	4.73e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.74	rs28521727	ENSG00000253893.2	FAM85B	5.34	1.47e-07	4.73e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.929	rs12050200	ENSG00000211974.3	IGHV2-70	-5.34	1.47e-07	4.73e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106780983	chr14:106723574~106724093:-
HNSC	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-5.34	1.47e-07	4.73e-05	-0.39	-0.24	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
HNSC	cis	rs2060793	0.712	rs6486202	ENSG00000251991.1	RNU7-49P	5.34	1.47e-07	4.74e-05	0.26	0.24	Vitamin D levels;	chr11:14777260	chr11:14478892~14478953:+
HNSC	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	5.34	1.47e-07	4.74e-05	0.23	0.24	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
HNSC	cis	rs2243480	1	rs1723269	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66007799	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781156	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66014154	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781150	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66015986	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781149	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66016297	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs451396	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66019087	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1167613	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66022452	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1715235	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66023407	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313798	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66028044	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313799	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66029343	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35396113	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66030474	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313807	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66034494	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313809	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66034996	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	5.34	1.47e-07	4.74e-05	0.26	0.24	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
HNSC	cis	rs7048146	0.531	rs10979908	ENSG00000213539.4	YBX1P6	5.34	1.48e-07	4.75e-05	0.31	0.24	Vascular brain injury;	chr9:109542257	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs10979909	ENSG00000213539.4	YBX1P6	5.34	1.48e-07	4.75e-05	0.31	0.24	Vascular brain injury;	chr9:109542258	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs10979910	ENSG00000213539.4	YBX1P6	5.34	1.48e-07	4.75e-05	0.31	0.24	Vascular brain injury;	chr9:109542340	chr9:109532830~109534332:-
HNSC	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	5.34	1.48e-07	4.75e-05	0.3	0.24	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
HNSC	cis	rs867371	0.896	rs8033831	ENSG00000259429.4	UBE2Q2P2	-5.34	1.48e-07	4.75e-05	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82355142~82420075:+
HNSC	cis	rs1056107	0.966	rs7041688	ENSG00000225513.1	RP11-165N19.2	-5.34	1.48e-07	4.75e-05	-0.26	-0.24	Colorectal cancer;	chr9:112272619	chr9:112173522~112173971:-
HNSC	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	5.34	1.48e-07	4.75e-05	0.32	0.24	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
HNSC	cis	rs12701220	0.894	rs12701406	ENSG00000229043.2	AC091729.9	-5.34	1.48e-07	4.75e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.894	rs12539012	ENSG00000229043.2	AC091729.9	-5.34	1.48e-07	4.75e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1160374~1165267:+
HNSC	cis	rs11846409	0.86	rs4774167	ENSG00000274576.2	IGHV2-70	-5.34	1.48e-07	4.76e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106619987	chr14:106770577~106771020:-
HNSC	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
HNSC	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	5.34	1.48e-07	4.76e-05	0.29	0.24	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
HNSC	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	5.34	1.48e-07	4.76e-05	0.29	0.24	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
HNSC	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-5.34	1.48e-07	4.76e-05	-0.29	-0.24	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
HNSC	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	5.34	1.48e-07	4.76e-05	0.3	0.24	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
HNSC	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-5.34	1.48e-07	4.76e-05	-0.33	-0.24	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
HNSC	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-5.34	1.48e-07	4.76e-05	-0.29	-0.24	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
HNSC	cis	rs17428076	0.793	rs12622772	ENSG00000228389.1	AC068039.4	-5.34	1.48e-07	4.76e-05	-0.29	-0.24	Myopia;	chr2:171769227	chr2:171773482~171775844:+
HNSC	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	5.34	1.48e-07	4.77e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
HNSC	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-5.34	1.49e-07	4.78e-05	-0.33	-0.24	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
HNSC	cis	rs2742234	0.541	rs12220534	ENSG00000273008.1	RP11-351D16.3	-5.34	1.49e-07	4.78e-05	-0.3	-0.24	Hirschsprung disease;	chr10:43238858	chr10:43136824~43138334:-
HNSC	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	5.34	1.49e-07	4.78e-05	0.29	0.24	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
HNSC	cis	rs7615952	0.546	rs2976733	ENSG00000248787.1	RP11-666A20.4	-5.34	1.49e-07	4.78e-05	-0.31	-0.24	Blood pressure (smoking interaction);	chr3:125695294	chr3:125908005~125910272:-
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	5.34	1.49e-07	4.78e-05	0.19	0.24	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
HNSC	cis	rs4218	0.528	rs57557135	ENSG00000277144.1	RP11-59H7.4	-5.34	1.49e-07	4.79e-05	-0.3	-0.24	Social communication problems;	chr15:59054018	chr15:59115547~59116089:-
HNSC	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	5.33	1.49e-07	4.79e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
HNSC	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-5.33	1.49e-07	4.79e-05	-0.21	-0.24	Height;	chr11:118786602	chr11:118791254~118793137:+
HNSC	cis	rs6723108	0.603	rs1592	ENSG00000224043.6	CCNT2-AS1	-5.33	1.49e-07	4.79e-05	-0.3	-0.24	Type 2 diabetes;	chr2:134964573	chr2:134735464~134918710:-
HNSC	cis	rs3733585	0.699	rs17245723	ENSG00000250413.1	RP11-448G15.1	5.33	1.49e-07	4.79e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9960594	chr4:10006482~10009725:+
HNSC	cis	rs7819412	0.875	rs6981523	ENSG00000255310.2	AF131215.2	-5.33	1.49e-07	4.8e-05	-0.23	-0.24	Triglycerides;	chr8:11204283	chr8:11107788~11109726:-
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-5.33	1.49e-07	4.8e-05	-0.14	-0.24	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
HNSC	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	5.33	1.5e-07	4.8e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-5.33	1.5e-07	4.8e-05	-0.14	-0.24	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
HNSC	cis	rs2337406	0.789	rs60000589	ENSG00000211974.3	IGHV2-70	-5.33	1.5e-07	4.8e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106782459	chr14:106723574~106724093:-
HNSC	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	5.33	1.5e-07	4.8e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	5.33	1.5e-07	4.8e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
HNSC	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	5.33	1.5e-07	4.81e-05	0.25	0.24	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
HNSC	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	5.33	1.5e-07	4.81e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
HNSC	cis	rs3733585	0.699	rs10001964	ENSG00000250413.1	RP11-448G15.1	5.33	1.5e-07	4.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957651	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.637	rs6850684	ENSG00000250413.1	RP11-448G15.1	5.33	1.5e-07	4.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962756	chr4:10006482~10009725:+
HNSC	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	5.33	1.5e-07	4.82e-05	0.36	0.24	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
HNSC	cis	rs2179367	0.632	rs2341774	ENSG00000216906.2	RP11-350J20.9	5.33	1.5e-07	4.82e-05	0.35	0.24	Dupuytren's disease;	chr6:149425014	chr6:149904243~149906418:+
HNSC	cis	rs42490	0.966	rs40377	ENSG00000251136.7	RP11-37B2.1	-5.33	1.5e-07	4.82e-05	-0.21	-0.24	Leprosy;	chr8:89769725	chr8:89609409~89757727:-
HNSC	cis	rs4664293	0.867	rs6720304	ENSG00000226266.5	AC009961.3	-5.33	1.5e-07	4.83e-05	-0.27	-0.24	Monocyte percentage of white cells;	chr2:159787321	chr2:159670708~159712435:-
HNSC	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-5.33	1.5e-07	4.83e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
HNSC	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	5.33	1.5e-07	4.83e-05	0.26	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
HNSC	cis	rs2303759	0.958	rs1465697	ENSG00000268686.1	AC010524.2	-5.33	1.51e-07	4.83e-05	-0.29	-0.24	Multiple sclerosis;	chr19:49333989	chr19:49368705~49388081:-
HNSC	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-5.33	1.51e-07	4.83e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
HNSC	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-5.33	1.51e-07	4.84e-05	-0.42	-0.24	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
HNSC	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	5.33	1.51e-07	4.84e-05	0.3	0.24	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
HNSC	cis	rs860295	0.665	rs12028416	ENSG00000203761.5	MSTO2P	-5.33	1.51e-07	4.84e-05	-0.19	-0.24	Body mass index;	chr1:155431370	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.629	rs12026638	ENSG00000203761.5	MSTO2P	-5.33	1.51e-07	4.84e-05	-0.19	-0.24	Body mass index;	chr1:155431469	chr1:155745829~155750137:+
HNSC	cis	rs1218582	0.772	rs10908448	ENSG00000270361.1	RP11-307C12.13	5.33	1.51e-07	4.84e-05	0.26	0.24	Prostate cancer;	chr1:154910068	chr1:154937370~154938059:+
HNSC	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	5.33	1.51e-07	4.84e-05	0.41	0.24	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	5.33	1.51e-07	4.84e-05	0.41	0.24	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
HNSC	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	5.33	1.51e-07	4.84e-05	0.27	0.24	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
HNSC	cis	rs9368481	0.761	rs12661756	ENSG00000224843.5	LINC00240	-5.33	1.51e-07	4.85e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26956992~27023924:+
HNSC	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	5.33	1.51e-07	4.85e-05	0.29	0.24	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
HNSC	cis	rs17428076	0.793	rs72881938	ENSG00000228389.1	AC068039.4	-5.33	1.51e-07	4.85e-05	-0.29	-0.24	Myopia;	chr2:171772242	chr2:171773482~171775844:+
HNSC	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	5.33	1.51e-07	4.85e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
HNSC	cis	rs3733585	0.699	rs6449158	ENSG00000250413.1	RP11-448G15.1	5.33	1.51e-07	4.85e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958835	chr4:10006482~10009725:+
HNSC	cis	rs4218	0.689	rs35555888	ENSG00000277144.1	RP11-59H7.4	-5.33	1.52e-07	4.86e-05	-0.32	-0.24	Social communication problems;	chr15:59093935	chr15:59115547~59116089:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	5.33	1.52e-07	4.86e-05	0.26	0.24	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	5.33	1.52e-07	4.86e-05	0.26	0.24	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000224373.3	IGHV4-59	5.33	1.52e-07	4.87e-05	0.15	0.24	Kawasaki disease;	chr14:106673171	chr14:106627249~106627825:-
HNSC	cis	rs67981189	0.542	rs17109053	ENSG00000274818.1	RP1-292L20.3	5.33	1.52e-07	4.87e-05	0.29	0.24	Schizophrenia;	chr14:71142981	chr14:70906657~70907111:-
HNSC	cis	rs9291683	0.655	rs3822242	ENSG00000250413.1	RP11-448G15.1	5.33	1.52e-07	4.87e-05	0.3	0.24	Bone mineral density;	chr4:10093280	chr4:10006482~10009725:+
HNSC	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	5.33	1.52e-07	4.87e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	5.33	1.52e-07	4.87e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
HNSC	cis	rs1218582	0.772	rs6683557	ENSG00000270361.1	RP11-307C12.13	-5.33	1.52e-07	4.87e-05	-0.26	-0.24	Prostate cancer;	chr1:154879831	chr1:154937370~154938059:+
HNSC	cis	rs2337406	0.866	rs8003852	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106776648	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs988131	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106776833	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs8005518	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777009	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs988130	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777154	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs57684263	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777263	chr14:106122420~106122709:-
HNSC	cis	rs8040855	0.621	rs6496796	ENSG00000259774.1	RP11-182J1.13	-5.33	1.52e-07	4.88e-05	-0.3	-0.24	Bulimia nervosa;	chr15:85183617	chr15:84422618~84425882:+
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	5.33	1.52e-07	4.89e-05	0.19	0.24	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-5.33	1.52e-07	4.89e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
HNSC	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	5.33	1.53e-07	4.89e-05	0.24	0.24	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
HNSC	cis	rs9992667	0.955	rs10025499	ENSG00000231160.8	KLF3-AS1	5.33	1.53e-07	4.89e-05	0.27	0.24	Eosinophil percentage of granulocytes;	chr4:38619373	chr4:38612701~38664883:-
HNSC	cis	rs28475163	0.958	rs7395116	ENSG00000255328.1	RP11-326C3.12	-5.33	1.53e-07	4.89e-05	-0.3	-0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:327171~330122:+
HNSC	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-5.33	1.53e-07	4.89e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
HNSC	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-5.33	1.53e-07	4.89e-05	-0.27	-0.24	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
HNSC	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	5.33	1.53e-07	4.89e-05	0.25	0.24	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
HNSC	cis	rs988913	1	rs988913	ENSG00000224984.1	RP11-524H19.2	5.33	1.53e-07	4.9e-05	0.27	0.24	Menarche (age at onset);	chr6:54891510	chr6:54840118~54840855:-
HNSC	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-5.33	1.53e-07	4.9e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
HNSC	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	5.33	1.53e-07	4.9e-05	0.27	0.24	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
HNSC	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	5.33	1.53e-07	4.9e-05	0.27	0.24	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
HNSC	cis	rs17594362	1	rs12869969	ENSG00000229473.2	RGS17P1	5.33	1.53e-07	4.9e-05	0.36	0.24	Multiple sclerosis;	chr13:41566204	chr13:40992779~40993331:-
HNSC	cis	rs860295	0.702	rs56675301	ENSG00000203761.5	MSTO2P	-5.33	1.53e-07	4.91e-05	-0.19	-0.24	Body mass index;	chr1:155394536	chr1:155745829~155750137:+
HNSC	cis	rs10504130	0.502	rs16916968	ENSG00000253844.1	RP11-546K22.1	-5.33	1.53e-07	4.91e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51931851	chr8:51961458~52022974:+
HNSC	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-5.33	1.53e-07	4.91e-05	-0.36	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
HNSC	cis	rs180730	0.5	rs6810734	ENSG00000251609.2	SETP12	5.33	1.53e-07	4.92e-05	0.29	0.24	Fasting plasma glucose;	chr4:120935625	chr4:120895494~120897083:-
HNSC	cis	rs8177876	0.915	rs6420418	ENSG00000261061.1	RP11-303E16.2	5.33	1.54e-07	4.92e-05	0.39	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094409	chr16:81030770~81031485:+
HNSC	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	5.33	1.54e-07	4.92e-05	0.23	0.24	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
HNSC	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-5.33	1.54e-07	4.92e-05	-0.3	-0.24	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000179406.6	LINC00174	5.33	1.54e-07	4.92e-05	0.51	0.24	Diabetic kidney disease;	chr7:65928187	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs78803505	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65917585	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34933526	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65918212	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34577383	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65920739	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6949812	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65922114	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6970243	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65923503	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7794661	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65924743	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7795242	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65925107	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65925372	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35058610	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65925938	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2177703	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65926730	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35432774	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65928032	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs56985706	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65929575	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs60683927	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65929781	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs58062456	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65929865	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34529418	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65938222	chr7:66376044~66401338:-
HNSC	cis	rs1971762	0.545	rs6580949	ENSG00000270175.1	RP11-793H13.11	-5.33	1.54e-07	4.93e-05	-0.2	-0.24	Height;	chr12:53530509	chr12:53500162~53500936:-
HNSC	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	5.33	1.54e-07	4.93e-05	0.29	0.24	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
HNSC	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-5.33	1.54e-07	4.93e-05	-0.26	-0.24	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.93e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66034886	chr7:66376044~66401338:-
HNSC	cis	rs4819052	0.851	rs2838842	ENSG00000223768.1	LINC00205	-5.33	1.54e-07	4.93e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45293285~45297354:+
HNSC	cis	rs9287719	0.649	rs12476554	ENSG00000243819.4	RN7SL832P	5.33	1.54e-07	4.94e-05	0.24	0.24	Prostate cancer;	chr2:10587621	chr2:10690344~10692099:+
HNSC	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	5.33	1.54e-07	4.94e-05	0.31	0.24	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-5.33	1.54e-07	4.94e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
HNSC	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-5.33	1.55e-07	4.95e-05	-0.26	-0.24	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
HNSC	cis	rs2243480	1	rs4718270	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.95e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65737415	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs2900904	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.95e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65739282	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.599	rs7652883	ENSG00000248787.1	RP11-666A20.4	-5.33	1.55e-07	4.95e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125989134	chr3:125908005~125910272:-
HNSC	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	5.33	1.55e-07	4.95e-05	0.27	0.24	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
HNSC	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-5.33	1.55e-07	4.96e-05	-0.23	-0.24	Height;	chr5:37072722	chr5:36666214~36725195:-
HNSC	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-5.33	1.55e-07	4.96e-05	-0.26	-0.24	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-5.33	1.55e-07	4.96e-05	-0.26	-0.24	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
HNSC	cis	rs12742923	0.534	rs323962	ENSG00000236268.4	LINC01361	-5.33	1.55e-07	4.96e-05	-0.28	-0.24	HIV-associated dementia;	chr1:83152534	chr1:82973882~82986208:-
HNSC	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-5.33	1.55e-07	4.97e-05	-0.3	-0.24	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
HNSC	cis	rs9611519	0.964	rs2092563	ENSG00000235513.1	RP4-756G23.5	5.33	1.55e-07	4.97e-05	0.27	0.24	Neuroticism;	chr22:41196673	chr22:41209122~41217627:-
HNSC	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-5.33	1.55e-07	4.97e-05	-0.31	-0.24	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
HNSC	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	5.33	1.55e-07	4.97e-05	0.58	0.24	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
HNSC	cis	rs2243480	1	rs73142121	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65846219	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs34004500	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65847191	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35825738	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65853040	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34702770	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65879836	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65892097	chr7:66376044~66401338:-
HNSC	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	5.33	1.55e-07	4.97e-05	0.21	0.24	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
HNSC	cis	rs860295	0.702	rs10796946	ENSG00000203761.5	MSTO2P	-5.33	1.55e-07	4.97e-05	-0.19	-0.24	Body mass index;	chr1:155459699	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.676	rs10908466	ENSG00000203761.5	MSTO2P	-5.33	1.55e-07	4.97e-05	-0.19	-0.24	Body mass index;	chr1:155459934	chr1:155745829~155750137:+
HNSC	cis	rs1056107	0.966	rs1538770	ENSG00000225513.1	RP11-165N19.2	-5.33	1.55e-07	4.97e-05	-0.25	-0.24	Colorectal cancer;	chr9:112300069	chr9:112173522~112173971:-
HNSC	cis	rs11846409	0.932	rs28617526	ENSG00000211974.3	IGHV2-70	-5.33	1.55e-07	4.97e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106637322	chr14:106723574~106724093:-
HNSC	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-5.33	1.56e-07	4.97e-05	-0.3	-0.24	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
HNSC	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	5.33	1.56e-07	4.98e-05	0.25	0.24	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
HNSC	cis	rs4388249	0.687	rs2300995	ENSG00000271849.1	CTC-332L22.1	-5.33	1.56e-07	4.99e-05	-0.32	-0.24	Schizophrenia;	chr5:109746724	chr5:109687802~109688329:-
HNSC	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	5.33	1.56e-07	4.99e-05	0.27	0.24	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
HNSC	cis	rs853679	0.76	rs9393910	ENSG00000204709.4	LINC01556	5.33	1.56e-07	4.99e-05	0.34	0.24	Depression;	chr6:28240414	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.76	rs9368563	ENSG00000204709.4	LINC01556	5.33	1.56e-07	4.99e-05	0.34	0.24	Depression;	chr6:28240780	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	5.33	1.56e-07	4.99e-05	0.29	0.24	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	5.33	1.56e-07	4.99e-05	0.29	0.24	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.662	rs156744	ENSG00000204709.4	LINC01556	5.33	1.56e-07	4.99e-05	0.32	0.24	Parkinson's disease;	chr6:27999496	chr6:28943877~28944537:+
HNSC	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
HNSC	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-5.33	1.56e-07	4.99e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-5.33	1.56e-07	4.99e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-5.33	1.56e-07	4.99e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
HNSC	cis	rs1555322	0.872	rs2425048	ENSG00000126005.14	MMP24-AS1	-5.33	1.56e-07	5e-05	-0.48	-0.24	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35216462~35278131:-
HNSC	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-5.33	1.56e-07	5e-05	-0.3	-0.24	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
HNSC	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-5.33	1.56e-07	5e-05	-0.29	-0.24	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
HNSC	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	5.33	1.57e-07	5e-05	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000211972.2	IGHV3-66	5.33	1.57e-07	5.01e-05	0.19	0.24	Kawasaki disease;	chr14:106704386	chr14:106675017~106675544:-
HNSC	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	5.33	1.57e-07	5.01e-05	0.29	0.24	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
HNSC	cis	rs6928977	0.896	rs2614257	ENSG00000231028.7	LINC00271	5.33	1.57e-07	5.01e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135355266	chr6:135497801~135716055:+
HNSC	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-5.33	1.57e-07	5.01e-05	-0.27	-0.24	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
HNSC	cis	rs9907295	0.901	rs11652536	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35891043	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs9789051	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35892000	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs3809769	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35892484	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs76016589	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35892923	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4796124	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35893280	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs11656556	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35894090	chr17:35893707~35911023:-
HNSC	cis	rs2337406	0.852	rs12050239	ENSG00000211974.3	IGHV2-70	-5.33	1.57e-07	5.02e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781132	chr14:106723574~106724093:-
HNSC	cis	rs2115630	1	rs11073730	ENSG00000229212.6	RP11-561C5.4	5.33	1.57e-07	5.02e-05	0.28	0.24	P wave terminal force;	chr15:84811365	chr15:85205440~85234795:-
HNSC	cis	rs10027350	0.964	rs10026230	ENSG00000281501.1	SEPSECS-AS1	5.33	1.57e-07	5.02e-05	0.3	0.24	Childhood ear infection;	chr4:25135784	chr4:25160641~25201440:+
HNSC	cis	rs7674212	0.51	rs2720468	ENSG00000246560.2	RP11-10L12.4	5.32	1.57e-07	5.02e-05	0.27	0.24	Type 2 diabetes;	chr4:103163996	chr4:102828055~102844075:+
HNSC	cis	rs6928977	0.832	rs9402703	ENSG00000231028.7	LINC00271	5.32	1.57e-07	5.03e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135325097	chr6:135497801~135716055:+
HNSC	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	5.32	1.58e-07	5.03e-05	0.29	0.24	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	5.32	1.58e-07	5.04e-05	0.26	0.24	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	5.32	1.58e-07	5.04e-05	0.14	0.24	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
HNSC	cis	rs202072	0.729	rs202038	ENSG00000215022.6	RP1-257A7.4	5.32	1.58e-07	5.04e-05	0.35	0.24	HIV-1 viral setpoint;	chr6:13288416	chr6:13264861~13295586:-
HNSC	cis	rs9914544	1	rs1037036	ENSG00000264885.1	RP11-815I9.4	-5.32	1.58e-07	5.04e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18860764	chr17:18667629~18669461:-
HNSC	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	5.32	1.58e-07	5.04e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
HNSC	cis	rs4938303	0.633	rs17092638	ENSG00000254851.1	RP11-109L13.1	5.32	1.58e-07	5.05e-05	0.39	0.24	Triglycerides;	chr11:116685520	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	5.32	1.58e-07	5.05e-05	0.27	0.24	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	5.32	1.58e-07	5.05e-05	0.26	0.24	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
HNSC	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	5.32	1.58e-07	5.05e-05	0.26	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
HNSC	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	5.32	1.58e-07	5.05e-05	0.26	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
HNSC	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-5.32	1.58e-07	5.05e-05	-0.28	-0.24	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
HNSC	cis	rs853679	0.76	rs9295768	ENSG00000204709.4	LINC01556	5.32	1.58e-07	5.05e-05	0.34	0.24	Depression;	chr6:28241324	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.699	rs9468318	ENSG00000204709.4	LINC01556	5.32	1.58e-07	5.05e-05	0.34	0.24	Depression;	chr6:28241753	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.76	rs9357067	ENSG00000204709.4	LINC01556	5.32	1.58e-07	5.05e-05	0.34	0.24	Depression;	chr6:28242515	chr6:28943877~28944537:+
HNSC	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.32	1.58e-07	5.06e-05	0.25	0.24	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
HNSC	cis	rs2337406	0.789	rs60390024	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781327	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092532	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781363	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092534	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781364	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092535	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781722	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092537	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781883	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.81	rs74092538	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781942	chr14:106723574~106724093:-
HNSC	cis	rs603446	0.901	rs180344	ENSG00000254851.1	RP11-109L13.1	-5.32	1.59e-07	5.06e-05	-0.32	-0.24	Triglycerides;	chr11:116742468	chr11:117135528~117138582:+
HNSC	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-5.32	1.59e-07	5.06e-05	-0.3	-0.24	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
HNSC	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	5.32	1.59e-07	5.07e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
HNSC	cis	rs6693567	0.516	rs7554686	ENSG00000228126.1	FALEC	-5.32	1.59e-07	5.07e-05	-0.29	-0.24	Migraine;	chr1:150293199	chr1:150515757~150518032:+
HNSC	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-5.32	1.59e-07	5.08e-05	-0.27	-0.24	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-5.32	1.59e-07	5.08e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-5.32	1.59e-07	5.08e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
HNSC	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	5.32	1.59e-07	5.08e-05	0.31	0.24	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
HNSC	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	5.32	1.59e-07	5.09e-05	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-5.32	1.59e-07	5.09e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
HNSC	cis	rs71520386	0.632	rs1029738	ENSG00000221740.1	SNORD93	-5.32	1.6e-07	5.09e-05	-0.28	-0.24	Fibrinogen levels;	chr7:22834428	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs9654968	ENSG00000221740.1	SNORD93	-5.32	1.6e-07	5.09e-05	-0.28	-0.24	Fibrinogen levels;	chr7:22836697	chr7:22856613~22856686:+
HNSC	cis	rs9525927	0.625	rs9562541	ENSG00000227258.4	SMIM2-AS1	5.32	1.6e-07	5.09e-05	0.35	0.24	Dupuytren's disease;	chr13:44249190	chr13:44110451~44240517:+
HNSC	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-5.32	1.6e-07	5.09e-05	-0.3	-0.24	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
HNSC	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-5.32	1.6e-07	5.09e-05	-0.23	-0.24	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
HNSC	cis	rs10256972	0.933	rs35696159	ENSG00000225146.1	AC073957.15	5.32	1.6e-07	5.1e-05	0.28	0.24	Endometriosis;Longevity;	chr7:1007558	chr7:1029025~1043891:+
HNSC	cis	rs8032939	0.533	rs17652674	ENSG00000259747.1	RP11-275I4.2	-5.32	1.6e-07	5.1e-05	-0.3	-0.24	Rheumatoid arthritis;	chr15:38608111	chr15:38671847~38689191:+
HNSC	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	5.32	1.6e-07	5.1e-05	0.28	0.24	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
HNSC	cis	rs7927592	0.645	rs7950900	ENSG00000212093.1	AP000807.1	5.32	1.6e-07	5.1e-05	0.26	0.24	Total body bone mineral density;	chr11:68526077	chr11:68506083~68506166:-
HNSC	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-5.32	1.6e-07	5.1e-05	-0.31	-0.24	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
HNSC	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	5.32	1.6e-07	5.11e-05	0.57	0.24	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
HNSC	cis	rs9840812	0.522	rs699165	ENSG00000239213.4	NCK1-AS1	5.32	1.6e-07	5.11e-05	0.23	0.24	Fibrinogen levels;	chr3:136505855	chr3:136841726~136862054:-
HNSC	cis	rs10027350	1	rs10027350	ENSG00000281501.1	SEPSECS-AS1	5.32	1.6e-07	5.11e-05	0.3	0.24	Childhood ear infection;	chr4:25130872	chr4:25160641~25201440:+
HNSC	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-5.32	1.6e-07	5.11e-05	-0.33	-0.24	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-5.32	1.6e-07	5.11e-05	-0.33	-0.24	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
HNSC	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-5.32	1.6e-07	5.12e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
HNSC	cis	rs7804306	1	rs34156160	ENSG00000233264.2	AC006042.8	5.32	1.6e-07	5.12e-05	0.48	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8043155	chr7:7980312~7982228:+
HNSC	cis	rs8062405	0.558	rs151228	ENSG00000251417.2	RP11-1348G14.4	-5.32	1.61e-07	5.12e-05	-0.27	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28802743~28817828:+
HNSC	cis	rs933688	1	rs1895448	ENSG00000281357.1	ARRDC3-AS1	5.32	1.61e-07	5.12e-05	0.35	0.24	Smoking behavior;	chr5:91448037	chr5:91380349~91439085:+
HNSC	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	5.32	1.61e-07	5.12e-05	0.29	0.24	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
HNSC	cis	rs988913	1	rs9382403	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54960889	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9349740	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54960910	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7744592	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54961547	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7753255	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54968175	chr6:54840118~54840855:-
HNSC	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-5.32	1.61e-07	5.13e-05	-0.22	-0.24	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
HNSC	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
HNSC	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	5.32	1.61e-07	5.14e-05	0.41	0.24	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
HNSC	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-5.32	1.61e-07	5.14e-05	-0.21	-0.24	Height;	chr11:118742526	chr11:118791254~118793137:+
HNSC	cis	rs9813712	1	rs9813712	ENSG00000249846.5	RP11-77P16.4	5.32	1.61e-07	5.14e-05	0.28	0.24	Response to amphetamines;	chr3:130252258	chr3:130112550~130120579:+
HNSC	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-5.32	1.61e-07	5.14e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
HNSC	cis	rs10466239	0.667	rs10899792	ENSG00000230555.2	RP11-517P14.2	5.32	1.61e-07	5.14e-05	0.31	0.24	Telomere length;	chr10:43364722	chr10:43420738~43422100:+
HNSC	cis	rs9921338	0.961	rs7200667	ENSG00000263080.1	RP11-485G7.5	5.32	1.61e-07	5.15e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.924	rs7202024	ENSG00000263080.1	RP11-485G7.5	5.32	1.61e-07	5.15e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs7206017	ENSG00000263080.1	RP11-485G7.5	5.32	1.61e-07	5.15e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11341809~11345211:-
HNSC	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-5.32	1.61e-07	5.15e-05	-0.26	-0.24	Height;	chr2:46640019	chr2:46668870~46670778:+
HNSC	cis	rs9840812	0.598	rs33999043	ENSG00000239213.4	NCK1-AS1	5.32	1.62e-07	5.15e-05	0.26	0.24	Fibrinogen levels;	chr3:136381198	chr3:136841726~136862054:-
HNSC	cis	rs3736485	0.808	rs28485410	ENSG00000259438.1	CTD-2650P22.1	5.32	1.62e-07	5.15e-05	0.24	0.24	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51657688	chr15:52010999~52019095:-
HNSC	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-5.32	1.62e-07	5.15e-05	-0.25	-0.24	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	5.32	1.62e-07	5.16e-05	0.26	0.24	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
HNSC	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	5.32	1.62e-07	5.16e-05	0.24	0.24	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.593	rs13009015	ENSG00000243819.4	RN7SL832P	5.32	1.62e-07	5.16e-05	0.24	0.24	Prostate cancer;	chr2:10622992	chr2:10690344~10692099:+
HNSC	cis	rs9921338	0.961	rs11545336	ENSG00000263080.1	RP11-485G7.5	5.32	1.62e-07	5.16e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11341809~11345211:-
HNSC	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	5.32	1.62e-07	5.16e-05	0.19	0.24	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
HNSC	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-5.32	1.62e-07	5.16e-05	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
HNSC	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-5.32	1.62e-07	5.16e-05	-0.35	-0.24	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
HNSC	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-5.32	1.62e-07	5.17e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
HNSC	cis	rs12701220	0.894	rs34712249	ENSG00000229043.2	AC091729.9	-5.32	1.62e-07	5.17e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:996998	chr7:1160374~1165267:+
HNSC	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-5.32	1.62e-07	5.17e-05	-0.3	-0.24	Depression;	chr6:28180209	chr6:28161781~28169594:+
HNSC	cis	rs9987353	0.566	rs34491841	ENSG00000173295.6	FAM86B3P	-5.32	1.63e-07	5.18e-05	-0.29	-0.24	Recombination measurement;	chr8:9208000	chr8:8228595~8244865:+
HNSC	cis	rs7819412	0.775	rs34094119	ENSG00000255310.2	AF131215.2	-5.32	1.63e-07	5.18e-05	-0.23	-0.24	Triglycerides;	chr8:11078388	chr8:11107788~11109726:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	5.32	1.63e-07	5.18e-05	0.26	0.24	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
HNSC	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-5.32	1.63e-07	5.18e-05	-0.27	-0.24	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
HNSC	cis	rs9840812	0.69	rs1618069	ENSG00000273486.1	RP11-731C17.2	5.32	1.63e-07	5.18e-05	0.21	0.24	Fibrinogen levels;	chr3:136308303	chr3:136837338~136839021:-
HNSC	cis	rs950169	0.887	rs220333	ENSG00000229212.6	RP11-561C5.4	-5.32	1.63e-07	5.18e-05	-0.33	-0.24	Schizophrenia;	chr15:84547902	chr15:85205440~85234795:-
HNSC	cis	rs638893	0.617	rs2156750	ENSG00000255422.1	AP002954.4	-5.32	1.63e-07	5.18e-05	-0.34	-0.24	Vitiligo;	chr11:118848545	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.561	rs2156749	ENSG00000255422.1	AP002954.4	-5.32	1.63e-07	5.18e-05	-0.34	-0.24	Vitiligo;	chr11:118848696	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.617	rs7116715	ENSG00000255422.1	AP002954.4	-5.32	1.63e-07	5.18e-05	-0.34	-0.24	Vitiligo;	chr11:118849033	chr11:118704607~118750263:+
HNSC	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	5.32	1.63e-07	5.18e-05	0.59	0.24	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	5.32	1.63e-07	5.18e-05	0.26	0.24	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
HNSC	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-5.32	1.63e-07	5.18e-05	-0.24	-0.24	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
HNSC	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-5.32	1.63e-07	5.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-5.32	1.63e-07	5.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-5.32	1.63e-07	5.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
HNSC	cis	rs1056107	0.931	rs6575	ENSG00000225513.1	RP11-165N19.2	-5.32	1.63e-07	5.19e-05	-0.26	-0.24	Colorectal cancer;	chr9:112218687	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.797	rs4979087	ENSG00000225513.1	RP11-165N19.2	-5.32	1.63e-07	5.19e-05	-0.26	-0.24	Colorectal cancer;	chr9:112179920	chr9:112173522~112173971:-
HNSC	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	5.32	1.63e-07	5.19e-05	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
HNSC	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	5.32	1.63e-07	5.19e-05	0.29	0.24	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.866	rs4774019	ENSG00000254174.1	IGHV1-12	5.32	1.63e-07	5.2e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106805386	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs58850145	ENSG00000254174.1	IGHV1-12	5.32	1.63e-07	5.2e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106806185	chr14:106122420~106122709:-
HNSC	cis	rs1113500	0.524	rs11185270	ENSG00000226822.1	RP11-356N1.2	5.32	1.63e-07	5.2e-05	0.29	0.24	Growth-regulated protein alpha levels;	chr1:108111740	chr1:108071482~108074519:+
HNSC	cis	rs9341808	0.519	rs7771593	ENSG00000272129.1	RP11-250B2.6	-5.32	1.63e-07	5.2e-05	-0.29	-0.24	Sitting height ratio;	chr6:80326410	chr6:80355424~80356859:+
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	5.32	1.63e-07	5.2e-05	0.26	0.24	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
HNSC	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	5.32	1.64e-07	5.21e-05	0.29	0.24	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
HNSC	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	5.32	1.64e-07	5.21e-05	0.26	0.24	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
HNSC	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-5.32	1.64e-07	5.21e-05	-0.29	-0.24	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
HNSC	cis	rs8012947	0.545	rs1190980	ENSG00000279636.2	LINC00216	-5.32	1.64e-07	5.21e-05	-0.26	-0.24	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58288033~58289158:+
HNSC	cis	rs2998286	0.862	rs2807728	ENSG00000254635.4	WAC-AS1	5.32	1.64e-07	5.21e-05	0.3	0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526504	chr10:28522652~28532743:-
HNSC	cis	rs712039	0.565	rs1714987	ENSG00000276054.1	RP11-378E13.3	5.32	1.64e-07	5.21e-05	0.33	0.24	Tuberculosis;	chr17:37386072	chr17:37386886~37387926:+
HNSC	cis	rs2235642	1	rs2076438	ENSG00000280231.1	LA16c-380F5.3	-5.32	1.64e-07	5.21e-05	-0.29	-0.24	Coronary artery disease;	chr16:1534617	chr16:1553655~1554130:-
HNSC	cis	rs1707322	0.963	rs10890373	ENSG00000234329.1	RP11-767N6.2	5.32	1.64e-07	5.22e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45651039~45651826:-
HNSC	cis	rs988913	1	rs9367600	ENSG00000224984.1	RP11-524H19.2	5.32	1.64e-07	5.22e-05	0.27	0.24	Menarche (age at onset);	chr6:54973179	chr6:54840118~54840855:-
HNSC	cis	rs9402743	0.671	rs9373137	ENSG00000217482.2	HMGB1P17	5.32	1.64e-07	5.22e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135629059	chr6:135636086~135636713:-
HNSC	cis	rs7615952	0.688	rs12485622	ENSG00000248787.1	RP11-666A20.4	-5.32	1.64e-07	5.22e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125991896	chr3:125908005~125910272:-
HNSC	cis	rs2337406	0.866	rs112089985	ENSG00000254174.1	IGHV1-12	5.32	1.64e-07	5.22e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106780074	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7152809	ENSG00000254174.1	IGHV1-12	5.32	1.64e-07	5.23e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778385	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7152832	ENSG00000254174.1	IGHV1-12	5.32	1.64e-07	5.23e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778427	chr14:106122420~106122709:-
HNSC	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-5.32	1.64e-07	5.23e-05	-0.34	-0.24	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
HNSC	cis	rs2579103	0.898	rs2579127	ENSG00000258183.4	RP11-753N8.1	-5.32	1.64e-07	5.23e-05	-0.3	-0.24	Body mass index;	chr12:90204420	chr12:90280894~90300340:+
HNSC	cis	rs732716	0.853	rs12459922	ENSG00000267980.1	AC007292.6	-5.32	1.64e-07	5.23e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4455865	chr19:4363789~4364640:+
HNSC	cis	rs1355223	1	rs1355221	ENSG00000271369.1	RP11-350D17.3	-5.32	1.65e-07	5.23e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737062	chr11:34709600~34710161:+
HNSC	cis	rs13126694	0.679	rs4072170	ENSG00000248429.4	RP11-597D13.9	5.32	1.65e-07	5.24e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157980683	chr4:158170752~158202877:+
HNSC	cis	rs7819412	0.775	rs4841489	ENSG00000255310.2	AF131215.2	-5.32	1.65e-07	5.24e-05	-0.23	-0.24	Triglycerides;	chr8:11079301	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.775	rs4841490	ENSG00000255310.2	AF131215.2	-5.32	1.65e-07	5.24e-05	-0.23	-0.24	Triglycerides;	chr8:11079381	chr8:11107788~11109726:-
HNSC	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-5.32	1.65e-07	5.24e-05	-0.39	-0.24	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
HNSC	cis	rs4218	0.681	rs34977427	ENSG00000277144.1	RP11-59H7.4	-5.32	1.65e-07	5.24e-05	-0.32	-0.24	Social communication problems;	chr15:59098172	chr15:59115547~59116089:-
HNSC	cis	rs2243480	1	rs427044	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66043558	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs437889	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66044247	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs402418	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66044482	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66044512	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs431318	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66046610	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313803	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66049744	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313802	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66051386	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66052736	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs458291	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66055492	chr7:66376044~66401338:-
HNSC	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-5.32	1.65e-07	5.25e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
HNSC	cis	rs2243480	1	rs11538349	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65956884	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35542501	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65966228	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65973566	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781142	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65973791	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	5.32	1.65e-07	5.25e-05	0.3	0.24	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
HNSC	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	5.32	1.65e-07	5.25e-05	0.23	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
HNSC	cis	rs3206736	0.548	rs10265125	ENSG00000197085.10	NPSR1-AS1	-5.32	1.65e-07	5.25e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:35021524	chr7:34346512~34871582:-
HNSC	cis	rs694739	0.628	rs475032	ENSG00000236935.1	AP003774.1	-5.32	1.65e-07	5.25e-05	-0.24	-0.24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373265	chr11:64325050~64329504:-
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	5.32	1.65e-07	5.26e-05	0.26	0.24	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
HNSC	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-5.32	1.65e-07	5.26e-05	-0.24	-0.24	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
HNSC	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-5.32	1.65e-07	5.26e-05	-0.24	-0.24	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
HNSC	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-5.31	1.66e-07	5.27e-05	-0.24	-0.24	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
HNSC	cis	rs7615952	0.599	rs66532274	ENSG00000248787.1	RP11-666A20.4	-5.31	1.66e-07	5.27e-05	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126013002	chr3:125908005~125910272:-
HNSC	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-5.31	1.66e-07	5.27e-05	-0.3	-0.24	Depression;	chr6:28176973	chr6:28161781~28169594:+
HNSC	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	5.31	1.66e-07	5.28e-05	0.25	0.24	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
HNSC	cis	rs442309	0.532	rs10995301	ENSG00000238280.1	RP11-436D10.3	5.31	1.66e-07	5.28e-05	0.3	0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62747535	chr10:62793562~62805887:-
HNSC	cis	rs2179367	0.632	rs11155642	ENSG00000216906.2	RP11-350J20.9	5.31	1.66e-07	5.28e-05	0.35	0.24	Dupuytren's disease;	chr6:149332984	chr6:149904243~149906418:+
HNSC	cis	rs889014	0.751	rs12520258	ENSG00000253768.1	CTB-33O18.1	-5.31	1.66e-07	5.28e-05	-0.26	-0.24	Height;	chr5:173553711	chr5:173562478~173573199:+
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	5.31	1.66e-07	5.29e-05	0.26	0.24	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
HNSC	cis	rs67981189	0.529	rs61990380	ENSG00000274818.1	RP1-292L20.3	5.31	1.66e-07	5.29e-05	0.29	0.24	Schizophrenia;	chr14:71005229	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	5.31	1.66e-07	5.29e-05	0.29	0.24	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
HNSC	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-5.31	1.66e-07	5.29e-05	-0.24	-0.24	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
HNSC	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	5.31	1.67e-07	5.29e-05	0.27	0.24	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	5.31	1.67e-07	5.29e-05	0.27	0.24	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	5.31	1.67e-07	5.29e-05	0.27	0.24	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
HNSC	cis	rs1707322	0.927	rs11211194	ENSG00000234329.1	RP11-767N6.2	5.31	1.67e-07	5.29e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45651039~45651826:-
HNSC	cis	rs2243480	1	rs2243480	ENSG00000179406.6	LINC00174	-5.31	1.67e-07	5.29e-05	-0.5	-0.24	Diabetic kidney disease;	chr7:66134209	chr7:66376044~66401338:-
HNSC	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	5.31	1.67e-07	5.3e-05	0.26	0.24	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
HNSC	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	5.31	1.67e-07	5.3e-05	0.23	0.24	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
HNSC	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-5.31	1.67e-07	5.31e-05	-0.33	-0.24	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
HNSC	cis	rs9840812	0.623	rs1394092	ENSG00000239213.4	NCK1-AS1	5.31	1.67e-07	5.31e-05	0.22	0.24	Fibrinogen levels;	chr3:136477229	chr3:136841726~136862054:-
HNSC	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	5.31	1.67e-07	5.31e-05	0.44	0.24	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
HNSC	cis	rs7615952	0.736	rs9862893	ENSG00000248787.1	RP11-666A20.4	-5.31	1.67e-07	5.31e-05	-0.4	-0.24	Blood pressure (smoking interaction);	chr3:125968131	chr3:125908005~125910272:-
HNSC	cis	rs73198271	0.74	rs28402110	ENSG00000253893.2	FAM85B	5.31	1.67e-07	5.32e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.74	rs10112989	ENSG00000253893.2	FAM85B	5.31	1.67e-07	5.32e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8167819~8226614:-
HNSC	cis	rs8054556	0.967	rs11150576	ENSG00000183604.13	SMG1P5	-5.31	1.67e-07	5.32e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:30267553~30335374:-
HNSC	cis	rs9840812	0.596	rs571513	ENSG00000239213.4	NCK1-AS1	5.31	1.68e-07	5.32e-05	0.22	0.24	Fibrinogen levels;	chr3:136376193	chr3:136841726~136862054:-
HNSC	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	5.31	1.68e-07	5.32e-05	0.37	0.24	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	5.31	1.68e-07	5.32e-05	0.37	0.24	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
HNSC	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-5.31	1.68e-07	5.33e-05	-0.3	-0.24	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
HNSC	cis	rs4713118	0.662	rs149901	ENSG00000204709.4	LINC01556	5.31	1.68e-07	5.33e-05	0.32	0.24	Parkinson's disease;	chr6:27997725	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs464312	ENSG00000204709.4	LINC01556	5.31	1.68e-07	5.33e-05	0.32	0.24	Parkinson's disease;	chr6:27999813	chr6:28943877~28944537:+
HNSC	cis	rs9840812	0.522	rs711976	ENSG00000239213.4	NCK1-AS1	5.31	1.68e-07	5.34e-05	0.23	0.24	Fibrinogen levels;	chr3:136510180	chr3:136841726~136862054:-
HNSC	cis	rs4699052	0.507	rs6533085	ENSG00000246560.2	RP11-10L12.4	5.31	1.68e-07	5.34e-05	0.3	0.24	Testicular germ cell tumor;	chr4:103360429	chr4:102828055~102844075:+
HNSC	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	5.31	1.68e-07	5.34e-05	0.23	0.24	Height;	chr5:37041491	chr5:36666214~36725195:-
HNSC	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	5.31	1.68e-07	5.34e-05	0.29	0.24	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	5.31	1.68e-07	5.35e-05	0.26	0.24	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-5.31	1.68e-07	5.35e-05	-0.14	-0.24	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
HNSC	cis	rs11969893	1	rs60993915	ENSG00000270987.1	RP3-467N11.2	5.31	1.69e-07	5.35e-05	0.65	0.24	Economic and political preferences (immigration/crime);	chr6:101132273	chr6:100889603~100890338:+
HNSC	cis	rs763567	0.967	rs736791	ENSG00000271811.1	RP1-79C4.4	-5.31	1.69e-07	5.35e-05	-0.26	-0.24	Tonsillectomy;	chr1:170617174	chr1:170667381~170669425:+
HNSC	cis	rs1355223	0.867	rs11821793	ENSG00000271369.1	RP11-350D17.3	-5.31	1.69e-07	5.36e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659915	chr11:34709600~34710161:+
HNSC	cis	rs11846409	0.872	rs2956482	ENSG00000274576.2	IGHV2-70	5.31	1.69e-07	5.36e-05	0.23	0.24	Rheumatic heart disease;	chr14:106630013	chr14:106770577~106771020:-
HNSC	cis	rs9987353	0.62	rs34455383	ENSG00000173295.6	FAM86B3P	-5.31	1.69e-07	5.36e-05	-0.3	-0.24	Recombination measurement;	chr8:9208948	chr8:8228595~8244865:+
HNSC	cis	rs860295	0.702	rs2025669	ENSG00000203761.5	MSTO2P	-5.31	1.69e-07	5.37e-05	-0.19	-0.24	Body mass index;	chr1:155387818	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs12081067	ENSG00000203761.5	MSTO2P	-5.31	1.69e-07	5.37e-05	-0.19	-0.24	Body mass index;	chr1:155389191	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs10908465	ENSG00000203761.5	MSTO2P	-5.31	1.69e-07	5.37e-05	-0.19	-0.24	Body mass index;	chr1:155419897	chr1:155745829~155750137:+
HNSC	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	5.31	1.69e-07	5.37e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
HNSC	cis	rs1862618	0.853	rs1423621	ENSG00000271828.1	CTD-2310F14.1	5.31	1.69e-07	5.37e-05	0.31	0.24	Initial pursuit acceleration;	chr5:56805208	chr5:56927874~56929573:+
HNSC	cis	rs1008375	0.966	rs7658240	ENSG00000249502.1	AC006160.5	5.31	1.69e-07	5.37e-05	0.27	0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587327	chr4:17587467~17614571:-
HNSC	cis	rs17270561	0.514	rs10946805	ENSG00000272810.1	U91328.22	-5.31	1.69e-07	5.38e-05	-0.27	-0.24	Iron status biomarkers;	chr6:26077663	chr6:26013241~26013757:+
HNSC	cis	rs3733585	0.775	rs13124007	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10042307	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.566	rs13144709	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10042558	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs13110307	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10042740	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.566	rs13122689	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10043024	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs13129453	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10043160	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs12504565	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10043521	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs7442336	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10044159	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs28613263	ENSG00000250413.1	RP11-448G15.1	5.31	1.7e-07	5.38e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9963256	chr4:10006482~10009725:+
HNSC	cis	rs13113518	1	rs11942279	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55439652	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805148	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55440643	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133380	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55441110	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12510110	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55441567	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12510990	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55441907	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805149	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55442184	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11945370	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55442875	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12647677	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55444253	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.902	rs3805150	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55446869	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4864990	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55447523	chr4:55387949~55388271:+
HNSC	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-5.31	1.7e-07	5.39e-05	-0.3	-0.24	Depression;	chr6:28143758	chr6:28161781~28169594:+
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	5.31	1.7e-07	5.4e-05	0.26	0.24	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	5.31	1.7e-07	5.4e-05	0.26	0.24	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
HNSC	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-5.31	1.7e-07	5.4e-05	-0.23	-0.24	Height;	chr5:36911514	chr5:36666214~36725195:-
HNSC	cis	rs4713118	0.539	rs200967	ENSG00000219392.1	RP1-265C24.5	-5.31	1.7e-07	5.4e-05	-0.29	-0.24	Parkinson's disease;	chr6:27894349	chr6:28115628~28116551:+
HNSC	cis	rs1971762	0.527	rs6580952	ENSG00000270175.1	RP11-793H13.11	-5.31	1.7e-07	5.4e-05	-0.2	-0.24	Height;	chr12:53543668	chr12:53500162~53500936:-
HNSC	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	5.31	1.7e-07	5.41e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
HNSC	cis	rs10504130	0.542	rs1589079	ENSG00000253844.1	RP11-546K22.1	-5.31	1.71e-07	5.41e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51923739	chr8:51961458~52022974:+
HNSC	cis	rs4763879	0.778	rs11052497	ENSG00000256673.1	RP11-599J14.2	5.31	1.71e-07	5.41e-05	0.22	0.24	Type 1 diabetes;	chr12:9696679	chr12:9398355~9414851:-
HNSC	cis	rs17428076	0.874	rs12614709	ENSG00000228389.1	AC068039.4	-5.31	1.71e-07	5.41e-05	-0.29	-0.24	Myopia;	chr2:171824362	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.874	rs62182372	ENSG00000228389.1	AC068039.4	-5.31	1.71e-07	5.41e-05	-0.29	-0.24	Myopia;	chr2:171827977	chr2:171773482~171775844:+
HNSC	cis	rs17270561	0.562	rs12199626	ENSG00000272810.1	U91328.22	-5.31	1.71e-07	5.42e-05	-0.28	-0.24	Iron status biomarkers;	chr6:26013376	chr6:26013241~26013757:+
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000173295.6	FAM86B3P	-5.31	1.71e-07	5.42e-05	-0.27	-0.24	Joint mobility (Beighton score);	chr8:8935355	chr8:8228595~8244865:+
HNSC	cis	rs11170631	0.504	rs10128880	ENSG00000270175.1	RP11-793H13.11	-5.31	1.71e-07	5.42e-05	-0.2	-0.24	Height;	chr12:53533999	chr12:53500162~53500936:-
HNSC	cis	rs7617773	0.963	rs12494304	ENSG00000228638.1	FCF1P2	5.31	1.71e-07	5.42e-05	0.22	0.24	Coronary artery disease;	chr3:48136539	chr3:48290793~48291375:-
HNSC	cis	rs1552244	1	rs6789156	ENSG00000180385.7	EMC3-AS1	5.31	1.71e-07	5.42e-05	0.28	0.24	Alzheimer's disease;	chr3:10082436	chr3:9986893~10006990:+
HNSC	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	5.31	1.71e-07	5.42e-05	0.57	0.24	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	5.31	1.71e-07	5.42e-05	0.57	0.24	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	5.31	1.71e-07	5.42e-05	0.57	0.24	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
HNSC	cis	rs2439831	1	rs2467740	ENSG00000205771.5	CATSPER2P1	-5.31	1.71e-07	5.42e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43454594	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2245054	ENSG00000205771.5	CATSPER2P1	-5.31	1.71e-07	5.42e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43459711	chr15:43726918~43747094:-
HNSC	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	5.31	1.71e-07	5.42e-05	0.29	0.24	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
HNSC	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-5.31	1.71e-07	5.43e-05	-0.24	-0.24	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
HNSC	cis	rs6540731	1	rs11119884	ENSG00000226251.4	RP11-15I11.3	-5.31	1.71e-07	5.43e-05	-0.28	-0.24	Intelligence (childhood);	chr1:212226804	chr1:212225278~212238977:-
HNSC	cis	rs35306767	0.953	rs11253517	ENSG00000229869.1	RP11-363N22.2	5.31	1.71e-07	5.43e-05	0.33	0.24	Eosinophil percentage of granulocytes;	chr10:924584	chr10:933026~942743:+
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	5.31	1.71e-07	5.43e-05	0.27	0.24	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000233609.3	RP11-62H7.2	5.31	1.71e-07	5.43e-05	0.24	0.24	Joint mobility (Beighton score);	chr8:8995760	chr8:8961200~8979025:+
HNSC	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	5.31	1.71e-07	5.43e-05	0.25	0.24	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
HNSC	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	5.31	1.71e-07	5.43e-05	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
HNSC	cis	rs1008375	0.931	rs1860592	ENSG00000249502.1	AC006160.5	-5.31	1.71e-07	5.43e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575405	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000233609.3	RP11-62H7.2	-5.31	1.72e-07	5.44e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8961200~8979025:+
HNSC	cis	rs7083	0.653	rs573442	ENSG00000254851.1	RP11-109L13.1	5.31	1.72e-07	5.44e-05	0.32	0.24	Blood protein levels;	chr11:117307204	chr11:117135528~117138582:+
HNSC	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	5.31	1.72e-07	5.44e-05	0.25	0.24	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
HNSC	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-5.31	1.72e-07	5.45e-05	-0.26	-0.24	Height;	chr2:46641180	chr2:46668870~46670778:+
HNSC	cis	rs11969893	0.85	rs9390697	ENSG00000270987.1	RP3-467N11.2	5.31	1.72e-07	5.46e-05	0.61	0.24	Economic and political preferences (immigration/crime);	chr6:100846555	chr6:100889603~100890338:+
HNSC	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	5.31	1.73e-07	5.47e-05	0.29	0.24	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
HNSC	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	5.31	1.73e-07	5.47e-05	0.28	0.24	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	5.31	1.73e-07	5.47e-05	0.28	0.24	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	5.31	1.73e-07	5.47e-05	0.28	0.24	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
HNSC	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	5.31	1.73e-07	5.47e-05	0.24	0.24	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
HNSC	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-5.31	1.73e-07	5.47e-05	-0.28	-0.24	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
HNSC	cis	rs7515577	0.588	rs17380378	ENSG00000223787.2	RP4-593M8.1	5.31	1.73e-07	5.48e-05	0.52	0.24	Cholesterol, total;	chr1:92580420	chr1:92580476~92580821:-
HNSC	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	5.31	1.73e-07	5.48e-05	0.21	0.24	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
HNSC	cis	rs11773103	1	rs73206984	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87182209	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208507	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87192492	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs11773103	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87192664	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.867	rs73208517	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87198251	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208522	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87198863	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208537	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87200814	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208546	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87203799	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs117742735	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87205452	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73210234	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87211844	chr7:87151423~87152420:-
HNSC	cis	rs7617773	0.963	rs12493256	ENSG00000228638.1	FCF1P2	5.31	1.74e-07	5.49e-05	0.22	0.24	Coronary artery disease;	chr3:48135257	chr3:48290793~48291375:-
HNSC	cis	rs1008375	0.9	rs1003413	ENSG00000249502.1	AC006160.5	5.31	1.74e-07	5.49e-05	0.27	0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17580819	chr4:17587467~17614571:-
HNSC	cis	rs6928977	0.897	rs2746431	ENSG00000234084.1	RP3-388E23.2	5.31	1.74e-07	5.5e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366063	chr6:135301568~135307158:+
HNSC	cis	rs4718428	1	rs1830070	ENSG00000179406.6	LINC00174	-5.31	1.74e-07	5.5e-05	-0.32	-0.24	Corneal structure;	chr7:66884684	chr7:66376044~66401338:-
HNSC	cis	rs17507216	0.718	rs4779034	ENSG00000276710.3	CSPG4P8	-5.31	1.74e-07	5.5e-05	-0.32	-0.24	Excessive daytime sleepiness;	chr15:82576799	chr15:82459472~82477258:+
HNSC	cis	rs1707322	1	rs4660334	ENSG00000234329.1	RP11-767N6.2	5.31	1.74e-07	5.51e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45651039~45651826:-
HNSC	cis	rs10504130	0.502	rs10087958	ENSG00000272024.1	RP11-546K22.3	-5.31	1.74e-07	5.51e-05	-0.31	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51954109	chr8:51950284~51950690:+
HNSC	cis	rs4763879	0.634	rs61915473	ENSG00000256673.1	RP11-599J14.2	5.31	1.74e-07	5.51e-05	0.22	0.24	Type 1 diabetes;	chr12:9705282	chr12:9398355~9414851:-
HNSC	cis	rs13126694	0.617	rs10008900	ENSG00000248429.4	RP11-597D13.9	5.31	1.74e-07	5.51e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157948827	chr4:158170752~158202877:+
HNSC	cis	rs1056107	0.966	rs7869209	ENSG00000225513.1	RP11-165N19.2	-5.3	1.74e-07	5.52e-05	-0.25	-0.24	Colorectal cancer;	chr9:112301133	chr9:112173522~112173971:-
HNSC	cis	rs7804306	1	rs34059590	ENSG00000233264.2	AC006042.8	5.3	1.74e-07	5.52e-05	0.45	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8026584	chr7:7980312~7982228:+
HNSC	cis	rs1355223	0.867	rs1869360	ENSG00000271369.1	RP11-350D17.3	-5.3	1.74e-07	5.52e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677043	chr11:34709600~34710161:+
HNSC	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-5.3	1.74e-07	5.52e-05	-0.3	-0.24	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
HNSC	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	5.3	1.75e-07	5.52e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
HNSC	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	5.3	1.75e-07	5.53e-05	0.28	0.24	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
HNSC	cis	rs116095464	1	rs6879758	ENSG00000277812.1	AC021087.1	5.3	1.75e-07	5.53e-05	0.55	0.24	Breast cancer;	chr5:350162	chr5:262769~262881:+
HNSC	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-5.3	1.75e-07	5.53e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-5.3	1.75e-07	5.53e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
HNSC	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	5.3	1.75e-07	5.53e-05	0.32	0.24	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
HNSC	cis	rs988913	1	rs9367601	ENSG00000224984.1	RP11-524H19.2	5.3	1.75e-07	5.53e-05	0.27	0.24	Menarche (age at onset);	chr6:54974364	chr6:54840118~54840855:-
HNSC	cis	rs2337406	0.85	rs10131280	ENSG00000211974.3	IGHV2-70	-5.3	1.75e-07	5.53e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106665591	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-5.3	1.75e-07	5.53e-05	-0.16	-0.24	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
HNSC	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
HNSC	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	5.3	1.75e-07	5.54e-05	0.31	0.24	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
HNSC	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	5.3	1.76e-07	5.55e-05	0.3	0.24	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
HNSC	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-5.3	1.76e-07	5.55e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
HNSC	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	5.3	1.76e-07	5.55e-05	0.3	0.24	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	5.3	1.76e-07	5.55e-05	0.3	0.24	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
HNSC	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	5.3	1.76e-07	5.56e-05	0.29	0.24	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-5.3	1.76e-07	5.56e-05	-0.14	-0.24	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
HNSC	cis	rs10462794	0.661	rs4702804	ENSG00000260763.1	RP11-445O3.3	-5.3	1.76e-07	5.56e-05	-0.35	-0.24	DNA methylation (variation);	chr5:4526310	chr5:4436850~4440259:-
HNSC	cis	rs6928977	0.66	rs2614267	ENSG00000234084.1	RP3-388E23.2	5.3	1.76e-07	5.56e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135455340	chr6:135301568~135307158:+
HNSC	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	5.3	1.76e-07	5.56e-05	0.3	0.24	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
HNSC	cis	rs10504130	0.569	rs4626585	ENSG00000272024.1	RP11-546K22.3	5.3	1.76e-07	5.57e-05	0.34	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51950284~51950690:+
HNSC	cis	rs42490	0.625	rs43229	ENSG00000251136.7	RP11-37B2.1	-5.3	1.76e-07	5.57e-05	-0.21	-0.24	Leprosy;	chr8:89826558	chr8:89609409~89757727:-
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	5.3	1.76e-07	5.57e-05	0.28	0.24	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
HNSC	cis	rs6928977	0.66	rs2757647	ENSG00000234084.1	RP3-388E23.2	5.3	1.76e-07	5.57e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135446416	chr6:135301568~135307158:+
HNSC	cis	rs7048146	0.509	rs7021081	ENSG00000213539.4	YBX1P6	5.3	1.76e-07	5.57e-05	0.31	0.24	Vascular brain injury;	chr9:109537580	chr9:109532830~109534332:-
HNSC	cis	rs6928977	0.66	rs2614263	ENSG00000234084.1	RP3-388E23.2	5.3	1.76e-07	5.57e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135459579	chr6:135301568~135307158:+
HNSC	cis	rs2834288	0.734	rs743336	ENSG00000237945.6	LINC00649	-5.3	1.76e-07	5.57e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33893080	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.734	rs743337	ENSG00000237945.6	LINC00649	-5.3	1.76e-07	5.57e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33893220	chr21:33915534~33977691:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000233609.3	RP11-62H7.2	5.3	1.76e-07	5.57e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9034711	chr8:8961200~8979025:+
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	5.3	1.77e-07	5.58e-05	0.21	0.24	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
HNSC	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-5.3	1.77e-07	5.58e-05	-0.23	-0.24	Height;	chr5:36882917	chr5:36666214~36725195:-
HNSC	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-5.3	1.77e-07	5.58e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
HNSC	cis	rs1075232	0.826	rs12437800	ENSG00000215302.7	CTD-3092A11.1	-5.3	1.77e-07	5.58e-05	-0.52	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30470779~30507623:+
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-5.3	1.77e-07	5.58e-05	-0.16	-0.24	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000254153.1	CTA-398F10.2	-5.3	1.77e-07	5.58e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9032531	chr8:8456909~8461337:-
HNSC	cis	rs2337406	0.714	rs115401799	ENSG00000211974.3	IGHV2-70	-5.3	1.77e-07	5.58e-05	-0.3	-0.24	Alzheimer's disease (late onset);	chr14:106813739	chr14:106723574~106724093:-
HNSC	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-5.3	1.77e-07	5.58e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
HNSC	cis	rs2115630	0.791	rs2008262	ENSG00000229212.6	RP11-561C5.4	5.3	1.77e-07	5.59e-05	0.29	0.24	P wave terminal force;	chr15:84762039	chr15:85205440~85234795:-
HNSC	cis	rs12468226	1	rs6739198	ENSG00000226261.1	AC064836.3	5.3	1.77e-07	5.59e-05	0.34	0.24	Urate levels;	chr2:202492273	chr2:202336024~202336727:-
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-5.3	1.77e-07	5.59e-05	-0.16	-0.24	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
HNSC	cis	rs6964833	0.786	rs35633336	ENSG00000184616.8	AC004166.6	5.3	1.77e-07	5.59e-05	0.3	0.24	Menarche (age at onset);	chr7:74643961	chr7:74906673~74913256:-
HNSC	cis	rs11846409	0.86	rs1858692	ENSG00000274576.2	IGHV2-70	5.3	1.77e-07	5.59e-05	0.24	0.24	Rheumatic heart disease;	chr14:106622776	chr14:106770577~106771020:-
HNSC	cis	rs17428076	0.874	rs17615262	ENSG00000228389.1	AC068039.4	-5.3	1.77e-07	5.59e-05	-0.29	-0.24	Myopia;	chr2:171826971	chr2:171773482~171775844:+
HNSC	cis	rs2235642	1	rs2235642	ENSG00000280231.1	LA16c-380F5.3	-5.3	1.77e-07	5.59e-05	-0.29	-0.24	Coronary artery disease;	chr16:1534865	chr16:1553655~1554130:-
HNSC	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	5.3	1.77e-07	5.6e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
HNSC	cis	rs9402743	0.597	rs34266043	ENSG00000217482.2	HMGB1P17	5.3	1.77e-07	5.6e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135763663	chr6:135636086~135636713:-
HNSC	cis	rs10504130	0.569	rs10958305	ENSG00000272024.1	RP11-546K22.3	-5.3	1.78e-07	5.6e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs11784869	ENSG00000272024.1	RP11-546K22.3	-5.3	1.78e-07	5.6e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51950284~51950690:+
HNSC	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	5.3	1.78e-07	5.61e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
HNSC	cis	rs7824557	0.507	rs7010590	ENSG00000269918.1	AF131215.9	5.3	1.78e-07	5.61e-05	0.24	0.24	Retinal vascular caliber;	chr8:11205373	chr8:11104691~11106704:-
HNSC	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-5.3	1.78e-07	5.61e-05	-0.27	-0.24	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
HNSC	cis	rs9840812	0.591	rs1291921	ENSG00000273486.1	RP11-731C17.2	5.3	1.78e-07	5.62e-05	0.2	0.24	Fibrinogen levels;	chr3:136317384	chr3:136837338~136839021:-
HNSC	cis	rs9326248	0.53	rs11216171	ENSG00000280143.1	AP000892.6	5.3	1.78e-07	5.62e-05	0.28	0.24	Blood protein levels;	chr11:116878397	chr11:117204967~117210292:+
HNSC	cis	rs2337406	0.866	rs4583128	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106780669	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.929	rs59263250	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781183	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs58083017	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781256	chr14:106723574~106724093:-
HNSC	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	5.3	1.78e-07	5.62e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
HNSC	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	5.3	1.78e-07	5.62e-05	0.29	0.24	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
HNSC	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	5.3	1.78e-07	5.62e-05	0.28	0.24	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	5.3	1.78e-07	5.62e-05	0.28	0.24	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
HNSC	cis	rs2337406	0.866	rs74092520	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779632	chr14:106723574~106724093:-
HNSC	cis	rs4664293	0.669	rs1549387	ENSG00000226266.5	AC009961.3	5.3	1.78e-07	5.63e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159561029	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.669	rs1863219	ENSG00000226266.5	AC009961.3	5.3	1.78e-07	5.63e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159561660	chr2:159670708~159712435:-
HNSC	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	5.3	1.78e-07	5.63e-05	0.31	0.24	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65940221	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35046236	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65943626	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs36068983	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65944004	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs68189316	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65944182	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65947955	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	5.3	1.79e-07	5.63e-05	0.21	0.24	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
HNSC	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	5.3	1.79e-07	5.64e-05	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
HNSC	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-5.3	1.79e-07	5.64e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
HNSC	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
HNSC	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-5.3	1.79e-07	5.65e-05	-0.3	-0.24	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
HNSC	cis	rs42490	0.635	rs42186	ENSG00000251136.7	RP11-37B2.1	-5.3	1.79e-07	5.65e-05	-0.22	-0.24	Leprosy;	chr8:89827257	chr8:89609409~89757727:-
HNSC	cis	rs7804306	0.826	rs35567393	ENSG00000233264.2	AC006042.8	5.3	1.79e-07	5.65e-05	0.46	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8033938	chr7:7980312~7982228:+
HNSC	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-5.3	1.79e-07	5.65e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-5.3	1.79e-07	5.65e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
HNSC	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-5.3	1.79e-07	5.65e-05	-0.21	-0.24	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
HNSC	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	5.3	1.79e-07	5.66e-05	0.28	0.24	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
HNSC	cis	rs9840812	0.598	rs1145101	ENSG00000239213.4	NCK1-AS1	5.3	1.8e-07	5.66e-05	0.26	0.24	Fibrinogen levels;	chr3:136350444	chr3:136841726~136862054:-
HNSC	cis	rs9840812	0.728	rs12635723	ENSG00000239213.4	NCK1-AS1	5.3	1.8e-07	5.66e-05	0.22	0.24	Fibrinogen levels;	chr3:136581890	chr3:136841726~136862054:-
HNSC	cis	rs3206736	0.548	rs2108690	ENSG00000197085.10	NPSR1-AS1	-5.3	1.8e-07	5.67e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:35043197	chr7:34346512~34871582:-
HNSC	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
HNSC	cis	rs11773103	1	rs73204890	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87148422	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs55834411	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87148864	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73204892	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87149381	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73204895	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87149801	chr7:87151423~87152420:-
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000233609.3	RP11-62H7.2	-5.3	1.8e-07	5.67e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9035094	chr8:8961200~8979025:+
HNSC	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	5.3	1.8e-07	5.68e-05	0.29	0.24	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	5.3	1.8e-07	5.68e-05	0.29	0.24	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	5.3	1.8e-07	5.68e-05	0.29	0.24	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-5.3	1.8e-07	5.68e-05	-0.25	-0.24	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
HNSC	cis	rs1971762	0.527	rs9737721	ENSG00000270175.1	RP11-793H13.11	-5.3	1.81e-07	5.69e-05	-0.21	-0.24	Height;	chr12:53680912	chr12:53500162~53500936:-
HNSC	cis	rs2439831	0.681	rs540031	ENSG00000205771.5	CATSPER2P1	-5.3	1.81e-07	5.7e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43316657	chr15:43726918~43747094:-
HNSC	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	5.3	1.81e-07	5.7e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
HNSC	cis	rs2115630	1	rs11854313	ENSG00000229212.6	RP11-561C5.4	5.3	1.81e-07	5.7e-05	0.27	0.24	P wave terminal force;	chr15:84760817	chr15:85205440~85234795:-
HNSC	cis	rs11969893	0.85	rs9498418	ENSG00000270987.1	RP3-467N11.2	5.3	1.81e-07	5.7e-05	0.58	0.24	Economic and political preferences (immigration/crime);	chr6:100883962	chr6:100889603~100890338:+
HNSC	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	5.3	1.81e-07	5.7e-05	0.32	0.24	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
HNSC	cis	rs6604026	1	rs6657809	ENSG00000223787.2	RP4-593M8.1	5.3	1.81e-07	5.71e-05	0.31	0.24	Multiple sclerosis;	chr1:92827506	chr1:92580476~92580821:-
HNSC	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-5.3	1.81e-07	5.71e-05	-0.27	-0.24	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
HNSC	cis	rs7048146	0.509	rs55796394	ENSG00000213539.4	YBX1P6	5.3	1.81e-07	5.71e-05	0.31	0.24	Vascular brain injury;	chr9:109538348	chr9:109532830~109534332:-
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	5.3	1.81e-07	5.71e-05	0.26	0.24	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
HNSC	cis	rs6604026	0.885	rs17614449	ENSG00000223787.2	RP4-593M8.1	5.3	1.81e-07	5.72e-05	0.33	0.24	Multiple sclerosis;	chr1:92810377	chr1:92580476~92580821:-
HNSC	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	5.3	1.82e-07	5.72e-05	0.29	0.24	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
HNSC	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	5.3	1.82e-07	5.72e-05	0.28	0.24	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
HNSC	cis	rs9840812	0.535	rs695983	ENSG00000239213.4	NCK1-AS1	5.3	1.82e-07	5.72e-05	0.21	0.24	Fibrinogen levels;	chr3:136345705	chr3:136841726~136862054:-
HNSC	cis	rs73198271	0.773	rs66618176	ENSG00000253893.2	FAM85B	5.3	1.82e-07	5.73e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8167819~8226614:-
HNSC	cis	rs2439831	0.867	rs4075674	ENSG00000205771.5	CATSPER2P1	-5.3	1.82e-07	5.74e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43358032	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	5.3	1.82e-07	5.74e-05	0.21	0.24	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
HNSC	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	5.3	1.82e-07	5.74e-05	0.43	0.24	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
HNSC	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-5.3	1.82e-07	5.74e-05	-0.27	-0.24	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-5.3	1.83e-07	5.75e-05	-0.16	-0.24	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
HNSC	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-5.3	1.83e-07	5.75e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-5.3	1.83e-07	5.75e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-5.3	1.83e-07	5.75e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000179406.6	LINC00174	-5.3	1.83e-07	5.75e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65999249	chr7:66376044~66401338:-
HNSC	cis	rs13113518	1	rs3749474	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55434518	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs1474271	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55435912	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11937487	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55436576	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805146	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55436985	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133378	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55439472	chr4:55387949~55388271:+
HNSC	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	-5.3	1.83e-07	5.76e-05	-0.3	-0.24	Depression;	chr6:28096845	chr6:28161781~28169594:+
HNSC	cis	rs7688540	0.8	rs11723492	ENSG00000211553.1	AC253576.2	-5.3	1.83e-07	5.77e-05	-0.31	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:136461~136568:+
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-5.3	1.83e-07	5.77e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
HNSC	cis	rs2060793	0.712	rs11023310	ENSG00000251991.1	RNU7-49P	5.3	1.83e-07	5.77e-05	0.26	0.24	Vitamin D levels;	chr11:14703717	chr11:14478892~14478953:+
HNSC	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-5.3	1.83e-07	5.77e-05	-0.23	-0.24	Height;	chr5:36880769	chr5:36666214~36725195:-
HNSC	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	5.3	1.83e-07	5.77e-05	0.25	0.24	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
HNSC	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	5.29	1.84e-07	5.78e-05	0.24	0.24	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	5.29	1.84e-07	5.78e-05	0.24	0.24	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
HNSC	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.78e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
HNSC	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	5.29	1.84e-07	5.79e-05	0.28	0.24	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
HNSC	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
HNSC	cis	rs12935418	0.673	rs2602428	ENSG00000261061.1	RP11-303E16.2	5.29	1.84e-07	5.79e-05	0.27	0.24	Mean corpuscular volume;	chr16:81028566	chr16:81030770~81031485:+
HNSC	cis	rs8032939	0.533	rs72729306	ENSG00000259747.1	RP11-275I4.2	-5.29	1.84e-07	5.8e-05	-0.3	-0.24	Rheumatoid arthritis;	chr15:38606887	chr15:38671847~38689191:+
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000235689.1	AP000351.13	-5.29	1.85e-07	5.81e-05	-0.24	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:24006305~24008258:-
HNSC	cis	rs3733585	0.598	rs28677023	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956702	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.664	rs28602527	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956703	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6815001	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957038	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs6849729	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957108	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs6850143	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957300	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6844316	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957353	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6834893	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957499	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6844787	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957609	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.648	rs28513781	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957710	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs4515163	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957979	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs62294331	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958265	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs62294332	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958365	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs57574512	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958558	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs7699609	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9959435	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs4588456	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962271	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs6836706	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962627	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.604	rs2389882	ENSG00000249244.1	RP11-548H18.2	5.29	1.85e-07	5.81e-05	0.31	0.24	Corneal astigmatism;	chr4:119645578	chr4:119391831~119395335:-
HNSC	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-5.29	1.85e-07	5.81e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-5.29	1.85e-07	5.81e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
HNSC	cis	rs9341808	0.538	rs7747327	ENSG00000272129.1	RP11-250B2.6	-5.29	1.85e-07	5.81e-05	-0.28	-0.24	Sitting height ratio;	chr6:80326057	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000254153.1	CTA-398F10.2	-5.29	1.85e-07	5.82e-05	-0.26	-0.24	Mood instability;	chr8:8934916	chr8:8456909~8461337:-
HNSC	cis	rs3733585	0.673	rs10018204	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962946	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.742	rs1533058	ENSG00000254340.1	RP11-10A14.3	5.29	1.85e-07	5.82e-05	0.3	0.24	Mood instability;	chr8:8827680	chr8:9141424~9145435:+
HNSC	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-5.29	1.85e-07	5.82e-05	-0.24	-0.24	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
HNSC	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	5.29	1.85e-07	5.83e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
HNSC	cis	rs4763879	0.778	rs2895989	ENSG00000256673.1	RP11-599J14.2	5.29	1.86e-07	5.83e-05	0.22	0.24	Type 1 diabetes;	chr12:9688735	chr12:9398355~9414851:-
HNSC	cis	rs1008375	0.9	rs4698622	ENSG00000249502.1	AC006160.5	-5.29	1.86e-07	5.83e-05	-0.27	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587934	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000254153.1	CTA-398F10.2	-5.29	1.86e-07	5.84e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9033292	chr8:8456909~8461337:-
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000254153.1	CTA-398F10.2	-5.29	1.86e-07	5.84e-05	-0.26	-0.24	Myopia (pathological);Myopia;	chr8:9033866	chr8:8456909~8461337:-
HNSC	cis	rs5758265	1	rs5758265	ENSG00000235513.1	RP4-756G23.5	5.29	1.86e-07	5.84e-05	0.25	0.24	Depressive symptoms (multi-trait analysis);	chr22:41221893	chr22:41209122~41217627:-
HNSC	cis	rs9840812	0.861	rs511154	ENSG00000239213.4	NCK1-AS1	5.29	1.86e-07	5.84e-05	0.23	0.24	Fibrinogen levels;	chr3:136232079	chr3:136841726~136862054:-
HNSC	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	5.29	1.86e-07	5.84e-05	0.29	0.24	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
HNSC	cis	rs9907295	0.818	rs11653204	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35894538	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.792	rs4796125	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35894847	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs74622050	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35895939	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs79730543	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35896537	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4796127	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35899127	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs11868801	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35900047	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4796130	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35904264	chr17:35893707~35911023:-
HNSC	cis	rs2179367	0.509	rs9485390	ENSG00000216906.2	RP11-350J20.9	5.29	1.86e-07	5.85e-05	0.34	0.24	Dupuytren's disease;	chr6:149421004	chr6:149904243~149906418:+
HNSC	cis	rs3733585	0.699	rs6449159	ENSG00000250413.1	RP11-448G15.1	5.29	1.86e-07	5.85e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958874	chr4:10006482~10009725:+
HNSC	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-5.29	1.86e-07	5.85e-05	-0.3	-0.24	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
HNSC	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-5.29	1.86e-07	5.85e-05	-0.3	-0.24	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
HNSC	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-5.29	1.87e-07	5.86e-05	-0.29	-0.24	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
HNSC	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	5.29	1.87e-07	5.87e-05	0.29	0.24	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
HNSC	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	5.29	1.87e-07	5.87e-05	0.29	0.24	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
HNSC	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	5.29	1.87e-07	5.87e-05	0.29	0.24	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
HNSC	cis	rs11096990	0.892	rs11931354	ENSG00000249207.1	RP11-360F5.1	5.29	1.87e-07	5.87e-05	0.27	0.24	Cognitive function;	chr4:39229856	chr4:39112677~39126818:-
HNSC	cis	rs7824557	0.534	rs10092549	ENSG00000269918.1	AF131215.9	-5.29	1.87e-07	5.88e-05	-0.24	-0.24	Retinal vascular caliber;	chr8:11231570	chr8:11104691~11106704:-
HNSC	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-5.29	1.87e-07	5.88e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-5.29	1.87e-07	5.88e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-5.29	1.87e-07	5.88e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
HNSC	cis	rs9402743	0.671	rs9376115	ENSG00000217482.2	HMGB1P17	-5.29	1.87e-07	5.88e-05	-0.26	-0.24	Systemic lupus erythematosus;	chr6:135616579	chr6:135636086~135636713:-
HNSC	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.29	1.87e-07	5.89e-05	0.24	0.24	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
HNSC	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	5.29	1.87e-07	5.89e-05	0.37	0.24	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	5.29	1.87e-07	5.89e-05	0.37	0.24	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	5.29	1.87e-07	5.89e-05	0.37	0.24	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
HNSC	cis	rs9813712	0.574	rs35856399	ENSG00000249846.5	RP11-77P16.4	-5.29	1.87e-07	5.89e-05	-0.25	-0.24	Response to amphetamines;	chr3:130241961	chr3:130112550~130120579:+
HNSC	cis	rs7665090	0.87	rs228625	ENSG00000246560.2	RP11-10L12.4	-5.29	1.88e-07	5.89e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102651594	chr4:102828055~102844075:+
HNSC	cis	rs2243480	1	rs10807702	ENSG00000179406.6	LINC00174	-5.29	1.88e-07	5.9e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66302856	chr7:66376044~66401338:-
HNSC	cis	rs7621025	0.586	rs12330725	ENSG00000273486.1	RP11-731C17.2	-5.29	1.88e-07	5.9e-05	-0.2	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136693738	chr3:136837338~136839021:-
HNSC	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-5.29	1.88e-07	5.9e-05	-0.3	-0.24	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
HNSC	cis	rs2439831	1	rs2444032	ENSG00000205771.5	CATSPER2P1	-5.29	1.88e-07	5.9e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43463148	chr15:43726918~43747094:-
HNSC	cis	rs11773103	1	rs73206905	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87155307	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.867	rs73206912	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87159075	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73206916	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87159697	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73206937	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87166076	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs55750589	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87168929	chr7:87151423~87152420:-
HNSC	cis	rs4388249	0.578	rs427691	ENSG00000271849.1	CTC-332L22.1	-5.29	1.88e-07	5.9e-05	-0.35	-0.24	Schizophrenia;	chr5:109678809	chr5:109687802~109688329:-
HNSC	cis	rs9987353	0.566	rs6998368	ENSG00000254340.1	RP11-10A14.3	-5.29	1.88e-07	5.91e-05	-0.31	-0.24	Recombination measurement;	chr8:9212778	chr8:9141424~9145435:+
HNSC	cis	rs2985684	0.894	rs7152110	ENSG00000278009.1	RP11-649E7.8	5.29	1.88e-07	5.91e-05	0.31	0.24	Carotid intima media thickness;	chr14:49551500	chr14:49601011~49601124:-
HNSC	cis	rs2337406	0.714	rs117798641	ENSG00000254174.1	IGHV1-12	5.29	1.88e-07	5.91e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777984	chr14:106122420~106122709:-
HNSC	cis	rs792448	0.545	rs7519168	ENSG00000226251.4	RP11-15I11.3	5.29	1.88e-07	5.91e-05	0.27	0.24	White blood cell count (basophil);	chr1:212220043	chr1:212225278~212238977:-
HNSC	cis	rs3806843	0.838	rs2262567	ENSG00000202515.1	VTRNA1-3	5.29	1.89e-07	5.92e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr5:140726158~140726246:+
HNSC	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	5.29	1.89e-07	5.92e-05	0.29	0.24	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.82	rs2389885	ENSG00000249244.1	RP11-548H18.2	5.29	1.89e-07	5.92e-05	0.3	0.24	Corneal astigmatism;	chr4:119612776	chr4:119391831~119395335:-
HNSC	cis	rs2243480	1	rs316322	ENSG00000179406.6	LINC00174	-5.29	1.89e-07	5.93e-05	-0.5	-0.24	Diabetic kidney disease;	chr7:66146246	chr7:66376044~66401338:-
HNSC	cis	rs4218	0.681	rs12913177	ENSG00000259732.1	RP11-59H7.3	5.29	1.89e-07	5.93e-05	0.34	0.24	Social communication problems;	chr15:59066273	chr15:59121034~59133250:+
HNSC	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-5.29	1.89e-07	5.93e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
HNSC	cis	rs1008375	0.966	rs6825133	ENSG00000249502.1	AC006160.5	-5.29	1.89e-07	5.94e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576153	chr4:17587467~17614571:-
HNSC	cis	rs9611519	1	rs5751069	ENSG00000235513.1	RP4-756G23.5	5.29	1.89e-07	5.94e-05	0.26	0.24	Neuroticism;	chr22:41231771	chr22:41209122~41217627:-
HNSC	cis	rs3743266	0.613	rs10851681	ENSG00000245534.5	RORA-AS1	-5.29	1.89e-07	5.94e-05	-0.3	-0.24	Menarche (age at onset);	chr15:60439939	chr15:60479178~60630637:+
HNSC	cis	rs4787491	0.658	rs11647753	ENSG00000183604.13	SMG1P5	5.29	1.89e-07	5.95e-05	0.23	0.24	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:29916794	chr16:30267553~30335374:-
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000233609.3	RP11-62H7.2	-5.29	1.89e-07	5.95e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9053798	chr8:8961200~8979025:+
HNSC	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	5.29	1.9e-07	5.95e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
HNSC	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
HNSC	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-5.29	1.9e-07	5.95e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
HNSC	cis	rs638893	0.588	rs4936440	ENSG00000255422.1	AP002954.4	-5.29	1.9e-07	5.96e-05	-0.33	-0.24	Vitiligo;	chr11:118849975	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.588	rs4938566	ENSG00000255422.1	AP002954.4	-5.29	1.9e-07	5.96e-05	-0.33	-0.24	Vitiligo;	chr11:118850480	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.617	rs4938567	ENSG00000255422.1	AP002954.4	-5.29	1.9e-07	5.96e-05	-0.33	-0.24	Vitiligo;	chr11:118850540	chr11:118704607~118750263:+
HNSC	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	5.29	1.9e-07	5.96e-05	0.25	0.24	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
HNSC	cis	rs2337406	0.714	rs117798641	ENSG00000211974.3	IGHV2-70	-5.29	1.9e-07	5.96e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777984	chr14:106723574~106724093:-
HNSC	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-5.29	1.9e-07	5.96e-05	-0.27	-0.24	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
HNSC	cis	rs7819412	0.594	rs17724226	ENSG00000255310.2	AF131215.2	-5.29	1.9e-07	5.97e-05	-0.24	-0.24	Triglycerides;	chr8:11111416	chr8:11107788~11109726:-
HNSC	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	5.29	1.9e-07	5.97e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
HNSC	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	5.29	1.91e-07	5.98e-05	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000254340.1	RP11-10A14.3	5.29	1.91e-07	5.98e-05	0.3	0.24	Neuroticism;	chr8:8866905	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	5.29	1.91e-07	5.99e-05	0.29	0.24	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.885	rs66649041	ENSG00000223787.2	RP4-593M8.1	5.29	1.91e-07	5.99e-05	0.33	0.24	Multiple sclerosis;	chr1:92809328	chr1:92580476~92580821:-
HNSC	cis	rs11971779	0.638	rs77668044	ENSG00000273391.1	RP11-634H22.1	5.29	1.91e-07	5.99e-05	0.31	0.24	Diisocyanate-induced asthma;	chr7:139426339	chr7:139359032~139359566:-
HNSC	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	5.29	1.91e-07	6e-05	0.29	0.24	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	5.29	1.91e-07	6e-05	0.25	0.24	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
HNSC	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-5.29	1.91e-07	6e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
HNSC	cis	rs7804306	1	rs13222718	ENSG00000233264.2	AC006042.8	5.29	1.92e-07	6e-05	0.43	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7974690	chr7:7980312~7982228:+
HNSC	cis	rs7804306	1	rs34438930	ENSG00000233264.2	AC006042.8	5.29	1.92e-07	6e-05	0.43	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7974740	chr7:7980312~7982228:+
HNSC	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-5.29	1.92e-07	6.01e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
HNSC	cis	rs3754214	0.836	rs12023277	ENSG00000228126.1	FALEC	5.29	1.92e-07	6.02e-05	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr1:150494261	chr1:150515757~150518032:+
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	5.29	1.92e-07	6.02e-05	0.25	0.24	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
HNSC	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	5.29	1.92e-07	6.02e-05	0.31	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	5.29	1.92e-07	6.02e-05	0.21	0.24	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
HNSC	cis	rs9611519	0.894	rs8136923	ENSG00000235513.1	RP4-756G23.5	5.29	1.92e-07	6.03e-05	0.27	0.24	Neuroticism;	chr22:41074518	chr22:41209122~41217627:-
HNSC	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	5.29	1.92e-07	6.03e-05	0.31	0.24	Height;	chr4:55415153	chr4:55387949~55388271:+
HNSC	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	5.29	1.92e-07	6.03e-05	0.29	0.24	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs1464490	ENSG00000273257.1	RP11-177J6.1	5.29	1.92e-07	6.03e-05	0.29	0.24	Height;	chr4:55456620	chr4:55387949~55388271:+
HNSC	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	5.29	1.93e-07	6.04e-05	0.35	0.24	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
HNSC	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-5.29	1.93e-07	6.04e-05	-0.27	-0.24	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
HNSC	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	5.29	1.93e-07	6.04e-05	0.41	0.24	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
HNSC	cis	rs2337406	0.789	rs74092514	ENSG00000211974.3	IGHV2-70	-5.29	1.93e-07	6.04e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779385	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs73378158	ENSG00000274576.2	IGHV2-70	-5.29	1.93e-07	6.05e-05	-0.23	-0.24	Rheumatic heart disease;	chr14:106638433	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	5.29	1.93e-07	6.05e-05	0.24	0.24	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
HNSC	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	5.29	1.93e-07	6.05e-05	0.31	0.24	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
HNSC	cis	rs7610312	0.681	rs7610449	ENSG00000273493.1	RP11-80H18.4	-5.29	1.93e-07	6.05e-05	-0.29	-0.24	Red blood cell count;	chr3:58334231	chr3:58329965~58330118:+
HNSC	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-5.29	1.93e-07	6.05e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
HNSC	cis	rs7209700	0.708	rs2292865	ENSG00000228782.6	CTD-2026D20.3	-5.28	1.93e-07	6.06e-05	-0.24	-0.24	IgG glycosylation;	chr17:47287356	chr17:47450568~47492492:-
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-5.28	1.94e-07	6.06e-05	-0.14	-0.24	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
HNSC	cis	rs860295	0.812	rs12407800	ENSG00000203761.5	MSTO2P	-5.28	1.94e-07	6.07e-05	-0.18	-0.24	Body mass index;	chr1:155790951	chr1:155745829~155750137:+
HNSC	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	5.28	1.94e-07	6.07e-05	0.29	0.24	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
HNSC	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-5.28	1.94e-07	6.08e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
HNSC	cis	rs4803480	1	rs7255679	ENSG00000270164.1	LINC01480	-5.28	1.95e-07	6.09e-05	-0.22	-0.24	Schizophrenia;	chr19:41557611	chr19:41535183~41536904:+
HNSC	cis	rs860295	0.615	rs656737	ENSG00000203761.5	MSTO2P	5.28	1.95e-07	6.1e-05	0.18	0.24	Body mass index;	chr1:155908104	chr1:155745829~155750137:+
HNSC	cis	rs3747113	0.732	rs28360612	ENSG00000128262.7	POM121L9P	-5.28	1.95e-07	6.1e-05	-0.27	-0.24	Gut microbiome composition (summer);	chr22:24487250	chr22:24251828~24265525:+
HNSC	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	5.28	1.95e-07	6.1e-05	0.26	0.24	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
HNSC	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.1e-05	0.24	0.24	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
HNSC	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-5.28	1.95e-07	6.1e-05	-0.23	-0.24	Height;	chr5:36878678	chr5:36666214~36725195:-
HNSC	cis	rs860295	0.702	rs10908470	ENSG00000203761.5	MSTO2P	-5.28	1.95e-07	6.11e-05	-0.18	-0.24	Body mass index;	chr1:155557222	chr1:155745829~155750137:+
HNSC	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-5.28	1.95e-07	6.11e-05	-0.37	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
HNSC	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
HNSC	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	5.28	1.95e-07	6.12e-05	0.25	0.24	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
HNSC	cis	rs2286503	0.752	rs59538378	ENSG00000221740.1	SNORD93	5.28	1.95e-07	6.12e-05	0.26	0.24	Fibrinogen;	chr7:22837478	chr7:22856613~22856686:+
HNSC	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-5.28	1.96e-07	6.12e-05	-0.33	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
HNSC	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	5.28	1.96e-07	6.13e-05	0.29	0.24	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
HNSC	cis	rs2337406	0.636	rs74090069	ENSG00000211974.3	IGHV2-70	-5.28	1.96e-07	6.13e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777532	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74090071	ENSG00000211974.3	IGHV2-70	-5.28	1.96e-07	6.13e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777533	chr14:106723574~106724093:-
HNSC	cis	rs4218	0.513	rs17302142	ENSG00000277144.1	RP11-59H7.4	-5.28	1.96e-07	6.14e-05	-0.3	-0.24	Social communication problems;	chr15:59053813	chr15:59115547~59116089:-
HNSC	cis	rs4947019	0.688	rs9480965	ENSG00000260273.1	RP11-425D10.10	5.28	1.96e-07	6.14e-05	0.68	0.24	Hematological parameters;	chr6:109478281	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	5.28	1.96e-07	6.14e-05	0.22	0.24	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000254153.1	CTA-398F10.2	-5.28	1.96e-07	6.14e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9035094	chr8:8456909~8461337:-
HNSC	cis	rs7000734	0.958	rs1561715	ENSG00000245080.5	RP11-320N21.1	5.28	1.97e-07	6.15e-05	0.32	0.24	Radiation response;	chr8:95107686	chr8:95066808~95073182:-
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000254153.1	CTA-398F10.2	-5.28	1.97e-07	6.15e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8456909~8461337:-
HNSC	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	5.28	1.97e-07	6.15e-05	0.25	0.24	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
HNSC	cis	rs7160336	0.713	rs7161293	ENSG00000259065.1	RP5-1021I20.1	5.28	1.97e-07	6.16e-05	0.28	0.24	Blood protein levels;	chr14:74031655	chr14:73787360~73803270:+
HNSC	cis	rs12682352	0.652	rs1567398	ENSG00000254340.1	RP11-10A14.3	-5.28	1.97e-07	6.16e-05	-0.28	-0.24	Neuroticism;	chr8:8869294	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.846	rs11779061	ENSG00000173295.6	FAM86B3P	-5.28	1.97e-07	6.17e-05	-0.27	-0.24	Mood instability;	chr8:8691922	chr8:8228595~8244865:+
HNSC	cis	rs9341808	0.538	rs688867	ENSG00000272129.1	RP11-250B2.6	5.28	1.97e-07	6.18e-05	0.28	0.24	Sitting height ratio;	chr6:80229511	chr6:80355424~80356859:+
HNSC	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-5.28	1.98e-07	6.18e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
HNSC	cis	rs13073817	0.563	rs4130090	ENSG00000228956.7	SATB1-AS1	5.28	1.98e-07	6.19e-05	0.25	0.24	Crohn's disease;	chr3:18630565	chr3:18445024~18920401:+
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	5.28	1.98e-07	6.19e-05	0.25	0.24	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
HNSC	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	5.28	1.98e-07	6.2e-05	0.27	0.24	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
HNSC	cis	rs763567	1	rs2022372	ENSG00000271811.1	RP1-79C4.4	-5.28	1.98e-07	6.2e-05	-0.26	-0.24	Tonsillectomy;	chr1:170620769	chr1:170667381~170669425:+
HNSC	cis	rs7535099	0.954	rs3790431	ENSG00000224570.1	RP11-430H12.2	-5.28	1.99e-07	6.21e-05	-0.31	-0.24	Blood protein levels;	chr1:65570345	chr1:65576129~65578380:-
HNSC	cis	rs2439831	1	rs689826	ENSG00000205771.5	CATSPER2P1	-5.28	1.99e-07	6.21e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43457718	chr15:43726918~43747094:-
HNSC	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	5.28	1.99e-07	6.22e-05	0.18	0.24	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
HNSC	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-5.28	1.99e-07	6.23e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
HNSC	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	5.28	1.99e-07	6.23e-05	0.31	0.24	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
HNSC	cis	rs2337406	0.866	rs74092511	ENSG00000211974.3	IGHV2-70	-5.28	1.99e-07	6.23e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779234	chr14:106723574~106724093:-
HNSC	cis	rs9907295	0.688	rs9754	ENSG00000270977.1	AC015849.16	-5.28	1.99e-07	6.23e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35934827	chr17:35893707~35911023:-
HNSC	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	5.28	1.99e-07	6.23e-05	0.26	0.24	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
HNSC	cis	rs3733585	0.673	rs6843873	ENSG00000250413.1	RP11-448G15.1	5.28	2e-07	6.24e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957164	chr4:10006482~10009725:+
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	5.28	2e-07	6.24e-05	0.26	0.24	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
HNSC	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-5.28	2e-07	6.24e-05	-0.39	-0.24	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
HNSC	cis	rs10504130	0.569	rs60153173	ENSG00000272024.1	RP11-546K22.3	-5.28	2e-07	6.25e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51950284~51950690:+
HNSC	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-5.28	2e-07	6.25e-05	-0.28	-0.24	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000254153.1	CTA-398F10.2	5.28	2e-07	6.26e-05	0.25	0.24	Systolic blood pressure;	chr8:8297953	chr8:8456909~8461337:-
HNSC	cis	rs17270561	0.525	rs12201678	ENSG00000272810.1	U91328.22	-5.28	2e-07	6.26e-05	-0.28	-0.24	Iron status biomarkers;	chr6:25978765	chr6:26013241~26013757:+
HNSC	cis	rs7688540	0.8	rs61792060	ENSG00000211553.1	AC253576.2	-5.28	2e-07	6.26e-05	-0.3	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:136461~136568:+
HNSC	cis	rs6867032	0.527	rs13153217	ENSG00000249731.1	RP11-259O2.3	-5.28	2.01e-07	6.27e-05	-0.26	-0.24	Gut microbiome composition (winter);	chr5:2012674	chr5:1968094~1969013:+
HNSC	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	5.28	2.01e-07	6.27e-05	0.28	0.24	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
HNSC	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	5.28	2.01e-07	6.27e-05	0.32	0.24	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
HNSC	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-5.28	2.01e-07	6.27e-05	-0.3	-0.24	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
HNSC	cis	rs2243480	1	rs313814	ENSG00000179406.6	LINC00174	-5.28	2.01e-07	6.27e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66038306	chr7:66376044~66401338:-
HNSC	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-5.28	2.01e-07	6.27e-05	-0.3	-0.24	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
HNSC	cis	rs4218	0.681	rs35204615	ENSG00000277144.1	RP11-59H7.4	-5.28	2.01e-07	6.28e-05	-0.32	-0.24	Social communication problems;	chr15:59099637	chr15:59115547~59116089:-
HNSC	cis	rs4699052	0.963	rs6533066	ENSG00000246560.2	RP11-10L12.4	5.28	2.01e-07	6.28e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103242450	chr4:102828055~102844075:+
HNSC	cis	rs7048146	0.509	rs7020926	ENSG00000213539.4	YBX1P6	-5.28	2.01e-07	6.28e-05	-0.33	-0.24	Vascular brain injury;	chr9:109567512	chr9:109532830~109534332:-
HNSC	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	5.28	2.01e-07	6.28e-05	0.29	0.24	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	5.28	2.01e-07	6.28e-05	0.25	0.24	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
HNSC	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-5.28	2.01e-07	6.28e-05	-0.27	-0.24	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	5.28	2.02e-07	6.29e-05	0.25	0.24	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	5.28	2.02e-07	6.29e-05	0.25	0.24	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
HNSC	cis	rs7587476	0.861	rs3768716	ENSG00000229267.2	AC072062.1	-5.28	2.02e-07	6.29e-05	-0.36	-0.24	Neuroblastoma;	chr2:214771070	chr2:214810229~214963274:+
HNSC	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-5.28	2.02e-07	6.3e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-5.28	2.02e-07	6.3e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
HNSC	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	5.28	2.02e-07	6.31e-05	0.28	0.24	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
HNSC	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-5.28	2.02e-07	6.31e-05	-0.3	-0.24	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
HNSC	cis	rs7617773	0.963	rs6766754	ENSG00000228638.1	FCF1P2	5.28	2.02e-07	6.31e-05	0.22	0.24	Coronary artery disease;	chr3:48141099	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.832	rs6775114	ENSG00000228638.1	FCF1P2	5.28	2.02e-07	6.31e-05	0.22	0.24	Coronary artery disease;	chr3:48141130	chr3:48290793~48291375:-
HNSC	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	5.28	2.02e-07	6.32e-05	0.24	0.24	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
HNSC	cis	rs7048146	0.509	rs10979936	ENSG00000213539.4	YBX1P6	5.28	2.03e-07	6.33e-05	0.34	0.24	Vascular brain injury;	chr9:109566227	chr9:109532830~109534332:-
HNSC	cis	rs9650657	0.504	rs10109167	ENSG00000269918.1	AF131215.9	-5.28	2.03e-07	6.33e-05	-0.24	-0.24	Neuroticism;	chr8:11176016	chr8:11104691~11106704:-
HNSC	cis	rs6928977	0.863	rs2223803	ENSG00000231028.7	LINC00271	5.28	2.03e-07	6.33e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366924	chr6:135497801~135716055:+
HNSC	cis	rs35542019	1	rs35542019	ENSG00000237945.6	LINC00649	5.28	2.03e-07	6.33e-05	0.29	0.24	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33915534~33977691:+
HNSC	cis	rs3736485	0.808	rs55982453	ENSG00000259438.1	CTD-2650P22.1	5.28	2.03e-07	6.34e-05	0.24	0.24	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51659048	chr15:52010999~52019095:-
HNSC	cis	rs2337406	0.866	rs7152038	ENSG00000254174.1	IGHV1-12	5.28	2.03e-07	6.34e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778230	chr14:106122420~106122709:-
HNSC	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	5.28	2.03e-07	6.34e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
HNSC	cis	rs867371	0.571	rs2654222	ENSG00000255769.6	GOLGA2P10	5.27	2.04e-07	6.35e-05	0.33	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82137496	chr15:82472993~82513950:-
HNSC	cis	rs763121	1	rs763121	ENSG00000273076.1	RP3-508I15.22	-5.27	2.04e-07	6.35e-05	-0.24	-0.24	Menopause (age at onset);	chr22:38483935	chr22:38743495~38743910:+
HNSC	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-5.27	2.04e-07	6.35e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
HNSC	cis	rs2243480	1	rs34136756	ENSG00000179406.6	LINC00174	-5.27	2.04e-07	6.36e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65916269	chr7:66376044~66401338:-
HNSC	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	5.27	2.04e-07	6.36e-05	0.28	0.24	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	5.27	2.04e-07	6.36e-05	0.28	0.24	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
HNSC	cis	rs8054556	0.967	rs7193532	ENSG00000183604.13	SMG1P5	-5.27	2.04e-07	6.36e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:30267553~30335374:-
HNSC	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-5.27	2.04e-07	6.36e-05	-0.23	-0.24	Height;	chr5:37068442	chr5:36666214~36725195:-
HNSC	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-5.27	2.04e-07	6.36e-05	-0.21	-0.24	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
HNSC	cis	rs36423	0.748	rs28138	ENSG00000266869.1	RP6-114E22.1	-5.27	2.04e-07	6.37e-05	-0.39	-0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71891970	chr14:71848606~71908430:+
HNSC	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-5.27	2.04e-07	6.37e-05	-0.23	-0.24	Height;	chr5:37061159	chr5:36666214~36725195:-
HNSC	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
HNSC	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	5.27	2.04e-07	6.37e-05	0.26	0.24	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
HNSC	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
HNSC	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
HNSC	cis	rs1008375	0.966	rs3775924	ENSG00000249502.1	AC006160.5	-5.27	2.05e-07	6.38e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17584361	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs4698621	ENSG00000249502.1	AC006160.5	-5.27	2.05e-07	6.38e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585942	chr4:17587467~17614571:-
HNSC	cis	rs2439831	1	rs2256764	ENSG00000205771.5	CATSPER2P1	-5.27	2.05e-07	6.38e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43443565	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000254153.1	CTA-398F10.2	-5.27	2.05e-07	6.38e-05	-0.26	-0.24	Mood instability;	chr8:8934707	chr8:8456909~8461337:-
HNSC	cis	rs9329221	0.502	rs11777364	ENSG00000269918.1	AF131215.9	5.27	2.05e-07	6.39e-05	0.23	0.24	Neuroticism;	chr8:10431036	chr8:11104691~11106704:-
HNSC	cis	rs2337406	0.866	rs79901786	ENSG00000211974.3	IGHV2-70	-5.27	2.05e-07	6.39e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777623	chr14:106723574~106724093:-
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	5.27	2.05e-07	6.39e-05	0.26	0.24	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
HNSC	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-5.27	2.06e-07	6.41e-05	-0.23	-0.24	Height;	chr5:37045739	chr5:36666214~36725195:-
HNSC	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	5.27	2.06e-07	6.41e-05	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
HNSC	cis	rs6928977	0.896	rs2614284	ENSG00000231028.7	LINC00271	5.27	2.06e-07	6.41e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135368697	chr6:135497801~135716055:+
HNSC	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	5.27	2.06e-07	6.41e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
HNSC	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	5.27	2.06e-07	6.42e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
HNSC	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	5.27	2.06e-07	6.42e-05	0.32	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000253893.2	FAM85B	-5.27	2.06e-07	6.43e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:8995760	chr8:8167819~8226614:-
HNSC	cis	rs393155	0.517	rs330050	ENSG00000254153.1	CTA-398F10.2	-5.27	2.06e-07	6.43e-05	-0.25	-0.24	Neuroticism;	chr8:9230169	chr8:8456909~8461337:-
HNSC	cis	rs453301	0.571	rs330054	ENSG00000254153.1	CTA-398F10.2	-5.27	2.06e-07	6.43e-05	-0.25	-0.24	Joint mobility (Beighton score);	chr8:9230781	chr8:8456909~8461337:-
HNSC	cis	rs1015362	0.503	rs1883708	ENSG00000276073.1	RP5-1125A11.7	-5.27	2.06e-07	6.43e-05	-0.32	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33985617~33988989:-
HNSC	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-5.27	2.06e-07	6.43e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
HNSC	cis	rs10504130	0.502	rs10087958	ENSG00000253844.1	RP11-546K22.1	-5.27	2.06e-07	6.43e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51954109	chr8:51961458~52022974:+
HNSC	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-5.27	2.06e-07	6.43e-05	-0.3	-0.24	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
HNSC	cis	rs4699052	0.507	rs10005997	ENSG00000246560.2	RP11-10L12.4	5.27	2.06e-07	6.43e-05	0.3	0.24	Testicular germ cell tumor;	chr4:103380554	chr4:102828055~102844075:+
HNSC	cis	rs9921338	0.887	rs6498183	ENSG00000263080.1	RP11-485G7.5	5.27	2.07e-07	6.44e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11341809~11345211:-
HNSC	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	5.27	2.07e-07	6.44e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
HNSC	cis	rs4218	0.689	rs12907187	ENSG00000277144.1	RP11-59H7.4	-5.27	2.07e-07	6.44e-05	-0.32	-0.24	Social communication problems;	chr15:59100607	chr15:59115547~59116089:-
HNSC	cis	rs7610312	0.583	rs2056119	ENSG00000273493.1	RP11-80H18.4	-5.27	2.07e-07	6.44e-05	-0.29	-0.24	Red blood cell count;	chr3:58323666	chr3:58329965~58330118:+
HNSC	cis	rs36093844	0.8	rs17744711	ENSG00000279742.1	RP11-700A24.1	-5.27	2.07e-07	6.45e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85889681	chr11:85852557~85854943:-
HNSC	cis	rs9650657	0.547	rs11250099	ENSG00000255310.2	AF131215.2	5.27	2.07e-07	6.45e-05	0.22	0.24	Neuroticism;	chr8:10961147	chr8:11107788~11109726:-
HNSC	cis	rs4388249	0.687	rs2301002	ENSG00000271849.1	CTC-332L22.1	-5.27	2.07e-07	6.45e-05	-0.32	-0.24	Schizophrenia;	chr5:109766130	chr5:109687802~109688329:-
HNSC	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-5.27	2.07e-07	6.45e-05	-0.22	-0.24	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
HNSC	cis	rs36093844	0.8	rs112468922	ENSG00000279742.1	RP11-700A24.1	-5.27	2.07e-07	6.45e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865651	chr11:85852557~85854943:-
HNSC	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	5.27	2.08e-07	6.46e-05	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
HNSC	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-5.27	2.08e-07	6.47e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
HNSC	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	5.27	2.08e-07	6.47e-05	0.27	0.24	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
HNSC	cis	rs9840812	0.861	rs1153871	ENSG00000239213.4	NCK1-AS1	5.27	2.08e-07	6.47e-05	0.23	0.24	Fibrinogen levels;	chr3:136235757	chr3:136841726~136862054:-
HNSC	cis	rs9907295	0.688	rs4795101	ENSG00000270977.1	AC015849.16	-5.27	2.08e-07	6.48e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35932989	chr17:35893707~35911023:-
HNSC	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-5.27	2.08e-07	6.48e-05	-0.33	-0.24	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
HNSC	cis	rs13126694	0.62	rs6844184	ENSG00000248429.4	RP11-597D13.9	5.27	2.08e-07	6.48e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:158094156	chr4:158170752~158202877:+
HNSC	cis	rs3806843	0.868	rs2262573	ENSG00000202515.1	VTRNA1-3	5.27	2.08e-07	6.49e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr5:140726158~140726246:+
HNSC	cis	rs442309	0.553	rs10761660	ENSG00000238280.1	RP11-436D10.3	-5.27	2.09e-07	6.49e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62756546	chr10:62793562~62805887:-
HNSC	cis	rs2337406	0.5	rs7152934	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106778702	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.789	rs12050392	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779073	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092505	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779163	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.789	rs74092507	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779174	chr14:106723574~106724093:-
HNSC	cis	rs8012947	0.916	rs78350060	ENSG00000279636.2	LINC00216	5.27	2.09e-07	6.49e-05	0.3	0.24	Alcohol consumption in current drinkers;	chr14:58381595	chr14:58288033~58289158:+
HNSC	cis	rs36423	0.748	rs36415	ENSG00000266869.1	RP6-114E22.1	-5.27	2.09e-07	6.5e-05	-0.39	-0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71888958	chr14:71848606~71908430:+
HNSC	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-5.27	2.09e-07	6.5e-05	-0.42	-0.24	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
HNSC	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	5.27	2.09e-07	6.51e-05	0.26	0.24	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	5.27	2.09e-07	6.51e-05	0.26	0.24	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
HNSC	cis	rs4321325	1	rs4321325	ENSG00000236682.1	AC068282.3	-5.27	2.09e-07	6.51e-05	-0.34	-0.24	Protein C levels;	chr2:127193421	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-5.27	2.1e-07	6.53e-05	-0.3	-0.24	Depression;	chr6:28144784	chr6:28161781~28169594:+
HNSC	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-5.27	2.1e-07	6.53e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
HNSC	cis	rs1008375	0.966	rs3796813	ENSG00000249502.1	AC006160.5	-5.27	2.1e-07	6.53e-05	-0.25	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17590025	chr4:17587467~17614571:-
HNSC	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-5.27	2.1e-07	6.53e-05	-0.26	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
HNSC	cis	rs2179367	0.537	rs6911411	ENSG00000216906.2	RP11-350J20.9	5.27	2.1e-07	6.53e-05	0.36	0.24	Dupuytren's disease;	chr6:149366954	chr6:149904243~149906418:+
HNSC	cis	rs860295	0.676	rs11264374	ENSG00000203761.5	MSTO2P	-5.27	2.1e-07	6.54e-05	-0.19	-0.24	Body mass index;	chr1:155451721	chr1:155745829~155750137:+
HNSC	cis	rs6928977	1	rs6928977	ENSG00000234084.1	RP3-388E23.2	5.27	2.1e-07	6.54e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135305210	chr6:135301568~135307158:+
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-5.27	2.1e-07	6.54e-05	-0.14	-0.24	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
HNSC	cis	rs860295	0.702	rs10796943	ENSG00000203761.5	MSTO2P	-5.27	2.11e-07	6.55e-05	-0.19	-0.24	Body mass index;	chr1:155444938	chr1:155745829~155750137:+
HNSC	cis	rs7535099	1	rs7524458	ENSG00000224570.1	RP11-430H12.2	-5.27	2.11e-07	6.55e-05	-0.31	-0.24	Blood protein levels;	chr1:65585217	chr1:65576129~65578380:-
HNSC	cis	rs7535099	1	rs7535099	ENSG00000224570.1	RP11-430H12.2	-5.27	2.11e-07	6.55e-05	-0.31	-0.24	Blood protein levels;	chr1:65585314	chr1:65576129~65578380:-
HNSC	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-5.27	2.11e-07	6.55e-05	-0.21	-0.24	Height;	chr11:118737823	chr11:118791254~118793137:+
HNSC	cis	rs741738	1	rs741738	ENSG00000251661.3	RP11-326C3.11	-5.27	2.11e-07	6.55e-05	-0.31	-0.24	Granulocyte percentage of myeloid white cells;	chr11:309508	chr11:318640~325631:+
HNSC	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	5.27	2.11e-07	6.55e-05	0.28	0.24	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000254340.1	RP11-10A14.3	5.27	2.11e-07	6.56e-05	0.29	0.24	Mood instability;	chr8:8516446	chr8:9141424~9145435:+
HNSC	cis	rs2985684	0.802	rs8015368	ENSG00000278009.1	RP11-649E7.8	5.27	2.11e-07	6.56e-05	0.3	0.24	Carotid intima media thickness;	chr14:49553792	chr14:49601011~49601124:-
HNSC	cis	rs2439831	0.681	rs2278858	ENSG00000205771.5	CATSPER2P1	-5.27	2.11e-07	6.57e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43340557	chr15:43726918~43747094:-
HNSC	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-5.27	2.11e-07	6.57e-05	-0.26	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
HNSC	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-5.27	2.11e-07	6.57e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
HNSC	cis	rs712039	0.565	rs1714988	ENSG00000276054.1	RP11-378E13.3	5.27	2.11e-07	6.57e-05	0.34	0.24	Tuberculosis;	chr17:37387113	chr17:37386886~37387926:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000233609.3	RP11-62H7.2	5.27	2.12e-07	6.58e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9001207	chr8:8961200~8979025:+
HNSC	cis	rs3206736	0.548	rs73110545	ENSG00000197085.10	NPSR1-AS1	-5.27	2.12e-07	6.58e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:35024182	chr7:34346512~34871582:-
HNSC	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-5.27	2.12e-07	6.58e-05	-0.33	-0.24	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
HNSC	cis	rs9291683	0.935	rs1860911	ENSG00000250413.1	RP11-448G15.1	-5.27	2.12e-07	6.58e-05	-0.29	-0.24	Bone mineral density;	chr4:10273433	chr4:10006482~10009725:+
HNSC	cis	rs1933112	0.5	rs1123864	ENSG00000227777.1	RP4-738P11.3	-5.27	2.12e-07	6.6e-05	-0.33	-0.24	Blood protein levels;	chr1:168559223	chr1:168542737~168543354:+
HNSC	cis	rs7777677	0.925	rs6956269	ENSG00000244273.1	PGBD4P1	-5.27	2.12e-07	6.6e-05	-0.25	-0.24	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs4726547	ENSG00000244273.1	PGBD4P1	-5.27	2.12e-07	6.6e-05	-0.25	-0.24	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142722358~142722764:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000179406.6	LINC00174	-5.27	2.12e-07	6.6e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65951319	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000179406.6	LINC00174	-5.27	2.12e-07	6.6e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65951525	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000179406.6	LINC00174	-5.27	2.12e-07	6.6e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65951549	chr7:66376044~66401338:-
HNSC	cis	rs7809950	0.817	rs2712224	ENSG00000238832.1	snoU109	-5.27	2.13e-07	6.61e-05	-0.35	-0.24	Coronary artery disease;	chr7:107540790	chr7:107603363~107603507:+
HNSC	cis	rs2834288	0.734	rs8126592	ENSG00000237945.6	LINC00649	-5.27	2.13e-07	6.61e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33895961	chr21:33915534~33977691:+
HNSC	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-5.27	2.13e-07	6.61e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-5.27	2.13e-07	6.61e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
HNSC	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	5.27	2.13e-07	6.61e-05	0.3	0.24	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
HNSC	cis	rs6723108	0.517	rs6729702	ENSG00000224043.6	CCNT2-AS1	-5.27	2.13e-07	6.62e-05	-0.28	-0.24	Type 2 diabetes;	chr2:134844586	chr2:134735464~134918710:-
HNSC	cis	rs5758659	1	rs5758677	ENSG00000227370.1	RP4-669P10.19	-5.27	2.13e-07	6.62e-05	-0.23	-0.24	Cognitive function;	chr22:42247033	chr22:42132543~42132998:+
HNSC	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
HNSC	cis	rs7048146	0.509	rs12554926	ENSG00000213539.4	YBX1P6	5.27	2.13e-07	6.62e-05	0.34	0.24	Vascular brain injury;	chr9:109567975	chr9:109532830~109534332:-
HNSC	cis	rs2243480	1	rs1404147	ENSG00000179406.6	LINC00174	-5.27	2.13e-07	6.63e-05	-0.46	-0.24	Diabetic kidney disease;	chr7:65799537	chr7:66376044~66401338:-
HNSC	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	5.27	2.13e-07	6.63e-05	0.33	0.24	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
HNSC	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	5.27	2.13e-07	6.63e-05	0.33	0.24	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
HNSC	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-5.27	2.14e-07	6.63e-05	-0.28	-0.24	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
HNSC	cis	rs1971762	0.527	rs6580950	ENSG00000270175.1	RP11-793H13.11	-5.27	2.14e-07	6.63e-05	-0.2	-0.24	Height;	chr12:53532872	chr12:53500162~53500936:-
HNSC	cis	rs28475163	1	rs28475163	ENSG00000255328.1	RP11-326C3.12	5.27	2.14e-07	6.64e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:327143	chr11:327171~330122:+
HNSC	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	5.27	2.14e-07	6.64e-05	0.3	0.24	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
HNSC	cis	rs6693567	0.565	rs3754214	ENSG00000228126.1	FALEC	5.27	2.14e-07	6.64e-05	0.29	0.24	Migraine;	chr1:150506147	chr1:150515757~150518032:+
HNSC	cis	rs9527	0.637	rs11191424	ENSG00000236937.2	PTGES3P4	5.27	2.14e-07	6.65e-05	0.3	0.24	Arsenic metabolism;	chr10:102866129	chr10:102845595~102845950:+
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	5.27	2.14e-07	6.65e-05	0.25	0.24	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
HNSC	cis	rs7760535	0.656	rs1883136	ENSG00000255389.1	C6orf3	-5.27	2.14e-07	6.65e-05	-0.21	-0.24	Metabolic traits;	chr6:111585820	chr6:111599875~111602295:+
HNSC	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	5.27	2.14e-07	6.65e-05	0.31	0.24	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
HNSC	cis	rs2439831	0.867	rs933941	ENSG00000205771.5	CATSPER2P1	-5.26	2.14e-07	6.65e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43340028	chr15:43726918~43747094:-
HNSC	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	5.26	2.15e-07	6.66e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
HNSC	cis	rs4699052	0.963	rs4698890	ENSG00000246560.2	RP11-10L12.4	5.26	2.15e-07	6.66e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103260721	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs2061646	ENSG00000246560.2	RP11-10L12.4	5.26	2.15e-07	6.66e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103262737	chr4:102828055~102844075:+
HNSC	cis	rs7819412	0.745	rs28464654	ENSG00000255310.2	AF131215.2	-5.26	2.15e-07	6.66e-05	-0.23	-0.24	Triglycerides;	chr8:11223156	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.745	rs28591576	ENSG00000255310.2	AF131215.2	-5.26	2.15e-07	6.66e-05	-0.23	-0.24	Triglycerides;	chr8:11223166	chr8:11107788~11109726:-
HNSC	cis	rs13434995	0.796	rs2412664	ENSG00000273257.1	RP11-177J6.1	5.26	2.15e-07	6.66e-05	0.36	0.24	Adiponectin levels;	chr4:55591220	chr4:55387949~55388271:+
HNSC	cis	rs2302464	1	rs73123607	ENSG00000214846.4	RP11-115L11.1	5.26	2.15e-07	6.67e-05	0.54	0.24	Cerebrospinal fluid biomarker levels;	chr4:15725058	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs6844968	ENSG00000214846.4	RP11-115L11.1	5.26	2.15e-07	6.67e-05	0.54	0.24	Cerebrospinal fluid biomarker levels;	chr4:15725641	chr4:15730962~15731627:-
HNSC	cis	rs8032939	0.533	rs56249992	ENSG00000259747.1	RP11-275I4.2	-5.26	2.15e-07	6.67e-05	-0.31	-0.24	Rheumatoid arthritis;	chr15:38611683	chr15:38671847~38689191:+
HNSC	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-5.26	2.15e-07	6.67e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-5.26	2.15e-07	6.67e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-5.26	2.15e-07	6.67e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
HNSC	cis	rs7615952	0.512	rs4234285	ENSG00000248787.1	RP11-666A20.4	-5.26	2.15e-07	6.67e-05	-0.31	-0.24	Blood pressure (smoking interaction);	chr3:125685633	chr3:125908005~125910272:-
HNSC	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-5.26	2.15e-07	6.67e-05	-0.29	-0.24	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
HNSC	cis	rs7048146	0.577	rs10979952	ENSG00000213539.4	YBX1P6	5.26	2.15e-07	6.68e-05	0.27	0.24	Vascular brain injury;	chr9:109587348	chr9:109532830~109534332:-
HNSC	cis	rs1218582	0.772	rs10796934	ENSG00000270361.1	RP11-307C12.13	-5.26	2.15e-07	6.68e-05	-0.26	-0.24	Prostate cancer;	chr1:154877003	chr1:154937370~154938059:+
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
HNSC	cis	rs933688	1	rs2059208	ENSG00000281357.1	ARRDC3-AS1	5.26	2.16e-07	6.69e-05	0.33	0.24	Smoking behavior;	chr5:91436248	chr5:91380349~91439085:+
HNSC	cis	rs10256972	0.605	rs10251094	ENSG00000225146.1	AC073957.15	-5.26	2.16e-07	6.69e-05	-0.43	-0.24	Endometriosis;Longevity;	chr7:977447	chr7:1029025~1043891:+
HNSC	cis	rs17507216	0.628	rs4513065	ENSG00000276710.3	CSPG4P8	-5.26	2.16e-07	6.7e-05	-0.33	-0.24	Excessive daytime sleepiness;	chr15:82712096	chr15:82459472~82477258:+
HNSC	cis	rs2337406	0.866	rs8003852	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106776648	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs988131	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106776833	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs8005518	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777009	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs988130	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777154	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs57684263	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777263	chr14:106723574~106724093:-
HNSC	cis	rs9813712	0.597	rs10934931	ENSG00000249846.5	RP11-77P16.4	-5.26	2.16e-07	6.7e-05	-0.25	-0.24	Response to amphetamines;	chr3:130261365	chr3:130112550~130120579:+
HNSC	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
HNSC	cis	rs7120173	0.571	rs634044	ENSG00000254851.1	RP11-109L13.1	-5.26	2.16e-07	6.71e-05	-0.39	-0.24	Visceral adipose tissue adjusted for BMI;	chr11:116881842	chr11:117135528~117138582:+
HNSC	cis	rs3733585	0.699	rs6449174	ENSG00000250413.1	RP11-448G15.1	5.26	2.16e-07	6.71e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9964798	chr4:10006482~10009725:+
HNSC	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	5.26	2.16e-07	6.71e-05	0.26	0.24	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
HNSC	cis	rs6540731	1	rs951623	ENSG00000226251.4	RP11-15I11.3	-5.26	2.17e-07	6.72e-05	-0.27	-0.24	Intelligence (childhood);	chr1:212225720	chr1:212225278~212238977:-
HNSC	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	5.26	2.17e-07	6.72e-05	0.29	0.24	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.866	rs8015361	ENSG00000211974.3	IGHV2-70	-5.26	2.17e-07	6.72e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783991	chr14:106723574~106724093:-
HNSC	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	5.26	2.17e-07	6.73e-05	0.26	0.24	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
HNSC	cis	rs67981189	0.758	rs221921	ENSG00000274818.1	RP1-292L20.3	-5.26	2.17e-07	6.73e-05	-0.28	-0.24	Schizophrenia;	chr14:71119411	chr14:70906657~70907111:-
HNSC	cis	rs9402743	0.671	rs9373138	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.74e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135630343	chr6:135636086~135636713:-
HNSC	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-5.26	2.18e-07	6.74e-05	-0.23	-0.24	Height;	chr5:36999896	chr5:36666214~36725195:-
HNSC	cis	rs7674212	0.541	rs2623070	ENSG00000246560.2	RP11-10L12.4	-5.26	2.18e-07	6.74e-05	-0.27	-0.24	Type 2 diabetes;	chr4:103116231	chr4:102828055~102844075:+
HNSC	cis	rs10504130	0.696	rs60796336	ENSG00000253844.1	RP11-546K22.1	-5.26	2.18e-07	6.75e-05	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51961458~52022974:+
HNSC	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	5.26	2.18e-07	6.75e-05	0.33	0.24	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	5.26	2.18e-07	6.75e-05	0.25	0.24	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	5.26	2.18e-07	6.75e-05	0.25	0.24	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	5.26	2.18e-07	6.75e-05	0.25	0.24	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
HNSC	cis	rs9402743	0.671	rs9399151	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.75e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135617920	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9376116	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.75e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135618763	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs4896157	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.75e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135620981	chr6:135636086~135636713:-
HNSC	cis	rs4140799	0.805	rs757744	ENSG00000266869.1	RP6-114E22.1	5.26	2.18e-07	6.75e-05	0.29	0.24	Neuroticism;	chr14:71731056	chr14:71848606~71908430:+
HNSC	cis	rs2337406	0.866	rs2027901	ENSG00000254174.1	IGHV1-12	5.26	2.18e-07	6.76e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106807164	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs28378201	ENSG00000211974.3	IGHV2-70	-5.26	2.18e-07	6.76e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106637262	chr14:106723574~106724093:-
HNSC	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-5.26	2.18e-07	6.76e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
HNSC	cis	rs1008375	0.866	rs12233712	ENSG00000249502.1	AC006160.5	-5.26	2.18e-07	6.76e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17568440	chr4:17587467~17614571:-
HNSC	cis	rs14027	0.512	rs7010808	ENSG00000279347.1	RP11-85I17.2	-5.26	2.18e-07	6.77e-05	-0.2	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712216	chr8:119838736~119840385:-
HNSC	cis	rs9287719	0.649	rs12618726	ENSG00000243819.4	RN7SL832P	5.26	2.18e-07	6.77e-05	0.24	0.24	Prostate cancer;	chr2:10588249	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6714787	ENSG00000243819.4	RN7SL832P	5.26	2.18e-07	6.77e-05	0.24	0.24	Prostate cancer;	chr2:10588906	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs2024432	ENSG00000243819.4	RN7SL832P	5.26	2.18e-07	6.77e-05	0.24	0.24	Prostate cancer;	chr2:10591348	chr2:10690344~10692099:+
HNSC	cis	rs6928977	0.832	rs2327613	ENSG00000231028.7	LINC00271	5.26	2.19e-07	6.77e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341234	chr6:135497801~135716055:+
HNSC	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-5.26	2.19e-07	6.78e-05	-0.24	-0.24	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	5.26	2.19e-07	6.78e-05	0.24	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
HNSC	cis	rs1864400	0.69	rs2565200	ENSG00000273008.1	RP11-351D16.3	-5.26	2.19e-07	6.78e-05	-0.32	-0.24	Hirschsprung disease;	chr10:43127485	chr10:43136824~43138334:-
HNSC	cis	rs2337406	0.866	rs2301536	ENSG00000254174.1	IGHV1-12	5.26	2.19e-07	6.78e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106790636	chr14:106122420~106122709:-
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	5.26	2.19e-07	6.78e-05	0.25	0.24	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	5.26	2.19e-07	6.78e-05	0.25	0.24	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
HNSC	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-5.26	2.19e-07	6.79e-05	-0.32	-0.24	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
HNSC	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-5.26	2.19e-07	6.79e-05	-0.26	-0.24	Height;	chr2:46616492	chr2:46668870~46670778:+
HNSC	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-5.26	2.19e-07	6.8e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
HNSC	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	5.26	2.2e-07	6.8e-05	0.35	0.24	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
HNSC	cis	rs17507216	0.718	rs4779033	ENSG00000276710.3	CSPG4P8	5.26	2.2e-07	6.8e-05	0.33	0.24	Excessive daytime sleepiness;	chr15:82576634	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	5.26	2.2e-07	6.8e-05	0.26	0.24	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	5.26	2.2e-07	6.8e-05	0.26	0.24	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
HNSC	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	5.26	2.2e-07	6.8e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
HNSC	cis	rs860295	0.702	rs12746592	ENSG00000203761.5	MSTO2P	-5.26	2.2e-07	6.8e-05	-0.18	-0.24	Body mass index;	chr1:155536176	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs10752611	ENSG00000203761.5	MSTO2P	-5.26	2.2e-07	6.8e-05	-0.18	-0.24	Body mass index;	chr1:155539316	chr1:155745829~155750137:+
HNSC	cis	rs11976180	1	rs13226728	ENSG00000273234.1	OR2A13P	-5.26	2.2e-07	6.8e-05	-0.27	-0.24	Obesity-related traits;	chr7:144049485	chr7:144142009~144142938:+
HNSC	cis	rs71520386	0.632	rs9692432	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829244	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs9691076	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829742	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs71520387	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830057	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs10224244	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830455	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs28526185	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22831699	chr7:22856613~22856686:+
HNSC	cis	rs7819412	0.875	rs11250121	ENSG00000269918.1	AF131215.9	-5.26	2.2e-07	6.81e-05	-0.24	-0.24	Triglycerides;	chr8:11202802	chr8:11104691~11106704:-
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	5.26	2.2e-07	6.81e-05	0.26	0.24	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
HNSC	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	5.26	2.2e-07	6.81e-05	0.26	0.24	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
HNSC	cis	rs2337406	0.789	rs60000589	ENSG00000254174.1	IGHV1-12	5.26	2.2e-07	6.82e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106782459	chr14:106122420~106122709:-
HNSC	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	5.26	2.2e-07	6.82e-05	0.36	0.24	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
HNSC	cis	rs10504130	0.569	rs7820177	ENSG00000253844.1	RP11-546K22.1	-5.26	2.2e-07	6.82e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51924373	chr8:51961458~52022974:+
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	5.26	2.2e-07	6.82e-05	0.25	0.24	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-5.26	2.21e-07	6.83e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
HNSC	cis	rs10946940	0.965	rs9393830	ENSG00000219392.1	RP1-265C24.5	-5.26	2.21e-07	6.83e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr6:27619248	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.86	rs2746433	ENSG00000231028.7	LINC00271	5.26	2.21e-07	6.83e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135379567	chr6:135497801~135716055:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-5.26	2.21e-07	6.84e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-5.26	2.21e-07	6.84e-05	-0.28	-0.24	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
HNSC	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-5.26	2.21e-07	6.84e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-5.26	2.21e-07	6.84e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-5.26	2.21e-07	6.84e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	5.26	2.21e-07	6.85e-05	0.19	0.24	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	5.26	2.21e-07	6.85e-05	0.25	0.24	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	5.26	2.21e-07	6.85e-05	0.25	0.24	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	5.26	2.21e-07	6.85e-05	0.25	0.24	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
HNSC	cis	rs4713118	0.662	rs149946	ENSG00000204709.4	LINC01556	-5.26	2.22e-07	6.86e-05	-0.32	-0.24	Parkinson's disease;	chr6:28002253	chr6:28943877~28944537:+
HNSC	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-5.26	2.22e-07	6.87e-05	-0.32	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
HNSC	cis	rs7733403	1	rs7733403	ENSG00000202515.1	VTRNA1-3	-5.26	2.22e-07	6.88e-05	-0.26	-0.24	Schizophrenia;	chr5:140774630	chr5:140726158~140726246:+
HNSC	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-5.26	2.22e-07	6.88e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
HNSC	cis	rs10504130	0.569	rs34364864	ENSG00000272024.1	RP11-546K22.3	-5.26	2.23e-07	6.88e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51950284~51950690:+
HNSC	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	5.26	2.23e-07	6.88e-05	0.28	0.24	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
HNSC	cis	rs2933343	0.7	rs789238	ENSG00000261159.1	RP11-723O4.9	5.26	2.23e-07	6.88e-05	0.24	0.24	IgG glycosylation;	chr3:128917872	chr3:128859716~128860526:-
HNSC	cis	rs712039	0.652	rs2946340	ENSG00000276054.1	RP11-378E13.3	5.26	2.23e-07	6.89e-05	0.34	0.24	Tuberculosis;	chr17:37392762	chr17:37386886~37387926:+
HNSC	cis	rs9879311	0.966	rs4684685	ENSG00000240288.6	GHRLOS	5.26	2.23e-07	6.89e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369869	chr3:10285754~10293449:+
HNSC	cis	rs2243480	1	rs316331	ENSG00000179406.6	LINC00174	5.26	2.23e-07	6.9e-05	0.5	0.24	Diabetic kidney disease;	chr7:66139635	chr7:66376044~66401338:-
HNSC	cis	rs1707322	1	rs11211200	ENSG00000234329.1	RP11-767N6.2	5.26	2.23e-07	6.9e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45651039~45651826:-
HNSC	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-5.26	2.23e-07	6.9e-05	-0.24	-0.24	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
HNSC	cis	rs9813712	0.953	rs9883455	ENSG00000249846.5	RP11-77P16.4	-5.26	2.23e-07	6.9e-05	-0.28	-0.24	Response to amphetamines;	chr3:130260088	chr3:130112550~130120579:+
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	5.26	2.24e-07	6.92e-05	0.27	0.24	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
HNSC	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-5.26	2.24e-07	6.92e-05	-0.2	-0.24	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
HNSC	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-5.26	2.24e-07	6.92e-05	-0.2	-0.24	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
HNSC	cis	rs13217239	0.646	rs7451149	ENSG00000224843.5	LINC00240	5.26	2.24e-07	6.93e-05	0.23	0.24	Schizophrenia;	chr6:27089739	chr6:26956992~27023924:+
HNSC	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-5.26	2.24e-07	6.93e-05	-0.29	-0.24	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
HNSC	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-5.26	2.24e-07	6.93e-05	-0.3	-0.24	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
HNSC	cis	rs3805389	0.504	rs17725163	ENSG00000273257.1	RP11-177J6.1	5.26	2.24e-07	6.93e-05	0.36	0.24	Waist-to-hip ratio adjusted for body mass index;	chr4:55609280	chr4:55387949~55388271:+
HNSC	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-5.26	2.24e-07	6.93e-05	-0.24	-0.24	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	5.26	2.25e-07	6.94e-05	0.25	0.24	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
HNSC	cis	rs5758659	1	rs134902	ENSG00000227370.1	RP4-669P10.19	-5.26	2.25e-07	6.95e-05	-0.23	-0.24	Cognitive function;	chr22:42287991	chr22:42132543~42132998:+
HNSC	cis	rs9907295	0.685	rs4796131	ENSG00000270977.1	AC015849.16	-5.26	2.25e-07	6.95e-05	-0.35	-0.24	Fibroblast growth factor basic levels;	chr17:35904812	chr17:35893707~35911023:-
HNSC	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-5.26	2.26e-07	6.97e-05	-0.37	-0.24	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
HNSC	cis	rs11992162	0.967	rs11250185	ENSG00000206014.6	OR7E161P	-5.25	2.26e-07	6.97e-05	-0.26	-0.24	Monocyte count;	chr8:11975614	chr8:11928597~11929563:-
HNSC	cis	rs11992162	1	rs12334769	ENSG00000206014.6	OR7E161P	-5.25	2.26e-07	6.97e-05	-0.26	-0.24	Monocyte count;	chr8:11975652	chr8:11928597~11929563:-
HNSC	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	5.25	2.26e-07	6.97e-05	0.24	0.24	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
HNSC	cis	rs651386	0.505	rs10919441	ENSG00000271811.1	RP1-79C4.4	5.25	2.26e-07	6.98e-05	0.26	0.24	Atrial fibrillation;	chr1:170609948	chr1:170667381~170669425:+
HNSC	cis	rs13113518	1	rs4864995	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55452853	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12651640	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55454154	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs1554483	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55455650	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs10517346	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55457027	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133384	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55457086	chr4:55387949~55388271:+
HNSC	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	5.25	2.26e-07	6.98e-05	0.37	0.24	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
HNSC	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	5.25	2.26e-07	6.99e-05	0.27	0.24	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
HNSC	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	5.25	2.26e-07	6.99e-05	0.35	0.24	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
HNSC	cis	rs5758511	0.508	rs28715885	ENSG00000226450.2	CYP2D8P	5.25	2.26e-07	6.99e-05	0.24	0.24	Birth weight;	chr22:42045087	chr22:42149886~42155001:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000179406.6	LINC00174	5.25	2.26e-07	7e-05	0.49	0.24	Diabetic kidney disease;	chr7:66144214	chr7:66376044~66401338:-
HNSC	cis	rs7688540	0.771	rs10005733	ENSG00000211553.1	AC253576.2	-5.25	2.27e-07	7e-05	-0.33	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:136461~136568:+
HNSC	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-5.25	2.27e-07	7e-05	-0.27	-0.24	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
HNSC	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	5.25	2.27e-07	7.01e-05	0.29	0.24	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
HNSC	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-5.25	2.27e-07	7.01e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-5.25	2.27e-07	7.01e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-5.25	2.27e-07	7.01e-05	-0.35	-0.24	Height;	chr6:109625358	chr6:109382795~109383666:+
HNSC	cis	rs4218	0.689	rs11853828	ENSG00000277144.1	RP11-59H7.4	-5.25	2.27e-07	7.02e-05	-0.32	-0.24	Social communication problems;	chr15:59136031	chr15:59115547~59116089:-
HNSC	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-5.25	2.27e-07	7.02e-05	-0.29	-0.24	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
HNSC	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-5.25	2.27e-07	7.02e-05	-0.32	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
HNSC	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-5.25	2.28e-07	7.03e-05	-0.28	-0.24	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-5.25	2.28e-07	7.03e-05	-0.25	-0.24	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
HNSC	cis	rs17428076	0.836	rs57775770	ENSG00000228389.1	AC068039.4	-5.25	2.28e-07	7.03e-05	-0.28	-0.24	Myopia;	chr2:171831221	chr2:171773482~171775844:+
HNSC	cis	rs638893	0.617	rs4938564	ENSG00000255422.1	AP002954.4	-5.25	2.28e-07	7.03e-05	-0.34	-0.24	Vitiligo;	chr11:118849881	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.617	rs11217059	ENSG00000255422.1	AP002954.4	-5.25	2.28e-07	7.03e-05	-0.34	-0.24	Vitiligo;	chr11:118852378	chr11:118704607~118750263:+
HNSC	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-5.25	2.28e-07	7.03e-05	-0.26	-0.24	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
HNSC	cis	rs860295	0.812	rs7556519	ENSG00000203761.5	MSTO2P	-5.25	2.28e-07	7.04e-05	-0.18	-0.24	Body mass index;	chr1:155857755	chr1:155745829~155750137:+
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-5.25	2.28e-07	7.04e-05	-0.28	-0.24	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.789	rs60390024	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781327	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092532	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781363	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092534	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781364	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092535	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781722	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092537	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781883	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.81	rs74092538	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781942	chr14:106122420~106122709:-
HNSC	cis	rs7621025	0.755	rs1017881	ENSG00000273486.1	RP11-731C17.2	5.25	2.28e-07	7.05e-05	0.2	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136638851	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000254153.1	CTA-398F10.2	5.25	2.29e-07	7.05e-05	0.25	0.24	Mood instability;	chr8:8933634	chr8:8456909~8461337:-
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-5.25	2.29e-07	7.05e-05	-0.25	-0.24	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
HNSC	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-5.25	2.29e-07	7.06e-05	-0.19	-0.24	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
HNSC	cis	rs2439831	0.867	rs6493082	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43342610	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs8041132	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43342938	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs7170489	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43344453	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs16957627	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43350459	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs16957630	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43350582	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs16957632	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43350699	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.717	rs7165471	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43352590	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs6493085	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43361984	chr15:43726918~43747094:-
HNSC	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-5.25	2.29e-07	7.06e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
HNSC	cis	rs2337406	0.866	rs7153964	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106790480	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7144369	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106793065	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs78525520	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106795643	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7140974	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106795976	chr14:106122420~106122709:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Kawasaki disease;	chr14:106799309	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs76871148	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106799722	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs61521632	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106801091	chr14:106122420~106122709:-
HNSC	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	5.25	2.29e-07	7.07e-05	0.29	0.24	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
HNSC	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-5.25	2.29e-07	7.07e-05	-0.38	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
HNSC	cis	rs9287719	0.578	rs62127189	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10621200	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.601	rs1861299	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10623631	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.601	rs1861300	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10623835	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.601	rs10084172	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10631102	chr2:10690344~10692099:+
HNSC	cis	rs950169	0.763	rs35372971	ENSG00000229212.6	RP11-561C5.4	-5.25	2.29e-07	7.08e-05	-0.34	-0.24	Schizophrenia;	chr15:84387097	chr15:85205440~85234795:-
HNSC	cis	rs792448	0.527	rs11119887	ENSG00000226251.4	RP11-15I11.3	-5.25	2.29e-07	7.08e-05	-0.27	-0.24	White blood cell count (basophil);	chr1:212234220	chr1:212225278~212238977:-
HNSC	cis	rs2243480	1	rs59794892	ENSG00000179406.6	LINC00174	-5.25	2.3e-07	7.08e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65950886	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
HNSC	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-5.25	2.3e-07	7.09e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
HNSC	cis	rs1355223	0.752	rs17359064	ENSG00000271369.1	RP11-350D17.3	-5.25	2.3e-07	7.1e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34652337	chr11:34709600~34710161:+
HNSC	cis	rs831571	0.774	rs254858	ENSG00000280620.1	SCAANT1	-5.25	2.31e-07	7.11e-05	-0.32	-0.24	Type 2 diabetes;	chr3:64070579	chr3:63911518~63911772:-
HNSC	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	5.25	2.31e-07	7.12e-05	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
HNSC	cis	rs7610312	0.681	rs6445971	ENSG00000273493.1	RP11-80H18.4	-5.25	2.31e-07	7.12e-05	-0.29	-0.24	Red blood cell count;	chr3:58328597	chr3:58329965~58330118:+
HNSC	cis	rs10504130	0.569	rs13265006	ENSG00000272024.1	RP11-546K22.3	-5.25	2.31e-07	7.13e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.597	rs34058697	ENSG00000272024.1	RP11-546K22.3	-5.25	2.31e-07	7.13e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51950284~51950690:+
HNSC	cis	rs17428076	0.751	rs788168	ENSG00000228389.1	AC068039.4	-5.25	2.32e-07	7.14e-05	-0.29	-0.24	Myopia;	chr2:172053071	chr2:171773482~171775844:+
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	5.25	2.32e-07	7.15e-05	0.26	0.24	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
HNSC	cis	rs11157436	0.958	rs61972231	ENSG00000211812.1	TRAV26-2	-5.25	2.32e-07	7.15e-05	-0.25	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22202583~22203368:+
HNSC	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	5.25	2.32e-07	7.16e-05	0.33	0.24	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
HNSC	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-5.25	2.32e-07	7.16e-05	-0.36	-0.24	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-5.25	2.32e-07	7.16e-05	-0.21	-0.24	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	5.25	2.32e-07	7.16e-05	0.24	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
HNSC	cis	rs2439831	0.681	rs2278859	ENSG00000205771.5	CATSPER2P1	-5.25	2.32e-07	7.17e-05	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43340762	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.681	rs7168940	ENSG00000205771.5	CATSPER2P1	-5.25	2.32e-07	7.17e-05	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43341136	chr15:43726918~43747094:-
HNSC	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-5.25	2.33e-07	7.17e-05	-0.28	-0.24	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-5.25	2.33e-07	7.17e-05	-0.28	-0.24	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
HNSC	cis	rs71520386	0.53	rs10256628	ENSG00000221740.1	SNORD93	-5.25	2.33e-07	7.17e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22843640	chr7:22856613~22856686:+
HNSC	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-5.25	2.33e-07	7.17e-05	-0.27	-0.24	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
HNSC	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	5.25	2.33e-07	7.17e-05	0.58	0.24	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	5.25	2.33e-07	7.17e-05	0.58	0.24	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
HNSC	cis	rs3206736	0.548	rs1649224	ENSG00000197085.10	NPSR1-AS1	-5.25	2.33e-07	7.17e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:34951384	chr7:34346512~34871582:-
HNSC	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	5.25	2.33e-07	7.18e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
HNSC	cis	rs6928977	0.896	rs9321501	ENSG00000231028.7	LINC00271	5.25	2.33e-07	7.18e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320279	chr6:135497801~135716055:+
HNSC	cis	rs925255	0.967	rs10199829	ENSG00000270210.1	RP11-373D23.3	5.25	2.33e-07	7.18e-05	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28380044	chr2:28425945~28426719:+
HNSC	cis	rs4763879	0.634	rs12424826	ENSG00000256673.1	RP11-599J14.2	5.25	2.33e-07	7.18e-05	0.22	0.24	Type 1 diabetes;	chr12:9701981	chr12:9398355~9414851:-
HNSC	cis	rs3733585	0.699	rs6852441	ENSG00000250413.1	RP11-448G15.1	5.25	2.33e-07	7.19e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9972120	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.725	rs6449201	ENSG00000250413.1	RP11-448G15.1	5.25	2.33e-07	7.19e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9972270	chr4:10006482~10009725:+
HNSC	cis	rs860295	0.702	rs5005770	ENSG00000203761.5	MSTO2P	5.25	2.33e-07	7.19e-05	0.18	0.24	Body mass index;	chr1:155375252	chr1:155745829~155750137:+
HNSC	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
HNSC	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	5.25	2.33e-07	7.19e-05	0.27	0.24	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
HNSC	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	5.25	2.34e-07	7.19e-05	0.27	0.24	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
HNSC	cis	rs5758659	0.714	rs5758578	ENSG00000227370.1	RP4-669P10.19	5.25	2.34e-07	7.21e-05	0.23	0.24	Cognitive function;	chr22:42094288	chr22:42132543~42132998:+
HNSC	cis	rs442309	0.553	rs7073430	ENSG00000238280.1	RP11-436D10.3	-5.25	2.34e-07	7.21e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62695121	chr10:62793562~62805887:-
HNSC	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-5.25	2.34e-07	7.21e-05	-0.3	-0.24	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
HNSC	cis	rs4834770	1	rs4834770	ENSG00000249244.1	RP11-548H18.2	5.25	2.34e-07	7.21e-05	0.26	0.24	Blood protein levels;	chr4:119320694	chr4:119391831~119395335:-
HNSC	cis	rs4834770	1	rs6823963	ENSG00000249244.1	RP11-548H18.2	5.25	2.34e-07	7.21e-05	0.26	0.24	Blood protein levels;	chr4:119321009	chr4:119391831~119395335:-
HNSC	cis	rs9291683	0.935	rs1860910	ENSG00000250413.1	RP11-448G15.1	-5.25	2.34e-07	7.22e-05	-0.29	-0.24	Bone mineral density;	chr4:10273846	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs13139055	ENSG00000250413.1	RP11-448G15.1	-5.25	2.34e-07	7.22e-05	-0.29	-0.24	Bone mineral density;	chr4:10037300	chr4:10006482~10009725:+
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	5.25	2.35e-07	7.23e-05	0.25	0.24	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
HNSC	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-5.25	2.35e-07	7.23e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
HNSC	cis	rs11969893	0.85	rs9404058	ENSG00000270987.1	RP3-467N11.2	5.25	2.35e-07	7.23e-05	0.6	0.24	Economic and political preferences (immigration/crime);	chr6:100875202	chr6:100889603~100890338:+
HNSC	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	5.25	2.35e-07	7.23e-05	0.28	0.24	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
HNSC	cis	rs7819412	0.745	rs6601569	ENSG00000269918.1	AF131215.9	-5.25	2.35e-07	7.24e-05	-0.25	-0.24	Triglycerides;	chr8:11216069	chr8:11104691~11106704:-
HNSC	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-5.25	2.35e-07	7.24e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
HNSC	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	5.25	2.36e-07	7.25e-05	0.27	0.24	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
HNSC	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	5.25	2.36e-07	7.25e-05	0.29	0.24	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
HNSC	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-5.25	2.36e-07	7.26e-05	-0.25	-0.24	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
HNSC	cis	rs73198271	0.74	rs1039910	ENSG00000253893.2	FAM85B	5.25	2.36e-07	7.26e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.714	rs11784052	ENSG00000254340.1	RP11-10A14.3	5.25	2.36e-07	7.26e-05	0.28	0.24	Mood instability;	chr8:8814452	chr8:9141424~9145435:+
HNSC	cis	rs6928977	0.896	rs2064431	ENSG00000231028.7	LINC00271	5.25	2.36e-07	7.26e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324065	chr6:135497801~135716055:+
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	5.25	2.36e-07	7.27e-05	0.25	0.24	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	5.25	2.36e-07	7.27e-05	0.25	0.24	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
HNSC	cis	rs2337406	1	rs17112416	ENSG00000254174.1	IGHV1-12	-5.25	2.36e-07	7.27e-05	-0.2	-0.24	Alzheimer's disease (late onset);	chr14:106686773	chr14:106122420~106122709:-
HNSC	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	5.25	2.36e-07	7.27e-05	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
HNSC	cis	rs7665090	0.743	rs228626	ENSG00000246560.2	RP11-10L12.4	-5.25	2.36e-07	7.27e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102651789	chr4:102828055~102844075:+
HNSC	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	5.25	2.37e-07	7.28e-05	0.27	0.24	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
HNSC	cis	rs3806843	0.966	rs6891559	ENSG00000202515.1	VTRNA1-3	-5.25	2.37e-07	7.29e-05	-0.26	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs11741994	ENSG00000202515.1	VTRNA1-3	-5.25	2.37e-07	7.29e-05	-0.26	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr5:140726158~140726246:+
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000233609.3	RP11-62H7.2	-5.25	2.37e-07	7.3e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9053494	chr8:8961200~8979025:+
HNSC	cis	rs2337406	0.866	rs111881598	ENSG00000254174.1	IGHV1-12	5.24	2.38e-07	7.3e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783113	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs61164979	ENSG00000254174.1	IGHV1-12	5.24	2.38e-07	7.3e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783133	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs61419485	ENSG00000254174.1	IGHV1-12	5.24	2.38e-07	7.3e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783374	chr14:106122420~106122709:-
HNSC	cis	rs9840812	0.728	rs12630999	ENSG00000239213.4	NCK1-AS1	5.24	2.38e-07	7.31e-05	0.21	0.24	Fibrinogen levels;	chr3:136582085	chr3:136841726~136862054:-
HNSC	cis	rs9910055	0.762	rs7213436	ENSG00000267080.4	ASB16-AS1	5.24	2.38e-07	7.31e-05	0.19	0.24	Total body bone mineral density;	chr17:44174795	chr17:44175973~44186717:-
HNSC	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-5.24	2.38e-07	7.31e-05	-0.28	-0.24	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-5.24	2.38e-07	7.31e-05	-0.14	-0.24	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
HNSC	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	5.24	2.38e-07	7.31e-05	0.28	0.24	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	5.24	2.38e-07	7.32e-05	0.25	0.24	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
HNSC	cis	rs638893	0.617	rs7103314	ENSG00000255422.1	AP002954.4	-5.24	2.38e-07	7.32e-05	-0.34	-0.24	Vitiligo;	chr11:118852828	chr11:118704607~118750263:+
HNSC	cis	rs11098499	0.71	rs6851130	ENSG00000249244.1	RP11-548H18.2	-5.24	2.38e-07	7.33e-05	-0.27	-0.24	Corneal astigmatism;	chr4:119212557	chr4:119391831~119395335:-
HNSC	cis	rs2904524	0.748	rs11178226	ENSG00000257815.4	RP11-611E13.2	-5.24	2.39e-07	7.33e-05	-0.3	-0.24	Amyotrophic lateral sclerosis (age of onset);	chr12:70409894	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.748	rs11178227	ENSG00000257815.4	RP11-611E13.2	-5.24	2.39e-07	7.33e-05	-0.3	-0.24	Amyotrophic lateral sclerosis (age of onset);	chr12:70409970	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.748	rs11178228	ENSG00000257815.4	RP11-611E13.2	-5.24	2.39e-07	7.33e-05	-0.3	-0.24	Amyotrophic lateral sclerosis (age of onset);	chr12:70410290	chr12:69904033~70243360:-
HNSC	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	5.24	2.39e-07	7.33e-05	0.28	0.24	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
HNSC	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-5.24	2.39e-07	7.34e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
HNSC	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-5.24	2.39e-07	7.34e-05	-0.3	-0.24	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	5.24	2.39e-07	7.35e-05	0.25	0.24	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
HNSC	cis	rs2337406	0.538	rs2015470	ENSG00000274576.2	IGHV2-70	-5.24	2.39e-07	7.35e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106631885	chr14:106770577~106771020:-
HNSC	cis	rs6928977	0.86	rs2614264	ENSG00000217482.2	HMGB1P17	5.24	2.39e-07	7.35e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135636086~135636713:-
HNSC	cis	rs73198271	0.74	rs10113326	ENSG00000253893.2	FAM85B	5.24	2.39e-07	7.35e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8167819~8226614:-
HNSC	cis	rs13113518	1	rs11133381	ENSG00000273257.1	RP11-177J6.1	5.24	2.39e-07	7.35e-05	0.29	0.24	Height;	chr4:55450812	chr4:55387949~55388271:+
HNSC	cis	rs2439831	0.681	rs1549523	ENSG00000205771.5	CATSPER2P1	-5.24	2.39e-07	7.36e-05	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43331991	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.681	rs1549525	ENSG00000205771.5	CATSPER2P1	-5.24	2.39e-07	7.36e-05	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43335657	chr15:43726918~43747094:-
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	5.24	2.4e-07	7.37e-05	0.28	0.24	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000253981.4	ALG1L13P	-5.24	2.4e-07	7.38e-05	-0.27	-0.24	Joint mobility (Beighton score);	chr8:9032588	chr8:8236003~8244667:-
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-5.24	2.4e-07	7.38e-05	-0.14	-0.24	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000233609.3	RP11-62H7.2	-5.24	2.4e-07	7.38e-05	-0.22	-0.24	Mood instability;	chr8:8932549	chr8:8961200~8979025:+
HNSC	cis	rs6928977	0.896	rs1012645	ENSG00000231028.7	LINC00271	5.24	2.41e-07	7.39e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324309	chr6:135497801~135716055:+
HNSC	cis	rs2276314	0.512	rs12458709	ENSG00000278986.1	RP11-723J4.3	5.24	2.41e-07	7.39e-05	0.27	0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35861928	chr18:35972151~35973916:+
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	5.24	2.41e-07	7.39e-05	0.27	0.24	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	5.24	2.41e-07	7.39e-05	0.25	0.24	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
HNSC	cis	rs6693567	0.545	rs12049177	ENSG00000228126.1	FALEC	5.24	2.41e-07	7.39e-05	0.29	0.24	Migraine;	chr1:150501861	chr1:150515757~150518032:+
HNSC	cis	rs1008375	0.646	rs13103430	ENSG00000249502.1	AC006160.5	5.24	2.41e-07	7.39e-05	0.26	0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565732	chr4:17587467~17614571:-
HNSC	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-5.24	2.41e-07	7.39e-05	-0.28	-0.24	Height;	chr2:46609767	chr2:46668870~46670778:+
HNSC	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-5.24	2.41e-07	7.39e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
HNSC	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	5.24	2.41e-07	7.4e-05	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
HNSC	cis	rs860818	0.793	rs2091491	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23153930	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs1406080	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23153985	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.557	rs2178138	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23154414	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs1358441	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23154850	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.557	rs6961136	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23155343	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs12700418	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23155701	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs6966420	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156346	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs4722227	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156399	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs6966929	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156455	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.546	rs4722228	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156479	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs4722229	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156485	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs4722230	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23157572	chr7:23206013~23208045:+
HNSC	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-5.24	2.41e-07	7.41e-05	-0.38	-0.24	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
HNSC	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.24	2.41e-07	7.41e-05	0.32	0.24	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
HNSC	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	5.24	2.41e-07	7.41e-05	0.3	0.24	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
HNSC	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-5.24	2.41e-07	7.41e-05	-0.32	-0.24	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
HNSC	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	5.24	2.41e-07	7.41e-05	0.38	0.24	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
HNSC	cis	rs72949976	0.646	rs11681232	ENSG00000270659.1	RP11-105N14.1	-5.24	2.41e-07	7.41e-05	-0.23	-0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213168278	chr2:213152970~213153659:+
HNSC	cis	rs6723108	0.517	rs6430552	ENSG00000224043.6	CCNT2-AS1	-5.24	2.42e-07	7.41e-05	-0.28	-0.24	Type 2 diabetes;	chr2:134865238	chr2:134735464~134918710:-
HNSC	cis	rs9840812	0.592	rs12489577	ENSG00000239213.4	NCK1-AS1	5.24	2.42e-07	7.42e-05	0.22	0.24	Fibrinogen levels;	chr3:136494303	chr3:136841726~136862054:-
HNSC	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-5.24	2.42e-07	7.42e-05	-0.34	-0.24	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
HNSC	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-5.24	2.42e-07	7.42e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
HNSC	cis	rs42490	0.589	rs39772	ENSG00000251136.7	RP11-37B2.1	-5.24	2.42e-07	7.42e-05	-0.2	-0.24	Leprosy;	chr8:89831636	chr8:89609409~89757727:-
HNSC	cis	rs2657294	0.603	rs11543	ENSG00000233313.2	HMGA1P5	-5.24	2.42e-07	7.43e-05	-0.26	-0.24	Pneumonia;	chr10:75210855	chr10:75276376~75276646:-
HNSC	cis	rs8054556	1	rs4787489	ENSG00000183604.13	SMG1P5	-5.24	2.43e-07	7.44e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29984559	chr16:30267553~30335374:-
HNSC	cis	rs17428076	0.874	rs62182373	ENSG00000228389.1	AC068039.4	-5.24	2.43e-07	7.44e-05	-0.28	-0.24	Myopia;	chr2:171829045	chr2:171773482~171775844:+
HNSC	cis	rs5758511	0.514	rs5751211	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42090052	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs3985938	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42115723	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs5751221	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42120362	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs5758586	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42121467	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs5751222	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42121918	chr22:42149886~42155001:-
HNSC	cis	rs2284378	0.506	rs6142059	ENSG00000275784.1	RP5-1125A11.6	-5.24	2.43e-07	7.45e-05	-0.28	-0.24	Breast cancer;	chr20:33956521	chr20:33989480~33991818:-
HNSC	cis	rs7083	0.84	rs509565	ENSG00000254851.1	RP11-109L13.1	5.24	2.43e-07	7.45e-05	0.29	0.24	Blood protein levels;	chr11:117249757	chr11:117135528~117138582:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	-5.24	2.43e-07	7.45e-05	-0.29	-0.24	Depression;	chr6:28197321	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	-5.24	2.43e-07	7.45e-05	-0.29	-0.24	Depression;	chr6:28197412	chr6:28161781~28169594:+
HNSC	cis	rs7621025	0.505	rs61789642	ENSG00000273486.1	RP11-731C17.2	-5.24	2.43e-07	7.45e-05	-0.3	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390854	chr3:136837338~136839021:-
HNSC	cis	rs7621025	0.505	rs61789643	ENSG00000273486.1	RP11-731C17.2	-5.24	2.43e-07	7.45e-05	-0.3	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390910	chr3:136837338~136839021:-
HNSC	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	5.24	2.43e-07	7.45e-05	0.24	0.24	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
HNSC	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-5.24	2.43e-07	7.45e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
HNSC	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	5.24	2.43e-07	7.46e-05	0.21	0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
HNSC	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	5.24	2.43e-07	7.46e-05	0.33	0.24	Height;	chr6:109694120	chr6:109382795~109383666:+
HNSC	cis	rs1223397	0.938	rs3817741	ENSG00000215022.6	RP1-257A7.4	5.24	2.44e-07	7.47e-05	0.29	0.24	Blood pressure;	chr6:13279275	chr6:13264861~13295586:-
HNSC	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-5.24	2.44e-07	7.47e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000254153.1	CTA-398F10.2	5.24	2.44e-07	7.48e-05	0.25	0.24	Neuroticism;	chr8:8312614	chr8:8456909~8461337:-
HNSC	cis	rs1555322	0.872	rs6579227	ENSG00000126005.14	MMP24-AS1	-5.24	2.44e-07	7.48e-05	-0.49	-0.24	Attention deficit hyperactivity disorder;	chr20:35291403	chr20:35216462~35278131:-
HNSC	cis	rs4699052	0.963	rs11097801	ENSG00000246560.2	RP11-10L12.4	5.24	2.44e-07	7.48e-05	0.27	0.24	Testicular germ cell tumor;	chr4:103229166	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs56144793	ENSG00000246560.2	RP11-10L12.4	5.24	2.44e-07	7.48e-05	0.27	0.24	Testicular germ cell tumor;	chr4:103229496	chr4:102828055~102844075:+
HNSC	cis	rs6964833	0.872	rs4717903	ENSG00000184616.8	AC004166.6	5.24	2.44e-07	7.48e-05	0.29	0.24	Menarche (age at onset);	chr7:74653827	chr7:74906673~74913256:-
HNSC	cis	rs4218	0.597	rs12438111	ENSG00000277144.1	RP11-59H7.4	-5.24	2.44e-07	7.49e-05	-0.31	-0.24	Social communication problems;	chr15:59057540	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.636	rs4775116	ENSG00000277144.1	RP11-59H7.4	5.24	2.44e-07	7.49e-05	0.28	0.24	Social communication problems;	chr15:59135608	chr15:59115547~59116089:-
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	5.24	2.44e-07	7.49e-05	0.21	0.24	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
HNSC	cis	rs4218	0.689	rs34338282	ENSG00000277144.1	RP11-59H7.4	-5.24	2.45e-07	7.5e-05	-0.32	-0.24	Social communication problems;	chr15:59096897	chr15:59115547~59116089:-
HNSC	cis	rs4713118	0.513	rs200971	ENSG00000219392.1	RP1-265C24.5	-5.24	2.45e-07	7.5e-05	-0.29	-0.24	Parkinson's disease;	chr6:27891126	chr6:28115628~28116551:+
HNSC	cis	rs72772090	0.908	rs17086588	ENSG00000248734.2	CTD-2260A17.1	5.24	2.45e-07	7.51e-05	0.33	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96709210	chr5:96784777~96785999:+
HNSC	cis	rs9840812	0.645	rs9883916	ENSG00000273486.1	RP11-731C17.2	5.24	2.45e-07	7.51e-05	0.22	0.24	Fibrinogen levels;	chr3:136489946	chr3:136837338~136839021:-
HNSC	cis	rs10504130	0.569	rs16916966	ENSG00000253844.1	RP11-546K22.1	-5.24	2.45e-07	7.51e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51930769	chr8:51961458~52022974:+
HNSC	cis	rs9921338	0.961	rs7199821	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs77552156	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs4781069	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs7187870	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11341809~11345211:-
HNSC	cis	rs7804306	1	rs35641104	ENSG00000233264.2	AC006042.8	5.24	2.45e-07	7.52e-05	0.47	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046289	chr7:7980312~7982228:+
HNSC	cis	rs7804306	1	rs12702689	ENSG00000233264.2	AC006042.8	5.24	2.45e-07	7.52e-05	0.47	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046767	chr7:7980312~7982228:+
HNSC	cis	rs2985684	0.894	rs2281837	ENSG00000278009.1	RP11-649E7.8	5.24	2.46e-07	7.52e-05	0.31	0.24	Carotid intima media thickness;	chr14:49598641	chr14:49601011~49601124:-
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	5.24	2.46e-07	7.53e-05	0.25	0.24	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
HNSC	cis	rs4834770	1	rs2282688	ENSG00000249244.1	RP11-548H18.2	5.24	2.46e-07	7.53e-05	0.26	0.24	Blood protein levels;	chr4:119322567	chr4:119391831~119395335:-
HNSC	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	5.24	2.46e-07	7.54e-05	0.36	0.24	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
HNSC	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-5.24	2.46e-07	7.54e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
HNSC	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-5.24	2.46e-07	7.54e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
HNSC	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	5.24	2.46e-07	7.54e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	5.24	2.46e-07	7.54e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
HNSC	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-5.24	2.46e-07	7.55e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
HNSC	cis	rs3808502	0.527	rs2736374	ENSG00000269918.1	AF131215.9	-5.24	2.47e-07	7.55e-05	-0.25	-0.24	Neuroticism;	chr8:11256319	chr8:11104691~11106704:-
HNSC	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	5.24	2.47e-07	7.55e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
HNSC	cis	rs11846409	0.932	rs2015469	ENSG00000211974.3	IGHV2-70	-5.24	2.47e-07	7.55e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106631857	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs56167903	ENSG00000211974.3	IGHV2-70	-5.24	2.47e-07	7.55e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106632070	chr14:106723574~106724093:-
HNSC	cis	rs11969893	0.85	rs9498409	ENSG00000270987.1	RP3-467N11.2	5.24	2.47e-07	7.56e-05	0.6	0.24	Economic and political preferences (immigration/crime);	chr6:100852090	chr6:100889603~100890338:+
HNSC	cis	rs11969893	0.85	rs3734351	ENSG00000270987.1	RP3-467N11.2	5.24	2.47e-07	7.56e-05	0.6	0.24	Economic and political preferences (immigration/crime);	chr6:100859255	chr6:100889603~100890338:+
HNSC	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	5.24	2.47e-07	7.56e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	5.24	2.47e-07	7.56e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
HNSC	cis	rs9341808	0.519	rs684251	ENSG00000272129.1	RP11-250B2.6	-5.24	2.47e-07	7.57e-05	-0.28	-0.24	Sitting height ratio;	chr6:80257620	chr6:80355424~80356859:+
HNSC	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-5.24	2.48e-07	7.58e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
HNSC	cis	rs17428076	0.874	rs72885529	ENSG00000228389.1	AC068039.4	-5.24	2.48e-07	7.58e-05	-0.28	-0.24	Myopia;	chr2:171827522	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.874	rs72885532	ENSG00000228389.1	AC068039.4	-5.24	2.48e-07	7.58e-05	-0.28	-0.24	Myopia;	chr2:171827523	chr2:171773482~171775844:+
HNSC	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-5.24	2.48e-07	7.58e-05	-0.25	-0.24	Height;	chr2:46615271	chr2:46668870~46670778:+
HNSC	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	5.24	2.48e-07	7.58e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	5.24	2.48e-07	7.58e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	5.24	2.48e-07	7.58e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
HNSC	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	5.24	2.48e-07	7.58e-05	0.28	0.24	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
HNSC	cis	rs950169	0.922	rs11630507	ENSG00000229212.6	RP11-561C5.4	-5.24	2.48e-07	7.58e-05	-0.33	-0.24	Schizophrenia;	chr15:84552494	chr15:85205440~85234795:-
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	5.24	2.48e-07	7.59e-05	0.25	0.24	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
HNSC	cis	rs9907295	0.748	rs4251719	ENSG00000270977.1	AC015849.16	-5.24	2.48e-07	7.59e-05	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35893707~35911023:-
HNSC	cis	rs10462794	0.661	rs16873538	ENSG00000260763.1	RP11-445O3.3	-5.24	2.48e-07	7.59e-05	-0.34	-0.24	DNA methylation (variation);	chr5:4515701	chr5:4436850~4440259:-
HNSC	cis	rs2337406	0.866	rs8015361	ENSG00000254174.1	IGHV1-12	5.24	2.48e-07	7.59e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783991	chr14:106122420~106122709:-
HNSC	cis	rs1933112	0.5	rs12049040	ENSG00000227777.1	RP4-738P11.3	5.24	2.48e-07	7.59e-05	0.33	0.24	Blood protein levels;	chr1:168552377	chr1:168542737~168543354:+
HNSC	cis	rs7115242	0.567	rs10047462	ENSG00000280143.1	AP000892.6	5.24	2.48e-07	7.6e-05	0.41	0.24	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117204967~117210292:+
HNSC	cis	rs4218	0.689	rs12900369	ENSG00000277144.1	RP11-59H7.4	-5.24	2.48e-07	7.6e-05	-0.31	-0.24	Social communication problems;	chr15:59099254	chr15:59115547~59116089:-
HNSC	cis	rs7048146	0.509	rs12551462	ENSG00000213539.4	YBX1P6	5.24	2.48e-07	7.6e-05	0.33	0.24	Vascular brain injury;	chr9:109568279	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs34738162	ENSG00000213539.4	YBX1P6	5.24	2.48e-07	7.6e-05	0.33	0.24	Vascular brain injury;	chr9:109568706	chr9:109532830~109534332:-
HNSC	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	5.24	2.49e-07	7.6e-05	0.28	0.24	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	5.24	2.49e-07	7.6e-05	0.28	0.24	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
HNSC	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	5.24	2.49e-07	7.62e-05	0.28	0.24	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
HNSC	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-5.24	2.49e-07	7.63e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
HNSC	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-5.24	2.49e-07	7.63e-05	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
HNSC	cis	rs9813712	0.571	rs9855777	ENSG00000249846.5	RP11-77P16.4	5.24	2.5e-07	7.64e-05	0.25	0.24	Response to amphetamines;	chr3:130214805	chr3:130112550~130120579:+
HNSC	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	5.24	2.5e-07	7.64e-05	0.29	0.24	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
HNSC	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	5.23	2.5e-07	7.64e-05	0.24	0.24	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
HNSC	cis	rs3806843	0.868	rs2262574	ENSG00000202515.1	VTRNA1-3	5.23	2.5e-07	7.65e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr5:140726158~140726246:+
HNSC	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-5.23	2.5e-07	7.65e-05	-0.25	-0.24	Height;	chr2:46635327	chr2:46668870~46670778:+
HNSC	cis	rs9611519	0.828	rs28814423	ENSG00000235513.1	RP4-756G23.5	5.23	2.5e-07	7.65e-05	0.26	0.24	Neuroticism;	chr22:41056297	chr22:41209122~41217627:-
HNSC	cis	rs4803480	1	rs3745937	ENSG00000270164.1	LINC01480	-5.23	2.5e-07	7.66e-05	-0.22	-0.24	Schizophrenia;	chr19:41564935	chr19:41535183~41536904:+
HNSC	cis	rs950169	0.84	rs12905223	ENSG00000229212.6	RP11-561C5.4	-5.23	2.5e-07	7.66e-05	-0.33	-0.24	Schizophrenia;	chr15:84571037	chr15:85205440~85234795:-
HNSC	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-5.23	2.51e-07	7.66e-05	-0.31	-0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
HNSC	cis	rs4388249	0.687	rs2300998	ENSG00000271849.1	CTC-332L22.1	-5.23	2.51e-07	7.66e-05	-0.31	-0.24	Schizophrenia;	chr5:109747421	chr5:109687802~109688329:-
HNSC	cis	rs638893	0.617	rs4938561	ENSG00000255422.1	AP002954.4	-5.23	2.51e-07	7.66e-05	-0.33	-0.24	Vitiligo;	chr11:118847776	chr11:118704607~118750263:+
HNSC	cis	rs9525927	0.625	rs4942301	ENSG00000227258.4	SMIM2-AS1	5.23	2.51e-07	7.66e-05	0.32	0.24	Dupuytren's disease;	chr13:44237111	chr13:44110451~44240517:+
HNSC	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	5.23	2.51e-07	7.66e-05	0.25	0.24	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
HNSC	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
HNSC	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	5.23	2.51e-07	7.68e-05	0.28	0.24	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
HNSC	cis	rs4834770	1	rs4834771	ENSG00000249244.1	RP11-548H18.2	5.23	2.51e-07	7.68e-05	0.26	0.24	Blood protein levels;	chr4:119321617	chr4:119391831~119395335:-
HNSC	cis	rs4834770	1	rs1397613	ENSG00000249244.1	RP11-548H18.2	5.23	2.51e-07	7.68e-05	0.26	0.24	Blood protein levels;	chr4:119321774	chr4:119391831~119395335:-
HNSC	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-5.23	2.51e-07	7.68e-05	-0.25	-0.24	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
HNSC	cis	rs73198271	0.74	rs1039911	ENSG00000253893.2	FAM85B	5.23	2.52e-07	7.69e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8167819~8226614:-
HNSC	cis	rs879620	1	rs2531995	ENSG00000262888.1	RP11-462G12.2	-5.23	2.52e-07	7.69e-05	-0.28	-0.24	Hip circumference;Body mass index;	chr16:3963466	chr16:3931217~3946305:-
HNSC	cis	rs9402743	0.671	rs7767066	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135623970	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.598	rs9483856	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135624088	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.635	rs9376118	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135624521	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs742738	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135625301	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9402728	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135626450	chr6:135636086~135636713:-
HNSC	cis	rs9910055	0.762	rs2526021	ENSG00000267080.4	ASB16-AS1	-5.23	2.52e-07	7.7e-05	-0.19	-0.24	Total body bone mineral density;	chr17:44135979	chr17:44175973~44186717:-
HNSC	cis	rs9910055	0.762	rs2631299	ENSG00000267080.4	ASB16-AS1	-5.23	2.52e-07	7.7e-05	-0.19	-0.24	Total body bone mineral density;	chr17:44142405	chr17:44175973~44186717:-
HNSC	cis	rs6723108	0.517	rs12473839	ENSG00000224043.6	CCNT2-AS1	-5.23	2.52e-07	7.7e-05	-0.28	-0.24	Type 2 diabetes;	chr2:134880474	chr2:134735464~134918710:-
HNSC	cis	rs9813712	0.953	rs6439222	ENSG00000249846.5	RP11-77P16.4	5.23	2.52e-07	7.7e-05	0.29	0.24	Response to amphetamines;	chr3:130256298	chr3:130112550~130120579:+
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-5.23	2.52e-07	7.7e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
HNSC	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	5.23	2.52e-07	7.71e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
HNSC	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	5.23	2.52e-07	7.71e-05	0.29	0.24	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
HNSC	cis	rs17428076	0.874	rs62182374	ENSG00000228389.1	AC068039.4	-5.23	2.53e-07	7.71e-05	-0.28	-0.24	Myopia;	chr2:171829172	chr2:171773482~171775844:+
HNSC	cis	rs9287719	0.614	rs12329184	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10582638	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.614	rs10929681	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10583157	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.614	rs6711473	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10583248	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.686	rs10174605	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585106	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10211190	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585302	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10166765	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585547	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6720112	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585593	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6730247	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585762	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6717431	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585920	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.6	rs10197187	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586513	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10199635	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586514	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10199831	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586737	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10187659	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586834	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10202370	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586917	chr2:10690344~10692099:+
HNSC	cis	rs2337406	1	rs1858677	ENSG00000254174.1	IGHV1-12	5.23	2.53e-07	7.72e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106706828	chr14:106122420~106122709:-
HNSC	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	5.23	2.53e-07	7.72e-05	0.25	0.24	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	5.23	2.53e-07	7.72e-05	0.26	0.24	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
HNSC	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-5.23	2.53e-07	7.73e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
HNSC	cis	rs7811142	1	rs73161762	ENSG00000078319.8	PMS2P1	-5.23	2.53e-07	7.73e-05	-0.31	-0.24	Platelet count;	chr7:100417223	chr7:100320992~100341908:-
HNSC	cis	rs9287719	0.615	rs12613769	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.73e-05	0.24	0.24	Prostate cancer;	chr2:10602164	chr2:10690344~10692099:+
HNSC	cis	rs11971779	1	rs11971779	ENSG00000273391.1	RP11-634H22.1	-5.23	2.53e-07	7.73e-05	-0.29	-0.24	Diisocyanate-induced asthma;	chr7:139355512	chr7:139359032~139359566:-
HNSC	cis	rs7937890	0.506	rs10741655	ENSG00000251991.1	RNU7-49P	5.23	2.53e-07	7.73e-05	0.26	0.24	Mitochondrial DNA levels;	chr11:14746838	chr11:14478892~14478953:+
HNSC	cis	rs2439831	0.867	rs45585139	ENSG00000205771.5	CATSPER2P1	-5.23	2.54e-07	7.74e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43408229	chr15:43726918~43747094:-
HNSC	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	5.23	2.54e-07	7.74e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
HNSC	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-5.23	2.54e-07	7.74e-05	-0.22	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
HNSC	cis	rs6928977	0.538	rs17064702	ENSG00000234084.1	RP3-388E23.2	-5.23	2.54e-07	7.74e-05	-0.25	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135301568~135307158:+
HNSC	cis	rs4947019	0.688	rs4946979	ENSG00000260273.1	RP11-425D10.10	5.23	2.54e-07	7.75e-05	0.66	0.24	Hematological parameters;	chr6:109484714	chr6:109382795~109383666:+
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	5.23	2.54e-07	7.75e-05	0.29	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	5.23	2.54e-07	7.75e-05	0.29	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
HNSC	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-5.23	2.54e-07	7.75e-05	-0.23	-0.24	Height;	chr5:37053881	chr5:36666214~36725195:-
HNSC	cis	rs7829975	0.684	rs546603	ENSG00000173295.6	FAM86B3P	-5.23	2.54e-07	7.76e-05	-0.27	-0.24	Mood instability;	chr8:8738328	chr8:8228595~8244865:+
HNSC	cis	rs3806843	0.864	rs2531343	ENSG00000202515.1	VTRNA1-3	5.23	2.55e-07	7.77e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr5:140726158~140726246:+
HNSC	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-5.23	2.55e-07	7.77e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
HNSC	cis	rs1056107	0.931	rs10981316	ENSG00000225513.1	RP11-165N19.2	-5.23	2.55e-07	7.77e-05	-0.25	-0.24	Colorectal cancer;	chr9:112211522	chr9:112173522~112173971:-
HNSC	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-5.23	2.55e-07	7.77e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
HNSC	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	5.23	2.55e-07	7.77e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
HNSC	cis	rs3206736	0.52	rs1637674	ENSG00000197085.10	NPSR1-AS1	-5.23	2.55e-07	7.78e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:34958475	chr7:34346512~34871582:-
HNSC	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-5.23	2.55e-07	7.78e-05	-0.3	-0.24	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-5.23	2.55e-07	7.78e-05	-0.28	-0.24	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
HNSC	cis	rs12817211	0.502	rs17124432	ENSG00000272368.2	RP4-605O3.4	5.23	2.56e-07	7.8e-05	0.23	0.24	Colorectal or endometrial cancer;	chr12:50116994	chr12:50112197~50165618:+
HNSC	cis	rs10504130	0.502	rs877248	ENSG00000253844.1	RP11-546K22.1	-5.23	2.56e-07	7.8e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51939074	chr8:51961458~52022974:+
HNSC	cis	rs59406912	1	rs59406912	ENSG00000261485.1	PAN3-AS1	5.23	2.56e-07	7.81e-05	0.38	0.24	Hepcidin/transferrin saturation ratio;	chr13:28269628	chr13:28136843~28138193:-
HNSC	cis	rs2337406	0.929	rs12050233	ENSG00000254174.1	IGHV1-12	5.23	2.56e-07	7.81e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106781123	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.852	rs12050466	ENSG00000254174.1	IGHV1-12	5.23	2.56e-07	7.81e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106781131	chr14:106122420~106122709:-
HNSC	cis	rs3733585	0.699	rs11724510	ENSG00000250413.1	RP11-448G15.1	5.23	2.56e-07	7.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956959	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs28837683	ENSG00000250413.1	RP11-448G15.1	5.23	2.56e-07	7.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958184	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6823361	ENSG00000250413.1	RP11-448G15.1	5.23	2.56e-07	7.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9961503	chr4:10006482~10009725:+
HNSC	cis	rs9611519	0.929	rs73174660	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41041300	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs12484971	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41043300	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs13055800	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41044420	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs4821991	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41044679	chr22:41209122~41217627:-
HNSC	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-5.23	2.57e-07	7.83e-05	-0.38	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
HNSC	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	5.23	2.57e-07	7.84e-05	0.43	0.24	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	5.23	2.57e-07	7.84e-05	0.28	0.24	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
HNSC	cis	rs12701220	0.803	rs12701432	ENSG00000229043.2	AC091729.9	-5.23	2.57e-07	7.84e-05	-0.32	-0.24	Bronchopulmonary dysplasia;	chr7:1012817	chr7:1160374~1165267:+
HNSC	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-5.23	2.57e-07	7.84e-05	-0.25	-0.24	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-5.23	2.57e-07	7.84e-05	-0.25	-0.24	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
HNSC	cis	rs4218	0.689	rs73418863	ENSG00000277144.1	RP11-59H7.4	-5.23	2.58e-07	7.86e-05	-0.31	-0.24	Social communication problems;	chr15:59098923	chr15:59115547~59116089:-
HNSC	cis	rs36093844	0.8	rs17817355	ENSG00000279742.1	RP11-700A24.1	-5.23	2.58e-07	7.86e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85888902	chr11:85852557~85854943:-
HNSC	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-5.23	2.58e-07	7.87e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
HNSC	cis	rs11846409	0.86	rs10150951	ENSG00000211974.3	IGHV2-70	-5.23	2.58e-07	7.87e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106632988	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.86	rs17112419	ENSG00000211974.3	IGHV2-70	-5.23	2.58e-07	7.87e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106633260	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs2583329	ENSG00000211974.3	IGHV2-70	5.23	2.58e-07	7.87e-05	0.26	0.24	Rheumatic heart disease;	chr14:106632971	chr14:106723574~106724093:-
HNSC	cis	rs3733585	0.673	rs6449156	ENSG00000250413.1	RP11-448G15.1	5.23	2.58e-07	7.87e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9955088	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6449157	ENSG00000250413.1	RP11-448G15.1	5.23	2.58e-07	7.87e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958818	chr4:10006482~10009725:+
HNSC	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-5.23	2.59e-07	7.88e-05	-0.4	-0.24	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
HNSC	cis	rs9840812	0.728	rs665200	ENSG00000273486.1	RP11-731C17.2	5.23	2.59e-07	7.88e-05	0.2	0.24	Fibrinogen levels;	chr3:136276174	chr3:136837338~136839021:-
HNSC	cis	rs728616	0.867	rs12413715	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.59e-07	7.88e-05	-0.55	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:79663088~79826594:-
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	5.23	2.59e-07	7.9e-05	0.26	0.24	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
HNSC	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	5.23	2.59e-07	7.9e-05	0.26	0.24	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
HNSC	cis	rs1707322	1	rs10890353	ENSG00000234329.1	RP11-767N6.2	5.23	2.6e-07	7.92e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45651039~45651826:-
HNSC	cis	rs1008375	0.966	rs2315645	ENSG00000249502.1	AC006160.5	-5.23	2.6e-07	7.92e-05	-0.25	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17578055	chr4:17587467~17614571:-
HNSC	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	5.23	2.6e-07	7.93e-05	0.32	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
HNSC	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	5.23	2.6e-07	7.93e-05	0.29	0.24	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	5.23	2.6e-07	7.93e-05	0.29	0.24	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
HNSC	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-5.23	2.6e-07	7.93e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-5.23	2.6e-07	7.93e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-5.23	2.6e-07	7.93e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
HNSC	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	5.23	2.61e-07	7.93e-05	0.42	0.24	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	5.23	2.61e-07	7.93e-05	0.2	0.24	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	5.23	2.61e-07	7.93e-05	0.2	0.24	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
HNSC	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	5.23	2.61e-07	7.93e-05	0.25	0.24	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
HNSC	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-5.23	2.61e-07	7.94e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	5.23	2.61e-07	7.94e-05	0.28	0.24	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
HNSC	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	5.23	2.61e-07	7.94e-05	0.38	0.24	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
HNSC	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-5.23	2.61e-07	7.94e-05	-0.22	-0.24	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
HNSC	cis	rs10504130	0.696	rs76522329	ENSG00000253844.1	RP11-546K22.1	-5.23	2.61e-07	7.95e-05	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51961458~52022974:+
HNSC	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	5.23	2.61e-07	7.95e-05	0.29	0.24	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
HNSC	cis	rs2179367	0.632	rs997682	ENSG00000216906.2	RP11-350J20.9	-5.23	2.61e-07	7.95e-05	-0.35	-0.24	Dupuytren's disease;	chr6:149345484	chr6:149904243~149906418:+
HNSC	cis	rs72949976	0.646	rs1441171	ENSG00000270659.1	RP11-105N14.1	-5.23	2.61e-07	7.95e-05	-0.23	-0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213168913	chr2:213152970~213153659:+
HNSC	cis	rs3206736	0.521	rs6948899	ENSG00000197085.10	NPSR1-AS1	-5.23	2.62e-07	7.96e-05	-0.28	-0.24	Diastolic blood pressure;	chr7:35193190	chr7:34346512~34871582:-
HNSC	cis	rs4834770	1	rs10034579	ENSG00000249244.1	RP11-548H18.2	5.23	2.62e-07	7.97e-05	0.26	0.24	Blood protein levels;	chr4:119322874	chr4:119391831~119395335:-
HNSC	cis	rs1707322	1	rs4606257	ENSG00000234329.1	RP11-767N6.2	5.23	2.62e-07	7.97e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45651039~45651826:-
HNSC	cis	rs2834288	0.734	rs8126669	ENSG00000237945.6	LINC00649	-5.23	2.62e-07	7.98e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33895836	chr21:33915534~33977691:+
HNSC	cis	rs1008375	0.966	rs3775925	ENSG00000249502.1	AC006160.5	-5.23	2.62e-07	7.98e-05	-0.25	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17586814	chr4:17587467~17614571:-
HNSC	cis	rs13073817	0.582	rs10865756	ENSG00000228956.7	SATB1-AS1	5.23	2.62e-07	7.98e-05	0.25	0.24	Crohn's disease;	chr3:18653645	chr3:18445024~18920401:+
HNSC	cis	rs1707322	0.963	rs11211202	ENSG00000234329.1	RP11-767N6.2	5.23	2.62e-07	7.98e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660889	ENSG00000234329.1	RP11-767N6.2	5.23	2.62e-07	7.98e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45651039~45651826:-
HNSC	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-5.23	2.62e-07	7.98e-05	-0.24	-0.24	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
HNSC	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	5.23	2.62e-07	7.98e-05	0.28	0.24	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	5.23	2.62e-07	7.98e-05	0.28	0.24	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
HNSC	cis	rs7404843	0.733	rs153003	ENSG00000263335.1	AF001548.5	5.23	2.62e-07	7.98e-05	0.41	0.24	Testicular germ cell tumor;	chr16:15397543	chr16:15726674~15732993:+
HNSC	cis	rs3806843	0.9	rs2262576	ENSG00000202515.1	VTRNA1-3	5.23	2.63e-07	7.98e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140755951	chr5:140726158~140726246:+
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000233609.3	RP11-62H7.2	5.23	2.63e-07	7.99e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9051726	chr8:8961200~8979025:+
HNSC	cis	rs853679	0.769	rs7752448	ENSG00000204709.4	LINC01556	5.23	2.63e-07	7.99e-05	0.41	0.24	Depression;	chr6:28333322	chr6:28943877~28944537:+
HNSC	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	5.22	2.63e-07	8e-05	0.35	0.24	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	5.22	2.63e-07	8e-05	0.35	0.24	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
HNSC	cis	rs9813712	0.83	rs9755184	ENSG00000249846.5	RP11-77P16.4	-5.22	2.63e-07	8e-05	-0.28	-0.24	Response to amphetamines;	chr3:130262278	chr3:130112550~130120579:+
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	5.22	2.63e-07	8e-05	0.25	0.24	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
HNSC	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-5.22	2.63e-07	8e-05	-0.34	-0.24	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	5.22	2.63e-07	8.01e-05	0.25	0.23	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	5.22	2.63e-07	8.01e-05	0.25	0.23	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
HNSC	cis	rs71520386	0.634	rs13240023	ENSG00000221740.1	SNORD93	-5.22	2.64e-07	8.01e-05	-0.27	-0.23	Fibrinogen levels;	chr7:22827874	chr7:22856613~22856686:+
HNSC	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-5.22	2.64e-07	8.01e-05	-0.27	-0.23	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
HNSC	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-5.22	2.64e-07	8.02e-05	-0.27	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
HNSC	cis	rs4834770	1	rs6857641	ENSG00000249244.1	RP11-548H18.2	5.22	2.64e-07	8.02e-05	0.26	0.23	Blood protein levels;	chr4:119322356	chr4:119391831~119395335:-
HNSC	cis	rs12701220	0.894	rs10263252	ENSG00000229043.2	AC091729.9	-5.22	2.64e-07	8.02e-05	-0.32	-0.23	Bronchopulmonary dysplasia;	chr7:1010313	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.894	rs2141274	ENSG00000229043.2	AC091729.9	-5.22	2.64e-07	8.02e-05	-0.32	-0.23	Bronchopulmonary dysplasia;	chr7:995081	chr7:1160374~1165267:+
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000254153.1	CTA-398F10.2	-5.22	2.64e-07	8.03e-05	-0.27	-0.23	Mood instability;	chr8:8489180	chr8:8456909~8461337:-
HNSC	cis	rs6964833	1	rs34324835	ENSG00000184616.8	AC004166.6	5.22	2.64e-07	8.04e-05	0.3	0.23	Menarche (age at onset);	chr7:74717986	chr7:74906673~74913256:-
HNSC	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-5.22	2.65e-07	8.04e-05	-0.23	-0.23	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
HNSC	cis	rs7819412	0.875	rs11250121	ENSG00000255310.2	AF131215.2	-5.22	2.65e-07	8.04e-05	-0.23	-0.23	Triglycerides;	chr8:11202802	chr8:11107788~11109726:-
HNSC	cis	rs9813712	0.574	rs11718032	ENSG00000249846.5	RP11-77P16.4	5.22	2.65e-07	8.04e-05	0.24	0.23	Response to amphetamines;	chr3:130257749	chr3:130112550~130120579:+
HNSC	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	5.22	2.65e-07	8.04e-05	0.32	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
HNSC	cis	rs1971762	0.527	rs11170590	ENSG00000270175.1	RP11-793H13.11	-5.22	2.65e-07	8.04e-05	-0.2	-0.23	Height;	chr12:53545129	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.527	rs7972401	ENSG00000270175.1	RP11-793H13.11	-5.22	2.65e-07	8.04e-05	-0.2	-0.23	Height;	chr12:53546262	chr12:53500162~53500936:-
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	5.22	2.65e-07	8.05e-05	0.25	0.23	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	5.22	2.65e-07	8.05e-05	0.25	0.23	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
HNSC	cis	rs9813712	0.548	rs9880123	ENSG00000249846.5	RP11-77P16.4	-5.22	2.65e-07	8.05e-05	-0.25	-0.23	Response to amphetamines;	chr3:130215275	chr3:130112550~130120579:+
HNSC	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	5.22	2.65e-07	8.06e-05	0.29	0.23	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
HNSC	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-5.22	2.65e-07	8.06e-05	-0.22	-0.23	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
HNSC	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-5.22	2.66e-07	8.08e-05	-0.38	-0.23	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
HNSC	cis	rs17772222	0.755	rs12435019	ENSG00000258789.1	RP11-507K2.3	-5.22	2.66e-07	8.08e-05	-0.26	-0.23	Coronary artery calcification;	chr14:88365074	chr14:88551597~88552493:+
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	5.22	2.66e-07	8.09e-05	0.25	0.23	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
HNSC	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-5.22	2.67e-07	8.11e-05	-0.25	-0.23	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
HNSC	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	5.22	2.67e-07	8.11e-05	0.35	0.23	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-5.22	2.67e-07	8.12e-05	-0.33	-0.23	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
HNSC	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	5.22	2.67e-07	8.12e-05	0.17	0.23	Breast size;	chr12:9220132	chr12:9277235~9313241:+
HNSC	cis	rs42490	0.625	rs438485	ENSG00000251136.7	RP11-37B2.1	-5.22	2.67e-07	8.12e-05	-0.2	-0.23	Leprosy;	chr8:89831190	chr8:89609409~89757727:-
HNSC	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	5.22	2.68e-07	8.13e-05	0.28	0.23	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
HNSC	cis	rs8054556	1	rs4283241	ENSG00000183604.13	SMG1P5	5.22	2.68e-07	8.13e-05	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:30267553~30335374:-
HNSC	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-5.22	2.68e-07	8.13e-05	-0.23	-0.23	Height;	chr5:37007527	chr5:36666214~36725195:-
HNSC	cis	rs3733585	0.673	rs116046986	ENSG00000250413.1	RP11-448G15.1	5.22	2.68e-07	8.13e-05	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9956170	chr4:10006482~10009725:+
HNSC	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	5.22	2.68e-07	8.14e-05	0.21	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
HNSC	cis	rs2337406	0.866	rs7152038	ENSG00000211974.3	IGHV2-70	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106778230	chr14:106723574~106724093:-
HNSC	cis	rs9921338	0.54	rs2868410	ENSG00000263080.1	RP11-485G7.5	5.22	2.68e-07	8.14e-05	0.22	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334244	chr16:11341809~11345211:-
HNSC	cis	rs5758659	0.714	rs133373	ENSG00000227370.1	RP4-669P10.19	-5.22	2.68e-07	8.14e-05	-0.23	-0.23	Cognitive function;	chr22:42069784	chr22:42132543~42132998:+
HNSC	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
HNSC	cis	rs2337406	0.866	rs112089985	ENSG00000211974.3	IGHV2-70	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106780074	chr14:106723574~106724093:-
HNSC	cis	rs4713118	0.662	rs175954	ENSG00000204709.4	LINC01556	5.22	2.68e-07	8.15e-05	0.32	0.23	Parkinson's disease;	chr6:28043807	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	5.22	2.69e-07	8.15e-05	0.25	0.23	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
HNSC	cis	rs2985684	0.894	rs2354439	ENSG00000278009.1	RP11-649E7.8	5.22	2.69e-07	8.15e-05	0.3	0.23	Carotid intima media thickness;	chr14:49552699	chr14:49601011~49601124:-
HNSC	cis	rs17608059	0.524	rs9897978	ENSG00000236088.8	COX10-AS1	5.22	2.69e-07	8.16e-05	0.26	0.23	Temperament;	chr17:13996939	chr17:13756478~14069495:-
HNSC	cis	rs7819412	0.775	rs4545055	ENSG00000255310.2	AF131215.2	-5.22	2.69e-07	8.16e-05	-0.22	-0.23	Triglycerides;	chr8:11077856	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.775	rs2898257	ENSG00000255310.2	AF131215.2	-5.22	2.69e-07	8.16e-05	-0.22	-0.23	Triglycerides;	chr8:11077858	chr8:11107788~11109726:-
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	5.22	2.69e-07	8.16e-05	0.21	0.23	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
HNSC	cis	rs7819412	0.936	rs7814499	ENSG00000255310.2	AF131215.2	-5.22	2.69e-07	8.17e-05	-0.23	-0.23	Triglycerides;	chr8:11183138	chr8:11107788~11109726:-
HNSC	cis	rs7811142	1	rs7783159	ENSG00000078319.8	PMS2P1	-5.22	2.69e-07	8.17e-05	-0.31	-0.23	Platelet count;	chr7:100419831	chr7:100320992~100341908:-
HNSC	cis	rs13126694	0.744	rs4521391	ENSG00000248429.4	RP11-597D13.9	5.22	2.69e-07	8.17e-05	0.27	0.23	Blood osmolality (transformed sodium);	chr4:158017310	chr4:158170752~158202877:+
HNSC	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	5.22	2.7e-07	8.18e-05	0.3	0.23	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
HNSC	cis	rs9907295	1	rs9908011	ENSG00000270977.1	AC015849.16	-5.22	2.7e-07	8.19e-05	-0.36	-0.23	Fibroblast growth factor basic levels;	chr17:35908371	chr17:35893707~35911023:-
HNSC	cis	rs1355223	0.867	rs7925421	ENSG00000271369.1	RP11-350D17.3	-5.22	2.7e-07	8.19e-05	-0.27	-0.23	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34660130	chr11:34709600~34710161:+
HNSC	cis	rs2985684	0.948	rs12897941	ENSG00000278009.1	RP11-649E7.8	5.22	2.7e-07	8.19e-05	0.31	0.23	Carotid intima media thickness;	chr14:49549983	chr14:49601011~49601124:-
HNSC	cis	rs36093844	0.752	rs80193798	ENSG00000279742.1	RP11-700A24.1	-5.22	2.7e-07	8.2e-05	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866486	chr11:85852557~85854943:-
HNSC	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	5.22	2.7e-07	8.2e-05	0.23	0.23	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
HNSC	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	5.22	2.71e-07	8.21e-05	0.28	0.23	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
HNSC	cis	rs7819412	0.775	rs11773990	ENSG00000255310.2	AF131215.2	-5.22	2.71e-07	8.21e-05	-0.22	-0.23	Triglycerides;	chr8:11077572	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
HNSC	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-5.22	2.71e-07	8.22e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
HNSC	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-5.22	2.71e-07	8.23e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
HNSC	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	5.22	2.71e-07	8.23e-05	0.25	0.23	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
HNSC	cis	rs2933343	0.7	rs789239	ENSG00000261159.1	RP11-723O4.9	5.22	2.72e-07	8.23e-05	0.23	0.23	IgG glycosylation;	chr3:128914965	chr3:128859716~128860526:-
HNSC	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-5.22	2.72e-07	8.23e-05	-0.3	-0.23	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
HNSC	cis	rs8054556	1	rs4788197	ENSG00000183604.13	SMG1P5	-5.22	2.72e-07	8.23e-05	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4788198	ENSG00000183604.13	SMG1P5	-5.22	2.72e-07	8.23e-05	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:30267553~30335374:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	5.22	2.72e-07	8.24e-05	0.24	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	5.22	2.72e-07	8.24e-05	0.24	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
HNSC	cis	rs14027	0.512	rs6997976	ENSG00000279347.1	RP11-85I17.2	5.22	2.72e-07	8.24e-05	0.2	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119722044	chr8:119838736~119840385:-
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-5.22	2.72e-07	8.24e-05	-0.28	-0.23	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
HNSC	cis	rs2898290	0.5	rs11998678	ENSG00000206014.6	OR7E161P	5.22	2.72e-07	8.24e-05	0.26	0.23	Systolic blood pressure;	chr8:11972641	chr8:11928597~11929563:-
HNSC	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-5.22	2.73e-07	8.26e-05	-0.33	-0.23	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-5.22	2.73e-07	8.26e-05	-0.33	-0.23	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
HNSC	cis	rs2060793	0.741	rs7119073	ENSG00000251991.1	RNU7-49P	5.22	2.73e-07	8.26e-05	0.26	0.23	Vitamin D levels;	chr11:14669416	chr11:14478892~14478953:+
HNSC	cis	rs2060793	0.741	rs10741653	ENSG00000251991.1	RNU7-49P	5.22	2.73e-07	8.26e-05	0.26	0.23	Vitamin D levels;	chr11:14683294	chr11:14478892~14478953:+
HNSC	cis	rs2060793	0.741	rs4344519	ENSG00000251991.1	RNU7-49P	5.22	2.73e-07	8.26e-05	0.26	0.23	Vitamin D levels;	chr11:14701347	chr11:14478892~14478953:+
HNSC	cis	rs860818	1	rs858256	ENSG00000226816.2	AC005082.12	5.22	2.73e-07	8.27e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23176017	chr7:23206013~23208045:+
HNSC	cis	rs5758659	0.714	rs5758574	ENSG00000227370.1	RP4-669P10.19	5.22	2.73e-07	8.28e-05	0.23	0.23	Cognitive function;	chr22:42085396	chr22:42132543~42132998:+
HNSC	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	5.22	2.73e-07	8.28e-05	0.55	0.23	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	5.22	2.73e-07	8.28e-05	0.55	0.23	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
HNSC	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	5.22	2.73e-07	8.28e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
HNSC	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-5.22	2.73e-07	8.28e-05	-0.24	-0.23	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
HNSC	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	5.22	2.73e-07	8.29e-05	0.42	0.23	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
HNSC	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-5.22	2.74e-07	8.29e-05	-0.28	-0.23	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-5.22	2.74e-07	8.29e-05	-0.28	-0.23	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
HNSC	cis	rs7829975	0.514	rs2979151	ENSG00000254340.1	RP11-10A14.3	-5.22	2.74e-07	8.3e-05	-0.28	-0.23	Mood instability;	chr8:8400509	chr8:9141424~9145435:+
HNSC	cis	rs10504130	0.597	rs4598243	ENSG00000272024.1	RP11-546K22.3	-5.22	2.74e-07	8.3e-05	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51950284~51950690:+
HNSC	cis	rs4388249	0.687	rs10059767	ENSG00000271849.1	CTC-332L22.1	-5.22	2.74e-07	8.31e-05	-0.32	-0.23	Schizophrenia;	chr5:109765049	chr5:109687802~109688329:-
HNSC	cis	rs330048	0.545	rs11249913	ENSG00000254340.1	RP11-10A14.3	-5.22	2.75e-07	8.31e-05	-0.29	-0.23	Systemic lupus erythematosus;	chr8:9286011	chr8:9141424~9145435:+
HNSC	cis	rs520525	0.927	rs1234282	ENSG00000271811.1	RP1-79C4.4	5.22	2.75e-07	8.32e-05	0.26	0.23	Atrial fibrillation;	chr1:170650183	chr1:170667381~170669425:+
HNSC	cis	rs453301	0.506	rs686189	ENSG00000254340.1	RP11-10A14.3	-5.22	2.75e-07	8.32e-05	-0.27	-0.23	Joint mobility (Beighton score);	chr8:8766127	chr8:9141424~9145435:+
HNSC	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	5.22	2.75e-07	8.32e-05	0.32	0.23	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-5.22	2.75e-07	8.33e-05	-0.14	-0.23	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
HNSC	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	5.22	2.75e-07	8.33e-05	0.26	0.23	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
HNSC	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	5.22	2.75e-07	8.33e-05	0.36	0.23	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
HNSC	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	5.22	2.75e-07	8.33e-05	0.36	0.23	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
HNSC	cis	rs9813712	0.597	rs1453255	ENSG00000249846.5	RP11-77P16.4	-5.22	2.75e-07	8.33e-05	-0.25	-0.23	Response to amphetamines;	chr3:130258815	chr3:130112550~130120579:+
HNSC	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-5.22	2.75e-07	8.33e-05	-0.21	-0.23	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
HNSC	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-5.22	2.75e-07	8.34e-05	-0.24	-0.23	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
HNSC	cis	rs17270561	0.525	rs10484432	ENSG00000272810.1	U91328.22	-5.22	2.76e-07	8.34e-05	-0.27	-0.23	Iron status biomarkers;	chr6:26008648	chr6:26013241~26013757:+
HNSC	cis	rs4664293	0.707	rs7563956	ENSG00000226266.5	AC009961.3	5.22	2.76e-07	8.35e-05	0.25	0.23	Monocyte percentage of white cells;	chr2:159815943	chr2:159670708~159712435:-
HNSC	cis	rs1008375	0.9	rs6812675	ENSG00000249502.1	AC006160.5	-5.22	2.76e-07	8.35e-05	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17595926	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.9	rs4698625	ENSG00000249502.1	AC006160.5	-5.22	2.76e-07	8.35e-05	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17597877	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000233609.3	RP11-62H7.2	-5.22	2.76e-07	8.35e-05	-0.23	-0.23	Joint mobility (Beighton score);	chr8:9041808	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000254340.1	RP11-10A14.3	5.22	2.76e-07	8.36e-05	0.29	0.23	Neuroticism;	chr8:8866141	chr8:9141424~9145435:+
HNSC	cis	rs8059260	0.541	rs6498167	ENSG00000274038.1	RP11-66H6.4	-5.22	2.76e-07	8.36e-05	-0.44	-0.23	Alcohol consumption over the past year;	chr16:11127727	chr16:11056556~11057034:+
HNSC	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-5.22	2.76e-07	8.36e-05	-0.32	-0.23	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
HNSC	cis	rs36093844	0.66	rs12274717	ENSG00000279742.1	RP11-700A24.1	-5.22	2.76e-07	8.37e-05	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866671	chr11:85852557~85854943:-
HNSC	cis	rs11846409	0.789	rs34917868	ENSG00000274576.2	IGHV2-70	-5.22	2.76e-07	8.37e-05	-0.24	-0.23	Rheumatic heart disease;	chr14:106618321	chr14:106770577~106771020:-
HNSC	cis	rs2933343	0.7	rs789240	ENSG00000261159.1	RP11-723O4.9	5.22	2.77e-07	8.37e-05	0.23	0.23	IgG glycosylation;	chr3:128911792	chr3:128859716~128860526:-
HNSC	cis	rs2058059	0.594	rs3015907	ENSG00000225648.4	SBDSP1	-5.22	2.77e-07	8.38e-05	-0.32	-0.23	Subcutaneous adipose tissue;	chr7:72670647	chr7:72829425~72836701:+
HNSC	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	5.21	2.77e-07	8.38e-05	0.27	0.23	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
HNSC	cis	rs1008375	0.898	rs2079892	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575540	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.931	rs10019482	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576456	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs4698619	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579332	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs10939736	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579994	chr4:17587467~17614571:-
HNSC	cis	rs6723108	0.627	rs766271	ENSG00000224043.6	CCNT2-AS1	-5.21	2.77e-07	8.39e-05	-0.29	-0.23	Type 2 diabetes;	chr2:134909561	chr2:134735464~134918710:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	5.21	2.77e-07	8.39e-05	0.25	0.23	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	5.21	2.77e-07	8.39e-05	0.25	0.23	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
HNSC	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	5.21	2.77e-07	8.4e-05	0.21	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
HNSC	cis	rs10462794	0.661	rs16873561	ENSG00000260763.1	RP11-445O3.3	-5.21	2.78e-07	8.4e-05	-0.34	-0.23	DNA methylation (variation);	chr5:4521189	chr5:4436850~4440259:-
HNSC	cis	rs13113518	0.507	rs4549456	ENSG00000273257.1	RP11-177J6.1	5.21	2.78e-07	8.41e-05	0.27	0.23	Height;	chr4:55398586	chr4:55387949~55388271:+
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000254174.1	IGHV1-12	5.21	2.78e-07	8.41e-05	0.2	0.23	Alzheimer's disease (late onset);	chr14:106700837	chr14:106122420~106122709:-
HNSC	cis	rs933688	0.941	rs2887007	ENSG00000281357.1	ARRDC3-AS1	5.21	2.78e-07	8.41e-05	0.34	0.23	Smoking behavior;	chr5:91444714	chr5:91380349~91439085:+
HNSC	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	5.21	2.78e-07	8.41e-05	0.28	0.23	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
HNSC	cis	rs5758511	0.508	rs2854827	ENSG00000226450.2	CYP2D8P	5.21	2.78e-07	8.42e-05	0.22	0.23	Birth weight;	chr22:42065914	chr22:42149886~42155001:-
HNSC	cis	rs11089937	0.584	rs6001213	ENSG00000211639.2	IGLV4-60	5.21	2.78e-07	8.42e-05	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22182108	chr22:22162199~22162681:+
HNSC	cis	rs1707322	1	rs4390216	ENSG00000234329.1	RP11-767N6.2	5.21	2.79e-07	8.43e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.964	rs10437063	ENSG00000234329.1	RP11-767N6.2	5.21	2.79e-07	8.43e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs6676982	ENSG00000234329.1	RP11-767N6.2	5.21	2.79e-07	8.43e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45651039~45651826:-
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000254153.1	CTA-398F10.2	-5.21	2.79e-07	8.43e-05	-0.27	-0.23	Mean corpuscular volume;	chr8:8993123	chr8:8456909~8461337:-
HNSC	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-5.21	2.8e-07	8.45e-05	-0.35	-0.23	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
HNSC	cis	rs2033711	0.905	rs1077420	ENSG00000269473.1	CTD-2619J13.19	5.21	2.8e-07	8.46e-05	0.29	0.23	Uric acid clearance;	chr19:58457508	chr19:58440448~58445849:+
HNSC	cis	rs7171171	0.718	rs56279249	ENSG00000259747.1	RP11-275I4.2	-5.21	2.8e-07	8.46e-05	-0.33	-0.23	Type 1 diabetes;	chr15:38623112	chr15:38671847~38689191:+
HNSC	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-5.21	2.8e-07	8.46e-05	-0.27	-0.23	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
HNSC	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-5.21	2.8e-07	8.46e-05	-0.23	-0.23	Height;	chr5:36865567	chr5:36666214~36725195:-
HNSC	cis	rs8062405	0.722	rs28729187	ENSG00000251417.2	RP11-1348G14.4	5.21	2.8e-07	8.47e-05	0.28	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615645	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.789	rs28480369	ENSG00000251417.2	RP11-1348G14.4	5.21	2.8e-07	8.47e-05	0.28	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615683	chr16:28802743~28817828:+
HNSC	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-5.21	2.8e-07	8.47e-05	-0.25	-0.23	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	5.21	2.8e-07	8.47e-05	0.25	0.23	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
HNSC	cis	rs2060793	0.741	rs10734227	ENSG00000251991.1	RNU7-49P	5.21	2.8e-07	8.48e-05	0.26	0.23	Vitamin D levels;	chr11:14767471	chr11:14478892~14478953:+
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	5.21	2.8e-07	8.48e-05	0.25	0.23	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
HNSC	cis	rs1012068	0.96	rs12167583	ENSG00000236132.1	CTA-440B3.1	-5.21	2.81e-07	8.48e-05	-0.28	-0.23	Chronic hepatitis C infection;	chr22:31873725	chr22:31816379~31817491:-
HNSC	cis	rs2235642	0.551	rs1966171	ENSG00000280231.1	LA16c-380F5.3	-5.21	2.81e-07	8.49e-05	-0.31	-0.23	Coronary artery disease;	chr16:1512803	chr16:1553655~1554130:-
HNSC	cis	rs3733585	0.699	rs6449172	ENSG00000250413.1	RP11-448G15.1	5.21	2.81e-07	8.49e-05	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9964412	chr4:10006482~10009725:+
HNSC	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-5.21	2.81e-07	8.49e-05	-0.23	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
HNSC	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-5.21	2.81e-07	8.49e-05	-0.35	-0.23	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
HNSC	cis	rs1008375	0.966	rs2010053	ENSG00000249502.1	AC006160.5	-5.21	2.81e-07	8.5e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17582183	chr4:17587467~17614571:-
HNSC	cis	rs520525	0.963	rs501680	ENSG00000271811.1	RP1-79C4.4	5.21	2.82e-07	8.52e-05	0.27	0.23	Atrial fibrillation;	chr1:170656726	chr1:170667381~170669425:+
HNSC	cis	rs8032939	0.533	rs72729314	ENSG00000259747.1	RP11-275I4.2	-5.21	2.82e-07	8.53e-05	-0.31	-0.23	Rheumatoid arthritis;	chr15:38613933	chr15:38671847~38689191:+
HNSC	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-5.21	2.82e-07	8.53e-05	-0.24	-0.23	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000254340.1	RP11-10A14.3	5.21	2.83e-07	8.54e-05	0.29	0.23	Mood instability;	chr8:8821020	chr8:9141424~9145435:+
HNSC	cis	rs4699052	0.928	rs2169511	ENSG00000246560.2	RP11-10L12.4	5.21	2.83e-07	8.54e-05	0.28	0.23	Testicular germ cell tumor;	chr4:103271423	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs6849319	ENSG00000246560.2	RP11-10L12.4	5.21	2.83e-07	8.54e-05	0.28	0.23	Testicular germ cell tumor;	chr4:103271585	chr4:102828055~102844075:+
HNSC	cis	rs3733585	0.699	rs6856127	ENSG00000250413.1	RP11-448G15.1	5.21	2.83e-07	8.54e-05	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9963819	chr4:10006482~10009725:+
HNSC	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	5.21	2.83e-07	8.55e-05	0.28	0.23	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
HNSC	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-5.21	2.83e-07	8.55e-05	-0.37	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
HNSC	cis	rs860295	0.812	rs12131079	ENSG00000203761.5	MSTO2P	5.21	2.84e-07	8.56e-05	0.18	0.23	Body mass index;	chr1:155349877	chr1:155745829~155750137:+
HNSC	cis	rs603446	0.967	rs108533	ENSG00000254851.1	RP11-109L13.1	5.21	2.84e-07	8.57e-05	0.3	0.23	Triglycerides;	chr11:116730995	chr11:117135528~117138582:+
HNSC	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	5.21	2.84e-07	8.57e-05	0.39	0.23	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
HNSC	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	5.21	2.84e-07	8.57e-05	0.33	0.23	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
HNSC	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	5.21	2.84e-07	8.57e-05	0.35	0.23	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
HNSC	cis	rs7674212	0.541	rs2720460	ENSG00000246560.2	RP11-10L12.4	-5.21	2.84e-07	8.57e-05	-0.26	-0.23	Type 2 diabetes;	chr4:103133529	chr4:102828055~102844075:+
HNSC	cis	rs712039	0.617	rs853201	ENSG00000276054.1	RP11-378E13.3	5.21	2.84e-07	8.58e-05	0.35	0.23	Tuberculosis;	chr17:37444086	chr17:37386886~37387926:+
HNSC	cis	rs42490	0.557	rs426240	ENSG00000251136.7	RP11-37B2.1	-5.21	2.84e-07	8.58e-05	-0.2	-0.23	Leprosy;	chr8:89834573	chr8:89609409~89757727:-
HNSC	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	5.21	2.84e-07	8.58e-05	0.2	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
HNSC	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	5.21	2.85e-07	8.6e-05	0.23	0.23	Height;	chr5:36948260	chr5:36666214~36725195:-
HNSC	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-5.21	2.85e-07	8.6e-05	-0.36	-0.23	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	5.21	2.85e-07	8.61e-05	0.29	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
HNSC	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	5.21	2.85e-07	8.61e-05	0.18	0.23	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
HNSC	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-5.21	2.85e-07	8.61e-05	-0.23	-0.23	Height;	chr5:37046524	chr5:36666214~36725195:-
HNSC	cis	rs17507216	0.628	rs4627310	ENSG00000276710.3	CSPG4P8	-5.21	2.86e-07	8.62e-05	-0.33	-0.23	Excessive daytime sleepiness;	chr15:82708330	chr15:82459472~82477258:+
HNSC	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	5.21	2.86e-07	8.63e-05	0.3	0.23	Depression;	chr6:28167882	chr6:28161781~28169594:+
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000236383.6	LINC00854	-5.21	2.86e-07	8.63e-05	-0.22	-0.23	Menopause (age at onset);	chr17:43105117	chr17:43216941~43305976:-
HNSC	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-5.21	2.86e-07	8.63e-05	-0.46	-0.23	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
HNSC	cis	rs4141404	0.561	rs5994376	ENSG00000236132.1	CTA-440B3.1	5.21	2.86e-07	8.64e-05	0.25	0.23	Paclitaxel-induced neuropathy;	chr22:31167569	chr22:31816379~31817491:-
HNSC	cis	rs1075232	1	rs9672214	ENSG00000215302.7	CTD-3092A11.1	-5.21	2.86e-07	8.64e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30470779~30507623:+
HNSC	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	5.21	2.86e-07	8.64e-05	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
HNSC	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	5.21	2.87e-07	8.66e-05	0.26	0.23	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
HNSC	cis	rs9987353	0.566	rs34389718	ENSG00000254340.1	RP11-10A14.3	-5.21	2.87e-07	8.66e-05	-0.3	-0.23	Recombination measurement;	chr8:9208015	chr8:9141424~9145435:+
HNSC	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	5.21	2.87e-07	8.66e-05	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
HNSC	cis	rs1075232	1	rs12439239	ENSG00000215302.7	CTD-3092A11.1	-5.21	2.87e-07	8.66e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30470779~30507623:+
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	5.21	2.87e-07	8.67e-05	0.25	0.23	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	-5.21	2.87e-07	8.67e-05	-0.29	-0.23	Depression;	chr6:28198669	chr6:28161781~28169594:+
HNSC	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	5.21	2.87e-07	8.67e-05	0.28	0.23	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
HNSC	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	5.21	2.88e-07	8.67e-05	0.28	0.23	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
HNSC	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	5.21	2.88e-07	8.67e-05	0.28	0.23	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
HNSC	cis	rs860818	0.793	rs1881202	ENSG00000226816.2	AC005082.12	-5.21	2.88e-07	8.68e-05	-0.56	-0.23	Initial pursuit acceleration;	chr7:23153889	chr7:23206013~23208045:+
HNSC	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-5.21	2.88e-07	8.68e-05	-0.23	-0.23	Height;	chr5:36968438	chr5:36666214~36725195:-
HNSC	cis	rs4388249	0.687	rs6877418	ENSG00000271849.1	CTC-332L22.1	-5.21	2.88e-07	8.69e-05	-0.32	-0.23	Schizophrenia;	chr5:109738408	chr5:109687802~109688329:-
HNSC	cis	rs2337406	0.587	rs10129888	ENSG00000254174.1	IGHV1-12	5.21	2.88e-07	8.69e-05	0.19	0.23	Alzheimer's disease (late onset);	chr14:106647421	chr14:106122420~106122709:-
HNSC	cis	rs9840812	0.559	rs6439640	ENSG00000239213.4	NCK1-AS1	5.21	2.88e-07	8.7e-05	0.26	0.23	Fibrinogen levels;	chr3:136466838	chr3:136841726~136862054:-
HNSC	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	5.21	2.88e-07	8.7e-05	0.25	0.23	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	5.21	2.88e-07	8.7e-05	0.25	0.23	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
HNSC	cis	rs2439831	1	rs561863	ENSG00000205771.5	CATSPER2P1	-5.21	2.88e-07	8.7e-05	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43469154	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs689596	ENSG00000205771.5	CATSPER2P1	-5.21	2.88e-07	8.7e-05	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43469519	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs689616	ENSG00000205771.5	CATSPER2P1	-5.21	2.88e-07	8.7e-05	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43469703	chr15:43726918~43747094:-
HNSC	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	5.21	2.89e-07	8.7e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
HNSC	cis	rs348196	0.767	rs12744132	ENSG00000203761.5	MSTO2P	-5.21	2.89e-07	8.71e-05	-0.19	-0.23	Breast cancer;	chr1:155693535	chr1:155745829~155750137:+
HNSC	cis	rs17507216	0.718	rs7165690	ENSG00000276710.3	CSPG4P8	-5.21	2.89e-07	8.71e-05	-0.33	-0.23	Excessive daytime sleepiness;	chr15:82654804	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	5.21	2.89e-07	8.71e-05	0.25	0.23	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	5.21	2.89e-07	8.71e-05	0.25	0.23	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
HNSC	cis	rs1707322	0.964	rs7546237	ENSG00000234329.1	RP11-767N6.2	5.21	2.89e-07	8.71e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45651039~45651826:-
HNSC	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-5.21	2.89e-07	8.71e-05	-0.24	-0.23	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000254340.1	RP11-10A14.3	5.21	2.89e-07	8.71e-05	0.28	0.23	Mood instability;	chr8:8401202	chr8:9141424~9145435:+
HNSC	cis	rs3206736	0.548	rs329234	ENSG00000197085.10	NPSR1-AS1	-5.21	2.89e-07	8.71e-05	-0.29	-0.23	Diastolic blood pressure;	chr7:35016268	chr7:34346512~34871582:-
HNSC	cis	rs4713118	0.662	rs149947	ENSG00000204709.4	LINC01556	5.21	2.89e-07	8.71e-05	0.32	0.23	Parkinson's disease;	chr6:28004655	chr6:28943877~28944537:+
HNSC	cis	rs9910055	0.718	rs2526022	ENSG00000267080.4	ASB16-AS1	-5.21	2.89e-07	8.71e-05	-0.19	-0.23	Total body bone mineral density;	chr17:44135848	chr17:44175973~44186717:-
HNSC	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	5.21	2.89e-07	8.72e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
HNSC	cis	rs17270561	0.541	rs2009610	ENSG00000272810.1	U91328.22	-5.21	2.89e-07	8.72e-05	-0.27	-0.23	Iron status biomarkers;	chr6:25966840	chr6:26013241~26013757:+
HNSC	cis	rs3806843	0.9	rs2337984	ENSG00000202515.1	VTRNA1-3	5.21	2.89e-07	8.72e-05	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr5:140726158~140726246:+
HNSC	cis	rs2976388	0.609	rs2717602	ENSG00000253741.1	CTD-2292P10.4	-5.21	2.9e-07	8.73e-05	-0.23	-0.23	Urinary tract infection frequency;	chr8:142724265	chr8:142702252~142726973:-
HNSC	cis	rs8177876	0.749	rs11865207	ENSG00000261061.1	RP11-303E16.2	-5.21	2.9e-07	8.74e-05	-0.36	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81030770~81031485:+
HNSC	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	5.21	2.91e-07	8.76e-05	0.44	0.23	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
HNSC	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	5.21	2.91e-07	8.76e-05	0.31	0.23	Height;	chr4:55501955	chr4:55387949~55388271:+
HNSC	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-5.21	2.91e-07	8.76e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000254340.1	RP11-10A14.3	-5.21	2.91e-07	8.77e-05	-0.29	-0.23	Mood instability;	chr8:8516047	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000164669.11	INTS4P1	-5.21	2.91e-07	8.78e-05	-0.27	-0.23	Aortic root size;	chr7:65998108	chr7:65141225~65234216:+
HNSC	cis	rs7789940	0.951	rs7787526	ENSG00000231087.2	FDPSP7	-5.2	2.91e-07	8.78e-05	-0.29	-0.23	Multiple sclerosis;	chr7:76318236	chr7:76968197~76969250:-
HNSC	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
HNSC	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-5.2	2.91e-07	8.78e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
HNSC	cis	rs9640161	0.789	rs34495356	ENSG00000261305.1	RP4-584D14.7	5.2	2.91e-07	8.78e-05	0.32	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150360702	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	5.2	2.91e-07	8.78e-05	0.32	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
HNSC	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	5.2	2.91e-07	8.78e-05	0.29	0.23	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
HNSC	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-5.2	2.92e-07	8.8e-05	-0.24	-0.23	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
HNSC	cis	rs4218	0.689	rs2121237	ENSG00000277144.1	RP11-59H7.4	-5.2	2.92e-07	8.81e-05	-0.31	-0.23	Social communication problems;	chr15:59091888	chr15:59115547~59116089:-
HNSC	cis	rs17507216	0.671	rs28582623	ENSG00000276710.3	CSPG4P8	-5.2	2.92e-07	8.81e-05	-0.32	-0.23	Excessive daytime sleepiness;	chr15:82577381	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	5.2	2.92e-07	8.81e-05	0.25	0.23	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	5.2	2.92e-07	8.81e-05	0.25	0.23	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
HNSC	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	5.2	2.93e-07	8.81e-05	0.28	0.23	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
HNSC	cis	rs1707322	0.964	rs6697830	ENSG00000234329.1	RP11-767N6.2	5.2	2.93e-07	8.82e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs12060274	ENSG00000234329.1	RP11-767N6.2	5.2	2.93e-07	8.82e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45651039~45651826:-
HNSC	cis	rs7590368	0.926	rs12623588	ENSG00000272275.1	RP11-791G15.2	-5.2	2.93e-07	8.82e-05	-0.3	-0.23	Educational attainment (years of education);	chr2:10817486	chr2:10767875~10770058:-
HNSC	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-5.2	2.93e-07	8.83e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
HNSC	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	5.2	2.93e-07	8.83e-05	0.38	0.23	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
HNSC	cis	rs6693567	0.565	rs10157197	ENSG00000228126.1	FALEC	-5.2	2.93e-07	8.83e-05	-0.29	-0.23	Migraine;	chr1:150278225	chr1:150515757~150518032:+
HNSC	cis	rs763567	0.933	rs588837	ENSG00000271811.1	RP1-79C4.4	5.2	2.93e-07	8.84e-05	0.25	0.23	Tonsillectomy;	chr1:170653968	chr1:170667381~170669425:+
HNSC	cis	rs11846409	0.86	rs74091720	ENSG00000211974.3	IGHV2-70	-5.2	2.94e-07	8.85e-05	-0.26	-0.23	Rheumatic heart disease;	chr14:106638192	chr14:106723574~106724093:-
HNSC	cis	rs67981189	0.579	rs2240533	ENSG00000274818.1	RP1-292L20.3	5.2	2.94e-07	8.85e-05	0.28	0.23	Schizophrenia;	chr14:71074309	chr14:70906657~70907111:-
HNSC	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-5.2	2.94e-07	8.86e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
HNSC	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	5.2	2.94e-07	8.86e-05	0.22	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
HNSC	cis	rs3206736	0.548	rs1559959	ENSG00000197085.10	NPSR1-AS1	-5.2	2.95e-07	8.88e-05	-0.3	-0.23	Diastolic blood pressure;	chr7:35034755	chr7:34346512~34871582:-
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000223648.3	IGHV3-64	5.2	2.95e-07	8.88e-05	0.19	0.23	Kawasaki disease;	chr14:106711838	chr14:106643132~106658258:-
HNSC	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-5.2	2.95e-07	8.88e-05	-0.4	-0.23	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	5.2	2.95e-07	8.88e-05	0.4	0.23	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	5.2	2.95e-07	8.89e-05	0.29	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
HNSC	cis	rs9813712	0.571	rs6795143	ENSG00000249846.5	RP11-77P16.4	-5.2	2.95e-07	8.89e-05	-0.25	-0.23	Response to amphetamines;	chr3:130224355	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.571	rs9289366	ENSG00000249846.5	RP11-77P16.4	-5.2	2.95e-07	8.89e-05	-0.25	-0.23	Response to amphetamines;	chr3:130225267	chr3:1